<SEC-DOCUMENT>0001628280-20-017370.txt : 20201210
<SEC-HEADER>0001628280-20-017370.hdr.sgml : 20201210
<ACCEPTANCE-DATETIME>20201210171848
ACCESSION NUMBER:		0001628280-20-017370
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		104
CONFORMED PERIOD OF REPORT:	20201210
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20201210
DATE AS OF CHANGE:		20201210

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		201381468

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cpix-20201210_d2.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:bbbd83ec-86cd-4852-a42b-62050b4598f2,g:afd11596-cbdf-45f6-87ac-39eae3274065,d:6d7c14b003c7407f85e7456705daa23a--><html xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:cpix="http://www.cumberlandpharma.com/20201210" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cpix-20201210_d2</title></head><body><div id="i6d7c14b003c7407f85e7456705daa23a_32"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">________________________________</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">FORM <ix:nonNumeric contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV8zMi9mcmFnOmQwMjUzMzYyOTZhYTQwNTdhNTY4NjQ4ODM2YjgzNWZiL3RleHRyZWdpb246ZDAyNTMzNjI5NmFhNDA1N2E1Njg2NDg4MzZiODM1ZmJfMjc0ODc3OTA3MjgyOA_056bb863-4f0b-4fa2-ad5c-1715081fe27a">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">________________________________</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 13 OR 15(D)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of Earliest Event Reported):  <ix:nonNumeric contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV8zMi9mcmFnOmQwMjUzMzYyOTZhYTQwNTdhNTY4NjQ4ODM2YjgzNWZiL3RleHRyZWdpb246ZDAyNTMzNjI5NmFhNDA1N2E1Njg2NDg4MzZiODM1ZmJfMjc0ODc3OTA3ODI0OA_1d685876-aef9-4c3f-8b8a-5af74ebbc4d4">December 10, 2020</ix:nonNumeric> (December 10, 2020)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><ix:nonNumeric contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV8zMi9mcmFnOmQwMjUzMzYyOTZhYTQwNTdhNTY4NjQ4ODM2YjgzNWZiL3RleHRyZWdpb246ZDAyNTMzNjI5NmFhNDA1N2E1Njg2NDg4MzZiODM1ZmJfMjc0ODc3OTA3MjgyOQ_2166f7e7-e9b1-4f9e-9a12-416787da3c80"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">.</span></ix:nonNumeric></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">    </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.913%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.935%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><ix:nonNumeric contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV8zMi9mcmFnOmQwMjUzMzYyOTZhYTQwNTdhNTY4NjQ4ODM2YjgzNWZiL3RhYmxlOmI3NGEzNjllNzVkNzRhNDQ5NWMwZjU5NGZjMGE2YjBlL3RhYmxlcmFuZ2U6Yjc0YTM2OWU3NWQ3NGE0NDk1YzBmNTk0ZmMwYTZiMGVfMS0wLTEtMS0xMDU_bffa6826-4410-45f1-8f14-92bd9a77730b">Tennessee</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><ix:nonNumeric contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV8zMi9mcmFnOmQwMjUzMzYyOTZhYTQwNTdhNTY4NjQ4ODM2YjgzNWZiL3RhYmxlOmI3NGEzNjllNzVkNzRhNDQ5NWMwZjU5NGZjMGE2YjBlL3RhYmxlcmFuZ2U6Yjc0YTM2OWU3NWQ3NGE0NDk1YzBmNTk0ZmMwYTZiMGVfMS0xLTEtMS0xMDU_86025e8f-524f-4ee8-b89b-9ada402f62e7">001-33637</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><ix:nonNumeric contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV8zMi9mcmFnOmQwMjUzMzYyOTZhYTQwNTdhNTY4NjQ4ODM2YjgzNWZiL3RhYmxlOmI3NGEzNjllNzVkNzRhNDQ5NWMwZjU5NGZjMGE2YjBlL3RhYmxlcmFuZ2U6Yjc0YTM2OWU3NWQ3NGE0NDk1YzBmNTk0ZmMwYTZiMGVfMS0yLTEtMS0xMDk_2743021d-5db1-472b-befb-4487560f8dc3">62-1765329</ix:nonNumeric></span></td></tr><tr style="height:6pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation)</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr style="height:11pt"><td colspan="9" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV8zMi9mcmFnOmQwMjUzMzYyOTZhYTQwNTdhNTY4NjQ4ODM2YjgzNWZiL3RhYmxlOmI3NGEzNjllNzVkNzRhNDQ5NWMwZjU5NGZjMGE2YjBlL3RhYmxlcmFuZ2U6Yjc0YTM2OWU3NWQ3NGE0NDk1YzBmNTk0ZmMwYTZiMGVfNS0wLTEtMS0yMTIvdGV4dHJlZ2lvbjowYTBiZjFhNjZhNTQ0N2Q1YTAyY2I1MDg1MjE0NGQ1MF8yNzQ4Nzc5MDY5NTI0_4d3f014c-3b49-4cfd-b34b-eab16b8e6ead">2525 West End Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV8zMi9mcmFnOmQwMjUzMzYyOTZhYTQwNTdhNTY4NjQ4ODM2YjgzNWZiL3RhYmxlOmI3NGEzNjllNzVkNzRhNDQ5NWMwZjU5NGZjMGE2YjBlL3RhYmxlcmFuZ2U6Yjc0YTM2OWU3NWQ3NGE0NDk1YzBmNTk0ZmMwYTZiMGVfNS0wLTEtMS0yMTIvdGV4dHJlZ2lvbjowYTBiZjFhNjZhNTQ0N2Q1YTAyY2I1MDg1MjE0NGQ1MF8yNzQ4Nzc5MDY5NTc2_344f5cd5-f990-48fc-8ff7-b6f3f972d7aa">Suite 950</ix:nonNumeric>, <ix:nonNumeric contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV8zMi9mcmFnOmQwMjUzMzYyOTZhYTQwNTdhNTY4NjQ4ODM2YjgzNWZiL3RhYmxlOmI3NGEzNjllNzVkNzRhNDQ5NWMwZjU5NGZjMGE2YjBlL3RhYmxlcmFuZ2U6Yjc0YTM2OWU3NWQ3NGE0NDk1YzBmNTk0ZmMwYTZiMGVfNS0wLTEtMS0yMTIvdGV4dHJlZ2lvbjowYTBiZjFhNjZhNTQ0N2Q1YTAyY2I1MDg1MjE0NGQ1MF8yNzQ4Nzc5MDY5NTg4_a89f295a-16bc-4d61-a4da-dd9774ff1fc8">Nashville</ix:nonNumeric>, <ix:nonNumeric contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV8zMi9mcmFnOmQwMjUzMzYyOTZhYTQwNTdhNTY4NjQ4ODM2YjgzNWZiL3RhYmxlOmI3NGEzNjllNzVkNzRhNDQ5NWMwZjU5NGZjMGE2YjBlL3RhYmxlcmFuZ2U6Yjc0YTM2OWU3NWQ3NGE0NDk1YzBmNTk0ZmMwYTZiMGVfNS0wLTEtMS0yMTIvdGV4dHJlZ2lvbjowYTBiZjFhNjZhNTQ0N2Q1YTAyY2I1MDg1MjE0NGQ1MF8yNzQ4Nzc5MDY5NjE4_44a1f8df-eca7-4706-ac46-25250a6c0f82">Tennessee</ix:nonNumeric> <ix:nonNumeric contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV8zMi9mcmFnOmQwMjUzMzYyOTZhYTQwNTdhNTY4NjQ4ODM2YjgzNWZiL3RhYmxlOmI3NGEzNjllNzVkNzRhNDQ5NWMwZjU5NGZjMGE2YjBlL3RhYmxlcmFuZ2U6Yjc0YTM2OWU3NWQ3NGE0NDk1YzBmNTk0ZmMwYTZiMGVfNS0wLTEtMS0yMTIvdGV4dHJlZ2lvbjowYTBiZjFhNjZhNTQ0N2Q1YTAyY2I1MDg1MjE0NGQ1MF8yNzQ4Nzc5MDY5NjI2_d097ee68-ee78-41f1-b0cd-b0d4d4d9b1a0">37203</ix:nonNumeric></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Address of principal executive offices) (Zip Code)</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonNumeric contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV8zMi9mcmFnOmQwMjUzMzYyOTZhYTQwNTdhNTY4NjQ4ODM2YjgzNWZiL3RhYmxlOmI3NGEzNjllNzVkNzRhNDQ5NWMwZjU5NGZjMGE2YjBlL3RhYmxlcmFuZ2U6Yjc0YTM2OWU3NWQ3NGE0NDk1YzBmNTk0ZmMwYTZiMGVfOC0wLTEtMS0yNDMvdGV4dHJlZ2lvbjo5NDE4MjgxMGZhZjg0ZjkyODM2YjZjN2EwMjVjNjkxOF8yNzQ4Nzc5MDY5NDYx_e3d42b6b-1d98-43dd-9100-3a4b44ad39a5">615</ix:nonNumeric>) <ix:nonNumeric contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV8zMi9mcmFnOmQwMjUzMzYyOTZhYTQwNTdhNTY4NjQ4ODM2YjgzNWZiL3RhYmxlOmI3NGEzNjllNzVkNzRhNDQ5NWMwZjU5NGZjMGE2YjBlL3RhYmxlcmFuZ2U6Yjc0YTM2OWU3NWQ3NGE0NDk1YzBmNTk0ZmMwYTZiMGVfOC0wLTEtMS0yNDMvdGV4dHJlZ2lvbjo5NDE4MjgxMGZhZjg0ZjkyODM2YjZjN2EwMjVjNjkxOF8yNzQ4Nzc5MDY5NDcy_595c0e8e-dfe0-4e45-b365-0f6253ad78c5">255-0068</ix:nonNumeric></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Registrant&#8217;s telephone number, including area code)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Not Applicable</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Former name or former address, if changed since last report)</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________________________________&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.878%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210" format="ixt:booleanfalse" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV8zMi9mcmFnOmQwMjUzMzYyOTZhYTQwNTdhNTY4NjQ4ODM2YjgzNWZiL3RhYmxlOmU1ZDVmM2Q1YmJjNDRjNjU5NTU2YTExMzBlNDYwYzliL3RhYmxlcmFuZ2U6ZTVkNWYzZDViYmM0NGM2NTk1NTZhMTEzMGU0NjBjOWJfMC0xLTEtMS0xMjY_3c37fc98-1fdd-48dc-8569-01c951e9a5d4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.878%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210" format="ixt:booleanfalse" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV8zMi9mcmFnOmQwMjUzMzYyOTZhYTQwNTdhNTY4NjQ4ODM2YjgzNWZiL3RhYmxlOjBkNmQ2MmUzNTBiNDQ1MGViNGNmMmZlZGI4YmZlNDgyL3RhYmxlcmFuZ2U6MGQ2ZDYyZTM1MGI0NDUwZWI0Y2YyZmVkYjhiZmU0ODJfMC0xLTEtMS0xMjg_e86823c7-cceb-4f19-8178-b57af37737a4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.878%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV8zMi9mcmFnOmQwMjUzMzYyOTZhYTQwNTdhNTY4NjQ4ODM2YjgzNWZiL3RhYmxlOmZlOTJiZTE2MGY0ZjQzZjRhMGVlZDc2ZDE1Y2U1NjFjL3RhYmxlcmFuZ2U6ZmU5MmJlMTYwZjRmNDNmNGEwZWVkNzZkMTVjZTU2MWNfMC0xLTEtMS0xMzA_606e04ac-aaa7-4d9b-8b33-4c96767c7a8f">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.878%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV8zMi9mcmFnOmQwMjUzMzYyOTZhYTQwNTdhNTY4NjQ4ODM2YjgzNWZiL3RhYmxlOjI5NGVjYjMyNzQ0ZjRkYTRiOWMyMGM4Y2QzNDBjZGEwL3RhYmxlcmFuZ2U6Mjk0ZWNiMzI3NDRmNGRhNGI5YzIwYzhjZDM0MGNkYTBfMC0xLTEtMS0xMzI_36cb0345-18e2-4d80-b424-a57625906510">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.755%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.238%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.141%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of exchanged on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV8zMi9mcmFnOmQwMjUzMzYyOTZhYTQwNTdhNTY4NjQ4ODM2YjgzNWZiL3RhYmxlOmIwMWRlZjgwOTM1ZjQ2MzI4M2QzZDRkYTQ3ZDMzZGVlL3RhYmxlcmFuZ2U6YjAxZGVmODA5MzVmNDYzMjgzZDNkNGRhNDdkMzNkZWVfMS0wLTEtMS0xMTM_551d30d7-1217-4215-b003-cbfc463458ef">Common stock, no par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV8zMi9mcmFnOmQwMjUzMzYyOTZhYTQwNTdhNTY4NjQ4ODM2YjgzNWZiL3RhYmxlOmIwMWRlZjgwOTM1ZjQ2MzI4M2QzZDRkYTQ3ZDMzZGVlL3RhYmxlcmFuZ2U6YjAxZGVmODA5MzVmNDYzMjgzZDNkNGRhNDdkMzNkZWVfMS0yLTEtMS0xMTU_0388496c-bd6b-4618-a7d0-d90fb4290a89">CPIX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV8zMi9mcmFnOmQwMjUzMzYyOTZhYTQwNTdhNTY4NjQ4ODM2YjgzNWZiL3RhYmxlOmIwMWRlZjgwOTM1ZjQ2MzI4M2QzZDRkYTQ3ZDMzZGVlL3RhYmxlcmFuZ2U6YjAxZGVmODA5MzVmNDYzMjgzZDNkNGRhNDdkMzNkZWVfMS00LTEtMS0xMTc_203f71dd-e35b-4a7f-9bf7-00a632101116">NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#160;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#160;240.12b-2 of this chapter). </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company <ix:nonNumeric contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV8zMi9mcmFnOmQwMjUzMzYyOTZhYTQwNTdhNTY4NjQ4ODM2YjgzNWZiL3RleHRyZWdpb246ZDAyNTMzNjI5NmFhNDA1N2E1Njg2NDg4MzZiODM1ZmJfMjc0ODc3OTA3Nzk4Mw_3a5db112-2f2d-4c4b-b5c1-7e761a5fe292">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  &#9744;</span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.01. &#160;&#160;&#160;&#160;Other Events</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span></div><ix:nonNumeric contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210" name="dei:AmendmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV8zMi9mcmFnOmQwMjUzMzYyOTZhYTQwNTdhNTY4NjQ4ODM2YjgzNWZiL3RleHRyZWdpb246ZDAyNTMzNjI5NmFhNDA1N2E1Njg2NDg4MzZiODM1ZmJfMjc0ODc3OTA4MDE3NQ_92307870-dfd2-43a8-80f0-4b4c97c75f9d"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cumberland Pharmaceuticals Inc. ("Cumberland", &#8220;we&#8221;, &#8220;our&#8221; or "the Company") is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. This Current Report on Form 8-K (&#8220;Form 8-K&#8221;) is being filed to recast historical financial information, originally included in our  Annual Report on Form 10-K for the year ended December 31, 2019 ("2019 Form 10-K") to reflect the presentation of two Products we no longer distribute as discontinued operations. We previously filed the 2019 Form 10-K with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March 20, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During May 2019, Cumberland entered into a Dissolution Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">("Dissolution Agreement") with Clinigen Healthcare Limited ("Clinigen") in which the Company returned the exclusive rights to commercialize Ethyol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and Totect</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(&#8220;the Products&#8221;) in the United States to Clinigen. Under the terms of the Dissolution Agreement, Cumberland is no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products following December 31, 2019. In exchange for the return of these product license rights and the non-compete provisions of the Dissolution Agreement, Cumberland is receiving $5 million in financial consideration paid in quarterly installments over the two-years following the transition date. The Company's exit from the Products meets the accounting criteria to be reported as discontinued operations and the discontinued operating results have been reclassified in the financial statements and footnotes for all periods presented, as required, to reflect the discontinued status of the Products, beginning in our Quarterly Report on Form 10-Q for the first quarter of 2020. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are issuing this Form 8-K to recast the Products as discontinued operations as of and for each of the periods covered by our 2019 Form 10-K. Accordingly, the Company has retrospectively recast its previously issued annual financial statements for the three years in the period ended December 31, 2019 to present the Products as discontinued operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The information included in Exhibit 99.1 to this Current Report on Form 8-K is presented solely in connection with the presentation changes described above and sections included in the 2019 Form 10-K that are not included in this report continue to speak only as of the original filing date.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exhibit 99.1 to this Form 8-K does not reflect events occurring after the Company filed its 2019 Form 10-K, and does not modify or update the disclosures therein in any way, other than to reflect the presentation of the Products as discontinued operations as described above. Therefore, Exhibit 99.1 to this Form 8-K should be read in conjunction with the Company&#8217;s other filings made with the SEC, including, and subsequent to the date of, the 2019 Form 10-K. These subsequent SEC filings contain important information regarding events, developments, and updates affecting Cumberland and our expectations that have occurred since the filing of the 2019 Form 10-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exhibit 99.1 of this Form 8-K presents a recast of the following historical financial information, originally included in our 2019 Form 10-K, to reflect the presentation of the Products as discontinued operations:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">Item 6. Selected Financial Data</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">Item 7. Management&#8217;s Discussion and Analysis of  Financial Condition and Results of Operations</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">Item 8. Financial Statements and Supplementary Data</span></div></ix:nonNumeric><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exhibit 99.1 to this Form 8-K is attached hereto and incorporated herein by reference.</span></div><div style="margin-top:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01. Financial Statements and Exhibits</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the Exhibit Index set forth below for a list of exhibits included with this Form 8-K. </span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:11.25pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"></td><td style="width:11.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.018%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a12920208-kex231.htm">Consent of BDO USA, LLP</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="cpix-20201210.htm">Recast of Cumberland Pharmaceuticals Inc. Selected Financial Data, Managements Discussion and Analysis of Financial Condition and Results of Operations, and Financial Statements and Supplementary Data </a></span></div></td></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL INSTANCE DOCUMENT - THE INSTANCE DOCUMENT DOES NOT APPEAR IN THE INTERACTIVE DATA FILE BECAUSE ITS XBRL TAGS ARE EMBEDDED WITHIN THE INLINE XBRL DOCUMENT.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><span><br/></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:11.25pt;text-align:center"><span><br/></span></div><div style="margin-top:11.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">SIGNATURES</span></div><div style="margin-top:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.112%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumberland Pharmaceuticals Inc.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 10, 2020</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">By: Michael Bonner</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael Bonner</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:11.25pt;text-align:center"><span><br/></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>a12920208-kex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i8349cd6d203b4a968247109cb5215da6_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Consent of Independent Registered Public Accounting Firm</font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nashville, Tennessee</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-221402) and Form S-8 (No. 333-164376) of Cumberland Pharmaceuticals Inc. of our report dated March 20, 2020 (except for the effects of presenting discontinued operations discussed in Note 20, as to which the date is December 10, 2020), relating to the consolidated financial statements and schedule, which appears in this Current Report on Form 8K.</font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; BDO USA, LLP</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nashville, Tennessee</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 10, 2020</font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-4.3pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.3pt;text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>cpix-20201210.htm
<DESCRIPTION>EX-99.1
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:bbbd83ec-86cd-4852-a42b-62050b4598f2,g:afd11596-cbdf-45f6-87ac-39eae3274065,d:d2bfa55304bd45bbaa9cdf09bb7673a3--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:cpix="http://www.cumberlandpharma.com/20201210" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2020-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cpix-20201210</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonFraction unitRef="usdPerShare" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:CommonStockNoParValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzUvZnJhZzo3MjRkNTkzNGQwOTg0ZmY4ODY5Nzk0MzMwMWZiZTlkNi90YWJsZTpiMThhMWMyMDQ0ZTc0MWE4YmEyNGE2MmFmYWMzZmZmNS90YWJsZXJhbmdlOmIxOGExYzIwNDRlNzQxYThiYTI0YTYyYWZhYzNmZmY1XzItMi0xLTEtMA_c80c9792-301a-4ced-9c75-5e8299321341">&#8212;</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="INF" format="ixt:zerodash" name="us-gaap:CommonStockNoParValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzUvZnJhZzo3MjRkNTkzNGQwOTg0ZmY4ODY5Nzk0MzMwMWZiZTlkNi90YWJsZTpiMThhMWMyMDQ0ZTc0MWE4YmEyNGE2MmFmYWMzZmZmNS90YWJsZXJhbmdlOmIxOGExYzIwNDRlNzQxYThiYTI0YTYyYWZhYzNmZmY1XzItNC0xLTEtMA_7724488e-362a-4c62-873d-bc358d35c4ce">&#8212;</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzUvZnJhZzo3MjRkNTkzNGQwOTg0ZmY4ODY5Nzk0MzMwMWZiZTlkNi90YWJsZTpiMThhMWMyMDQ0ZTc0MWE4YmEyNGE2MmFmYWMzZmZmNS90YWJsZXJhbmdlOmIxOGExYzIwNDRlNzQxYThiYTI0YTYyYWZhYzNmZmY1XzMtMi0xLTEtMA_1702172f-f114-4be5-8e6f-d23723915c28">100,000,000</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzUvZnJhZzo3MjRkNTkzNGQwOTg0ZmY4ODY5Nzk0MzMwMWZiZTlkNi90YWJsZTpiMThhMWMyMDQ0ZTc0MWE4YmEyNGE2MmFmYWMzZmZmNS90YWJsZXJhbmdlOmIxOGExYzIwNDRlNzQxYThiYTI0YTYyYWZhYzNmZmY1XzMtNC0xLTEtMA_7caf0a83-a7f0-4497-9ae0-c84a29651dff">100,000,000</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzUvZnJhZzo3MjRkNTkzNGQwOTg0ZmY4ODY5Nzk0MzMwMWZiZTlkNi90YWJsZTpiMThhMWMyMDQ0ZTc0MWE4YmEyNGE2MmFmYWMzZmZmNS90YWJsZXJhbmdlOmIxOGExYzIwNDRlNzQxYThiYTI0YTYyYWZhYzNmZmY1XzQtMi0xLTEtMA_08c579cc-1253-4bda-ae16-938740fba6f4">15,263,555</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzUvZnJhZzo3MjRkNTkzNGQwOTg0ZmY4ODY5Nzk0MzMwMWZiZTlkNi90YWJsZTpiMThhMWMyMDQ0ZTc0MWE4YmEyNGE2MmFmYWMzZmZmNS90YWJsZXJhbmdlOmIxOGExYzIwNDRlNzQxYThiYTI0YTYyYWZhYzNmZmY1XzQtNC0xLTEtMA_e6086cd0-caaa-4d04-b5cf-0b10066485b4">15,481,497</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzUvZnJhZzo3MjRkNTkzNGQwOTg0ZmY4ODY5Nzk0MzMwMWZiZTlkNi90YWJsZTpiMThhMWMyMDQ0ZTc0MWE4YmEyNGE2MmFmYWMzZmZmNS90YWJsZXJhbmdlOmIxOGExYzIwNDRlNzQxYThiYTI0YTYyYWZhYzNmZmY1XzUtMi0xLTEtMA_7f6f6f61-1256-4643-b746-ea13f066cf96">15,263,555</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzUvZnJhZzo3MjRkNTkzNGQwOTg0ZmY4ODY5Nzk0MzMwMWZiZTlkNi90YWJsZTpiMThhMWMyMDQ0ZTc0MWE4YmEyNGE2MmFmYWMzZmZmNS90YWJsZXJhbmdlOmIxOGExYzIwNDRlNzQxYThiYTI0YTYyYWZhYzNmZmY1XzUtNC0xLTEtMA_6a7374be-3541-4021-9872-1a49cf3f4a23">15,481,497</ix:nonFraction><ix:nonNumeric contextRef="id5c37f17bdd045d8876714d588be095a_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTEvZnJhZzozZjdkMGU0M2JkZjY0MGM3YTU1NzFjNjFmNzkxZDM4NS90YWJsZTo2YmYwNTI4OWIyYWQ0OTUyYjkwMGFmYTA4ZmJlNDU2Yy90YWJsZXJhbmdlOjZiZjA1Mjg5YjJhZDQ5NTJiOTAwYWZhMDhmYmU0NTZjXzEtNC0xLTEtMA_386e12f1-024a-41ca-aa54-41573f54cf6a">3</ix:nonNumeric><ix:nonNumeric contextRef="i171ae0e4eec14d9f868621f1dba24be1_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTEvZnJhZzozZjdkMGU0M2JkZjY0MGM3YTU1NzFjNjFmNzkxZDM4NS90YWJsZTo2YmYwNTI4OWIyYWQ0OTUyYjkwMGFmYTA4ZmJlNDU2Yy90YWJsZXJhbmdlOjZiZjA1Mjg5YjJhZDQ5NTJiOTAwYWZhMDhmYmU0NTZjXzEtNi0xLTEtMA_a5a242ca-fb59-4a08-bccd-55631be87b65">5</ix:nonNumeric><ix:nonNumeric contextRef="ic27611c0dbc04b7988dcc9331bfbe1cb_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTEvZnJhZzozZjdkMGU0M2JkZjY0MGM3YTU1NzFjNjFmNzkxZDM4NS90YWJsZTo2YmYwNTI4OWIyYWQ0OTUyYjkwMGFmYTA4ZmJlNDU2Yy90YWJsZXJhbmdlOjZiZjA1Mjg5YjJhZDQ5NTJiOTAwYWZhMDhmYmU0NTZjXzItNC0xLTEtMA_9bf291ee-ebed-4453-8fc7-a824c8e3d68d">3</ix:nonNumeric><ix:nonNumeric contextRef="i947f330f1863460ea96eb801e0df3cde_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTEvZnJhZzozZjdkMGU0M2JkZjY0MGM3YTU1NzFjNjFmNzkxZDM4NS90YWJsZTo2YmYwNTI4OWIyYWQ0OTUyYjkwMGFmYTA4ZmJlNDU2Yy90YWJsZXJhbmdlOjZiZjA1Mjg5YjJhZDQ5NTJiOTAwYWZhMDhmYmU0NTZjXzItNi0xLTEtMA_e362691e-7a1b-4513-a988-91c6727e3299">15</ix:nonNumeric><ix:nonNumeric contextRef="if1b631d150a9425d83302ca84d5acf6f_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTEvZnJhZzozZjdkMGU0M2JkZjY0MGM3YTU1NzFjNjFmNzkxZDM4NS90YWJsZTo2YmYwNTI4OWIyYWQ0OTUyYjkwMGFmYTA4ZmJlNDU2Yy90YWJsZXJhbmdlOjZiZjA1Mjg5YjJhZDQ5NTJiOTAwYWZhMDhmYmU0NTZjXzMtNC0xLTEtMA_a3c70d36-b84e-4443-8d64-d2a0fdf42347">5</ix:nonNumeric><ix:nonNumeric contextRef="i2beb96285c7c4c4c9e3166c0f1577edc_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTEvZnJhZzozZjdkMGU0M2JkZjY0MGM3YTU1NzFjNjFmNzkxZDM4NS90YWJsZTo2YmYwNTI4OWIyYWQ0OTUyYjkwMGFmYTA4ZmJlNDU2Yy90YWJsZXJhbmdlOjZiZjA1Mjg5YjJhZDQ5NTJiOTAwYWZhMDhmYmU0NTZjXzMtNi0xLTEtMA_b978d091-c6d3-4bf8-bdcb-406a441c8f63">15</ix:nonNumeric><ix:nonNumeric contextRef="ifa90d2ee803c421baadb41895368ae03_D20190101-20191231" name="cpix:PropertyAndEquipmentUsefulLifeTextual" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTEvZnJhZzozZjdkMGU0M2JkZjY0MGM3YTU1NzFjNjFmNzkxZDM4NS90YWJsZTo2YmYwNTI4OWIyYWQ0OTUyYjkwMGFmYTA4ZmJlNDU2Yy90YWJsZXJhbmdlOjZiZjA1Mjg5YjJhZDQ5NTJiOTAwYWZhMDhmYmU0NTZjXzQtMi0xLTEtMA_dd1ab64d-9455-4bb4-b420-6458fa85bf5d">3&#160;&#8211;&#160;15&#160;years,&#160;or remaining&#160;lease&#160;term</ix:nonNumeric><ix:nonNumeric contextRef="i35e4a7c76589409caba0ef887cf3d6c8_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTEvZnJhZzozZjdkMGU0M2JkZjY0MGM3YTU1NzFjNjFmNzkxZDM4NS90YWJsZTo2YmYwNTI4OWIyYWQ0OTUyYjkwMGFmYTA4ZmJlNDU2Yy90YWJsZXJhbmdlOjZiZjA1Mjg5YjJhZDQ5NTJiOTAwYWZhMDhmYmU0NTZjXzQtNC0xLTEtMA_9f483c38-ad8f-4354-8922-7052a6bec453">3</ix:nonNumeric><ix:nonNumeric contextRef="ieba1c5b99e794cc887ea29cce7db35d5_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTEvZnJhZzozZjdkMGU0M2JkZjY0MGM3YTU1NzFjNjFmNzkxZDM4NS90YWJsZTo2YmYwNTI4OWIyYWQ0OTUyYjkwMGFmYTA4ZmJlNDU2Yy90YWJsZXJhbmdlOjZiZjA1Mjg5YjJhZDQ5NTJiOTAwYWZhMDhmYmU0NTZjXzQtNi0xLTEtMA_5543448b-6169-4036-9ac4-7eb565c18390">15</ix:nonNumeric><ix:nonNumeric contextRef="i53e4a12de53b4b0c99c928fb854c6569_D20190101-20191231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90ZXh0cmVnaW9uOmM5ODUzNWNiMmJkMTQ4N2U4ODgxNTg4MWY0MTI2Y2ZkXzQzOTgwNDY1MTM3MjU_e4aa551b-a49e-47c8-ae2e-da92a179d352">P4Y</ix:nonNumeric><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="cpix:FinancialConsiderationPaymentPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90ZXh0cmVnaW9uOjEzZmIyMzg2ZmEwMDQ0OWNhOTQzZmUwYWM0YTU3ZTE5XzQzOTgwNDY1MjI4MDI_72facf0f-0ab8-4e03-8486-1d05338389f9">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV82MC9mcmFnOmNkNzk4OTQyZjFjZDQwNDRiZGMwMWYwOWUxZmU2M2U1L3RhYmxlOjlmYjQzNDM3ZDQ2NDQ3ZDM5MzU0MmJkYjU4MmMxMDZiL3RhYmxlcmFuZ2U6OWZiNDM0MzdkNDY0NDdkMzkzNTQyYmRiNTgyYzEwNmJfMS0xLTEtMS0xNDQ_0e471d2c-7b8f-45bb-a7fb-4f661ddb975a">0001087294</ix:nonNumeric><ix:nonNumeric contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210" format="ixt:booleantrue" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV82MC9mcmFnOmNkNzk4OTQyZjFjZDQwNDRiZGMwMWYwOWUxZmU2M2U1L3RhYmxlOjlmYjQzNDM3ZDQ2NDQ3ZDM5MzU0MmJkYjU4MmMxMDZiL3RhYmxlcmFuZ2U6OWZiNDM0MzdkNDY0NDdkMzkzNTQyYmRiNTgyYzEwNmJfMi0xLTEtMS0xNDQ_8a730d69-a8e3-49a8-8df2-13e16db6faaf">TRUE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cpix-20201210.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="iaa474b82645f415f9a942431b7e23907_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90392aced265439a8a45b88619999ce0_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="iede275917f1d4f6ab16130b2891da5ca_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a75f009943b411484603265cc918c63_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7565a83142144039aa664a5158a4f3a1_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12130cb8adf747bc917372e57661c37d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManufacturedProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80b0be59c71148caa508bedc7c0aa249_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManufacturedProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a3679cdc7a7417d9491addba442e136_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManufacturedProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12da030761f5478185c9c43f4257f503_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19f7709a57f34358b074d8ab2cd1410f_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2153d838d1a64103b08e67d86300e4f6_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id69c7a64b03046d994369dd8619e693b_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ca22cafe70c4402827abcd065642a85_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6067dd95a57b478f9581c66c6de9ce8d_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f7afaa399514dcdbcfdaa5e2bb28ea7_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4861d915e194b9b953dd7e515035d55_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51ac9d639e514ecc9a1253c74c8715e3_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07bb27d9de334b51acf632637d46c3ec_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6921ef0b4c9446b6a5f25b2084bdc3ca_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i512c6090aab845a3bfe38fb3e6f61dbb_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c5b1b36eaf747aea3881c4b9c3884a8_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42508aef6d0b489d9d6f2bc2b649384d_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98582b13998d4d998af541abee8ec14c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cffc6b13dc64ca49a9f14419a551793_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b9e95130dc146f9aa56d8d1d11bc534_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e55eb8a26d0400ab1ddbb5aa6ac9d0c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie93040da022f4f208946b77301e73ade_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4644d0f807ed4bce8b2b23227a41a2f2_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8fc2928cf4640edbddc3867d462e258_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i570bc31a791840209b4f80fc77772940_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52ca8e03f38a46ab80ee3b1b2a37a943_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbcaca0519364200b49f7a89d6fa09f7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48893159b76243539afc56c165b13ce5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0ea12224ffe4a29838858a3bdb9268c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefb6ff4d74154d8685cd13777224de1f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">cpix:CumberlandEmergingTechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:HarbinGloriaPharmaceuticalsCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i917430c8015149c18c59ded862b49717_I20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:HongKongWinHealthPharmaGroupCoLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f1c7f34352d4f90823b583604c2e094_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:HongKongWinHealthPharmaGroupCoLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3522d1a659a04358b4f6ed8b764dd9e5_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:GloriaPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ie1b2c35fc3b6418cb8cc3c920e5ae3d6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">cpix:CumberlandEmergingTechnologiesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>cpix:segment</xbrli:measure></xbrli:unit><xbrli:context id="i6a4ee4b80c85405aa9011089eea73f13_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3faf6260efdc450498cc8cb573bbc167_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icef1ce4e74b54672b3b04ac67a70e22b_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia75e1df3d4b74017bd1b51e0b2b3cff5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cpix:AccountsReceivableAllowancesByComponentAxis">cpix:ChargebacksCashDiscountsAndDamagedGoodsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e91f9a0d19840b7b2aff337c95edc24_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cpix:AccountsReceivableAllowancesByComponentAxis">cpix:ChargebacksCashDiscountsAndDamagedGoodsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib06a29ad4edd4918a967323242b0142d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cpix:ProductRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9796d25c7c94244a85df974cff3caf9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9264ef6a01f546dca65e6adec1f967fe_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a05405482c64e9e8fe092b821aeb335_D20131028-20131029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">cpix:PernixTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cpix:AmendedInternationalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-10-28</xbrli:startDate><xbrli:endDate>2013-10-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62d1338de7314d30a069c29708d22188_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0c9147a91864842a7ac6266279fa374_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafa9e83c0991457dbecd945d1f0eb0a8_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebd5c24d9fc142c0b899398d6d3c153d_D20161101-20161130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-01</xbrli:startDate><xbrli:endDate>2016-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00c91a50edb844d99bb320b2490ff8d6_D20161101-20161130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-01</xbrli:startDate><xbrli:endDate>2016-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dc00a50885944de8bd18286fb857d2a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0bf4ffa056349039b29b90f3009e187_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b955a67143f40b994546bcffda9b554_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35eae0bc26094a639bb7e4c0640fb7ea_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2b0bcf3278442f08417f95c2f0b677a_D20190308-20190308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-08</xbrli:startDate><xbrli:endDate>2019-03-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f2a5edba28144ad932b2ce0fd047ab3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb606e761ca74e0fb88c19ca9f7345f7_I20181112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54bf1d15e917470abd4a457ea8b0a9b5_D20181113-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-13</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2859968ba8084d4f9a9f00fafe0202a4_D20181112-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-12</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8286cfe2c4684a39972d0ce5371ad480_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd15955102ce48909e6253ea8529c09b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4af7f789d58345659c0394f24e9c9d71_I20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f1333c86d8745489e79ec97651cf898_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief373c33e252406ba170c90d1219f6dd_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8169ad28217c4db3b21d9f9eeee9c392_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07a58e2ca82d468d914ab4d50fee24b8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee48a107bb7c466ebfe24ff0624d8263_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie774ce371d1f4360a413d7cd01f67f7a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6071c9045bf147eda9c3489832bb5075_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc6447e28536413ebc8660631a042645_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c7af9859e7b4d49bc0d4cfb8caec5b5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e8af893ce924072831291283cf7341a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17481b3eb00f41c493ce3e18607ab92f_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56db8e8bb906489db9d57373574874aa_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i320e6951e476481187afd7fdc00da9a3_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89b467d3bb2a460e991f8a90b333ff4d_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfd2f30676c34f82a88e1052658a9b37_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductVibativMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic88d54bc58134580bd4649c7afe08bf6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductVibativMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id16bbbe7271043b3b909c6f3fa6611d0_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductVibativMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80881f50116942c79eeedbc60d086b43_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if00c3bf918d24cc3aaeb84d0fbd302a3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cpix:CollaborativeArrangementFederalSmallBusinessGrantProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f14c6eb615f4396a69694ec3bbf3a78_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cpix:CollaborativeArrangementFederalSmallBusinessGrantProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14230e23d1f14fddaceba899b44a4986_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cpix:CollaborativeArrangementFederalSmallBusinessGrantProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i156f2acf482f4da8b0851cb775ba0501_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:IfetrobanClinicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica008517cc804be682f6f8928de46011_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ab1d686afef4f47af443ddb3c69c912_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8369853c76754322967bb52653385028_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67191970b6dc4dbab12c4bdce59ca551_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f0e55caff6347b08baa66daf67632aa_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia11c0ba867c24e56850a7ffe421f6852_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa90d2ee803c421baadb41895368ae03_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id13db87e21e745bfaebf06c3e97b18e1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f90fef1f7bd4deaa1cf05dcd6c9cc19_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5c37f17bdd045d8876714d588be095a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i171ae0e4eec14d9f868621f1dba24be1_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic27611c0dbc04b7988dcc9331bfbe1cb_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i947f330f1863460ea96eb801e0df3cde_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1b631d150a9425d83302ca84d5acf6f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2beb96285c7c4c4c9e3166c0f1577edc_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35e4a7c76589409caba0ef887cf3d6c8_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieba1c5b99e794cc887ea29cce7db35d5_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibda132d30f764f18ba15f5b11ef8640c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cpix:ProductAndLicenseRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1596ec01ad648109aa7a8774201aebf_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cpix:ProductAndLicenseRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc95de064baa44309a420dcb73dd5d32_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13bd22341d9c430cb1cd4edc13102d50_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85b3f22a44da44e0b4f3300a912b0dc5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i988d5245b3374e39af5d4ec1f43b092f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34cdca865b434ae68e675f3de541d80f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">cpix:PernixTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cpix:AmendedInternationalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06508a7d5ed34904a9e7ba4b89125dfa_I20140228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cpix:ProductAndLicenseRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i741e5bc06ece4d28a49fb727a3756a7e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:NordicMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a52841e4c724bb9936223a8fd642381_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72d98b8b6d2b49ec92a95f7f52a21bb0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20968f0f5b524d799086597dfddc2a8d_I20181017"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:SecondAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5275515928ca439196af82cb649ddae9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:SecondAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba0ec1144cb840b3a4076d92998f6ae8_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd700ec4abf947049e74967c3f1ebec7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3296f434993a41289fb9d9eab42374e7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i870374f6814b4d6cb3842ed1bada7231_D20170731-20170731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-31</xbrli:startDate><xbrli:endDate>2017-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9249561602f042ba980b18815fa29971_D20090809-20090810"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-08-09</xbrli:startDate><xbrli:endDate>2009-08-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b76324a8a3c4073a8a827f31c55b373_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8a09f2f029d4cf5b809b640237883a1_D20180101-20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia45e033a0968470a87498cc6e80e79bb_I20061231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cpix:WarrantsIssuedInConsiderationOf2006CreditFacilityAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2006-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65091fc0eec54e3ebe7cadf845bfc5c3_I20091231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cpix:WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2009-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb984696887341bdb3d482415e883068_I20100531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cpix:ShareRepurchaseProgramAuthorizedIn2010Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2010-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42d555993abb411fbcfac8eefe7bfc92_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cpix:SharesRepurchaseActivityTypeAxis">cpix:SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd076322bd3e4e45812f30f6e0265418_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cpix:SharesRepurchaseActivityTypeAxis">cpix:SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0be3acf257f24f79aeb0cfd8403ccd87_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cpix:SharesRepurchaseActivityTypeAxis">cpix:SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5465c80566344695bc41a215e251af48_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e71f9e142114cb1a967ae279d7a32d8_D20140401-20140430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2014-04-01</xbrli:startDate><xbrli:endDate>2014-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2b3b044fded4d4a96267ff40f75f41d_D20191127-20191127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:NordicMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-27</xbrli:startDate><xbrli:endDate>2019-11-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c1e105600e74750a10354cbeaad8205_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfde25ec7427462aba77d555bf0b4ebc_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7f0355a74da4690bb8381a211624d38_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bc29ea825b54377a95392502611cdcd_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i811017016cf741b2be0e3e987f3eb761_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0be1be11078f412084defc44e8714a79_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab82716daa96407a81d6e9e0259dbb45_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bd88221af1b4196a3229b6b611f66c0_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfc8673e890d447cb4c97a9429f48da8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:IndefiniteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b3d8839a10943299527a3616540c882_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:IndefiniteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf6dd30a84fc4e6fbec6716f5833f1be_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i919816e4ae6e49cbbc09d39640cee418_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="plan"><xbrli:measure>cpix:plan</xbrli:measure></xbrli:unit><xbrli:context id="i4da90f76e4104888a18e3d18b29d9b37_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cpix:LongTermIncentiveCompensationPlan2007Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i198eca0df24c455580fe1f7aad3d37bf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cpix:DirectorsIncentivePlan2007Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61c32b7b06154a0caffb1b27ffd29a90_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:NonprincipalOwnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib15a6538ecd34529a63f571722d0a1c9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:NonprincipalOwnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6083199dd2a42f391637d804e105c86_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53e4a12de53b4b0c99c928fb854c6569_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6325bab52b3e497181b41d02564bc694_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc452512a3cb412faa57ddaf029b98df_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e05d70302894bebb067dddab8121842_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2699606b9dca4e75864d2ce5471d263f_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7baa6ff5d72047a0ada0ed31a5bb2e5f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:NonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic70796d261de4b7785011e9a52b6ab8b_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:NonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a9593962195492199a34a509d355036_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:NonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if432a686a41c4c4494b432b8de61cfd0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:FoundationContributionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1758466063744cb928ad1f2170609f0_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:FoundationContributionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ab32de2ce97414b8fa9e5599fbaa6c9_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:FoundationContributionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7a81f8fb9634254a32248497adf8453_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:EmployeeNonemployeeandFoundationContributionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1709635ce5bd48ef8b8e1c0e99885c21_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:EmployeeNonemployeeandFoundationContributionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia61891dab2a04a62b49d997680aed24e_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:EmployeeNonemployeeandFoundationContributionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaaaacea9a57e4e758bc406a2ecaef76a_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a46cecd6d924e33bda5ccdd4c0e3b43_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84fb9bc25ed941ce90338733d28f5d92_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fd085fc709647d9997c4b52bdd4cc7c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38570ddc79c14639aa269d9013600dec_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76f168e8263b4700be275c05007c5731_I20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46b68c95812c4585ad2800f7e762d7ef_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">cpix:USTreasuryNotesAndBondsSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6967c2f466014730a8901a2bbff4743a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">cpix:USTreasuryNotesAndBondsSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcaec0f707064e14843280c588b63de9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">cpix:USTreasuryNotesAndBondsSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if40add46a67d4c1b959ea74b3095136d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">cpix:USTreasuryNotesAndBondsSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i871d23f00b9d4522a41b0f48f1812cb8_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">cpix:USTreasuryNotesAndBondsSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id41b97cccddf404587b71109d9148bd9_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">cpix:USTreasuryNotesAndBondsSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c77d83b0d784f95a8c57dc2c69a1ae1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">cpix:LoanPoolsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5261d06b396a496e83c3994a329a6adb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">cpix:LoanPoolsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia491869f8f8e4444a463caa044907b2a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">cpix:LoanPoolsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6180b75c51584214a21798f206007fd2_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">cpix:LoanPoolsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebd574df43534324bb75dd95355cde9d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">cpix:LoanPoolsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2390f7b0f62e4227ae756897529dc3e8_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">cpix:LoanPoolsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5de80c3842fe4ead883716b857a3ab60_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61fc59376d074db2a4ed2e33996a40ae_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80849ef0fff8453994464dd9e4263335_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia476a3c32a024ea799663e72ef23fe02_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20e0531514c241aca726450993124452_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40d16a645ee641218f7703ab03b0d941_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52e850d4caf6459cb3f900290e148294_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i539d6d44a9ae44f485c1050e287da81b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4df16753bd334ba3b2e0980d61fa84e3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42f63da2feed4ee1a967d286f376accb_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e331fd58cd14866b6404f53b122155e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cd20af5088e4c7ba1a916823027ba00_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i780bdd9adff04751adcd1b6f35439d2f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c0f572b430a45c5bf9009619128671c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67dfb3a3f9004593be1dd06a75668d57_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i943d44213b5845cd9d5b5d5a2ebe891e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i957590befb9d4e11af4357cac09d5a2e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4311d59a68c14a2c85db7649a6e2817c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45aae0c5083b4158a10518d39b977929_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i633f3a7886904df3bc2c1a118b38b5b5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie40ef9fa31bd4ff8a234daae70ffaf5f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i023693e081e647c2959d4531c232be23_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dcb5d79a1304c1a805e8f68f0a8fad3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fe8c7998adb4a09a50f50ebe5dc2cfe_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60785c35eb4e4574a2eeeed10b448ec6_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f1d9c99bd274435b9a4a98946740ee0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e32cc9a0bea46d0b461b09960568c0b_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="supplier"><xbrli:measure>cpix:supplier</xbrli:measure></xbrli:unit><xbrli:context id="i1a21420517ea4647a67d7b1217a674ef_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8471ffa3b49c4d27b527e605477129a5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if22100deab024544b321dc081da4ceff_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8909cd57fb5146798a8b845d82644b0b_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if26164363c2e4a7d8fd5139d8f56f49c_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i670fdffefb0c4fefba494de91fb35afc_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie54433cb2ec74b5eb0446c048a926870_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3568f3154e034913831ef831b3d23e91_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2efc1fa703c94708b6b3fc4d341efa16_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41abbb021c424bc3a185261bb47b2490_D20181001-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i285233d399574db2bf4cbbce58a8ee38_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ec1fa83cd4f4bcd80502e9a9be962e1_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie72430d18bed427fb73e3a0c86f3902b_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0b0b3681b184a71afd2ed8070814188_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i320d53db383d4ac7aecd406d90ef5114_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idaebef75259c4828b8dd1e0a936b843b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7a49735b602483d8a41720b2aa89de2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic63ad7ea20c046e9929381f321c356c0_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17c72a67be474fd0bf7e5aefd742a269_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i529dda5be0c0459188e6d0ab6e604b33_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9d74b7bafab423992f09ba352af1356_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b11cb5d5b164dc88a8a5aa3bd48fe48_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a0dc042738147c39f0f1c8b83d36fad_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae4edd9cd21d4bff9f039d252bcc383b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-10</xbrli:startDate><xbrli:endDate>2020-12-10</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="id2bfa55304bd45bbaa9cdf09bb7673a3_7"></div><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Index</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:77.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.387%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Page Number</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id2bfa55304bd45bbaa9cdf09bb7673a3_106">PART II</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id2bfa55304bd45bbaa9cdf09bb7673a3_106">2</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id2bfa55304bd45bbaa9cdf09bb7673a3_112">Item&#160;6: Selected Financial Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id2bfa55304bd45bbaa9cdf09bb7673a3_112">2</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id2bfa55304bd45bbaa9cdf09bb7673a3_115">Item&#160;7: Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id2bfa55304bd45bbaa9cdf09bb7673a3_115">4</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id2bfa55304bd45bbaa9cdf09bb7673a3_139">Item&#160;8: Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id2bfa55304bd45bbaa9cdf09bb7673a3_139">19</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id2bfa55304bd45bbaa9cdf09bb7673a3_169">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id2bfa55304bd45bbaa9cdf09bb7673a3_169">1</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id2bfa55304bd45bbaa9cdf09bb7673a3_172">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id2bfa55304bd45bbaa9cdf09bb7673a3_172">2</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id2bfa55304bd45bbaa9cdf09bb7673a3_178">Consolidated Statements of Operations and Comprehensive Income (Loss)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id2bfa55304bd45bbaa9cdf09bb7673a3_178">3</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id2bfa55304bd45bbaa9cdf09bb7673a3_181">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id2bfa55304bd45bbaa9cdf09bb7673a3_181">4</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id2bfa55304bd45bbaa9cdf09bb7673a3_184">Consolidated Statements of Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id2bfa55304bd45bbaa9cdf09bb7673a3_184">6</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id2bfa55304bd45bbaa9cdf09bb7673a3_187">Notes to the Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id2bfa55304bd45bbaa9cdf09bb7673a3_187">7</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id2bfa55304bd45bbaa9cdf09bb7673a3_274">Schedule II Valuation and Qualifying Accounts</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id2bfa55304bd45bbaa9cdf09bb7673a3_274">38</a></span></div></td></tr></table></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="id2bfa55304bd45bbaa9cdf09bb7673a3_106"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="id2bfa55304bd45bbaa9cdf09bb7673a3_112"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;6. Selected Financial Data.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The selected consolidated financial data set forth below should be read in conjunction with the audited consolidated financial statements and related notes and Item&#160;7, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and other financial information appearing elsewhere herein. The historical results are not necessarily indicative of the results to be expected for any future periods.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cumberland Pharmaceuticals Inc. ("Cumberland", &#8220;we&#8221;, &#8220;our&#8221; or "the Company") is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. This Current Report on Form 8-K (&#8220;Form 8-K&#8221;) is being filed to recast historical financial information, originally included in our  Annual Report on Form 10-K for the year ended December 31, 2019 ("2019 Form 10-K") to reflect the presentation of two Products we no longer distribute as discontinued operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During May 2019, Cumberland entered into a Dissolution Agreement  ("Dissolution Agreement") with Clinigen Healthcare Limited ("Clinigen") in which the Company returned the exclusive rights to commercialize Ethyol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and Totect</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(&#8220;the Products&#8221;) in the United States to Clinigen. Under the terms of the Dissolution Agreement, Cumberland is no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products following December 31, 2019.  The Company's exit from the Products meets the accounting criteria to be reported as discontinued operations and the discontinued operating results have been reclassified in the financial statements and footnotes for all periods presented. </span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.323%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.758%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="30" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Statement of income data:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2016</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2015</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="30" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,388&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,519&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,676&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,518&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,202&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,753&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,407&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,288)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,173)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,879)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,566)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,212)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,821)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,847)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,137)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">731&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,782&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,538)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,963)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,979)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(945)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">731&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - basic</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.60)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.69)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.80)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.04&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share &#8211; basic</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.23)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.45)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.50)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.04&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - diluted</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.60)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.69)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.80)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.04&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share &#8211; diluted</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.23)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.45)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.50)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.04&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:8pt;padding-left:4.5pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:8pt;padding-left:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.246%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="30" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance sheet data:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2016</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2015</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="30" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,291&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,672&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,622&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,561&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,549&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,694&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,232&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,405&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,919&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt (including current portion) and other long-term obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,319&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,208&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,746&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,709&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,605&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,550&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,085&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,820&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:8pt;padding-left:4.5pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="id2bfa55304bd45bbaa9cdf09bb7673a3_115"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion and analysis of our financial position and results of operations should be read together with our audited consolidated financial statements and related notes appearing elsewhere in this Form 8-K.</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Statements in this Form 8-K that are not historical factual statements are &#8220;forward-looking statements.&#8221; Forward-looking statements include, among other things, statements regarding our intent, belief or expectations, and can be identified by the use of terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;estimate,&#8221; &#8220;should,&#8221; &#8220;seek,&#8221; &#8220;anticipate&#8221; and other comparable terms or the negative thereof. In addition, we, through our senior management, from time to time make forward-looking oral and written public statements concerning our expected future operations and other developments. While forward-looking statements reflect our good-faith beliefs and best judgment based upon current information, they are not guarantees of future performance and are subject to known and unknown risks and uncertainties, including those risk factors contained in our 2019 Form 10-K and other periodic filings with the Securities Exchange Commission. Accordingly, investors are cautioned not to place undue reliance on any forward-looking statements. Actual results may differ materially from the expectations contained in the forward-looking statements as a result of various factors. Such factors include, but are not limited to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Impacts on our business as well as national and international markets and economies resulting from the 2020 COVID-19 pandemic;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">The possible or assumed future results of operations, including the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Our competitive position and competitors, including the size and growth potential of the markets for our products and product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">The success, cost and timing of our product acquisition and development activities and clinical trials; and our ability to successfully commercialize our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Product efficacy or safety concerns, whether or not based on scientific evidence, resulting in product withdrawals, recalls, regulatory action on the part of the Food and Drug Administration (or international counterparts) or declining sales;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">The performance of our third-party suppliers and manufacturers which impacts our supply chain and could create business shutdowns or product shortages; and the retention of key scientific and management personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Challenges to our patents and the introduction of generic versions of our products and product candidates, which could negatively impact our ability to commercialize and sell our products and product candidates and decrease sales a result of market exclusivity;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Changes in reimbursement available to us, including changes in Medicare and Medicaid payment levels and availability of third-party insurance coverage and the effects of future legislation or regulations, including changes to regulatory approval of new products, licensing and patent rights, environmental protection and possible drug re-importation legislation; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Interruptions and breaches of our computer and communications systems, and those of our vendors, including computer viruses, hacking and cyber-attacks, that could impair our ability to conduct business and communicate internally and with our customers, or result in the theft of trade secrets or other misappropriation of assets, or otherwise compromise privacy of sensitive information belonging to us, our customers or other business partners.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The list above contains many, but not all, of the factors that could impact our ability to achieve results described in any forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider this list to be a complete statement of all potential risks and uncertainties. We have identified the factors on this list as permitted by the Private Securities Litigation Reform Act of 1995.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="id2bfa55304bd45bbaa9cdf09bb7673a3_118"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXECUTIVE SUMMARY </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. Our primary target markets are hospital acute care and gastroenterology. These medical specialties are characterized by relatively concentrated prescriber bases that we believe can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve the quality of care for patients and address unmet or poorly met medical needs.  We promote our approved products through our hospital and field sales forces in the United States and are establishing a network of international partners to bring our medicines to patients in their countries.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of FDA approved brands includes:</span></div><div style="margin-top:8pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Acetadote</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">acetylcysteine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) Injection, for the treatment of acetaminophen poisoning; </span></div><div style="margin-top:8pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Caldolor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ibuprofen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) Injection, for the treatment of pain and fever;</span></div><div style="margin-top:8pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Kristalose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">lactulose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for Oral Solution, a prescription laxative, for the treatment of chronic and acute constipation;</span></div><div style="margin-top:8pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Omeclamox</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-Pak</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">omeprazole, clarithromycin, amoxicillin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for the treatment of Helicobacter pylori (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">H. pylori</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) infection and related duodenal ulcer disease;</span></div><div style="margin-top:8pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Vaprisol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">conivaptan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) Injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia;</span></div><div style="margin-top:8pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Vibativ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">telavancin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) Injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and</span></div><div style="margin-top:8pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.15pt">RediTrex</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">methotrexate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) Injection, for the treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis, as well as disabling psoriasis.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we have Phase II clinical programs underway evaluating our ifetroban product candidates in patients with cardiomyopathy associated with Duchenne Muscular Dystrophy (&#8220;DMD&#8221;), Systemic Sclerosis (&#8220;SSc&#8221;), and Aspirin-Exacerbated Respiratory Disease ("AERD"). We have also completed Phase II clinical programs with ifetroban in patients with Hepatorenal Syndrome (&#8220;HRS&#8221;) and patients with Portal Hypertension (&#8220;PH&#8221;).</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We promote our approved products through our hospital and gastroenterology sales forces in the United States, which together comprised approximately 40 sales representatives and managers as of December&#160;31, 2019.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have both product development and commercial capabilities and believe we can leverage our existing infrastructure to support our expected growth. Our management team consists of pharmaceutical industry veterans experienced in business development, product development, regulatory, manufacturing, sales marketing and finance. Our business development team identifies, evaluates and negotiates product acquisition, licensing and co-promotion opportunities. Our product development team creates proprietary product formulations, manages our clinical studies, prepares all regulatory submissions and manages our medical call center. Our quality and manufacturing professionals oversee the manufacture, release and shipment of our products. Our marketing and sales professionals are responsible for our commercial activities, and we work closely with our distribution partners to ensure availability and delivery of our products.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of our 2019 highlights and recent developments. For more information, please see Part I, Item I, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in our 2019 Form 10-K. </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Early in 2019, we announced a strategic review of our brands, capabilities, and international partners. This review followed an accelerated business development initiative, which resulted in a series of transactions. Because of that progress, we felt that it was prudent to take a fresh look at our product portfolio, partners, and organization to ensure proper focus and capabilities. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We executed a License and Distribution agreement with HongKong WinHealth Pharma Group Co. Limited (&#8220;WinHealth&#8221;) for our Caldolor and Acetadote brands in China and Hong Kong.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We also entered into a Strategic Alliance agreement with WinHealth to explore future business opportunities that will further the mission and goals of each organization. </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We completed the assignment and amendment of a Commercialization Agreement with R-Pharma JSC (&#8220;R Pharma&#8221;) associated with ongoing distribution of Vibativ in Russia and a number of adjacent countries in Eastern Europe. </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We completed the assignment and amendment of a Commercialization Agreement with Hikma Pharmaceuticals LLC (&#8220;Hikma&#8221;) to register and distribute Vibativ in a number of countries throughout the Middle East. </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We also completed the assignment and amendment of a Commercialization Agreement with Dr. Reddy&#8217;s Laboratories Limited (&#8220;Dr. Reddy&#8217;s&#8221;) for the registration and distribution of Vibativ in India. </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We concluded our distribution and support for Ethyol and Totect at the end of 2019 and transitioned the responsibility for these products back to Clinigen.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net revenue from sales of each of Caldolor, Omeclamox, Kristalose and Ethyol grew in 2019 compared to 2018.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In January 2019, the FDA approved the application for our next generation Caldolor product. In April 2019, we began initial shipments of the product to select customers. During the third and fourth quarters of 2019, there was a growing demand for the new product from these select accounts and we began planning for a full-scale launch in 2020</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In late 2019, we received FDA approval for RediTrex and began planning for a 2020 launch of this product line.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On September 24, 2019, Cumberland announced U.S. Food and Drug Administration ("FDA") Orphan Drug Grant funding for a new Phase II clinical program. The Company has initiated the clinical development of ifetroban for the treatment of cardiomyopathy associated with Duchenne Muscular Dystrophy (&#8220;DMD&#8221;). In addition, Cumberland has been awarded just over $1 million in funding from the FDA through their Orphan Drug Grant program to support this Phase II DMD clinical study. </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In October 2019, a new study was published revealing the superiority of Vibativ (telavancin) over vancomycin in select patients with bacterial pneumonia. </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In November 2019, we announced another study, published online in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Drugs - Real World Outcomes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, detailing the positive clinical outcomes that resulted from treating multiple infection types with Vibativ. </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">During 2019, Cumberland largely completed the transition of activities to support Vibativ, which Cumberland acquired from Theravance Biopharma during 2018. </span></div><div id="id2bfa55304bd45bbaa9cdf09bb7673a3_121"></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING POLICIES AND SIGNIFICANT JUDGMENTS AND ESTIMATES</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Estimates and Judgments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. We base our estimates on past experience and on other factors we deem reasonable given the circumstances. Past results help form the basis of our judgments about the carrying value of assets and liabilities that are not determined from other sources. Actual results could differ from these estimates. These estimates, judgments and assumptions are most critical with respect to our accounting for revenue recognition, marketable securities, inventory, intangible assets, research and development accounting, contingent consideration liability, provision for income taxes and share-based payments.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue in accordance with the Accounting Standards Codification (ASC) Topic 606. Effective January 1, 2018, we adopted the Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;) amended guidance in the form of Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-09, "Revenue from Contracts with Customers," (ASC 606). Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts were not adjusted and are reported in accordance with ASC 605.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is derived primarily from the product sales of our FDA approved pharmaceutical brands. Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which occurs upon either shipment of the product or arrival at its destination, depending upon the shipping terms of the transaction. Payment terms typically range from 30 to 60 days from date of shipment. Our net product revenue reflects the reduction from gross product revenue for estimated allowances for chargebacks, discounts and damaged goods, and reflects sales related accruals for rebates, coupons, product returns, and certain administrative and service fees. Significant judgments must be made in determining the transaction price for our sales of products related to these adjustments. Other revenue, which is a component of net revenues, includes non-refundable upfront payments and milestone payments under licensing agreements along with grant and rental income. Other income was approximately 5.8% percent of net revenues in 2019, 1.8% in 2018, and 2.9% in 2017 respectively.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial statements reflect accounts receivable allowances of $0.8 million and $0.7 million at December&#160;31, 2019 and 2018, respectively, for chargebacks, discounts and allowances for product damaged in shipment. </span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects our sales-related accrual activity for the periods indicated below:</span></div><div style="margin-bottom:6pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.833%"><tr><td style="width:1.0%"></td><td style="width:45.722%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.622%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.622%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,961,631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,140,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,988,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current provision</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,081,251&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,192,489&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,960,243&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual product returns and credits issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,449,715)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,371,838)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,807,863)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,593,167&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,961,631&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,140,980&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The allowances for chargebacks, discounts, and damaged products and sales related accruals for rebates and product returns are determined on a product-by-product basis. We establish them using our best estimate at the time of sale based on: </span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Each product&#8217;s historical experience adjusted to reflect known changes in the factors that impact such allowances; </span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The contractual terms with direct and indirect customers;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Analyses of historical levels of chargebacks, discounts and credits claimed for damaged and expired product; </span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Communications with customers;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Purchased information about the rate of prescriptions being written and the level of inventory remaining in the distribution channel, if known; and</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expectations about the market for each product, including any anticipated introduction of competitive products.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from us based on either negotiated contracts to carry our products or reimbursements for filled prescriptions. These entities are considered our indirect customers. When recognizing a sale to a wholesaler, sales revenues are reduced and accrued liabilities are increased by our estimate of the rebate that may be claimed. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowances for chargebacks and accruals for rebates and product returns are the most significant estimates used in the recognition of our revenue from product sales. Of the accounts receivable allowances and our sales related accruals, our accrual for fee for services and product returns represents the majority of the balance. Sales related accrued liabilities for rebates, product returns, service fees, and administrative fees totaled $4.6 million, $5.0 million and $4.1 million as of December&#160;31, 2019, 2018 and 2017, respectively. Of these amounts, our estimated liability for fee for services represented $1.4 million, $1.8 million and $1.1 million, respectively, while our accrual for product returns totaled $1.9 million, $1.8 million and $1.9 million, respectively. If the actual amount of cash discounts, chargebacks, rebates, and product returns differs from the amounts estimated by management, material differences may result from the amount of our revenue recognized from product sales. A change in our rebate estimate of one percentage point would have impacted net sales by approximately $0.4 million for the year ended December&#160;31, 2019 and $0.3 million for the years ended December&#160;31, 2018 and 2017, respectively.  A change in our product return estimate of one percentage point would have impacted net sales by $0.3 million for the years ended December&#160;31, 2019, 2018 and 2017. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Marketable Securities</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically invested a portion of our cash reserves in short-term cash investments, U.S. Treasury notes and bonds, corporate bonds and commercial paper in order to maximize our return on cash.  We classify these investments as trading securities, and mark the investments to fair value at the end of each reporting period, with the adjustment being recognized in the statement of income as a component of interest income.  These investments are generally valued using observable market prices by third-party pricing services, or are derived from such services' pricing models. The level of management judgment required in establishing fair value of financial instruments for which there is a quoted price in an active market is minimal. Similarly, there is little subjectivity or judgment required for instruments valued using valuation models that are standard across the industry and where all parameter inputs are quoted in active markets. Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record amounts for estimated obsolescence or unmarketable inventory in an amount equal to the difference between the cost of inventory and the net realizable value based upon assumptions about remaining shelf life, future demand and market conditions. The estimated inventory obsolescence amounts are calculated based upon specific review of the inventory expiration dates and the quantity on-hand at December&#160;31, 2019 in comparison to our expected inventory usage. The amount of actual inventory obsolescence and unmarketable inventory could differ (either higher or lower) in the near term from the estimated amounts. Changes in our estimates would be recorded in our statement of operations in the period of the change.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide for deferred taxes using the asset and liability approach. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to operating loss and tax credit carry-forwards and differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Our principal differences are related to the timing of deductibility of certain items such as depreciation, amortization and expense for options issued to nonemployees. Deferred tax assets and liabilities are measured using management&#8217;s estimate of tax rates expected to apply to taxable income in the years in which management believes those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in our results of operations in the period that includes the enactment date.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adopted FASB ASU 2016-09,&#160;"Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting" effective January 1, 2017. The impact of adoption on our consolidated financial statements included the recording of $44.1 million in previously unrecognized net operating loss carryforwards, net of valuation allowances, generated from the exercise of nonqualified options during 2009.  These net operating loss carryforwards occurred as a result of the actual tax benefit realized upon employee exercise exceeding the cumulative book compensation charge associated with the options. </span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The adoption resulted in the recording of $1.1 million in net non-current deferred tax assets and retained earnings effective as of January 1, 2017.   The $1.1 million in net non-current deferred tax assets was the result of a deferred tax asset of $17.0 million, net of a related valuation allowance of $15.9 million.  Under the previous accounting guidance, these benefits had been recognized in the year in which they were able to reduce current income taxes payable and we recorded these benefits directly to equity.  As part of our adoption of the FASB guidance and its continued evaluation of our utilization of net operating loss carryforwards and other deferred tax assets, including updates to our forecasts of future taxable income, we also recorded an additional valuation allowance of $1.0 million for our federal Orphan Drug and Research and Development tax credits that expire between 2021 and 2036.   </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2017, as part of our continued evaluation of the utilization of our net operating loss carryforwards we recorded an additional valuation allowance of $3.5 million for our remaining deferred tax assets. All deferred tax assets have a full valuation allowance. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net operating loss carryforwards generated during 2009 consisted of $44.1 million in federal and $45.4 million in state amounts.  Since they were generated, we have utilized these net operating loss carryforwards to pay minimal income taxes. We will continue to experience a reduction in income taxes paid in future years, through the continued utilization of these net operating loss carryforwards, as we are able to achieve taxable income through our operations. The Company&#8217;s accounting policy with respect to interest and penalties arising from income tax settlements is to recognize them as part of the provision for income taxes.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 22, 2017, the Tax Cut and Jobs Act (the "Tax Act&#8221;) was signed into law. The Tax Act provides for significant changes in the U.S. Internal Revenue Code of 1986, as amended. The Tax Act contains provisions with separate effective dates but is generally effective for taxable years beginning after December 31, 2017. Certain provisions of the Tax Act were effective during our fiscal year ending December 31, 2018 with all provisions of the Tax Act effective as of the beginning of our fiscal year ending December 31, 2019.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC Topic 740, Income Taxes (&#8220;ASC 740&#8221;), we are required to revalue any deferred tax assets or liabilities in the period of enactment of change in tax rates. The Tax Act lowers the corporate income tax rate from 35% to 21%. As a result of the Tax Act discussed above, we will experience a positive impact to our future results of operations to the extent we achieve taxable income through our operations. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-Based Payments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize compensation expense for all share-based payments based on the fair value of the award on the date of grant. In addition, incremental compensation expense is recognized upon the modification of equity awards. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issue restricted stock awards at no cost in lieu of stock options to employees, directors and consultants. Compensation expense for restricted stock granted to employees and directors is generally equal to the fair market value of the underlying common stock on the date of grant. If a sufficient disincentive for nonperformance does not exist at the date of grant, the compensation cost is remeasured at each reporting date at the then-current fair market value of the underlying common stock until the award vests.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue for and expense research and development costs based on estimates of work performed, patient enrollment or fixed-fee-for-services. As work is performed and/or invoices are received, we adjust our estimates and accruals. To date, our accruals have not differed materially from our estimates. Total research and development costs are a function of studies being conducted and will increase or decrease based on the level of activity in any particular year.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets and Goodwill</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets include product rights, license agreements, other identifiable intangible assets and goodwill associated with the Vibativ acquisition. We assess the impairment of goodwill at least annually. We assess the impairment of identifiable intangible assets subject to amortization whenever events or changes in circumstances indicate the carrying value may not be recoverable. In determining the recoverability of our intangible assets, we make assumptions regarding estimated future cash flows and other factors. If the estimated undiscounted future cash flows do not exceed the carrying value of the intangible assets, we must determine the fair value of the intangible assets. If the fair value of the intangible assets is less than the carrying value, an impairment loss will be recognized in an amount equal to the difference. Fair value is determined through various valuation techniques including quoted market prices, third-party independent appraisals and discounted cash flow models, as considered necessary.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="id2bfa55304bd45bbaa9cdf09bb7673a3_124"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December&#160;31, 2019 compared to year ended December&#160;31, 2018</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the statements of operations for continuing operations for the years ended December&#160;31, 2019 and 2018:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.604%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,388,295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,344,894&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,043,401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,421,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,016,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,404,494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and marketing</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,277,740&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,004,933&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,272,807&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,868,480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,575,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(707,412)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,974,384&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,150,777&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176,393)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,134,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,769,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,365,091&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,676,477&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,517,890&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,158,587&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,288,182)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,172,996)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,884,814&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,364&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564,484&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(321,120)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(246,186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(195,848)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,338)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from continuing operations before income taxes</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,291,004)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,804,360)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,513,356&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,636)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,952&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,211,688)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,820,996)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,609,308&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes net revenues for the years presented:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.169%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.132%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,824,449&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,284,111&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(459,662)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837,829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,895,120&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,055,625&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">839,495&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,763,874&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(827,259)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,222,282&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,001,997&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,285&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,691,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,075,057&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,616,493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,980,450&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,933&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,439,517&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,388,295&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,344,894&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,043,401&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Net revenues for the year ended December&#160;31, 2019 were approximately $34.4 million compared to $29.3 million for the year ended December&#160;31, 2018, representing an increase of $5.0 million or 17.2%.  Four of our products, Omeclamox-Pak, Kristalose, Caldolor and Vibativ, experienced an increase in revenue during 2019. The 17.2% improvement was led by our newest product, Vibativ, which delivered an additional  $3.6 million during the full year of 2019 compared to a partial year during 2018. These increases were partially offset by decreased net product sales of Acetadote and Vaprisol.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  We returned the exclusive rights to commercialize Ethyol and Totect in the United States to Clinigen effective January 1, 2020.  As a result, the 2019 and 2018 revenues and expenses associated with the products are combined and reclassified into discontinued operations in our financial statements. In exchange for the return of these product </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license rights and associated non-compete provision, Cumberland is receiving $5 million in financial consideration paid over the two-years following the return date.  We do not incur expenses associated with these payments from Clinigen.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kristalose revenue increased by $0.8 million, or 7.0%, compared to December&#160;31, 2018 primarily as a result of increased wholesale prices. The product's net revenue was also positively impacted by lower managed care rebates, resulting in improved net pricing for the product for the year ended December 31, 2019.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caldolor revenue experienced a 4.4% increase to $5.2 million during the year ended December 31, 2019 compared to $5.0 million in the same period last year. This increase in Caldolor revenue for the year ended December 31, 2019 was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the result of an 11% increase in domestic shipments of the product and improved net pricing. The changes were partially offset by a reduction in international shipments of Caldolor in 2019 over 2018.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Omeclamox-Pak revenue increased $0.2 million or 34.4% during the year ended December 31, 2019 compared to the prior year.  The increase was largely the result of increased sales volume partially offset by higher expired product sales returns. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vaprisol revenue decreased $0.8 million during the year ended December 31, 2019 compared to the prior year period due primarily to decreased sales of the product.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The prior year period sales were higher as a result of the arrival of a new lot of the product during April 2018 resolving temporary supply issues associated with the product.    </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acetadote revenue included net sales of our branded product and our share of net sales from our Authorized Generic. For the year ended December 31, 2019, the Acetadote net revenue decreased $0.5 million or 10.7% compared to the prior year due to a reduction in sales volume as a result of generic competition.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of products sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Cost of products sold for the year ended December&#160;31, 2019 were $7.4 million, compared to $6.0&#160;million in the prior year.  As a percentage of net revenues, cost of products sold were 21.6% compared to 20.5% during the prior year.  The change in costs of products sold as a percentage of revenue was attributable to a change in the product sales mix during the period compared to the prior year.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling and marketing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Selling and marketing expense for the year ended December&#160;31, 2019 were $15.3 million, which was an increase of $1.3 million compared to the prior year's expense of $14.0 million. This increase was primarily attributable to promotional spending and sales force costs, including salary and benefits for the increased sales force.  The increase in the sales force and promotional spending is due largely to the addition of our newest brand, Vibativ, during the fourth quarter of 2018.   </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Research and development costs for the year ended December&#160;31, 2019 were $6.9 million, compared to $7.6 million last year, representing a decrease of $0.7 million. A portion of our research and development costs are variable based on the number of trials, study sites and patients involved in the development of our product candidates. The decrease was primarily the result of the FDA program fee of $1.3 million paid during 2018 associated with the successful RediTrex FDA submission.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  General and administrative expense for the year ended December&#160;31, 2019 was $10.0 million for 2019, compared to $10.2 million last year. The $0.2&#160;million or, 1.7%, decrease from the same period for the prior year was primarily driven by a decrease in compensation and benefits, including non-cash stock based compensation and deferred compensation.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Amortization expense is the ratable use of our capitalized intangible assets including product and license rights, patents, trademarks and patent defense costs.  Amortization for 2019 totaled approximately $4.1 million, which was an increase of $1.4 million over the prior year.  The increase in expense was attributable to the amortization of additional product rights and capitalized patents, including those assets associated with the Vibativ acquisition.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Income tax benefit for the year ended December&#160;31, 2019 was $79,316. As a percentage of income (loss) before income taxes, income taxes were a benefit of  0.9% for the year ended December&#160;31, 2019 compared to income tax expense as a percentage of loss before income taxes of 0.2% for the year ended December&#160;31, 2018. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December&#160;31, 2018 compared to year ended December&#160;31, 2017 </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the statements of operations for continuing operations for the years ended December&#160;31, 2018 and 2017:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,344,894&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,322,627&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,022,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,016,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,418,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and marketing</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,004,933&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,489,178&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515,755&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,575,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,247,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,328,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,150,777&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,610,967&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539,810&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,769,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,436,222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,517,890&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,202,000&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,315,890&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,172,996)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,879,373)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,293,623)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564,484&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299,326&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,158&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(195,848)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92,904)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102,944)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from continuing operations before income taxes</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,804,360)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,672,951)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,131,409)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,636)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,174,889)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,158,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,820,996)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,847,840)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,026,844&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.397%"><tr><td style="width:1.0%"></td><td style="width:40.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,284,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,576,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,292,609)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,761,868&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,138,571)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,055,625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,455,805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599,820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,763,874&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,576,222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,001,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,178,443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,075,057&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,075,057&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">773,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(232,636)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,344,894&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,322,627&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,022,267&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Net revenues for the year ended December&#160;31, 2018 were approximately $29.3 compared to $26.3 for the year ended December&#160;31, 2017, representing an increase of $3.0 million.  This increase in revenue was led by the initial product sales of our newest product, Vibativ, as well as three of our marketed products experiencing increases in net revenue during the period: Kristalose, Vaprisol and Caldolor. Two of our products: Acetadote and Omeclamox-Pak experienced a decrease in revenue during 2018. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We returned the exclusive rights to commercialize Ethyol and Totect in the United States to Clinigen effective January 1, 2020.  As a result, the 2018 and 2017 revenues and expenses associated with the products are combined and reclassified into discontinued operations in our financial statements. In exchange for the return of these product license rights and associated non-compete provision, Cumberland is receiving $5 million in financial consideration paid over the two-years following the return date.  We do not incur expenses associated with these payments from Clinigen. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kristalose revenue increased by $0.6 million, or 5.2%, compared to December&#160;31, 2017 primarily as a result of increased sales volume. The product's net revenue was positively impacted by increased sales volumes and lower managed care and Medicare rebates, that resulted in improved net pricing for the product for the year ended December 31, 2018.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caldolor revenue experienced a 20% increase to $5.0 million during the year ended December 31, 2018 compared to $4.2 million in the same period last year. This increase in Caldolor revenue for the year ended December 31, 2018 was positively impacted by increased domestic and international shipments. Domestic net revenue improved from increased sales volumes and improved pricing.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vaprisol revenue increased $0.2 million during the year ended December 31, 2018 compared to the prior year period due to increased sales of the product.  Sales of Vaprisol surged during the second quarter of 2018 due to shipments of newly arrived inventory following a period of time when there were limited supplies of the product. During April 2018, the Vaprisol supply issue was resolved as we received new shipments from our manufacturer. The 12% net revenue increase was partially offset by an increase in expired product sales returns during the period. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Omeclamox-Pak revenue decreased $1.1 million during the year ended December 31, 2018 compared to the prior year.  The decrease was largely the result of lower sales volume and much higher expired product sales returns.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acetadote revenue included net sales of our branded product and our share of net sales from our Authorized Generic. For the year ended December 31, 2018, the Acetadote net revenue decreased $2.3 million compared to the prior year due to a reduction in sales volume as a result of generic competition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of products sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Cost of products sold for the year ended December&#160;31, 2018 were $6.0 million, compared to $5.4 million in the prior year.  As a percentage of net revenues, cost of products sold were 20.5% compared to 20.6% during the prior year.  The change in costs of products sold as a percentage of revenue was attributable to a change in the product sales mix during the period compared to the prior year.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling and marketing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Selling and marketing expense for the year ended December&#160;31, 2018 were $14.0 million, which was an increase of $0.5 million compared to the prior year's expense of $13.5 million. The increase was primarily salary, wages and benefits for the year ended December 31, 2018.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Research and development costs for the year ended December&#160;31, 2018 were $7.6 million, compared to $4.2 million last year, which represented an increase of $3.4 million. A portion of our research and development costs are variable based on the number of trials, study sites and patients involved in the development of our product candidates. The increase was partially the result of additional investments in our ongoing clinical initiatives associated with our pipeline products of $1.6 million.  There was also an increase in our products FDA program fees including the $1.3 million fee associated with our RediTrex submission.  Research and development costs also increased for salary, wages and benefits.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  General and administrative expense for the year ended December&#160;31, 2018 was $10.2 million for 2018, compared to $9.6 million last year. The $0.6 million increase from the prior year was primarily driven by an increase in compensation and benefits along with increases in legal and consulting expenses. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Amortization expense is the ratable use of our capitalized intangible assets including product and license rights, patents, trademarks and patent defense costs.  Amortization for 2018 totaled approximately $2.8 million, which was an increase of $0.3 million over the prior year.  The increase in amortization was attributable to additional product and license rights and capitalized patents.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income tax expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Income tax expense for the year ended December&#160;31, 2018 was $16,636, compared to approximately $4.2 million in the year ended December&#160;31, 2017. As a percentage of income (loss) before income taxes, income taxes were 0.2% for the year ended December&#160;31, 2018 compared to 48.1% for the year ended December&#160;31, 2017. As discussed in our consolidated financial statements, the effective tax rate for the year ended December&#160;31, 2017 was primarily impacted by recording a valuation allowance of $1.0 million for our federal Orphan Drug and Research and Development tax credits and an additional valuation allowance of $3.5 million for our remaining deferred tax assets.  These non-cash valuation allowance adjustments impacted our effective tax rate during the year ended December&#160;31, 2017.  </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="id2bfa55304bd45bbaa9cdf09bb7673a3_127"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of liquidity are cash flows provided by our operations, the amounts borrowed and available under our line of credit and the cash proceeds from our initial public offering of common stock that was completed in August 2009.  We believe that our internally generated cash flows, existing working capital and our line of credit, will be adequate to finance internal growth, finance business development initiatives, and fund capital expenditures for the foreseeable future.  </span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest a portion of our cash reserves in marketable securities including short-term cash investments, U.S. Treasury notes and bonds, corporate bonds, commercial paper and other marketable securities.   At December&#160;31, 2019, all our investments were in commercial paper with maturity dates under thirty days and classified as cash.  At December&#160;31, 2018, we had approximately $8.3 million invested in marketable securities.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our liquidity and working capital as of the years ended December 31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.339%"><tr><td style="width:1.0%"></td><td style="width:61.652%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:7pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,212,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,938,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,290,679&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,212,635&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,229,639&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital (current assets less current liabilities)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,012,840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,311,813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current ratio (multiple of current assets to current liabilities)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving line of credit availability</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500,000&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our net changes in cash and cash equivalents for the years ended December&#160;31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.179%"><tr><td style="width:1.0%"></td><td style="width:43.201%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.179%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.995%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.908%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by (used in):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,056,356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,112,737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(557,714)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,297,848&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,724,818)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,512,577&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,080,529)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,138,173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,947,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (decrease) increase in cash and </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">cash equivalents </span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,675&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,473,908)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,902,538&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net $0.3 million increase in cash and cash equivalents for the year ended December&#160;31, 2019 was attributable to cash provided by operating and investing activities offset by cash used in financing activities.  Cash provided by operating activities of $3.1&#160;million included non-cash expense add backs for depreciation and amortization and share-based compensation expense totaling $5.9 million. The cash provided by operating activities included $5.5 million provided by discontinued operations.  These increases were partially offset by a net loss for the period of $3.5 million. Changes in our working capital provided net cash of $1.6 million.  Cash provided by investing activities of  $2.3 million included net sales of marketable securities of $8.3 million, partially offset by the $5 million payment to Theravance as part of the acquisition of Vibativ and the addition to intangibles of $0.8 million.  Our financing activities included a net repayment of  $1.5&#160;million under our line of credit net and $3.5 million in cash used to repurchase shares of our common stock. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, we continue to repurchase shares of our common stock, as discussed in Part II, Item&#160;5, "Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of our 2019 Form 10-K.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net $17.5 million decrease in cash and cash equivalents for the year ended December 31, 2018 was attributable to cash used by investing activities offset by cash provided by operating and financing activities.  Cash provided by operating activities of $3.1 million was impacted by a net loss for the period of $7.0 million. This use of operating cash was offset by non-cash expenses of depreciation and amortization and share-based compensation expense totaling $4.3 million. Changes in our working capital provided net cash of $5.2 million.  The cash provided by operating activities included $4.5 million provided by discontinued operations.  Cash used in investing activities included $20 million in cash paid for the acquisition of Vibativ during 2018, the use of cash to complete a net increase in marketable securities of $3.4 million, and the addition to intangibles of $3.8 million.  Our financing activities included  $10.2&#160;million in net cash provided by borrowings under our line of credit net of $2.9 million in cash used to repurchase shares of our common stock. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net $10.9 million increase in cash and cash equivalents for the year ended December&#160;31, 2017 was attributable to cash provided by investing and financing activities offset by cash used in operating activities.  Cash used in operating activities of $0.6 million was primarily impacted by a net loss for the period of $8.0 million. These uses of operating cash were offset by deferred tax expenses of $4.2 million and non-cash expenses of depreciation and amortization and share-based compensation expense totaling $4.1 million. The cash used by operating activities were partially offset by $4.0 million provided by discontinued operations. Changes in our working capital provided net cash of $0.1 million, including cash provided by accounts payable increases of $0.3 million.  Cash provided by investing activities included net proceeds from marketable securities of $11.0 million offset by additions to intangibles of $1.2 million.  Our financing activities included $5.7 million in net cash provided by borrowings under our line of credit and $3.7 million in cash used to repurchase shares of our common stock. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shelf Registration</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, the Company filed its Shelf Registration on Form S-3 with the SEC associated with the sale of up to $100 million in corporate securities. The Shelf Registration which was declared effective in January 2018. It also included an At the Market ("ATM") feature that allows the Company to sell common shares at market prices, along with an agreement with B. Riley FBR to support such a placement of shares.  The Company did not issue any shares under this ATM during the year ended December&#160;31, 2019.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Agreement</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2019, we entered into a third amendment ("Third Amendment") to the Revolving Credit Loan Agreement, dated July 28, 2017, with Pinnacle Bank (&#8220;Pinnacle Agreement&#8221;). The Third Amendment extended the term of the Pinnacle Agreement through July 31, 2021 as well as modified certain definitions and terms of the existing financial covenants.  On October 17, 2018, we entered into a second amendment (&#8220;Second Amendment&#8221;) which increased the maximum aggregate principal available for borrowing under the Pinnacle Agreement to $20.0 million. For a summary of the material terms of the Pinnacle Agreement, as amended, see Note 9 to the accompanying notes to consolidated financial statements.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Pinnacle Agreement, we were initially subject to one financial covenant, the maintenance of a Funded Debt Ratio, as such term is defined in the agreement and determined on a quarterly basis.  On August 14, 2018 we amended the Pinnacle Agreement ("First Amendment") to replace the single financial covenant with the maintenance of either the Funded Debt Ratio or a Tangible Capital Ratio, as defined in the First Amendment.  The Third Amendment modified the definition of the Funded Debt Ratio and the compliance target of the Tangible Capital Ratio. Both Third Amendment modifications were related to the Vibativ transaction. We were in compliance with the Tangible Capital Ratio financial covenant as of  December&#160;31, 2019 and we expect to maintain compliance with the Tangible Capital Ratio financial covenant in future periods. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Minimum Product Purchase Requirements</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing and supply agreements do not require minimum annual purchase obligations. </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual cash obligations</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our contractual cash obligations as of December&#160;31, 2019:</span></div><div style="margin-bottom:6pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:22.001%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.854%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.854%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.854%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.177%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.208%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.208%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.454%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Payments Due by Year</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contractual obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023 and thereafter</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Line of credit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated interest on debt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416,250&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liability payments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,633,589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,114,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,139,617&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997,491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,647,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,376,746&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,120,066&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,144,889&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019,313&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,478&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase obligations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,759,085&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,066,606&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,200,756&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,016,804&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827,883&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,647,036&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.25pt">The sum of the individual amounts may not agree due to rounding.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.25pt">The line of credit payments represent the estimated unused line of credit payments and the amount due at maturity. The estimated interest on debt represents the interest on the principal outstanding on the line of credit.  These amounts are based on the $18.5 million line of credit assuming the current $18.5 million balance outstanding on December&#160;31, 2019 is consistently outstanding through maturity of July 2021.  Interest and unused line of credit payments are due and payable quarterly in arrears. </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.25pt">The contingent consideration liability represents the fair value of the royalty payments of up to 20% of future net sales as part of the Vibativ acquisition.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.25pt">Represents minimum purchase obligations under our manufacturing agreements.</span></div><div id="id2bfa55304bd45bbaa9cdf09bb7673a3_130"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OFF-BALANCE SHEET ARRANGEMENTS</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, 2018 and 2017, we did not engage in any off-balance sheet arrangements.</span></div><div id="id2bfa55304bd45bbaa9cdf09bb7673a3_133"></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECENT ACCOUNTING PRONOUNCEMENTS</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Adopted Accounting Pronouncements</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2014, the FASB issued amended guidance in the form of ASU No. 2014-09, &#8220;Revenue from Contracts with Customers&#8221; (&#8220;ASC 606&#8221;).  The core principle of the new guidance is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. The new guidance defines a five-step process to achieve this core principle and, in doing so, additional judgments and estimates may be required within the revenue recognition process. The new standard replaced most of the existing revenue recognition standards in U.S. GAAP when it became effective. In July 2015, the FASB issued a one-year deferral of the adoption date, which extended the effective date for us to January 1, 2018, at which point Cumberland adopted the standard. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated its revenues and the new guidance had immaterial impacts to recognition practices upon adoption on January 1, 2018.  As part of the adoption, the Company elected to apply the new guidance on a modified retrospective basis. We did not record a cumulative effect adjustment to historical retained earnings for initially applying the new guidance as no revenue recognition differences were identified in the timing or amount of revenue. </span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the Financial Accounting Standards Board ("FASB") issued guidance in the form of a FASB Accounting Standards Update ("ASU") No. 2016-02, &#8220;Leases.&#8221; The new standard establishes a right-of-use (&#8220;ROU&#8221;) model that requires a lessee to record an ROU asset and a lease liability on the balance sheet for all leases with terms longer than twelve months. Leases will be classified as either finance (formerly "capital leases") or operating, with classification affecting the pattern of expense recognition in the income statement. The standard provides for a modified retrospective transition approach for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain optional practical expedients.  In July 2018, the FASB issued ASU 2018-11, "Leases: Targeted Improvements", allowing for an alternative transition method (the effective date approach). It allows an entity to initially apply the new lease guidance at the adoption date (rather than at the beginning of the earliest period presented). Cumberland adopted the lease guidance effective January 1, 2019 using the package of transition practical expedients.  This allowed us to retain the lease classification for any leases existing prior to adoption, in addition to other benefits. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements - Not Yet Adopted</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses.  Companies will apply the standard&#8217;s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. This standard is effective for Cumberland on January 1, 2020. We continue to evaluate this new standard on our trade and other receivables but do not expect a material impact on our consolidated financial statements. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met, the election must be applied on an instrument-by-instrument basis, and the election is not available for either available-for-sale or held-to-maturity debt securities. The effective date is the same as ASU 2016-13, January 1, 2020. We continue to evaluate this new standard on our trade and other receivables but do not expect a material impact on our consolidated financial statements.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued ASU No. 2018-18, &#8220;Collaboration Arrangements: Clarifying the Interaction between Topic 808 and Topic 606&#8221; (ASU 2018-18). The issuance of ASU 2014-09 raised questions about the interaction between the guidance on collaborative arrangements and revenue recognition. ASU 2018-18 addresses this uncertainty by (1) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASU 2014-09 when the collaboration arrangement participant is a customer, (2) adding unit of account guidance to assess whether the collaboration arrangement or a part of the arrangement is with a customer and (3) precluding a company from presenting transactions with collaboration arrangement participants that are not directly related to sales to third parties together with revenue from contracts with customers. The new standard will be effective for Cumberland on January 1, 2020.  We continue to evaluate this new standard on our trade and other receivables but do not expect a material impact on our consolidated financial statements.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the FASB issued ASU No. 2017-04, &#8220;Simplifying the Test for Goodwill Impairment&#8221; (ASU 2017-04). The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation.  As a result of the revised guidance, a goodwill impairment will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The new standard will be effective for Cumberland on January 1, 2020. We continue to evaluate this new standard but do not expect a material impact on our consolidated financial statements and related disclosures.</span></div><div id="id2bfa55304bd45bbaa9cdf09bb7673a3_139"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;8. Financial Statements and Supplementary Data.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See consolidated financial statements, including the reports of the independent registered public accounting firm, starting on page F-1.</span></div><div id="id2bfa55304bd45bbaa9cdf09bb7673a3_166"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div id="id2bfa55304bd45bbaa9cdf09bb7673a3_169"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shareholders and Board of Directors</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nashville, Tennessee</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Consolidated Financial Statements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;) as of December&#160;31, 2019 and 2018, the related consolidated statements of operations and comprehensive income (loss), equity, and cash flows for each of the three years in the period ended December&#160;31, 2019 and the related notes and financial statement schedule listed in the accompanying index (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2019 and 2018, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2019</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in conformity with accounting principles generally accepted in the United States of America.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of</span><span style="color:#ff00ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ BDO USA, LLP</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company's auditor since 2017.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nashville, Tennessee</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;20, 2020, except for the effects of presenting discontinued operations as discussed in Note 20, as to which the date is December 10, 2020</span></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="id2bfa55304bd45bbaa9cdf09bb7673a3_172"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Balance Sheets</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2019 and 2018 </span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.764%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzQtMi0xLTEtMA_b19c17d5-722e-4b87-9409-db4d610ee8fb">28,212,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzQtNC0xLTEtMA_75293d7f-d7ca-4fa6-97fb-048f465bea1b">27,938,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:MarketableSecuritiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzUtMi0xLTEtMA_85a4237e-5f7f-4241-9f62-dbc8ebd6fb5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzUtNC0xLTEtMA_a9d41153-9b02-4c96-b79f-726127c74b98">8,290,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzYtMi0xLTEtMA_ce69dacc-e8e3-4b73-b4cb-cb6a711f8846">7,859,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzYtNC0xLTEtMA_d1f86007-e621-45aa-8703-d435ee0d3321">6,459,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzctMi0xLTEtMA_6f5604af-16cb-4b9d-b2ad-90f8120e8e91">8,871,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzctNC0xLTEtMA_e4c86178-b993-481a-9d49-e74c6ec31435">9,783,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzgtMi0xLTEtMA_8994eb27-9a33-4f39-a858-0d7aa27dc03d">2,757,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzgtNC0xLTEtMA_cbb90478-49ac-4e43-8e84-bad0ea1f7935">2,936,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets associated with discontinued operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzgtMi0xLTEtMjA3OA_0b19d068-f383-4b72-a3a0-61d2edf0115d">2,462,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzgtNC0xLTEtMjA4MA_a58caf9c-72e2-4e90-9a62-7f14b7514903">3,706,897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzktMi0xLTEtMA_4eeb1353-6fb3-4a4f-a300-e6959b2244d8">50,163,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzktNC0xLTEtMA_76d8a067-1d1b-4792-a5fb-b870ac218d8e">59,116,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzEwLTItMS0xLTA_3b903242-6698-4aa5-af2c-144793d63720">15,554,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzEwLTQtMS0xLTA_793ae818-fccd-4ecd-9d87-312bd436f1f1">15,749,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzExLTItMS0xLTA_068f09de-3567-4557-9a6e-946a9da40fc5">747,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzExLTQtMS0xLTA_071b569a-b16a-4a6b-a931-37f211aebad7">771,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzEyLTItMS0xLTA_d1bcc20e-6803-403a-b549-59a8afcb8c46">30,920,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzEyLTQtMS0xLTA_20c79dcc-0390-40f6-b254-ebc5355da75c">33,655,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzEzLTItMS0xLTA_c6fde496-ab40-41fb-855e-9aa40730d894">882,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzEzLTQtMS0xLTA_43211833-2be9-4820-bb8d-0caac1074d27">784,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzE0LTItMS0xLTA_96c54551-683e-42c7-94d5-908811ddfbab">21,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzE0LTQtMS0xLTA_dea60172-0d62-4e22-806c-28a5b78a99d4">87,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzE1LTItMS0xLTA_28340ecf-541b-4cbd-981c-db219d82e09b">2,960,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzE2LTItMS0xLTA_b285e6d5-afe0-4d79-8b07-236d1a6e0065">3,298,725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzE2LTQtMS0xLTA_aac5f162-1fe6-430d-9865-256c2aabb79e">2,531,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzE3LTItMS0xLTA_b71bf87a-9ce6-4780-9451-020627815ae5">104,549,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzE3LTQtMS0xLTA_9fb17739-1dba-4da7-9871-71c803d53bb5">112,693,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzIxLTItMS0xLTA_de6979a8-35af-45ca-b463-e3bfc56268bf">9,993,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzIxLTQtMS0xLTA_245652ed-12e6-4b11-98ed-eea55deeeadc">8,210,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzIyLTItMS0xLTA_81efae0c-f915-46a5-9ff9-8c3ea6af8aac">920,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzIzLTItMS0xLTA_5afac0ad-c54e-4f46-8ed8-c3c8201fe531">11,084,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzIzLTQtMS0xLTA_6e237ac0-231d-4dc7-8789-757f50867e12">16,044,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities associated with discontinued operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzI0LTItMS0xLTIwODI_96b37603-59e3-4ddd-8f92-66c845276d0a">2,151,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzI0LTQtMS0xLTIwODQ_e71187fb-c341-4eba-9bb2-3e2cfcb06a66">3,549,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzI0LTItMS0xLTA_cffc2bcd-8fc7-4bcd-a1c9-93f94a0af657">24,150,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzI0LTQtMS0xLTA_dcec5097-e254-4b8b-907c-46f75845b56f">27,804,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving line of credit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermLineOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzI1LTItMS0xLTA_64e9c75a-1feb-4471-ab87-8ab8e6a4104b">18,500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermLineOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzI1LTQtMS0xLTA_348eebf6-b11b-4a95-9332-c63be68a6f20">20,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzI2LTItMS0xLTA_55db9af3-a317-4c1d-a056-754a7d719ee9">2,076,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzI3LTItMS0xLTA_c682ffc3-1c35-44f1-b0a3-eb91f3f673ea">8,737,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzI3LTQtMS0xLTA_ad6c85d2-ca11-414b-b094-76ffc2edaa0e">9,319,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzI4LTItMS0xLTA_dafcb1bd-feec-4c75-af32-ecc134005ba1">53,464,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzI4LTQtMS0xLTA_8ee5e242-2926-4b79-99ef-0cf5357fe228">57,123,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzI5LTItMS0xLTA_c653c06d-d475-47cc-b1d0-a2f5e0afe8ea"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzI5LTQtMS0xLTA_a7cb226f-0ab1-4052-a1e0-d099f046eff2"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock &#8211; no par value; 100,000,000 shares authorized; 15,263,555 and 15,481,497 shares issued and outstanding as of December&#160;31, 2019 and 2018, respectively</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValueOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzMyLTItMS0xLTA_154af6cd-c00c-44b6-933c-83c55680e2b2">49,914,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValueOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzMyLTQtMS0xLTA_976e9a0c-6fbe-41fe-954b-a09be7451dc4">51,098,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzMzLTItMS0xLTA_0a5095e7-4238-466a-bba0-91d6e4b0df39">1,208,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzMzLTQtMS0xLTA_e6dabc36-93bf-458a-b9a4-eb2f560d9511">4,746,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzM0LTItMS0xLTA_4f95ab19-ead1-47e1-8347-8741a1d47929">51,122,873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzM0LTQtMS0xLTA_0564f999-b13b-4de3-a7a6-dd9e24f87bda">55,844,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:MinorityInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzM1LTItMS0xLTA_8cc33cfe-48ef-4182-a1c5-3371821bc17f">37,620</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:MinorityInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzM1LTQtMS0xLTA_852b9dba-d9ae-47c5-839a-314fdc5999f1">274,266</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzM2LTItMS0xLTA_0d3d9855-315a-4310-819a-e5d9d4db74f7">51,085,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzM2LTQtMS0xLTA_a157a0db-4bb0-489c-bca9-79b65c581523">55,570,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzM3LTItMS0xLTA_7011710b-4921-4732-988e-5ae51f841570">104,549,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzM3LTQtMS0xLTA_6430d4e1-ecac-4f33-926d-fcc28e7d59d7">112,693,868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><div id="id2bfa55304bd45bbaa9cdf09bb7673a3_178"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Operations and Comprehensive Income (Loss)</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Years ended December&#160;31, 2019, 2018 and 2017 </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.188%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iede275917f1d4f6ab16130b2891da5ca_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzMtMi0xLTEtMA_8c07927a-41cd-48dc-8144-a78c87cc2378">32,407,245</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a75f009943b411484603265cc918c63_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzMtNC0xLTEtMA_ca3dbf8c-3f86-4687-811e-3739cd9b0bb4">28,803,961</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7565a83142144039aa664a5158a4f3a1_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzMtNi0xLTEtMA_3839bf6a-0126-47af-869d-4624ee596ae3">25,549,059</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12130cb8adf747bc917372e57661c37d_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzQtMi0xLTEtMA_ff3d603a-1a3d-4ac8-8ba4-65eb02d3dd06">1,981,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80b0be59c71148caa508bedc7c0aa249_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzQtNC0xLTEtMA_bb1dc299-727e-420b-88c3-f3fd747e7d24">540,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a3679cdc7a7417d9491addba442e136_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzQtNi0xLTEtMA_48805c69-58ef-464d-aa78-149b5c88e5b2">773,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzUtMi0xLTEtMA_9330aba7-6e0c-4117-a96c-28fb4c274b2d">34,388,295</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzUtNC0xLTEtMA_363f99c0-bffe-43da-9a41-f03309a84d66">29,344,894</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzUtNi0xLTEtMA_c40971ea-2c57-45e3-8e72-0fee1694233d">26,322,627</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzctMi0xLTEtMA_7c294355-9b71-4a14-9c68-ec9e514d1a87">7,421,316</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzctNC0xLTEtMA_fdb49ed9-8a58-479b-a254-8f44e4909fa1">6,016,822</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzctNi0xLTEtMA_095c6b17-91bb-4886-9cfb-969655d42a07">5,418,010</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and marketing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzgtMi0xLTEtMA_37ab75cc-195b-478c-b3f6-efc6395cebb5">15,277,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzgtNC0xLTEtMA_ac0237e0-b224-476a-bff8-e6145518dc81">14,004,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzgtNi0xLTEtMA_e51a2f3b-1bbb-4048-8f52-6ffae4c6d4f5">13,489,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzktMi0xLTEtMA_d2b7e98a-a70e-44c0-9410-8ead2c91164c">6,868,480</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzktNC0xLTEtMA_90e9c77c-d81e-4282-8ff6-ed48425ced78">7,575,892</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzktNi0xLTEtMA_d349091f-40ca-47c0-adc9-69fd9fa02ccc">4,247,623</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzEwLTItMS0xLTA_86d72542-be36-4a23-9549-efcf01503691">9,974,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzEwLTQtMS0xLTA_10bca782-b443-4bb3-a3ff-b0730eba3dca">10,150,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzEwLTYtMS0xLTA_b7632241-f19b-4ce4-99bc-8a13b6066907">9,610,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzExLTItMS0xLTA_0a3f8a40-dced-46db-84b3-24c46f6dd07f">4,134,557</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzExLTQtMS0xLTA_94e88050-e28d-42e3-a2d5-cad3df3a64b4">2,769,466</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzExLTYtMS0xLTA_3505f7ed-04a8-404e-91e3-f42124ceff2f">2,436,222</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzEyLTItMS0xLTA_6e64db81-7f32-44f4-9b5d-16eab253c632">43,676,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzEyLTQtMS0xLTA_12be04cb-0ee3-46e5-91f1-f73896b73f5c">40,517,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzEyLTYtMS0xLTA_74406b56-0354-4234-8dfb-7a8aaca8abec">35,202,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzEzLTItMS0xLTA_5dd549c9-40a9-4fee-b30b-7e7a6260c1bf">9,288,182</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzEzLTQtMS0xLTA_8a7fb8a1-84d1-40d0-b34e-eb7ac703a6af">11,172,996</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzEzLTYtMS0xLTA_30fcc8f2-ea6a-465b-9a21-605f971dc9fc">8,879,373</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE0LTItMS0xLTA_958ae051-6b47-4ce8-ad0f-3c64609bbfff">243,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE0LTQtMS0xLTA_483acf5b-70a9-4f6a-a9c6-568ea5572d43">564,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE0LTYtMS0xLTA_04d2a15c-0aad-42b2-8020-e3860046d67e">299,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE1LTItMS0xLTA_8c5dbdec-7536-487b-9921-e25dd6faaef1">246,186</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE1LTQtMS0xLTA_504ae354-d08e-4019-9552-6db0fb585652">195,848</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE1LTYtMS0xLTA_c59fd32b-e73c-45a8-aee8-4f17a2a2872b">92,904</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE2LTItMS0xLTA_06765b1b-20a9-4f06-806d-bbadc1ae9943">9,291,004</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE2LTQtMS0xLTA_617bd941-9b2d-46d0-9bbb-e0807d7d4f23">10,804,360</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE2LTYtMS0xLTA_fa2cfb04-a67e-4f8c-a13e-81085a64bda3">8,672,951</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE3LTItMS0xLTA_260532e7-f028-41de-ac4f-61ad0969aa94">79,316</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE3LTQtMS0xLTA_b278048c-13ca-4a6f-aa11-519f61b34ca6">16,636</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE3LTYtMS0xLTA_84457095-afcb-4fc1-b6da-240981cac506">4,174,889</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE4LTItMS0xLTA_dedbe145-6bdb-493f-9048-b520b606e267">9,211,688</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE4LTQtMS0xLTA_7f096769-99c8-4530-9cbb-788588bbda24">10,820,996</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE4LTYtMS0xLTA_57f222eb-8412-4022-a07f-bcc49808879c">12,847,840</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE4LTItMS0xLTQwNQ_127ab94a-6c52-407f-90b1-9de92cbd0807">5,665,177</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE4LTQtMS0xLTQwNQ_cd961af5-4104-47d1-b891-43d77603bb31">3,782,224</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE4LTYtMS0xLTExODM_40177350-47be-49de-ac56-d4e5b3e56beb">4,798,025</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE5LTItMS0xLTExODg_03ac504f-d5e1-478f-bed3-f82861bd6972">3,546,511</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE5LTQtMS0xLTExODY_039995f2-14e6-4110-8289-a83040586a1b">7,038,772</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE5LTYtMS0xLTExODM_e461cb0c-df8c-46ce-8c7a-55f45394341b">8,049,815</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss at subsidiary attributable to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE5LTItMS0xLTA_2a41210e-25fd-442e-8987-2dfc460a8d44">8,752</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE5LTQtMS0xLTA_90ad1b36-e51b-4bb9-8465-4ff71d995088">75,704</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE5LTYtMS0xLTA_a37afbff-780b-40bc-9324-5b3bb249f69b">71,182</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzIwLTItMS0xLTA_3d7a56a6-b326-4273-bb5a-8319fc5dc3eb">3,537,759</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzIwLTQtMS0xLTA_9ad0f662-5514-4726-ab54-0d2948139c9f">6,963,068</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzIwLTYtMS0xLTA_a3b042a1-f29b-41fc-923e-5ec1bad7ded8">7,978,633</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share attributable to common shareholders:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Continuing operations-basic</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzIzLTItMS0xLTA_11b6cd95-3ea8-4160-82c5-9063f0bea46a">0.60</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzIzLTQtMS0xLTA_da2a372a-5499-4398-9355-9adfa1376c67">0.70</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzIzLTYtMS0xLTA_4244e14b-d96f-41ee-83fc-758da54ad006">0.80</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Discontinued operations-basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzI0LTItMS0xLTA_5828c226-1dff-4646-85d8-cf172ec49489">0.37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzI0LTQtMS0xLTA_6e59a5d7-cde5-493c-ba2b-1f81e866dae4">0.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzI0LTYtMS0xLTA_caa5d099-8bf3-493b-958c-eebbc92f76b9">0.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzI2LTItMS0xLTExOTY_d1e6ad0f-e6b8-48b3-a916-0a7dddecb46a">0.23</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzI2LTQtMS0xLTExOTg_68532524-6ea9-49d3-9c88-a62bb462edd2">0.45</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzI2LTYtMS0xLTEyMDA_bb348cbe-085e-48f7-9ff5-ba8f9cc989e8">0.50</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Continuing operations-diluted</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzI4LTItMS0xLTEyMDI_ab87b9a4-9c51-4368-8a13-3ba2ea2168fd">0.60</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzI4LTQtMS0xLTEyMDQ_95362776-c855-4237-a5d5-966b06c0cb6f">0.70</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzI4LTYtMS0xLTEyMDY_de762687-bed1-4ee4-9cb8-fa60a2add0b8">0.80</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Discontinued operations-diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzI5LTItMS0xLTEyMDI_554720c6-bfbb-40ee-973a-7c9b2adddaa4">0.37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzI5LTQtMS0xLTEyMDQ_a5ca9de4-4199-427d-8bd7-6760fd223e48">0.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzI5LTYtMS0xLTEyMDY_96e7e157-1a4b-42bf-842b-83cf3bdfc5c6">0.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzMwLTItMS0xLTEyMDI_74604961-7c99-4bce-b953-eff6066717b5">0.23</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzMwLTQtMS0xLTEyMDQ_62b985cf-1f1c-417b-bdf2-2b0238646593">0.45</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzMwLTYtMS0xLTEyMDY_038b02f4-5d9b-482e-afc5-336224f46789">0.50</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzI2LTItMS0xLTA_8336ad6e-0cb9-4a71-a8b4-26fd7511d9bd">15,396,098</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzI2LTQtMS0xLTA_f71e8a35-a95d-4b33-98f8-3172381af055">15,614,052</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzI2LTYtMS0xLTA_cfdd7e38-46c1-448f-82f3-d482e9d216f7">15,911,577</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzI3LTItMS0xLTA_da2519a4-4fe5-4928-8814-3b6abfbf2438">15,396,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzI3LTQtMS0xLTA_b18487b8-ba0d-46f2-aa65-41b8081966e7">15,614,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzI3LTYtMS0xLTA_67927dd3-97b6-47d5-bf12-12db277619dc">15,911,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss) attributable to common shareholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzI5LTItMS0xLTA_1e746336-4be2-482c-a7ff-2439541fea37">3,537,759</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzI5LTQtMS0xLTA_cd02d6e8-021f-4d79-9935-398ba4c3eea1">6,963,068</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzI5LTYtMS0xLTA_b128611a-ed65-4f71-b425-d8526c6f32f0">7,978,633</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss at subsidiary attributable to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzMwLTItMS0xLTA_3ff7c7c6-66a3-429e-8531-c6a71c6d38c3">8,752</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzMwLTQtMS0xLTA_097794b0-0e78-42a7-9dbe-64aa9cf64764">75,704</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzMwLTYtMS0xLTA_a64b77a0-394b-45a9-b08e-d2c03b2c9d45">71,182</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzMxLTItMS0xLTA_46ada651-b234-408d-8d0b-502a588796a0">3,546,511</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzMxLTQtMS0xLTA_dac91437-25fb-4336-94da-6a8a7ef3ba42">7,038,772</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,049,815)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="id2bfa55304bd45bbaa9cdf09bb7673a3_181"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Cash Flows </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Years ended December&#160;31, 2019, 2018 and 2017 </span></div><div style="margin-bottom:6pt;margin-top:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.078%"><tr><td style="width:1.0%"></td><td style="width:57.792%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.584%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzMtMi0xLTEtMA_a3367ca2-de62-4098-b47e-312d7a1caf47">3,546,511</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzMtNC0xLTEtMA_2ce0b56f-bfef-47ac-8f8b-d2497784a2a6">7,038,772</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzMtNi0xLTEtMA_7117da81-646a-4831-8315-6e99cdf540f0">8,049,815</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzQtMi0xLTEtNjQ2_aa2137ce-7c43-457f-851e-3c289ee8e2b0">5,665,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzQtNC0xLTEtNjQ2_d24b2a8e-11f9-414e-92a4-f880cbc85ea5">3,782,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzQtNi0xLTEtNjQ2_ac12445b-ae9f-436c-94f3-e718cf0d9ee2">4,798,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzUtMi0xLTEtNjQ2_f149db9f-654d-433a-8738-15be9dd31004">9,211,688</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzUtNC0xLTEtNjQ2_8c6c8f71-065e-4133-85b7-9495ed7abc5b">10,820,996</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzUtNi0xLTEtNjQ2_74576b25-fb92-4f00-bd03-ef46afc0d4d7">12,847,840</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income (loss) to net cash flows provided by (used in) operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzUtMi0xLTEtMA_0ed9c62b-2860-4586-b47e-e0adb1f70f56">4,404,175</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzUtNC0xLTEtMA_d638ea02-4854-4022-a2c8-4b6f8299b385">2,982,703</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzUtNi0xLTEtMA_1402ffbf-bc6a-4879-a226-64b28005a8f1">2,647,753</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzYtMi0xLTEtMA_6307ad31-490c-4393-80ff-1d57367d534a">65,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzYtNC0xLTEtMA_618bc4a1-745b-4b13-a87e-524f78aced42">81,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzYtNi0xLTEtMA_f806ef37-50f3-4193-bc2e-efb4460bea8a">4,206,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzctMi0xLTEtMA_d28ed3b7-363a-4dcf-abf1-19ecf6161ef1">1,485,898</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzctNC0xLTEtMA_71e0d0fa-4e3d-4620-95b6-262c948d1ed6">1,364,698</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzctNi0xLTEtMA_f63bbb43-8dac-4f13-973a-2fc4eb396d71">1,115,063</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation (foundation contribution)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:zerodash" name="cpix:SharebasedCompensationFoundationContribution" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzgtMi0xLTEtMA_1699eeca-5470-4ad7-9246-87b4fe32ae1a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:zerodash" name="cpix:SharebasedCompensationFoundationContribution" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzgtNC0xLTEtMA_1da89833-3e25-4084-bc6c-31d06f359f6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="cpix:SharebasedCompensationFoundationContribution" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzgtNi0xLTEtMA_8f5738c3-de2a-415d-8dc9-702630ba780a">372,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess tax (benefit) expense derived from exercise of stock options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzktMi0xLTEtMA_416ffe3e-05bc-4e99-b034-719146320726">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzktNC0xLTEtMA_d364d832-da53-41c8-8f8e-891f36b4757d">81,886</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzktNi0xLTEtMA_550d873d-2605-4d72-bd2e-0d310afd8af1">91,109</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in non-cash contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzEwLTItMS0xLTA_6cfff0c6-ed25-491e-87d7-7d4589563e28">804,167</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzEwLTQtMS0xLTA_666a8fba-9676-496a-9bd6-7afe0821d11e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzEwLTYtMS0xLTA_61fae01c-350a-4599-84b8-bbaa9fe3bf75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncash interest expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzExLTItMS0xLTA_7eb3299a-830f-4ada-a514-c0ccff2ad465">47,525</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzExLTQtMS0xLTA_5fd901db-13e7-493f-a5b2-3884d3cf001c">99,883</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzExLTYtMS0xLTA_30530967-59a7-495c-ae54-5ee251e2f1f3">77,911</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncash investment gains</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingGainsLosses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzEyLTItMS0xLTA_3fb1d7ad-5a91-4846-8b24-726502ccb6ff">26,315</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingGainsLosses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzEyLTQtMS0xLTA_339f31fe-dc5f-4bca-93ec-eaae64af7fb2">168,440</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingGainsLosses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzEyLTYtMS0xLTA_2d669fb5-133c-4c96-82ff-a9d736ed09e0">52,012</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net changes in assets and liabilities affecting operating activities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzE0LTItMS0xLTA_c44e21a5-f8aa-4d3b-b41b-609c30aba22c">1,399,012</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzE0LTQtMS0xLTA_3efbc298-cebd-4d0c-9df0-17e61d01a4d8">47,288</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzE0LTYtMS0xLTA_2639f55a-b16a-4e09-accd-84a0c917c132">753,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzE1LTItMS0xLTA_604b0ac6-1911-4aee-b024-4bb263a1da6b">1,106,175</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzE1LTQtMS0xLTA_b1c7cca6-9468-4f28-ab28-fbe39a8a1a69">528,153</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzE1LTYtMS0xLTA_c9fb1b10-0206-4878-99c2-980482ac5725">292,710</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets and other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzE2LTItMS0xLTA_cf74f003-2eda-4277-8fcf-30caf3c41413">615,199</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzE2LTQtMS0xLTA_1b1795aa-ea5a-4ec8-a2f2-7c14cd0e24bd">676,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzE2LTYtMS0xLTA_269f160c-38ea-40a2-86ee-b43f670c5ff1">1,155,630</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzE3LTItMS0xLTA_d1bf93ea-2a8a-4491-8157-bf821a3278de">3,221,780</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzE3LTQtMS0xLTA_e7af26ce-9646-4dc5-9e74-08405c009cf2">4,153,287</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzE3LTYtMS0xLTA_d6319daf-7701-4641-9eda-deada04cc3f4">339,751</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzE4LTItMS0xLTA_b39fecf8-99d5-45bb-9db2-7bdd868cc01f">729,820</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzE4LTQtMS0xLTA_111b8f23-b0ab-453d-91dd-2a0c1d9f058e">159,558</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzE4LTYtMS0xLTA_03131ca1-38f2-46d5-94cc-f35740acbdab">413,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 49pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) operating activities from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzE5LTItMS0xLTA_7a2c6848-7154-4715-9df6-e3b2e8fe9073">2,455,240</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzE5LTQtMS0xLTA_de50d1cf-ce11-4f50-994a-c6c6f37ca1cd">1,390,808</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzE5LTYtMS0xLTA_3e83c541-91aa-4600-a0ad-df83d5a5955f">4,512,952</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzIyLTItMS0xLTY2Nw_19d9b0f2-9000-49d0-bf0b-6e4a2bb5e043">5,511,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzIyLTQtMS0xLTY2Nw_1159fbf0-d206-4553-bdb1-2afc7e2e0825">4,503,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzIyLTYtMS0xLTY2Nw_5e42b07c-72aa-4350-914e-e35599a4c8f9">3,955,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 49pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) operating activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzIzLTItMS0xLTEyMzA_95a691f1-484f-44b2-b4f3-ec9f880507f1">3,056,356</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzIzLTQtMS0xLTEyMjg_9e9597db-33e3-4685-a173-b7e70bc201aa">3,112,737</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzIzLTYtMS0xLTEyMzI_cb5accf6-e775-4919-9193-6b9e0b310137">557,714</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to property and equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzIxLTItMS0xLTA_bbbbf00d-e3f0-48de-b96a-bd2bf1fe0210">246,202</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzIxLTQtMS0xLTA_9f273daa-6098-4b1d-9a92-dccfca9771de">455,569</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzIxLTYtMS0xLTA_fc89ddd1-3ab6-41af-aa8a-3710e0d7fdcb">275,960</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzIyLTItMS0xLTA_4a05faa6-c9f5-42a7-ba2f-51a5b996393a">772,944</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzIyLTQtMS0xLTA_b3851db8-f164-42b4-a774-76d5d57d3bad">3,819,486</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzIyLTYtMS0xLTA_5f71ce5a-1363-4473-9e12-d6d4f73c5dd6">1,213,110</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for acquisition</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzIzLTItMS0xLTA_f7cd3c07-944b-4f00-87b1-9f74b8b272f6">5,000,000</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzIzLTQtMS0xLTA_028dfa8a-4f02-42d2-915b-f7db9f89164a">20,000,000</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzIzLTYtMS0xLTA_9ff69cd3-4970-4e58-8944-af4a6b738691">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzI0LTItMS0xLTA_7e34be7c-6cae-4efb-9f0a-96fa57e3ab9b">20,062,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzI0LTQtMS0xLTA_d097e854-a265-4097-8b18-c1c331ac4532">16,122,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzI0LTYtMS0xLTA_6e9b95ec-ee4d-4fc1-9a7f-f578fc1d2409">13,381,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzI1LTItMS0xLTA_69c20389-330d-4aee-aac3-4c22ee8b046b">11,745,138</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzI1LTQtMS0xLTA_0d385138-8af1-428c-9cfa-3aa871f1d996">19,572,139</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzI1LTYtMS0xLTA_996486c0-8b66-48b2-b522-a74375023ca9">2,379,414</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzI2LTItMS0xLTA_243acc57-9565-4d64-a368-dfcb0b5db1ef">2,297,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzI2LTQtMS0xLTA_24bd5d5b-be43-4ee1-b4f8-2669562df1e2">27,724,818</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzI2LTYtMS0xLTA_41d066b2-6a17-4252-9825-fa3cd08b2503">9,512,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">See accompanying notes to consolidated financial statements</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.078%"><tr><td style="width:1.0%"></td><td style="width:57.792%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.584%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Borrowings on line of credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfLinesOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzI4LTItMS0xLTA_aab4c854-cd44-41bb-859d-6ce4419bc59b">76,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfLinesOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzI4LTQtMS0xLTA_bc31db1f-363e-4a02-a0ec-f95c199a1fb8">56,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfLinesOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzI4LTYtMS0xLTA_b6e6bd70-ebbe-4ce6-b803-75880a50deda">24,500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayments on line of credit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzI5LTItMS0xLTA_18c746c1-a916-4007-b69c-4c9791db1129">77,500,000</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzI5LTQtMS0xLTA_127d4372-36f6-4be5-92ae-5dff443bdcbf">45,800,000</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzI5LTYtMS0xLTA_379b7248-8b7e-472d-8d6f-35a3497fd7b6">18,800,000</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzMwLTItMS0xLTA_5bf8979a-a87b-419b-9cb8-00862b5121f0">3,494,921</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzMwLTQtMS0xLTA_2d9e3544-288a-47c4-b8ac-50da9aef8ab9">2,879,426</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzMwLTYtMS0xLTA_458d613c-e2a5-41d0-98ed-e37257384163">3,724,375</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments of deferred equity offering costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzMxLTItMS0xLTA_bba2e71c-5f9c-4755-bd14-2c7b8c6d3654">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzMxLTQtMS0xLTA_b7dd467b-7654-4276-be2e-a7e51423f391">383,310</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzMxLTYtMS0xLTA_1b8d8d9a-6fe0-4851-92fa-679734fae39f">27,950</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of shares of common stock, net of offering costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzMyLTItMS0xLTA_20cad27b-4b64-4154-8daa-3a377c6becdd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzMyLTQtMS0xLTA_5d07c540-16f6-43c0-b4eb-a64c1d640535">200,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzMyLTYtMS0xLTA_a25fdca3-4082-4b57-9d43-ed05ffc615d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments of financing costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfFinancingCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzMzLTItMS0xLTA_5e31b876-27b4-44e0-883a-32a2646f3c03">52,500</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentsOfFinancingCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzMzLTQtMS0xLTA_d2ff8895-dc4f-45ab-b638-d77ad8441538">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentsOfFinancingCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzMzLTYtMS0xLTA_f1a5539d-6f58-49a8-9ba0-c07f9dbac545">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments of contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzM0LTItMS0xLTA_d2f9d73c-d7f3-467b-acb1-4677aeab8671">1,033,108</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzM0LTQtMS0xLTA_358ae676-795e-4569-bf30-2f5cc53411bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzM0LTYtMS0xLTA_3a209a22-7587-4af4-8655-f812a8bfe0cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of subsidiary shares to noncontrolling interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMinorityShareholders" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzM1LTItMS0xLTA_87807f89-6dde-43b6-9c85-689c954a9066">1,000,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromMinorityShareholders" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzM1LTQtMS0xLTA_2b8d2eaf-6e05-48e8-8b73-d435649a1aa5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromMinorityShareholders" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzM1LTYtMS0xLTA_068c153c-721c-4a95-9b24-16ddc6392b7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzM2LTItMS0xLTA_164c067c-53a5-4699-b596-2206d8d23e64">5,080,529</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzM2LTQtMS0xLTA_86951661-776d-45e9-bbe7-3d9b853f49e6">7,138,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzM2LTYtMS0xLTA_5e1af68b-1399-4396-ba51-a735c1ccf856">1,947,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 49pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzM3LTItMS0xLTA_28c4c142-ab20-4490-ba2b-2184ae339fc1">273,675</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzM3LTQtMS0xLTA_03acfa17-86d1-4b9a-b1ca-6c6893fe12d7">17,473,908</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzM3LTYtMS0xLTA_40ff4e7d-0d53-4dbb-990d-f39194bdfa1a">10,902,538</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzM4LTItMS0xLTA_4e120fa6-dcab-4cc5-8eec-bb6abcc82636">27,938,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19f7709a57f34358b074d8ab2cd1410f_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzM4LTQtMS0xLTA_c508096e-c1f4-4d51-a526-9db3484aed28">45,412,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2153d838d1a64103b08e67d86300e4f6_I20161231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzM4LTYtMS0xLTA_d06d5f4d-d62e-4bed-94d9-7f0ca9324582">34,510,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of year</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzM5LTItMS0xLTA_66d00369-b304-4dcd-91cc-d9e62cfff8ca">28,212,635</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzM5LTQtMS0xLTA_181f7073-a39b-44e4-a901-c1887a64f9ff">27,938,960</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19f7709a57f34358b074d8ab2cd1410f_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzM5LTYtMS0xLTA_b55e50c0-b24a-462d-9309-5793624cffcf">45,412,868</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="21" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.358%"><tr><td style="width:1.0%"></td><td style="width:57.620%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.817%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.817%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid (refunded) during the year for:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzItMi0xLTEtMA_7a65b790-aa3e-4767-a6a1-5787a57ecd09">198,661</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzItNC0xLTEtMA_e5b0c049-029e-49f1-a016-5e59910d4bdd">95,965</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzItNi0xLTEtMA_7a24a774-ae8f-455d-b451-e58764d23993">14,993</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaidNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzMtMi0xLTEtMA_2a3aca09-941f-430f-b20e-92228bd759d2">16,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaidNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzMtNC0xLTEtMA_e2b50f85-1dbc-4e17-94bd-123767e6d1fa">15,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaidNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzMtNi0xLTEtMA_3fc242d0-98f2-4ea3-b7f4-45509cdb505b">18,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncash investing and financing activities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in unpaid invoices for purchases of intangibles</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="cpix:PurchasesOfIntangibleAssetsIncurredButNotYetPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzUtMi0xLTEtMA_eccf13bd-7045-447b-aef4-990f572968b7">576,837</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="cpix:PurchasesOfIntangibleAssetsIncurredButNotYetPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzUtNC0xLTEtMA_1bcb188c-e622-4bd1-bdb2-a7768e79382e">539,467</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" sign="-" format="ixt:numdotdecimal" name="cpix:PurchasesOfIntangibleAssetsIncurredButNotYetPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzUtNi0xLTEtMA_4637e45f-6e2c-4387-8815-0da59509c5c3">513,481</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred offering costs included in accounts payable and other accrued expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:zerodash" name="cpix:DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzYtMi0xLTEtMA_43182f11-9909-4019-a2db-b5cc2ce97521">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:zerodash" name="cpix:DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzYtNC0xLTEtMA_d594c0c2-e213-4c1e-a3b0-863fe1ff8830">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="cpix:DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzYtNi0xLTEtMA_48526411-4821-4e2e-8173-61353461bcfc">97,254</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non cash increase in liabilities related to acquisition (see Note 3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzctMi0xLTEtMA_dae5b837-289c-4406-b570-e2b1ec719320">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzctNC0xLTEtMA_7176ee24-cab4-4d6a-a2e3-d48958958f5a">14,034,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:zerodash" name="us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzctNi0xLTEtMA_a6058d34-3036-49d7-9fa1-890d8cd83b1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of operating lease assets and liabilities through adoption of ASC 842</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzgtMi0xLTEtMA_7e0a2ad8-e0db-47fe-ab9e-42c4e481b918">3,629,320</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of shares related to RediTrex approval</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="cpix:NoncashOrPartNoncashTransactionVestingOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzktMi0xLTEtMA_43228601-940c-4d43-a370-21be5c080f40">862,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:zerodash" name="cpix:NoncashOrPartNoncashTransactionVestingOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzktNC0xLTEtMA_2fd395fd-be58-4186-a0bc-afe0c698cf68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:zerodash" name="cpix:NoncashOrPartNoncashTransactionVestingOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzktNi0xLTEtMA_9984c12a-e560-4c92-9611-e676ebec440e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of subsidiary shares from noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzEwLTItMS0xLTA_0cbf7011-314b-4ca9-aa31-9e7477aa495b">800,000</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzEwLTQtMS0xLTA_4005e70a-07a2-4efc-8735-8e27fd3ac0a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:zerodash" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzEwLTYtMS0xLTA_d930c40e-b7fc-4d86-a41f-08a7139354f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to intangible assets from final purchase price allocation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzExLTItMS0xLTA_bda09f9b-7f05-48ab-8993-3e659e6d5dd3">148,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzExLTQtMS0xLTA_18f3c26c-bf29-4154-bb3b-eac6239a6074">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:zerodash" name="us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzExLTYtMS0xLTA_11c77fd9-164d-4c08-8cff-14a180d1247a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span><br/></span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="id2bfa55304bd45bbaa9cdf09bb7673a3_184"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Equity</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Years ended December&#160;31, 2019, 2018 and 2017 </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.717%"><tr><td style="width:1.0%"></td><td style="width:29.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumberland Pharmaceuticals Inc. Shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retained earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-controlling interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total equity</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December&#160;31, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id69c7a64b03046d994369dd8619e693b_I20161231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzQtMi0xLTEtMA_808c576d-de6b-43d2-9c01-de4ebd7d1e5c">16,074,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id69c7a64b03046d994369dd8619e693b_I20161231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzQtNC0xLTEtMA_e7547121-9737-493f-9eda-e44498954eac">54,643,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca22cafe70c4402827abcd065642a85_I20161231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzQtNi0xLTEtMA_b5e5c981-eba6-44f1-847b-a89c72e514d2">18,604,931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6067dd95a57b478f9581c66c6de9ce8d_I20161231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzQtOC0xLTEtMA_ae6579b4-09da-42cd-8641-fd3f81f6dba6">127,380</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2153d838d1a64103b08e67d86300e4f6_I20161231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzQtMTAtMS0xLTA_92d6ec05-e287-4be4-b48b-e1bf6d7ee52d">73,120,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f7afaa399514dcdbcfdaa5e2bb28ea7_D20170101-20171231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzUtNi0xLTEtMA_a1bc511e-183b-4531-9329-deb07825725f">7,978,633</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4861d915e194b9b953dd7e515035d55_D20170101-20171231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzUtOC0xLTEtMA_6194d359-33b7-491c-844d-ced2d5a920d9">71,182</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzUtMTAtMS0xLTA_c261952e-c073-471b-8d13-1f2f1996cb7b">8,049,815</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative effect from change in accounting principle</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ac9d639e514ecc9a1253c74c8715e3_I20161231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzYtNi0xLTEtMA_40043b39-8550-4430-bc4a-c342935f1b84">1,082,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07bb27d9de334b51acf632637d46c3ec_I20161231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzYtMTAtMS0xLTA_5cff55c3-4b0e-409e-b0fe-70ede55ec1e5">1,082,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6921ef0b4c9446b6a5f25b2084bdc3ca_D20170101-20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzctMi0xLTEtMA_94dbe81d-0904-48f5-a9a8-696c650913cd">146,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6921ef0b4c9446b6a5f25b2084bdc3ca_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzctNC0xLTEtMA_0eda4c89-fc11-417d-9a13-b562002a42d8">1,115,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzctMTAtMS0xLTA_03363da1-afa0-4abf-a595-594291307de2">1,115,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of options and related tax benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6921ef0b4c9446b6a5f25b2084bdc3ca_D20170101-20171231" decimals="INF" format="ixt:numdotdecimal" name="cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzgtMi0xLTEtMA_f81c3e2a-3358-42a2-9fcd-2129d98d2d95">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6921ef0b4c9446b6a5f25b2084bdc3ca_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzgtNC0xLTEtMA_2a9d6326-1056-4602-9424-f7b8cd74b157">372,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzgtMTAtMS0xLTA_d06ecbd7-25df-433b-98e8-7657093e0486">372,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6921ef0b4c9446b6a5f25b2084bdc3ca_D20170101-20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzktMi0xLTEtMA_5fc7359e-2783-487a-9d44-7a92a5278d05">547,376</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6921ef0b4c9446b6a5f25b2084bdc3ca_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzktNC0xLTEtMA_752cf8f1-1ef4-4a44-a92a-9248ea554fd5">3,719,890</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzktMTAtMS0xLTA_84ad56bc-2bc3-448a-a00d-985dd5fb5560">3,719,890</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December&#160;31, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i512c6090aab845a3bfe38fb3e6f61dbb_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzEwLTItMS0xLTA_4de5ac84-838a-4af6-9c5f-2091ef8ff3db">15,723,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i512c6090aab845a3bfe38fb3e6f61dbb_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzEwLTQtMS0xLTA_421627ad-ebdf-45d8-a98d-f16db007a586">52,410,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c5b1b36eaf747aea3881c4b9c3884a8_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzEwLTYtMS0xLTA_45e20ddb-dfd5-4594-8af6-623125305ded">11,709,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42508aef6d0b489d9d6f2bc2b649384d_I20171231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzEwLTgtMS0xLTA_aeca95b2-9698-4228-94c0-b2b465cb1050">198,562</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19f7709a57f34358b074d8ab2cd1410f_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzEwLTEwLTEtMS0w_9085c0e1-2a52-41f8-bad8-3c8f1ba628fc">63,921,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98582b13998d4d998af541abee8ec14c_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzExLTYtMS0xLTA_c63630f5-20e7-44e0-9d27-55737a6ecf33">6,963,068</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cffc6b13dc64ca49a9f14419a551793_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzExLTgtMS0xLTA_e3e7f396-32f7-4b50-96b5-9ce7cb3a1af5">75,704</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzExLTEwLTEtMS0w_a5a98592-133f-4ad9-a581-7d5ee426bd57">7,038,772</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8b9e95130dc146f9aa56d8d1d11bc534_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzEyLTItMS0xLTA_4523518d-d58d-48cd-9025-24c0ad2b075b">170,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b9e95130dc146f9aa56d8d1d11bc534_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzEyLTQtMS0xLTA_cd59a5eb-39a0-41ee-9d8a-7de4eec71677">1,364,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzEyLTEwLTEtMS0w_c0b989ce-17dd-4a5c-bae6-14154f9959d6">1,364,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of common stock, net of offering costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8b9e95130dc146f9aa56d8d1d11bc534_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzEzLTItMS0xLTA_ffc5e35b-cbdb-4ae3-b7c9-1704a6c52f75">30,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b9e95130dc146f9aa56d8d1d11bc534_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzEzLTQtMS0xLTA_1ded95d8-19ae-4db7-b714-29b141d9340e">200,909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzEzLTEwLTEtMS0w_953d0d7a-16ff-406a-83a1-fe2b66edb093">200,909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8b9e95130dc146f9aa56d8d1d11bc534_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzE0LTItMS0xLTA_a04cef7f-ef04-47e6-add6-9d8c917d3edd">443,041</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b9e95130dc146f9aa56d8d1d11bc534_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzE0LTQtMS0xLTA_985fca2c-24a4-4fac-9e22-bf2c3a508ffd">2,877,935</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzE0LTEwLTEtMS0w_c0cf45cb-48f5-4c31-a10a-deb0a61d8b09">2,877,935</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December&#160;31, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1e55eb8a26d0400ab1ddbb5aa6ac9d0c_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzE1LTItMS0xLTA_7a02a94c-09ad-4e27-86f6-eb5d488c7059">15,481,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e55eb8a26d0400ab1ddbb5aa6ac9d0c_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzE1LTQtMS0xLTA_f5f7c7d0-be50-48b1-811a-7a13590cae08">51,098,613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie93040da022f4f208946b77301e73ade_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzE1LTYtMS0xLTA_e998a866-34b5-4b79-8be5-88254c15d56e">4,746,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4644d0f807ed4bce8b2b23227a41a2f2_I20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzE1LTgtMS0xLTA_148a7e41-06d2-4264-931d-124aa0006eed">274,266</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzE1LTEwLTEtMS0w_ee0dc77e-4756-43ac-a6c6-2bbd442145ab">55,570,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8fc2928cf4640edbddc3867d462e258_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzE2LTYtMS0xLTA_9ea62cdd-04b5-478a-a40d-03ec79770836">3,537,759</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570bc31a791840209b4f80fc77772940_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzE2LTgtMS0xLTA_c1dad570-0e30-42e9-a7a8-bb35b468942d">8,752</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzE2LTEwLTEtMS0w_1a8e47e7-2454-46c3-831e-49b9d7789323">3,546,511</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of subsidiary shares to noncontrolling interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52ca8e03f38a46ab80ee3b1b2a37a943_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzE3LTQtMS0xLTA_7e42b9c0-7b53-4754-ba28-c7b86fc3f450">685,805</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570bc31a791840209b4f80fc77772940_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzE3LTgtMS0xLTA_12ff4141-83e0-4159-b6ad-8369485cd0a9">114,195</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzE3LTEwLTEtMS0w_124e1aa8-aae9-4e3a-8f16-7b6b9f094c40">800,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of subsidiary shares to noncontrolling interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52ca8e03f38a46ab80ee3b1b2a37a943_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzE4LTQtMS0xLTA_fa802f9a-e678-4e08-88c5-0c6f9fcd2985">640,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570bc31a791840209b4f80fc77772940_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzE4LTgtMS0xLTA_a2754486-7b49-4b42-9eb1-666543407328">359,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzE4LTEwLTEtMS0w_aff4ee3c-eac4-4b98-8bf2-932f30dd500a">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i52ca8e03f38a46ab80ee3b1b2a37a943_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzE5LTItMS0xLTA_3d4fbcf9-3426-451a-a04a-a62e9b30f9b6">180,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52ca8e03f38a46ab80ee3b1b2a37a943_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzE5LTQtMS0xLTA_697ce540-78b2-4f77-8f68-ba7d0252b9fc">862,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzE5LTEwLTEtMS0w_12addb39-3131-49b0-a6d6-7309e189f64c">862,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i52ca8e03f38a46ab80ee3b1b2a37a943_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzIwLTItMS0xLTA_db43d325-bcd1-432c-9d1d-f310ccd7612d">225,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52ca8e03f38a46ab80ee3b1b2a37a943_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzIwLTQtMS0xLTA_1fe93382-7e5b-4f55-8f60-b794001680f3">1,485,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzIwLTEwLTEtMS0w_cef1e325-0e37-455e-b3c6-00fa884cdbcf">1,485,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i52ca8e03f38a46ab80ee3b1b2a37a943_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzIxLTItMS0xLTA_90699818-94da-4615-a19f-20c7b5317142">623,478</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52ca8e03f38a46ab80ee3b1b2a37a943_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzIxLTQtMS0xLTA_dc26a7c4-17bd-43c6-b2ce-a4e2445d429e">3,486,835</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzIxLTEwLTEtMS0w_d8d6c70b-25ba-46ba-9f58-37cceb9f213c">3,486,835</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December&#160;31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibbcaca0519364200b49f7a89d6fa09f7_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzIyLTItMS0xLTA_0a4ba7b6-ae98-4946-ad54-8562c77adf3d">15,263,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbcaca0519364200b49f7a89d6fa09f7_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzIyLTQtMS0xLTA_54d4d050-708e-4da3-8281-7ad7534734db">49,914,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48893159b76243539afc56c165b13ce5_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzIyLTYtMS0xLTA_efc9fd9e-ccf0-4335-bbcf-730682fe9673">1,208,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0ea12224ffe4a29838858a3bdb9268c_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzIyLTgtMS0xLTA_633fbc4b-1ec4-4e4e-a82f-6ecfdf052577">37,620</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzIyLTEwLTEtMS0w_e3315279-b30f-406b-be6a-e0b9386b0ac5">51,085,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="id2bfa55304bd45bbaa9cdf09bb7673a3_187"></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-top:4pt;text-align:center"><span><br/></span></div><div id="id2bfa55304bd45bbaa9cdf09bb7673a3_190"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1)   <ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTAvZnJhZzoyN2Y4MjYwMGIxN2E0ZTM4OWU3MTE3MDVhMjBkOTA2My90ZXh0cmVnaW9uOjI3ZjgyNjAwYjE3YTRlMzg5ZTcxMTcwNWEyMGQ5MDYzXzMyOTk_d358f671-1eda-4b3a-b323-36dc828c14b8" continuedAt="i7384986344f44162bb7525b95c820832" escape="true">Organization</ix:nonNumeric></span></div><ix:continuation id="i7384986344f44162bb7525b95c820832"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products.  The Company's primary target markets are hospital acute care and gastroenterology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.  The Company promotes its approved products through its hospital and field sales forces in the United States and is establishing a network of international partners to bring its medicines to patients in their countries.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#8217;s products are manufactured by third parties, which are overseen by Cumberland&#8217;s quality and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to build a pipeline of early-stage product candidates, the Company formed a subsidiary, Cumberland Emerging Technologies, Inc. ("CET"), which teams with universities and other research organizations to help advance scientific discoveries from the laboratory to the marketplace.  In 2014, the Company organized equity financing to recapitalize and strengthen the financial position of CET including an investment of approximately $<ix:nonFraction unitRef="usd" contextRef="iefb6ff4d74154d8685cd13777224de1f_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTAvZnJhZzoyN2Y4MjYwMGIxN2E0ZTM4OWU3MTE3MDVhMjBkOTA2My90ZXh0cmVnaW9uOjI3ZjgyNjAwYjE3YTRlMzg5ZTcxMTcwNWEyMGQ5MDYzXzE3OTA_803f2038-aded-404a-b8fc-6364bb90d288">1.0</ix:nonFraction> million from Gloria Pharmaceuticals Co., Ltd. (&#8220;Gloria&#8221;).  As a result, Gloria received shares in CET and joined the CET ownership group. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April, 2019, CET entered into an agreement with HongKong WinHealth Pharma Group Co. Limited (WinHealth) </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">whereby WinHealth made a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="i917430c8015149c18c59ded862b49717_I20190430" decimals="-5" format="ixt:numdotdecimal" name="cpix:SubsidiaryInvestmentPurchaseOfShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTAvZnJhZzoyN2Y4MjYwMGIxN2E0ZTM4OWU3MTE3MDVhMjBkOTA2My90ZXh0cmVnaW9uOjI3ZjgyNjAwYjE3YTRlMzg5ZTcxMTcwNWEyMGQ5MDYzXzIwNTY_39dd3cd3-3832-4165-b201-4e263a4d7a4c">1.0</ix:nonFraction>&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investment through the purchase of shares of CET stock. As part of the agreement, WinHealth obtained a Board position at CET and the first opportunity to license CET products for the Chinese market. In connection with WinHealth's investment in CET, Cumberland also made an additional $<ix:nonFraction unitRef="usd" contextRef="i917430c8015149c18c59ded862b49717_I20190430" decimals="-5" format="ixt:numdotdecimal" name="cpix:SubsidiaryInvestmentPurchaseOfShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTAvZnJhZzoyN2Y4MjYwMGIxN2E0ZTM4OWU3MTE3MDVhMjBkOTA2My90ZXh0cmVnaW9uOjI3ZjgyNjAwYjE3YTRlMzg5ZTcxMTcwNWEyMGQ5MDYzXzIzNDM_a7e9c8e8-b858-4b79-b604-464e29bac058">1.0</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investment in CET.  Cumberland purchased additional CET shares through contribution of $<ix:nonFraction unitRef="usd" contextRef="i9f1c7f34352d4f90823b583604c2e094_D20190401-20190430" decimals="-5" format="ixt:numdotdecimal" name="cpix:ContributionOfCashAdditionalSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTAvZnJhZzoyN2Y4MjYwMGIxN2E0ZTM4OWU3MTE3MDVhMjBkOTA2My90ZXh0cmVnaW9uOjI3ZjgyNjAwYjE3YTRlMzg5ZTcxMTcwNWEyMGQ5MDYzXzI0MzM_426d53af-d975-4e90-a2a3-29871a09334c">0.3</ix:nonFraction>&#160;million in cash and a conversion of $<ix:nonFraction unitRef="usd" contextRef="i917430c8015149c18c59ded862b49717_I20190430" decimals="-5" format="ixt:numdotdecimal" name="cpix:IntercompanyLoansPayableConvertedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTAvZnJhZzoyN2Y4MjYwMGIxN2E0ZTM4OWU3MTE3MDVhMjBkOTA2My90ZXh0cmVnaW9uOjI3ZjgyNjAwYjE3YTRlMzg5ZTcxMTcwNWEyMGQ5MDYzXzI0NjQ_794a4829-731e-409b-a475-9b41f68c7048">0.7</ix:nonFraction>&#160;million in intercompany loans payable.  Upon completion of the additional investment by WinHealth and Cumberland, Gloria Pharmaceuticals agreed to return its shares in CET in exchange for consideration of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="i3522d1a659a04358b4f6ed8b764dd9e5_D20190401-20190430" decimals="-5" format="ixt:numdotdecimal" name="cpix:SubsidiaryInvestmentPaymentsForReturnOfCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTAvZnJhZzoyN2Y4MjYwMGIxN2E0ZTM4OWU3MTE3MDVhMjBkOTA2My90ZXh0cmVnaW9uOjI3ZjgyNjAwYjE3YTRlMzg5ZTcxMTcwNWEyMGQ5MDYzXzI2NjU_aec2b106-0b20-4987-ba5c-3bc578988a46">0.8</ix:nonFraction> million.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's ownership in CET is now <ix:nonFraction unitRef="number" contextRef="ie1b2c35fc3b6418cb8cc3c920e5ae3d6_I20191231" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTAvZnJhZzoyN2Y4MjYwMGIxN2E0ZTM4OWU3MTE3MDVhMjBkOTA2My90ZXh0cmVnaW9uOjI3ZjgyNjAwYjE3YTRlMzg5ZTcxMTcwNWEyMGQ5MDYzXzI3MDc_7588577f-b0d7-4bc1-8144-24c04084bba9">85</ix:nonFraction>%.  As noted above, the ownership interests of CET includes WinHealth and Cumberland, while the remaining interest is owned by Vanderbilt University and the Tennessee Technology Development Corporation. The operating results of CET allocated to noncontrolling interests in the consolidated statements of operations were  $<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTAvZnJhZzoyN2Y4MjYwMGIxN2E0ZTM4OWU3MTE3MDVhMjBkOTA2My90ZXh0cmVnaW9uOjI3ZjgyNjAwYjE3YTRlMzg5ZTcxMTcwNWEyMGQ5MDYzXzMwMzA_9ba595f9-689b-46d6-a320-d9ccb1281546">8,752</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTAvZnJhZzoyN2Y4MjYwMGIxN2E0ZTM4OWU3MTE3MDVhMjBkOTA2My90ZXh0cmVnaW9uOjI3ZjgyNjAwYjE3YTRlMzg5ZTcxMTcwNWEyMGQ5MDYzXzMwMzU_5e7463f2-d48f-4c25-8c17-9160a74752d9">75,704</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTAvZnJhZzoyN2Y4MjYwMGIxN2E0ZTM4OWU3MTE3MDVhMjBkOTA2My90ZXh0cmVnaW9uOjI3ZjgyNjAwYjE3YTRlMzg5ZTcxMTcwNWEyMGQ5MDYzXzMwNDM_6d94bebd-f2bb-4587-bf04-e25764ce70b5">71,182</ix:nonFraction> for the years ended December&#160;31, 2019, 2018 and 2017, respectively.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January&#160;1, 2007, the Company formed a wholly-owned subsidiary, Cumberland Pharma Sales Corp. ("CPSC").  CPSC is the subsidiary that employs the Company's hospital and field sales force personnel.</span></div></ix:continuation><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><div id="id2bfa55304bd45bbaa9cdf09bb7673a3_193"></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2)   <ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTQ2_61f78b0f-35a5-4c98-bc55-4923338fa704" continuedAt="i34e05abe4ba3403c9926b9fbea3f7fd3" escape="true">Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i34e05abe4ba3403c9926b9fbea3f7fd3" continuedAt="i80fb7b61e0f8420a995f37793c9bce8b"><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTQ3_e2658dfb-620c-4006-a049-12f8e29cfd5b" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements of the Company are stated in U.S. dollars and are prepared using U.S. generally accepted accounting principles. These financial statements include the accounts of the Company and its wholly and majority-owned subsidiaries. All significant intercompany transactions and accounts have been eliminated in consolidation.</span></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTQ1_ae653fad-0ca5-45c3-be55-409a6f713dd0" continuedAt="if9034addeef64de3a88a79470c49850e" escape="true">Use of Estimates</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if9034addeef64de3a88a79470c49850e">The preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.</ix:continuation>  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns (2) the allowances for obsolescent or unmarketable inventory (3) assumptions used in estimating acquisition date fair value of assets acquired in business combinations and (4) valuation of contingent consideration liability associated with business combinations.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTUy_7903e396-79ef-4988-84c8-980346776c01" continuedAt="id31c0aa11cc34da3a9c0ec3b6fdc835a" escape="true">Segment Reporting</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id31c0aa11cc34da3a9c0ec3b6fdc835a">The Company has <ix:nonFraction unitRef="segment" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzEzNzg_f21a49f4-a88a-42dc-b807-8b8ab35fd3d1">one</ix:nonFraction> operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, evaluated that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States. Total revenues are primarily attributable to U.S.&#160;customers.</ix:continuation>  Net revenues from customers outside the United States were approximately $<ix:nonFraction unitRef="usd" contextRef="i6a4ee4b80c85405aa9011089eea73f13_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzIyNTA_267212ec-8c08-4452-a7ab-ab6f0fd641ff">1.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i3faf6260efdc450498cc8cb573bbc167_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzIyNTU_146f1c07-3233-4a59-a4d4-3c6c7d661cf8">2.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icef1ce4e74b54672b3b04ac67a70e22b_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzIyNjM_be858ca8-aa29-4ba3-9f7d-cac279335586">1.6</ix:nonFraction> million for the years ended December&#160;31, 2019, 2018 and 2017, respectively.</span></div><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTY2_8a13b1be-9acf-41e4-afce-29616d470536" continuedAt="i506c7b80b0c34a11bfb4df20a9dba53b" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of financial assets and liabilities is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date.  The Company's fair value measurements follow the appropriate rules as well as the fair value hierarchy that prioritizes the information used to develop the measurements.  It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:</span></div><div style="margin-top:8pt;padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 -   Quoted prices for identical instruments in active markets.</span></div><div style="margin-top:8pt;padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 -  Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.</span></div><div style="margin-top:8pt;padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 -    Significant inputs to the valuation model are unobservable.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain policies and procedures to value instruments using the best and most relevant data available. The following section describes the valuation methodologies we use to measure different financial instruments at fair value on a recurring basis.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="i80fb7b61e0f8420a995f37793c9bce8b" continuedAt="i9ca00fb17f78440f9d3582e8486f8175"><ix:continuation id="i506c7b80b0c34a11bfb4df20a9dba53b" continuedAt="i292c282329a24c39b625c5dd1ca1ae29"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments include cash and cash equivalents, marketable securities, accounts receivable, accounts payable, accrued liabilities, contingent consideration liability and a revolving line of credit. The carrying values for cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to their short-term nature. The revolving line of credit has a variable interest rate, which approximates the current market rate.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's fair values of marketable securities are determined based on valuations provided by a third-party pricing service, as derived from such services' pricing models, and are considered either Level 1 or Level 2 measurements, depending on the nature of the investment.  The Company has no marketable securities in which the fair value is determined based on Level 3.  The level of management judgment required in evaluating fair value for Level 1 investments is minimal.  Similarly, there is little subjectivity or judgment required for Level 2 investments valued using valuation models that are standard across the industry and whose parameter inputs are quoted in active markets.  Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. The Company believes that the valuations provided by the third-party pricing service, as derived from such services' pricing models, represent prices that would be received to sell the assets at the measurement date (exit prices).</span></div></ix:continuation><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i292c282329a24c39b625c5dd1ca1ae29">The Company's contingent consideration liability is a Level 3 fair value measurement that is updated on a recurring basis at each reporting period using a valuation model.  Consistent with Level 3 fair value measurements, there are significant inputs to the valuation model that are unobservable.</ix:continuation> </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTY3_71dbf44d-1582-40ab-b326-29d9106ab8d2" continuedAt="i354b8193499040b695cd72c11de7ed09" escape="true">Cash and Cash Equivalents</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i354b8193499040b695cd72c11de7ed09">Cash and cash equivalents include highly liquid investments with original maturities of three months or less.  As of December&#160;31, 2019 and 2018, cash equivalents consist primarily of money market funds as well as trading securities with original maturities of less than ninety days.</ix:continuation> </span></div><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTY0_d7473a31-e987-4f8a-b7bd-ba6915e8bd61" escape="true"><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests in marketable debt securities in order to maximize its return on cash. Marketable securities consist of short-term cash investments, U.S. Treasury notes and bonds, corporate bonds, and commercial paper.  At the time of purchase, the Company classifies marketable securities as either trading securities or available-for-sale securities, depending on the intent at that time.  As of December&#160;31, 2019 and 2018, marketable securities were comprised solely of trading securities.  Trading securities are carried at fair value with unrealized gains and losses recognized as a component of interest income in the consolidated statements of operations.  As of December&#160;31, 2019, all the trading securities were commercial paper with original maturities of less than ninety days and as a result, were classified as cash equivalents.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTQ4_6df9f509-524e-42ca-9e57-c6520ac050c3" continuedAt="ib015c7af0dd347e0a7e96b160db0f46c" escape="true"><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable are recorded at the invoiced amount.  The Company records allowances for amounts that could become uncollectible in the future based on historical experience, including amounts related to chargebacks, cash discounts and credits for damaged product. The Company reviews each customer balance to assess collection status.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s products are distributed through independent pharmaceutical wholesalers.  The allowances against accounts receivable for chargebacks and discounts are determined on a product-by-product basis, and established by management as the Company&#8217;s best estimate at the time of sale based on each product&#8217;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks, discounts and credits claimed for damaged and expired product. The allowances in accounts receivable for chargebacks, cash discounts and damaged goods were $<ix:nonFraction unitRef="usd" contextRef="ia75e1df3d4b74017bd1b51e0b2b3cff5_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzgxMDc_22c375a5-2639-4edb-8ae5-cc05d6c3fba4">0.8</ix:nonFraction> million at December&#160;31, 2019 and $<ix:nonFraction unitRef="usd" contextRef="i3e91f9a0d19840b7b2aff337c95edc24_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzgxMjA_27e7ad46-e39a-4f53-8ab3-44bd86d6a691">0.7</ix:nonFraction> million at December 31, 2018. </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="i9ca00fb17f78440f9d3582e8486f8175" continuedAt="i8d79c7b0fe1c41b0a6ea1830e104c845"><ix:continuation id="ib015c7af0dd347e0a7e96b160db0f46c"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company&#8217;s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, revenues are reduced and accrued liabilities are increased by the Company&#8217;s estimate of the rebate that may be claimed as well as the reserves for expired and damaged goods.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash discounts are reductions to invoiced amounts offered to customers for payment within a specified period of time from the date of the invoice.</span></div></ix:continuation><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTUz_191b13e6-b958-4e70-87d9-0dc826d48245" continuedAt="i296570b743c34fff9579a3881930cd61" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company works closely with third parties to manufacture and package finished goods for sale.  Based on the customer relationship with the manufacturer or packager, the Company will either take title to finished goods at the time of shipment or at the time of arrival from the manufacturer.  The Company then warehouses such goods until distribution and sale.  As discussed below, effective January 1, 2017, inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.</span></div></ix:nonNumeric><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i296570b743c34fff9579a3881930cd61">The Company continually evaluates inventories for potential losses due to expired, short-dated or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates the carrying value of a product may not be recoverable, a charge is recorded to reduce the inventory to its current net realizable value.  The Company classifies the Vibativ inventories that it does not expect to sell within one year as non-current inventories.</ix:continuation> </span></div><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="cpix:PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTcw_0e6dbc59-b472-43f7-bc68-007594bc16bc" escape="true"><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid and Other Current Assets</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid and other current assets consist of deferred offering costs, prepaid insurance premiums, prepaid consulting services, deposits and annual fees paid to the U.S. Food and Drug Administration ("FDA").  The Company expenses all prepaid and other current asset amounts as used or over the period of benefit primarily on a straight-line basis, as applicable.</span></div></ix:nonNumeric><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred offering costs are expenses directly related to the Form S-3 or Shelf Registration filed with the SEC on November 11, 2017 and declared effective on January 16, 2018. These costs consist of legal, accounting, printing, and filing fees that the Company has capitalized. Deferred costs associated with the Shelf Registration will be reclassified to additional paid in capital on a pro-rata basis as the Company completes sales of shares under the Shelf Registration, with any remaining deferred offering costs to be charged to the results of operations at the end of the three-year life of the Shelf Registration. During the year ended December&#160;31, 2019, the Company has not expensed any deferred offering costs associated with the Shelf Registration.</span></div><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTU0_8e362f73-be68-4da4-8450-bbeb867a6255" escape="true"><div style="margin-top:7pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, including leasehold improvements, are stated at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the initial lease term plus renewal options, if reasonably assured, or the remaining useful life of the asset. Upon retirement or disposal of assets, any gain or loss is reflected as a component of operating income (loss) in the consolidated statement of operations.  Improvements that extend an asset&#8217;s useful life are capitalized.  Repairs and maintenance costs are expensed as incurred.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTQ5_03699412-f597-4e7b-8650-9f564929a209" continuedAt="i2302f079bb6548ee98b17f9ba2b454da" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Goodwill</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intangible assets and goodwill consist of capitalized costs related to product and license rights, patents, trademarks and goodwill obtained in the Vibativ acquisition. Goodwill is not amortized for financial reporting purposes, but is subject to impairment analysis at least annually.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="i8d79c7b0fe1c41b0a6ea1830e104c845" continuedAt="ie6207e8081cc4598aacdc34fa4775410"><ix:continuation id="i2302f079bb6548ee98b17f9ba2b454da"><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of acquiring product and license rights are capitalized at fair value at the date of acquisition for products that are approved by the FDA for commercial use.  These costs are amortized ratably over the estimated economic life of the product. The economic life is estimated based upon several factors.  This includes the term of the license agreement, the patent life or market exclusivity of the product and as well as  management's expectations of continued involvement with the product and the assessment of future sales, the future periods under which the product will be sold and the profitability of the product. This estimate is evaluated on a regular basis during the amortization period and adjusted if appropriate.  If there are any changes made to the useful life of the product and license rights, the costs associated with such a change, if any, will be capitalized and amortized over the revised useful life.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized patent costs consist of outside legal costs associated with obtaining and protecting patents on products that have been approved for marketing by the FDA. If it becomes probable that a patent will not be issued or a patent has been declared invalid, related costs associated with the patent application are expensed at the time such determination is made. All costs associated with obtaining patents for products that have not been approved for marketing by the FDA are expensed as incurred.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="cpix:ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTY4_d71b10f4-4342-4cce-82ae-7df48ece45f9" continuedAt="if150935d424e4f08a0a9db99265eddbb" escape="true">Amortization expense is recognized ratably over the following periods:</ix:nonNumeric></span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><ix:continuation id="if150935d424e4f08a0a9db99265eddbb"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:63.141%"><tr><td style="width:1.0%"></td><td style="width:46.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rights</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib06a29ad4edd4918a967323242b0142d_D20190101-20191231" name="cpix:FiniteLivedIntangibleAssetsUsefulLivesTextual" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90YWJsZToyYTdkMmRiZDNjYmI0ZGZiYTU2N2YzZjY4NmIyY2JmNi90YWJsZXJhbmdlOjJhN2QyZGJkM2NiYjRkZmJhNTY3ZjNmNjg2YjJjYmY2XzAtMi0xLTEtMA_6629e581-3403-4fb0-a257-d806079f42e3">Estimated economic life</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License rights</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib9796d25c7c94244a85df974cff3caf9_D20190101-20191231" name="cpix:FiniteLivedIntangibleAssetsUsefulLivesTextual" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90YWJsZToyYTdkMmRiZDNjYmI0ZGZiYTU2N2YzZjY4NmIyY2JmNi90YWJsZXJhbmdlOjJhN2QyZGJkM2NiYjRkZmJhNTY3ZjNmNjg2YjJjYmY2XzEtMi0xLTEtMA_3331ddb7-697a-4631-8b2a-2452f614b75f">Term of license agreement</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9264ef6a01f546dca65e6adec1f967fe_D20190101-20191231" name="cpix:FiniteLivedIntangibleAssetsUsefulLivesTextual" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90YWJsZToyYTdkMmRiZDNjYmI0ZGZiYTU2N2YzZjY4NmIyY2JmNi90YWJsZXJhbmdlOjJhN2QyZGJkM2NiYjRkZmJhNTY3ZjNmNjg2YjJjYmY2XzItMi0xLTEtMA_fb781c0e-1cd5-409e-b0ee-9c4503483c03">Life of patent</ix:nonNumeric></span></td></tr></table></ix:continuation></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTYw_8404c2a2-7082-48cd-bba1-d6697443e33c" continuedAt="if65f777f16b74624906a96b422ada82b" escape="true">Impairment of Long-Lived Assets</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if65f777f16b74624906a96b422ada82b">Long-lived assets, such as property and equipment, operating lease right-of-use assets and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If events or circumstances arise that require a long-lived asset to be tested for potential impairment, the Company first compares undiscounted cash flows expected to be generated by the asset to its carrying value. If the carrying amount of the long-lived asset is not recoverable on an undiscounted cash flow basis, an impairment charge is recognized to the extent that the carrying value exceeds the fair value. Fair value is determined through various valuation techniques including quoted market prices, third-party independent appraisals and discounted cash flow models.</ix:continuation>  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and other indefinite lived intangible assets that are not subject to amortization are tested at least annually for impairment.  The impairment analysis for goodwill requires a comparison of fair value to the carrying value of the reporting unit.  The Company's goodwill was acquired in November 2018 with the Vibativ acquisition. As a result, the Vibativ component of the Company is the reporting unit evaluated for goodwill impairment.  Cumberland determined the fair value of the reporting unit through current and future estimated revenue and profitability of the product.  The Company recorded no impairment charges during 2019, 2018 and 2017.</span></div><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTYx_b1fb062d-1407-4ed2-9bda-15e938d7f49d" continuedAt="i71769f13d0d7422dae1e8902b6fb0a0e" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2018, the Company adopted the Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;) amended guidance in the form of Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-09, "Revenue from Contracts with Customers," (ASC 606). Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts were not adjusted and are reported in accordance with ASC 605.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Product Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recognized in the amount that reflects the consideration that we expect to receive for these goods.  Depending upon the shipping terms of the transaction, the revenue is recognized.at the point where the customer obtains control of the goods and we satisfy our performance obligation.  This occurs upon either shipment of the product or arrival at its ship to destination.  Payment terms typically range from 30 to 60 days from date of shipment. The Company&#8217;s net product revenue reflects the reduction from gross product revenue for </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="ie6207e8081cc4598aacdc34fa4775410" continuedAt="i916909c7e3754a96a01790642c61be24"><ix:continuation id="i71769f13d0d7422dae1e8902b6fb0a0e" continuedAt="i86e9b49e19444469b6e9d2bd81e94ae0"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">estimated allowances for chargebacks, discounts and damaged goods, and reflects sales related accruals for rebates, coupons, product returns, and certain administrative and service fees. Significant judgments must be made in determining the transaction price for our sales of products related to these adjustments. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Rebates and Discounts</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowances against accounts receivable for chargebacks, discounts, expired and damaged goods are determined on a product-by-product basis, and established by management as the Company&#8217;s best estimate at the time of sale based on each product&#8217;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks, discounts and credits claimed for damaged and expired product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company&#8217;s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, sales revenues are reduced and accrued liabilities are increased by the Company&#8217;s estimate of the rebate that may be claimed.</span></div><div style="margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Returns</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, the Company maintains a return policy that allows customers to return product within a specified period prior to and subsequent to the expiration date. The Company&#8217;s estimate of the provision for returns is based upon historical experience, expiration date by product as well as any other factor expected to impact future returns. Any changes in the assumptions used to estimate the provision for returns are recognized in the period those assumptions are changed.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Revenues</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues primarily consist of income from grant funding programs, licensing agreements, leases and contract services.  Revenue related to grants is recognized when all conditions related to such grants have been met.  All other revenue is recognized when earned.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Products Sold</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products sold consists principally of the cost to acquire each unit of product sold, including in-bound freight expense as well as any adjustment in the net realizable value of inventory acquired in acquisitions. Cost of products sold also includes expenses associated with the reduction in the net realizable value of slow-moving or expired product.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling and Marketing Expense</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling and marketing expense consists primarily of expenses relating to the advertising, promotion, distribution and sale of products, including royalty expense, salaries and related costs.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Distribution Costs</span></div></ix:continuation><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i86e9b49e19444469b6e9d2bd81e94ae0">Distribution costs are expensed as incurred and are included as a component of selling and marketing expenses in the consolidated statements of operations.</ix:continuation> Distribution costs were as follows for the years ended December 31:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.897%"><tr><td style="width:1.0%"></td><td style="width:41.064%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.064%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.559%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2017</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProductionAndDistributionCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90YWJsZTo2MjFlZjFiZmU5NjE0ZGZlOGZlMDc1ZGY1MzU0NWVjZS90YWJsZXJhbmdlOjYyMWVmMWJmZTk2MTRkZmU4ZmUwNzVkZjUzNTQ1ZWNlXzItMi0xLTEtMA_53e2c235-0d48-43af-a8aa-8683ada4c82c">613,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProductionAndDistributionCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90YWJsZTo2MjFlZjFiZmU5NjE0ZGZlOGZlMDc1ZGY1MzU0NWVjZS90YWJsZXJhbmdlOjYyMWVmMWJmZTk2MTRkZmU4ZmUwNzVkZjUzNTQ1ZWNlXzItNC0xLTEtMA_217d62f9-8516-412d-a49f-b983bb56eea4">457,814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProductionAndDistributionCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90YWJsZTo2MjFlZjFiZmU5NjE0ZGZlOGZlMDc1ZGY1MzU0NWVjZS90YWJsZXJhbmdlOjYyMWVmMWJmZTk2MTRkZmU4ZmUwNzVkZjUzNTQ1ZWNlXzItNi0xLTEtMA_116859c8-e47f-4fb2-8edc-dc1fdcc95b56">487,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="i916909c7e3754a96a01790642c61be24" continuedAt="i98d9cd43a60d4390b920361ffd2aca0b"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTYz_7e76093b-9f5b-498f-85f0-4e20b5c86030" continuedAt="i7dbcb7e71fe6489abe72127e81bd1d3c" escape="true">Advertising Costs</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7dbcb7e71fe6489abe72127e81bd1d3c">Advertising costs are expensed as incurred and are included as a component of selling and marketing expenses in the consolidated statements of operations.</ix:continuation> Advertising costs were as follows for the years ended December 31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.897%"><tr><td style="width:1.0%"></td><td style="width:41.064%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.064%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.559%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2017</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advertising costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90YWJsZTo3OTg5Y2ViNWFjZDE0MDA1YWY4M2U4MzBjMmRjYmQwNi90YWJsZXJhbmdlOjc5ODljZWI1YWNkMTQwMDVhZjgzZTgzMGMyZGNiZDA2XzItMi0xLTEtMA_be2d5c61-5682-491b-8b68-b25fe43c2942">2,594,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90YWJsZTo3OTg5Y2ViNWFjZDE0MDA1YWY4M2U4MzBjMmRjYmQwNi90YWJsZXJhbmdlOjc5ODljZWI1YWNkMTQwMDVhZjgzZTgzMGMyZGNiZDA2XzItNC0xLTEtMA_4f5a958a-fddb-4d94-a5db-51aa609572a1">2,005,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90YWJsZTo3OTg5Y2ViNWFjZDE0MDA1YWY4M2U4MzBjMmRjYmQwNi90YWJsZXJhbmdlOjc5ODljZWI1YWNkMTQwMDVhZjgzZTgzMGMyZGNiZDA2XzItNi0xLTEtMA_b7249bc1-5d81-4966-965a-5f146e1522aa">2,377,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTYy_7424d78e-8e26-4194-8783-45ea1b42db36" escape="true"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed in the period incurred. Research and development costs are comprised mainly of clinical trial expenses, salaries, wages and other related costs such as materials and supplies. Research and development expense includes activities performed by third-party providers participating in the Company&#8217;s clinical studies. The Company accounts for these costs based on estimates of work performed, patients enrolled or fixed fees for services over the period of time the clinical trials are performed.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTcx_371cbdd4-00d0-4be1-9a7a-94d775ebe5d0" escape="true"><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides for deferred taxes using the asset and liability approach. Under this method, deferred tax assets and liabilities are recognized for future tax consequences attributable to operating loss and tax credit carryforwards, as well as differences between the carrying amounts of existing assets and liabilities and their respective tax bases. The Company&#8217;s principal differences are related to the timing of deductibility of certain items, such as inventory, depreciation, amortization and share-based compensation. Deferred tax assets and liabilities are measured using enacted statutory tax rates that are expected to apply to taxable income in the years such temporary differences are anticipated to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. The Company only recognizes income tax benefits associated with an income tax position in which it is &#8220;more likely than not&#8221; that the position would be sustained upon examination by the taxing authorities.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, management considers whether some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of existing temporary differences, projected future taxable income and tax planning strategies in making this assessment. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounting policy with respect to interest and penalties arising from income tax settlements is to recognize them as part of the provision for income taxes.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTcy_e9de1efc-08f2-4a45-987f-a8c096df0a28" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total comprehensive income (loss) was comprised solely of net income (loss) for all periods presented.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTU1_160f2a6e-714c-4345-862c-609234089946" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings (Loss) per Share</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings (loss) per share is calculated by dividing net income (loss) attributable to common shareholders by the weighted-average number of shares outstanding. Except where the result would be antidilutive to income from continuing operations, diluted earnings (loss) per share is calculated by assuming the vesting of unvested restricted stock and the exercise of stock options and warrants and unrecognized compensation costs.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span><br/></span></div><ix:continuation id="i98d9cd43a60d4390b920361ffd2aca0b" continuedAt="i7efac6b6007d4672a29591568aa8fdc5"><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTU4_b96456d4-988b-4c83-9d16-66f18bb6be6c" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Payments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation cost for all share-based payments issued, modified, repurchased or canceled. Depending on the nature of the vesting provisions, restricted stock awards are measured using either the fair value on the grant date or the fair value of common stock on the date the vesting provisions lapse. Prior to the lapse for those equity grants not valued on the grant date, the fair value is measured on the last day of the reporting period.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTU2_6e267ebe-0207-4ea7-aeff-e54fb74dc94b" continuedAt="ia0fb7c377653465ca8fcad162ae80379" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Agreements</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party to several collaborative arrangements with certain research institutions to identify and pursue promising preclinical pharmaceutical product candidates. The Company has determined these collaborative agreements do not meet the criteria for accounting under Accounting Standards Codification 808, Collaborative Agreements. The agreements do not specifically designate each party's rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party. The funding for these programs is generally provided through private sector investments or federal Small Business Administration ("SBIR/STTR") grant programs. Expenses incurred under these collaborative agreements are included in research and development expenses in the consolidated statements of operations. Funding received from private sector investments and grants are recorded as net revenues in the consolidated statements of operations.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassification of prior period amounts</span></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia0fb7c377653465ca8fcad162ae80379">The Company has made certain reclassifications to prior period amounts to conform to the current-year presentation of the reporting of research and development expense and general and administrative expense on the consolidated statements of operations. Certain costs and expenses related to research and development were previously reported as general and administrative expenses on the consolidated statements of operations. These reclassifications have no effect on the reported operating loss or equity for the years ended December 31, 2018 and 2017.</ix:continuation> </span></div><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTU3_1bcc72ba-158e-4958-832d-158a994638c4" continuedAt="i9627ee7dde5249e4a3dfabdb155cad17" escape="true"><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance </span></div><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Adopted Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2014, the FASB issued amended guidance in the form of ASU No. 2014-09, &#8220;Revenue from Contracts with Customers&#8221; (&#8220;ASC 606&#8221;).  The core principle of the new guidance is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. The new guidance defines a five-step process to achieve this core principle and, in doing so, additional judgments and estimates may be required within the revenue recognition process. The new standard replaced most of the existing revenue recognition standards in U.S. GAAP when it became effective. In July 2015, the FASB issued a one-year deferral of the adoption date, which extended the effective date for us to January 1, 2018, at which point Cumberland adopted the standard. </span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated its revenues and the new guidance had immaterial impacts to recognition practices upon adoption on January 1, 2018.  As part of the adoption, the Company elected to apply the new guidance on a modified retrospective basis. The Company did not record a cumulative effect adjustment to historical retained earnings for initially applying the new guidance as no revenue recognition differences were identified in the timing or amount of revenue. </span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the Financial Accounting Standards Board ("FASB") issued guidance in the form of a FASB Accounting Standards Update ("ASU") No. 2016-02, &#8220;Leases.&#8221; The new standard establishes a right-of-use (&#8220;ROU&#8221;) model that requires a lessee to record an ROU asset and a lease liability on the balance sheet for all leases with terms longer than twelve months. Leases will be classified as either finance (formerly "capital leases") or </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="i7efac6b6007d4672a29591568aa8fdc5" continuedAt="ie18c535b4a094daa9508de079f720bca"><ix:continuation id="i9627ee7dde5249e4a3dfabdb155cad17" continuedAt="i7a59ab374c8b4d28aa5cd724621edced"><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operating, with classification affecting the pattern of expense recognition in the income statement. The standard provides for a modified retrospective transition approach for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain optional practical expedients.  In July 2018, the FASB issued ASU 2018-11, "Leases: Targeted Improvements", allowing for an alternative transition method (the effective date approach). It allows an entity to initially apply the new lease guidance at the adoption date (rather than at the beginning of the earliest period presented). Cumberland adopted the lease guidance effective January 1, 2019 using the package of transition practical expedients.  This allowed the Company to retain the lease classification for any leases existing prior to adoption, in addition to other benefits. See additional discussion of the impact of adopting the lease accounting guidance in Note 15.</span></div><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements - Not Yet Adopted</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose more information, including the information they use to track credit quality by year of origination for most financing receivables. Companies will apply the standard&#8217;s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. This standard is effective for the Company on January 1, 2020. The Company continues to evaluate this new standard on its trade and other receivables but does not expect a material impact on its consolidated financial statements. </span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met, the election must be applied on an instrument-by-instrument basis, and the election is not available for either available-for-sale or held-to-maturity debt securities. The effective date is the same as ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January 1, 2020. The Company continues to evaluate this new standard but does not expect a material impact on its consolidated financial statements. </span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued ASU No. 2018-18, &#8220;Collaboration Arrangements: Clarifying the Interaction between Topic 808 and Topic 606&#8221; (ASU 2018-18). The issuance of ASU 2014-09 raised questions about the interaction between the guidance on collaborative arrangements and revenue recognition. ASU 2018-18 addresses this uncertainty by (1) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASU 2014-09 when the collaboration arrangement participant is a customer, (2) adding unit of account guidance to assess whether the collaboration arrangement or a part of the arrangement is with a customer and (3) precluding a company from presenting transactions with collaboration arrangement participants that are not directly related to sales to third parties together with revenue from contracts with customers. The new standard will be effective for the Company on January 1, 2020.  The Company continues to evaluate this new standard but does not expect a material impact on its consolidated financial statements. </span></div></ix:continuation></ix:continuation><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie18c535b4a094daa9508de079f720bca"><ix:continuation id="i7a59ab374c8b4d28aa5cd724621edced">In January 2017, the FASB issued ASU No. 2017-04, &#8220;Simplifying the Test for Goodwill Impairment&#8221; (ASU 2017-04). The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation.  As a result of the revised guidance, a goodwill impairment will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The new standard will be effective for the Company on January 1, 2020. The Company continues to evaluate this new standard but does not expect a material impact on its consolidated financial statements and related disclosures.</ix:continuation></ix:continuation> </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><div id="id2bfa55304bd45bbaa9cdf09bb7673a3_199"></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:7pt;text-align:justify"><span><br/></span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90ZXh0cmVnaW9uOjA3MDRiZjQ2MTQzZTQzMjI4ZGNkNjBmZDZiMWU1Njc5XzU4MTQ_ac84a299-a3a9-459c-9b0b-6f07cafc8524" continuedAt="i41e56188898c4b57b5b33c032f58c0b7" escape="true">Omeclamox</ix:nonNumeric></span><ix:continuation id="i41e56188898c4b57b5b33c032f58c0b7" continuedAt="ie82baec5cedc40c9a7602dd2039dca90"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-Pak, RediTrex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> and Vibativ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></ix:continuation></div><ix:continuation id="ie82baec5cedc40c9a7602dd2039dca90" continuedAt="i1b7ca472769e498681abecbc3309956b"><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Omeclamox-Pak</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, Cumberland completed an agreement with Gasto-enterlogics Inc. ("GEL") to acquire the remaining product rights associated with Omeclamox-Pak including the product&#8217;s FDA-approved New Drug Application and the domestic and international trademarks. As part of the transaction, which was accounted for as an asset acquisition, Cumberland paid $<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="cpix:PaymentsForAssetAcquisitions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90ZXh0cmVnaW9uOjA3MDRiZjQ2MTQzZTQzMjI4ZGNkNjBmZDZiMWU1Njc5XzQyMA_1292c256-6cfc-4e3b-882e-94f78610646b">2.3</ix:nonFraction> million during 2018 and ended Cumberland&#8217;s payments of royalties and manufacturing fees to GEL.  The Company has now assumed responsibility for the maintenance of the product&#8217;s FDA approval and for the oversight of the product&#8217;s manufacturing and packaging.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This agreement follows the November 2015 agreement between Cumberland and GEL to assume the remaining commercial rights to Omeclamox-Pak for the United States. The Company had previously signed an agreement with Pernix Therapeutics ("Pernix") to jointly commercialize the product in the United States in October 2013.  As part of the November 2015 GEL Agreement, Cumberland and Pernix terminated their arrangements. </span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $<ix:nonFraction unitRef="usd" contextRef="i0a05405482c64e9e8fe092b821aeb335_D20131028-20131029" decimals="-5" format="ixt:numdotdecimal" name="cpix:RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90ZXh0cmVnaW9uOjA3MDRiZjQ2MTQzZTQzMjI4ZGNkNjBmZDZiMWU1Njc5XzEwOTQ_33478ffe-be03-47a6-80c1-2de68ca940af">4.0</ix:nonFraction> million upfront payment that the Company paid in October 2013 to Pernix along with the payments made to GEL during 2018 are included in product and license rights and are being amortized over the remaining expected useful life of the acquired asset. The Company evaluated the remaining expected useful life and maintained the existing estimated life of the product, June 2032.  Omeclamox-Pak contributed $<ix:nonFraction unitRef="usd" contextRef="i62d1338de7314d30a069c29708d22188_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90ZXh0cmVnaW9uOjA3MDRiZjQ2MTQzZTQzMjI4ZGNkNjBmZDZiMWU1Njc5XzE0OTM_62abca79-7d33-4ff7-ab5c-a8d7a3b94bc6">0.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ie0c9147a91864842a7ac6266279fa374_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90ZXh0cmVnaW9uOjA3MDRiZjQ2MTQzZTQzMjI4ZGNkNjBmZDZiMWU1Njc5XzE0OTc_da9fbfe4-0fce-4630-8756-37597f45f631">0.6</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="iafa9e83c0991457dbecd945d1f0eb0a8_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90ZXh0cmVnaW9uOjA3MDRiZjQ2MTQzZTQzMjI4ZGNkNjBmZDZiMWU1Njc5XzE1MDU_dfc8be49-255e-4089-a822-2a5425bd765b">1.8</ix:nonFraction> million in net revenues during 2019, 2018, and 2017, respectively.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RediTrex</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, the Company announced an Agreement to acquire the exclusive U.S. rights to Nordic Group B.V.&#8217;s ("Nordic") injectable methotrexate product line as an asset purchase. The products are designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Agreement, Cumberland is responsible for the products&#8217; FDA submission and registration. As consideration for the license, at closing, Cumberland paid a deposit of $<ix:nonFraction unitRef="usd" contextRef="iebd5c24d9fc142c0b899398d6d3c153d_D20161101-20161130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90ZXh0cmVnaW9uOjA3MDRiZjQ2MTQzZTQzMjI4ZGNkNjBmZDZiMWU1Njc5XzIxMDc_91547538-e6c9-4a39-b5f6-aba1500d1636">100,000</ix:nonFraction>.  The Company also recorded a liability of $<ix:nonFraction unitRef="usd" contextRef="iebd5c24d9fc142c0b899398d6d3c153d_D20161101-20161130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90ZXh0cmVnaW9uOjA3MDRiZjQ2MTQzZTQzMjI4ZGNkNjBmZDZiMWU1Njc5XzIxNTM_2640bc8c-a885-42e5-b456-2b3ccede1078">0.9</ix:nonFraction> million that will be settled through <ix:nonFraction unitRef="shares" contextRef="i00c91a50edb844d99bb320b2490ff8d6_D20161101-20161130" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90ZXh0cmVnaW9uOjA3MDRiZjQ2MTQzZTQzMjI4ZGNkNjBmZDZiMWU1Njc5XzIxODU_8e1ddeb6-65ab-4853-9ab9-f7633662ac6c">180,000</ix:nonFraction> unvested restricted shares of Cumberland common stock that vest upon the FDA approval of the first Nordic product. Cumberland also agreed to provide Nordic a series of payments tied to the products&#8217; FDA approval, launch and achievement of certain sales milestones. Nordic is responsible for manufacturing and supply of the products. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2019, Cumberland received FDA approval of the pre-filled syringe. The <ix:nonFraction unitRef="shares" contextRef="i00c91a50edb844d99bb320b2490ff8d6_D20161101-20161130" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90ZXh0cmVnaW9uOjA3MDRiZjQ2MTQzZTQzMjI4ZGNkNjBmZDZiMWU1Njc5XzI2MDg_8e1ddeb6-65ab-4853-9ab9-f7633662ac6c">180,000</ix:nonFraction> shares of restricted Cumberland common stock vested and were valued at $<ix:nonFraction unitRef="usd" contextRef="i3dc00a50885944de8bd18286fb857d2a_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90ZXh0cmVnaW9uOjA3MDRiZjQ2MTQzZTQzMjI4ZGNkNjBmZDZiMWU1Njc5XzI2ODI_a3ea59e4-0219-42bd-bdb3-9a0e10494056">0.9</ix:nonFraction> million on the vesting date. In addition, the FDA approval resulted in an additional $<ix:nonFraction unitRef="usd" contextRef="ie0bf4ffa056349039b29b90f3009e187_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90ZXh0cmVnaW9uOjA3MDRiZjQ2MTQzZTQzMjI4ZGNkNjBmZDZiMWU1Njc5XzI3NjI_38ac489f-7eeb-4936-9518-e96eb4f4edd3">1.0</ix:nonFraction>&#160;million liability to Nordic that will be paid during 2020.  The value of the then unvested restricted Cumberland common stock shares was a liability of $<ix:nonFraction unitRef="usd" contextRef="i5b955a67143f40b994546bcffda9b554_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90ZXh0cmVnaW9uOjA3MDRiZjQ2MTQzZTQzMjI4ZGNkNjBmZDZiMWU1Njc5XzI5MDk_f1e163cf-1aa8-4af6-b91e-2ed962d73861">1.1</ix:nonFraction> million at December&#160;31, 2018.   </span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vibativ</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand.  Vibativ is a patented, FDA approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.  Cumberland acquired Vibativ to further add to its product offerings, increase its net revenue and positively contribute to the Company's operating results.  Cumberland expects to deduct the goodwill acquired in the acquisition for tax purposes.    </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="i1b7ca472769e498681abecbc3309956b" continuedAt="i17a8df1a96624e68ab443f0efeed565e"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company paid an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i35eae0bc26094a639bb7e4c0640fb7ea_D20181101-20181130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90ZXh0cmVnaW9uOjA3MDRiZjQ2MTQzZTQzMjI4ZGNkNjBmZDZiMWU1Njc5XzQwNTY_88924b5a-18ed-48b5-95b3-6cb5d761a6eb">20.0</ix:nonFraction> million at closing and a $<ix:nonFraction unitRef="usd" contextRef="ie2b0bcf3278442f08417f95c2f0b677a_D20190308-20190308" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherPaymentsToAcquireBusinesses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90ZXh0cmVnaW9uOjA3MDRiZjQ2MTQzZTQzMjI4ZGNkNjBmZDZiMWU1Njc5XzQwNzY_25299168-90c8-46d5-a1f6-d789162d5735">5.0</ix:nonFraction> million cash payment during early 2019. In addition, Cumberland agreed to pay a royalty of up to <ix:nonFraction unitRef="number" contextRef="i35eae0bc26094a639bb7e4c0640fb7ea_D20181101-20181130" decimals="2" name="cpix:TieredRoyaltyPaymentsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90ZXh0cmVnaW9uOjA3MDRiZjQ2MTQzZTQzMjI4ZGNkNjBmZDZiMWU1Njc5XzQxNjg_739656c6-c6d4-48f0-84cb-2fc874eefb9d">20</ix:nonFraction>% on future net sales of the product.  The future royalty payments were required to be recognized at their acquisition-date fair value as part of the contingent consideration transferred in the business combination. </span></div><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90ZXh0cmVnaW9uOjA3MDRiZjQ2MTQzZTQzMjI4ZGNkNjBmZDZiMWU1Njc5XzU4MTY_852599e2-985e-440f-aaf6-4f3438316974" escape="true"><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the initial payments and consideration for the business combination:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:74.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.578%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid at closing</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f2a5edba28144ad932b2ce0fd047ab3_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90YWJsZTpjMmMxYjI2NWIwMWI0NjMxYmRmOTEzZjdkM2FmMmYzYi90YWJsZXJhbmdlOmMyYzFiMjY1YjAxYjQ2MzFiZGY5MTNmN2QzYWYyZjNiXzItMS0xLTEtMA_e8f65b40-0139-407b-a0e6-adc442ec3851">20,000,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment during early 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f2a5edba28144ad932b2ce0fd047ab3_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherPaymentsToAcquireBusinesses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90YWJsZTpjMmMxYjI2NWIwMWI0NjMxYmRmOTEzZjdkM2FmMmYzYi90YWJsZXJhbmdlOmMyYzFiMjY1YjAxYjQ2MzFiZGY5MTNmN2QzYWYyZjNiXzMtMS0xLTEtMA_6cb3d5c4-fd5b-486c-affa-974d0adbf56f">5,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration - net sales royalty</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f2a5edba28144ad932b2ce0fd047ab3_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="cpix:PaymentsForContingentConsideration" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90YWJsZTpjMmMxYjI2NWIwMWI0NjMxYmRmOTEzZjdkM2FmMmYzYi90YWJsZXJhbmdlOmMyYzFiMjY1YjAxYjQ2MzFiZGY5MTNmN2QzYWYyZjNiXzQtMS0xLTEtMA_b031d625-b7b2-4009-b2e1-a55018228079">9,182,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f2a5edba28144ad932b2ce0fd047ab3_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90YWJsZTpjMmMxYjI2NWIwMWI0NjMxYmRmOTEzZjdkM2FmMmYzYi90YWJsZXJhbmdlOmMyYzFiMjY1YjAxYjQ2MzFiZGY5MTNmN2QzYWYyZjNiXzUtMS0xLTEtMA_f2856074-4196-4959-9cdb-800bffd1263f">34,182,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liability represents the future net sales royalty payments discussed above.  Cumberland prepared the valuations of the contingent consideration liability and the intangible assets utilizing significant unobservable inputs.  As a result, the valuations are classified as Level 3 fair value measurements.  The Company will continue to evaluate the assets acquired and liabilities assumed during the measurement period. </span></div><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90ZXh0cmVnaW9uOjA3MDRiZjQ2MTQzZTQzMjI4ZGNkNjBmZDZiMWU1Njc5XzU4MTc_93b4beda-14a3-4e06-a0b7-e6ba187e368b" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the Company's Level 3 contingent consideration liability that is measured at fair value on a recurring basis.  The current and long-term portions of this liability are disclosed in Note 8.  The contingent consideration earned and accrued in operating expenses is paid to the seller quarterly.</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent consideration liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at November 12, 2018</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb606e761ca74e0fb88c19ca9f7345f7_I20181112" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90YWJsZTozMDQ1MGIxMjdjMDk0YzA2YTI0YWNmZGNjZWI4NDA0ZC90YWJsZXJhbmdlOjMwNDUwYjEyN2MwOTRjMDZhMjRhY2ZkY2NlYjg0MDRkXzEtMS0xLTEtMA_64f9b986-bdc6-4506-961e-35478122c717">9,034,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54bf1d15e917470abd4a457ea8b0a9b5_D20181113-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90YWJsZTozMDQ1MGIxMjdjMDk0YzA2YTI0YWNmZGNjZWI4NDA0ZC90YWJsZXJhbmdlOjMwNDUwYjEyN2MwOTRjMDZhMjRhY2ZkY2NlYjg0MDRkXzItMS0xLTEtMA_136fddbb-e5b3-479e-a50b-468dad5448cd">40,000</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2859968ba8084d4f9a9f00fafe0202a4_D20181112-20181231" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90YWJsZTozMDQ1MGIxMjdjMDk0YzA2YTI0YWNmZGNjZWI4NDA0ZC90YWJsZXJhbmdlOjMwNDUwYjEyN2MwOTRjMDZhMjRhY2ZkY2NlYjg0MDRkXzMtMS0xLTEtMA_ca8f6bb9-963e-4585-8d68-835369296099">508,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2018</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8286cfe2c4684a39972d0ce5371ad480_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90YWJsZTozMDQ1MGIxMjdjMDk0YzA2YTI0YWNmZGNjZWI4NDA0ZC90YWJsZXJhbmdlOjMwNDUwYjEyN2MwOTRjMDZhMjRhY2ZkY2NlYjg0MDRkXzQtMS0xLTEtMA_8fab50d0-bf1b-4b73-8cf2-0d78be19d3ba">9,502,000</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment to initial fair value of the contingent consideration liability</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f2a5edba28144ad932b2ce0fd047ab3_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90YWJsZTozMDQ1MGIxMjdjMDk0YzA2YTI0YWNmZGNjZWI4NDA0ZC90YWJsZXJhbmdlOjMwNDUwYjEyN2MwOTRjMDZhMjRhY2ZkY2NlYjg0MDRkXzUtMS0xLTEtMA_fe201061-a575-4793-bbe6-07473ba3c386">148,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f2a5edba28144ad932b2ce0fd047ab3_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRoyalties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90YWJsZTozMDQ1MGIxMjdjMDk0YzA2YTI0YWNmZGNjZWI4NDA0ZC90YWJsZXJhbmdlOjMwNDUwYjEyN2MwOTRjMDZhMjRhY2ZkY2NlYjg0MDRkXzYtMS0xLTEtMA_ddf9c9af-5b0a-46bf-8774-0adf569bcecf">1,033,108</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f2a5edba28144ad932b2ce0fd047ab3_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90YWJsZTozMDQ1MGIxMjdjMDk0YzA2YTI0YWNmZGNjZWI4NDA0ZC90YWJsZXJhbmdlOjMwNDUwYjEyN2MwOTRjMDZhMjRhY2ZkY2NlYjg0MDRkXzctMS0xLTEtMA_db466a56-a0c1-49d5-abb8-47d13a0856b4">804,167</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f2a5edba28144ad932b2ce0fd047ab3_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90YWJsZTozMDQ1MGIxMjdjMDk0YzA2YTI0YWNmZGNjZWI4NDA0ZC90YWJsZXJhbmdlOjMwNDUwYjEyN2MwOTRjMDZhMjRhY2ZkY2NlYjg0MDRkXzgtMS0xLTEtMA_18d22411-4b7a-468e-9361-7618074544c4">820,864</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd15955102ce48909e6253ea8529c09b_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90YWJsZTozMDQ1MGIxMjdjMDk0YzA2YTI0YWNmZGNjZWI4NDA0ZC90YWJsZXJhbmdlOjMwNDUwYjEyN2MwOTRjMDZhMjRhY2ZkY2NlYjg0MDRkXzktMS0xLTEtMA_d15bfd56-9e55-4c99-bc29-084ed5dfb7c5">8,633,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:8pt;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="i17a8df1a96624e68ab443f0efeed565e" continuedAt="i6bac8d7554cc439d9a70f38cdad45703"><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90ZXh0cmVnaW9uOjA3MDRiZjQ2MTQzZTQzMjI4ZGNkNjBmZDZiMWU1Njc5XzU4MTg_ea36b8ec-68b0-4f59-8630-684a01109e66" escape="true"><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the allocation of the fair values of the assets acquired as of the acquisition date for Vibativ:</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.743%"><tr><td style="width:1.0%"></td><td style="width:63.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.615%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4af7f789d58345659c0394f24e9c9d71_I20181130" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90YWJsZTowOWQ1OGEwNjJkMWQ0YTc0YTQ2NTU5NGQ4ZGZkN2MyMC90YWJsZXJhbmdlOjA5ZDU4YTA2MmQxZDRhNzRhNDY1NTk0ZDhkZmQ3YzIwXzAtMS0xLTEtMA_0dabeff3-fef6-44a5-9bfb-b44c052d0556">6,624,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process - unlabeled vials</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4af7f789d58345659c0394f24e9c9d71_I20181130" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90YWJsZTowOWQ1OGEwNjJkMWQ0YTc0YTQ2NTU5NGQ4ZGZkN2MyMC90YWJsZXJhbmdlOjA5ZDU4YTA2MmQxZDRhNzRhNDY1NTk0ZDhkZmQ3YzIwXzEtMS0xLTEtMA_5dbeeecb-2e53-4ba2-823a-d7b1c7b49080">3,970,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process - validation vials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4af7f789d58345659c0394f24e9c9d71_I20181130" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90YWJsZTowOWQ1OGEwNjJkMWQ0YTc0YTQ2NTU5NGQ4ZGZkN2MyMC90YWJsZXJhbmdlOjA5ZDU4YTA2MmQxZDRhNzRhNDY1NTk0ZDhkZmQ3YzIwXzItMS0xLTEtMA_0afd1e95-8bb2-4da6-9363-97255a9f903b">1,827,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4af7f789d58345659c0394f24e9c9d71_I20181130" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90YWJsZTowOWQ1OGEwNjJkMWQ0YTc0YTQ2NTU5NGQ4ZGZkN2MyMC90YWJsZXJhbmdlOjA5ZDU4YTA2MmQxZDRhNzRhNDY1NTk0ZDhkZmQ3YzIwXzMtMS0xLTEtMA_79810b63-6b06-4604-af7a-ffa13f8aa231">9,129,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4af7f789d58345659c0394f24e9c9d71_I20181130" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90YWJsZTowOWQ1OGEwNjJkMWQ0YTc0YTQ2NTU5NGQ4ZGZkN2MyMC90YWJsZXJhbmdlOjA5ZDU4YTA2MmQxZDRhNzRhNDY1NTk0ZDhkZmQ3YzIwXzQtMS0xLTEtMA_aae1bcc4-9d8f-41d0-983d-8fcf45166244">21,550,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property amortizable intangible assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4af7f789d58345659c0394f24e9c9d71_I20181130" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90YWJsZTowOWQ1OGEwNjJkMWQ0YTc0YTQ2NTU5NGQ4ZGZkN2MyMC90YWJsZXJhbmdlOjA5ZDU4YTA2MmQxZDRhNzRhNDY1NTk0ZDhkZmQ3YzIwXzYtMS0xLTEtMA_7abee862-0f54-4849-ba3c-0be77a3ca48b">11,750,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4af7f789d58345659c0394f24e9c9d71_I20181130" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90YWJsZTowOWQ1OGEwNjJkMWQ0YTc0YTQ2NTU5NGQ4ZGZkN2MyMC90YWJsZXJhbmdlOjA5ZDU4YTA2MmQxZDRhNzRhNDY1NTk0ZDhkZmQ3YzIwXzctMS0xLTEtMA_9f61a115-51a5-4818-b373-c2ef830dab42">882,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangibles and goodwill</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4af7f789d58345659c0394f24e9c9d71_I20181130" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90YWJsZTowOWQ1OGEwNjJkMWQ0YTc0YTQ2NTU5NGQ4ZGZkN2MyMC90YWJsZXJhbmdlOjA5ZDU4YTA2MmQxZDRhNzRhNDY1NTk0ZDhkZmQ3YzIwXzgtMS0xLTEtMA_5b8b4cc1-d601-4290-8a71-d6ee6de34fed">12,632,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4af7f789d58345659c0394f24e9c9d71_I20181130" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90YWJsZTowOWQ1OGEwNjJkMWQ0YTc0YTQ2NTU5NGQ4ZGZkN2MyMC90YWJsZXJhbmdlOjA5ZDU4YTA2MmQxZDRhNzRhNDY1NTk0ZDhkZmQ3YzIwXzktMS0xLTEtMA_59ea2ffb-f476-485b-9cd8-623f282513ba">34,182,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6bac8d7554cc439d9a70f38cdad45703">The Company's contingent consideration liability is a Level 3 fair value measurement that is updated on a recurring basis at each reporting period using a valuation model.  Consistent with Level 3 fair value measurements, there are significant inputs to the valuation model that are unobservable. The current portion of the contingent consideration liability is $<ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90ZXh0cmVnaW9uOjA3MDRiZjQ2MTQzZTQzMjI4ZGNkNjBmZDZiMWU1Njc5XzU3Njc_e323cc63-caaf-4170-9b11-618aa2cdd3ea">2.4</ix:nonFraction>&#160;million and the non-current portion is $<ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90ZXh0cmVnaW9uOjA3MDRiZjQ2MTQzZTQzMjI4ZGNkNjBmZDZiMWU1Njc5XzU4MDE_9021424f-f983-4870-8212-75acba41f503">6.3</ix:nonFraction>&#160;million, as of December&#160;31, 2019.</ix:continuation> </span></div><div id="id2bfa55304bd45bbaa9cdf09bb7673a3_202"></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(4)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90ZXh0cmVnaW9uOjU4N2RlYTM1YjE1MzQ2MWFhYTY0MTlhNzMzYWRlZDY5XzI3NTA_56c9f748-71a3-4546-93e4-672c05dde941" continuedAt="ie38ccd8a470a44d893b842cd1353006a" escape="true">Revenues</ix:nonNumeric></span></div><ix:continuation id="ie38ccd8a470a44d893b842cd1353006a" continuedAt="i95d4a97420dc47888df0d3e2d9a9bcbf"><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenues</span></div><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90ZXh0cmVnaW9uOjU4N2RlYTM1YjE1MzQ2MWFhYTY0MTlhNzMzYWRlZDY5XzI3NTI_f1bc53ee-8737-400d-84d3-88474117a16a" escape="true"><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net product revenues consisted of the following for the years ended December&#160;31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.698%"><tr><td style="width:1.0%"></td><td style="width:40.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.909%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.644%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.909%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.909%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.386%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f1333c86d8745489e79ec97651cf898_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90YWJsZTo4ZmJkMTVkZTk1MTI0NDk3YTI2OTQzYzg4ZTAzMTVhMC90YWJsZXJhbmdlOjhmYmQxNWRlOTUxMjQ0OTdhMjY5NDNjODhlMDMxNWEwXzItMi0xLTEtMA_06a27804-cb3e-4b8a-be06-ae5d17e90f48">3,824,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief373c33e252406ba170c90d1219f6dd_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90YWJsZTo4ZmJkMTVkZTk1MTI0NDk3YTI2OTQzYzg4ZTAzMTVhMC90YWJsZXJhbmdlOjhmYmQxNWRlOTUxMjQ0OTdhMjY5NDNjODhlMDMxNWEwXzItNC0xLTEtMA_2f679945-2826-4c38-a397-25b0f6cff761">4,284,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8169ad28217c4db3b21d9f9eeee9c392_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90YWJsZTo4ZmJkMTVkZTk1MTI0NDk3YTI2OTQzYzg4ZTAzMTVhMC90YWJsZXJhbmdlOjhmYmQxNWRlOTUxMjQ0OTdhMjY5NDNjODhlMDMxNWEwXzItNi0xLTEtMA_be8d77a3-3372-4ab0-bf8b-697c188f438d">6,576,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07a58e2ca82d468d914ab4d50fee24b8_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90YWJsZTo4ZmJkMTVkZTk1MTI0NDk3YTI2OTQzYzg4ZTAzMTVhMC90YWJsZXJhbmdlOjhmYmQxNWRlOTUxMjQ0OTdhMjY5NDNjODhlMDMxNWEwXzMtMi0xLTEtMA_3075fb5f-7093-4cbe-8ce2-dd9048b52385">837,829</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48a107bb7c466ebfe24ff0624d8263_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90YWJsZTo4ZmJkMTVkZTk1MTI0NDk3YTI2OTQzYzg4ZTAzMTVhMC90YWJsZXJhbmdlOjhmYmQxNWRlOTUxMjQ0OTdhMjY5NDNjODhlMDMxNWEwXzMtNC0xLTEtMA_b69810b4-6c2e-4c2e-bff2-42e468703986">623,297</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafa9e83c0991457dbecd945d1f0eb0a8_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90YWJsZTo4ZmJkMTVkZTk1MTI0NDk3YTI2OTQzYzg4ZTAzMTVhMC90YWJsZXJhbmdlOjhmYmQxNWRlOTUxMjQ0OTdhMjY5NDNjODhlMDMxNWEwXzMtNi0xLTEtMA_b048b622-e3f3-4804-ba41-44901664b09b">1,761,868</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie774ce371d1f4360a413d7cd01f67f7a_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90YWJsZTo4ZmJkMTVkZTk1MTI0NDk3YTI2OTQzYzg4ZTAzMTVhMC90YWJsZXJhbmdlOjhmYmQxNWRlOTUxMjQ0OTdhMjY5NDNjODhlMDMxNWEwXzQtMi0xLTEtMA_00877011-7cff-43b1-b38e-aa81940549f3">12,895,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6071c9045bf147eda9c3489832bb5075_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90YWJsZTo4ZmJkMTVkZTk1MTI0NDk3YTI2OTQzYzg4ZTAzMTVhMC90YWJsZXJhbmdlOjhmYmQxNWRlOTUxMjQ0OTdhMjY5NDNjODhlMDMxNWEwXzQtNC0xLTEtMA_d572b44a-3b1f-4f87-b7ae-1d8cf8c085a7">12,055,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc6447e28536413ebc8660631a042645_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90YWJsZTo4ZmJkMTVkZTk1MTI0NDk3YTI2OTQzYzg4ZTAzMTVhMC90YWJsZXJhbmdlOjhmYmQxNWRlOTUxMjQ0OTdhMjY5NDNjODhlMDMxNWEwXzQtNi0xLTEtMA_3e6c6dd3-9433-447a-bd86-62c72263a564">11,455,805</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c7af9859e7b4d49bc0d4cfb8caec5b5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90YWJsZTo4ZmJkMTVkZTk1MTI0NDk3YTI2OTQzYzg4ZTAzMTVhMC90YWJsZXJhbmdlOjhmYmQxNWRlOTUxMjQ0OTdhMjY5NDNjODhlMDMxNWEwXzUtMi0xLTEtMA_c40bd195-8875-41ca-9e80-4954ce0fd0fa">936,615</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e8af893ce924072831291283cf7341a_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90YWJsZTo4ZmJkMTVkZTk1MTI0NDk3YTI2OTQzYzg4ZTAzMTVhMC90YWJsZXJhbmdlOjhmYmQxNWRlOTUxMjQ0OTdhMjY5NDNjODhlMDMxNWEwXzUtNC0xLTEtMA_b33a2c99-6312-4c89-8427-e6d3c584ad1d">1,763,874</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17481b3eb00f41c493ce3e18607ab92f_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90YWJsZTo4ZmJkMTVkZTk1MTI0NDk3YTI2OTQzYzg4ZTAzMTVhMC90YWJsZXJhbmdlOjhmYmQxNWRlOTUxMjQ0OTdhMjY5NDNjODhlMDMxNWEwXzUtNi0xLTEtMA_80f56608-b05d-4c03-ad2e-1a0b70daf394">1,576,222</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56db8e8bb906489db9d57373574874aa_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90YWJsZTo4ZmJkMTVkZTk1MTI0NDk3YTI2OTQzYzg4ZTAzMTVhMC90YWJsZXJhbmdlOjhmYmQxNWRlOTUxMjQ0OTdhMjY5NDNjODhlMDMxNWEwXzYtMi0xLTEtMA_8d6808da-b170-47ce-b4f4-b7428fd9805d">5,222,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i320e6951e476481187afd7fdc00da9a3_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90YWJsZTo4ZmJkMTVkZTk1MTI0NDk3YTI2OTQzYzg4ZTAzMTVhMC90YWJsZXJhbmdlOjhmYmQxNWRlOTUxMjQ0OTdhMjY5NDNjODhlMDMxNWEwXzYtNC0xLTEtMA_cad75e05-4b06-4ecd-ac52-91014023f329">5,001,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b467d3bb2a460e991f8a90b333ff4d_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90YWJsZTo4ZmJkMTVkZTk1MTI0NDk3YTI2OTQzYzg4ZTAzMTVhMC90YWJsZXJhbmdlOjhmYmQxNWRlOTUxMjQ0OTdhMjY5NDNjODhlMDMxNWEwXzYtNi0xLTEtMA_a4e5a33d-6156-468f-85f4-aee6aa856c39">4,178,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfd2f30676c34f82a88e1052658a9b37_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90YWJsZTo4ZmJkMTVkZTk1MTI0NDk3YTI2OTQzYzg4ZTAzMTVhMC90YWJsZXJhbmdlOjhmYmQxNWRlOTUxMjQ0OTdhMjY5NDNjODhlMDMxNWEwXzktMi0xLTEtMA_7892119f-a44a-4d28-9bf9-adca894d808e">8,691,550</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic88d54bc58134580bd4649c7afe08bf6_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90YWJsZTo4ZmJkMTVkZTk1MTI0NDk3YTI2OTQzYzg4ZTAzMTVhMC90YWJsZXJhbmdlOjhmYmQxNWRlOTUxMjQ0OTdhMjY5NDNjODhlMDMxNWEwXzktNC0xLTEtMA_fda4907f-2946-4c1f-9594-b6ab343002ac">5,075,057</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id16bbbe7271043b3b909c6f3fa6611d0_D20170101-20171231" decimals="0" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90YWJsZTo4ZmJkMTVkZTk1MTI0NDk3YTI2OTQzYzg4ZTAzMTVhMC90YWJsZXJhbmdlOjhmYmQxNWRlOTUxMjQ0OTdhMjY5NDNjODhlMDMxNWEwXzktNi0xLTEtMA_6e4de2d5-75c4-4146-ab44-6fd658801600">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net product revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90YWJsZTo4ZmJkMTVkZTk1MTI0NDk3YTI2OTQzYzg4ZTAzMTVhMC90YWJsZXJhbmdlOjhmYmQxNWRlOTUxMjQ0OTdhMjY5NDNjODhlMDMxNWEwXzEwLTItMS0xLTA_cac38bf6-f82f-433c-9065-cbed2c9b7b1d">32,407,845</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90YWJsZTo4ZmJkMTVkZTk1MTI0NDk3YTI2OTQzYzg4ZTAzMTVhMC90YWJsZXJhbmdlOjhmYmQxNWRlOTUxMjQ0OTdhMjY5NDNjODhlMDMxNWEwXzEwLTQtMS0xLTA_a66b1cc2-6a83-4c5e-8755-f377ee56bd67">28,803,961</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90YWJsZTo4ZmJkMTVkZTk1MTI0NDk3YTI2OTQzYzg4ZTAzMTVhMC90YWJsZXJhbmdlOjhmYmQxNWRlOTUxMjQ0OTdhMjY5NDNjODhlMDMxNWEwXzEwLTYtMS0xLTA_76904e6d-abac-4d61-8cc4-78e11fed8ce8">25,549,058</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:16pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, Cumberland executed a License and Distribution agreement with HongKong WinHealth Pharma Group Co. Limited (&#8220;WinHealth&#8221;) for our Caldolor and Acetadote</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">brands in China and Hong Kong.  In conjunction with these new arrangements, the Company terminated a previous License and Distribution agreement with Gloria Pharmaceuticals Co ("Gloria Pharmaceuticals") for the two brands.  In addition, we also signed a new License and Distribution agreement with DB Pharm Korea Co., Ltd. (&#8220;DB Pharm&#8221;) for Vibativ in South Korea. As a result of these agreements, Cumberland recognized approximately $<ix:nonFraction unitRef="usd" contextRef="i80881f50116942c79eeedbc60d086b43_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90ZXh0cmVnaW9uOjU4N2RlYTM1YjE1MzQ2MWFhYTY0MTlhNzMzYWRlZDY5Xzc0Ng_be02b677-1c21-4b83-8bbc-7fe547975cd7">0.3</ix:nonFraction>&#160;million of non-refundable up-front payments as other revenue in the consolidated statement of operations during 2019.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into agreements, beginning in 2012, with international partners for commercialization of the Company's products.  The international agreements provide that each of the partners are responsible for seeking regulatory approvals for the products, and following approvals, each partner will handle ongoing </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="i95d4a97420dc47888df0d3e2d9a9bcbf"><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">distribution and sales in the respective international territories.  The Company maintains responsibility for the intellectual property and product formulations.  Under the international agreements, the Company is entitled to receive non-refundable up-front payments at the time the agreements are entered into and payments upon the partners' achievement of defined regulatory approvals and sales milestones.  The Company will recognize revenue for these achievements once it is probable that these consideration amounts are no longer constrained. The Company is also entitled to receive royalties on future sales of the products under the agreements. The international agreements provide for $<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="cpix:RevenueRecognitionUpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90ZXh0cmVnaW9uOjU4N2RlYTM1YjE1MzQ2MWFhYTY0MTlhNzMzYWRlZDY5XzE4NzY_214c7a03-8680-4c9c-9bfb-0320c133df9d">1.0</ix:nonFraction> million in non-refundable up-front payments, milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="cpix:RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90ZXh0cmVnaW9uOjU4N2RlYTM1YjE1MzQ2MWFhYTY0MTlhNzMzYWRlZDY5XzE5NDQ_8ff1413b-4c62-43c8-883e-4b62d485bb31">2.2</ix:nonFraction> million related to regulatory approvals and up to $<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="cpix:RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90ZXh0cmVnaW9uOjU4N2RlYTM1YjE1MzQ2MWFhYTY0MTlhNzMzYWRlZDY5XzE5ODk_36f5f3b4-37c3-492e-bb07-ec2ca35615df">4.8</ix:nonFraction> million in payments related to product sales.  From 2012 through December&#160;31, 2019, the Company has recognized a cumulative $<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="cpix:RevenueRecognitionCumulativeUpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90ZXh0cmVnaW9uOjU4N2RlYTM1YjE1MzQ2MWFhYTY0MTlhNzMzYWRlZDY5XzIwOTM_36cd6677-3adb-4ba4-b116-a929173cd6e3">1.2</ix:nonFraction> million in upfront payments as other revenue and has recognized $<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="cpix:RevenueRecognitionMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90ZXh0cmVnaW9uOjU4N2RlYTM1YjE1MzQ2MWFhYTY0MTlhNzMzYWRlZDY5XzIxNTI_ec785713-01ba-414c-ab16-390787997865">0.1</ix:nonFraction>&#160;million in revenue related to the milestone payments associated with these international agreements.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues during 2019, 2018 and 2017 also includes revenue generated by CET through grant funding from federal Small Business grant programs, and lease income generated by CET&#8217;s Life Sciences Center and contract services. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from SBIR/STTR programs totaled approximately $<ix:nonFraction unitRef="usd" contextRef="if00c3bf918d24cc3aaeb84d0fbd302a3_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90ZXh0cmVnaW9uOjU4N2RlYTM1YjE1MzQ2MWFhYTY0MTlhNzMzYWRlZDY5XzI2ODY_6e51b639-e280-4234-8f4f-d2eb2bb6a630">1.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i9f14c6eb615f4396a69694ec3bbf3a78_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90ZXh0cmVnaW9uOjU4N2RlYTM1YjE1MzQ2MWFhYTY0MTlhNzMzYWRlZDY5XzI2OTE_d786ff6f-b44b-47ee-b6f6-e51977a10589">0.1</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i14230e23d1f14fddaceba899b44a4986_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90ZXh0cmVnaW9uOjU4N2RlYTM1YjE1MzQ2MWFhYTY0MTlhNzMzYWRlZDY5XzI2OTk_dd4601e8-5529-4d2d-a45d-faa3aea095de">0.2</ix:nonFraction> million for the years ending December&#160;31, 2019, 2018 and 2017, respectively.</span></div></ix:continuation><div id="id2bfa55304bd45bbaa9cdf09bb7673a3_205"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(5)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDUvZnJhZzo3YTcyYmNlYzVhYWM0NDZhODdjZmY4NjljYTc0ZTYwMy90ZXh0cmVnaW9uOjdhNzJiY2VjNWFhYzQ0NmE4N2NmZjg2OWNhNzRlNjAzXzE3NjI_d03cf487-9094-4f9a-9a14-2c8f8bb9ecff" continuedAt="iffe8c58706cf4e8c967be2ca8a102f3f" escape="true">Inventories</ix:nonNumeric></span></div><ix:continuation id="iffe8c58706cf4e8c967be2ca8a102f3f"><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDUvZnJhZzo3YTcyYmNlYzVhYWM0NDZhODdjZmY4NjljYTc0ZTYwMy90ZXh0cmVnaW9uOjdhNzJiY2VjNWFhYzQ0NmE4N2NmZjg2OWNhNzRlNjAzXzE3NjM_02a8c883-7ae5-4cb5-a88a-5e0913b8e18e" escape="true"><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's net inventories consisted of the following as of December 31:</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.339%"><tr><td style="width:1.0%"></td><td style="width:60.000%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.248%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDUvZnJhZzo3YTcyYmNlYzVhYWM0NDZhODdjZmY4NjljYTc0ZTYwMy90YWJsZTo4Mzg4OTU5NGMzYTU0N2M4OTJlMjRjNTQ2NzE4MGFhNS90YWJsZXJhbmdlOjgzODg5NTk0YzNhNTQ3Yzg5MmUyNGM1NDY3MTgwYWE1XzItMi0xLTEtMA_d90bb68b-c06f-4bc9-baff-4388e73f444e">19,345,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDUvZnJhZzo3YTcyYmNlYzVhYWM0NDZhODdjZmY4NjljYTc0ZTYwMy90YWJsZTo4Mzg4OTU5NGMzYTU0N2M4OTJlMjRjNTQ2NzE4MGFhNS90YWJsZXJhbmdlOjgzODg5NTk0YzNhNTQ3Yzg5MmUyNGM1NDY3MTgwYWE1XzItNC0xLTEtMA_8f292b7a-70ec-4677-ae06-bef74f47e809">18,378,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDUvZnJhZzo3YTcyYmNlYzVhYWM0NDZhODdjZmY4NjljYTc0ZTYwMy90YWJsZTo4Mzg4OTU5NGMzYTU0N2M4OTJlMjRjNTQ2NzE4MGFhNS90YWJsZXJhbmdlOjgzODg5NTk0YzNhNTQ3Yzg5MmUyNGM1NDY3MTgwYWE1XzMtMi0xLTEtMA_b822e97e-a3f1-42c2-bce1-aa2d7ff98c2f">416,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDUvZnJhZzo3YTcyYmNlYzVhYWM0NDZhODdjZmY4NjljYTc0ZTYwMy90YWJsZTo4Mzg4OTU5NGMzYTU0N2M4OTJlMjRjNTQ2NzE4MGFhNS90YWJsZXJhbmdlOjgzODg5NTk0YzNhNTQ3Yzg5MmUyNGM1NDY3MTgwYWE1XzMtNC0xLTEtMA_950dc904-ebbd-40a0-9918-b313187c0d6d">937,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods, net of reserve</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDUvZnJhZzo3YTcyYmNlYzVhYWM0NDZhODdjZmY4NjljYTc0ZTYwMy90YWJsZTo4Mzg4OTU5NGMzYTU0N2M4OTJlMjRjNTQ2NzE4MGFhNS90YWJsZXJhbmdlOjgzODg5NTk0YzNhNTQ3Yzg5MmUyNGM1NDY3MTgwYWE1XzQtMi0xLTEtMA_a36cd63b-9b5f-48f9-8add-ccdd9b407eff">4,664,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDUvZnJhZzo3YTcyYmNlYzVhYWM0NDZhODdjZmY4NjljYTc0ZTYwMy90YWJsZTo4Mzg4OTU5NGMzYTU0N2M4OTJlMjRjNTQ2NzE4MGFhNS90YWJsZXJhbmdlOjgzODg5NTk0YzNhNTQ3Yzg5MmUyNGM1NDY3MTgwYWE1XzQtNC0xLTEtMA_c5a85ca7-df97-449f-9ad6-ad75a67daf01">6,216,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDUvZnJhZzo3YTcyYmNlYzVhYWM0NDZhODdjZmY4NjljYTc0ZTYwMy90YWJsZTo4Mzg4OTU5NGMzYTU0N2M4OTJlMjRjNTQ2NzE4MGFhNS90YWJsZXJhbmdlOjgzODg5NTk0YzNhNTQ3Yzg5MmUyNGM1NDY3MTgwYWE1XzUtMi0xLTEtMA_e3983bc4-7b59-4009-ae7c-fb167e6edb73">24,426,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDUvZnJhZzo3YTcyYmNlYzVhYWM0NDZhODdjZmY4NjljYTc0ZTYwMy90YWJsZTo4Mzg4OTU5NGMzYTU0N2M4OTJlMjRjNTQ2NzE4MGFhNS90YWJsZXJhbmdlOjgzODg5NTk0YzNhNTQ3Yzg5MmUyNGM1NDY3MTgwYWE1XzUtNC0xLTEtMA_3b653b3a-e5c3-45ba-aea6-91c5f6f86da4">25,532,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDUvZnJhZzo3YTcyYmNlYzVhYWM0NDZhODdjZmY4NjljYTc0ZTYwMy90YWJsZTo4Mzg4OTU5NGMzYTU0N2M4OTJlMjRjNTQ2NzE4MGFhNS90YWJsZXJhbmdlOjgzODg5NTk0YzNhNTQ3Yzg5MmUyNGM1NDY3MTgwYWE1XzYtMi0xLTEtMA_e328cdc0-db99-4b7f-8f9a-9102fbd989a1">15,554,992</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDUvZnJhZzo3YTcyYmNlYzVhYWM0NDZhODdjZmY4NjljYTc0ZTYwMy90YWJsZTo4Mzg4OTU5NGMzYTU0N2M4OTJlMjRjNTQ2NzE4MGFhNS90YWJsZXJhbmdlOjgzODg5NTk0YzNhNTQ3Yzg5MmUyNGM1NDY3MTgwYWE1XzYtNC0xLTEtMA_86f74dba-237a-4594-baea-a66512616e65">15,749,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDUvZnJhZzo3YTcyYmNlYzVhYWM0NDZhODdjZmY4NjljYTc0ZTYwMy90YWJsZTo4Mzg4OTU5NGMzYTU0N2M4OTJlMjRjNTQ2NzE4MGFhNS90YWJsZXJhbmdlOjgzODg5NTk0YzNhNTQ3Yzg5MmUyNGM1NDY3MTgwYWE1XzctMi0xLTEtMA_e7e45875-c8ea-4159-aa50-70881c5988fe">8,871,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDUvZnJhZzo3YTcyYmNlYzVhYWM0NDZhODdjZmY4NjljYTc0ZTYwMy90YWJsZTo4Mzg4OTU5NGMzYTU0N2M4OTJlMjRjNTQ2NzE4MGFhNS90YWJsZXJhbmdlOjgzODg5NTk0YzNhNTQ3Yzg5MmUyNGM1NDY3MTgwYWE1XzctNC0xLTEtMA_bc066a4d-1e61-4e87-9a86-10eea0de180e">9,783,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company continually evaluates inventories for potential losses due to expired, short-dated or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates the carrying value of a product may not be recoverable, a charge is recorded to reduce the inventory to its current net realizable value. At December&#160;31, 2019 and 2018, the Company had recognized and maintained cumulative charges for potential obsolescence and discontinuance losses of approximately $<ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryValuationReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDUvZnJhZzo3YTcyYmNlYzVhYWM0NDZhODdjZmY4NjljYTc0ZTYwMy90ZXh0cmVnaW9uOjdhNzJiY2VjNWFhYzQ0NmE4N2NmZjg2OWNhNzRlNjAzXzYwMg_0f303a50-e258-4116-921e-94d406250335">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryValuationReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDUvZnJhZzo3YTcyYmNlYzVhYWM0NDZhODdjZmY4NjljYTc0ZTYwMy90ZXh0cmVnaW9uOjdhNzJiY2VjNWFhYzQ0NmE4N2NmZjg2OWNhNzRlNjAzXzYwOQ_a5b3afe7-d3cd-4215-9d3f-1db485aa8de6">0.3</ix:nonFraction> million, respectively.  At December&#160;31, 2019 there were no cumulative obsolescence or discontinuance losses necessary.  </span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of certain product rights related to the Kristalose brand, the Company is responsible for the purchase of the active pharmaceutical ingredient ("API") for Kristalose and maintains the inventory at the third-party packagers.  As the API is consumed in production, the value of the API is transferred from raw materials to finished goods.  API for the Company's Vaprisol brand is also included in the raw materials inventory total at December&#160;31, 2019 and 2018. Consigned inventory represents Authorized Generic inventory stored with Perrigo until shipment.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories of $<ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDUvZnJhZzo3YTcyYmNlYzVhYWM0NDZhODdjZmY4NjljYTc0ZTYwMy90ZXh0cmVnaW9uOjdhNzJiY2VjNWFhYzQ0NmE4N2NmZjg2OWNhNzRlNjAzXzEzODE_b224d9e3-ad13-4f89-b5cd-1b60bbc71372">15.7</ix:nonFraction> million  that are classified as non-current inventories at December&#160;31, 2018.  At December&#160;31, 2019, the Vibativ non-current inventory was $<ix:nonFraction unitRef="usd" contextRef="ifd15955102ce48909e6253ea8529c09b_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDUvZnJhZzo3YTcyYmNlYzVhYWM0NDZhODdjZmY4NjljYTc0ZTYwMy90ZXh0cmVnaW9uOjdhNzJiY2VjNWFhYzQ0NmE4N2NmZjg2OWNhNzRlNjAzXzE0ODU_5be6448b-20bb-44d1-9038-db2445915b39">15.3</ix:nonFraction> million.  Although the Company did not have any finished goods included in the non-current inventories at December&#160;31, 2019, we had $<ix:nonFraction unitRef="usd" contextRef="i8286cfe2c4684a39972d0ce5371ad480_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDUvZnJhZzo3YTcyYmNlYzVhYWM0NDZhODdjZmY4NjljYTc0ZTYwMy90ZXh0cmVnaW9uOjdhNzJiY2VjNWFhYzQ0NmE4N2NmZjg2OWNhNzRlNjAzXzE1OTc_ef93cb96-256a-4904-a279-cd2589f33ccd">0.8</ix:nonFraction>&#160;million in Vibativ finished goods included at December&#160;31, 2018.  During 2019, Cumberland also obtained $<ix:nonFraction unitRef="usd" contextRef="i156f2acf482f4da8b0851cb775ba0501_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDUvZnJhZzo3YTcyYmNlYzVhYWM0NDZhODdjZmY4NjljYTc0ZTYwMy90ZXh0cmVnaW9uOjdhNzJiY2VjNWFhYzQ0NmE4N2NmZjg2OWNhNzRlNjAzXzE2ODE_660d75ee-f628-41d1-a49d-66bc47338001">0.3</ix:nonFraction>&#160;million in non-current inventory for API related to its ifetroban clinical initiatives.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><div id="id2bfa55304bd45bbaa9cdf09bb7673a3_208"></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(6)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDgvZnJhZzplMzNkMjRiNWM2NTM0MDcxYjdlNmNhNTJjODQyY2ExYi90ZXh0cmVnaW9uOmUzM2QyNGI1YzY1MzQwNzFiN2U2Y2E1MmM4NDJjYTFiXzM1OA_d63a38e8-2015-4c63-a3e8-fa59f0f07a90" continuedAt="i846d9549c36145af85df0aa6069ff616" escape="true">Property and Equipment</ix:nonNumeric></span></div><ix:continuation id="i846d9549c36145af85df0aa6069ff616"><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDgvZnJhZzplMzNkMjRiNWM2NTM0MDcxYjdlNmNhNTJjODQyY2ExYi90ZXh0cmVnaW9uOmUzM2QyNGI1YzY1MzQwNzFiN2U2Y2E1MmM4NDJjYTFiXzM2MA_16344dd6-0064-4ae7-9fa1-62e2ffb2ce99" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following at December&#160;31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.980%"><tr><td style="width:1.0%"></td><td style="width:34.965%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.892%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.125%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.892%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.892%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">useful lives</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;&#8211;&#160;5&#160;years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica008517cc804be682f6f8928de46011_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDgvZnJhZzplMzNkMjRiNWM2NTM0MDcxYjdlNmNhNTJjODQyY2ExYi90YWJsZTo2NGIwNzYxNTAxZGM0MzAyOTkwODEzYmUzNDY4ZDQ1MC90YWJsZXJhbmdlOjY0YjA3NjE1MDFkYzQzMDI5OTA4MTNiZTM0NjhkNDUwXzItNC0xLTEtMA_d715a2f4-4348-49dd-bd99-eff382c1af5f">1,260,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ab1d686afef4f47af443ddb3c69c912_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDgvZnJhZzplMzNkMjRiNWM2NTM0MDcxYjdlNmNhNTJjODQyY2ExYi90YWJsZTo2NGIwNzYxNTAxZGM0MzAyOTkwODEzYmUzNDY4ZDQ1MC90YWJsZXJhbmdlOjY0YjA3NjE1MDFkYzQzMDI5OTA4MTNiZTM0NjhkNDUwXzItNi0xLTEtMA_963490ba-b440-456b-81b4-8ef31a6789a0">1,148,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;&#8211;&#160;15&#160;years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8369853c76754322967bb52653385028_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDgvZnJhZzplMzNkMjRiNWM2NTM0MDcxYjdlNmNhNTJjODQyY2ExYi90YWJsZTo2NGIwNzYxNTAxZGM0MzAyOTkwODEzYmUzNDY4ZDQ1MC90YWJsZXJhbmdlOjY0YjA3NjE1MDFkYzQzMDI5OTA4MTNiZTM0NjhkNDUwXzMtNC0xLTEtMA_fad59770-9107-40c4-ab0c-950c41c86d0f">878,350</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67191970b6dc4dbab12c4bdce59ca551_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDgvZnJhZzplMzNkMjRiNWM2NTM0MDcxYjdlNmNhNTJjODQyY2ExYi90YWJsZTo2NGIwNzYxNTAxZGM0MzAyOTkwODEzYmUzNDY4ZDQ1MC90YWJsZXJhbmdlOjY0YjA3NjE1MDFkYzQzMDI5OTA4MTNiZTM0NjhkNDUwXzMtNi0xLTEtMA_349f270b-782e-4792-b069-09c7f0380eed">809,153</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;&#8211;&#160;15 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f0e55caff6347b08baa66daf67632aa_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDgvZnJhZzplMzNkMjRiNWM2NTM0MDcxYjdlNmNhNTJjODQyY2ExYi90YWJsZTo2NGIwNzYxNTAxZGM0MzAyOTkwODEzYmUzNDY4ZDQ1MC90YWJsZXJhbmdlOjY0YjA3NjE1MDFkYzQzMDI5OTA4MTNiZTM0NjhkNDUwXzQtNC0xLTEtMA_5b1f9a71-421b-4eb0-910e-2da4fc9ab9f7">646,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia11c0ba867c24e56850a7ffe421f6852_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDgvZnJhZzplMzNkMjRiNWM2NTM0MDcxYjdlNmNhNTJjODQyY2ExYi90YWJsZTo2NGIwNzYxNTAxZGM0MzAyOTkwODEzYmUzNDY4ZDQ1MC90YWJsZXJhbmdlOjY0YjA3NjE1MDFkYzQzMDI5OTA4MTNiZTM0NjhkNDUwXzQtNi0xLTEtMA_0dfdde36-8881-48d8-b940-8fad3958124c">639,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifa90d2ee803c421baadb41895368ae03_D20190101-20191231" name="cpix:PropertyAndEquipmentUsefulLifeTextual" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDgvZnJhZzplMzNkMjRiNWM2NTM0MDcxYjdlNmNhNTJjODQyY2ExYi90YWJsZTo2NGIwNzYxNTAxZGM0MzAyOTkwODEzYmUzNDY4ZDQ1MC90YWJsZXJhbmdlOjY0YjA3NjE1MDFkYzQzMDI5OTA4MTNiZTM0NjhkNDUwXzUtMi0xLTEtMA_dd1ab64d-9455-4bb4-b420-6458fa85bf5d">3&#160;&#8211;&#160;15&#160;years,&#160;or remaining&#160;lease&#160;term</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13db87e21e745bfaebf06c3e97b18e1_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDgvZnJhZzplMzNkMjRiNWM2NTM0MDcxYjdlNmNhNTJjODQyY2ExYi90YWJsZTo2NGIwNzYxNTAxZGM0MzAyOTkwODEzYmUzNDY4ZDQ1MC90YWJsZXJhbmdlOjY0YjA3NjE1MDFkYzQzMDI5OTA4MTNiZTM0NjhkNDUwXzUtNC0xLTEtMA_716f6bdf-d2e7-48cf-9deb-d8ea8d4444af">1,356,640</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f90fef1f7bd4deaa1cf05dcd6c9cc19_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDgvZnJhZzplMzNkMjRiNWM2NTM0MDcxYjdlNmNhNTJjODQyY2ExYi90YWJsZTo2NGIwNzYxNTAxZGM0MzAyOTkwODEzYmUzNDY4ZDQ1MC90YWJsZXJhbmdlOjY0YjA3NjE1MDFkYzQzMDI5OTA4MTNiZTM0NjhkNDUwXzUtNi0xLTEtMA_160e20b9-2277-400c-b0ab-c6f2f0f0f5bc">1,299,363</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and </span></div><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">equipment, gross</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDgvZnJhZzplMzNkMjRiNWM2NTM0MDcxYjdlNmNhNTJjODQyY2ExYi90YWJsZTo2NGIwNzYxNTAxZGM0MzAyOTkwODEzYmUzNDY4ZDQ1MC90YWJsZXJhbmdlOjY0YjA3NjE1MDFkYzQzMDI5OTA4MTNiZTM0NjhkNDUwXzYtNC0xLTEtMA_2e968241-6bfc-428b-bec5-80738eb39487">4,142,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDgvZnJhZzplMzNkMjRiNWM2NTM0MDcxYjdlNmNhNTJjODQyY2ExYi90YWJsZTo2NGIwNzYxNTAxZGM0MzAyOTkwODEzYmUzNDY4ZDQ1MC90YWJsZXJhbmdlOjY0YjA3NjE1MDFkYzQzMDI5OTA4MTNiZTM0NjhkNDUwXzYtNi0xLTEtMA_83b74caa-59a6-45ea-87ad-f2771fc9e685">3,895,923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and amortization</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDgvZnJhZzplMzNkMjRiNWM2NTM0MDcxYjdlNmNhNTJjODQyY2ExYi90YWJsZTo2NGIwNzYxNTAxZGM0MzAyOTkwODEzYmUzNDY4ZDQ1MC90YWJsZXJhbmdlOjY0YjA3NjE1MDFkYzQzMDI5OTA4MTNiZTM0NjhkNDUwXzctNC0xLTEtMA_a1b8c85c-b838-4818-b202-43118995205f">3,394,329</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDgvZnJhZzplMzNkMjRiNWM2NTM0MDcxYjdlNmNhNTJjODQyY2ExYi90YWJsZTo2NGIwNzYxNTAxZGM0MzAyOTkwODEzYmUzNDY4ZDQ1MC90YWJsZXJhbmdlOjY0YjA3NjE1MDFkYzQzMDI5OTA4MTNiZTM0NjhkNDUwXzctNi0xLTEtMA_95f55fcc-d516-4ee3-80f8-db7c0efb85a7">3,124,710</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and </span></div><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">equipment, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDgvZnJhZzplMzNkMjRiNWM2NTM0MDcxYjdlNmNhNTJjODQyY2ExYi90YWJsZTo2NGIwNzYxNTAxZGM0MzAyOTkwODEzYmUzNDY4ZDQ1MC90YWJsZXJhbmdlOjY0YjA3NjE1MDFkYzQzMDI5OTA4MTNiZTM0NjhkNDUwXzgtNC0xLTEtMA_8c150c05-00ba-4dc1-a8f3-cd554f1b4a8b">747,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDgvZnJhZzplMzNkMjRiNWM2NTM0MDcxYjdlNmNhNTJjODQyY2ExYi90YWJsZTo2NGIwNzYxNTAxZGM0MzAyOTkwODEzYmUzNDY4ZDQ1MC90YWJsZXJhbmdlOjY0YjA3NjE1MDFkYzQzMDI5OTA4MTNiZTM0NjhkNDUwXzgtNi0xLTEtMA_e049e755-846f-4e72-b15a-7f995885e873">771,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense, including amortization expense related to leasehold improvements, is included in general and administrative expense in the consolidated statements of operations.  <ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="cpix:ScheduleofDepreciationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDgvZnJhZzplMzNkMjRiNWM2NTM0MDcxYjdlNmNhNTJjODQyY2ExYi90ZXh0cmVnaW9uOmUzM2QyNGI1YzY1MzQwNzFiN2U2Y2E1MmM4NDJjYTFiXzM1Ng_13a07426-edb3-4999-82d2-e74bd8abb881" continuedAt="i59ccb41a5cc54d0fae963b519de258e9" escape="true">Depreciation expense was as follows for the years ended December 31:</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><ix:continuation id="i59ccb41a5cc54d0fae963b519de258e9"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.897%"><tr><td style="width:1.0%"></td><td style="width:41.064%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.064%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.559%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2017</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="cpix:DepreciationIncludingAmortizationRelatedToLeaseholdImprovements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDgvZnJhZzplMzNkMjRiNWM2NTM0MDcxYjdlNmNhNTJjODQyY2ExYi90YWJsZTozZjZmMDc3NWM3NTI0OTFlOGEyZjlkNjVhNmUwODRmOC90YWJsZXJhbmdlOjNmNmYwNzc1Yzc1MjQ5MWU4YTJmOWQ2NWE2ZTA4NGY4XzItMi0xLTEtMA_03fd3eb8-3d28-4d42-a8f4-1d7167e982d0">269,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="cpix:DepreciationIncludingAmortizationRelatedToLeaseholdImprovements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDgvZnJhZzplMzNkMjRiNWM2NTM0MDcxYjdlNmNhNTJjODQyY2ExYi90YWJsZTozZjZmMDc3NWM3NTI0OTFlOGEyZjlkNjVhNmUwODRmOC90YWJsZXJhbmdlOjNmNmYwNzc1Yzc1MjQ5MWU4YTJmOWQ2NWE2ZTA4NGY4XzItNC0xLTEtMA_f4414db5-10c6-41bb-9e56-6c157d0172c5">213,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="cpix:DepreciationIncludingAmortizationRelatedToLeaseholdImprovements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDgvZnJhZzplMzNkMjRiNWM2NTM0MDcxYjdlNmNhNTJjODQyY2ExYi90YWJsZTozZjZmMDc3NWM3NTI0OTFlOGEyZjlkNjVhNmUwODRmOC90YWJsZXJhbmdlOjNmNmYwNzc1Yzc1MjQ5MWU4YTJmOWQ2NWE2ZTA4NGY4XzItNi0xLTEtMA_b3274843-aab1-4f2a-8ae4-54ef4b417379">211,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="id2bfa55304bd45bbaa9cdf09bb7673a3_214"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(7)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90ZXh0cmVnaW9uOmQ0MzVlOWNkMGI0ZTRiN2U4YmRjY2ZjYjYxOGRlMDI2XzMxNzM_52f58842-9eff-4845-9ef0-5dec5f97a594" continuedAt="i7610deab962f4d5c92903e900797bc56" escape="true">Intangible Assets and Goodwill</ix:nonNumeric></span></div><ix:continuation id="i7610deab962f4d5c92903e900797bc56" continuedAt="i5dd16a8f46b94bb4a8c56ca652731e0d"><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90ZXh0cmVnaW9uOmQ0MzVlOWNkMGI0ZTRiN2U4YmRjY2ZjYjYxOGRlMDI2XzMxNjg_f72b8014-1ed2-4b4c-9b14-7e1213461686" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets and Goodwill consisted of the following at December&#160;31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.217%"><tr><td style="width:1.0%"></td><td style="width:59.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.915%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.487%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.915%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.489%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product and license rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibda132d30f764f18ba15f5b11ef8640c_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTpjZWQwNTdjMzA2ZmE0NWNjYTdhMTVkMzRkNmYzYzk3MS90YWJsZXJhbmdlOmNlZDA1N2MzMDZmYTQ1Y2NhN2ExNWQzNGQ2ZjNjOTcxXzItMi0xLTEtMA_ad5086ed-c771-49b4-a378-bd99cd005e8f">37,400,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1596ec01ad648109aa7a8774201aebf_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTpjZWQwNTdjMzA2ZmE0NWNjYTdhMTVkMzRkNmYzYzk3MS90YWJsZXJhbmdlOmNlZDA1N2MzMDZmYTQ1Y2NhN2ExNWQzNGQ2ZjNjOTcxXzItNC0xLTEtMA_a7b2f540-249e-4e80-8607-fc3ce6ebf595">36,573,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibda132d30f764f18ba15f5b11ef8640c_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTpjZWQwNTdjMzA2ZmE0NWNjYTdhMTVkMzRkNmYzYzk3MS90YWJsZXJhbmdlOmNlZDA1N2MzMDZmYTQ1Y2NhN2ExNWQzNGQ2ZjNjOTcxXzMtMi0xLTEtMA_98b17155-b513-48b6-90b1-ea3809f97d0f">11,499,141</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1596ec01ad648109aa7a8774201aebf_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTpjZWQwNTdjMzA2ZmE0NWNjYTdhMTVkMzRkNmYzYzk3MS90YWJsZXJhbmdlOmNlZDA1N2MzMDZmYTQ1Y2NhN2ExNWQzNGQ2ZjNjOTcxXzMtNC0xLTEtMA_3208a3c4-f176-4182-9e2b-3cec053bb0dd">8,405,188</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product and license rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibda132d30f764f18ba15f5b11ef8640c_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTpjZWQwNTdjMzA2ZmE0NWNjYTdhMTVkMzRkNmYzYzk3MS90YWJsZXJhbmdlOmNlZDA1N2MzMDZmYTQ1Y2NhN2ExNWQzNGQ2ZjNjOTcxXzQtMi0xLTEtMA_a6964e4f-2032-4d71-9c92-e5ae0b98fe73">25,901,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1596ec01ad648109aa7a8774201aebf_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTpjZWQwNTdjMzA2ZmE0NWNjYTdhMTVkMzRkNmYzYzk3MS90YWJsZXJhbmdlOmNlZDA1N2MzMDZmYTQ1Y2NhN2ExNWQzNGQ2ZjNjOTcxXzQtNC0xLTEtMA_4a41bab8-b528-4cc6-9154-285a04edc017">28,168,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc95de064baa44309a420dcb73dd5d32_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTpjZWQwNTdjMzA2ZmE0NWNjYTdhMTVkMzRkNmYzYzk3MS90YWJsZXJhbmdlOmNlZDA1N2MzMDZmYTQ1Y2NhN2ExNWQzNGQ2ZjNjOTcxXzUtMi0xLTEtMA_92855384-2681-43fe-b0df-ce7b5882dc2a">9,882,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13bd22341d9c430cb1cd4edc13102d50_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTpjZWQwNTdjMzA2ZmE0NWNjYTdhMTVkMzRkNmYzYzk3MS90YWJsZXJhbmdlOmNlZDA1N2MzMDZmYTQ1Y2NhN2ExNWQzNGQ2ZjNjOTcxXzUtNC0xLTEtMA_a4ecac23-eeb7-43ba-9f05-965afda6e38a">9,428,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc95de064baa44309a420dcb73dd5d32_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTpjZWQwNTdjMzA2ZmE0NWNjYTdhMTVkMzRkNmYzYzk3MS90YWJsZXJhbmdlOmNlZDA1N2MzMDZmYTQ1Y2NhN2ExNWQzNGQ2ZjNjOTcxXzYtMi0xLTEtMA_a6594927-69f9-4af0-bf7f-0161b4052965">5,127,878</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13bd22341d9c430cb1cd4edc13102d50_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTpjZWQwNTdjMzA2ZmE0NWNjYTdhMTVkMzRkNmYzYzk3MS90YWJsZXJhbmdlOmNlZDA1N2MzMDZmYTQ1Y2NhN2ExNWQzNGQ2ZjNjOTcxXzYtNC0xLTEtMA_1b267256-ef1d-47be-9932-8f166cc3578a">4,087,273</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc95de064baa44309a420dcb73dd5d32_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTpjZWQwNTdjMzA2ZmE0NWNjYTdhMTVkMzRkNmYzYzk3MS90YWJsZXJhbmdlOmNlZDA1N2MzMDZmYTQ1Y2NhN2ExNWQzNGQ2ZjNjOTcxXzctMi0xLTEtMA_68135610-f132-4acb-96d2-10f8aef12a36">4,754,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13bd22341d9c430cb1cd4edc13102d50_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTpjZWQwNTdjMzA2ZmE0NWNjYTdhMTVkMzRkNmYzYzk3MS90YWJsZXJhbmdlOmNlZDA1N2MzMDZmYTQ1Y2NhN2ExNWQzNGQ2ZjNjOTcxXzctNC0xLTEtMA_22f1668c-8950-4aa7-a670-f10484036a2d">5,340,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85b3f22a44da44e0b4f3300a912b0dc5_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTpjZWQwNTdjMzA2ZmE0NWNjYTdhMTVkMzRkNmYzYzk3MS90YWJsZXJhbmdlOmNlZDA1N2MzMDZmYTQ1Y2NhN2ExNWQzNGQ2ZjNjOTcxXzgtMi0xLTEtMA_2e1ac567-a115-4841-a4fc-d117a24b3cae">273,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i988d5245b3374e39af5d4ec1f43b092f_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTpjZWQwNTdjMzA2ZmE0NWNjYTdhMTVkMzRkNmYzYzk3MS90YWJsZXJhbmdlOmNlZDA1N2MzMDZmYTQ1Y2NhN2ExNWQzNGQ2ZjNjOTcxXzgtNC0xLTEtMA_35d966f5-ecbc-40ee-abe2-67095ceadf39">154,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85b3f22a44da44e0b4f3300a912b0dc5_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTpjZWQwNTdjMzA2ZmE0NWNjYTdhMTVkMzRkNmYzYzk3MS90YWJsZXJhbmdlOmNlZDA1N2MzMDZmYTQ1Y2NhN2ExNWQzNGQ2ZjNjOTcxXzktMi0xLTEtMA_26314015-abb5-4578-81f7-c1335a4a7d6d">9,020</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i988d5245b3374e39af5d4ec1f43b092f_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTpjZWQwNTdjMzA2ZmE0NWNjYTdhMTVkMzRkNmYzYzk3MS90YWJsZXJhbmdlOmNlZDA1N2MzMDZmYTQ1Y2NhN2ExNWQzNGQ2ZjNjOTcxXzktNC0xLTEtMA_af6f235b-7bb7-4d2f-98b9-afd2aeffea7d">9,020</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85b3f22a44da44e0b4f3300a912b0dc5_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTpjZWQwNTdjMzA2ZmE0NWNjYTdhMTVkMzRkNmYzYzk3MS90YWJsZXJhbmdlOmNlZDA1N2MzMDZmYTQ1Y2NhN2ExNWQzNGQ2ZjNjOTcxXzEwLTItMS0xLTA_a8fae69b-ef58-4a79-9ff1-b818a5cc4e70">264,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i988d5245b3374e39af5d4ec1f43b092f_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTpjZWQwNTdjMzA2ZmE0NWNjYTdhMTVkMzRkNmYzYzk3MS90YWJsZXJhbmdlOmNlZDA1N2MzMDZmYTQ1Y2NhN2ExNWQzNGQ2ZjNjOTcxXzEwLTQtMS0xLTA_241bd205-dc0f-4de3-b6f4-96a26e687190">145,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTpjZWQwNTdjMzA2ZmE0NWNjYTdhMTVkMzRkNmYzYzk3MS90YWJsZXJhbmdlOmNlZDA1N2MzMDZmYTQ1Y2NhN2ExNWQzNGQ2ZjNjOTcxXzExLTItMS0xLTA_bfb2aa98-dfbe-4a89-8e72-ace70cfca560">30,920,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTpjZWQwNTdjMzA2ZmE0NWNjYTdhMTVkMzRkNmYzYzk3MS90YWJsZXJhbmdlOmNlZDA1N2MzMDZmYTQ1Y2NhN2ExNWQzNGQ2ZjNjOTcxXzExLTQtMS0xLTA_8512db8a-c4af-46c6-9598-781c706cae05">33,655,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTpjZWQwNTdjMzA2ZmE0NWNjYTdhMTVkMzRkNmYzYzk3MS90YWJsZXJhbmdlOmNlZDA1N2MzMDZmYTQ1Y2NhN2ExNWQzNGQ2ZjNjOTcxXzEzLTItMS0xLTA_c6fde496-ab40-41fb-855e-9aa40730d894">882,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTpjZWQwNTdjMzA2ZmE0NWNjYTdhMTVkMzRkNmYzYzk3MS90YWJsZXJhbmdlOmNlZDA1N2MzMDZmYTQ1Y2NhN2ExNWQzNGQ2ZjNjOTcxXzEzLTQtMS0xLTA_43211833-2be9-4820-bb8d-0caac1074d27">784,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="i5dd16a8f46b94bb4a8c56ca652731e0d"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2013, the Company entered into an agreement with Pernix to distribute and promote the branded prescription product Omeclamox-Pak. The </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i0a05405482c64e9e8fe092b821aeb335_D20131028-20131029" decimals="-5" format="ixt:numdotdecimal" name="cpix:RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90ZXh0cmVnaW9uOmQ0MzVlOWNkMGI0ZTRiN2U4YmRjY2ZjYjYxOGRlMDI2XzY4Ng_33478ffe-be03-47a6-80c1-2de68ca940af">4.0</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> upfront payment the Company paid to Pernix during October 2013 and the $<ix:nonFraction unitRef="usd" contextRef="i34cdca865b434ae68e675f3de541d80f_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="cpix:RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90ZXh0cmVnaW9uOmQ0MzVlOWNkMGI0ZTRiN2U4YmRjY2ZjYjYxOGRlMDI2Xzc2MA_b6eb2339-d9b0-4350-80fa-9082d447ba0c">2.3</ix:nonFraction> million payments made to GEL during 2018 (discussed more fully in Note 3) are included in product and license rights and are being amortized through June 2032, the remaining expected useful life of the acquired asset. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2014, the Company acquired the rights of the branded prescription product Vaprisol from Astellas.  The intangible asset value is $<ix:nonFraction unitRef="usd" contextRef="i06508a7d5ed34904a9e7ba4b89125dfa_I20140228" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90ZXh0cmVnaW9uOmQ0MzVlOWNkMGI0ZTRiN2U4YmRjY2ZjYjYxOGRlMDI2XzExMTA_38d26dca-5d0d-414d-a07d-52082269d5e0">3.0</ix:nonFraction> million and is included in product and license rights.  The asset is being amortized through February 2022, the remaining expected useful life of the acquired asset, which coincides with the life of the primary intellectual property asset.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 3, in November 2016, the Company acquired the U.S. rights to Nordic Group B.V.&#8217;s injectable methotrexate product line as an asset purchase. The agreement requires the Company to provide unvested restricted shares of Cumberland common stock and make a series of payments tied to the products&#8217; FDA approval, launch and achievement of certain sales milestones. The payments are being treated as consideration for the assets acquired and are being capitalized and amortized over the expected useful life of the acquired asset. To date, the intangible assets related to the product include the $<ix:nonFraction unitRef="usd" contextRef="iebd5c24d9fc142c0b899398d6d3c153d_D20161101-20161130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90ZXh0cmVnaW9uOmQ0MzVlOWNkMGI0ZTRiN2U4YmRjY2ZjYjYxOGRlMDI2XzE5NTU_91547538-e6c9-4a39-b5f6-aba1500d1636">100,000</ix:nonFraction> deposit paid at closing, the <ix:nonFraction unitRef="shares" contextRef="i00c91a50edb844d99bb320b2490ff8d6_D20161101-20161130" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90ZXh0cmVnaW9uOmQ0MzVlOWNkMGI0ZTRiN2U4YmRjY2ZjYjYxOGRlMDI2XzE5ODc_8e1ddeb6-65ab-4853-9ab9-f7633662ac6c">180,000</ix:nonFraction> restricted shares valued at $<ix:nonFraction unitRef="usd" contextRef="i3dc00a50885944de8bd18286fb857d2a_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90ZXh0cmVnaW9uOmQ0MzVlOWNkMGI0ZTRiN2U4YmRjY2ZjYjYxOGRlMDI2XzIwMTg_a3ea59e4-0219-42bd-bdb3-9a0e10494056">0.9</ix:nonFraction> million that vested upon the November 2019 FDA approval and the additional $<ix:nonFraction unitRef="usd" contextRef="i741e5bc06ece4d28a49fb727a3756a7e_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90ZXh0cmVnaW9uOmQ0MzVlOWNkMGI0ZTRiN2U4YmRjY2ZjYjYxOGRlMDI2XzIwODg_0bb21c77-e31b-4fd7-815b-0d48c07bd98e">1.0</ix:nonFraction>&#160;million owed to Nordic during 2020, also based on the FDA approval. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 3, during November 2018, the Company acquired Vibativ from Theravance. This resulted in amortizable intangible assets related to the product rights of  $<ix:nonFraction unitRef="usd" contextRef="i4af7f789d58345659c0394f24e9c9d71_I20181130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90ZXh0cmVnaW9uOmQ0MzVlOWNkMGI0ZTRiN2U4YmRjY2ZjYjYxOGRlMDI2XzIzMjU_aded0194-abb3-41e4-ad0b-c9bc22391129">11.8</ix:nonFraction> million and goodwill of $<ix:nonFraction unitRef="usd" contextRef="i4af7f789d58345659c0394f24e9c9d71_I20181130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90ZXh0cmVnaW9uOmQ0MzVlOWNkMGI0ZTRiN2U4YmRjY2ZjYjYxOGRlMDI2XzIzNDQ_b271b242-0889-4b56-8926-7d15ff58f531">0.9</ix:nonFraction> million. The intangible assets are being amortized through November 2028, the expected useful life of the acquired asset.  The $<ix:nonFraction unitRef="usd" contextRef="i9f2a5edba28144ad932b2ce0fd047ab3_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GoodwillPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90ZXh0cmVnaW9uOmQ0MzVlOWNkMGI0ZTRiN2U4YmRjY2ZjYjYxOGRlMDI2XzI0NjY_d8d6c25a-6471-4102-9c2f-724784e6a347">0.1</ix:nonFraction>&#160;million increase in goodwill during 2019 was a result of changes in the purchase price allocation during the measurement period.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019 and 2018, the Company recorded an additional $<ix:nonFraction unitRef="usd" contextRef="i9264ef6a01f546dca65e6adec1f967fe_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90ZXh0cmVnaW9uOmQ0MzVlOWNkMGI0ZTRiN2U4YmRjY2ZjYjYxOGRlMDI2XzI2NDU_156cfb2d-8c7f-4e10-b631-f8aabba0c7e7">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0a52841e4c724bb9936223a8fd642381_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90ZXh0cmVnaW9uOmQ0MzVlOWNkMGI0ZTRiN2U4YmRjY2ZjYjYxOGRlMDI2XzI2NTI_2c003814-4135-404a-8c40-ac429e2c3eae">0.4</ix:nonFraction> million, respectively, in intangible assets for patents, trademarks and capitalized patent costs, including amounts incurred in the protection of the Company's intellectual property.  These costs will be amortized over the remaining expected useful life of the associated patents.</span></div><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90ZXh0cmVnaW9uOmQ0MzVlOWNkMGI0ZTRiN2U4YmRjY2ZjYjYxOGRlMDI2XzMxNzA_7871c292-8235-497f-b885-b8bdafd31936" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to product and license rights, trademarks and patents were as follows for the years ended December 31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:81.730%"><tr><td style="width:1.0%"></td><td style="width:38.115%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.939%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.507%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.511%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2017</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTo4NGU1MjViODc4Nzk0NzI4YjQ2ZTk4Y2QzMjYyZjdiZi90YWJsZXJhbmdlOjg0ZTUyNWI4Nzg3OTQ3MjhiNDZlOThjZDMyNjJmN2JmXzItMi0xLTEtMA_d74ac5fa-8dd6-42ee-aef2-1148ad301d2a">4,134,557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTo4NGU1MjViODc4Nzk0NzI4YjQ2ZTk4Y2QzMjYyZjdiZi90YWJsZXJhbmdlOjg0ZTUyNWI4Nzg3OTQ3MjhiNDZlOThjZDMyNjJmN2JmXzItNC0xLTEtMA_a07729b4-ac6d-415e-b469-15426b2c0a9b">2,769,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTo4NGU1MjViODc4Nzk0NzI4YjQ2ZTk4Y2QzMjYyZjdiZi90YWJsZXJhbmdlOjg0ZTUyNWI4Nzg3OTQ3MjhiNDZlOThjZDMyNjJmN2JmXzItNi0xLTEtMA_85ec8eaf-9b46-42e3-9189-e5d9b0028716">2,436,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected amortization expense for the Company's current balance of intangible assets are as follows:</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:80.769%"><tr><td style="width:1.0%"></td><td style="width:72.907%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.703%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTphYzZmMWE3MzQ0Njc0ZDdjOWE5YTA0NGNlN2Q0ZjkxMC90YWJsZXJhbmdlOmFjNmYxYTczNDQ2NzRkN2M5YTlhMDQ0Y2U3ZDRmOTEwXzEtMi0xLTEtMA_8bbddcf8-84ea-40d8-8d36-9b58c91c92d6">4,286,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTphYzZmMWE3MzQ0Njc0ZDdjOWE5YTA0NGNlN2Q0ZjkxMC90YWJsZXJhbmdlOmFjNmYxYTczNDQ2NzRkN2M5YTlhMDQ0Y2U3ZDRmOTEwXzItMi0xLTEtMA_7dfeccde-aca1-4869-b5c1-3748b65d3f99">4,084,702</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTphYzZmMWE3MzQ0Njc0ZDdjOWE5YTA0NGNlN2Q0ZjkxMC90YWJsZXJhbmdlOmFjNmYxYTczNDQ2NzRkN2M5YTlhMDQ0Y2U3ZDRmOTEwXzMtMi0xLTEtMA_7d25ec14-3a41-405f-86b0-1d91242fd8f6">3,530,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTphYzZmMWE3MzQ0Njc0ZDdjOWE5YTA0NGNlN2Q0ZjkxMC90YWJsZXJhbmdlOmFjNmYxYTczNDQ2NzRkN2M5YTlhMDQ0Y2U3ZDRmOTEwXzQtMi0xLTEtMA_13889ec7-5549-470d-9a0f-162e5d56a823">3,743,526</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="cpix:FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTphYzZmMWE3MzQ0Njc0ZDdjOWE5YTA0NGNlN2Q0ZjkxMC90YWJsZXJhbmdlOmFjNmYxYTczNDQ2NzRkN2M5YTlhMDQ0Y2U3ZDRmOTEwXzUtMi0xLTEtMA_b8a9f326-4509-4535-b438-4af72a10e0a1">15,274,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTphYzZmMWE3MzQ0Njc0ZDdjOWE5YTA0NGNlN2Q0ZjkxMC90YWJsZXJhbmdlOmFjNmYxYTczNDQ2NzRkN2M5YTlhMDQ0Y2U3ZDRmOTEwXzYtMi0xLTEtMA_56196795-67b4-4a7d-9fc2-d74778794974">30,920,324</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><div id="id2bfa55304bd45bbaa9cdf09bb7673a3_217"></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(8)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:OtherLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90ZXh0cmVnaW9uOjM5YmQzMTg2Nzc1MTRiZWRhNDIwZDJiNDMzNDY0YTg1XzEzMg_210f4cea-6dc0-4209-8dab-f3876a3f2806" continuedAt="i86d2ed052c4547c6addd455cccbd660a" escape="true">Other Current and Other Long-term Liabilities</ix:nonNumeric></span></div><ix:continuation id="i86d2ed052c4547c6addd455cccbd660a"><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90ZXh0cmVnaW9uOjM5YmQzMTg2Nzc1MTRiZWRhNDIwZDJiNDMzNDY0YTg1XzEyOA_0f0d8378-17ac-41a5-abbb-c45ba7793c9b" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities consisted of the following at December&#160;31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.378%"><tr><td style="width:1.0%"></td><td style="width:59.567%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.913%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.913%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.455%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates, product returns, administrative fees </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and service fees</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="cpix:ProductSalesRelatedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo2YmRmZDMwZTE1M2U0NDdkOWNlZDZkYWNjNGM0ZjhkZS90YWJsZXJhbmdlOjZiZGZkMzBlMTUzZTQ0N2Q5Y2VkNmRhY2M0YzRmOGRlXzItMi0xLTEtMA_7ab72c4c-553c-4bce-b7c4-693c3c73ad75">4,593,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="cpix:ProductSalesRelatedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo2YmRmZDMwZTE1M2U0NDdkOWNlZDZkYWNjNGM0ZjhkZS90YWJsZXJhbmdlOjZiZGZkMzBlMTUzZTQ0N2Q5Y2VkNmRhY2M0YzRmOGRlXzItNC0xLTEtMA_399bdbfd-b8ee-488f-a5c3-5565bd5e6c2a">4,969,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee wages and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo2YmRmZDMwZTE1M2U0NDdkOWNlZDZkYWNjNGM0ZjhkZS90YWJsZXJhbmdlOjZiZGZkMzBlMTUzZTQ0N2Q5Y2VkNmRhY2M0YzRmOGRlXzMtMi0xLTEtMA_bb25b69a-0829-40be-b001-8f0aed87cbd8">1,295,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo2YmRmZDMwZTE1M2U0NDdkOWNlZDZkYWNjNGM0ZjhkZS90YWJsZXJhbmdlOjZiZGZkMzBlMTUzZTQ0N2Q5Y2VkNmRhY2M0YzRmOGRlXzMtNC0xLTEtMA_29163c63-f382-446c-97ec-45353086ebce">1,263,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:zerodash" name="cpix:AccruedLiabilitiesStockPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo2YmRmZDMwZTE1M2U0NDdkOWNlZDZkYWNjNGM0ZjhkZS90YWJsZXJhbmdlOjZiZGZkMzBlMTUzZTQ0N2Q5Y2VkNmRhY2M0YzRmOGRlXzQtMi0xLTEtMA_38bf048f-a0d0-47e8-8e10-ec8e1411096f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="cpix:AccruedLiabilitiesStockPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo2YmRmZDMwZTE1M2U0NDdkOWNlZDZkYWNjNGM0ZjhkZS90YWJsZXJhbmdlOjZiZGZkMzBlMTUzZTQ0N2Q5Y2VkNmRhY2M0YzRmOGRlXzQtNC0xLTEtMA_8c07c52f-479d-4e38-a94a-0aacc309e226">1,085,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of accrued contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo2YmRmZDMwZTE1M2U0NDdkOWNlZDZkYWNjNGM0ZjhkZS90YWJsZXJhbmdlOjZiZGZkMzBlMTUzZTQ0N2Q5Y2VkNmRhY2M0YzRmOGRlXzUtMi0xLTEtMA_1275788a-832f-4646-9f4e-9a3acdf0cda9">2,374,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo2YmRmZDMwZTE1M2U0NDdkOWNlZDZkYWNjNGM0ZjhkZS90YWJsZXJhbmdlOjZiZGZkMzBlMTUzZTQ0N2Q5Y2VkNmRhY2M0YzRmOGRlXzUtNC0xLTEtMA_04ed34de-cd98-41cb-b4bf-4ab76d2935a6">2,290,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred acquisition liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:zerodash" name="cpix:DeferredAcquisitionLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo2YmRmZDMwZTE1M2U0NDdkOWNlZDZkYWNjNGM0ZjhkZS90YWJsZXJhbmdlOjZiZGZkMzBlMTUzZTQ0N2Q5Y2VkNmRhY2M0YzRmOGRlXzYtMi0xLTEtMA_95ff8128-0333-4995-b354-7acdef403b63">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="cpix:DeferredAcquisitionLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo2YmRmZDMwZTE1M2U0NDdkOWNlZDZkYWNjNGM0ZjhkZS90YWJsZXJhbmdlOjZiZGZkMzBlMTUzZTQ0N2Q5Y2VkNmRhY2M0YzRmOGRlXzYtNC0xLTEtMA_7315b883-cc3f-434e-8cd9-1f7ff8efc179">5,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued inventory purchases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="cpix:AccruedLiabilitiesInventoryPurchases" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo2YmRmZDMwZTE1M2U0NDdkOWNlZDZkYWNjNGM0ZjhkZS90YWJsZXJhbmdlOjZiZGZkMzBlMTUzZTQ0N2Q5Y2VkNmRhY2M0YzRmOGRlXzctMi0xLTEtMA_5c5c03f8-e630-4545-9717-0df7d1c1ce8a">829,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="cpix:AccruedLiabilitiesInventoryPurchases" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo2YmRmZDMwZTE1M2U0NDdkOWNlZDZkYWNjNGM0ZjhkZS90YWJsZXJhbmdlOjZiZGZkMzBlMTUzZTQ0N2Q5Y2VkNmRhY2M0YzRmOGRlXzctNC0xLTEtMA_77af1f15-c383-4c9c-9392-641da589bbe8">434,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payment for asset purchase</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="cpix:AccruedPaymentForAssetPurchaseCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo2YmRmZDMwZTE1M2U0NDdkOWNlZDZkYWNjNGM0ZjhkZS90YWJsZXJhbmdlOjZiZGZkMzBlMTUzZTQ0N2Q5Y2VkNmRhY2M0YzRmOGRlXzgtMi0xLTEtMA_97c15834-1ca3-4d51-ad90-60b67d0d293f">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:zerodash" name="cpix:AccruedPaymentForAssetPurchaseCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo2YmRmZDMwZTE1M2U0NDdkOWNlZDZkYWNjNGM0ZjhkZS90YWJsZXJhbmdlOjZiZGZkMzBlMTUzZTQ0N2Q5Y2VkNmRhY2M0YzRmOGRlXzgtNC0xLTEtMA_865c4f92-5d59-4305-a41b-f9ab1f69254a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo2YmRmZDMwZTE1M2U0NDdkOWNlZDZkYWNjNGM0ZjhkZS90YWJsZXJhbmdlOjZiZGZkMzBlMTUzZTQ0N2Q5Y2VkNmRhY2M0YzRmOGRlXzktMi0xLTEtMA_13bbdd42-8350-4210-9376-eefd5cdc3033">991,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo2YmRmZDMwZTE1M2U0NDdkOWNlZDZkYWNjNGM0ZjhkZS90YWJsZXJhbmdlOjZiZGZkMzBlMTUzZTQ0N2Q5Y2VkNmRhY2M0YzRmOGRlXzktNC0xLTEtMA_bc30846f-40e2-4ab0-92f7-485f28d492df">1,001,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo2YmRmZDMwZTE1M2U0NDdkOWNlZDZkYWNjNGM0ZjhkZS90YWJsZXJhbmdlOjZiZGZkMzBlMTUzZTQ0N2Q5Y2VkNmRhY2M0YzRmOGRlXzEwLTItMS0xLTA_e2496777-527f-4302-8428-22ffbbc0a39c">11,084,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo2YmRmZDMwZTE1M2U0NDdkOWNlZDZkYWNjNGM0ZjhkZS90YWJsZXJhbmdlOjZiZGZkMzBlMTUzZTQ0N2Q5Y2VkNmRhY2M0YzRmOGRlXzEwLTQtMS0xLTA_065a7441-e14b-4524-9ef5-aef6f9d7fd74">16,044,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt"><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:OtherNoncurrentLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90ZXh0cmVnaW9uOjM5YmQzMTg2Nzc1MTRiZWRhNDIwZDJiNDMzNDY0YTg1XzEyOQ_47475599-d7df-44bc-9d6e-f0e2de7620b6" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.897%"><tr><td style="width:1.0%"></td><td style="width:59.907%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.559%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent portion of accrued contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo5Mzc5YjYzYWRkYmE0NzY2ODhmZmFmYWIwN2E2ODk1Yy90YWJsZXJhbmdlOjkzNzliNjNhZGRiYTQ3NjY4OGZmYWZhYjA3YTY4OTVjXzItMi0xLTEtMA_e63ec625-2fe7-4266-9659-c064ee5f236a">6,258,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo5Mzc5YjYzYWRkYmE0NzY2ODhmZmFmYWIwN2E2ODk1Yy90YWJsZXJhbmdlOjkzNzliNjNhZGRiYTQ3NjY4OGZmYWZhYjA3YTY4OTVjXzItNC0xLTEtMA_118e2077-32d2-481a-bc85-db2ccb13768a">7,212,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo5Mzc5YjYzYWRkYmE0NzY2ODhmZmFmYWIwN2E2ODk1Yy90YWJsZXJhbmdlOjkzNzliNjNhZGRiYTQ3NjY4OGZmYWZhYjA3YTY4OTVjXzMtMi0xLTEtMA_43716bf2-c127-4bae-af9f-ff36270dbaa0">2,278,164</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo5Mzc5YjYzYWRkYmE0NzY2ODhmZmFmYWIwN2E2ODk1Yy90YWJsZXJhbmdlOjkzNzliNjNhZGRiYTQ3NjY4OGZmYWZhYjA3YTY4OTVjXzMtNC0xLTEtMA_bd10ae8a-d1a9-4ac0-b0bd-45fb7145ca4f">1,588,123</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo5Mzc5YjYzYWRkYmE0NzY2ODhmZmFmYWIwN2E2ODk1Yy90YWJsZXJhbmdlOjkzNzliNjNhZGRiYTQ3NjY4OGZmYWZhYjA3YTY4OTVjXzQtMi0xLTEtMA_5cce5822-238d-4b17-8b98-916bf7a61e92">200,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo5Mzc5YjYzYWRkYmE0NzY2ODhmZmFmYWIwN2E2ODk1Yy90YWJsZXJhbmdlOjkzNzliNjNhZGRiYTQ3NjY4OGZmYWZhYjA3YTY4OTVjXzQtNC0xLTEtMA_9711be0b-f427-438a-9d28-bfc18c719982">519,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo5Mzc5YjYzYWRkYmE0NzY2ODhmZmFmYWIwN2E2ODk1Yy90YWJsZXJhbmdlOjkzNzliNjNhZGRiYTQ3NjY4OGZmYWZhYjA3YTY4OTVjXzUtMi0xLTEtMA_54b6c853-20d3-4641-b9e7-a05909d2c557">8,737,323</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo5Mzc5YjYzYWRkYmE0NzY2ODhmZmFmYWIwN2E2ODk1Yy90YWJsZXJhbmdlOjkzNzliNjNhZGRiYTQ3NjY4OGZmYWZhYjA3YTY4OTVjXzUtNC0xLTEtMA_57a721fa-15b4-4f43-b53d-f4b6a0d6e006">9,319,143</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="id2bfa55304bd45bbaa9cdf09bb7673a3_220"></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(9)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjAvZnJhZzpjNGU5NzJlZDlmMGY0MDU2YTZiZGI3MWVkNDZmYjBjYy90ZXh0cmVnaW9uOmM0ZTk3MmVkOWYwZjQwNTZhNmJkYjcxZWQ0NmZiMGNjXzIwODc_655c81a9-0fa6-4557-ad6e-d5d8bab7c25b" continuedAt="if23e042a827c426e8c5a41b4788e2de6" escape="true">Debt</ix:nonNumeric></span></div><div style="text-indent:18pt"><span><br/></span></div><ix:continuation id="if23e042a827c426e8c5a41b4788e2de6" continuedAt="if6922b86bcb345d78b01bee323cf6e46"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May 10, 2019, the Company entered into a third amendment ("Third Amendment") to the Revolving Credit Loan Agreement, dated July 28, 2017, with Pinnacle Bank (&#8220;Pinnacle Agreement&#8221;). The Third Amendment extended the term of the Pinnacle Agreement through July 31, 2021 as well as modified certain definitions and terms of the existing financial covenants, including the definition of the Funded Debt Ratio and the compliance target of the Tangible Capital Ratio. Both Third Amendment modifications were related to the Vibativ transaction.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the Pinnacle Agreement, Cumberland was initially subject to one financial covenant, the maintenance of a Funded Debt Ratio, as such term is defined in the agreement and determined on a quarterly basis.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 14, 2018, the Company amended the Pinnacle Agreement ("First Amendment") to replace the single financial covenant with the maintenance of either the Funded Debt Ratio or a Tangible Capital Ratio, as defined in the First Amendment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company achieved compliance with the Tangible Capital Ratio financial covenant as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December&#160;31, 2019.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The initial revolving line of credit under the Pinnacle Agreement was for up to an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i72d98b8b6d2b49ec92a95f7f52a21bb0_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjAvZnJhZzpjNGU5NzJlZDlmMGY0MDU2YTZiZGI3MWVkNDZmYjBjYy90ZXh0cmVnaW9uOmM0ZTk3MmVkOWYwZjQwNTZhNmJkYjcxZWQ0NmZiMGNjXzEyMTU_6c0f0a46-4105-40a2-a43f-e0b2eacc76ef">12.0</ix:nonFraction> million with the ability to increase the principal amount available for borrowing up to $<ix:nonFraction unitRef="usd" contextRef="i72d98b8b6d2b49ec92a95f7f52a21bb0_I20191231" decimals="INF" format="ixt:numdotdecimal" name="cpix:LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjAvZnJhZzpjNGU5NzJlZDlmMGY0MDU2YTZiZGI3MWVkNDZmYjBjYy90ZXh0cmVnaW9uOmM0ZTk3MmVkOWYwZjQwNTZhNmJkYjcxZWQ0NmZiMGNjXzEyOTg_d5aa60ba-c71c-4415-95fc-63c33f5105dc">20.0</ix:nonFraction> million, upon the satisfaction of certain conditions.  On October 17, 2018, the Company entered into a second amendment (&#8220;Second Amendment&#8221;) which increased the maximum aggregate principal available for borrowing under the Pinnacle Agreement to $<ix:nonFraction unitRef="usd" contextRef="i20968f0f5b524d799086597dfddc2a8d_I20181017" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjAvZnJhZzpjNGU5NzJlZDlmMGY0MDU2YTZiZGI3MWVkNDZmYjBjYy90ZXh0cmVnaW9uOmM0ZTk3MmVkOWYwZjQwNTZhNmJkYjcxZWQ0NmZiMGNjXzE1Mzg_67aa3e65-4b8d-463a-8275-e5a03d63463c">20.0</ix:nonFraction> million.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company had $<ix:nonFraction unitRef="usd" contextRef="i5275515928ca439196af82cb649ddae9_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermLineOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjAvZnJhZzpjNGU5NzJlZDlmMGY0MDU2YTZiZGI3MWVkNDZmYjBjYy90ZXh0cmVnaW9uOmM0ZTk3MmVkOWYwZjQwNTZhNmJkYjcxZWQ0NmZiMGNjXzE1NjE_14ab1b08-fccb-454c-8127-dcf75af76630">18.5</ix:nonFraction> million in borrowings under the Pinnacle Agreement at December&#160;31, 2019 and $<ix:nonFraction unitRef="usd" contextRef="iba0ec1144cb840b3a4076d92998f6ae8_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermLineOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjAvZnJhZzpjNGU5NzJlZDlmMGY0MDU2YTZiZGI3MWVkNDZmYjBjYy90ZXh0cmVnaW9uOmM0ZTk3MmVkOWYwZjQwNTZhNmJkYjcxZWQ0NmZiMGNjXzE2MTc_b705e576-fc2a-4c27-8eee-2e42dbd74627">20.0</ix:nonFraction> million at December&#160;31, 2018.  </span></div></ix:continuation><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if6922b86bcb345d78b01bee323cf6e46">The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. There is no LIBOR minimum and the LIBOR pricing provides for an interest rate spread of <ix:nonFraction unitRef="number" contextRef="icd700ec4abf947049e74967c3f1ebec7_I20191231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjAvZnJhZzpjNGU5NzJlZDlmMGY0MDU2YTZiZGI3MWVkNDZmYjBjYy90ZXh0cmVnaW9uOmM0ZTk3MmVkOWYwZjQwNTZhNmJkYjcxZWQ0NmZiMGNjXzE4MDk_7d1547cf-4963-4b08-8248-17d957b337c8">1.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i3296f434993a41289fb9d9eab42374e7_I20191231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjAvZnJhZzpjNGU5NzJlZDlmMGY0MDU2YTZiZGI3MWVkNDZmYjBjYy90ZXh0cmVnaW9uOmM0ZTk3MmVkOWYwZjQwNTZhNmJkYjcxZWQ0NmZiMGNjXzE4MTU_09f30bf6-e951-4ad8-b37e-8ea8ffca6806">2.75</ix:nonFraction>% (representing an interest rate of <ix:nonFraction unitRef="number" contextRef="i72d98b8b6d2b49ec92a95f7f52a21bb0_I20191231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjAvZnJhZzpjNGU5NzJlZDlmMGY0MDU2YTZiZGI3MWVkNDZmYjBjYy90ZXh0cmVnaW9uOmM0ZTk3MmVkOWYwZjQwNTZhNmJkYjcxZWQ0NmZiMGNjXzE4NTI_75834d8e-535f-43d3-a709-8131a5476820">4.5</ix:nonFraction>% at December&#160;31, 2019).  In addition, a fee of <ix:nonFraction unitRef="number" contextRef="i870374f6814b4d6cb3842ed1bada7231_D20170731-20170731" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjAvZnJhZzpjNGU5NzJlZDlmMGY0MDU2YTZiZGI3MWVkNDZmYjBjYy90ZXh0cmVnaW9uOmM0ZTk3MmVkOWYwZjQwNTZhNmJkYjcxZWQ0NmZiMGNjXzE4ODY_e80d7a59-6ff6-434f-8379-1fc01a011637">0.25</ix:nonFraction>% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  Borrowings under the line of credit are collateralized by substantially all of our assets.</ix:continuation> </span></div><div id="id2bfa55304bd45bbaa9cdf09bb7673a3_223"></div><div style="margin-top:8pt;text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(10)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzUzOTU_58e96794-4766-48ae-aa32-dbb252da2659" continuedAt="i683536c9bbb7459d8d7651262e5ed94a" escape="true">Shareholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="i683536c9bbb7459d8d7651262e5ed94a" continuedAt="i1b5c9efdd2934909805456d318629f0e"><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Initial Public Offering</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="i9249561602f042ba980b18815fa29971_D20090809-20090810" format="ixt:datemonthdayyearen" name="us-gaap:SaleOfStockTransactionDate" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzYy_746f549d-985e-46a9-990f-e74c4d6b7053">August&#160;10, 2009</ix:nonNumeric>, the Company completed its initial public offering of <ix:nonFraction unitRef="shares" contextRef="i9249561602f042ba980b18815fa29971_D20090809-20090810" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzExOQ_a8bee154-753b-4ce2-9b12-bfb2548869e0">5,000,000</ix:nonFraction> shares of common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i9249561602f042ba980b18815fa29971_D20090809-20090810" decimals="INF" name="cpix:StockIssuedDuringPeriodPricePerShareNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzE2MA_392a467d-7ac9-4404-a558-2dac955fe1db">17.00</ix:nonFraction> per share, raising gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i9249561602f042ba980b18815fa29971_D20090809-20090810" decimals="-5" format="ixt:numdotdecimal" name="cpix:StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzIwMQ_8620504a-f5ea-4e0a-a508-c1b1250e31be">85.0</ix:nonFraction> million. After deducting underwriting discounts of approximately $<ix:nonFraction unitRef="usd" contextRef="i9249561602f042ba980b18815fa29971_D20090809-20090810" decimals="-5" format="ixt:numdotdecimal" name="cpix:StockIssuedDuringPeriodNewSharesUnderwritingDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzI2Mg_74360878-c598-4f02-9b4d-15335a6d6065">6.0</ix:nonFraction> million and offering costs incurred of approximately $<ix:nonFraction unitRef="usd" contextRef="i9249561602f042ba980b18815fa29971_D20090809-20090810" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzMxMQ_6a3f00b5-162d-4c5d-8006-867e3cd3cdb2">4.2</ix:nonFraction> million, the net proceeds to the Company were approximately $<ix:nonFraction unitRef="usd" contextRef="i9249561602f042ba980b18815fa29971_D20090809-20090810" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzM2Nw_fe84e69e-d1c5-4070-a73b-20cb2705d72b">74.8</ix:nonFraction> million. Contemporaneously with the offering, each outstanding share of preferred stock was automatically converted into <ix:nonFraction unitRef="number" contextRef="i9249561602f042ba980b18815fa29971_D20090809-20090810" decimals="INF" format="ixt-sec:numwordsen" name="cpix:StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzQ4Mw_d607c534-0d51-4a32-bac1-18a8160d2478">two million</ix:nonFraction> shares of common stock.</span></div><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Preferred Stock</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue <ix:nonFraction unitRef="shares" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzU2NQ_de4a3f1c-f5e2-4c85-bfca-11765fb48d9f">20,000,000</ix:nonFraction>&#160;shares of preferred stock. The Board of Directors is authorized to divide these shares into classes or series, and to fix and determine the relative rights, preferences, qualifications and limitations of the shares of any class or series so established. At December&#160;31, 2019 and 2018, there was no preferred stock outstanding.</span></div><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Common Stock</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, 2018 and 2017, the Company issued <ix:nonFraction unitRef="shares" contextRef="i52ca8e03f38a46ab80ee3b1b2a37a943_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzkzNg_db43d325-bcd1-432c-9d1d-f310ccd7612d">225,536</ix:nonFraction> shares, <ix:nonFraction unitRef="shares" contextRef="i8b9e95130dc146f9aa56d8d1d11bc534_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzk0Nw_4523518d-d58d-48cd-9025-24c0ad2b075b">170,759</ix:nonFraction> shares, and <ix:nonFraction unitRef="shares" contextRef="i6921ef0b4c9446b6a5f25b2084bdc3ca_D20170101-20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzk2Mg_94dbe81d-0904-48f5-a9a8-696c650913cd">146,275</ix:nonFraction> shares of common stock, respectively, as a result of restricted shares vesting as well as other common share issuances.  Cumberland issued <ix:nonFraction unitRef="shares" contextRef="i1b76324a8a3c4073a8a827f31c55b373_D20160101-20161231" decimals="INF" format="ixt:numdotdecimal" name="cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzExMDQ_98fc5144-1f1e-425f-a399-09ba5f1a3b1b">3,409</ix:nonFraction> common shares under option exercise transactions during 2016.  There were no option exercise transactions during 2019,  2018 and 2017.  </span></div></ix:continuation><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="i1b5c9efdd2934909805456d318629f0e" continuedAt="icb5cd50cf6ea4d73ab352ee03aa2adb4"><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, the Company's Form S-3 or Shelf Registration associated with the sale of up to $<ix:nonFraction unitRef="usd" contextRef="ic8a09f2f029d4cf5b809b640237883a1_D20180101-20180131" decimals="-6" format="ixt:numdotdecimal" name="cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzEzMzU_d471e221-e933-41ca-b9c7-2eb3bc473e5b">100</ix:nonFraction> million in corporate securities was declared effective. The Shelf Registration also included an At-the-Market ("ATM") feature enabling the Company to sell common shares at market prices, along with an agreement with B. Riley FBR to support such a placement of shares.</span></div><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Warrants</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2006, the Company signed a new line of credit agreement along with a term loan agreement with a financial institution. In conjunction with these agreements, the Company issued warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="ia45e033a0968470a87498cc6e80e79bb_I20061231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzE4MTc_ad1b4e8a-2b19-45d1-94a6-931e12b59373">3,958</ix:nonFraction>&#160;shares of common stock at $<ix:nonFraction unitRef="usdPerShare" contextRef="ia45e033a0968470a87498cc6e80e79bb_I20061231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzE4NDc_895ffdf7-fb63-4271-b4fb-9d812659f6fb">9.00</ix:nonFraction> per share within 10 years of issuance.  All of these warrants expired during 2017.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the amendment to the debt agreements in 2009, the Company issued warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="i65091fc0eec54e3ebe7cadf845bfc5c3_I20091231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzIwNDQ_59fa06ee-0fbf-4267-97be-de5070c942a5">7,500</ix:nonFraction> shares of common stock at $<ix:nonFraction unitRef="usdPerShare" contextRef="i65091fc0eec54e3ebe7cadf845bfc5c3_I20091231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzIwNzQ_f5a9b8bc-80ac-4104-9e6a-f66d3055c53f">17.00</ix:nonFraction> per share that expired in July 2019.  As of December&#160;31, 2019, there were no outstanding warrants.  </span></div><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(e)&#160;&#160;&#160;&#160;Share Repurchases</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company currently has a share repurchase program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="ieb984696887341bdb3d482415e883068_I20100531" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzIyNTM_fe92b2f5-70bc-4090-a767-524b2d93b6f4">10</ix:nonFraction> million of its common stock pursuant to Rule 10b-18 of the Securities Act. In January 2019, the Company's Board of Directors established the current $<ix:nonFraction unitRef="usd" contextRef="ieb984696887341bdb3d482415e883068_I20100531" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzIzOTg_7de7418c-83c6-4ce8-9ebe-7cea6e7a060b">10</ix:nonFraction> million repurchase program to replace the prior authorizations. The Company repurchased <ix:nonFraction unitRef="shares" contextRef="i42d555993abb411fbcfac8eefe7bfc92_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzI0ODE_69bee440-2a15-4bc7-902a-ca072200b908">623,478</ix:nonFraction> shares, <ix:nonFraction unitRef="shares" contextRef="icd076322bd3e4e45812f30f6e0265418_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzI0OTI_d35569ef-6de5-4046-9a20-eab25c1b2535">443,041</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i0be3acf257f24f79aeb0cfd8403ccd87_D20170101-20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzI1MDY_13a7016c-7eef-4936-beea-ea94edf643ac">547,376</ix:nonFraction> shares of common stock for approximately $<ix:nonFraction unitRef="usd" contextRef="i42d555993abb411fbcfac8eefe7bfc92_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzI1NTA_efa31285-05c7-41d5-b3fa-cad4c094fadb">3.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="icd076322bd3e4e45812f30f6e0265418_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzI1NTQ_ce10dffc-f04f-45c2-9b79-17bb47b1308d">2.9</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i0be3acf257f24f79aeb0cfd8403ccd87_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzI1NjI_2936d73a-1418-4d9f-b911-ab7953af07c8">3.7</ix:nonFraction> million during the years ended December&#160;31, 2019, 2018 and 2017, respectively. There remains $<ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzI2MzE_8b12e312-1af5-4b47-a7e5-a4fe89a4afe0">8.0</ix:nonFraction> million available under the current repurchase program available for share repurchases at December&#160;31, 2019.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(f)&#160;&#160;&#160;&#160;Cumberland Emerging Technologies</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, Cumberland Emerging Technologies ("CET"), our majority-owned subsidiary, entered into </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an agreement with WinHealth whereby WinHealth made a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="i5465c80566344695bc41a215e251af48_D20190401-20190430" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzI5MTE_bde42759-7201-4a8f-8db1-d3c7e3cbe497">1</ix:nonFraction> million </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investment through the purchase of shares of CET stock. As part of the agreement, WinHealth obtained a Board position at CET and the first opportunity to license CET products for the Chinese market. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  In connection with WinHealth&#8217;s investment in CET, the Company also made an additional $<ix:nonFraction unitRef="usd" contextRef="i917430c8015149c18c59ded862b49717_I20190430" decimals="-5" format="ixt:numdotdecimal" name="cpix:SubsidiaryInvestmentPurchaseOfShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzMyMDE_a7e9c8e8-b858-4b79-b604-464e29bac058">1</ix:nonFraction> million investment in CET.  Cumberland </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">purchased additional CET shares through contribution of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="i8e71f9e142114cb1a967ae279d7a32d8_D20140401-20140430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzMyOTE_56d85eca-cdfe-43be-9b61-c1e0c8bbfa1f">0.3</ix:nonFraction> million in cash and a conversion of $<ix:nonFraction unitRef="usd" contextRef="i8e71f9e142114cb1a967ae279d7a32d8_D20140401-20140430" decimals="-5" format="ixt:numdotdecimal" name="cpix:LoansForgiveninExchangeForShareIssuedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzMzMjI_bfc62ab8-3254-4a53-9235-4bdbb05382b5">0.7</ix:nonFraction> million in intercompany loans payable.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon completion of the additional investment by WinHealth and Cumberland, Gloria Pharmaceuticals agreed to return its shares in CET in exchange for consideration of  $<ix:nonFraction unitRef="usd" contextRef="i3522d1a659a04358b4f6ed8b764dd9e5_D20190401-20190430" decimals="-5" name="cpix:SubsidiaryInvestmentPaymentsForReturnOfCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzM1MjM_aec2b106-0b20-4987-ba5c-3bc578988a46">0.8</ix:nonFraction>&#160;million. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> After the additional investment, the Company&#8217;s ownership in CET is <ix:nonFraction unitRef="number" contextRef="ie1b2c35fc3b6418cb8cc3c920e5ae3d6_I20191231" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzM2MDM_7588577f-b0d7-4bc1-8144-24c04084bba9">85</ix:nonFraction>%.  As CET is a consolidated subsidiary, the Company reports the operating results of CET and allocates the noncontrolling interests to the non-majority partners.  </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(g)  &#160;&#160;&#160;&#160;Cumberland Foundation </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Company formed the Cumberland Pharma Foundation (the "Foundation") to serve as a vehicle to facilitate the ongoing philanthropic endeavors of Cumberland Pharmaceuticals Inc. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Foundation was formed as a nonprofit corporation designed to qualify as a tax-exempt organization pursuant to Section 501(a) of the Internal Revenue Code. The Foundation&#8217;s Board of Directors is comprised of Cumberland Pharmaceuticals executives who are responsible for overseeing the Foundation&#8217;s ongoing activities including charitable contributions. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2018, Cumberland provided a grant of <ix:nonFraction unitRef="shares" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="cpix:SharebasedCompensationCharitableContributionofSharesShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzQzOTM_60dea78d-2636-4aec-a33c-8800d7f96fe5">50,000</ix:nonFraction> shares of the Company's common stock to the Foundation. The shares will address the ongoing financial needs of the organization, with most of the shares expected to be held for the opportunity to realize long term appreciation to support the Foundation&#8217;s future. The Foundation maintains separate financial statements and its ongoing operations will not impact the financial statements of Cumberland Pharmaceuticals. Initial annual grants by the Foundation have been and are expected to remain consistent with the historic level of contributions made by Cumberland Pharmaceuticals.  During 2019, Cumberland Pharmaceuticals committed approximately $<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="cpix:ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzUwNDM_59590114-c264-45f1-ab52-cb2fd69d341d">50,000</ix:nonFraction> in cash contributions to be paid to the Foundation during 2020. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><ix:continuation id="icb5cd50cf6ea4d73ab352ee03aa2adb4"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nordic Group B.V.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2019, Cumberland received approval from the FDA for the pre-filled syringe of the Methotrexate product.  With this approval, Nordic's <ix:nonFraction unitRef="shares" contextRef="ib2b3b044fded4d4a96267ff40f75f41d_D20191127-20191127" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzUyODQ_3b7d94d6-f4cf-4043-b44f-e59b07772972">180,000</ix:nonFraction> shares of Cumberland's common stock became vested.  The value of these shares at the date of approval was $<ix:nonFraction unitRef="usd" contextRef="ib2b3b044fded4d4a96267ff40f75f41d_D20191127-20191127" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzUzOTM_f598f2a6-1a2d-415a-9a0f-127f3cab5a81">0.9</ix:nonFraction>&#160;million.</span></div></ix:continuation><div id="id2bfa55304bd45bbaa9cdf09bb7673a3_226"></div><div style="margin-top:8pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(11)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90ZXh0cmVnaW9uOjYwYzA1OTZkYWNjZjQ3NjY4MDliMzkzZGM1NmQ5OGUyXzMzMg_79ccd160-a612-4859-822a-e11e14776316" continuedAt="i167987f8dd12435f9ecdaa41662fc23e" escape="true">Earnings (Loss) Per Share </ix:nonNumeric></span></div><ix:continuation id="i167987f8dd12435f9ecdaa41662fc23e"><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90ZXh0cmVnaW9uOjYwYzA1OTZkYWNjZjQ3NjY4MDliMzkzZGM1NmQ5OGUyXzMyOQ_2d0b2ce0-7564-432d-82fd-fe439dfc4d9f" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the computation of the numerator and the denominator used to calculate diluted earnings (loss) per share for the years ended December 31:</span></div><div style="margin-bottom:10pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.294%"><tr><td style="width:1.0%"></td><td style="width:41.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.010%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.531%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.534%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzMtMi0xLTEtMTUxMQ_e6c2c40d-8bc3-43df-b81f-246f366e35f0">9,211,688</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzMtNC0xLTEtMTUxMw_a8a4b4d6-7773-4394-aa5d-46e70762ac4b">10,820,996</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzMtNi0xLTEtMTUxNQ_644433f8-a8f5-493f-8429-aa9b20213ad9">12,847,840</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzQtMi0xLTEtMTUxMQ_2d5b7e42-e5fa-44f5-9d12-bd04792b941c">5,665,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzQtNC0xLTEtMTUxMw_bbfc539d-4ccc-4e15-9874-f66722bf2d76">3,782,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzQtNi0xLTEtMTUxNQ_7784ee07-9950-4c24-b7f3-f3ac0d091233">4,798,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzUtMi0xLTEtMjIyOA_03ac504f-d5e1-478f-bed3-f82861bd6972">3,546,511</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzUtNC0xLTEtMjIyOA_039995f2-14e6-4110-8289-a83040586a1b">7,038,772</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzUtNi0xLTEtMjIyOA_e461cb0c-df8c-46ce-8c7a-55f45394341b">8,049,815</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss at subsidiary attributable to noncontrolling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzYtMi0xLTEtMjIyOA_2a41210e-25fd-442e-8987-2dfc460a8d44">8,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzYtNC0xLTEtMjIyOA_90ad1b36-e51b-4bb9-8465-4ff71d995088">75,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzYtNi0xLTEtMjIyOA_a37afbff-780b-40bc-9324-5b3bb249f69b">71,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzMtMi0xLTEtMA_f1651aa2-4a79-4695-a1df-9f5652a29f77">3,537,759</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzMtNC0xLTEtMA_a3374253-63e7-43d9-a6e4-0d6bafe90236">6,963,068</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzMtNi0xLTEtMA_a3b042a1-f29b-41fc-923e-5ec1bad7ded8">7,978,633</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzYtMi0xLTEtMA_c1306e0e-cc70-491e-98a6-f15a57a61645">15,396,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzYtNC0xLTEtMA_1d3ab8c3-ff3a-407a-9d90-19b5d8c6fa24">15,614,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzYtNi0xLTEtMA_1fa6313b-1ce0-48c5-95bf-819cfcbab505">15,911,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of restricted stock and stock options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzctMi0xLTEtMA_9c1c13c3-9263-4393-bb1b-bec968e015de">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzctNC0xLTEtMA_e1a0262c-5f52-49e5-b315-78f22315a0ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzctNi0xLTEtMA_6cc1e16a-313b-45fc-a58b-ae16d52947cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzgtMi0xLTEtMA_5c292cf6-baff-49e3-a7a4-09e9baedf40e">15,396,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzgtNC0xLTEtMA_5394aef4-10b1-4f6b-8ea2-6147449e9295">15,614,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzgtNi0xLTEtMA_6cb6387f-0579-4cf9-8fd4-85078bbd039e">15,911,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90ZXh0cmVnaW9uOjYwYzA1OTZkYWNjZjQ3NjY4MDliMzkzZGM1NmQ5OGUyXzMzMQ_e4bd20f7-0dc7-4ede-b291-889175bb1d12" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's anti-dilutive restricted shares and stock options outstanding were as follows for the years ended December 31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:88.301%"><tr><td style="width:1.0%"></td><td style="width:38.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.048%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2017</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive shares and options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZToyNTkzN2FkMzlhOGY0OTJhODY5MmYwOGE2NWM0YTVjZC90YWJsZXJhbmdlOjI1OTM3YWQzOWE4ZjQ5MmE4NjkyZjA4YTY1YzRhNWNkXzItMi0xLTEtMA_0fb9fb70-dd6e-424d-b978-8b9993940bfb">4,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZToyNTkzN2FkMzlhOGY0OTJhODY5MmYwOGE2NWM0YTVjZC90YWJsZXJhbmdlOjI1OTM3YWQzOWE4ZjQ5MmE4NjkyZjA4YTY1YzRhNWNkXzItNC0xLTEtMA_61e38a45-c838-430f-8e90-5672d19bb900">41,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZToyNTkzN2FkMzlhOGY0OTJhODY5MmYwOGE2NWM0YTVjZC90YWJsZXJhbmdlOjI1OTM3YWQzOWE4ZjQ5MmE4NjkyZjA4YTY1YzRhNWNkXzItNi0xLTEtMA_68834f12-3586-4d5f-8c7f-d44e55c28228">18,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><div id="id2bfa55304bd45bbaa9cdf09bb7673a3_229"></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:8pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(12)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90ZXh0cmVnaW9uOjEzZjkwZjc3YzAyNDQxNjY4Njg1ZTQ4OThjOTc1M2Q5XzI1NzU_21c6e8bb-7535-4a32-9589-6bbfcf4ad933" continuedAt="i8a17972210a84286a96245cb5ac075da" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i8a17972210a84286a96245cb5ac075da" continuedAt="if08fdc6ecc954b2d90c5899cb053a73f"><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90ZXh0cmVnaW9uOjEzZjkwZjc3YzAyNDQxNjY4Njg1ZTQ4OThjOTc1M2Q5XzI1Nzc_32d5ba34-da28-40e9-9afb-8b880063ca79" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company's net deferred tax assets at December&#160;31 are as follows:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.544%"><tr><td style="width:1.0%"></td><td style="width:61.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.861%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.599%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.861%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss and tax credits</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="cpix:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzMtMi0xLTEtMA_57b631c8-dc01-4385-a06e-196fad874e4d">16,964,685</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="cpix:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzMtNC0xLTEtMA_7b4163b7-ebcb-4e98-9ab6-eb15da932ded">16,410,403</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment and intangibles</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="cpix:DeferredTaxAssetsPropertyAndEquipmentAndIntangibles" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzQtMi0xLTEtMA_413653f6-e8e7-430e-a1af-0b4e182ad3c9">227,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="cpix:DeferredTaxAssetsPropertyAndEquipmentAndIntangibles" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzQtNC0xLTEtMA_ff2535f4-3cba-423c-85fd-cf2f25c5ec00">236,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for accounts receivable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzUtMi0xLTEtMA_3056afe3-cdd0-42ef-80eb-08a03ad64d12">257,564</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzUtNC0xLTEtMA_a06ff2a0-768e-46a9-a22d-a2bb0fef5de4">251,068</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for expired product</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="cpix:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzYtMi0xLTEtMA_118c579d-44d0-41bc-8102-fe82dc6ef5e9">469,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="cpix:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzYtNC0xLTEtMA_923e2a55-a766-41d9-9389-40f7b84c3a61">558,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInventory" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzctMi0xLTEtMA_dc54a9a8-8f56-46bd-83d2-bb33406fc5ec">35,227</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInventory" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzctNC0xLTEtMA_4915ec65-e0eb-474e-b18b-82e1887ad4f9">193,150</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="cpix:DeferredTaxAssetsDeferredCharges" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzgtMi0xLTEtMA_39950b99-88f0-4f17-b0df-d8b379f52684">845,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="cpix:DeferredTaxAssetsDeferredCharges" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzgtNC0xLTEtMA_57535e51-d0b1-4007-a8a8-9ebdfc625fb1">910,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative compensation costs incurred on deductible equity awards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzktMi0xLTEtMA_2232fbfe-93cd-42e0-a5f6-0bbae2077677">1,047,149</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzktNC0xLTEtMA_37136903-37f7-4f52-8aa2-087612ee572d">884,049</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzEwLTItMS0xLTA_3134d7c5-c2e1-430a-b3af-20d2c904578c">19,846,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzEwLTQtMS0xLTA_6d8371e6-d51b-49c0-bab3-3470b42e7d58">19,444,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzEzLTItMS0xLTA_c968166d-374d-42d1-a916-aca315e544ab">1,313,965</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzEzLTQtMS0xLTA_63216e96-ae7f-4a86-85fe-26c94b647dbb">1,974,787</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets, before valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="cpix:NetDeferredTaxAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzE0LTItMS0xLTA_bacd7360-d9dc-4d35-ad5b-eef338b10da5">18,532,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="cpix:NetDeferredTaxAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzE0LTQtMS0xLTA_aa472242-a15f-4d6b-967c-bfc2076af332">17,469,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: deferred tax asset valuation allowance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzE1LTItMS0xLTA_fdfd0acd-a047-494c-9660-a4444b137d7f">18,511,161</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzE1LTQtMS0xLTA_cc47639d-a3d5-4f2b-b20e-15922ee6ddd2">17,382,052</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzE2LTItMS0xLTA_9bf19561-a036-4811-9e0d-c778510fc5a7">21,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzE2LTQtMS0xLTA_dc1a3209-9c6b-4662-905d-398c6a45905a">87,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90ZXh0cmVnaW9uOjEzZjkwZjc3YzAyNDQxNjY4Njg1ZTQ4OThjOTc1M2Q5XzI1Nzk_87116e82-24fd-441e-a0e5-6dcb72117348" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amount and year of expiration of the Company's federal and state net operating loss carryforwards as of December&#160;31, 2019:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.339%"><tr><td style="width:1.0%"></td><td style="width:60.000%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.248%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years of expiration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Federal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">State</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1e105600e74750a10354cbeaad8205_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:OperatingLossCarryforwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZToxODk5OTEyYmM5YTE0YmYzYmRjNzBhY2QzZDc3NmQxMy90YWJsZXJhbmdlOjE4OTk5MTJiYzlhMTRiZjNiZGM3MGFjZDNkNzc2ZDEzXzItMi0xLTEtMA_0763f1a1-bfec-4d8b-a9ee-11b0815b6c33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfde25ec7427462aba77d555bf0b4ebc_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZToxODk5OTEyYmM5YTE0YmYzYmRjNzBhY2QzZDc3NmQxMy90YWJsZXJhbmdlOjE4OTk5MTJiYzlhMTRiZjNiZGM3MGFjZDNkNzc2ZDEzXzItNC0xLTEtMA_2da5ecc0-e3b5-413f-9efe-811690375d38">13,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 - 2029</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f0355a74da4690bb8381a211624d38_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:OperatingLossCarryforwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZToxODk5OTEyYmM5YTE0YmYzYmRjNzBhY2QzZDc3NmQxMy90YWJsZXJhbmdlOjE4OTk5MTJiYzlhMTRiZjNiZGM3MGFjZDNkNzc2ZDEzXzMtMi0xLTEtMA_8ad7b7d7-5ff0-4acb-a7ac-ab971e4945e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc29ea825b54377a95392502611cdcd_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZToxODk5OTEyYmM5YTE0YmYzYmRjNzBhY2QzZDc3NmQxMy90YWJsZXJhbmdlOjE4OTk5MTJiYzlhMTRiZjNiZGM3MGFjZDNkNzc2ZDEzXzMtNC0xLTEtMA_cebbcc4f-0c99-4cc2-9c91-9b22b58a3003">49,392,824</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i811017016cf741b2be0e3e987f3eb761_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZToxODk5OTEyYmM5YTE0YmYzYmRjNzBhY2QzZDc3NmQxMy90YWJsZXJhbmdlOjE4OTk5MTJiYzlhMTRiZjNiZGM3MGFjZDNkNzc2ZDEzXzQtMi0xLTEtMA_002c2d8f-d73d-44db-98bd-ec8d5d332a18">44,153,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0be1be11078f412084defc44e8714a79_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZToxODk5OTEyYmM5YTE0YmYzYmRjNzBhY2QzZDc3NmQxMy90YWJsZXJhbmdlOjE4OTk5MTJiYzlhMTRiZjNiZGM3MGFjZDNkNzc2ZDEzXzQtNC0xLTEtMA_292a5fb7-81db-4aa4-9d08-cda6a5ca38c8">461,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2031 - 2039</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab82716daa96407a81d6e9e0259dbb45_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZToxODk5OTEyYmM5YTE0YmYzYmRjNzBhY2QzZDc3NmQxMy90YWJsZXJhbmdlOjE4OTk5MTJiYzlhMTRiZjNiZGM3MGFjZDNkNzc2ZDEzXzUtMi0xLTEtMA_7d07783d-8e74-40c1-ba1a-3fe67d42f63b">7,534,351</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bd88221af1b4196a3229b6b611f66c0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZToxODk5OTEyYmM5YTE0YmYzYmRjNzBhY2QzZDc3NmQxMy90YWJsZXJhbmdlOjE4OTk5MTJiYzlhMTRiZjNiZGM3MGFjZDNkNzc2ZDEzXzUtNC0xLTEtMA_bdea2b6b-a077-4ae0-a6df-927b9a9b9612">9,947,070</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfc8673e890d447cb4c97a9429f48da8_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZToxODk5OTEyYmM5YTE0YmYzYmRjNzBhY2QzZDc3NmQxMy90YWJsZXJhbmdlOjE4OTk5MTJiYzlhMTRiZjNiZGM3MGFjZDNkNzc2ZDEzXzYtMi0xLTEtMA_de7b05bf-1f34-406f-a9a2-efeeb766b525">5,493,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b3d8839a10943299527a3616540c882_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZToxODk5OTEyYmM5YTE0YmYzYmRjNzBhY2QzZDc3NmQxMy90YWJsZXJhbmdlOjE4OTk5MTJiYzlhMTRiZjNiZGM3MGFjZDNkNzc2ZDEzXzYtNC0xLTEtMA_52e7082e-3731-44ed-8ed1-6c006946afac">383,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total federal and state net operating loss carryforwards</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf6dd30a84fc4e6fbec6716f5833f1be_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZToxODk5OTEyYmM5YTE0YmYzYmRjNzBhY2QzZDc3NmQxMy90YWJsZXJhbmdlOjE4OTk5MTJiYzlhMTRiZjNiZGM3MGFjZDNkNzc2ZDEzXzgtMi0xLTEtMA_5899a8a8-4b06-47e0-b237-e099d89176dc">57,181,428</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i919816e4ae6e49cbbc09d39640cee418_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZToxODk5OTEyYmM5YTE0YmYzYmRjNzBhY2QzZDc3NmQxMy90YWJsZXJhbmdlOjE4OTk5MTJiYzlhMTRiZjNiZGM3MGFjZDNkNzc2ZDEzXzgtNC0xLTEtMA_ee7c8779-3975-48f1-b695-27691e1bdc7f">60,198,158</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:8pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="if08fdc6ecc954b2d90c5899cb053a73f" continuedAt="ib09e05a29e464109aa4f5e0de369fb7d"><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90ZXh0cmVnaW9uOjEzZjkwZjc3YzAyNDQxNjY4Njg1ZTQ4OThjOTc1M2Q5XzI1NzE_1c0f8447-df06-48c2-b270-b12c61a93420" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax (expense) benefit includes the following components for the years ended December 31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.179%"><tr><td style="width:1.0%"></td><td style="width:40.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo0YmVhZDA4MGY4MzY0YTMwYTExNzAxN2NhMGVhNjFmYy90YWJsZXJhbmdlOjRiZWFkMDgwZjgzNjRhMzBhMTE3MDE3Y2EwZWE2MWZjXzMtMi0xLTEtMA_5cfcda2b-c289-4fc3-910f-85aab9a236df">65,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo0YmVhZDA4MGY4MzY0YTMwYTExNzAxN2NhMGVhNjFmYy90YWJsZXJhbmdlOjRiZWFkMDgwZjgzNjRhMzBhMTE3MDE3Y2EwZWE2MWZjXzMtNC0xLTEtMA_138f778b-6f3e-44f2-acc6-b22e8ac7673a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:zerodash" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo0YmVhZDA4MGY4MzY0YTMwYTExNzAxN2NhMGVhNjFmYy90YWJsZXJhbmdlOjRiZWFkMDgwZjgzNjRhMzBhMTE3MDE3Y2EwZWE2MWZjXzMtNi0xLTEtMA_604a347d-2a98-4f14-8840-e0209e2b3b4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo0YmVhZDA4MGY4MzY0YTMwYTExNzAxN2NhMGVhNjFmYy90YWJsZXJhbmdlOjRiZWFkMDgwZjgzNjRhMzBhMTE3MDE3Y2EwZWE2MWZjXzQtMi0xLTEtMA_e0715dd8-9689-467c-a0fb-a45bc426baf5">79,316</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo0YmVhZDA4MGY4MzY0YTMwYTExNzAxN2NhMGVhNjFmYy90YWJsZXJhbmdlOjRiZWFkMDgwZjgzNjRhMzBhMTE3MDE3Y2EwZWE2MWZjXzQtNC0xLTEtMA_213c6cd2-0084-4444-922a-edfc806296ea">16,636</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo0YmVhZDA4MGY4MzY0YTMwYTExNzAxN2NhMGVhNjFmYy90YWJsZXJhbmdlOjRiZWFkMDgwZjgzNjRhMzBhMTE3MDE3Y2EwZWE2MWZjXzQtNi0xLTEtMA_086cd4cf-5610-4af4-a91b-0c460c74338f">59,243</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current income tax (expense) benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo0YmVhZDA4MGY4MzY0YTMwYTExNzAxN2NhMGVhNjFmYy90YWJsZXJhbmdlOjRiZWFkMDgwZjgzNjRhMzBhMTE3MDE3Y2EwZWE2MWZjXzUtMi0xLTEtMA_22415255-d0dc-4d55-9e72-517e76639a77">144,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo0YmVhZDA4MGY4MzY0YTMwYTExNzAxN2NhMGVhNjFmYy90YWJsZXJhbmdlOjRiZWFkMDgwZjgzNjRhMzBhMTE3MDE3Y2EwZWE2MWZjXzUtNC0xLTEtMA_f6524571-e4e6-4968-ab48-edc7bb9daea9">16,636</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo0YmVhZDA4MGY4MzY0YTMwYTExNzAxN2NhMGVhNjFmYy90YWJsZXJhbmdlOjRiZWFkMDgwZjgzNjRhMzBhMTE3MDE3Y2EwZWE2MWZjXzUtNi0xLTEtMA_6edc86c3-e5f8-4e73-b44e-89f6fbd15f70">59,243</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo0YmVhZDA4MGY4MzY0YTMwYTExNzAxN2NhMGVhNjFmYy90YWJsZXJhbmdlOjRiZWFkMDgwZjgzNjRhMzBhMTE3MDE3Y2EwZWE2MWZjXzgtMi0xLTEtMA_be69a448-bdf8-4a6f-8b17-5609e2c6dfea">65,408</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo0YmVhZDA4MGY4MzY0YTMwYTExNzAxN2NhMGVhNjFmYy90YWJsZXJhbmdlOjRiZWFkMDgwZjgzNjRhMzBhMTE3MDE3Y2EwZWE2MWZjXzgtNC0xLTEtMA_8c27f5d3-832f-47da-9823-024402a63e1a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo0YmVhZDA4MGY4MzY0YTMwYTExNzAxN2NhMGVhNjFmYy90YWJsZXJhbmdlOjRiZWFkMDgwZjgzNjRhMzBhMTE3MDE3Y2EwZWE2MWZjXzgtNi0xLTEtMA_bde9d228-6871-43df-8171-6b4813bcb2e9">3,682,772</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo0YmVhZDA4MGY4MzY0YTMwYTExNzAxN2NhMGVhNjFmYy90YWJsZXJhbmdlOjRiZWFkMDgwZjgzNjRhMzBhMTE3MDE3Y2EwZWE2MWZjXzktMi0xLTEtMA_2e735a41-11cc-4542-8d1e-dc942e0c18cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo0YmVhZDA4MGY4MzY0YTMwYTExNzAxN2NhMGVhNjFmYy90YWJsZXJhbmdlOjRiZWFkMDgwZjgzNjRhMzBhMTE3MDE3Y2EwZWE2MWZjXzktNC0xLTEtMA_8facbcdb-4ac4-4d03-b9c4-824c06b58d9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo0YmVhZDA4MGY4MzY0YTMwYTExNzAxN2NhMGVhNjFmYy90YWJsZXJhbmdlOjRiZWFkMDgwZjgzNjRhMzBhMTE3MDE3Y2EwZWE2MWZjXzktNi0xLTEtMA_e5f870a1-2ea7-41a4-93a2-64cc2a790845">432,874</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax (expense) benefit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredOtherTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo0YmVhZDA4MGY4MzY0YTMwYTExNzAxN2NhMGVhNjFmYy90YWJsZXJhbmdlOjRiZWFkMDgwZjgzNjRhMzBhMTE3MDE3Y2EwZWE2MWZjXzEwLTItMS0xLTA_82384aed-3fc9-437e-b5e2-d2348568f2e1">65,408</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:DeferredOtherTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo0YmVhZDA4MGY4MzY0YTMwYTExNzAxN2NhMGVhNjFmYy90YWJsZXJhbmdlOjRiZWFkMDgwZjgzNjRhMzBhMTE3MDE3Y2EwZWE2MWZjXzEwLTQtMS0xLTA_48d48f8a-b50a-4d03-8b44-f183fd3893a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredOtherTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo0YmVhZDA4MGY4MzY0YTMwYTExNzAxN2NhMGVhNjFmYy90YWJsZXJhbmdlOjRiZWFkMDgwZjgzNjRhMzBhMTE3MDE3Y2EwZWE2MWZjXzEwLTYtMS0xLTA_fa3219f5-dde3-4036-aac9-b1fd1c86c820">4,115,646</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax (expense) benefit </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo0YmVhZDA4MGY4MzY0YTMwYTExNzAxN2NhMGVhNjFmYy90YWJsZXJhbmdlOjRiZWFkMDgwZjgzNjRhMzBhMTE3MDE3Y2EwZWE2MWZjXzExLTItMS0xLTA_bf7d589e-390f-4cfa-aa80-309999fde4fa">79,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo0YmVhZDA4MGY4MzY0YTMwYTExNzAxN2NhMGVhNjFmYy90YWJsZXJhbmdlOjRiZWFkMDgwZjgzNjRhMzBhMTE3MDE3Y2EwZWE2MWZjXzExLTQtMS0xLTA_7e340f3a-9459-45d1-abbc-77098f8e9c8e">16,636</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo0YmVhZDA4MGY4MzY0YTMwYTExNzAxN2NhMGVhNjFmYy90YWJsZXJhbmdlOjRiZWFkMDgwZjgzNjRhMzBhMTE3MDE3Y2EwZWE2MWZjXzExLTYtMS0xLTA_a17bcde5-b116-4620-b705-cfc1354942f1">4,174,889</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90ZXh0cmVnaW9uOjEzZjkwZjc3YzAyNDQxNjY4Njg1ZTQ4OThjOTc1M2Q5XzI1NzI_608c906b-2dd1-47ed-9f3f-b0f51a174b7e" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s effective income tax rate for 2019, 2018 and 2017 reconciles with the federal statutory tax rate as follows:&#160;</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.179%"><tr><td style="width:1.0%"></td><td style="width:40.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal tax expense at statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzItMi0xLTEtMA_35cf27bf-ad17-41c1-b0ad-74f1c0813c91">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzItNC0xLTEtMA_1319efac-e0c7-4adf-967a-c9cc776557a8">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzItNi0xLTEtMA_e13e30ad-71de-4737-9a32-eb3da7a81ddd">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax expense (net of federal income tax benefit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzMtMi0xLTEtMA_138cec92-6b87-4363-ba9f-50801e5b1286">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzMtNC0xLTEtMA_ff135586-a00e-4625-b191-03b145624d06">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzMtNi0xLTEtMA_6592a731-5ade-4d13-ae03-38f3ae61cb37">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences associated with general business credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzQtMi0xLTEtMA_167c40d7-533a-4175-8ad3-0c9a52809be8">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzQtNC0xLTEtMA_1c819cdc-ce55-4778-ab4b-91ee28d208a2">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzQtNi0xLTEtMA_8ab4e071-f135-41fa-8339-96e8a68bbf4b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzUtMi0xLTEtMA_af5404c5-f09f-40fe-bbdb-e5ae17079f86">31</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzUtNC0xLTEtMA_86c701dd-3750-4261-84a7-2087ca8185b9">25</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzUtNi0xLTEtMA_8e850abd-dac0-4b52-9ad3-38837c1819b1">148</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="2" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzYtMi0xLTEtMA_a19c19d8-ad14-4b79-889f-2799d131519a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="2" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzYtNC0xLTEtMA_801e6a62-5629-41c9-ae8f-33efd0e8a556">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzYtNi0xLTEtMA_acb5931f-886e-44c1-95fe-46a76612b4ab">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzctMi0xLTEtMA_94f26ded-15ad-4a5e-a84d-b5d323eba687">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzctNC0xLTEtMA_d2de0024-4373-4f02-b9e6-f266329dc5b1">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzctNi0xLTEtMA_c2ba0f95-d506-4ac9-a2ed-41982369ec75">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="2" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzgtMi0xLTEtMA_30a540d0-5cef-4fb9-9259-4d69e605738c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="2" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzgtNC0xLTEtMA_a15f5a7b-639f-46fb-84c0-ad129657c7e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzgtNi0xLTEtMA_21176e14-81a5-4696-a4ad-f325fd98ea02">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income tax expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzktMi0xLTEtMA_c6545006-3629-4035-9027-6b5373ea8101">2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="2" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzktNC0xLTEtMA_54d6e611-471a-4811-b72b-691dfe31d60a">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzktNi0xLTEtMA_633a5f6e-d62c-4a71-9abd-8887028f95cd">108</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Company determined that it was not more likely than not that its net deferred tax assets would be realized.  As such, the Company&#8217;s income tax provision for the year ended December 31, 2017 reflected a full valuation allowance against net deferred tax assets with the exception of the deferred tax asset for alternative minimum tax (&#8220;AMT&#8221;) credit carryforwards discussed further below.  The Company&#8217;s position is unchanged as of  both December 31, 2018 and December 31, 2019.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (&#8220;the Tax Act&#8221;).  The Tax Act makes broad and complex changes to the U.S. tax code, including, but not limited to, (1) reducing the U.S. federal corporate tax rate to 21%; (2) eliminating the corporate alternative minimum tax (&#8220;AMT&#8221;) and changing how AMT credits can be realized; (3) capital expensing; and (4) creating new limitations on deductible interest expense and executive compensation.</span></div></ix:continuation><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="ib09e05a29e464109aa4f5e0de369fb7d"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our analysis of the impact of the Tax Act, we recorded a net tax benefit of $<ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90ZXh0cmVnaW9uOjEzZjkwZjc3YzAyNDQxNjY4Njg1ZTQ4OThjOTc1M2Q5XzE1ODk_59ee451a-1a05-4f73-8090-6b85fe0716dc">0.1</ix:nonFraction> million in the period ended December 31, 2017.  This net tax benefit consisted entirely of the release of the valuation allowance against AMT credits that will be realizable under the Tax Act in future periods. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects it will continue to pay minimal taxes in future periods through the continued utilization of net operating loss carryforwards, as it is able to achieve taxable income through its operations.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is no longer subject to U.S. federal tax examinations for tax years before 2016, and with few exceptions, the Company is not subject to examination by state tax authorities for tax years which ended before 2016.  Loss carryforwards and credit carryforwards generated or utilized in years earlier than 2016 remain subject to examination and adjustment.  During 2012, the 2009 federal tax return was examined by the Internal Revenue Service with no significant findings or adjustments.  The Company has no unrecognized tax benefits in 2019, 2018 and 2017.</span></div></ix:continuation><div id="id2bfa55304bd45bbaa9cdf09bb7673a3_232"></div><div style="margin-top:8pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(13)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90ZXh0cmVnaW9uOmM5ODUzNWNiMmJkMTQ4N2U4ODgxNTg4MWY0MTI2Y2ZkXzI2MDU_da71b2ea-cf02-41ff-9b70-cfe3525bc71e" continuedAt="ie5709775a4b741ef9e4da71967d555e3" escape="true">Stock-Based Compensation Plans</ix:nonNumeric></span></div><ix:continuation id="ie5709775a4b741ef9e4da71967d555e3" continuedAt="i742ff48ebb694674bd50fc905c04a4b7"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has grants outstanding under <ix:nonFraction unitRef="plan" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90ZXh0cmVnaW9uOmM5ODUzNWNiMmJkMTQ4N2U4ODgxNTg4MWY0MTI2Y2ZkXzgy_4305a45a-f0b4-4d26-a1d4-6ab6c408cfe3">three</ix:nonFraction> equity compensation plans, with <ix:nonFraction unitRef="plan" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90ZXh0cmVnaW9uOmM5ODUzNWNiMmJkMTQ4N2U4ODgxNTg4MWY0MTI2Y2ZkXzExNw_f9bcc741-4b3c-4e72-976c-7420fafb6b48">two</ix:nonFraction> of the plans available for future grants of equity compensation awards to employees, consultants and directors. All of the equity plans were approved by shareholders. The 2007 Long-Term Incentive Compensation Plan (the "2007 Plan") and the 2007 Directors&#8217; Incentive Plan (the "Directors&#8217; Plan") superseded the 1999 Stock Option Plan. The 2007 Plan and the Directors&#8217; Plan provide for the issuance of stock options, stock appreciation rights and restricted stock. Vesting is determined on a grant-by-grant basis in accordance with the terms of the plans and the related grant agreements. The Company has reserved <ix:nonFraction unitRef="shares" contextRef="i4da90f76e4104888a18e3d18b29d9b37_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90ZXh0cmVnaW9uOmM5ODUzNWNiMmJkMTQ4N2U4ODgxNTg4MWY0MTI2Y2ZkXzczMg_3b1a3b07-e184-43ed-9411-bea5fe893884">2.4</ix:nonFraction> million shares of common stock for issuance under the 2007 Plan and <ix:nonFraction unitRef="shares" contextRef="i198eca0df24c455580fe1f7aad3d37bf_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90ZXh0cmVnaW9uOmM5ODUzNWNiMmJkMTQ4N2U4ODgxNTg4MWY0MTI2Y2ZkXzc5NQ_95b0d5c0-e137-4435-af02-8810b03b157b">250,000</ix:nonFraction> shares for issuance under the Directors&#8217; Plan.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price of stock options is generally <ix:nonFraction unitRef="number" contextRef="i61c32b7b06154a0caffb1b27ffd29a90_D20190101-20191231" decimals="INF" name="cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90ZXh0cmVnaW9uOmM5ODUzNWNiMmJkMTQ4N2U4ODgxNTg4MWY0MTI2Y2ZkXzg5NA_f7b5b143-2134-425d-b243-5c379bc37ea5">100</ix:nonFraction>% of the fair market value of the underlying common stock on the grant date. The maximum contractual term of stock options is <ix:nonNumeric contextRef="ib15a6538ecd34529a63f571722d0a1c9_D20190101-20191231" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90ZXh0cmVnaW9uOmM5ODUzNWNiMmJkMTQ4N2U4ODgxNTg4MWY0MTI2Y2ZkXzEwMjE_2d2c2cc1-a1d6-4f1e-808d-73167c932bff">ten years</ix:nonNumeric> from the date of grant, except for incentive stock options granted to 10% shareholders, which is <ix:nonNumeric contextRef="id6083199dd2a42f391637d804e105c86_D20190101-20191231" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90ZXh0cmVnaW9uOmM5ODUzNWNiMmJkMTQ4N2U4ODgxNTg4MWY0MTI2Y2ZkXzExMjA_20098c88-cdae-4ca4-bf14-16d25e2b6047">five years</ix:nonNumeric>.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2011, the Company began issuing shares of restricted stock with no exercise price to employees and directors. Restricted stock issued to employees generally cliff-vests on the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90ZXh0cmVnaW9uOmM5ODUzNWNiMmJkMTQ4N2U4ODgxNTg4MWY0MTI2Y2ZkXzQzOTgwNDY1MTM3MjU_e4aa551b-a49e-47c8-ae2e-da92a179d352">four</span>th anniversary of the date of grant. Restricted stock issued to directors vests on the <ix:nonNumeric contextRef="i6325bab52b3e497181b41d02564bc694_D20190101-20191231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90ZXh0cmVnaW9uOmM5ODUzNWNiMmJkMTQ4N2U4ODgxNTg4MWY0MTI2Y2ZkXzEzOTQ_07191cc5-aad9-4334-b890-51f181b246fb">one year</ix:nonNumeric> anniversary of the date of grant.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock compensation expense is presented as a component of general and administrative expense in the consolidated statements of operations. <ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90ZXh0cmVnaW9uOmM5ODUzNWNiMmJkMTQ4N2U4ODgxNTg4MWY0MTI2Y2ZkXzI2MDY_55ea4a30-289f-46fa-9de2-ff4d5f2bd7fb" continuedAt="i5559e7c7d966489e8ef9a7818e2a0a44" escape="true">Stock compensation expense consisted of the following for the years ended December 31:</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><ix:continuation id="i5559e7c7d966489e8ef9a7818e2a0a44"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.179%"><tr><td style="width:1.0%"></td><td style="width:40.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation - employees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc452512a3cb412faa57ddaf029b98df_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTpmNGFjMWRjNzE3YTE0OTZhOThkMDZjYjNlZDdhYmFkMy90YWJsZXJhbmdlOmY0YWMxZGM3MTdhMTQ5NmE5OGQwNmNiM2VkN2FiYWQzXzItMi0xLTEtMA_66f7ec89-d16c-4ce7-a470-ca66cb60316f">1,481,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e05d70302894bebb067dddab8121842_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTpmNGFjMWRjNzE3YTE0OTZhOThkMDZjYjNlZDdhYmFkMy90YWJsZXJhbmdlOmY0YWMxZGM3MTdhMTQ5NmE5OGQwNmNiM2VkN2FiYWQzXzItNC0xLTEtMA_28194da9-1a10-4420-81aa-65c0fb102173">1,244,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2699606b9dca4e75864d2ce5471d263f_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTpmNGFjMWRjNzE3YTE0OTZhOThkMDZjYjNlZDdhYmFkMy90YWJsZXJhbmdlOmY0YWMxZGM3MTdhMTQ5NmE5OGQwNmNiM2VkN2FiYWQzXzItNi0xLTEtMA_459fff74-c382-47b7-9286-b61d6bc619a8">1,032,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation - nonemployees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7baa6ff5d72047a0ada0ed31a5bb2e5f_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTpmNGFjMWRjNzE3YTE0OTZhOThkMDZjYjNlZDdhYmFkMy90YWJsZXJhbmdlOmY0YWMxZGM3MTdhMTQ5NmE5OGQwNmNiM2VkN2FiYWQzXzMtMi0xLTEtMA_3d070447-0c46-4f51-ac59-0781af2afdcc">4,882</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic70796d261de4b7785011e9a52b6ab8b_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTpmNGFjMWRjNzE3YTE0OTZhOThkMDZjYjNlZDdhYmFkMy90YWJsZXJhbmdlOmY0YWMxZGM3MTdhMTQ5NmE5OGQwNmNiM2VkN2FiYWQzXzMtNC0xLTEtMA_c546247d-4fdf-4c09-a65c-771a6ebc462e">120,092</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a9593962195492199a34a509d355036_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTpmNGFjMWRjNzE3YTE0OTZhOThkMDZjYjNlZDdhYmFkMy90YWJsZXJhbmdlOmY0YWMxZGM3MTdhMTQ5NmE5OGQwNmNiM2VkN2FiYWQzXzMtNi0xLTEtMA_288e9825-bdd3-4c18-b3ca-9f692c7a97c8">82,969</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation - foundation contribution</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if432a686a41c4c4494b432b8de61cfd0_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTpmNGFjMWRjNzE3YTE0OTZhOThkMDZjYjNlZDdhYmFkMy90YWJsZXJhbmdlOmY0YWMxZGM3MTdhMTQ5NmE5OGQwNmNiM2VkN2FiYWQzXzQtMi0xLTEtMA_bb3e27da-8a07-4bf1-b126-7bc95bc3f55f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1758466063744cb928ad1f2170609f0_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTpmNGFjMWRjNzE3YTE0OTZhOThkMDZjYjNlZDdhYmFkMy90YWJsZXJhbmdlOmY0YWMxZGM3MTdhMTQ5NmE5OGQwNmNiM2VkN2FiYWQzXzQtNC0xLTEtMA_c9630034-14c4-40db-9e19-0fda12c57996">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ab32de2ce97414b8fa9e5599fbaa6c9_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTpmNGFjMWRjNzE3YTE0OTZhOThkMDZjYjNlZDdhYmFkMy90YWJsZXJhbmdlOmY0YWMxZGM3MTdhMTQ5NmE5OGQwNmNiM2VkN2FiYWQzXzQtNi0xLTEtMA_77f30564-8627-43db-9da8-975aa427bae3">372,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7a81f8fb9634254a32248497adf8453_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTpmNGFjMWRjNzE3YTE0OTZhOThkMDZjYjNlZDdhYmFkMy90YWJsZXJhbmdlOmY0YWMxZGM3MTdhMTQ5NmE5OGQwNmNiM2VkN2FiYWQzXzUtMi0xLTEtMA_c532267c-4b95-42d1-a8f0-7e56de94478a">1,485,898</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1709635ce5bd48ef8b8e1c0e99885c21_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTpmNGFjMWRjNzE3YTE0OTZhOThkMDZjYjNlZDdhYmFkMy90YWJsZXJhbmdlOmY0YWMxZGM3MTdhMTQ5NmE5OGQwNmNiM2VkN2FiYWQzXzUtNC0xLTEtMA_7dc8e50d-fe71-4f04-848b-9e9756ffe994">1,364,698</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia61891dab2a04a62b49d997680aed24e_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTpmNGFjMWRjNzE3YTE0OTZhOThkMDZjYjNlZDdhYmFkMy90YWJsZXJhbmdlOmY0YWMxZGM3MTdhMTQ5NmE5OGQwNmNiM2VkN2FiYWQzXzUtNi0xLTEtMA_a9cf2c78-df00-4cae-8ec1-88891f790db6">1,487,563</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2019, there was approximately $<ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90ZXh0cmVnaW9uOmM5ODUzNWNiMmJkMTQ4N2U4ODgxNTg4MWY0MTI2Y2ZkXzE2OTE_53607470-df5b-4e50-b9b2-484d23977de8">2.1</ix:nonFraction> million of unrecognized compensation cost related to share-based payments, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90ZXh0cmVnaW9uOmM5ODUzNWNiMmJkMTQ4N2U4ODgxNTg4MWY0MTI2Y2ZkXzE4MzA_4b05d323-c5f8-4815-a079-326299e849db">2.5</ix:nonNumeric> years. This amount relates primarily to unrecognized compensation cost for employee restricted stock awards.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="i742ff48ebb694674bd50fc905c04a4b7" continuedAt="i92b3dad24daa4f99869d267f69c5c92a"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90ZXh0cmVnaW9uOmM5ODUzNWNiMmJkMTQ4N2U4ODgxNTg4MWY0MTI2Y2ZkXzI2MTE_07deee4d-3464-479f-91cf-2113cca1e983" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity for 2019 and 2018 was as follows:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.064%"><tr><td style="width:1.0%"></td><td style="width:34.487%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.024%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.024%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.139%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average exercise price per share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">term&#160;(years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">value</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i19f7709a57f34358b074d8ab2cd1410f_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzItMi0xLTEtMA_ff787876-b904-4bd2-9740-b29d2cc3983f">5,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i19f7709a57f34358b074d8ab2cd1410f_I20171231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzItNC0xLTEtMA_6f7b7813-69e0-46d0-996a-15bd0272f03c">13.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzItNi0xLTEtMA_aacdc01e-8098-4fb4-a3a3-6dc4e101dfaf">1.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19f7709a57f34358b074d8ab2cd1410f_I20171231" decimals="0" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzItOC0xLTEtMA_3408d4ba-796a-47a2-afd2-7264f53d49fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzMtMi0xLTEtMA_e0ef69dd-4a89-4456-a28d-462fde26ed4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzMtNC0xLTEtMA_eed8bcf8-c93f-4b51-9157-d28c224e9e43">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="INF" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzQtMi0xLTEtMA_beaf584d-16cc-4821-a1f7-4e211b53b72a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzQtNC0xLTEtMA_1418af03-7c02-4e2f-a9eb-15ec34720f3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited or expired</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzUtMi0xLTEtMA_0351c260-393a-4b98-be17-9726f668b266">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzUtNC0xLTEtMA_1e8cd30b-4686-471c-a147-f556bb780897">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzYtMi0xLTEtMA_eb4648b3-6a22-4535-a554-fb8736f1bc63">5,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzYtNC0xLTEtMA_793e5c01-4901-4d67-8335-e0730550df28">13.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzYtNi0xLTEtMA_37613700-15b3-4785-bb36-b1dc129c5c0a">0.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzYtOC0xLTEtMA_8b2c2911-e484-41db-8453-f67a21051ef5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzctMi0xLTEtMA_8adde812-f96c-4a8f-babf-91c41c13f464">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzctNC0xLTEtMA_afa9bb41-9953-4d99-9fde-10133e6e8487">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzgtMi0xLTEtMA_b93269bf-da6c-414c-8f2a-29c3778d8577">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzgtNC0xLTEtMA_af4663eb-06f2-41df-ae1f-73721645f29b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited or expired</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzktMi0xLTEtMA_5ea12e63-0231-44bc-a395-7521525e302e">5,800</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzktNC0xLTEtMA_1e4c9eee-4835-481c-995f-0b3e7558b4ae">13.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzEwLTItMS0xLTA_ea8dfe25-6a46-49ab-8818-008a4b9c4305">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzEwLTQtMS0xLTA_e9c8a6be-5999-4bd3-a7e3-3af49db80878">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzEwLTYtMS0xLTA_58737b61-fd9a-4cbc-9f4c-35e1a74ecac5">0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzEwLTgtMS0xLTA_a20d215f-98fb-4a54-89f1-4b079a8238cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzExLTItMS0xLTA_73aac9f4-cda5-43f2-b8ce-b359a279c123">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzExLTQtMS0xLTA_25a2b49b-0f1e-49ec-ab98-8649087083c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzExLTYtMS0xLTA_c10fba42-15d2-4ee9-9e8e-ef348c10eafc">0</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzExLTgtMS0xLTA_473b98c9-3d16-415e-9229-9309e036deb1">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not grant any stock options and there were no options exercised during 2019, 2018 and 2017.    <ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="cpix:ScheduleOfStockOptionActivityAdditionalDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90ZXh0cmVnaW9uOmM5ODUzNWNiMmJkMTQ4N2U4ODgxNTg4MWY0MTI2Y2ZkXzI2MTI_80d53551-e9a2-47b1-843c-8f21a520b996" continuedAt="ia63f217fa12442ca810cddb79bccb96f" escape="true">Information related to the stock option plans during 2019, 2018 and 2017 was as follows:</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><ix:continuation id="ia63f217fa12442ca810cddb79bccb96f"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.179%"><tr><td style="width:1.0%"></td><td style="width:40.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrinsic value of options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo2MTIzYmUzODFhMjg0YTA3OTYxYTJmYzY5MTFmMzdjOS90YWJsZXJhbmdlOjYxMjNiZTM4MWEyODRhMDc5NjFhMmZjNjkxMWYzN2M5XzItMi0xLTEtMA_537c757e-55b5-48bf-950a-2354ad019035">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo2MTIzYmUzODFhMjg0YTA3OTYxYTJmYzY5MTFmMzdjOS90YWJsZXJhbmdlOjYxMjNiZTM4MWEyODRhMDc5NjFhMmZjNjkxMWYzN2M5XzItNC0xLTEtMA_395d7707-b037-4a31-9568-18731ac1786a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo2MTIzYmUzODFhMjg0YTA3OTYxYTJmYzY5MTFmMzdjOS90YWJsZXJhbmdlOjYxMjNiZTM4MWEyODRhMDc5NjFhMmZjNjkxMWYzN2M5XzItNi0xLTEtMA_af121955-5b82-4a13-9ad5-bc9e44e31efa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value of </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">options exercised</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="2" format="ixt:zerodash" name="cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo2MTIzYmUzODFhMjg0YTA3OTYxYTJmYzY5MTFmMzdjOS90YWJsZXJhbmdlOjYxMjNiZTM4MWEyODRhMDc5NjFhMmZjNjkxMWYzN2M5XzMtMi0xLTEtMA_8918a396-377d-4ae5-b92a-5519df8deacd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="2" format="ixt:zerodash" name="cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo2MTIzYmUzODFhMjg0YTA3OTYxYTJmYzY5MTFmMzdjOS90YWJsZXJhbmdlOjYxMjNiZTM4MWEyODRhMDc5NjFhMmZjNjkxMWYzN2M5XzMtNC0xLTEtMA_5166a711-aedc-421a-be56-bb988be8dce9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="2" format="ixt:zerodash" name="cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo2MTIzYmUzODFhMjg0YTA3OTYxYTJmYzY5MTFmMzdjOS90YWJsZXJhbmdlOjYxMjNiZTM4MWEyODRhMDc5NjFhMmZjNjkxMWYzN2M5XzMtNi0xLTEtMA_97877c33-8ee5-47fb-a1fe-ab36d4dc2661">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Awards</span></div><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90ZXh0cmVnaW9uOmM5ODUzNWNiMmJkMTQ4N2U4ODgxNTg4MWY0MTI2Y2ZkXzI2MTM_f7c37146-e2bb-40f3-bf2b-5ef25c1d26a3" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock activity was as follows:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:70.192%"><tr><td style="width:1.0%"></td><td style="width:50.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.733%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">of shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">grant-date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">fair value</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaaaacea9a57e4e758bc406a2ecaef76a_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZToxNzNmMzBmNTYzZGM0NTY2OTZmZDAyOTMwMDU4ZjM4NC90YWJsZXJhbmdlOjE3M2YzMGY1NjNkYzQ1NjY5NmZkMDI5MzAwNThmMzg0XzItMi0xLTEtMA_5174af03-0e47-4708-bfc6-639212cb6e7a">767,845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaaaacea9a57e4e758bc406a2ecaef76a_I20171231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZToxNzNmMzBmNTYzZGM0NTY2OTZmZDAyOTMwMDU4ZjM4NC90YWJsZXJhbmdlOjE3M2YzMGY1NjNkYzQ1NjY5NmZkMDI5MzAwNThmMzg0XzItNC0xLTEtMA_926ddb5a-7725-4c07-b62f-0afce799d113">5.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1a46cecd6d924e33bda5ccdd4c0e3b43_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZToxNzNmMzBmNTYzZGM0NTY2OTZmZDAyOTMwMDU4ZjM4NC90YWJsZXJhbmdlOjE3M2YzMGY1NjNkYzQ1NjY5NmZkMDI5MzAwNThmMzg0XzMtMi0xLTEtMA_2950469b-bf23-4581-be29-3e1387430e97">261,680</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1a46cecd6d924e33bda5ccdd4c0e3b43_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZToxNzNmMzBmNTYzZGM0NTY2OTZmZDAyOTMwMDU4ZjM4NC90YWJsZXJhbmdlOjE3M2YzMGY1NjNkYzQ1NjY5NmZkMDI5MzAwNThmMzg0XzMtNC0xLTEtMA_30ad9194-da0e-4a31-981b-8cb5e5dd2625">6.66</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1a46cecd6d924e33bda5ccdd4c0e3b43_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZToxNzNmMzBmNTYzZGM0NTY2OTZmZDAyOTMwMDU4ZjM4NC90YWJsZXJhbmdlOjE3M2YzMGY1NjNkYzQ1NjY5NmZkMDI5MzAwNThmMzg0XzQtMi0xLTEtMA_91f64a8c-8a7d-4b2f-82af-666aab61d864">170,759</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1a46cecd6d924e33bda5ccdd4c0e3b43_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZToxNzNmMzBmNTYzZGM0NTY2OTZmZDAyOTMwMDU4ZjM4NC90YWJsZXJhbmdlOjE3M2YzMGY1NjNkYzQ1NjY5NmZkMDI5MzAwNThmMzg0XzQtNC0xLTEtMA_fbe2688d-40f8-4846-aef2-83e54e822e61">4.79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1a46cecd6d924e33bda5ccdd4c0e3b43_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZToxNzNmMzBmNTYzZGM0NTY2OTZmZDAyOTMwMDU4ZjM4NC90YWJsZXJhbmdlOjE3M2YzMGY1NjNkYzQ1NjY5NmZkMDI5MzAwNThmMzg0XzUtMi0xLTEtMA_a5bea659-2bac-4dc5-b32b-ccd46c738a7b">25,025</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1a46cecd6d924e33bda5ccdd4c0e3b43_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZToxNzNmMzBmNTYzZGM0NTY2OTZmZDAyOTMwMDU4ZjM4NC90YWJsZXJhbmdlOjE3M2YzMGY1NjNkYzQ1NjY5NmZkMDI5MzAwNThmMzg0XzUtNC0xLTEtMA_abeb256d-0330-44e3-92ce-73aa1734b6c7">6.19</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i84fb9bc25ed941ce90338733d28f5d92_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZToxNzNmMzBmNTYzZGM0NTY2OTZmZDAyOTMwMDU4ZjM4NC90YWJsZXJhbmdlOjE3M2YzMGY1NjNkYzQ1NjY5NmZkMDI5MzAwNThmMzg0XzYtMi0xLTEtMA_58d5e26d-9b40-43c7-bb85-dda1ecf3a814">833,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i84fb9bc25ed941ce90338733d28f5d92_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZToxNzNmMzBmNTYzZGM0NTY2OTZmZDAyOTMwMDU4ZjM4NC90YWJsZXJhbmdlOjE3M2YzMGY1NjNkYzQ1NjY5NmZkMDI5MzAwNThmMzg0XzYtNC0xLTEtMA_9dc733db-1072-424c-a5e3-5884b58f2951">6.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1fd085fc709647d9997c4b52bdd4cc7c_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZToxNzNmMzBmNTYzZGM0NTY2OTZmZDAyOTMwMDU4ZjM4NC90YWJsZXJhbmdlOjE3M2YzMGY1NjNkYzQ1NjY5NmZkMDI5MzAwNThmMzg0XzctMi0xLTEtMA_a045f346-7b4c-4aee-82ae-eb903b2e3a8c">229,669</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1fd085fc709647d9997c4b52bdd4cc7c_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZToxNzNmMzBmNTYzZGM0NTY2OTZmZDAyOTMwMDU4ZjM4NC90YWJsZXJhbmdlOjE3M2YzMGY1NjNkYzQ1NjY5NmZkMDI5MzAwNThmMzg0XzctNC0xLTEtMA_c7b44d90-8905-4570-8e60-e0926583ff92">5.95</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1fd085fc709647d9997c4b52bdd4cc7c_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZToxNzNmMzBmNTYzZGM0NTY2OTZmZDAyOTMwMDU4ZjM4NC90YWJsZXJhbmdlOjE3M2YzMGY1NjNkYzQ1NjY5NmZkMDI5MzAwNThmMzg0XzgtMi0xLTEtMA_af9e25e9-2a34-4af7-8685-0bff2a44d18d">225,536</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1fd085fc709647d9997c4b52bdd4cc7c_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZToxNzNmMzBmNTYzZGM0NTY2OTZmZDAyOTMwMDU4ZjM4NC90YWJsZXJhbmdlOjE3M2YzMGY1NjNkYzQ1NjY5NmZkMDI5MzAwNThmMzg0XzgtNC0xLTEtMA_0d928a39-8847-4978-a55c-c987320f50d9">6.71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1fd085fc709647d9997c4b52bdd4cc7c_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZToxNzNmMzBmNTYzZGM0NTY2OTZmZDAyOTMwMDU4ZjM4NC90YWJsZXJhbmdlOjE3M2YzMGY1NjNkYzQ1NjY5NmZkMDI5MzAwNThmMzg0XzktMi0xLTEtMA_fe8cc056-7998-4337-a68f-ae468db31906">22,925</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1fd085fc709647d9997c4b52bdd4cc7c_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZToxNzNmMzBmNTYzZGM0NTY2OTZmZDAyOTMwMDU4ZjM4NC90YWJsZXJhbmdlOjE3M2YzMGY1NjNkYzQ1NjY5NmZkMDI5MzAwNThmMzg0XzktNC0xLTEtMA_77e1d2a7-0653-4957-b588-80f0e467e8f1">6.20</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38570ddc79c14639aa269d9013600dec_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZToxNzNmMzBmNTYzZGM0NTY2OTZmZDAyOTMwMDU4ZjM4NC90YWJsZXJhbmdlOjE3M2YzMGY1NjNkYzQ1NjY5NmZkMDI5MzAwNThmMzg0XzEwLTItMS0xLTA_5598ce66-406f-4a92-89d1-2ff41e7f68bb">814,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i38570ddc79c14639aa269d9013600dec_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZToxNzNmMzBmNTYzZGM0NTY2OTZmZDAyOTMwMDU4ZjM4NC90YWJsZXJhbmdlOjE3M2YzMGY1NjNkYzQ1NjY5NmZkMDI5MzAwNThmMzg0XzEwLTQtMS0xLTA_64c16ef1-958f-42da-b27b-b5005f1fba47">5.88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i92b3dad24daa4f99869d267f69c5c92a">The fair value of restricted stock granted was based on the closing market price of the Company&#8217;s common stock on the date of grant.  The restricted stock grants are included in the diluted weighted shares outstanding computation until they cliff-vest.  Once vested they are included in the basic weighted shares outstanding computation.</ix:continuation> </span></div><div id="id2bfa55304bd45bbaa9cdf09bb7673a3_238"></div><div style="margin-top:8pt;text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(14)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzgvZnJhZzoyZjQ5ZWM5ZTRhMjk0OGUzYTg5NzZjOGIxYWY3N2JmYi90ZXh0cmVnaW9uOjJmNDllYzllNGEyOTQ4ZTNhODk3NmM4YjFhZjc3YmZiXzEzMjk_bcb415a9-3c94-49fc-bc18-f65b8a8446e1" continuedAt="i26eaab7ca5eb4e9f983e17bae06fb37c" escape="true">Employee Benefit Plans</ix:nonNumeric></span></div><ix:continuation id="i26eaab7ca5eb4e9f983e17bae06fb37c"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors an employee benefit plan that was established on January&#160;1, 2006, the Cumberland Pharmaceuticals 401(k) Plan (the&#160;"Plan"), under Section&#160;401(k) of the Internal Revenue Code of 1986, as amended, for the benefit of all employees over the age of <ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" format="ixt-sec:duryear" name="cpix:DefinedContributionPlanEligibilityMinimumEmployeeAge" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzgvZnJhZzoyZjQ5ZWM5ZTRhMjk0OGUzYTg5NzZjOGIxYWY3N2JmYi90ZXh0cmVnaW9uOjJmNDllYzllNGEyOTQ4ZTNhODk3NmM4YjFhZjc3YmZiXzI5Nw_ffb4dea3-64cb-4c6f-bf00-2cc44d6796a5">21</ix:nonNumeric>, having been employed by the Company for at least <ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="cpix:DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzgvZnJhZzoyZjQ5ZWM5ZTRhMjk0OGUzYTg5NzZjOGIxYWY3N2JmYi90ZXh0cmVnaW9uOjJmNDllYzllNGEyOTQ4ZTNhODk3NmM4YjFhZjc3YmZiXzM1MA_6125691f-2b97-4c22-a7d5-3b4b270a824b">six months</ix:nonNumeric>. The Plan provides that participants may contribute up to the maximum amount of their compensation as set forth by the Internal Revenue Service each year. Employee contributions are invested in various investment funds based upon elections made by the employees. During 2019, 2018 and 2017, the Company contributed approximately $<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzgvZnJhZzoyZjQ5ZWM5ZTRhMjk0OGUzYTg5NzZjOGIxYWY3N2JmYi90ZXh0cmVnaW9uOjJmNDllYzllNGEyOTQ4ZTNhODk3NmM4YjFhZjc3YmZiXzY3Nw_7ba8b1f2-8b11-4f52-9e76-5f8a33d4078b"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzgvZnJhZzoyZjQ5ZWM5ZTRhMjk0OGUzYTg5NzZjOGIxYWY3N2JmYi90ZXh0cmVnaW9uOjJmNDllYzllNGEyOTQ4ZTNhODk3NmM4YjFhZjc3YmZiXzY3Nw_895b7a3c-49b3-4d89-b375-f7904987730a"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzgvZnJhZzoyZjQ5ZWM5ZTRhMjk0OGUzYTg5NzZjOGIxYWY3N2JmYi90ZXh0cmVnaW9uOjJmNDllYzllNGEyOTQ4ZTNhODk3NmM4YjFhZjc3YmZiXzY3Nw_f4812111-c22d-424a-833e-f0b9dd2a1405">50,000</ix:nonFraction></ix:nonFraction></ix:nonFraction> in each year to the Plan as an employer match of participant contributions.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012 and 2013, the Company established non-qualified unfunded deferred compensation plans that allow participants to defer receipt of a portion of their compensation. The liability under the plans, reflected in other long term liabilities in the consolidated balance sheet, was $<ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzgvZnJhZzoyZjQ5ZWM5ZTRhMjk0OGUzYTg5NzZjOGIxYWY3N2JmYi90ZXh0cmVnaW9uOjJmNDllYzllNGEyOTQ4ZTNhODk3NmM4YjFhZjc3YmZiXzEwMzc_7c945c37-f1e3-4cca-b052-db757fef2527">2.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i19f7709a57f34358b074d8ab2cd1410f_I20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzgvZnJhZzoyZjQ5ZWM5ZTRhMjk0OGUzYTg5NzZjOGIxYWY3N2JmYi90ZXh0cmVnaW9uOjJmNDllYzllNGEyOTQ4ZTNhODk3NmM4YjFhZjc3YmZiXzEwNDQ_e869efec-1bb0-4cff-ab4e-d20ebd8b0005">1.6</ix:nonFraction> million as of December&#160;31, 2019 and 2018, respectively.  The Company had assets consisting of company-owned life insurance contracts generally designated to pay benefits of the deferred compensation plans reflected in other assets in the consolidated balance sheet of $<ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzgvZnJhZzoyZjQ5ZWM5ZTRhMjk0OGUzYTg5NzZjOGIxYWY3N2JmYi90ZXh0cmVnaW9uOjJmNDllYzllNGEyOTQ4ZTNhODk3NmM4YjFhZjc3YmZiXzEyOTA_57d2e6b8-ac41-4391-bfa3-61068da0478a">3.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i19f7709a57f34358b074d8ab2cd1410f_I20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzgvZnJhZzoyZjQ5ZWM5ZTRhMjk0OGUzYTg5NzZjOGIxYWY3N2JmYi90ZXh0cmVnaW9uOjJmNDllYzllNGEyOTQ4ZTNhODk3NmM4YjFhZjc3YmZiXzEyOTc_b37e90c5-022c-403e-9a49-0a03137c086e">2.3</ix:nonFraction> million as of December&#160;31, 2019 and 2018, respectively.</span></div></ix:continuation><div id="id2bfa55304bd45bbaa9cdf09bb7673a3_244"></div><div style="margin-top:8pt;text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(15)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:LeasesOfLesseeDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90ZXh0cmVnaW9uOmUzNjUzZDFmZjNlMTQ2NTNhZTBjM2I0NzM1ZWQ3NzA4XzQwOTM_321d5c72-6358-4cd6-9466-2840191c542b" continuedAt="ia0ccc50cce8949b78295e0aa801fef35" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="ia0ccc50cce8949b78295e0aa801fef35" continuedAt="i4059d88e24884a57a9b9db674a78b926"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is obligated under long-term real estate leases for corporate office space that was extended during the third quarter of 2015.  Prior to this extension, the lease would have expired in October 2016, the lease is now set to expire in October 2022. In addition, the research lab space at CET, under an agreement amended in July 2012, is leased through April 2023, with an option to extend the lease through April 2028. The Company also subleases a portion of the space under these leases. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense is recognized over the expected term of the lease, including renewal option periods, if applicable, on a straight-line basis as a component of general and administrative expense. <ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="cpix:ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90ZXh0cmVnaW9uOmUzNjUzZDFmZjNlMTQ2NTNhZTBjM2I0NzM1ZWQ3NzA4XzQwOTA_25ee5e02-d5be-4e70-a4af-44077790e24e" continuedAt="iff97bd01557140eaba3b68a0eb9f6d3b" escape="true">Rent expense and sublease income  as follows for the years ended December 31:</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><ix:continuation id="iff97bd01557140eaba3b68a0eb9f6d3b"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.897%"><tr><td style="width:1.0%"></td><td style="width:41.064%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.064%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.559%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2017</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZTo5NGU1YmEyMzA0NDU0MDhlOTBmMGNjMmRhZjYwYzcyZC90YWJsZXJhbmdlOjk0ZTViYTIzMDQ0NTQwOGU5MGYwY2MyZGFmNjBjNzJkXzItMi0xLTEtMA_48666a72-38ba-4039-9a42-164624a53ed9">1,246,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZTo5NGU1YmEyMzA0NDU0MDhlOTBmMGNjMmRhZjYwYzcyZC90YWJsZXJhbmdlOjk0ZTViYTIzMDQ0NTQwOGU5MGYwY2MyZGFmNjBjNzJkXzItNC0xLTEtMA_3b96ae47-89d1-408f-9604-d7fd9fbd4937">1,136,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZTo5NGU1YmEyMzA0NDU0MDhlOTBmMGNjMmRhZjYwYzcyZC90YWJsZXJhbmdlOjk0ZTViYTIzMDQ0NTQwOGU5MGYwY2MyZGFmNjBjNzJkXzItNi0xLTEtMA_0dd68030-ebda-4a88-8fd5-5589483ce815">1,074,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesRentExpenseSubleaseRentals1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZTo5NGU1YmEyMzA0NDU0MDhlOTBmMGNjMmRhZjYwYzcyZC90YWJsZXJhbmdlOjk0ZTViYTIzMDQ0NTQwOGU5MGYwY2MyZGFmNjBjNzJkXzQtMi0xLTEtMA_f2b7d75b-4f92-422d-b61f-ecc24c419cfa">688,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesRentExpenseSubleaseRentals1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZTo5NGU1YmEyMzA0NDU0MDhlOTBmMGNjMmRhZjYwYzcyZC90YWJsZXJhbmdlOjk0ZTViYTIzMDQ0NTQwOGU5MGYwY2MyZGFmNjBjNzJkXzQtNC0xLTEtMA_4097c033-4876-404f-881f-19329a5d026a">662,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesRentExpenseSubleaseRentals1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZTo5NGU1YmEyMzA0NDU0MDhlOTBmMGNjMmRhZjYwYzcyZC90YWJsZXJhbmdlOjk0ZTViYTIzMDQ0NTQwOGU5MGYwY2MyZGFmNjBjNzJkXzQtNi0xLTEtMA_17792eb2-cffb-4722-aba2-8751a4c233fb">573,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the FASB issued ASU 2016-02. ASU 2016-02&#8217;s core principle is to increase transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information. The Company adopted ASU 2016-02 under the alternative transition method (the effective date approach). It allowed the Company to initially apply the new lease guidance at the adoption date (rather than at the beginning of the earliest period presented). Prior periods have not been adjusted.   </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary effect of adopting ASU 2016-02 to the Company was to record right-of-use assets and obligations for the leases currently classified as operating leases.  The Company&#8217;s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters.  This lease currently expires in October 2022.  The operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by Cumberland Emerging Technologies (&#8220;CET&#8221;), </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="i4059d88e24884a57a9b9db674a78b926" continuedAt="i9ff624f5698b4727be5927809cb2f5a0"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our majority-owned subsidiary, where it operates the CET Life Sciences Center.  This lease currently expires in April 2023. The Company did not have any leases classified as finance leases at January 1, 2019 or December&#160;31, 2019.  The new lease accounting standard did not have a significant impact on the Company's Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for any period presented. </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company elected the package of practical expedients offered in the transition guidance which allows management not to reassess lease identification, lease classification and initial direct costs at the adoption date. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These operating leases resulted in initial ROU assets of $<ix:nonFraction unitRef="usd" contextRef="i76f168e8263b4700be275c05007c5731_I20190101" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90ZXh0cmVnaW9uOmUzNjUzZDFmZjNlMTQ2NTNhZTBjM2I0NzM1ZWQ3NzA4XzI1NzU_821200ae-cea4-4d10-a6f0-d0dff9538994">3.6</ix:nonFraction> million and lease liabilities of $<ix:nonFraction unitRef="usd" contextRef="i76f168e8263b4700be275c05007c5731_I20190101" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90ZXh0cmVnaW9uOmUzNjUzZDFmZjNlMTQ2NTNhZTBjM2I0NzM1ZWQ3NzA4XzI2MTE_826d6d1e-074a-484c-9f3f-4e54e97931e2">3.8</ix:nonFraction> million as of January 1, 2019 for non-cancelable operating leases with original lease terms in excess of one year.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities were recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As the Company&#8217;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019. Incremental borrowing rates reflect the Company&#8217;s estimated interest rates for collateralized borrowings over similar lease terms. The weighted-average remaining lease term is <ix:nonNumeric contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90ZXh0cmVnaW9uOmUzNjUzZDFmZjNlMTQ2NTNhZTBjM2I0NzM1ZWQ3NzA4XzMzOTg_a832540a-a7f6-4666-9a25-5b445cfc7ddb">3.4</ix:nonNumeric> years and the weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments is <ix:nonFraction unitRef="number" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90ZXh0cmVnaW9uOmUzNjUzZDFmZjNlMTQ2NTNhZTBjM2I0NzM1ZWQ3NzA4XzM1Mjk_e0e24d9f-6802-47a2-ae84-a34578a9f0fd">7.42</ix:nonFraction>%.</span></div><div style="margin-top:8pt;padding-left:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease Position</span></div><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="cpix:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90ZXh0cmVnaW9uOmUzNjUzZDFmZjNlMTQ2NTNhZTBjM2I0NzM1ZWQ3NzA4XzQwOTY_9388c2cf-5d4c-42e3-8452-7e383f006436" escape="true"><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2019, the Company recorded the following on the Condensed Consolidated Balance Sheet: </span></div><div style="margin-top:8pt;padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.688%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-Use Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZTo1NmU3YTY5NTgyNzI0NWNhYTVjOGU0ZDQxZWMwZGI3NC90YWJsZXJhbmdlOjU2ZTdhNjk1ODI3MjQ1Y2FhNWM4ZTRkNDFlYzBkYjc0XzEtNC0xLTEtMA_a06c5635-aaf0-43dd-ac84-fa1c82605c7f">2,960,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="cpix:LeaseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZTo1NmU3YTY5NTgyNzI0NWNhYTVjOGU0ZDQxZWMwZGI3NC90YWJsZXJhbmdlOjU2ZTdhNjk1ODI3MjQ1Y2FhNWM4ZTRkNDFlYzBkYjc0XzItNC0xLTEtMA_5539eee7-858d-4f68-9fe2-13e897add44b">2,960,569</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;padding-left:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.688%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZToyNTY3MjUyODlhYzg0YzQ4YjYwOTA5MjQwOWI5NDJkZC90YWJsZXJhbmdlOjI1NjcyNTI4OWFjODRjNDhiNjA5MDkyNDA5Yjk0MmRkXzItNC0xLTEtMA_df5aa16a-3f4d-4ce0-8629-93c92284d5b5">920,431</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZToyNTY3MjUyODlhYzg0YzQ4YjYwOTA5MjQwOWI5NDJkZC90YWJsZXJhbmdlOjI1NjcyNTI4OWFjODRjNDhiNjA5MDkyNDA5Yjk0MmRkXzQtNC0xLTEtMA_a4d7f5e1-32b5-48f9-b012-ef3a86f43da5">2,076,472</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="cpix:LeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZToyNTY3MjUyODlhYzg0YzQ4YjYwOTA5MjQwOWI5NDJkZC90YWJsZXJhbmdlOjI1NjcyNTI4OWFjODRjNDhiNjA5MDkyNDA5Yjk0MmRkXzUtNC0xLTEtMA_e12c3d43-e833-4c25-8dba-031db9945708">2,996,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="i9ff624f5698b4727be5927809cb2f5a0"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumulative future minimum sublease income under non-cancelable operating subleases totals approximately $<ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90ZXh0cmVnaW9uOmUzNjUzZDFmZjNlMTQ2NTNhZTBjM2I0NzM1ZWQ3NzA4XzM3NTU_836b6d99-09f3-42a6-834b-d1589b5b0704">0.7</ix:nonFraction> million and will be paid through the leases ending in October 2022 and April 2023. <ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90ZXh0cmVnaW9uOmUzNjUzZDFmZjNlMTQ2NTNhZTBjM2I0NzM1ZWQ3NzA4XzQwOTc_7470d323-d776-48a6-8d9c-8dbe70f0fb30" continuedAt="i1309debb9e6c4b5e868e296926f298b1" escape="true">Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:center"><ix:continuation id="i1309debb9e6c4b5e868e296926f298b1"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:66.025%"><tr><td style="width:1.0%"></td><td style="width:73.171%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.173%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of  December&#160;31, 2019:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZToyMzQ0NjI1YTFkZjU0NmMyYWMyZmJlYmZkNjVkYTBmYy90YWJsZXJhbmdlOjIzNDQ2MjVhMWRmNTQ2YzJhYzJmYmViZmQ2NWRhMGZjXzEtMi0xLTEtMA_696c5063-440d-4d11-bdae-725f0f6b5f94">1,120,066</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZToyMzQ0NjI1YTFkZjU0NmMyYWMyZmJlYmZkNjVkYTBmYy90YWJsZXJhbmdlOjIzNDQ2MjVhMWRmNTQ2YzJhYzJmYmViZmQ2NWRhMGZjXzItMi0xLTEtMA_18d37495-90a7-433a-a043-e65cc09b5d6c">1,144,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZToyMzQ0NjI1YTFkZjU0NmMyYWMyZmJlYmZkNjVkYTBmYy90YWJsZXJhbmdlOjIzNDQ2MjVhMWRmNTQ2YzJhYzJmYmViZmQ2NWRhMGZjXzMtMi0xLTEtMA_7f5d2529-9b1d-48b4-9a9a-b1cc6d333ddf">1,019,313</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZToyMzQ0NjI1YTFkZjU0NmMyYWMyZmJlYmZkNjVkYTBmYy90YWJsZXJhbmdlOjIzNDQ2MjVhMWRmNTQ2YzJhYzJmYmViZmQ2NWRhMGZjXzQtMi0xLTEtMA_0b1f0e8f-6090-4d6f-887a-4449e4f90ec3">92,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZToyMzQ0NjI1YTFkZjU0NmMyYWMyZmJlYmZkNjVkYTBmYy90YWJsZXJhbmdlOjIzNDQ2MjVhMWRmNTQ2YzJhYzJmYmViZmQ2NWRhMGZjXzUtMi0xLTEtMA_b42dd05f-1c6e-4e40-a3be-07d01228851c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZToyMzQ0NjI1YTFkZjU0NmMyYWMyZmJlYmZkNjVkYTBmYy90YWJsZXJhbmdlOjIzNDQ2MjVhMWRmNTQ2YzJhYzJmYmViZmQ2NWRhMGZjXzYtMi0xLTEtMA_bd60ed1a-9a69-492f-b03a-bd7afdd4f7da">3,376,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZToyMzQ0NjI1YTFkZjU0NmMyYWMyZmJlYmZkNjVkYTBmYy90YWJsZXJhbmdlOjIzNDQ2MjVhMWRmNTQ2YzJhYzJmYmViZmQ2NWRhMGZjXzctMi0xLTEtMA_7f6c3cb8-a190-4b24-aa61-32daf8651111">379,843</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZToyMzQ0NjI1YTFkZjU0NmMyYWMyZmJlYmZkNjVkYTBmYy90YWJsZXJhbmdlOjIzNDQ2MjVhMWRmNTQ2YzJhYzJmYmViZmQ2NWRhMGZjXzgtMi0xLTEtMA_7f455002-2170-4d8d-ac83-bfdeebb7f848">2,996,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90ZXh0cmVnaW9uOmUzNjUzZDFmZjNlMTQ2NTNhZTBjM2I0NzM1ZWQ3NzA4XzQwOTI_9287e05a-8697-45ef-b313-a5c0544eeb08" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's future minimum lease commitments, under Topic 840, predecessor to Topic 842, are as follows:</span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:66.025%"><tr><td style="width:1.0%"></td><td style="width:73.171%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.173%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December 31, 2018:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZTo3OWU1ZjFiZTViMGE0MTk0ODllNTZkNGM3NDg5MTY2Ny90YWJsZXJhbmdlOjc5ZTVmMWJlNWIwYTQxOTQ4OWU1NmQ0Yzc0ODkxNjY3XzEtMi0xLTEtMA_b56645fa-5493-42ec-9652-c6144cd77dd3">959,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZTo3OWU1ZjFiZTViMGE0MTk0ODllNTZkNGM3NDg5MTY2Ny90YWJsZXJhbmdlOjc5ZTVmMWJlNWIwYTQxOTQ4OWU1NmQ0Yzc0ODkxNjY3XzItMi0xLTEtMA_a0ced345-22dd-4460-aac1-f37d6314373a">980,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZTo3OWU1ZjFiZTViMGE0MTk0ODllNTZkNGM3NDg5MTY2Ny90YWJsZXJhbmdlOjc5ZTVmMWJlNWIwYTQxOTQ4OWU1NmQ0Yzc0ODkxNjY3XzMtMi0xLTEtMA_b3644dd3-81a1-4418-8cbe-1797ac2df2cf">1,001,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZTo3OWU1ZjFiZTViMGE0MTk0ODllNTZkNGM3NDg5MTY2Ny90YWJsZXJhbmdlOjc5ZTVmMWJlNWIwYTQxOTQ4OWU1NmQ0Yzc0ODkxNjY3XzQtMi0xLTEtMA_55d49403-cdfb-4635-af72-fb10b37ec1cb">871,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZTo3OWU1ZjFiZTViMGE0MTk0ODllNTZkNGM3NDg5MTY2Ny90YWJsZXJhbmdlOjc5ZTVmMWJlNWIwYTQxOTQ4OWU1NmQ0Yzc0ODkxNjY3XzUtMi0xLTEtMA_3cc1d5da-2201-42cf-bdbb-df71f459e04b">44,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:zerodash" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZTo3OWU1ZjFiZTViMGE0MTk0ODllNTZkNGM3NDg5MTY2Ny90YWJsZXJhbmdlOjc5ZTVmMWJlNWIwYTQxOTQ4OWU1NmQ0Yzc0ODkxNjY3XzYtMi0xLTEtMA_a5a53be2-7b17-40c6-9c6a-c9ab4e11bcc5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZTo3OWU1ZjFiZTViMGE0MTk0ODllNTZkNGM3NDg5MTY2Ny90YWJsZXJhbmdlOjc5ZTVmMWJlNWIwYTQxOTQ4OWU1NmQ0Yzc0ODkxNjY3XzctMi0xLTEtMA_85fe2864-6084-431c-98e5-115435f65ec3">3,858,702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:8pt;text-align:center;text-indent:18pt"><span><br/></span></div><div id="id2bfa55304bd45bbaa9cdf09bb7673a3_247"></div><div style="text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(16)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90ZXh0cmVnaW9uOmI2NzI1N2RkNDIzNDQ0NDhiNDFiOThlODljYjljMmQ5XzY4OA_ac9ccd25-f4f8-4c7a-8510-e1a871cbf234" continuedAt="iae3545c470ac4a56a000704ca245ecca" escape="true">Fair Value of Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="iae3545c470ac4a56a000704ca245ecca" continuedAt="i2993a79e44e64bd7a2e20f7887747dd7"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company owns marketable securities that are solely classified as trading securities as of December&#160;31, 2019.  All of these securities had a maturity date of less than ninety days and classified as cash and cash equivalents at December&#160;31, 2019.  There were no transfers of assets between levels within the fair value hierarchy. <ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90ZXh0cmVnaW9uOmI2NzI1N2RkNDIzNDQ0NDhiNDFiOThlODljYjljMmQ5XzY5MA_a6bea589-844b-4191-b4f0-48022b1b27cd" continuedAt="iaa6ab25954c14e629fa9320e20006852" escape="true">The following table summarizes the fair value of these marketable securities by level within the fair value hierarchy:</ix:nonNumeric></span></div><div style="margin-bottom:12pt;margin-top:8pt;text-align:center"><ix:continuation id="iaa6ab25954c14e629fa9320e20006852"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.380%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.117%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.117%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.117%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.117%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.407%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2018</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes and bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46b68c95812c4585ad2800f7e762d7ef_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzMtMi0xLTEtMA_2ed0c55d-5063-4ce7-aa21-f78f450843b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6967c2f466014730a8901a2bbff4743a_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzMtNC0xLTEtMA_d14b847c-0539-475b-8e88-f0c7f2062637">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcaec0f707064e14843280c588b63de9_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzMtNi0xLTEtMA_39e68ade-dfa4-4133-9a55-ff8c8f8dddfa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if40add46a67d4c1b959ea74b3095136d_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzMtOC0xLTEtMA_08d39aa1-80e3-4c58-98ca-ead2115bb4d4">5,034,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i871d23f00b9d4522a41b0f48f1812cb8_I20181231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzMtMTAtMS0xLTA_e99136e9-06b7-4130-9706-c86715337b66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id41b97cccddf404587b71109d9148bd9_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzMtMTItMS0xLTA_570638e1-2fa7-427e-9337-94ea354288be">5,034,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SBA loan pools - variable rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c77d83b0d784f95a8c57dc2c69a1ae1_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzctMi0xLTEtMA_3dd76f6f-5494-4ef4-8d24-cc30d99ded09">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5261d06b396a496e83c3994a329a6adb_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzctNC0xLTEtMA_844f9888-9b0f-4ba5-b219-32f444e515bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia491869f8f8e4444a463caa044907b2a_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzctNi0xLTEtMA_17364187-b488-454c-bab8-c4951ebb038a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6180b75c51584214a21798f206007fd2_I20181231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzctOC0xLTEtMA_2ec4413d-616a-463b-ac6e-223eeef1ed0c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd574df43534324bb75dd95355cde9d_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzctMTAtMS0xLTA_858a7f00-853a-4dcd-bb35-2fa7e8681f58">2,504,551</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2390f7b0f62e4227ae756897529dc3e8_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzctMTItMS0xLTA_b8a75a8a-4b29-4455-a0cc-46e95144aa83">2,504,551</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term cash investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5de80c3842fe4ead883716b857a3ab60_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzgtMi0xLTEtMA_5f06d034-7946-4217-9523-948ce975da48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61fc59376d074db2a4ed2e33996a40ae_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzgtNC0xLTEtMA_53fd16ab-3623-40dc-a342-50c46a2d7065">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80849ef0fff8453994464dd9e4263335_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzgtNi0xLTEtMA_00edd405-dafd-4f4c-8289-50eb07595e1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia476a3c32a024ea799663e72ef23fe02_I20181231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzgtOC0xLTEtMA_5736eecd-b678-4074-8644-4315f6993fbd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e0531514c241aca726450993124452_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzgtMTAtMS0xLTA_6f240b84-7e8c-42f0-a06b-d9beb1bce9f8">751,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40d16a645ee641218f7703ab03b0d941_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzgtMTItMS0xLTA_19aaeeae-b150-4ed3-8f46-d52afa80d4d1">751,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial Paper</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52e850d4caf6459cb3f900290e148294_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzktMi0xLTEtMA_9ffd9955-2f66-4a7d-ba0b-df0d96672081">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539d6d44a9ae44f485c1050e287da81b_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzktNC0xLTEtMA_efe9abe7-08ea-48fe-abe9-21631ee2d7c2">2,119,607</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4df16753bd334ba3b2e0980d61fa84e3_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzktNi0xLTEtMA_be4e6f6c-aa47-48d4-954c-635ff7e4acf2">2,119,607</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42f63da2feed4ee1a967d286f376accb_I20181231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzktOC0xLTEtMA_de390829-cf8d-4dc3-9e90-be90c648da19">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e331fd58cd14866b6404f53b122155e_I20181231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzktMTAtMS0xLTA_28301acb-ad3e-4ee0-b281-56c936800f89">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cd20af5088e4c7ba1a916823027ba00_I20181231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzktMTItMS0xLTA_d5084e5b-8109-4dcf-af3c-b8b8f14d3c74">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i780bdd9adff04751adcd1b6f35439d2f_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzEwLTItMS0xLTA_e32ea536-ffba-4b00-bb58-d423aa142086">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c0f572b430a45c5bf9009619128671c_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzEwLTQtMS0xLTA_3c89fd8a-6be3-4831-8eef-8feb477092ce">2,119,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzEwLTYtMS0xLTA_8e60da4e-d4e6-400f-aa52-69551b1660fe">2,119,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67dfb3a3f9004593be1dd06a75668d57_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzEwLTgtMS0xLTA_58a539a1-25be-4efd-b389-a4fe84cb3096">5,034,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i943d44213b5845cd9d5b5d5a2ebe891e_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzEwLTEwLTEtMS0w_4858582b-a320-493a-a18a-e70ccb1f5133">3,255,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzEwLTEyLTEtMS0w_c89b6345-2981-4927-aa3a-369d9cb69016">8,290,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2993a79e44e64bd7a2e20f7887747dd7">The fair values of all other financial instruments outstanding as of December&#160;31, 2019 and 2018 approximate their carrying values.  There were no changes to the valuation techniques for the Level 2 marketable securities during 2019 or 2018.</ix:continuation> </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-32</span></div></div></div><div id="id2bfa55304bd45bbaa9cdf09bb7673a3_250"></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(17)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:ConcentrationRiskDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNTAvZnJhZzpiNmU5ZDk2MzU2OTY0ZTUwYjJiZjViYWFlZGExMDY3Yy90ZXh0cmVnaW9uOmI2ZTlkOTYzNTY5NjRlNTBiMmJmNWJhYWVkYTEwNjdjXzkwNA_7b0521ca-be0f-4c23-ac7e-2910bc1ee433" continuedAt="i05722d5674a94db3865ad0b7697cd111" escape="true">Market Concentrations</ix:nonNumeric></span></div><ix:continuation id="i05722d5674a94db3865ad0b7697cd111"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is focused on the acquisition, development and commercialization of branded prescription products.  The Company&#8217;s principal financial instruments subject to potential concentration of credit risk are accounts receivable, which are unsecured, and cash equivalents. The Company&#8217;s cash equivalents consist primarily of money market funds. Certain bank deposits may be in excess of the insurance limits provided by the Federal Deposit Insurance Corporation.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s primary customers are wholesale pharmaceutical distributors in the U.S. &#160;<ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNTAvZnJhZzpiNmU5ZDk2MzU2OTY0ZTUwYjJiZjViYWFlZGExMDY3Yy90ZXh0cmVnaW9uOmI2ZTlkOTYzNTY5NjRlNTBiMmJmNWJhYWVkYTEwNjdjXzkwMw_de6b769d-7c39-46b8-85bd-84cba0bdb9cf" continuedAt="i2ee0bbd97831480dbabd132f72baedd9" escape="true">Total revenues by customer for each customer representing 10% or more of consolidated revenues are summarized below for the years ended December 31:</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><ix:continuation id="i2ee0bbd97831480dbabd132f72baedd9"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:76.602%"><tr><td style="width:1.0%"></td><td style="width:39.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.520%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i957590befb9d4e11af4357cac09d5a2e_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNTAvZnJhZzpiNmU5ZDk2MzU2OTY0ZTUwYjJiZjViYWFlZGExMDY3Yy90YWJsZTo0MjJhNTU1ZWQ1ZDU0ZDU5YjI2ZmNmNDlkZjBhYjlhNy90YWJsZXJhbmdlOjQyMmE1NTVlZDVkNTRkNTliMjZmY2Y0OWRmMGFiOWE3XzItMi0xLTEtMA_f4063e0f-a968-48a2-a62d-315e65bbf821">31</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4311d59a68c14a2c85db7649a6e2817c_D20180101-20181231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNTAvZnJhZzpiNmU5ZDk2MzU2OTY0ZTUwYjJiZjViYWFlZGExMDY3Yy90YWJsZTo0MjJhNTU1ZWQ1ZDU0ZDU5YjI2ZmNmNDlkZjBhYjlhNy90YWJsZXJhbmdlOjQyMmE1NTVlZDVkNTRkNTliMjZmY2Y0OWRmMGFiOWE3XzItNC0xLTEtMA_d5438523-0246-43ed-8b64-cb374b69ef81">28</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i45aae0c5083b4158a10518d39b977929_D20170101-20171231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNTAvZnJhZzpiNmU5ZDk2MzU2OTY0ZTUwYjJiZjViYWFlZGExMDY3Yy90YWJsZTo0MjJhNTU1ZWQ1ZDU0ZDU5YjI2ZmNmNDlkZjBhYjlhNy90YWJsZXJhbmdlOjQyMmE1NTVlZDVkNTRkNTliMjZmY2Y0OWRmMGFiOWE3XzItNi0xLTEtMA_812df4ad-0266-48c4-8f92-19e36e85dd15">28</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i633f3a7886904df3bc2c1a118b38b5b5_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNTAvZnJhZzpiNmU5ZDk2MzU2OTY0ZTUwYjJiZjViYWFlZGExMDY3Yy90YWJsZTo0MjJhNTU1ZWQ1ZDU0ZDU5YjI2ZmNmNDlkZjBhYjlhNy90YWJsZXJhbmdlOjQyMmE1NTVlZDVkNTRkNTliMjZmY2Y0OWRmMGFiOWE3XzMtMi0xLTEtMA_f513db93-5c09-40ad-8161-e5e233bd165f">28</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie40ef9fa31bd4ff8a234daae70ffaf5f_D20180101-20181231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNTAvZnJhZzpiNmU5ZDk2MzU2OTY0ZTUwYjJiZjViYWFlZGExMDY3Yy90YWJsZTo0MjJhNTU1ZWQ1ZDU0ZDU5YjI2ZmNmNDlkZjBhYjlhNy90YWJsZXJhbmdlOjQyMmE1NTVlZDVkNTRkNTliMjZmY2Y0OWRmMGFiOWE3XzMtNC0xLTEtMA_d96eca74-6306-4128-8d14-a201200a0451">25</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i023693e081e647c2959d4531c232be23_D20170101-20171231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNTAvZnJhZzpiNmU5ZDk2MzU2OTY0ZTUwYjJiZjViYWFlZGExMDY3Yy90YWJsZTo0MjJhNTU1ZWQ1ZDU0ZDU5YjI2ZmNmNDlkZjBhYjlhNy90YWJsZXJhbmdlOjQyMmE1NTVlZDVkNTRkNTliMjZmY2Y0OWRmMGFiOWE3XzMtNi0xLTEtMA_ea2dce8e-0837-4dd0-b7ec-a762cb7a1281">29</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0dcb5d79a1304c1a805e8f68f0a8fad3_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNTAvZnJhZzpiNmU5ZDk2MzU2OTY0ZTUwYjJiZjViYWFlZGExMDY3Yy90YWJsZTo0MjJhNTU1ZWQ1ZDU0ZDU5YjI2ZmNmNDlkZjBhYjlhNy90YWJsZXJhbmdlOjQyMmE1NTVlZDVkNTRkNTliMjZmY2Y0OWRmMGFiOWE3XzQtMi0xLTEtMA_6239c986-b60f-45cb-922b-c313b893d430">17</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0fe8c7998adb4a09a50f50ebe5dc2cfe_D20180101-20181231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNTAvZnJhZzpiNmU5ZDk2MzU2OTY0ZTUwYjJiZjViYWFlZGExMDY3Yy90YWJsZTo0MjJhNTU1ZWQ1ZDU0ZDU5YjI2ZmNmNDlkZjBhYjlhNy90YWJsZXJhbmdlOjQyMmE1NTVlZDVkNTRkNTliMjZmY2Y0OWRmMGFiOWE3XzQtNC0xLTEtMA_456295fc-4c87-4b12-8966-6a5738a85a66">26</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i60785c35eb4e4574a2eeeed10b448ec6_D20170101-20171231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNTAvZnJhZzpiNmU5ZDk2MzU2OTY0ZTUwYjJiZjViYWFlZGExMDY3Yy90YWJsZTo0MjJhNTU1ZWQ1ZDU0ZDU5YjI2ZmNmNDlkZjBhYjlhNy90YWJsZXJhbmdlOjQyMmE1NTVlZDVkNTRkNTliMjZmY2Y0OWRmMGFiOWE3XzQtNi0xLTEtMA_daa8a9ce-2363-41d8-a003-158b553bcd72">21</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">*: less than 10% of total</span></div><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></ix:continuation></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts receivable, net of allowances, due from the customers representing 10% or more of consolidated revenue was <ix:nonFraction unitRef="number" contextRef="i6f1d9c99bd274435b9a4a98946740ee0_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNTAvZnJhZzpiNmU5ZDk2MzU2OTY0ZTUwYjJiZjViYWFlZGExMDY3Yy90ZXh0cmVnaW9uOmI2ZTlkOTYzNTY5NjRlNTBiMmJmNWJhYWVkYTEwNjdjXzQzOTgwNDY1MTIwMjc_5a5ff977-ca37-4be7-af31-195069bbe813">59</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i5e32cc9a0bea46d0b461b09960568c0b_D20180101-20181231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNTAvZnJhZzpiNmU5ZDk2MzU2OTY0ZTUwYjJiZjViYWFlZGExMDY3Yy90ZXh0cmVnaW9uOmI2ZTlkOTYzNTY5NjRlNTBiMmJmNWJhYWVkYTEwNjdjXzQzOTgwNDY1MTIwMzI_81417c64-53c7-4223-8347-c8540b55d5c8">72</ix:nonFraction>% at December&#160;31, 2019 and 2018, respectively.</span></div></ix:continuation><div id="id2bfa55304bd45bbaa9cdf09bb7673a3_256"></div><div style="margin-top:8pt;text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(18)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="cpix:ManufacturingAndSupplyAgreementsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNTYvZnJhZzo3ODgwM2FjYjQ3MzA0ZWE4OTA2MDYyYzI2MTI2YmM2MS90ZXh0cmVnaW9uOjc4ODAzYWNiNDczMDRlYTg5MDYwNjJjMjYxMjZiYzYxXzYzOQ_13ed9951-7942-4358-a215-7b1eced9775a" continuedAt="i102ab06910d04cda8517cf22a98b9f8b" escape="true">Manufacturing and Supply Agreements</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i102ab06910d04cda8517cf22a98b9f8b">The Company utilizes <ix:nonFraction unitRef="supplier" contextRef="i1a21420517ea4647a67d7b1217a674ef_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="cpix:ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNTYvZnJhZzo3ODgwM2FjYjQ3MzA0ZWE4OTA2MDYyYzI2MTI2YmM2MS90ZXh0cmVnaW9uOjc4ODAzYWNiNDczMDRlYTg5MDYwNjJjMjYxMjZiYzYxXzY3_5aea397a-f27c-4b5a-8a68-785dad006297">one</ix:nonFraction> or <ix:nonFraction unitRef="supplier" contextRef="i8471ffa3b49c4d27b527e605477129a5_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="cpix:ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNTYvZnJhZzo3ODgwM2FjYjQ3MzA0ZWE4OTA2MDYyYzI2MTI2YmM2MS90ZXh0cmVnaW9uOjc4ODAzYWNiNDczMDRlYTg5MDYwNjJjMjYxMjZiYzYxXzcz_649f89e9-50ee-41b5-baec-161b329f491a">two</ix:nonFraction> primary suppliers to manufacture each of its products and product candidates. Although there are a limited number of manufacturers of pharmaceutical products, the Company believes it could utilize other suppliers to manufacture its prescription products on comparable terms.  A change in suppliers, problems with its third-party manufacturing operations or related production capacity, or contract disputes with suppliers could cause a delay in manufacturing or shipment of finished goods and possible loss of sales, which could adversely affect operating results.</ix:continuation></span></div><div id="id2bfa55304bd45bbaa9cdf09bb7673a3_259"></div><div style="margin-top:8pt;text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(19)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="cpix:EmploymentAgreementsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNTkvZnJhZzo4ZGMwZTIzNDQ2YmI0NWI3YjA2MWE3OTg2OGY2MDczNi90ZXh0cmVnaW9uOjhkYzBlMjM0NDZiYjQ1YjdiMDYxYTc5ODY4ZjYwNzM2XzMxMA_a2a7e401-85f9-43d4-ad72-5f6d05214d75" continuedAt="i435e7d2dbf984321962eac91c7261062" escape="true">Employment Agreements</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i435e7d2dbf984321962eac91c7261062">The Company has entered into employment agreements with all its full-time employees. Each employment agreement provides for a salary for services performed, a potential annual bonus and, if applicable, a grant of restricted common shares pursuant to a restricted stock agreement.</ix:continuation></span></div><div id="id2bfa55304bd45bbaa9cdf09bb7673a3_262"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(20)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90ZXh0cmVnaW9uOjEzZmIyMzg2ZmEwMDQ0OWNhOTQzZmUwYWM0YTU3ZTE5XzIzMzk_43102b9b-722d-4fa7-95ab-cff87267629b" continuedAt="ib975007654bd4cca9001affe67cb69ed" escape="true">Discontinued Operations</ix:nonNumeric></span></div><ix:continuation id="ib975007654bd4cca9001affe67cb69ed" continuedAt="ia63e164647514c1d88035e0e031994cb"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, Cumberland entered into an agreement with Clinigen Group Plc ("Clinigen") for the rights and responsibilities associated with the commercialization of Ethyol in the United States.  In 2017, the Company entered into another agreement with Clinigen for the rights and responsibilities associated with the commercialization of Totect in the United States.  Ethyol and Totect are collectively referred to herein as the "Products."</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Early in 2019, Cumberland announced a strategic review the Company's brands, capabilities, and international partners. This review followed an accelerated business development initiative, which resulted in a series of transactions. Because of that progress, Cumberland felt that it was prudent to take a fresh look at our product portfolio, partners, and organization to ensure proper focus and capabilities.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During May 2019, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">following the strategic review, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland entered into the Dissolution Agreement with Clinigen in which the Company returned the exclusive rights to commercialize Ethyol and Totect (&#8220;the Products&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States to Clinigen. This Dissolution Agreement originally targeted a transition from the Company's arrangements with Clinigen effective September 30, 2019, but was then amended to change the transition date to December 31, 2019. Under the terms of the Dissolution Agreement, Cumberland was no longer responsible for the distribution, marketing and promotion of </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="ia63e164647514c1d88035e0e031994cb"><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">either the Products or any competing products after December 31, 2019.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In exchange for the return of these product license rights and the non-compete provisions of the Dissolution Agreement, Cumberland is receiving $<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90ZXh0cmVnaW9uOjEzZmIyMzg2ZmEwMDQ0OWNhOTQzZmUwYWM0YTU3ZTE5XzMyOTg1MzQ4ODg3NzI_6282e2b1-fd74-4aab-8692-bc9c258ad7d4">5</ix:nonFraction>&#160;million in financial consideration paid in quarterly installments over the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90ZXh0cmVnaW9uOjEzZmIyMzg2ZmEwMDQ0OWNhOTQzZmUwYWM0YTU3ZTE5XzQzOTgwNDY1MjI4MDI_72facf0f-0ab8-4e03-8486-1d05338389f9">two</span>-years following the transition date.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exit from the Ethyol and Totect Products meets the accounting criteria to be reported as discontinued operations. December 31, 2019, as the transition date, was the final day Cumberland was responsible for the Products. Cumberland was responsible for the Products through December 31, 2019 and beginning on January 1, 2020, the Products' rights transitioned back to Clinigen. As a result, January 1, 2020, was the first day of discontinued operations for the Ethyol and Totect products.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Products provided revenue, incurred direct expenses and resulted in discontinued operations income during the periods presented.  The following amounts have been separated from continuing operations, as discontinued operations, for all periods presented. The direct expenses separated for discontinued operations do not reflect the direct selling and marketing costs attributable to the individuals at Cumberland responsible for promotion of the Products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Subsequent to the transaction date, th</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ose sales and marketing individuals who supported the Products shifted their efforts from the Products and continue to support other Cumberland brands.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90ZXh0cmVnaW9uOjEzZmIyMzg2ZmEwMDQ0OWNhOTQzZmUwYWM0YTU3ZTE5XzQzOTgwNDY1MjI3OTk_9cff37d7-c4d6-40e3-8c86-a047ba903257" continuedAt="ie34a806376474bb8ae48a22e556acf13" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:49.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.439%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.735%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZTpkM2M4M2NiODZlZTk0ZjM2YmU4NTMyYjVlN2JlN2Y4ZC90YWJsZXJhbmdlOmQzYzgzY2I4NmVlOTRmMzZiZTg1MzJiNWU3YmU3ZjhkXzItMi0xLTEtMjEwOQ_a7f5ddd7-d579-461b-9dc8-226c217541bf">13,145,344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZTpkM2M4M2NiODZlZTk0ZjM2YmU4NTMyYjVlN2JlN2Y4ZC90YWJsZXJhbmdlOmQzYzgzY2I4NmVlOTRmMzZiZTg1MzJiNWU3YmU3ZjhkXzItNC0xLTEtMjExMQ_56c5e0be-2cf5-45c3-93ee-70520845a111">11,396,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZTpkM2M4M2NiODZlZTk0ZjM2YmU4NTMyYjVlN2JlN2Y4ZC90YWJsZXJhbmdlOmQzYzgzY2I4NmVlOTRmMzZiZTg1MzJiNWU3YmU3ZjhkXzItNi0xLTEtMjExMw_c9d1bf38-60ef-46b0-9666-6a56c5ccab77">14,827,504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs of products sold</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZTpkM2M4M2NiODZlZTk0ZjM2YmU4NTMyYjVlN2JlN2Y4ZC90YWJsZXJhbmdlOmQzYzgzY2I4NmVlOTRmMzZiZTg1MzJiNWU3YmU3ZjhkXzMtMi0xLTEtMjEwOQ_6f6f9262-f766-44c3-af95-6143eff423b6">1,330,704</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZTpkM2M4M2NiODZlZTk0ZjM2YmU4NTMyYjVlN2JlN2Y4ZC90YWJsZXJhbmdlOmQzYzgzY2I4NmVlOTRmMzZiZTg1MzJiNWU3YmU3ZjhkXzMtNC0xLTEtMjExMQ_c3d39d63-7045-436f-af11-e2ba04b022ee">1,361,273</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZTpkM2M4M2NiODZlZTk0ZjM2YmU4NTMyYjVlN2JlN2Y4ZC90YWJsZXJhbmdlOmQzYzgzY2I4NmVlOTRmMzZiZTg1MzJiNWU3YmU3ZjhkXzMtNi0xLTEtMjExMw_0c972a9d-c189-42cd-82b5-436a28088a89">1,952,575</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, Marketing and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZTpkM2M4M2NiODZlZTk0ZjM2YmU4NTMyYjVlN2JlN2Y4ZC90YWJsZXJhbmdlOmQzYzgzY2I4NmVlOTRmMzZiZTg1MzJiNWU3YmU3ZjhkXzQtMi0xLTEtMjEwOQ_12037fba-4f09-4b7b-b926-47e73b1087ca">6,149,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZTpkM2M4M2NiODZlZTk0ZjM2YmU4NTMyYjVlN2JlN2Y4ZC90YWJsZXJhbmdlOmQzYzgzY2I4NmVlOTRmMzZiZTg1MzJiNWU3YmU3ZjhkXzQtNC0xLTEtMjExMQ_641a9915-6a07-4239-b43b-38ecfbc0571a">6,253,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZTpkM2M4M2NiODZlZTk0ZjM2YmU4NTMyYjVlN2JlN2Y4ZC90YWJsZXJhbmdlOmQzYzgzY2I4NmVlOTRmMzZiZTg1MzJiNWU3YmU3ZjhkXzQtNi0xLTEtMjExMw_13cfcd10-8c71-4699-93d8-1a66d9dba82a">8,076,904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZTpkM2M4M2NiODZlZTk0ZjM2YmU4NTMyYjVlN2JlN2Y4ZC90YWJsZXJhbmdlOmQzYzgzY2I4NmVlOTRmMzZiZTg1MzJiNWU3YmU3ZjhkXzUtMi0xLTEtMjEwOQ_1571e299-669b-4152-8f9c-db4ddb08e4e3">5,665,177</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZTpkM2M4M2NiODZlZTk0ZjM2YmU4NTMyYjVlN2JlN2Y4ZC90YWJsZXJhbmdlOmQzYzgzY2I4NmVlOTRmMzZiZTg1MzJiNWU3YmU3ZjhkXzUtNC0xLTEtMjExMQ_0cfd2f18-e7b2-4336-a2e6-9b38aa7dbbca">3,782,224</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZTpkM2M4M2NiODZlZTk0ZjM2YmU4NTMyYjVlN2JlN2Y4ZC90YWJsZXJhbmdlOmQzYzgzY2I4NmVlOTRmMzZiZTg1MzJiNWU3YmU3ZjhkXzUtNi0xLTEtMjExMw_cc344e43-3679-4089-85a6-a80499e65e81">4,798,025</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2019 current assets associated with discontinued operations included $<ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="-5" format="ixt:numdotdecimal" name="cpix:DisposalGroupIncludingDiscontinuedOperationRemainingInventoryCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90ZXh0cmVnaW9uOjEzZmIyMzg2ZmEwMDQ0OWNhOTQzZmUwYWM0YTU3ZTE5XzE2NDkyNjc0NDU3NTc_24f35e92-780f-44fc-83a5-b6a349051d9c">0.5</ix:nonFraction>&#160;million in the remaining </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inventory for the Products sold and returned to Clinigen as part of the transaction.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Except for the Products' inventory as of December 31, 2019, no other operating assets and no liabilities were transferred to Clinigen, as such t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he accounts receivable and accounts payable associated with discontinued operations were not sold or disposed of as part of the Dissolution Agreement. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assets and liabilities have been presented as assets associated with discontinued operations or liabilities associated with discontinued operations, as appropriate, in the consolidated balance sheets.   </span></div><ix:continuation id="ie34a806376474bb8ae48a22e556acf13"><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.384%"><tr><td style="width:1.0%"></td><td style="width:61.843%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.686%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZTo2Njg5MGQ1MzVkMGM0MTA2OTZkNzU1NmNkNjYzNjYxNi90YWJsZXJhbmdlOjY2ODkwZDUzNWQwYzQxMDY5NmQ3NTU2Y2Q2NjM2NjE2XzItMi0xLTEtMjExNQ_a1376dbd-e942-4452-a0c1-b382865ec956">1,922,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZTo2Njg5MGQ1MzVkMGM0MTA2OTZkNzU1NmNkNjYzNjYxNi90YWJsZXJhbmdlOjY2ODkwZDUzNWQwYzQxMDY5NmQ3NTU2Y2Q2NjM2NjE2XzItNC0xLTEtMjExNw_33e750ca-3ba5-4a4f-9edf-e599faec365d">1,384,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZTo2Njg5MGQ1MzVkMGM0MTA2OTZkNzU1NmNkNjYzNjYxNi90YWJsZXJhbmdlOjY2ODkwZDUzNWQwYzQxMDY5NmQ3NTU2Y2Q2NjM2NjE2XzMtMi0xLTEtMjExNQ_73602597-9710-4f57-9a08-a9dc1fced469">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZTo2Njg5MGQ1MzVkMGM0MTA2OTZkNzU1NmNkNjYzNjYxNi90YWJsZXJhbmdlOjY2ODkwZDUzNWQwYzQxMDY5NmQ3NTU2Y2Q2NjM2NjE2XzMtNC0xLTEtMjExNw_93f03b01-5254-4049-88f3-0a5fe4e54dfc">27,721</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZTo2Njg5MGQ1MzVkMGM0MTA2OTZkNzU1NmNkNjYzNjYxNi90YWJsZXJhbmdlOjY2ODkwZDUzNWQwYzQxMDY5NmQ3NTU2Y2Q2NjM2NjE2XzQtMi0xLTEtMjExNQ_d9fd623e-24b4-46fe-b2d6-9cf28de970fc">540,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZTo2Njg5MGQ1MzVkMGM0MTA2OTZkNzU1NmNkNjYzNjYxNi90YWJsZXJhbmdlOjY2ODkwZDUzNWQwYzQxMDY5NmQ3NTU2Y2Q2NjM2NjE2XzQtNC0xLTEtMjExNw_61ad8f5f-5a56-4f72-89f1-49674e22f2b8">2,294,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets associated with discontinued operations</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZTo2Njg5MGQ1MzVkMGM0MTA2OTZkNzU1NmNkNjYzNjYxNi90YWJsZXJhbmdlOjY2ODkwZDUzNWQwYzQxMDY5NmQ3NTU2Y2Q2NjM2NjE2XzUtMi0xLTEtMjExNQ_9e6f0dc3-0dac-4fcc-bc57-eadc508e984f">2,462,724</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZTo2Njg5MGQ1MzVkMGM0MTA2OTZkNzU1NmNkNjYzNjYxNi90YWJsZXJhbmdlOjY2ODkwZDUzNWQwYzQxMDY5NmQ3NTU2Y2Q2NjM2NjE2XzUtNC0xLTEtMjExNw_586e3364-c658-4889-b086-b23ae9e63984">3,706,897</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.384%"><tr><td style="width:1.0%"></td><td style="width:61.843%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.686%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZToyOTJhOTdkMmE3MmE0MTg1YWQzMzI0NGZhMTk3OTZiNS90YWJsZXJhbmdlOjI5MmE5N2QyYTcyYTQxODVhZDMzMjQ0ZmExOTc5NmI1XzItMi0xLTEtMjExOQ_71ef59b0-3ff7-48fa-9725-3e9d28668028">1,918,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZToyOTJhOTdkMmE3MmE0MTg1YWQzMzI0NGZhMTk3OTZiNS90YWJsZXJhbmdlOjI5MmE5N2QyYTcyYTQxODVhZDMzMjQ0ZmExOTc5NmI1XzItNC0xLTEtMjEyMQ_c81ae441-54df-4980-8e10-531e762f786e">2,882,656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZToyOTJhOTdkMmE3MmE0MTg1YWQzMzI0NGZhMTk3OTZiNS90YWJsZXJhbmdlOjI5MmE5N2QyYTcyYTQxODVhZDMzMjQ0ZmExOTc5NmI1XzMtMi0xLTEtMjExOQ_6e67eb78-1350-49d4-8e41-ea9457685311">232,489</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZToyOTJhOTdkMmE3MmE0MTg1YWQzMzI0NGZhMTk3OTZiNS90YWJsZXJhbmdlOjI5MmE5N2QyYTcyYTQxODVhZDMzMjQ0ZmExOTc5NmI1XzMtNC0xLTEtMjEyMQ_26fc8221-53dc-4f5a-a61a-7948c136607e">666,457</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities associated with discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa474b82645f415f9a942431b7e23907_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZToyOTJhOTdkMmE3MmE0MTg1YWQzMzI0NGZhMTk3OTZiNS90YWJsZXJhbmdlOjI5MmE5N2QyYTcyYTQxODVhZDMzMjQ0ZmExOTc5NmI1XzQtMi0xLTEtMjExOQ_012eb65e-d4d2-4400-957f-e13088521f0b">2,151,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90392aced265439a8a45b88619999ce0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZToyOTJhOTdkMmE3MmE0MTg1YWQzMzI0NGZhMTk3OTZiNS90YWJsZXJhbmdlOjI5MmE5N2QyYTcyYTQxODVhZDMzMjQ0ZmExOTc5NmI1XzQtNC0xLTEtMjEyMQ_f6cf18e2-40f9-4b33-94d7-5bbd7d879bc5">3,549,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div><span><br/></span></div><div id="id2bfa55304bd45bbaa9cdf09bb7673a3_265"></div><div style="margin-top:8pt;text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(21)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjUvZnJhZzo0YjU4YTQyZGQ0NGI0ZWRiYTVlYjVlZjliYTcyMDcyYy90ZXh0cmVnaW9uOjRiNThhNDJkZDQ0YjRlZGJhNWViNWVmOWJhNzIwNzJjXzI1MDU_cba420cb-0b40-43bd-8f41-20d3fcdb2e40" continuedAt="i7994515cfce249c48d388f51c7cbeede" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i7994515cfce249c48d388f51c7cbeede" continuedAt="i8ce016f8cfde4f14b6dc156b27377280"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of certain Kristalose assets during 2011, the Company was required to make quarterly payments based on a percentage of Kristalose net sales through November 2018. The payments were treated as consideration for the assets acquired and were capitalized.  They are being amortized over the remaining expected useful life of the acquired asset, currently through 2026. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with its licensing agreements for Caldolor,  the Company is required to pay royalties based on net sales over the life of the product. Royalty expense is recognized as a component of selling and marketing expense in the period that revenue is recognized. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with its licensing agreements for Ethyol and Totect, the Company was required to pay royalties based on net sales.  The royalty expense was recognized as a component of selling and marketing expense in the period the associated revenue was recognized through the end of the licensing period, December 31, 2019.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Vibativ, the Company is required to pay royalties based on net sales of the product.  At the purchase date, Cumberland recorded the fair value of this liability and will continue to evaluate the liability each period and the royalty expense is recognized as a component of selling and marketing expense in the period that the change in fair value is recognized. </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has a number of  Patents issued through the United States Patent and Trademark Office (the &#8220;USPTO&#8221;) including U.S. Patent number 8,148,356 (the &#8220;356 Acetadote Patent&#8221;) which is assigned to the Company. The claims of the 356 Acetadote Patent encompass the new Acetadote formulation and include composition of matter claims. Following its issuance, the 356 Acetadote Patent was listed in the FDA Orange Book. The 356 Acetadote Patent is scheduled to expire in May 2026, which time period includes a 270-day patent term adjustment granted by the USPTO.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2012, Cumberland has to continued to vigorously defend and protect its Acetadote product and related intellectual property rights including the use of all its legal options. </span></div></ix:continuation><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8ce016f8cfde4f14b6dc156b27377280">The Company is a party to various other legal proceedings in the ordinary course of its business. In the opinion of management, the liability associated with these matters, will not have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows.</ix:continuation>  </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-35</span></div></div></div><div id="id2bfa55304bd45bbaa9cdf09bb7673a3_268"></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(22)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:QuarterlyFinancialInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90ZXh0cmVnaW9uOjYyNzM2NzAxZmJjNTRhM2M4MjU5NWQyZWFlOTFjYmNjXzM1Mw_6f8923cd-28a0-4ea2-a9c1-08759eecb93c" continuedAt="ib92154d709ca449685ddda52cbd418eb" escape="true">Quarterly Financial Information (Unaudited)</ix:nonNumeric></span></div><ix:continuation id="ib92154d709ca449685ddda52cbd418eb"><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90ZXh0cmVnaW9uOjYyNzM2NzAxZmJjNTRhM2M4MjU5NWQyZWFlOTFjYmNjXzM1NA_7beb4b35-d45f-4886-aeaa-45dedf61cbd1" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the unaudited operating results for each fiscal quarter of 2019 and 2018:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.474%"><tr><td style="width:1.0%"></td><td style="width:33.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.031%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">First</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Second</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Third</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fourth</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if22100deab024544b321dc081da4ceff_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzMtMi0xLTEtMA_aaae5e5a-0c90-4118-bd89-2b789b5de78b">8,729,860</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8909cd57fb5146798a8b845d82644b0b_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzMtNC0xLTEtMA_399d5ca7-5e3b-48f4-99fb-6cd2d4681278">9,417,443</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if26164363c2e4a7d8fd5139d8f56f49c_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzMtNi0xLTEtMA_665205f4-8495-4dc7-ac14-2f455e7815c2">6,935,439</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i670fdffefb0c4fefba494de91fb35afc_D20191001-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzMtOC0xLTEtMA_ae43b926-a785-4b76-b4d1-e6aed279e89c">9,305,553</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzMtMTAtMS0xLTA_c24a47fc-bfe2-41e4-9812-28b9a540c767">34,388,295</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if22100deab024544b321dc081da4ceff_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzQtMi0xLTEtMA_67549c4f-70c3-4437-b816-a8b8ae9eec20">1,323,932</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8909cd57fb5146798a8b845d82644b0b_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzQtNC0xLTEtMA_57351176-e6bf-438c-bbf8-d64fd0d88273">1,373,424</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if26164363c2e4a7d8fd5139d8f56f49c_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzQtNi0xLTEtMA_230cb804-cd1f-4dde-aaf5-3582b0390ea2">3,196,436</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i670fdffefb0c4fefba494de91fb35afc_D20191001-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzQtOC0xLTEtMA_d33e53b9-2135-4eb7-8b68-8756022e5f07">3,394,390</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzQtMTAtMS0xLTA_7cec0cd7-1b29-4bc0-a60a-5fbaac85fb1c">9,288,182</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if22100deab024544b321dc081da4ceff_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzUtMi0xLTEtMTI1OA_f3a71c1c-22d5-4606-9609-f1537214c5d9">1,187,553</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8909cd57fb5146798a8b845d82644b0b_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzUtNC0xLTEtMTI2MA_9926e22c-7401-4fde-bc9f-75c9063075bd">1,338,521</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if26164363c2e4a7d8fd5139d8f56f49c_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzUtNi0xLTEtMTI2Mg_7c30e014-c499-4883-8265-7d0b10dd7b6f">3,316,286</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i670fdffefb0c4fefba494de91fb35afc_D20191001-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzUtOC0xLTEtMTI2NA_25a963be-4521-469c-9646-3a3a2adef7f7">3,369,328</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzUtMTAtMS0xLTEyNjY_3dfd2737-3ed5-43a2-8b6a-255f4eff7e16">9,211,688</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if22100deab024544b321dc081da4ceff_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzYtMi0xLTEtMTI1OA_bb78ce02-f9a5-489b-9c99-8c48abe858c2">1,147,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8909cd57fb5146798a8b845d82644b0b_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzYtNC0xLTEtMTI2MA_55c2c9f6-52a8-4cfa-9817-3b113c8412a8">771,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if26164363c2e4a7d8fd5139d8f56f49c_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzYtNi0xLTEtMTI2Mg_a0bfc89f-d9df-4dd5-b017-d0679314ee36">1,349,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i670fdffefb0c4fefba494de91fb35afc_D20191001-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzYtOC0xLTEtMTI2NA_5396a8c8-6c42-4ac4-b8be-f18742040455">2,396,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzYtMTAtMS0xLTEyNjY_81e19cd2-fac9-43bd-ae7e-d16c7797624b">5,665,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if22100deab024544b321dc081da4ceff_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzUtMi0xLTEtMA_be130808-bef0-4370-bec0-d53ba6c707ff">73,878</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8909cd57fb5146798a8b845d82644b0b_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzUtNC0xLTEtMA_248c8dc9-42c5-4574-9aae-166414919fc9">549,507</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if26164363c2e4a7d8fd5139d8f56f49c_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzUtNi0xLTEtMA_841c8926-6132-4f83-8bad-5bbccb4642e9">1,953,668</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i670fdffefb0c4fefba494de91fb35afc_D20191001-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzUtOC0xLTEtMA_26d1f057-a180-438d-b0df-77fda5cf8d12">960,706</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzUtMTAtMS0xLTA_39674003-5d29-4ed5-bc64-a2cb7d004e65">3,537,759</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share attributable to common shareholders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - basic</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if22100deab024544b321dc081da4ceff_D20190101-20190331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzktMi0xLTEtMTI2OA_c159e1bc-9826-47cf-be19-20154b9cc050">0.08</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8909cd57fb5146798a8b845d82644b0b_D20190401-20190630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzktNC0xLTEtMTI3MA_d49e5c61-7b89-4750-8742-39f6ca53fd7e">0.09</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if26164363c2e4a7d8fd5139d8f56f49c_D20190701-20190930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzktNi0xLTEtMTI3Mg_a73986ff-cde1-4409-869d-5b0271ed5808">0.22</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i670fdffefb0c4fefba494de91fb35afc_D20191001-20191231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzktOC0xLTEtMTI3NA_e239e22e-33c5-4dc5-a924-fabe9e82de73">0.22</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzktMTAtMS0xLTEyNzc_bc702fc9-f029-4fe0-9c0e-cf96fc336140">0.60</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-13.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if22100deab024544b321dc081da4ceff_D20190101-20190331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzEwLTItMS0xLTEyNjg_f7804289-8b19-4105-8ae9-e003ffe27f15">0.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8909cd57fb5146798a8b845d82644b0b_D20190401-20190630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzEwLTQtMS0xLTEyNzA_57239905-d429-4135-b4cc-bf2ab91f60ea">0.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if26164363c2e4a7d8fd5139d8f56f49c_D20190701-20190930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzEwLTYtMS0xLTEyNzI_15ea0184-c022-4b2a-b0c5-ebd2189571ac">0.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i670fdffefb0c4fefba494de91fb35afc_D20191001-20191231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzEwLTgtMS0xLTEyNzQ_72650812-47e4-477b-bc9d-9def6e6151a4">0.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzEwLTEwLTEtMS0xMjc3_e6ba6440-39a0-457b-9d9f-c2e9cc90b5e7">0.37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if22100deab024544b321dc081da4ceff_D20190101-20190331" decimals="2" format="ixt:zerodash" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzctMi0xLTEtMA_d20fae9e-eab8-4777-bd73-4508bf60a98f">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8909cd57fb5146798a8b845d82644b0b_D20190401-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzctNC0xLTEtMA_2f7a8484-d850-4b31-b377-e4bc7f46b3fe">0.04</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if26164363c2e4a7d8fd5139d8f56f49c_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzctNi0xLTEtMA_59e133cb-8f80-4ea6-a3e7-19e0c033cc9f">0.13</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i670fdffefb0c4fefba494de91fb35afc_D20191001-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzctOC0xLTEtMA_c0e12901-7ff9-477b-b203-25b602096607">0.06</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzctMTAtMS0xLTA_5bfbe3f6-773b-4532-a9d3-09a4b6c40d6e">0.23</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - diluted</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if22100deab024544b321dc081da4ceff_D20190101-20190331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzEzLTItMS0xLTEyNzk_756a8cf4-e768-4b3a-a85d-5486d6e925e6">0.08</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8909cd57fb5146798a8b845d82644b0b_D20190401-20190630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzEzLTQtMS0xLTEyODE_1f3fff45-b439-4553-a508-f477e8283073">0.09</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if26164363c2e4a7d8fd5139d8f56f49c_D20190701-20190930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzEzLTYtMS0xLTEyODM_fad39734-b6ac-49c6-beed-591924e23574">0.22</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i670fdffefb0c4fefba494de91fb35afc_D20191001-20191231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzEzLTgtMS0xLTEyODU_72777e13-0d8c-40fd-b555-4efb27b5b2e1">0.22</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzEzLTEwLTEtMS0xMjg3_71685190-445c-4657-bfd5-89fbc08703d0">0.60</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if22100deab024544b321dc081da4ceff_D20190101-20190331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzE0LTItMS0xLTEyNzk_48029cf2-ce17-4ecb-9f64-9c7354563423">0.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8909cd57fb5146798a8b845d82644b0b_D20190401-20190630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzE0LTQtMS0xLTEyODE_1dac08fc-8eec-4bc8-97ca-28c65f94e8d9">0.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if26164363c2e4a7d8fd5139d8f56f49c_D20190701-20190930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzE0LTYtMS0xLTEyODM_4005003a-be2e-4df0-bc4a-88b514a5c039">0.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i670fdffefb0c4fefba494de91fb35afc_D20191001-20191231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzE0LTgtMS0xLTEyODU_476e3c15-e612-4a6b-8a33-83578112559c">0.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzE0LTEwLTEtMS0xMjg3_e56a591c-406b-4ba1-a12e-94a435334b87">0.37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if22100deab024544b321dc081da4ceff_D20190101-20190331" decimals="2" format="ixt:zerodash" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzgtMi0xLTEtMA_8e9d6845-7918-4523-b3d3-c6e8633f4b46">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8909cd57fb5146798a8b845d82644b0b_D20190401-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzgtNC0xLTEtMA_98dbd5bb-b087-40f8-a9ce-a127ed5897eb">0.04</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if26164363c2e4a7d8fd5139d8f56f49c_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzgtNi0xLTEtMA_625d24df-3a29-43e6-8469-daae99f93711">0.13</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i670fdffefb0c4fefba494de91fb35afc_D20191001-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzgtOC0xLTEtMA_136fc64c-9500-4fcd-95f9-454c93608c35">0.06</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzgtMTAtMS0xLTA_04dbe70d-160a-40e3-a267-9af39eb2ddc8">0.23</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie54433cb2ec74b5eb0446c048a926870_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzExLTItMS0xLTA_69a16446-ec43-4b73-9011-d92e004c0acf">5,918,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3568f3154e034913831ef831b3d23e91_D20180401-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzExLTQtMS0xLTA_fd5814eb-b830-4def-a4e4-716fb8dfee97">7,084,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2efc1fa703c94708b6b3fc4d341efa16_D20180701-20180930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzExLTYtMS0xLTA_6912247b-a54b-4765-9bb6-16088f705a13">5,853,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41abbb021c424bc3a185261bb47b2490_D20181001-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzExLTgtMS0xLTA_aa04feba-b040-4541-b90d-96ce3b965dec">10,487,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzExLTEwLTEtMS0w_58fb8a8c-f4bc-41f8-b642-d3db36202a83">29,344,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie54433cb2ec74b5eb0446c048a926870_D20180101-20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzEyLTItMS0xLTA_0d90c4fa-f872-40e1-a76a-1604f92ce1cd">3,315,936</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3568f3154e034913831ef831b3d23e91_D20180401-20180630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzEyLTQtMS0xLTA_718d7d56-15fe-4a49-bb30-6984f4a03088">1,919,189</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2efc1fa703c94708b6b3fc4d341efa16_D20180701-20180930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzEyLTYtMS0xLTA_f0274123-92fe-4d57-81d4-604b5b7678aa">2,644,614</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41abbb021c424bc3a185261bb47b2490_D20181001-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzEyLTgtMS0xLTA_645a667e-c2c7-4037-b098-9e2f8cb442bb">3,293,257</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzEyLTEwLTEtMS0w_3f82af5b-375c-4889-86a3-2f00216f3204">11,172,996</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie54433cb2ec74b5eb0446c048a926870_D20180101-20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzE5LTItMS0xLTE0MzI_87a4013f-2fa7-4ad0-9f10-6dcf275e10fa">3,255,903</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3568f3154e034913831ef831b3d23e91_D20180401-20180630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzE5LTQtMS0xLTE0MzQ_fd04681b-8a6f-46ff-bd0b-a68d7ae72146">1,795,661</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2efc1fa703c94708b6b3fc4d341efa16_D20180701-20180930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzE5LTYtMS0xLTE0MzY_cec17175-6d6d-41e7-aeb7-222ae63f1ed9">2,501,752</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41abbb021c424bc3a185261bb47b2490_D20181001-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzE5LTgtMS0xLTE0MzA_48d20f23-310e-4759-8492-01017b6b28f1">3,267,680</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzE5LTEwLTEtMS0xNDM4_0e7aca2e-4460-4460-803d-cb2d0ca691e1">10,820,996</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from discontinued operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie54433cb2ec74b5eb0446c048a926870_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzIwLTItMS0xLTE0MzI_0fa0991e-8107-43ca-9e5d-6412a9a8f4fe">863,714</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3568f3154e034913831ef831b3d23e91_D20180401-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzIwLTQtMS0xLTE0MzQ_1bdc9c3f-a530-4ef0-a280-94b061e84e5b">1,050,211</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2efc1fa703c94708b6b3fc4d341efa16_D20180701-20180930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzIwLTYtMS0xLTE0MzY_49313fc7-f582-4d22-ab71-fea86017d0ce">837,731</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41abbb021c424bc3a185261bb47b2490_D20181001-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzIwLTgtMS0xLTE0MzA_018ee4f9-e78c-483c-9999-76815337c8ad">1,030,568</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzIwLTEwLTEtMS0xNDM4_23c3f18b-02e9-4dc0-b675-e1489f481a55">3,782,224</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie54433cb2ec74b5eb0446c048a926870_D20180101-20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzEzLTItMS0xLTA_e8b9351e-34d8-472f-a34d-a757d67894bd">2,379,239</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3568f3154e034913831ef831b3d23e91_D20180401-20180630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzEzLTQtMS0xLTA_4b23fe08-2d9e-44c4-891e-c7c38cbfea0a">720,688</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2efc1fa703c94708b6b3fc4d341efa16_D20180701-20180930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzEzLTYtMS0xLTA_f0b84c86-0e89-496c-8070-d0b097d86ec1">1,643,044</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41abbb021c424bc3a185261bb47b2490_D20181001-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzEzLTgtMS0xLTA_fb9ce1ac-4bb9-42c6-b4f9-edfbc2648078">2,220,097</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzEzLTEwLTEtMS0w_78c764db-04b6-45a2-859d-978f14a15a91">6,963,068</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share attributable to common shareholders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie54433cb2ec74b5eb0446c048a926870_D20180101-20180331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzIzLTItMS0xLTE0NDA_92993d3a-089d-4d5d-a5ce-f92319706c71">0.21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3568f3154e034913831ef831b3d23e91_D20180401-20180630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzIzLTQtMS0xLTE0NDI_6d63ed33-6535-4d37-9f31-a79a07442e4b">0.11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2efc1fa703c94708b6b3fc4d341efa16_D20180701-20180930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzIzLTYtMS0xLTE0NDQ_f449c5e6-f423-4c54-aba5-8a6ab646890c">0.16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i41abbb021c424bc3a185261bb47b2490_D20181001-20181231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzIzLTgtMS0xLTE0NDY_f96d8572-26be-4b92-a4a6-4be9c3318265">0.21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzIzLTEwLTEtMS0xNDQ4_1e53a38c-e338-4ba2-b4e1-b0dd87f5039a">0.70</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;text-indent:-13.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations - basic</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie54433cb2ec74b5eb0446c048a926870_D20180101-20180331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzI0LTItMS0xLTE0NDA_4237754b-bb51-46ff-ac75-f505dfd90464">0.06</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3568f3154e034913831ef831b3d23e91_D20180401-20180630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzI0LTQtMS0xLTE0NDI_d8ca3971-2ebf-469b-8b45-bd4732cbe717">0.06</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2efc1fa703c94708b6b3fc4d341efa16_D20180701-20180930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzI0LTYtMS0xLTE0NDQ_136c37e4-c236-4797-aa16-24bbc0fddfe4">0.05</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i41abbb021c424bc3a185261bb47b2490_D20181001-20181231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzI0LTgtMS0xLTE0NDY_c04e9234-5db0-473b-9686-0a5d58a216e6">0.07</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzI0LTEwLTEtMS0xNDQ4_3fdcf483-392e-4b31-8d25-42230d5f30ed">0.25</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie54433cb2ec74b5eb0446c048a926870_D20180101-20180331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzE1LTItMS0xLTA_98aa23e4-33a4-4755-b6d9-f5fb68d76835">0.15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3568f3154e034913831ef831b3d23e91_D20180401-20180630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzE1LTQtMS0xLTA_ad1e98d5-cf3d-4f3a-b944-105a55188867">0.05</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2efc1fa703c94708b6b3fc4d341efa16_D20180701-20180930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzE1LTYtMS0xLTA_68024823-93c7-4117-b925-5d617f5e91f7">0.11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i41abbb021c424bc3a185261bb47b2490_D20181001-20181231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzE1LTgtMS0xLTA_7908edca-0331-436d-9831-a7ee08dfbd1c">0.14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzE1LTEwLTEtMS0w_9e46fcf7-3d16-4385-b701-f8502fd154c7">0.45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie54433cb2ec74b5eb0446c048a926870_D20180101-20180331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzI3LTItMS0xLTE0NTA_712ccb54-e806-45a7-a7f2-c522c7152f80">0.21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3568f3154e034913831ef831b3d23e91_D20180401-20180630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzI3LTQtMS0xLTE0NTI_224ee1ab-7a9d-443d-b772-28be0441eff9">0.11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2efc1fa703c94708b6b3fc4d341efa16_D20180701-20180930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzI3LTYtMS0xLTE0NTQ_4ee446b6-b54b-4e3c-811f-5589d83ca8ff">0.16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i41abbb021c424bc3a185261bb47b2490_D20181001-20181231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzI3LTgtMS0xLTE0NTY_0c05af61-6b82-4079-951f-87d08227e2a3">0.21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzI3LTEwLTEtMS0xNDU4_87d0f940-d886-461f-95c5-a2f6c8761586">0.70</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations - diluted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie54433cb2ec74b5eb0446c048a926870_D20180101-20180331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzI4LTItMS0xLTE0NTA_caf0592d-f310-4948-89bd-aa544e5879e8">0.06</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3568f3154e034913831ef831b3d23e91_D20180401-20180630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzI4LTQtMS0xLTE0NTI_c7af01c2-0b69-463d-a087-fbcc56c28409">0.06</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2efc1fa703c94708b6b3fc4d341efa16_D20180701-20180930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzI4LTYtMS0xLTE0NTQ_d5597ca4-9a68-4b91-9c7e-da77bf48d100">0.05</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i41abbb021c424bc3a185261bb47b2490_D20181001-20181231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzI4LTgtMS0xLTE0NTY_91ff5517-9d70-413c-a657-ec2ca0ec4c04">0.07</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzI4LTEwLTEtMS0xNDU4_44d8fc08-4418-4e78-895d-0a69fa70cff2">0.25</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie54433cb2ec74b5eb0446c048a926870_D20180101-20180331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzE2LTItMS0xLTA_2f1de787-50cb-4881-86e4-e45cca0ca791">0.15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3568f3154e034913831ef831b3d23e91_D20180401-20180630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzE2LTQtMS0xLTA_d67db899-e29e-4576-8ed3-a4a9cdc3daa2">0.05</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2efc1fa703c94708b6b3fc4d341efa16_D20180701-20180930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzE2LTYtMS0xLTA_41c31ad9-7d09-4c8d-aa74-8a477ff6a6cc">0.11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i41abbb021c424bc3a185261bb47b2490_D20181001-20181231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzE2LTgtMS0xLTA_e6132f19-602e-4380-8237-f96429ff280e">0.14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzE2LTEwLTEtMS0w_5157dcbb-beb3-4c8f-ab15-4c898dd6cf55">0.45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Due to the nature of interim earnings per share calculations, the sum of the quarterly earnings (loss) per share amounts may not equal the reported earnings (loss) per share for the full year.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-36</span></div></div></div><div id="id2bfa55304bd45bbaa9cdf09bb7673a3_271"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(23)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzEvZnJhZzo5ZTI3MTYwNjljZDQ0Y2QxYjRhNmQ1Zjk4Njk3Y2IxMS90ZXh0cmVnaW9uOjllMjcxNjA2OWNkNDRjZDFiNGE2ZDVmOTg2OTdjYjExXzQzOTgwNDY1MTE4NTI_487dcfb0-3c9e-4c2e-9cab-02b3ddb1ff64" continuedAt="ia904e132d3a24b17a32813ef037c5f8e" escape="true">Subsequent events</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia904e132d3a24b17a32813ef037c5f8e">On March 11, 2020, the World Health Organization declared the outbreak of a novel coronavirus (&#8220;COVID-19&#8221;) as a global pandemic, which continues to spread throughout the United States and around the world.  As of March 20, 2020, the Company is aware of changes in its business as a result of COVID-19 but uncertain of the impacts of those changes on its consolidated statements of position, operations or cash flows. Management believes any disruption, when and if experienced, could be temporary; however, there is uncertainty around when any disruption might occur, the duration and hence the potential impact. As a result, we are unable to estimate the potential impact on our business as of the date of this filing.</ix:continuation> </span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-37</span></div></div></div><div id="id2bfa55304bd45bbaa9cdf09bb7673a3_274"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:right"><span><br/></span></div><div style="margin-top:8pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Schedule II</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><ix:nonNumeric contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231" name="srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90ZXh0cmVnaW9uOmNjMzdjZWQ3OWU4NzQxNzJhY2NlN2JlODc3NTgwNTZlXzQwMw_76681f1a-6a97-4468-9b68-13be39f5aac2" escape="true"><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation and Qualifying Accounts</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Years ended December&#160;31, 2019, 2018 and 2017</span></div><div style="margin-bottom:6pt;margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.182%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.724%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">beginning&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">period</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Charged to</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">costs and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">expenses</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Charged&#160;to</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">accounts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">end&#160;of&#160;period</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for uncollectible amounts, cash discounts, chargebacks, and credits issued for damaged products:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the years ended </span></div><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285233d399574db2bf4cbbce58a8ee38_I20161231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzQtMi0xLTEtMA_c0f003ad-5f1d-4ddf-bed7-e08502c4eb9a">446,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ec1fa83cd4f4bcd80502e9a9be962e1_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzQtNC0xLTEtMA_bc68ceeb-9764-459f-8ace-5636d9c117be">3,371,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ec1fa83cd4f4bcd80502e9a9be962e1_D20170101-20171231" decimals="0" format="ixt:zerodash" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzQtNi0xLTEtMA_10d8b649-f381-41cd-91a6-90f0657abbbe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ec1fa83cd4f4bcd80502e9a9be962e1_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzQtOC0xLTEtMA_5b9ba864-f3f8-476b-9ab7-36ff4ff0da68">3,491,263</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie72430d18bed427fb73e3a0c86f3902b_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzQtMTAtMS0xLTA_6aeceb92-735c-44ed-a57a-2c5d412e448a">326,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie72430d18bed427fb73e3a0c86f3902b_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzUtMi0xLTEtMA_ef8b7c40-c804-4488-9e6c-2fdd3ff9d825">326,697</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0b0b3681b184a71afd2ed8070814188_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzUtNC0xLTEtMA_87f07e79-b7e8-4dfa-b7f8-d5722833997e">4,610,899</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0b0b3681b184a71afd2ed8070814188_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzUtNi0xLTEtMA_017db3f9-0723-4d05-b87a-23680d8c5c93">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0b0b3681b184a71afd2ed8070814188_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzUtOC0xLTEtMA_50f8a6bc-6b4e-437a-af46-4218788f1b59">4,133,176</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i320d53db383d4ac7aecd406d90ef5114_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzUtMTAtMS0xLTA_11ec047a-8d0d-4b4a-a365-2dba96d2d3cb">804,420</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i320d53db383d4ac7aecd406d90ef5114_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzYtMi0xLTEtMA_00fc7368-7c5f-41c0-9d43-4e7db5e16fc2">804,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaebef75259c4828b8dd1e0a936b843b_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzYtNC0xLTEtMA_1bcd7282-5f03-4e7c-97b4-6ef8a546b4d3">5,915,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaebef75259c4828b8dd1e0a936b843b_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzYtNi0xLTEtMA_850a9142-4219-4b04-beb4-9f15bc93ff52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idaebef75259c4828b8dd1e0a936b843b_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzYtOC0xLTEtMA_5ceca96e-249e-4487-9811-6d1fc422beb1">5,927,435</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a49735b602483d8a41720b2aa89de2_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzYtMTAtMS0xLTA_8fd13d5f-6ee3-4067-b08a-3fddf421b9c8">792,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the years ended </span></div><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic63ad7ea20c046e9929381f321c356c0_I20161231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzEwLTItMS0xLTA_96fe9a8a-60d3-480d-8700-48d170316c3b">388,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17c72a67be474fd0bf7e5aefd742a269_D20170101-20171231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzEwLTQtMS0xLTA_affd6bd7-2444-4ff7-a53b-cb9782572b93">665,039</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17c72a67be474fd0bf7e5aefd742a269_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzEwLTYtMS0xLTA_f77df587-17d2-4037-90fe-6f79c9ae47ca">15,908,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17c72a67be474fd0bf7e5aefd742a269_D20170101-20171231" decimals="0" format="ixt:zerodash" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzEwLTgtMS0xLTA_fd450ff6-5492-4710-bd80-36172cb94380">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i529dda5be0c0459188e6d0ab6e604b33_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzEwLTEwLTEtMS0w_73ce093b-f0fa-4b43-a6e5-09b55473da05">15,632,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i529dda5be0c0459188e6d0ab6e604b33_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzExLTItMS0xLTA_59394adc-e6ac-442b-9276-d81def026b19">15,632,235</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d74b7bafab423992f09ba352af1356_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzExLTQtMS0xLTA_29dd7306-8f15-4409-930d-a91f05334ee6">1,749,817</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d74b7bafab423992f09ba352af1356_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzExLTYtMS0xLTA_99392c9a-e9c7-4c0e-9514-94a6110622bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d74b7bafab423992f09ba352af1356_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzExLTgtMS0xLTA_f5ba742f-6590-4c70-8a99-daa8d537fe4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b11cb5d5b164dc88a8a5aa3bd48fe48_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzExLTEwLTEtMS0w_e3d5c7da-17c7-46a0-8aba-a57b7ab8bfab">17,382,052</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b11cb5d5b164dc88a8a5aa3bd48fe48_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzEyLTItMS0xLTA_b8e3e104-b5e0-4e00-b5d0-6a156b8f9db0">17,382,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a0dc042738147c39f0f1c8b83d36fad_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzEyLTQtMS0xLTA_ce7a477b-4cc6-40d7-8fb6-0935dc238aeb">1,129,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a0dc042738147c39f0f1c8b83d36fad_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzEyLTYtMS0xLTA_f0d89dbe-4011-42d0-be66-d3b01d2348a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a0dc042738147c39f0f1c8b83d36fad_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzEyLTgtMS0xLTA_6ac78af4-bba7-4aa1-8a5b-8e32ac54e361">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae4edd9cd21d4bff9f039d252bcc383b_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzEyLTEwLTEtMS0w_ede022c2-dae2-4e63-be32-3cb92e06bccd">18,511,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)   Composed of actual returns and credits for chargebacks and cash discounts.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)   Amount includes $<ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90ZXh0cmVnaW9uOmNjMzdjZWQ3OWU4NzQxNzJhY2NlN2JlODc3NTgwNTZlXzIzMw_421318bc-f848-49a4-a576-eaee192c2846">4,202,854</ix:nonFraction> related to increase in the valuation allowance during the year, net of $<ix:nonFraction unitRef="usd" contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="cpix:TaxCutsandJobsActof2017ChangeinTaxRateDeferredTaxAssetIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90ZXh0cmVnaW9uOmNjMzdjZWQ3OWU4NzQxNzJhY2NlN2JlODc3NTgwNTZlXzMwNw_9bac186e-4159-469f-ad4a-4f9c26bc7e9b">4,867,893</ix:nonFraction> related to the revaluation of deferred income tax balances for new rates under the Tax Act.</span></div></ix:nonNumeric><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-38</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>cpix-20201210.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:bbbd83ec-86cd-4852-a42b-62050b4598f2,g:afd11596-cbdf-45f6-87ac-39eae3274065-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cpix="http://www.cumberlandpharma.com/20201210" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2020-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cumberlandpharma.com/20201210">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20201210_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20201210_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20201210_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20201210_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.cumberlandpharma.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss" roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss">
        <link:definition>1003004 - Statement - Consolidated Statements of Income and Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1004005 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEquity" roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity">
        <link:definition>1005006 - Statement - Consolidated Statements of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organization" roleURI="http://www.cumberlandpharma.com/role/Organization">
        <link:definition>2101101 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails">
        <link:definition>2402401 - Disclosure - Organization (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPolicies" roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesPolicies" roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesTables" roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2406402 - Disclosure - Significant Accounting Policies (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails" roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails">
        <link:definition>2407403 - Disclosure - Significant Accounting Policies (Schedule of Intangible Assets, Useful Lives) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OmeclamoxPakRediTrexandVibativ" roleURI="http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativ">
        <link:definition>2108103 - Disclosure - Omeclamox&#174;-Pak, RediTrex&#174; and Vibativ&#174;</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OmeclamoxPakRediTrexandVibativTables" roleURI="http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativTables">
        <link:definition>2309302 - Disclosure - Omeclamox&#174;-Pak, RediTrex&#174; and Vibativ&#174; (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OmeclamoxPakRediTrexandVibativNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails">
        <link:definition>2410404 - Disclosure - Omeclamox&#174;-Pak, RediTrex&#174; and Vibativ&#174; - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OmeclamoxPakRediTrexandVibativVibativAcquisitionNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionNarrativeDetails">
        <link:definition>2411405 - Disclosure - Omeclamox&#174;-Pak, RediTrex&#174; and Vibativ&#174; - Vibativ Acquisition - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails" roleURI="http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails">
        <link:definition>2412406 - Disclosure - Omeclamox&#174;-Pak, RediTrex&#174; and Vibativ&#174; - Vibativ Acquisition - Schedule of Contingent Consideration and Preliminary Allocation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.cumberlandpharma.com/role/Revenues">
        <link:definition>2113104 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.cumberlandpharma.com/role/RevenuesTables">
        <link:definition>2314303 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesScheduleofNetProductRevenuesbyProductDetails" roleURI="http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails">
        <link:definition>2415407 - Disclosure - Revenues (Schedule of Net Product Revenues by Product) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails">
        <link:definition>2416408 - Disclosure - Revenues (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.cumberlandpharma.com/role/Inventories">
        <link:definition>2117105 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.cumberlandpharma.com/role/InventoriesTables">
        <link:definition>2318304 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesScheduleofInventoriesDetails" roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails">
        <link:definition>2419409 - Disclosure - Inventories (Schedule of Inventories) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails">
        <link:definition>2420410 - Disclosure - Inventories (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipment">
        <link:definition>2121106 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipmentTables">
        <link:definition>2322305 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentScheduleofPropertyandEquipmentDetails" roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails">
        <link:definition>2423411 - Disclosure - Property and Equipment (Schedule of Property and Equipment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentDepreciationExpenseDetails" roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipmentDepreciationExpenseDetails">
        <link:definition>2424412 - Disclosure - Property and Equipment (Depreciation Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssets" roleURI="http://www.cumberlandpharma.com/role/IntangibleAssets">
        <link:definition>2125107 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsTables" roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsTables">
        <link:definition>2326306 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsScheduleofIntangibleAssetsDetails" roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails">
        <link:definition>2427413 - Disclosure - Intangible Assets (Schedule of Intangible Assets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails">
        <link:definition>2428414 - Disclosure - Intangible Assets (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsFutureAmortizationExpenseDetails" roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails">
        <link:definition>2429415 - Disclosure - Intangible Assets Future Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCurrentandOtherLongtermLiabilities" roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilities">
        <link:definition>2130108 - Disclosure - Other Current and Other Long-term Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCurrentandOtherLongtermLiabilitiesTables" roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables">
        <link:definition>2331307 - Disclosure - Other Current and Other Long-term Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails" roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails">
        <link:definition>2432416 - Disclosure - Other Current and Other Long-term Liabilities (Schedule of Other Current and Noncurrent Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.cumberlandpharma.com/role/Debt">
        <link:definition>2133109 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtLineofCreditDetails" roleURI="http://www.cumberlandpharma.com/role/DebtLineofCreditDetails">
        <link:definition>2434417 - Disclosure - Debt (Line of Credit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquity" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquity">
        <link:definition>2135110 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails">
        <link:definition>2436418 - Disclosure - Shareholders' Equity (Initial Public Offering, Preferred Stock and Common Stock, Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityWarrantsNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityWarrantsNarrativeDetails">
        <link:definition>2437419 - Disclosure - Shareholders' Equity (Warrants, Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails">
        <link:definition>2438420 - Disclosure - Shareholders' Equity (Share Repurchases, Cumberland Emerging Technologies and Cumberland Foundation Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShare" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare">
        <link:definition>2139111 - Disclosure - Earnings (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareTables" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables">
        <link:definition>2340308 - Disclosure - Earnings (Loss) Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails">
        <link:definition>2441421 - Disclosure - Earnings (Loss) Per Share (Schedule of Computation of Numerator and Denominator in Earnings Per Share) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails">
        <link:definition>2442422 - Disclosure - Earnings (Loss) Per Share (Schedule of Anti-dilutive Securities Excluded From Computation of Earnings Per Share) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes">
        <link:definition>2143112 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesTables">
        <link:definition>2344309 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesOperatingLossCarryforwardsNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails">
        <link:definition>2445423 - Disclosure - Income Taxes (Operating Loss Carryforwards, Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails">
        <link:definition>2446424 - Disclosure - Income Taxes (Schedule of Deferred Tax Assets and Liabilities, Net) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails">
        <link:definition>2447425 - Disclosure - Income Taxes (Schedule of Net Operating Loss Carryforwards) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails">
        <link:definition>2448426 - Disclosure - Income Taxes (Schedule of the Components of Income Tax Benefit (Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>2449427 - Disclosure - Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlans" roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlans">
        <link:definition>2150113 - Disclosure - Stock-Based Compensation Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansTables" roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables">
        <link:definition>2351310 - Disclosure - Stock-Based Compensation Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails">
        <link:definition>2452428 - Disclosure - Stock-Based Compensation Plans (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails" roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails">
        <link:definition>2453429 - Disclosure - Stock-Based Compensation Plans (Schedule of Share-Based Compensation Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansScheduleofStockOptionsActivityDetails" roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails">
        <link:definition>2454430 - Disclosure - Stock-Based Compensation Plans (Schedule of Stock Options Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansScheduleofStockOptionActivityAdditionalDisclosuresDetails" roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityAdditionalDisclosuresDetails">
        <link:definition>2455431 - Disclosure - Stock-Based Compensation Plans (Schedule of Stock Option Activity, Additional Disclosures) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails" roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails">
        <link:definition>2456432 - Disclosure - Stock-Based Compensation Plans (Schedule of Restricted Stock Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlans" roleURI="http://www.cumberlandpharma.com/role/EmployeeBenefitPlans">
        <link:definition>2157114 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/EmployeeBenefitPlansNarrativeDetails">
        <link:definition>2458433 - Disclosure - Employee Benefit Plans (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.cumberlandpharma.com/role/Leases">
        <link:definition>2159115 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.cumberlandpharma.com/role/LeasesTables">
        <link:definition>2360311 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails">
        <link:definition>2461434 - Disclosure - Leases (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofRentExpenseandSubleaseIncomeDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofRentExpenseandSubleaseIncomeDetails">
        <link:definition>2462435 - Disclosure - Leases (Schedule of Rent Expense and Sublease Income) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeasePositionDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails">
        <link:definition>2463436 - Disclosure - Leases (Lease Position) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails">
        <link:definition>2464437 - Disclosure - Leases (Schedule of Lease Liability Maturities and Future Minimum Payments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails_1" roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails_1">
        <link:definition>2464437 - Disclosure - Leases (Schedule of Lease Liability Maturities and Future Minimum Payments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstruments" roleURI="http://www.cumberlandpharma.com/role/FairValueofFinancialInstruments">
        <link:definition>2165116 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsTables" roleURI="http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsTables">
        <link:definition>2366312 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails">
        <link:definition>2467438 - Disclosure - Fair Value of Financial Instruments (Schedule of Fair Value of Financial Instruments by Level in Hierarchy and Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketConcentrations" roleURI="http://www.cumberlandpharma.com/role/MarketConcentrations">
        <link:definition>2168117 - Disclosure - Market Concentrations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketConcentrationsTables" roleURI="http://www.cumberlandpharma.com/role/MarketConcentrationsTables">
        <link:definition>2369313 - Disclosure - Market Concentrations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails">
        <link:definition>2470439 - Disclosure - Market Concentrations (Schedule of Revenues Concentration from Major Customers and Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ManufacturingandSupplyAgreements" roleURI="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreements">
        <link:definition>2171118 - Disclosure - Manufacturing and Supply Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails">
        <link:definition>2472440 - Disclosure - Manufacturing and Supply Agreements Manufacturing and Supply Agreements (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmploymentAgreements" roleURI="http://www.cumberlandpharma.com/role/EmploymentAgreements">
        <link:definition>2173119 - Disclosure - Employment Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperations" roleURI="http://www.cumberlandpharma.com/role/DiscontinuedOperations">
        <link:definition>2174120 - Disclosure - Discontinued Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsandDisposalGroupsTables" roleURI="http://www.cumberlandpharma.com/role/DiscontinuedOperationsandDisposalGroupsTables">
        <link:definition>2375314 - Disclosure - Discontinued Operations and Disposal Groups (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsDetails" roleURI="http://www.cumberlandpharma.com/role/DiscontinuedOperationsDetails">
        <link:definition>2476441 - Disclosure - Discontinued Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.cumberlandpharma.com/role/CommitmentsandContingencies">
        <link:definition>2177121 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialInformationUnaudited" roleURI="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnaudited">
        <link:definition>2178122 - Disclosure - Quarterly Financial Information (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialInformationUnauditedTables" roleURI="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnauditedTables">
        <link:definition>2379315 - Disclosure - Quarterly Financial Information (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails" roleURI="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails">
        <link:definition>2480442 - Disclosure - Quarterly Financial Information (Schedule of Quarterly Financial Information (Unaudited)) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.cumberlandpharma.com/role/SubsequentEvents">
        <link:definition>2181123 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ValuationandQualifyingAccounts" roleURI="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccounts">
        <link:definition>1106124 - Statement - Valuation and Qualifying Accounts</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ValuationandQualifyingAccountsDetails" roleURI="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails">
        <link:definition>2482443 - Disclosure - Valuation and Qualifying Accounts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" abstract="false" name="BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_EmploymentAgreementsAbstract" abstract="true" name="EmploymentAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_USTreasuryNotesAndBondsSecuritiesMember" abstract="true" name="USTreasuryNotesAndBondsSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_EmployeeNonemployeeandFoundationContributionMember" abstract="true" name="EmployeeNonemployeeandFoundationContributionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter" abstract="false" name="FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_DenominatorAbstract" abstract="true" name="DenominatorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cpix_ExpirationTermThreeMember" abstract="true" name="ExpirationTermThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_FinancialConsiderationPaymentPeriod" abstract="false" name="FinancialConsiderationPaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct" abstract="false" name="ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cpix_CustomerOneMember" abstract="true" name="CustomerOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="cpix_DeferredAcquisitionLiabilityCurrent" abstract="false" name="DeferredAcquisitionLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_GloriaPharmaceuticalsMember" abstract="true" name="GloriaPharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ChangeInContingentConsiderationHeadingRollForward" abstract="false" name="ChangeInContingentConsiderationHeadingRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_CustomerTwoMember" abstract="true" name="CustomerTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_CustomerThreeMember" abstract="true" name="CustomerThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_RevenueRecognitionCumulativeUpfrontPayment" abstract="false" name="RevenueRecognitionCumulativeUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ManufacturingandSupplyAgreementLineItems" abstract="true" name="ManufacturingandSupplyAgreementLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="cpix_StockIssuedDuringPeriodPricePerShareNewIssues" abstract="false" name="StockIssuedDuringPeriodPricePerShareNewIssues" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="cpix_PernixTherapeuticsMember" abstract="true" name="PernixTherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses" abstract="false" name="DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_DeferredTaxAssetsDeferredCharges" abstract="false" name="DeferredTaxAssetsDeferredCharges" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct" abstract="false" name="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_KristaloseMember" abstract="true" name="KristaloseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_WarrantsIssuedInConsiderationOf2006CreditFacilityAmendmentMember" abstract="true" name="WarrantsIssuedInConsiderationOf2006CreditFacilityAmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval" abstract="false" name="RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_PinnacleBankMember" abstract="true" name="PinnacleBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_SalesRevenueGoodsGrossMember" abstract="true" name="SalesRevenueGoodsGrossMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_NoncashOrPartNoncashTransactionVestingOfShares" abstract="false" name="NoncashOrPartNoncashTransactionVestingOfShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_LoansForgiveninExchangeForShareIssuedAmount" abstract="false" name="LoansForgiveninExchangeForShareIssuedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ProductAndLicenseRightsMember" abstract="true" name="ProductAndLicenseRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock" abstract="false" name="PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="cpix_ShareRepurchaseProgramAuthorizedIn2010Member" abstract="true" name="ShareRepurchaseProgramAuthorizedIn2010Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_TaxCutsandJobsActof2017ChangeinTaxRateDeferredTaxAssetIncomeTaxExpenseBenefit" abstract="false" name="TaxCutsandJobsActof2017ChangeinTaxRateDeferredTaxAssetIncomeTaxExpenseBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_CumberlandEmergingTechnologiesIncMember" abstract="true" name="CumberlandEmergingTechnologiesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_CommonStockAbstract" abstract="true" name="CommonStockAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_LongTermIncentiveCompensationPlan2007Member" abstract="true" name="LongTermIncentiveCompensationPlan2007Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_PaymentsForContingentConsideration" abstract="false" name="PaymentsForContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge" abstract="false" name="DefinedContributionPlanEligibilityMinimumEmployeeAge" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cpix_ScheduleOfStockOptionActivityAdditionalDisclosuresTableTextBlock" abstract="false" name="ScheduleOfStockOptionActivityAdditionalDisclosuresTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="cpix_PaymentsForAssetAcquisitions" abstract="false" name="PaymentsForAssetAcquisitions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember" abstract="true" name="CollaborativeArrangementFederalSmallBusinessGrantProgramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_ExpirationTimePeriodDomain" abstract="true" name="ExpirationTimePeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" abstract="false" name="DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="cpix_LeaseLiability" abstract="false" name="LeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember" abstract="true" name="SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements" abstract="false" name="DepreciationIncludingAmortizationRelatedToLeaseholdImprovements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_InitialPublicOfferingAbstract" abstract="true" name="InitialPublicOfferingAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock" abstract="false" name="ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cpix_RevenueRecognitionMilestonePayments" abstract="false" name="RevenueRecognitionMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ScheduleofDepreciationExpenseTableTextBlock" abstract="false" name="ScheduleofDepreciationExpenseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="cpix_ProductRightsMember" abstract="true" name="ProductRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_ChargebacksCashDiscountsAndDamagedGoodsMember" abstract="true" name="ChargebacksCashDiscountsAndDamagedGoodsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_PreferredStockAbstract" abstract="true" name="PreferredStockAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_OmeclamoxPakMember" abstract="true" name="OmeclamoxPakMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions" abstract="false" name="ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts" abstract="false" name="StockIssuedDuringPeriodNewSharesUnderwritingDiscounts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember" abstract="true" name="HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering" abstract="false" name="StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_CaldolorMember" abstract="true" name="CaldolorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_LoanPoolsMember" abstract="true" name="LoanPoolsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_VaprisolMember" abstract="true" name="VaprisolMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_MethotrexateMember" abstract="true" name="MethotrexateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" abstract="false" name="SubsidiaryInvestmentPaymentsForReturnOfCapital" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual" abstract="false" name="FiniteLivedIntangibleAssetsUsefulLivesTextual" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_SharebasedCompensationFoundationContribution" abstract="false" name="SharebasedCompensationFoundationContribution" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_SharesRepurchaseActivityTypeDomain" abstract="true" name="SharesRepurchaseActivityTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_AccruedLiabilitiesInventoryPurchases" abstract="false" name="AccruedLiabilitiesInventoryPurchases" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_AccruedLiabilitiesStockPayable" abstract="false" name="AccruedLiabilitiesStockPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ExpirationTermTwoMember" abstract="true" name="ExpirationTermTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_ExpirationTimePeriodAxis" abstract="true" name="ExpirationTimePeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cpix_EmploymentAgreementsTextBlock" abstract="false" name="EmploymentAgreementsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="cpix_NordicMember" abstract="true" name="NordicMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_ProductSalesRelatedLiabilitiesCurrent" abstract="false" name="ProductSalesRelatedLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_EmployeeMember" abstract="true" name="EmployeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid" abstract="false" name="PurchasesOfIntangibleAssetsIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_DirectorsIncentivePlan2007Member" abstract="true" name="DirectorsIncentivePlan2007Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_SecondAmendmentMember" abstract="true" name="SecondAmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_ExpirationTermFourMember" abstract="true" name="ExpirationTermFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_TieredRoyaltyPaymentsPercentage" abstract="false" name="TieredRoyaltyPaymentsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="cpix_ManufacturingAndSupplyAgreementsTextBlock" abstract="false" name="ManufacturingAndSupplyAgreementsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" abstract="false" name="ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="cpix_ManufacturingandSupplyAgreementTable" abstract="true" name="ManufacturingandSupplyAgreementTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="cpix_IfetrobanClinicalMember" abstract="true" name="IfetrobanClinicalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_IndefiniteMember" abstract="true" name="IndefiniteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales" abstract="false" name="RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_AmendedInternationalAgreementMember" abstract="true" name="AmendedInternationalAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_ProductRevenuesAbstract" abstract="true" name="ProductRevenuesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_NonprincipalOwnerMember" abstract="true" name="NonprincipalOwnerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_NetDeferredTaxAssetsGross" abstract="false" name="NetDeferredTaxAssetsGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_VIBATIVMember" abstract="true" name="VIBATIVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_DisposalGroupIncludingDiscontinuedOperationRemainingInventoryCurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationRemainingInventoryCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_OtherRevenuesAbstract" abstract="true" name="OtherRevenuesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles" abstract="false" name="DeferredTaxAssetsPropertyAndEquipmentAndIntangibles" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_AccountsReceivableAllowancesByComponentAxis" abstract="true" name="AccountsReceivableAllowancesByComponentAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility" abstract="false" name="DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="us-types:durationStringItemType"/>
  <xs:element id="cpix_ProductVibativMember" abstract="true" name="ProductVibativMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_ContributionOfCashAdditionalSharesPurchased" abstract="false" name="ContributionOfCashAdditionalSharesPurchased" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" abstract="false" name="StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_SharesRepurchaseActivityTypeAxis" abstract="true" name="SharesRepurchaseActivityTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cpix_IntercompanyLoansPayableConvertedAmount" abstract="false" name="IntercompanyLoansPayableConvertedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_NonemployeeMember" abstract="true" name="NonemployeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" abstract="false" name="BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_NumeratorAbstract" abstract="true" name="NumeratorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_AcetadoteMember" abstract="true" name="AcetadoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_AccruedPaymentForAssetPurchaseCurrent" abstract="false" name="AccruedPaymentForAssetPurchaseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering" abstract="false" name="StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="cpix_PropertyAndEquipmentUsefulLifeTextual" abstract="false" name="PropertyAndEquipmentUsefulLifeTextual" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_HarbinGloriaPharmaceuticalsCoMember" abstract="true" name="HarbinGloriaPharmaceuticalsCoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_AccountsReceivableAllowancesByComponentDomain" abstract="true" name="AccountsReceivableAllowancesByComponentDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember" abstract="true" name="WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_CashPaidDuringYearForAbstract" abstract="true" name="CashPaidDuringYearForAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_ExpirationTermOneMember" abstract="true" name="ExpirationTermOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_FoundationContributionMember" abstract="true" name="FoundationContributionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_LeaseAsset" abstract="false" name="LeaseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" abstract="false" name="LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ManufacturingAndSupplyAgreementsAbstract" abstract="true" name="ManufacturingAndSupplyAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_HongKongWinHealthPharmaGroupCoLimitedMember" abstract="true" name="HongKongWinHealthPharmaGroupCoLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_SubsidiaryInvestmentPurchaseOfShares" abstract="false" name="SubsidiaryInvestmentPurchaseOfShares" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_RevenueRecognitionUpfrontPayment" abstract="false" name="RevenueRecognitionUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_SharebasedCompensationCharitableContributionofSharesShares" abstract="false" name="SharebasedCompensationCharitableContributionofSharesShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>5
<FILENAME>cpix-20201210_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:bbbd83ec-86cd-4852-a42b-62050b4598f2,g:afd11596-cbdf-45f6-87ac-39eae3274065-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="simple" xlink:href="cpix-20201210.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cpix-20201210.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_91b9716c-299a-45b8-a768-19a6e6f67a63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f1bfe88d-b5e9-4f83-9f51-3210a41b34ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_91b9716c-299a-45b8-a768-19a6e6f67a63" xlink:to="loc_us-gaap_Liabilities_f1bfe88d-b5e9-4f83-9f51-3210a41b34ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4e908a9f-7fe7-4dd0-976e-2b4ae5188dae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_91b9716c-299a-45b8-a768-19a6e6f67a63" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4e908a9f-7fe7-4dd0-976e-2b4ae5188dae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e9bdfc98-6f6c-4694-ac99-a3860b9ee6e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_91b9716c-299a-45b8-a768-19a6e6f67a63" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e9bdfc98-6f6c-4694-ac99-a3860b9ee6e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9a42a6f0-5234-4d39-a448-f03984363505" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_30cf3fbd-03ec-4242-b9da-c633ff061ac5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9a42a6f0-5234-4d39-a448-f03984363505" xlink:to="loc_us-gaap_StockholdersEquity_30cf3fbd-03ec-4242-b9da-c633ff061ac5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_846aa679-1942-4d24-94d0-0c6b6ea59e23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9a42a6f0-5234-4d39-a448-f03984363505" xlink:to="loc_us-gaap_MinorityInterest_846aa679-1942-4d24-94d0-0c6b6ea59e23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_129a6ee1-edc5-4269-be60-aaeff9114ede" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c4ab34a3-c72e-4120-95b8-a65520423f61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_129a6ee1-edc5-4269-be60-aaeff9114ede" xlink:to="loc_us-gaap_LiabilitiesCurrent_c4ab34a3-c72e-4120-95b8-a65520423f61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_b6d4697d-ecc9-451b-bc90-173e22b28c4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_129a6ee1-edc5-4269-be60-aaeff9114ede" xlink:to="loc_us-gaap_LongTermLineOfCredit_b6d4697d-ecc9-451b-bc90-173e22b28c4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_d2c12a97-ad87-4df5-be30-e33767451747" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_129a6ee1-edc5-4269-be60-aaeff9114ede" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_d2c12a97-ad87-4df5-be30-e33767451747" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b2375956-a6c2-4f81-bfab-3b79c839e4b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_129a6ee1-edc5-4269-be60-aaeff9114ede" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b2375956-a6c2-4f81-bfab-3b79c839e4b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_3c96dac0-0dde-431d-a9c9-85620f99025f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3dc78512-4046-4386-a1ea-0f1869a8842a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3c96dac0-0dde-431d-a9c9-85620f99025f" xlink:to="loc_us-gaap_AssetsCurrent_3dc78512-4046-4386-a1ea-0f1869a8842a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6b526fe4-bcf1-4c13-b770-621e0589092c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3c96dac0-0dde-431d-a9c9-85620f99025f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6b526fe4-bcf1-4c13-b770-621e0589092c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_aa54771f-f7ac-40cc-bfea-7731087455c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3c96dac0-0dde-431d-a9c9-85620f99025f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_aa54771f-f7ac-40cc-bfea-7731087455c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_be3d0d79-a3d3-481e-ad80-39c3581a7251" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3c96dac0-0dde-431d-a9c9-85620f99025f" xlink:to="loc_us-gaap_Goodwill_be3d0d79-a3d3-481e-ad80-39c3581a7251" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_f31f39dc-a980-4a0d-9ca4-09488054f0c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3c96dac0-0dde-431d-a9c9-85620f99025f" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_f31f39dc-a980-4a0d-9ca4-09488054f0c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_f8ee2be1-2a09-45a8-9e3e-5d84eededdad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3c96dac0-0dde-431d-a9c9-85620f99025f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_f8ee2be1-2a09-45a8-9e3e-5d84eededdad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_3963f8b3-9b6d-4f7b-8b53-7c0a016ad860" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3c96dac0-0dde-431d-a9c9-85620f99025f" xlink:to="loc_us-gaap_InventoryNoncurrent_3963f8b3-9b6d-4f7b-8b53-7c0a016ad860" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_bbac6fc9-c576-4e69-802c-169b1b940065" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3c96dac0-0dde-431d-a9c9-85620f99025f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_bbac6fc9-c576-4e69-802c-169b1b940065" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_512530f7-e80f-4f1d-a6ee-5d4eaffa7fb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_e2eeaed1-56ba-46aa-b746-1116a0396e9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_512530f7-e80f-4f1d-a6ee-5d4eaffa7fb2" xlink:to="loc_us-gaap_AccountsPayableCurrent_e2eeaed1-56ba-46aa-b746-1116a0396e9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e75bf370-ffee-4db6-869a-f2e004f0f26b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_512530f7-e80f-4f1d-a6ee-5d4eaffa7fb2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e75bf370-ffee-4db6-869a-f2e004f0f26b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_412e41df-ad6f-4ead-ba66-8bcbd93ba00f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_512530f7-e80f-4f1d-a6ee-5d4eaffa7fb2" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_412e41df-ad6f-4ead-ba66-8bcbd93ba00f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_9240fc1a-5981-4dd5-8fdf-8f7957d8e20c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_512530f7-e80f-4f1d-a6ee-5d4eaffa7fb2" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_9240fc1a-5981-4dd5-8fdf-8f7957d8e20c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5faccb19-a782-4555-b899-a441c7272976" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2b7bfa3b-397e-4f68-be8a-a0a7ac1b411a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5faccb19-a782-4555-b899-a441c7272976" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2b7bfa3b-397e-4f68-be8a-a0a7ac1b411a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_33f2bfa2-f7c3-4c45-98c0-ca459071dcb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5faccb19-a782-4555-b899-a441c7272976" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_33f2bfa2-f7c3-4c45-98c0-ca459071dcb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_1a9e1094-83c3-42ba-9af6-dae1e728f665" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5faccb19-a782-4555-b899-a441c7272976" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_1a9e1094-83c3-42ba-9af6-dae1e728f665" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_c89c774c-bd12-4245-b97d-a65f249ea274" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5faccb19-a782-4555-b899-a441c7272976" xlink:to="loc_us-gaap_InventoryNet_c89c774c-bd12-4245-b97d-a65f249ea274" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a51690b0-9d60-47df-abff-61369c133c11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5faccb19-a782-4555-b899-a441c7272976" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a51690b0-9d60-47df-abff-61369c133c11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_13e39a78-6a01-4391-9cec-b61b102f9dbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5faccb19-a782-4555-b899-a441c7272976" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_13e39a78-6a01-4391-9cec-b61b102f9dbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6e494598-8d92-439f-8f1a-55ec7e1836e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_f218421b-0160-44b4-ba49-be4db028ffd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6e494598-8d92-439f-8f1a-55ec7e1836e3" xlink:to="loc_us-gaap_CommonStockValueOutstanding_f218421b-0160-44b4-ba49-be4db028ffd9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_89f5b5c6-a153-4d37-8d2d-cc29059d5b2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6e494598-8d92-439f-8f1a-55ec7e1836e3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_89f5b5c6-a153-4d37-8d2d-cc29059d5b2c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cpix-20201210.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss" xlink:type="simple" xlink:href="cpix-20201210.xsd#ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8a785e31-cacf-46e2-a1f7-cc3efa1e35fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_140f2acf-b023-4661-adfa-d04ce6b38f19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_8a785e31-cacf-46e2-a1f7-cc3efa1e35fd" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_140f2acf-b023-4661-adfa-d04ce6b38f19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_15cb317d-3811-4951-97c4-f981e5b67203" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_8a785e31-cacf-46e2-a1f7-cc3efa1e35fd" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_15cb317d-3811-4951-97c4-f981e5b67203" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_306c4728-6caa-4e34-a9e2-d8f00e7f0555" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_4f23da3e-7432-4ac7-ba49-1744c38fd6e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_306c4728-6caa-4e34-a9e2-d8f00e7f0555" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_4f23da3e-7432-4ac7-ba49-1744c38fd6e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_e64c7325-6202-4f7a-bbcd-dd7e19d2e7bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_306c4728-6caa-4e34-a9e2-d8f00e7f0555" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_e64c7325-6202-4f7a-bbcd-dd7e19d2e7bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2efc449f-88a4-4c2f-92c9-63f141fc6e4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_6a807746-e184-49af-b3d6-a868f15634fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_2efc449f-88a4-4c2f-92c9-63f141fc6e4e" xlink:to="loc_us-gaap_CostsAndExpenses_6a807746-e184-49af-b3d6-a868f15634fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_7207df61-dfac-4057-ac93-ed1b0bc69de1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_2efc449f-88a4-4c2f-92c9-63f141fc6e4e" xlink:to="loc_us-gaap_Revenues_7207df61-dfac-4057-ac93-ed1b0bc69de1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_330b07be-3d2e-4143-b8e8-7232fe236231" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7eb338df-2d81-41ba-b8b1-4f869811154d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_330b07be-3d2e-4143-b8e8-7232fe236231" xlink:to="loc_us-gaap_OperatingIncomeLoss_7eb338df-2d81-41ba-b8b1-4f869811154d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_9eaa1c58-78d9-4f6a-8ef4-5ed4e59890ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_330b07be-3d2e-4143-b8e8-7232fe236231" xlink:to="loc_us-gaap_InvestmentIncomeInterest_9eaa1c58-78d9-4f6a-8ef4-5ed4e59890ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_ad2e8a38-49ae-4171-a44f-ef038baf41bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_330b07be-3d2e-4143-b8e8-7232fe236231" xlink:to="loc_us-gaap_InterestExpense_ad2e8a38-49ae-4171-a44f-ef038baf41bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_244b0c44-0c94-4888-a970-2b5bec767d52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_6a704694-1d6f-4fc4-9f4e-1a8e7b48f258" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_244b0c44-0c94-4888-a970-2b5bec767d52" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_6a704694-1d6f-4fc4-9f4e-1a8e7b48f258" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_b7c98e7b-7962-453b-b138-77e554dec75e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_244b0c44-0c94-4888-a970-2b5bec767d52" xlink:to="loc_us-gaap_SellingAndMarketingExpense_b7c98e7b-7962-453b-b138-77e554dec75e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_5772e90b-fddf-4984-9ac9-6c0409ab04c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_244b0c44-0c94-4888-a970-2b5bec767d52" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_5772e90b-fddf-4984-9ac9-6c0409ab04c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_72445c6d-0c06-4079-9640-4f08ac5497f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_244b0c44-0c94-4888-a970-2b5bec767d52" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_72445c6d-0c06-4079-9640-4f08ac5497f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_7ff71475-473c-4d53-95ec-cc75c5481238" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_244b0c44-0c94-4888-a970-2b5bec767d52" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_7ff71475-473c-4d53-95ec-cc75c5481238" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_c4a5f08e-d5a2-4ce6-9245-20b50d55c136" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9749ed64-a436-4a5a-8458-3f4426f154d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_c4a5f08e-d5a2-4ce6-9245-20b50d55c136" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9749ed64-a436-4a5a-8458-3f4426f154d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_b2cf6aed-70e0-4203-a545-54a2a2ec9003" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_c4a5f08e-d5a2-4ce6-9245-20b50d55c136" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_b2cf6aed-70e0-4203-a545-54a2a2ec9003" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8a0ac2ed-3073-4ab7-a18d-a8962085a6b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_69b6979b-6835-477b-8ec7-b9b8a56476d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8a0ac2ed-3073-4ab7-a18d-a8962085a6b7" xlink:to="loc_us-gaap_ProfitLoss_69b6979b-6835-477b-8ec7-b9b8a56476d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_76773cf0-f22b-4d5e-b9cc-7f118cb9537f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8a0ac2ed-3073-4ab7-a18d-a8962085a6b7" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_76773cf0-f22b-4d5e-b9cc-7f118cb9537f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_5b711dc4-29f5-4b73-99f3-18686a04f3bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_28f0302e-73e6-4d4e-871c-ecaeecbe7f28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_5b711dc4-29f5-4b73-99f3-18686a04f3bf" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_28f0302e-73e6-4d4e-871c-ecaeecbe7f28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_35915a58-b661-4da4-bbfe-65c16502f6f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_5b711dc4-29f5-4b73-99f3-18686a04f3bf" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_35915a58-b661-4da4-bbfe-65c16502f6f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_a2851f95-5f27-4e1a-838d-407cc092ce4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_5d6fa407-cf02-49bf-8dc3-8191fcd926b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_a2851f95-5f27-4e1a-838d-407cc092ce4e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_5d6fa407-cf02-49bf-8dc3-8191fcd926b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_72fa3d9d-d28d-4773-b312-cda4e0c2c576" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_a2851f95-5f27-4e1a-838d-407cc092ce4e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_72fa3d9d-d28d-4773-b312-cda4e0c2c576" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cpix-20201210.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c022c633-150d-44e8-aa55-b7407269fcaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_edb80ef6-2eb7-4cc6-ac91-057d46db9149" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c022c633-150d-44e8-aa55-b7407269fcaa" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_edb80ef6-2eb7-4cc6-ac91-057d46db9149" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_4279f6de-9a59-488a-8869-eab325f6aca7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c022c633-150d-44e8-aa55-b7407269fcaa" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_4279f6de-9a59-488a-8869-eab325f6aca7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_ba47e5e1-62aa-4940-9832-ccc72d8c9dce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c022c633-150d-44e8-aa55-b7407269fcaa" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_ba47e5e1-62aa-4940-9832-ccc72d8c9dce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_b465dc70-5498-4965-a922-8b1f84da1d8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c022c633-150d-44e8-aa55-b7407269fcaa" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_b465dc70-5498-4965-a922-8b1f84da1d8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_d7726c7d-9fc7-48d3-981b-85e6583421d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c022c633-150d-44e8-aa55-b7407269fcaa" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_d7726c7d-9fc7-48d3-981b-85e6583421d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_e57458d5-a52c-4e3e-9fe4-169e992c138a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c022c633-150d-44e8-aa55-b7407269fcaa" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_e57458d5-a52c-4e3e-9fe4-169e992c138a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_3fe38766-bfcf-4039-a5da-2267e814e465" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c022c633-150d-44e8-aa55-b7407269fcaa" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_3fe38766-bfcf-4039-a5da-2267e814e465" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_a4fa9867-c886-4bb9-9c1e-fe3e5a942ac3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c022c633-150d-44e8-aa55-b7407269fcaa" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_a4fa9867-c886-4bb9-9c1e-fe3e5a942ac3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_0f0d43ee-a685-4c90-b958-faae47be5f2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_4848d2a4-3ed4-462f-876f-f80319c2c6d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_0f0d43ee-a685-4c90-b958-faae47be5f2b" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_4848d2a4-3ed4-462f-876f-f80319c2c6d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_6f4fc53f-66de-4efb-9628-737a3e9b2ba0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_0f0d43ee-a685-4c90-b958-faae47be5f2b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_6f4fc53f-66de-4efb-9628-737a3e9b2ba0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1a8c372d-da3e-427f-92ea-48dba1a41d3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_0f0d43ee-a685-4c90-b958-faae47be5f2b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1a8c372d-da3e-427f-92ea-48dba1a41d3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_b19e8966-3f0b-4a9b-a10a-0ac3da5d7d21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_0f0d43ee-a685-4c90-b958-faae47be5f2b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_b19e8966-3f0b-4a9b-a10a-0ac3da5d7d21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_33636cdd-b776-4f39-909e-eb99680f3d1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_0f0d43ee-a685-4c90-b958-faae47be5f2b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_33636cdd-b776-4f39-909e-eb99680f3d1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharebasedCompensationFoundationContribution_fa1cb18d-ee2a-478e-8b94-1baff083987b" xlink:href="cpix-20201210.xsd#cpix_SharebasedCompensationFoundationContribution"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_0f0d43ee-a685-4c90-b958-faae47be5f2b" xlink:to="loc_cpix_SharebasedCompensationFoundationContribution_fa1cb18d-ee2a-478e-8b94-1baff083987b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_63795301-bf03-4669-8e25-ac4ef9bdcd87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_0f0d43ee-a685-4c90-b958-faae47be5f2b" xlink:to="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_63795301-bf03-4669-8e25-ac4ef9bdcd87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_fe8ec2db-7c25-4a78-bb3d-d7f21c623c5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_0f0d43ee-a685-4c90-b958-faae47be5f2b" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_fe8ec2db-7c25-4a78-bb3d-d7f21c623c5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2ff3a7a8-0f28-447d-aacc-4fbe6423bedd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_0f0d43ee-a685-4c90-b958-faae47be5f2b" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2ff3a7a8-0f28-447d-aacc-4fbe6423bedd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_abcccf4a-208d-42b1-b4d8-48c44158b17a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_0f0d43ee-a685-4c90-b958-faae47be5f2b" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_abcccf4a-208d-42b1-b4d8-48c44158b17a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingGainsLosses_9e906f5c-6940-4b0c-9854-078c44a6ee94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingGainsLosses"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_0f0d43ee-a685-4c90-b958-faae47be5f2b" xlink:to="loc_us-gaap_OtherNonoperatingGainsLosses_9e906f5c-6940-4b0c-9854-078c44a6ee94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_52b9494d-972d-4b4a-9855-c1ff35592c90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_0f0d43ee-a685-4c90-b958-faae47be5f2b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_52b9494d-972d-4b4a-9855-c1ff35592c90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_4603e5a9-69c6-4078-a65f-323e7d902eff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_0f0d43ee-a685-4c90-b958-faae47be5f2b" xlink:to="loc_us-gaap_ShareBasedCompensation_4603e5a9-69c6-4078-a65f-323e7d902eff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_022b9c15-d43c-4917-9133-02c6d0b248b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_0f0d43ee-a685-4c90-b958-faae47be5f2b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_022b9c15-d43c-4917-9133-02c6d0b248b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b8330103-f4f6-4586-a2ac-9fd3596030b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_caa7b36b-c94e-4831-951a-4842b8dec0d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b8330103-f4f6-4586-a2ac-9fd3596030b8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_caa7b36b-c94e-4831-951a-4842b8dec0d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_26732c3a-ef47-4b12-aec2-9bec44de6bf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b8330103-f4f6-4586-a2ac-9fd3596030b8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_26732c3a-ef47-4b12-aec2-9bec44de6bf4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a09e5fa6-022b-45a8-bb18-5a035941fc86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b8330103-f4f6-4586-a2ac-9fd3596030b8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a09e5fa6-022b-45a8-bb18-5a035941fc86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_80339a8d-92b5-4f20-a078-20f850f5f923" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2da72469-308e-4e7e-936d-5165c812b205" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_80339a8d-92b5-4f20-a078-20f850f5f923" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2da72469-308e-4e7e-936d-5165c812b205" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_eaf066b1-da52-466f-a51a-d92ff9bbd34c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_80339a8d-92b5-4f20-a078-20f850f5f923" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_eaf066b1-da52-466f-a51a-d92ff9bbd34c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_f892a37c-10ae-462c-8d87-57d436e59052" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_80339a8d-92b5-4f20-a078-20f850f5f923" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_f892a37c-10ae-462c-8d87-57d436e59052" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_14434970-1548-4a7d-9de3-17b9d725749a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_80339a8d-92b5-4f20-a078-20f850f5f923" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_14434970-1548-4a7d-9de3-17b9d725749a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_514cb4ad-14c5-4d88-b0de-da0c0e68f809" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_80339a8d-92b5-4f20-a078-20f850f5f923" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_514cb4ad-14c5-4d88-b0de-da0c0e68f809" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e90595e2-7c15-4cf6-b66b-99dc57bb92a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_86c21b6a-8ad5-4010-b77b-3aa015c15070" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e90595e2-7c15-4cf6-b66b-99dc57bb92a6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_86c21b6a-8ad5-4010-b77b-3aa015c15070" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_dce908a5-5840-477d-aea8-3ba4f3fbb9b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e90595e2-7c15-4cf6-b66b-99dc57bb92a6" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_dce908a5-5840-477d-aea8-3ba4f3fbb9b4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="cpix-20201210.xsd#ConsolidatedStatementsofEquity"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Organization" xlink:type="simple" xlink:href="cpix-20201210.xsd#Organization"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/Organization" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#OrganizationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPolicies" xlink:type="simple" xlink:href="cpix-20201210.xsd#SignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="cpix-20201210.xsd#SignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#SignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#SignificantAccountingPoliciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativ" xlink:type="simple" xlink:href="cpix-20201210.xsd#OmeclamoxPakRediTrexandVibativ"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativ" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#OmeclamoxPakRediTrexandVibativTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#OmeclamoxPakRediTrexandVibativNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#OmeclamoxPakRediTrexandVibativVibativAcquisitionNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_e1aca10e-438a-43da-90fb-1c76f8767ea4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_8f6e8f89-4b88-48c9-af13-5a316a628827" xlink:href="cpix-20201210.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_e1aca10e-438a-43da-90fb-1c76f8767ea4" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_8f6e8f89-4b88-48c9-af13-5a316a628827" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_8736b8f6-08a4-4b9b-a8a6-54b840e0bf04" xlink:href="cpix-20201210.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_e1aca10e-438a-43da-90fb-1c76f8767ea4" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_8736b8f6-08a4-4b9b-a8a6-54b840e0bf04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_727aa761-5d94-491b-848a-2a4fd2b35a8b" xlink:href="cpix-20201210.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_e1aca10e-438a-43da-90fb-1c76f8767ea4" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_727aa761-5d94-491b-848a-2a4fd2b35a8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_834929ae-697d-4d1c-94fe-2c9c5f84b3b0" xlink:href="cpix-20201210.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_e1aca10e-438a-43da-90fb-1c76f8767ea4" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_834929ae-697d-4d1c-94fe-2c9c5f84b3b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_b3889c02-16d6-470f-b39d-80764696ac8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_f20ff7af-cbf1-429b-abf4-ed34db8e6e58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_b3889c02-16d6-470f-b39d-80764696ac8a" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_f20ff7af-cbf1-429b-abf4-ed34db8e6e58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_216c79e8-8ef3-42bd-8a77-813133a20e40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_b3889c02-16d6-470f-b39d-80764696ac8a" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_216c79e8-8ef3-42bd-8a77-813133a20e40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsForContingentConsideration_f4805a0b-93d7-4c86-a242-05f3b365d8fa" xlink:href="cpix-20201210.xsd#cpix_PaymentsForContingentConsideration"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_b3889c02-16d6-470f-b39d-80764696ac8a" xlink:to="loc_cpix_PaymentsForContingentConsideration_f4805a0b-93d7-4c86-a242-05f3b365d8fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_5d5dba3b-c64c-4ace-9d25-7e33dcafdbbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_0d4f7781-9687-44c5-8dd9-4c198eed8e86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_5d5dba3b-c64c-4ace-9d25-7e33dcafdbbf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_0d4f7781-9687-44c5-8dd9-4c198eed8e86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_49fc7ca9-c142-4beb-afa9-e66291138cff" xlink:href="cpix-20201210.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_5d5dba3b-c64c-4ace-9d25-7e33dcafdbbf" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_49fc7ca9-c142-4beb-afa9-e66291138cff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_199f33d3-e88c-4a76-b220-d73a7b395d8d" xlink:href="cpix-20201210.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_51404c8d-8c9e-4706-9002-c507b40509cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_199f33d3-e88c-4a76-b220-d73a7b395d8d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_51404c8d-8c9e-4706-9002-c507b40509cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_10bf54bb-7408-4b87-8027-2054d20ca363" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_199f33d3-e88c-4a76-b220-d73a7b395d8d" xlink:to="loc_us-gaap_Goodwill_10bf54bb-7408-4b87-8027-2054d20ca363" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Revenues" xlink:type="simple" xlink:href="cpix-20201210.xsd#Revenues"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/Revenues" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#RevenuesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#RevenuesScheduleofNetProductRevenuesbyProductDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#RevenuesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Inventories" xlink:type="simple" xlink:href="cpix-20201210.xsd#Inventories"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/Inventories" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#InventoriesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_62bf465c-4400-4cd9-bd38-13903a0efb39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_f3d7d121-281d-4872-ac0e-582632b6752c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_62bf465c-4400-4cd9-bd38-13903a0efb39" xlink:to="loc_us-gaap_InventoryGross_f3d7d121-281d-4872-ac0e-582632b6752c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_0dbdbb59-9eb2-41d1-8983-bc7f60256948" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_62bf465c-4400-4cd9-bd38-13903a0efb39" xlink:to="loc_us-gaap_InventoryNoncurrent_0dbdbb59-9eb2-41d1-8983-bc7f60256948" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_71e89252-fa73-4d23-9aea-2b8176cd3c7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_f6f1f2c1-0dde-463c-9313-b8f9ca8dfc00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_71e89252-fa73-4d23-9aea-2b8176cd3c7f" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_f6f1f2c1-0dde-463c-9313-b8f9ca8dfc00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_81377a42-ff4f-4784-b681-b50194331f7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_71e89252-fa73-4d23-9aea-2b8176cd3c7f" xlink:to="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_81377a42-ff4f-4784-b681-b50194331f7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_2a38fb59-2a02-4561-8498-15d9348246fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_71e89252-fa73-4d23-9aea-2b8176cd3c7f" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_2a38fb59-2a02-4561-8498-15d9348246fc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#InventoriesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="cpix-20201210.xsd#PropertyandEquipment"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/PropertyandEquipment" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#PropertyandEquipmentTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/PropertyandEquipmentTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#PropertyandEquipmentScheduleofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a6d8b6a8-e282-42ee-a2be-e3b0ecae3fd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_23bfb3f2-e39e-43f8-bca9-c32d301fccae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_a6d8b6a8-e282-42ee-a2be-e3b0ecae3fd6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_23bfb3f2-e39e-43f8-bca9-c32d301fccae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_23fe27ed-4d83-41aa-a24a-0a176b7acff1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_a6d8b6a8-e282-42ee-a2be-e3b0ecae3fd6" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_23fe27ed-4d83-41aa-a24a-0a176b7acff1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipmentDepreciationExpenseDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#PropertyandEquipmentDepreciationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/PropertyandEquipmentDepreciationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssets" xlink:type="simple" xlink:href="cpix-20201210.xsd#IntangibleAssets"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssets" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#IntangibleAssetsTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#IntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fabce158-458e-4fb6-8ae2-0ee4794d4db6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_2473fe19-333a-4190-8d96-3a2882be4ce8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fabce158-458e-4fb6-8ae2-0ee4794d4db6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_2473fe19-333a-4190-8d96-3a2882be4ce8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f6d35984-0ce0-4cb0-85b5-94ecfca46ae0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fabce158-458e-4fb6-8ae2-0ee4794d4db6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f6d35984-0ce0-4cb0-85b5-94ecfca46ae0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#IntangibleAssetsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#IntangibleAssetsFutureAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e830bfed-26c8-4f05-88d1-61a8c8bc49a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_4074dd70-2682-4fa5-a0a1-a1dbd55459e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e830bfed-26c8-4f05-88d1-61a8c8bc49a8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_4074dd70-2682-4fa5-a0a1-a1dbd55459e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_6acfcaa0-7687-41fb-ad9d-afbc54afe377" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e830bfed-26c8-4f05-88d1-61a8c8bc49a8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_6acfcaa0-7687-41fb-ad9d-afbc54afe377" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_f562ab3a-e93a-4aa3-bb40-b0af71d4f95d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e830bfed-26c8-4f05-88d1-61a8c8bc49a8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_f562ab3a-e93a-4aa3-bb40-b0af71d4f95d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_8c91d286-f434-4582-855f-9f8611eda29d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e830bfed-26c8-4f05-88d1-61a8c8bc49a8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_8c91d286-f434-4582-855f-9f8611eda29d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter_be5abb73-e275-4760-885d-813f04600f00" xlink:href="cpix-20201210.xsd#cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e830bfed-26c8-4f05-88d1-61a8c8bc49a8" xlink:to="loc_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter_be5abb73-e275-4760-885d-813f04600f00" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilities" xlink:type="simple" xlink:href="cpix-20201210.xsd#OtherCurrentandOtherLongtermLiabilities"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#OtherCurrentandOtherLongtermLiabilitiesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_a1a89fba-35c3-4604-a282-56ffb7142377" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_b3fc3047-8a21-4a93-89f3-2e39c96ef03f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_a1a89fba-35c3-4604-a282-56ffb7142377" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_b3fc3047-8a21-4a93-89f3-2e39c96ef03f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_f29e4d78-f626-42dd-a785-cec172b51367" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_a1a89fba-35c3-4604-a282-56ffb7142377" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_f29e4d78-f626-42dd-a785-cec172b51367" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_ce5d2d96-7fb8-44d7-9dcd-272e01d5cb4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_a1a89fba-35c3-4604-a282-56ffb7142377" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_ce5d2d96-7fb8-44d7-9dcd-272e01d5cb4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4c09008b-f44d-415d-a78e-0b2d3127bdeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductSalesRelatedLiabilitiesCurrent_49213635-58c6-4dbe-a6a9-00907425e86b" xlink:href="cpix-20201210.xsd#cpix_ProductSalesRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4c09008b-f44d-415d-a78e-0b2d3127bdeb" xlink:to="loc_cpix_ProductSalesRelatedLiabilitiesCurrent_49213635-58c6-4dbe-a6a9-00907425e86b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_82cda4e4-d851-4439-ba6f-1b7dc8ba81d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4c09008b-f44d-415d-a78e-0b2d3127bdeb" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_82cda4e4-d851-4439-ba6f-1b7dc8ba81d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccruedLiabilitiesStockPayable_d839a683-2fd9-4d6e-8a03-f74369144ef2" xlink:href="cpix-20201210.xsd#cpix_AccruedLiabilitiesStockPayable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4c09008b-f44d-415d-a78e-0b2d3127bdeb" xlink:to="loc_cpix_AccruedLiabilitiesStockPayable_d839a683-2fd9-4d6e-8a03-f74369144ef2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_5af57c94-e984-4f8a-92e9-98a7e57c4984" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4c09008b-f44d-415d-a78e-0b2d3127bdeb" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_5af57c94-e984-4f8a-92e9-98a7e57c4984" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredAcquisitionLiabilityCurrent_8594c6bb-b2a5-45f3-8672-0e14e5a47201" xlink:href="cpix-20201210.xsd#cpix_DeferredAcquisitionLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4c09008b-f44d-415d-a78e-0b2d3127bdeb" xlink:to="loc_cpix_DeferredAcquisitionLiabilityCurrent_8594c6bb-b2a5-45f3-8672-0e14e5a47201" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccruedLiabilitiesInventoryPurchases_86209619-6e0e-475a-8451-00eac75b7823" xlink:href="cpix-20201210.xsd#cpix_AccruedLiabilitiesInventoryPurchases"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4c09008b-f44d-415d-a78e-0b2d3127bdeb" xlink:to="loc_cpix_AccruedLiabilitiesInventoryPurchases_86209619-6e0e-475a-8451-00eac75b7823" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_5806cbb3-dcea-44c1-ba06-614880e80123" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4c09008b-f44d-415d-a78e-0b2d3127bdeb" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_5806cbb3-dcea-44c1-ba06-614880e80123" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccruedPaymentForAssetPurchaseCurrent_e79f07ff-a943-4a68-b4ec-65bb52087b6b" xlink:href="cpix-20201210.xsd#cpix_AccruedPaymentForAssetPurchaseCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4c09008b-f44d-415d-a78e-0b2d3127bdeb" xlink:to="loc_cpix_AccruedPaymentForAssetPurchaseCurrent_e79f07ff-a943-4a68-b4ec-65bb52087b6b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Debt" xlink:type="simple" xlink:href="cpix-20201210.xsd#Debt"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/Debt" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/DebtLineofCreditDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#DebtLineofCreditDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/DebtLineofCreditDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="cpix-20201210.xsd#ShareholdersEquity"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityWarrantsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#ShareholdersEquityWarrantsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityWarrantsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="simple" xlink:href="cpix-20201210.xsd#EarningsLossPerShare"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#EarningsLossPerShareTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_247f0c8a-2d70-4346-aef6-e4b4b22b7d62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_70509287-8116-43b1-9137-7d6b18d905ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_247f0c8a-2d70-4346-aef6-e4b4b22b7d62" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_70509287-8116-43b1-9137-7d6b18d905ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_057846cf-0c1c-4775-8efb-f9ee4b455583" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_247f0c8a-2d70-4346-aef6-e4b4b22b7d62" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_057846cf-0c1c-4775-8efb-f9ee4b455583" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#EarningsLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cpix-20201210.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#IncomeTaxesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#IncomeTaxesOperatingLossCarryforwardsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NetDeferredTaxAssetsGross_9fe696ae-622a-4c5e-9e85-f54be218935c" xlink:href="cpix-20201210.xsd#cpix_NetDeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_718ff067-5e75-40a9-aefe-1e7c05a50854" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cpix_NetDeferredTaxAssetsGross_9fe696ae-622a-4c5e-9e85-f54be218935c" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_718ff067-5e75-40a9-aefe-1e7c05a50854" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_b7c99578-a5bd-45c2-93ca-5f00fd4950df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cpix_NetDeferredTaxAssetsGross_9fe696ae-622a-4c5e-9e85-f54be218935c" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_b7c99578-a5bd-45c2-93ca-5f00fd4950df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_6da57b9b-eb6c-49e0-a90c-24257dfd6d84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NetDeferredTaxAssetsGross_c9e5bbbc-03cf-4f55-b2c0-3cd5ccbcfa6e" xlink:href="cpix-20201210.xsd#cpix_NetDeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_6da57b9b-eb6c-49e0-a90c-24257dfd6d84" xlink:to="loc_cpix_NetDeferredTaxAssetsGross_c9e5bbbc-03cf-4f55-b2c0-3cd5ccbcfa6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_492cb97c-1630-45a7-8aef-c990a0c783c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_6da57b9b-eb6c-49e0-a90c-24257dfd6d84" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_492cb97c-1630-45a7-8aef-c990a0c783c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_c35c3702-5b23-4e5e-b482-4191e0629929" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_dc1c307b-d5c5-4d8c-b83c-cdec26ce7586" xlink:href="cpix-20201210.xsd#cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c35c3702-5b23-4e5e-b482-4191e0629929" xlink:to="loc_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_dc1c307b-d5c5-4d8c-b83c-cdec26ce7586" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles_41799ced-a6e1-46a2-b49a-4e205557ba19" xlink:href="cpix-20201210.xsd#cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c35c3702-5b23-4e5e-b482-4191e0629929" xlink:to="loc_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles_41799ced-a6e1-46a2-b49a-4e205557ba19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_0a780c27-77d3-4867-a374-2fd135c2d8bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c35c3702-5b23-4e5e-b482-4191e0629929" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_0a780c27-77d3-4867-a374-2fd135c2d8bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct_b0f60ff0-f8e3-465b-8518-85b9035aa3a7" xlink:href="cpix-20201210.xsd#cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c35c3702-5b23-4e5e-b482-4191e0629929" xlink:to="loc_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct_b0f60ff0-f8e3-465b-8518-85b9035aa3a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_873f5c48-30ce-4c0a-b19d-b11a32a7f068" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c35c3702-5b23-4e5e-b482-4191e0629929" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_873f5c48-30ce-4c0a-b19d-b11a32a7f068" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsDeferredCharges_213876f1-59dd-4b0c-8962-641dd4d82236" xlink:href="cpix-20201210.xsd#cpix_DeferredTaxAssetsDeferredCharges"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c35c3702-5b23-4e5e-b482-4191e0629929" xlink:to="loc_cpix_DeferredTaxAssetsDeferredCharges_213876f1-59dd-4b0c-8962-641dd4d82236" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_aedced0d-de12-49e7-bebe-037aa8c24c7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c35c3702-5b23-4e5e-b482-4191e0629929" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_aedced0d-de12-49e7-bebe-037aa8c24c7d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c0492f75-ca59-471f-8d2c-430eef4b1ed6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2b982c61-0a9d-4b49-9b2f-079109c3a624" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_c0492f75-ca59-471f-8d2c-430eef4b1ed6" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2b982c61-0a9d-4b49-9b2f-079109c3a624" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOtherTaxExpenseBenefit_4e1d18af-8936-4b97-b21c-d0bdc0750f43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOtherTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_c0492f75-ca59-471f-8d2c-430eef4b1ed6" xlink:to="loc_us-gaap_DeferredOtherTaxExpenseBenefit_4e1d18af-8936-4b97-b21c-d0bdc0750f43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_deaf0fd4-df5f-4689-81ba-0d8227968d91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_060a82ad-9176-4ff7-88fb-b635bf1489c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_deaf0fd4-df5f-4689-81ba-0d8227968d91" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_060a82ad-9176-4ff7-88fb-b635bf1489c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2bffa1cd-eae9-4627-a67f-3de3eb1ad967" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_deaf0fd4-df5f-4689-81ba-0d8227968d91" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2bffa1cd-eae9-4627-a67f-3de3eb1ad967" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOtherTaxExpenseBenefit_8281b73e-15f2-4a4e-ba41-f6f767b0f9d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOtherTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_cddfc9a1-55fe-47a1-aed2-3f34e3851a37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredOtherTaxExpenseBenefit_8281b73e-15f2-4a4e-ba41-f6f767b0f9d4" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_cddfc9a1-55fe-47a1-aed2-3f34e3851a37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_017cc250-686e-45c2-8ac5-b4a706cf6532" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredOtherTaxExpenseBenefit_8281b73e-15f2-4a4e-ba41-f6f767b0f9d4" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_017cc250-686e-45c2-8ac5-b4a706cf6532" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_670b582d-c99d-48a9-b66a-37db32775853" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0891dcd4-3a24-4d02-94d0-60bcaf4e0f9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_670b582d-c99d-48a9-b66a-37db32775853" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0891dcd4-3a24-4d02-94d0-60bcaf4e0f9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_04375505-43a8-4e7c-acca-992d909c3625" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_670b582d-c99d-48a9-b66a-37db32775853" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_04375505-43a8-4e7c-acca-992d909c3625" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_fa768115-2887-4911-bff2-0aa2a4595610" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_670b582d-c99d-48a9-b66a-37db32775853" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_fa768115-2887-4911-bff2-0aa2a4595610" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_6d5091d5-0cdf-44bd-8825-623c6c56bce0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_670b582d-c99d-48a9-b66a-37db32775853" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_6d5091d5-0cdf-44bd-8825-623c6c56bce0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_02e49dd3-bee5-4168-9165-862a0a1b4ecf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_670b582d-c99d-48a9-b66a-37db32775853" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_02e49dd3-bee5-4168-9165-862a0a1b4ecf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_23d67b38-05d1-45eb-aff7-6cd08dad09da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_670b582d-c99d-48a9-b66a-37db32775853" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_23d67b38-05d1-45eb-aff7-6cd08dad09da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_cdabc35c-c1ff-4641-a737-5b747e8343bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_670b582d-c99d-48a9-b66a-37db32775853" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_cdabc35c-c1ff-4641-a737-5b747e8343bc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlans" xlink:type="simple" xlink:href="cpix-20201210.xsd#StockBasedCompensationPlans"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlans" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#StockBasedCompensationPlansTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#StockBasedCompensationPlansNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#StockBasedCompensationPlansScheduleofStockOptionsActivityDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityAdditionalDisclosuresDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#StockBasedCompensationPlansScheduleofStockOptionActivityAdditionalDisclosuresDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityAdditionalDisclosuresDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EmployeeBenefitPlans" xlink:type="simple" xlink:href="cpix-20201210.xsd#EmployeeBenefitPlans"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EmployeeBenefitPlans" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EmployeeBenefitPlansNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#EmployeeBenefitPlansNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EmployeeBenefitPlansNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Leases" xlink:type="simple" xlink:href="cpix-20201210.xsd#Leases"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#LeasesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofRentExpenseandSubleaseIncomeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#LeasesScheduleofRentExpenseandSubleaseIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofRentExpenseandSubleaseIncomeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#LeasesLeasePositionDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2375917a-39db-4eef-98b3-ecf63339115c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_d9bec1f9-f254-43bb-b9ee-a49e950e2afc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2375917a-39db-4eef-98b3-ecf63339115c" xlink:to="loc_us-gaap_OperatingLeaseLiability_d9bec1f9-f254-43bb-b9ee-a49e950e2afc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5a5b578b-f4d6-45b7-a4bd-f96efb9448db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2375917a-39db-4eef-98b3-ecf63339115c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5a5b578b-f4d6-45b7-a4bd-f96efb9448db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2396f56f-9a1f-4b8d-b42c-6cc2e87c8258" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_278fd127-77b3-4bd3-b4d7-c046c9d688bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2396f56f-9a1f-4b8d-b42c-6cc2e87c8258" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_278fd127-77b3-4bd3-b4d7-c046c9d688bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_8775ad62-ab04-4072-8bb3-d0389ec01ad2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2396f56f-9a1f-4b8d-b42c-6cc2e87c8258" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_8775ad62-ab04-4072-8bb3-d0389ec01ad2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_7f2ef612-6ad6-402f-a8cd-c47d30fbc04e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2396f56f-9a1f-4b8d-b42c-6cc2e87c8258" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_7f2ef612-6ad6-402f-a8cd-c47d30fbc04e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_c6b2903a-f4bb-41f1-982a-7308b95c6a6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2396f56f-9a1f-4b8d-b42c-6cc2e87c8258" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_c6b2903a-f4bb-41f1-982a-7308b95c6a6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_2441c4d7-a52d-400d-bd6c-877377268d56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2396f56f-9a1f-4b8d-b42c-6cc2e87c8258" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_2441c4d7-a52d-400d-bd6c-877377268d56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_ed92b30f-04d1-45f0-a4f4-1babb1e25e2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2396f56f-9a1f-4b8d-b42c-6cc2e87c8258" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_ed92b30f-04d1-45f0-a4f4-1babb1e25e2c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails_1" xlink:type="simple" xlink:href="cpix-20201210.xsd#LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_94ae69a5-b3e7-4276-a998-6e0473804303" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b1d7d1a8-3039-4be4-a189-6f26b447f1ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_94ae69a5-b3e7-4276-a998-6e0473804303" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b1d7d1a8-3039-4be4-a189-6f26b447f1ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e7448914-79d5-4642-b812-094afd6c353b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_94ae69a5-b3e7-4276-a998-6e0473804303" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e7448914-79d5-4642-b812-094afd6c353b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_56a1d7cf-216a-413c-b922-fac288f956d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_94ae69a5-b3e7-4276-a998-6e0473804303" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_56a1d7cf-216a-413c-b922-fac288f956d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_42391988-a58d-4b8c-9634-2f77a85caad6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_94ae69a5-b3e7-4276-a998-6e0473804303" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_42391988-a58d-4b8c-9634-2f77a85caad6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_606027af-2aec-4c16-a882-37eb2da2edec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_94ae69a5-b3e7-4276-a998-6e0473804303" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_606027af-2aec-4c16-a882-37eb2da2edec" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/FairValueofFinancialInstruments" xlink:type="simple" xlink:href="cpix-20201210.xsd#FairValueofFinancialInstruments"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/FairValueofFinancialInstruments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#FairValueofFinancialInstrumentsTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketConcentrations" xlink:type="simple" xlink:href="cpix-20201210.xsd#MarketConcentrations"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/MarketConcentrations" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketConcentrationsTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#MarketConcentrationsTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/MarketConcentrationsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreements" xlink:type="simple" xlink:href="cpix-20201210.xsd#ManufacturingandSupplyAgreements"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EmploymentAgreements" xlink:type="simple" xlink:href="cpix-20201210.xsd#EmploymentAgreements"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EmploymentAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/DiscontinuedOperations" xlink:type="simple" xlink:href="cpix-20201210.xsd#DiscontinuedOperations"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/DiscontinuedOperations" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/DiscontinuedOperationsandDisposalGroupsTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#DiscontinuedOperationsandDisposalGroupsTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/DiscontinuedOperationsandDisposalGroupsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/DiscontinuedOperationsDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#DiscontinuedOperationsDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/DiscontinuedOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_66ed6d2c-a614-47b7-a892-80bc2148355f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_2217fb5e-8abd-4628-958a-ea922febc1ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_66ed6d2c-a614-47b7-a892-80bc2148355f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_2217fb5e-8abd-4628-958a-ea922febc1ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_123e8c16-6f80-479a-82d6-df2d79925334" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_66ed6d2c-a614-47b7-a892-80bc2148355f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_123e8c16-6f80-479a-82d6-df2d79925334" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_7c54b562-bf5a-47c6-a3d3-2240a4ca0055" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_66ed6d2c-a614-47b7-a892-80bc2148355f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_7c54b562-bf5a-47c6-a3d3-2240a4ca0055" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_16454dd2-2577-429b-9809-a26dba8a46c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_35bd8cad-1910-431b-8729-d092cc186c54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_16454dd2-2577-429b-9809-a26dba8a46c6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_35bd8cad-1910-431b-8729-d092cc186c54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_1e62a52f-7fa1-4bed-be17-b6b995400af1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_16454dd2-2577-429b-9809-a26dba8a46c6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_1e62a52f-7fa1-4bed-be17-b6b995400af1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_2ea71f9c-66c3-42ee-8530-19e85d6225b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_59032ab4-bd59-49fa-8e58-018b0056b322" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_2ea71f9c-66c3-42ee-8530-19e85d6225b3" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_59032ab4-bd59-49fa-8e58-018b0056b322" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_ad057cd2-430a-4030-8507-48a72d1ea511" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_2ea71f9c-66c3-42ee-8530-19e85d6225b3" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_ad057cd2-430a-4030-8507-48a72d1ea511" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_c1bed002-6e35-4838-8861-d2783e7d3757" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_2ea71f9c-66c3-42ee-8530-19e85d6225b3" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_c1bed002-6e35-4838-8861-d2783e7d3757" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="cpix-20201210.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="simple" xlink:href="cpix-20201210.xsd#QuarterlyFinancialInformationUnaudited"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#QuarterlyFinancialInformationUnauditedTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SubsequentEvents" xlink:type="simple" xlink:href="cpix-20201210.xsd#SubsequentEvents"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/SubsequentEvents" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccounts" xlink:type="simple" xlink:href="cpix-20201210.xsd#ValuationandQualifyingAccounts"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccounts" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#ValuationandQualifyingAccountsDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>6
<FILENAME>cpix-20201210_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:bbbd83ec-86cd-4852-a42b-62050b4598f2,g:afd11596-cbdf-45f6-87ac-39eae3274065-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="simple" xlink:href="cpix-20201210.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="extended" id="i53a0fd69a54745369f7ccf8c9c2f4d32_CoverPage"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cpix-20201210.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended" id="i168785f3f44a4977924ec6b27f942208_ConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cpix-20201210.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="i3ba79c551e4e4f98bab957f1256eea3b_ConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss" xlink:type="simple" xlink:href="cpix-20201210.xsd#ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss" xlink:type="extended" id="i73e8d11c66d9400fa47327a215e3bcdc_ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d947b1ce-0586-4dbf-a6e2-d60834f8ad8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_1862e968-a155-4f3f-b926-19d7573d9e11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d947b1ce-0586-4dbf-a6e2-d60834f8ad8e" xlink:to="loc_us-gaap_RevenuesAbstract_1862e968-a155-4f3f-b926-19d7573d9e11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_3ba7602a-990b-4684-9791-e7180e2badb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_1862e968-a155-4f3f-b926-19d7573d9e11" xlink:to="loc_us-gaap_Revenues_3ba7602a-990b-4684-9791-e7180e2badb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_1b8a9dd6-61ef-4b91-9371-9c5029cfb86b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d947b1ce-0586-4dbf-a6e2-d60834f8ad8e" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_1b8a9dd6-61ef-4b91-9371-9c5029cfb86b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_88d578e6-a9db-4297-a32e-d73b5864028b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1b8a9dd6-61ef-4b91-9371-9c5029cfb86b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_88d578e6-a9db-4297-a32e-d73b5864028b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_a6d1bddc-7d4d-4ff7-8cc8-d7b21543a4af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1b8a9dd6-61ef-4b91-9371-9c5029cfb86b" xlink:to="loc_us-gaap_SellingAndMarketingExpense_a6d1bddc-7d4d-4ff7-8cc8-d7b21543a4af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0c124c69-7f93-4ed7-96e0-299cb4df6f42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1b8a9dd6-61ef-4b91-9371-9c5029cfb86b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0c124c69-7f93-4ed7-96e0-299cb4df6f42" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_eeb865cc-ca8d-49e3-96a9-2664d559eeaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1b8a9dd6-61ef-4b91-9371-9c5029cfb86b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_eeb865cc-ca8d-49e3-96a9-2664d559eeaf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_7b710207-b2c6-4d3f-9539-c4487d736f0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1b8a9dd6-61ef-4b91-9371-9c5029cfb86b" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_7b710207-b2c6-4d3f-9539-c4487d736f0a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_eea807ec-0458-4927-9c59-80c340b0f011" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1b8a9dd6-61ef-4b91-9371-9c5029cfb86b" xlink:to="loc_us-gaap_CostsAndExpenses_eea807ec-0458-4927-9c59-80c340b0f011" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e0bfac26-dc30-491b-b0c4-5d7645d2d3d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d947b1ce-0586-4dbf-a6e2-d60834f8ad8e" xlink:to="loc_us-gaap_OperatingIncomeLoss_e0bfac26-dc30-491b-b0c4-5d7645d2d3d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_8559ad6d-a4ae-4b05-a22a-570a603c3bc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d947b1ce-0586-4dbf-a6e2-d60834f8ad8e" xlink:to="loc_us-gaap_InvestmentIncomeInterest_8559ad6d-a4ae-4b05-a22a-570a603c3bc1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_8eb3c555-09d5-48b5-ad57-641510f39a03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d947b1ce-0586-4dbf-a6e2-d60834f8ad8e" xlink:to="loc_us-gaap_InterestExpense_8eb3c555-09d5-48b5-ad57-641510f39a03" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_ffe6bfd9-af1c-4e36-b87b-a0c713a80e5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d947b1ce-0586-4dbf-a6e2-d60834f8ad8e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_ffe6bfd9-af1c-4e36-b87b-a0c713a80e5f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f3ba28d7-a62b-4686-a820-e8c3cc5cc65a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d947b1ce-0586-4dbf-a6e2-d60834f8ad8e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f3ba28d7-a62b-4686-a820-e8c3cc5cc65a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_0d13d9ff-6225-471e-94a4-7d76c17b25f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d947b1ce-0586-4dbf-a6e2-d60834f8ad8e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_0d13d9ff-6225-471e-94a4-7d76c17b25f1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_6eaf669c-d135-4149-ae41-ea1075978825" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d947b1ce-0586-4dbf-a6e2-d60834f8ad8e" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_6eaf669c-d135-4149-ae41-ea1075978825" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_988525f8-2449-4919-975e-da0b287642f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d947b1ce-0586-4dbf-a6e2-d60834f8ad8e" xlink:to="loc_us-gaap_ProfitLoss_988525f8-2449-4919-975e-da0b287642f1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_04689d2e-dba1-49b9-a5eb-349967d6cfe3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d947b1ce-0586-4dbf-a6e2-d60834f8ad8e" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_04689d2e-dba1-49b9-a5eb-349967d6cfe3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_47f54a7e-6326-43c6-a544-4ba01c6d0616" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d947b1ce-0586-4dbf-a6e2-d60834f8ad8e" xlink:to="loc_us-gaap_NetIncomeLoss_47f54a7e-6326-43c6-a544-4ba01c6d0616" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_195e7b48-05a8-4a61-bdd5-9d9db6ccc27b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d947b1ce-0586-4dbf-a6e2-d60834f8ad8e" xlink:to="loc_us-gaap_EarningsPerShareAbstract_195e7b48-05a8-4a61-bdd5-9d9db6ccc27b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_edcfd888-8d93-4b35-a824-8a6a00a11538" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_195e7b48-05a8-4a61-bdd5-9d9db6ccc27b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_edcfd888-8d93-4b35-a824-8a6a00a11538" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_9de292fa-80b7-4b36-9ede-c1c6896c2da2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_195e7b48-05a8-4a61-bdd5-9d9db6ccc27b" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_9de292fa-80b7-4b36-9ede-c1c6896c2da2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_bf14df83-14e2-427a-b010-627391758aa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_195e7b48-05a8-4a61-bdd5-9d9db6ccc27b" xlink:to="loc_us-gaap_EarningsPerShareBasic_bf14df83-14e2-427a-b010-627391758aa8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_87f85db9-561e-48db-93a1-132a6c64c3c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_195e7b48-05a8-4a61-bdd5-9d9db6ccc27b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_87f85db9-561e-48db-93a1-132a6c64c3c7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_233fe259-27f0-420c-ab01-d91d73deaf3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_195e7b48-05a8-4a61-bdd5-9d9db6ccc27b" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_233fe259-27f0-420c-ab01-d91d73deaf3e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_86430432-05e7-46bc-98b8-7acaf8e6d45a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_195e7b48-05a8-4a61-bdd5-9d9db6ccc27b" xlink:to="loc_us-gaap_EarningsPerShareDiluted_86430432-05e7-46bc-98b8-7acaf8e6d45a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f6436475-7e47-45dc-af23-1223908a366e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d947b1ce-0586-4dbf-a6e2-d60834f8ad8e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f6436475-7e47-45dc-af23-1223908a366e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ca53ca5f-d652-40a8-80b8-9152c6ea0f72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f6436475-7e47-45dc-af23-1223908a366e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ca53ca5f-d652-40a8-80b8-9152c6ea0f72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_395b3704-a137-4a69-a8a7-10b57736fb56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f6436475-7e47-45dc-af23-1223908a366e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_395b3704-a137-4a69-a8a7-10b57736fb56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_08c04d51-4ecf-4492-87fa-c519e34deb03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d947b1ce-0586-4dbf-a6e2-d60834f8ad8e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_08c04d51-4ecf-4492-87fa-c519e34deb03" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_069f78af-70a0-4de1-affd-09a96f5517c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d947b1ce-0586-4dbf-a6e2-d60834f8ad8e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_069f78af-70a0-4de1-affd-09a96f5517c3" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_4fe0c86a-7c4a-46ce-9e17-5187236c06bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d947b1ce-0586-4dbf-a6e2-d60834f8ad8e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_4fe0c86a-7c4a-46ce-9e17-5187236c06bd" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6fc3736d-46ea-4f00-bd57-1c97b0b8366f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_d947b1ce-0586-4dbf-a6e2-d60834f8ad8e" xlink:to="loc_us-gaap_StatementTable_6fc3736d-46ea-4f00-bd57-1c97b0b8366f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_00c55c57-6751-4e81-963e-7e2356a43e9f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6fc3736d-46ea-4f00-bd57-1c97b0b8366f" xlink:to="loc_srt_ProductOrServiceAxis_00c55c57-6751-4e81-963e-7e2356a43e9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_00c55c57-6751-4e81-963e-7e2356a43e9f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_00c55c57-6751-4e81-963e-7e2356a43e9f" xlink:to="loc_srt_ProductsAndServicesDomain_00c55c57-6751-4e81-963e-7e2356a43e9f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a4249143-b88f-4236-9dd1-faa324917622" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_00c55c57-6751-4e81-963e-7e2356a43e9f" xlink:to="loc_srt_ProductsAndServicesDomain_a4249143-b88f-4236-9dd1-faa324917622" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_d9233c70-7dc0-4ec7-9e4e-c1b862772576" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a4249143-b88f-4236-9dd1-faa324917622" xlink:to="loc_us-gaap_ProductMember_d9233c70-7dc0-4ec7-9e4e-c1b862772576" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManufacturedProductOtherMember_33be5a92-1809-4133-a712-8809d3edbc1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ManufacturedProductOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a4249143-b88f-4236-9dd1-faa324917622" xlink:to="loc_us-gaap_ManufacturedProductOtherMember_33be5a92-1809-4133-a712-8809d3edbc1c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cpix-20201210.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" id="i3b86f63f628d47a697e6721f2bfb0937_ConsolidatedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="cpix-20201210.xsd#ConsolidatedStatementsofEquity"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity" xlink:type="extended" id="i5908c2db408a401f826017b1ef44e343_ConsolidatedStatementsofEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_63af6ac2-e241-47d4-959c-06c32c3d7d79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7cddd321-56c8-4936-aaf3-038e81731871" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_63af6ac2-e241-47d4-959c-06c32c3d7d79" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7cddd321-56c8-4936-aaf3-038e81731871" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_923fd996-d48e-44b2-855b-2ae598e03fc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7cddd321-56c8-4936-aaf3-038e81731871" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_923fd996-d48e-44b2-855b-2ae598e03fc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_620ff910-fc4f-4f62-9e1a-e423cbdb8dc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7cddd321-56c8-4936-aaf3-038e81731871" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_620ff910-fc4f-4f62-9e1a-e423cbdb8dc5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_17d63b43-d906-49b0-ac17-292a7523f6ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7cddd321-56c8-4936-aaf3-038e81731871" xlink:to="loc_us-gaap_NetIncomeLoss_17d63b43-d906-49b0-ac17-292a7523f6ae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_fb68365b-734c-4b94-8609-e62bd14d0bf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7cddd321-56c8-4936-aaf3-038e81731871" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_fb68365b-734c-4b94-8609-e62bd14d0bf4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_fae2b43e-617c-4a34-b2a9-734d2c1e4602" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7cddd321-56c8-4936-aaf3-038e81731871" xlink:to="loc_us-gaap_ProfitLoss_fae2b43e-617c-4a34-b2a9-734d2c1e4602" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_7bb34141-0e26-45c9-b054-98eff9ada97c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7cddd321-56c8-4936-aaf3-038e81731871" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_7bb34141-0e26-45c9-b054-98eff9ada97c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_be65c6e5-c266-4da2-9bd6-1add547b9e42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7cddd321-56c8-4936-aaf3-038e81731871" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_be65c6e5-c266-4da2-9bd6-1add547b9e42" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_db6faa50-b267-4b29-8cef-345a29a0ef14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7cddd321-56c8-4936-aaf3-038e81731871" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_db6faa50-b267-4b29-8cef-345a29a0ef14" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c6f6af7b-0310-4b35-b052-7b05c805d4b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7cddd321-56c8-4936-aaf3-038e81731871" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c6f6af7b-0310-4b35-b052-7b05c805d4b0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_860f9703-a280-4201-94ac-78ddfe607f2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7cddd321-56c8-4936-aaf3-038e81731871" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_860f9703-a280-4201-94ac-78ddfe607f2c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_ff8c39c0-b73b-4b93-80c5-acef4e89d1b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7cddd321-56c8-4936-aaf3-038e81731871" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_ff8c39c0-b73b-4b93-80c5-acef4e89d1b4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_79b92363-29f9-4c83-b193-fdcdcc0ecaf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7cddd321-56c8-4936-aaf3-038e81731871" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_79b92363-29f9-4c83-b193-fdcdcc0ecaf7" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding_1337493a-487b-4c0d-acaf-40b103962d0f" xlink:href="cpix-20201210.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7cddd321-56c8-4936-aaf3-038e81731871" xlink:to="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding_1337493a-487b-4c0d-acaf-40b103962d0f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c4b5c0a6-5103-4131-9966-3587141d92a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7cddd321-56c8-4936-aaf3-038e81731871" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c4b5c0a6-5103-4131-9966-3587141d92a0" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3d5fc763-cac6-473b-be03-e3c2a2e21b90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7cddd321-56c8-4936-aaf3-038e81731871" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3d5fc763-cac6-473b-be03-e3c2a2e21b90" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_4336ecf0-f48c-442e-9c5c-eac8f2adb50f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7cddd321-56c8-4936-aaf3-038e81731871" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_4336ecf0-f48c-442e-9c5c-eac8f2adb50f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_b4f243a4-2f7e-42d4-b766-d9875fea98b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7cddd321-56c8-4936-aaf3-038e81731871" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_b4f243a4-2f7e-42d4-b766-d9875fea98b4" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3466d39a-9884-4444-a6e8-a71a72e6aa49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_312135b4-3c18-4bfb-aab0-88b47d3000bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cf971610-c906-405e-a18c-b5bd45164f0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_63af6ac2-e241-47d4-959c-06c32c3d7d79" xlink:to="loc_us-gaap_StatementTable_cf971610-c906-405e-a18c-b5bd45164f0a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9bef24fa-4d6b-44b3-acf0-a2a09a8de7a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cf971610-c906-405e-a18c-b5bd45164f0a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9bef24fa-4d6b-44b3-acf0-a2a09a8de7a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9bef24fa-4d6b-44b3-acf0-a2a09a8de7a7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9bef24fa-4d6b-44b3-acf0-a2a09a8de7a7" xlink:to="loc_us-gaap_EquityComponentDomain_9bef24fa-4d6b-44b3-acf0-a2a09a8de7a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f382cf62-55cd-48f9-93e5-5815790484dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9bef24fa-4d6b-44b3-acf0-a2a09a8de7a7" xlink:to="loc_us-gaap_EquityComponentDomain_f382cf62-55cd-48f9-93e5-5815790484dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_937bd501-bec5-4a8e-86a0-6de211d9899e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f382cf62-55cd-48f9-93e5-5815790484dc" xlink:to="loc_us-gaap_CommonStockMember_937bd501-bec5-4a8e-86a0-6de211d9899e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_6d65d511-2029-4ea1-9ed3-2bc8907e9557" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f382cf62-55cd-48f9-93e5-5815790484dc" xlink:to="loc_us-gaap_RetainedEarningsMember_6d65d511-2029-4ea1-9ed3-2bc8907e9557" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_2e77b5c9-bd99-4a8d-a7d9-59680388aed2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f382cf62-55cd-48f9-93e5-5815790484dc" xlink:to="loc_us-gaap_NoncontrollingInterestMember_2e77b5c9-bd99-4a8d-a7d9-59680388aed2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_41b54c43-935b-47d4-b15a-1885d79e8647" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cf971610-c906-405e-a18c-b5bd45164f0a" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_41b54c43-935b-47d4-b15a-1885d79e8647" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_41b54c43-935b-47d4-b15a-1885d79e8647_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_41b54c43-935b-47d4-b15a-1885d79e8647" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_41b54c43-935b-47d4-b15a-1885d79e8647_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e9c9b887-bf56-4ed4-abf2-ac93e0b33541" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_41b54c43-935b-47d4-b15a-1885d79e8647" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e9c9b887-bf56-4ed4-abf2-ac93e0b33541" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_ddc2846d-eebf-483b-a4e3-c96fb8e837c5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e9c9b887-bf56-4ed4-abf2-ac93e0b33541" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_ddc2846d-eebf-483b-a4e3-c96fb8e837c5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Organization" xlink:type="simple" xlink:href="cpix-20201210.xsd#Organization"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/Organization" xlink:type="extended" id="i36bb337e580847bb92fdb338f587b50c_Organization"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#OrganizationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails" xlink:type="extended" id="i9e376e678ac849aaa1d52edc9f0183c8_OrganizationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_08ce7077-dc05-4595-a6b9-6885df2f5495" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_3dd6a9cb-f465-4fd8-bfd9-de5f5c36a85c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_08ce7077-dc05-4595-a6b9-6885df2f5495" xlink:to="loc_us-gaap_NoncontrollingInterestAbstract_3dd6a9cb-f465-4fd8-bfd9-de5f5c36a85c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_79c60a4f-8d77-4b6c-acb8-706e6d52a3d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_3dd6a9cb-f465-4fd8-bfd9-de5f5c36a85c" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_79c60a4f-8d77-4b6c-acb8-706e6d52a3d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPurchaseOfShares_9d39f625-45cf-48af-9294-1e1c24b1e021" xlink:href="cpix-20201210.xsd#cpix_SubsidiaryInvestmentPurchaseOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_3dd6a9cb-f465-4fd8-bfd9-de5f5c36a85c" xlink:to="loc_cpix_SubsidiaryInvestmentPurchaseOfShares_9d39f625-45cf-48af-9294-1e1c24b1e021" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ContributionOfCashAdditionalSharesPurchased_504729e1-2583-4862-bea2-49790bf35b83" xlink:href="cpix-20201210.xsd#cpix_ContributionOfCashAdditionalSharesPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_3dd6a9cb-f465-4fd8-bfd9-de5f5c36a85c" xlink:to="loc_cpix_ContributionOfCashAdditionalSharesPurchased_504729e1-2583-4862-bea2-49790bf35b83" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IntercompanyLoansPayableConvertedAmount_0a735b18-84d9-41bc-936a-b15f69f4a60c" xlink:href="cpix-20201210.xsd#cpix_IntercompanyLoansPayableConvertedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_3dd6a9cb-f465-4fd8-bfd9-de5f5c36a85c" xlink:to="loc_cpix_IntercompanyLoansPayableConvertedAmount_0a735b18-84d9-41bc-936a-b15f69f4a60c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_fcac81a7-1151-4fbb-a899-6094c8a8bc9f" xlink:href="cpix-20201210.xsd#cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_3dd6a9cb-f465-4fd8-bfd9-de5f5c36a85c" xlink:to="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_fcac81a7-1151-4fbb-a899-6094c8a8bc9f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_3e633288-f898-441c-9f66-6ecc826e8511" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_3dd6a9cb-f465-4fd8-bfd9-de5f5c36a85c" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_3e633288-f898-441c-9f66-6ecc826e8511" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_413c6789-9894-4940-ab06-7e8e11668fae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_3dd6a9cb-f465-4fd8-bfd9-de5f5c36a85c" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_413c6789-9894-4940-ab06-7e8e11668fae" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_7245fcae-e0df-4934-afca-fadf2fef9ae8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_08ce7077-dc05-4595-a6b9-6885df2f5495" xlink:to="loc_dei_EntitiesTable_7245fcae-e0df-4934-afca-fadf2fef9ae8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_3bf62b1a-a94e-4a81-bccf-13cadd4a742a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_7245fcae-e0df-4934-afca-fadf2fef9ae8" xlink:to="loc_dei_LegalEntityAxis_3bf62b1a-a94e-4a81-bccf-13cadd4a742a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_3bf62b1a-a94e-4a81-bccf-13cadd4a742a_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_3bf62b1a-a94e-4a81-bccf-13cadd4a742a" xlink:to="loc_dei_EntityDomain_3bf62b1a-a94e-4a81-bccf-13cadd4a742a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_42c61558-a9da-4995-8a2a-9bdafaf1e90a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_3bf62b1a-a94e-4a81-bccf-13cadd4a742a" xlink:to="loc_dei_EntityDomain_42c61558-a9da-4995-8a2a-9bdafaf1e90a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CumberlandEmergingTechnologiesIncMember_8094ef38-c8de-43f0-bdb9-9b8a9024d42b" xlink:href="cpix-20201210.xsd#cpix_CumberlandEmergingTechnologiesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_42c61558-a9da-4995-8a2a-9bdafaf1e90a" xlink:to="loc_cpix_CumberlandEmergingTechnologiesIncMember_8094ef38-c8de-43f0-bdb9-9b8a9024d42b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5c04fef7-4a7a-4158-af6a-90e5350970b4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_7245fcae-e0df-4934-afca-fadf2fef9ae8" xlink:to="loc_srt_CounterpartyNameAxis_5c04fef7-4a7a-4158-af6a-90e5350970b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5c04fef7-4a7a-4158-af6a-90e5350970b4_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_5c04fef7-4a7a-4158-af6a-90e5350970b4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5c04fef7-4a7a-4158-af6a-90e5350970b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_38753fa9-ee94-45b7-8bfd-08b681ca69ee" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_5c04fef7-4a7a-4158-af6a-90e5350970b4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_38753fa9-ee94-45b7-8bfd-08b681ca69ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HarbinGloriaPharmaceuticalsCoMember_adba9232-9772-41b7-9203-1b8fd73bec7d" xlink:href="cpix-20201210.xsd#cpix_HarbinGloriaPharmaceuticalsCoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_38753fa9-ee94-45b7-8bfd-08b681ca69ee" xlink:to="loc_cpix_HarbinGloriaPharmaceuticalsCoMember_adba9232-9772-41b7-9203-1b8fd73bec7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_fbd7c86e-ee4e-4f6b-ab01-5f6556881ab4" xlink:href="cpix-20201210.xsd#cpix_HongKongWinHealthPharmaGroupCoLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_38753fa9-ee94-45b7-8bfd-08b681ca69ee" xlink:to="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_fbd7c86e-ee4e-4f6b-ab01-5f6556881ab4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_GloriaPharmaceuticalsMember_ee81ae9d-d2e0-47af-b00c-3181228357c8" xlink:href="cpix-20201210.xsd#cpix_GloriaPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_38753fa9-ee94-45b7-8bfd-08b681ca69ee" xlink:to="loc_cpix_GloriaPharmaceuticalsMember_ee81ae9d-d2e0-47af-b00c-3181228357c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_5bbd76ab-4616-4900-8ca0-a74d16cf9fb0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_7245fcae-e0df-4934-afca-fadf2fef9ae8" xlink:to="loc_srt_OwnershipAxis_5bbd76ab-4616-4900-8ca0-a74d16cf9fb0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_5bbd76ab-4616-4900-8ca0-a74d16cf9fb0_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_5bbd76ab-4616-4900-8ca0-a74d16cf9fb0" xlink:to="loc_srt_OwnershipDomain_5bbd76ab-4616-4900-8ca0-a74d16cf9fb0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_d1fc2d48-a723-467f-a213-ea66dc89ae68" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_5bbd76ab-4616-4900-8ca0-a74d16cf9fb0" xlink:to="loc_srt_OwnershipDomain_d1fc2d48-a723-467f-a213-ea66dc89ae68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CumberlandEmergingTechnologiesIncMember_f36e4d18-1fe9-4557-b708-431fc9e1a8e4" xlink:href="cpix-20201210.xsd#cpix_CumberlandEmergingTechnologiesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_d1fc2d48-a723-467f-a213-ea66dc89ae68" xlink:to="loc_cpix_CumberlandEmergingTechnologiesIncMember_f36e4d18-1fe9-4557-b708-431fc9e1a8e4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPolicies" xlink:type="simple" xlink:href="cpix-20201210.xsd#SignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPolicies" xlink:type="extended" id="if737e9f464f94a6bb989ba678afc6a63_SignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="cpix-20201210.xsd#SignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended" id="i5b460565e49649bb9fb11b95ecbcc7c3_SignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#SignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables" xlink:type="extended" id="i7681a4d168ea4530bb53891307195280_SignificantAccountingPoliciesTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#SignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="i6aa0d67ed7f448b887a1fb5e208cbca8_SignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_01c11c27-b2ad-4741-938c-e5408187b00f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_0e2a9aaa-d860-451a-8309-b0274647b8a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_01c11c27-b2ad-4741-938c-e5408187b00f" xlink:to="loc_us-gaap_SegmentReportingAbstract_0e2a9aaa-d860-451a-8309-b0274647b8a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_bf0bc2b2-8bb0-49ca-8000-143eb44a4f67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAbstract_0e2a9aaa-d860-451a-8309-b0274647b8a2" xlink:to="loc_us-gaap_NumberOfOperatingSegments_bf0bc2b2-8bb0-49ca-8000-143eb44a4f67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_597208b5-2682-4834-8543-42526f9547cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAbstract_0e2a9aaa-d860-451a-8309-b0274647b8a2" xlink:to="loc_us-gaap_Revenues_597208b5-2682-4834-8543-42526f9547cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_dab62058-eec2-43a5-a046-b4dc3cfdc7be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAbstract_0e2a9aaa-d860-451a-8309-b0274647b8a2" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_dab62058-eec2-43a5-a046-b4dc3cfdc7be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ec310439-5b62-4e4a-a2a3-9259e48391d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAbstract_0e2a9aaa-d860-451a-8309-b0274647b8a2" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ec310439-5b62-4e4a-a2a3-9259e48391d8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f214a6ca-942a-488f-9047-805e53082209" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAbstract_0e2a9aaa-d860-451a-8309-b0274647b8a2" xlink:to="loc_us-gaap_OperatingLeaseLiability_f214a6ca-942a-488f-9047-805e53082209" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductionAndDistributionCosts_38020a48-5de4-47ea-8c65-f37896adc896" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductionAndDistributionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_01c11c27-b2ad-4741-938c-e5408187b00f" xlink:to="loc_us-gaap_ProductionAndDistributionCosts_38020a48-5de4-47ea-8c65-f37896adc896" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_6cdb717e-e71f-4a94-b46c-dcd6a33631c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_01c11c27-b2ad-4741-938c-e5408187b00f" xlink:to="loc_us-gaap_AdvertisingExpense_6cdb717e-e71f-4a94-b46c-dcd6a33631c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_65bc9168-f6f6-403c-9695-e93b4dd15250" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_01c11c27-b2ad-4741-938c-e5408187b00f" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_65bc9168-f6f6-403c-9695-e93b4dd15250" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_71ce79f4-062c-44b0-a35d-48b8bc4ad983" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_65bc9168-f6f6-403c-9695-e93b4dd15250" xlink:to="loc_srt_StatementGeographicalAxis_71ce79f4-062c-44b0-a35d-48b8bc4ad983" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_71ce79f4-062c-44b0-a35d-48b8bc4ad983_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_71ce79f4-062c-44b0-a35d-48b8bc4ad983" xlink:to="loc_srt_SegmentGeographicalDomain_71ce79f4-062c-44b0-a35d-48b8bc4ad983_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e8d2e148-ca8a-46c1-baf6-f6f8264ace06" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_71ce79f4-062c-44b0-a35d-48b8bc4ad983" xlink:to="loc_srt_SegmentGeographicalDomain_e8d2e148-ca8a-46c1-baf6-f6f8264ace06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_2cdd9dfc-0487-4eb9-84ba-bb54e8f8eeb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e8d2e148-ca8a-46c1-baf6-f6f8264ace06" xlink:to="loc_us-gaap_NonUsMember_2cdd9dfc-0487-4eb9-84ba-bb54e8f8eeb6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b1242fbc-4356-4f90-9777-0532d8fb0620" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_65bc9168-f6f6-403c-9695-e93b4dd15250" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b1242fbc-4356-4f90-9777-0532d8fb0620" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b1242fbc-4356-4f90-9777-0532d8fb0620_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b1242fbc-4356-4f90-9777-0532d8fb0620" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b1242fbc-4356-4f90-9777-0532d8fb0620_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fc7467b2-0019-4263-b7e2-b87851ead471" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b1242fbc-4356-4f90-9777-0532d8fb0620" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fc7467b2-0019-4263-b7e2-b87851ead471" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_1bbea756-ee96-4d2f-a583-394ee3c1a601" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_fc7467b2-0019-4263-b7e2-b87851ead471" xlink:to="loc_us-gaap_SubsequentEventMember_1bbea756-ee96-4d2f-a583-394ee3c1a601" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9c742c62-c775-427c-8192-481ec23d8ae0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_65bc9168-f6f6-403c-9695-e93b4dd15250" xlink:to="loc_srt_RangeAxis_9c742c62-c775-427c-8192-481ec23d8ae0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9c742c62-c775-427c-8192-481ec23d8ae0_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9c742c62-c775-427c-8192-481ec23d8ae0" xlink:to="loc_srt_RangeMember_9c742c62-c775-427c-8192-481ec23d8ae0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8a9a487e-8f2a-40f7-99cb-fd9bcef1815e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9c742c62-c775-427c-8192-481ec23d8ae0" xlink:to="loc_srt_RangeMember_8a9a487e-8f2a-40f7-99cb-fd9bcef1815e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5abde195-9b9f-42cc-9413-2b12f8017145" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8a9a487e-8f2a-40f7-99cb-fd9bcef1815e" xlink:to="loc_srt_MinimumMember_5abde195-9b9f-42cc-9413-2b12f8017145" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_610c9af3-208b-40b0-9080-73fe27282ef2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8a9a487e-8f2a-40f7-99cb-fd9bcef1815e" xlink:to="loc_srt_MaximumMember_610c9af3-208b-40b0-9080-73fe27282ef2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccountsReceivableAllowancesByComponentAxis_684c2ea9-1e9e-4aea-9176-c5df75663d0c" xlink:href="cpix-20201210.xsd#cpix_AccountsReceivableAllowancesByComponentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_65bc9168-f6f6-403c-9695-e93b4dd15250" xlink:to="loc_cpix_AccountsReceivableAllowancesByComponentAxis_684c2ea9-1e9e-4aea-9176-c5df75663d0c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccountsReceivableAllowancesByComponentDomain_684c2ea9-1e9e-4aea-9176-c5df75663d0c_default" xlink:href="cpix-20201210.xsd#cpix_AccountsReceivableAllowancesByComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cpix_AccountsReceivableAllowancesByComponentAxis_684c2ea9-1e9e-4aea-9176-c5df75663d0c" xlink:to="loc_cpix_AccountsReceivableAllowancesByComponentDomain_684c2ea9-1e9e-4aea-9176-c5df75663d0c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccountsReceivableAllowancesByComponentDomain_45f524d4-745e-49cc-b9b8-73eb46791e1d" xlink:href="cpix-20201210.xsd#cpix_AccountsReceivableAllowancesByComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cpix_AccountsReceivableAllowancesByComponentAxis_684c2ea9-1e9e-4aea-9176-c5df75663d0c" xlink:to="loc_cpix_AccountsReceivableAllowancesByComponentDomain_45f524d4-745e-49cc-b9b8-73eb46791e1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember_7626af12-60cf-4c9b-8077-75d22ace4420" xlink:href="cpix-20201210.xsd#cpix_ChargebacksCashDiscountsAndDamagedGoodsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_AccountsReceivableAllowancesByComponentDomain_45f524d4-745e-49cc-b9b8-73eb46791e1d" xlink:to="loc_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember_7626af12-60cf-4c9b-8077-75d22ace4420" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails" xlink:type="extended" id="ie44fcd2c83a44672a6bf806540142760_SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cf11c9e2-f445-4609-86e8-3ca85e9e8509" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual_82e4fe9b-4fc0-4880-9809-a24b43e4b669" xlink:href="cpix-20201210.xsd#cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cf11c9e2-f445-4609-86e8-3ca85e9e8509" xlink:to="loc_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual_82e4fe9b-4fc0-4880-9809-a24b43e4b669" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_27dc47bf-3510-45d6-96c6-fd14d4a25874" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cf11c9e2-f445-4609-86e8-3ca85e9e8509" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_27dc47bf-3510-45d6-96c6-fd14d4a25874" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1b714a41-3252-4fc6-98ec-321548d68d56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_27dc47bf-3510-45d6-96c6-fd14d4a25874" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1b714a41-3252-4fc6-98ec-321548d68d56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1b714a41-3252-4fc6-98ec-321548d68d56_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1b714a41-3252-4fc6-98ec-321548d68d56" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1b714a41-3252-4fc6-98ec-321548d68d56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce5755f2-bda8-48c0-b6f5-7b71cce4dfb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1b714a41-3252-4fc6-98ec-321548d68d56" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce5755f2-bda8-48c0-b6f5-7b71cce4dfb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductRightsMember_67b0a4c9-7331-4885-a9c0-88acc66817c8" xlink:href="cpix-20201210.xsd#cpix_ProductRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce5755f2-bda8-48c0-b6f5-7b71cce4dfb3" xlink:to="loc_cpix_ProductRightsMember_67b0a4c9-7331-4885-a9c0-88acc66817c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_7cc511df-c5ed-4975-a65c-ecc4655f71cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce5755f2-bda8-48c0-b6f5-7b71cce4dfb3" xlink:to="loc_us-gaap_LicensingAgreementsMember_7cc511df-c5ed-4975-a65c-ecc4655f71cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_2619d4e1-b4d3-46e8-b2a2-f535ddea1b6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce5755f2-bda8-48c0-b6f5-7b71cce4dfb3" xlink:to="loc_us-gaap_PatentsMember_2619d4e1-b4d3-46e8-b2a2-f535ddea1b6c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativ" xlink:type="simple" xlink:href="cpix-20201210.xsd#OmeclamoxPakRediTrexandVibativ"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativ" xlink:type="extended" id="i4fb086912daa4fe1934594b68428dcbc_OmeclamoxPakRediTrexandVibativ"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#OmeclamoxPakRediTrexandVibativTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativTables" xlink:type="extended" id="ib5d1b91977e24ffabca3aae176ebc1ac_OmeclamoxPakRediTrexandVibativTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#OmeclamoxPakRediTrexandVibativNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails" xlink:type="extended" id="i36cde0bb370543568239f1ca88d1c44d_OmeclamoxPakRediTrexandVibativNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_fa901419-fc66-483e-b263-6bae6681c75f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsForAssetAcquisitions_4301a8a1-6a2e-49f7-a9c7-52431b289ff5" xlink:href="cpix-20201210.xsd#cpix_PaymentsForAssetAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fa901419-fc66-483e-b263-6bae6681c75f" xlink:to="loc_cpix_PaymentsForAssetAcquisitions_4301a8a1-6a2e-49f7-a9c7-52431b289ff5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_56107d30-0ccd-40c6-86fe-1d8de5deec2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fa901419-fc66-483e-b263-6bae6681c75f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_56107d30-0ccd-40c6-86fe-1d8de5deec2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales_82ff4e75-9543-48bf-9cf2-a348ad72a0ae" xlink:href="cpix-20201210.xsd#cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fa901419-fc66-483e-b263-6bae6681c75f" xlink:to="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales_82ff4e75-9543-48bf-9cf2-a348ad72a0ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_17166d04-4e7e-43bd-8246-defe167af6a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fa901419-fc66-483e-b263-6bae6681c75f" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_17166d04-4e7e-43bd-8246-defe167af6a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_e5bff230-cb38-46dd-9efd-e37f5f62327b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fa901419-fc66-483e-b263-6bae6681c75f" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_e5bff230-cb38-46dd-9efd-e37f5f62327b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_9ac93fb9-d8ee-4f54-a0b1-ccc0ef31451b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fa901419-fc66-483e-b263-6bae6681c75f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_9ac93fb9-d8ee-4f54-a0b1-ccc0ef31451b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_37f1d802-1f4e-4efb-9d49-9b1dc8ba8f7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fa901419-fc66-483e-b263-6bae6681c75f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_37f1d802-1f4e-4efb-9d49-9b1dc8ba8f7c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b85d1108-2036-4c41-9ee0-4efbe35b735a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fa901419-fc66-483e-b263-6bae6681c75f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b85d1108-2036-4c41-9ee0-4efbe35b735a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2dfc8d6c-e5f3-4a70-81dc-9fe3630932f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fa901419-fc66-483e-b263-6bae6681c75f" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2dfc8d6c-e5f3-4a70-81dc-9fe3630932f8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2c5ab1a3-32e9-43da-b017-fc13adf80742" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2dfc8d6c-e5f3-4a70-81dc-9fe3630932f8" xlink:to="loc_us-gaap_AwardTypeAxis_2c5ab1a3-32e9-43da-b017-fc13adf80742" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2c5ab1a3-32e9-43da-b017-fc13adf80742_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2c5ab1a3-32e9-43da-b017-fc13adf80742" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2c5ab1a3-32e9-43da-b017-fc13adf80742_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_824809c9-137a-41d5-a7b9-fc81472b6f41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2c5ab1a3-32e9-43da-b017-fc13adf80742" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_824809c9-137a-41d5-a7b9-fc81472b6f41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_4c8d51cf-9030-4f7e-a4d8-91a80ec6b459" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_824809c9-137a-41d5-a7b9-fc81472b6f41" xlink:to="loc_us-gaap_RestrictedStockMember_4c8d51cf-9030-4f7e-a4d8-91a80ec6b459" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6c105dfe-cce8-4fa0-9307-e1c28d6322cf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2dfc8d6c-e5f3-4a70-81dc-9fe3630932f8" xlink:to="loc_srt_ProductOrServiceAxis_6c105dfe-cce8-4fa0-9307-e1c28d6322cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6c105dfe-cce8-4fa0-9307-e1c28d6322cf_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_6c105dfe-cce8-4fa0-9307-e1c28d6322cf" xlink:to="loc_srt_ProductsAndServicesDomain_6c105dfe-cce8-4fa0-9307-e1c28d6322cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7f0346b7-b879-435e-b46d-a007611a12e0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_6c105dfe-cce8-4fa0-9307-e1c28d6322cf" xlink:to="loc_srt_ProductsAndServicesDomain_7f0346b7-b879-435e-b46d-a007611a12e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember_6ecf4f72-cdd6-434f-b8a8-3ee52a95094e" xlink:href="cpix-20201210.xsd#cpix_OmeclamoxPakMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7f0346b7-b879-435e-b46d-a007611a12e0" xlink:to="loc_cpix_OmeclamoxPakMember_6ecf4f72-cdd6-434f-b8a8-3ee52a95094e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_916db95d-8da2-4ee4-9441-4e6524c080ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2dfc8d6c-e5f3-4a70-81dc-9fe3630932f8" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_916db95d-8da2-4ee4-9441-4e6524c080ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_916db95d-8da2-4ee4-9441-4e6524c080ac_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_916db95d-8da2-4ee4-9441-4e6524c080ac" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_916db95d-8da2-4ee4-9441-4e6524c080ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_217aa544-b1a6-41e8-b703-3b34773d58f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_916db95d-8da2-4ee4-9441-4e6524c080ac" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_217aa544-b1a6-41e8-b703-3b34773d58f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember_d8a20cb9-1851-47a7-882d-ac91d46ddddd" xlink:href="cpix-20201210.xsd#cpix_OmeclamoxPakMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_217aa544-b1a6-41e8-b703-3b34773d58f0" xlink:to="loc_cpix_OmeclamoxPakMember_d8a20cb9-1851-47a7-882d-ac91d46ddddd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MethotrexateMember_f22e1ac0-7c21-40ca-97a3-4602bcc7305c" xlink:href="cpix-20201210.xsd#cpix_MethotrexateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_217aa544-b1a6-41e8-b703-3b34773d58f0" xlink:to="loc_cpix_MethotrexateMember_f22e1ac0-7c21-40ca-97a3-4602bcc7305c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e444be84-05cc-42fc-8bbf-1a93570657c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2dfc8d6c-e5f3-4a70-81dc-9fe3630932f8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e444be84-05cc-42fc-8bbf-1a93570657c8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e444be84-05cc-42fc-8bbf-1a93570657c8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e444be84-05cc-42fc-8bbf-1a93570657c8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e444be84-05cc-42fc-8bbf-1a93570657c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76bcd7d7-a578-42bb-ba08-21ac87276682" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e444be84-05cc-42fc-8bbf-1a93570657c8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76bcd7d7-a578-42bb-ba08-21ac87276682" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AmendedInternationalAgreementMember_77d7c31a-1c87-46ff-a0a5-8c6629c9a747" xlink:href="cpix-20201210.xsd#cpix_AmendedInternationalAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76bcd7d7-a578-42bb-ba08-21ac87276682" xlink:to="loc_cpix_AmendedInternationalAgreementMember_77d7c31a-1c87-46ff-a0a5-8c6629c9a747" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_ee98043a-e37d-46f6-a209-37ba419b5064" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2dfc8d6c-e5f3-4a70-81dc-9fe3630932f8" xlink:to="loc_dei_LegalEntityAxis_ee98043a-e37d-46f6-a209-37ba419b5064" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ee98043a-e37d-46f6-a209-37ba419b5064_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_ee98043a-e37d-46f6-a209-37ba419b5064" xlink:to="loc_dei_EntityDomain_ee98043a-e37d-46f6-a209-37ba419b5064_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ad26a27e-d61a-4c38-bf19-2d896d5f0a2c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_ee98043a-e37d-46f6-a209-37ba419b5064" xlink:to="loc_dei_EntityDomain_ad26a27e-d61a-4c38-bf19-2d896d5f0a2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PernixTherapeuticsMember_14d902bf-2dd1-48b4-b091-20d6cc07bef9" xlink:href="cpix-20201210.xsd#cpix_PernixTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_ad26a27e-d61a-4c38-bf19-2d896d5f0a2c" xlink:to="loc_cpix_PernixTherapeuticsMember_14d902bf-2dd1-48b4-b091-20d6cc07bef9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d1917fc7-d40e-432d-9056-600be860a2a1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2dfc8d6c-e5f3-4a70-81dc-9fe3630932f8" xlink:to="loc_srt_RangeAxis_d1917fc7-d40e-432d-9056-600be860a2a1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d1917fc7-d40e-432d-9056-600be860a2a1_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d1917fc7-d40e-432d-9056-600be860a2a1" xlink:to="loc_srt_RangeMember_d1917fc7-d40e-432d-9056-600be860a2a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_155a2c31-01d7-4ebf-ad14-374916c75f3e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d1917fc7-d40e-432d-9056-600be860a2a1" xlink:to="loc_srt_RangeMember_155a2c31-01d7-4ebf-ad14-374916c75f3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0d751846-7b3d-40e8-ba9d-611649bb77b8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_155a2c31-01d7-4ebf-ad14-374916c75f3e" xlink:to="loc_srt_MinimumMember_0d751846-7b3d-40e8-ba9d-611649bb77b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6487d7f0-8d84-4a6b-b8c9-9424ab5656a4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_155a2c31-01d7-4ebf-ad14-374916c75f3e" xlink:to="loc_srt_MaximumMember_6487d7f0-8d84-4a6b-b8c9-9424ab5656a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5e9e248f-f3c4-4087-b04c-8f1734db8c75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2dfc8d6c-e5f3-4a70-81dc-9fe3630932f8" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5e9e248f-f3c4-4087-b04c-8f1734db8c75" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_5e9e248f-f3c4-4087-b04c-8f1734db8c75_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5e9e248f-f3c4-4087-b04c-8f1734db8c75" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_5e9e248f-f3c4-4087-b04c-8f1734db8c75_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1865f0d0-b440-4f68-aa80-75c90096eb2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5e9e248f-f3c4-4087-b04c-8f1734db8c75" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1865f0d0-b440-4f68-aa80-75c90096eb2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_debb29a5-7ee8-4536-bd52-5b814e238615" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1865f0d0-b440-4f68-aa80-75c90096eb2a" xlink:to="loc_us-gaap_SubsequentEventMember_debb29a5-7ee8-4536-bd52-5b814e238615" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#OmeclamoxPakRediTrexandVibativVibativAcquisitionNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionNarrativeDetails" xlink:type="extended" id="id39b6ca26076478897c5aff8342a754f_OmeclamoxPakRediTrexandVibativVibativAcquisitionNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7fd84ac2-033e-4938-a22a-176db2deac20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_d3b140ed-f572-46e5-b259-8a1ce25a6b05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7fd84ac2-033e-4938-a22a-176db2deac20" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_d3b140ed-f572-46e5-b259-8a1ce25a6b05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_eb4cf732-d6eb-430b-9f77-9068c9b254f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7fd84ac2-033e-4938-a22a-176db2deac20" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_eb4cf732-d6eb-430b-9f77-9068c9b254f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsPercentage_bb3266b5-48db-41fe-85bd-ce88f80fb6dc" xlink:href="cpix-20201210.xsd#cpix_TieredRoyaltyPaymentsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7fd84ac2-033e-4938-a22a-176db2deac20" xlink:to="loc_cpix_TieredRoyaltyPaymentsPercentage_bb3266b5-48db-41fe-85bd-ce88f80fb6dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_f1f83929-98f3-425d-aa0f-1dfd9356bcc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7fd84ac2-033e-4938-a22a-176db2deac20" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_f1f83929-98f3-425d-aa0f-1dfd9356bcc9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_25026630-292b-4e27-8b7e-270b3e0bf999" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7fd84ac2-033e-4938-a22a-176db2deac20" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_25026630-292b-4e27-8b7e-270b3e0bf999" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b7d89e13-bc7b-4c98-a6e8-7415829403d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7fd84ac2-033e-4938-a22a-176db2deac20" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b7d89e13-bc7b-4c98-a6e8-7415829403d5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_63016a6f-31d2-40b1-858d-2e03be38e3b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b7d89e13-bc7b-4c98-a6e8-7415829403d5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_63016a6f-31d2-40b1-858d-2e03be38e3b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_63016a6f-31d2-40b1-858d-2e03be38e3b9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_63016a6f-31d2-40b1-858d-2e03be38e3b9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_63016a6f-31d2-40b1-858d-2e03be38e3b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dbc03579-fa8d-4145-9a76-a02028183c40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_63016a6f-31d2-40b1-858d-2e03be38e3b9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dbc03579-fa8d-4145-9a76-a02028183c40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_08f797ce-0dd3-4426-9775-65badb7a749c" xlink:href="cpix-20201210.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dbc03579-fa8d-4145-9a76-a02028183c40" xlink:to="loc_cpix_VIBATIVMember_08f797ce-0dd3-4426-9775-65badb7a749c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1627a8bc-1d64-4715-b4fb-9c548637f692" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b7d89e13-bc7b-4c98-a6e8-7415829403d5" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1627a8bc-1d64-4715-b4fb-9c548637f692" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1627a8bc-1d64-4715-b4fb-9c548637f692_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1627a8bc-1d64-4715-b4fb-9c548637f692" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1627a8bc-1d64-4715-b4fb-9c548637f692_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d1e8fb48-1859-4d89-8c43-2e938b8feb8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1627a8bc-1d64-4715-b4fb-9c548637f692" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d1e8fb48-1859-4d89-8c43-2e938b8feb8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_beef6e29-5b84-4bbc-9cf2-6a864bee4007" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d1e8fb48-1859-4d89-8c43-2e938b8feb8b" xlink:to="loc_us-gaap_SubsequentEventMember_beef6e29-5b84-4bbc-9cf2-6a864bee4007" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails" xlink:type="extended" id="i8bc549bb568d4b1b8a96ae9274441a4d_OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_94f69c2d-76df-4850-b6d2-0fa17a94c018" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_446f23c1-dbba-489d-80e6-a3ffcd8fce4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_94f69c2d-76df-4850-b6d2-0fa17a94c018" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_446f23c1-dbba-489d-80e6-a3ffcd8fce4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_621dfb37-fefb-457a-a53e-411e9ffebc3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_94f69c2d-76df-4850-b6d2-0fa17a94c018" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_621dfb37-fefb-457a-a53e-411e9ffebc3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsForContingentConsideration_797a8fcb-b1ee-4ba6-b8fa-25601de2d742" xlink:href="cpix-20201210.xsd#cpix_PaymentsForContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_94f69c2d-76df-4850-b6d2-0fa17a94c018" xlink:to="loc_cpix_PaymentsForContingentConsideration_797a8fcb-b1ee-4ba6-b8fa-25601de2d742" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_bcc3c3aa-13aa-4f76-b082-e67437c1c019" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_94f69c2d-76df-4850-b6d2-0fa17a94c018" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_bcc3c3aa-13aa-4f76-b082-e67437c1c019" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ChangeInContingentConsiderationHeadingRollForward_2e428767-8b75-4ee2-9fe1-6a68f4cab0bd" xlink:href="cpix-20201210.xsd#cpix_ChangeInContingentConsiderationHeadingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_94f69c2d-76df-4850-b6d2-0fa17a94c018" xlink:to="loc_cpix_ChangeInContingentConsiderationHeadingRollForward_2e428767-8b75-4ee2-9fe1-6a68f4cab0bd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3b6e03ad-bab2-4e64-9231-e3b123db9ae3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ChangeInContingentConsiderationHeadingRollForward_2e428767-8b75-4ee2-9fe1-6a68f4cab0bd" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3b6e03ad-bab2-4e64-9231-e3b123db9ae3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_9890610e-df6a-4e89-bc6b-a3cb01579886" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ChangeInContingentConsiderationHeadingRollForward_2e428767-8b75-4ee2-9fe1-6a68f4cab0bd" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_9890610e-df6a-4e89-bc6b-a3cb01579886" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_0e7f3ee4-20f6-468a-b81f-4800cc00b41f" xlink:href="cpix-20201210.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ChangeInContingentConsiderationHeadingRollForward_2e428767-8b75-4ee2-9fe1-6a68f4cab0bd" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_0e7f3ee4-20f6-468a-b81f-4800cc00b41f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment_231ec1aa-8259-4d1c-ad80-39d189b284b2" xlink:href="cpix-20201210.xsd#cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ChangeInContingentConsiderationHeadingRollForward_2e428767-8b75-4ee2-9fe1-6a68f4cab0bd" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment_231ec1aa-8259-4d1c-ad80-39d189b284b2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_76c17d6f-c10d-48d6-a988-90009a3d8111" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ChangeInContingentConsiderationHeadingRollForward_2e428767-8b75-4ee2-9fe1-6a68f4cab0bd" xlink:to="loc_us-gaap_PaymentsForRoyalties_76c17d6f-c10d-48d6-a988-90009a3d8111" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_40fd6a99-cbc2-4403-9778-bc8c501cccbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_a99e6aaa-9038-4536-9ee2-9d16af5ac78c" xlink:href="cpix-20201210.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_94f69c2d-76df-4850-b6d2-0fa17a94c018" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_a99e6aaa-9038-4536-9ee2-9d16af5ac78c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_b9eb82bb-25d6-4b19-9bcb-67fcc700c1fb" xlink:href="cpix-20201210.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_94f69c2d-76df-4850-b6d2-0fa17a94c018" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_b9eb82bb-25d6-4b19-9bcb-67fcc700c1fb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_2214c22f-0195-481b-8ffb-63580306b79f" xlink:href="cpix-20201210.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_94f69c2d-76df-4850-b6d2-0fa17a94c018" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_2214c22f-0195-481b-8ffb-63580306b79f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_21aa2c4a-e3d7-4644-ab45-2efec0824a55" xlink:href="cpix-20201210.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_94f69c2d-76df-4850-b6d2-0fa17a94c018" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_21aa2c4a-e3d7-4644-ab45-2efec0824a55" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_5450ba75-edf0-415e-84cf-fde8770371ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_94f69c2d-76df-4850-b6d2-0fa17a94c018" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_5450ba75-edf0-415e-84cf-fde8770371ad" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_0e8099cf-bbed-4f87-b7ce-e6c1da58bea2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_94f69c2d-76df-4850-b6d2-0fa17a94c018" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_0e8099cf-bbed-4f87-b7ce-e6c1da58bea2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_73b5a5c6-d2c0-40c8-93f0-aaac71d2be5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_94f69c2d-76df-4850-b6d2-0fa17a94c018" xlink:to="loc_us-gaap_Goodwill_73b5a5c6-d2c0-40c8-93f0-aaac71d2be5e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_8776bb90-f192-4c1c-9622-7a53f703601b" xlink:href="cpix-20201210.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_94f69c2d-76df-4850-b6d2-0fa17a94c018" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_8776bb90-f192-4c1c-9622-7a53f703601b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_6b785e96-af7e-4130-a78a-63a63289c987" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_94f69c2d-76df-4850-b6d2-0fa17a94c018" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_6b785e96-af7e-4130-a78a-63a63289c987" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5f58985a-89e8-47d6-9c70-65028ad2b7c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_94f69c2d-76df-4850-b6d2-0fa17a94c018" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5f58985a-89e8-47d6-9c70-65028ad2b7c0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_49e2d97b-bebb-4581-a508-871f19fcff06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5f58985a-89e8-47d6-9c70-65028ad2b7c0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_49e2d97b-bebb-4581-a508-871f19fcff06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_49e2d97b-bebb-4581-a508-871f19fcff06_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_49e2d97b-bebb-4581-a508-871f19fcff06" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_49e2d97b-bebb-4581-a508-871f19fcff06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6a9336c0-e29e-4fc1-a051-e23d71d00da7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_49e2d97b-bebb-4581-a508-871f19fcff06" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6a9336c0-e29e-4fc1-a051-e23d71d00da7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_20c8a127-748f-4e36-acc8-2f8a15c5f4b4" xlink:href="cpix-20201210.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6a9336c0-e29e-4fc1-a051-e23d71d00da7" xlink:to="loc_cpix_VIBATIVMember_20c8a127-748f-4e36-acc8-2f8a15c5f4b4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Revenues" xlink:type="simple" xlink:href="cpix-20201210.xsd#Revenues"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/Revenues" xlink:type="extended" id="i61401f4c612f4f9a9906604c7173c101_Revenues"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#RevenuesTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="extended" id="iec2845b1b1864777b3e90ddd8f7d9b56_RevenuesTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#RevenuesScheduleofNetProductRevenuesbyProductDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails" xlink:type="extended" id="i81c0d95081fc47eca7c2cfff0ef961dd_RevenuesScheduleofNetProductRevenuesbyProductDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_236ff48e-923b-4694-999f-25a253dd70f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_330d3d4d-b17e-4757-b319-d3b1c518ea37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_236ff48e-923b-4694-999f-25a253dd70f8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_330d3d4d-b17e-4757-b319-d3b1c518ea37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_2668281f-99d7-412c-b86b-b65935db9bc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_236ff48e-923b-4694-999f-25a253dd70f8" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_2668281f-99d7-412c-b86b-b65935db9bc0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_19736ea1-dc30-420b-8e41-f54551e5bbef" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_2668281f-99d7-412c-b86b-b65935db9bc0" xlink:to="loc_srt_ProductOrServiceAxis_19736ea1-dc30-420b-8e41-f54551e5bbef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_19736ea1-dc30-420b-8e41-f54551e5bbef_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_19736ea1-dc30-420b-8e41-f54551e5bbef" xlink:to="loc_srt_ProductsAndServicesDomain_19736ea1-dc30-420b-8e41-f54551e5bbef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_53024802-a6f3-473b-8ec9-e4dcd027715f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_19736ea1-dc30-420b-8e41-f54551e5bbef" xlink:to="loc_srt_ProductsAndServicesDomain_53024802-a6f3-473b-8ec9-e4dcd027715f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember_20df25f4-cd41-4e7f-a4dd-95962d9a166d" xlink:href="cpix-20201210.xsd#cpix_AcetadoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_53024802-a6f3-473b-8ec9-e4dcd027715f" xlink:to="loc_cpix_AcetadoteMember_20df25f4-cd41-4e7f-a4dd-95962d9a166d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember_4e0fd8c8-ba49-4af4-9095-e393bf8e1123" xlink:href="cpix-20201210.xsd#cpix_OmeclamoxPakMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_53024802-a6f3-473b-8ec9-e4dcd027715f" xlink:to="loc_cpix_OmeclamoxPakMember_4e0fd8c8-ba49-4af4-9095-e393bf8e1123" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember_f6e2a258-495d-4c6e-9e49-d788afd16071" xlink:href="cpix-20201210.xsd#cpix_KristaloseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_53024802-a6f3-473b-8ec9-e4dcd027715f" xlink:to="loc_cpix_KristaloseMember_f6e2a258-495d-4c6e-9e49-d788afd16071" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember_799d474a-a8bd-4be2-a3d5-3459130ceb92" xlink:href="cpix-20201210.xsd#cpix_VaprisolMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_53024802-a6f3-473b-8ec9-e4dcd027715f" xlink:to="loc_cpix_VaprisolMember_799d474a-a8bd-4be2-a3d5-3459130ceb92" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember_70a28968-f3ea-4ed8-9006-8e4915bb7c6b" xlink:href="cpix-20201210.xsd#cpix_CaldolorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_53024802-a6f3-473b-8ec9-e4dcd027715f" xlink:to="loc_cpix_CaldolorMember_70a28968-f3ea-4ed8-9006-8e4915bb7c6b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductVibativMember_a1d3261b-1d22-42c0-920a-dd94039f29e9" xlink:href="cpix-20201210.xsd#cpix_ProductVibativMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_53024802-a6f3-473b-8ec9-e4dcd027715f" xlink:to="loc_cpix_ProductVibativMember_a1d3261b-1d22-42c0-920a-dd94039f29e9" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#RevenuesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails" xlink:type="extended" id="ic488c40c242a4ee68a36b94cc2283520_RevenuesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_f5008613-066c-41fe-92a2-58e66541ece8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductRevenuesAbstract_0ef97b23-78d5-4a08-8546-32ad16a7a609" xlink:href="cpix-20201210.xsd#cpix_ProductRevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_f5008613-066c-41fe-92a2-58e66541ece8" xlink:to="loc_cpix_ProductRevenuesAbstract_0ef97b23-78d5-4a08-8546-32ad16a7a609" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_93ab0fa7-e17d-43d5-97b6-9aa0b0932a76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ProductRevenuesAbstract_0ef97b23-78d5-4a08-8546-32ad16a7a609" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_93ab0fa7-e17d-43d5-97b6-9aa0b0932a76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherRevenuesAbstract_6a9c060c-a2df-4185-92f6-6e8b0d30e407" xlink:href="cpix-20201210.xsd#cpix_OtherRevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_f5008613-066c-41fe-92a2-58e66541ece8" xlink:to="loc_cpix_OtherRevenuesAbstract_6a9c060c-a2df-4185-92f6-6e8b0d30e407" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionUpfrontPayment_1a834ed1-f2d9-4218-a485-daedafb00ccb" xlink:href="cpix-20201210.xsd#cpix_RevenueRecognitionUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_OtherRevenuesAbstract_6a9c060c-a2df-4185-92f6-6e8b0d30e407" xlink:to="loc_cpix_RevenueRecognitionUpfrontPayment_1a834ed1-f2d9-4218-a485-daedafb00ccb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval_b9504786-6bcf-41f5-b43e-b0d44335eb17" xlink:href="cpix-20201210.xsd#cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_OtherRevenuesAbstract_6a9c060c-a2df-4185-92f6-6e8b0d30e407" xlink:to="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval_b9504786-6bcf-41f5-b43e-b0d44335eb17" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales_760856e9-d9ae-4039-8167-0f07f102e0ba" xlink:href="cpix-20201210.xsd#cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_OtherRevenuesAbstract_6a9c060c-a2df-4185-92f6-6e8b0d30e407" xlink:to="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales_760856e9-d9ae-4039-8167-0f07f102e0ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionCumulativeUpfrontPayment_bbdfd1f6-36cc-45d5-ac75-9df304bb2bde" xlink:href="cpix-20201210.xsd#cpix_RevenueRecognitionCumulativeUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_OtherRevenuesAbstract_6a9c060c-a2df-4185-92f6-6e8b0d30e407" xlink:to="loc_cpix_RevenueRecognitionCumulativeUpfrontPayment_bbdfd1f6-36cc-45d5-ac75-9df304bb2bde" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionMilestonePayments_659b0cdb-b47a-4c10-bec2-38401e4a88f5" xlink:href="cpix-20201210.xsd#cpix_RevenueRecognitionMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_OtherRevenuesAbstract_6a9c060c-a2df-4185-92f6-6e8b0d30e407" xlink:to="loc_cpix_RevenueRecognitionMilestonePayments_659b0cdb-b47a-4c10-bec2-38401e4a88f5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AirlineProductsAndServicesTable_2ecfe4fd-98c2-4922-8384-23c52b89509c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AirlineProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_f5008613-066c-41fe-92a2-58e66541ece8" xlink:to="loc_us-gaap_AirlineProductsAndServicesTable_2ecfe4fd-98c2-4922-8384-23c52b89509c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7c60b85a-124a-4c48-8635-65ce1f35ebf8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_2ecfe4fd-98c2-4922-8384-23c52b89509c" xlink:to="loc_srt_CounterpartyNameAxis_7c60b85a-124a-4c48-8635-65ce1f35ebf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7c60b85a-124a-4c48-8635-65ce1f35ebf8_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_7c60b85a-124a-4c48-8635-65ce1f35ebf8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7c60b85a-124a-4c48-8635-65ce1f35ebf8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_74b08555-709d-4ca2-ad67-15cb0a08f24f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_7c60b85a-124a-4c48-8635-65ce1f35ebf8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_74b08555-709d-4ca2-ad67-15cb0a08f24f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember_69ae0652-e0a6-46ec-96ad-d899ef789639" xlink:href="cpix-20201210.xsd#cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_74b08555-709d-4ca2-ad67-15cb0a08f24f" xlink:to="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember_69ae0652-e0a6-46ec-96ad-d899ef789639" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9a4ec214-17a1-4186-967b-92be8b011b2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_2ecfe4fd-98c2-4922-8384-23c52b89509c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9a4ec214-17a1-4186-967b-92be8b011b2c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9a4ec214-17a1-4186-967b-92be8b011b2c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9a4ec214-17a1-4186-967b-92be8b011b2c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9a4ec214-17a1-4186-967b-92be8b011b2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_32eb683d-cdc3-4305-b3c7-2033879972a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9a4ec214-17a1-4186-967b-92be8b011b2c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_32eb683d-cdc3-4305-b3c7-2033879972a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember_cac74e7d-bc2d-43e1-86c1-ef577696a1e5" xlink:href="cpix-20201210.xsd#cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_32eb683d-cdc3-4305-b3c7-2033879972a8" xlink:to="loc_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember_cac74e7d-bc2d-43e1-86c1-ef577696a1e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1314984f-ee49-464f-bad8-a650056cf59d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_2ecfe4fd-98c2-4922-8384-23c52b89509c" xlink:to="loc_srt_ProductOrServiceAxis_1314984f-ee49-464f-bad8-a650056cf59d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1314984f-ee49-464f-bad8-a650056cf59d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1314984f-ee49-464f-bad8-a650056cf59d" xlink:to="loc_srt_ProductsAndServicesDomain_1314984f-ee49-464f-bad8-a650056cf59d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_899f43d7-d1c3-45f1-a2db-7d0642c44f34" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1314984f-ee49-464f-bad8-a650056cf59d" xlink:to="loc_srt_ProductsAndServicesDomain_899f43d7-d1c3-45f1-a2db-7d0642c44f34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_27a59f2c-c4c3-4e29-8a49-409c9d3026e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_899f43d7-d1c3-45f1-a2db-7d0642c44f34" xlink:to="loc_us-gaap_GrantMember_27a59f2c-c4c3-4e29-8a49-409c9d3026e9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Inventories" xlink:type="simple" xlink:href="cpix-20201210.xsd#Inventories"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/Inventories" xlink:type="extended" id="ia264d546f7c144608ac5352ecd67638b_Inventories"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#InventoriesTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="extended" id="i20d406e8fb6546d284ec9a7e416580b3_InventoriesTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended" id="i2965f259d10e4d7e8f5385214812e51f_InventoriesScheduleofInventoriesDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#InventoriesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="extended" id="ia7068e8deb70444888cbaf71760f27b3_InventoriesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_a1f67728-5f49-4dce-85a6-2726c76d3fac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_a99545de-6778-4416-bf8c-92ccb94bbfeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_a1f67728-5f49-4dce-85a6-2726c76d3fac" xlink:to="loc_us-gaap_InventoryValuationReserves_a99545de-6778-4416-bf8c-92ccb94bbfeb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_a4d2aac4-4e17-4d27-abf6-c334d5f9df73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_a1f67728-5f49-4dce-85a6-2726c76d3fac" xlink:to="loc_us-gaap_InventoryNoncurrent_a4d2aac4-4e17-4d27-abf6-c334d5f9df73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_ff99a38d-7256-40bc-8978-dbad0bf92eca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_a1f67728-5f49-4dce-85a6-2726c76d3fac" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_ff99a38d-7256-40bc-8978-dbad0bf92eca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_c04079af-9188-4733-b27f-efccb462db9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_a1f67728-5f49-4dce-85a6-2726c76d3fac" xlink:to="loc_us-gaap_InventoryCurrentTable_c04079af-9188-4733-b27f-efccb462db9a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1a44c95a-82c5-4411-a22a-4894083644fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_c04079af-9188-4733-b27f-efccb462db9a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1a44c95a-82c5-4411-a22a-4894083644fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1a44c95a-82c5-4411-a22a-4894083644fb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1a44c95a-82c5-4411-a22a-4894083644fb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1a44c95a-82c5-4411-a22a-4894083644fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_393c48cc-df15-4e42-aa1d-c59bb376f77b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1a44c95a-82c5-4411-a22a-4894083644fb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_393c48cc-df15-4e42-aa1d-c59bb376f77b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_193de535-5ae1-4b12-89f9-0d9c4736de26" xlink:href="cpix-20201210.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_393c48cc-df15-4e42-aa1d-c59bb376f77b" xlink:to="loc_cpix_VIBATIVMember_193de535-5ae1-4b12-89f9-0d9c4736de26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember_aa5b4a54-e31f-4be4-96f0-ff4b3cbae461" xlink:href="cpix-20201210.xsd#cpix_IfetrobanClinicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_393c48cc-df15-4e42-aa1d-c59bb376f77b" xlink:to="loc_cpix_IfetrobanClinicalMember_aa5b4a54-e31f-4be4-96f0-ff4b3cbae461" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="cpix-20201210.xsd#PropertyandEquipment"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/PropertyandEquipment" xlink:type="extended" id="i740137d07fae484c9743bcec32f1d5af_PropertyandEquipment"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#PropertyandEquipmentTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/PropertyandEquipmentTables" xlink:type="extended" id="if225f2e1a1ec4f58808b204818bd9340_PropertyandEquipmentTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#PropertyandEquipmentScheduleofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="extended" id="if421796942dd4fa6bb632efacd635ee5_PropertyandEquipmentScheduleofPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c6d8b993-f340-47f4-8aa8-723501771bea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_311cc3fc-51d7-46fa-b333-6082f7cd2397" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c6d8b993-f340-47f4-8aa8-723501771bea" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_311cc3fc-51d7-46fa-b333-6082f7cd2397" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2801085c-67fe-4fcc-92a0-dbb20dfc5b7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c6d8b993-f340-47f4-8aa8-723501771bea" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2801085c-67fe-4fcc-92a0-dbb20dfc5b7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5c639bae-0ede-42c1-bd91-9d0ca50aa57e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c6d8b993-f340-47f4-8aa8-723501771bea" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5c639bae-0ede-42c1-bd91-9d0ca50aa57e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_e31e2ca7-49ce-47eb-b816-7d4f700a4270" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c6d8b993-f340-47f4-8aa8-723501771bea" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_e31e2ca7-49ce-47eb-b816-7d4f700a4270" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PropertyAndEquipmentUsefulLifeTextual_82bf5e22-1ca1-4f7c-8980-0d8713ab926c" xlink:href="cpix-20201210.xsd#cpix_PropertyAndEquipmentUsefulLifeTextual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c6d8b993-f340-47f4-8aa8-723501771bea" xlink:to="loc_cpix_PropertyAndEquipmentUsefulLifeTextual_82bf5e22-1ca1-4f7c-8980-0d8713ab926c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_15b27b12-4716-4408-8af0-289386e119ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c6d8b993-f340-47f4-8aa8-723501771bea" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_15b27b12-4716-4408-8af0-289386e119ac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ef2f4155-19c6-4ff3-b52b-91e19d0e9168" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_15b27b12-4716-4408-8af0-289386e119ac" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ef2f4155-19c6-4ff3-b52b-91e19d0e9168" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ef2f4155-19c6-4ff3-b52b-91e19d0e9168_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ef2f4155-19c6-4ff3-b52b-91e19d0e9168" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ef2f4155-19c6-4ff3-b52b-91e19d0e9168_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9224f86e-212a-4ef3-89c7-847e1d7a740b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ef2f4155-19c6-4ff3-b52b-91e19d0e9168" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9224f86e-212a-4ef3-89c7-847e1d7a740b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_b0fe3d86-dfab-4b2f-a46f-fefc61c7a705" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9224f86e-212a-4ef3-89c7-847e1d7a740b" xlink:to="loc_us-gaap_ComputerEquipmentMember_b0fe3d86-dfab-4b2f-a46f-fefc61c7a705" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_b07a815c-b3f9-4fff-ac09-385c6894af83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9224f86e-212a-4ef3-89c7-847e1d7a740b" xlink:to="loc_us-gaap_OfficeEquipmentMember_b07a815c-b3f9-4fff-ac09-385c6894af83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_53fa669e-819d-4a58-ba7c-927c66285877" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9224f86e-212a-4ef3-89c7-847e1d7a740b" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_53fa669e-819d-4a58-ba7c-927c66285877" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_5a9fcc5d-8ece-4bda-91d3-750590d58f80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9224f86e-212a-4ef3-89c7-847e1d7a740b" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_5a9fcc5d-8ece-4bda-91d3-750590d58f80" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_98aee886-af59-4c62-9a69-d67f20841659" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_15b27b12-4716-4408-8af0-289386e119ac" xlink:to="loc_srt_RangeAxis_98aee886-af59-4c62-9a69-d67f20841659" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_98aee886-af59-4c62-9a69-d67f20841659_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_98aee886-af59-4c62-9a69-d67f20841659" xlink:to="loc_srt_RangeMember_98aee886-af59-4c62-9a69-d67f20841659_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_033b6e06-3c9d-4c33-8c9e-f333015ed1b7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_98aee886-af59-4c62-9a69-d67f20841659" xlink:to="loc_srt_RangeMember_033b6e06-3c9d-4c33-8c9e-f333015ed1b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7215688d-ff03-41c2-97ab-373adc5f516d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_033b6e06-3c9d-4c33-8c9e-f333015ed1b7" xlink:to="loc_srt_MinimumMember_7215688d-ff03-41c2-97ab-373adc5f516d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e8a9b410-8597-4698-b8f1-1e6833aedd96" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_033b6e06-3c9d-4c33-8c9e-f333015ed1b7" xlink:to="loc_srt_MaximumMember_e8a9b410-8597-4698-b8f1-1e6833aedd96" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipmentDepreciationExpenseDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#PropertyandEquipmentDepreciationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/PropertyandEquipmentDepreciationExpenseDetails" xlink:type="extended" id="i664aa230d95c43f2b6966ae1a5d65e8f_PropertyandEquipmentDepreciationExpenseDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssets" xlink:type="simple" xlink:href="cpix-20201210.xsd#IntangibleAssets"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssets" xlink:type="extended" id="i4e31c0f00bb74a308d87dbbbe9ee0bb9_IntangibleAssets"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#IntangibleAssetsTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsTables" xlink:type="extended" id="i70c0f5139ba648f0b4c0b2e979afaa51_IntangibleAssetsTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#IntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended" id="i3f713a8060fc436a9f23a7821549f85e_IntangibleAssetsScheduleofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fd941708-3d6b-4301-b081-6645355ccc22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e93bd5c1-3e80-487e-ae74-7145c6fbe954" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fd941708-3d6b-4301-b081-6645355ccc22" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e93bd5c1-3e80-487e-ae74-7145c6fbe954" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f8653fb4-4499-401a-9d4a-aac0613836e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fd941708-3d6b-4301-b081-6645355ccc22" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f8653fb4-4499-401a-9d4a-aac0613836e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_41c13eab-e688-43e0-8eff-49110938fc6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fd941708-3d6b-4301-b081-6645355ccc22" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_41c13eab-e688-43e0-8eff-49110938fc6d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a413e63c-0db6-42ef-a31f-323165f9a36b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fd941708-3d6b-4301-b081-6645355ccc22" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a413e63c-0db6-42ef-a31f-323165f9a36b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ebb2b9eb-eed5-47c6-acd8-fd349caa3421" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a413e63c-0db6-42ef-a31f-323165f9a36b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ebb2b9eb-eed5-47c6-acd8-fd349caa3421" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ebb2b9eb-eed5-47c6-acd8-fd349caa3421_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ebb2b9eb-eed5-47c6-acd8-fd349caa3421" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ebb2b9eb-eed5-47c6-acd8-fd349caa3421_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8c391d52-66ae-4f00-9b5f-120678028281" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ebb2b9eb-eed5-47c6-acd8-fd349caa3421" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8c391d52-66ae-4f00-9b5f-120678028281" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductAndLicenseRightsMember_a9130801-34df-4290-b462-eda9d8e265fc" xlink:href="cpix-20201210.xsd#cpix_ProductAndLicenseRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8c391d52-66ae-4f00-9b5f-120678028281" xlink:to="loc_cpix_ProductAndLicenseRightsMember_a9130801-34df-4290-b462-eda9d8e265fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_8ebfaf95-7009-40be-abe6-356e54fe3287" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8c391d52-66ae-4f00-9b5f-120678028281" xlink:to="loc_us-gaap_PatentsMember_8ebfaf95-7009-40be-abe6-356e54fe3287" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_ce92f2bc-00c4-42f3-9148-fa74d9d47b99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8c391d52-66ae-4f00-9b5f-120678028281" xlink:to="loc_us-gaap_TrademarksMember_ce92f2bc-00c4-42f3-9148-fa74d9d47b99" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#IntangibleAssetsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails" xlink:type="extended" id="i49fdd2fc10d844d785d17d3d7e190c65_IntangibleAssetsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_80293749-2b8c-49d6-96c9-1c8395626006" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9ae7c7ff-9a0d-43d7-ab16-31aefdaa2541" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_80293749-2b8c-49d6-96c9-1c8395626006" xlink:to="loc_us-gaap_Goodwill_9ae7c7ff-9a0d-43d7-ab16-31aefdaa2541" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales_fa8c6c84-d233-4a0e-86ec-fb9c998b8264" xlink:href="cpix-20201210.xsd#cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_80293749-2b8c-49d6-96c9-1c8395626006" xlink:to="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales_fa8c6c84-d233-4a0e-86ec-fb9c998b8264" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_665c05e6-cfc6-4e01-9602-cc793ddfe37b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_80293749-2b8c-49d6-96c9-1c8395626006" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_665c05e6-cfc6-4e01-9602-cc793ddfe37b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_9b217e6a-c1d2-48a1-a5c3-777e361536a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_80293749-2b8c-49d6-96c9-1c8395626006" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_9b217e6a-c1d2-48a1-a5c3-777e361536a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_02bdf830-7737-4af9-b35e-04c7b1e181db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_80293749-2b8c-49d6-96c9-1c8395626006" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_02bdf830-7737-4af9-b35e-04c7b1e181db" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_da401fee-afc9-4422-9104-c84f0babd9e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_80293749-2b8c-49d6-96c9-1c8395626006" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_da401fee-afc9-4422-9104-c84f0babd9e1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_ac84820c-2f14-4295-861f-3ca47c9448fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_80293749-2b8c-49d6-96c9-1c8395626006" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_ac84820c-2f14-4295-861f-3ca47c9448fa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease_f6743dd4-0ab1-493e-8dea-3988f330a18d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_80293749-2b8c-49d6-96c9-1c8395626006" xlink:to="loc_us-gaap_GoodwillPeriodIncreaseDecrease_f6743dd4-0ab1-493e-8dea-3988f330a18d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_4640fcdf-cbca-4144-b968-873cc7ca37a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_80293749-2b8c-49d6-96c9-1c8395626006" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_4640fcdf-cbca-4144-b968-873cc7ca37a8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_44ef6372-17be-4329-ab25-74d9cb5c20a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_80293749-2b8c-49d6-96c9-1c8395626006" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_44ef6372-17be-4329-ab25-74d9cb5c20a6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d53e9d74-ccfb-436e-92e0-d6dcc02eff6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_80293749-2b8c-49d6-96c9-1c8395626006" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d53e9d74-ccfb-436e-92e0-d6dcc02eff6a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_be95cf21-d687-4c32-b333-802de2741633" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d53e9d74-ccfb-436e-92e0-d6dcc02eff6a" xlink:to="loc_dei_LegalEntityAxis_be95cf21-d687-4c32-b333-802de2741633" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_be95cf21-d687-4c32-b333-802de2741633_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_be95cf21-d687-4c32-b333-802de2741633" xlink:to="loc_dei_EntityDomain_be95cf21-d687-4c32-b333-802de2741633_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a20c6ad1-d98e-4655-a114-d20f429bdc62" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_be95cf21-d687-4c32-b333-802de2741633" xlink:to="loc_dei_EntityDomain_a20c6ad1-d98e-4655-a114-d20f429bdc62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember_1ff61bd8-9080-4979-8425-84a637435eb5" xlink:href="cpix-20201210.xsd#cpix_VaprisolMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a20c6ad1-d98e-4655-a114-d20f429bdc62" xlink:to="loc_cpix_VaprisolMember_1ff61bd8-9080-4979-8425-84a637435eb5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PernixTherapeuticsMember_0d7044f1-0074-410a-986f-5d2c60bc9cb5" xlink:href="cpix-20201210.xsd#cpix_PernixTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a20c6ad1-d98e-4655-a114-d20f429bdc62" xlink:to="loc_cpix_PernixTherapeuticsMember_0d7044f1-0074-410a-986f-5d2c60bc9cb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_988bb77c-2e93-44d8-bf92-88ecdb4a3458" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d53e9d74-ccfb-436e-92e0-d6dcc02eff6a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_988bb77c-2e93-44d8-bf92-88ecdb4a3458" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_988bb77c-2e93-44d8-bf92-88ecdb4a3458_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_988bb77c-2e93-44d8-bf92-88ecdb4a3458" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_988bb77c-2e93-44d8-bf92-88ecdb4a3458_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_50f15427-5f70-4ae6-bd2b-3a2f9932f9bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_988bb77c-2e93-44d8-bf92-88ecdb4a3458" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_50f15427-5f70-4ae6-bd2b-3a2f9932f9bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MethotrexateMember_c80b2d61-e91e-4e0c-82a5-0c3d178f007c" xlink:href="cpix-20201210.xsd#cpix_MethotrexateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_50f15427-5f70-4ae6-bd2b-3a2f9932f9bc" xlink:to="loc_cpix_MethotrexateMember_c80b2d61-e91e-4e0c-82a5-0c3d178f007c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_9082c143-76dc-4a1b-af65-b12525370810" xlink:href="cpix-20201210.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_50f15427-5f70-4ae6-bd2b-3a2f9932f9bc" xlink:to="loc_cpix_VIBATIVMember_9082c143-76dc-4a1b-af65-b12525370810" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_df897cc0-57fa-46b8-ab7c-6eadded007b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d53e9d74-ccfb-436e-92e0-d6dcc02eff6a" xlink:to="loc_us-gaap_AwardTypeAxis_df897cc0-57fa-46b8-ab7c-6eadded007b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df897cc0-57fa-46b8-ab7c-6eadded007b4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_df897cc0-57fa-46b8-ab7c-6eadded007b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df897cc0-57fa-46b8-ab7c-6eadded007b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f52694ed-39e0-4f6e-a5c0-84df25c3f774" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_df897cc0-57fa-46b8-ab7c-6eadded007b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f52694ed-39e0-4f6e-a5c0-84df25c3f774" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_6673d2c1-16d3-451c-9e74-5cdb130c6630" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f52694ed-39e0-4f6e-a5c0-84df25c3f774" xlink:to="loc_us-gaap_RestrictedStockMember_6673d2c1-16d3-451c-9e74-5cdb130c6630" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4f263b0c-f2c5-41ed-8815-48a6398d6a5a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d53e9d74-ccfb-436e-92e0-d6dcc02eff6a" xlink:to="loc_srt_ProductOrServiceAxis_4f263b0c-f2c5-41ed-8815-48a6398d6a5a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4f263b0c-f2c5-41ed-8815-48a6398d6a5a_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4f263b0c-f2c5-41ed-8815-48a6398d6a5a" xlink:to="loc_srt_ProductsAndServicesDomain_4f263b0c-f2c5-41ed-8815-48a6398d6a5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4605001f-fa7e-41b7-949d-0c82c838ebe2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4f263b0c-f2c5-41ed-8815-48a6398d6a5a" xlink:to="loc_srt_ProductsAndServicesDomain_4605001f-fa7e-41b7-949d-0c82c838ebe2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember_1125dddd-5a69-489a-91cc-9719c81e9074" xlink:href="cpix-20201210.xsd#cpix_KristaloseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4605001f-fa7e-41b7-949d-0c82c838ebe2" xlink:to="loc_cpix_KristaloseMember_1125dddd-5a69-489a-91cc-9719c81e9074" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9e958f26-ff35-4d42-963a-ca39c28356fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d53e9d74-ccfb-436e-92e0-d6dcc02eff6a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9e958f26-ff35-4d42-963a-ca39c28356fb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9e958f26-ff35-4d42-963a-ca39c28356fb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9e958f26-ff35-4d42-963a-ca39c28356fb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9e958f26-ff35-4d42-963a-ca39c28356fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8cc3bb11-5a5f-458b-86ae-97db2b44925e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9e958f26-ff35-4d42-963a-ca39c28356fb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8cc3bb11-5a5f-458b-86ae-97db2b44925e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductAndLicenseRightsMember_66e7ef0f-52d9-41b4-896a-e72b9c011041" xlink:href="cpix-20201210.xsd#cpix_ProductAndLicenseRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8cc3bb11-5a5f-458b-86ae-97db2b44925e" xlink:to="loc_cpix_ProductAndLicenseRightsMember_66e7ef0f-52d9-41b4-896a-e72b9c011041" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_ea41a957-8b56-40da-b5af-dbcf4944c3dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8cc3bb11-5a5f-458b-86ae-97db2b44925e" xlink:to="loc_us-gaap_PatentsMember_ea41a957-8b56-40da-b5af-dbcf4944c3dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c47f2e21-9c73-4ee8-81b2-b27bf9c19bec" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d53e9d74-ccfb-436e-92e0-d6dcc02eff6a" xlink:to="loc_srt_CounterpartyNameAxis_c47f2e21-9c73-4ee8-81b2-b27bf9c19bec" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c47f2e21-9c73-4ee8-81b2-b27bf9c19bec_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c47f2e21-9c73-4ee8-81b2-b27bf9c19bec" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c47f2e21-9c73-4ee8-81b2-b27bf9c19bec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e84ef6c6-7406-42e0-921d-dca279a24666" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c47f2e21-9c73-4ee8-81b2-b27bf9c19bec" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e84ef6c6-7406-42e0-921d-dca279a24666" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NordicMember_ebae9c48-1551-4ebc-af91-5b382c0e4377" xlink:href="cpix-20201210.xsd#cpix_NordicMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e84ef6c6-7406-42e0-921d-dca279a24666" xlink:to="loc_cpix_NordicMember_ebae9c48-1551-4ebc-af91-5b382c0e4377" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#IntangibleAssetsFutureAmortizationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="extended" id="ie9b443efc60d465bbc70a22ff9bfe971_IntangibleAssetsFutureAmortizationExpenseDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilities" xlink:type="simple" xlink:href="cpix-20201210.xsd#OtherCurrentandOtherLongtermLiabilities"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilities" xlink:type="extended" id="i4e53844376f9473a90cc7c91d44f82c6_OtherCurrentandOtherLongtermLiabilities"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#OtherCurrentandOtherLongtermLiabilitiesTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables" xlink:type="extended" id="i01208ca797264902a6e706885ca68d0b_OtherCurrentandOtherLongtermLiabilitiesTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails" xlink:type="extended" id="i4f5cf01011724e62952c798f8c65ef22_OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Debt" xlink:type="simple" xlink:href="cpix-20201210.xsd#Debt"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/Debt" xlink:type="extended" id="i738c295b26a64e3087d5eebad108d5c2_Debt"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/DebtLineofCreditDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#DebtLineofCreditDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/DebtLineofCreditDetails" xlink:type="extended" id="i02a82b6fcab047eba61e56ff57edf78e_DebtLineofCreditDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_54f525fb-ebf2-429e-8117-183c6b68ebfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f0b2bb43-0e55-4d6b-83ad-400ffcb7980d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_54f525fb-ebf2-429e-8117-183c6b68ebfb" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f0b2bb43-0e55-4d6b-83ad-400ffcb7980d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_fdfa5a90-8406-4098-922e-3af00526f968" xlink:href="cpix-20201210.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_54f525fb-ebf2-429e-8117-183c6b68ebfb" xlink:to="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_fdfa5a90-8406-4098-922e-3af00526f968" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_e02aae0b-c548-40e8-a7c2-edc3253b6489" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_54f525fb-ebf2-429e-8117-183c6b68ebfb" xlink:to="loc_us-gaap_LongTermLineOfCredit_e02aae0b-c548-40e8-a7c2-edc3253b6489" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7c26cfaa-6253-4a50-a3b3-1963c36c57be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_54f525fb-ebf2-429e-8117-183c6b68ebfb" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7c26cfaa-6253-4a50-a3b3-1963c36c57be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_f4f6e9e2-4173-426d-b72f-4ffbbfd7413d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_54f525fb-ebf2-429e-8117-183c6b68ebfb" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_f4f6e9e2-4173-426d-b72f-4ffbbfd7413d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_4ba67da8-0d48-4309-b524-8729e63b4ce0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_54f525fb-ebf2-429e-8117-183c6b68ebfb" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_4ba67da8-0d48-4309-b524-8729e63b4ce0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_606ea66d-6936-42ad-aae4-889e1b8d28df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_4ba67da8-0d48-4309-b524-8729e63b4ce0" xlink:to="loc_us-gaap_CreditFacilityAxis_606ea66d-6936-42ad-aae4-889e1b8d28df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_606ea66d-6936-42ad-aae4-889e1b8d28df_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_606ea66d-6936-42ad-aae4-889e1b8d28df" xlink:to="loc_us-gaap_CreditFacilityDomain_606ea66d-6936-42ad-aae4-889e1b8d28df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_22b4913f-aed4-425e-bb5a-eb1228452acf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_606ea66d-6936-42ad-aae4-889e1b8d28df" xlink:to="loc_us-gaap_CreditFacilityDomain_22b4913f-aed4-425e-bb5a-eb1228452acf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_d0ffa4f8-ddab-4b2c-be66-8aed1c63f34c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_22b4913f-aed4-425e-bb5a-eb1228452acf" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_d0ffa4f8-ddab-4b2c-be66-8aed1c63f34c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_b64c220d-7fc5-43f8-a05e-7f58e30b5a66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_4ba67da8-0d48-4309-b524-8729e63b4ce0" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_b64c220d-7fc5-43f8-a05e-7f58e30b5a66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_b64c220d-7fc5-43f8-a05e-7f58e30b5a66_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_b64c220d-7fc5-43f8-a05e-7f58e30b5a66" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_b64c220d-7fc5-43f8-a05e-7f58e30b5a66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_eca28b4a-5805-49b6-82ce-8fff98b0695f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_b64c220d-7fc5-43f8-a05e-7f58e30b5a66" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_eca28b4a-5805-49b6-82ce-8fff98b0695f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember_4decf04f-9f84-413b-ba31-e8b13bab0862" xlink:href="cpix-20201210.xsd#cpix_PinnacleBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_eca28b4a-5805-49b6-82ce-8fff98b0695f" xlink:to="loc_cpix_PinnacleBankMember_4decf04f-9f84-413b-ba31-e8b13bab0862" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_50cee7f2-1e55-4411-83a3-026f38a5f040" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_4ba67da8-0d48-4309-b524-8729e63b4ce0" xlink:to="loc_us-gaap_DebtInstrumentAxis_50cee7f2-1e55-4411-83a3-026f38a5f040" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_50cee7f2-1e55-4411-83a3-026f38a5f040_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_50cee7f2-1e55-4411-83a3-026f38a5f040" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_50cee7f2-1e55-4411-83a3-026f38a5f040_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_421eece8-9593-4a59-a9f7-4dbe08f198ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_50cee7f2-1e55-4411-83a3-026f38a5f040" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_421eece8-9593-4a59-a9f7-4dbe08f198ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SecondAmendmentMember_29926307-d3cc-47dd-b726-a7ce429f6e31" xlink:href="cpix-20201210.xsd#cpix_SecondAmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_421eece8-9593-4a59-a9f7-4dbe08f198ac" xlink:to="loc_cpix_SecondAmendmentMember_29926307-d3cc-47dd-b726-a7ce429f6e31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_134c11f1-5969-40c8-9f87-627673bf01c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_421eece8-9593-4a59-a9f7-4dbe08f198ac" xlink:to="loc_us-gaap_LineOfCreditMember_134c11f1-5969-40c8-9f87-627673bf01c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_035332f7-490b-40bd-a923-f52e65ebce4d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_4ba67da8-0d48-4309-b524-8729e63b4ce0" xlink:to="loc_srt_RangeAxis_035332f7-490b-40bd-a923-f52e65ebce4d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_035332f7-490b-40bd-a923-f52e65ebce4d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_035332f7-490b-40bd-a923-f52e65ebce4d" xlink:to="loc_srt_RangeMember_035332f7-490b-40bd-a923-f52e65ebce4d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e0dd811c-2fe2-4567-8871-87d9d3f0f7b4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_035332f7-490b-40bd-a923-f52e65ebce4d" xlink:to="loc_srt_RangeMember_e0dd811c-2fe2-4567-8871-87d9d3f0f7b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4671f40f-9024-47cc-86cf-8301f1357df5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e0dd811c-2fe2-4567-8871-87d9d3f0f7b4" xlink:to="loc_srt_MinimumMember_4671f40f-9024-47cc-86cf-8301f1357df5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1a760e52-1c8a-45ba-85b2-8a38d2dd3d75" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e0dd811c-2fe2-4567-8871-87d9d3f0f7b4" xlink:to="loc_srt_MaximumMember_1a760e52-1c8a-45ba-85b2-8a38d2dd3d75" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="cpix-20201210.xsd#ShareholdersEquity"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquity" xlink:type="extended" id="i548c4cc71a1046fea51261ca6456974b_ShareholdersEquity"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails" xlink:type="extended" id="i5f5ec8b6f5694047a8a9b116241e957d_ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_1fbbf363-ce42-4adc-8e24-6d249d2edb18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_InitialPublicOfferingAbstract_cef65d71-1349-4132-84d3-f324ffa7601f" xlink:href="cpix-20201210.xsd#cpix_InitialPublicOfferingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1fbbf363-ce42-4adc-8e24-6d249d2edb18" xlink:to="loc_cpix_InitialPublicOfferingAbstract_cef65d71-1349-4132-84d3-f324ffa7601f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockTransactionDate_2b373179-3391-4701-9f27-b4e78a670f40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockTransactionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_InitialPublicOfferingAbstract_cef65d71-1349-4132-84d3-f324ffa7601f" xlink:to="loc_us-gaap_SaleOfStockTransactionDate_2b373179-3391-4701-9f27-b4e78a670f40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7930b04c-a914-4d61-b1db-5dac35e224ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_InitialPublicOfferingAbstract_cef65d71-1349-4132-84d3-f324ffa7601f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7930b04c-a914-4d61-b1db-5dac35e224ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodPricePerShareNewIssues_65783d33-171d-4f38-877b-f6e873879dc6" xlink:href="cpix-20201210.xsd#cpix_StockIssuedDuringPeriodPricePerShareNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_InitialPublicOfferingAbstract_cef65d71-1349-4132-84d3-f324ffa7601f" xlink:to="loc_cpix_StockIssuedDuringPeriodPricePerShareNewIssues_65783d33-171d-4f38-877b-f6e873879dc6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering_42998bff-d1c3-4fa8-a3fa-4ce315498da2" xlink:href="cpix-20201210.xsd#cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_InitialPublicOfferingAbstract_cef65d71-1349-4132-84d3-f324ffa7601f" xlink:to="loc_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering_42998bff-d1c3-4fa8-a3fa-4ce315498da2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts_d80cbe4d-76f5-4879-adcd-198ba7f6a7bb" xlink:href="cpix-20201210.xsd#cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_InitialPublicOfferingAbstract_cef65d71-1349-4132-84d3-f324ffa7601f" xlink:to="loc_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts_d80cbe4d-76f5-4879-adcd-198ba7f6a7bb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_0717be15-2af5-435b-b39f-d1696e74213d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_InitialPublicOfferingAbstract_cef65d71-1349-4132-84d3-f324ffa7601f" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_0717be15-2af5-435b-b39f-d1696e74213d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_164038ef-ec8e-4aa2-a792-be783335dff1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_InitialPublicOfferingAbstract_cef65d71-1349-4132-84d3-f324ffa7601f" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_164038ef-ec8e-4aa2-a792-be783335dff1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering_1fcd3d4c-15fc-46e4-ba0c-86c894266b99" xlink:href="cpix-20201210.xsd#cpix_StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_InitialPublicOfferingAbstract_cef65d71-1349-4132-84d3-f324ffa7601f" xlink:to="loc_cpix_StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering_1fcd3d4c-15fc-46e4-ba0c-86c894266b99" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PreferredStockAbstract_7394ddd9-1cfc-4c74-bb64-533bb8c49592" xlink:href="cpix-20201210.xsd#cpix_PreferredStockAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1fbbf363-ce42-4adc-8e24-6d249d2edb18" xlink:to="loc_cpix_PreferredStockAbstract_7394ddd9-1cfc-4c74-bb64-533bb8c49592" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2284658f-d3bd-4d48-9243-63df1df16a3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_PreferredStockAbstract_7394ddd9-1cfc-4c74-bb64-533bb8c49592" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2284658f-d3bd-4d48-9243-63df1df16a3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CommonStockAbstract_6928ff1f-d784-4c99-928c-ba7f99b62840" xlink:href="cpix-20201210.xsd#cpix_CommonStockAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1fbbf363-ce42-4adc-8e24-6d249d2edb18" xlink:to="loc_cpix_CommonStockAbstract_6928ff1f-d784-4c99-928c-ba7f99b62840" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_d36200b8-914a-4c16-b3f7-d4c3feb955ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_CommonStockAbstract_6928ff1f-d784-4c99-928c-ba7f99b62840" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_d36200b8-914a-4c16-b3f7-d4c3feb955ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding_5e8c5bd9-28d0-4164-a86c-ddd0744d992a" xlink:href="cpix-20201210.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_CommonStockAbstract_6928ff1f-d784-4c99-928c-ba7f99b62840" xlink:to="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding_5e8c5bd9-28d0-4164-a86c-ddd0744d992a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_9a37de78-27fa-4be0-8b22-7b6d4818215b" xlink:href="cpix-20201210.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_CommonStockAbstract_6928ff1f-d784-4c99-928c-ba7f99b62840" xlink:to="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_9a37de78-27fa-4be0-8b22-7b6d4818215b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_738ce325-82ab-425f-ae3f-60ca3f14bb76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_1fbbf363-ce42-4adc-8e24-6d249d2edb18" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_738ce325-82ab-425f-ae3f-60ca3f14bb76" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f04b9c08-f56a-4a5f-bfa5-ded26de4d162" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_738ce325-82ab-425f-ae3f-60ca3f14bb76" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f04b9c08-f56a-4a5f-bfa5-ded26de4d162" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f04b9c08-f56a-4a5f-bfa5-ded26de4d162_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f04b9c08-f56a-4a5f-bfa5-ded26de4d162" xlink:to="loc_us-gaap_EquityComponentDomain_f04b9c08-f56a-4a5f-bfa5-ded26de4d162_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2a92e071-fc4d-462d-9df4-ac64dc5d85a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f04b9c08-f56a-4a5f-bfa5-ded26de4d162" xlink:to="loc_us-gaap_EquityComponentDomain_2a92e071-fc4d-462d-9df4-ac64dc5d85a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b0a87ee0-f501-41e1-81f2-ff339fd33bc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2a92e071-fc4d-462d-9df4-ac64dc5d85a3" xlink:to="loc_us-gaap_CommonStockMember_b0a87ee0-f501-41e1-81f2-ff339fd33bc3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3d93901a-f386-4583-83af-40edd080db54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_738ce325-82ab-425f-ae3f-60ca3f14bb76" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3d93901a-f386-4583-83af-40edd080db54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3d93901a-f386-4583-83af-40edd080db54_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3d93901a-f386-4583-83af-40edd080db54" xlink:to="loc_us-gaap_ClassOfStockDomain_3d93901a-f386-4583-83af-40edd080db54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d952f465-32b0-407c-905f-0fae4f277025" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3d93901a-f386-4583-83af-40edd080db54" xlink:to="loc_us-gaap_ClassOfStockDomain_d952f465-32b0-407c-905f-0fae4f277025" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_cce74aa1-b889-48bb-84d9-5acca0a7cebc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d952f465-32b0-407c-905f-0fae4f277025" xlink:to="loc_us-gaap_CommonStockMember_cce74aa1-b889-48bb-84d9-5acca0a7cebc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityWarrantsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#ShareholdersEquityWarrantsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityWarrantsNarrativeDetails" xlink:type="extended" id="i546e034826d9430aaf80b267142c85c6_ShareholdersEquityWarrantsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_23618661-9c75-4c0f-ac40-de56dfaaff0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_9eaf9906-3d0a-401e-a8ae-24884623aaf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_23618661-9c75-4c0f-ac40-de56dfaaff0f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_9eaf9906-3d0a-401e-a8ae-24884623aaf4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_42b51d1d-c77e-4d97-90fd-1fd868cb5c95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_23618661-9c75-4c0f-ac40-de56dfaaff0f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_42b51d1d-c77e-4d97-90fd-1fd868cb5c95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_850395a2-0585-4f6e-85db-f35a34aa4e5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_23618661-9c75-4c0f-ac40-de56dfaaff0f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_850395a2-0585-4f6e-85db-f35a34aa4e5d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_3c3721ac-ab41-4976-8f99-0a6bc486f76b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_850395a2-0585-4f6e-85db-f35a34aa4e5d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_3c3721ac-ab41-4976-8f99-0a6bc486f76b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3c3721ac-ab41-4976-8f99-0a6bc486f76b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_3c3721ac-ab41-4976-8f99-0a6bc486f76b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3c3721ac-ab41-4976-8f99-0a6bc486f76b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_74edfd61-b3f2-4aab-b1dd-9848c02d10c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_3c3721ac-ab41-4976-8f99-0a6bc486f76b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_74edfd61-b3f2-4aab-b1dd-9848c02d10c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_WarrantsIssuedInConsiderationOf2006CreditFacilityAmendmentMember_d4f69c38-fe56-4cb4-992b-32a77c742b8d" xlink:href="cpix-20201210.xsd#cpix_WarrantsIssuedInConsiderationOf2006CreditFacilityAmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_74edfd61-b3f2-4aab-b1dd-9848c02d10c2" xlink:to="loc_cpix_WarrantsIssuedInConsiderationOf2006CreditFacilityAmendmentMember_d4f69c38-fe56-4cb4-992b-32a77c742b8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember_e043d832-7486-486b-8e4f-d3033e46753c" xlink:href="cpix-20201210.xsd#cpix_WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_74edfd61-b3f2-4aab-b1dd-9848c02d10c2" xlink:to="loc_cpix_WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember_e043d832-7486-486b-8e4f-d3033e46753c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" xlink:type="extended" id="ibf4a55b640c240d08523f1077c933287_ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_dd766272-ac5b-429d-92ea-a654314f34d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_4f73d204-3b48-41e8-8f42-f6ea5f73aa26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_dd766272-ac5b-429d-92ea-a654314f34d1" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_4f73d204-3b48-41e8-8f42-f6ea5f73aa26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_1c98126c-971f-438c-b106-82a2275a37da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_dd766272-ac5b-429d-92ea-a654314f34d1" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_1c98126c-971f-438c-b106-82a2275a37da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_2006521e-105e-46ff-9ffd-b8922e6e6465" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_dd766272-ac5b-429d-92ea-a654314f34d1" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_2006521e-105e-46ff-9ffd-b8922e6e6465" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_7677d622-6ab3-4fb0-a03b-7410eb384561" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_dd766272-ac5b-429d-92ea-a654314f34d1" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_7677d622-6ab3-4fb0-a03b-7410eb384561" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_88589b38-a18d-4b96-8d04-85989d068f11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_dd766272-ac5b-429d-92ea-a654314f34d1" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_88589b38-a18d-4b96-8d04-85989d068f11" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPurchaseOfShares_7be1ae41-dac9-4380-88a9-03cf28aa6dd2" xlink:href="cpix-20201210.xsd#cpix_SubsidiaryInvestmentPurchaseOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_dd766272-ac5b-429d-92ea-a654314f34d1" xlink:to="loc_cpix_SubsidiaryInvestmentPurchaseOfShares_7be1ae41-dac9-4380-88a9-03cf28aa6dd2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_bc30794c-efe2-4982-88e1-04b3022e84d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_dd766272-ac5b-429d-92ea-a654314f34d1" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_bc30794c-efe2-4982-88e1-04b3022e84d0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LoansForgiveninExchangeForShareIssuedAmount_39a760cd-f70a-4302-b496-27033346d4ac" xlink:href="cpix-20201210.xsd#cpix_LoansForgiveninExchangeForShareIssuedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_dd766272-ac5b-429d-92ea-a654314f34d1" xlink:to="loc_cpix_LoansForgiveninExchangeForShareIssuedAmount_39a760cd-f70a-4302-b496-27033346d4ac" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_9f2833a9-320f-47b0-874b-270eca14248f" xlink:href="cpix-20201210.xsd#cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_dd766272-ac5b-429d-92ea-a654314f34d1" xlink:to="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_9f2833a9-320f-47b0-874b-270eca14248f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_6298fc58-56a5-48fa-a90a-2e63af903445" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_dd766272-ac5b-429d-92ea-a654314f34d1" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_6298fc58-56a5-48fa-a90a-2e63af903445" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharebasedCompensationCharitableContributionofSharesShares_855d8045-e6c9-431c-bfd1-5294149fa080" xlink:href="cpix-20201210.xsd#cpix_SharebasedCompensationCharitableContributionofSharesShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_dd766272-ac5b-429d-92ea-a654314f34d1" xlink:to="loc_cpix_SharebasedCompensationCharitableContributionofSharesShares_855d8045-e6c9-431c-bfd1-5294149fa080" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions_0032d733-043f-4375-ad52-2171f7bd02a0" xlink:href="cpix-20201210.xsd#cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_dd766272-ac5b-429d-92ea-a654314f34d1" xlink:to="loc_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions_0032d733-043f-4375-ad52-2171f7bd02a0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_fb5be0ae-80c1-45af-9ba1-286b9d8e7432" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_dd766272-ac5b-429d-92ea-a654314f34d1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_fb5be0ae-80c1-45af-9ba1-286b9d8e7432" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_de30673e-cf17-4cb3-9239-4a982a912484" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_dd766272-ac5b-429d-92ea-a654314f34d1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_de30673e-cf17-4cb3-9239-4a982a912484" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_d91f6e32-cc5b-4801-9a96-ac6314fd4f4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_dd766272-ac5b-429d-92ea-a654314f34d1" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_d91f6e32-cc5b-4801-9a96-ac6314fd4f4c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_0770d02f-c7e4-465e-9b04-c9bad8be9402" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_d91f6e32-cc5b-4801-9a96-ac6314fd4f4c" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_0770d02f-c7e4-465e-9b04-c9bad8be9402" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_0770d02f-c7e4-465e-9b04-c9bad8be9402_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_0770d02f-c7e4-465e-9b04-c9bad8be9402" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_0770d02f-c7e4-465e-9b04-c9bad8be9402_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_92cedbd7-ed47-43e6-bbd0-67414f57a28f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_0770d02f-c7e4-465e-9b04-c9bad8be9402" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_92cedbd7-ed47-43e6-bbd0-67414f57a28f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareRepurchaseProgramAuthorizedIn2010Member_09b30f4e-c979-4215-a5a4-974014425dfd" xlink:href="cpix-20201210.xsd#cpix_ShareRepurchaseProgramAuthorizedIn2010Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_92cedbd7-ed47-43e6-bbd0-67414f57a28f" xlink:to="loc_cpix_ShareRepurchaseProgramAuthorizedIn2010Member_09b30f4e-c979-4215-a5a4-974014425dfd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharesRepurchaseActivityTypeAxis_5d4f7d57-35a1-407e-8668-d9c3d1801d1d" xlink:href="cpix-20201210.xsd#cpix_SharesRepurchaseActivityTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_d91f6e32-cc5b-4801-9a96-ac6314fd4f4c" xlink:to="loc_cpix_SharesRepurchaseActivityTypeAxis_5d4f7d57-35a1-407e-8668-d9c3d1801d1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharesRepurchaseActivityTypeDomain_5d4f7d57-35a1-407e-8668-d9c3d1801d1d_default" xlink:href="cpix-20201210.xsd#cpix_SharesRepurchaseActivityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cpix_SharesRepurchaseActivityTypeAxis_5d4f7d57-35a1-407e-8668-d9c3d1801d1d" xlink:to="loc_cpix_SharesRepurchaseActivityTypeDomain_5d4f7d57-35a1-407e-8668-d9c3d1801d1d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharesRepurchaseActivityTypeDomain_9a2f317b-6487-4bf2-8ff6-02c2b7a1c26c" xlink:href="cpix-20201210.xsd#cpix_SharesRepurchaseActivityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cpix_SharesRepurchaseActivityTypeAxis_5d4f7d57-35a1-407e-8668-d9c3d1801d1d" xlink:to="loc_cpix_SharesRepurchaseActivityTypeDomain_9a2f317b-6487-4bf2-8ff6-02c2b7a1c26c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember_c0f22838-d6a9-493f-a144-7d29e7b78364" xlink:href="cpix-20201210.xsd#cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_SharesRepurchaseActivityTypeDomain_9a2f317b-6487-4bf2-8ff6-02c2b7a1c26c" xlink:to="loc_cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember_c0f22838-d6a9-493f-a144-7d29e7b78364" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_4ae2ab39-6795-419f-8968-300b44b7314e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_d91f6e32-cc5b-4801-9a96-ac6314fd4f4c" xlink:to="loc_dei_LegalEntityAxis_4ae2ab39-6795-419f-8968-300b44b7314e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4ae2ab39-6795-419f-8968-300b44b7314e_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_4ae2ab39-6795-419f-8968-300b44b7314e" xlink:to="loc_dei_EntityDomain_4ae2ab39-6795-419f-8968-300b44b7314e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_5803dd86-9e09-4b81-b997-f44b6695c7a3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_4ae2ab39-6795-419f-8968-300b44b7314e" xlink:to="loc_dei_EntityDomain_5803dd86-9e09-4b81-b997-f44b6695c7a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CumberlandEmergingTechnologiesIncMember_ed098290-d4e6-4459-b28e-a0de9614ac7a" xlink:href="cpix-20201210.xsd#cpix_CumberlandEmergingTechnologiesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_5803dd86-9e09-4b81-b997-f44b6695c7a3" xlink:to="loc_cpix_CumberlandEmergingTechnologiesIncMember_ed098290-d4e6-4459-b28e-a0de9614ac7a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d46efc63-d3f1-40c9-afb6-c45242656e7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_d91f6e32-cc5b-4801-9a96-ac6314fd4f4c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d46efc63-d3f1-40c9-afb6-c45242656e7c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d46efc63-d3f1-40c9-afb6-c45242656e7c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d46efc63-d3f1-40c9-afb6-c45242656e7c" xlink:to="loc_us-gaap_EquityComponentDomain_d46efc63-d3f1-40c9-afb6-c45242656e7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b5ef989f-219e-4d50-a7cd-6c3cda2600c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d46efc63-d3f1-40c9-afb6-c45242656e7c" xlink:to="loc_us-gaap_EquityComponentDomain_b5ef989f-219e-4d50-a7cd-6c3cda2600c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e50be7b6-c24f-4317-9742-58fbde42edf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b5ef989f-219e-4d50-a7cd-6c3cda2600c3" xlink:to="loc_us-gaap_CommonStockMember_e50be7b6-c24f-4317-9742-58fbde42edf9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b3bf3e26-105c-4e37-9e84-dca741f4fdef" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_d91f6e32-cc5b-4801-9a96-ac6314fd4f4c" xlink:to="loc_srt_CounterpartyNameAxis_b3bf3e26-105c-4e37-9e84-dca741f4fdef" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b3bf3e26-105c-4e37-9e84-dca741f4fdef_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_b3bf3e26-105c-4e37-9e84-dca741f4fdef" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b3bf3e26-105c-4e37-9e84-dca741f4fdef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2e7c340e-3c41-4784-980e-19a366fead24" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_b3bf3e26-105c-4e37-9e84-dca741f4fdef" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2e7c340e-3c41-4784-980e-19a366fead24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_702c7fa4-3975-4116-889a-28fe17134c6d" xlink:href="cpix-20201210.xsd#cpix_HongKongWinHealthPharmaGroupCoLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2e7c340e-3c41-4784-980e-19a366fead24" xlink:to="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_702c7fa4-3975-4116-889a-28fe17134c6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_GloriaPharmaceuticalsMember_e0304dd5-51ec-466f-bf97-ea14a4353a9f" xlink:href="cpix-20201210.xsd#cpix_GloriaPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2e7c340e-3c41-4784-980e-19a366fead24" xlink:to="loc_cpix_GloriaPharmaceuticalsMember_e0304dd5-51ec-466f-bf97-ea14a4353a9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NordicMember_c755f554-48b4-474e-ac33-61f45b253860" xlink:href="cpix-20201210.xsd#cpix_NordicMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2e7c340e-3c41-4784-980e-19a366fead24" xlink:to="loc_cpix_NordicMember_c755f554-48b4-474e-ac33-61f45b253860" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="simple" xlink:href="cpix-20201210.xsd#EarningsLossPerShare"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="extended" id="idd02efa6e9de4402adbac1c73c56d34f_EarningsLossPerShare"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#EarningsLossPerShareTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="extended" id="i91d39e7f80dc47f7837e1fcf02f6995c_EarningsLossPerShareTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails" xlink:type="extended" id="ib3c1c8573bc94c27b345b2c5c2876403_EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#EarningsLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails" xlink:type="extended" id="i4ec71e0b05854aacbc875cf1a40e8a59_EarningsLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cpix-20201210.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="extended" id="id3afbde7856c4bf2b6f170e131a5152a_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#IncomeTaxesTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesTables" xlink:type="extended" id="i06d0b0b4902d40bcacab0de344921792_IncomeTaxesTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#IncomeTaxesOperatingLossCarryforwardsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails" xlink:type="extended" id="i60344cf19ee049c9880dd00b6203b049_IncomeTaxesOperatingLossCarryforwardsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_713eadf9-0642-42ce-850a-c964b9519444" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_c6bf556c-c587-4168-b0e6-6451be20f302" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_713eadf9-0642-42ce-850a-c964b9519444" xlink:to="loc_us-gaap_OperatingLossCarryforwards_c6bf556c-c587-4168-b0e6-6451be20f302" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f7bea890-2c6e-4848-9309-0d47b9fcd30f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_713eadf9-0642-42ce-850a-c964b9519444" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f7bea890-2c6e-4848-9309-0d47b9fcd30f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_f45b9fab-7c56-45ac-b818-ff09c2fd7f36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_713eadf9-0642-42ce-850a-c964b9519444" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_f45b9fab-7c56-45ac-b818-ff09c2fd7f36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_82fd0f1a-5ef0-4ca1-810e-29315b8b3faa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_713eadf9-0642-42ce-850a-c964b9519444" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_82fd0f1a-5ef0-4ca1-810e-29315b8b3faa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_c5ddc622-1569-45d2-b6a3-dbd59b29756c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_713eadf9-0642-42ce-850a-c964b9519444" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_c5ddc622-1569-45d2-b6a3-dbd59b29756c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_414508a8-4d0e-44a9-abc5-3217bc6cc343" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_c5ddc622-1569-45d2-b6a3-dbd59b29756c" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_414508a8-4d0e-44a9-abc5-3217bc6cc343" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_414508a8-4d0e-44a9-abc5-3217bc6cc343_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_414508a8-4d0e-44a9-abc5-3217bc6cc343" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_414508a8-4d0e-44a9-abc5-3217bc6cc343_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_79cceda4-6003-4243-b68c-9129836db29e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_414508a8-4d0e-44a9-abc5-3217bc6cc343" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_79cceda4-6003-4243-b68c-9129836db29e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_fe7e4412-9c17-4fc5-9b8f-e4713403c53d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_79cceda4-6003-4243-b68c-9129836db29e" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_fe7e4412-9c17-4fc5-9b8f-e4713403c53d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_4433f449-42d3-4292-9560-9ff03de25938" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_79cceda4-6003-4243-b68c-9129836db29e" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_4433f449-42d3-4292-9560-9ff03de25938" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_61235add-c2b4-42de-835b-ee4c3f75c7b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_c5ddc622-1569-45d2-b6a3-dbd59b29756c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_61235add-c2b4-42de-835b-ee4c3f75c7b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_61235add-c2b4-42de-835b-ee4c3f75c7b5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_61235add-c2b4-42de-835b-ee4c3f75c7b5" xlink:to="loc_us-gaap_EquityComponentDomain_61235add-c2b4-42de-835b-ee4c3f75c7b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_26500e47-cb08-485e-9e12-eaf02e472c0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_61235add-c2b4-42de-835b-ee4c3f75c7b5" xlink:to="loc_us-gaap_EquityComponentDomain_26500e47-cb08-485e-9e12-eaf02e472c0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_de3234a7-f860-4523-8071-1c457d004ae2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_26500e47-cb08-485e-9e12-eaf02e472c0e" xlink:to="loc_us-gaap_RetainedEarningsMember_de3234a7-f860-4523-8071-1c457d004ae2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_5de2855f-338c-4efa-9ce4-a56ecb14a83a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_c5ddc622-1569-45d2-b6a3-dbd59b29756c" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_5de2855f-338c-4efa-9ce4-a56ecb14a83a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_5de2855f-338c-4efa-9ce4-a56ecb14a83a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_5de2855f-338c-4efa-9ce4-a56ecb14a83a" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_5de2855f-338c-4efa-9ce4-a56ecb14a83a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_4e70cb2a-c13e-4b39-8bee-695ec78557f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_5de2855f-338c-4efa-9ce4-a56ecb14a83a" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_4e70cb2a-c13e-4b39-8bee-695ec78557f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_3b21859a-4e03-42cb-91fe-80168a356d84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_4e70cb2a-c13e-4b39-8bee-695ec78557f4" xlink:to="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_3b21859a-4e03-42cb-91fe-80168a356d84" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails" xlink:type="extended" id="icf8150baa7e145c5a59aff8db8499ed5_IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails" xlink:type="extended" id="ic483a185f7cf448db6e3738175713391_IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_6d2e9c5f-ee23-4419-9c87-cc611eadc6f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_ebe97208-3659-4734-aba4-fc8df50afa19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6d2e9c5f-ee23-4419-9c87-cc611eadc6f4" xlink:to="loc_us-gaap_OperatingLossCarryforwards_ebe97208-3659-4734-aba4-fc8df50afa19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_f44878ca-8b28-44c7-be3c-df7fdb19a04c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6d2e9c5f-ee23-4419-9c87-cc611eadc6f4" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_f44878ca-8b28-44c7-be3c-df7fdb19a04c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTimePeriodAxis_f546368c-b5e4-4b94-a167-0177e9137912" xlink:href="cpix-20201210.xsd#cpix_ExpirationTimePeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_f44878ca-8b28-44c7-be3c-df7fdb19a04c" xlink:to="loc_cpix_ExpirationTimePeriodAxis_f546368c-b5e4-4b94-a167-0177e9137912" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTimePeriodDomain_f546368c-b5e4-4b94-a167-0177e9137912_default" xlink:href="cpix-20201210.xsd#cpix_ExpirationTimePeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cpix_ExpirationTimePeriodAxis_f546368c-b5e4-4b94-a167-0177e9137912" xlink:to="loc_cpix_ExpirationTimePeriodDomain_f546368c-b5e4-4b94-a167-0177e9137912_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTimePeriodDomain_d31efa41-3a0a-4c5a-bf16-47a06700b1fd" xlink:href="cpix-20201210.xsd#cpix_ExpirationTimePeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cpix_ExpirationTimePeriodAxis_f546368c-b5e4-4b94-a167-0177e9137912" xlink:to="loc_cpix_ExpirationTimePeriodDomain_d31efa41-3a0a-4c5a-bf16-47a06700b1fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermOneMember_9602f691-006c-4851-b0e5-25b5b34adf12" xlink:href="cpix-20201210.xsd#cpix_ExpirationTermOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ExpirationTimePeriodDomain_d31efa41-3a0a-4c5a-bf16-47a06700b1fd" xlink:to="loc_cpix_ExpirationTermOneMember_9602f691-006c-4851-b0e5-25b5b34adf12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermTwoMember_e85ed622-01e5-4876-93d3-caa1a0e8f9e0" xlink:href="cpix-20201210.xsd#cpix_ExpirationTermTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ExpirationTimePeriodDomain_d31efa41-3a0a-4c5a-bf16-47a06700b1fd" xlink:to="loc_cpix_ExpirationTermTwoMember_e85ed622-01e5-4876-93d3-caa1a0e8f9e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermThreeMember_c3eba813-2f24-43dc-b9d1-2914117a1226" xlink:href="cpix-20201210.xsd#cpix_ExpirationTermThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ExpirationTimePeriodDomain_d31efa41-3a0a-4c5a-bf16-47a06700b1fd" xlink:to="loc_cpix_ExpirationTermThreeMember_c3eba813-2f24-43dc-b9d1-2914117a1226" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermFourMember_d1236bc3-bcd0-4cc7-8d65-3a441cbef359" xlink:href="cpix-20201210.xsd#cpix_ExpirationTermFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ExpirationTimePeriodDomain_d31efa41-3a0a-4c5a-bf16-47a06700b1fd" xlink:to="loc_cpix_ExpirationTermFourMember_d1236bc3-bcd0-4cc7-8d65-3a441cbef359" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IndefiniteMember_05c87a99-4f29-4fd4-a6d1-f633f8cf184c" xlink:href="cpix-20201210.xsd#cpix_IndefiniteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ExpirationTimePeriodDomain_d31efa41-3a0a-4c5a-bf16-47a06700b1fd" xlink:to="loc_cpix_IndefiniteMember_05c87a99-4f29-4fd4-a6d1-f633f8cf184c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_8ac2b588-4868-4e5e-b582-21131b68019c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_f44878ca-8b28-44c7-be3c-df7fdb19a04c" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_8ac2b588-4868-4e5e-b582-21131b68019c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_8ac2b588-4868-4e5e-b582-21131b68019c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_8ac2b588-4868-4e5e-b582-21131b68019c" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_8ac2b588-4868-4e5e-b582-21131b68019c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_6fc4bb59-f01b-4401-9dff-d96159bd67c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_8ac2b588-4868-4e5e-b582-21131b68019c" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_6fc4bb59-f01b-4401-9dff-d96159bd67c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_9978a86c-c5ba-4563-bec7-767c3da3ace7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_6fc4bb59-f01b-4401-9dff-d96159bd67c0" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_9978a86c-c5ba-4563-bec7-767c3da3ace7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_2c24cf9c-e535-4b34-9a31-f2c891c3212a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_6fc4bb59-f01b-4401-9dff-d96159bd67c0" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_2c24cf9c-e535-4b34-9a31-f2c891c3212a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails" xlink:type="extended" id="i890a9f98f7834904a45a0da3d06c522d_IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended" id="i2a075a3925b34e6bbfcbfc6dab779b9c_IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlans" xlink:type="simple" xlink:href="cpix-20201210.xsd#StockBasedCompensationPlans"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlans" xlink:type="extended" id="i686e46f0391d4b94bf2e7940ff3279ae_StockBasedCompensationPlans"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#StockBasedCompensationPlansTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables" xlink:type="extended" id="id9915ea6a4b348eebfa2d9f2a9945213_StockBasedCompensationPlansTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#StockBasedCompensationPlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails" xlink:type="extended" id="i027fe0326e3b4e7f8852579549bec68e_StockBasedCompensationPlansNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baa09e5-c8ab-465d-9e7f-18969b5b2fb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans_bb3c9d40-8454-421f-96a3-9be0abc61dde" xlink:href="cpix-20201210.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baa09e5-c8ab-465d-9e7f-18969b5b2fb7" xlink:to="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans_bb3c9d40-8454-421f-96a3-9be0abc61dde" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants_3a44e4c7-1491-45c7-9e5c-2bbfdd0317f4" xlink:href="cpix-20201210.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baa09e5-c8ab-465d-9e7f-18969b5b2fb7" xlink:to="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants_3a44e4c7-1491-45c7-9e5c-2bbfdd0317f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_78ab451f-9969-44e1-94a9-c07c3f0b488c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baa09e5-c8ab-465d-9e7f-18969b5b2fb7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_78ab451f-9969-44e1-94a9-c07c3f0b488c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue_192477d2-0407-4899-ad98-6edd9ba1b17a" xlink:href="cpix-20201210.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baa09e5-c8ab-465d-9e7f-18969b5b2fb7" xlink:to="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue_192477d2-0407-4899-ad98-6edd9ba1b17a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5ed69212-e01d-45a8-ab42-99d6d3c1875e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baa09e5-c8ab-465d-9e7f-18969b5b2fb7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5ed69212-e01d-45a8-ab42-99d6d3c1875e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1569e64f-f0c3-41b0-88a3-30685afc5209" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baa09e5-c8ab-465d-9e7f-18969b5b2fb7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1569e64f-f0c3-41b0-88a3-30685afc5209" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d32d1702-952b-4cd7-ab54-526f44e153fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baa09e5-c8ab-465d-9e7f-18969b5b2fb7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d32d1702-952b-4cd7-ab54-526f44e153fc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_980d1567-58d6-4b91-b8c3-e457b46d0685" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baa09e5-c8ab-465d-9e7f-18969b5b2fb7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_980d1567-58d6-4b91-b8c3-e457b46d0685" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0d18e818-8ee8-4eeb-88ef-f1e306acdec5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baa09e5-c8ab-465d-9e7f-18969b5b2fb7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0d18e818-8ee8-4eeb-88ef-f1e306acdec5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_508bb66b-ce9f-4d4e-9fe8-6c35d818d4e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0d18e818-8ee8-4eeb-88ef-f1e306acdec5" xlink:to="loc_us-gaap_AwardTypeAxis_508bb66b-ce9f-4d4e-9fe8-6c35d818d4e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_508bb66b-ce9f-4d4e-9fe8-6c35d818d4e4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_508bb66b-ce9f-4d4e-9fe8-6c35d818d4e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_508bb66b-ce9f-4d4e-9fe8-6c35d818d4e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_da3d0d8c-d9bc-4d7b-b779-97b36dff8eb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_508bb66b-ce9f-4d4e-9fe8-6c35d818d4e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_da3d0d8c-d9bc-4d7b-b779-97b36dff8eb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_37299fef-7c92-4973-80ba-9666c76aba55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_da3d0d8c-d9bc-4d7b-b779-97b36dff8eb4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_37299fef-7c92-4973-80ba-9666c76aba55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_836af22b-c13d-47b7-b044-4e3fcbe2720d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_da3d0d8c-d9bc-4d7b-b779-97b36dff8eb4" xlink:to="loc_us-gaap_RestrictedStockMember_836af22b-c13d-47b7-b044-4e3fcbe2720d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_14c087bf-fef7-4715-8b2c-8f5551b5334e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0d18e818-8ee8-4eeb-88ef-f1e306acdec5" xlink:to="loc_us-gaap_PlanNameAxis_14c087bf-fef7-4715-8b2c-8f5551b5334e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_14c087bf-fef7-4715-8b2c-8f5551b5334e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_14c087bf-fef7-4715-8b2c-8f5551b5334e" xlink:to="loc_us-gaap_PlanNameDomain_14c087bf-fef7-4715-8b2c-8f5551b5334e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_500c7616-867c-4998-986c-c16208755ede" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_14c087bf-fef7-4715-8b2c-8f5551b5334e" xlink:to="loc_us-gaap_PlanNameDomain_500c7616-867c-4998-986c-c16208755ede" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LongTermIncentiveCompensationPlan2007Member_22500a83-d6a6-4b5b-a451-793140fc0423" xlink:href="cpix-20201210.xsd#cpix_LongTermIncentiveCompensationPlan2007Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_500c7616-867c-4998-986c-c16208755ede" xlink:to="loc_cpix_LongTermIncentiveCompensationPlan2007Member_22500a83-d6a6-4b5b-a451-793140fc0423" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DirectorsIncentivePlan2007Member_b937bdce-87cf-4ef2-9d0c-0183a7b7265d" xlink:href="cpix-20201210.xsd#cpix_DirectorsIncentivePlan2007Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_500c7616-867c-4998-986c-c16208755ede" xlink:to="loc_cpix_DirectorsIncentivePlan2007Member_b937bdce-87cf-4ef2-9d0c-0183a7b7265d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_3071bb94-059c-4b9e-9c91-58eefff76ac1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0d18e818-8ee8-4eeb-88ef-f1e306acdec5" xlink:to="loc_srt_TitleOfIndividualAxis_3071bb94-059c-4b9e-9c91-58eefff76ac1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3071bb94-059c-4b9e-9c91-58eefff76ac1_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_3071bb94-059c-4b9e-9c91-58eefff76ac1" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3071bb94-059c-4b9e-9c91-58eefff76ac1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_58697528-4e72-4cce-9eb0-a9f6f6691c9f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_3071bb94-059c-4b9e-9c91-58eefff76ac1" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_58697528-4e72-4cce-9eb0-a9f6f6691c9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EmployeeMember_722a36fc-5910-4f1c-b851-7186a4fe5101" xlink:href="cpix-20201210.xsd#cpix_EmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_58697528-4e72-4cce-9eb0-a9f6f6691c9f" xlink:to="loc_cpix_EmployeeMember_722a36fc-5910-4f1c-b851-7186a4fe5101" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrincipalOwnerMember_980016dc-d53e-4122-8032-f13a7d3f4a5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrincipalOwnerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_58697528-4e72-4cce-9eb0-a9f6f6691c9f" xlink:to="loc_us-gaap_PrincipalOwnerMember_980016dc-d53e-4122-8032-f13a7d3f4a5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NonprincipalOwnerMember_6a7faeaa-f9fd-4ee4-a7ad-480a30223fa7" xlink:href="cpix-20201210.xsd#cpix_NonprincipalOwnerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_58697528-4e72-4cce-9eb0-a9f6f6691c9f" xlink:to="loc_cpix_NonprincipalOwnerMember_6a7faeaa-f9fd-4ee4-a7ad-480a30223fa7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_8746c700-04dc-4f87-9acf-dd646869e8bd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_58697528-4e72-4cce-9eb0-a9f6f6691c9f" xlink:to="loc_srt_DirectorMember_8746c700-04dc-4f87-9acf-dd646869e8bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ba9fb421-4694-4117-a342-c77a6eab609a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0d18e818-8ee8-4eeb-88ef-f1e306acdec5" xlink:to="loc_srt_RangeAxis_ba9fb421-4694-4117-a342-c77a6eab609a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ba9fb421-4694-4117-a342-c77a6eab609a_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ba9fb421-4694-4117-a342-c77a6eab609a" xlink:to="loc_srt_RangeMember_ba9fb421-4694-4117-a342-c77a6eab609a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_32047539-db97-4f83-bf14-a1cb5dc9b927" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ba9fb421-4694-4117-a342-c77a6eab609a" xlink:to="loc_srt_RangeMember_32047539-db97-4f83-bf14-a1cb5dc9b927" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6f219603-68a7-4a14-b68e-f154b14182bd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_32047539-db97-4f83-bf14-a1cb5dc9b927" xlink:to="loc_srt_MinimumMember_6f219603-68a7-4a14-b68e-f154b14182bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bad29a61-456f-432e-b580-38a87c8636aa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_32047539-db97-4f83-bf14-a1cb5dc9b927" xlink:to="loc_srt_MaximumMember_bad29a61-456f-432e-b580-38a87c8636aa" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails" xlink:type="extended" id="iabaf6254730649ee9b1c2252e4090514_StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dfbf0e75-5e5e-4184-bdab-f31990e62c93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_7b836ce1-08d7-486a-9a35-00f0ae78bb6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dfbf0e75-5e5e-4184-bdab-f31990e62c93" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_7b836ce1-08d7-486a-9a35-00f0ae78bb6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bebeedd5-4e1b-4531-90bb-8dd3fee1a211" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dfbf0e75-5e5e-4184-bdab-f31990e62c93" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bebeedd5-4e1b-4531-90bb-8dd3fee1a211" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_470cf1ba-88e4-4609-ba25-7158ef571e36" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bebeedd5-4e1b-4531-90bb-8dd3fee1a211" xlink:to="loc_srt_TitleOfIndividualAxis_470cf1ba-88e4-4609-ba25-7158ef571e36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_470cf1ba-88e4-4609-ba25-7158ef571e36_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_470cf1ba-88e4-4609-ba25-7158ef571e36" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_470cf1ba-88e4-4609-ba25-7158ef571e36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6fc807d7-45c8-49d0-9360-38c2379edaa3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_470cf1ba-88e4-4609-ba25-7158ef571e36" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6fc807d7-45c8-49d0-9360-38c2379edaa3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EmployeeMember_e9649e57-024b-477c-9754-adbf48d336d4" xlink:href="cpix-20201210.xsd#cpix_EmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6fc807d7-45c8-49d0-9360-38c2379edaa3" xlink:to="loc_cpix_EmployeeMember_e9649e57-024b-477c-9754-adbf48d336d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NonemployeeMember_4cbf24bc-f60e-4b8c-aac9-9439ab0c8061" xlink:href="cpix-20201210.xsd#cpix_NonemployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6fc807d7-45c8-49d0-9360-38c2379edaa3" xlink:to="loc_cpix_NonemployeeMember_4cbf24bc-f60e-4b8c-aac9-9439ab0c8061" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FoundationContributionMember_9ef7feff-ea03-445b-8f6c-b28b777d1851" xlink:href="cpix-20201210.xsd#cpix_FoundationContributionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6fc807d7-45c8-49d0-9360-38c2379edaa3" xlink:to="loc_cpix_FoundationContributionMember_9ef7feff-ea03-445b-8f6c-b28b777d1851" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EmployeeNonemployeeandFoundationContributionMember_6df2299d-1748-45e8-9dcb-22b681be6ada" xlink:href="cpix-20201210.xsd#cpix_EmployeeNonemployeeandFoundationContributionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6fc807d7-45c8-49d0-9360-38c2379edaa3" xlink:to="loc_cpix_EmployeeNonemployeeandFoundationContributionMember_6df2299d-1748-45e8-9dcb-22b681be6ada" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#StockBasedCompensationPlansScheduleofStockOptionsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails" xlink:type="extended" id="i4de4ec3b48c74be9870e461fd2d80db4_StockBasedCompensationPlansScheduleofStockOptionsActivityDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityAdditionalDisclosuresDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#StockBasedCompensationPlansScheduleofStockOptionActivityAdditionalDisclosuresDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityAdditionalDisclosuresDetails" xlink:type="extended" id="i4ce25434c72846e88c138f1b982e7ef9_StockBasedCompensationPlansScheduleofStockOptionActivityAdditionalDisclosuresDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails" xlink:type="extended" id="ieb6191c169eb49fab73d5f482523ced7_StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_95e26a9d-aa89-4ca4-a849-c210347f44d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_12c94451-b629-4521-8006-22dc8b30d7e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_95e26a9d-aa89-4ca4-a849-c210347f44d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_12c94451-b629-4521-8006-22dc8b30d7e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_99b63a37-cdea-4687-bbb8-dd5cf6e4ec26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_12c94451-b629-4521-8006-22dc8b30d7e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_99b63a37-cdea-4687-bbb8-dd5cf6e4ec26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2e8eaf0a-eaec-4262-8d2f-9379345b4bf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_12c94451-b629-4521-8006-22dc8b30d7e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2e8eaf0a-eaec-4262-8d2f-9379345b4bf6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_274309e5-354d-4ef7-8d77-e267f96c07da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_12c94451-b629-4521-8006-22dc8b30d7e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_274309e5-354d-4ef7-8d77-e267f96c07da" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5ec2a7b1-b1ef-43ee-afcb-9941d770defd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_12c94451-b629-4521-8006-22dc8b30d7e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5ec2a7b1-b1ef-43ee-afcb-9941d770defd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_01296477-4ae9-49af-92ff-8ae05cd120fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_27794b5a-2496-42b8-9809-0fe35960c77c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_95e26a9d-aa89-4ca4-a849-c210347f44d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_27794b5a-2496-42b8-9809-0fe35960c77c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2e0cb6b7-49a5-4a55-9aaa-05d1673f31d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_27794b5a-2496-42b8-9809-0fe35960c77c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2e0cb6b7-49a5-4a55-9aaa-05d1673f31d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d278bb2c-006b-45e7-9983-35a03ed253c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_27794b5a-2496-42b8-9809-0fe35960c77c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d278bb2c-006b-45e7-9983-35a03ed253c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9884d717-c92e-4de1-8979-c00867693b38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_27794b5a-2496-42b8-9809-0fe35960c77c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9884d717-c92e-4de1-8979-c00867693b38" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5f9205a4-70c1-4ebf-8b65-eba59bd9fcfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_27794b5a-2496-42b8-9809-0fe35960c77c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5f9205a4-70c1-4ebf-8b65-eba59bd9fcfc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_56af89d4-9495-419b-88a0-79184e8713f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9624a8f-ea78-47b4-868d-5d37c414fa87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_95e26a9d-aa89-4ca4-a849-c210347f44d9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9624a8f-ea78-47b4-868d-5d37c414fa87" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_609fc5d1-607f-4bb8-a0b4-ef590408de8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9624a8f-ea78-47b4-868d-5d37c414fa87" xlink:to="loc_us-gaap_AwardTypeAxis_609fc5d1-607f-4bb8-a0b4-ef590408de8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_609fc5d1-607f-4bb8-a0b4-ef590408de8a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_609fc5d1-607f-4bb8-a0b4-ef590408de8a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_609fc5d1-607f-4bb8-a0b4-ef590408de8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_27b494e6-d16b-4773-a26e-f1347ae376bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_609fc5d1-607f-4bb8-a0b4-ef590408de8a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_27b494e6-d16b-4773-a26e-f1347ae376bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_ae2fc261-ceae-4e32-a8e6-eb1fbb3b4a72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_27b494e6-d16b-4773-a26e-f1347ae376bc" xlink:to="loc_us-gaap_RestrictedStockMember_ae2fc261-ceae-4e32-a8e6-eb1fbb3b4a72" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EmployeeBenefitPlans" xlink:type="simple" xlink:href="cpix-20201210.xsd#EmployeeBenefitPlans"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/EmployeeBenefitPlans" xlink:type="extended" id="i19f67f75f3914a839c051ff8667a9aa5_EmployeeBenefitPlans"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EmployeeBenefitPlansNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#EmployeeBenefitPlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/EmployeeBenefitPlansNarrativeDetails" xlink:type="extended" id="i2a997abf55ba44969393e2be4917898d_EmployeeBenefitPlansNarrativeDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Leases" xlink:type="simple" xlink:href="cpix-20201210.xsd#Leases"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/Leases" xlink:type="extended" id="i2233440e4e9f4d27b56eb9bfc48e5111_Leases"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#LeasesTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="extended" id="ic808caf53bb546f99c043a955bdc1a6d_LeasesTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i1740a2594b464236be61749a85079f5a_LeasesNarrativeDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofRentExpenseandSubleaseIncomeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#LeasesScheduleofRentExpenseandSubleaseIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofRentExpenseandSubleaseIncomeDetails" xlink:type="extended" id="i4b31027b053b4294aa3594a81398acbe_LeasesScheduleofRentExpenseandSubleaseIncomeDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#LeasesLeasePositionDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="extended" id="ie26e49c3db144f0da8a82f79751a8974_LeasesLeasePositionDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails" xlink:type="extended" id="ie59a7a3b4e5a4bfba048b821826b986e_LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/FairValueofFinancialInstruments" xlink:type="simple" xlink:href="cpix-20201210.xsd#FairValueofFinancialInstruments"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/FairValueofFinancialInstruments" xlink:type="extended" id="i9433e8cdd064454588cdc22a32f090f3_FairValueofFinancialInstruments"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#FairValueofFinancialInstrumentsTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsTables" xlink:type="extended" id="i8cc91ad1d4f647c4abd16b3bcf0b0d6d_FairValueofFinancialInstrumentsTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails" xlink:type="extended" id="i62dbc93e42b344f08b1b4942c60edbf8_FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_515defec-e456-4c92-8260-518e1d63faee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_42c87729-72cb-4d30-8d6e-bcf031010c69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradingSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_515defec-e456-4c92-8260-518e1d63faee" xlink:to="loc_us-gaap_TradingSecurities_42c87729-72cb-4d30-8d6e-bcf031010c69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aaa660e3-7e22-46b0-aab1-b838376b45b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_515defec-e456-4c92-8260-518e1d63faee" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aaa660e3-7e22-46b0-aab1-b838376b45b3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_5542f335-a31f-4610-af39-cfe30cba60a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aaa660e3-7e22-46b0-aab1-b838376b45b3" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_5542f335-a31f-4610-af39-cfe30cba60a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5542f335-a31f-4610-af39-cfe30cba60a8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_5542f335-a31f-4610-af39-cfe30cba60a8" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5542f335-a31f-4610-af39-cfe30cba60a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_34b6d6c4-f4ee-4b05-870b-b100dff03b57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_5542f335-a31f-4610-af39-cfe30cba60a8" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_34b6d6c4-f4ee-4b05-870b-b100dff03b57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_USTreasuryNotesAndBondsSecuritiesMember_07d7ee25-0cd1-4548-b366-be025f4ec9f6" xlink:href="cpix-20201210.xsd#cpix_USTreasuryNotesAndBondsSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_34b6d6c4-f4ee-4b05-870b-b100dff03b57" xlink:to="loc_cpix_USTreasuryNotesAndBondsSecuritiesMember_07d7ee25-0cd1-4548-b366-be025f4ec9f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LoanPoolsMember_9d0eb423-0e8f-436c-8f64-b498736756b4" xlink:href="cpix-20201210.xsd#cpix_LoanPoolsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_34b6d6c4-f4ee-4b05-870b-b100dff03b57" xlink:to="loc_cpix_LoanPoolsMember_9d0eb423-0e8f-436c-8f64-b498736756b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_be598417-198b-4c8f-8b80-e29ad3f2c333" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_34b6d6c4-f4ee-4b05-870b-b100dff03b57" xlink:to="loc_us-gaap_MunicipalBondsMember_be598417-198b-4c8f-8b80-e29ad3f2c333" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_16ae942f-a5e3-45bd-b501-d65e00ff9c52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_34b6d6c4-f4ee-4b05-870b-b100dff03b57" xlink:to="loc_us-gaap_CommercialPaperMember_16ae942f-a5e3-45bd-b501-d65e00ff9c52" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_49173e3a-2913-4c1f-8c7f-6db1de10e22f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aaa660e3-7e22-46b0-aab1-b838376b45b3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_49173e3a-2913-4c1f-8c7f-6db1de10e22f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_49173e3a-2913-4c1f-8c7f-6db1de10e22f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_49173e3a-2913-4c1f-8c7f-6db1de10e22f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_49173e3a-2913-4c1f-8c7f-6db1de10e22f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1a0e84aa-7721-454e-abfc-72729999e854" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_49173e3a-2913-4c1f-8c7f-6db1de10e22f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1a0e84aa-7721-454e-abfc-72729999e854" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_95d15f9c-d6e0-4c77-837c-210363f72d7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1a0e84aa-7721-454e-abfc-72729999e854" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_95d15f9c-d6e0-4c77-837c-210363f72d7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e1a4b0fc-facb-414d-a4ac-d988dbd02408" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1a0e84aa-7721-454e-abfc-72729999e854" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e1a4b0fc-facb-414d-a4ac-d988dbd02408" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketConcentrations" xlink:type="simple" xlink:href="cpix-20201210.xsd#MarketConcentrations"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/MarketConcentrations" xlink:type="extended" id="iaae10e0b41e349a9869d5297e9453f33_MarketConcentrations"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketConcentrationsTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#MarketConcentrationsTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/MarketConcentrationsTables" xlink:type="extended" id="i15b96b6934ef4f0fa7e6d8a71754804d_MarketConcentrationsTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails" xlink:type="extended" id="i401d4cb9e63346b7b9933e40204b0deb_MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_3cfc0447-ede5-4ad6-8e9a-cac3477142c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_85672499-05a4-4c90-9d1d-8c4d97dc0b42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_3cfc0447-ede5-4ad6-8e9a-cac3477142c5" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_85672499-05a4-4c90-9d1d-8c4d97dc0b42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_3832e9e9-9e0b-40c0-a830-d791b1d046e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_3cfc0447-ede5-4ad6-8e9a-cac3477142c5" xlink:to="loc_us-gaap_ConcentrationRiskTable_3832e9e9-9e0b-40c0-a830-d791b1d046e9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_111ea499-599e-4ec7-a230-a515ee5378b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_3832e9e9-9e0b-40c0-a830-d791b1d046e9" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_111ea499-599e-4ec7-a230-a515ee5378b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_111ea499-599e-4ec7-a230-a515ee5378b6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_111ea499-599e-4ec7-a230-a515ee5378b6" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_111ea499-599e-4ec7-a230-a515ee5378b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_322c5836-def4-4cae-8530-048269ca44d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_111ea499-599e-4ec7-a230-a515ee5378b6" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_322c5836-def4-4cae-8530-048269ca44d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_9fca648d-9498-496c-99ca-6c5412307854" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_322c5836-def4-4cae-8530-048269ca44d6" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_9fca648d-9498-496c-99ca-6c5412307854" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_28046076-d03a-421b-9cf6-dea9ae2716f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_3832e9e9-9e0b-40c0-a830-d791b1d046e9" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_28046076-d03a-421b-9cf6-dea9ae2716f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_28046076-d03a-421b-9cf6-dea9ae2716f7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_28046076-d03a-421b-9cf6-dea9ae2716f7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_28046076-d03a-421b-9cf6-dea9ae2716f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_71cb8a25-b930-4c26-976a-978bf8da482b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_28046076-d03a-421b-9cf6-dea9ae2716f7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_71cb8a25-b930-4c26-976a-978bf8da482b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SalesRevenueGoodsGrossMember_830bc3cf-afe9-44a3-98bd-2614e6c1bcc0" xlink:href="cpix-20201210.xsd#cpix_SalesRevenueGoodsGrossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_71cb8a25-b930-4c26-976a-978bf8da482b" xlink:to="loc_cpix_SalesRevenueGoodsGrossMember_830bc3cf-afe9-44a3-98bd-2614e6c1bcc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_695023a0-1bbb-4bcd-b1d5-b250e184206d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_71cb8a25-b930-4c26-976a-978bf8da482b" xlink:to="loc_us-gaap_AccountsReceivableMember_695023a0-1bbb-4bcd-b1d5-b250e184206d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_0ff92a47-e689-4057-88fa-754ffadfc9ee" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_3832e9e9-9e0b-40c0-a830-d791b1d046e9" xlink:to="loc_srt_MajorCustomersAxis_0ff92a47-e689-4057-88fa-754ffadfc9ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0ff92a47-e689-4057-88fa-754ffadfc9ee_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_0ff92a47-e689-4057-88fa-754ffadfc9ee" xlink:to="loc_srt_NameOfMajorCustomerDomain_0ff92a47-e689-4057-88fa-754ffadfc9ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_20a4c143-ad0f-4bd9-acb5-ad085b5d831a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_0ff92a47-e689-4057-88fa-754ffadfc9ee" xlink:to="loc_srt_NameOfMajorCustomerDomain_20a4c143-ad0f-4bd9-acb5-ad085b5d831a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CustomerOneMember_d3f0f3e5-f307-43f0-877f-650c5c44d2ce" xlink:href="cpix-20201210.xsd#cpix_CustomerOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_20a4c143-ad0f-4bd9-acb5-ad085b5d831a" xlink:to="loc_cpix_CustomerOneMember_d3f0f3e5-f307-43f0-877f-650c5c44d2ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CustomerTwoMember_34d6aa67-587e-4a10-97a8-84945e93e664" xlink:href="cpix-20201210.xsd#cpix_CustomerTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_20a4c143-ad0f-4bd9-acb5-ad085b5d831a" xlink:to="loc_cpix_CustomerTwoMember_34d6aa67-587e-4a10-97a8-84945e93e664" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CustomerThreeMember_ce47a472-4ab3-4638-a93a-25c4b06e3c7a" xlink:href="cpix-20201210.xsd#cpix_CustomerThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_20a4c143-ad0f-4bd9-acb5-ad085b5d831a" xlink:to="loc_cpix_CustomerThreeMember_ce47a472-4ab3-4638-a93a-25c4b06e3c7a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreements" xlink:type="simple" xlink:href="cpix-20201210.xsd#ManufacturingandSupplyAgreements"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreements" xlink:type="extended" id="i4fa50ff98f824cbb9c8ebdbcd7d26c8a_ManufacturingandSupplyAgreements"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails" xlink:type="extended" id="ibe968840b04f4171a2368ea4d0d413a0_ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingandSupplyAgreementLineItems_d88e19ce-3235-4d6c-8fcf-71f52bcd0b09" xlink:href="cpix-20201210.xsd#cpix_ManufacturingandSupplyAgreementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct_6a6011f0-aa4e-47fe-9da3-aeedf349fca5" xlink:href="cpix-20201210.xsd#cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ManufacturingandSupplyAgreementLineItems_d88e19ce-3235-4d6c-8fcf-71f52bcd0b09" xlink:to="loc_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct_6a6011f0-aa4e-47fe-9da3-aeedf349fca5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingandSupplyAgreementTable_410418cc-29ae-4b2d-8199-bedda5b0d14e" xlink:href="cpix-20201210.xsd#cpix_ManufacturingandSupplyAgreementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cpix_ManufacturingandSupplyAgreementLineItems_d88e19ce-3235-4d6c-8fcf-71f52bcd0b09" xlink:to="loc_cpix_ManufacturingandSupplyAgreementTable_410418cc-29ae-4b2d-8199-bedda5b0d14e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9cc3520c-4cc4-408d-a5e4-283613d9af6b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cpix_ManufacturingandSupplyAgreementTable_410418cc-29ae-4b2d-8199-bedda5b0d14e" xlink:to="loc_srt_RangeAxis_9cc3520c-4cc4-408d-a5e4-283613d9af6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9cc3520c-4cc4-408d-a5e4-283613d9af6b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9cc3520c-4cc4-408d-a5e4-283613d9af6b" xlink:to="loc_srt_RangeMember_9cc3520c-4cc4-408d-a5e4-283613d9af6b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7514c2e8-0ed0-42bf-af52-f0258e4140ae" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9cc3520c-4cc4-408d-a5e4-283613d9af6b" xlink:to="loc_srt_RangeMember_7514c2e8-0ed0-42bf-af52-f0258e4140ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bc49f5d7-20bd-4460-a21b-d5a5f8f33393" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7514c2e8-0ed0-42bf-af52-f0258e4140ae" xlink:to="loc_srt_MinimumMember_bc49f5d7-20bd-4460-a21b-d5a5f8f33393" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7c204c01-0f82-4a95-8075-880d8b88f1c7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7514c2e8-0ed0-42bf-af52-f0258e4140ae" xlink:to="loc_srt_MaximumMember_7c204c01-0f82-4a95-8075-880d8b88f1c7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EmploymentAgreements" xlink:type="simple" xlink:href="cpix-20201210.xsd#EmploymentAgreements"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/EmploymentAgreements" xlink:type="extended" id="i1bd8bfe38f0c4a0a83986212733e72bc_EmploymentAgreements"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/DiscontinuedOperations" xlink:type="simple" xlink:href="cpix-20201210.xsd#DiscontinuedOperations"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/DiscontinuedOperations" xlink:type="extended" id="iccee6fca513b43f5af445110e20106b6_DiscontinuedOperations"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/DiscontinuedOperationsandDisposalGroupsTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#DiscontinuedOperationsandDisposalGroupsTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/DiscontinuedOperationsandDisposalGroupsTables" xlink:type="extended" id="ib68b5a15bdcd461a99cc7a6ad9afef9e_DiscontinuedOperationsandDisposalGroupsTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/DiscontinuedOperationsDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#DiscontinuedOperationsDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/DiscontinuedOperationsDetails" xlink:type="extended" id="ia0d4c3eaac904fbfb829fe87698ba8fb_DiscontinuedOperationsDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="cpix-20201210.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CommitmentsandContingencies" xlink:type="extended" id="i60dc12dcbb96425aa763120a8bf3be3d_CommitmentsandContingencies"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="simple" xlink:href="cpix-20201210.xsd#QuarterlyFinancialInformationUnaudited"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="extended" id="i167f704703754bc29cd6cadd1440bf0f_QuarterlyFinancialInformationUnaudited"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#QuarterlyFinancialInformationUnauditedTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="extended" id="iea7b643fbd7f4004b40db165244004f6_QuarterlyFinancialInformationUnauditedTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails" xlink:type="extended" id="i7adc4e9c5f164009bb4a5c4a738ef41b_QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SubsequentEvents" xlink:type="simple" xlink:href="cpix-20201210.xsd#SubsequentEvents"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/SubsequentEvents" xlink:type="extended" id="i4151a991b897467f98e21438ca3f3928_SubsequentEvents"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccounts" xlink:type="simple" xlink:href="cpix-20201210.xsd#ValuationandQualifyingAccounts"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccounts" xlink:type="extended" id="i7397a78e221148509cbd79c6e10922e3_ValuationandQualifyingAccounts"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#ValuationandQualifyingAccountsDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails" xlink:type="extended" id="i71f4b9915d404cf8b674549ecd6503ea_ValuationandQualifyingAccountsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b65ce010-ac19-495e-a795-9140ea55ccc7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_5af212da-76bb-4b12-a93a-7de386b81b22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b65ce010-ac19-495e-a795-9140ea55ccc7" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_5af212da-76bb-4b12-a93a-7de386b81b22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_c7c1f755-85f9-479b-984d-82df1a9930cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_5af212da-76bb-4b12-a93a-7de386b81b22" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_c7c1f755-85f9-479b-984d-82df1a9930cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_0a0c4318-5e5e-4f29-a338-2e418f465dfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_5af212da-76bb-4b12-a93a-7de386b81b22" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_0a0c4318-5e5e-4f29-a338-2e418f465dfe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_0c623c80-03aa-4a1e-be9b-b690c76809af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_5af212da-76bb-4b12-a93a-7de386b81b22" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_0c623c80-03aa-4a1e-be9b-b690c76809af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_9ef7103a-3b73-4770-a7ac-0e60fa16a26a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_5af212da-76bb-4b12-a93a-7de386b81b22" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_9ef7103a-3b73-4770-a7ac-0e60fa16a26a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_f9522eff-c381-4820-b992-a2e351fce395" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_b73d127b-3a1e-4dab-999b-35572cbd34b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b65ce010-ac19-495e-a795-9140ea55ccc7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_b73d127b-3a1e-4dab-999b-35572cbd34b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TaxCutsandJobsActof2017ChangeinTaxRateDeferredTaxAssetIncomeTaxExpenseBenefit_df4aade6-d735-4ee3-900f-11e5c1050b1d" xlink:href="cpix-20201210.xsd#cpix_TaxCutsandJobsActof2017ChangeinTaxRateDeferredTaxAssetIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b65ce010-ac19-495e-a795-9140ea55ccc7" xlink:to="loc_cpix_TaxCutsandJobsActof2017ChangeinTaxRateDeferredTaxAssetIncomeTaxExpenseBenefit_df4aade6-d735-4ee3-900f-11e5c1050b1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_d4d8da49-e30a-42e3-84c5-c30c32db27bc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b65ce010-ac19-495e-a795-9140ea55ccc7" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_d4d8da49-e30a-42e3-84c5-c30c32db27bc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_9a708c3e-9884-49a3-bc2c-12ab50f0fb34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_d4d8da49-e30a-42e3-84c5-c30c32db27bc" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_9a708c3e-9884-49a3-bc2c-12ab50f0fb34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_9a708c3e-9884-49a3-bc2c-12ab50f0fb34_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_9a708c3e-9884-49a3-bc2c-12ab50f0fb34" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_9a708c3e-9884-49a3-bc2c-12ab50f0fb34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_fa6aa5ce-7106-4758-ba35-a88aa5cd4ab9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_9a708c3e-9884-49a3-bc2c-12ab50f0fb34" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_fa6aa5ce-7106-4758-ba35-a88aa5cd4ab9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossMember_6d476421-0de3-451c-b947-12c22a65dd4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForCreditLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_fa6aa5ce-7106-4758-ba35-a88aa5cd4ab9" xlink:to="loc_us-gaap_AllowanceForCreditLossMember_6d476421-0de3-451c-b947-12c22a65dd4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_034fa538-8eb1-4da0-801e-bba7a8e08f71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_fa6aa5ce-7106-4758-ba35-a88aa5cd4ab9" xlink:to="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_034fa538-8eb1-4da0-801e-bba7a8e08f71" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>cpix-20201210_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:bbbd83ec-86cd-4852-a42b-62050b4598f2,g:afd11596-cbdf-45f6-87ac-39eae3274065-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_cpix_ProductRevenuesAbstract_bf15e46b-9772-4210-a689-c1b79aae5b9c_terseLabel_en-US" xlink:label="lab_cpix_ProductRevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Revenues</link:label>
    <link:label id="lab_cpix_ProductRevenuesAbstract_label_en-US" xlink:label="lab_cpix_ProductRevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Revenues [Abstract]</link:label>
    <link:label id="lab_cpix_ProductRevenuesAbstract_documentation_en-US" xlink:label="lab_cpix_ProductRevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductRevenuesAbstract" xlink:href="cpix-20201210.xsd#cpix_ProductRevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProductRevenuesAbstract" xlink:to="lab_cpix_ProductRevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_21078fef-0892-4d4d-809a-2872bb9e36a3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares granted, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_d695e6fe-697d-40cc-a089-aa8935afaa7e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_c6510c5e-65f8-4fe9-9afb-0e661f356f8b_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IfetrobanClinicalMember_64e35500-cbf6-4cde-8179-329561ab0a93_terseLabel_en-US" xlink:label="lab_cpix_IfetrobanClinicalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ifetroban Clinical</link:label>
    <link:label id="lab_cpix_IfetrobanClinicalMember_label_en-US" xlink:label="lab_cpix_IfetrobanClinicalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ifetroban Clinical [Member]</link:label>
    <link:label id="lab_cpix_IfetrobanClinicalMember_documentation_en-US" xlink:label="lab_cpix_IfetrobanClinicalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ifetroban Clinical</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember" xlink:href="cpix-20201210.xsd#cpix_IfetrobanClinicalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IfetrobanClinicalMember" xlink:to="lab_cpix_IfetrobanClinicalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding_3a2eb332-6a4d-4ba9-8a28-3f0a58c61d03_terseLabel_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of options and related tax benefit, shares</link:label>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding_label_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Net of Shares for Tax Withholding</link:label>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding_documentation_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Net of Shares for Tax Withholding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding" xlink:href="cpix-20201210.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding" xlink:to="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_69334132-3c75-43fa-a7df-810fea22d3c6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of period, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SharesRepurchaseActivityTypeDomain_351df7c4-28bf-4186-8d65-ab6cd9c638f6_terseLabel_en-US" xlink:label="lab_cpix_SharesRepurchaseActivityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Repurchase Activity, Type [Domain]</link:label>
    <link:label id="lab_cpix_SharesRepurchaseActivityTypeDomain_label_en-US" xlink:label="lab_cpix_SharesRepurchaseActivityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Repurchase Activity, Type [Domain]</link:label>
    <link:label id="lab_cpix_SharesRepurchaseActivityTypeDomain_documentation_en-US" xlink:label="lab_cpix_SharesRepurchaseActivityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Shares Repurchase Activity, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharesRepurchaseActivityTypeDomain" xlink:href="cpix-20201210.xsd#cpix_SharesRepurchaseActivityTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SharesRepurchaseActivityTypeDomain" xlink:to="lab_cpix_SharesRepurchaseActivityTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_31b3f1e5-a7b9-440c-a678-b5d751f55896_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2f45c6bd-3cab-4c7d-a11b-e40c9c39adb2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductionAndDistributionCosts_6a2f43ef-01c6-4b9b-b21b-da337d7c8b41_terseLabel_en-US" xlink:label="lab_us-gaap_ProductionAndDistributionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution costs</link:label>
    <link:label id="lab_us-gaap_ProductionAndDistributionCosts_label_en-US" xlink:label="lab_us-gaap_ProductionAndDistributionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Production and Distribution Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductionAndDistributionCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductionAndDistributionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductionAndDistributionCosts" xlink:to="lab_us-gaap_ProductionAndDistributionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_21b1e010-2105-48a3-9281-f052d4213d1b_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_a242de82-d599-4044-8590-785b1ffc2b13_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_16045467-a999-4293-9803-73a614b2a660_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_dd2e3a48-7b4a-4778-9f3b-5bb4555f97fe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares vested, weighted-average grant-date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CumberlandEmergingTechnologiesIncMember_3af70fcc-f298-40a4-997b-3f37c6bd7b73_terseLabel_en-US" xlink:label="lab_cpix_CumberlandEmergingTechnologiesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumberland Emerging Technologies, Inc (CET)</link:label>
    <link:label id="lab_cpix_CumberlandEmergingTechnologiesIncMember_label_en-US" xlink:label="lab_cpix_CumberlandEmergingTechnologiesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumberland Emerging Technologies, Inc [Member]</link:label>
    <link:label id="lab_cpix_CumberlandEmergingTechnologiesIncMember_documentation_en-US" xlink:label="lab_cpix_CumberlandEmergingTechnologiesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumberland Emerging Technologies, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CumberlandEmergingTechnologiesIncMember" xlink:href="cpix-20201210.xsd#cpix_CumberlandEmergingTechnologiesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CumberlandEmergingTechnologiesIncMember" xlink:to="lab_cpix_CumberlandEmergingTechnologiesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_c23b5a8b-26b2-4537-b815-8f3f3d440042_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common shares, shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_615ecff9-facb-4dd5-bb99-e0a3ca1363cf_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common shares, shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SharebasedCompensationFoundationContribution_6ca0578f-e94a-42bf-a80d-a3efd4811793_terseLabel_en-US" xlink:label="lab_cpix_SharebasedCompensationFoundationContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation (foundation contribution)</link:label>
    <link:label id="lab_cpix_SharebasedCompensationFoundationContribution_label_en-US" xlink:label="lab_cpix_SharebasedCompensationFoundationContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Foundation Contribution</link:label>
    <link:label id="lab_cpix_SharebasedCompensationFoundationContribution_documentation_en-US" xlink:label="lab_cpix_SharebasedCompensationFoundationContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Foundation Contribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharebasedCompensationFoundationContribution" xlink:href="cpix-20201210.xsd#cpix_SharebasedCompensationFoundationContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SharebasedCompensationFoundationContribution" xlink:to="lab_cpix_SharebasedCompensationFoundationContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NumeratorAbstract_f94b5fad-19e5-4e5d-bb82-9ad286e16257_verboseLabel_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_cpix_NumeratorAbstract_label_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator [Abstract]</link:label>
    <link:label id="lab_cpix_NumeratorAbstract_documentation_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NumeratorAbstract" xlink:href="cpix-20201210.xsd#cpix_NumeratorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NumeratorAbstract" xlink:to="lab_cpix_NumeratorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LoanPoolsMember_b373df10-594c-4929-8c54-fa19a3f07713_verboseLabel_en-US" xlink:label="lab_cpix_LoanPoolsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SBA loan pools - variable rate</link:label>
    <link:label id="lab_cpix_LoanPoolsMember_label_en-US" xlink:label="lab_cpix_LoanPoolsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Pools [Member]</link:label>
    <link:label id="lab_cpix_LoanPoolsMember_documentation_en-US" xlink:label="lab_cpix_LoanPoolsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan pools.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LoanPoolsMember" xlink:href="cpix-20201210.xsd#cpix_LoanPoolsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LoanPoolsMember" xlink:to="lab_cpix_LoanPoolsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_102dda03-08bf-4795-950b-fa7659176622_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Rights</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_249a7bf9-e746-414b-8d15-10f1dd9d12bc_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a8bb3216-d940-46ff-83ed-992c6261f830_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_1b0b76dc-b449-4e4b-a1ec-c926eac50079_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RisksAndUncertaintiesAbstract_label_en-US" xlink:label="lab_us-gaap_RisksAndUncertaintiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract" xlink:to="lab_us-gaap_RisksAndUncertaintiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8a44473-1718-41df-9ad5-b95fff26e41b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_045b679a-8303-49bc-a5a4-2137801c5a4d_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire interest in subsidiaries</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Interest in Subsidiaries and Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:to="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_8ba08387-f5f8-4f6b-816e-fe95779615f7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_277555e5-92ac-4ef2-981c-3dfd110081cd_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts_960c5a92-7c09-4e88-b237-73fe73a93667_terseLabel_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial public offering, underwriting discounts</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts_label_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, New Shares, Underwriting Discounts</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts_documentation_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, New Shares, Underwriting Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts" xlink:href="cpix-20201210.xsd#cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts" xlink:to="lab_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_5c80ce44-6a8b-46cc-be2f-d58770e68444_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_01d94d04-f911-4f6b-8719-7f564fd68e7a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct_116df725-772e-4ba6-8e98-f1516be02298_terseLabel_en-US" xlink:label="lab_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing agreements, number of primary suppliers for each product</link:label>
    <link:label id="lab_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct_label_en-US" xlink:label="lab_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing agreements, number of primary suppliers for each product</link:label>
    <link:label id="lab_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct_documentation_en-US" xlink:label="lab_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing agreements, number of primary suppliers for each product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct" xlink:href="cpix-20201210.xsd#cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct" xlink:to="lab_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements_1d41a733-0d65-40b1-b8cd-9ded86b6ceb4_terseLabel_en-US" xlink:label="lab_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, including amortization related to leasehold improvements</link:label>
    <link:label id="lab_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements_label_en-US" xlink:label="lab_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Including Amortization Related to Leasehold Improvements</link:label>
    <link:label id="lab_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements_documentation_en-US" xlink:label="lab_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Including Amortization Related to Leasehold Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements" xlink:href="cpix-20201210.xsd#cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements" xlink:to="lab_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_0d53728b-2885-4f2b-a936-3c5d0924ac1d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember_5d967f65-64d7-4665-b49a-cb16b838561c_terseLabel_en-US" xlink:label="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HongKong WinHealth Pharma Group Co. Limited And DB Pharm Korea Co., Ltd.</link:label>
    <link:label id="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember_label_en-US" xlink:label="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HongKong WinHealth Pharma Group Co. Limited And DB Pharm Korea Co., Ltd. [Member]</link:label>
    <link:label id="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember_documentation_en-US" xlink:label="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HongKong WinHealth Pharma Group Co. Limited And DB Pharm Korea Co., Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember" xlink:href="cpix-20201210.xsd#cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember" xlink:to="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_4c05d86f-b664-4e1f-9347-5e8792169b6f_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_EmploymentAgreementsAbstract_label_en-US" xlink:label="lab_cpix_EmploymentAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employment Agreements [Abstract]</link:label>
    <link:label id="lab_cpix_EmploymentAgreementsAbstract_documentation_en-US" xlink:label="lab_cpix_EmploymentAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employment Agreements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EmploymentAgreementsAbstract" xlink:href="cpix-20201210.xsd#cpix_EmploymentAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_EmploymentAgreementsAbstract" xlink:to="lab_cpix_EmploymentAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_92cea85d-e2ec-492b-bbb9-fc64ab6fbb4a_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods inventory</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_label_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finished Goods Inventory</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finished Goods Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" xlink:href="cpix-20201210.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" xlink:to="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e2f96fcf-1dd1-4c76-8333-b44170829f3c_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_975be91b-7bbd-44d1-b92b-ef5aa4bfd293_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested, beginning of period, weighted-average grant-date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_32bb8b73-1b7e-41df-be7a-1bd18b8bf5bc_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested, end of period, weighted-average grant-date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_42e63182-3210-40f0-b0c0-84cd1eb34110_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) operating activities from continuing operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember_a6eca62d-f971-4a75-8793-eef39916ff25_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Federal Small Business Grant Programs</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Federal Small Business Grant Programs [Member]</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Federal Small Business Grant Programs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember" xlink:href="cpix-20201210.xsd#cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember" xlink:to="lab_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_788e4820-d0cb-48db-a06e-a518e5a43794_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_1977cc39-2c27-4c3e-8f2e-eef1b35b6bea_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_4402c59f-6aca-4eb4-995e-4226fe9de445_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_f81e0726-fc0e-470e-b88e-47c7b89017aa_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common shares</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_32801391-fa61-4e57-8972-2c552bbc7541_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6cae1a93-3186-4bc8-ae75-c4a58c80b31a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ce43977a-aa62-4172-b10d-083318dd9eb8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_2f80398f-fe00-4f43-9f2c-81612bbbebdc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After 2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_ea75f0e0-264f-4575-a6a3-9124bf17c408_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_e4046284-de77-427c-8f5e-23c7b7ff4195_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation, amount</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_8264f626-7f3d-464a-9ddc-d6dc6400f1c1_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_06093128-274b-4b46-879a-835856ca2c4e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_593381d4-102f-4325-b73f-9776b49d042e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares vested, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_95562262-5904-431e-a258-6acf329b588f_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IntercompanyLoansPayableConvertedAmount_81c1cedd-2526-48c2-8d18-a5217651c389_terseLabel_en-US" xlink:label="lab_cpix_IntercompanyLoansPayableConvertedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of intercompany loans payable</link:label>
    <link:label id="lab_cpix_IntercompanyLoansPayableConvertedAmount_label_en-US" xlink:label="lab_cpix_IntercompanyLoansPayableConvertedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intercompany Loans Payable, Converted Amount</link:label>
    <link:label id="lab_cpix_IntercompanyLoansPayableConvertedAmount_documentation_en-US" xlink:label="lab_cpix_IntercompanyLoansPayableConvertedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intercompany Loans Payable, Converted Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IntercompanyLoansPayableConvertedAmount" xlink:href="cpix-20201210.xsd#cpix_IntercompanyLoansPayableConvertedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IntercompanyLoansPayableConvertedAmount" xlink:to="lab_cpix_IntercompanyLoansPayableConvertedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_a8109d7f-1c68-4591-ac03-f2db33de5e1a_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_5738512e-8a90-43ad-9e1a-3be4e1f5c32b_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_bb427996-99ff-4138-b78f-7e27978374e3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DenominatorAbstract_5d30edd7-c580-4f40-8619-956ceb6de2d3_verboseLabel_en-US" xlink:label="lab_cpix_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_cpix_DenominatorAbstract_label_en-US" xlink:label="lab_cpix_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator [Abstract]</link:label>
    <link:label id="lab_cpix_DenominatorAbstract_documentation_en-US" xlink:label="lab_cpix_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DenominatorAbstract" xlink:href="cpix-20201210.xsd#cpix_DenominatorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DenominatorAbstract" xlink:to="lab_cpix_DenominatorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e285a58b-a929-420a-b2af-f548df4b1610_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ebbb6e60-0187-4f46-b82d-7c7485a5ff33_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of period, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2d11e10b-d72f-447a-a046-ec97eb79a09d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of period, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ExpirationTermTwoMember_555290ae-6b67-4e08-82d0-43b79e4cb0fa_terseLabel_en-US" xlink:label="lab_cpix_ExpirationTermTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 - 2029</link:label>
    <link:label id="lab_cpix_ExpirationTermTwoMember_label_en-US" xlink:label="lab_cpix_ExpirationTermTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration, Term Two [Member]</link:label>
    <link:label id="lab_cpix_ExpirationTermTwoMember_documentation_en-US" xlink:label="lab_cpix_ExpirationTermTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration, Term Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermTwoMember" xlink:href="cpix-20201210.xsd#cpix_ExpirationTermTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ExpirationTermTwoMember" xlink:to="lab_cpix_ExpirationTermTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3d7cd1b7-98e1-4c6f-b2d5-e3dcec732dd5_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b4e59488-ef71-4c67-a5b1-9b6a13945865_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_e4b41899-174c-460a-8271-6aff1acb0e23_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost related to share-based payments</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_df8a7402-89eb-4bf6-8a90-71e3cbcd5f3f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense, Sublease Rentals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_FinancialConsiderationPaymentPeriod_e086879b-52c6-449f-b51c-4e3004626eea_terseLabel_en-US" xlink:label="lab_cpix_FinancialConsiderationPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial consideration, payment period</link:label>
    <link:label id="lab_cpix_FinancialConsiderationPaymentPeriod_label_en-US" xlink:label="lab_cpix_FinancialConsiderationPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Consideration, Payment Period</link:label>
    <link:label id="lab_cpix_FinancialConsiderationPaymentPeriod_documentation_en-US" xlink:label="lab_cpix_FinancialConsiderationPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Consideration, Payment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FinancialConsiderationPaymentPeriod" xlink:href="cpix-20201210.xsd#cpix_FinancialConsiderationPaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_FinancialConsiderationPaymentPeriod" xlink:to="lab_cpix_FinancialConsiderationPaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_797f359d-ea22-4897-a17d-4ca04e831b29_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Customers [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_e272e777-0e80-4098-8760-19812bcac8e8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and other</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid_1b816969-6d23-4cbe-8084-2473c65f5852_terseLabel_en-US" xlink:label="lab_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in unpaid invoices for purchases of intangibles</link:label>
    <link:label id="lab_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid_label_en-US" xlink:label="lab_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of Intangible Assets Incurred But Not Yet Paid</link:label>
    <link:label id="lab_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of Intangible Assets Incurred But Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid" xlink:href="cpix-20201210.xsd#cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid" xlink:to="lab_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_cd6fd567-4b67-46df-b96b-8a2fa5400a56_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders-Continuing operations-diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_f5e3f53d-0c9e-4e21-ac70-3bf0a6ec7c8d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_fa22ec51-d03c-43e7-8482-573345097e12_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders-Discontinued operations-diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_5e3bd498-ae01-40d5-92a7-4293eb2eb942_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, exerciseable, end of period, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ExpirationTimePeriodDomain_8b35d2c9-1308-4ffe-b085-5ed58aa17163_terseLabel_en-US" xlink:label="lab_cpix_ExpirationTimePeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Time Period [Domain]</link:label>
    <link:label id="lab_cpix_ExpirationTimePeriodDomain_label_en-US" xlink:label="lab_cpix_ExpirationTimePeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Time Period [Domain]</link:label>
    <link:label id="lab_cpix_ExpirationTimePeriodDomain_documentation_en-US" xlink:label="lab_cpix_ExpirationTimePeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Expiration Time Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTimePeriodDomain" xlink:href="cpix-20201210.xsd#cpix_ExpirationTimePeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ExpirationTimePeriodDomain" xlink:to="lab_cpix_ExpirationTimePeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_a2b3678a-953e-4890-8ac7-34339e643013_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_cde6842c-549b-4818-9147-366057a27b27_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of financing costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_78e7fd45-8574-4917-b8f9-12668ddd9274_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_6aa712b2-47d7-4d0d-8fcc-25289285b8c0_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent, Total</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_1dba655a-7e58-4343-b5dc-79ee7d030224_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_a843011a-10ae-4475-bb89-1f39ba0cfbaf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options forfeited or expired, weighted-average exercise price per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_c233c755-ad36-4ef4-b9ab-205abd06980a_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_485ac250-b3ab-43b2-bb7f-1026a73b0c36_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_a0a4c060-1b61-46f4-bd8e-cb646ca013a2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of common stock</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProductSalesRelatedLiabilitiesCurrent_8994e754-fd94-40c0-aeb8-ceb13d4d0e62_terseLabel_en-US" xlink:label="lab_cpix_ProductSalesRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates, product returns, administrative fees and service fees</link:label>
    <link:label id="lab_cpix_ProductSalesRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_cpix_ProductSalesRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Sales-Related Liabilities, Current</link:label>
    <link:label id="lab_cpix_ProductSalesRelatedLiabilitiesCurrent_documentation_en-US" xlink:label="lab_cpix_ProductSalesRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Sales-Related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductSalesRelatedLiabilitiesCurrent" xlink:href="cpix-20201210.xsd#cpix_ProductSalesRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProductSalesRelatedLiabilitiesCurrent" xlink:to="lab_cpix_ProductSalesRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LeaseLiability_f41fc285-a0d6-46c2-9383-9e52056257aa_terseLabel_en-US" xlink:label="lab_cpix_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_cpix_LeaseLiability_label_en-US" xlink:label="lab_cpix_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:label id="lab_cpix_LeaseLiability_documentation_en-US" xlink:label="lab_cpix_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LeaseLiability" xlink:href="cpix-20201210.xsd#cpix_LeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LeaseLiability" xlink:to="lab_cpix_LeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_52c7b193-484a-443c-84f6-8dfb16addef6_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance for deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:to="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock_58870d19-56d8-4974-9c52-bb18e12e208e_terseLabel_en-US" xlink:label="lab_cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of intangible assets, useful lives</link:label>
    <link:label id="lab_cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock_label_en-US" xlink:label="lab_cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets UseFul Lives [Table Text Block]</link:label>
    <link:label id="lab_cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock_documentation_en-US" xlink:label="lab_cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets UseFul Lives [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock" xlink:href="cpix-20201210.xsd#cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock" xlink:to="lab_cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2798e103-8f98-4981-b3c3-55829052635c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options forfeited or expired, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_OtherRevenuesAbstract_a59ac30d-584b-43b1-844b-581d2e9f0376_terseLabel_en-US" xlink:label="lab_cpix_OtherRevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenues</link:label>
    <link:label id="lab_cpix_OtherRevenuesAbstract_label_en-US" xlink:label="lab_cpix_OtherRevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenues [Abstract]</link:label>
    <link:label id="lab_cpix_OtherRevenuesAbstract_documentation_en-US" xlink:label="lab_cpix_OtherRevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherRevenuesAbstract" xlink:href="cpix-20201210.xsd#cpix_OtherRevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OtherRevenuesAbstract" xlink:to="lab_cpix_OtherRevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_89c1d9d6-6a9c-495c-9c66-7eb113a9e775_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_5471341c-cb93-435b-a037-f79d2e20b51c_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_437addbe-f6f4-4174-99fa-dbc865103dc3_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e02fd8a2-6c1d-4eb9-8384-82d35269fcc7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_36302596-5c07-44eb-b43a-9a326f270e16_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_b67484f0-db50-4e1c-8965-22b6d97ea32f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_764d4bc2-9073-42ef-ae22-c5a583712e0b_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_26f4b5d8-c813-4089-bf21-b92d4b58f72f_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_9bf4fcab-3894-415e-bea9-0c237a8d783c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentDescription_5aa5f0b5-9750-4f16-8a29-7f5abb7efe4d_terseLabel_en-US" xlink:label="lab_dei_AmendmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Description</link:label>
    <link:label id="lab_dei_AmendmentDescription_label_en-US" xlink:label="lab_dei_AmendmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Description</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentDescription" xlink:to="lab_dei_AmendmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SalesRevenueGoodsGrossMember_9d122585-fae8-4cf4-898d-49827eec9035_terseLabel_en-US" xlink:label="lab_cpix_SalesRevenueGoodsGrossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue, Goods, Gross</link:label>
    <link:label id="lab_cpix_SalesRevenueGoodsGrossMember_label_en-US" xlink:label="lab_cpix_SalesRevenueGoodsGrossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue, Goods, Gross [Member]</link:label>
    <link:label id="lab_cpix_SalesRevenueGoodsGrossMember_documentation_en-US" xlink:label="lab_cpix_SalesRevenueGoodsGrossMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue, Goods, Gross [Member] [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SalesRevenueGoodsGrossMember" xlink:href="cpix-20201210.xsd#cpix_SalesRevenueGoodsGrossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SalesRevenueGoodsGrossMember" xlink:to="lab_cpix_SalesRevenueGoodsGrossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CashPaidDuringYearForAbstract_d336f49d-c80f-422a-bbfd-f850c786d33b_terseLabel_en-US" xlink:label="lab_cpix_CashPaidDuringYearForAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash paid (refunded) during the year for:</link:label>
    <link:label id="lab_cpix_CashPaidDuringYearForAbstract_label_en-US" xlink:label="lab_cpix_CashPaidDuringYearForAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid During Year For [Abstract]</link:label>
    <link:label id="lab_cpix_CashPaidDuringYearForAbstract_documentation_en-US" xlink:label="lab_cpix_CashPaidDuringYearForAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid During Year For [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CashPaidDuringYearForAbstract" xlink:href="cpix-20201210.xsd#cpix_CashPaidDuringYearForAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CashPaidDuringYearForAbstract" xlink:to="lab_cpix_CashPaidDuringYearForAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_VaprisolMember_e46227f2-d715-4c86-a5f1-cd9a05e1e6ad_verboseLabel_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol</link:label>
    <link:label id="lab_cpix_VaprisolMember_label_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol [Member]</link:label>
    <link:label id="lab_cpix_VaprisolMember_documentation_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember" xlink:href="cpix-20201210.xsd#cpix_VaprisolMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_VaprisolMember" xlink:to="lab_cpix_VaprisolMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_ba175e30-80fd-4ec5-8c5e-4f7e5bc7ca9e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_e67faa14-552c-4a25-91ef-e1d409e3e791_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_fcd773bf-f4d9-40cb-bb2c-137efeac5fb8_verboseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_259c3196-e95d-4482-a609-c74ed4cb9b52_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_355e9a10-76be-4f6d-8bee-dccadd512f60_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_028b2909-e6d4-4153-8016-5e45d7cee1fc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_f10890d1-bfdc-40ff-bb01-69d4067bb8c2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during period, acquisitions (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_dafa875b-d919-43a1-938f-afbbb774cf7c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of anti-dilutive securities excluded from computation of earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_27f4322f-cec0-48b3-a3ed-efdb6f0b15df_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_2da56d36-8dc4-444c-9232-f8df643c1c80_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_e606af99-9a9a-484c-81f7-7d66d3916f77_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent portion of accrued contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_11763a40-fe8c-41b5-b159-a4c3fae7da7a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of common stock, shares</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility_6d1f4204-9d58-4821-bad7-fe4569e6db23_terseLabel_en-US" xlink:label="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, eligibility, minimum employee service time for participation eligibility</link:label>
    <link:label id="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility_label_en-US" xlink:label="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Eligibility, Minimum Employee Service Time for Participation Eligibility</link:label>
    <link:label id="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility_documentation_en-US" xlink:label="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Eligibility, Minimum Employee Service Time for Participation Eligibility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility" xlink:href="cpix-20201210.xsd#cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility" xlink:to="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_778b1df9-b2f1-4f5f-b6bd-3b265b29ed77_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_6bb1fb70-0399-45a1-a461-1c4112c79edd_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNoParValue_18f577a5-09d4-46cf-bcf3-be9df4c5f2fc_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNoParValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, no par value (dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockNoParValue_label_en-US" xlink:label="lab_us-gaap_CommonStockNoParValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, No Par Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNoParValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNoParValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNoParValue" xlink:to="lab_us-gaap_CommonStockNoParValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_57196420-28a5-4042-9015-939775c17e89_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TextBlockAbstract_label_en-US" xlink:label="lab_us-gaap_TextBlockAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Text Block [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TextBlockAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TextBlockAbstract" xlink:to="lab_us-gaap_TextBlockAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_OmeclamoxPakMember_9056d3db-8f24-4552-8d8e-33179db76acf_terseLabel_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak</link:label>
    <link:label id="lab_cpix_OmeclamoxPakMember_156ec50a-5479-453d-a937-dc356d6ebe2d_verboseLabel_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak</link:label>
    <link:label id="lab_cpix_OmeclamoxPakMember_label_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak [Member]</link:label>
    <link:label id="lab_cpix_OmeclamoxPakMember_documentation_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember" xlink:href="cpix-20201210.xsd#cpix_OmeclamoxPakMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OmeclamoxPakMember" xlink:to="lab_cpix_OmeclamoxPakMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_d83f05d1-ed49-47eb-9168-b08340aa8194_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation liability</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Liability, Current and Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:to="lab_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0f8c78c8-8d29-4ae7-b8ec-fb09a83e54d3_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, exercise price</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_da012c88-8f38-4c6d-acc5-78267a4825d8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_8f7b376e-80e9-4f1b-8b2d-a73d8fa7fc89_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_5689b94b-ce8a-46da-9cfe-cff51c264895_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d9fdc394-6faf-4d19-ab03-df0ce749287a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liabilities, Payments Due [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_17d467b2-183a-4629-acab-42c81d1c5234_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Shareholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter_c25c0b27-eb09-43ce-9557-8926373076b6_terseLabel_en-US" xlink:label="lab_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024 and thereafter</link:label>
    <link:label id="lab_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter_label_en-US" xlink:label="lab_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five and After</link:label>
    <link:label id="lab_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter_documentation_en-US" xlink:label="lab_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five and After</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter" xlink:href="cpix-20201210.xsd#cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter" xlink:to="lab_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5ad18269-5506-4b10-8f86-4d053a50836a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_2e13962f-1baf-4aa5-a5a5-d26b4fbbbc3f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_117b2f33-f65e-4d3a-a320-c82b71173b43_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8ba359e9-18fd-4d2b-a4e9-1f75b5f92d2f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, end of period, weighted-average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_a27c15ca-051a-4846-b109-93a217ec3b61_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_098e3ffd-6c15-44c2-9e33-3357fc56ed5e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillPeriodIncreaseDecrease_476d350a-af03-4169-8a8d-9aebb3bf3b54_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NetDeferredTaxAssetsGross_07859304-7783-4b71-8761-cf50b33519cc_totalLabel_en-US" xlink:label="lab_cpix_NetDeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets, before valuation allowance</link:label>
    <link:label id="lab_cpix_NetDeferredTaxAssetsGross_label_en-US" xlink:label="lab_cpix_NetDeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Deferred Tax Assets, Gross</link:label>
    <link:label id="lab_cpix_NetDeferredTaxAssetsGross_documentation_en-US" xlink:label="lab_cpix_NetDeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NetDeferredTaxAssetsGross" xlink:href="cpix-20201210.xsd#cpix_NetDeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NetDeferredTaxAssetsGross" xlink:to="lab_cpix_NetDeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_b9bc2d17-9e71-40d6-848a-01b8f544ae8e_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_183b51f6-0618-4a92-b8b2-256ad1e5d6f3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of calculation of numerator and denominator in earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_f22f2380-d0e6-4d04-bc6c-5c46c0ea807f_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PernixTherapeuticsMember_4111b390-6fa3-4176-a67d-0e5810afe108_terseLabel_en-US" xlink:label="lab_cpix_PernixTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pernix Therapeutics</link:label>
    <link:label id="lab_cpix_PernixTherapeuticsMember_label_en-US" xlink:label="lab_cpix_PernixTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pernix Therapeutics [Member]</link:label>
    <link:label id="lab_cpix_PernixTherapeuticsMember_documentation_en-US" xlink:label="lab_cpix_PernixTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pernix Therapeutics [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PernixTherapeuticsMember" xlink:href="cpix-20201210.xsd#cpix_PernixTherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PernixTherapeuticsMember" xlink:to="lab_cpix_PernixTherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_815f67c0-e27b-4f50-a56e-8a34ad17a576_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_28df83f5-3d40-4d26-be93-6b4f238c942e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CustomerTwoMember_6d54ac81-32fd-43d8-a183-85a18e85e41d_terseLabel_en-US" xlink:label="lab_cpix_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer 2</link:label>
    <link:label id="lab_cpix_CustomerTwoMember_label_en-US" xlink:label="lab_cpix_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Two [Member]</link:label>
    <link:label id="lab_cpix_CustomerTwoMember_documentation_en-US" xlink:label="lab_cpix_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CustomerTwoMember" xlink:href="cpix-20201210.xsd#cpix_CustomerTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CustomerTwoMember" xlink:to="lab_cpix_CustomerTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_e50bdcc8-b8aa-41a0-8056-9b563d6a3fc3_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs of products sold</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs of Goods Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_94c33aa5-25cb-46c7-9fdc-4c394bee2a78_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares reserved for issuance under equity compensation plans</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_0adc43a7-5006-4e2f-8230-4f10f745c2fb_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_a061bad5-0461-42af-a623-2d46f2bfc792_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_dfb63a45-8325-4c91-bdab-4a445c2bd1f6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AccruedPaymentForAssetPurchaseCurrent_aec6616d-f630-4620-9453-79241ab3344c_terseLabel_en-US" xlink:label="lab_cpix_AccruedPaymentForAssetPurchaseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payment for asset purchase</link:label>
    <link:label id="lab_cpix_AccruedPaymentForAssetPurchaseCurrent_label_en-US" xlink:label="lab_cpix_AccruedPaymentForAssetPurchaseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Payment For Asset Purchase, Current</link:label>
    <link:label id="lab_cpix_AccruedPaymentForAssetPurchaseCurrent_documentation_en-US" xlink:label="lab_cpix_AccruedPaymentForAssetPurchaseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Payment For Asset Purchase, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccruedPaymentForAssetPurchaseCurrent" xlink:href="cpix-20201210.xsd#cpix_AccruedPaymentForAssetPurchaseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AccruedPaymentForAssetPurchaseCurrent" xlink:to="lab_cpix_AccruedPaymentForAssetPurchaseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_b88a70ba-23dd-4d10-b3cc-146a1db654f5_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff0ef9ae-a893-4d0c-87fe-b94b658550f0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_ec4e63c6-696e-4dea-90c5-49fc1a9a1621_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_StockIssuedDuringPeriodPricePerShareNewIssues_d9b43f3b-5653-42c7-a9b3-07468babd29d_terseLabel_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodPricePerShareNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial public offering, price per share</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodPricePerShareNewIssues_label_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodPricePerShareNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Price Per Share, New Issues</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodPricePerShareNewIssues_documentation_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodPricePerShareNewIssues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Price Per Share, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodPricePerShareNewIssues" xlink:href="cpix-20201210.xsd#cpix_StockIssuedDuringPeriodPricePerShareNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_StockIssuedDuringPeriodPricePerShareNewIssues" xlink:to="lab_cpix_StockIssuedDuringPeriodPricePerShareNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1c21d864-44c4-4bee-8dfe-37d0648c7304_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LongTermIncentiveCompensationPlan2007Member_1b639930-b682-44ab-b294-edbfd11488b6_terseLabel_en-US" xlink:label="lab_cpix_LongTermIncentiveCompensationPlan2007Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Incentive Compensation Plan 2007</link:label>
    <link:label id="lab_cpix_LongTermIncentiveCompensationPlan2007Member_label_en-US" xlink:label="lab_cpix_LongTermIncentiveCompensationPlan2007Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Incentive Compensation Plan 2007 [Member]</link:label>
    <link:label id="lab_cpix_LongTermIncentiveCompensationPlan2007Member_documentation_en-US" xlink:label="lab_cpix_LongTermIncentiveCompensationPlan2007Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Incentive Compensation Plan 2007 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LongTermIncentiveCompensationPlan2007Member" xlink:href="cpix-20201210.xsd#cpix_LongTermIncentiveCompensationPlan2007Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LongTermIncentiveCompensationPlan2007Member" xlink:to="lab_cpix_LongTermIncentiveCompensationPlan2007Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_be58115e-232f-415e-99bd-226d3736b10a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_45106e5f-0eea-47b2-bd1c-9a8adcf6d3ce_verboseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_102e332c-2773-4564-a0e8-9b0c94fe3b0b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_5a840c60-84a2-441d-b18d-24ebc2f2ecf8_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charged to other accounts</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PinnacleBankMember_45bae920-1ea4-4baa-a85b-36824541dd49_terseLabel_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank</link:label>
    <link:label id="lab_cpix_PinnacleBankMember_label_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank [Member]</link:label>
    <link:label id="lab_cpix_PinnacleBankMember_documentation_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember" xlink:href="cpix-20201210.xsd#cpix_PinnacleBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PinnacleBankMember" xlink:to="lab_cpix_PinnacleBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_FoundationContributionMember_c7f40d14-4c05-461e-86d0-453c410da226_terseLabel_en-US" xlink:label="lab_cpix_FoundationContributionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foundation Contribution</link:label>
    <link:label id="lab_cpix_FoundationContributionMember_label_en-US" xlink:label="lab_cpix_FoundationContributionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foundation Contribution [Member]</link:label>
    <link:label id="lab_cpix_FoundationContributionMember_documentation_en-US" xlink:label="lab_cpix_FoundationContributionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foundation Contribution [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FoundationContributionMember" xlink:href="cpix-20201210.xsd#cpix_FoundationContributionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_FoundationContributionMember" xlink:to="lab_cpix_FoundationContributionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1276ec85-d5ea-4735-aac6-483d798f0771_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_d07b02e5-9eb9-427c-af95-ba6849048cf0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of restricted stock activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_82bc0fe5-ec95-4c59-9a64-7eb5aae8638f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_74ccd0ee-afd9-4ed9-8eb5-b36a0b197944_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CommonStockAbstract_79869c5d-4df1-496d-ac90-dacc826b1fd1_terseLabel_en-US" xlink:label="lab_cpix_CommonStockAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Abstract]</link:label>
    <link:label id="lab_cpix_CommonStockAbstract_label_en-US" xlink:label="lab_cpix_CommonStockAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Abstract]</link:label>
    <link:label id="lab_cpix_CommonStockAbstract_documentation_en-US" xlink:label="lab_cpix_CommonStockAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CommonStockAbstract" xlink:href="cpix-20201210.xsd#cpix_CommonStockAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CommonStockAbstract" xlink:to="lab_cpix_CommonStockAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_889d171f-b349-4a83-95d8-10f880a35425_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of net product revenues by product</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_89e7afa8-d443-4a95-a75b-f91c1e34ec2f_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, allowances, current</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_21b359df-bf7e-4e5b-911b-b8f5c1533176_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during period, acquisitions</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e0a5c04f-7331-4405-8d65-894e5d0b1675_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_234d94b8-b96a-4799-9066-ed5b025a5185_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2dc9ce93-3773-4295-83a7-0fbc7604eae0_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_9b2e46b3-7289-466e-b5b6-bf7da45abb99_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_ff002d60-5807-4c70-ba29-a36ca8038c47_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_0e664adb-2446-4811-9cf7-fee54257049c_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_b33eadd5-83bc-4ab8-a7ed-ba26a46f62a2_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other permanent differences</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_5430efd0-f848-4830-87d6-283934faf365_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_RevenueRecognitionCumulativeUpfrontPayment_6ca62f05-124a-49b1-8654-f14e8ef573d4_terseLabel_en-US" xlink:label="lab_cpix_RevenueRecognitionCumulativeUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative upfront payment</link:label>
    <link:label id="lab_cpix_RevenueRecognitionCumulativeUpfrontPayment_label_en-US" xlink:label="lab_cpix_RevenueRecognitionCumulativeUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Cumulative Upfront Payment</link:label>
    <link:label id="lab_cpix_RevenueRecognitionCumulativeUpfrontPayment_documentation_en-US" xlink:label="lab_cpix_RevenueRecognitionCumulativeUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Cumulative Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionCumulativeUpfrontPayment" xlink:href="cpix-20201210.xsd#cpix_RevenueRecognitionCumulativeUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_RevenueRecognitionCumulativeUpfrontPayment" xlink:to="lab_cpix_RevenueRecognitionCumulativeUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_59d6db1a-d8e4-4a2b-8d81-e06232a8c45d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_4e51f703-71ab-4da2-8e8f-3a0bd087e4b5_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_535a5840-9cb0-497e-9c15-fb7bdba4cb0f_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_e7bacfce-ed87-43db-a951-0338e0dd1b2d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_2ad43aa2-1495-47db-a72b-5c298dc70254_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_1bbda189-fa3c-448b-a62c-ba5e2a3db72c_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_ece8974a-b1a5-4a0b-9a17-956db467fca1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consigned inventory</link:label>
    <link:label id="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_label_en-US" xlink:label="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:to="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_24e6a156-9206-48cc-bdeb-d79a72e4ea69_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_14e604ac-1463-4862-8242-e156312dcfe3_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested, beginning of period, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_69e1dc6b-0d56-49b8-b955-341c817eb007_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested, end of period, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_f7ffdccc-fad4-4e13-8993-25edc20f0668_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_2c117a3e-2405-474d-b5a9-efafec7b2e06_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accrued liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_c4f4d4f2-3894-4520-9ad8-a0003dd301d0_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_3326e990-0801-4206-943f-a646c549c6c6_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_94d1819e-3b67-4b48-9811-acfa265928b6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ShareRepurchaseProgramAuthorizedIn2010Member_ae236c90-f03a-4049-8aec-be2ef29c3bfb_terseLabel_en-US" xlink:label="lab_cpix_ShareRepurchaseProgramAuthorizedIn2010Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program Authorized in 2010</link:label>
    <link:label id="lab_cpix_ShareRepurchaseProgramAuthorizedIn2010Member_label_en-US" xlink:label="lab_cpix_ShareRepurchaseProgramAuthorizedIn2010Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program Authorized in 2010 [Member]</link:label>
    <link:label id="lab_cpix_ShareRepurchaseProgramAuthorizedIn2010Member_documentation_en-US" xlink:label="lab_cpix_ShareRepurchaseProgramAuthorizedIn2010Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program Authorized in 2010 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareRepurchaseProgramAuthorizedIn2010Member" xlink:href="cpix-20201210.xsd#cpix_ShareRepurchaseProgramAuthorizedIn2010Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ShareRepurchaseProgramAuthorizedIn2010Member" xlink:to="lab_cpix_ShareRepurchaseProgramAuthorizedIn2010Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses_d48999a1-27b5-4443-b45d-84922ed2cc6a_terseLabel_en-US" xlink:label="lab_cpix_DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred offering costs included in accounts payable and other accrued expenses</link:label>
    <link:label id="lab_cpix_DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses_label_en-US" xlink:label="lab_cpix_DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs Included in Accounts Payable and Other Accrued Expenses</link:label>
    <link:label id="lab_cpix_DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses_documentation_en-US" xlink:label="lab_cpix_DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs Included in Accounts Payable and Other Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses" xlink:href="cpix-20201210.xsd#cpix_DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses" xlink:to="lab_cpix_DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_b601e7b0-136c-4dd7-90a7-312c4f614bb4_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_95b0fd68-b26b-4bdb-bccd-bc4d029fd5e8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_42d03483-eb57-4116-851a-a468877e29a8_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_0f60bffe-06c1-4889-bbbf-41700bf21552_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_label_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Raw Materials Inventory</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Raw Materials Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" xlink:href="cpix-20201210.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" xlink:to="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProductVibativMember_1957a7b4-eb6f-4882-bad5-b5cbd6a94e41_terseLabel_en-US" xlink:label="lab_cpix_ProductVibativMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vibativ</link:label>
    <link:label id="lab_cpix_ProductVibativMember_label_en-US" xlink:label="lab_cpix_ProductVibativMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Vibativ [Member]</link:label>
    <link:label id="lab_cpix_ProductVibativMember_documentation_en-US" xlink:label="lab_cpix_ProductVibativMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Vibativ</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductVibativMember" xlink:href="cpix-20201210.xsd#cpix_ProductVibativMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProductVibativMember" xlink:to="lab_cpix_ProductVibativMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_cff53dc9-a9b3-4b45-941e-0594e9903dec_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_bb67329b-1193-4108-bf19-673a3fc48fdf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the components of income tax benefit (expense)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_c0c8a4ec-fa4c-4805-ade3-aa623fdfaa51_terseLabel_en-US" xlink:label="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of rent expense and sublease income</link:label>
    <link:label id="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_label_en-US" xlink:label="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Rent Expense and Sublease Income [Table Text Block]</link:label>
    <link:label id="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_documentation_en-US" xlink:label="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Rent Expense and Sublease Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:href="cpix-20201210.xsd#cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:to="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_b01d0b52-a722-445d-9559-79dcac3f53c1_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_35a2cac6-d9b4-4ac5-b8eb-0f406e61ae83_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ManufacturingandSupplyAgreementTable_5b25e146-9807-426f-b842-bf842d3c7a55_terseLabel_en-US" xlink:label="lab_cpix_ManufacturingandSupplyAgreementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and Supply Agreement [Table]</link:label>
    <link:label id="lab_cpix_ManufacturingandSupplyAgreementTable_label_en-US" xlink:label="lab_cpix_ManufacturingandSupplyAgreementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and Supply Agreement [Table]</link:label>
    <link:label id="lab_cpix_ManufacturingandSupplyAgreementTable_documentation_en-US" xlink:label="lab_cpix_ManufacturingandSupplyAgreementTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and Supply Agreement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingandSupplyAgreementTable" xlink:href="cpix-20201210.xsd#cpix_ManufacturingandSupplyAgreementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ManufacturingandSupplyAgreementTable" xlink:to="lab_cpix_ManufacturingandSupplyAgreementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_87f2d3fc-e92d-4a3f-8353-cc9341c2e5e0_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9ff2e0e3-ccab-4245-bc05-75510212e72e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost related to share-based payments, period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_873fe83b-288f-4d28-b2a6-044a7112b2f4_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_6e606387-9da1-452c-91f4-438b53c6cc4e_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_ae00901e-a216-4474-9692-16136511c712_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_8b6ea507-829f-4282-8702-8e44f6e019bd_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to intangible assets from final purchase price allocation</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_5138075f-52f8-4b42-b3a0-eb1c9d1679a5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_c1bb3dae-2197-4203-ad63-41124d52a80d_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in non-cash contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_c6f060f0-5aa6-4131-8c38-1a7adbe5bfce_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_f8c69d6b-8e33-4713-84a0-6be346de6133_negatedLabel_en-US" xlink:label="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess tax (benefit) expense derived from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_label_en-US" xlink:label="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess Tax Benefit from Share-based Compensation, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:to="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_86eda3e3-e965-4c5f-af47-40afe51050bb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AccountsReceivableAllowancesByComponentDomain_9fe00f3b-e4c1-4d52-bfc0-578e3bd3384d_terseLabel_en-US" xlink:label="lab_cpix_AccountsReceivableAllowancesByComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowances by Component [Domain]</link:label>
    <link:label id="lab_cpix_AccountsReceivableAllowancesByComponentDomain_label_en-US" xlink:label="lab_cpix_AccountsReceivableAllowancesByComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowances by Component [Domain]</link:label>
    <link:label id="lab_cpix_AccountsReceivableAllowancesByComponentDomain_documentation_en-US" xlink:label="lab_cpix_AccountsReceivableAllowancesByComponentDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Accounts Receivable, Allowances by Component [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccountsReceivableAllowancesByComponentDomain" xlink:href="cpix-20201210.xsd#cpix_AccountsReceivableAllowancesByComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AccountsReceivableAllowancesByComponentDomain" xlink:to="lab_cpix_AccountsReceivableAllowancesByComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c95babab-2823-47df-ba03-863a9318b014_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_3a5f0881-252b-4620-9067-ad43184a25ab_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials and work in process</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_0a9568d2-7cc6-4538-9158-a661177f45e3_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of federal and state net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Operating Loss Carryforwards [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:to="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_52754c02-80a8-41f1-a607-bea9466383b4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_e94e8893-f25b-4ec4-ae08-61ccebe1c4ee_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of options and related tax benefit</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Sale of Parent Equity Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_d120f4f8-f5f7-4b7a-afde-d5c57a5d3220_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_4915e955-2fb6-490e-9ee2-893464c5877f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_a790e02b-2353-47b0-a18e-39b2e3515196_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of quarterly financial information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_5be2b2cb-0ec7-4764-b2d0-1c0307d73658_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_ea885ada-331a-42d7-bbc5-05d3fe4bb8dc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b255688a-56ef-4315-aca8-59452472317b_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash flows provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_d58db096-b5cd-4c74-a372-5201797efbf0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders-Continuing operations-basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_577c8098-6331-4703-b05b-6cde2c9b77a0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future minimum sublease income under noncancelable operating subleases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_ae69cc90-740b-491f-9a74-0a0a0b77bedd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_49f326c1-f5a3-42cd-8a9a-eb9f0b5f1c7f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of subsidiary shares from noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_4dc446c2-4be9-4769-8708-ae0f1eb8bedf_negatedLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of subsidiary shares to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_0d548fa1-3cf6-4cee-a2ad-1a9e40245692_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInventory" xlink:to="lab_us-gaap_DeferredTaxAssetsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_03c56a85-67a5-43bb-9495-ee8c12a1bfcf_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_bbc4c8b3-05ee-4461-95b9-5c89709b9cb9_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, number of shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ed8b2301-eddc-424d-9fcf-5c3d70072901_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, common shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_76254392-11d2-4120-a18d-449e93045fc0_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, common shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityAbstract_9ddb8d87-61bf-4ff4-8d76-937a4eebe548_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Arrangements [Abstract]</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationLiabilityAbstract" xlink:to="lab_us-gaap_DeferredCompensationLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_RevenueRecognitionMilestonePayments_70123e3e-65aa-4dd0-b0ae-4f364450666c_terseLabel_en-US" xlink:label="lab_cpix_RevenueRecognitionMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments associated with international agreements</link:label>
    <link:label id="lab_cpix_RevenueRecognitionMilestonePayments_label_en-US" xlink:label="lab_cpix_RevenueRecognitionMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Payments</link:label>
    <link:label id="lab_cpix_RevenueRecognitionMilestonePayments_documentation_en-US" xlink:label="lab_cpix_RevenueRecognitionMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionMilestonePayments" xlink:href="cpix-20201210.xsd#cpix_RevenueRecognitionMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_RevenueRecognitionMilestonePayments" xlink:to="lab_cpix_RevenueRecognitionMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_22d9b7a8-3a06-4275-ab0f-6351add3ecd3_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_7c44bbcd-9061-490c-9da7-297047fc76d9_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_EmploymentAgreementsTextBlock_51b0e7ad-1428-431a-904e-209e424d0abc_terseLabel_en-US" xlink:label="lab_cpix_EmploymentAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employment Agreements</link:label>
    <link:label id="lab_cpix_EmploymentAgreementsTextBlock_label_en-US" xlink:label="lab_cpix_EmploymentAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employment Agreements [Text Block]</link:label>
    <link:label id="lab_cpix_EmploymentAgreementsTextBlock_documentation_en-US" xlink:label="lab_cpix_EmploymentAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employment Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EmploymentAgreementsTextBlock" xlink:href="cpix-20201210.xsd#cpix_EmploymentAgreementsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_EmploymentAgreementsTextBlock" xlink:to="lab_cpix_EmploymentAgreementsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_f52c4301-3d99-440b-9aa1-c39697f30134_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_fd056b99-2d5f-4813-a978-8088f30aba54_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6db8f098-2db9-4e57-ba4f-fa6b1c1aca71_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of period, weighted-average exercise price per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8e19054a-cc49-4d13-8f29-99fcf4f0b5ef_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of period, weighted-average exercise price per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_f8112587-a1b7-4fd0-81a7-52d73414b105_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember_a5dc303c-9576-4372-8015-2df03c4ea16f_terseLabel_en-US" xlink:label="lab_cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Repurchase, All, Except Settlement of Tax Liabilities Related to Exercise of Stock Options</link:label>
    <link:label id="lab_cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember_label_en-US" xlink:label="lab_cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Repurchase, All, Except Settlement of Tax Liabilities Related to Exercise of Stock Options [Member]</link:label>
    <link:label id="lab_cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember_documentation_en-US" xlink:label="lab_cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Repurchase, All, Except Settlement of Tax Liabilities Related to Exercise of Stock Options [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember" xlink:href="cpix-20201210.xsd#cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember" xlink:to="lab_cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_f52854a5-c8c7-43b1-87bc-5d67d02f5958_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, number of shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_02cf6d32-326f-40af-8963-35f7b28fa1d2_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock_df9c1134-25aa-4dbd-89e4-46fc6b9cff23_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases of Lessee Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DeferredTaxAssetsDeferredCharges_d0e3510c-4ffd-48ac-9fb1-8040df8da553_terseLabel_en-US" xlink:label="lab_cpix_DeferredTaxAssetsDeferredCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred charges</link:label>
    <link:label id="lab_cpix_DeferredTaxAssetsDeferredCharges_label_en-US" xlink:label="lab_cpix_DeferredTaxAssetsDeferredCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Charges</link:label>
    <link:label id="lab_cpix_DeferredTaxAssetsDeferredCharges_documentation_en-US" xlink:label="lab_cpix_DeferredTaxAssetsDeferredCharges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsDeferredCharges" xlink:href="cpix-20201210.xsd#cpix_DeferredTaxAssetsDeferredCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DeferredTaxAssetsDeferredCharges" xlink:to="lab_cpix_DeferredTaxAssetsDeferredCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_86e572b0-85e3-4e6e-a2df-f5dbccbca589_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive effect of restricted stock and stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_305c9586-7f09-4380-9dd8-d6dfccae7348_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_09f72c2d-f3fa-4504-abb3-e37c5e1539aa_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of shares of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_a9adc18a-0a01-40c9-9104-fdced718b976_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_MethotrexateMember_4491e46d-e9a9-4d23-984d-9136ac0cfbc5_terseLabel_en-US" xlink:label="lab_cpix_MethotrexateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Methotrexate</link:label>
    <link:label id="lab_cpix_MethotrexateMember_label_en-US" xlink:label="lab_cpix_MethotrexateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Methotrexate [Member]</link:label>
    <link:label id="lab_cpix_MethotrexateMember_documentation_en-US" xlink:label="lab_cpix_MethotrexateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Methotrexate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MethotrexateMember" xlink:href="cpix-20201210.xsd#cpix_MethotrexateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_MethotrexateMember" xlink:to="lab_cpix_MethotrexateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ExpirationTimePeriodAxis_c9713fb1-64b7-41bb-a5d3-ceffbdb2c42c_terseLabel_en-US" xlink:label="lab_cpix_ExpirationTimePeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Time Period [Axis]</link:label>
    <link:label id="lab_cpix_ExpirationTimePeriodAxis_label_en-US" xlink:label="lab_cpix_ExpirationTimePeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Time Period [Axis]</link:label>
    <link:label id="lab_cpix_ExpirationTimePeriodAxis_documentation_en-US" xlink:label="lab_cpix_ExpirationTimePeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Time Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTimePeriodAxis" xlink:href="cpix-20201210.xsd#cpix_ExpirationTimePeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ExpirationTimePeriodAxis" xlink:to="lab_cpix_ExpirationTimePeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrincipalOwnerMember_e314b108-19d2-43b1-ab4a-94cbfcdec267_terseLabel_en-US" xlink:label="lab_us-gaap_PrincipalOwnerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Owner</link:label>
    <link:label id="lab_us-gaap_PrincipalOwnerMember_label_en-US" xlink:label="lab_us-gaap_PrincipalOwnerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Owner [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrincipalOwnerMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrincipalOwnerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrincipalOwnerMember" xlink:to="lab_us-gaap_PrincipalOwnerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_ebb20daf-83e6-417b-a0c8-9e2eb5693aa9_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_f1a38d1b-e528-477d-bd25-d2fd3add02d5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities incurred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering_d63fb4d5-794a-4a18-90f4-56c73e57e051_terseLabel_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial public offering, gross proceeds</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering_label_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Gross Proceeds from Initial Public Offering</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering_documentation_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Gross Proceeds from Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering" xlink:href="cpix-20201210.xsd#cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering" xlink:to="lab_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_5bb9a697-6cb2-47a6-9f49-02b77ca52340_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_042aa132-b932-423f-855e-5fb39e9158ae_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_f2953a10-5450-478d-8d81-ad93d69a173c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_22c694c8-e815-4f48-88d3-abed337fa68a_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense" xlink:to="lab_us-gaap_LeaseAndRentalExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_d6eacd11-45fd-4a69-837c-7d2c5a571722_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellectual property amortizable intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_639049b5-edd4-413c-9333-cc85a27004ae_terseLabel_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value of options exercised</link:label>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:href="cpix-20201210.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_66ae1a4b-c51c-4f70-b20a-d968f6d6e487_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_d2cbf904-f3e8-417d-b702-c2c5b0b28aa3_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_b519e536-88a4-4d4a-94a3-484b3f2e6686_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Permanent differences associated with general business credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_706f056b-fb18-4486-a992-443217c5cc94_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_RevenueRecognitionUpfrontPayment_119d2ef4-3b3b-4ff6-b18e-fb637d850386_terseLabel_en-US" xlink:label="lab_cpix_RevenueRecognitionUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenue, upfront payment</link:label>
    <link:label id="lab_cpix_RevenueRecognitionUpfrontPayment_label_en-US" xlink:label="lab_cpix_RevenueRecognitionUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Upfront Payment</link:label>
    <link:label id="lab_cpix_RevenueRecognitionUpfrontPayment_documentation_en-US" xlink:label="lab_cpix_RevenueRecognitionUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionUpfrontPayment" xlink:href="cpix-20201210.xsd#cpix_RevenueRecognitionUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_RevenueRecognitionUpfrontPayment" xlink:to="lab_cpix_RevenueRecognitionUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_9dee22ce-5cdb-43a7-a6bc-15ea237342c7_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_cb981cdf-9db7-4bf7-a8e2-5647f016f86d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_6878057a-d2ff-44d9-aa20-4abe7963cf70_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount available under current repurchase program</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_c181ccc3-5026-4ea9-aee5-49e69cd064ef_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermLineOfCredit_55b55250-921c-497b-a03d-9ea69f9d933b_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermLineOfCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving line of credit</link:label>
    <link:label id="lab_us-gaap_LongTermLineOfCredit_label_en-US" xlink:label="lab_us-gaap_LongTermLineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermLineOfCredit" xlink:to="lab_us-gaap_LongTermLineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredOtherTaxExpenseBenefit_ef93a3b7-bb30-4e74-8c33-6faeecc6e3b5_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredOtherTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_DeferredOtherTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredOtherTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Other Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOtherTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOtherTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOtherTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredOtherTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PatentsMember_2abfde1f-19aa-46df-b6a3-9a75d7b98a90_terseLabel_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents</link:label>
    <link:label id="lab_us-gaap_PatentsMember_label_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember" xlink:to="lab_us-gaap_PatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LeaseAsset_8c328c07-7c5c-4d7f-9766-29f32ed18293_terseLabel_en-US" xlink:label="lab_cpix_LeaseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_cpix_LeaseAsset_label_en-US" xlink:label="lab_cpix_LeaseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Asset</link:label>
    <link:label id="lab_cpix_LeaseAsset_documentation_en-US" xlink:label="lab_cpix_LeaseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LeaseAsset" xlink:href="cpix-20201210.xsd#cpix_LeaseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LeaseAsset" xlink:to="lab_cpix_LeaseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_53a11937-ca0f-4e7b-ac55-e17bd9953506_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of effective tax rate reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PaymentsForContingentConsideration_404ada02-8594-44e4-bab4-99b5f377f56f_terseLabel_en-US" xlink:label="lab_cpix_PaymentsForContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent consideration - net sales royalty</link:label>
    <link:label id="lab_cpix_PaymentsForContingentConsideration_label_en-US" xlink:label="lab_cpix_PaymentsForContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Contingent Consideration</link:label>
    <link:label id="lab_cpix_PaymentsForContingentConsideration_documentation_en-US" xlink:label="lab_cpix_PaymentsForContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsForContingentConsideration" xlink:href="cpix-20201210.xsd#cpix_PaymentsForContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PaymentsForContingentConsideration" xlink:to="lab_cpix_PaymentsForContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_e50ca553-cd8d-4e6f-9ff8-989c038c4446_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_739fdf94-87b6-487d-b978-d3a75e092eda_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for accounts receivable</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_f1424fd5-0f21-46a2-a9e6-ca620e14dc97_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_c9f01372-fcc6-4e1a-9cfb-c669f2f1b21c_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_55710e2f-1113-47a5-9b78-e3f9c92c91e8_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_297fad14-8117-4829-92a6-deecb90458c8_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_a80f3cff-7cf1-4701-92bf-3d202ede0552_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue_c5d9fed8-a572-40d4-8265-52ba8a255221_terseLabel_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, exercise price as percent of weighted-average grant date fair value</link:label>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price as Percent of Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price as Percent of Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue" xlink:href="cpix-20201210.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue" xlink:to="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_152db5dc-4008-4195-baa4-bcf405d5d83f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_d23cc145-9b46-4a83-9a62-b6c3456b58ce_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_GloriaPharmaceuticalsMember_0fada99b-8022-47a1-b50f-88dd5ae78930_terseLabel_en-US" xlink:label="lab_cpix_GloriaPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gloria Pharmaceuticals</link:label>
    <link:label id="lab_cpix_GloriaPharmaceuticalsMember_label_en-US" xlink:label="lab_cpix_GloriaPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gloria Pharmaceuticals [Member]</link:label>
    <link:label id="lab_cpix_GloriaPharmaceuticalsMember_documentation_en-US" xlink:label="lab_cpix_GloriaPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gloria Pharmaceuticals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_GloriaPharmaceuticalsMember" xlink:href="cpix-20201210.xsd#cpix_GloriaPharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_GloriaPharmaceuticalsMember" xlink:to="lab_cpix_GloriaPharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_c980d505-40cd-4894-ab48-9b476079c731_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability to be paid</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_947cc5fe-696c-47ce-8379-79000259952a_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at November 12, 2018</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_380f027d-592c-4d8a-8d8f-bece0164934e_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December 31, 2018</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales_57832284-7830-482e-a406-eb9a8ebd78ca_terseLabel_en-US" xlink:label="lab_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenue, potential upfront payment related to product sales</link:label>
    <link:label id="lab_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales_label_en-US" xlink:label="lab_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Potential Upfront Payment Related to Product Sales</link:label>
    <link:label id="lab_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales_documentation_en-US" xlink:label="lab_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Potential Upfront Payment Related to Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales" xlink:href="cpix-20201210.xsd#cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales" xlink:to="lab_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_9606054b-68ba-4710-b7af-0d940502cd6f_verboseLabel_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net tax benefit, impact of Tax Act</link:label>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts and Jobs Act, Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_191387eb-b195-4bab-97ca-06dad53c91b9_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_aba1a74e-c736-442a-b65d-913de7e902e6_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share repurchase program, number of shares authorized to be repurchased</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_5f37f0dd-31d3-4edc-9761-d3c44d856f77_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current and Other Long-term Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_962de699-a5f3-4bc7-a61f-67cbde8f798b_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_38fb2399-9467-4d2a-adce-d5cf884b424a_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8a494cd8-4bfc-43e7-b89e-c22f2749cd49_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_092eacf0-bf72-4713-8a5b-6768c3a0fb3e_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ManufacturingAndSupplyAgreementsTextBlock_33add0b7-4c8b-4916-804c-e652ebc80038_terseLabel_en-US" xlink:label="lab_cpix_ManufacturingAndSupplyAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and Supply Agreements</link:label>
    <link:label id="lab_cpix_ManufacturingAndSupplyAgreementsTextBlock_label_en-US" xlink:label="lab_cpix_ManufacturingAndSupplyAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and Supply Agreements [Text Block]</link:label>
    <link:label id="lab_cpix_ManufacturingAndSupplyAgreementsTextBlock_documentation_en-US" xlink:label="lab_cpix_ManufacturingAndSupplyAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and Supply Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingAndSupplyAgreementsTextBlock" xlink:href="cpix-20201210.xsd#cpix_ManufacturingAndSupplyAgreementsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ManufacturingAndSupplyAgreementsTextBlock" xlink:to="lab_cpix_ManufacturingAndSupplyAgreementsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_ba507caa-32f8-4e62-96b9-604275c57349_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_5d9b255a-5c9b-4c04-8408-85a991d54729_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of inventories, current</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_32d5a7a0-0f8f-4533-b7a9-df0fa47ed384_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradingSecurities_f2f59f06-4a2e-4138-b69c-bbd51d2d813b_terseLabel_en-US" xlink:label="lab_us-gaap_TradingSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of marketable securities</link:label>
    <link:label id="lab_us-gaap_TradingSecurities_label_en-US" xlink:label="lab_us-gaap_TradingSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradingSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingSecurities" xlink:to="lab_us-gaap_TradingSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_383053d0-874c-404c-9589-7ae58f70ff78_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_eb411a0a-18be-455a-bb06-315a66fb3bfa_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common shares, value</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_1e31b9c2-be7f-4b07-a580-650654506058_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CaldolorMember_6e36a4f5-74d9-4561-84d5-6742856cb957_terseLabel_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor</link:label>
    <link:label id="lab_cpix_CaldolorMember_label_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor [Member]</link:label>
    <link:label id="lab_cpix_CaldolorMember_documentation_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember" xlink:href="cpix-20201210.xsd#cpix_CaldolorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CaldolorMember" xlink:to="lab_cpix_CaldolorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_1beacfc7-853e-4f9d-9af4-bf15fc6ad98b_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans_eec6c5d5-f12b-4922-96ec-2a9d568c7da6_terseLabel_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of equity compensation plans</link:label>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans_label_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Plans</link:label>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans_documentation_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans" xlink:href="cpix-20201210.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans" xlink:to="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_a2d3d885-8ea4-41ae-8a68-960d3d987f99_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_a5add33a-369e-4cbf-8db5-692cec5490dd_negatedLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">less non-current inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_ebb7f3cf-726e-4854-861f-b0ecce290b16_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_13310b87-0b68-4a43-8edb-e224565afbb2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss at subsidiary attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_2698dcb7-f3bc-455b-87d5-db26a8a24faa_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information (Unaudited)</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NoncashOrPartNoncashTransactionVestingOfShares_f341b4ec-d33a-4d68-a20e-0cb5447dc35b_terseLabel_en-US" xlink:label="lab_cpix_NoncashOrPartNoncashTransactionVestingOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of shares related to RediTrex approval</link:label>
    <link:label id="lab_cpix_NoncashOrPartNoncashTransactionVestingOfShares_label_en-US" xlink:label="lab_cpix_NoncashOrPartNoncashTransactionVestingOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Transaction, Vesting of Shares</link:label>
    <link:label id="lab_cpix_NoncashOrPartNoncashTransactionVestingOfShares_documentation_en-US" xlink:label="lab_cpix_NoncashOrPartNoncashTransactionVestingOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Transaction, Vesting of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NoncashOrPartNoncashTransactionVestingOfShares" xlink:href="cpix-20201210.xsd#cpix_NoncashOrPartNoncashTransactionVestingOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NoncashOrPartNoncashTransactionVestingOfShares" xlink:to="lab_cpix_NoncashOrPartNoncashTransactionVestingOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_3dedc0d1-c9dc-4c82-bda5-633c395f1246_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_e4372831-145b-47dc-9c0b-46b2f721b93e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_aacdd02b-f1e8-4450-9b86-f34e986b99da_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After 2023</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_06aa10a0-a474-44fd-ae8d-808c968de759_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in valuation allowance during the year</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_997178d2-65ac-4ef6-88db-2e6c5ef94b31_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingGainsLosses_76bcf990-7e31-4e69-a680-887b0189c97c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash investment gains</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingGainsLosses_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Gains (Losses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingGainsLosses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingGainsLosses" xlink:to="lab_us-gaap_OtherNonoperatingGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_9ee8fe17-7e72-4436-8171-de9719424034_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_77a100c5-ef47-4bf2-8be4-ff070f36f8f2_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SharebasedCompensationCharitableContributionofSharesShares_b4d3b010-8d3a-4868-a95b-fe91bdb20c6a_terseLabel_en-US" xlink:label="lab_cpix_SharebasedCompensationCharitableContributionofSharesShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charitable contribution of shares, shares</link:label>
    <link:label id="lab_cpix_SharebasedCompensationCharitableContributionofSharesShares_label_en-US" xlink:label="lab_cpix_SharebasedCompensationCharitableContributionofSharesShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Charitable Contribution of Shares, Shares</link:label>
    <link:label id="lab_cpix_SharebasedCompensationCharitableContributionofSharesShares_documentation_en-US" xlink:label="lab_cpix_SharebasedCompensationCharitableContributionofSharesShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Charitable Contribution of Shares, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharebasedCompensationCharitableContributionofSharesShares" xlink:href="cpix-20201210.xsd#cpix_SharebasedCompensationCharitableContributionofSharesShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SharebasedCompensationCharitableContributionofSharesShares" xlink:to="lab_cpix_SharebasedCompensationCharitableContributionofSharesShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_61a45e23-1ec6-4eda-b555-4457c6cf8e58_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_6e79410b-f12e-4f66-a4ed-157335f61268_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_63ab0a51-a457-4f8f-85fd-26d6b8e7145d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_da444dbe-1134-464c-b6a7-634c7d1014c7_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_cfd8efe1-2adb-4585-91c5-ecc4b7a676d1_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods, net of reserve</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_5363f0f4-44d7-49be-bc83-526c5d353509_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_3869b54b-c11a-4cb4-b191-b6321cead753_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process - unlabeled vials</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_label_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Unlabeled Vials</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Unlabeled Vials</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" xlink:href="cpix-20201210.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" xlink:to="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_a416f0ec-9993-4854-9c08-f8dd2017ec8b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_6b236f60-799f-4556-867f-5fb2f48e3821_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings on line of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_b16c06f9-3e09-4f82-a88d-1faa94bb133f_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_6e7ba8eb-180b-4f98-b5de-47bcb7fae135_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_5cb28318-cbcd-4aef-ba92-6b87e3c4d6d2_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_3caaf17d-291a-4dc6-afb9-389a6caa6917_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_47f9ec3a-1918-4ceb-ae82-8f1f3e1caea7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments on line of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_735219ec-5318-4d21-b572-10e689ef8e46_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_8c46aa74-7929-4f68-8c70-11ad065db547_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AcetadoteMember_08ae2cb8-8733-4cbc-9635-c2c146dab0de_terseLabel_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote</link:label>
    <link:label id="lab_cpix_AcetadoteMember_label_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote [Member]</link:label>
    <link:label id="lab_cpix_AcetadoteMember_documentation_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember" xlink:href="cpix-20201210.xsd#cpix_AcetadoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AcetadoteMember" xlink:to="lab_cpix_AcetadoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember_ea88098c-6cfa-43ba-96f2-2762c0691468_terseLabel_en-US" xlink:label="lab_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Sales Related Allowances - Chargebacks, Cash Discounts and Damaged Goods</link:label>
    <link:label id="lab_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember_label_en-US" xlink:label="lab_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks, Cash Discounts and Damaged Goods [Member]</link:label>
    <link:label id="lab_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember_documentation_en-US" xlink:label="lab_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks, Cash Discounts and Damaged Goods [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember" xlink:href="cpix-20201210.xsd#cpix_ChargebacksCashDiscountsAndDamagedGoodsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember" xlink:to="lab_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_f2fce76e-ca3b-4cc0-a91e-1ca3c90a5c18_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7358d2ec-179e-4345-be8a-b6cc6609106d_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss at subsidiary attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0c426f32-a64b-459c-b94a-02c732a56e45_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss at subsidiary attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1381419c-8ebb-42f8-8ff0-110de41218a0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss at subsidiary allocated to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ManufacturingAndSupplyAgreementsAbstract_label_en-US" xlink:label="lab_cpix_ManufacturingAndSupplyAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and Supply Agreements [Abstract]</link:label>
    <link:label id="lab_cpix_ManufacturingAndSupplyAgreementsAbstract_documentation_en-US" xlink:label="lab_cpix_ManufacturingAndSupplyAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and Supply Agreements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingAndSupplyAgreementsAbstract" xlink:href="cpix-20201210.xsd#cpix_ManufacturingAndSupplyAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ManufacturingAndSupplyAgreementsAbstract" xlink:to="lab_cpix_ManufacturingAndSupplyAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_110fcf35-c19d-4d61-bfd6-e4472bc22ae7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares forfeited, weighted-average grant-date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8f722c47-a3c8-4a4e-af8b-a21720bb4ad2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised, weighted-average exercise price per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_ba13651c-0b5a-4f6e-b9a5-e2c91699e3d4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_509f1659-7e9c-4b12-b967-5e1355fba538_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b08567a3-58fc-4621-95bb-4660f5546c68_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockTransactionDate_6556eeeb-a389-4d00-b78f-21292dee562e_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockTransactionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial public offering, effective date</link:label>
    <link:label id="lab_us-gaap_SaleOfStockTransactionDate_label_en-US" xlink:label="lab_us-gaap_SaleOfStockTransactionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Transaction Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockTransactionDate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockTransactionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockTransactionDate" xlink:to="lab_us-gaap_SaleOfStockTransactionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6916beed-2736-4f88-92cc-6bf22bc31093_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3da02ffd-7e23-4822-aaa6-026bbf6262e1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of stock options activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_811190bf-f199-49a2-a911-4330e527a070_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_a5611260-103c-4234-97d8-93799ff96851_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payments</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_35c74205-3d14-452a-bf3a-d7554eca42ca_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_e82c47a2-41ea-424f-b27c-63ad4243c4b2_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Major Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_69e08230-3e0b-471a-a95c-fc22afafef09_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_097be077-b2a8-4b0c-8d14-a1e25e8f3786_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_c7403050-da48-4358-a187-22d5dca01a6a_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets associated with discontinued operations</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_b244128b-ad2e-48d7-b404-42186848c84d_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_0a1b43a0-af90-40fe-b6dd-fa7b2f752429_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember_03b1c090-d619-482d-a77c-5246a8a9fa78_terseLabel_en-US" xlink:label="lab_cpix_WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Issued in Consideration of 2009 Credit Facility Amendment</link:label>
    <link:label id="lab_cpix_WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember_label_en-US" xlink:label="lab_cpix_WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Issued in Consideration of 2009 Credit Facility Amendment [Member]</link:label>
    <link:label id="lab_cpix_WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember_documentation_en-US" xlink:label="lab_cpix_WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Issued in Consideration of 2009 Credit Facility Amendment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember" xlink:href="cpix-20201210.xsd#cpix_WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember" xlink:to="lab_cpix_WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_92b68cc9-6dbe-402f-918a-cafaeeb9b3f7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ExpirationTermOneMember_c6355c72-d8e0-410e-89fd-435c0bd63659_terseLabel_en-US" xlink:label="lab_cpix_ExpirationTermOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_cpix_ExpirationTermOneMember_label_en-US" xlink:label="lab_cpix_ExpirationTermOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration, Term One [Member]</link:label>
    <link:label id="lab_cpix_ExpirationTermOneMember_documentation_en-US" xlink:label="lab_cpix_ExpirationTermOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration, Term One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermOneMember" xlink:href="cpix-20201210.xsd#cpix_ExpirationTermOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ExpirationTermOneMember" xlink:to="lab_cpix_ExpirationTermOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_f2ef6e36-f842-418b-a49c-5b67959071cc_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_81519a57-0309-4ecc-8fab-4a95dc63d3f5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_2ad741b1-7933-44f9-8a36-21386d629842_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_34d4a04f-4694-4440-ab15-15bd54cb29bd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average incremental borrowing rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment_9a7299fa-bf8d-4806-8175-2ff5b0f4aa22_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to initial fair value of the contingent consideration liability</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment_label_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Contingent Consideration, Liability, Initial Fair Value Adjustment</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Contingent Consideration, Liability, Initial Fair Value Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" xlink:href="cpix-20201210.xsd#cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" xlink:to="lab_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_bea228a9-e31d-4133-a0c4-75fa492b1be6_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_EmployeeNonemployeeandFoundationContributionMember_c71c18fe-9e92-418c-adae-aad40cc97e64_terseLabel_en-US" xlink:label="lab_cpix_EmployeeNonemployeeandFoundationContributionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee, Nonemployee and Foundation Contribution</link:label>
    <link:label id="lab_cpix_EmployeeNonemployeeandFoundationContributionMember_label_en-US" xlink:label="lab_cpix_EmployeeNonemployeeandFoundationContributionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee, Nonemployee and Foundation Contribution [Member]</link:label>
    <link:label id="lab_cpix_EmployeeNonemployeeandFoundationContributionMember_documentation_en-US" xlink:label="lab_cpix_EmployeeNonemployeeandFoundationContributionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee, Nonemployee and Foundation Contribution [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EmployeeNonemployeeandFoundationContributionMember" xlink:href="cpix-20201210.xsd#cpix_EmployeeNonemployeeandFoundationContributionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_EmployeeNonemployeeandFoundationContributionMember" xlink:to="lab_cpix_EmployeeNonemployeeandFoundationContributionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantMember_e6cb8329-3c30-4159-9324-524b28212d06_terseLabel_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant</link:label>
    <link:label id="lab_us-gaap_GrantMember_label_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember" xlink:to="lab_us-gaap_GrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b5046d1c-55b4-415b-a6b8-7304b8294da3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price per share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_70736de4-5241-47ac-a8f4-9243f6f8c501_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration included in operating expenses</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_80c65976-fa68-4d98-b841-25d71bb49c99_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_9920a01d-597f-459a-b85a-1b0979519efe_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charged to costs and expenses</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SharesRepurchaseActivityTypeAxis_7c1cbde2-72a6-46d6-9d8b-d64f3ee4fbd8_terseLabel_en-US" xlink:label="lab_cpix_SharesRepurchaseActivityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Repurchase Activity, Type [Axis]</link:label>
    <link:label id="lab_cpix_SharesRepurchaseActivityTypeAxis_label_en-US" xlink:label="lab_cpix_SharesRepurchaseActivityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Repurchase Activity, Type [Axis]</link:label>
    <link:label id="lab_cpix_SharesRepurchaseActivityTypeAxis_documentation_en-US" xlink:label="lab_cpix_SharesRepurchaseActivityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Repurchase Activity, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharesRepurchaseActivityTypeAxis" xlink:href="cpix-20201210.xsd#cpix_SharesRepurchaseActivityTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SharesRepurchaseActivityTypeAxis" xlink:to="lab_cpix_SharesRepurchaseActivityTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_b81b0551-e8f0-4557-a9cd-210a14e5c972_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non cash increase in liabilities related to acquisition (see Note 3)</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Other Liabilities Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_VIBATIVMember_41ff2cc5-5450-464d-ba64-3f48b1476f53_terseLabel_en-US" xlink:label="lab_cpix_VIBATIVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIBATIV</link:label>
    <link:label id="lab_cpix_VIBATIVMember_label_en-US" xlink:label="lab_cpix_VIBATIVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIBATIV [Member]</link:label>
    <link:label id="lab_cpix_VIBATIVMember_documentation_en-US" xlink:label="lab_cpix_VIBATIVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIBATIV</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember" xlink:href="cpix-20201210.xsd#cpix_VIBATIVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_VIBATIVMember" xlink:to="lab_cpix_VIBATIVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DisposalGroupIncludingDiscontinuedOperationRemainingInventoryCurrent_65dc68ce-0952-45cf-b8d3-cd2d93b320ed_terseLabel_en-US" xlink:label="lab_cpix_DisposalGroupIncludingDiscontinuedOperationRemainingInventoryCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining inventory</link:label>
    <link:label id="lab_cpix_DisposalGroupIncludingDiscontinuedOperationRemainingInventoryCurrent_label_en-US" xlink:label="lab_cpix_DisposalGroupIncludingDiscontinuedOperationRemainingInventoryCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Remaining Inventory, Current</link:label>
    <link:label id="lab_cpix_DisposalGroupIncludingDiscontinuedOperationRemainingInventoryCurrent_documentation_en-US" xlink:label="lab_cpix_DisposalGroupIncludingDiscontinuedOperationRemainingInventoryCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Remaining Inventory, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DisposalGroupIncludingDiscontinuedOperationRemainingInventoryCurrent" xlink:href="cpix-20201210.xsd#cpix_DisposalGroupIncludingDiscontinuedOperationRemainingInventoryCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DisposalGroupIncludingDiscontinuedOperationRemainingInventoryCurrent" xlink:to="lab_cpix_DisposalGroupIncludingDiscontinuedOperationRemainingInventoryCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_5be961a6-abf2-4819-a4cd-885ecdd2dc59_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_539b396c-af82-4f77-83eb-2d89397a3015_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net of allowances</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_54b51739-4414-4bf8-9d91-dcad21da6b26_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_7dbb3d35-eb8b-4e6b-a2ca-e5b509ba6903_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest, ownership percentage by parent</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_0f4f9e4e-d976-49e0-bb5c-5d1fc3acf93c_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract" xlink:to="lab_us-gaap_NoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CustomerOneMember_a09424a4-285d-4b0c-bf76-c06cd1a6286c_terseLabel_en-US" xlink:label="lab_cpix_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer 1</link:label>
    <link:label id="lab_cpix_CustomerOneMember_label_en-US" xlink:label="lab_cpix_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer One [Member]</link:label>
    <link:label id="lab_cpix_CustomerOneMember_documentation_en-US" xlink:label="lab_cpix_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CustomerOneMember" xlink:href="cpix-20201210.xsd#cpix_CustomerOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CustomerOneMember" xlink:to="lab_cpix_CustomerOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_f91bdc7e-2e5d-479e-bbb9-9a43a791683a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_e0b2aad3-ca27-4b17-8756-72f0d2b2676b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksMember_2da78f65-41bb-4a51-9b3f-411aa5cfb428_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks</link:label>
    <link:label id="lab_us-gaap_TrademarksMember_label_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksMember" xlink:to="lab_us-gaap_TrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual_15020858-ef5a-45a3-b035-714388c83ade_terseLabel_en-US" xlink:label="lab_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, useful life</link:label>
    <link:label id="lab_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual_label_en-US" xlink:label="lab_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Useful Lives, (Textual)</link:label>
    <link:label id="lab_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual_documentation_en-US" xlink:label="lab_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Useful Lives, (Textual)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual" xlink:href="cpix-20201210.xsd#cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual" xlink:to="lab_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_b92be05b-054d-449a-b5ce-c7db0af468f7_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_e855015d-18bf-449e-9399-5d76b07870f6_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_18c2760b-6706-477b-84df-354ff85b345a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_01cc2d36-abee-41b8-925b-ac39a78c333a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of accrued contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8841045e-9b27-4e06-a1e5-74ce61308f3b_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b841a9df-02e0-4818-a6aa-0ab5918a2157_verboseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_3bd4e39e-4aa7-43e2-8835-5a9297c6141e_terseLabel_en-US" xlink:label="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HongKong WinHealth Pharma Group Co. Limited</link:label>
    <link:label id="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_label_en-US" xlink:label="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HongKong WinHealth Pharma Group Co. Limited [Member]</link:label>
    <link:label id="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_documentation_en-US" xlink:label="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HongKong WinHealth Pharma Group Co. Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:href="cpix-20201210.xsd#cpix_HongKongWinHealthPharmaGroupCoLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:to="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval_4593fec7-e98f-43da-bac0-6dde9d76b21e_terseLabel_en-US" xlink:label="lab_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenue, potential upfront payments related to regulatory approval</link:label>
    <link:label id="lab_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval_label_en-US" xlink:label="lab_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Potential Upfront Payments Related to Regulatory Approval</link:label>
    <link:label id="lab_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval_documentation_en-US" xlink:label="lab_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Potential Upfront Payments Related to Regulatory Approval</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval" xlink:href="cpix-20201210.xsd#cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval" xlink:to="lab_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NonemployeeMember_b6708f4a-2480-4deb-b377-9dbe5b9679a3_terseLabel_en-US" xlink:label="lab_cpix_NonemployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonemployee</link:label>
    <link:label id="lab_cpix_NonemployeeMember_label_en-US" xlink:label="lab_cpix_NonemployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonemployee [Member]</link:label>
    <link:label id="lab_cpix_NonemployeeMember_documentation_en-US" xlink:label="lab_cpix_NonemployeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonemployee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NonemployeeMember" xlink:href="cpix-20201210.xsd#cpix_NonemployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NonemployeeMember" xlink:to="lab_cpix_NonemployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_b550f059-592c-41c8-949f-fde73d5a7c01_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct_a1d09b14-83e9-4e1d-9e7e-c0e0f893b915_terseLabel_en-US" xlink:label="lab_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for expired product</link:label>
    <link:label id="lab_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct_label_en-US" xlink:label="lab_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves for Expired Product</link:label>
    <link:label id="lab_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct_documentation_en-US" xlink:label="lab_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves for Expired Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct" xlink:href="cpix-20201210.xsd#cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct" xlink:to="lab_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SubsidiaryInvestmentPurchaseOfShares_fc0755c7-9951-4fdf-9142-afcbaac29472_terseLabel_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in CET</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentPurchaseOfShares_label_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Investment, Purchase Of Shares</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentPurchaseOfShares_documentation_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Investment, Purchase Of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:href="cpix-20201210.xsd#cpix_SubsidiaryInvestmentPurchaseOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:to="lab_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_f0ac7c49-847c-4068-8f62-b593fa585875_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_dc1af569-3748-4328-bfbe-525dfe1db51d_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SecondAmendmentMember_e1acb6dd-6fc4-4508-8617-a307fed27eb8_terseLabel_en-US" xlink:label="lab_cpix_SecondAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Amendment</link:label>
    <link:label id="lab_cpix_SecondAmendmentMember_label_en-US" xlink:label="lab_cpix_SecondAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Amendment [Member]</link:label>
    <link:label id="lab_cpix_SecondAmendmentMember_documentation_en-US" xlink:label="lab_cpix_SecondAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SecondAmendmentMember" xlink:href="cpix-20201210.xsd#cpix_SecondAmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SecondAmendmentMember" xlink:to="lab_cpix_SecondAmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b34b8db4-fbb1-462d-8d78-6c0c24f22be3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_6234e56a-6218-43cd-977f-f4ac0a210557_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2ab5519a-c0e1-4fa1-8077-871fb02afb0c_verboseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_c0c4b63a-4d3e-4097-97a8-edc29e57f75b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders-Discontinued operations-basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_6eeb58fe-83dc-4184-8646-5e78a4adc7cf_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5793ce6d-bc18-4c86-8195-c991cf50d6e8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted, weighted-average exercise price per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_62f25f07-7103-4b43-bf0a-8bf0e40a6eb8_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_8a56aa1e-e7e5-4213-b00a-19225fe888e3_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_85a58060-95fc-41e6-b2ab-ef6e98fefe38_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_e1a7e4c5-a28a-4100-b5fe-ca058110e96f_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AmendedInternationalAgreementMember_8bc41e38-650c-41ee-9d7a-9ac8c5fc98b8_terseLabel_en-US" xlink:label="lab_cpix_AmendedInternationalAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended International Agreement</link:label>
    <link:label id="lab_cpix_AmendedInternationalAgreementMember_label_en-US" xlink:label="lab_cpix_AmendedInternationalAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended International Agreement [Member]</link:label>
    <link:label id="lab_cpix_AmendedInternationalAgreementMember_documentation_en-US" xlink:label="lab_cpix_AmendedInternationalAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended International Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AmendedInternationalAgreementMember" xlink:href="cpix-20201210.xsd#cpix_AmendedInternationalAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AmendedInternationalAgreementMember" xlink:to="lab_cpix_AmendedInternationalAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_944ad97e-0103-4d7d-af87-cd471933ac67_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of expected amortization expense of intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d9f6ced1-2606-4da1-abb2-a5edd71e71f9_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0d8b1f1e-0542-41ba-9d60-3f7e73b20e81_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding &#8211; diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_a7a0f29c-0edb-4b81-95c8-e79a3fdceeb2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of fair value of financial instruments by level in hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_1f18285a-9e56-4be0-9d15-f5536cc290e2_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants_48b92587-fa12-45f3-9944-ea1c75ae4012_terseLabel_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of equity compensation plans available for future grants</link:label>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants_label_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Plans Available for Future Grants</link:label>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants_documentation_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Plans Available for Future Grants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants" xlink:href="cpix-20201210.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants" xlink:to="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_47177908-ca6f-4abe-a3d8-5a8170fc1459_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_afeefb1b-50e6-4480-8446-c75a1fc0a2ca_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_be130033-fd49-4813-9a5d-fbacaadff6a5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares forfeited, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_61c44247-78d7-459d-a746-ece768a44048_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_fb74848d-2c19-4f5a-ac14-feab6e0c9190_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_706a9983-7acc-4c93-afa1-b8e73a03c739_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_e3ca53eb-2f01-4359-ba00-eeb0a87dc9f8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_2b046c7e-4f62-46f7-a4ef-076d297dcb0a_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) from discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_b0462977-fab4-470d-a7b6-b23b31a4a2d1_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock &#8211; no par value; 100,000,000 shares authorized; 15,263,555 and 15,481,497 shares issued and outstanding as of December&#160;31, 2019 and 2018, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_b10b50cb-4898-4736-84fd-af2558d3f6c5_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_58cd5779-a0b9-4ee7-9d31-693f6b081d92_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1acdeae5-0d22-4a9e-a392-da7583559717_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_57088c76-34f9-464c-ac4b-ebf97d26de0a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of subsidiary shares to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:to="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_9bbee7f6-bd53-48ec-9060-2c549dea30f4_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory reserves, obsolescence and discontinuance</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AirlineProductsAndServicesTable_b3901611-71ee-466b-8a13-738ed2b2c0e0_terseLabel_en-US" xlink:label="lab_us-gaap_AirlineProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_AirlineProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_AirlineProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and Services [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AirlineProductsAndServicesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AirlineProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable" xlink:to="lab_us-gaap_AirlineProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions_6614d0c9-3a45-45b6-8d56-b0ac31c540a6_terseLabel_en-US" xlink:label="lab_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Committed cash contributions</link:label>
    <link:label id="lab_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions_label_en-US" xlink:label="lab_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Charitable Contribution of Shares, Committed Cash Contributions</link:label>
    <link:label id="lab_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions_documentation_en-US" xlink:label="lab_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Charitable Contribution of Shares, Committed Cash Contributions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions" xlink:href="cpix-20201210.xsd#cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions" xlink:to="lab_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_5b5e21ae-4403-4127-ba3c-27c5c697dc2a_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_d5db2e63-6ecc-4caf-bf2e-de22041dba57_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge_b51986d2-5e6c-4996-9e00-7c5b76a4979f_terseLabel_en-US" xlink:label="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, eligibiilty, minimum employee age</link:label>
    <link:label id="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge_label_en-US" xlink:label="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Eligibility, Minimum Employee Age</link:label>
    <link:label id="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge_documentation_en-US" xlink:label="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Eligibility, Minimum Employee Age</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge" xlink:href="cpix-20201210.xsd#cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge" xlink:to="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PaymentsForAssetAcquisitions_08f9c905-37a3-4814-aaa1-bbcb3e245dac_terseLabel_en-US" xlink:label="lab_cpix_PaymentsForAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for asset acquisitions</link:label>
    <link:label id="lab_cpix_PaymentsForAssetAcquisitions_label_en-US" xlink:label="lab_cpix_PaymentsForAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Asset Acquisitions</link:label>
    <link:label id="lab_cpix_PaymentsForAssetAcquisitions_documentation_en-US" xlink:label="lab_cpix_PaymentsForAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Asset Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsForAssetAcquisitions" xlink:href="cpix-20201210.xsd#cpix_PaymentsForAssetAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PaymentsForAssetAcquisitions" xlink:to="lab_cpix_PaymentsForAssetAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_08c05bab-72df-456f-bfc1-484363ca84b1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5e70be2b-5141-40fc-a2e3-bd428b6c237e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_834ba103-a022-42fb-afbb-175eea02e85f_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2311ab38-36cc-4283-b81e-5b59a9f33aad_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, end of period, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:to="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationPlanAssets_7885f161-9917-4073-b7e9-b3074b36b88d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation assets</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationPlanAssets_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationPlanAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationPlanAssets" xlink:to="lab_us-gaap_DeferredCompensationPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_d0d64dbe-2659-4647-a773-f3fcce3badcb_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ScheduleofDepreciationExpenseTableTextBlock_5dfb0a9f-cfea-448d-abdb-bdb49d1d74bb_terseLabel_en-US" xlink:label="lab_cpix_ScheduleofDepreciationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of depreciation expense</link:label>
    <link:label id="lab_cpix_ScheduleofDepreciationExpenseTableTextBlock_label_en-US" xlink:label="lab_cpix_ScheduleofDepreciationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Depreciation Expense [Table Text Block]</link:label>
    <link:label id="lab_cpix_ScheduleofDepreciationExpenseTableTextBlock_documentation_en-US" xlink:label="lab_cpix_ScheduleofDepreciationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Depreciation Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ScheduleofDepreciationExpenseTableTextBlock" xlink:href="cpix-20201210.xsd#cpix_ScheduleofDepreciationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ScheduleofDepreciationExpenseTableTextBlock" xlink:to="lab_cpix_ScheduleofDepreciationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_0b0a63c3-07f4-4646-9d5a-b501a173196b_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment of royalty during the period</link:label>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_label_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRoyalties" xlink:to="lab_us-gaap_PaymentsForRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_f2e6be08-f7dd-44ec-a73b-00e6379938a4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_78c70060-33d5-4886-8320-a4358e8edf61_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_eb9cb38c-db48-43a4-a0f4-bd61cbea0188_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss) attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_83aef571-3aaa-4a35-a991-5f351e88a03d_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_46729b21-8cb5-49e1-a5e1-9da5fd28dc41_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e8e73bc7-3296-4102-b9cd-7aaaa9b164f1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares granted, weighted-average grant-date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CustomerThreeMember_542a9caa-686c-4b5b-ba5d-82c37c4e6ce2_terseLabel_en-US" xlink:label="lab_cpix_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer 3</link:label>
    <link:label id="lab_cpix_CustomerThreeMember_label_en-US" xlink:label="lab_cpix_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Three [Member]</link:label>
    <link:label id="lab_cpix_CustomerThreeMember_documentation_en-US" xlink:label="lab_cpix_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CustomerThreeMember" xlink:href="cpix-20201210.xsd#cpix_CustomerThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CustomerThreeMember" xlink:to="lab_cpix_CustomerThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_3fd38cb2-dac0-499a-8457-e5b33610dbe4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c8881cf8-df5e-4a21-8463-95ca661929b1_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_e7378bb6-d206-497d-a433-c8769ef23d52_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, number of shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_123d6b11-2733-49b1-92a2-5baa514d4f7b_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_284286b9-2b98-4fa8-b46b-f93495c3ace1_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ContributionOfCashAdditionalSharesPurchased_1434ab26-407f-495c-9836-bcda99b4cf5f_terseLabel_en-US" xlink:label="lab_cpix_ContributionOfCashAdditionalSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution of cash</link:label>
    <link:label id="lab_cpix_ContributionOfCashAdditionalSharesPurchased_label_en-US" xlink:label="lab_cpix_ContributionOfCashAdditionalSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution of Cash, Additional Shares Purchased</link:label>
    <link:label id="lab_cpix_ContributionOfCashAdditionalSharesPurchased_documentation_en-US" xlink:label="lab_cpix_ContributionOfCashAdditionalSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution of Cash, Additional Shares Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ContributionOfCashAdditionalSharesPurchased" xlink:href="cpix-20201210.xsd#cpix_ContributionOfCashAdditionalSharesPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ContributionOfCashAdditionalSharesPurchased" xlink:to="lab_cpix_ContributionOfCashAdditionalSharesPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PropertyAndEquipmentUsefulLifeTextual_dceda746-20d6-4461-95a0-93d8281a6005_terseLabel_en-US" xlink:label="lab_cpix_PropertyAndEquipmentUsefulLifeTextual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, useful life (Textual)</link:label>
    <link:label id="lab_cpix_PropertyAndEquipmentUsefulLifeTextual_label_en-US" xlink:label="lab_cpix_PropertyAndEquipmentUsefulLifeTextual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, useful life (Textual)</link:label>
    <link:label id="lab_cpix_PropertyAndEquipmentUsefulLifeTextual_documentation_en-US" xlink:label="lab_cpix_PropertyAndEquipmentUsefulLifeTextual" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, useful life (Textual)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PropertyAndEquipmentUsefulLifeTextual" xlink:href="cpix-20201210.xsd#cpix_PropertyAndEquipmentUsefulLifeTextual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PropertyAndEquipmentUsefulLifeTextual" xlink:to="lab_cpix_PropertyAndEquipmentUsefulLifeTextual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_bf088656-9238-4cb9-bf33-ab2e0a250b74_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_761af1dd-e57f-440f-b8be-63fe1f4d62f6_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_e07c16a7-101c-48b0-846a-985168777f76_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_92a2877b-0171-47bd-9ba4-96f64b70360f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_4e062113-a63f-4763-a08a-e6e1e06881cd_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_USTreasuryNotesAndBondsSecuritiesMember_1443a537-4a83-4e36-b7e5-1c0c2820d3b8_terseLabel_en-US" xlink:label="lab_cpix_USTreasuryNotesAndBondsSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury notes and bonds</link:label>
    <link:label id="lab_cpix_USTreasuryNotesAndBondsSecuritiesMember_label_en-US" xlink:label="lab_cpix_USTreasuryNotesAndBondsSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Notes And Bonds Securities [Member]</link:label>
    <link:label id="lab_cpix_USTreasuryNotesAndBondsSecuritiesMember_documentation_en-US" xlink:label="lab_cpix_USTreasuryNotesAndBondsSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Notes And Bonds Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_USTreasuryNotesAndBondsSecuritiesMember" xlink:href="cpix-20201210.xsd#cpix_USTreasuryNotesAndBondsSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_USTreasuryNotesAndBondsSecuritiesMember" xlink:to="lab_cpix_USTreasuryNotesAndBondsSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsPercentage_f03315b8-19d9-4e89-9b0c-b526664c1d5b_terseLabel_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered royalty payments (percentage)</link:label>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsPercentage_label_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered Royalty Payments, Percentage</link:label>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsPercentage_documentation_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered Royalty Payments, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsPercentage" xlink:href="cpix-20201210.xsd#cpix_TieredRoyaltyPaymentsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_TieredRoyaltyPaymentsPercentage" xlink:to="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_48c45db3-5816-4211-9e23-eda133b205f9_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_498d2d11-045d-4208-8075-aec490576ef1_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities associated with discontinued operations</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_464704e2-adff-4429-b27f-97d322e310b7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of deferred equity offering costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_a8a28a1d-1ada-42e7-b043-5c7e71515e02_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial public offering, issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_dc63389a-49f3-4b52-b160-4a54baf14cca_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_1c159aa7-8dcb-458c-acc9-94d9aebba055_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_09ab8d1e-f81c-470b-9364-b2cfc1b56b80_terseLabel_en-US" xlink:label="lab_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss and tax credits</link:label>
    <link:label id="lab_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_label_en-US" xlink:label="lab_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards and Tax Credit Carryforwards</link:label>
    <link:label id="lab_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_documentation_en-US" xlink:label="lab_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards and Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" xlink:href="cpix-20201210.xsd#cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" xlink:to="lab_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_e7369594-d0ff-409a-b696-020232b5590d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_c43ddb4a-1e3d-4705-b700-46fda1cec7aa_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, Marketing and other</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_4f45bc16-6f8d-4798-a71e-7bf287dc71b3_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_2ff80f32-0d5f-4c5f-a6cb-6c908a1851a7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_cd5918db-8e93-45b0-9d24-d45a1d8838eb_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of revenues concentration from major customers</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_29ff1896-ae3f-4333-9a75-d4fafa1a6605_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee wages and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_c5f9c858-c0d5-4ed2-94f8-3335c461abfa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_5e131333-25a5-403e-9084-b3d10d0b4c40_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_97e8b29c-330a-4d6c-af83-12237b657712_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AccountsReceivableAllowancesByComponentAxis_7a08d747-1066-4ebc-87c8-1bcff24b37ce_terseLabel_en-US" xlink:label="lab_cpix_AccountsReceivableAllowancesByComponentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowances by Component [Axis]</link:label>
    <link:label id="lab_cpix_AccountsReceivableAllowancesByComponentAxis_label_en-US" xlink:label="lab_cpix_AccountsReceivableAllowancesByComponentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowances by Component [Axis]</link:label>
    <link:label id="lab_cpix_AccountsReceivableAllowancesByComponentAxis_documentation_en-US" xlink:label="lab_cpix_AccountsReceivableAllowancesByComponentAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowances by Component [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccountsReceivableAllowancesByComponentAxis" xlink:href="cpix-20201210.xsd#cpix_AccountsReceivableAllowancesByComponentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AccountsReceivableAllowancesByComponentAxis" xlink:to="lab_cpix_AccountsReceivableAllowancesByComponentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_795da43a-e9b4-4a3b-85ca-1502d73c89f1_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_28a48d06-3f4e-4194-b154-3ecb5f742f87_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_92da8a40-c13b-40e8-a541-85193b565f0c_terseLabel_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit, maximum borrowing capacity upon satisfaction of certain conditions</link:label>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_label_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity Upon Satisfaction of Certain Conditions</link:label>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_documentation_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity Upon Satisfaction of Certain Conditions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:href="cpix-20201210.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:to="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_ea68a672-5995-454a-85ad-eb9a4056cafe_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_73ade226-6cde-4c51-8c61-f4a689c75919_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive shares (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_99a87776-fd3a-4179-a8ae-d31bc5c18190_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current income tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_c6e63467-e7a5-4bbc-a10b-f0085ea63858_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_baed05d0-10ce-4f83-89dc-e7564216a5b0_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_1275bf67-192e-4171-852a-9e1df0355ef5_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_a55d7681-ea00-4ad7-ad69-ce89d9138878_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_0d8177c9-d893-42e3-8c3c-7ad593c8147c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: deferred tax asset valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_KristaloseMember_1aac4bf6-cd01-4e94-a8b6-8e0a97983e15_terseLabel_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose</link:label>
    <link:label id="lab_cpix_KristaloseMember_label_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose [Member]</link:label>
    <link:label id="lab_cpix_KristaloseMember_documentation_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember" xlink:href="cpix-20201210.xsd#cpix_KristaloseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_KristaloseMember" xlink:to="lab_cpix_KristaloseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_00369f36-446f-4869-8747-641a7383fbf5_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_8c19e6dd-a781-4a19-a371-58d05a4fac44_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PreferredStockAbstract_32190ccc-036b-41f8-922f-7b5fc79f792c_terseLabel_en-US" xlink:label="lab_cpix_PreferredStockAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Abstract]</link:label>
    <link:label id="lab_cpix_PreferredStockAbstract_label_en-US" xlink:label="lab_cpix_PreferredStockAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Abstract]</link:label>
    <link:label id="lab_cpix_PreferredStockAbstract_documentation_en-US" xlink:label="lab_cpix_PreferredStockAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PreferredStockAbstract" xlink:href="cpix-20201210.xsd#cpix_PreferredStockAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PreferredStockAbstract" xlink:to="lab_cpix_PreferredStockAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_8af1b88f-23dd-4700-a478-52121c5e3e96_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_58d61387-ec95-44ab-9758-4d64e49508b3_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_0623c7d0-c617-4add-979e-90837c36498f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_36173bbd-9957-4b1e-bbdb-b0c8fffb0fe5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Liability, Classified, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:to="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f5d3986c-bb0b-4d9f-9ddd-18fb470aa1a0_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_516a12a9-bee6-4bd4-bae4-d6b4581b48ca_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_f7c5c63d-2812-467b-bdd4-1d906dda719f_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_76d87a84-e6d0-4f2f-9319-218b25f4164c_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net changes in assets and liabilities affecting operating activities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_99d1131c-2892-4c99-aba2-4e2b7c6ba1ec_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_WarrantsIssuedInConsiderationOf2006CreditFacilityAmendmentMember_ed57daa5-e435-43b0-bb04-d873985e093c_terseLabel_en-US" xlink:label="lab_cpix_WarrantsIssuedInConsiderationOf2006CreditFacilityAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Issued in Consideration of 2006 Credit Facility Amendment</link:label>
    <link:label id="lab_cpix_WarrantsIssuedInConsiderationOf2006CreditFacilityAmendmentMember_label_en-US" xlink:label="lab_cpix_WarrantsIssuedInConsiderationOf2006CreditFacilityAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Issued in Consideration of 2006 Credit Facility Amendment [Member]</link:label>
    <link:label id="lab_cpix_WarrantsIssuedInConsiderationOf2006CreditFacilityAmendmentMember_documentation_en-US" xlink:label="lab_cpix_WarrantsIssuedInConsiderationOf2006CreditFacilityAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Issued in Consideration of 2006 Credit Facility Amendment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_WarrantsIssuedInConsiderationOf2006CreditFacilityAmendmentMember" xlink:href="cpix-20201210.xsd#cpix_WarrantsIssuedInConsiderationOf2006CreditFacilityAmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_WarrantsIssuedInConsiderationOf2006CreditFacilityAmendmentMember" xlink:to="lab_cpix_WarrantsIssuedInConsiderationOf2006CreditFacilityAmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_fcf8719c-d67c-40eb-b44b-e00eae18c240_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_4e108c23-77b0-4e32-9b52-a0658f2261a7_terseLabel_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of balance sheet classification</link:label>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="cpix-20201210.xsd#cpix_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_620451a8-e389-4f93-9e75-342fa7e4e949_totalLabel_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangibles and goodwill</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_label_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles and Goodwill</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles and Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" xlink:href="cpix-20201210.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" xlink:to="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_2306cc1b-4739-4a1b-b14d-83a0390d9727_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_82a498c1-59e0-463a-a3f6-8282ad41216e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_f708dfcc-c6e5-4b5f-b1b7-8c90d6d87d2c_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_be1a131b-f51f-4c5e-9c6c-44aeee2cfa60_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_aad404cb-bce9-494b-8c1f-1275ac9a71cd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of deferred tax assets and liabilities, net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DirectorsIncentivePlan2007Member_14ba79ea-9d40-4dc2-a794-e47a762d51c1_terseLabel_en-US" xlink:label="lab_cpix_DirectorsIncentivePlan2007Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Directors&#8217; Incentive Plan 2007</link:label>
    <link:label id="lab_cpix_DirectorsIncentivePlan2007Member_label_en-US" xlink:label="lab_cpix_DirectorsIncentivePlan2007Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Directors&#8217; Incentive Plan 2007 [Member]</link:label>
    <link:label id="lab_cpix_DirectorsIncentivePlan2007Member_documentation_en-US" xlink:label="lab_cpix_DirectorsIncentivePlan2007Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Directors&#8217; Incentive Plan 2007 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DirectorsIncentivePlan2007Member" xlink:href="cpix-20201210.xsd#cpix_DirectorsIncentivePlan2007Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DirectorsIncentivePlan2007Member" xlink:to="lab_cpix_DirectorsIncentivePlan2007Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_53b7ddeb-d26e-4905-9e54-65b9c1e055de_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income tax expense (net of federal income tax benefit)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ManufacturingandSupplyAgreementLineItems_101cab6f-89b6-476b-9332-78c783c1f38c_terseLabel_en-US" xlink:label="lab_cpix_ManufacturingandSupplyAgreementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and Supply Agreement [Line Items]</link:label>
    <link:label id="lab_cpix_ManufacturingandSupplyAgreementLineItems_label_en-US" xlink:label="lab_cpix_ManufacturingandSupplyAgreementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and Supply Agreement [Line Items]</link:label>
    <link:label id="lab_cpix_ManufacturingandSupplyAgreementLineItems_documentation_en-US" xlink:label="lab_cpix_ManufacturingandSupplyAgreementLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Manufacturing and Supply Agreement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingandSupplyAgreementLineItems" xlink:href="cpix-20201210.xsd#cpix_ManufacturingandSupplyAgreementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ManufacturingandSupplyAgreementLineItems" xlink:to="lab_cpix_ManufacturingandSupplyAgreementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NonprincipalOwnerMember_5b1fe166-e74b-4457-ba11-8c57e82832f3_terseLabel_en-US" xlink:label="lab_cpix_NonprincipalOwnerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NonPrincipal Owner</link:label>
    <link:label id="lab_cpix_NonprincipalOwnerMember_label_en-US" xlink:label="lab_cpix_NonprincipalOwnerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NonPrincipal Owner [Member]</link:label>
    <link:label id="lab_cpix_NonprincipalOwnerMember_documentation_en-US" xlink:label="lab_cpix_NonprincipalOwnerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NonPrincipal Owner [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NonprincipalOwnerMember" xlink:href="cpix-20201210.xsd#cpix_NonprincipalOwnerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NonprincipalOwnerMember" xlink:to="lab_cpix_NonprincipalOwnerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_409c8206-505c-4e01-8721-b86b7071c7ed_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of subsidiary shares to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Subsidiary Equity Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_1bf4779b-74a0-4fe6-87cf-976dc9786288_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3a75aa25-24c6-4e60-b0b3-1ade5c9e61c9_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, number of shares called by warrants</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f42766fe-b6aa-48d3-858c-6f983b49ecd7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_c6197c2f-0e66-40fd-9283-11e1ac0eb971_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProductAndLicenseRightsMember_4ae21939-1cd8-4655-85b8-de636afebe67_terseLabel_en-US" xlink:label="lab_cpix_ProductAndLicenseRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and License Rights</link:label>
    <link:label id="lab_cpix_ProductAndLicenseRightsMember_label_en-US" xlink:label="lab_cpix_ProductAndLicenseRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and License Rights [Member]</link:label>
    <link:label id="lab_cpix_ProductAndLicenseRightsMember_documentation_en-US" xlink:label="lab_cpix_ProductAndLicenseRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and License Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductAndLicenseRightsMember" xlink:href="cpix-20201210.xsd#cpix_ProductAndLicenseRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProductAndLicenseRightsMember" xlink:to="lab_cpix_ProductAndLicenseRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_0a78ef82-56ef-47dc-82e6-884998ae91d6_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_5ed3d8d1-fd5c-47bc-9ee7-42747ba5d6dd_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProductRightsMember_3d28a07c-e4c3-475e-ab5b-d17359bf92fd_verboseLabel_en-US" xlink:label="lab_cpix_ProductRightsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Rights</link:label>
    <link:label id="lab_cpix_ProductRightsMember_label_en-US" xlink:label="lab_cpix_ProductRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Rights [Member]</link:label>
    <link:label id="lab_cpix_ProductRightsMember_documentation_en-US" xlink:label="lab_cpix_ProductRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductRightsMember" xlink:href="cpix-20201210.xsd#cpix_ProductRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProductRightsMember" xlink:to="lab_cpix_ProductRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_8b137187-ca55-4ba0-bd31-a0f21372ac4b_verboseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_169676b9-92d9-4d53-8a06-4bf48d8cd264_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_e5cdd23d-baaa-42b0-b751-fcd64c67ce98_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_2711b448-2fda-4b61-8fa3-9564a34e722f_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AccruedLiabilitiesStockPayable_59ed68b5-bd08-4b4b-bfa4-81a1b07ac8d3_terseLabel_en-US" xlink:label="lab_cpix_AccruedLiabilitiesStockPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock payable</link:label>
    <link:label id="lab_cpix_AccruedLiabilitiesStockPayable_label_en-US" xlink:label="lab_cpix_AccruedLiabilitiesStockPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Stock Payable</link:label>
    <link:label id="lab_cpix_AccruedLiabilitiesStockPayable_documentation_en-US" xlink:label="lab_cpix_AccruedLiabilitiesStockPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Stock Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccruedLiabilitiesStockPayable" xlink:href="cpix-20201210.xsd#cpix_AccruedLiabilitiesStockPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AccruedLiabilitiesStockPayable" xlink:to="lab_cpix_AccruedLiabilitiesStockPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_4c8f30a0-5c14-4c43-955b-67150d342bd8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_1c31d7d1-980f-4178-992d-078c9bd506d1_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_4900073a-3532-4d17-b6c5-c20bea5e78a3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_ae736c64-d1e6-42f6-a3ac-75f5857adb42_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForCreditLossMember_3b7d65b5-9fe1-480d-8d88-c31f21c88817_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForCreditLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for uncollectible amounts, cash discounts, chargebacks, and credits issued for damaged products:</link:label>
    <link:label id="lab_us-gaap_AllowanceForCreditLossMember_label_en-US" xlink:label="lab_us-gaap_AllowanceForCreditLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Allowance, Credit Loss [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForCreditLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForCreditLossMember" xlink:to="lab_us-gaap_AllowanceForCreditLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset_f2697793-8ab4-4608-b912-2609fc3563c6_terseLabel_en-US" xlink:label="lab_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial consideration</link:label>
    <link:label id="lab_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset_label_en-US" xlink:label="lab_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration Received for Beneficial Interest Obtained for Transferring Financial Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset" xlink:to="lab_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_1aa7c7bb-3983-4678-b390-3ad97c2ee130_terseLabel_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange for consideration, amount</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_label_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Investment, Payments For Return Of Capital</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_documentation_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Investment, Payments For Return Of Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" xlink:href="cpix-20201210.xsd#cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" xlink:to="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_fcd58ffb-39bc-49c4-af21-f1424d878e99_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_9881485e-df96-46c5-9160-7d2b6ed2f8a5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7627822e-6329-4d4e-827d-81bf640fb396_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the sale of common stock, net of offering costs, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9e996ea0-bce3-492b-9a8b-badff6db1e9b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial public offering, shares issued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_d8e719d6-f14c-4423-9d97-a7ec71a23d72_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_label_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable" xlink:to="lab_us-gaap_ClassOfTreasuryStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ScheduleOfStockOptionActivityAdditionalDisclosuresTableTextBlock_12c510a3-db62-4432-919f-9d9ac4bdb82b_terseLabel_en-US" xlink:label="lab_cpix_ScheduleOfStockOptionActivityAdditionalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of stock options activity, additional disclosures</link:label>
    <link:label id="lab_cpix_ScheduleOfStockOptionActivityAdditionalDisclosuresTableTextBlock_label_en-US" xlink:label="lab_cpix_ScheduleOfStockOptionActivityAdditionalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity, Additional Disclosures [Table Text Block]</link:label>
    <link:label id="lab_cpix_ScheduleOfStockOptionActivityAdditionalDisclosuresTableTextBlock_documentation_en-US" xlink:label="lab_cpix_ScheduleOfStockOptionActivityAdditionalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity, Additional Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ScheduleOfStockOptionActivityAdditionalDisclosuresTableTextBlock" xlink:href="cpix-20201210.xsd#cpix_ScheduleOfStockOptionActivityAdditionalDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ScheduleOfStockOptionActivityAdditionalDisclosuresTableTextBlock" xlink:to="lab_cpix_ScheduleOfStockOptionActivityAdditionalDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_ea926441-f397-482c-ab00-a1d69abb52b9_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_0b20edd0-3070-4ebd-8bf7-ae0291fb2fdb_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_94660e7a-9161-43a1-8028-7d6cbbf56f85_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_b08ecf92-e288-4b4b-bc52-9fe7224ec408_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MunicipalBondsMember_841bfcd8-769e-4742-a9e2-de5e8dde8dbb_verboseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term cash investments</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_label_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MunicipalBondsMember" xlink:to="lab_us-gaap_MunicipalBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ManufacturedProductOtherMember_9ca6e707-5ab9-49a3-beb7-d8ce79662619_terseLabel_en-US" xlink:label="lab_us-gaap_ManufacturedProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ManufacturedProductOtherMember_label_en-US" xlink:label="lab_us-gaap_ManufacturedProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufactured Product, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManufacturedProductOtherMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ManufacturedProductOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ManufacturedProductOtherMember" xlink:to="lab_us-gaap_ManufacturedProductOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7ecfa4dc-cd40-4a70-a705-2aa860ac8c38_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NordicMember_2075c7b2-8b52-40d9-8834-27f7f3d1df2b_terseLabel_en-US" xlink:label="lab_cpix_NordicMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nordic</link:label>
    <link:label id="lab_cpix_NordicMember_label_en-US" xlink:label="lab_cpix_NordicMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nordic [Member]</link:label>
    <link:label id="lab_cpix_NordicMember_documentation_en-US" xlink:label="lab_cpix_NordicMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nordic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NordicMember" xlink:href="cpix-20201210.xsd#cpix_NordicMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NordicMember" xlink:to="lab_cpix_NordicMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1a8392ca-8f33-47d5-9b9c-ccebdd256530_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_68bb3cf7-bfc2-4548-97a4-4d5b935d8664_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_90bb67ef-9dd7-4ede-9cfe-7f1e042480c0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox&#174;-Pak, RediTrex&#174; and Vibativ&#174;</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LoansForgiveninExchangeForShareIssuedAmount_99017d8b-2017-4990-957c-06aa4bec89f2_terseLabel_en-US" xlink:label="lab_cpix_LoansForgiveninExchangeForShareIssuedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Forgiven in Exchange For Share Issued, Amount</link:label>
    <link:label id="lab_cpix_LoansForgiveninExchangeForShareIssuedAmount_label_en-US" xlink:label="lab_cpix_LoansForgiveninExchangeForShareIssuedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Forgiven in Exchange For Share Issued, Amount</link:label>
    <link:label id="lab_cpix_LoansForgiveninExchangeForShareIssuedAmount_documentation_en-US" xlink:label="lab_cpix_LoansForgiveninExchangeForShareIssuedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Forgiven in Exchange For Share Issued, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LoansForgiveninExchangeForShareIssuedAmount" xlink:href="cpix-20201210.xsd#cpix_LoansForgiveninExchangeForShareIssuedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LoansForgiveninExchangeForShareIssuedAmount" xlink:to="lab_cpix_LoansForgiveninExchangeForShareIssuedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_HarbinGloriaPharmaceuticalsCoMember_9b892028-ea49-4813-865e-396b4d19aa8f_terseLabel_en-US" xlink:label="lab_cpix_HarbinGloriaPharmaceuticalsCoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Harbin Gloria Pharmaceuticals Co</link:label>
    <link:label id="lab_cpix_HarbinGloriaPharmaceuticalsCoMember_label_en-US" xlink:label="lab_cpix_HarbinGloriaPharmaceuticalsCoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Harbin Gloria Pharmaceuticals Co [Member]</link:label>
    <link:label id="lab_cpix_HarbinGloriaPharmaceuticalsCoMember_documentation_en-US" xlink:label="lab_cpix_HarbinGloriaPharmaceuticalsCoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Harbin Gloria Pharmaceuticals Co [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HarbinGloriaPharmaceuticalsCoMember" xlink:href="cpix-20201210.xsd#cpix_HarbinGloriaPharmaceuticalsCoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_HarbinGloriaPharmaceuticalsCoMember" xlink:to="lab_cpix_HarbinGloriaPharmaceuticalsCoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5dfbdabc-329d-4890-8423-9e3dc684bf5f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of operating lease liability maturities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_fb98e05b-8a60-483a-9e78-591a2fa5ec7e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_780d5eac-9e6f-4353-8ae4-98f0d909d233_terseLabel_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_label_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AccruedLiabilitiesInventoryPurchases_11cd7668-3f05-4a63-ac7d-5165bbf51044_terseLabel_en-US" xlink:label="lab_cpix_AccruedLiabilitiesInventoryPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued inventory purchases</link:label>
    <link:label id="lab_cpix_AccruedLiabilitiesInventoryPurchases_label_en-US" xlink:label="lab_cpix_AccruedLiabilitiesInventoryPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Inventory Purchases</link:label>
    <link:label id="lab_cpix_AccruedLiabilitiesInventoryPurchases_documentation_en-US" xlink:label="lab_cpix_AccruedLiabilitiesInventoryPurchases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Inventory Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccruedLiabilitiesInventoryPurchases" xlink:href="cpix-20201210.xsd#cpix_AccruedLiabilitiesInventoryPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AccruedLiabilitiesInventoryPurchases" xlink:to="lab_cpix_AccruedLiabilitiesInventoryPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5468dded-8b29-42a1-9ad5-83a1ca1701f9_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ed5fd073-50b8-4a13-aa9b-f85182912752_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding &#8211; basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_ed961c85-04d7-4fd8-abda-d334bdf523f2_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_0d3b3b9d-b567-4c2b-9503-01aa48b01ee6_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering_f0eccf60-1b61-42e5-a845-73b557b07e97_terseLabel_en-US" xlink:label="lab_cpix_StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial public offering, number of shares common stock received in exchange for preferred stock</link:label>
    <link:label id="lab_cpix_StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering_label_en-US" xlink:label="lab_cpix_StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued in Initial Public Offering, Number of Shares Common Stock Received for Preferred Stock Contemporareous With Offering</link:label>
    <link:label id="lab_cpix_StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering_documentation_en-US" xlink:label="lab_cpix_StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued in Initial Public Offering, Number of Shares Common Stock Received for Preferred Stock Contemporareous With Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering" xlink:href="cpix-20201210.xsd#cpix_StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering" xlink:to="lab_cpix_StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_8164f5c0-a4b7-4413-8ea7-aa387aac233b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_15e31440-0f7a-48ec-ae33-bd1718e8fbe6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of future minimum lease payments for operating leases</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_4f23861c-1e64-45fb-98cf-547c84915795_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_2cfe4e82-ce50-4b3c-ab88-6c569211a74f_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_EmployeeMember_503b397e-6d61-49d5-8dff-7c5a7c60ed76_terseLabel_en-US" xlink:label="lab_cpix_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee</link:label>
    <link:label id="lab_cpix_EmployeeMember_label_en-US" xlink:label="lab_cpix_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee [Member]</link:label>
    <link:label id="lab_cpix_EmployeeMember_documentation_en-US" xlink:label="lab_cpix_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EmployeeMember" xlink:href="cpix-20201210.xsd#cpix_EmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_EmployeeMember" xlink:to="lab_cpix_EmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ExpirationTermFourMember_75f8ed43-8ce4-45d3-abc4-726d41b38d5a_terseLabel_en-US" xlink:label="lab_cpix_ExpirationTermFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2031 - 2039</link:label>
    <link:label id="lab_cpix_ExpirationTermFourMember_label_en-US" xlink:label="lab_cpix_ExpirationTermFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration, Term Four [Member]</link:label>
    <link:label id="lab_cpix_ExpirationTermFourMember_documentation_en-US" xlink:label="lab_cpix_ExpirationTermFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration, Term Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermFourMember" xlink:href="cpix-20201210.xsd#cpix_ExpirationTermFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ExpirationTermFourMember" xlink:to="lab_cpix_ExpirationTermFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_0b9203de-8056-4b07-96fd-34cacbbedd07_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_9152d77e-5979-4b4b-b58d-0302572b7074_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration earned and accrued in operating expenses</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_label_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:href="cpix-20201210.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:to="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e64691bc-06a2-41e8-b7a3-0845629cc70c_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4fa3e7f2-b69e-4053-9256-36840e4e7e1f_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cdd34ed5-dfc5-405e-944b-f7f98002db54_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_2a03fdee-7234-4371-9433-a5f50a426d61_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_a768b07a-6cc3-4189-917e-28fef7125043_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of operating lease assets and liabilities through adoption of ASC 842</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_b9281c04-1be1-486e-9f86-c12496b8a92c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial public offering, net proceeds</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_5a61269e-3bd0-4c32-b759-ce4ecd6e12c0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_d5dc6091-c99c-4bb1-ab7d-b67a7665fcfa_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_31a76aa4-68b1-4ddc-bbef-5ea3d63bf5c6_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_7915a414-fa8b-4158-9ed6-7f378a836769_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net revenues from customers outside the United States</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_964ca4b0-037e-4c76-8672-89d31f298cb5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_42443719-7ecf-470a-9dde-bd6a365e2494_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_192ee121-4975-4d0b-bcc7-3809fae8cb8e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_acd0545b-ac93-4601-90f0-97e4e2af7f8c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_6f1ffc82-4f09-40e0-8c40-2e90bc38b23e_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total income tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_5e062595-0518-42db-b603-23f7be9b2db4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_3fe7dbfe-1dcd-4019-8918-e33f48df8f1e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_08517063-f601-4c6a-af1c-6e9485f5e1fd_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_69597600-fe9b-450d-8b70-3f67fd184068_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_c0febf54-1e08-4eb4-930b-90e74993cf18_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, employer discretionary contribution amount</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_ac7863d0-e977-4faa-b16f-fcede8685b9d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_3e034696-1566-4cb8-83af-6ae534793f04_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_aa5da997-5579-4441-8538-e9fd7d70ab26_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual with Relationship to Entity [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_462c6efc-288c-402c-965c-2ef66e5d5ec3_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_a56ce18e-0d24-45bb-ab59-1f68e8604873_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_2c27f588-ff6a-47be-91fc-bcfc6c709f5f_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_3e638585-f563-418e-b8df-0ffeb0fd79d8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_2e0ce178-6bbd-4a35-8b6b-d16deaf580d2_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_dd996dad-91c1-4409-82cf-5eee9fa74dc7_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process - validation vials</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_label_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Validation Vials</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Validation Vials</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" xlink:href="cpix-20201210.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" xlink:to="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_95547844-f15f-455c-973e-da345ca61c6f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_15002e65-ac0a-4040-9762-a85eca7e021a_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire businesses</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_47bf6d10-3f1a-4cec-94a0-3ff194780452_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid at closing</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_02e96e71-337e-4aed-b4de-d970165c7414_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_de33045e-7410-496e-9ef1-0762e434b40e_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from discontinued operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_c3a6173e-d77f-4974-8e30-bf275c87eac2_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_3ac3a520-c5f2-4a74-b631-017581f85e69_verboseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangements [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_ab65461e-56f6-4bb8-9f45-960d62ea73df_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_7854020c-db72-439c-8a7e-909a7958ff2f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_TaxCutsandJobsActof2017ChangeinTaxRateDeferredTaxAssetIncomeTaxExpenseBenefit_a89bcbbd-a633-4274-8d24-1a77f93380c3_terseLabel_en-US" xlink:label="lab_cpix_TaxCutsandJobsActof2017ChangeinTaxRateDeferredTaxAssetIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revaluation of deferred income tax balances for new rates under TCJA</link:label>
    <link:label id="lab_cpix_TaxCutsandJobsActof2017ChangeinTaxRateDeferredTaxAssetIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_cpix_TaxCutsandJobsActof2017ChangeinTaxRateDeferredTaxAssetIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts and Jobs Act of 2017, Change in Tax Rate, Deferred Tax Asset, Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_cpix_TaxCutsandJobsActof2017ChangeinTaxRateDeferredTaxAssetIncomeTaxExpenseBenefit_documentation_en-US" xlink:label="lab_cpix_TaxCutsandJobsActof2017ChangeinTaxRateDeferredTaxAssetIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts and Jobs Act of 2017, Change in Tax Rate, Deferred Tax Asset, Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TaxCutsandJobsActof2017ChangeinTaxRateDeferredTaxAssetIncomeTaxExpenseBenefit" xlink:href="cpix-20201210.xsd#cpix_TaxCutsandJobsActof2017ChangeinTaxRateDeferredTaxAssetIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_TaxCutsandJobsActof2017ChangeinTaxRateDeferredTaxAssetIncomeTaxExpenseBenefit" xlink:to="lab_cpix_TaxCutsandJobsActof2017ChangeinTaxRateDeferredTaxAssetIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ChangeInContingentConsiderationHeadingRollForward_d3fe64fc-2e91-44ec-97af-ef6955ba8c05_terseLabel_en-US" xlink:label="lab_cpix_ChangeInContingentConsiderationHeadingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liability</link:label>
    <link:label id="lab_cpix_ChangeInContingentConsiderationHeadingRollForward_label_en-US" xlink:label="lab_cpix_ChangeInContingentConsiderationHeadingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contingent Consideration [Heading Roll Forward]</link:label>
    <link:label id="lab_cpix_ChangeInContingentConsiderationHeadingRollForward_documentation_en-US" xlink:label="lab_cpix_ChangeInContingentConsiderationHeadingRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ChangeInContingentConsiderationHeadingRollForward" xlink:href="cpix-20201210.xsd#cpix_ChangeInContingentConsiderationHeadingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ChangeInContingentConsiderationHeadingRollForward" xlink:to="lab_cpix_ChangeInContingentConsiderationHeadingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_e83b124a-d73e-49a5-8534-06eac0101f22_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_81b36d53-7d25-4432-97c2-2e98adf1a4d1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9feee213-5209-4768-b4d3-6201c26550d7_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid, other current assets and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_d55ebb56-1334-4aa0-b3f7-55323d674f1b_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_c5cd817f-cdfc-474b-a4ad-7fd1ee7111fc_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation and Qualifying Accounts</link:label>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_label_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:to="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_67ad1649-40d7-4fe4-bbbd-75f7bb3f8c4d_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of options and related tax benefit</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPaymentsToAcquireBusinesses_b5b36640-906b-443b-aca0-b51f6f114397_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional payments to acquire businesses</link:label>
    <link:label id="lab_us-gaap_OtherPaymentsToAcquireBusinesses_32ba8a20-3117-4af7-a1c2-69d6eb9d2e31_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment during early 2019</link:label>
    <link:label id="lab_us-gaap_OtherPaymentsToAcquireBusinesses_label_en-US" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Payments to Acquire Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:to="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_63a439d0-eb17-41de-920c-2362b5005d57_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_1460bfff-c870-47e7-983a-1f2bc2e3d85a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax expense</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_InitialPublicOfferingAbstract_389da058-30dc-45ab-9b1c-d83e02164d35_terseLabel_en-US" xlink:label="lab_cpix_InitialPublicOfferingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Public Offering [Abstract]</link:label>
    <link:label id="lab_cpix_InitialPublicOfferingAbstract_label_en-US" xlink:label="lab_cpix_InitialPublicOfferingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Public Offering [Abstract]</link:label>
    <link:label id="lab_cpix_InitialPublicOfferingAbstract_documentation_en-US" xlink:label="lab_cpix_InitialPublicOfferingAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Public Offering [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_InitialPublicOfferingAbstract" xlink:href="cpix-20201210.xsd#cpix_InitialPublicOfferingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_InitialPublicOfferingAbstract" xlink:to="lab_cpix_InitialPublicOfferingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_fc088a8c-fd15-40a2-add0-09159fa9ead0_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_0aa14efd-1729-4519-af70-b27353817671_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_b5a531c6-a9c4-4687-baed-df76f4bd484c_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4a264351-ce47-444f-ac7f-6ca1817bb2cc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- average grant-date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9b32013f-6914-43ec-9e00-9ef879a367e5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_ab4d352a-690f-4d63-852d-65b45e9adb75_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_8b2b0833-c15e-4d68-8d40-d9a5be033cdf_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash interest expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_70179d0d-fe8a-4870-a69d-a59bd3199a80_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_6a8a90e3-1d1c-46eb-96a6-1e63dc453d2e_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_e7746302-9888-4eeb-844b-41102f89cb82_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative compensation costs incurred on deductible equity awards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_b5add2c8-be5d-475a-8eb1-c017f27dc8c6_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IndefiniteMember_e3cef069-f69c-4d6a-8905-f345f4863417_terseLabel_en-US" xlink:label="lab_cpix_IndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite Period</link:label>
    <link:label id="lab_cpix_IndefiniteMember_label_en-US" xlink:label="lab_cpix_IndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite [Member]</link:label>
    <link:label id="lab_cpix_IndefiniteMember_documentation_en-US" xlink:label="lab_cpix_IndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IndefiniteMember" xlink:href="cpix-20201210.xsd#cpix_IndefiniteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IndefiniteMember" xlink:to="lab_cpix_IndefiniteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock_b38912dd-82a6-4c07-bf9c-6f2563eb1663_terseLabel_en-US" xlink:label="lab_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and Other Current Assets</link:label>
    <link:label id="lab_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaids and Other Current Assets, Policy [Policy Text Block]</link:label>
    <link:label id="lab_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaids and Other Current Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock" xlink:href="cpix-20201210.xsd#cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock" xlink:to="lab_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_72261a1b-5793-4432-8a93-54af71023a26_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments of contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DeferredAcquisitionLiabilityCurrent_5d5bdfa0-6a11-4df1-b75e-2928301fb3a9_terseLabel_en-US" xlink:label="lab_cpix_DeferredAcquisitionLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred acquisition liability</link:label>
    <link:label id="lab_cpix_DeferredAcquisitionLiabilityCurrent_label_en-US" xlink:label="lab_cpix_DeferredAcquisitionLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Acquisition Liability, Current</link:label>
    <link:label id="lab_cpix_DeferredAcquisitionLiabilityCurrent_documentation_en-US" xlink:label="lab_cpix_DeferredAcquisitionLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Acquisition Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredAcquisitionLiabilityCurrent" xlink:href="cpix-20201210.xsd#cpix_DeferredAcquisitionLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DeferredAcquisitionLiabilityCurrent" xlink:to="lab_cpix_DeferredAcquisitionLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d4ea8df2-44db-4866-9ce1-a4b6c288ee93_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5dad5873-f584-4d58-afde-a73187697a42_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income tax expense</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_e611f525-f188-49d3-87ac-f32823a9ed5b_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_cf370204-f453-4d5b-8c5a-dd9b564b4e8a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_0f8f8e1d-2b91-4809-b262-bb0c85f708d6_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Concentrations</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1eec143a-1b52-441a-a023-dfac5442810a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of period, weighted-average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3fd012ed-e9d7-4b2f-a796-5b5a40975893_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ExpirationTermThreeMember_75e8e0e4-3d95-44c3-ad31-0e0c8a48a6e0_terseLabel_en-US" xlink:label="lab_cpix_ExpirationTermThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2030</link:label>
    <link:label id="lab_cpix_ExpirationTermThreeMember_label_en-US" xlink:label="lab_cpix_ExpirationTermThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration, Term Three [Member]</link:label>
    <link:label id="lab_cpix_ExpirationTermThreeMember_documentation_en-US" xlink:label="lab_cpix_ExpirationTermThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration, Term Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermThreeMember" xlink:href="cpix-20201210.xsd#cpix_ExpirationTermThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ExpirationTermThreeMember" xlink:to="lab_cpix_ExpirationTermThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles_69389593-ae4d-4d4c-9efa-3a962cda3260_terseLabel_en-US" xlink:label="lab_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment and intangibles</link:label>
    <link:label id="lab_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles_label_en-US" xlink:label="lab_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Property and Equipment and Intangibles</link:label>
    <link:label id="lab_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles_documentation_en-US" xlink:label="lab_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Property and Equipment and Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles" xlink:href="cpix-20201210.xsd#cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles" xlink:to="lab_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f03c6d5d-f5b7-4a0f-b017-84a0319e9f48_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_5dd715e4-667f-4a43-924b-cf90e6d3a252_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4bc5dcde-d1ba-46cd-9c93-1452a871cf21_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, end of period, weighted-average exercise price per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_b73bca1c-1821-483f-98ed-79828fcee10e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_aef4c16f-9703-405a-8972-0d8a01a7d2f9_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit, unused capacity, commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_25b20993-4c06-493c-9450-c295f895caa7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_e0146faf-6965-44b5-8663-1b6a13bb36c3_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_a8a52220-fee4-47a1-9680-30b39dbe33cd_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_81231930-44b0-4109-a5e9-7121e8218389_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal tax expense at statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_c7ef5d5d-8fd0-4db0-8d60-07987a65606b_terseLabel_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration, sale of corporate securities (up to)</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_label_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shelf Registration, Proceeds From Sale of Corporate Securities</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_documentation_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shelf Registration, Proceeds From Sale of Corporate Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:href="cpix-20201210.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:to="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_09784025-f3be-49f3-859b-765404f3bdc3_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_ad34a7e6-0548-4c35-a2aa-c7ddae022aa4_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Guidance</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>cpix-20201210_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:bbbd83ec-86cd-4852-a42b-62050b4598f2,g:afd11596-cbdf-45f6-87ac-39eae3274065-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="simple" xlink:href="cpix-20201210.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_a3c46c9b-1ee0-4fd1-8677-deadc3027e2b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_5febc9c5-5fd5-428c-abd4-b47a3af7b3be" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3c46c9b-1ee0-4fd1-8677-deadc3027e2b" xlink:to="loc_dei_DocumentType_5febc9c5-5fd5-428c-abd4-b47a3af7b3be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_780b8ccf-3618-4145-9871-5e24c26ee0cd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3c46c9b-1ee0-4fd1-8677-deadc3027e2b" xlink:to="loc_dei_DocumentPeriodEndDate_780b8ccf-3618-4145-9871-5e24c26ee0cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_faaba720-5011-4b26-b4be-91c458f48f32" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3c46c9b-1ee0-4fd1-8677-deadc3027e2b" xlink:to="loc_dei_EntityRegistrantName_faaba720-5011-4b26-b4be-91c458f48f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_2b2b6d2b-4afd-4dcb-985f-15e119017645" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3c46c9b-1ee0-4fd1-8677-deadc3027e2b" xlink:to="loc_dei_EntityIncorporationStateCountryCode_2b2b6d2b-4afd-4dcb-985f-15e119017645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_13f5c1c8-16c8-4c1b-a8d0-f48050c19d36" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3c46c9b-1ee0-4fd1-8677-deadc3027e2b" xlink:to="loc_dei_EntityFileNumber_13f5c1c8-16c8-4c1b-a8d0-f48050c19d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_3b3367ca-cfe1-488b-8d7c-2fabc9ce72b2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3c46c9b-1ee0-4fd1-8677-deadc3027e2b" xlink:to="loc_dei_EntityTaxIdentificationNumber_3b3367ca-cfe1-488b-8d7c-2fabc9ce72b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_34932575-538e-4143-8ebe-f76d41a6ea64" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3c46c9b-1ee0-4fd1-8677-deadc3027e2b" xlink:to="loc_dei_EntityCentralIndexKey_34932575-538e-4143-8ebe-f76d41a6ea64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_cb58b18c-8890-4869-992b-e207ad907f7f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3c46c9b-1ee0-4fd1-8677-deadc3027e2b" xlink:to="loc_dei_AmendmentFlag_cb58b18c-8890-4869-992b-e207ad907f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_0cb7b1a8-98ca-4830-bc45-015198b20617" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3c46c9b-1ee0-4fd1-8677-deadc3027e2b" xlink:to="loc_dei_EntityAddressAddressLine1_0cb7b1a8-98ca-4830-bc45-015198b20617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_dd00e675-a92a-4239-9bba-130c298e7b4c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3c46c9b-1ee0-4fd1-8677-deadc3027e2b" xlink:to="loc_dei_EntityAddressAddressLine2_dd00e675-a92a-4239-9bba-130c298e7b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_b75cca2f-1c02-4e00-a6da-b77fc2e19b4a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3c46c9b-1ee0-4fd1-8677-deadc3027e2b" xlink:to="loc_dei_EntityAddressCityOrTown_b75cca2f-1c02-4e00-a6da-b77fc2e19b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_e2a6b148-74d3-4740-9da5-c75c1fa5a37c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3c46c9b-1ee0-4fd1-8677-deadc3027e2b" xlink:to="loc_dei_EntityAddressStateOrProvince_e2a6b148-74d3-4740-9da5-c75c1fa5a37c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_7c210cf5-bff6-4053-9120-6e10bebf5074" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3c46c9b-1ee0-4fd1-8677-deadc3027e2b" xlink:to="loc_dei_EntityAddressPostalZipCode_7c210cf5-bff6-4053-9120-6e10bebf5074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_39471fb3-0dcd-4beb-9fa9-59e163078b89" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3c46c9b-1ee0-4fd1-8677-deadc3027e2b" xlink:to="loc_dei_CityAreaCode_39471fb3-0dcd-4beb-9fa9-59e163078b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_b0568b5e-8e85-4a05-bc1b-5bb2af68d064" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3c46c9b-1ee0-4fd1-8677-deadc3027e2b" xlink:to="loc_dei_LocalPhoneNumber_b0568b5e-8e85-4a05-bc1b-5bb2af68d064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_06d4d702-2498-4ae0-aa9a-4f30dd7a7f0f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3c46c9b-1ee0-4fd1-8677-deadc3027e2b" xlink:to="loc_dei_WrittenCommunications_06d4d702-2498-4ae0-aa9a-4f30dd7a7f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_dd5ca4be-3b9b-4d47-a88c-0e8648c77468" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3c46c9b-1ee0-4fd1-8677-deadc3027e2b" xlink:to="loc_dei_SolicitingMaterial_dd5ca4be-3b9b-4d47-a88c-0e8648c77468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_5095fdfd-c19f-4b3e-a0e6-61f2aa1e73b0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3c46c9b-1ee0-4fd1-8677-deadc3027e2b" xlink:to="loc_dei_PreCommencementTenderOffer_5095fdfd-c19f-4b3e-a0e6-61f2aa1e73b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_ec142181-3fa7-4e83-9acf-b1524a197ea1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3c46c9b-1ee0-4fd1-8677-deadc3027e2b" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_ec142181-3fa7-4e83-9acf-b1524a197ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_2aa2e60b-96dd-4cf3-894d-1c066dd20520" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3c46c9b-1ee0-4fd1-8677-deadc3027e2b" xlink:to="loc_dei_Security12bTitle_2aa2e60b-96dd-4cf3-894d-1c066dd20520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_0f136b22-f5f0-4242-8ae8-a928708727f6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3c46c9b-1ee0-4fd1-8677-deadc3027e2b" xlink:to="loc_dei_TradingSymbol_0f136b22-f5f0-4242-8ae8-a928708727f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_6755043d-da0d-477b-8d96-b67873defc53" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3c46c9b-1ee0-4fd1-8677-deadc3027e2b" xlink:to="loc_dei_SecurityExchangeName_6755043d-da0d-477b-8d96-b67873defc53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_d02e06a5-8180-450e-b0f6-128a31a6eddb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3c46c9b-1ee0-4fd1-8677-deadc3027e2b" xlink:to="loc_dei_EntityEmergingGrowthCompany_d02e06a5-8180-450e-b0f6-128a31a6eddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentDescription_efd662f2-c337-413f-9b96-f92989ac2afb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3c46c9b-1ee0-4fd1-8677-deadc3027e2b" xlink:to="loc_dei_AmendmentDescription_efd662f2-c337-413f-9b96-f92989ac2afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cpix-20201210.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_240844eb-88f7-47c1-928d-a76540bb700c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_292d464a-0caf-4363-ab73-dcef1026e0ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_240844eb-88f7-47c1-928d-a76540bb700c" xlink:to="loc_us-gaap_AssetsAbstract_292d464a-0caf-4363-ab73-dcef1026e0ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_f1f4e760-a18e-41bc-8e11-70c60e01370e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_292d464a-0caf-4363-ab73-dcef1026e0ee" xlink:to="loc_us-gaap_AssetsCurrentAbstract_f1f4e760-a18e-41bc-8e11-70c60e01370e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_855e9c15-d983-43d3-9b6b-6b46a9c311c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f1f4e760-a18e-41bc-8e11-70c60e01370e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_855e9c15-d983-43d3-9b6b-6b46a9c311c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_845f977c-64c6-40c1-822c-58e207435005" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f1f4e760-a18e-41bc-8e11-70c60e01370e" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_845f977c-64c6-40c1-822c-58e207435005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_1471b169-bdbb-44a9-94af-b454dbccc37e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f1f4e760-a18e-41bc-8e11-70c60e01370e" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_1471b169-bdbb-44a9-94af-b454dbccc37e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_29408a2f-374f-459d-bbe9-599e86e1450c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f1f4e760-a18e-41bc-8e11-70c60e01370e" xlink:to="loc_us-gaap_InventoryNet_29408a2f-374f-459d-bbe9-599e86e1450c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_05acc63a-3da4-4f99-99ea-6c3aec3886cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f1f4e760-a18e-41bc-8e11-70c60e01370e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_05acc63a-3da4-4f99-99ea-6c3aec3886cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_a0d43976-8714-4386-8314-a8b4a7a7f341" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f1f4e760-a18e-41bc-8e11-70c60e01370e" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_a0d43976-8714-4386-8314-a8b4a7a7f341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_41fae350-f4b8-4a5f-96eb-f672c0a4a77a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f1f4e760-a18e-41bc-8e11-70c60e01370e" xlink:to="loc_us-gaap_AssetsCurrent_41fae350-f4b8-4a5f-96eb-f672c0a4a77a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_505e4f03-3174-46a7-8776-a1630bdc4feb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_292d464a-0caf-4363-ab73-dcef1026e0ee" xlink:to="loc_us-gaap_InventoryNoncurrent_505e4f03-3174-46a7-8776-a1630bdc4feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ae13b649-419c-475e-a1c4-361aa4f3d811" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_292d464a-0caf-4363-ab73-dcef1026e0ee" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ae13b649-419c-475e-a1c4-361aa4f3d811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3191a09e-5c84-4f76-b8ef-2f27500c3641" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_292d464a-0caf-4363-ab73-dcef1026e0ee" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3191a09e-5c84-4f76-b8ef-2f27500c3641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c4db4ba1-d16d-4241-b317-d21fc3f4c45d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_292d464a-0caf-4363-ab73-dcef1026e0ee" xlink:to="loc_us-gaap_Goodwill_c4db4ba1-d16d-4241-b317-d21fc3f4c45d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_c4edfc77-a81b-4511-80e6-207aafd57b6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_292d464a-0caf-4363-ab73-dcef1026e0ee" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_c4edfc77-a81b-4511-80e6-207aafd57b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_0c10cb4e-cc2e-479a-a151-b8e104c6776b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_292d464a-0caf-4363-ab73-dcef1026e0ee" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_0c10cb4e-cc2e-479a-a151-b8e104c6776b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_a6c39738-d81c-4b69-b733-a04f53b5a9cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_292d464a-0caf-4363-ab73-dcef1026e0ee" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_a6c39738-d81c-4b69-b733-a04f53b5a9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_bf891068-5e99-4923-ad36-f43c911fd6e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_292d464a-0caf-4363-ab73-dcef1026e0ee" xlink:to="loc_us-gaap_Assets_bf891068-5e99-4923-ad36-f43c911fd6e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e88d50fa-87d9-4e0e-ba70-cd480b71880c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_240844eb-88f7-47c1-928d-a76540bb700c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e88d50fa-87d9-4e0e-ba70-cd480b71880c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_9d49888a-f56a-4ae0-8817-a9b8faca89b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e88d50fa-87d9-4e0e-ba70-cd480b71880c" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_9d49888a-f56a-4ae0-8817-a9b8faca89b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_c639132d-7c2a-42bc-bf2a-0162a85c1c1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9d49888a-f56a-4ae0-8817-a9b8faca89b8" xlink:to="loc_us-gaap_AccountsPayableCurrent_c639132d-7c2a-42bc-bf2a-0162a85c1c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_030976a3-57d3-4558-8b53-7998bcc6356e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9d49888a-f56a-4ae0-8817-a9b8faca89b8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_030976a3-57d3-4558-8b53-7998bcc6356e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b617cb4e-02fc-44fe-a2b5-930df2ca799d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9d49888a-f56a-4ae0-8817-a9b8faca89b8" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_b617cb4e-02fc-44fe-a2b5-930df2ca799d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_be66184a-3509-4510-88ac-f0a0a919b67f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9d49888a-f56a-4ae0-8817-a9b8faca89b8" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_be66184a-3509-4510-88ac-f0a0a919b67f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d7f460f9-04cd-409f-ab76-d01db2c5b106" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9d49888a-f56a-4ae0-8817-a9b8faca89b8" xlink:to="loc_us-gaap_LiabilitiesCurrent_d7f460f9-04cd-409f-ab76-d01db2c5b106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_1c35d868-102c-4aa1-96bb-3e1524bad6b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e88d50fa-87d9-4e0e-ba70-cd480b71880c" xlink:to="loc_us-gaap_LongTermLineOfCredit_1c35d868-102c-4aa1-96bb-3e1524bad6b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2646b847-da35-40dd-864b-5cad72cebf46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e88d50fa-87d9-4e0e-ba70-cd480b71880c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2646b847-da35-40dd-864b-5cad72cebf46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_acafbf7d-718f-4dcd-affe-203875288fd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e88d50fa-87d9-4e0e-ba70-cd480b71880c" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_acafbf7d-718f-4dcd-affe-203875288fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0257389f-0624-4f5d-8794-1786df8857ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e88d50fa-87d9-4e0e-ba70-cd480b71880c" xlink:to="loc_us-gaap_Liabilities_0257389f-0624-4f5d-8794-1786df8857ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_2012bb86-39ee-4c82-a8ae-c5e6a32040f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e88d50fa-87d9-4e0e-ba70-cd480b71880c" xlink:to="loc_us-gaap_CommitmentsAndContingencies_2012bb86-39ee-4c82-a8ae-c5e6a32040f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_06bfa747-dd3e-4de1-8f89-f99f52f97736" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e88d50fa-87d9-4e0e-ba70-cd480b71880c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_06bfa747-dd3e-4de1-8f89-f99f52f97736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_2fe8a45e-7063-4a8f-81d0-a890a366ddd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_06bfa747-dd3e-4de1-8f89-f99f52f97736" xlink:to="loc_us-gaap_StockholdersEquityAbstract_2fe8a45e-7063-4a8f-81d0-a890a366ddd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_55752b4c-9d2d-48d1-86e0-05fe7969811c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2fe8a45e-7063-4a8f-81d0-a890a366ddd3" xlink:to="loc_us-gaap_CommonStockValueOutstanding_55752b4c-9d2d-48d1-86e0-05fe7969811c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b6141550-f2e6-44ad-a7fc-e91df54d65eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2fe8a45e-7063-4a8f-81d0-a890a366ddd3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b6141550-f2e6-44ad-a7fc-e91df54d65eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d6204b7b-289c-401e-9347-137d1ac1711d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2fe8a45e-7063-4a8f-81d0-a890a366ddd3" xlink:to="loc_us-gaap_StockholdersEquity_d6204b7b-289c-401e-9347-137d1ac1711d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_4d7abafc-dec5-4432-af30-ce6cc3f5a28b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_06bfa747-dd3e-4de1-8f89-f99f52f97736" xlink:to="loc_us-gaap_MinorityInterest_4d7abafc-dec5-4432-af30-ce6cc3f5a28b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_157b36b1-c6bb-456e-be44-320fe63e4fb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_06bfa747-dd3e-4de1-8f89-f99f52f97736" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_157b36b1-c6bb-456e-be44-320fe63e4fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_71e657b0-9976-4414-94f8-8e6ad050e950" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e88d50fa-87d9-4e0e-ba70-cd480b71880c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_71e657b0-9976-4414-94f8-8e6ad050e950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cpix-20201210.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_e4484f14-6328-4ac3-b917-92b61bbb1a74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNoParValue_c4c5fd12-5034-4293-9078-fc24ebd91829" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNoParValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e4484f14-6328-4ac3-b917-92b61bbb1a74" xlink:to="loc_us-gaap_CommonStockNoParValue_c4c5fd12-5034-4293-9078-fc24ebd91829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_8c6248bb-bb76-4881-8e22-5efabb820f41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e4484f14-6328-4ac3-b917-92b61bbb1a74" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_8c6248bb-bb76-4881-8e22-5efabb820f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_befe4130-c2ef-4692-9742-04d4360313ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e4484f14-6328-4ac3-b917-92b61bbb1a74" xlink:to="loc_us-gaap_CommonStockSharesIssued_befe4130-c2ef-4692-9742-04d4360313ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6509b217-86b3-4fbf-aaf4-2895b42b0c92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e4484f14-6328-4ac3-b917-92b61bbb1a74" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6509b217-86b3-4fbf-aaf4-2895b42b0c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss" xlink:type="simple" xlink:href="cpix-20201210.xsd#ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_36b0e22e-87ab-4c4a-804a-69a53de5ba6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6fc3736d-46ea-4f00-bd57-1c97b0b8366f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_36b0e22e-87ab-4c4a-804a-69a53de5ba6d" xlink:to="loc_us-gaap_StatementTable_6fc3736d-46ea-4f00-bd57-1c97b0b8366f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_00c55c57-6751-4e81-963e-7e2356a43e9f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6fc3736d-46ea-4f00-bd57-1c97b0b8366f" xlink:to="loc_srt_ProductOrServiceAxis_00c55c57-6751-4e81-963e-7e2356a43e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a4249143-b88f-4236-9dd1-faa324917622" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_00c55c57-6751-4e81-963e-7e2356a43e9f" xlink:to="loc_srt_ProductsAndServicesDomain_a4249143-b88f-4236-9dd1-faa324917622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_d9233c70-7dc0-4ec7-9e4e-c1b862772576" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a4249143-b88f-4236-9dd1-faa324917622" xlink:to="loc_us-gaap_ProductMember_d9233c70-7dc0-4ec7-9e4e-c1b862772576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManufacturedProductOtherMember_33be5a92-1809-4133-a712-8809d3edbc1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ManufacturedProductOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a4249143-b88f-4236-9dd1-faa324917622" xlink:to="loc_us-gaap_ManufacturedProductOtherMember_33be5a92-1809-4133-a712-8809d3edbc1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d947b1ce-0586-4dbf-a6e2-d60834f8ad8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6fc3736d-46ea-4f00-bd57-1c97b0b8366f" xlink:to="loc_us-gaap_StatementLineItems_d947b1ce-0586-4dbf-a6e2-d60834f8ad8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_1862e968-a155-4f3f-b926-19d7573d9e11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d947b1ce-0586-4dbf-a6e2-d60834f8ad8e" xlink:to="loc_us-gaap_RevenuesAbstract_1862e968-a155-4f3f-b926-19d7573d9e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_3ba7602a-990b-4684-9791-e7180e2badb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_1862e968-a155-4f3f-b926-19d7573d9e11" xlink:to="loc_us-gaap_Revenues_3ba7602a-990b-4684-9791-e7180e2badb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_1b8a9dd6-61ef-4b91-9371-9c5029cfb86b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d947b1ce-0586-4dbf-a6e2-d60834f8ad8e" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_1b8a9dd6-61ef-4b91-9371-9c5029cfb86b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_88d578e6-a9db-4297-a32e-d73b5864028b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1b8a9dd6-61ef-4b91-9371-9c5029cfb86b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_88d578e6-a9db-4297-a32e-d73b5864028b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_a6d1bddc-7d4d-4ff7-8cc8-d7b21543a4af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1b8a9dd6-61ef-4b91-9371-9c5029cfb86b" xlink:to="loc_us-gaap_SellingAndMarketingExpense_a6d1bddc-7d4d-4ff7-8cc8-d7b21543a4af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0c124c69-7f93-4ed7-96e0-299cb4df6f42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1b8a9dd6-61ef-4b91-9371-9c5029cfb86b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0c124c69-7f93-4ed7-96e0-299cb4df6f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_eeb865cc-ca8d-49e3-96a9-2664d559eeaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1b8a9dd6-61ef-4b91-9371-9c5029cfb86b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_eeb865cc-ca8d-49e3-96a9-2664d559eeaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_7b710207-b2c6-4d3f-9539-c4487d736f0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1b8a9dd6-61ef-4b91-9371-9c5029cfb86b" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_7b710207-b2c6-4d3f-9539-c4487d736f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_eea807ec-0458-4927-9c59-80c340b0f011" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1b8a9dd6-61ef-4b91-9371-9c5029cfb86b" xlink:to="loc_us-gaap_CostsAndExpenses_eea807ec-0458-4927-9c59-80c340b0f011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e0bfac26-dc30-491b-b0c4-5d7645d2d3d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d947b1ce-0586-4dbf-a6e2-d60834f8ad8e" xlink:to="loc_us-gaap_OperatingIncomeLoss_e0bfac26-dc30-491b-b0c4-5d7645d2d3d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_8559ad6d-a4ae-4b05-a22a-570a603c3bc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d947b1ce-0586-4dbf-a6e2-d60834f8ad8e" xlink:to="loc_us-gaap_InvestmentIncomeInterest_8559ad6d-a4ae-4b05-a22a-570a603c3bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_8eb3c555-09d5-48b5-ad57-641510f39a03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d947b1ce-0586-4dbf-a6e2-d60834f8ad8e" xlink:to="loc_us-gaap_InterestExpense_8eb3c555-09d5-48b5-ad57-641510f39a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_ffe6bfd9-af1c-4e36-b87b-a0c713a80e5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d947b1ce-0586-4dbf-a6e2-d60834f8ad8e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_ffe6bfd9-af1c-4e36-b87b-a0c713a80e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f3ba28d7-a62b-4686-a820-e8c3cc5cc65a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d947b1ce-0586-4dbf-a6e2-d60834f8ad8e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f3ba28d7-a62b-4686-a820-e8c3cc5cc65a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_0d13d9ff-6225-471e-94a4-7d76c17b25f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d947b1ce-0586-4dbf-a6e2-d60834f8ad8e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_0d13d9ff-6225-471e-94a4-7d76c17b25f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_6eaf669c-d135-4149-ae41-ea1075978825" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d947b1ce-0586-4dbf-a6e2-d60834f8ad8e" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_6eaf669c-d135-4149-ae41-ea1075978825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_988525f8-2449-4919-975e-da0b287642f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d947b1ce-0586-4dbf-a6e2-d60834f8ad8e" xlink:to="loc_us-gaap_ProfitLoss_988525f8-2449-4919-975e-da0b287642f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_04689d2e-dba1-49b9-a5eb-349967d6cfe3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d947b1ce-0586-4dbf-a6e2-d60834f8ad8e" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_04689d2e-dba1-49b9-a5eb-349967d6cfe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_47f54a7e-6326-43c6-a544-4ba01c6d0616" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d947b1ce-0586-4dbf-a6e2-d60834f8ad8e" xlink:to="loc_us-gaap_NetIncomeLoss_47f54a7e-6326-43c6-a544-4ba01c6d0616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_195e7b48-05a8-4a61-bdd5-9d9db6ccc27b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d947b1ce-0586-4dbf-a6e2-d60834f8ad8e" xlink:to="loc_us-gaap_EarningsPerShareAbstract_195e7b48-05a8-4a61-bdd5-9d9db6ccc27b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_edcfd888-8d93-4b35-a824-8a6a00a11538" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_195e7b48-05a8-4a61-bdd5-9d9db6ccc27b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_edcfd888-8d93-4b35-a824-8a6a00a11538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_9de292fa-80b7-4b36-9ede-c1c6896c2da2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_195e7b48-05a8-4a61-bdd5-9d9db6ccc27b" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_9de292fa-80b7-4b36-9ede-c1c6896c2da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_bf14df83-14e2-427a-b010-627391758aa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_195e7b48-05a8-4a61-bdd5-9d9db6ccc27b" xlink:to="loc_us-gaap_EarningsPerShareBasic_bf14df83-14e2-427a-b010-627391758aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_87f85db9-561e-48db-93a1-132a6c64c3c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_195e7b48-05a8-4a61-bdd5-9d9db6ccc27b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_87f85db9-561e-48db-93a1-132a6c64c3c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_233fe259-27f0-420c-ab01-d91d73deaf3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_195e7b48-05a8-4a61-bdd5-9d9db6ccc27b" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_233fe259-27f0-420c-ab01-d91d73deaf3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_86430432-05e7-46bc-98b8-7acaf8e6d45a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_195e7b48-05a8-4a61-bdd5-9d9db6ccc27b" xlink:to="loc_us-gaap_EarningsPerShareDiluted_86430432-05e7-46bc-98b8-7acaf8e6d45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f6436475-7e47-45dc-af23-1223908a366e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d947b1ce-0586-4dbf-a6e2-d60834f8ad8e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f6436475-7e47-45dc-af23-1223908a366e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ca53ca5f-d652-40a8-80b8-9152c6ea0f72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f6436475-7e47-45dc-af23-1223908a366e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ca53ca5f-d652-40a8-80b8-9152c6ea0f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_395b3704-a137-4a69-a8a7-10b57736fb56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f6436475-7e47-45dc-af23-1223908a366e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_395b3704-a137-4a69-a8a7-10b57736fb56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_08c04d51-4ecf-4492-87fa-c519e34deb03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d947b1ce-0586-4dbf-a6e2-d60834f8ad8e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_08c04d51-4ecf-4492-87fa-c519e34deb03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_069f78af-70a0-4de1-affd-09a96f5517c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d947b1ce-0586-4dbf-a6e2-d60834f8ad8e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_069f78af-70a0-4de1-affd-09a96f5517c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_4fe0c86a-7c4a-46ce-9e17-5187236c06bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d947b1ce-0586-4dbf-a6e2-d60834f8ad8e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_4fe0c86a-7c4a-46ce-9e17-5187236c06bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cpix-20201210.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_97c582c5-3c1f-4c93-9a11-2ae50cac34a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_918f66bf-cdd2-44c1-a96f-8946f8e28bc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_97c582c5-3c1f-4c93-9a11-2ae50cac34a8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_918f66bf-cdd2-44c1-a96f-8946f8e28bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0c597daa-bae1-42eb-b123-0df12dfaafe2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_918f66bf-cdd2-44c1-a96f-8946f8e28bc6" xlink:to="loc_us-gaap_ProfitLoss_0c597daa-bae1-42eb-b123-0df12dfaafe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_104f5e91-166e-457e-9764-283d7b09bcfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_918f66bf-cdd2-44c1-a96f-8946f8e28bc6" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_104f5e91-166e-457e-9764-283d7b09bcfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_5c127bdf-5744-4af9-98a9-a1497df0c8a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_918f66bf-cdd2-44c1-a96f-8946f8e28bc6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_5c127bdf-5744-4af9-98a9-a1497df0c8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c0d9a97-624a-45c3-9267-83e9243cb0be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_918f66bf-cdd2-44c1-a96f-8946f8e28bc6" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c0d9a97-624a-45c3-9267-83e9243cb0be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_57a83990-9e9d-4476-ac45-6c6c2991aa84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c0d9a97-624a-45c3-9267-83e9243cb0be" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_57a83990-9e9d-4476-ac45-6c6c2991aa84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8c3ba75f-f440-47ee-a056-01355a0d2c51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c0d9a97-624a-45c3-9267-83e9243cb0be" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8c3ba75f-f440-47ee-a056-01355a0d2c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_58cf69be-d207-4d05-ad62-f860c7600e01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c0d9a97-624a-45c3-9267-83e9243cb0be" xlink:to="loc_us-gaap_ShareBasedCompensation_58cf69be-d207-4d05-ad62-f860c7600e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharebasedCompensationFoundationContribution_95f408e3-4940-4512-b90f-620a90497cfa" xlink:href="cpix-20201210.xsd#cpix_SharebasedCompensationFoundationContribution"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c0d9a97-624a-45c3-9267-83e9243cb0be" xlink:to="loc_cpix_SharebasedCompensationFoundationContribution_95f408e3-4940-4512-b90f-620a90497cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_73d040a5-4b3a-4e3f-b18f-39a0e8aac01a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c0d9a97-624a-45c3-9267-83e9243cb0be" xlink:to="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_73d040a5-4b3a-4e3f-b18f-39a0e8aac01a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_eab27315-86d1-4cc5-93dd-f1cb265f66a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c0d9a97-624a-45c3-9267-83e9243cb0be" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_eab27315-86d1-4cc5-93dd-f1cb265f66a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_bcf6307c-7cbb-4d00-b264-8c4ea8c777f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c0d9a97-624a-45c3-9267-83e9243cb0be" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_bcf6307c-7cbb-4d00-b264-8c4ea8c777f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingGainsLosses_cccd584f-06b6-4d79-8874-d2d1cfb56a81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingGainsLosses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c0d9a97-624a-45c3-9267-83e9243cb0be" xlink:to="loc_us-gaap_OtherNonoperatingGainsLosses_cccd584f-06b6-4d79-8874-d2d1cfb56a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_181b38d0-de7c-438d-a5a3-c67f850b5fd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c0d9a97-624a-45c3-9267-83e9243cb0be" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_181b38d0-de7c-438d-a5a3-c67f850b5fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_723136f4-6e75-40b2-91e2-185c56eb5732" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_181b38d0-de7c-438d-a5a3-c67f850b5fd0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_723136f4-6e75-40b2-91e2-185c56eb5732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_9b629207-79ff-4b26-ae27-0ced98b89934" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_181b38d0-de7c-438d-a5a3-c67f850b5fd0" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_9b629207-79ff-4b26-ae27-0ced98b89934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9ab1ac3e-25a5-4875-9a54-ac5c4d8284bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_181b38d0-de7c-438d-a5a3-c67f850b5fd0" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9ab1ac3e-25a5-4875-9a54-ac5c4d8284bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_dc4fcb52-8d4e-4017-9cda-59cf8ba0e4ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_181b38d0-de7c-438d-a5a3-c67f850b5fd0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_dc4fcb52-8d4e-4017-9cda-59cf8ba0e4ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_0bfcd5d5-99bc-408f-89e2-b718b1ea9a8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_181b38d0-de7c-438d-a5a3-c67f850b5fd0" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_0bfcd5d5-99bc-408f-89e2-b718b1ea9a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_09819be9-9fd3-46a4-929d-9b0f858ed6bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_918f66bf-cdd2-44c1-a96f-8946f8e28bc6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_09819be9-9fd3-46a4-929d-9b0f858ed6bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_1b190d6f-0a53-480d-bf02-be3890be8ffd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_918f66bf-cdd2-44c1-a96f-8946f8e28bc6" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_1b190d6f-0a53-480d-bf02-be3890be8ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aa163a28-4e78-4de7-912c-b60cf4d02071" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_918f66bf-cdd2-44c1-a96f-8946f8e28bc6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aa163a28-4e78-4de7-912c-b60cf4d02071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b3fc832b-203a-490a-9d7a-2888d8c672da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_97c582c5-3c1f-4c93-9a11-2ae50cac34a8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b3fc832b-203a-490a-9d7a-2888d8c672da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f5300ed6-6293-4875-9082-b50317147f7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b3fc832b-203a-490a-9d7a-2888d8c672da" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f5300ed6-6293-4875-9082-b50317147f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_d66c86a2-e816-4c62-b701-0eb6287126ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b3fc832b-203a-490a-9d7a-2888d8c672da" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_d66c86a2-e816-4c62-b701-0eb6287126ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_aaa0c5b8-88cd-4bd8-bb54-955a3fa7b661" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b3fc832b-203a-490a-9d7a-2888d8c672da" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_aaa0c5b8-88cd-4bd8-bb54-955a3fa7b661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_fdb06853-a45e-43b7-9fe7-c06fc446d6e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b3fc832b-203a-490a-9d7a-2888d8c672da" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_fdb06853-a45e-43b7-9fe7-c06fc446d6e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_4a8ebb82-0194-46bb-a30a-b5c9f47c27e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b3fc832b-203a-490a-9d7a-2888d8c672da" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_4a8ebb82-0194-46bb-a30a-b5c9f47c27e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b556ec0c-3d03-47e5-aa0e-4237ee8bd750" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b3fc832b-203a-490a-9d7a-2888d8c672da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b556ec0c-3d03-47e5-aa0e-4237ee8bd750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_da8c5221-8bfe-4b4b-9f88-47574072fc30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_97c582c5-3c1f-4c93-9a11-2ae50cac34a8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_da8c5221-8bfe-4b4b-9f88-47574072fc30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_45068c62-f6ea-4cf2-afb6-1c7cf204d103" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_da8c5221-8bfe-4b4b-9f88-47574072fc30" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_45068c62-f6ea-4cf2-afb6-1c7cf204d103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_7aeca7f4-ea75-46ac-9911-95997638033a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_da8c5221-8bfe-4b4b-9f88-47574072fc30" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_7aeca7f4-ea75-46ac-9911-95997638033a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_46ac8e94-f494-46fa-81f6-b421220177aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_da8c5221-8bfe-4b4b-9f88-47574072fc30" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_46ac8e94-f494-46fa-81f6-b421220177aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_0776dc7b-17de-46be-a86e-ca062734aae6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_da8c5221-8bfe-4b4b-9f88-47574072fc30" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_0776dc7b-17de-46be-a86e-ca062734aae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_bfbe245e-4098-4efc-a766-eb9b508714ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_da8c5221-8bfe-4b4b-9f88-47574072fc30" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_bfbe245e-4098-4efc-a766-eb9b508714ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_0fb736ce-707f-4d52-a229-78cd41a5afd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_da8c5221-8bfe-4b4b-9f88-47574072fc30" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_0fb736ce-707f-4d52-a229-78cd41a5afd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_106640b1-5010-4092-b903-2cd86ccaa2b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_da8c5221-8bfe-4b4b-9f88-47574072fc30" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_106640b1-5010-4092-b903-2cd86ccaa2b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_f57ecc19-4f0b-43b9-8705-a40536f9ebfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_da8c5221-8bfe-4b4b-9f88-47574072fc30" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_f57ecc19-4f0b-43b9-8705-a40536f9ebfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e974406f-69d2-454f-90b7-23fa4a8f16f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_da8c5221-8bfe-4b4b-9f88-47574072fc30" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e974406f-69d2-454f-90b7-23fa4a8f16f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_55863399-b2f3-4237-8487-6faf818a3464" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_97c582c5-3c1f-4c93-9a11-2ae50cac34a8" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_55863399-b2f3-4237-8487-6faf818a3464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_14ce7177-1232-479b-a920-d447a5daa126" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_97c582c5-3c1f-4c93-9a11-2ae50cac34a8" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_14ce7177-1232-479b-a920-d447a5daa126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b3caa56c-1651-45e1-ac56-dd0888a44587" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_97c582c5-3c1f-4c93-9a11-2ae50cac34a8" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b3caa56c-1651-45e1-ac56-dd0888a44587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_c20f0a54-443d-40e7-b295-cdc3f92a6707" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_97c582c5-3c1f-4c93-9a11-2ae50cac34a8" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_c20f0a54-443d-40e7-b295-cdc3f92a6707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CashPaidDuringYearForAbstract_635f3ec6-7aa7-49c6-b6f3-3727f7165ba1" xlink:href="cpix-20201210.xsd#cpix_CashPaidDuringYearForAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_c20f0a54-443d-40e7-b295-cdc3f92a6707" xlink:to="loc_cpix_CashPaidDuringYearForAbstract_635f3ec6-7aa7-49c6-b6f3-3727f7165ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_a6eb2e08-f9b1-441b-8b46-a9d2e1c4ec1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_CashPaidDuringYearForAbstract_635f3ec6-7aa7-49c6-b6f3-3727f7165ba1" xlink:to="loc_us-gaap_InterestPaidNet_a6eb2e08-f9b1-441b-8b46-a9d2e1c4ec1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_09a94554-e421-4372-b2f0-612e3543c7b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_CashPaidDuringYearForAbstract_635f3ec6-7aa7-49c6-b6f3-3727f7165ba1" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_09a94554-e421-4372-b2f0-612e3543c7b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0ec54e9b-7c2a-4098-94e3-9a09c3108f3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_c20f0a54-443d-40e7-b295-cdc3f92a6707" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0ec54e9b-7c2a-4098-94e3-9a09c3108f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid_9722b18f-4b2e-465d-9f5b-d31a82023fbf" xlink:href="cpix-20201210.xsd#cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0ec54e9b-7c2a-4098-94e3-9a09c3108f3f" xlink:to="loc_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid_9722b18f-4b2e-465d-9f5b-d31a82023fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses_cbec399c-3621-47a4-8577-69e13b705e59" xlink:href="cpix-20201210.xsd#cpix_DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0ec54e9b-7c2a-4098-94e3-9a09c3108f3f" xlink:to="loc_cpix_DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses_cbec399c-3621-47a4-8577-69e13b705e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_96782303-81c8-41a9-838c-da6de4334c65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0ec54e9b-7c2a-4098-94e3-9a09c3108f3f" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_96782303-81c8-41a9-838c-da6de4334c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_e0548403-3cdf-4637-97f7-3a8eb75e5eae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0ec54e9b-7c2a-4098-94e3-9a09c3108f3f" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_e0548403-3cdf-4637-97f7-3a8eb75e5eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NoncashOrPartNoncashTransactionVestingOfShares_ab4688b6-2064-4290-8ab5-f8bc9737b348" xlink:href="cpix-20201210.xsd#cpix_NoncashOrPartNoncashTransactionVestingOfShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0ec54e9b-7c2a-4098-94e3-9a09c3108f3f" xlink:to="loc_cpix_NoncashOrPartNoncashTransactionVestingOfShares_ab4688b6-2064-4290-8ab5-f8bc9737b348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_0d924de1-04aa-454c-9084-0b259325c82d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0ec54e9b-7c2a-4098-94e3-9a09c3108f3f" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_0d924de1-04aa-454c-9084-0b259325c82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_9efe0735-8de1-41ac-9f62-3edefc658621" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0ec54e9b-7c2a-4098-94e3-9a09c3108f3f" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_9efe0735-8de1-41ac-9f62-3edefc658621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="cpix-20201210.xsd#ConsolidatedStatementsofEquity"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_886c8619-7a0b-4413-9944-54ead2503a9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cf971610-c906-405e-a18c-b5bd45164f0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_886c8619-7a0b-4413-9944-54ead2503a9a" xlink:to="loc_us-gaap_StatementTable_cf971610-c906-405e-a18c-b5bd45164f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9bef24fa-4d6b-44b3-acf0-a2a09a8de7a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cf971610-c906-405e-a18c-b5bd45164f0a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9bef24fa-4d6b-44b3-acf0-a2a09a8de7a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f382cf62-55cd-48f9-93e5-5815790484dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9bef24fa-4d6b-44b3-acf0-a2a09a8de7a7" xlink:to="loc_us-gaap_EquityComponentDomain_f382cf62-55cd-48f9-93e5-5815790484dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_937bd501-bec5-4a8e-86a0-6de211d9899e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f382cf62-55cd-48f9-93e5-5815790484dc" xlink:to="loc_us-gaap_CommonStockMember_937bd501-bec5-4a8e-86a0-6de211d9899e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_6d65d511-2029-4ea1-9ed3-2bc8907e9557" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f382cf62-55cd-48f9-93e5-5815790484dc" xlink:to="loc_us-gaap_RetainedEarningsMember_6d65d511-2029-4ea1-9ed3-2bc8907e9557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_2e77b5c9-bd99-4a8d-a7d9-59680388aed2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f382cf62-55cd-48f9-93e5-5815790484dc" xlink:to="loc_us-gaap_NoncontrollingInterestMember_2e77b5c9-bd99-4a8d-a7d9-59680388aed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_41b54c43-935b-47d4-b15a-1885d79e8647" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cf971610-c906-405e-a18c-b5bd45164f0a" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_41b54c43-935b-47d4-b15a-1885d79e8647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e9c9b887-bf56-4ed4-abf2-ac93e0b33541" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_41b54c43-935b-47d4-b15a-1885d79e8647" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e9c9b887-bf56-4ed4-abf2-ac93e0b33541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_ddc2846d-eebf-483b-a4e3-c96fb8e837c5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e9c9b887-bf56-4ed4-abf2-ac93e0b33541" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_ddc2846d-eebf-483b-a4e3-c96fb8e837c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_63af6ac2-e241-47d4-959c-06c32c3d7d79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cf971610-c906-405e-a18c-b5bd45164f0a" xlink:to="loc_us-gaap_StatementLineItems_63af6ac2-e241-47d4-959c-06c32c3d7d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7cddd321-56c8-4936-aaf3-038e81731871" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_63af6ac2-e241-47d4-959c-06c32c3d7d79" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7cddd321-56c8-4936-aaf3-038e81731871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_923fd996-d48e-44b2-855b-2ae598e03fc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7cddd321-56c8-4936-aaf3-038e81731871" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_923fd996-d48e-44b2-855b-2ae598e03fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_620ff910-fc4f-4f62-9e1a-e423cbdb8dc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7cddd321-56c8-4936-aaf3-038e81731871" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_620ff910-fc4f-4f62-9e1a-e423cbdb8dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_17d63b43-d906-49b0-ac17-292a7523f6ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7cddd321-56c8-4936-aaf3-038e81731871" xlink:to="loc_us-gaap_NetIncomeLoss_17d63b43-d906-49b0-ac17-292a7523f6ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_fb68365b-734c-4b94-8609-e62bd14d0bf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7cddd321-56c8-4936-aaf3-038e81731871" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_fb68365b-734c-4b94-8609-e62bd14d0bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_fae2b43e-617c-4a34-b2a9-734d2c1e4602" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7cddd321-56c8-4936-aaf3-038e81731871" xlink:to="loc_us-gaap_ProfitLoss_fae2b43e-617c-4a34-b2a9-734d2c1e4602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_7bb34141-0e26-45c9-b054-98eff9ada97c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7cddd321-56c8-4936-aaf3-038e81731871" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_7bb34141-0e26-45c9-b054-98eff9ada97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_be65c6e5-c266-4da2-9bd6-1add547b9e42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7cddd321-56c8-4936-aaf3-038e81731871" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_be65c6e5-c266-4da2-9bd6-1add547b9e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_db6faa50-b267-4b29-8cef-345a29a0ef14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7cddd321-56c8-4936-aaf3-038e81731871" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_db6faa50-b267-4b29-8cef-345a29a0ef14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c6f6af7b-0310-4b35-b052-7b05c805d4b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7cddd321-56c8-4936-aaf3-038e81731871" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c6f6af7b-0310-4b35-b052-7b05c805d4b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_860f9703-a280-4201-94ac-78ddfe607f2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7cddd321-56c8-4936-aaf3-038e81731871" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_860f9703-a280-4201-94ac-78ddfe607f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_ff8c39c0-b73b-4b93-80c5-acef4e89d1b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7cddd321-56c8-4936-aaf3-038e81731871" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_ff8c39c0-b73b-4b93-80c5-acef4e89d1b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_79b92363-29f9-4c83-b193-fdcdcc0ecaf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7cddd321-56c8-4936-aaf3-038e81731871" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_79b92363-29f9-4c83-b193-fdcdcc0ecaf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding_1337493a-487b-4c0d-acaf-40b103962d0f" xlink:href="cpix-20201210.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7cddd321-56c8-4936-aaf3-038e81731871" xlink:to="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding_1337493a-487b-4c0d-acaf-40b103962d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c4b5c0a6-5103-4131-9966-3587141d92a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7cddd321-56c8-4936-aaf3-038e81731871" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c4b5c0a6-5103-4131-9966-3587141d92a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3d5fc763-cac6-473b-be03-e3c2a2e21b90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7cddd321-56c8-4936-aaf3-038e81731871" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3d5fc763-cac6-473b-be03-e3c2a2e21b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_4336ecf0-f48c-442e-9c5c-eac8f2adb50f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7cddd321-56c8-4936-aaf3-038e81731871" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_4336ecf0-f48c-442e-9c5c-eac8f2adb50f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_b4f243a4-2f7e-42d4-b766-d9875fea98b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7cddd321-56c8-4936-aaf3-038e81731871" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_b4f243a4-2f7e-42d4-b766-d9875fea98b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3466d39a-9884-4444-a6e8-a71a72e6aa49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7cddd321-56c8-4936-aaf3-038e81731871" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3466d39a-9884-4444-a6e8-a71a72e6aa49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_312135b4-3c18-4bfb-aab0-88b47d3000bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7cddd321-56c8-4936-aaf3-038e81731871" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_312135b4-3c18-4bfb-aab0-88b47d3000bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Organization" xlink:type="simple" xlink:href="cpix-20201210.xsd#Organization"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Organization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ae7d7d85-fb7f-40e7-9bd4-ba066bbcd3de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_6f0974b7-fbc6-4f80-a4bf-239b7a7e1210" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ae7d7d85-fb7f-40e7-9bd4-ba066bbcd3de" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_6f0974b7-fbc6-4f80-a4bf-239b7a7e1210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#OrganizationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_22032a97-7169-4c69-aa83-c46911cfc545" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_7245fcae-e0df-4934-afca-fadf2fef9ae8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_22032a97-7169-4c69-aa83-c46911cfc545" xlink:to="loc_dei_EntitiesTable_7245fcae-e0df-4934-afca-fadf2fef9ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_3bf62b1a-a94e-4a81-bccf-13cadd4a742a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_7245fcae-e0df-4934-afca-fadf2fef9ae8" xlink:to="loc_dei_LegalEntityAxis_3bf62b1a-a94e-4a81-bccf-13cadd4a742a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_42c61558-a9da-4995-8a2a-9bdafaf1e90a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_3bf62b1a-a94e-4a81-bccf-13cadd4a742a" xlink:to="loc_dei_EntityDomain_42c61558-a9da-4995-8a2a-9bdafaf1e90a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CumberlandEmergingTechnologiesIncMember_8094ef38-c8de-43f0-bdb9-9b8a9024d42b" xlink:href="cpix-20201210.xsd#cpix_CumberlandEmergingTechnologiesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_42c61558-a9da-4995-8a2a-9bdafaf1e90a" xlink:to="loc_cpix_CumberlandEmergingTechnologiesIncMember_8094ef38-c8de-43f0-bdb9-9b8a9024d42b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5c04fef7-4a7a-4158-af6a-90e5350970b4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_7245fcae-e0df-4934-afca-fadf2fef9ae8" xlink:to="loc_srt_CounterpartyNameAxis_5c04fef7-4a7a-4158-af6a-90e5350970b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_38753fa9-ee94-45b7-8bfd-08b681ca69ee" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_5c04fef7-4a7a-4158-af6a-90e5350970b4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_38753fa9-ee94-45b7-8bfd-08b681ca69ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HarbinGloriaPharmaceuticalsCoMember_adba9232-9772-41b7-9203-1b8fd73bec7d" xlink:href="cpix-20201210.xsd#cpix_HarbinGloriaPharmaceuticalsCoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_38753fa9-ee94-45b7-8bfd-08b681ca69ee" xlink:to="loc_cpix_HarbinGloriaPharmaceuticalsCoMember_adba9232-9772-41b7-9203-1b8fd73bec7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_fbd7c86e-ee4e-4f6b-ab01-5f6556881ab4" xlink:href="cpix-20201210.xsd#cpix_HongKongWinHealthPharmaGroupCoLimitedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_38753fa9-ee94-45b7-8bfd-08b681ca69ee" xlink:to="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_fbd7c86e-ee4e-4f6b-ab01-5f6556881ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_GloriaPharmaceuticalsMember_ee81ae9d-d2e0-47af-b00c-3181228357c8" xlink:href="cpix-20201210.xsd#cpix_GloriaPharmaceuticalsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_38753fa9-ee94-45b7-8bfd-08b681ca69ee" xlink:to="loc_cpix_GloriaPharmaceuticalsMember_ee81ae9d-d2e0-47af-b00c-3181228357c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_5bbd76ab-4616-4900-8ca0-a74d16cf9fb0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_7245fcae-e0df-4934-afca-fadf2fef9ae8" xlink:to="loc_srt_OwnershipAxis_5bbd76ab-4616-4900-8ca0-a74d16cf9fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_d1fc2d48-a723-467f-a213-ea66dc89ae68" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_5bbd76ab-4616-4900-8ca0-a74d16cf9fb0" xlink:to="loc_srt_OwnershipDomain_d1fc2d48-a723-467f-a213-ea66dc89ae68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CumberlandEmergingTechnologiesIncMember_f36e4d18-1fe9-4557-b708-431fc9e1a8e4" xlink:href="cpix-20201210.xsd#cpix_CumberlandEmergingTechnologiesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_d1fc2d48-a723-467f-a213-ea66dc89ae68" xlink:to="loc_cpix_CumberlandEmergingTechnologiesIncMember_f36e4d18-1fe9-4557-b708-431fc9e1a8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_08ce7077-dc05-4595-a6b9-6885df2f5495" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_7245fcae-e0df-4934-afca-fadf2fef9ae8" xlink:to="loc_dei_EntityInformationLineItems_08ce7077-dc05-4595-a6b9-6885df2f5495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_3dd6a9cb-f465-4fd8-bfd9-de5f5c36a85c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_08ce7077-dc05-4595-a6b9-6885df2f5495" xlink:to="loc_us-gaap_NoncontrollingInterestAbstract_3dd6a9cb-f465-4fd8-bfd9-de5f5c36a85c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_79c60a4f-8d77-4b6c-acb8-706e6d52a3d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_3dd6a9cb-f465-4fd8-bfd9-de5f5c36a85c" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_79c60a4f-8d77-4b6c-acb8-706e6d52a3d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPurchaseOfShares_9d39f625-45cf-48af-9294-1e1c24b1e021" xlink:href="cpix-20201210.xsd#cpix_SubsidiaryInvestmentPurchaseOfShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_3dd6a9cb-f465-4fd8-bfd9-de5f5c36a85c" xlink:to="loc_cpix_SubsidiaryInvestmentPurchaseOfShares_9d39f625-45cf-48af-9294-1e1c24b1e021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ContributionOfCashAdditionalSharesPurchased_504729e1-2583-4862-bea2-49790bf35b83" xlink:href="cpix-20201210.xsd#cpix_ContributionOfCashAdditionalSharesPurchased"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_3dd6a9cb-f465-4fd8-bfd9-de5f5c36a85c" xlink:to="loc_cpix_ContributionOfCashAdditionalSharesPurchased_504729e1-2583-4862-bea2-49790bf35b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IntercompanyLoansPayableConvertedAmount_0a735b18-84d9-41bc-936a-b15f69f4a60c" xlink:href="cpix-20201210.xsd#cpix_IntercompanyLoansPayableConvertedAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_3dd6a9cb-f465-4fd8-bfd9-de5f5c36a85c" xlink:to="loc_cpix_IntercompanyLoansPayableConvertedAmount_0a735b18-84d9-41bc-936a-b15f69f4a60c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_fcac81a7-1151-4fbb-a899-6094c8a8bc9f" xlink:href="cpix-20201210.xsd#cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_3dd6a9cb-f465-4fd8-bfd9-de5f5c36a85c" xlink:to="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_fcac81a7-1151-4fbb-a899-6094c8a8bc9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_3e633288-f898-441c-9f66-6ecc826e8511" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_3dd6a9cb-f465-4fd8-bfd9-de5f5c36a85c" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_3e633288-f898-441c-9f66-6ecc826e8511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_413c6789-9894-4940-ab06-7e8e11668fae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_3dd6a9cb-f465-4fd8-bfd9-de5f5c36a85c" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_413c6789-9894-4940-ab06-7e8e11668fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPolicies" xlink:type="simple" xlink:href="cpix-20201210.xsd#SignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c56d1ae6-41cb-44b0-a364-b04b2c5c68ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_456495c8-10ea-4243-b944-de2087bbd0f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c56d1ae6-41cb-44b0-a364-b04b2c5c68ef" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_456495c8-10ea-4243-b944-de2087bbd0f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="cpix-20201210.xsd#SignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9658c4ac-56ec-45d0-9c9b-0df6c651a802" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_8a9170ea-7bd4-4a63-9e48-00bb6d0227b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9658c4ac-56ec-45d0-9c9b-0df6c651a802" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_8a9170ea-7bd4-4a63-9e48-00bb6d0227b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_2f341ac4-08c8-44df-9764-ac65d6a73b57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9658c4ac-56ec-45d0-9c9b-0df6c651a802" xlink:to="loc_us-gaap_UseOfEstimates_2f341ac4-08c8-44df-9764-ac65d6a73b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_56cb6021-2d6c-4c86-972f-13a9e1a27489" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9658c4ac-56ec-45d0-9c9b-0df6c651a802" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_56cb6021-2d6c-4c86-972f-13a9e1a27489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_598a44d4-b831-47c8-80f1-1e28160f471f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9658c4ac-56ec-45d0-9c9b-0df6c651a802" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_598a44d4-b831-47c8-80f1-1e28160f471f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_00953ef1-d2bb-4411-bb8d-fa93d2f27d88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9658c4ac-56ec-45d0-9c9b-0df6c651a802" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_00953ef1-d2bb-4411-bb8d-fa93d2f27d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_55a2d462-7272-4527-ae22-e32a2e6339d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9658c4ac-56ec-45d0-9c9b-0df6c651a802" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_55a2d462-7272-4527-ae22-e32a2e6339d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_c3be88bf-5ab5-4791-b08d-55a837943d59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9658c4ac-56ec-45d0-9c9b-0df6c651a802" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_c3be88bf-5ab5-4791-b08d-55a837943d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_7d18ebab-c5b8-47e8-aec3-e0976824bfe1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9658c4ac-56ec-45d0-9c9b-0df6c651a802" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_7d18ebab-c5b8-47e8-aec3-e0976824bfe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock_eec538f5-c258-4122-b022-a0a738157971" xlink:href="cpix-20201210.xsd#cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9658c4ac-56ec-45d0-9c9b-0df6c651a802" xlink:to="loc_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock_eec538f5-c258-4122-b022-a0a738157971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_fb04e54f-329d-4499-9713-a0476a970d62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9658c4ac-56ec-45d0-9c9b-0df6c651a802" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_fb04e54f-329d-4499-9713-a0476a970d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_dd9744fd-d9d7-40d1-9f5a-7d086f6fdc4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9658c4ac-56ec-45d0-9c9b-0df6c651a802" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_dd9744fd-d9d7-40d1-9f5a-7d086f6fdc4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_3640884f-706a-4fd2-af89-1c67b3c0efbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9658c4ac-56ec-45d0-9c9b-0df6c651a802" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_3640884f-706a-4fd2-af89-1c67b3c0efbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_725eaa4a-36f0-4c17-a7cb-4546f4f6a43c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9658c4ac-56ec-45d0-9c9b-0df6c651a802" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_725eaa4a-36f0-4c17-a7cb-4546f4f6a43c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_eaa82a05-87e0-46b2-b8f4-ecd7dcae375e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9658c4ac-56ec-45d0-9c9b-0df6c651a802" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_eaa82a05-87e0-46b2-b8f4-ecd7dcae375e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_8722305e-9996-4479-b5df-3977ca654a3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9658c4ac-56ec-45d0-9c9b-0df6c651a802" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_8722305e-9996-4479-b5df-3977ca654a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_4211049d-c096-44cb-8c3b-82ad14b5c93c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9658c4ac-56ec-45d0-9c9b-0df6c651a802" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_4211049d-c096-44cb-8c3b-82ad14b5c93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_8f2d1cf0-1e10-49f5-b9e2-17d1fc39784f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9658c4ac-56ec-45d0-9c9b-0df6c651a802" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_8f2d1cf0-1e10-49f5-b9e2-17d1fc39784f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_a5b19744-2fc6-4ee6-85c9-c87168122dcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9658c4ac-56ec-45d0-9c9b-0df6c651a802" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_a5b19744-2fc6-4ee6-85c9-c87168122dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_604400ef-33f9-4e1a-920d-7589b04d6382" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9658c4ac-56ec-45d0-9c9b-0df6c651a802" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_604400ef-33f9-4e1a-920d-7589b04d6382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_ef2e8f3b-e291-49fe-aa41-92cec9e93fb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9658c4ac-56ec-45d0-9c9b-0df6c651a802" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_ef2e8f3b-e291-49fe-aa41-92cec9e93fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_16abf2d2-5ff7-4b4c-bc8c-55ad5b95e4d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9658c4ac-56ec-45d0-9c9b-0df6c651a802" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_16abf2d2-5ff7-4b4c-bc8c-55ad5b95e4d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#SignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bc3cbc2e-318b-4d1d-9269-202d4da26ef4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock_c65e98bf-1bb9-43d2-bdc0-902f487b586d" xlink:href="cpix-20201210.xsd#cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bc3cbc2e-318b-4d1d-9269-202d4da26ef4" xlink:to="loc_cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock_c65e98bf-1bb9-43d2-bdc0-902f487b586d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#SignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_99ce584b-7824-4ac2-80f1-96ecce98168e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_65bc9168-f6f6-403c-9695-e93b4dd15250" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_99ce584b-7824-4ac2-80f1-96ecce98168e" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_65bc9168-f6f6-403c-9695-e93b4dd15250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_71ce79f4-062c-44b0-a35d-48b8bc4ad983" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_65bc9168-f6f6-403c-9695-e93b4dd15250" xlink:to="loc_srt_StatementGeographicalAxis_71ce79f4-062c-44b0-a35d-48b8bc4ad983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e8d2e148-ca8a-46c1-baf6-f6f8264ace06" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_71ce79f4-062c-44b0-a35d-48b8bc4ad983" xlink:to="loc_srt_SegmentGeographicalDomain_e8d2e148-ca8a-46c1-baf6-f6f8264ace06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_2cdd9dfc-0487-4eb9-84ba-bb54e8f8eeb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e8d2e148-ca8a-46c1-baf6-f6f8264ace06" xlink:to="loc_us-gaap_NonUsMember_2cdd9dfc-0487-4eb9-84ba-bb54e8f8eeb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b1242fbc-4356-4f90-9777-0532d8fb0620" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_65bc9168-f6f6-403c-9695-e93b4dd15250" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b1242fbc-4356-4f90-9777-0532d8fb0620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fc7467b2-0019-4263-b7e2-b87851ead471" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b1242fbc-4356-4f90-9777-0532d8fb0620" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fc7467b2-0019-4263-b7e2-b87851ead471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_1bbea756-ee96-4d2f-a583-394ee3c1a601" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_fc7467b2-0019-4263-b7e2-b87851ead471" xlink:to="loc_us-gaap_SubsequentEventMember_1bbea756-ee96-4d2f-a583-394ee3c1a601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9c742c62-c775-427c-8192-481ec23d8ae0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_65bc9168-f6f6-403c-9695-e93b4dd15250" xlink:to="loc_srt_RangeAxis_9c742c62-c775-427c-8192-481ec23d8ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8a9a487e-8f2a-40f7-99cb-fd9bcef1815e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9c742c62-c775-427c-8192-481ec23d8ae0" xlink:to="loc_srt_RangeMember_8a9a487e-8f2a-40f7-99cb-fd9bcef1815e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5abde195-9b9f-42cc-9413-2b12f8017145" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8a9a487e-8f2a-40f7-99cb-fd9bcef1815e" xlink:to="loc_srt_MinimumMember_5abde195-9b9f-42cc-9413-2b12f8017145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_610c9af3-208b-40b0-9080-73fe27282ef2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8a9a487e-8f2a-40f7-99cb-fd9bcef1815e" xlink:to="loc_srt_MaximumMember_610c9af3-208b-40b0-9080-73fe27282ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccountsReceivableAllowancesByComponentAxis_684c2ea9-1e9e-4aea-9176-c5df75663d0c" xlink:href="cpix-20201210.xsd#cpix_AccountsReceivableAllowancesByComponentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_65bc9168-f6f6-403c-9695-e93b4dd15250" xlink:to="loc_cpix_AccountsReceivableAllowancesByComponentAxis_684c2ea9-1e9e-4aea-9176-c5df75663d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccountsReceivableAllowancesByComponentDomain_45f524d4-745e-49cc-b9b8-73eb46791e1d" xlink:href="cpix-20201210.xsd#cpix_AccountsReceivableAllowancesByComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_AccountsReceivableAllowancesByComponentAxis_684c2ea9-1e9e-4aea-9176-c5df75663d0c" xlink:to="loc_cpix_AccountsReceivableAllowancesByComponentDomain_45f524d4-745e-49cc-b9b8-73eb46791e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember_7626af12-60cf-4c9b-8077-75d22ace4420" xlink:href="cpix-20201210.xsd#cpix_ChargebacksCashDiscountsAndDamagedGoodsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_AccountsReceivableAllowancesByComponentDomain_45f524d4-745e-49cc-b9b8-73eb46791e1d" xlink:to="loc_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember_7626af12-60cf-4c9b-8077-75d22ace4420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_01c11c27-b2ad-4741-938c-e5408187b00f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_65bc9168-f6f6-403c-9695-e93b4dd15250" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_01c11c27-b2ad-4741-938c-e5408187b00f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_0e2a9aaa-d860-451a-8309-b0274647b8a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_01c11c27-b2ad-4741-938c-e5408187b00f" xlink:to="loc_us-gaap_SegmentReportingAbstract_0e2a9aaa-d860-451a-8309-b0274647b8a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_bf0bc2b2-8bb0-49ca-8000-143eb44a4f67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0e2a9aaa-d860-451a-8309-b0274647b8a2" xlink:to="loc_us-gaap_NumberOfOperatingSegments_bf0bc2b2-8bb0-49ca-8000-143eb44a4f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_597208b5-2682-4834-8543-42526f9547cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0e2a9aaa-d860-451a-8309-b0274647b8a2" xlink:to="loc_us-gaap_Revenues_597208b5-2682-4834-8543-42526f9547cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_dab62058-eec2-43a5-a046-b4dc3cfdc7be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0e2a9aaa-d860-451a-8309-b0274647b8a2" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_dab62058-eec2-43a5-a046-b4dc3cfdc7be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ec310439-5b62-4e4a-a2a3-9259e48391d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0e2a9aaa-d860-451a-8309-b0274647b8a2" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ec310439-5b62-4e4a-a2a3-9259e48391d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f214a6ca-942a-488f-9047-805e53082209" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0e2a9aaa-d860-451a-8309-b0274647b8a2" xlink:to="loc_us-gaap_OperatingLeaseLiability_f214a6ca-942a-488f-9047-805e53082209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductionAndDistributionCosts_38020a48-5de4-47ea-8c65-f37896adc896" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductionAndDistributionCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_01c11c27-b2ad-4741-938c-e5408187b00f" xlink:to="loc_us-gaap_ProductionAndDistributionCosts_38020a48-5de4-47ea-8c65-f37896adc896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_6cdb717e-e71f-4a94-b46c-dcd6a33631c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_01c11c27-b2ad-4741-938c-e5408187b00f" xlink:to="loc_us-gaap_AdvertisingExpense_6cdb717e-e71f-4a94-b46c-dcd6a33631c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b7558faa-668b-40e0-866c-f9429690d1f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_27dc47bf-3510-45d6-96c6-fd14d4a25874" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7558faa-668b-40e0-866c-f9429690d1f7" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_27dc47bf-3510-45d6-96c6-fd14d4a25874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1b714a41-3252-4fc6-98ec-321548d68d56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_27dc47bf-3510-45d6-96c6-fd14d4a25874" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1b714a41-3252-4fc6-98ec-321548d68d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce5755f2-bda8-48c0-b6f5-7b71cce4dfb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1b714a41-3252-4fc6-98ec-321548d68d56" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce5755f2-bda8-48c0-b6f5-7b71cce4dfb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductRightsMember_67b0a4c9-7331-4885-a9c0-88acc66817c8" xlink:href="cpix-20201210.xsd#cpix_ProductRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce5755f2-bda8-48c0-b6f5-7b71cce4dfb3" xlink:to="loc_cpix_ProductRightsMember_67b0a4c9-7331-4885-a9c0-88acc66817c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_7cc511df-c5ed-4975-a65c-ecc4655f71cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce5755f2-bda8-48c0-b6f5-7b71cce4dfb3" xlink:to="loc_us-gaap_LicensingAgreementsMember_7cc511df-c5ed-4975-a65c-ecc4655f71cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_2619d4e1-b4d3-46e8-b2a2-f535ddea1b6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce5755f2-bda8-48c0-b6f5-7b71cce4dfb3" xlink:to="loc_us-gaap_PatentsMember_2619d4e1-b4d3-46e8-b2a2-f535ddea1b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cf11c9e2-f445-4609-86e8-3ca85e9e8509" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_27dc47bf-3510-45d6-96c6-fd14d4a25874" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cf11c9e2-f445-4609-86e8-3ca85e9e8509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual_82e4fe9b-4fc0-4880-9809-a24b43e4b669" xlink:href="cpix-20201210.xsd#cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cf11c9e2-f445-4609-86e8-3ca85e9e8509" xlink:to="loc_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual_82e4fe9b-4fc0-4880-9809-a24b43e4b669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativ" xlink:type="simple" xlink:href="cpix-20201210.xsd#OmeclamoxPakRediTrexandVibativ"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativ" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_3a605b1e-1d73-4dea-b541-7a844bb6181d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_6822c525-c2c1-49f5-a049-179f8985b801" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_3a605b1e-1d73-4dea-b541-7a844bb6181d" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_6822c525-c2c1-49f5-a049-179f8985b801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#OmeclamoxPakRediTrexandVibativTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_7f7c38a0-759c-43f0-b24b-f3166ce53e7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_32034c80-961c-4591-8b97-85e5b7f75252" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_7f7c38a0-759c-43f0-b24b-f3166ce53e7e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_32034c80-961c-4591-8b97-85e5b7f75252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_7d9a93f6-1083-490d-ab4b-1c4651f646e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_7f7c38a0-759c-43f0-b24b-f3166ce53e7e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_7d9a93f6-1083-490d-ab4b-1c4651f646e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_a349fcd9-7275-4134-9b15-e46fe9f439b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_7f7c38a0-759c-43f0-b24b-f3166ce53e7e" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_a349fcd9-7275-4134-9b15-e46fe9f439b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#OmeclamoxPakRediTrexandVibativNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_3b65bc40-f3f2-42c6-966e-5286bec0d667" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2dfc8d6c-e5f3-4a70-81dc-9fe3630932f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_3b65bc40-f3f2-42c6-966e-5286bec0d667" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2dfc8d6c-e5f3-4a70-81dc-9fe3630932f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2c5ab1a3-32e9-43da-b017-fc13adf80742" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2dfc8d6c-e5f3-4a70-81dc-9fe3630932f8" xlink:to="loc_us-gaap_AwardTypeAxis_2c5ab1a3-32e9-43da-b017-fc13adf80742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_824809c9-137a-41d5-a7b9-fc81472b6f41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2c5ab1a3-32e9-43da-b017-fc13adf80742" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_824809c9-137a-41d5-a7b9-fc81472b6f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_4c8d51cf-9030-4f7e-a4d8-91a80ec6b459" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_824809c9-137a-41d5-a7b9-fc81472b6f41" xlink:to="loc_us-gaap_RestrictedStockMember_4c8d51cf-9030-4f7e-a4d8-91a80ec6b459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6c105dfe-cce8-4fa0-9307-e1c28d6322cf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2dfc8d6c-e5f3-4a70-81dc-9fe3630932f8" xlink:to="loc_srt_ProductOrServiceAxis_6c105dfe-cce8-4fa0-9307-e1c28d6322cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7f0346b7-b879-435e-b46d-a007611a12e0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_6c105dfe-cce8-4fa0-9307-e1c28d6322cf" xlink:to="loc_srt_ProductsAndServicesDomain_7f0346b7-b879-435e-b46d-a007611a12e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember_6ecf4f72-cdd6-434f-b8a8-3ee52a95094e" xlink:href="cpix-20201210.xsd#cpix_OmeclamoxPakMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7f0346b7-b879-435e-b46d-a007611a12e0" xlink:to="loc_cpix_OmeclamoxPakMember_6ecf4f72-cdd6-434f-b8a8-3ee52a95094e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_916db95d-8da2-4ee4-9441-4e6524c080ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2dfc8d6c-e5f3-4a70-81dc-9fe3630932f8" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_916db95d-8da2-4ee4-9441-4e6524c080ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_217aa544-b1a6-41e8-b703-3b34773d58f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_916db95d-8da2-4ee4-9441-4e6524c080ac" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_217aa544-b1a6-41e8-b703-3b34773d58f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember_d8a20cb9-1851-47a7-882d-ac91d46ddddd" xlink:href="cpix-20201210.xsd#cpix_OmeclamoxPakMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_217aa544-b1a6-41e8-b703-3b34773d58f0" xlink:to="loc_cpix_OmeclamoxPakMember_d8a20cb9-1851-47a7-882d-ac91d46ddddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MethotrexateMember_f22e1ac0-7c21-40ca-97a3-4602bcc7305c" xlink:href="cpix-20201210.xsd#cpix_MethotrexateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_217aa544-b1a6-41e8-b703-3b34773d58f0" xlink:to="loc_cpix_MethotrexateMember_f22e1ac0-7c21-40ca-97a3-4602bcc7305c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e444be84-05cc-42fc-8bbf-1a93570657c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2dfc8d6c-e5f3-4a70-81dc-9fe3630932f8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e444be84-05cc-42fc-8bbf-1a93570657c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76bcd7d7-a578-42bb-ba08-21ac87276682" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e444be84-05cc-42fc-8bbf-1a93570657c8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76bcd7d7-a578-42bb-ba08-21ac87276682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AmendedInternationalAgreementMember_77d7c31a-1c87-46ff-a0a5-8c6629c9a747" xlink:href="cpix-20201210.xsd#cpix_AmendedInternationalAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76bcd7d7-a578-42bb-ba08-21ac87276682" xlink:to="loc_cpix_AmendedInternationalAgreementMember_77d7c31a-1c87-46ff-a0a5-8c6629c9a747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_ee98043a-e37d-46f6-a209-37ba419b5064" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2dfc8d6c-e5f3-4a70-81dc-9fe3630932f8" xlink:to="loc_dei_LegalEntityAxis_ee98043a-e37d-46f6-a209-37ba419b5064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ad26a27e-d61a-4c38-bf19-2d896d5f0a2c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_ee98043a-e37d-46f6-a209-37ba419b5064" xlink:to="loc_dei_EntityDomain_ad26a27e-d61a-4c38-bf19-2d896d5f0a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PernixTherapeuticsMember_14d902bf-2dd1-48b4-b091-20d6cc07bef9" xlink:href="cpix-20201210.xsd#cpix_PernixTherapeuticsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_ad26a27e-d61a-4c38-bf19-2d896d5f0a2c" xlink:to="loc_cpix_PernixTherapeuticsMember_14d902bf-2dd1-48b4-b091-20d6cc07bef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d1917fc7-d40e-432d-9056-600be860a2a1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2dfc8d6c-e5f3-4a70-81dc-9fe3630932f8" xlink:to="loc_srt_RangeAxis_d1917fc7-d40e-432d-9056-600be860a2a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_155a2c31-01d7-4ebf-ad14-374916c75f3e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d1917fc7-d40e-432d-9056-600be860a2a1" xlink:to="loc_srt_RangeMember_155a2c31-01d7-4ebf-ad14-374916c75f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0d751846-7b3d-40e8-ba9d-611649bb77b8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_155a2c31-01d7-4ebf-ad14-374916c75f3e" xlink:to="loc_srt_MinimumMember_0d751846-7b3d-40e8-ba9d-611649bb77b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6487d7f0-8d84-4a6b-b8c9-9424ab5656a4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_155a2c31-01d7-4ebf-ad14-374916c75f3e" xlink:to="loc_srt_MaximumMember_6487d7f0-8d84-4a6b-b8c9-9424ab5656a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5e9e248f-f3c4-4087-b04c-8f1734db8c75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2dfc8d6c-e5f3-4a70-81dc-9fe3630932f8" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5e9e248f-f3c4-4087-b04c-8f1734db8c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1865f0d0-b440-4f68-aa80-75c90096eb2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5e9e248f-f3c4-4087-b04c-8f1734db8c75" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1865f0d0-b440-4f68-aa80-75c90096eb2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_debb29a5-7ee8-4536-bd52-5b814e238615" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1865f0d0-b440-4f68-aa80-75c90096eb2a" xlink:to="loc_us-gaap_SubsequentEventMember_debb29a5-7ee8-4536-bd52-5b814e238615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_fa901419-fc66-483e-b263-6bae6681c75f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2dfc8d6c-e5f3-4a70-81dc-9fe3630932f8" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_fa901419-fc66-483e-b263-6bae6681c75f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsForAssetAcquisitions_4301a8a1-6a2e-49f7-a9c7-52431b289ff5" xlink:href="cpix-20201210.xsd#cpix_PaymentsForAssetAcquisitions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fa901419-fc66-483e-b263-6bae6681c75f" xlink:to="loc_cpix_PaymentsForAssetAcquisitions_4301a8a1-6a2e-49f7-a9c7-52431b289ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_56107d30-0ccd-40c6-86fe-1d8de5deec2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fa901419-fc66-483e-b263-6bae6681c75f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_56107d30-0ccd-40c6-86fe-1d8de5deec2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales_82ff4e75-9543-48bf-9cf2-a348ad72a0ae" xlink:href="cpix-20201210.xsd#cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fa901419-fc66-483e-b263-6bae6681c75f" xlink:to="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales_82ff4e75-9543-48bf-9cf2-a348ad72a0ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_17166d04-4e7e-43bd-8246-defe167af6a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fa901419-fc66-483e-b263-6bae6681c75f" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_17166d04-4e7e-43bd-8246-defe167af6a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_e5bff230-cb38-46dd-9efd-e37f5f62327b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fa901419-fc66-483e-b263-6bae6681c75f" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_e5bff230-cb38-46dd-9efd-e37f5f62327b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_9ac93fb9-d8ee-4f54-a0b1-ccc0ef31451b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fa901419-fc66-483e-b263-6bae6681c75f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_9ac93fb9-d8ee-4f54-a0b1-ccc0ef31451b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_37f1d802-1f4e-4efb-9d49-9b1dc8ba8f7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fa901419-fc66-483e-b263-6bae6681c75f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_37f1d802-1f4e-4efb-9d49-9b1dc8ba8f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b85d1108-2036-4c41-9ee0-4efbe35b735a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fa901419-fc66-483e-b263-6bae6681c75f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b85d1108-2036-4c41-9ee0-4efbe35b735a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#OmeclamoxPakRediTrexandVibativVibativAcquisitionNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_8dfa204c-69d8-4329-8b0e-a92823bcfef1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b7d89e13-bc7b-4c98-a6e8-7415829403d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_8dfa204c-69d8-4329-8b0e-a92823bcfef1" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b7d89e13-bc7b-4c98-a6e8-7415829403d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_63016a6f-31d2-40b1-858d-2e03be38e3b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b7d89e13-bc7b-4c98-a6e8-7415829403d5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_63016a6f-31d2-40b1-858d-2e03be38e3b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dbc03579-fa8d-4145-9a76-a02028183c40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_63016a6f-31d2-40b1-858d-2e03be38e3b9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dbc03579-fa8d-4145-9a76-a02028183c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_08f797ce-0dd3-4426-9775-65badb7a749c" xlink:href="cpix-20201210.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dbc03579-fa8d-4145-9a76-a02028183c40" xlink:to="loc_cpix_VIBATIVMember_08f797ce-0dd3-4426-9775-65badb7a749c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1627a8bc-1d64-4715-b4fb-9c548637f692" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b7d89e13-bc7b-4c98-a6e8-7415829403d5" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1627a8bc-1d64-4715-b4fb-9c548637f692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d1e8fb48-1859-4d89-8c43-2e938b8feb8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1627a8bc-1d64-4715-b4fb-9c548637f692" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d1e8fb48-1859-4d89-8c43-2e938b8feb8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_beef6e29-5b84-4bbc-9cf2-6a864bee4007" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d1e8fb48-1859-4d89-8c43-2e938b8feb8b" xlink:to="loc_us-gaap_SubsequentEventMember_beef6e29-5b84-4bbc-9cf2-6a864bee4007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7fd84ac2-033e-4938-a22a-176db2deac20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b7d89e13-bc7b-4c98-a6e8-7415829403d5" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_7fd84ac2-033e-4938-a22a-176db2deac20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_d3b140ed-f572-46e5-b259-8a1ce25a6b05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7fd84ac2-033e-4938-a22a-176db2deac20" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_d3b140ed-f572-46e5-b259-8a1ce25a6b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_eb4cf732-d6eb-430b-9f77-9068c9b254f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7fd84ac2-033e-4938-a22a-176db2deac20" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_eb4cf732-d6eb-430b-9f77-9068c9b254f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsPercentage_bb3266b5-48db-41fe-85bd-ce88f80fb6dc" xlink:href="cpix-20201210.xsd#cpix_TieredRoyaltyPaymentsPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7fd84ac2-033e-4938-a22a-176db2deac20" xlink:to="loc_cpix_TieredRoyaltyPaymentsPercentage_bb3266b5-48db-41fe-85bd-ce88f80fb6dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_f1f83929-98f3-425d-aa0f-1dfd9356bcc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7fd84ac2-033e-4938-a22a-176db2deac20" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_f1f83929-98f3-425d-aa0f-1dfd9356bcc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_25026630-292b-4e27-8b7e-270b3e0bf999" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7fd84ac2-033e-4938-a22a-176db2deac20" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_25026630-292b-4e27-8b7e-270b3e0bf999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_19ce1c5d-8649-4c4f-8bcb-ca14b157959c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5f58985a-89e8-47d6-9c70-65028ad2b7c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_19ce1c5d-8649-4c4f-8bcb-ca14b157959c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5f58985a-89e8-47d6-9c70-65028ad2b7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_49e2d97b-bebb-4581-a508-871f19fcff06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5f58985a-89e8-47d6-9c70-65028ad2b7c0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_49e2d97b-bebb-4581-a508-871f19fcff06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6a9336c0-e29e-4fc1-a051-e23d71d00da7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_49e2d97b-bebb-4581-a508-871f19fcff06" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6a9336c0-e29e-4fc1-a051-e23d71d00da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_20c8a127-748f-4e36-acc8-2f8a15c5f4b4" xlink:href="cpix-20201210.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6a9336c0-e29e-4fc1-a051-e23d71d00da7" xlink:to="loc_cpix_VIBATIVMember_20c8a127-748f-4e36-acc8-2f8a15c5f4b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_94f69c2d-76df-4850-b6d2-0fa17a94c018" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5f58985a-89e8-47d6-9c70-65028ad2b7c0" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_94f69c2d-76df-4850-b6d2-0fa17a94c018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_446f23c1-dbba-489d-80e6-a3ffcd8fce4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_94f69c2d-76df-4850-b6d2-0fa17a94c018" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_446f23c1-dbba-489d-80e6-a3ffcd8fce4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_621dfb37-fefb-457a-a53e-411e9ffebc3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_94f69c2d-76df-4850-b6d2-0fa17a94c018" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_621dfb37-fefb-457a-a53e-411e9ffebc3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsForContingentConsideration_797a8fcb-b1ee-4ba6-b8fa-25601de2d742" xlink:href="cpix-20201210.xsd#cpix_PaymentsForContingentConsideration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_94f69c2d-76df-4850-b6d2-0fa17a94c018" xlink:to="loc_cpix_PaymentsForContingentConsideration_797a8fcb-b1ee-4ba6-b8fa-25601de2d742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_bcc3c3aa-13aa-4f76-b082-e67437c1c019" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_94f69c2d-76df-4850-b6d2-0fa17a94c018" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_bcc3c3aa-13aa-4f76-b082-e67437c1c019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ChangeInContingentConsiderationHeadingRollForward_2e428767-8b75-4ee2-9fe1-6a68f4cab0bd" xlink:href="cpix-20201210.xsd#cpix_ChangeInContingentConsiderationHeadingRollForward"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_94f69c2d-76df-4850-b6d2-0fa17a94c018" xlink:to="loc_cpix_ChangeInContingentConsiderationHeadingRollForward_2e428767-8b75-4ee2-9fe1-6a68f4cab0bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3b6e03ad-bab2-4e64-9231-e3b123db9ae3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ChangeInContingentConsiderationHeadingRollForward_2e428767-8b75-4ee2-9fe1-6a68f4cab0bd" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3b6e03ad-bab2-4e64-9231-e3b123db9ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_9890610e-df6a-4e89-bc6b-a3cb01579886" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ChangeInContingentConsiderationHeadingRollForward_2e428767-8b75-4ee2-9fe1-6a68f4cab0bd" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_9890610e-df6a-4e89-bc6b-a3cb01579886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_0e7f3ee4-20f6-468a-b81f-4800cc00b41f" xlink:href="cpix-20201210.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ChangeInContingentConsiderationHeadingRollForward_2e428767-8b75-4ee2-9fe1-6a68f4cab0bd" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_0e7f3ee4-20f6-468a-b81f-4800cc00b41f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment_231ec1aa-8259-4d1c-ad80-39d189b284b2" xlink:href="cpix-20201210.xsd#cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ChangeInContingentConsiderationHeadingRollForward_2e428767-8b75-4ee2-9fe1-6a68f4cab0bd" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment_231ec1aa-8259-4d1c-ad80-39d189b284b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_76c17d6f-c10d-48d6-a988-90009a3d8111" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ChangeInContingentConsiderationHeadingRollForward_2e428767-8b75-4ee2-9fe1-6a68f4cab0bd" xlink:to="loc_us-gaap_PaymentsForRoyalties_76c17d6f-c10d-48d6-a988-90009a3d8111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_40fd6a99-cbc2-4403-9778-bc8c501cccbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ChangeInContingentConsiderationHeadingRollForward_2e428767-8b75-4ee2-9fe1-6a68f4cab0bd" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_40fd6a99-cbc2-4403-9778-bc8c501cccbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_a99e6aaa-9038-4536-9ee2-9d16af5ac78c" xlink:href="cpix-20201210.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_94f69c2d-76df-4850-b6d2-0fa17a94c018" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_a99e6aaa-9038-4536-9ee2-9d16af5ac78c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_b9eb82bb-25d6-4b19-9bcb-67fcc700c1fb" xlink:href="cpix-20201210.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_94f69c2d-76df-4850-b6d2-0fa17a94c018" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_b9eb82bb-25d6-4b19-9bcb-67fcc700c1fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_2214c22f-0195-481b-8ffb-63580306b79f" xlink:href="cpix-20201210.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_94f69c2d-76df-4850-b6d2-0fa17a94c018" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_2214c22f-0195-481b-8ffb-63580306b79f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_21aa2c4a-e3d7-4644-ab45-2efec0824a55" xlink:href="cpix-20201210.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_94f69c2d-76df-4850-b6d2-0fa17a94c018" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_21aa2c4a-e3d7-4644-ab45-2efec0824a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_5450ba75-edf0-415e-84cf-fde8770371ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_94f69c2d-76df-4850-b6d2-0fa17a94c018" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_5450ba75-edf0-415e-84cf-fde8770371ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_0e8099cf-bbed-4f87-b7ce-e6c1da58bea2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_94f69c2d-76df-4850-b6d2-0fa17a94c018" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_0e8099cf-bbed-4f87-b7ce-e6c1da58bea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_73b5a5c6-d2c0-40c8-93f0-aaac71d2be5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_94f69c2d-76df-4850-b6d2-0fa17a94c018" xlink:to="loc_us-gaap_Goodwill_73b5a5c6-d2c0-40c8-93f0-aaac71d2be5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_8776bb90-f192-4c1c-9622-7a53f703601b" xlink:href="cpix-20201210.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_94f69c2d-76df-4850-b6d2-0fa17a94c018" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_8776bb90-f192-4c1c-9622-7a53f703601b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_6b785e96-af7e-4130-a78a-63a63289c987" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_94f69c2d-76df-4850-b6d2-0fa17a94c018" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_6b785e96-af7e-4130-a78a-63a63289c987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Revenues" xlink:type="simple" xlink:href="cpix-20201210.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_f9c15a15-d24c-4394-9429-5aabb55dcbc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_d85f2fe8-1d33-4f06-abf2-d380ad15d0c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_f9c15a15-d24c-4394-9429-5aabb55dcbc8" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_d85f2fe8-1d33-4f06-abf2-d380ad15d0c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_8b1c09cc-f879-4196-b36b-98a33fd64c2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_222985f2-637a-4a13-b7e5-1af14a513875" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_8b1c09cc-f879-4196-b36b-98a33fd64c2a" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_222985f2-637a-4a13-b7e5-1af14a513875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#RevenuesScheduleofNetProductRevenuesbyProductDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_d11bf7af-fc84-4e7b-987a-4a0278581d2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_2668281f-99d7-412c-b86b-b65935db9bc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_d11bf7af-fc84-4e7b-987a-4a0278581d2e" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_2668281f-99d7-412c-b86b-b65935db9bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_19736ea1-dc30-420b-8e41-f54551e5bbef" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_2668281f-99d7-412c-b86b-b65935db9bc0" xlink:to="loc_srt_ProductOrServiceAxis_19736ea1-dc30-420b-8e41-f54551e5bbef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_53024802-a6f3-473b-8ec9-e4dcd027715f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_19736ea1-dc30-420b-8e41-f54551e5bbef" xlink:to="loc_srt_ProductsAndServicesDomain_53024802-a6f3-473b-8ec9-e4dcd027715f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember_20df25f4-cd41-4e7f-a4dd-95962d9a166d" xlink:href="cpix-20201210.xsd#cpix_AcetadoteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_53024802-a6f3-473b-8ec9-e4dcd027715f" xlink:to="loc_cpix_AcetadoteMember_20df25f4-cd41-4e7f-a4dd-95962d9a166d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember_4e0fd8c8-ba49-4af4-9095-e393bf8e1123" xlink:href="cpix-20201210.xsd#cpix_OmeclamoxPakMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_53024802-a6f3-473b-8ec9-e4dcd027715f" xlink:to="loc_cpix_OmeclamoxPakMember_4e0fd8c8-ba49-4af4-9095-e393bf8e1123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember_f6e2a258-495d-4c6e-9e49-d788afd16071" xlink:href="cpix-20201210.xsd#cpix_KristaloseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_53024802-a6f3-473b-8ec9-e4dcd027715f" xlink:to="loc_cpix_KristaloseMember_f6e2a258-495d-4c6e-9e49-d788afd16071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember_799d474a-a8bd-4be2-a3d5-3459130ceb92" xlink:href="cpix-20201210.xsd#cpix_VaprisolMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_53024802-a6f3-473b-8ec9-e4dcd027715f" xlink:to="loc_cpix_VaprisolMember_799d474a-a8bd-4be2-a3d5-3459130ceb92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember_70a28968-f3ea-4ed8-9006-8e4915bb7c6b" xlink:href="cpix-20201210.xsd#cpix_CaldolorMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_53024802-a6f3-473b-8ec9-e4dcd027715f" xlink:to="loc_cpix_CaldolorMember_70a28968-f3ea-4ed8-9006-8e4915bb7c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductVibativMember_a1d3261b-1d22-42c0-920a-dd94039f29e9" xlink:href="cpix-20201210.xsd#cpix_ProductVibativMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_53024802-a6f3-473b-8ec9-e4dcd027715f" xlink:to="loc_cpix_ProductVibativMember_a1d3261b-1d22-42c0-920a-dd94039f29e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_236ff48e-923b-4694-999f-25a253dd70f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_2668281f-99d7-412c-b86b-b65935db9bc0" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_236ff48e-923b-4694-999f-25a253dd70f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_330d3d4d-b17e-4757-b319-d3b1c518ea37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_236ff48e-923b-4694-999f-25a253dd70f8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_330d3d4d-b17e-4757-b319-d3b1c518ea37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#RevenuesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_9249bad2-a5e4-40cb-934f-a7de4978b406" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AirlineProductsAndServicesTable_2ecfe4fd-98c2-4922-8384-23c52b89509c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AirlineProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_9249bad2-a5e4-40cb-934f-a7de4978b406" xlink:to="loc_us-gaap_AirlineProductsAndServicesTable_2ecfe4fd-98c2-4922-8384-23c52b89509c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7c60b85a-124a-4c48-8635-65ce1f35ebf8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_2ecfe4fd-98c2-4922-8384-23c52b89509c" xlink:to="loc_srt_CounterpartyNameAxis_7c60b85a-124a-4c48-8635-65ce1f35ebf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_74b08555-709d-4ca2-ad67-15cb0a08f24f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_7c60b85a-124a-4c48-8635-65ce1f35ebf8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_74b08555-709d-4ca2-ad67-15cb0a08f24f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember_69ae0652-e0a6-46ec-96ad-d899ef789639" xlink:href="cpix-20201210.xsd#cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_74b08555-709d-4ca2-ad67-15cb0a08f24f" xlink:to="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember_69ae0652-e0a6-46ec-96ad-d899ef789639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9a4ec214-17a1-4186-967b-92be8b011b2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_2ecfe4fd-98c2-4922-8384-23c52b89509c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9a4ec214-17a1-4186-967b-92be8b011b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_32eb683d-cdc3-4305-b3c7-2033879972a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9a4ec214-17a1-4186-967b-92be8b011b2c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_32eb683d-cdc3-4305-b3c7-2033879972a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember_cac74e7d-bc2d-43e1-86c1-ef577696a1e5" xlink:href="cpix-20201210.xsd#cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_32eb683d-cdc3-4305-b3c7-2033879972a8" xlink:to="loc_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember_cac74e7d-bc2d-43e1-86c1-ef577696a1e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1314984f-ee49-464f-bad8-a650056cf59d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_2ecfe4fd-98c2-4922-8384-23c52b89509c" xlink:to="loc_srt_ProductOrServiceAxis_1314984f-ee49-464f-bad8-a650056cf59d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_899f43d7-d1c3-45f1-a2db-7d0642c44f34" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1314984f-ee49-464f-bad8-a650056cf59d" xlink:to="loc_srt_ProductsAndServicesDomain_899f43d7-d1c3-45f1-a2db-7d0642c44f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_27a59f2c-c4c3-4e29-8a49-409c9d3026e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_899f43d7-d1c3-45f1-a2db-7d0642c44f34" xlink:to="loc_us-gaap_GrantMember_27a59f2c-c4c3-4e29-8a49-409c9d3026e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_f5008613-066c-41fe-92a2-58e66541ece8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_2ecfe4fd-98c2-4922-8384-23c52b89509c" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_f5008613-066c-41fe-92a2-58e66541ece8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductRevenuesAbstract_0ef97b23-78d5-4a08-8546-32ad16a7a609" xlink:href="cpix-20201210.xsd#cpix_ProductRevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_f5008613-066c-41fe-92a2-58e66541ece8" xlink:to="loc_cpix_ProductRevenuesAbstract_0ef97b23-78d5-4a08-8546-32ad16a7a609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_93ab0fa7-e17d-43d5-97b6-9aa0b0932a76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ProductRevenuesAbstract_0ef97b23-78d5-4a08-8546-32ad16a7a609" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_93ab0fa7-e17d-43d5-97b6-9aa0b0932a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherRevenuesAbstract_6a9c060c-a2df-4185-92f6-6e8b0d30e407" xlink:href="cpix-20201210.xsd#cpix_OtherRevenuesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_f5008613-066c-41fe-92a2-58e66541ece8" xlink:to="loc_cpix_OtherRevenuesAbstract_6a9c060c-a2df-4185-92f6-6e8b0d30e407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionUpfrontPayment_1a834ed1-f2d9-4218-a485-daedafb00ccb" xlink:href="cpix-20201210.xsd#cpix_RevenueRecognitionUpfrontPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_OtherRevenuesAbstract_6a9c060c-a2df-4185-92f6-6e8b0d30e407" xlink:to="loc_cpix_RevenueRecognitionUpfrontPayment_1a834ed1-f2d9-4218-a485-daedafb00ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval_b9504786-6bcf-41f5-b43e-b0d44335eb17" xlink:href="cpix-20201210.xsd#cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_OtherRevenuesAbstract_6a9c060c-a2df-4185-92f6-6e8b0d30e407" xlink:to="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval_b9504786-6bcf-41f5-b43e-b0d44335eb17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales_760856e9-d9ae-4039-8167-0f07f102e0ba" xlink:href="cpix-20201210.xsd#cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_OtherRevenuesAbstract_6a9c060c-a2df-4185-92f6-6e8b0d30e407" xlink:to="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales_760856e9-d9ae-4039-8167-0f07f102e0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionCumulativeUpfrontPayment_bbdfd1f6-36cc-45d5-ac75-9df304bb2bde" xlink:href="cpix-20201210.xsd#cpix_RevenueRecognitionCumulativeUpfrontPayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_OtherRevenuesAbstract_6a9c060c-a2df-4185-92f6-6e8b0d30e407" xlink:to="loc_cpix_RevenueRecognitionCumulativeUpfrontPayment_bbdfd1f6-36cc-45d5-ac75-9df304bb2bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionMilestonePayments_659b0cdb-b47a-4c10-bec2-38401e4a88f5" xlink:href="cpix-20201210.xsd#cpix_RevenueRecognitionMilestonePayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_OtherRevenuesAbstract_6a9c060c-a2df-4185-92f6-6e8b0d30e407" xlink:to="loc_cpix_RevenueRecognitionMilestonePayments_659b0cdb-b47a-4c10-bec2-38401e4a88f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Inventories" xlink:type="simple" xlink:href="cpix-20201210.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_4048920d-a10f-4e6f-ac08-32681c9d0a52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_baa8ab59-af07-4ad9-9127-566a093ccd8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_4048920d-a10f-4e6f-ac08-32681c9d0a52" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_baa8ab59-af07-4ad9-9127-566a093ccd8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_a74fc82a-3885-41f3-b9a0-c1737171d227" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_5e126657-a879-45c0-94e7-bea64ef6fcfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a74fc82a-3885-41f3-b9a0-c1737171d227" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_5e126657-a879-45c0-94e7-bea64ef6fcfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_daebf1ab-4ac0-439d-bbd5-70f912151df8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_54433905-76ec-4332-a9be-1e82baf30400" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_daebf1ab-4ac0-439d-bbd5-70f912151df8" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_54433905-76ec-4332-a9be-1e82baf30400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_e852718c-4059-420f-820d-13f27703465f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_daebf1ab-4ac0-439d-bbd5-70f912151df8" xlink:to="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_e852718c-4059-420f-820d-13f27703465f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_7383b7bd-4a8d-4fad-b7dc-c5b28cdc7e44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_daebf1ab-4ac0-439d-bbd5-70f912151df8" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_7383b7bd-4a8d-4fad-b7dc-c5b28cdc7e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_7c7aabb7-4f6b-40ef-9fbb-944d134a0761" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_daebf1ab-4ac0-439d-bbd5-70f912151df8" xlink:to="loc_us-gaap_InventoryGross_7c7aabb7-4f6b-40ef-9fbb-944d134a0761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_41c80627-35d1-4833-a7e2-f7a8983414c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_daebf1ab-4ac0-439d-bbd5-70f912151df8" xlink:to="loc_us-gaap_InventoryNoncurrent_41c80627-35d1-4833-a7e2-f7a8983414c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e549b4bd-4b81-42eb-be56-273988462c3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_daebf1ab-4ac0-439d-bbd5-70f912151df8" xlink:to="loc_us-gaap_InventoryNet_e549b4bd-4b81-42eb-be56-273988462c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#InventoriesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_b893920a-5541-4772-b5ef-d13b33315924" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_c04079af-9188-4733-b27f-efccb462db9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b893920a-5541-4772-b5ef-d13b33315924" xlink:to="loc_us-gaap_InventoryCurrentTable_c04079af-9188-4733-b27f-efccb462db9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1a44c95a-82c5-4411-a22a-4894083644fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_c04079af-9188-4733-b27f-efccb462db9a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1a44c95a-82c5-4411-a22a-4894083644fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_393c48cc-df15-4e42-aa1d-c59bb376f77b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1a44c95a-82c5-4411-a22a-4894083644fb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_393c48cc-df15-4e42-aa1d-c59bb376f77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_193de535-5ae1-4b12-89f9-0d9c4736de26" xlink:href="cpix-20201210.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_393c48cc-df15-4e42-aa1d-c59bb376f77b" xlink:to="loc_cpix_VIBATIVMember_193de535-5ae1-4b12-89f9-0d9c4736de26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember_aa5b4a54-e31f-4be4-96f0-ff4b3cbae461" xlink:href="cpix-20201210.xsd#cpix_IfetrobanClinicalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_393c48cc-df15-4e42-aa1d-c59bb376f77b" xlink:to="loc_cpix_IfetrobanClinicalMember_aa5b4a54-e31f-4be4-96f0-ff4b3cbae461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_a1f67728-5f49-4dce-85a6-2726c76d3fac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_c04079af-9188-4733-b27f-efccb462db9a" xlink:to="loc_us-gaap_InventoryLineItems_a1f67728-5f49-4dce-85a6-2726c76d3fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_a99545de-6778-4416-bf8c-92ccb94bbfeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_a1f67728-5f49-4dce-85a6-2726c76d3fac" xlink:to="loc_us-gaap_InventoryValuationReserves_a99545de-6778-4416-bf8c-92ccb94bbfeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_a4d2aac4-4e17-4d27-abf6-c334d5f9df73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_a1f67728-5f49-4dce-85a6-2726c76d3fac" xlink:to="loc_us-gaap_InventoryNoncurrent_a4d2aac4-4e17-4d27-abf6-c334d5f9df73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_ff99a38d-7256-40bc-8978-dbad0bf92eca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_a1f67728-5f49-4dce-85a6-2726c76d3fac" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_ff99a38d-7256-40bc-8978-dbad0bf92eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="cpix-20201210.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_07b50a9b-973b-45eb-8da5-ec28b115be51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_6c27d6f5-6429-4f0b-9639-9173134779c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_07b50a9b-973b-45eb-8da5-ec28b115be51" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_6c27d6f5-6429-4f0b-9639-9173134779c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2b716021-9e39-4499-94d9-d2fc6f89f90e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_939aa6e6-909f-4142-8a2e-a05c1ca5b281" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2b716021-9e39-4499-94d9-d2fc6f89f90e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_939aa6e6-909f-4142-8a2e-a05c1ca5b281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ScheduleofDepreciationExpenseTableTextBlock_e99ecbd5-2cb6-49c6-8909-92412d52efab" xlink:href="cpix-20201210.xsd#cpix_ScheduleofDepreciationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2b716021-9e39-4499-94d9-d2fc6f89f90e" xlink:to="loc_cpix_ScheduleofDepreciationExpenseTableTextBlock_e99ecbd5-2cb6-49c6-8909-92412d52efab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#PropertyandEquipmentScheduleofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_872d459f-9d63-4145-8775-70ecef1058cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_15b27b12-4716-4408-8af0-289386e119ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_872d459f-9d63-4145-8775-70ecef1058cc" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_15b27b12-4716-4408-8af0-289386e119ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ef2f4155-19c6-4ff3-b52b-91e19d0e9168" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_15b27b12-4716-4408-8af0-289386e119ac" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ef2f4155-19c6-4ff3-b52b-91e19d0e9168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9224f86e-212a-4ef3-89c7-847e1d7a740b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ef2f4155-19c6-4ff3-b52b-91e19d0e9168" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9224f86e-212a-4ef3-89c7-847e1d7a740b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_b0fe3d86-dfab-4b2f-a46f-fefc61c7a705" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9224f86e-212a-4ef3-89c7-847e1d7a740b" xlink:to="loc_us-gaap_ComputerEquipmentMember_b0fe3d86-dfab-4b2f-a46f-fefc61c7a705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_b07a815c-b3f9-4fff-ac09-385c6894af83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9224f86e-212a-4ef3-89c7-847e1d7a740b" xlink:to="loc_us-gaap_OfficeEquipmentMember_b07a815c-b3f9-4fff-ac09-385c6894af83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_53fa669e-819d-4a58-ba7c-927c66285877" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9224f86e-212a-4ef3-89c7-847e1d7a740b" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_53fa669e-819d-4a58-ba7c-927c66285877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_5a9fcc5d-8ece-4bda-91d3-750590d58f80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9224f86e-212a-4ef3-89c7-847e1d7a740b" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_5a9fcc5d-8ece-4bda-91d3-750590d58f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_98aee886-af59-4c62-9a69-d67f20841659" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_15b27b12-4716-4408-8af0-289386e119ac" xlink:to="loc_srt_RangeAxis_98aee886-af59-4c62-9a69-d67f20841659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_033b6e06-3c9d-4c33-8c9e-f333015ed1b7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_98aee886-af59-4c62-9a69-d67f20841659" xlink:to="loc_srt_RangeMember_033b6e06-3c9d-4c33-8c9e-f333015ed1b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7215688d-ff03-41c2-97ab-373adc5f516d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_033b6e06-3c9d-4c33-8c9e-f333015ed1b7" xlink:to="loc_srt_MinimumMember_7215688d-ff03-41c2-97ab-373adc5f516d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e8a9b410-8597-4698-b8f1-1e6833aedd96" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_033b6e06-3c9d-4c33-8c9e-f333015ed1b7" xlink:to="loc_srt_MaximumMember_e8a9b410-8597-4698-b8f1-1e6833aedd96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c6d8b993-f340-47f4-8aa8-723501771bea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_15b27b12-4716-4408-8af0-289386e119ac" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c6d8b993-f340-47f4-8aa8-723501771bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_311cc3fc-51d7-46fa-b333-6082f7cd2397" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c6d8b993-f340-47f4-8aa8-723501771bea" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_311cc3fc-51d7-46fa-b333-6082f7cd2397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2801085c-67fe-4fcc-92a0-dbb20dfc5b7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c6d8b993-f340-47f4-8aa8-723501771bea" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2801085c-67fe-4fcc-92a0-dbb20dfc5b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5c639bae-0ede-42c1-bd91-9d0ca50aa57e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c6d8b993-f340-47f4-8aa8-723501771bea" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5c639bae-0ede-42c1-bd91-9d0ca50aa57e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_e31e2ca7-49ce-47eb-b816-7d4f700a4270" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c6d8b993-f340-47f4-8aa8-723501771bea" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_e31e2ca7-49ce-47eb-b816-7d4f700a4270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PropertyAndEquipmentUsefulLifeTextual_82bf5e22-1ca1-4f7c-8980-0d8713ab926c" xlink:href="cpix-20201210.xsd#cpix_PropertyAndEquipmentUsefulLifeTextual"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c6d8b993-f340-47f4-8aa8-723501771bea" xlink:to="loc_cpix_PropertyAndEquipmentUsefulLifeTextual_82bf5e22-1ca1-4f7c-8980-0d8713ab926c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipmentDepreciationExpenseDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#PropertyandEquipmentDepreciationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/PropertyandEquipmentDepreciationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_491b6160-8b9b-429c-bbf6-fc98d4f4e08b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements_83f6eb4a-955b-47c0-8bc8-4235b98dbbec" xlink:href="cpix-20201210.xsd#cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_491b6160-8b9b-429c-bbf6-fc98d4f4e08b" xlink:to="loc_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements_83f6eb4a-955b-47c0-8bc8-4235b98dbbec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssets" xlink:type="simple" xlink:href="cpix-20201210.xsd#IntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7e9243fa-bdc6-4363-8084-b7e4b036cb17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_2bff5756-5fbe-4113-be73-7a55c4071e23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7e9243fa-bdc6-4363-8084-b7e4b036cb17" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_2bff5756-5fbe-4113-be73-7a55c4071e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#IntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8fea6da3-0357-48e5-b67c-552c558c6aa0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_146a7169-6ffb-4829-85bd-1145a72b2414" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8fea6da3-0357-48e5-b67c-552c558c6aa0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_146a7169-6ffb-4829-85bd-1145a72b2414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_e658d3c2-a79f-49fe-8292-64762af559a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8fea6da3-0357-48e5-b67c-552c558c6aa0" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_e658d3c2-a79f-49fe-8292-64762af559a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#IntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4b11aa6c-c917-4b66-b731-0e53ab2b7793" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a413e63c-0db6-42ef-a31f-323165f9a36b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4b11aa6c-c917-4b66-b731-0e53ab2b7793" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a413e63c-0db6-42ef-a31f-323165f9a36b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ebb2b9eb-eed5-47c6-acd8-fd349caa3421" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a413e63c-0db6-42ef-a31f-323165f9a36b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ebb2b9eb-eed5-47c6-acd8-fd349caa3421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8c391d52-66ae-4f00-9b5f-120678028281" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ebb2b9eb-eed5-47c6-acd8-fd349caa3421" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8c391d52-66ae-4f00-9b5f-120678028281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductAndLicenseRightsMember_a9130801-34df-4290-b462-eda9d8e265fc" xlink:href="cpix-20201210.xsd#cpix_ProductAndLicenseRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8c391d52-66ae-4f00-9b5f-120678028281" xlink:to="loc_cpix_ProductAndLicenseRightsMember_a9130801-34df-4290-b462-eda9d8e265fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_8ebfaf95-7009-40be-abe6-356e54fe3287" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8c391d52-66ae-4f00-9b5f-120678028281" xlink:to="loc_us-gaap_PatentsMember_8ebfaf95-7009-40be-abe6-356e54fe3287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_ce92f2bc-00c4-42f3-9148-fa74d9d47b99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8c391d52-66ae-4f00-9b5f-120678028281" xlink:to="loc_us-gaap_TrademarksMember_ce92f2bc-00c4-42f3-9148-fa74d9d47b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fd941708-3d6b-4301-b081-6645355ccc22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a413e63c-0db6-42ef-a31f-323165f9a36b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fd941708-3d6b-4301-b081-6645355ccc22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e93bd5c1-3e80-487e-ae74-7145c6fbe954" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fd941708-3d6b-4301-b081-6645355ccc22" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e93bd5c1-3e80-487e-ae74-7145c6fbe954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f8653fb4-4499-401a-9d4a-aac0613836e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fd941708-3d6b-4301-b081-6645355ccc22" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f8653fb4-4499-401a-9d4a-aac0613836e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_41c13eab-e688-43e0-8eff-49110938fc6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fd941708-3d6b-4301-b081-6645355ccc22" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_41c13eab-e688-43e0-8eff-49110938fc6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#IntangibleAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0b1cb06c-66ad-4acb-a6e6-0504529cda38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d53e9d74-ccfb-436e-92e0-d6dcc02eff6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0b1cb06c-66ad-4acb-a6e6-0504529cda38" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d53e9d74-ccfb-436e-92e0-d6dcc02eff6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_be95cf21-d687-4c32-b333-802de2741633" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d53e9d74-ccfb-436e-92e0-d6dcc02eff6a" xlink:to="loc_dei_LegalEntityAxis_be95cf21-d687-4c32-b333-802de2741633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a20c6ad1-d98e-4655-a114-d20f429bdc62" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_be95cf21-d687-4c32-b333-802de2741633" xlink:to="loc_dei_EntityDomain_a20c6ad1-d98e-4655-a114-d20f429bdc62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember_1ff61bd8-9080-4979-8425-84a637435eb5" xlink:href="cpix-20201210.xsd#cpix_VaprisolMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a20c6ad1-d98e-4655-a114-d20f429bdc62" xlink:to="loc_cpix_VaprisolMember_1ff61bd8-9080-4979-8425-84a637435eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PernixTherapeuticsMember_0d7044f1-0074-410a-986f-5d2c60bc9cb5" xlink:href="cpix-20201210.xsd#cpix_PernixTherapeuticsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a20c6ad1-d98e-4655-a114-d20f429bdc62" xlink:to="loc_cpix_PernixTherapeuticsMember_0d7044f1-0074-410a-986f-5d2c60bc9cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_988bb77c-2e93-44d8-bf92-88ecdb4a3458" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d53e9d74-ccfb-436e-92e0-d6dcc02eff6a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_988bb77c-2e93-44d8-bf92-88ecdb4a3458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_50f15427-5f70-4ae6-bd2b-3a2f9932f9bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_988bb77c-2e93-44d8-bf92-88ecdb4a3458" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_50f15427-5f70-4ae6-bd2b-3a2f9932f9bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MethotrexateMember_c80b2d61-e91e-4e0c-82a5-0c3d178f007c" xlink:href="cpix-20201210.xsd#cpix_MethotrexateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_50f15427-5f70-4ae6-bd2b-3a2f9932f9bc" xlink:to="loc_cpix_MethotrexateMember_c80b2d61-e91e-4e0c-82a5-0c3d178f007c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_9082c143-76dc-4a1b-af65-b12525370810" xlink:href="cpix-20201210.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_50f15427-5f70-4ae6-bd2b-3a2f9932f9bc" xlink:to="loc_cpix_VIBATIVMember_9082c143-76dc-4a1b-af65-b12525370810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_df897cc0-57fa-46b8-ab7c-6eadded007b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d53e9d74-ccfb-436e-92e0-d6dcc02eff6a" xlink:to="loc_us-gaap_AwardTypeAxis_df897cc0-57fa-46b8-ab7c-6eadded007b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f52694ed-39e0-4f6e-a5c0-84df25c3f774" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_df897cc0-57fa-46b8-ab7c-6eadded007b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f52694ed-39e0-4f6e-a5c0-84df25c3f774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_6673d2c1-16d3-451c-9e74-5cdb130c6630" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f52694ed-39e0-4f6e-a5c0-84df25c3f774" xlink:to="loc_us-gaap_RestrictedStockMember_6673d2c1-16d3-451c-9e74-5cdb130c6630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4f263b0c-f2c5-41ed-8815-48a6398d6a5a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d53e9d74-ccfb-436e-92e0-d6dcc02eff6a" xlink:to="loc_srt_ProductOrServiceAxis_4f263b0c-f2c5-41ed-8815-48a6398d6a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4605001f-fa7e-41b7-949d-0c82c838ebe2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4f263b0c-f2c5-41ed-8815-48a6398d6a5a" xlink:to="loc_srt_ProductsAndServicesDomain_4605001f-fa7e-41b7-949d-0c82c838ebe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember_1125dddd-5a69-489a-91cc-9719c81e9074" xlink:href="cpix-20201210.xsd#cpix_KristaloseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4605001f-fa7e-41b7-949d-0c82c838ebe2" xlink:to="loc_cpix_KristaloseMember_1125dddd-5a69-489a-91cc-9719c81e9074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9e958f26-ff35-4d42-963a-ca39c28356fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d53e9d74-ccfb-436e-92e0-d6dcc02eff6a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9e958f26-ff35-4d42-963a-ca39c28356fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8cc3bb11-5a5f-458b-86ae-97db2b44925e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9e958f26-ff35-4d42-963a-ca39c28356fb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8cc3bb11-5a5f-458b-86ae-97db2b44925e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductAndLicenseRightsMember_66e7ef0f-52d9-41b4-896a-e72b9c011041" xlink:href="cpix-20201210.xsd#cpix_ProductAndLicenseRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8cc3bb11-5a5f-458b-86ae-97db2b44925e" xlink:to="loc_cpix_ProductAndLicenseRightsMember_66e7ef0f-52d9-41b4-896a-e72b9c011041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_ea41a957-8b56-40da-b5af-dbcf4944c3dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8cc3bb11-5a5f-458b-86ae-97db2b44925e" xlink:to="loc_us-gaap_PatentsMember_ea41a957-8b56-40da-b5af-dbcf4944c3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c47f2e21-9c73-4ee8-81b2-b27bf9c19bec" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d53e9d74-ccfb-436e-92e0-d6dcc02eff6a" xlink:to="loc_srt_CounterpartyNameAxis_c47f2e21-9c73-4ee8-81b2-b27bf9c19bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e84ef6c6-7406-42e0-921d-dca279a24666" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c47f2e21-9c73-4ee8-81b2-b27bf9c19bec" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e84ef6c6-7406-42e0-921d-dca279a24666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NordicMember_ebae9c48-1551-4ebc-af91-5b382c0e4377" xlink:href="cpix-20201210.xsd#cpix_NordicMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e84ef6c6-7406-42e0-921d-dca279a24666" xlink:to="loc_cpix_NordicMember_ebae9c48-1551-4ebc-af91-5b382c0e4377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_80293749-2b8c-49d6-96c9-1c8395626006" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d53e9d74-ccfb-436e-92e0-d6dcc02eff6a" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_80293749-2b8c-49d6-96c9-1c8395626006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9ae7c7ff-9a0d-43d7-ab16-31aefdaa2541" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_80293749-2b8c-49d6-96c9-1c8395626006" xlink:to="loc_us-gaap_Goodwill_9ae7c7ff-9a0d-43d7-ab16-31aefdaa2541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales_fa8c6c84-d233-4a0e-86ec-fb9c998b8264" xlink:href="cpix-20201210.xsd#cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_80293749-2b8c-49d6-96c9-1c8395626006" xlink:to="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales_fa8c6c84-d233-4a0e-86ec-fb9c998b8264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_665c05e6-cfc6-4e01-9602-cc793ddfe37b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_80293749-2b8c-49d6-96c9-1c8395626006" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_665c05e6-cfc6-4e01-9602-cc793ddfe37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_9b217e6a-c1d2-48a1-a5c3-777e361536a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_80293749-2b8c-49d6-96c9-1c8395626006" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_9b217e6a-c1d2-48a1-a5c3-777e361536a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_02bdf830-7737-4af9-b35e-04c7b1e181db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_80293749-2b8c-49d6-96c9-1c8395626006" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_02bdf830-7737-4af9-b35e-04c7b1e181db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_da401fee-afc9-4422-9104-c84f0babd9e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_80293749-2b8c-49d6-96c9-1c8395626006" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_da401fee-afc9-4422-9104-c84f0babd9e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_ac84820c-2f14-4295-861f-3ca47c9448fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_80293749-2b8c-49d6-96c9-1c8395626006" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_ac84820c-2f14-4295-861f-3ca47c9448fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease_f6743dd4-0ab1-493e-8dea-3988f330a18d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillPeriodIncreaseDecrease"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_80293749-2b8c-49d6-96c9-1c8395626006" xlink:to="loc_us-gaap_GoodwillPeriodIncreaseDecrease_f6743dd4-0ab1-493e-8dea-3988f330a18d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_4640fcdf-cbca-4144-b968-873cc7ca37a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_80293749-2b8c-49d6-96c9-1c8395626006" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_4640fcdf-cbca-4144-b968-873cc7ca37a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_44ef6372-17be-4329-ab25-74d9cb5c20a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_80293749-2b8c-49d6-96c9-1c8395626006" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_44ef6372-17be-4329-ab25-74d9cb5c20a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#IntangibleAssetsFutureAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6b74d1a2-c853-4fea-8bae-4ed780c657a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_4b2cfefe-b4c2-4e63-b4f8-937463035847" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6b74d1a2-c853-4fea-8bae-4ed780c657a6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_4b2cfefe-b4c2-4e63-b4f8-937463035847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1d8d802a-57e5-485e-afd7-48d189527276" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6b74d1a2-c853-4fea-8bae-4ed780c657a6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1d8d802a-57e5-485e-afd7-48d189527276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_734ec36a-e233-409a-96af-5d8a62ee479a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6b74d1a2-c853-4fea-8bae-4ed780c657a6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_734ec36a-e233-409a-96af-5d8a62ee479a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_52ccf6ce-49ab-4a45-a076-3e9e7bd80805" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6b74d1a2-c853-4fea-8bae-4ed780c657a6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_52ccf6ce-49ab-4a45-a076-3e9e7bd80805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter_12b839fb-2202-4d71-b112-828ef38a81fb" xlink:href="cpix-20201210.xsd#cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6b74d1a2-c853-4fea-8bae-4ed780c657a6" xlink:to="loc_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter_12b839fb-2202-4d71-b112-828ef38a81fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2ae0daed-080c-482f-a3fe-12fe3191ed31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6b74d1a2-c853-4fea-8bae-4ed780c657a6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2ae0daed-080c-482f-a3fe-12fe3191ed31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilities" xlink:type="simple" xlink:href="cpix-20201210.xsd#OtherCurrentandOtherLongtermLiabilities"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrentAbstract_9ab8213a-76c5-4f46-a5e2-743b342999a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_38605d0d-d380-4847-a345-af8521b312be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_9ab8213a-76c5-4f46-a5e2-743b342999a2" xlink:to="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_38605d0d-d380-4847-a345-af8521b312be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#OtherCurrentandOtherLongtermLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrentAbstract_3d99425e-95ce-4070-ab60-200b9a62ad21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_71f614b2-62a9-4ed1-8fe1-b6635042dbad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_3d99425e-95ce-4070-ab60-200b9a62ad21" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_71f614b2-62a9-4ed1-8fe1-b6635042dbad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_7904bab9-773e-45d2-89ab-9c1366de82a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_3d99425e-95ce-4070-ab60-200b9a62ad21" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_7904bab9-773e-45d2-89ab-9c1366de82a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrentAbstract_886b423d-cd74-4583-b54f-50ccd0ace6bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductSalesRelatedLiabilitiesCurrent_337be1e2-bbc5-4a6a-834a-44faf3ef11bf" xlink:href="cpix-20201210.xsd#cpix_ProductSalesRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_886b423d-cd74-4583-b54f-50ccd0ace6bb" xlink:to="loc_cpix_ProductSalesRelatedLiabilitiesCurrent_337be1e2-bbc5-4a6a-834a-44faf3ef11bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f0e7c7e4-13dd-4ac7-90c4-612a466ed964" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_886b423d-cd74-4583-b54f-50ccd0ace6bb" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f0e7c7e4-13dd-4ac7-90c4-612a466ed964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccruedLiabilitiesStockPayable_4d9f6947-3f04-4998-af18-2dbcf0ca8293" xlink:href="cpix-20201210.xsd#cpix_AccruedLiabilitiesStockPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_886b423d-cd74-4583-b54f-50ccd0ace6bb" xlink:to="loc_cpix_AccruedLiabilitiesStockPayable_4d9f6947-3f04-4998-af18-2dbcf0ca8293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_59958741-f875-4409-8bca-f78b90cdc991" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_886b423d-cd74-4583-b54f-50ccd0ace6bb" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_59958741-f875-4409-8bca-f78b90cdc991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredAcquisitionLiabilityCurrent_f4aa3fc7-6aa4-4820-b1a2-f692a875200a" xlink:href="cpix-20201210.xsd#cpix_DeferredAcquisitionLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_886b423d-cd74-4583-b54f-50ccd0ace6bb" xlink:to="loc_cpix_DeferredAcquisitionLiabilityCurrent_f4aa3fc7-6aa4-4820-b1a2-f692a875200a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccruedLiabilitiesInventoryPurchases_45b2e106-13b7-4fe3-9014-22576afd0950" xlink:href="cpix-20201210.xsd#cpix_AccruedLiabilitiesInventoryPurchases"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_886b423d-cd74-4583-b54f-50ccd0ace6bb" xlink:to="loc_cpix_AccruedLiabilitiesInventoryPurchases_45b2e106-13b7-4fe3-9014-22576afd0950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccruedPaymentForAssetPurchaseCurrent_e415f8f1-e9aa-452f-b997-ca4197272aae" xlink:href="cpix-20201210.xsd#cpix_AccruedPaymentForAssetPurchaseCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_886b423d-cd74-4583-b54f-50ccd0ace6bb" xlink:to="loc_cpix_AccruedPaymentForAssetPurchaseCurrent_e415f8f1-e9aa-452f-b997-ca4197272aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_822fe670-efc7-4271-9623-1e247d281b00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_886b423d-cd74-4583-b54f-50ccd0ace6bb" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_822fe670-efc7-4271-9623-1e247d281b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_829ceacb-9c59-4231-8a06-2da6d28c2372" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_886b423d-cd74-4583-b54f-50ccd0ace6bb" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_829ceacb-9c59-4231-8a06-2da6d28c2372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_d526b37c-493b-45b3-96ac-3bf4481d8644" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_886b423d-cd74-4583-b54f-50ccd0ace6bb" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_d526b37c-493b-45b3-96ac-3bf4481d8644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_b7c9af12-db4a-4385-a32d-fe6b96146742" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_886b423d-cd74-4583-b54f-50ccd0ace6bb" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_b7c9af12-db4a-4385-a32d-fe6b96146742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_b6901702-1558-415c-9001-2d2ec70ad4ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_886b423d-cd74-4583-b54f-50ccd0ace6bb" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_b6901702-1558-415c-9001-2d2ec70ad4ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_e958d6d3-c80f-4e8a-a13c-bd7937fea366" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_886b423d-cd74-4583-b54f-50ccd0ace6bb" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_e958d6d3-c80f-4e8a-a13c-bd7937fea366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Debt" xlink:type="simple" xlink:href="cpix-20201210.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_917ac6f2-f6a5-4ed1-a329-e71e201dae3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_3cf6c07c-9d40-4c30-bdae-078346b7acc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_917ac6f2-f6a5-4ed1-a329-e71e201dae3d" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_3cf6c07c-9d40-4c30-bdae-078346b7acc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/DebtLineofCreditDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#DebtLineofCreditDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/DebtLineofCreditDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1648fa48-b387-4514-9ccf-e3ce37a662ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_4ba67da8-0d48-4309-b524-8729e63b4ce0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1648fa48-b387-4514-9ccf-e3ce37a662ec" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_4ba67da8-0d48-4309-b524-8729e63b4ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_606ea66d-6936-42ad-aae4-889e1b8d28df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_4ba67da8-0d48-4309-b524-8729e63b4ce0" xlink:to="loc_us-gaap_CreditFacilityAxis_606ea66d-6936-42ad-aae4-889e1b8d28df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_22b4913f-aed4-425e-bb5a-eb1228452acf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_606ea66d-6936-42ad-aae4-889e1b8d28df" xlink:to="loc_us-gaap_CreditFacilityDomain_22b4913f-aed4-425e-bb5a-eb1228452acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_d0ffa4f8-ddab-4b2c-be66-8aed1c63f34c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_22b4913f-aed4-425e-bb5a-eb1228452acf" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_d0ffa4f8-ddab-4b2c-be66-8aed1c63f34c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_b64c220d-7fc5-43f8-a05e-7f58e30b5a66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_4ba67da8-0d48-4309-b524-8729e63b4ce0" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_b64c220d-7fc5-43f8-a05e-7f58e30b5a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_eca28b4a-5805-49b6-82ce-8fff98b0695f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_b64c220d-7fc5-43f8-a05e-7f58e30b5a66" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_eca28b4a-5805-49b6-82ce-8fff98b0695f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember_4decf04f-9f84-413b-ba31-e8b13bab0862" xlink:href="cpix-20201210.xsd#cpix_PinnacleBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_eca28b4a-5805-49b6-82ce-8fff98b0695f" xlink:to="loc_cpix_PinnacleBankMember_4decf04f-9f84-413b-ba31-e8b13bab0862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_50cee7f2-1e55-4411-83a3-026f38a5f040" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_4ba67da8-0d48-4309-b524-8729e63b4ce0" xlink:to="loc_us-gaap_DebtInstrumentAxis_50cee7f2-1e55-4411-83a3-026f38a5f040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_421eece8-9593-4a59-a9f7-4dbe08f198ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_50cee7f2-1e55-4411-83a3-026f38a5f040" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_421eece8-9593-4a59-a9f7-4dbe08f198ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SecondAmendmentMember_29926307-d3cc-47dd-b726-a7ce429f6e31" xlink:href="cpix-20201210.xsd#cpix_SecondAmendmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_421eece8-9593-4a59-a9f7-4dbe08f198ac" xlink:to="loc_cpix_SecondAmendmentMember_29926307-d3cc-47dd-b726-a7ce429f6e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_134c11f1-5969-40c8-9f87-627673bf01c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_421eece8-9593-4a59-a9f7-4dbe08f198ac" xlink:to="loc_us-gaap_LineOfCreditMember_134c11f1-5969-40c8-9f87-627673bf01c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_035332f7-490b-40bd-a923-f52e65ebce4d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_4ba67da8-0d48-4309-b524-8729e63b4ce0" xlink:to="loc_srt_RangeAxis_035332f7-490b-40bd-a923-f52e65ebce4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e0dd811c-2fe2-4567-8871-87d9d3f0f7b4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_035332f7-490b-40bd-a923-f52e65ebce4d" xlink:to="loc_srt_RangeMember_e0dd811c-2fe2-4567-8871-87d9d3f0f7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4671f40f-9024-47cc-86cf-8301f1357df5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e0dd811c-2fe2-4567-8871-87d9d3f0f7b4" xlink:to="loc_srt_MinimumMember_4671f40f-9024-47cc-86cf-8301f1357df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1a760e52-1c8a-45ba-85b2-8a38d2dd3d75" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e0dd811c-2fe2-4567-8871-87d9d3f0f7b4" xlink:to="loc_srt_MaximumMember_1a760e52-1c8a-45ba-85b2-8a38d2dd3d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_54f525fb-ebf2-429e-8117-183c6b68ebfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_4ba67da8-0d48-4309-b524-8729e63b4ce0" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_54f525fb-ebf2-429e-8117-183c6b68ebfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f0b2bb43-0e55-4d6b-83ad-400ffcb7980d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_54f525fb-ebf2-429e-8117-183c6b68ebfb" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f0b2bb43-0e55-4d6b-83ad-400ffcb7980d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_fdfa5a90-8406-4098-922e-3af00526f968" xlink:href="cpix-20201210.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_54f525fb-ebf2-429e-8117-183c6b68ebfb" xlink:to="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_fdfa5a90-8406-4098-922e-3af00526f968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_e02aae0b-c548-40e8-a7c2-edc3253b6489" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_54f525fb-ebf2-429e-8117-183c6b68ebfb" xlink:to="loc_us-gaap_LongTermLineOfCredit_e02aae0b-c548-40e8-a7c2-edc3253b6489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7c26cfaa-6253-4a50-a3b3-1963c36c57be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_54f525fb-ebf2-429e-8117-183c6b68ebfb" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7c26cfaa-6253-4a50-a3b3-1963c36c57be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_f4f6e9e2-4173-426d-b72f-4ffbbfd7413d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_54f525fb-ebf2-429e-8117-183c6b68ebfb" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_f4f6e9e2-4173-426d-b72f-4ffbbfd7413d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="cpix-20201210.xsd#ShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_30d86dd2-2be2-4584-8685-395c7a62af49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_aa1139eb-8f28-4f90-b662-e3b6374acaaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_30d86dd2-2be2-4584-8685-395c7a62af49" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_aa1139eb-8f28-4f90-b662-e3b6374acaaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_f511ebe4-e847-4f29-ba8c-25a5fc383c26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_738ce325-82ab-425f-ae3f-60ca3f14bb76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_f511ebe4-e847-4f29-ba8c-25a5fc383c26" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_738ce325-82ab-425f-ae3f-60ca3f14bb76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f04b9c08-f56a-4a5f-bfa5-ded26de4d162" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_738ce325-82ab-425f-ae3f-60ca3f14bb76" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f04b9c08-f56a-4a5f-bfa5-ded26de4d162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2a92e071-fc4d-462d-9df4-ac64dc5d85a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f04b9c08-f56a-4a5f-bfa5-ded26de4d162" xlink:to="loc_us-gaap_EquityComponentDomain_2a92e071-fc4d-462d-9df4-ac64dc5d85a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b0a87ee0-f501-41e1-81f2-ff339fd33bc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2a92e071-fc4d-462d-9df4-ac64dc5d85a3" xlink:to="loc_us-gaap_CommonStockMember_b0a87ee0-f501-41e1-81f2-ff339fd33bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3d93901a-f386-4583-83af-40edd080db54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_738ce325-82ab-425f-ae3f-60ca3f14bb76" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3d93901a-f386-4583-83af-40edd080db54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d952f465-32b0-407c-905f-0fae4f277025" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3d93901a-f386-4583-83af-40edd080db54" xlink:to="loc_us-gaap_ClassOfStockDomain_d952f465-32b0-407c-905f-0fae4f277025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_cce74aa1-b889-48bb-84d9-5acca0a7cebc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d952f465-32b0-407c-905f-0fae4f277025" xlink:to="loc_us-gaap_CommonStockMember_cce74aa1-b889-48bb-84d9-5acca0a7cebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_1fbbf363-ce42-4adc-8e24-6d249d2edb18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_738ce325-82ab-425f-ae3f-60ca3f14bb76" xlink:to="loc_us-gaap_ClassOfStockLineItems_1fbbf363-ce42-4adc-8e24-6d249d2edb18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_InitialPublicOfferingAbstract_cef65d71-1349-4132-84d3-f324ffa7601f" xlink:href="cpix-20201210.xsd#cpix_InitialPublicOfferingAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1fbbf363-ce42-4adc-8e24-6d249d2edb18" xlink:to="loc_cpix_InitialPublicOfferingAbstract_cef65d71-1349-4132-84d3-f324ffa7601f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockTransactionDate_2b373179-3391-4701-9f27-b4e78a670f40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockTransactionDate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_InitialPublicOfferingAbstract_cef65d71-1349-4132-84d3-f324ffa7601f" xlink:to="loc_us-gaap_SaleOfStockTransactionDate_2b373179-3391-4701-9f27-b4e78a670f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7930b04c-a914-4d61-b1db-5dac35e224ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_InitialPublicOfferingAbstract_cef65d71-1349-4132-84d3-f324ffa7601f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7930b04c-a914-4d61-b1db-5dac35e224ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodPricePerShareNewIssues_65783d33-171d-4f38-877b-f6e873879dc6" xlink:href="cpix-20201210.xsd#cpix_StockIssuedDuringPeriodPricePerShareNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_InitialPublicOfferingAbstract_cef65d71-1349-4132-84d3-f324ffa7601f" xlink:to="loc_cpix_StockIssuedDuringPeriodPricePerShareNewIssues_65783d33-171d-4f38-877b-f6e873879dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering_42998bff-d1c3-4fa8-a3fa-4ce315498da2" xlink:href="cpix-20201210.xsd#cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_InitialPublicOfferingAbstract_cef65d71-1349-4132-84d3-f324ffa7601f" xlink:to="loc_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering_42998bff-d1c3-4fa8-a3fa-4ce315498da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts_d80cbe4d-76f5-4879-adcd-198ba7f6a7bb" xlink:href="cpix-20201210.xsd#cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_InitialPublicOfferingAbstract_cef65d71-1349-4132-84d3-f324ffa7601f" xlink:to="loc_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts_d80cbe4d-76f5-4879-adcd-198ba7f6a7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_0717be15-2af5-435b-b39f-d1696e74213d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_InitialPublicOfferingAbstract_cef65d71-1349-4132-84d3-f324ffa7601f" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_0717be15-2af5-435b-b39f-d1696e74213d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_164038ef-ec8e-4aa2-a792-be783335dff1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_InitialPublicOfferingAbstract_cef65d71-1349-4132-84d3-f324ffa7601f" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_164038ef-ec8e-4aa2-a792-be783335dff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering_1fcd3d4c-15fc-46e4-ba0c-86c894266b99" xlink:href="cpix-20201210.xsd#cpix_StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_InitialPublicOfferingAbstract_cef65d71-1349-4132-84d3-f324ffa7601f" xlink:to="loc_cpix_StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering_1fcd3d4c-15fc-46e4-ba0c-86c894266b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PreferredStockAbstract_7394ddd9-1cfc-4c74-bb64-533bb8c49592" xlink:href="cpix-20201210.xsd#cpix_PreferredStockAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1fbbf363-ce42-4adc-8e24-6d249d2edb18" xlink:to="loc_cpix_PreferredStockAbstract_7394ddd9-1cfc-4c74-bb64-533bb8c49592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2284658f-d3bd-4d48-9243-63df1df16a3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_PreferredStockAbstract_7394ddd9-1cfc-4c74-bb64-533bb8c49592" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2284658f-d3bd-4d48-9243-63df1df16a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CommonStockAbstract_6928ff1f-d784-4c99-928c-ba7f99b62840" xlink:href="cpix-20201210.xsd#cpix_CommonStockAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1fbbf363-ce42-4adc-8e24-6d249d2edb18" xlink:to="loc_cpix_CommonStockAbstract_6928ff1f-d784-4c99-928c-ba7f99b62840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_d36200b8-914a-4c16-b3f7-d4c3feb955ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_CommonStockAbstract_6928ff1f-d784-4c99-928c-ba7f99b62840" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_d36200b8-914a-4c16-b3f7-d4c3feb955ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding_5e8c5bd9-28d0-4164-a86c-ddd0744d992a" xlink:href="cpix-20201210.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_CommonStockAbstract_6928ff1f-d784-4c99-928c-ba7f99b62840" xlink:to="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding_5e8c5bd9-28d0-4164-a86c-ddd0744d992a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_9a37de78-27fa-4be0-8b22-7b6d4818215b" xlink:href="cpix-20201210.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_CommonStockAbstract_6928ff1f-d784-4c99-928c-ba7f99b62840" xlink:to="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_9a37de78-27fa-4be0-8b22-7b6d4818215b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityWarrantsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#ShareholdersEquityWarrantsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityWarrantsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_1f0bfd5f-214d-44f6-8bd9-2a8454edf0bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_850395a2-0585-4f6e-85db-f35a34aa4e5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_1f0bfd5f-214d-44f6-8bd9-2a8454edf0bb" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_850395a2-0585-4f6e-85db-f35a34aa4e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_3c3721ac-ab41-4976-8f99-0a6bc486f76b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_850395a2-0585-4f6e-85db-f35a34aa4e5d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_3c3721ac-ab41-4976-8f99-0a6bc486f76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_74edfd61-b3f2-4aab-b1dd-9848c02d10c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_3c3721ac-ab41-4976-8f99-0a6bc486f76b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_74edfd61-b3f2-4aab-b1dd-9848c02d10c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_WarrantsIssuedInConsiderationOf2006CreditFacilityAmendmentMember_d4f69c38-fe56-4cb4-992b-32a77c742b8d" xlink:href="cpix-20201210.xsd#cpix_WarrantsIssuedInConsiderationOf2006CreditFacilityAmendmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_74edfd61-b3f2-4aab-b1dd-9848c02d10c2" xlink:to="loc_cpix_WarrantsIssuedInConsiderationOf2006CreditFacilityAmendmentMember_d4f69c38-fe56-4cb4-992b-32a77c742b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember_e043d832-7486-486b-8e4f-d3033e46753c" xlink:href="cpix-20201210.xsd#cpix_WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_74edfd61-b3f2-4aab-b1dd-9848c02d10c2" xlink:to="loc_cpix_WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember_e043d832-7486-486b-8e4f-d3033e46753c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_23618661-9c75-4c0f-ac40-de56dfaaff0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_850395a2-0585-4f6e-85db-f35a34aa4e5d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_23618661-9c75-4c0f-ac40-de56dfaaff0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_9eaf9906-3d0a-401e-a8ae-24884623aaf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_23618661-9c75-4c0f-ac40-de56dfaaff0f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_9eaf9906-3d0a-401e-a8ae-24884623aaf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_42b51d1d-c77e-4d97-90fd-1fd868cb5c95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_23618661-9c75-4c0f-ac40-de56dfaaff0f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_42b51d1d-c77e-4d97-90fd-1fd868cb5c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_d0d4d8bd-b157-4da2-9b48-eb4bbf76fb83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_d91f6e32-cc5b-4801-9a96-ac6314fd4f4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_d0d4d8bd-b157-4da2-9b48-eb4bbf76fb83" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_d91f6e32-cc5b-4801-9a96-ac6314fd4f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_0770d02f-c7e4-465e-9b04-c9bad8be9402" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_d91f6e32-cc5b-4801-9a96-ac6314fd4f4c" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_0770d02f-c7e4-465e-9b04-c9bad8be9402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_92cedbd7-ed47-43e6-bbd0-67414f57a28f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_0770d02f-c7e4-465e-9b04-c9bad8be9402" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_92cedbd7-ed47-43e6-bbd0-67414f57a28f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareRepurchaseProgramAuthorizedIn2010Member_09b30f4e-c979-4215-a5a4-974014425dfd" xlink:href="cpix-20201210.xsd#cpix_ShareRepurchaseProgramAuthorizedIn2010Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_92cedbd7-ed47-43e6-bbd0-67414f57a28f" xlink:to="loc_cpix_ShareRepurchaseProgramAuthorizedIn2010Member_09b30f4e-c979-4215-a5a4-974014425dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharesRepurchaseActivityTypeAxis_5d4f7d57-35a1-407e-8668-d9c3d1801d1d" xlink:href="cpix-20201210.xsd#cpix_SharesRepurchaseActivityTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_d91f6e32-cc5b-4801-9a96-ac6314fd4f4c" xlink:to="loc_cpix_SharesRepurchaseActivityTypeAxis_5d4f7d57-35a1-407e-8668-d9c3d1801d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharesRepurchaseActivityTypeDomain_9a2f317b-6487-4bf2-8ff6-02c2b7a1c26c" xlink:href="cpix-20201210.xsd#cpix_SharesRepurchaseActivityTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_SharesRepurchaseActivityTypeAxis_5d4f7d57-35a1-407e-8668-d9c3d1801d1d" xlink:to="loc_cpix_SharesRepurchaseActivityTypeDomain_9a2f317b-6487-4bf2-8ff6-02c2b7a1c26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember_c0f22838-d6a9-493f-a144-7d29e7b78364" xlink:href="cpix-20201210.xsd#cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_SharesRepurchaseActivityTypeDomain_9a2f317b-6487-4bf2-8ff6-02c2b7a1c26c" xlink:to="loc_cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember_c0f22838-d6a9-493f-a144-7d29e7b78364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_4ae2ab39-6795-419f-8968-300b44b7314e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_d91f6e32-cc5b-4801-9a96-ac6314fd4f4c" xlink:to="loc_dei_LegalEntityAxis_4ae2ab39-6795-419f-8968-300b44b7314e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_5803dd86-9e09-4b81-b997-f44b6695c7a3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_4ae2ab39-6795-419f-8968-300b44b7314e" xlink:to="loc_dei_EntityDomain_5803dd86-9e09-4b81-b997-f44b6695c7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CumberlandEmergingTechnologiesIncMember_ed098290-d4e6-4459-b28e-a0de9614ac7a" xlink:href="cpix-20201210.xsd#cpix_CumberlandEmergingTechnologiesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_5803dd86-9e09-4b81-b997-f44b6695c7a3" xlink:to="loc_cpix_CumberlandEmergingTechnologiesIncMember_ed098290-d4e6-4459-b28e-a0de9614ac7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d46efc63-d3f1-40c9-afb6-c45242656e7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_d91f6e32-cc5b-4801-9a96-ac6314fd4f4c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d46efc63-d3f1-40c9-afb6-c45242656e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b5ef989f-219e-4d50-a7cd-6c3cda2600c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d46efc63-d3f1-40c9-afb6-c45242656e7c" xlink:to="loc_us-gaap_EquityComponentDomain_b5ef989f-219e-4d50-a7cd-6c3cda2600c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e50be7b6-c24f-4317-9742-58fbde42edf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b5ef989f-219e-4d50-a7cd-6c3cda2600c3" xlink:to="loc_us-gaap_CommonStockMember_e50be7b6-c24f-4317-9742-58fbde42edf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b3bf3e26-105c-4e37-9e84-dca741f4fdef" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_d91f6e32-cc5b-4801-9a96-ac6314fd4f4c" xlink:to="loc_srt_CounterpartyNameAxis_b3bf3e26-105c-4e37-9e84-dca741f4fdef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2e7c340e-3c41-4784-980e-19a366fead24" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_b3bf3e26-105c-4e37-9e84-dca741f4fdef" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2e7c340e-3c41-4784-980e-19a366fead24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_702c7fa4-3975-4116-889a-28fe17134c6d" xlink:href="cpix-20201210.xsd#cpix_HongKongWinHealthPharmaGroupCoLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2e7c340e-3c41-4784-980e-19a366fead24" xlink:to="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_702c7fa4-3975-4116-889a-28fe17134c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_GloriaPharmaceuticalsMember_e0304dd5-51ec-466f-bf97-ea14a4353a9f" xlink:href="cpix-20201210.xsd#cpix_GloriaPharmaceuticalsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2e7c340e-3c41-4784-980e-19a366fead24" xlink:to="loc_cpix_GloriaPharmaceuticalsMember_e0304dd5-51ec-466f-bf97-ea14a4353a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NordicMember_c755f554-48b4-474e-ac33-61f45b253860" xlink:href="cpix-20201210.xsd#cpix_NordicMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2e7c340e-3c41-4784-980e-19a366fead24" xlink:to="loc_cpix_NordicMember_c755f554-48b4-474e-ac33-61f45b253860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_dd766272-ac5b-429d-92ea-a654314f34d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_d91f6e32-cc5b-4801-9a96-ac6314fd4f4c" xlink:to="loc_us-gaap_EquityClassOfTreasuryStockLineItems_dd766272-ac5b-429d-92ea-a654314f34d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_4f73d204-3b48-41e8-8f42-f6ea5f73aa26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_dd766272-ac5b-429d-92ea-a654314f34d1" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_4f73d204-3b48-41e8-8f42-f6ea5f73aa26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_1c98126c-971f-438c-b106-82a2275a37da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_dd766272-ac5b-429d-92ea-a654314f34d1" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_1c98126c-971f-438c-b106-82a2275a37da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_2006521e-105e-46ff-9ffd-b8922e6e6465" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_dd766272-ac5b-429d-92ea-a654314f34d1" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_2006521e-105e-46ff-9ffd-b8922e6e6465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_7677d622-6ab3-4fb0-a03b-7410eb384561" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_dd766272-ac5b-429d-92ea-a654314f34d1" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_7677d622-6ab3-4fb0-a03b-7410eb384561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_88589b38-a18d-4b96-8d04-85989d068f11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_dd766272-ac5b-429d-92ea-a654314f34d1" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_88589b38-a18d-4b96-8d04-85989d068f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPurchaseOfShares_7be1ae41-dac9-4380-88a9-03cf28aa6dd2" xlink:href="cpix-20201210.xsd#cpix_SubsidiaryInvestmentPurchaseOfShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_dd766272-ac5b-429d-92ea-a654314f34d1" xlink:to="loc_cpix_SubsidiaryInvestmentPurchaseOfShares_7be1ae41-dac9-4380-88a9-03cf28aa6dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_bc30794c-efe2-4982-88e1-04b3022e84d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_dd766272-ac5b-429d-92ea-a654314f34d1" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_bc30794c-efe2-4982-88e1-04b3022e84d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LoansForgiveninExchangeForShareIssuedAmount_39a760cd-f70a-4302-b496-27033346d4ac" xlink:href="cpix-20201210.xsd#cpix_LoansForgiveninExchangeForShareIssuedAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_dd766272-ac5b-429d-92ea-a654314f34d1" xlink:to="loc_cpix_LoansForgiveninExchangeForShareIssuedAmount_39a760cd-f70a-4302-b496-27033346d4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_9f2833a9-320f-47b0-874b-270eca14248f" xlink:href="cpix-20201210.xsd#cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_dd766272-ac5b-429d-92ea-a654314f34d1" xlink:to="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_9f2833a9-320f-47b0-874b-270eca14248f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_6298fc58-56a5-48fa-a90a-2e63af903445" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_dd766272-ac5b-429d-92ea-a654314f34d1" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_6298fc58-56a5-48fa-a90a-2e63af903445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharebasedCompensationCharitableContributionofSharesShares_855d8045-e6c9-431c-bfd1-5294149fa080" xlink:href="cpix-20201210.xsd#cpix_SharebasedCompensationCharitableContributionofSharesShares"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_dd766272-ac5b-429d-92ea-a654314f34d1" xlink:to="loc_cpix_SharebasedCompensationCharitableContributionofSharesShares_855d8045-e6c9-431c-bfd1-5294149fa080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions_0032d733-043f-4375-ad52-2171f7bd02a0" xlink:href="cpix-20201210.xsd#cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_dd766272-ac5b-429d-92ea-a654314f34d1" xlink:to="loc_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions_0032d733-043f-4375-ad52-2171f7bd02a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_fb5be0ae-80c1-45af-9ba1-286b9d8e7432" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_dd766272-ac5b-429d-92ea-a654314f34d1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_fb5be0ae-80c1-45af-9ba1-286b9d8e7432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_de30673e-cf17-4cb3-9239-4a982a912484" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_dd766272-ac5b-429d-92ea-a654314f34d1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_de30673e-cf17-4cb3-9239-4a982a912484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="simple" xlink:href="cpix-20201210.xsd#EarningsLossPerShare"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b73dfdcc-8b6e-4673-b0b2-397319205805" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_83f6281d-bd18-4921-bb53-078371575b93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b73dfdcc-8b6e-4673-b0b2-397319205805" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_83f6281d-bd18-4921-bb53-078371575b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#EarningsLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d074ae76-c8aa-4173-bdc9-9b060d858c11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_17d31324-7537-43d6-942c-819c12bf4dcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d074ae76-c8aa-4173-bdc9-9b060d858c11" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_17d31324-7537-43d6-942c-819c12bf4dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_6403d61a-5e33-4fbd-90f4-f9aad5de2037" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d074ae76-c8aa-4173-bdc9-9b060d858c11" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_6403d61a-5e33-4fbd-90f4-f9aad5de2037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a634aa1e-4311-4b21-8ab7-e7cd6d7e5c65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NumeratorAbstract_9a9ef540-b620-4161-9b63-4364c4f7b98f" xlink:href="cpix-20201210.xsd#cpix_NumeratorAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a634aa1e-4311-4b21-8ab7-e7cd6d7e5c65" xlink:to="loc_cpix_NumeratorAbstract_9a9ef540-b620-4161-9b63-4364c4f7b98f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_ef83c253-3959-4036-b985-1938e2e426f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_9a9ef540-b620-4161-9b63-4364c4f7b98f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_ef83c253-3959-4036-b985-1938e2e426f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_52642b9f-2833-4445-8be7-0fe1c94eabee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_9a9ef540-b620-4161-9b63-4364c4f7b98f" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_52642b9f-2833-4445-8be7-0fe1c94eabee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8c7b0e87-136f-4916-a49f-a80d0bd055b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_9a9ef540-b620-4161-9b63-4364c4f7b98f" xlink:to="loc_us-gaap_ProfitLoss_8c7b0e87-136f-4916-a49f-a80d0bd055b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f81ad34c-ebb7-4a9c-9a5f-6cabbddebf5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_9a9ef540-b620-4161-9b63-4364c4f7b98f" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f81ad34c-ebb7-4a9c-9a5f-6cabbddebf5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_460f32d4-5168-49ca-be2e-5c8a54947191" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_9a9ef540-b620-4161-9b63-4364c4f7b98f" xlink:to="loc_us-gaap_NetIncomeLoss_460f32d4-5168-49ca-be2e-5c8a54947191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DenominatorAbstract_8bfcdd74-56c6-4017-b79e-741929c056c3" xlink:href="cpix-20201210.xsd#cpix_DenominatorAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a634aa1e-4311-4b21-8ab7-e7cd6d7e5c65" xlink:to="loc_cpix_DenominatorAbstract_8bfcdd74-56c6-4017-b79e-741929c056c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2852c7d4-d9a7-4d7c-af42-5aeeebbdbbff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DenominatorAbstract_8bfcdd74-56c6-4017-b79e-741929c056c3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2852c7d4-d9a7-4d7c-af42-5aeeebbdbbff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4be55018-1a69-4911-b758-202c5f222f74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DenominatorAbstract_8bfcdd74-56c6-4017-b79e-741929c056c3" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4be55018-1a69-4911-b758-202c5f222f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_76127e1e-ca3e-4713-a8fc-4febcbf3a7a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DenominatorAbstract_8bfcdd74-56c6-4017-b79e-741929c056c3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_76127e1e-ca3e-4713-a8fc-4febcbf3a7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#EarningsLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9c250583-1966-4046-84d1-86e7b9c4256e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_551d31ae-e4c5-4e3f-a62d-df1f7d7dc145" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9c250583-1966-4046-84d1-86e7b9c4256e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_551d31ae-e4c5-4e3f-a62d-df1f7d7dc145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cpix-20201210.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_771a2427-f132-4d99-9169-8c952df7953b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_d212f39d-a59f-4a9c-a7be-923330938297" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_771a2427-f132-4d99-9169-8c952df7953b" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_d212f39d-a59f-4a9c-a7be-923330938297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1115aefd-430a-4c8c-8864-ca4477dd2682" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_9201f622-c5bc-4565-905d-de251ddfd250" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1115aefd-430a-4c8c-8864-ca4477dd2682" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_9201f622-c5bc-4565-905d-de251ddfd250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_2f7dc475-0b29-4f1e-b010-b36e16539696" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1115aefd-430a-4c8c-8864-ca4477dd2682" xlink:to="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_2f7dc475-0b29-4f1e-b010-b36e16539696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_5e6a4d50-7afc-4f4c-a00d-90cb67ce0400" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1115aefd-430a-4c8c-8864-ca4477dd2682" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_5e6a4d50-7afc-4f4c-a00d-90cb67ce0400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_da2d2824-a545-4f1b-9ad0-2ec71573f91e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1115aefd-430a-4c8c-8864-ca4477dd2682" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_da2d2824-a545-4f1b-9ad0-2ec71573f91e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#IncomeTaxesOperatingLossCarryforwardsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1f61f8ec-99a6-4f4a-a03a-0f0f7c4d9e9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_c5ddc622-1569-45d2-b6a3-dbd59b29756c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1f61f8ec-99a6-4f4a-a03a-0f0f7c4d9e9f" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_c5ddc622-1569-45d2-b6a3-dbd59b29756c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_414508a8-4d0e-44a9-abc5-3217bc6cc343" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_c5ddc622-1569-45d2-b6a3-dbd59b29756c" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_414508a8-4d0e-44a9-abc5-3217bc6cc343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_79cceda4-6003-4243-b68c-9129836db29e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_414508a8-4d0e-44a9-abc5-3217bc6cc343" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_79cceda4-6003-4243-b68c-9129836db29e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_fe7e4412-9c17-4fc5-9b8f-e4713403c53d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_79cceda4-6003-4243-b68c-9129836db29e" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_fe7e4412-9c17-4fc5-9b8f-e4713403c53d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_4433f449-42d3-4292-9560-9ff03de25938" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_79cceda4-6003-4243-b68c-9129836db29e" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_4433f449-42d3-4292-9560-9ff03de25938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_61235add-c2b4-42de-835b-ee4c3f75c7b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_c5ddc622-1569-45d2-b6a3-dbd59b29756c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_61235add-c2b4-42de-835b-ee4c3f75c7b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_26500e47-cb08-485e-9e12-eaf02e472c0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_61235add-c2b4-42de-835b-ee4c3f75c7b5" xlink:to="loc_us-gaap_EquityComponentDomain_26500e47-cb08-485e-9e12-eaf02e472c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_de3234a7-f860-4523-8071-1c457d004ae2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_26500e47-cb08-485e-9e12-eaf02e472c0e" xlink:to="loc_us-gaap_RetainedEarningsMember_de3234a7-f860-4523-8071-1c457d004ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_5de2855f-338c-4efa-9ce4-a56ecb14a83a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_c5ddc622-1569-45d2-b6a3-dbd59b29756c" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_5de2855f-338c-4efa-9ce4-a56ecb14a83a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_4e70cb2a-c13e-4b39-8bee-695ec78557f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_5de2855f-338c-4efa-9ce4-a56ecb14a83a" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_4e70cb2a-c13e-4b39-8bee-695ec78557f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_3b21859a-4e03-42cb-91fe-80168a356d84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_4e70cb2a-c13e-4b39-8bee-695ec78557f4" xlink:to="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_3b21859a-4e03-42cb-91fe-80168a356d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_713eadf9-0642-42ce-850a-c964b9519444" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_c5ddc622-1569-45d2-b6a3-dbd59b29756c" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_713eadf9-0642-42ce-850a-c964b9519444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_c6bf556c-c587-4168-b0e6-6451be20f302" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_713eadf9-0642-42ce-850a-c964b9519444" xlink:to="loc_us-gaap_OperatingLossCarryforwards_c6bf556c-c587-4168-b0e6-6451be20f302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f7bea890-2c6e-4848-9309-0d47b9fcd30f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_713eadf9-0642-42ce-850a-c964b9519444" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f7bea890-2c6e-4848-9309-0d47b9fcd30f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_f45b9fab-7c56-45ac-b818-ff09c2fd7f36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_713eadf9-0642-42ce-850a-c964b9519444" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_f45b9fab-7c56-45ac-b818-ff09c2fd7f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_82fd0f1a-5ef0-4ca1-810e-29315b8b3faa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_713eadf9-0642-42ce-850a-c964b9519444" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_82fd0f1a-5ef0-4ca1-810e-29315b8b3faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_de01060e-0a4e-4b12-8869-0525a9bf0141" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_cae1fa66-c646-4438-8c94-e856277db0dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_de01060e-0a4e-4b12-8869-0525a9bf0141" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_cae1fa66-c646-4438-8c94-e856277db0dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_1ff4be4a-2583-49ec-8b55-14ba925f8d7c" xlink:href="cpix-20201210.xsd#cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_cae1fa66-c646-4438-8c94-e856277db0dc" xlink:to="loc_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_1ff4be4a-2583-49ec-8b55-14ba925f8d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles_cfce448f-28b6-49c5-bb64-cdd51ed5c00a" xlink:href="cpix-20201210.xsd#cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_cae1fa66-c646-4438-8c94-e856277db0dc" xlink:to="loc_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles_cfce448f-28b6-49c5-bb64-cdd51ed5c00a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_10eaaa14-434a-4674-9636-344e47c447d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_cae1fa66-c646-4438-8c94-e856277db0dc" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_10eaaa14-434a-4674-9636-344e47c447d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct_d8f4331d-2418-4d85-871b-39d812d90275" xlink:href="cpix-20201210.xsd#cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_cae1fa66-c646-4438-8c94-e856277db0dc" xlink:to="loc_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct_d8f4331d-2418-4d85-871b-39d812d90275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_bd14d30f-aef3-4dd2-9885-971231cf28cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_cae1fa66-c646-4438-8c94-e856277db0dc" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_bd14d30f-aef3-4dd2-9885-971231cf28cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsDeferredCharges_e4e038a9-20a4-4516-8a14-cc8b22c21827" xlink:href="cpix-20201210.xsd#cpix_DeferredTaxAssetsDeferredCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_cae1fa66-c646-4438-8c94-e856277db0dc" xlink:to="loc_cpix_DeferredTaxAssetsDeferredCharges_e4e038a9-20a4-4516-8a14-cc8b22c21827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_11a79434-badb-445b-b840-47d3f948cb0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_cae1fa66-c646-4438-8c94-e856277db0dc" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_11a79434-badb-445b-b840-47d3f948cb0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_97ca06df-2722-4652-9617-6b0cd151123c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_cae1fa66-c646-4438-8c94-e856277db0dc" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_97ca06df-2722-4652-9617-6b0cd151123c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_4273b95b-62dd-43d0-9bb4-f0c3d4337995" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_de01060e-0a4e-4b12-8869-0525a9bf0141" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_4273b95b-62dd-43d0-9bb4-f0c3d4337995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_8d4e93e8-fc62-4e30-a31a-4fdbb4ad58f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_4273b95b-62dd-43d0-9bb4-f0c3d4337995" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_8d4e93e8-fc62-4e30-a31a-4fdbb4ad58f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NetDeferredTaxAssetsGross_55b14454-e2ca-418c-b195-63df937588b8" xlink:href="cpix-20201210.xsd#cpix_NetDeferredTaxAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_4273b95b-62dd-43d0-9bb4-f0c3d4337995" xlink:to="loc_cpix_NetDeferredTaxAssetsGross_55b14454-e2ca-418c-b195-63df937588b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_3a868279-9a4d-4116-91fa-dd65c75de7f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_4273b95b-62dd-43d0-9bb4-f0c3d4337995" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_3a868279-9a4d-4116-91fa-dd65c75de7f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_e0358235-ca64-4b95-a71c-631f58674488" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_4273b95b-62dd-43d0-9bb4-f0c3d4337995" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_e0358235-ca64-4b95-a71c-631f58674488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_59df05e2-373d-48b8-bb97-438f0bdc0ac3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_f44878ca-8b28-44c7-be3c-df7fdb19a04c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_59df05e2-373d-48b8-bb97-438f0bdc0ac3" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_f44878ca-8b28-44c7-be3c-df7fdb19a04c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTimePeriodAxis_f546368c-b5e4-4b94-a167-0177e9137912" xlink:href="cpix-20201210.xsd#cpix_ExpirationTimePeriodAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_f44878ca-8b28-44c7-be3c-df7fdb19a04c" xlink:to="loc_cpix_ExpirationTimePeriodAxis_f546368c-b5e4-4b94-a167-0177e9137912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTimePeriodDomain_d31efa41-3a0a-4c5a-bf16-47a06700b1fd" xlink:href="cpix-20201210.xsd#cpix_ExpirationTimePeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ExpirationTimePeriodAxis_f546368c-b5e4-4b94-a167-0177e9137912" xlink:to="loc_cpix_ExpirationTimePeriodDomain_d31efa41-3a0a-4c5a-bf16-47a06700b1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermOneMember_9602f691-006c-4851-b0e5-25b5b34adf12" xlink:href="cpix-20201210.xsd#cpix_ExpirationTermOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ExpirationTimePeriodDomain_d31efa41-3a0a-4c5a-bf16-47a06700b1fd" xlink:to="loc_cpix_ExpirationTermOneMember_9602f691-006c-4851-b0e5-25b5b34adf12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermTwoMember_e85ed622-01e5-4876-93d3-caa1a0e8f9e0" xlink:href="cpix-20201210.xsd#cpix_ExpirationTermTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ExpirationTimePeriodDomain_d31efa41-3a0a-4c5a-bf16-47a06700b1fd" xlink:to="loc_cpix_ExpirationTermTwoMember_e85ed622-01e5-4876-93d3-caa1a0e8f9e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermThreeMember_c3eba813-2f24-43dc-b9d1-2914117a1226" xlink:href="cpix-20201210.xsd#cpix_ExpirationTermThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ExpirationTimePeriodDomain_d31efa41-3a0a-4c5a-bf16-47a06700b1fd" xlink:to="loc_cpix_ExpirationTermThreeMember_c3eba813-2f24-43dc-b9d1-2914117a1226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermFourMember_d1236bc3-bcd0-4cc7-8d65-3a441cbef359" xlink:href="cpix-20201210.xsd#cpix_ExpirationTermFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ExpirationTimePeriodDomain_d31efa41-3a0a-4c5a-bf16-47a06700b1fd" xlink:to="loc_cpix_ExpirationTermFourMember_d1236bc3-bcd0-4cc7-8d65-3a441cbef359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IndefiniteMember_05c87a99-4f29-4fd4-a6d1-f633f8cf184c" xlink:href="cpix-20201210.xsd#cpix_IndefiniteMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ExpirationTimePeriodDomain_d31efa41-3a0a-4c5a-bf16-47a06700b1fd" xlink:to="loc_cpix_IndefiniteMember_05c87a99-4f29-4fd4-a6d1-f633f8cf184c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_8ac2b588-4868-4e5e-b582-21131b68019c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_f44878ca-8b28-44c7-be3c-df7fdb19a04c" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_8ac2b588-4868-4e5e-b582-21131b68019c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_6fc4bb59-f01b-4401-9dff-d96159bd67c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_8ac2b588-4868-4e5e-b582-21131b68019c" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_6fc4bb59-f01b-4401-9dff-d96159bd67c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_9978a86c-c5ba-4563-bec7-767c3da3ace7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_6fc4bb59-f01b-4401-9dff-d96159bd67c0" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_9978a86c-c5ba-4563-bec7-767c3da3ace7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_2c24cf9c-e535-4b34-9a31-f2c891c3212a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_6fc4bb59-f01b-4401-9dff-d96159bd67c0" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_2c24cf9c-e535-4b34-9a31-f2c891c3212a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_6d2e9c5f-ee23-4419-9c87-cc611eadc6f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_f44878ca-8b28-44c7-be3c-df7fdb19a04c" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_6d2e9c5f-ee23-4419-9c87-cc611eadc6f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_ebe97208-3659-4734-aba4-fc8df50afa19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6d2e9c5f-ee23-4419-9c87-cc611eadc6f4" xlink:to="loc_us-gaap_OperatingLossCarryforwards_ebe97208-3659-4734-aba4-fc8df50afa19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4d015ad1-31aa-4d8f-a1d9-d5f66760a4a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_ce32b0b0-9952-4393-90a1-021fc5644f2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4d015ad1-31aa-4d8f-a1d9-d5f66760a4a3" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_ce32b0b0-9952-4393-90a1-021fc5644f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_86324325-fd07-4bef-8afd-c2e3bdc9fad0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_ce32b0b0-9952-4393-90a1-021fc5644f2d" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_86324325-fd07-4bef-8afd-c2e3bdc9fad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_63d76608-7da5-4ccc-850b-61ab711154f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_ce32b0b0-9952-4393-90a1-021fc5644f2d" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_63d76608-7da5-4ccc-850b-61ab711154f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_644487c9-5a9d-492c-afa8-7c3a13a372b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_ce32b0b0-9952-4393-90a1-021fc5644f2d" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_644487c9-5a9d-492c-afa8-7c3a13a372b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3eb7f43a-120e-4320-88d0-cac48c8ddc18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4d015ad1-31aa-4d8f-a1d9-d5f66760a4a3" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3eb7f43a-120e-4320-88d0-cac48c8ddc18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_3dddb341-974b-4c12-95fb-8f66d4ea9a1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3eb7f43a-120e-4320-88d0-cac48c8ddc18" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_3dddb341-974b-4c12-95fb-8f66d4ea9a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_55b83786-85b1-4101-a233-9986f3e666ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3eb7f43a-120e-4320-88d0-cac48c8ddc18" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_55b83786-85b1-4101-a233-9986f3e666ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOtherTaxExpenseBenefit_dc7de8a2-977f-4109-9e2a-82fe443f5459" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOtherTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3eb7f43a-120e-4320-88d0-cac48c8ddc18" xlink:to="loc_us-gaap_DeferredOtherTaxExpenseBenefit_dc7de8a2-977f-4109-9e2a-82fe443f5459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_172d0112-e3ae-4b4b-bdc5-c86dfa88eeab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4d015ad1-31aa-4d8f-a1d9-d5f66760a4a3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_172d0112-e3ae-4b4b-bdc5-c86dfa88eeab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c8b5a295-a99d-4e08-b179-9f547f538156" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_d73fbc4d-99cb-4ebf-b0a4-9f1f32e665d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c8b5a295-a99d-4e08-b179-9f547f538156" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_d73fbc4d-99cb-4ebf-b0a4-9f1f32e665d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_2def74a1-4872-422f-805a-a9be7c30e349" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c8b5a295-a99d-4e08-b179-9f547f538156" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_2def74a1-4872-422f-805a-a9be7c30e349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_7b7fb213-161f-4898-82bf-d42a8f1446ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c8b5a295-a99d-4e08-b179-9f547f538156" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_7b7fb213-161f-4898-82bf-d42a8f1446ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_ae0c17cd-aa2f-4da6-a543-8b6253ba0653" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c8b5a295-a99d-4e08-b179-9f547f538156" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_ae0c17cd-aa2f-4da6-a543-8b6253ba0653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_5bb75c8c-d9bb-4cb9-b3ed-2f9f53741ade" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c8b5a295-a99d-4e08-b179-9f547f538156" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_5bb75c8c-d9bb-4cb9-b3ed-2f9f53741ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_411aea41-7f67-47df-ade8-ad8bb162355f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c8b5a295-a99d-4e08-b179-9f547f538156" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_411aea41-7f67-47df-ade8-ad8bb162355f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_51a9fa6f-9fb1-4ccf-a4c9-abd00c1b6ded" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c8b5a295-a99d-4e08-b179-9f547f538156" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_51a9fa6f-9fb1-4ccf-a4c9-abd00c1b6ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8b172b6f-5933-4608-8066-3c63cb9b3e8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c8b5a295-a99d-4e08-b179-9f547f538156" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8b172b6f-5933-4608-8066-3c63cb9b3e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlans" xlink:type="simple" xlink:href="cpix-20201210.xsd#StockBasedCompensationPlans"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2081b116-bb6f-414c-a665-9969b2ea3450" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6d7ec8fb-88dd-4128-a769-2f77ce98213d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2081b116-bb6f-414c-a665-9969b2ea3450" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6d7ec8fb-88dd-4128-a769-2f77ce98213d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#StockBasedCompensationPlansTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fc69bb5f-a4d2-4a5b-8a61-94bc379c4691" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_523580f0-4ec1-44ac-b280-0ae233e86b67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fc69bb5f-a4d2-4a5b-8a61-94bc379c4691" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_523580f0-4ec1-44ac-b280-0ae233e86b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_a4f8cb59-089d-4d2b-ad9a-2d719731f1ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fc69bb5f-a4d2-4a5b-8a61-94bc379c4691" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_a4f8cb59-089d-4d2b-ad9a-2d719731f1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ScheduleOfStockOptionActivityAdditionalDisclosuresTableTextBlock_06eb2ef9-57ac-48ff-9208-befa70f39447" xlink:href="cpix-20201210.xsd#cpix_ScheduleOfStockOptionActivityAdditionalDisclosuresTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fc69bb5f-a4d2-4a5b-8a61-94bc379c4691" xlink:to="loc_cpix_ScheduleOfStockOptionActivityAdditionalDisclosuresTableTextBlock_06eb2ef9-57ac-48ff-9208-befa70f39447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_2480dbef-f252-46ee-bb79-e9688d5a41af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fc69bb5f-a4d2-4a5b-8a61-94bc379c4691" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_2480dbef-f252-46ee-bb79-e9688d5a41af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#StockBasedCompensationPlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ea6250c6-a036-4ddc-b96d-758f94f32bb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0d18e818-8ee8-4eeb-88ef-f1e306acdec5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ea6250c6-a036-4ddc-b96d-758f94f32bb6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0d18e818-8ee8-4eeb-88ef-f1e306acdec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_508bb66b-ce9f-4d4e-9fe8-6c35d818d4e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0d18e818-8ee8-4eeb-88ef-f1e306acdec5" xlink:to="loc_us-gaap_AwardTypeAxis_508bb66b-ce9f-4d4e-9fe8-6c35d818d4e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_da3d0d8c-d9bc-4d7b-b779-97b36dff8eb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_508bb66b-ce9f-4d4e-9fe8-6c35d818d4e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_da3d0d8c-d9bc-4d7b-b779-97b36dff8eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_37299fef-7c92-4973-80ba-9666c76aba55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_da3d0d8c-d9bc-4d7b-b779-97b36dff8eb4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_37299fef-7c92-4973-80ba-9666c76aba55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_836af22b-c13d-47b7-b044-4e3fcbe2720d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_da3d0d8c-d9bc-4d7b-b779-97b36dff8eb4" xlink:to="loc_us-gaap_RestrictedStockMember_836af22b-c13d-47b7-b044-4e3fcbe2720d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_14c087bf-fef7-4715-8b2c-8f5551b5334e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0d18e818-8ee8-4eeb-88ef-f1e306acdec5" xlink:to="loc_us-gaap_PlanNameAxis_14c087bf-fef7-4715-8b2c-8f5551b5334e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_500c7616-867c-4998-986c-c16208755ede" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_14c087bf-fef7-4715-8b2c-8f5551b5334e" xlink:to="loc_us-gaap_PlanNameDomain_500c7616-867c-4998-986c-c16208755ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LongTermIncentiveCompensationPlan2007Member_22500a83-d6a6-4b5b-a451-793140fc0423" xlink:href="cpix-20201210.xsd#cpix_LongTermIncentiveCompensationPlan2007Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_500c7616-867c-4998-986c-c16208755ede" xlink:to="loc_cpix_LongTermIncentiveCompensationPlan2007Member_22500a83-d6a6-4b5b-a451-793140fc0423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DirectorsIncentivePlan2007Member_b937bdce-87cf-4ef2-9d0c-0183a7b7265d" xlink:href="cpix-20201210.xsd#cpix_DirectorsIncentivePlan2007Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_500c7616-867c-4998-986c-c16208755ede" xlink:to="loc_cpix_DirectorsIncentivePlan2007Member_b937bdce-87cf-4ef2-9d0c-0183a7b7265d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_3071bb94-059c-4b9e-9c91-58eefff76ac1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0d18e818-8ee8-4eeb-88ef-f1e306acdec5" xlink:to="loc_srt_TitleOfIndividualAxis_3071bb94-059c-4b9e-9c91-58eefff76ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_58697528-4e72-4cce-9eb0-a9f6f6691c9f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_3071bb94-059c-4b9e-9c91-58eefff76ac1" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_58697528-4e72-4cce-9eb0-a9f6f6691c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EmployeeMember_722a36fc-5910-4f1c-b851-7186a4fe5101" xlink:href="cpix-20201210.xsd#cpix_EmployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_58697528-4e72-4cce-9eb0-a9f6f6691c9f" xlink:to="loc_cpix_EmployeeMember_722a36fc-5910-4f1c-b851-7186a4fe5101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrincipalOwnerMember_980016dc-d53e-4122-8032-f13a7d3f4a5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrincipalOwnerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_58697528-4e72-4cce-9eb0-a9f6f6691c9f" xlink:to="loc_us-gaap_PrincipalOwnerMember_980016dc-d53e-4122-8032-f13a7d3f4a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NonprincipalOwnerMember_6a7faeaa-f9fd-4ee4-a7ad-480a30223fa7" xlink:href="cpix-20201210.xsd#cpix_NonprincipalOwnerMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_58697528-4e72-4cce-9eb0-a9f6f6691c9f" xlink:to="loc_cpix_NonprincipalOwnerMember_6a7faeaa-f9fd-4ee4-a7ad-480a30223fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_8746c700-04dc-4f87-9acf-dd646869e8bd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_58697528-4e72-4cce-9eb0-a9f6f6691c9f" xlink:to="loc_srt_DirectorMember_8746c700-04dc-4f87-9acf-dd646869e8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ba9fb421-4694-4117-a342-c77a6eab609a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0d18e818-8ee8-4eeb-88ef-f1e306acdec5" xlink:to="loc_srt_RangeAxis_ba9fb421-4694-4117-a342-c77a6eab609a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_32047539-db97-4f83-bf14-a1cb5dc9b927" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ba9fb421-4694-4117-a342-c77a6eab609a" xlink:to="loc_srt_RangeMember_32047539-db97-4f83-bf14-a1cb5dc9b927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6f219603-68a7-4a14-b68e-f154b14182bd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_32047539-db97-4f83-bf14-a1cb5dc9b927" xlink:to="loc_srt_MinimumMember_6f219603-68a7-4a14-b68e-f154b14182bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bad29a61-456f-432e-b580-38a87c8636aa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_32047539-db97-4f83-bf14-a1cb5dc9b927" xlink:to="loc_srt_MaximumMember_bad29a61-456f-432e-b580-38a87c8636aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baa09e5-c8ab-465d-9e7f-18969b5b2fb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0d18e818-8ee8-4eeb-88ef-f1e306acdec5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baa09e5-c8ab-465d-9e7f-18969b5b2fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans_bb3c9d40-8454-421f-96a3-9be0abc61dde" xlink:href="cpix-20201210.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baa09e5-c8ab-465d-9e7f-18969b5b2fb7" xlink:to="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans_bb3c9d40-8454-421f-96a3-9be0abc61dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants_3a44e4c7-1491-45c7-9e5c-2bbfdd0317f4" xlink:href="cpix-20201210.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baa09e5-c8ab-465d-9e7f-18969b5b2fb7" xlink:to="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants_3a44e4c7-1491-45c7-9e5c-2bbfdd0317f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_78ab451f-9969-44e1-94a9-c07c3f0b488c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baa09e5-c8ab-465d-9e7f-18969b5b2fb7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_78ab451f-9969-44e1-94a9-c07c3f0b488c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue_192477d2-0407-4899-ad98-6edd9ba1b17a" xlink:href="cpix-20201210.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baa09e5-c8ab-465d-9e7f-18969b5b2fb7" xlink:to="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue_192477d2-0407-4899-ad98-6edd9ba1b17a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5ed69212-e01d-45a8-ab42-99d6d3c1875e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baa09e5-c8ab-465d-9e7f-18969b5b2fb7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5ed69212-e01d-45a8-ab42-99d6d3c1875e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1569e64f-f0c3-41b0-88a3-30685afc5209" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baa09e5-c8ab-465d-9e7f-18969b5b2fb7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1569e64f-f0c3-41b0-88a3-30685afc5209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d32d1702-952b-4cd7-ab54-526f44e153fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baa09e5-c8ab-465d-9e7f-18969b5b2fb7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d32d1702-952b-4cd7-ab54-526f44e153fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_980d1567-58d6-4b91-b8c3-e457b46d0685" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baa09e5-c8ab-465d-9e7f-18969b5b2fb7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_980d1567-58d6-4b91-b8c3-e457b46d0685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5ce2274a-1277-4519-8044-75075f8f3e4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bebeedd5-4e1b-4531-90bb-8dd3fee1a211" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5ce2274a-1277-4519-8044-75075f8f3e4a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bebeedd5-4e1b-4531-90bb-8dd3fee1a211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_470cf1ba-88e4-4609-ba25-7158ef571e36" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bebeedd5-4e1b-4531-90bb-8dd3fee1a211" xlink:to="loc_srt_TitleOfIndividualAxis_470cf1ba-88e4-4609-ba25-7158ef571e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6fc807d7-45c8-49d0-9360-38c2379edaa3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_470cf1ba-88e4-4609-ba25-7158ef571e36" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6fc807d7-45c8-49d0-9360-38c2379edaa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EmployeeMember_e9649e57-024b-477c-9754-adbf48d336d4" xlink:href="cpix-20201210.xsd#cpix_EmployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6fc807d7-45c8-49d0-9360-38c2379edaa3" xlink:to="loc_cpix_EmployeeMember_e9649e57-024b-477c-9754-adbf48d336d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NonemployeeMember_4cbf24bc-f60e-4b8c-aac9-9439ab0c8061" xlink:href="cpix-20201210.xsd#cpix_NonemployeeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6fc807d7-45c8-49d0-9360-38c2379edaa3" xlink:to="loc_cpix_NonemployeeMember_4cbf24bc-f60e-4b8c-aac9-9439ab0c8061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FoundationContributionMember_9ef7feff-ea03-445b-8f6c-b28b777d1851" xlink:href="cpix-20201210.xsd#cpix_FoundationContributionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6fc807d7-45c8-49d0-9360-38c2379edaa3" xlink:to="loc_cpix_FoundationContributionMember_9ef7feff-ea03-445b-8f6c-b28b777d1851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EmployeeNonemployeeandFoundationContributionMember_6df2299d-1748-45e8-9dcb-22b681be6ada" xlink:href="cpix-20201210.xsd#cpix_EmployeeNonemployeeandFoundationContributionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6fc807d7-45c8-49d0-9360-38c2379edaa3" xlink:to="loc_cpix_EmployeeNonemployeeandFoundationContributionMember_6df2299d-1748-45e8-9dcb-22b681be6ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dfbf0e75-5e5e-4184-bdab-f31990e62c93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bebeedd5-4e1b-4531-90bb-8dd3fee1a211" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dfbf0e75-5e5e-4184-bdab-f31990e62c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_7b836ce1-08d7-486a-9a35-00f0ae78bb6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dfbf0e75-5e5e-4184-bdab-f31990e62c93" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_7b836ce1-08d7-486a-9a35-00f0ae78bb6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#StockBasedCompensationPlansScheduleofStockOptionsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7b1a2b99-0cb3-4ed0-b8e9-ed46ddf97e9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7abe99a0-1f93-410b-a81b-42313fde5201" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7b1a2b99-0cb3-4ed0-b8e9-ed46ddf97e9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7abe99a0-1f93-410b-a81b-42313fde5201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4176a711-cdd3-4077-bbb3-7a6b90c82eef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7abe99a0-1f93-410b-a81b-42313fde5201" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4176a711-cdd3-4077-bbb3-7a6b90c82eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a22e8d42-2da7-4dd3-b628-af6ee3ae7129" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7abe99a0-1f93-410b-a81b-42313fde5201" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a22e8d42-2da7-4dd3-b628-af6ee3ae7129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4e8b9be9-5f4c-4dad-a9c5-fd3acf7c2614" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7abe99a0-1f93-410b-a81b-42313fde5201" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4e8b9be9-5f4c-4dad-a9c5-fd3acf7c2614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_cc1b8fd7-b7d4-49d4-a6a8-34a92e913ea3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7abe99a0-1f93-410b-a81b-42313fde5201" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_cc1b8fd7-b7d4-49d4-a6a8-34a92e913ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b8ffcb0d-d568-4ff3-94f1-fce270b90e8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7abe99a0-1f93-410b-a81b-42313fde5201" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b8ffcb0d-d568-4ff3-94f1-fce270b90e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_cf5606b1-e4aa-4778-b28b-bb3b2d857b47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7b1a2b99-0cb3-4ed0-b8e9-ed46ddf97e9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_cf5606b1-e4aa-4778-b28b-bb3b2d857b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_da8a1a4a-c185-4299-bc6d-d47a26cac224" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7b1a2b99-0cb3-4ed0-b8e9-ed46ddf97e9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_da8a1a4a-c185-4299-bc6d-d47a26cac224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_85ee8c87-822f-4c97-82cd-f91f0c705a5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_da8a1a4a-c185-4299-bc6d-d47a26cac224" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_85ee8c87-822f-4c97-82cd-f91f0c705a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_32a2574c-e7e7-410f-a879-1cc1a89092df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_da8a1a4a-c185-4299-bc6d-d47a26cac224" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_32a2574c-e7e7-410f-a879-1cc1a89092df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_505eb530-e379-4595-b5bf-015ca52fd290" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_da8a1a4a-c185-4299-bc6d-d47a26cac224" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_505eb530-e379-4595-b5bf-015ca52fd290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_2bc5a871-a878-4295-9994-0e76bb38f390" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_da8a1a4a-c185-4299-bc6d-d47a26cac224" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_2bc5a871-a878-4295-9994-0e76bb38f390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_be640c03-6b26-4cea-95bb-08109d6a8972" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_da8a1a4a-c185-4299-bc6d-d47a26cac224" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_be640c03-6b26-4cea-95bb-08109d6a8972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_fef087c7-e862-42e8-96cb-9de24c01a4bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7b1a2b99-0cb3-4ed0-b8e9-ed46ddf97e9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_fef087c7-e862-42e8-96cb-9de24c01a4bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8b4ab9e5-f81a-46c9-b98f-a8ef4dacd805" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7b1a2b99-0cb3-4ed0-b8e9-ed46ddf97e9f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8b4ab9e5-f81a-46c9-b98f-a8ef4dacd805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f2468d3b-5bf4-4423-887e-1dab07808665" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7b1a2b99-0cb3-4ed0-b8e9-ed46ddf97e9f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f2468d3b-5bf4-4423-887e-1dab07808665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2e7aa337-ed8b-4fb2-a0c0-7917ef318250" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7b1a2b99-0cb3-4ed0-b8e9-ed46ddf97e9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2e7aa337-ed8b-4fb2-a0c0-7917ef318250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_12167990-6e21-4d36-83a5-be882de01807" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7b1a2b99-0cb3-4ed0-b8e9-ed46ddf97e9f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_12167990-6e21-4d36-83a5-be882de01807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityAdditionalDisclosuresDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#StockBasedCompensationPlansScheduleofStockOptionActivityAdditionalDisclosuresDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityAdditionalDisclosuresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ba909bf1-e640-4215-8e8f-b7f8481068e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_89d51991-3bd0-47c9-8ed4-0a8b5f7e3902" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ba909bf1-e640-4215-8e8f-b7f8481068e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_89d51991-3bd0-47c9-8ed4-0a8b5f7e3902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_2211fb75-0365-4157-997b-f5084cf820c2" xlink:href="cpix-20201210.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ba909bf1-e640-4215-8e8f-b7f8481068e5" xlink:to="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_2211fb75-0365-4157-997b-f5084cf820c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b652cade-37b4-4a17-8583-9b459f01311b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9624a8f-ea78-47b4-868d-5d37c414fa87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b652cade-37b4-4a17-8583-9b459f01311b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9624a8f-ea78-47b4-868d-5d37c414fa87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_609fc5d1-607f-4bb8-a0b4-ef590408de8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9624a8f-ea78-47b4-868d-5d37c414fa87" xlink:to="loc_us-gaap_AwardTypeAxis_609fc5d1-607f-4bb8-a0b4-ef590408de8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_27b494e6-d16b-4773-a26e-f1347ae376bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_609fc5d1-607f-4bb8-a0b4-ef590408de8a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_27b494e6-d16b-4773-a26e-f1347ae376bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_ae2fc261-ceae-4e32-a8e6-eb1fbb3b4a72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_27b494e6-d16b-4773-a26e-f1347ae376bc" xlink:to="loc_us-gaap_RestrictedStockMember_ae2fc261-ceae-4e32-a8e6-eb1fbb3b4a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_95e26a9d-aa89-4ca4-a849-c210347f44d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9624a8f-ea78-47b4-868d-5d37c414fa87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_95e26a9d-aa89-4ca4-a849-c210347f44d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_12c94451-b629-4521-8006-22dc8b30d7e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_95e26a9d-aa89-4ca4-a849-c210347f44d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_12c94451-b629-4521-8006-22dc8b30d7e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_99b63a37-cdea-4687-bbb8-dd5cf6e4ec26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_12c94451-b629-4521-8006-22dc8b30d7e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_99b63a37-cdea-4687-bbb8-dd5cf6e4ec26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2e8eaf0a-eaec-4262-8d2f-9379345b4bf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_12c94451-b629-4521-8006-22dc8b30d7e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2e8eaf0a-eaec-4262-8d2f-9379345b4bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_274309e5-354d-4ef7-8d77-e267f96c07da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_12c94451-b629-4521-8006-22dc8b30d7e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_274309e5-354d-4ef7-8d77-e267f96c07da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5ec2a7b1-b1ef-43ee-afcb-9941d770defd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_12c94451-b629-4521-8006-22dc8b30d7e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5ec2a7b1-b1ef-43ee-afcb-9941d770defd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_01296477-4ae9-49af-92ff-8ae05cd120fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_12c94451-b629-4521-8006-22dc8b30d7e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_01296477-4ae9-49af-92ff-8ae05cd120fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_27794b5a-2496-42b8-9809-0fe35960c77c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_95e26a9d-aa89-4ca4-a849-c210347f44d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_27794b5a-2496-42b8-9809-0fe35960c77c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2e0cb6b7-49a5-4a55-9aaa-05d1673f31d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_27794b5a-2496-42b8-9809-0fe35960c77c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2e0cb6b7-49a5-4a55-9aaa-05d1673f31d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d278bb2c-006b-45e7-9983-35a03ed253c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_27794b5a-2496-42b8-9809-0fe35960c77c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d278bb2c-006b-45e7-9983-35a03ed253c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9884d717-c92e-4de1-8979-c00867693b38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_27794b5a-2496-42b8-9809-0fe35960c77c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9884d717-c92e-4de1-8979-c00867693b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5f9205a4-70c1-4ebf-8b65-eba59bd9fcfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_27794b5a-2496-42b8-9809-0fe35960c77c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5f9205a4-70c1-4ebf-8b65-eba59bd9fcfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_56af89d4-9495-419b-88a0-79184e8713f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_27794b5a-2496-42b8-9809-0fe35960c77c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_56af89d4-9495-419b-88a0-79184e8713f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EmployeeBenefitPlans" xlink:type="simple" xlink:href="cpix-20201210.xsd#EmployeeBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_098f69e7-c472-458a-b7b3-356744912597" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_0214c2bc-556c-4a77-b4cb-5abae1cbc112" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_098f69e7-c472-458a-b7b3-356744912597" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_0214c2bc-556c-4a77-b4cb-5abae1cbc112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EmployeeBenefitPlansNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#EmployeeBenefitPlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EmployeeBenefitPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f9c32585-cbe8-4bd9-aac7-6e843ba65cfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge_2de3569e-bbda-4c92-8254-f0228bebdf86" xlink:href="cpix-20201210.xsd#cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f9c32585-cbe8-4bd9-aac7-6e843ba65cfb" xlink:to="loc_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge_2de3569e-bbda-4c92-8254-f0228bebdf86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility_91ae2bc4-4dba-4f97-b483-aa6c5a6fe3b1" xlink:href="cpix-20201210.xsd#cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f9c32585-cbe8-4bd9-aac7-6e843ba65cfb" xlink:to="loc_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility_91ae2bc4-4dba-4f97-b483-aa6c5a6fe3b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_74af549b-9fa0-41b9-9946-724c455a0143" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f9c32585-cbe8-4bd9-aac7-6e843ba65cfb" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_74af549b-9fa0-41b9-9946-724c455a0143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityAbstract_187eca65-34d6-4c64-9787-8b3d1aab5102" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationLiabilityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f9c32585-cbe8-4bd9-aac7-6e843ba65cfb" xlink:to="loc_us-gaap_DeferredCompensationLiabilityAbstract_187eca65-34d6-4c64-9787-8b3d1aab5102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_1faf1152-d852-4ddb-ac1b-a5f1fc87d997" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationLiabilityAbstract_187eca65-34d6-4c64-9787-8b3d1aab5102" xlink:to="loc_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_1faf1152-d852-4ddb-ac1b-a5f1fc87d997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationPlanAssets_201a48d7-7f1e-477b-87ba-09ddef8e2460" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationLiabilityAbstract_187eca65-34d6-4c64-9787-8b3d1aab5102" xlink:to="loc_us-gaap_DeferredCompensationPlanAssets_201a48d7-7f1e-477b-87ba-09ddef8e2460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Leases" xlink:type="simple" xlink:href="cpix-20201210.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_42241a80-ae36-4207-bc8b-8bd7a129a902" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock_2922c4cf-067a-4a0e-8d17-b398191c27fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_42241a80-ae36-4207-bc8b-8bd7a129a902" xlink:to="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock_2922c4cf-067a-4a0e-8d17-b398191c27fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3d396700-ed16-468f-8995-26fbed035c72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_0a4f4749-feb9-47c8-b8d2-fe609e561678" xlink:href="cpix-20201210.xsd#cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3d396700-ed16-468f-8995-26fbed035c72" xlink:to="loc_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_0a4f4749-feb9-47c8-b8d2-fe609e561678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_f94ac3bd-e6af-4391-9f7e-ff7479dc424d" xlink:href="cpix-20201210.xsd#cpix_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3d396700-ed16-468f-8995-26fbed035c72" xlink:to="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_f94ac3bd-e6af-4391-9f7e-ff7479dc424d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d99f9d59-c6c0-4a86-b65e-b3c9b38a16e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3d396700-ed16-468f-8995-26fbed035c72" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d99f9d59-c6c0-4a86-b65e-b3c9b38a16e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_aadf146a-5b54-49bc-bdb1-9b2937fee209" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3d396700-ed16-468f-8995-26fbed035c72" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_aadf146a-5b54-49bc-bdb1-9b2937fee209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f65f45fb-c48e-4c4f-8b54-8259152adf77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d4623907-c15d-4850-8924-968141ea4e9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f65f45fb-c48e-4c4f-8b54-8259152adf77" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d4623907-c15d-4850-8924-968141ea4e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_cb182690-b508-4ded-872d-9711635d61c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f65f45fb-c48e-4c4f-8b54-8259152adf77" xlink:to="loc_us-gaap_OperatingLeaseLiability_cb182690-b508-4ded-872d-9711635d61c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6689af16-bd88-4c52-a116-46b0ed8c15d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f65f45fb-c48e-4c4f-8b54-8259152adf77" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6689af16-bd88-4c52-a116-46b0ed8c15d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_86788a2d-3bb8-4664-acc7-d070816db02e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f65f45fb-c48e-4c4f-8b54-8259152adf77" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_86788a2d-3bb8-4664-acc7-d070816db02e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofRentExpenseandSubleaseIncomeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#LeasesScheduleofRentExpenseandSubleaseIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofRentExpenseandSubleaseIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_59fd210f-b42e-4d10-b2a0-6354f5f2c5b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_4ab71358-fe8b-4dc7-9710-3b30f3642fdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_59fd210f-b42e-4d10-b2a0-6354f5f2c5b2" xlink:to="loc_us-gaap_LeaseAndRentalExpense_4ab71358-fe8b-4dc7-9710-3b30f3642fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_d15ade1d-f47a-4bc6-b4d2-d4bbb6e5ba58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_59fd210f-b42e-4d10-b2a0-6354f5f2c5b2" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_d15ade1d-f47a-4bc6-b4d2-d4bbb6e5ba58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_92a9bdef-264f-4a53-b67b-67d0aea217c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_59fd210f-b42e-4d10-b2a0-6354f5f2c5b2" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_92a9bdef-264f-4a53-b67b-67d0aea217c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#LeasesLeasePositionDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TextBlockAbstract_c6ba02f3-2a63-4871-ad02-2abd153dd6ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_cc43b17e-4323-4b40-acf4-d61041ec241b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_c6ba02f3-2a63-4871-ad02-2abd153dd6ac" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_cc43b17e-4323-4b40-acf4-d61041ec241b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LeaseAsset_e218f591-e3d4-4afd-8709-aab5e6658d1f" xlink:href="cpix-20201210.xsd#cpix_LeaseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_c6ba02f3-2a63-4871-ad02-2abd153dd6ac" xlink:to="loc_cpix_LeaseAsset_e218f591-e3d4-4afd-8709-aab5e6658d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_41676943-0814-4db3-a170-ef3604a06f95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_c6ba02f3-2a63-4871-ad02-2abd153dd6ac" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_41676943-0814-4db3-a170-ef3604a06f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_358c2597-1c01-46e6-a755-12491f524486" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_c6ba02f3-2a63-4871-ad02-2abd153dd6ac" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_358c2597-1c01-46e6-a755-12491f524486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LeaseLiability_e46874c0-491e-4718-a37f-f3b7b6f6fb4c" xlink:href="cpix-20201210.xsd#cpix_LeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_c6ba02f3-2a63-4871-ad02-2abd153dd6ac" xlink:to="loc_cpix_LeaseLiability_e46874c0-491e-4718-a37f-f3b7b6f6fb4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_bb558a6a-79ae-479e-b59f-e34e025542e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e89870d1-1de3-49db-beb1-db88506e9844" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bb558a6a-79ae-479e-b59f-e34e025542e7" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e89870d1-1de3-49db-beb1-db88506e9844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_480ae949-92fc-4eb9-acf6-68cdef6d3664" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e89870d1-1de3-49db-beb1-db88506e9844" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_480ae949-92fc-4eb9-acf6-68cdef6d3664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9d644246-2d80-4e53-bd2f-9bf347381b52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e89870d1-1de3-49db-beb1-db88506e9844" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9d644246-2d80-4e53-bd2f-9bf347381b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_13cdde12-c586-47ec-b25a-4c233e58887d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e89870d1-1de3-49db-beb1-db88506e9844" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_13cdde12-c586-47ec-b25a-4c233e58887d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_578fbc0d-697c-483b-992d-c563e6631347" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e89870d1-1de3-49db-beb1-db88506e9844" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_578fbc0d-697c-483b-992d-c563e6631347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_8817faf2-6e21-4f7d-a17b-32797526da09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e89870d1-1de3-49db-beb1-db88506e9844" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_8817faf2-6e21-4f7d-a17b-32797526da09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d35a2471-d0ac-410d-aa2d-220f763f3279" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e89870d1-1de3-49db-beb1-db88506e9844" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d35a2471-d0ac-410d-aa2d-220f763f3279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_69e10e6c-e525-448b-ac22-302f1ba23ac6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e89870d1-1de3-49db-beb1-db88506e9844" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_69e10e6c-e525-448b-ac22-302f1ba23ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_3adaebfa-d8c8-46cd-9ed2-791b79779d3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e89870d1-1de3-49db-beb1-db88506e9844" xlink:to="loc_us-gaap_OperatingLeaseLiability_3adaebfa-d8c8-46cd-9ed2-791b79779d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_911a9c80-fd02-4890-94d1-87f8edce6bd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bb558a6a-79ae-479e-b59f-e34e025542e7" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_911a9c80-fd02-4890-94d1-87f8edce6bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_acd3ab58-985f-4366-b5f6-c6921d3f6611" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_911a9c80-fd02-4890-94d1-87f8edce6bd8" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_acd3ab58-985f-4366-b5f6-c6921d3f6611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_2f5d7b14-b6b3-4ff5-bdbe-10c6d2749543" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_911a9c80-fd02-4890-94d1-87f8edce6bd8" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_2f5d7b14-b6b3-4ff5-bdbe-10c6d2749543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_3b666ec3-8174-4e32-a40a-9afc4f7693f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_911a9c80-fd02-4890-94d1-87f8edce6bd8" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_3b666ec3-8174-4e32-a40a-9afc4f7693f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_6a470ddb-82e7-4638-aab5-9589bd1fec8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_911a9c80-fd02-4890-94d1-87f8edce6bd8" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_6a470ddb-82e7-4638-aab5-9589bd1fec8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_3d2da6c7-3deb-445e-9746-0b9bf1712d1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_911a9c80-fd02-4890-94d1-87f8edce6bd8" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_3d2da6c7-3deb-445e-9746-0b9bf1712d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_a3848c47-ca3c-4a73-b1d7-b93e79d910e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_911a9c80-fd02-4890-94d1-87f8edce6bd8" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_a3848c47-ca3c-4a73-b1d7-b93e79d910e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_31f2127b-2580-4ecd-81a1-c995011e4ee7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_911a9c80-fd02-4890-94d1-87f8edce6bd8" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_31f2127b-2580-4ecd-81a1-c995011e4ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails_1" xlink:type="simple" xlink:href="cpix-20201210.xsd#LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/FairValueofFinancialInstruments" xlink:type="simple" xlink:href="cpix-20201210.xsd#FairValueofFinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/FairValueofFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4eda411c-a777-4560-bf8c-b25e38bd2591" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_e18722ff-1a9c-4484-b355-9f941d6dc986" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4eda411c-a777-4560-bf8c-b25e38bd2591" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_e18722ff-1a9c-4484-b355-9f941d6dc986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#FairValueofFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_709aeb2c-9c51-4ca7-9801-0125fbb4acc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_31ac4491-826f-468e-8f97-dcb708256c9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_709aeb2c-9c51-4ca7-9801-0125fbb4acc8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_31ac4491-826f-468e-8f97-dcb708256c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_06fe4425-f532-48b4-9f43-b01938f80c64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aaa660e3-7e22-46b0-aab1-b838376b45b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_06fe4425-f532-48b4-9f43-b01938f80c64" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aaa660e3-7e22-46b0-aab1-b838376b45b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_5542f335-a31f-4610-af39-cfe30cba60a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aaa660e3-7e22-46b0-aab1-b838376b45b3" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_5542f335-a31f-4610-af39-cfe30cba60a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_34b6d6c4-f4ee-4b05-870b-b100dff03b57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_5542f335-a31f-4610-af39-cfe30cba60a8" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_34b6d6c4-f4ee-4b05-870b-b100dff03b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_USTreasuryNotesAndBondsSecuritiesMember_07d7ee25-0cd1-4548-b366-be025f4ec9f6" xlink:href="cpix-20201210.xsd#cpix_USTreasuryNotesAndBondsSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_34b6d6c4-f4ee-4b05-870b-b100dff03b57" xlink:to="loc_cpix_USTreasuryNotesAndBondsSecuritiesMember_07d7ee25-0cd1-4548-b366-be025f4ec9f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LoanPoolsMember_9d0eb423-0e8f-436c-8f64-b498736756b4" xlink:href="cpix-20201210.xsd#cpix_LoanPoolsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_34b6d6c4-f4ee-4b05-870b-b100dff03b57" xlink:to="loc_cpix_LoanPoolsMember_9d0eb423-0e8f-436c-8f64-b498736756b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_be598417-198b-4c8f-8b80-e29ad3f2c333" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_34b6d6c4-f4ee-4b05-870b-b100dff03b57" xlink:to="loc_us-gaap_MunicipalBondsMember_be598417-198b-4c8f-8b80-e29ad3f2c333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_16ae942f-a5e3-45bd-b501-d65e00ff9c52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_34b6d6c4-f4ee-4b05-870b-b100dff03b57" xlink:to="loc_us-gaap_CommercialPaperMember_16ae942f-a5e3-45bd-b501-d65e00ff9c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_49173e3a-2913-4c1f-8c7f-6db1de10e22f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aaa660e3-7e22-46b0-aab1-b838376b45b3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_49173e3a-2913-4c1f-8c7f-6db1de10e22f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1a0e84aa-7721-454e-abfc-72729999e854" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_49173e3a-2913-4c1f-8c7f-6db1de10e22f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1a0e84aa-7721-454e-abfc-72729999e854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_95d15f9c-d6e0-4c77-837c-210363f72d7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1a0e84aa-7721-454e-abfc-72729999e854" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_95d15f9c-d6e0-4c77-837c-210363f72d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e1a4b0fc-facb-414d-a4ac-d988dbd02408" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1a0e84aa-7721-454e-abfc-72729999e854" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e1a4b0fc-facb-414d-a4ac-d988dbd02408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_515defec-e456-4c92-8260-518e1d63faee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aaa660e3-7e22-46b0-aab1-b838376b45b3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_515defec-e456-4c92-8260-518e1d63faee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_42c87729-72cb-4d30-8d6e-bcf031010c69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradingSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_515defec-e456-4c92-8260-518e1d63faee" xlink:to="loc_us-gaap_TradingSecurities_42c87729-72cb-4d30-8d6e-bcf031010c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketConcentrations" xlink:type="simple" xlink:href="cpix-20201210.xsd#MarketConcentrations"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/MarketConcentrations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_01802a7a-c895-4417-8ea3-c5f01434f6ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_cc5e00f1-c90a-489f-b4b0-644828c99ee2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_01802a7a-c895-4417-8ea3-c5f01434f6ac" xlink:to="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_cc5e00f1-c90a-489f-b4b0-644828c99ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketConcentrationsTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#MarketConcentrationsTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/MarketConcentrationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_8437fa3a-4670-4c8a-8be8-e3a86a220e8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_fd7001ee-09e8-43c5-9a18-052b851cee49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_8437fa3a-4670-4c8a-8be8-e3a86a220e8b" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_fd7001ee-09e8-43c5-9a18-052b851cee49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_2ad8bbe9-6977-4248-89b9-0744286c80e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_3832e9e9-9e0b-40c0-a830-d791b1d046e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_2ad8bbe9-6977-4248-89b9-0744286c80e2" xlink:to="loc_us-gaap_ConcentrationRiskTable_3832e9e9-9e0b-40c0-a830-d791b1d046e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_111ea499-599e-4ec7-a230-a515ee5378b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_3832e9e9-9e0b-40c0-a830-d791b1d046e9" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_111ea499-599e-4ec7-a230-a515ee5378b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_322c5836-def4-4cae-8530-048269ca44d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_111ea499-599e-4ec7-a230-a515ee5378b6" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_322c5836-def4-4cae-8530-048269ca44d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_9fca648d-9498-496c-99ca-6c5412307854" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_322c5836-def4-4cae-8530-048269ca44d6" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_9fca648d-9498-496c-99ca-6c5412307854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_28046076-d03a-421b-9cf6-dea9ae2716f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_3832e9e9-9e0b-40c0-a830-d791b1d046e9" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_28046076-d03a-421b-9cf6-dea9ae2716f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_71cb8a25-b930-4c26-976a-978bf8da482b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_28046076-d03a-421b-9cf6-dea9ae2716f7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_71cb8a25-b930-4c26-976a-978bf8da482b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SalesRevenueGoodsGrossMember_830bc3cf-afe9-44a3-98bd-2614e6c1bcc0" xlink:href="cpix-20201210.xsd#cpix_SalesRevenueGoodsGrossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_71cb8a25-b930-4c26-976a-978bf8da482b" xlink:to="loc_cpix_SalesRevenueGoodsGrossMember_830bc3cf-afe9-44a3-98bd-2614e6c1bcc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_695023a0-1bbb-4bcd-b1d5-b250e184206d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_71cb8a25-b930-4c26-976a-978bf8da482b" xlink:to="loc_us-gaap_AccountsReceivableMember_695023a0-1bbb-4bcd-b1d5-b250e184206d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_0ff92a47-e689-4057-88fa-754ffadfc9ee" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_3832e9e9-9e0b-40c0-a830-d791b1d046e9" xlink:to="loc_srt_MajorCustomersAxis_0ff92a47-e689-4057-88fa-754ffadfc9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_20a4c143-ad0f-4bd9-acb5-ad085b5d831a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_0ff92a47-e689-4057-88fa-754ffadfc9ee" xlink:to="loc_srt_NameOfMajorCustomerDomain_20a4c143-ad0f-4bd9-acb5-ad085b5d831a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CustomerOneMember_d3f0f3e5-f307-43f0-877f-650c5c44d2ce" xlink:href="cpix-20201210.xsd#cpix_CustomerOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_20a4c143-ad0f-4bd9-acb5-ad085b5d831a" xlink:to="loc_cpix_CustomerOneMember_d3f0f3e5-f307-43f0-877f-650c5c44d2ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CustomerTwoMember_34d6aa67-587e-4a10-97a8-84945e93e664" xlink:href="cpix-20201210.xsd#cpix_CustomerTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_20a4c143-ad0f-4bd9-acb5-ad085b5d831a" xlink:to="loc_cpix_CustomerTwoMember_34d6aa67-587e-4a10-97a8-84945e93e664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CustomerThreeMember_ce47a472-4ab3-4638-a93a-25c4b06e3c7a" xlink:href="cpix-20201210.xsd#cpix_CustomerThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_20a4c143-ad0f-4bd9-acb5-ad085b5d831a" xlink:to="loc_cpix_CustomerThreeMember_ce47a472-4ab3-4638-a93a-25c4b06e3c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_3cfc0447-ede5-4ad6-8e9a-cac3477142c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_3832e9e9-9e0b-40c0-a830-d791b1d046e9" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_3cfc0447-ede5-4ad6-8e9a-cac3477142c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_85672499-05a4-4c90-9d1d-8c4d97dc0b42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_3cfc0447-ede5-4ad6-8e9a-cac3477142c5" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_85672499-05a4-4c90-9d1d-8c4d97dc0b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreements" xlink:type="simple" xlink:href="cpix-20201210.xsd#ManufacturingandSupplyAgreements"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingAndSupplyAgreementsAbstract_49a8fd66-2c14-4e8a-aed3-2afcb3a51acd" xlink:href="cpix-20201210.xsd#cpix_ManufacturingAndSupplyAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingAndSupplyAgreementsTextBlock_0b05381f-5d2b-467c-bb8f-1a9ff436cb4e" xlink:href="cpix-20201210.xsd#cpix_ManufacturingAndSupplyAgreementsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ManufacturingAndSupplyAgreementsAbstract_49a8fd66-2c14-4e8a-aed3-2afcb3a51acd" xlink:to="loc_cpix_ManufacturingAndSupplyAgreementsTextBlock_0b05381f-5d2b-467c-bb8f-1a9ff436cb4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingAndSupplyAgreementsAbstract_aeb6e767-2eac-48c0-becc-894c4beb2a47" xlink:href="cpix-20201210.xsd#cpix_ManufacturingAndSupplyAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingandSupplyAgreementTable_410418cc-29ae-4b2d-8199-bedda5b0d14e" xlink:href="cpix-20201210.xsd#cpix_ManufacturingandSupplyAgreementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ManufacturingAndSupplyAgreementsAbstract_aeb6e767-2eac-48c0-becc-894c4beb2a47" xlink:to="loc_cpix_ManufacturingandSupplyAgreementTable_410418cc-29ae-4b2d-8199-bedda5b0d14e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9cc3520c-4cc4-408d-a5e4-283613d9af6b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ManufacturingandSupplyAgreementTable_410418cc-29ae-4b2d-8199-bedda5b0d14e" xlink:to="loc_srt_RangeAxis_9cc3520c-4cc4-408d-a5e4-283613d9af6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7514c2e8-0ed0-42bf-af52-f0258e4140ae" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9cc3520c-4cc4-408d-a5e4-283613d9af6b" xlink:to="loc_srt_RangeMember_7514c2e8-0ed0-42bf-af52-f0258e4140ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bc49f5d7-20bd-4460-a21b-d5a5f8f33393" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7514c2e8-0ed0-42bf-af52-f0258e4140ae" xlink:to="loc_srt_MinimumMember_bc49f5d7-20bd-4460-a21b-d5a5f8f33393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7c204c01-0f82-4a95-8075-880d8b88f1c7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7514c2e8-0ed0-42bf-af52-f0258e4140ae" xlink:to="loc_srt_MaximumMember_7c204c01-0f82-4a95-8075-880d8b88f1c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingandSupplyAgreementLineItems_d88e19ce-3235-4d6c-8fcf-71f52bcd0b09" xlink:href="cpix-20201210.xsd#cpix_ManufacturingandSupplyAgreementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ManufacturingandSupplyAgreementTable_410418cc-29ae-4b2d-8199-bedda5b0d14e" xlink:to="loc_cpix_ManufacturingandSupplyAgreementLineItems_d88e19ce-3235-4d6c-8fcf-71f52bcd0b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct_6a6011f0-aa4e-47fe-9da3-aeedf349fca5" xlink:href="cpix-20201210.xsd#cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ManufacturingandSupplyAgreementLineItems_d88e19ce-3235-4d6c-8fcf-71f52bcd0b09" xlink:to="loc_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct_6a6011f0-aa4e-47fe-9da3-aeedf349fca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EmploymentAgreements" xlink:type="simple" xlink:href="cpix-20201210.xsd#EmploymentAgreements"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EmploymentAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EmploymentAgreementsAbstract_70836114-3d63-4dcb-91bb-af9a243c91b2" xlink:href="cpix-20201210.xsd#cpix_EmploymentAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EmploymentAgreementsTextBlock_0ddd83b9-8429-4ca0-adeb-593b0b26411f" xlink:href="cpix-20201210.xsd#cpix_EmploymentAgreementsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_EmploymentAgreementsAbstract_70836114-3d63-4dcb-91bb-af9a243c91b2" xlink:to="loc_cpix_EmploymentAgreementsTextBlock_0ddd83b9-8429-4ca0-adeb-593b0b26411f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/DiscontinuedOperations" xlink:type="simple" xlink:href="cpix-20201210.xsd#DiscontinuedOperations"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/DiscontinuedOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_27ebc362-dad9-42c2-9710-e313610b12ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_61451210-21a8-4017-a18f-04a302f1aed9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_27ebc362-dad9-42c2-9710-e313610b12ac" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_61451210-21a8-4017-a18f-04a302f1aed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/DiscontinuedOperationsandDisposalGroupsTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#DiscontinuedOperationsandDisposalGroupsTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/DiscontinuedOperationsandDisposalGroupsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_45e33479-a883-4d1e-8b42-c455d7c6aafb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_d1fa6828-67d7-42c6-9cf5-7b2d525fc6cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_45e33479-a883-4d1e-8b42-c455d7c6aafb" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_d1fa6828-67d7-42c6-9cf5-7b2d525fc6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/DiscontinuedOperationsDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#DiscontinuedOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/DiscontinuedOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_bc922b79-d465-4703-8f4e-c302294b8d40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset_05933b82-bbfb-45ec-ad5b-561513afb1c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_bc922b79-d465-4703-8f4e-c302294b8d40" xlink:to="loc_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset_05933b82-bbfb-45ec-ad5b-561513afb1c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FinancialConsiderationPaymentPeriod_59182804-f46a-4078-9d1d-999528aaec55" xlink:href="cpix-20201210.xsd#cpix_FinancialConsiderationPaymentPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_bc922b79-d465-4703-8f4e-c302294b8d40" xlink:to="loc_cpix_FinancialConsiderationPaymentPeriod_59182804-f46a-4078-9d1d-999528aaec55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_ea266b6a-57ec-430f-a2ca-1495b0f156b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_bc922b79-d465-4703-8f4e-c302294b8d40" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_ea266b6a-57ec-430f-a2ca-1495b0f156b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_001974e4-821b-4e64-84c5-7bf16d165cbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_bc922b79-d465-4703-8f4e-c302294b8d40" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_001974e4-821b-4e64-84c5-7bf16d165cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_bfd33af8-dd57-4b08-8dd8-d0420bb408cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_bc922b79-d465-4703-8f4e-c302294b8d40" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_bfd33af8-dd57-4b08-8dd8-d0420bb408cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_18775f5f-32da-42db-bf04-ec8466dca39d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_bc922b79-d465-4703-8f4e-c302294b8d40" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_18775f5f-32da-42db-bf04-ec8466dca39d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DisposalGroupIncludingDiscontinuedOperationRemainingInventoryCurrent_6feb5061-bd12-4a1e-af4e-93b391964f72" xlink:href="cpix-20201210.xsd#cpix_DisposalGroupIncludingDiscontinuedOperationRemainingInventoryCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_bc922b79-d465-4703-8f4e-c302294b8d40" xlink:to="loc_cpix_DisposalGroupIncludingDiscontinuedOperationRemainingInventoryCurrent_6feb5061-bd12-4a1e-af4e-93b391964f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_f6fea9af-17b3-4a6e-a0b1-e414fc598df0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_bc922b79-d465-4703-8f4e-c302294b8d40" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_f6fea9af-17b3-4a6e-a0b1-e414fc598df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_1e24891c-635d-4f64-9468-d50a90595e99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_bc922b79-d465-4703-8f4e-c302294b8d40" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_1e24891c-635d-4f64-9468-d50a90595e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_4cb7409a-14d7-422f-ae4f-6bab454e3f38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_bc922b79-d465-4703-8f4e-c302294b8d40" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_4cb7409a-14d7-422f-ae4f-6bab454e3f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_3149163b-e5a1-46e7-a9c7-1ce9aea20bc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_bc922b79-d465-4703-8f4e-c302294b8d40" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_3149163b-e5a1-46e7-a9c7-1ce9aea20bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_41c0e1c0-99da-4581-ad42-bf85972b4a37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_bc922b79-d465-4703-8f4e-c302294b8d40" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_41c0e1c0-99da-4581-ad42-bf85972b4a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_aeb859dc-ed06-4a7e-a156-84c6cb78870a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_bc922b79-d465-4703-8f4e-c302294b8d40" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_aeb859dc-ed06-4a7e-a156-84c6cb78870a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_801b7c67-e72d-42ad-807e-a2111df1e042" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_bc922b79-d465-4703-8f4e-c302294b8d40" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_801b7c67-e72d-42ad-807e-a2111df1e042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="cpix-20201210.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_96721696-0515-4703-a595-305803c8baf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_624a6ce4-5209-4acc-8fa3-525a92189eef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_96721696-0515-4703-a595-305803c8baf0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_624a6ce4-5209-4acc-8fa3-525a92189eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="simple" xlink:href="cpix-20201210.xsd#QuarterlyFinancialInformationUnaudited"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_18f2bec5-d036-4f37-afc7-90f6dd4e8f68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_a6adfe34-2cf1-496b-9241-65d7d4f6b669" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_18f2bec5-d036-4f37-afc7-90f6dd4e8f68" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_a6adfe34-2cf1-496b-9241-65d7d4f6b669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="simple" xlink:href="cpix-20201210.xsd#QuarterlyFinancialInformationUnauditedTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_c96246e8-d511-4a5b-a44e-3953658b323f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_b5dfbd30-eab6-40bf-a660-e79e06d10818" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_c96246e8-d511-4a5b-a44e-3953658b323f" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_b5dfbd30-eab6-40bf-a660-e79e06d10818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_1ce817ce-3e21-4a20-879d-3f9dcf8a0ee3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_bcb9cc47-3d17-43ad-a4c2-52fadf6c8c2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_1ce817ce-3e21-4a20-879d-3f9dcf8a0ee3" xlink:to="loc_us-gaap_Revenues_bcb9cc47-3d17-43ad-a4c2-52fadf6c8c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_216d78f2-0800-477d-876a-a5792f7494eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_1ce817ce-3e21-4a20-879d-3f9dcf8a0ee3" xlink:to="loc_us-gaap_OperatingIncomeLoss_216d78f2-0800-477d-876a-a5792f7494eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f137fdfe-e48b-4c7e-81ef-92b10030ce3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_1ce817ce-3e21-4a20-879d-3f9dcf8a0ee3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f137fdfe-e48b-4c7e-81ef-92b10030ce3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_aabbd9d3-fa3d-476d-8768-b606065ef8ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_1ce817ce-3e21-4a20-879d-3f9dcf8a0ee3" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_aabbd9d3-fa3d-476d-8768-b606065ef8ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_710986f5-1f27-43cd-9363-c118fcf211a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_1ce817ce-3e21-4a20-879d-3f9dcf8a0ee3" xlink:to="loc_us-gaap_NetIncomeLoss_710986f5-1f27-43cd-9363-c118fcf211a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8531b953-d771-4694-b38c-22ddcc25d5b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_1ce817ce-3e21-4a20-879d-3f9dcf8a0ee3" xlink:to="loc_us-gaap_EarningsPerShareAbstract_8531b953-d771-4694-b38c-22ddcc25d5b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_87269790-69a6-41a5-824f-575830e977d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8531b953-d771-4694-b38c-22ddcc25d5b5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_87269790-69a6-41a5-824f-575830e977d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_3484641d-4db4-4821-a0bc-23cbe8ceddca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8531b953-d771-4694-b38c-22ddcc25d5b5" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_3484641d-4db4-4821-a0bc-23cbe8ceddca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_13a8b836-f03e-45cb-8507-9c3905516dc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8531b953-d771-4694-b38c-22ddcc25d5b5" xlink:to="loc_us-gaap_EarningsPerShareBasic_13a8b836-f03e-45cb-8507-9c3905516dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_be568127-89e5-46b4-9c32-6284086fc04a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8531b953-d771-4694-b38c-22ddcc25d5b5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_be568127-89e5-46b4-9c32-6284086fc04a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_0f8ad5eb-9074-43ba-9827-cdf63daf734c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8531b953-d771-4694-b38c-22ddcc25d5b5" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_0f8ad5eb-9074-43ba-9827-cdf63daf734c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_09436816-419a-4b74-9b90-91b582532746" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8531b953-d771-4694-b38c-22ddcc25d5b5" xlink:to="loc_us-gaap_EarningsPerShareDiluted_09436816-419a-4b74-9b90-91b582532746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SubsequentEvents" xlink:type="simple" xlink:href="cpix-20201210.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_2b843630-104b-4efe-af5b-a991c5143a2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_c4ca3945-346e-4883-85c0-ae676b2b27fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_2b843630-104b-4efe-af5b-a991c5143a2e" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_c4ca3945-346e-4883-85c0-ae676b2b27fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccounts" xlink:type="simple" xlink:href="cpix-20201210.xsd#ValuationandQualifyingAccounts"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccounts" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_f3610e05-8715-4307-be91-1fd9b897e27b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_48a2bb34-8187-42a8-b05b-fefb7007f479" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_f3610e05-8715-4307-be91-1fd9b897e27b" xlink:to="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_48a2bb34-8187-42a8-b05b-fefb7007f479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails" xlink:type="simple" xlink:href="cpix-20201210.xsd#ValuationandQualifyingAccountsDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_aa4905a4-a73c-4e59-9274-521d0b702ff5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_d4d8da49-e30a-42e3-84c5-c30c32db27bc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_aa4905a4-a73c-4e59-9274-521d0b702ff5" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_d4d8da49-e30a-42e3-84c5-c30c32db27bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_9a708c3e-9884-49a3-bc2c-12ab50f0fb34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_d4d8da49-e30a-42e3-84c5-c30c32db27bc" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_9a708c3e-9884-49a3-bc2c-12ab50f0fb34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_fa6aa5ce-7106-4758-ba35-a88aa5cd4ab9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_9a708c3e-9884-49a3-bc2c-12ab50f0fb34" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_fa6aa5ce-7106-4758-ba35-a88aa5cd4ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossMember_6d476421-0de3-451c-b947-12c22a65dd4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForCreditLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_fa6aa5ce-7106-4758-ba35-a88aa5cd4ab9" xlink:to="loc_us-gaap_AllowanceForCreditLossMember_6d476421-0de3-451c-b947-12c22a65dd4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_034fa538-8eb1-4da0-801e-bba7a8e08f71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_fa6aa5ce-7106-4758-ba35-a88aa5cd4ab9" xlink:to="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_034fa538-8eb1-4da0-801e-bba7a8e08f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b65ce010-ac19-495e-a795-9140ea55ccc7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_d4d8da49-e30a-42e3-84c5-c30c32db27bc" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b65ce010-ac19-495e-a795-9140ea55ccc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_5af212da-76bb-4b12-a93a-7de386b81b22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b65ce010-ac19-495e-a795-9140ea55ccc7" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_5af212da-76bb-4b12-a93a-7de386b81b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_c7c1f755-85f9-479b-984d-82df1a9930cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_5af212da-76bb-4b12-a93a-7de386b81b22" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_c7c1f755-85f9-479b-984d-82df1a9930cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_0a0c4318-5e5e-4f29-a338-2e418f465dfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_5af212da-76bb-4b12-a93a-7de386b81b22" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_0a0c4318-5e5e-4f29-a338-2e418f465dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_0c623c80-03aa-4a1e-be9b-b690c76809af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_5af212da-76bb-4b12-a93a-7de386b81b22" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_0c623c80-03aa-4a1e-be9b-b690c76809af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_9ef7103a-3b73-4770-a7ac-0e60fa16a26a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_5af212da-76bb-4b12-a93a-7de386b81b22" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_9ef7103a-3b73-4770-a7ac-0e60fa16a26a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_f9522eff-c381-4820-b992-a2e351fce395" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_5af212da-76bb-4b12-a93a-7de386b81b22" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_f9522eff-c381-4820-b992-a2e351fce395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_b73d127b-3a1e-4dab-999b-35572cbd34b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b65ce010-ac19-495e-a795-9140ea55ccc7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_b73d127b-3a1e-4dab-999b-35572cbd34b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TaxCutsandJobsActof2017ChangeinTaxRateDeferredTaxAssetIncomeTaxExpenseBenefit_df4aade6-d735-4ee3-900f-11e5c1050b1d" xlink:href="cpix-20201210.xsd#cpix_TaxCutsandJobsActof2017ChangeinTaxRateDeferredTaxAssetIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b65ce010-ac19-495e-a795-9140ea55ccc7" xlink:to="loc_cpix_TaxCutsandJobsActof2017ChangeinTaxRateDeferredTaxAssetIncomeTaxExpenseBenefit_df4aade6-d735-4ee3-900f-11e5c1050b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>cpix-20201210_d2_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cpix="http://www.cumberlandpharma.com/20201210"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cpix-20201210.xsd" xlink:type="simple"/>
    <context id="iaa474b82645f415f9a942431b7e23907_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i90392aced265439a8a45b88619999ce0_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iede275917f1d4f6ab16130b2891da5ca_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3a75f009943b411484603265cc918c63_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7565a83142144039aa664a5158a4f3a1_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i12130cb8adf747bc917372e57661c37d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManufacturedProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i80b0be59c71148caa508bedc7c0aa249_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManufacturedProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6a3679cdc7a7417d9491addba442e136_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManufacturedProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i12da030761f5478185c9c43f4257f503_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i19f7709a57f34358b074d8ab2cd1410f_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i2153d838d1a64103b08e67d86300e4f6_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="id69c7a64b03046d994369dd8619e693b_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="i0ca22cafe70c4402827abcd065642a85_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="i6067dd95a57b478f9581c66c6de9ce8d_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="i4f7afaa399514dcdbcfdaa5e2bb28ea7_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ie4861d915e194b9b953dd7e515035d55_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i51ac9d639e514ecc9a1253c74c8715e3_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="i07bb27d9de334b51acf632637d46c3ec_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="i6921ef0b4c9446b6a5f25b2084bdc3ca_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i512c6090aab845a3bfe38fb3e6f61dbb_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i9c5b1b36eaf747aea3881c4b9c3884a8_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i42508aef6d0b489d9d6f2bc2b649384d_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i98582b13998d4d998af541abee8ec14c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3cffc6b13dc64ca49a9f14419a551793_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8b9e95130dc146f9aa56d8d1d11bc534_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1e55eb8a26d0400ab1ddbb5aa6ac9d0c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie93040da022f4f208946b77301e73ade_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4644d0f807ed4bce8b2b23227a41a2f2_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if8fc2928cf4640edbddc3867d462e258_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i570bc31a791840209b4f80fc77772940_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i52ca8e03f38a46ab80ee3b1b2a37a943_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibbcaca0519364200b49f7a89d6fa09f7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i48893159b76243539afc56c165b13ce5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia0ea12224ffe4a29838858a3bdb9268c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iefb6ff4d74154d8685cd13777224de1f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:HarbinGloriaPharmaceuticalsCoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cpix:CumberlandEmergingTechnologiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i917430c8015149c18c59ded862b49717_I20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:HongKongWinHealthPharmaGroupCoLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="i9f1c7f34352d4f90823b583604c2e094_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:HongKongWinHealthPharmaGroupCoLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="i3522d1a659a04358b4f6ed8b764dd9e5_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:GloriaPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="ie1b2c35fc3b6418cb8cc3c920e5ae3d6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">cpix:CumberlandEmergingTechnologiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6a4ee4b80c85405aa9011089eea73f13_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3faf6260efdc450498cc8cb573bbc167_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="icef1ce4e74b54672b3b04ac67a70e22b_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ia75e1df3d4b74017bd1b51e0b2b3cff5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cpix:AccountsReceivableAllowancesByComponentAxis">cpix:ChargebacksCashDiscountsAndDamagedGoodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3e91f9a0d19840b7b2aff337c95edc24_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cpix:AccountsReceivableAllowancesByComponentAxis">cpix:ChargebacksCashDiscountsAndDamagedGoodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib06a29ad4edd4918a967323242b0142d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cpix:ProductRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib9796d25c7c94244a85df974cff3caf9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9264ef6a01f546dca65e6adec1f967fe_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0a05405482c64e9e8fe092b821aeb335_D20131028-20131029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cpix:AmendedInternationalAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cpix:PernixTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-10-28</startDate>
            <endDate>2013-10-29</endDate>
        </period>
    </context>
    <context id="i62d1338de7314d30a069c29708d22188_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie0c9147a91864842a7ac6266279fa374_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iafa9e83c0991457dbecd945d1f0eb0a8_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="iebd5c24d9fc142c0b899398d6d3c153d_D20161101-20161130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-01</startDate>
            <endDate>2016-11-30</endDate>
        </period>
    </context>
    <context id="i00c91a50edb844d99bb320b2490ff8d6_D20161101-20161130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-01</startDate>
            <endDate>2016-11-30</endDate>
        </period>
    </context>
    <context id="i3dc00a50885944de8bd18286fb857d2a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie0bf4ffa056349039b29b90f3009e187_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5b955a67143f40b994546bcffda9b554_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i35eae0bc26094a639bb7e4c0640fb7ea_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="ie2b0bcf3278442f08417f95c2f0b677a_D20190308-20190308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-08</startDate>
            <endDate>2019-03-08</endDate>
        </period>
    </context>
    <context id="i9f2a5edba28144ad932b2ce0fd047ab3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idb606e761ca74e0fb88c19ca9f7345f7_I20181112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-12</instant>
        </period>
    </context>
    <context id="i54bf1d15e917470abd4a457ea8b0a9b5_D20181113-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-13</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2859968ba8084d4f9a9f00fafe0202a4_D20181112-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-12</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8286cfe2c4684a39972d0ce5371ad480_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ifd15955102ce48909e6253ea8529c09b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4af7f789d58345659c0394f24e9c9d71_I20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-30</instant>
        </period>
    </context>
    <context id="i2f1333c86d8745489e79ec97651cf898_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ief373c33e252406ba170c90d1219f6dd_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8169ad28217c4db3b21d9f9eeee9c392_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i07a58e2ca82d468d914ab4d50fee24b8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iee48a107bb7c466ebfe24ff0624d8263_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie774ce371d1f4360a413d7cd01f67f7a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6071c9045bf147eda9c3489832bb5075_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="icc6447e28536413ebc8660631a042645_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i4c7af9859e7b4d49bc0d4cfb8caec5b5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0e8af893ce924072831291283cf7341a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i17481b3eb00f41c493ce3e18607ab92f_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i56db8e8bb906489db9d57373574874aa_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i320e6951e476481187afd7fdc00da9a3_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i89b467d3bb2a460e991f8a90b333ff4d_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="idfd2f30676c34f82a88e1052658a9b37_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductVibativMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic88d54bc58134580bd4649c7afe08bf6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductVibativMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id16bbbe7271043b3b909c6f3fa6611d0_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductVibativMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i80881f50116942c79eeedbc60d086b43_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if00c3bf918d24cc3aaeb84d0fbd302a3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cpix:CollaborativeArrangementFederalSmallBusinessGrantProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9f14c6eb615f4396a69694ec3bbf3a78_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cpix:CollaborativeArrangementFederalSmallBusinessGrantProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i14230e23d1f14fddaceba899b44a4986_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cpix:CollaborativeArrangementFederalSmallBusinessGrantProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i156f2acf482f4da8b0851cb775ba0501_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:IfetrobanClinicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ica008517cc804be682f6f8928de46011_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2ab1d686afef4f47af443ddb3c69c912_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8369853c76754322967bb52653385028_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i67191970b6dc4dbab12c4bdce59ca551_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4f0e55caff6347b08baa66daf67632aa_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia11c0ba867c24e56850a7ffe421f6852_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ifa90d2ee803c421baadb41895368ae03_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id13db87e21e745bfaebf06c3e97b18e1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7f90fef1f7bd4deaa1cf05dcd6c9cc19_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id5c37f17bdd045d8876714d588be095a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i171ae0e4eec14d9f868621f1dba24be1_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic27611c0dbc04b7988dcc9331bfbe1cb_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i947f330f1863460ea96eb801e0df3cde_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if1b631d150a9425d83302ca84d5acf6f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2beb96285c7c4c4c9e3166c0f1577edc_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i35e4a7c76589409caba0ef887cf3d6c8_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ieba1c5b99e794cc887ea29cce7db35d5_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ibda132d30f764f18ba15f5b11ef8640c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cpix:ProductAndLicenseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie1596ec01ad648109aa7a8774201aebf_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cpix:ProductAndLicenseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="icc95de064baa44309a420dcb73dd5d32_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i13bd22341d9c430cb1cd4edc13102d50_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i85b3f22a44da44e0b4f3300a912b0dc5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i988d5245b3374e39af5d4ec1f43b092f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i34cdca865b434ae68e675f3de541d80f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cpix:AmendedInternationalAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cpix:PernixTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i06508a7d5ed34904a9e7ba4b89125dfa_I20140228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cpix:ProductAndLicenseRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-02-28</instant>
        </period>
    </context>
    <context id="i741e5bc06ece4d28a49fb727a3756a7e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:NordicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0a52841e4c724bb9936223a8fd642381_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i72d98b8b6d2b49ec92a95f7f52a21bb0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i20968f0f5b524d799086597dfddc2a8d_I20181017">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:SecondAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-17</instant>
        </period>
    </context>
    <context id="i5275515928ca439196af82cb649ddae9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:SecondAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iba0ec1144cb840b3a4076d92998f6ae8_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="icd700ec4abf947049e74967c3f1ebec7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3296f434993a41289fb9d9eab42374e7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i870374f6814b4d6cb3842ed1bada7231_D20170731-20170731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-31</startDate>
            <endDate>2017-07-31</endDate>
        </period>
    </context>
    <context id="i9249561602f042ba980b18815fa29971_D20090809-20090810">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-08-09</startDate>
            <endDate>2009-08-10</endDate>
        </period>
    </context>
    <context id="i1b76324a8a3c4073a8a827f31c55b373_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="ic8a09f2f029d4cf5b809b640237883a1_D20180101-20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="ia45e033a0968470a87498cc6e80e79bb_I20061231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cpix:WarrantsIssuedInConsiderationOf2006CreditFacilityAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2006-12-31</instant>
        </period>
    </context>
    <context id="i65091fc0eec54e3ebe7cadf845bfc5c3_I20091231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cpix:WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2009-12-31</instant>
        </period>
    </context>
    <context id="ieb984696887341bdb3d482415e883068_I20100531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cpix:ShareRepurchaseProgramAuthorizedIn2010Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2010-05-31</instant>
        </period>
    </context>
    <context id="i42d555993abb411fbcfac8eefe7bfc92_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cpix:SharesRepurchaseActivityTypeAxis">cpix:SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icd076322bd3e4e45812f30f6e0265418_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cpix:SharesRepurchaseActivityTypeAxis">cpix:SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0be3acf257f24f79aeb0cfd8403ccd87_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cpix:SharesRepurchaseActivityTypeAxis">cpix:SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i5465c80566344695bc41a215e251af48_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="i8e71f9e142114cb1a967ae279d7a32d8_D20140401-20140430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2014-04-01</startDate>
            <endDate>2014-04-30</endDate>
        </period>
    </context>
    <context id="ib2b3b044fded4d4a96267ff40f75f41d_D20191127-20191127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:NordicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-27</startDate>
            <endDate>2019-11-27</endDate>
        </period>
    </context>
    <context id="i9c1e105600e74750a10354cbeaad8205_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icfde25ec7427462aba77d555bf0b4ebc_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie7f0355a74da4690bb8381a211624d38_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0bc29ea825b54377a95392502611cdcd_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i811017016cf741b2be0e3e987f3eb761_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0be1be11078f412084defc44e8714a79_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iab82716daa96407a81d6e9e0259dbb45_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8bd88221af1b4196a3229b6b611f66c0_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ibfc8673e890d447cb4c97a9429f48da8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:IndefiniteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0b3d8839a10943299527a3616540c882_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:IndefiniteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="idf6dd30a84fc4e6fbec6716f5833f1be_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i919816e4ae6e49cbbc09d39640cee418_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4da90f76e4104888a18e3d18b29d9b37_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cpix:LongTermIncentiveCompensationPlan2007Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i198eca0df24c455580fe1f7aad3d37bf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cpix:DirectorsIncentivePlan2007Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i61c32b7b06154a0caffb1b27ffd29a90_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:NonprincipalOwnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib15a6538ecd34529a63f571722d0a1c9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:NonprincipalOwnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id6083199dd2a42f391637d804e105c86_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i53e4a12de53b4b0c99c928fb854c6569_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6325bab52b3e497181b41d02564bc694_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifc452512a3cb412faa57ddaf029b98df_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6e05d70302894bebb067dddab8121842_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2699606b9dca4e75864d2ce5471d263f_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i7baa6ff5d72047a0ada0ed31a5bb2e5f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:NonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic70796d261de4b7785011e9a52b6ab8b_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:NonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5a9593962195492199a34a509d355036_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:NonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="if432a686a41c4c4494b432b8de61cfd0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:FoundationContributionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie1758466063744cb928ad1f2170609f0_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:FoundationContributionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9ab32de2ce97414b8fa9e5599fbaa6c9_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:FoundationContributionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ic7a81f8fb9634254a32248497adf8453_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:EmployeeNonemployeeandFoundationContributionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1709635ce5bd48ef8b8e1c0e99885c21_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:EmployeeNonemployeeandFoundationContributionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia61891dab2a04a62b49d997680aed24e_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:EmployeeNonemployeeandFoundationContributionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="iaaaacea9a57e4e758bc406a2ecaef76a_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i1a46cecd6d924e33bda5ccdd4c0e3b43_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i84fb9bc25ed941ce90338733d28f5d92_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i1fd085fc709647d9997c4b52bdd4cc7c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i38570ddc79c14639aa269d9013600dec_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i76f168e8263b4700be275c05007c5731_I20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="i46b68c95812c4585ad2800f7e762d7ef_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">cpix:USTreasuryNotesAndBondsSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6967c2f466014730a8901a2bbff4743a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">cpix:USTreasuryNotesAndBondsSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idcaec0f707064e14843280c588b63de9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">cpix:USTreasuryNotesAndBondsSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if40add46a67d4c1b959ea74b3095136d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">cpix:USTreasuryNotesAndBondsSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i871d23f00b9d4522a41b0f48f1812cb8_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">cpix:USTreasuryNotesAndBondsSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id41b97cccddf404587b71109d9148bd9_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">cpix:USTreasuryNotesAndBondsSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6c77d83b0d784f95a8c57dc2c69a1ae1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">cpix:LoanPoolsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5261d06b396a496e83c3994a329a6adb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">cpix:LoanPoolsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia491869f8f8e4444a463caa044907b2a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">cpix:LoanPoolsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6180b75c51584214a21798f206007fd2_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">cpix:LoanPoolsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iebd574df43534324bb75dd95355cde9d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">cpix:LoanPoolsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i2390f7b0f62e4227ae756897529dc3e8_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">cpix:LoanPoolsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5de80c3842fe4ead883716b857a3ab60_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i61fc59376d074db2a4ed2e33996a40ae_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i80849ef0fff8453994464dd9e4263335_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia476a3c32a024ea799663e72ef23fe02_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i20e0531514c241aca726450993124452_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i40d16a645ee641218f7703ab03b0d941_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i52e850d4caf6459cb3f900290e148294_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i539d6d44a9ae44f485c1050e287da81b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4df16753bd334ba3b2e0980d61fa84e3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i42f63da2feed4ee1a967d286f376accb_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7e331fd58cd14866b6404f53b122155e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8cd20af5088e4c7ba1a916823027ba00_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i780bdd9adff04751adcd1b6f35439d2f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6c0f572b430a45c5bf9009619128671c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i67dfb3a3f9004593be1dd06a75668d57_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i943d44213b5845cd9d5b5d5a2ebe891e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i957590befb9d4e11af4357cac09d5a2e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4311d59a68c14a2c85db7649a6e2817c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i45aae0c5083b4158a10518d39b977929_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i633f3a7886904df3bc2c1a118b38b5b5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie40ef9fa31bd4ff8a234daae70ffaf5f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i023693e081e647c2959d4531c232be23_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i0dcb5d79a1304c1a805e8f68f0a8fad3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0fe8c7998adb4a09a50f50ebe5dc2cfe_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i60785c35eb4e4574a2eeeed10b448ec6_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i6f1d9c99bd274435b9a4a98946740ee0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5e32cc9a0bea46d0b461b09960568c0b_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1a21420517ea4647a67d7b1217a674ef_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8471ffa3b49c4d27b527e605477129a5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if22100deab024544b321dc081da4ceff_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i8909cd57fb5146798a8b845d82644b0b_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="if26164363c2e4a7d8fd5139d8f56f49c_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i670fdffefb0c4fefba494de91fb35afc_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie54433cb2ec74b5eb0446c048a926870_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i3568f3154e034913831ef831b3d23e91_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i2efc1fa703c94708b6b3fc4d341efa16_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i41abbb021c424bc3a185261bb47b2490_D20181001-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i285233d399574db2bf4cbbce58a8ee38_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="i3ec1fa83cd4f4bcd80502e9a9be962e1_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ie72430d18bed427fb73e3a0c86f3902b_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="if0b0b3681b184a71afd2ed8070814188_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i320d53db383d4ac7aecd406d90ef5114_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="idaebef75259c4828b8dd1e0a936b843b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia7a49735b602483d8a41720b2aa89de2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic63ad7ea20c046e9929381f321c356c0_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="i17c72a67be474fd0bf7e5aefd742a269_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i529dda5be0c0459188e6d0ab6e604b33_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ia9d74b7bafab423992f09ba352af1356_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3b11cb5d5b164dc88a8a5aa3bd48fe48_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i2a0dc042738147c39f0f1c8b83d36fad_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iae4edd9cd21d4bff9f039d252bcc383b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2020-12-10</startDate>
            <endDate>2020-12-10</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>cpix:segment</measure>
    </unit>
    <unit id="plan">
        <measure>cpix:plan</measure>
    </unit>
    <unit id="supplier">
        <measure>cpix:supplier</measure>
    </unit>
    <dei:DocumentType
      contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV8zMi9mcmFnOmQwMjUzMzYyOTZhYTQwNTdhNTY4NjQ4ODM2YjgzNWZiL3RleHRyZWdpb246ZDAyNTMzNjI5NmFhNDA1N2E1Njg2NDg4MzZiODM1ZmJfMjc0ODc3OTA3MjgyOA_056bb863-4f0b-4fa2-ad5c-1715081fe27a">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV8zMi9mcmFnOmQwMjUzMzYyOTZhYTQwNTdhNTY4NjQ4ODM2YjgzNWZiL3RleHRyZWdpb246ZDAyNTMzNjI5NmFhNDA1N2E1Njg2NDg4MzZiODM1ZmJfMjc0ODc3OTA3ODI0OA_1d685876-aef9-4c3f-8b8a-5af74ebbc4d4">2020-12-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV8zMi9mcmFnOmQwMjUzMzYyOTZhYTQwNTdhNTY4NjQ4ODM2YjgzNWZiL3RleHRyZWdpb246ZDAyNTMzNjI5NmFhNDA1N2E1Njg2NDg4MzZiODM1ZmJfMjc0ODc3OTA3MjgyOQ_2166f7e7-e9b1-4f9e-9a12-416787da3c80">CUMBERLAND PHARMACEUTICALS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV8zMi9mcmFnOmQwMjUzMzYyOTZhYTQwNTdhNTY4NjQ4ODM2YjgzNWZiL3RhYmxlOmI3NGEzNjllNzVkNzRhNDQ5NWMwZjU5NGZjMGE2YjBlL3RhYmxlcmFuZ2U6Yjc0YTM2OWU3NWQ3NGE0NDk1YzBmNTk0ZmMwYTZiMGVfMS0wLTEtMS0xMDU_bffa6826-4410-45f1-8f14-92bd9a77730b">TN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV8zMi9mcmFnOmQwMjUzMzYyOTZhYTQwNTdhNTY4NjQ4ODM2YjgzNWZiL3RhYmxlOmI3NGEzNjllNzVkNzRhNDQ5NWMwZjU5NGZjMGE2YjBlL3RhYmxlcmFuZ2U6Yjc0YTM2OWU3NWQ3NGE0NDk1YzBmNTk0ZmMwYTZiMGVfMS0xLTEtMS0xMDU_86025e8f-524f-4ee8-b89b-9ada402f62e7">001-33637</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV8zMi9mcmFnOmQwMjUzMzYyOTZhYTQwNTdhNTY4NjQ4ODM2YjgzNWZiL3RhYmxlOmI3NGEzNjllNzVkNzRhNDQ5NWMwZjU5NGZjMGE2YjBlL3RhYmxlcmFuZ2U6Yjc0YTM2OWU3NWQ3NGE0NDk1YzBmNTk0ZmMwYTZiMGVfMS0yLTEtMS0xMDk_2743021d-5db1-472b-befb-4487560f8dc3">62-1765329</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV8zMi9mcmFnOmQwMjUzMzYyOTZhYTQwNTdhNTY4NjQ4ODM2YjgzNWZiL3RhYmxlOmI3NGEzNjllNzVkNzRhNDQ5NWMwZjU5NGZjMGE2YjBlL3RhYmxlcmFuZ2U6Yjc0YTM2OWU3NWQ3NGE0NDk1YzBmNTk0ZmMwYTZiMGVfNS0wLTEtMS0yMTIvdGV4dHJlZ2lvbjowYTBiZjFhNjZhNTQ0N2Q1YTAyY2I1MDg1MjE0NGQ1MF8yNzQ4Nzc5MDY5NTI0_4d3f014c-3b49-4cfd-b34b-eab16b8e6ead">2525 West End Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV8zMi9mcmFnOmQwMjUzMzYyOTZhYTQwNTdhNTY4NjQ4ODM2YjgzNWZiL3RhYmxlOmI3NGEzNjllNzVkNzRhNDQ5NWMwZjU5NGZjMGE2YjBlL3RhYmxlcmFuZ2U6Yjc0YTM2OWU3NWQ3NGE0NDk1YzBmNTk0ZmMwYTZiMGVfNS0wLTEtMS0yMTIvdGV4dHJlZ2lvbjowYTBiZjFhNjZhNTQ0N2Q1YTAyY2I1MDg1MjE0NGQ1MF8yNzQ4Nzc5MDY5NTc2_344f5cd5-f990-48fc-8ff7-b6f3f972d7aa">Suite 950</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV8zMi9mcmFnOmQwMjUzMzYyOTZhYTQwNTdhNTY4NjQ4ODM2YjgzNWZiL3RhYmxlOmI3NGEzNjllNzVkNzRhNDQ5NWMwZjU5NGZjMGE2YjBlL3RhYmxlcmFuZ2U6Yjc0YTM2OWU3NWQ3NGE0NDk1YzBmNTk0ZmMwYTZiMGVfNS0wLTEtMS0yMTIvdGV4dHJlZ2lvbjowYTBiZjFhNjZhNTQ0N2Q1YTAyY2I1MDg1MjE0NGQ1MF8yNzQ4Nzc5MDY5NTg4_a89f295a-16bc-4d61-a4da-dd9774ff1fc8">Nashville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV8zMi9mcmFnOmQwMjUzMzYyOTZhYTQwNTdhNTY4NjQ4ODM2YjgzNWZiL3RhYmxlOmI3NGEzNjllNzVkNzRhNDQ5NWMwZjU5NGZjMGE2YjBlL3RhYmxlcmFuZ2U6Yjc0YTM2OWU3NWQ3NGE0NDk1YzBmNTk0ZmMwYTZiMGVfNS0wLTEtMS0yMTIvdGV4dHJlZ2lvbjowYTBiZjFhNjZhNTQ0N2Q1YTAyY2I1MDg1MjE0NGQ1MF8yNzQ4Nzc5MDY5NjE4_44a1f8df-eca7-4706-ac46-25250a6c0f82">TN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV8zMi9mcmFnOmQwMjUzMzYyOTZhYTQwNTdhNTY4NjQ4ODM2YjgzNWZiL3RhYmxlOmI3NGEzNjllNzVkNzRhNDQ5NWMwZjU5NGZjMGE2YjBlL3RhYmxlcmFuZ2U6Yjc0YTM2OWU3NWQ3NGE0NDk1YzBmNTk0ZmMwYTZiMGVfNS0wLTEtMS0yMTIvdGV4dHJlZ2lvbjowYTBiZjFhNjZhNTQ0N2Q1YTAyY2I1MDg1MjE0NGQ1MF8yNzQ4Nzc5MDY5NjI2_d097ee68-ee78-41f1-b0cd-b0d4d4d9b1a0">37203</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV8zMi9mcmFnOmQwMjUzMzYyOTZhYTQwNTdhNTY4NjQ4ODM2YjgzNWZiL3RhYmxlOmI3NGEzNjllNzVkNzRhNDQ5NWMwZjU5NGZjMGE2YjBlL3RhYmxlcmFuZ2U6Yjc0YTM2OWU3NWQ3NGE0NDk1YzBmNTk0ZmMwYTZiMGVfOC0wLTEtMS0yNDMvdGV4dHJlZ2lvbjo5NDE4MjgxMGZhZjg0ZjkyODM2YjZjN2EwMjVjNjkxOF8yNzQ4Nzc5MDY5NDYx_e3d42b6b-1d98-43dd-9100-3a4b44ad39a5">615</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV8zMi9mcmFnOmQwMjUzMzYyOTZhYTQwNTdhNTY4NjQ4ODM2YjgzNWZiL3RhYmxlOmI3NGEzNjllNzVkNzRhNDQ5NWMwZjU5NGZjMGE2YjBlL3RhYmxlcmFuZ2U6Yjc0YTM2OWU3NWQ3NGE0NDk1YzBmNTk0ZmMwYTZiMGVfOC0wLTEtMS0yNDMvdGV4dHJlZ2lvbjo5NDE4MjgxMGZhZjg0ZjkyODM2YjZjN2EwMjVjNjkxOF8yNzQ4Nzc5MDY5NDcy_595c0e8e-dfe0-4e45-b365-0f6253ad78c5">255-0068</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV8zMi9mcmFnOmQwMjUzMzYyOTZhYTQwNTdhNTY4NjQ4ODM2YjgzNWZiL3RhYmxlOmU1ZDVmM2Q1YmJjNDRjNjU5NTU2YTExMzBlNDYwYzliL3RhYmxlcmFuZ2U6ZTVkNWYzZDViYmM0NGM2NTk1NTZhMTEzMGU0NjBjOWJfMC0xLTEtMS0xMjY_3c37fc98-1fdd-48dc-8569-01c951e9a5d4">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV8zMi9mcmFnOmQwMjUzMzYyOTZhYTQwNTdhNTY4NjQ4ODM2YjgzNWZiL3RhYmxlOjBkNmQ2MmUzNTBiNDQ1MGViNGNmMmZlZGI4YmZlNDgyL3RhYmxlcmFuZ2U6MGQ2ZDYyZTM1MGI0NDUwZWI0Y2YyZmVkYjhiZmU0ODJfMC0xLTEtMS0xMjg_e86823c7-cceb-4f19-8178-b57af37737a4">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV8zMi9mcmFnOmQwMjUzMzYyOTZhYTQwNTdhNTY4NjQ4ODM2YjgzNWZiL3RhYmxlOmZlOTJiZTE2MGY0ZjQzZjRhMGVlZDc2ZDE1Y2U1NjFjL3RhYmxlcmFuZ2U6ZmU5MmJlMTYwZjRmNDNmNGEwZWVkNzZkMTVjZTU2MWNfMC0xLTEtMS0xMzA_606e04ac-aaa7-4d9b-8b33-4c96767c7a8f">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV8zMi9mcmFnOmQwMjUzMzYyOTZhYTQwNTdhNTY4NjQ4ODM2YjgzNWZiL3RhYmxlOjI5NGVjYjMyNzQ0ZjRkYTRiOWMyMGM4Y2QzNDBjZGEwL3RhYmxlcmFuZ2U6Mjk0ZWNiMzI3NDRmNGRhNGI5YzIwYzhjZDM0MGNkYTBfMC0xLTEtMS0xMzI_36cb0345-18e2-4d80-b424-a57625906510">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV8zMi9mcmFnOmQwMjUzMzYyOTZhYTQwNTdhNTY4NjQ4ODM2YjgzNWZiL3RhYmxlOmIwMWRlZjgwOTM1ZjQ2MzI4M2QzZDRkYTQ3ZDMzZGVlL3RhYmxlcmFuZ2U6YjAxZGVmODA5MzVmNDYzMjgzZDNkNGRhNDdkMzNkZWVfMS0wLTEtMS0xMTM_551d30d7-1217-4215-b003-cbfc463458ef">Common stock, no par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV8zMi9mcmFnOmQwMjUzMzYyOTZhYTQwNTdhNTY4NjQ4ODM2YjgzNWZiL3RhYmxlOmIwMWRlZjgwOTM1ZjQ2MzI4M2QzZDRkYTQ3ZDMzZGVlL3RhYmxlcmFuZ2U6YjAxZGVmODA5MzVmNDYzMjgzZDNkNGRhNDdkMzNkZWVfMS0yLTEtMS0xMTU_0388496c-bd6b-4618-a7d0-d90fb4290a89">CPIX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV8zMi9mcmFnOmQwMjUzMzYyOTZhYTQwNTdhNTY4NjQ4ODM2YjgzNWZiL3RhYmxlOmIwMWRlZjgwOTM1ZjQ2MzI4M2QzZDRkYTQ3ZDMzZGVlL3RhYmxlcmFuZ2U6YjAxZGVmODA5MzVmNDYzMjgzZDNkNGRhNDdkMzNkZWVfMS00LTEtMS0xMTc_203f71dd-e35b-4a7f-9bf7-00a632101116">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV8zMi9mcmFnOmQwMjUzMzYyOTZhYTQwNTdhNTY4NjQ4ODM2YjgzNWZiL3RleHRyZWdpb246ZDAyNTMzNjI5NmFhNDA1N2E1Njg2NDg4MzZiODM1ZmJfMjc0ODc3OTA3Nzk4Mw_3a5db112-2f2d-4c4b-b5c1-7e761a5fe292">false</dei:EntityEmergingGrowthCompany>
    <dei:AmendmentDescription
      contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV8zMi9mcmFnOmQwMjUzMzYyOTZhYTQwNTdhNTY4NjQ4ODM2YjgzNWZiL3RleHRyZWdpb246ZDAyNTMzNjI5NmFhNDA1N2E1Njg2NDg4MzZiODM1ZmJfMjc0ODc3OTA4MDE3NQ_92307870-dfd2-43a8-80f0-4b4c97c75f9d">Cumberland Pharmaceuticals Inc. ("Cumberland", &#x201c;we&#x201d;, &#x201c;our&#x201d; or "the Company") is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. This Current Report on Form 8-K (&#x201c;Form 8-K&#x201d;) is being filed to recast historical financial information, originally included in our  Annual Report on Form 10-K for the year ended December 31, 2019 ("2019 Form 10-K") to reflect the presentation of two Products we no longer distribute as discontinued operations. We previously filed the 2019 Form 10-K with the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March 20, 2020.During May 2019, Cumberland entered into a Dissolution Agreement  ("Dissolution Agreement") with Clinigen Healthcare Limited ("Clinigen") in which the Company returned the exclusive rights to commercialize Ethyol&#xae; and Totect&#xae; (&#x201c;the Products&#x201d;) in the United States to Clinigen. Under the terms of the Dissolution Agreement, Cumberland is no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products following December 31, 2019. In exchange for the return of these product license rights and the non-compete provisions of the Dissolution Agreement, Cumberland is receiving $5 million in financial consideration paid in quarterly installments over the two-years following the transition date. The Company's exit from the Products meets the accounting criteria to be reported as discontinued operations and the discontinued operating results have been reclassified in the financial statements and footnotes for all periods presented, as required, to reflect the discontinued status of the Products, beginning in our Quarterly Report on Form 10-Q for the first quarter of 2020.  We are issuing this Form 8-K to recast the Products as discontinued operations as of and for each of the periods covered by our 2019 Form 10-K. Accordingly, the Company has retrospectively recast its previously issued annual financial statements for the three years in the period ended December 31, 2019 to present the Products as discontinued operations.The information included in Exhibit 99.1 to this Current Report on Form 8-K is presented solely in connection with the presentation changes described above and sections included in the 2019 Form 10-K that are not included in this report continue to speak only as of the original filing date.  Exhibit 99.1 to this Form 8-K does not reflect events occurring after the Company filed its 2019 Form 10-K, and does not modify or update the disclosures therein in any way, other than to reflect the presentation of the Products as discontinued operations as described above. Therefore, Exhibit 99.1 to this Form 8-K should be read in conjunction with the Company&#x2019;s other filings made with the SEC, including, and subsequent to the date of, the 2019 Form 10-K. These subsequent SEC filings contain important information regarding events, developments, and updates affecting Cumberland and our expectations that have occurred since the filing of the 2019 Form 10-K.Exhibit 99.1 of this Form 8-K presents a recast of the following historical financial information, originally included in our 2019 Form 10-K, to reflect the presentation of the Products as discontinued operations:&#x2022;Item 6. Selected Financial Data&#x2022;Item 7. Management&#x2019;s Discussion and Analysis of  Financial Condition and Results of Operations&#x2022;Item 8. Financial Statements and Supplementary Data</dei:AmendmentDescription>
    <us-gaap:CommonStockNoParValue
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzUvZnJhZzo3MjRkNTkzNGQwOTg0ZmY4ODY5Nzk0MzMwMWZiZTlkNi90YWJsZTpiMThhMWMyMDQ0ZTc0MWE4YmEyNGE2MmFmYWMzZmZmNS90YWJsZXJhbmdlOmIxOGExYzIwNDRlNzQxYThiYTI0YTYyYWZhYzNmZmY1XzItMi0xLTEtMA_c80c9792-301a-4ced-9c75-5e8299321341"
      unitRef="usdPerShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzUvZnJhZzo3MjRkNTkzNGQwOTg0ZmY4ODY5Nzk0MzMwMWZiZTlkNi90YWJsZTpiMThhMWMyMDQ0ZTc0MWE4YmEyNGE2MmFmYWMzZmZmNS90YWJsZXJhbmdlOmIxOGExYzIwNDRlNzQxYThiYTI0YTYyYWZhYzNmZmY1XzItNC0xLTEtMA_7724488e-362a-4c62-873d-bc358d35c4ce"
      unitRef="usdPerShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzUvZnJhZzo3MjRkNTkzNGQwOTg0ZmY4ODY5Nzk0MzMwMWZiZTlkNi90YWJsZTpiMThhMWMyMDQ0ZTc0MWE4YmEyNGE2MmFmYWMzZmZmNS90YWJsZXJhbmdlOmIxOGExYzIwNDRlNzQxYThiYTI0YTYyYWZhYzNmZmY1XzMtMi0xLTEtMA_1702172f-f114-4be5-8e6f-d23723915c28"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzUvZnJhZzo3MjRkNTkzNGQwOTg0ZmY4ODY5Nzk0MzMwMWZiZTlkNi90YWJsZTpiMThhMWMyMDQ0ZTc0MWE4YmEyNGE2MmFmYWMzZmZmNS90YWJsZXJhbmdlOmIxOGExYzIwNDRlNzQxYThiYTI0YTYyYWZhYzNmZmY1XzMtNC0xLTEtMA_7caf0a83-a7f0-4497-9ae0-c84a29651dff"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzUvZnJhZzo3MjRkNTkzNGQwOTg0ZmY4ODY5Nzk0MzMwMWZiZTlkNi90YWJsZTpiMThhMWMyMDQ0ZTc0MWE4YmEyNGE2MmFmYWMzZmZmNS90YWJsZXJhbmdlOmIxOGExYzIwNDRlNzQxYThiYTI0YTYyYWZhYzNmZmY1XzQtMi0xLTEtMA_08c579cc-1253-4bda-ae16-938740fba6f4"
      unitRef="shares">15263555</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzUvZnJhZzo3MjRkNTkzNGQwOTg0ZmY4ODY5Nzk0MzMwMWZiZTlkNi90YWJsZTpiMThhMWMyMDQ0ZTc0MWE4YmEyNGE2MmFmYWMzZmZmNS90YWJsZXJhbmdlOmIxOGExYzIwNDRlNzQxYThiYTI0YTYyYWZhYzNmZmY1XzQtNC0xLTEtMA_e6086cd0-caaa-4d04-b5cf-0b10066485b4"
      unitRef="shares">15481497</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzUvZnJhZzo3MjRkNTkzNGQwOTg0ZmY4ODY5Nzk0MzMwMWZiZTlkNi90YWJsZTpiMThhMWMyMDQ0ZTc0MWE4YmEyNGE2MmFmYWMzZmZmNS90YWJsZXJhbmdlOmIxOGExYzIwNDRlNzQxYThiYTI0YTYyYWZhYzNmZmY1XzUtMi0xLTEtMA_7f6f6f61-1256-4643-b746-ea13f066cf96"
      unitRef="shares">15263555</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzUvZnJhZzo3MjRkNTkzNGQwOTg0ZmY4ODY5Nzk0MzMwMWZiZTlkNi90YWJsZTpiMThhMWMyMDQ0ZTc0MWE4YmEyNGE2MmFmYWMzZmZmNS90YWJsZXJhbmdlOmIxOGExYzIwNDRlNzQxYThiYTI0YTYyYWZhYzNmZmY1XzUtNC0xLTEtMA_6a7374be-3541-4021-9872-1a49cf3f4a23"
      unitRef="shares">15481497</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="id5c37f17bdd045d8876714d588be095a_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTEvZnJhZzozZjdkMGU0M2JkZjY0MGM3YTU1NzFjNjFmNzkxZDM4NS90YWJsZTo2YmYwNTI4OWIyYWQ0OTUyYjkwMGFmYTA4ZmJlNDU2Yy90YWJsZXJhbmdlOjZiZjA1Mjg5YjJhZDQ5NTJiOTAwYWZhMDhmYmU0NTZjXzEtNC0xLTEtMA_386e12f1-024a-41ca-aa54-41573f54cf6a">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i171ae0e4eec14d9f868621f1dba24be1_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTEvZnJhZzozZjdkMGU0M2JkZjY0MGM3YTU1NzFjNjFmNzkxZDM4NS90YWJsZTo2YmYwNTI4OWIyYWQ0OTUyYjkwMGFmYTA4ZmJlNDU2Yy90YWJsZXJhbmdlOjZiZjA1Mjg5YjJhZDQ5NTJiOTAwYWZhMDhmYmU0NTZjXzEtNi0xLTEtMA_a5a242ca-fb59-4a08-bccd-55631be87b65">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ic27611c0dbc04b7988dcc9331bfbe1cb_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTEvZnJhZzozZjdkMGU0M2JkZjY0MGM3YTU1NzFjNjFmNzkxZDM4NS90YWJsZTo2YmYwNTI4OWIyYWQ0OTUyYjkwMGFmYTA4ZmJlNDU2Yy90YWJsZXJhbmdlOjZiZjA1Mjg5YjJhZDQ5NTJiOTAwYWZhMDhmYmU0NTZjXzItNC0xLTEtMA_9bf291ee-ebed-4453-8fc7-a824c8e3d68d">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i947f330f1863460ea96eb801e0df3cde_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTEvZnJhZzozZjdkMGU0M2JkZjY0MGM3YTU1NzFjNjFmNzkxZDM4NS90YWJsZTo2YmYwNTI4OWIyYWQ0OTUyYjkwMGFmYTA4ZmJlNDU2Yy90YWJsZXJhbmdlOjZiZjA1Mjg5YjJhZDQ5NTJiOTAwYWZhMDhmYmU0NTZjXzItNi0xLTEtMA_e362691e-7a1b-4513-a988-91c6727e3299">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="if1b631d150a9425d83302ca84d5acf6f_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTEvZnJhZzozZjdkMGU0M2JkZjY0MGM3YTU1NzFjNjFmNzkxZDM4NS90YWJsZTo2YmYwNTI4OWIyYWQ0OTUyYjkwMGFmYTA4ZmJlNDU2Yy90YWJsZXJhbmdlOjZiZjA1Mjg5YjJhZDQ5NTJiOTAwYWZhMDhmYmU0NTZjXzMtNC0xLTEtMA_a3c70d36-b84e-4443-8d64-d2a0fdf42347">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i2beb96285c7c4c4c9e3166c0f1577edc_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTEvZnJhZzozZjdkMGU0M2JkZjY0MGM3YTU1NzFjNjFmNzkxZDM4NS90YWJsZTo2YmYwNTI4OWIyYWQ0OTUyYjkwMGFmYTA4ZmJlNDU2Yy90YWJsZXJhbmdlOjZiZjA1Mjg5YjJhZDQ5NTJiOTAwYWZhMDhmYmU0NTZjXzMtNi0xLTEtMA_b978d091-c6d3-4bf8-bdcb-406a441c8f63">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <cpix:PropertyAndEquipmentUsefulLifeTextual
      contextRef="ifa90d2ee803c421baadb41895368ae03_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTEvZnJhZzozZjdkMGU0M2JkZjY0MGM3YTU1NzFjNjFmNzkxZDM4NS90YWJsZTo2YmYwNTI4OWIyYWQ0OTUyYjkwMGFmYTA4ZmJlNDU2Yy90YWJsZXJhbmdlOjZiZjA1Mjg5YjJhZDQ5NTJiOTAwYWZhMDhmYmU0NTZjXzQtMi0xLTEtMA_dd1ab64d-9455-4bb4-b420-6458fa85bf5d">3&#160;&#x2013;&#160;15&#160;years,&#160;or remaining&#160;lease&#160;term</cpix:PropertyAndEquipmentUsefulLifeTextual>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i35e4a7c76589409caba0ef887cf3d6c8_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTEvZnJhZzozZjdkMGU0M2JkZjY0MGM3YTU1NzFjNjFmNzkxZDM4NS90YWJsZTo2YmYwNTI4OWIyYWQ0OTUyYjkwMGFmYTA4ZmJlNDU2Yy90YWJsZXJhbmdlOjZiZjA1Mjg5YjJhZDQ5NTJiOTAwYWZhMDhmYmU0NTZjXzQtNC0xLTEtMA_9f483c38-ad8f-4354-8922-7052a6bec453">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ieba1c5b99e794cc887ea29cce7db35d5_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTEvZnJhZzozZjdkMGU0M2JkZjY0MGM3YTU1NzFjNjFmNzkxZDM4NS90YWJsZTo2YmYwNTI4OWIyYWQ0OTUyYjkwMGFmYTA4ZmJlNDU2Yy90YWJsZXJhbmdlOjZiZjA1Mjg5YjJhZDQ5NTJiOTAwYWZhMDhmYmU0NTZjXzQtNi0xLTEtMA_5543448b-6169-4036-9ac4-7eb565c18390">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i53e4a12de53b4b0c99c928fb854c6569_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90ZXh0cmVnaW9uOmM5ODUzNWNiMmJkMTQ4N2U4ODgxNTg4MWY0MTI2Y2ZkXzQzOTgwNDY1MTM3MjU_e4aa551b-a49e-47c8-ae2e-da92a179d352">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <cpix:FinancialConsiderationPaymentPeriod
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90ZXh0cmVnaW9uOjEzZmIyMzg2ZmEwMDQ0OWNhOTQzZmUwYWM0YTU3ZTE5XzQzOTgwNDY1MjI4MDI_72facf0f-0ab8-4e03-8486-1d05338389f9">P2Y</cpix:FinancialConsiderationPaymentPeriod>
    <dei:EntityCentralIndexKey
      contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV82MC9mcmFnOmNkNzk4OTQyZjFjZDQwNDRiZGMwMWYwOWUxZmU2M2U1L3RhYmxlOjlmYjQzNDM3ZDQ2NDQ3ZDM5MzU0MmJkYjU4MmMxMDZiL3RhYmxlcmFuZ2U6OWZiNDM0MzdkNDY0NDdkMzkzNTQyYmRiNTgyYzEwNmJfMS0xLTEtMS0xNDQ_0e471d2c-7b8f-45bb-a7fb-4f661ddb975a">0001087294</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i7a6e879bfd2c43f08102604657a76057_D20201210-20201210"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkN2MxNGIwMDNjNzQwN2Y4NWU3NDU2NzA1ZGFhMjNhL3NlYzo2ZDdjMTRiMDAzYzc0MDdmODVlNzQ1NjcwNWRhYTIzYV82MC9mcmFnOmNkNzk4OTQyZjFjZDQwNDRiZGMwMWYwOWUxZmU2M2U1L3RhYmxlOjlmYjQzNDM3ZDQ2NDQ3ZDM5MzU0MmJkYjU4MmMxMDZiL3RhYmxlcmFuZ2U6OWZiNDM0MzdkNDY0NDdkMzkzNTQyYmRiNTgyYzEwNmJfMi0xLTEtMS0xNDQ_8a730d69-a8e3-49a8-8df2-13e16db6faaf">true</dei:AmendmentFlag>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzQtMi0xLTEtMA_b19c17d5-722e-4b87-9409-db4d610ee8fb"
      unitRef="usd">28212635</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzQtNC0xLTEtMA_75293d7f-d7ca-4fa6-97fb-048f465bea1b"
      unitRef="usd">27938960</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzUtMi0xLTEtMA_85a4237e-5f7f-4241-9f62-dbc8ebd6fb5d"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzUtNC0xLTEtMA_a9d41153-9b02-4c96-b79f-726127c74b98"
      unitRef="usd">8290679</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzYtMi0xLTEtMA_ce69dacc-e8e3-4b73-b4cb-cb6a711f8846"
      unitRef="usd">7859006</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzYtNC0xLTEtMA_d1f86007-e621-45aa-8703-d435ee0d3321"
      unitRef="usd">6459995</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzctMi0xLTEtMA_6f5604af-16cb-4b9d-b2ad-90f8120e8e91"
      unitRef="usd">8871254</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzctNC0xLTEtMA_e4c86178-b993-481a-9d49-e74c6ec31435"
      unitRef="usd">9783421</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzgtMi0xLTEtMA_8994eb27-9a33-4f39-a858-0d7aa27dc03d"
      unitRef="usd">2757456</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzgtNC0xLTEtMA_cbb90478-49ac-4e43-8e84-bad0ea1f7935"
      unitRef="usd">2936085</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzgtMi0xLTEtMjA3OA_0b19d068-f383-4b72-a3a0-61d2edf0115d"
      unitRef="usd">2462724</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzgtNC0xLTEtMjA4MA_a58caf9c-72e2-4e90-9a62-7f14b7514903"
      unitRef="usd">3706897</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsCurrent
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzktMi0xLTEtMA_4eeb1353-6fb3-4a4f-a300-e6959b2244d8"
      unitRef="usd">50163075</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzktNC0xLTEtMA_76d8a067-1d1b-4792-a5fb-b870ac218d8e"
      unitRef="usd">59116037</us-gaap:AssetsCurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzEwLTItMS0xLTA_3b903242-6698-4aa5-af2c-144793d63720"
      unitRef="usd">15554992</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzEwLTQtMS0xLTA_793ae818-fccd-4ecd-9d87-312bd436f1f1"
      unitRef="usd">15749000</us-gaap:InventoryNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzExLTItMS0xLTA_068f09de-3567-4557-9a6e-946a9da40fc5"
      unitRef="usd">747796</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzExLTQtMS0xLTA_071b569a-b16a-4a6b-a931-37f211aebad7"
      unitRef="usd">771213</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzEyLTItMS0xLTA_d1bcc20e-6803-403a-b549-59a8afcb8c46"
      unitRef="usd">30920324</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzEyLTQtMS0xLTA_20c79dcc-0390-40f6-b254-ebc5355da75c"
      unitRef="usd">33655099</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzEzLTItMS0xLTA_c6fde496-ab40-41fb-855e-9aa40730d894"
      unitRef="usd">882000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzEzLTQtMS0xLTA_43211833-2be9-4820-bb8d-0caac1074d27"
      unitRef="usd">784000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzE0LTItMS0xLTA_96c54551-683e-42c7-94d5-908811ddfbab"
      unitRef="usd">21802</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzE0LTQtMS0xLTA_dea60172-0d62-4e22-806c-28a5b78a99d4"
      unitRef="usd">87210</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzE1LTItMS0xLTA_28340ecf-541b-4cbd-981c-db219d82e09b"
      unitRef="usd">2960569</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzE2LTItMS0xLTA_b285e6d5-afe0-4d79-8b07-236d1a6e0065"
      unitRef="usd">3298725</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzE2LTQtMS0xLTA_aac5f162-1fe6-430d-9865-256c2aabb79e"
      unitRef="usd">2531309</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzE3LTItMS0xLTA_b71bf87a-9ce6-4780-9451-020627815ae5"
      unitRef="usd">104549283</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzE3LTQtMS0xLTA_9fb17739-1dba-4da7-9871-71c803d53bb5"
      unitRef="usd">112693868</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzIxLTItMS0xLTA_de6979a8-35af-45ca-b463-e3bfc56268bf"
      unitRef="usd">9993578</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzIxLTQtMS0xLTA_245652ed-12e6-4b11-98ed-eea55deeeadc"
      unitRef="usd">8210641</us-gaap:AccountsPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzIyLTItMS0xLTA_81efae0c-f915-46a5-9ff9-8c3ea6af8aac"
      unitRef="usd">920431</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzIzLTItMS0xLTA_5afac0ad-c54e-4f46-8ed8-c3c8201fe531"
      unitRef="usd">11084869</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzIzLTQtMS0xLTA_6e237ac0-231d-4dc7-8789-757f50867e12"
      unitRef="usd">16044470</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzI0LTItMS0xLTIwODI_96b37603-59e3-4ddd-8f92-66c845276d0a"
      unitRef="usd">2151357</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzI0LTQtMS0xLTIwODQ_e71187fb-c341-4eba-9bb2-3e2cfcb06a66"
      unitRef="usd">3549113</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzI0LTItMS0xLTA_cffc2bcd-8fc7-4bcd-a1c9-93f94a0af657"
      unitRef="usd">24150235</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzI0LTQtMS0xLTA_dcec5097-e254-4b8b-907c-46f75845b56f"
      unitRef="usd">27804224</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermLineOfCredit
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzI1LTItMS0xLTA_64e9c75a-1feb-4471-ab87-8ab8e6a4104b"
      unitRef="usd">18500000</us-gaap:LongTermLineOfCredit>
    <us-gaap:LongTermLineOfCredit
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzI1LTQtMS0xLTA_348eebf6-b11b-4a95-9332-c63be68a6f20"
      unitRef="usd">20000000</us-gaap:LongTermLineOfCredit>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzI2LTItMS0xLTA_55db9af3-a317-4c1d-a056-754a7d719ee9"
      unitRef="usd">2076472</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzI3LTItMS0xLTA_c682ffc3-1c35-44f1-b0a3-eb91f3f673ea"
      unitRef="usd">8737323</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzI3LTQtMS0xLTA_ad6c85d2-ca11-414b-b094-76ffc2edaa0e"
      unitRef="usd">9319143</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzI4LTItMS0xLTA_dafcb1bd-feec-4c75-af32-ecc134005ba1"
      unitRef="usd">53464030</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzI4LTQtMS0xLTA_8ee5e242-2926-4b79-99ef-0cf5357fe228"
      unitRef="usd">57123367</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzI5LTItMS0xLTA_c653c06d-d475-47cc-b1d0-a2f5e0afe8ea"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzI5LTQtMS0xLTA_a7cb226f-0ab1-4052-a1e0-d099f046eff2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockValueOutstanding
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzMyLTItMS0xLTA_154af6cd-c00c-44b6-933c-83c55680e2b2"
      unitRef="usd">49914478</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzMyLTQtMS0xLTA_976e9a0c-6fbe-41fe-954b-a09be7451dc4"
      unitRef="usd">51098613</us-gaap:CommonStockValueOutstanding>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzMzLTItMS0xLTA_0a5095e7-4238-466a-bba0-91d6e4b0df39"
      unitRef="usd">1208395</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzMzLTQtMS0xLTA_e6dabc36-93bf-458a-b9a4-eb2f560d9511"
      unitRef="usd">4746154</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzM0LTItMS0xLTA_4f95ab19-ead1-47e1-8347-8741a1d47929"
      unitRef="usd">51122873</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzM0LTQtMS0xLTA_0564f999-b13b-4de3-a7a6-dd9e24f87bda"
      unitRef="usd">55844767</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzM1LTItMS0xLTA_8cc33cfe-48ef-4182-a1c5-3371821bc17f"
      unitRef="usd">-37620</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzM1LTQtMS0xLTA_852b9dba-d9ae-47c5-839a-314fdc5999f1"
      unitRef="usd">-274266</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzM2LTItMS0xLTA_0d3d9855-315a-4310-819a-e5d9d4db74f7"
      unitRef="usd">51085253</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzM2LTQtMS0xLTA_a157a0db-4bb0-489c-bca9-79b65c581523"
      unitRef="usd">55570501</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzM3LTItMS0xLTA_7011710b-4921-4732-988e-5ae51f841570"
      unitRef="usd">104549283</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzIvZnJhZzozN2RhMDUwODhjNDM0MGEyOTMzOWQ0ZDdmMjBiYTQ0NC90YWJsZTo3NWE1NWE2MjI3MTk0YzNkYjdiNzE3YjE4YTI2YzY2My90YWJsZXJhbmdlOjc1YTU1YTYyMjcxOTRjM2RiN2I3MTdiMThhMjZjNjYzXzM3LTQtMS0xLTA_6430d4e1-ecac-4f33-926d-fcc28e7d59d7"
      unitRef="usd">112693868</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="iede275917f1d4f6ab16130b2891da5ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzMtMi0xLTEtMA_8c07927a-41cd-48dc-8144-a78c87cc2378"
      unitRef="usd">32407245</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3a75f009943b411484603265cc918c63_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzMtNC0xLTEtMA_ca3dbf8c-3f86-4687-811e-3739cd9b0bb4"
      unitRef="usd">28803961</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7565a83142144039aa664a5158a4f3a1_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzMtNi0xLTEtMA_3839bf6a-0126-47af-869d-4624ee596ae3"
      unitRef="usd">25549059</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i12130cb8adf747bc917372e57661c37d_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzQtMi0xLTEtMA_ff3d603a-1a3d-4ac8-8ba4-65eb02d3dd06"
      unitRef="usd">1981050</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i80b0be59c71148caa508bedc7c0aa249_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzQtNC0xLTEtMA_bb1dc299-727e-420b-88c3-f3fd747e7d24"
      unitRef="usd">540933</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6a3679cdc7a7417d9491addba442e136_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzQtNi0xLTEtMA_48805c69-58ef-464d-aa78-149b5c88e5b2"
      unitRef="usd">773568</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzUtMi0xLTEtMA_9330aba7-6e0c-4117-a96c-28fb4c274b2d"
      unitRef="usd">34388295</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzUtNC0xLTEtMA_363f99c0-bffe-43da-9a41-f03309a84d66"
      unitRef="usd">29344894</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzUtNi0xLTEtMA_c40971ea-2c57-45e3-8e72-0fee1694233d"
      unitRef="usd">26322627</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzctMi0xLTEtMA_7c294355-9b71-4a14-9c68-ec9e514d1a87"
      unitRef="usd">7421316</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzctNC0xLTEtMA_fdb49ed9-8a58-479b-a254-8f44e4909fa1"
      unitRef="usd">6016822</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzctNi0xLTEtMA_095c6b17-91bb-4886-9cfb-969655d42a07"
      unitRef="usd">5418010</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzgtMi0xLTEtMA_37ab75cc-195b-478c-b3f6-efc6395cebb5"
      unitRef="usd">15277740</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzgtNC0xLTEtMA_ac0237e0-b224-476a-bff8-e6145518dc81"
      unitRef="usd">14004933</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzgtNi0xLTEtMA_e51a2f3b-1bbb-4048-8f52-6ffae4c6d4f5"
      unitRef="usd">13489178</us-gaap:SellingAndMarketingExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzktMi0xLTEtMA_d2b7e98a-a70e-44c0-9410-8ead2c91164c"
      unitRef="usd">6868480</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzktNC0xLTEtMA_90e9c77c-d81e-4282-8ff6-ed48425ced78"
      unitRef="usd">7575892</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzktNi0xLTEtMA_d349091f-40ca-47c0-adc9-69fd9fa02ccc"
      unitRef="usd">4247623</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzEwLTItMS0xLTA_86d72542-be36-4a23-9549-efcf01503691"
      unitRef="usd">9974384</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzEwLTQtMS0xLTA_10bca782-b443-4bb3-a3ff-b0730eba3dca"
      unitRef="usd">10150777</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzEwLTYtMS0xLTA_b7632241-f19b-4ce4-99bc-8a13b6066907"
      unitRef="usd">9610967</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzExLTItMS0xLTA_0a3f8a40-dced-46db-84b3-24c46f6dd07f"
      unitRef="usd">4134557</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzExLTQtMS0xLTA_94e88050-e28d-42e3-a2d5-cad3df3a64b4"
      unitRef="usd">2769466</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzExLTYtMS0xLTA_3505f7ed-04a8-404e-91e3-f42124ceff2f"
      unitRef="usd">2436222</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:CostsAndExpenses
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzEyLTItMS0xLTA_6e64db81-7f32-44f4-9b5d-16eab253c632"
      unitRef="usd">43676477</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzEyLTQtMS0xLTA_12be04cb-0ee3-46e5-91f1-f73896b73f5c"
      unitRef="usd">40517890</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzEyLTYtMS0xLTA_74406b56-0354-4234-8dfb-7a8aaca8abec"
      unitRef="usd">35202000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzEzLTItMS0xLTA_5dd549c9-40a9-4fee-b30b-7e7a6260c1bf"
      unitRef="usd">-9288182</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzEzLTQtMS0xLTA_8a7fb8a1-84d1-40d0-b34e-eb7ac703a6af"
      unitRef="usd">-11172996</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzEzLTYtMS0xLTA_30fcc8f2-ea6a-465b-9a21-605f971dc9fc"
      unitRef="usd">-8879373</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE0LTItMS0xLTA_958ae051-6b47-4ce8-ad0f-3c64609bbfff"
      unitRef="usd">243364</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE0LTQtMS0xLTA_483acf5b-70a9-4f6a-a9c6-568ea5572d43"
      unitRef="usd">564484</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE0LTYtMS0xLTA_04d2a15c-0aad-42b2-8020-e3860046d67e"
      unitRef="usd">299326</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE1LTItMS0xLTA_8c5dbdec-7536-487b-9921-e25dd6faaef1"
      unitRef="usd">246186</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE1LTQtMS0xLTA_504ae354-d08e-4019-9552-6db0fb585652"
      unitRef="usd">195848</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE1LTYtMS0xLTA_c59fd32b-e73c-45a8-aee8-4f17a2a2872b"
      unitRef="usd">92904</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE2LTItMS0xLTA_06765b1b-20a9-4f06-806d-bbadc1ae9943"
      unitRef="usd">-9291004</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE2LTQtMS0xLTA_617bd941-9b2d-46d0-9bbb-e0807d7d4f23"
      unitRef="usd">-10804360</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE2LTYtMS0xLTA_fa2cfb04-a67e-4f8c-a13e-81085a64bda3"
      unitRef="usd">-8672951</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE3LTItMS0xLTA_260532e7-f028-41de-ac4f-61ad0969aa94"
      unitRef="usd">-79316</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE3LTQtMS0xLTA_b278048c-13ca-4a6f-aa11-519f61b34ca6"
      unitRef="usd">16636</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE3LTYtMS0xLTA_84457095-afcb-4fc1-b6da-240981cac506"
      unitRef="usd">4174889</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE4LTItMS0xLTA_dedbe145-6bdb-493f-9048-b520b606e267"
      unitRef="usd">-9211688</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE4LTQtMS0xLTA_7f096769-99c8-4530-9cbb-788588bbda24"
      unitRef="usd">-10820996</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE4LTYtMS0xLTA_57f222eb-8412-4022-a07f-bcc49808879c"
      unitRef="usd">-12847840</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE4LTItMS0xLTQwNQ_127ab94a-6c52-407f-90b1-9de92cbd0807"
      unitRef="usd">5665177</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE4LTQtMS0xLTQwNQ_cd961af5-4104-47d1-b891-43d77603bb31"
      unitRef="usd">3782224</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE4LTYtMS0xLTExODM_40177350-47be-49de-ac56-d4e5b3e56beb"
      unitRef="usd">4798025</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE5LTItMS0xLTExODg_03ac504f-d5e1-478f-bed3-f82861bd6972"
      unitRef="usd">-3546511</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE5LTQtMS0xLTExODY_039995f2-14e6-4110-8289-a83040586a1b"
      unitRef="usd">-7038772</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE5LTYtMS0xLTExODM_e461cb0c-df8c-46ce-8c7a-55f45394341b"
      unitRef="usd">-8049815</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE5LTItMS0xLTA_2a41210e-25fd-442e-8987-2dfc460a8d44"
      unitRef="usd">-8752</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE5LTQtMS0xLTA_90ad1b36-e51b-4bb9-8465-4ff71d995088"
      unitRef="usd">-75704</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzE5LTYtMS0xLTA_a37afbff-780b-40bc-9324-5b3bb249f69b"
      unitRef="usd">-71182</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzIwLTItMS0xLTA_3d7a56a6-b326-4273-bb5a-8319fc5dc3eb"
      unitRef="usd">-3537759</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzIwLTQtMS0xLTA_9ad0f662-5514-4726-ab54-0d2948139c9f"
      unitRef="usd">-6963068</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzIwLTYtMS0xLTA_a3b042a1-f29b-41fc-923e-5ec1bad7ded8"
      unitRef="usd">-7978633</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzIzLTItMS0xLTA_11b6cd95-3ea8-4160-82c5-9063f0bea46a"
      unitRef="usdPerShare">-0.60</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzIzLTQtMS0xLTA_da2a372a-5499-4398-9355-9adfa1376c67"
      unitRef="usdPerShare">-0.70</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzIzLTYtMS0xLTA_4244e14b-d96f-41ee-83fc-758da54ad006"
      unitRef="usdPerShare">-0.80</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzI0LTItMS0xLTA_5828c226-1dff-4646-85d8-cf172ec49489"
      unitRef="usdPerShare">0.37</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzI0LTQtMS0xLTA_6e59a5d7-cde5-493c-ba2b-1f81e866dae4"
      unitRef="usdPerShare">0.25</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzI0LTYtMS0xLTA_caa5d099-8bf3-493b-958c-eebbc92f76b9"
      unitRef="usdPerShare">0.30</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzI2LTItMS0xLTExOTY_d1e6ad0f-e6b8-48b3-a916-0a7dddecb46a"
      unitRef="usdPerShare">-0.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzI2LTQtMS0xLTExOTg_68532524-6ea9-49d3-9c88-a62bb462edd2"
      unitRef="usdPerShare">-0.45</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzI2LTYtMS0xLTEyMDA_bb348cbe-085e-48f7-9ff5-ba8f9cc989e8"
      unitRef="usdPerShare">-0.50</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzI4LTItMS0xLTEyMDI_ab87b9a4-9c51-4368-8a13-3ba2ea2168fd"
      unitRef="usdPerShare">-0.60</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzI4LTQtMS0xLTEyMDQ_95362776-c855-4237-a5d5-966b06c0cb6f"
      unitRef="usdPerShare">-0.70</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzI4LTYtMS0xLTEyMDY_de762687-bed1-4ee4-9cb8-fa60a2add0b8"
      unitRef="usdPerShare">-0.80</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzI5LTItMS0xLTEyMDI_554720c6-bfbb-40ee-973a-7c9b2adddaa4"
      unitRef="usdPerShare">0.37</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzI5LTQtMS0xLTEyMDQ_a5ca9de4-4199-427d-8bd7-6760fd223e48"
      unitRef="usdPerShare">0.25</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzI5LTYtMS0xLTEyMDY_96e7e157-1a4b-42bf-842b-83cf3bdfc5c6"
      unitRef="usdPerShare">0.30</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzMwLTItMS0xLTEyMDI_74604961-7c99-4bce-b953-eff6066717b5"
      unitRef="usdPerShare">-0.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzMwLTQtMS0xLTEyMDQ_62b985cf-1f1c-417b-bdf2-2b0238646593"
      unitRef="usdPerShare">-0.45</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzMwLTYtMS0xLTEyMDY_038b02f4-5d9b-482e-afc5-336224f46789"
      unitRef="usdPerShare">-0.50</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzI2LTItMS0xLTA_8336ad6e-0cb9-4a71-a8b4-26fd7511d9bd"
      unitRef="shares">15396098</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzI2LTQtMS0xLTA_f71e8a35-a95d-4b33-98f8-3172381af055"
      unitRef="shares">15614052</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzI2LTYtMS0xLTA_cfdd7e38-46c1-448f-82f3-d482e9d216f7"
      unitRef="shares">15911577</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzI3LTItMS0xLTA_da2519a4-4fe5-4928-8814-3b6abfbf2438"
      unitRef="shares">15396098</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzI3LTQtMS0xLTA_b18487b8-ba0d-46f2-aa65-41b8081966e7"
      unitRef="shares">15614052</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzI3LTYtMS0xLTA_67927dd3-97b6-47d5-bf12-12db277619dc"
      unitRef="shares">15911577</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzI5LTItMS0xLTA_1e746336-4be2-482c-a7ff-2439541fea37"
      unitRef="usd">-3537759</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzI5LTQtMS0xLTA_cd02d6e8-021f-4d79-9935-398ba4c3eea1"
      unitRef="usd">-6963068</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzI5LTYtMS0xLTA_b128611a-ed65-4f71-b425-d8526c6f32f0"
      unitRef="usd">-7978633</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzMwLTItMS0xLTA_3ff7c7c6-66a3-429e-8531-c6a71c6d38c3"
      unitRef="usd">-8752</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzMwLTQtMS0xLTA_097794b0-0e78-42a7-9dbe-64aa9cf64764"
      unitRef="usd">-75704</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzMwLTYtMS0xLTA_a64b77a0-394b-45a9-b08e-d2c03b2c9d45"
      unitRef="usd">-71182</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzMxLTItMS0xLTA_46ada651-b234-408d-8d0b-502a588796a0"
      unitRef="usd">-3546511</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xNzgvZnJhZzphNWFmYjdlZGMxYjY0YzUxOGFhYzkzNjQ5ODA2ZjNmYS90YWJsZTo0NTZhMzcyNzg3ZmE0MzdmYjc1NzdjMjMyYzBiNGIwYy90YWJsZXJhbmdlOjQ1NmEzNzI3ODdmYTQzN2ZiNzU3N2MyMzJjMGI0YjBjXzMxLTQtMS0xLTA_dac91437-25fb-4336-94da-6a8a7ef3ba42"
      unitRef="usd">-7038772</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzMtMi0xLTEtMA_a3367ca2-de62-4098-b47e-312d7a1caf47"
      unitRef="usd">-3546511</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzMtNC0xLTEtMA_2ce0b56f-bfef-47ac-8f8b-d2497784a2a6"
      unitRef="usd">-7038772</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzMtNi0xLTEtMA_7117da81-646a-4831-8315-6e99cdf540f0"
      unitRef="usd">-8049815</us-gaap:ProfitLoss>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzQtMi0xLTEtNjQ2_aa2137ce-7c43-457f-851e-3c289ee8e2b0"
      unitRef="usd">5665177</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzQtNC0xLTEtNjQ2_d24b2a8e-11f9-414e-92a4-f880cbc85ea5"
      unitRef="usd">3782224</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzQtNi0xLTEtNjQ2_ac12445b-ae9f-436c-94f3-e718cf0d9ee2"
      unitRef="usd">4798025</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzUtMi0xLTEtNjQ2_f149db9f-654d-433a-8738-15be9dd31004"
      unitRef="usd">-9211688</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzUtNC0xLTEtNjQ2_8c6c8f71-065e-4133-85b7-9495ed7abc5b"
      unitRef="usd">-10820996</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzUtNi0xLTEtNjQ2_74576b25-fb92-4f00-bd03-ef46afc0d4d7"
      unitRef="usd">-12847840</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzUtMi0xLTEtMA_0ed9c62b-2860-4586-b47e-e0adb1f70f56"
      unitRef="usd">4404175</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzUtNC0xLTEtMA_d638ea02-4854-4022-a2c8-4b6f8299b385"
      unitRef="usd">2982703</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzUtNi0xLTEtMA_1402ffbf-bc6a-4879-a226-64b28005a8f1"
      unitRef="usd">2647753</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzYtMi0xLTEtMA_6307ad31-490c-4393-80ff-1d57367d534a"
      unitRef="usd">65408</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzYtNC0xLTEtMA_618bc4a1-745b-4b13-a87e-524f78aced42"
      unitRef="usd">81886</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzYtNi0xLTEtMA_f806ef37-50f3-4193-bc2e-efb4460bea8a"
      unitRef="usd">4206753</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensation
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzctMi0xLTEtMA_d28ed3b7-363a-4dcf-abf1-19ecf6161ef1"
      unitRef="usd">1485898</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzctNC0xLTEtMA_71e0d0fa-4e3d-4620-95b6-262c948d1ed6"
      unitRef="usd">1364698</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzctNi0xLTEtMA_f63bbb43-8dac-4f13-973a-2fc4eb396d71"
      unitRef="usd">1115063</us-gaap:ShareBasedCompensation>
    <cpix:SharebasedCompensationFoundationContribution
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzgtMi0xLTEtMA_1699eeca-5470-4ad7-9246-87b4fe32ae1a"
      unitRef="usd">0</cpix:SharebasedCompensationFoundationContribution>
    <cpix:SharebasedCompensationFoundationContribution
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzgtNC0xLTEtMA_1da89833-3e25-4084-bc6c-31d06f359f6f"
      unitRef="usd">0</cpix:SharebasedCompensationFoundationContribution>
    <cpix:SharebasedCompensationFoundationContribution
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzgtNi0xLTEtMA_8f5738c3-de2a-415d-8dc9-702630ba780a"
      unitRef="usd">372500</cpix:SharebasedCompensationFoundationContribution>
    <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzktMi0xLTEtMA_416ffe3e-05bc-4e99-b034-719146320726"
      unitRef="usd">0</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
    <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzktNC0xLTEtMA_d364d832-da53-41c8-8f8e-891f36b4757d"
      unitRef="usd">81886</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
    <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzktNi0xLTEtMA_550d873d-2605-4d72-bd2e-0d310afd8af1"
      unitRef="usd">91109</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzEwLTItMS0xLTA_6cfff0c6-ed25-491e-87d7-7d4589563e28"
      unitRef="usd">804167</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzEwLTQtMS0xLTA_666a8fba-9676-496a-9bd6-7afe0821d11e"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzEwLTYtMS0xLTA_61fae01c-350a-4599-84b8-bbaa9fe3bf75"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzExLTItMS0xLTA_7eb3299a-830f-4ada-a514-c0ccff2ad465"
      unitRef="usd">47525</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzExLTQtMS0xLTA_5fd901db-13e7-493f-a5b2-3884d3cf001c"
      unitRef="usd">99883</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzExLTYtMS0xLTA_30530967-59a7-495c-ae54-5ee251e2f1f3"
      unitRef="usd">77911</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:OtherNonoperatingGainsLosses
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzEyLTItMS0xLTA_3fb1d7ad-5a91-4846-8b24-726502ccb6ff"
      unitRef="usd">26315</us-gaap:OtherNonoperatingGainsLosses>
    <us-gaap:OtherNonoperatingGainsLosses
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzEyLTQtMS0xLTA_339f31fe-dc5f-4bca-93ec-eaae64af7fb2"
      unitRef="usd">168440</us-gaap:OtherNonoperatingGainsLosses>
    <us-gaap:OtherNonoperatingGainsLosses
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzEyLTYtMS0xLTA_2d669fb5-133c-4c96-82ff-a9d736ed09e0"
      unitRef="usd">52012</us-gaap:OtherNonoperatingGainsLosses>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzE0LTItMS0xLTA_c44e21a5-f8aa-4d3b-b41b-609c30aba22c"
      unitRef="usd">1399012</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzE0LTQtMS0xLTA_3efbc298-cebd-4d0c-9df0-17e61d01a4d8"
      unitRef="usd">47288</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzE0LTYtMS0xLTA_2639f55a-b16a-4e09-accd-84a0c917c132"
      unitRef="usd">-753521</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzE1LTItMS0xLTA_604b0ac6-1911-4aee-b024-4bb263a1da6b"
      unitRef="usd">-1106175</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzE1LTQtMS0xLTA_b1c7cca6-9468-4f28-ab28-fbe39a8a1a69"
      unitRef="usd">-528153</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzE1LTYtMS0xLTA_c9fb1b10-0206-4878-99c2-980482ac5725"
      unitRef="usd">292710</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzE2LTItMS0xLTA_cf74f003-2eda-4277-8fcf-30caf3c41413"
      unitRef="usd">615199</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzE2LTQtMS0xLTA_1b1795aa-ea5a-4ec8-a2f2-7c14cd0e24bd"
      unitRef="usd">-676750</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzE2LTYtMS0xLTA_269f160c-38ea-40a2-86ee-b43f670c5ff1"
      unitRef="usd">1155630</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzE3LTItMS0xLTA_d1bf93ea-2a8a-4491-8157-bf821a3278de"
      unitRef="usd">3221780</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzE3LTQtMS0xLTA_e7af26ce-9646-4dc5-9e74-08405c009cf2"
      unitRef="usd">4153287</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzE3LTYtMS0xLTA_d6319daf-7701-4641-9eda-deada04cc3f4"
      unitRef="usd">339751</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzE4LTItMS0xLTA_b39fecf8-99d5-45bb-9db2-7bdd868cc01f"
      unitRef="usd">-729820</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzE4LTQtMS0xLTA_111b8f23-b0ab-453d-91dd-2a0c1d9f058e"
      unitRef="usd">-159558</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzE4LTYtMS0xLTA_03131ca1-38f2-46d5-94cc-f35740acbdab"
      unitRef="usd">413097</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzE5LTItMS0xLTA_7a2c6848-7154-4715-9df6-e3b2e8fe9073"
      unitRef="usd">-2455240</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzE5LTQtMS0xLTA_de50d1cf-ce11-4f50-994a-c6c6f37ca1cd"
      unitRef="usd">-1390808</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzE5LTYtMS0xLTA_3e83c541-91aa-4600-a0ad-df83d5a5955f"
      unitRef="usd">-4512952</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzIyLTItMS0xLTY2Nw_19d9b0f2-9000-49d0-bf0b-6e4a2bb5e043"
      unitRef="usd">5511596</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzIyLTQtMS0xLTY2Nw_1159fbf0-d206-4553-bdb1-2afc7e2e0825"
      unitRef="usd">4503545</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzIyLTYtMS0xLTY2Nw_5e42b07c-72aa-4350-914e-e35599a4c8f9"
      unitRef="usd">3955238</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzIzLTItMS0xLTEyMzA_95a691f1-484f-44b2-b4f3-ec9f880507f1"
      unitRef="usd">3056356</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzIzLTQtMS0xLTEyMjg_9e9597db-33e3-4685-a173-b7e70bc201aa"
      unitRef="usd">3112737</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzIzLTYtMS0xLTEyMzI_cb5accf6-e775-4919-9193-6b9e0b310137"
      unitRef="usd">-557714</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzIxLTItMS0xLTA_bbbbf00d-e3f0-48de-b96a-bd2bf1fe0210"
      unitRef="usd">246202</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzIxLTQtMS0xLTA_9f273daa-6098-4b1d-9a92-dccfca9771de"
      unitRef="usd">455569</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzIxLTYtMS0xLTA_fc89ddd1-3ab6-41af-aa8a-3710e0d7fdcb"
      unitRef="usd">275960</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzIyLTItMS0xLTA_4a05faa6-c9f5-42a7-ba2f-51a5b996393a"
      unitRef="usd">772944</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzIyLTQtMS0xLTA_b3851db8-f164-42b4-a774-76d5d57d3bad"
      unitRef="usd">3819486</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzIyLTYtMS0xLTA_5f71ce5a-1363-4473-9e12-d6d4f73c5dd6"
      unitRef="usd">1213110</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzIzLTItMS0xLTA_f7cd3c07-944b-4f00-87b1-9f74b8b272f6"
      unitRef="usd">5000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzIzLTQtMS0xLTA_028dfa8a-4f02-42d2-915b-f7db9f89164a"
      unitRef="usd">20000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzIzLTYtMS0xLTA_9ff69cd3-4970-4e58-8944-af4a6b738691"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzI0LTItMS0xLTA_7e34be7c-6cae-4efb-9f0a-96fa57e3ab9b"
      unitRef="usd">20062132</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzI0LTQtMS0xLTA_d097e854-a265-4097-8b18-c1c331ac4532"
      unitRef="usd">16122376</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzI0LTYtMS0xLTA_6e9b95ec-ee4d-4fc1-9a7f-f578fc1d2409"
      unitRef="usd">13381061</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzI1LTItMS0xLTA_69c20389-330d-4aee-aac3-4c22ee8b046b"
      unitRef="usd">11745138</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzI1LTQtMS0xLTA_0d385138-8af1-428c-9cfa-3aa871f1d996"
      unitRef="usd">19572139</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzI1LTYtMS0xLTA_996486c0-8b66-48b2-b522-a74375023ca9"
      unitRef="usd">2379414</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzI2LTItMS0xLTA_243acc57-9565-4d64-a368-dfcb0b5db1ef"
      unitRef="usd">2297848</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzI2LTQtMS0xLTA_24bd5d5b-be43-4ee1-b4f8-2669562df1e2"
      unitRef="usd">-27724818</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzI2LTYtMS0xLTA_41d066b2-6a17-4252-9825-fa3cd08b2503"
      unitRef="usd">9512577</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzI4LTItMS0xLTA_aab4c854-cd44-41bb-859d-6ce4419bc59b"
      unitRef="usd">76000000</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzI4LTQtMS0xLTA_bc31db1f-363e-4a02-a0ec-f95c199a1fb8"
      unitRef="usd">56000000</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzI4LTYtMS0xLTA_b6e6bd70-ebbe-4ce6-b803-75880a50deda"
      unitRef="usd">24500000</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzI5LTItMS0xLTA_18c746c1-a916-4007-b69c-4c9791db1129"
      unitRef="usd">77500000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzI5LTQtMS0xLTA_127d4372-36f6-4be5-92ae-5dff443bdcbf"
      unitRef="usd">45800000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzI5LTYtMS0xLTA_379b7248-8b7e-472d-8d6f-35a3497fd7b6"
      unitRef="usd">18800000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzMwLTItMS0xLTA_5bf8979a-a87b-419b-9cb8-00862b5121f0"
      unitRef="usd">3494921</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzMwLTQtMS0xLTA_2d9e3544-288a-47c4-b8ac-50da9aef8ab9"
      unitRef="usd">2879426</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzMwLTYtMS0xLTA_458d613c-e2a5-41d0-98ed-e37257384163"
      unitRef="usd">3724375</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzMxLTItMS0xLTA_bba2e71c-5f9c-4755-bd14-2c7b8c6d3654"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzMxLTQtMS0xLTA_b7dd467b-7654-4276-be2e-a7e51423f391"
      unitRef="usd">383310</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzMxLTYtMS0xLTA_1b8d8d9a-6fe0-4851-92fa-679734fae39f"
      unitRef="usd">27950</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzMyLTItMS0xLTA_20cad27b-4b64-4154-8daa-3a377c6becdd"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzMyLTQtMS0xLTA_5d07c540-16f6-43c0-b4eb-a64c1d640535"
      unitRef="usd">200909</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzMyLTYtMS0xLTA_a25fdca3-4082-4b57-9d43-ed05ffc615d9"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzMzLTItMS0xLTA_5e31b876-27b4-44e0-883a-32a2646f3c03"
      unitRef="usd">52500</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzMzLTQtMS0xLTA_d2ff8895-dc4f-45ab-b638-d77ad8441538"
      unitRef="usd">0</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzMzLTYtMS0xLTA_f1a5539d-6f58-49a8-9ba0-c07f9dbac545"
      unitRef="usd">0</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzM0LTItMS0xLTA_d2f9d73c-d7f3-467b-acb1-4677aeab8671"
      unitRef="usd">1033108</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzM0LTQtMS0xLTA_358ae676-795e-4569-bf30-2f5cc53411bc"
      unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzM0LTYtMS0xLTA_3a209a22-7587-4af4-8655-f812a8bfe0cd"
      unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzM1LTItMS0xLTA_87807f89-6dde-43b6-9c85-689c954a9066"
      unitRef="usd">1000000</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzM1LTQtMS0xLTA_2b8d2eaf-6e05-48e8-8b73-d435649a1aa5"
      unitRef="usd">0</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzM1LTYtMS0xLTA_068c153c-721c-4a95-9b24-16ddc6392b7a"
      unitRef="usd">0</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzM2LTItMS0xLTA_164c067c-53a5-4699-b596-2206d8d23e64"
      unitRef="usd">-5080529</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzM2LTQtMS0xLTA_86951661-776d-45e9-bbe7-3d9b853f49e6"
      unitRef="usd">7138173</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzM2LTYtMS0xLTA_5e1af68b-1399-4396-ba51-a735c1ccf856"
      unitRef="usd">1947675</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzM3LTItMS0xLTA_28c4c142-ab20-4490-ba2b-2184ae339fc1"
      unitRef="usd">273675</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzM3LTQtMS0xLTA_03acfa17-86d1-4b9a-b1ca-6c6893fe12d7"
      unitRef="usd">-17473908</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzM3LTYtMS0xLTA_40ff4e7d-0d53-4dbb-990d-f39194bdfa1a"
      unitRef="usd">10902538</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzM4LTItMS0xLTA_4e120fa6-dcab-4cc5-8eec-bb6abcc82636"
      unitRef="usd">27938960</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i19f7709a57f34358b074d8ab2cd1410f_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzM4LTQtMS0xLTA_c508096e-c1f4-4d51-a526-9db3484aed28"
      unitRef="usd">45412868</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2153d838d1a64103b08e67d86300e4f6_I20161231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzM4LTYtMS0xLTA_d06d5f4d-d62e-4bed-94d9-7f0ca9324582"
      unitRef="usd">34510330</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzM5LTItMS0xLTA_66d00369-b304-4dcd-91cc-d9e62cfff8ca"
      unitRef="usd">28212635</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzM5LTQtMS0xLTA_181f7073-a39b-44e4-a901-c1887a64f9ff"
      unitRef="usd">27938960</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i19f7709a57f34358b074d8ab2cd1410f_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZToyN2Q4M2VhMDUyOGI0YjdjOTAzN2E2MTBmMzY0MWEzMS90YWJsZXJhbmdlOjI3ZDgzZWEwNTI4YjRiN2M5MDM3YTYxMGYzNjQxYTMxXzM5LTYtMS0xLTA_b55e50c0-b24a-462d-9309-5793624cffcf"
      unitRef="usd">45412868</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzItMi0xLTEtMA_7a65b790-aa3e-4767-a6a1-5787a57ecd09"
      unitRef="usd">198661</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzItNC0xLTEtMA_e5b0c049-029e-49f1-a016-5e59910d4bdd"
      unitRef="usd">95965</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzItNi0xLTEtMA_7a24a774-ae8f-455d-b451-e58764d23993"
      unitRef="usd">14993</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzMtMi0xLTEtMA_2a3aca09-941f-430f-b20e-92228bd759d2"
      unitRef="usd">16694</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzMtNC0xLTEtMA_e2b50f85-1dbc-4e17-94bd-123767e6d1fa"
      unitRef="usd">15441</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzMtNi0xLTEtMA_3fc242d0-98f2-4ea3-b7f4-45509cdb505b"
      unitRef="usd">18000</us-gaap:IncomeTaxesPaidNet>
    <cpix:PurchasesOfIntangibleAssetsIncurredButNotYetPaid
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzUtMi0xLTEtMA_eccf13bd-7045-447b-aef4-990f572968b7"
      unitRef="usd">-576837</cpix:PurchasesOfIntangibleAssetsIncurredButNotYetPaid>
    <cpix:PurchasesOfIntangibleAssetsIncurredButNotYetPaid
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzUtNC0xLTEtMA_1bcb188c-e622-4bd1-bdb2-a7768e79382e"
      unitRef="usd">-539467</cpix:PurchasesOfIntangibleAssetsIncurredButNotYetPaid>
    <cpix:PurchasesOfIntangibleAssetsIncurredButNotYetPaid
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzUtNi0xLTEtMA_4637e45f-6e2c-4387-8815-0da59509c5c3"
      unitRef="usd">-513481</cpix:PurchasesOfIntangibleAssetsIncurredButNotYetPaid>
    <cpix:DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzYtMi0xLTEtMA_43182f11-9909-4019-a2db-b5cc2ce97521"
      unitRef="usd">0</cpix:DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses>
    <cpix:DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzYtNC0xLTEtMA_d594c0c2-e213-4c1e-a3b0-863fe1ff8830"
      unitRef="usd">0</cpix:DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses>
    <cpix:DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzYtNi0xLTEtMA_48526411-4821-4e2e-8173-61353461bcfc"
      unitRef="usd">97254</cpix:DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses>
    <us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzctMi0xLTEtMA_dae5b837-289c-4406-b570-e2b1ec719320"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzctNC0xLTEtMA_7176ee24-cab4-4d6a-a2e3-d48958958f5a"
      unitRef="usd">14034000</us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzctNi0xLTEtMA_a6058d34-3036-49d7-9fa1-890d8cd83b1c"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzgtMi0xLTEtMA_7e0a2ad8-e0db-47fe-ab9e-42c4e481b918"
      unitRef="usd">3629320</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <cpix:NoncashOrPartNoncashTransactionVestingOfShares
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzktMi0xLTEtMA_43228601-940c-4d43-a370-21be5c080f40"
      unitRef="usd">862200</cpix:NoncashOrPartNoncashTransactionVestingOfShares>
    <cpix:NoncashOrPartNoncashTransactionVestingOfShares
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzktNC0xLTEtMA_2fd395fd-be58-4186-a0bc-afe0c698cf68"
      unitRef="usd">0</cpix:NoncashOrPartNoncashTransactionVestingOfShares>
    <cpix:NoncashOrPartNoncashTransactionVestingOfShares
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzktNi0xLTEtMA_9984c12a-e560-4c92-9611-e676ebec440e"
      unitRef="usd">0</cpix:NoncashOrPartNoncashTransactionVestingOfShares>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzEwLTItMS0xLTA_0cbf7011-314b-4ca9-aa31-9e7477aa495b"
      unitRef="usd">800000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzEwLTQtMS0xLTA_4005e70a-07a2-4efc-8735-8e27fd3ac0a3"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzEwLTYtMS0xLTA_d930c40e-b7fc-4d86-a41f-08a7139354f5"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzExLTItMS0xLTA_bda09f9b-7f05-48ab-8993-3e659e6d5dd3"
      unitRef="usd">148000</us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzExLTQtMS0xLTA_18f3c26c-bf29-4154-bb3b-eac6239a6074"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODEvZnJhZzpjZDUyODNkNWViMWE0YjgwOTI0MGU3ZWExZDZhMTlkZi90YWJsZTpmYTA4M2RjMDEyMTQ0ZGZhYWQ3NDg1NDBhODM2ZmNmMS90YWJsZXJhbmdlOmZhMDgzZGMwMTIxNDRkZmFhZDc0ODU0MGE4MzZmY2YxXzExLTYtMS0xLTA_11c77fd9-164d-4c08-8cff-14a180d1247a"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id69c7a64b03046d994369dd8619e693b_I20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzQtMi0xLTEtMA_808c576d-de6b-43d2-9c01-de4ebd7d1e5c"
      unitRef="shares">16074176</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id69c7a64b03046d994369dd8619e693b_I20161231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzQtNC0xLTEtMA_e7547121-9737-493f-9eda-e44498954eac"
      unitRef="usd">54643268</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0ca22cafe70c4402827abcd065642a85_I20161231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzQtNi0xLTEtMA_b5e5c981-eba6-44f1-847b-a89c72e514d2"
      unitRef="usd">18604931</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6067dd95a57b478f9581c66c6de9ce8d_I20161231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzQtOC0xLTEtMA_ae6579b4-09da-42cd-8641-fd3f81f6dba6"
      unitRef="usd">-127380</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2153d838d1a64103b08e67d86300e4f6_I20161231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzQtMTAtMS0xLTA_92d6ec05-e287-4be4-b48b-e1bf6d7ee52d"
      unitRef="usd">73120819</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i4f7afaa399514dcdbcfdaa5e2bb28ea7_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzUtNi0xLTEtMA_a1bc511e-183b-4531-9329-deb07825725f"
      unitRef="usd">-7978633</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ie4861d915e194b9b953dd7e515035d55_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzUtOC0xLTEtMA_6194d359-33b7-491c-844d-ced2d5a920d9"
      unitRef="usd">-71182</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzUtMTAtMS0xLTA_c261952e-c073-471b-8d13-1f2f1996cb7b"
      unitRef="usd">-8049815</us-gaap:ProfitLoss>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i51ac9d639e514ecc9a1253c74c8715e3_I20161231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzYtNi0xLTEtMA_40043b39-8550-4430-bc4a-c342935f1b84"
      unitRef="usd">1082924</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i07bb27d9de334b51acf632637d46c3ec_I20161231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzYtMTAtMS0xLTA_5cff55c3-4b0e-409e-b0fe-70ede55ec1e5"
      unitRef="usd">1082924</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i6921ef0b4c9446b6a5f25b2084bdc3ca_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzctMi0xLTEtMA_94dbe81d-0904-48f5-a9a8-696c650913cd"
      unitRef="shares">146275</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6921ef0b4c9446b6a5f25b2084bdc3ca_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzctNC0xLTEtMA_0eda4c89-fc11-417d-9a13-b562002a42d8"
      unitRef="usd">1115063</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzctMTAtMS0xLTA_03363da1-afa0-4abf-a595-594291307de2"
      unitRef="usd">1115063</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding
      contextRef="i6921ef0b4c9446b6a5f25b2084bdc3ca_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzgtMi0xLTEtMA_f81c3e2a-3358-42a2-9fcd-2129d98d2d95"
      unitRef="shares">50000</cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6921ef0b4c9446b6a5f25b2084bdc3ca_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzgtNC0xLTEtMA_2a9d6326-1056-4602-9424-f7b8cd74b157"
      unitRef="usd">372500</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzgtMTAtMS0xLTA_d06ecbd7-25df-433b-98e8-7657093e0486"
      unitRef="usd">372500</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i6921ef0b4c9446b6a5f25b2084bdc3ca_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzktMi0xLTEtMA_5fc7359e-2783-487a-9d44-7a92a5278d05"
      unitRef="shares">547376</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i6921ef0b4c9446b6a5f25b2084bdc3ca_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzktNC0xLTEtMA_752cf8f1-1ef4-4a44-a92a-9248ea554fd5"
      unitRef="usd">3719890</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzktMTAtMS0xLTA_84ad56bc-2bc3-448a-a00d-985dd5fb5560"
      unitRef="usd">3719890</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i512c6090aab845a3bfe38fb3e6f61dbb_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzEwLTItMS0xLTA_4de5ac84-838a-4af6-9c5f-2091ef8ff3db"
      unitRef="shares">15723075</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i512c6090aab845a3bfe38fb3e6f61dbb_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzEwLTQtMS0xLTA_421627ad-ebdf-45d8-a98d-f16db007a586"
      unitRef="usd">52410941</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9c5b1b36eaf747aea3881c4b9c3884a8_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzEwLTYtMS0xLTA_45e20ddb-dfd5-4594-8af6-623125305ded"
      unitRef="usd">11709222</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i42508aef6d0b489d9d6f2bc2b649384d_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzEwLTgtMS0xLTA_aeca95b2-9698-4228-94c0-b2b465cb1050"
      unitRef="usd">-198562</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i19f7709a57f34358b074d8ab2cd1410f_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzEwLTEwLTEtMS0w_9085c0e1-2a52-41f8-bad8-3c8f1ba628fc"
      unitRef="usd">63921601</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i98582b13998d4d998af541abee8ec14c_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzExLTYtMS0xLTA_c63630f5-20e7-44e0-9d27-55737a6ecf33"
      unitRef="usd">-6963068</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i3cffc6b13dc64ca49a9f14419a551793_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzExLTgtMS0xLTA_e3e7f396-32f7-4b50-96b5-9ce7cb3a1af5"
      unitRef="usd">-75704</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzExLTEwLTEtMS0w_a5a98592-133f-4ad9-a581-7d5ee426bd57"
      unitRef="usd">-7038772</us-gaap:ProfitLoss>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i8b9e95130dc146f9aa56d8d1d11bc534_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzEyLTItMS0xLTA_4523518d-d58d-48cd-9025-24c0ad2b075b"
      unitRef="shares">170759</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8b9e95130dc146f9aa56d8d1d11bc534_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzEyLTQtMS0xLTA_cd59a5eb-39a0-41ee-9d8a-7de4eec71677"
      unitRef="usd">1364698</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzEyLTEwLTEtMS0w_c0b989ce-17dd-4a5c-bae6-14154f9959d6"
      unitRef="usd">1364698</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i8b9e95130dc146f9aa56d8d1d11bc534_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzEzLTItMS0xLTA_ffc5e35b-cbdb-4ae3-b7c9-1704a6c52f75"
      unitRef="shares">30704</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i8b9e95130dc146f9aa56d8d1d11bc534_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzEzLTQtMS0xLTA_1ded95d8-19ae-4db7-b714-29b141d9340e"
      unitRef="usd">200909</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzEzLTEwLTEtMS0w_953d0d7a-16ff-406a-83a1-fe2b66edb093"
      unitRef="usd">200909</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i8b9e95130dc146f9aa56d8d1d11bc534_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzE0LTItMS0xLTA_a04cef7f-ef04-47e6-add6-9d8c917d3edd"
      unitRef="shares">443041</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i8b9e95130dc146f9aa56d8d1d11bc534_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzE0LTQtMS0xLTA_985fca2c-24a4-4fac-9e22-bf2c3a508ffd"
      unitRef="usd">2877935</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzE0LTEwLTEtMS0w_c0cf45cb-48f5-4c31-a10a-deb0a61d8b09"
      unitRef="usd">2877935</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1e55eb8a26d0400ab1ddbb5aa6ac9d0c_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzE1LTItMS0xLTA_7a02a94c-09ad-4e27-86f6-eb5d488c7059"
      unitRef="shares">15481497</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1e55eb8a26d0400ab1ddbb5aa6ac9d0c_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzE1LTQtMS0xLTA_f5f7c7d0-be50-48b1-811a-7a13590cae08"
      unitRef="usd">51098613</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie93040da022f4f208946b77301e73ade_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzE1LTYtMS0xLTA_e998a866-34b5-4b79-8be5-88254c15d56e"
      unitRef="usd">4746154</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4644d0f807ed4bce8b2b23227a41a2f2_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzE1LTgtMS0xLTA_148a7e41-06d2-4264-931d-124aa0006eed"
      unitRef="usd">-274266</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzE1LTEwLTEtMS0w_ee0dc77e-4756-43ac-a6c6-2bbd442145ab"
      unitRef="usd">55570501</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="if8fc2928cf4640edbddc3867d462e258_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzE2LTYtMS0xLTA_9ea62cdd-04b5-478a-a40d-03ec79770836"
      unitRef="usd">-3537759</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i570bc31a791840209b4f80fc77772940_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzE2LTgtMS0xLTA_c1dad570-0e30-42e9-a7a8-bb35b468942d"
      unitRef="usd">-8752</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzE2LTEwLTEtMS0w_1a8e47e7-2454-46c3-831e-49b9d7789323"
      unitRef="usd">-3546511</us-gaap:ProfitLoss>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i52ca8e03f38a46ab80ee3b1b2a37a943_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzE3LTQtMS0xLTA_7e42b9c0-7b53-4754-ba28-c7b86fc3f450"
      unitRef="usd">685805</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i570bc31a791840209b4f80fc77772940_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzE3LTgtMS0xLTA_12ff4141-83e0-4159-b6ad-8369485cd0a9"
      unitRef="usd">114195</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzE3LTEwLTEtMS0w_124e1aa8-aae9-4e3a-8f16-7b6b9f094c40"
      unitRef="usd">800000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i52ca8e03f38a46ab80ee3b1b2a37a943_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzE4LTQtMS0xLTA_fa802f9a-e678-4e08-88c5-0c6f9fcd2985"
      unitRef="usd">640407</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i570bc31a791840209b4f80fc77772940_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzE4LTgtMS0xLTA_a2754486-7b49-4b42-9eb1-666543407328"
      unitRef="usd">359593</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzE4LTEwLTEtMS0w_aff4ee3c-eac4-4b98-8bf2-932f30dd500a"
      unitRef="usd">1000000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="i52ca8e03f38a46ab80ee3b1b2a37a943_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzE5LTItMS0xLTA_3d4fbcf9-3426-451a-a04a-a62e9b30f9b6"
      unitRef="shares">180000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i52ca8e03f38a46ab80ee3b1b2a37a943_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzE5LTQtMS0xLTA_697ce540-78b2-4f77-8f68-ba7d0252b9fc"
      unitRef="usd">862200</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzE5LTEwLTEtMS0w_12addb39-3131-49b0-a6d6-7309e189f64c"
      unitRef="usd">862200</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i52ca8e03f38a46ab80ee3b1b2a37a943_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzIwLTItMS0xLTA_db43d325-bcd1-432c-9d1d-f310ccd7612d"
      unitRef="shares">225536</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i52ca8e03f38a46ab80ee3b1b2a37a943_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzIwLTQtMS0xLTA_1fe93382-7e5b-4f55-8f60-b794001680f3"
      unitRef="usd">1485898</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzIwLTEwLTEtMS0w_cef1e325-0e37-455e-b3c6-00fa884cdbcf"
      unitRef="usd">1485898</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i52ca8e03f38a46ab80ee3b1b2a37a943_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzIxLTItMS0xLTA_90699818-94da-4615-a19f-20c7b5317142"
      unitRef="shares">623478</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i52ca8e03f38a46ab80ee3b1b2a37a943_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzIxLTQtMS0xLTA_dc26a7c4-17bd-43c6-b2ce-a4e2445d429e"
      unitRef="usd">3486835</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzIxLTEwLTEtMS0w_d8d6c70b-25ba-46ba-9f58-37cceb9f213c"
      unitRef="usd">3486835</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ibbcaca0519364200b49f7a89d6fa09f7_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzIyLTItMS0xLTA_0a4ba7b6-ae98-4946-ad54-8562c77adf3d"
      unitRef="shares">15263555</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibbcaca0519364200b49f7a89d6fa09f7_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzIyLTQtMS0xLTA_54d4d050-708e-4da3-8281-7ad7534734db"
      unitRef="usd">49914478</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i48893159b76243539afc56c165b13ce5_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzIyLTYtMS0xLTA_efc9fd9e-ccf0-4335-bbcf-730682fe9673"
      unitRef="usd">1208395</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia0ea12224ffe4a29838858a3bdb9268c_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzIyLTgtMS0xLTA_633fbc4b-1ec4-4e4e-a82f-6ecfdf052577"
      unitRef="usd">-37620</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xODQvZnJhZzpjYjhiMzNlNmVjYjY0OTFiYTA3MDFiZmQ2YjkwY2E3Yi90YWJsZTo0ZGNjMzg5NjMzZmU0ZjlkYmM1Yjg3MmFkZjZhZTI5Yy90YWJsZXJhbmdlOjRkY2MzODk2MzNmZTRmOWRiYzViODcyYWRmNmFlMjljXzIyLTEwLTEtMS0w_e3315279-b30f-406b-be6a-e0b9386b0ac5"
      unitRef="usd">51085253</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTAvZnJhZzoyN2Y4MjYwMGIxN2E0ZTM4OWU3MTE3MDVhMjBkOTA2My90ZXh0cmVnaW9uOjI3ZjgyNjAwYjE3YTRlMzg5ZTcxMTcwNWEyMGQ5MDYzXzMyOTk_d358f671-1eda-4b3a-b323-36dc828c14b8">Organization&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland Pharmaceuticals Inc. (&#x201c;Cumberland,&#x201d; the &#x201c;Company,&#x201d; or as used in the context of &#x201c;we,&#x201d; &#x201c;us,&#x201d; or &#x201c;our&#x201d;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products.  The Company's primary target markets are hospital acute care and gastroenterology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.  The Company promotes its approved products through its hospital and field sales forces in the United States and is establishing a network of international partners to bring its medicines to patients in their countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#x2019;s products are manufactured by third parties, which are overseen by Cumberland&#x2019;s quality and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to build a pipeline of early-stage product candidates, the Company formed a subsidiary, Cumberland Emerging Technologies, Inc. ("CET"), which teams with universities and other research organizations to help advance scientific discoveries from the laboratory to the marketplace.  In 2014, the Company organized equity financing to recapitalize and strengthen the financial position of CET including an investment of approximately $1.0 million from Gloria Pharmaceuticals Co., Ltd. (&#x201c;Gloria&#x201d;).  As a result, Gloria received shares in CET and joined the CET ownership group. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April, 2019, CET entered into an agreement with HongKong WinHealth Pharma Group Co. Limited (WinHealth) &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;whereby WinHealth made a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $1.0&#160;million &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;investment through the purchase of shares of CET stock. As part of the agreement, WinHealth obtained a Board position at CET and the first opportunity to license CET products for the Chinese market. In connection with WinHealth's investment in CET, Cumberland also made an additional $1.0 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;investment in CET.  Cumberland purchased additional CET shares through contribution of $0.3&#160;million in cash and a conversion of $0.7&#160;million in intercompany loans payable.  Upon completion of the additional investment by WinHealth and Cumberland, Gloria Pharmaceuticals agreed to return its shares in CET in exchange for consideration of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $0.8 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's ownership in CET is now 85%.  As noted above, the ownership interests of CET includes WinHealth and Cumberland, while the remaining interest is owned by Vanderbilt University and the Tennessee Technology Development Corporation. The operating results of CET allocated to noncontrolling interests in the consolidated statements of operations were  $8,752, $75,704 and $71,182 for the years ended December&#160;31, 2019, 2018 and 2017, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January&#160;1, 2007, the Company formed a wholly-owned subsidiary, Cumberland Pharma Sales Corp. ("CPSC").  CPSC is the subsidiary that employs the Company's hospital and field sales force personnel.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
      contextRef="iefb6ff4d74154d8685cd13777224de1f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTAvZnJhZzoyN2Y4MjYwMGIxN2E0ZTM4OWU3MTE3MDVhMjBkOTA2My90ZXh0cmVnaW9uOjI3ZjgyNjAwYjE3YTRlMzg5ZTcxMTcwNWEyMGQ5MDYzXzE3OTA_803f2038-aded-404a-b8fc-6364bb90d288"
      unitRef="usd">1000000.0</us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest>
    <cpix:SubsidiaryInvestmentPurchaseOfShares
      contextRef="i917430c8015149c18c59ded862b49717_I20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTAvZnJhZzoyN2Y4MjYwMGIxN2E0ZTM4OWU3MTE3MDVhMjBkOTA2My90ZXh0cmVnaW9uOjI3ZjgyNjAwYjE3YTRlMzg5ZTcxMTcwNWEyMGQ5MDYzXzIwNTY_39dd3cd3-3832-4165-b201-4e263a4d7a4c"
      unitRef="usd">1000000.0</cpix:SubsidiaryInvestmentPurchaseOfShares>
    <cpix:SubsidiaryInvestmentPurchaseOfShares
      contextRef="i917430c8015149c18c59ded862b49717_I20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTAvZnJhZzoyN2Y4MjYwMGIxN2E0ZTM4OWU3MTE3MDVhMjBkOTA2My90ZXh0cmVnaW9uOjI3ZjgyNjAwYjE3YTRlMzg5ZTcxMTcwNWEyMGQ5MDYzXzIzNDM_a7e9c8e8-b858-4b79-b604-464e29bac058"
      unitRef="usd">1000000.0</cpix:SubsidiaryInvestmentPurchaseOfShares>
    <cpix:ContributionOfCashAdditionalSharesPurchased
      contextRef="i9f1c7f34352d4f90823b583604c2e094_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTAvZnJhZzoyN2Y4MjYwMGIxN2E0ZTM4OWU3MTE3MDVhMjBkOTA2My90ZXh0cmVnaW9uOjI3ZjgyNjAwYjE3YTRlMzg5ZTcxMTcwNWEyMGQ5MDYzXzI0MzM_426d53af-d975-4e90-a2a3-29871a09334c"
      unitRef="usd">300000</cpix:ContributionOfCashAdditionalSharesPurchased>
    <cpix:IntercompanyLoansPayableConvertedAmount
      contextRef="i917430c8015149c18c59ded862b49717_I20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTAvZnJhZzoyN2Y4MjYwMGIxN2E0ZTM4OWU3MTE3MDVhMjBkOTA2My90ZXh0cmVnaW9uOjI3ZjgyNjAwYjE3YTRlMzg5ZTcxMTcwNWEyMGQ5MDYzXzI0NjQ_794a4829-731e-409b-a475-9b41f68c7048"
      unitRef="usd">700000</cpix:IntercompanyLoansPayableConvertedAmount>
    <cpix:SubsidiaryInvestmentPaymentsForReturnOfCapital
      contextRef="i3522d1a659a04358b4f6ed8b764dd9e5_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTAvZnJhZzoyN2Y4MjYwMGIxN2E0ZTM4OWU3MTE3MDVhMjBkOTA2My90ZXh0cmVnaW9uOjI3ZjgyNjAwYjE3YTRlMzg5ZTcxMTcwNWEyMGQ5MDYzXzI2NjU_aec2b106-0b20-4987-ba5c-3bc578988a46"
      unitRef="usd">800000</cpix:SubsidiaryInvestmentPaymentsForReturnOfCapital>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="ie1b2c35fc3b6418cb8cc3c920e5ae3d6_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTAvZnJhZzoyN2Y4MjYwMGIxN2E0ZTM4OWU3MTE3MDVhMjBkOTA2My90ZXh0cmVnaW9uOjI3ZjgyNjAwYjE3YTRlMzg5ZTcxMTcwNWEyMGQ5MDYzXzI3MDc_7588577f-b0d7-4bc1-8144-24c04084bba9"
      unitRef="number">0.85</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTAvZnJhZzoyN2Y4MjYwMGIxN2E0ZTM4OWU3MTE3MDVhMjBkOTA2My90ZXh0cmVnaW9uOjI3ZjgyNjAwYjE3YTRlMzg5ZTcxMTcwNWEyMGQ5MDYzXzMwMzA_9ba595f9-689b-46d6-a320-d9ccb1281546"
      unitRef="usd">-8752</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTAvZnJhZzoyN2Y4MjYwMGIxN2E0ZTM4OWU3MTE3MDVhMjBkOTA2My90ZXh0cmVnaW9uOjI3ZjgyNjAwYjE3YTRlMzg5ZTcxMTcwNWEyMGQ5MDYzXzMwMzU_5e7463f2-d48f-4c25-8c17-9160a74752d9"
      unitRef="usd">-75704</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTAvZnJhZzoyN2Y4MjYwMGIxN2E0ZTM4OWU3MTE3MDVhMjBkOTA2My90ZXh0cmVnaW9uOjI3ZjgyNjAwYjE3YTRlMzg5ZTcxMTcwNWEyMGQ5MDYzXzMwNDM_6d94bebd-f2bb-4587-bf04-e25764ce70b5"
      unitRef="usd">-71182</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTQ2_61f78b0f-35a5-4c98-bc55-4923338fa704">Significant Accounting Policies&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements of the Company are stated in U.S. dollars and are prepared using U.S. generally accepted accounting principles. These financial statements include the accounts of the Company and its wholly and majority-owned subsidiaries. All significant intercompany transactions and accounts have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns (2) the allowances for obsolescent or unmarketable inventory (3) assumptions used in estimating acquisition date fair value of assets acquired in business combinations and (4) valuation of contingent consideration liability associated with business combinations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, evaluated that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#x2019;s assets are located in the United States. Total revenues are primarily attributable to U.S.&#160;customers.  Net revenues from customers outside the United States were approximately $1.5 million, $2.1 million and $1.6 million for the years ended December&#160;31, 2019, 2018 and 2017, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of financial assets and liabilities is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date.  The Company's fair value measurements follow the appropriate rules as well as the fair value hierarchy that prioritizes the information used to develop the measurements.  It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:72pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 -   Quoted prices for identical instruments in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:72pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 -  Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:72pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 -    Significant inputs to the valuation model are unobservable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain policies and procedures to value instruments using the best and most relevant data available. The following section describes the valuation methodologies we use to measure different financial instruments at fair value on a recurring basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments include cash and cash equivalents, marketable securities, accounts receivable, accounts payable, accrued liabilities, contingent consideration liability and a revolving line of credit. The carrying values for cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to their short-term nature. The revolving line of credit has a variable interest rate, which approximates the current market rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's fair values of marketable securities are determined based on valuations provided by a third-party pricing service, as derived from such services' pricing models, and are considered either Level 1 or Level 2 measurements, depending on the nature of the investment.  The Company has no marketable securities in which the fair value is determined based on Level 3.  The level of management judgment required in evaluating fair value for Level 1 investments is minimal.  Similarly, there is little subjectivity or judgment required for Level 2 investments valued using valuation models that are standard across the industry and whose parameter inputs are quoted in active markets.  Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. The Company believes that the valuations provided by the third-party pricing service, as derived from such services' pricing models, represent prices that would be received to sell the assets at the measurement date (exit prices).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's contingent consideration liability is a Level 3 fair value measurement that is updated on a recurring basis at each reporting period using a valuation model.  Consistent with Level 3 fair value measurements, there are significant inputs to the valuation model that are unobservable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents include highly liquid investments with original maturities of three months or less.  As of December&#160;31, 2019 and 2018, cash equivalents consist primarily of money market funds as well as trading securities with original maturities of less than ninety days. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company invests in marketable debt securities in order to maximize its return on cash. Marketable securities consist of short-term cash investments, U.S. Treasury notes and bonds, corporate bonds, and commercial paper.  At the time of purchase, the Company classifies marketable securities as either trading securities or available-for-sale securities, depending on the intent at that time.  As of December&#160;31, 2019 and 2018, marketable securities were comprised solely of trading securities.  Trading securities are carried at fair value with unrealized gains and losses recognized as a component of interest income in the consolidated statements of operations.  As of December&#160;31, 2019, all the trading securities were commercial paper with original maturities of less than ninety days and as a result, were classified as cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade accounts receivable are recorded at the invoiced amount.  The Company records allowances for amounts that could become uncollectible in the future based on historical experience, including amounts related to chargebacks, cash discounts and credits for damaged product. The Company reviews each customer balance to assess collection status.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of the Company&#x2019;s products are distributed through independent pharmaceutical wholesalers.  The allowances against accounts receivable for chargebacks and discounts are determined on a product-by-product basis, and established by management as the Company&#x2019;s best estimate at the time of sale based on each product&#x2019;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks, discounts and credits claimed for damaged and expired product. The allowances in accounts receivable for chargebacks, cash discounts and damaged goods were $0.8 million at December&#160;31, 2019 and $0.7 million at December 31, 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company&#x2019;s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, revenues are reduced and accrued liabilities are increased by the Company&#x2019;s estimate of the rebate that may be claimed as well as the reserves for expired and damaged goods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash discounts are reductions to invoiced amounts offered to customers for payment within a specified period of time from the date of the invoice.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company works closely with third parties to manufacture and package finished goods for sale.  Based on the customer relationship with the manufacturer or packager, the Company will either take title to finished goods at the time of shipment or at the time of arrival from the manufacturer.  The Company then warehouses such goods until distribution and sale.  As discussed below, effective January 1, 2017, inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continually evaluates inventories for potential losses due to expired, short-dated or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates the carrying value of a product may not be recoverable, a charge is recorded to reduce the inventory to its current net realizable value.  The Company classifies the Vibativ inventories that it does not expect to sell within one year as non-current inventories. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid and other current assets consist of deferred offering costs, prepaid insurance premiums, prepaid consulting services, deposits and annual fees paid to the U.S. Food and Drug Administration ("FDA").  The Company expenses all prepaid and other current asset amounts as used or over the period of benefit primarily on a straight-line basis, as applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred offering costs are expenses directly related to the Form S-3 or Shelf Registration filed with the SEC on November 11, 2017 and declared effective on January 16, 2018. These costs consist of legal, accounting, printing, and filing fees that the Company has capitalized. Deferred costs associated with the Shelf Registration will be reclassified to additional paid in capital on a pro-rata basis as the Company completes sales of shares under the Shelf Registration, with any remaining deferred offering costs to be charged to the results of operations at the end of the three-year life of the Shelf Registration. During the year ended December&#160;31, 2019, the Company has not expensed any deferred offering costs associated with the Shelf Registration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, including leasehold improvements, are stated at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the initial lease term plus renewal options, if reasonably assured, or the remaining useful life of the asset. Upon retirement or disposal of assets, any gain or loss is reflected as a component of operating income (loss) in the consolidated statement of operations.  Improvements that extend an asset&#x2019;s useful life are capitalized.  Repairs and maintenance costs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets and Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s intangible assets and goodwill consist of capitalized costs related to product and license rights, patents, trademarks and goodwill obtained in the Vibativ acquisition. Goodwill is not amortized for financial reporting purposes, but is subject to impairment analysis at least annually.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cost of acquiring product and license rights are capitalized at fair value at the date of acquisition for products that are approved by the FDA for commercial use.  These costs are amortized ratably over the estimated economic life of the product. The economic life is estimated based upon several factors.  This includes the term of the license agreement, the patent life or market exclusivity of the product and as well as  management's expectations of continued involvement with the product and the assessment of future sales, the future periods under which the product will be sold and the profitability of the product. This estimate is evaluated on a regular basis during the amortization period and adjusted if appropriate.  If there are any changes made to the useful life of the product and license rights, the costs associated with such a change, if any, will be capitalized and amortized over the revised useful life.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitalized patent costs consist of outside legal costs associated with obtaining and protecting patents on products that have been approved for marketing by the FDA. If it becomes probable that a patent will not be issued or a patent has been declared invalid, related costs associated with the patent application are expensed at the time such determination is made. All costs associated with obtaining patents for products that have not been approved for marketing by the FDA are expensed as incurred.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense is recognized ratably over the following periods:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:63.141%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated economic life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term of license agreement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Life of patent&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets, such as property and equipment, operating lease right-of-use assets and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If events or circumstances arise that require a long-lived asset to be tested for potential impairment, the Company first compares undiscounted cash flows expected to be generated by the asset to its carrying value. If the carrying amount of the long-lived asset is not recoverable on an undiscounted cash flow basis, an impairment charge is recognized to the extent that the carrying value exceeds the fair value. Fair value is determined through various valuation techniques including quoted market prices, third-party independent appraisals and discounted cash flow models.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill and other indefinite lived intangible assets that are not subject to amortization are tested at least annually for impairment.  The impairment analysis for goodwill requires a comparison of fair value to the carrying value of the reporting unit.  The Company's goodwill was acquired in November 2018 with the Vibativ acquisition. As a result, the Vibativ component of the Company is the reporting unit evaluated for goodwill impairment.  Cumberland determined the fair value of the reporting unit through current and future estimated revenue and profitability of the product.  The Company recorded no impairment charges during 2019, 2018 and 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2018, the Company adopted the Financial Accounting Standards Board&#x2019;s (&#x201c;FASB&#x201d;) amended guidance in the form of Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2014-09, "Revenue from Contracts with Customers," (ASC 606). Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts were not adjusted and are reported in accordance with ASC 605.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from product sales are recognized in the amount that reflects the consideration that we expect to receive for these goods.  Depending upon the shipping terms of the transaction, the revenue is recognized.at the point where the customer obtains control of the goods and we satisfy our performance obligation.  This occurs upon either shipment of the product or arrival at its ship to destination.  Payment terms typically range from 30 to 60 days from date of shipment. The Company&#x2019;s net product revenue reflects the reduction from gross product revenue for &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;estimated allowances for chargebacks, discounts and damaged goods, and reflects sales related accruals for rebates, coupons, product returns, and certain administrative and service fees. Significant judgments must be made in determining the transaction price for our sales of products related to these adjustments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sales Rebates and Discounts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allowances against accounts receivable for chargebacks, discounts, expired and damaged goods are determined on a product-by-product basis, and established by management as the Company&#x2019;s best estimate at the time of sale based on each product&#x2019;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks, discounts and credits claimed for damaged and expired product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company&#x2019;s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, sales revenues are reduced and accrued liabilities are increased by the Company&#x2019;s estimate of the rebate that may be claimed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sales Returns&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consistent with industry practice, the Company maintains a return policy that allows customers to return product within a specified period prior to and subsequent to the expiration date. The Company&#x2019;s estimate of the provision for returns is based upon historical experience, expiration date by product as well as any other factor expected to impact future returns. Any changes in the assumptions used to estimate the provision for returns are recognized in the period those assumptions are changed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenues primarily consist of income from grant funding programs, licensing agreements, leases and contract services.  Revenue related to grants is recognized when all conditions related to such grants have been met.  All other revenue is recognized when earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of products sold consists principally of the cost to acquire each unit of product sold, including in-bound freight expense as well as any adjustment in the net realizable value of inventory acquired in acquisitions. Cost of products sold also includes expenses associated with the reduction in the net realizable value of slow-moving or expired product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Selling and Marketing Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling and marketing expense consists primarily of expenses relating to the advertising, promotion, distribution and sale of products, including royalty expense, salaries and related costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Distribution Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Distribution costs are expensed as incurred and are included as a component of selling and marketing expenses in the consolidated statements of operations. Distribution costs were as follows for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.897%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distribution costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;457,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advertising costs are expensed as incurred and are included as a component of selling and marketing expenses in the consolidated statements of operations. Advertising costs were as follows for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.897%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Advertising costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,594,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,005,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,377,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed in the period incurred. Research and development costs are comprised mainly of clinical trial expenses, salaries, wages and other related costs such as materials and supplies. Research and development expense includes activities performed by third-party providers participating in the Company&#x2019;s clinical studies. The Company accounts for these costs based on estimates of work performed, patients enrolled or fixed fees for services over the period of time the clinical trials are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides for deferred taxes using the asset and liability approach. Under this method, deferred tax assets and liabilities are recognized for future tax consequences attributable to operating loss and tax credit carryforwards, as well as differences between the carrying amounts of existing assets and liabilities and their respective tax bases. The Company&#x2019;s principal differences are related to the timing of deductibility of certain items, such as inventory, depreciation, amortization and share-based compensation. Deferred tax assets and liabilities are measured using enacted statutory tax rates that are expected to apply to taxable income in the years such temporary differences are anticipated to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. The Company only recognizes income tax benefits associated with an income tax position in which it is &#x201c;more likely than not&#x201d; that the position would be sustained upon examination by the taxing authorities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In assessing the realizability of deferred tax assets, management considers whether some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of existing temporary differences, projected future taxable income and tax planning strategies in making this assessment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accounting policy with respect to interest and penalties arising from income tax settlements is to recognize them as part of the provision for income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total comprehensive income (loss) was comprised solely of net income (loss) for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Earnings (Loss) per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings (loss) per share is calculated by dividing net income (loss) attributable to common shareholders by the weighted-average number of shares outstanding. Except where the result would be antidilutive to income from continuing operations, diluted earnings (loss) per share is calculated by assuming the vesting of unvested restricted stock and the exercise of stock options and warrants and unrecognized compensation costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes compensation cost for all share-based payments issued, modified, repurchased or canceled. Depending on the nature of the vesting provisions, restricted stock awards are measured using either the fair value on the grant date or the fair value of common stock on the date the vesting provisions lapse. Prior to the lapse for those equity grants not valued on the grant date, the fair value is measured on the last day of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaborative Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is a party to several collaborative arrangements with certain research institutions to identify and pursue promising preclinical pharmaceutical product candidates. The Company has determined these collaborative agreements do not meet the criteria for accounting under Accounting Standards Codification 808, Collaborative Agreements. The agreements do not specifically designate each party's rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party. The funding for these programs is generally provided through private sector investments or federal Small Business Administration ("SBIR/STTR") grant programs. Expenses incurred under these collaborative agreements are included in research and development expenses in the consolidated statements of operations. Funding received from private sector investments and grants are recorded as net revenues in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassification of prior period amounts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has made certain reclassifications to prior period amounts to conform to the current-year presentation of the reporting of research and development expense and general and administrative expense on the consolidated statements of operations. Certain costs and expenses related to research and development were previously reported as general and administrative expenses on the consolidated statements of operations. These reclassifications have no effect on the reported operating loss or equity for the years ended December 31, 2018 and 2017. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Guidance &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2014, the FASB issued amended guidance in the form of ASU No. 2014-09, &#x201c;Revenue from Contracts with Customers&#x201d; (&#x201c;ASC 606&#x201d;).  The core principle of the new guidance is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. The new guidance defines a five-step process to achieve this core principle and, in doing so, additional judgments and estimates may be required within the revenue recognition process. The new standard replaced most of the existing revenue recognition standards in U.S. GAAP when it became effective. In July 2015, the FASB issued a one-year deferral of the adoption date, which extended the effective date for us to January 1, 2018, at which point Cumberland adopted the standard. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated its revenues and the new guidance had immaterial impacts to recognition practices upon adoption on January 1, 2018.  As part of the adoption, the Company elected to apply the new guidance on a modified retrospective basis. The Company did not record a cumulative effect adjustment to historical retained earnings for initially applying the new guidance as no revenue recognition differences were identified in the timing or amount of revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2016, the Financial Accounting Standards Board ("FASB") issued guidance in the form of a FASB Accounting Standards Update ("ASU") No. 2016-02, &#x201c;Leases.&#x201d; The new standard establishes a right-of-use (&#x201c;ROU&#x201d;) model that requires a lessee to record an ROU asset and a lease liability on the balance sheet for all leases with terms longer than twelve months. Leases will be classified as either finance (formerly "capital leases") or &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;operating, with classification affecting the pattern of expense recognition in the income statement. The standard provides for a modified retrospective transition approach for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain optional practical expedients.  In July 2018, the FASB issued ASU 2018-11, "Leases: Targeted Improvements", allowing for an alternative transition method (the effective date approach). It allows an entity to initially apply the new lease guidance at the adoption date (rather than at the beginning of the earliest period presented). Cumberland adopted the lease guidance effective January 1, 2019 using the package of transition practical expedients.  This allowed the Company to retain the lease classification for any leases existing prior to adoption, in addition to other benefits. See additional discussion of the impact of adopting the lease accounting guidance in Note 15.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements - Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU No. 2016-13, &#x201c;Financial Instruments-Credit Losses,&#x201d; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#x201c;expected loss&#x201d; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose more information, including the information they use to track credit quality by year of origination for most financing receivables. Companies will apply the standard&#x2019;s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. This standard is effective for the Company on January 1, 2020. The Company continues to evaluate this new standard on its trade and other receivables but does not expect a material impact on its consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met, the election must be applied on an instrument-by-instrument basis, and the election is not available for either available-for-sale or held-to-maturity debt securities. The effective date is the same as ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;January 1, 2020. The Company continues to evaluate this new standard but does not expect a material impact on its consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, the FASB issued ASU No. 2018-18, &#x201c;Collaboration Arrangements: Clarifying the Interaction between Topic 808 and Topic 606&#x201d; (ASU 2018-18). The issuance of ASU 2014-09 raised questions about the interaction between the guidance on collaborative arrangements and revenue recognition. ASU 2018-18 addresses this uncertainty by (1) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASU 2014-09 when the collaboration arrangement participant is a customer, (2) adding unit of account guidance to assess whether the collaboration arrangement or a part of the arrangement is with a customer and (3) precluding a company from presenting transactions with collaboration arrangement participants that are not directly related to sales to third parties together with revenue from contracts with customers. The new standard will be effective for the Company on January 1, 2020.  The Company continues to evaluate this new standard but does not expect a material impact on its consolidated financial statements. &lt;/span&gt;&lt;/div&gt;In January 2017, the FASB issued ASU No. 2017-04, &#x201c;Simplifying the Test for Goodwill Impairment&#x201d; (ASU 2017-04). The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation.  As a result of the revised guidance, a goodwill impairment will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The new standard will be effective for the Company on January 1, 2020. The Company continues to evaluate this new standard but does not expect a material impact on its consolidated financial statements and related disclosures.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTQ3_e2658dfb-620c-4006-a049-12f8e29cfd5b">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements of the Company are stated in U.S. dollars and are prepared using U.S. generally accepted accounting principles. These financial statements include the accounts of the Company and its wholly and majority-owned subsidiaries. All significant intercompany transactions and accounts have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTQ1_ae653fad-0ca5-45c3-be55-409a6f713dd0">Use of EstimatesThe preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTUy_7903e396-79ef-4988-84c8-980346776c01">Segment ReportingThe Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, evaluated that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#x2019;s assets are located in the United States. Total revenues are primarily attributable to U.S.&#160;customers.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzEzNzg_f21a49f4-a88a-42dc-b807-8b8ab35fd3d1"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:Revenues
      contextRef="i6a4ee4b80c85405aa9011089eea73f13_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzIyNTA_267212ec-8c08-4452-a7ab-ab6f0fd641ff"
      unitRef="usd">1500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3faf6260efdc450498cc8cb573bbc167_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzIyNTU_146f1c07-3233-4a59-a4d4-3c6c7d661cf8"
      unitRef="usd">2100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icef1ce4e74b54672b3b04ac67a70e22b_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzIyNjM_be858ca8-aa29-4ba3-9f7d-cac279335586"
      unitRef="usd">1600000</us-gaap:Revenues>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTY2_8a13b1be-9acf-41e4-afce-29616d470536">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of financial assets and liabilities is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date.  The Company's fair value measurements follow the appropriate rules as well as the fair value hierarchy that prioritizes the information used to develop the measurements.  It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:72pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 -   Quoted prices for identical instruments in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:72pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 -  Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:72pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 -    Significant inputs to the valuation model are unobservable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain policies and procedures to value instruments using the best and most relevant data available. The following section describes the valuation methodologies we use to measure different financial instruments at fair value on a recurring basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments include cash and cash equivalents, marketable securities, accounts receivable, accounts payable, accrued liabilities, contingent consideration liability and a revolving line of credit. The carrying values for cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to their short-term nature. The revolving line of credit has a variable interest rate, which approximates the current market rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's fair values of marketable securities are determined based on valuations provided by a third-party pricing service, as derived from such services' pricing models, and are considered either Level 1 or Level 2 measurements, depending on the nature of the investment.  The Company has no marketable securities in which the fair value is determined based on Level 3.  The level of management judgment required in evaluating fair value for Level 1 investments is minimal.  Similarly, there is little subjectivity or judgment required for Level 2 investments valued using valuation models that are standard across the industry and whose parameter inputs are quoted in active markets.  Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. The Company believes that the valuations provided by the third-party pricing service, as derived from such services' pricing models, represent prices that would be received to sell the assets at the measurement date (exit prices).&lt;/span&gt;&lt;/div&gt;The Company's contingent consideration liability is a Level 3 fair value measurement that is updated on a recurring basis at each reporting period using a valuation model.  Consistent with Level 3 fair value measurements, there are significant inputs to the valuation model that are unobservable.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTY3_71dbf44d-1582-40ab-b326-29d9106ab8d2">Cash and Cash EquivalentsCash and cash equivalents include highly liquid investments with original maturities of three months or less.  As of December&#160;31, 2019 and 2018, cash equivalents consist primarily of money market funds as well as trading securities with original maturities of less than ninety days.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTY0_d7473a31-e987-4f8a-b7bd-ba6915e8bd61">&lt;div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company invests in marketable debt securities in order to maximize its return on cash. Marketable securities consist of short-term cash investments, U.S. Treasury notes and bonds, corporate bonds, and commercial paper.  At the time of purchase, the Company classifies marketable securities as either trading securities or available-for-sale securities, depending on the intent at that time.  As of December&#160;31, 2019 and 2018, marketable securities were comprised solely of trading securities.  Trading securities are carried at fair value with unrealized gains and losses recognized as a component of interest income in the consolidated statements of operations.  As of December&#160;31, 2019, all the trading securities were commercial paper with original maturities of less than ninety days and as a result, were classified as cash equivalents.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTQ4_6df9f509-524e-42ca-9e57-c6520ac050c3">&lt;div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade accounts receivable are recorded at the invoiced amount.  The Company records allowances for amounts that could become uncollectible in the future based on historical experience, including amounts related to chargebacks, cash discounts and credits for damaged product. The Company reviews each customer balance to assess collection status.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of the Company&#x2019;s products are distributed through independent pharmaceutical wholesalers.  The allowances against accounts receivable for chargebacks and discounts are determined on a product-by-product basis, and established by management as the Company&#x2019;s best estimate at the time of sale based on each product&#x2019;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks, discounts and credits claimed for damaged and expired product. The allowances in accounts receivable for chargebacks, cash discounts and damaged goods were $0.8 million at December&#160;31, 2019 and $0.7 million at December 31, 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company&#x2019;s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, revenues are reduced and accrued liabilities are increased by the Company&#x2019;s estimate of the rebate that may be claimed as well as the reserves for expired and damaged goods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash discounts are reductions to invoiced amounts offered to customers for payment within a specified period of time from the date of the invoice.&lt;/span&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="ia75e1df3d4b74017bd1b51e0b2b3cff5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzgxMDc_22c375a5-2639-4edb-8ae5-cc05d6c3fba4"
      unitRef="usd">800000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i3e91f9a0d19840b7b2aff337c95edc24_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzgxMjA_27e7ad46-e39a-4f53-8ab3-44bd86d6a691"
      unitRef="usd">700000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTUz_191b13e6-b958-4e70-87d9-0dc826d48245">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company works closely with third parties to manufacture and package finished goods for sale.  Based on the customer relationship with the manufacturer or packager, the Company will either take title to finished goods at the time of shipment or at the time of arrival from the manufacturer.  The Company then warehouses such goods until distribution and sale.  As discussed below, effective January 1, 2017, inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.&lt;/span&gt;&lt;/div&gt;The Company continually evaluates inventories for potential losses due to expired, short-dated or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates the carrying value of a product may not be recoverable, a charge is recorded to reduce the inventory to its current net realizable value.  The Company classifies the Vibativ inventories that it does not expect to sell within one year as non-current inventories.</us-gaap:InventoryPolicyTextBlock>
    <cpix:PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTcw_0e6dbc59-b472-43f7-bc68-007594bc16bc">&lt;div style="margin-top:7pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid and other current assets consist of deferred offering costs, prepaid insurance premiums, prepaid consulting services, deposits and annual fees paid to the U.S. Food and Drug Administration ("FDA").  The Company expenses all prepaid and other current asset amounts as used or over the period of benefit primarily on a straight-line basis, as applicable.&lt;/span&gt;&lt;/div&gt;</cpix:PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTU0_8e362f73-be68-4da4-8450-bbeb867a6255">&lt;div style="margin-top:7pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, including leasehold improvements, are stated at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the initial lease term plus renewal options, if reasonably assured, or the remaining useful life of the asset. Upon retirement or disposal of assets, any gain or loss is reflected as a component of operating income (loss) in the consolidated statement of operations.  Improvements that extend an asset&#x2019;s useful life are capitalized.  Repairs and maintenance costs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTQ5_03699412-f597-4e7b-8650-9f564929a209">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets and Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s intangible assets and goodwill consist of capitalized costs related to product and license rights, patents, trademarks and goodwill obtained in the Vibativ acquisition. Goodwill is not amortized for financial reporting purposes, but is subject to impairment analysis at least annually.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cost of acquiring product and license rights are capitalized at fair value at the date of acquisition for products that are approved by the FDA for commercial use.  These costs are amortized ratably over the estimated economic life of the product. The economic life is estimated based upon several factors.  This includes the term of the license agreement, the patent life or market exclusivity of the product and as well as  management's expectations of continued involvement with the product and the assessment of future sales, the future periods under which the product will be sold and the profitability of the product. This estimate is evaluated on a regular basis during the amortization period and adjusted if appropriate.  If there are any changes made to the useful life of the product and license rights, the costs associated with such a change, if any, will be capitalized and amortized over the revised useful life.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitalized patent costs consist of outside legal costs associated with obtaining and protecting patents on products that have been approved for marketing by the FDA. If it becomes probable that a patent will not be issued or a patent has been declared invalid, related costs associated with the patent application are expensed at the time such determination is made. All costs associated with obtaining patents for products that have not been approved for marketing by the FDA are expensed as incurred.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense is recognized ratably over the following periods:&lt;/span&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <cpix:ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTY4_d71b10f4-4342-4cce-82ae-7df48ece45f9">Amortization expense is recognized ratably over the following periods:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:63.141%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated economic life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term of license agreement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Life of patent&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</cpix:ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock>
    <cpix:FiniteLivedIntangibleAssetsUsefulLivesTextual
      contextRef="ib06a29ad4edd4918a967323242b0142d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90YWJsZToyYTdkMmRiZDNjYmI0ZGZiYTU2N2YzZjY4NmIyY2JmNi90YWJsZXJhbmdlOjJhN2QyZGJkM2NiYjRkZmJhNTY3ZjNmNjg2YjJjYmY2XzAtMi0xLTEtMA_6629e581-3403-4fb0-a257-d806079f42e3">Estimated economic life</cpix:FiniteLivedIntangibleAssetsUsefulLivesTextual>
    <cpix:FiniteLivedIntangibleAssetsUsefulLivesTextual
      contextRef="ib9796d25c7c94244a85df974cff3caf9_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90YWJsZToyYTdkMmRiZDNjYmI0ZGZiYTU2N2YzZjY4NmIyY2JmNi90YWJsZXJhbmdlOjJhN2QyZGJkM2NiYjRkZmJhNTY3ZjNmNjg2YjJjYmY2XzEtMi0xLTEtMA_3331ddb7-697a-4631-8b2a-2452f614b75f">Term of license agreement</cpix:FiniteLivedIntangibleAssetsUsefulLivesTextual>
    <cpix:FiniteLivedIntangibleAssetsUsefulLivesTextual
      contextRef="i9264ef6a01f546dca65e6adec1f967fe_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90YWJsZToyYTdkMmRiZDNjYmI0ZGZiYTU2N2YzZjY4NmIyY2JmNi90YWJsZXJhbmdlOjJhN2QyZGJkM2NiYjRkZmJhNTY3ZjNmNjg2YjJjYmY2XzItMi0xLTEtMA_fb781c0e-1cd5-409e-b0ee-9c4503483c03">Life of patent</cpix:FiniteLivedIntangibleAssetsUsefulLivesTextual>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTYw_8404c2a2-7082-48cd-bba1-d6697443e33c">Impairment of Long-Lived AssetsLong-lived assets, such as property and equipment, operating lease right-of-use assets and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If events or circumstances arise that require a long-lived asset to be tested for potential impairment, the Company first compares undiscounted cash flows expected to be generated by the asset to its carrying value. If the carrying amount of the long-lived asset is not recoverable on an undiscounted cash flow basis, an impairment charge is recognized to the extent that the carrying value exceeds the fair value. Fair value is determined through various valuation techniques including quoted market prices, third-party independent appraisals and discounted cash flow models.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTYx_b1fb062d-1407-4ed2-9bda-15e938d7f49d">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2018, the Company adopted the Financial Accounting Standards Board&#x2019;s (&#x201c;FASB&#x201d;) amended guidance in the form of Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2014-09, "Revenue from Contracts with Customers," (ASC 606). Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts were not adjusted and are reported in accordance with ASC 605.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from product sales are recognized in the amount that reflects the consideration that we expect to receive for these goods.  Depending upon the shipping terms of the transaction, the revenue is recognized.at the point where the customer obtains control of the goods and we satisfy our performance obligation.  This occurs upon either shipment of the product or arrival at its ship to destination.  Payment terms typically range from 30 to 60 days from date of shipment. The Company&#x2019;s net product revenue reflects the reduction from gross product revenue for &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;estimated allowances for chargebacks, discounts and damaged goods, and reflects sales related accruals for rebates, coupons, product returns, and certain administrative and service fees. Significant judgments must be made in determining the transaction price for our sales of products related to these adjustments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sales Rebates and Discounts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allowances against accounts receivable for chargebacks, discounts, expired and damaged goods are determined on a product-by-product basis, and established by management as the Company&#x2019;s best estimate at the time of sale based on each product&#x2019;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks, discounts and credits claimed for damaged and expired product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company&#x2019;s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, sales revenues are reduced and accrued liabilities are increased by the Company&#x2019;s estimate of the rebate that may be claimed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sales Returns&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consistent with industry practice, the Company maintains a return policy that allows customers to return product within a specified period prior to and subsequent to the expiration date. The Company&#x2019;s estimate of the provision for returns is based upon historical experience, expiration date by product as well as any other factor expected to impact future returns. Any changes in the assumptions used to estimate the provision for returns are recognized in the period those assumptions are changed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenues primarily consist of income from grant funding programs, licensing agreements, leases and contract services.  Revenue related to grants is recognized when all conditions related to such grants have been met.  All other revenue is recognized when earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of products sold consists principally of the cost to acquire each unit of product sold, including in-bound freight expense as well as any adjustment in the net realizable value of inventory acquired in acquisitions. Cost of products sold also includes expenses associated with the reduction in the net realizable value of slow-moving or expired product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Selling and Marketing Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling and marketing expense consists primarily of expenses relating to the advertising, promotion, distribution and sale of products, including royalty expense, salaries and related costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Distribution Costs&lt;/span&gt;&lt;/div&gt;Distribution costs are expensed as incurred and are included as a component of selling and marketing expenses in the consolidated statements of operations.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ProductionAndDistributionCosts
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90YWJsZTo2MjFlZjFiZmU5NjE0ZGZlOGZlMDc1ZGY1MzU0NWVjZS90YWJsZXJhbmdlOjYyMWVmMWJmZTk2MTRkZmU4ZmUwNzVkZjUzNTQ1ZWNlXzItMi0xLTEtMA_53e2c235-0d48-43af-a8aa-8683ada4c82c"
      unitRef="usd">613637</us-gaap:ProductionAndDistributionCosts>
    <us-gaap:ProductionAndDistributionCosts
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90YWJsZTo2MjFlZjFiZmU5NjE0ZGZlOGZlMDc1ZGY1MzU0NWVjZS90YWJsZXJhbmdlOjYyMWVmMWJmZTk2MTRkZmU4ZmUwNzVkZjUzNTQ1ZWNlXzItNC0xLTEtMA_217d62f9-8516-412d-a49f-b983bb56eea4"
      unitRef="usd">457814</us-gaap:ProductionAndDistributionCosts>
    <us-gaap:ProductionAndDistributionCosts
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90YWJsZTo2MjFlZjFiZmU5NjE0ZGZlOGZlMDc1ZGY1MzU0NWVjZS90YWJsZXJhbmdlOjYyMWVmMWJmZTk2MTRkZmU4ZmUwNzVkZjUzNTQ1ZWNlXzItNi0xLTEtMA_116859c8-e47f-4fb2-8edc-dc1fdcc95b56"
      unitRef="usd">487669</us-gaap:ProductionAndDistributionCosts>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTYz_7e76093b-9f5b-498f-85f0-4e20b5c86030">Advertising CostsAdvertising costs are expensed as incurred and are included as a component of selling and marketing expenses in the consolidated statements of operations.</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90YWJsZTo3OTg5Y2ViNWFjZDE0MDA1YWY4M2U4MzBjMmRjYmQwNi90YWJsZXJhbmdlOjc5ODljZWI1YWNkMTQwMDVhZjgzZTgzMGMyZGNiZDA2XzItMi0xLTEtMA_be2d5c61-5682-491b-8b68-b25fe43c2942"
      unitRef="usd">2594630</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90YWJsZTo3OTg5Y2ViNWFjZDE0MDA1YWY4M2U4MzBjMmRjYmQwNi90YWJsZXJhbmdlOjc5ODljZWI1YWNkMTQwMDVhZjgzZTgzMGMyZGNiZDA2XzItNC0xLTEtMA_4f5a958a-fddb-4d94-a5db-51aa609572a1"
      unitRef="usd">2005113</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90YWJsZTo3OTg5Y2ViNWFjZDE0MDA1YWY4M2U4MzBjMmRjYmQwNi90YWJsZXJhbmdlOjc5ODljZWI1YWNkMTQwMDVhZjgzZTgzMGMyZGNiZDA2XzItNi0xLTEtMA_b7249bc1-5d81-4966-965a-5f146e1522aa"
      unitRef="usd">2377338</us-gaap:AdvertisingExpense>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTYy_7424d78e-8e26-4194-8783-45ea1b42db36">&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed in the period incurred. Research and development costs are comprised mainly of clinical trial expenses, salaries, wages and other related costs such as materials and supplies. Research and development expense includes activities performed by third-party providers participating in the Company&#x2019;s clinical studies. The Company accounts for these costs based on estimates of work performed, patients enrolled or fixed fees for services over the period of time the clinical trials are performed.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTcx_371cbdd4-00d0-4be1-9a7a-94d775ebe5d0">&lt;div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides for deferred taxes using the asset and liability approach. Under this method, deferred tax assets and liabilities are recognized for future tax consequences attributable to operating loss and tax credit carryforwards, as well as differences between the carrying amounts of existing assets and liabilities and their respective tax bases. The Company&#x2019;s principal differences are related to the timing of deductibility of certain items, such as inventory, depreciation, amortization and share-based compensation. Deferred tax assets and liabilities are measured using enacted statutory tax rates that are expected to apply to taxable income in the years such temporary differences are anticipated to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. The Company only recognizes income tax benefits associated with an income tax position in which it is &#x201c;more likely than not&#x201d; that the position would be sustained upon examination by the taxing authorities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In assessing the realizability of deferred tax assets, management considers whether some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of existing temporary differences, projected future taxable income and tax planning strategies in making this assessment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accounting policy with respect to interest and penalties arising from income tax settlements is to recognize them as part of the provision for income taxes.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTcy_e9de1efc-08f2-4a45-987f-a8c096df0a28">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total comprehensive income (loss) was comprised solely of net income (loss) for all periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTU1_160f2a6e-714c-4345-862c-609234089946">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Earnings (Loss) per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings (loss) per share is calculated by dividing net income (loss) attributable to common shareholders by the weighted-average number of shares outstanding. Except where the result would be antidilutive to income from continuing operations, diluted earnings (loss) per share is calculated by assuming the vesting of unvested restricted stock and the exercise of stock options and warrants and unrecognized compensation costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTU4_b96456d4-988b-4c83-9d16-66f18bb6be6c">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes compensation cost for all share-based payments issued, modified, repurchased or canceled. Depending on the nature of the vesting provisions, restricted stock awards are measured using either the fair value on the grant date or the fair value of common stock on the date the vesting provisions lapse. Prior to the lapse for those equity grants not valued on the grant date, the fair value is measured on the last day of the reporting period.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:CollaborativeArrangementAccountingPolicy
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTU2_6e267ebe-0207-4ea7-aeff-e54fb74dc94b">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaborative Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is a party to several collaborative arrangements with certain research institutions to identify and pursue promising preclinical pharmaceutical product candidates. The Company has determined these collaborative agreements do not meet the criteria for accounting under Accounting Standards Codification 808, Collaborative Agreements. The agreements do not specifically designate each party's rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party. The funding for these programs is generally provided through private sector investments or federal Small Business Administration ("SBIR/STTR") grant programs. Expenses incurred under these collaborative agreements are included in research and development expenses in the consolidated statements of operations. Funding received from private sector investments and grants are recorded as net revenues in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassification of prior period amounts&lt;/span&gt;&lt;/div&gt;The Company has made certain reclassifications to prior period amounts to conform to the current-year presentation of the reporting of research and development expense and general and administrative expense on the consolidated statements of operations. Certain costs and expenses related to research and development were previously reported as general and administrative expenses on the consolidated statements of operations. These reclassifications have no effect on the reported operating loss or equity for the years ended December 31, 2018 and 2017.</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTMvZnJhZzphMDY1Yzg4YmNmZmQ0YmNmOTM5MmZhOWI0NmNhZjA4ZC90ZXh0cmVnaW9uOmEwNjVjODhiY2ZmZDRiY2Y5MzkyZmE5YjQ2Y2FmMDhkXzMxMTU3_1bcc72ba-158e-4958-832d-158a994638c4">&lt;div style="margin-top:7pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Guidance &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2014, the FASB issued amended guidance in the form of ASU No. 2014-09, &#x201c;Revenue from Contracts with Customers&#x201d; (&#x201c;ASC 606&#x201d;).  The core principle of the new guidance is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. The new guidance defines a five-step process to achieve this core principle and, in doing so, additional judgments and estimates may be required within the revenue recognition process. The new standard replaced most of the existing revenue recognition standards in U.S. GAAP when it became effective. In July 2015, the FASB issued a one-year deferral of the adoption date, which extended the effective date for us to January 1, 2018, at which point Cumberland adopted the standard. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated its revenues and the new guidance had immaterial impacts to recognition practices upon adoption on January 1, 2018.  As part of the adoption, the Company elected to apply the new guidance on a modified retrospective basis. The Company did not record a cumulative effect adjustment to historical retained earnings for initially applying the new guidance as no revenue recognition differences were identified in the timing or amount of revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2016, the Financial Accounting Standards Board ("FASB") issued guidance in the form of a FASB Accounting Standards Update ("ASU") No. 2016-02, &#x201c;Leases.&#x201d; The new standard establishes a right-of-use (&#x201c;ROU&#x201d;) model that requires a lessee to record an ROU asset and a lease liability on the balance sheet for all leases with terms longer than twelve months. Leases will be classified as either finance (formerly "capital leases") or &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;operating, with classification affecting the pattern of expense recognition in the income statement. The standard provides for a modified retrospective transition approach for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain optional practical expedients.  In July 2018, the FASB issued ASU 2018-11, "Leases: Targeted Improvements", allowing for an alternative transition method (the effective date approach). It allows an entity to initially apply the new lease guidance at the adoption date (rather than at the beginning of the earliest period presented). Cumberland adopted the lease guidance effective January 1, 2019 using the package of transition practical expedients.  This allowed the Company to retain the lease classification for any leases existing prior to adoption, in addition to other benefits. See additional discussion of the impact of adopting the lease accounting guidance in Note 15.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements - Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU No. 2016-13, &#x201c;Financial Instruments-Credit Losses,&#x201d; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#x201c;expected loss&#x201d; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose more information, including the information they use to track credit quality by year of origination for most financing receivables. Companies will apply the standard&#x2019;s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. This standard is effective for the Company on January 1, 2020. The Company continues to evaluate this new standard on its trade and other receivables but does not expect a material impact on its consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met, the election must be applied on an instrument-by-instrument basis, and the election is not available for either available-for-sale or held-to-maturity debt securities. The effective date is the same as ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;January 1, 2020. The Company continues to evaluate this new standard but does not expect a material impact on its consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, the FASB issued ASU No. 2018-18, &#x201c;Collaboration Arrangements: Clarifying the Interaction between Topic 808 and Topic 606&#x201d; (ASU 2018-18). The issuance of ASU 2014-09 raised questions about the interaction between the guidance on collaborative arrangements and revenue recognition. ASU 2018-18 addresses this uncertainty by (1) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASU 2014-09 when the collaboration arrangement participant is a customer, (2) adding unit of account guidance to assess whether the collaboration arrangement or a part of the arrangement is with a customer and (3) precluding a company from presenting transactions with collaboration arrangement participants that are not directly related to sales to third parties together with revenue from contracts with customers. The new standard will be effective for the Company on January 1, 2020.  The Company continues to evaluate this new standard but does not expect a material impact on its consolidated financial statements. &lt;/span&gt;&lt;/div&gt;In January 2017, the FASB issued ASU No. 2017-04, &#x201c;Simplifying the Test for Goodwill Impairment&#x201d; (ASU 2017-04). The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation.  As a result of the revised guidance, a goodwill impairment will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The new standard will be effective for the Company on January 1, 2020. The Company continues to evaluate this new standard but does not expect a material impact on its consolidated financial statements and related disclosures.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90ZXh0cmVnaW9uOjA3MDRiZjQ2MTQzZTQzMjI4ZGNkNjBmZDZiMWU1Njc5XzU4MTQ_ac84a299-a3a9-459c-9b0b-6f07cafc8524">Omeclamox&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;-Pak, RediTrex&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; and Vibativ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;div style="margin-top:7pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Omeclamox-Pak&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2018, Cumberland completed an agreement with Gasto-enterlogics Inc. ("GEL") to acquire the remaining product rights associated with Omeclamox-Pak including the product&#x2019;s FDA-approved New Drug Application and the domestic and international trademarks. As part of the transaction, which was accounted for as an asset acquisition, Cumberland paid $2.3 million during 2018 and ended Cumberland&#x2019;s payments of royalties and manufacturing fees to GEL.  The Company has now assumed responsibility for the maintenance of the product&#x2019;s FDA approval and for the oversight of the product&#x2019;s manufacturing and packaging.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This agreement follows the November 2015 agreement between Cumberland and GEL to assume the remaining commercial rights to Omeclamox-Pak for the United States. The Company had previously signed an agreement with Pernix Therapeutics ("Pernix") to jointly commercialize the product in the United States in October 2013.  As part of the November 2015 GEL Agreement, Cumberland and Pernix terminated their arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The $4.0 million upfront payment that the Company paid in October 2013 to Pernix along with the payments made to GEL during 2018 are included in product and license rights and are being amortized over the remaining expected useful life of the acquired asset. The Company evaluated the remaining expected useful life and maintained the existing estimated life of the product, June 2032.  Omeclamox-Pak contributed $0.8 million, $0.6 million, and $1.8 million in net revenues during 2019, 2018, and 2017, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;RediTrex&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2016, the Company announced an Agreement to acquire the exclusive U.S. rights to Nordic Group B.V.&#x2019;s ("Nordic") injectable methotrexate product line as an asset purchase. The products are designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Agreement, Cumberland is responsible for the products&#x2019; FDA submission and registration. As consideration for the license, at closing, Cumberland paid a deposit of $100,000.  The Company also recorded a liability of $0.9 million that will be settled through 180,000 unvested restricted shares of Cumberland common stock that vest upon the FDA approval of the first Nordic product. Cumberland also agreed to provide Nordic a series of payments tied to the products&#x2019; FDA approval, launch and achievement of certain sales milestones. Nordic is responsible for manufacturing and supply of the products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 27, 2019, Cumberland received FDA approval of the pre-filled syringe. The 180,000 shares of restricted Cumberland common stock vested and were valued at $0.9 million on the vesting date. In addition, the FDA approval resulted in an additional $1.0&#160;million liability to Nordic that will be paid during 2020.  The value of the then unvested restricted Cumberland common stock shares was a liability of $1.1 million at December&#160;31, 2018.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Vibativ&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand.  Vibativ is a patented, FDA approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.  Cumberland acquired Vibativ to further add to its product offerings, increase its net revenue and positively contribute to the Company's operating results.  Cumberland expects to deduct the goodwill acquired in the acquisition for tax purposes.    &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company paid an upfront payment of $20.0 million at closing and a $5.0 million cash payment during early 2019. In addition, Cumberland agreed to pay a royalty of up to 20% on future net sales of the product.  The future royalty payments were required to be recognized at their acquisition-date fair value as part of the contingent consideration transferred in the business combination. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the initial payments and consideration for the business combination:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid at closing&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payment during early 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of contingent consideration - net sales royalty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contingent consideration liability represents the future net sales royalty payments discussed above.  Cumberland prepared the valuations of the contingent consideration liability and the intangible assets utilizing significant unobservable inputs.  As a result, the valuations are classified as Level 3 fair value measurements.  The Company will continue to evaluate the assets acquired and liabilities assumed during the measurement period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the Company's Level 3 contingent consideration liability that is measured at fair value on a recurring basis.  The current and long-term portions of this liability are disclosed in Note 8.  The contingent consideration earned and accrued in operating expenses is paid to the seller quarterly.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contingent consideration liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at November 12, 2018&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,034,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration earned and accrued in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,502,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustment to initial fair value of the contingent consideration liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,033,108)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(804,167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration earned and accrued in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;820,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,633,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the allocation of the fair values of the assets acquired as of the acquisition date for Vibativ:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.743%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.615%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,624,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process - unlabeled vials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,970,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process - validation vials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,827,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,129,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,550,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intellectual property amortizable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;882,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangibles and goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,632,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The Company's contingent consideration liability is a Level 3 fair value measurement that is updated on a recurring basis at each reporting period using a valuation model.  Consistent with Level 3 fair value measurements, there are significant inputs to the valuation model that are unobservable. The current portion of the contingent consideration liability is $2.4&#160;million and the non-current portion is $6.3&#160;million, as of December&#160;31, 2019.</us-gaap:BusinessCombinationDisclosureTextBlock>
    <cpix:PaymentsForAssetAcquisitions
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90ZXh0cmVnaW9uOjA3MDRiZjQ2MTQzZTQzMjI4ZGNkNjBmZDZiMWU1Njc5XzQyMA_1292c256-6cfc-4e3b-882e-94f78610646b"
      unitRef="usd">2300000</cpix:PaymentsForAssetAcquisitions>
    <cpix:RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales
      contextRef="i0a05405482c64e9e8fe092b821aeb335_D20131028-20131029"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90ZXh0cmVnaW9uOjA3MDRiZjQ2MTQzZTQzMjI4ZGNkNjBmZDZiMWU1Njc5XzEwOTQ_33478ffe-be03-47a6-80c1-2de68ca940af"
      unitRef="usd">4000000.0</cpix:RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i62d1338de7314d30a069c29708d22188_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90ZXh0cmVnaW9uOjA3MDRiZjQ2MTQzZTQzMjI4ZGNkNjBmZDZiMWU1Njc5XzE0OTM_62abca79-7d33-4ff7-ab5c-a8d7a3b94bc6"
      unitRef="usd">800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie0c9147a91864842a7ac6266279fa374_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90ZXh0cmVnaW9uOjA3MDRiZjQ2MTQzZTQzMjI4ZGNkNjBmZDZiMWU1Njc5XzE0OTc_da9fbfe4-0fce-4630-8756-37597f45f631"
      unitRef="usd">600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iafa9e83c0991457dbecd945d1f0eb0a8_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90ZXh0cmVnaW9uOjA3MDRiZjQ2MTQzZTQzMjI4ZGNkNjBmZDZiMWU1Njc5XzE1MDU_dfc8be49-255e-4089-a822-2a5425bd765b"
      unitRef="usd">1800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="iebd5c24d9fc142c0b899398d6d3c153d_D20161101-20161130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90ZXh0cmVnaW9uOjA3MDRiZjQ2MTQzZTQzMjI4ZGNkNjBmZDZiMWU1Njc5XzIxMDc_91547538-e6c9-4a39-b5f6-aba1500d1636"
      unitRef="usd">100000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="iebd5c24d9fc142c0b899398d6d3c153d_D20161101-20161130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90ZXh0cmVnaW9uOjA3MDRiZjQ2MTQzZTQzMjI4ZGNkNjBmZDZiMWU1Njc5XzIxNTM_2640bc8c-a885-42e5-b456-2b3ccede1078"
      unitRef="usd">900000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="i00c91a50edb844d99bb320b2490ff8d6_D20161101-20161130"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90ZXh0cmVnaW9uOjA3MDRiZjQ2MTQzZTQzMjI4ZGNkNjBmZDZiMWU1Njc5XzIxODU_8e1ddeb6-65ab-4853-9ab9-f7633662ac6c"
      unitRef="shares">180000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="i00c91a50edb844d99bb320b2490ff8d6_D20161101-20161130"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90ZXh0cmVnaW9uOjA3MDRiZjQ2MTQzZTQzMjI4ZGNkNjBmZDZiMWU1Njc5XzI2MDg_8e1ddeb6-65ab-4853-9ab9-f7633662ac6c"
      unitRef="shares">180000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i3dc00a50885944de8bd18286fb857d2a_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90ZXh0cmVnaW9uOjA3MDRiZjQ2MTQzZTQzMjI4ZGNkNjBmZDZiMWU1Njc5XzI2ODI_a3ea59e4-0219-42bd-bdb3-9a0e10494056"
      unitRef="usd">900000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ie0bf4ffa056349039b29b90f3009e187_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90ZXh0cmVnaW9uOjA3MDRiZjQ2MTQzZTQzMjI4ZGNkNjBmZDZiMWU1Njc5XzI3NjI_38ac489f-7eeb-4936-9518-e96eb4f4edd3"
      unitRef="usd">1000000.0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i5b955a67143f40b994546bcffda9b554_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90ZXh0cmVnaW9uOjA3MDRiZjQ2MTQzZTQzMjI4ZGNkNjBmZDZiMWU1Njc5XzI5MDk_f1e163cf-1aa8-4af6-b91e-2ed962d73861"
      unitRef="usd">1100000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i35eae0bc26094a639bb7e4c0640fb7ea_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90ZXh0cmVnaW9uOjA3MDRiZjQ2MTQzZTQzMjI4ZGNkNjBmZDZiMWU1Njc5XzQwNTY_88924b5a-18ed-48b5-95b3-6cb5d761a6eb"
      unitRef="usd">20000000.0</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:OtherPaymentsToAcquireBusinesses
      contextRef="ie2b0bcf3278442f08417f95c2f0b677a_D20190308-20190308"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90ZXh0cmVnaW9uOjA3MDRiZjQ2MTQzZTQzMjI4ZGNkNjBmZDZiMWU1Njc5XzQwNzY_25299168-90c8-46d5-a1f6-d789162d5735"
      unitRef="usd">5000000.0</us-gaap:OtherPaymentsToAcquireBusinesses>
    <cpix:TieredRoyaltyPaymentsPercentage
      contextRef="i35eae0bc26094a639bb7e4c0640fb7ea_D20181101-20181130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90ZXh0cmVnaW9uOjA3MDRiZjQ2MTQzZTQzMjI4ZGNkNjBmZDZiMWU1Njc5XzQxNjg_739656c6-c6d4-48f0-84cb-2fc874eefb9d"
      unitRef="number">0.20</cpix:TieredRoyaltyPaymentsPercentage>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90ZXh0cmVnaW9uOjA3MDRiZjQ2MTQzZTQzMjI4ZGNkNjBmZDZiMWU1Njc5XzU4MTY_852599e2-985e-440f-aaf6-4f3438316974">&lt;div style="margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the initial payments and consideration for the business combination:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid at closing&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payment during early 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of contingent consideration - net sales royalty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i9f2a5edba28144ad932b2ce0fd047ab3_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90YWJsZTpjMmMxYjI2NWIwMWI0NjMxYmRmOTEzZjdkM2FmMmYzYi90YWJsZXJhbmdlOmMyYzFiMjY1YjAxYjQ2MzFiZGY5MTNmN2QzYWYyZjNiXzItMS0xLTEtMA_e8f65b40-0139-407b-a0e6-adc442ec3851"
      unitRef="usd">20000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:OtherPaymentsToAcquireBusinesses
      contextRef="i9f2a5edba28144ad932b2ce0fd047ab3_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90YWJsZTpjMmMxYjI2NWIwMWI0NjMxYmRmOTEzZjdkM2FmMmYzYi90YWJsZXJhbmdlOmMyYzFiMjY1YjAxYjQ2MzFiZGY5MTNmN2QzYWYyZjNiXzMtMS0xLTEtMA_6cb3d5c4-fd5b-486c-affa-974d0adbf56f"
      unitRef="usd">5000000</us-gaap:OtherPaymentsToAcquireBusinesses>
    <cpix:PaymentsForContingentConsideration
      contextRef="i9f2a5edba28144ad932b2ce0fd047ab3_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90YWJsZTpjMmMxYjI2NWIwMWI0NjMxYmRmOTEzZjdkM2FmMmYzYi90YWJsZXJhbmdlOmMyYzFiMjY1YjAxYjQ2MzFiZGY5MTNmN2QzYWYyZjNiXzQtMS0xLTEtMA_b031d625-b7b2-4009-b2e1-a55018228079"
      unitRef="usd">9182000</cpix:PaymentsForContingentConsideration>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i9f2a5edba28144ad932b2ce0fd047ab3_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90YWJsZTpjMmMxYjI2NWIwMWI0NjMxYmRmOTEzZjdkM2FmMmYzYi90YWJsZXJhbmdlOmMyYzFiMjY1YjAxYjQ2MzFiZGY5MTNmN2QzYWYyZjNiXzUtMS0xLTEtMA_f2856074-4196-4959-9cdb-800bffd1263f"
      unitRef="usd">34182000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90ZXh0cmVnaW9uOjA3MDRiZjQ2MTQzZTQzMjI4ZGNkNjBmZDZiMWU1Njc5XzU4MTc_93b4beda-14a3-4e06-a0b7-e6ba187e368b">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the Company's Level 3 contingent consideration liability that is measured at fair value on a recurring basis.  The current and long-term portions of this liability are disclosed in Note 8.  The contingent consideration earned and accrued in operating expenses is paid to the seller quarterly.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contingent consideration liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at November 12, 2018&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,034,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration earned and accrued in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,502,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustment to initial fair value of the contingent consideration liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,033,108)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(804,167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration earned and accrued in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;820,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,633,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="idb606e761ca74e0fb88c19ca9f7345f7_I20181112"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90YWJsZTozMDQ1MGIxMjdjMDk0YzA2YTI0YWNmZGNjZWI4NDA0ZC90YWJsZXJhbmdlOjMwNDUwYjEyN2MwOTRjMDZhMjRhY2ZkY2NlYjg0MDRkXzEtMS0xLTEtMA_64f9b986-bdc6-4506-961e-35478122c717"
      unitRef="usd">9034000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i54bf1d15e917470abd4a457ea8b0a9b5_D20181113-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90YWJsZTozMDQ1MGIxMjdjMDk0YzA2YTI0YWNmZGNjZWI4NDA0ZC90YWJsZXJhbmdlOjMwNDUwYjEyN2MwOTRjMDZhMjRhY2ZkY2NlYjg0MDRkXzItMS0xLTEtMA_136fddbb-e5b3-479e-a50b-468dad5448cd"
      unitRef="usd">-40000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses
      contextRef="i2859968ba8084d4f9a9f00fafe0202a4_D20181112-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90YWJsZTozMDQ1MGIxMjdjMDk0YzA2YTI0YWNmZGNjZWI4NDA0ZC90YWJsZXJhbmdlOjMwNDUwYjEyN2MwOTRjMDZhMjRhY2ZkY2NlYjg0MDRkXzMtMS0xLTEtMA_ca8f6bb9-963e-4585-8d68-835369296099"
      unitRef="usd">508000</cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i8286cfe2c4684a39972d0ce5371ad480_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90YWJsZTozMDQ1MGIxMjdjMDk0YzA2YTI0YWNmZGNjZWI4NDA0ZC90YWJsZXJhbmdlOjMwNDUwYjEyN2MwOTRjMDZhMjRhY2ZkY2NlYjg0MDRkXzQtMS0xLTEtMA_8fab50d0-bf1b-4b73-8cf2-0d78be19d3ba"
      unitRef="usd">9502000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <cpix:BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment
      contextRef="i9f2a5edba28144ad932b2ce0fd047ab3_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90YWJsZTozMDQ1MGIxMjdjMDk0YzA2YTI0YWNmZGNjZWI4NDA0ZC90YWJsZXJhbmdlOjMwNDUwYjEyN2MwOTRjMDZhMjRhY2ZkY2NlYjg0MDRkXzUtMS0xLTEtMA_fe201061-a575-4793-bbe6-07473ba3c386"
      unitRef="usd">148000</cpix:BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment>
    <us-gaap:PaymentsForRoyalties
      contextRef="i9f2a5edba28144ad932b2ce0fd047ab3_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90YWJsZTozMDQ1MGIxMjdjMDk0YzA2YTI0YWNmZGNjZWI4NDA0ZC90YWJsZXJhbmdlOjMwNDUwYjEyN2MwOTRjMDZhMjRhY2ZkY2NlYjg0MDRkXzYtMS0xLTEtMA_ddf9c9af-5b0a-46bf-8774-0adf569bcecf"
      unitRef="usd">1033108</us-gaap:PaymentsForRoyalties>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i9f2a5edba28144ad932b2ce0fd047ab3_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90YWJsZTozMDQ1MGIxMjdjMDk0YzA2YTI0YWNmZGNjZWI4NDA0ZC90YWJsZXJhbmdlOjMwNDUwYjEyN2MwOTRjMDZhMjRhY2ZkY2NlYjg0MDRkXzctMS0xLTEtMA_db466a56-a0c1-49d5-abb8-47d13a0856b4"
      unitRef="usd">-804167</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses
      contextRef="i9f2a5edba28144ad932b2ce0fd047ab3_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90YWJsZTozMDQ1MGIxMjdjMDk0YzA2YTI0YWNmZGNjZWI4NDA0ZC90YWJsZXJhbmdlOjMwNDUwYjEyN2MwOTRjMDZhMjRhY2ZkY2NlYjg0MDRkXzgtMS0xLTEtMA_18d22411-4b7a-468e-9361-7618074544c4"
      unitRef="usd">820864</cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ifd15955102ce48909e6253ea8529c09b_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90YWJsZTozMDQ1MGIxMjdjMDk0YzA2YTI0YWNmZGNjZWI4NDA0ZC90YWJsZXJhbmdlOjMwNDUwYjEyN2MwOTRjMDZhMjRhY2ZkY2NlYjg0MDRkXzktMS0xLTEtMA_d15bfd56-9e55-4c99-bc29-084ed5dfb7c5"
      unitRef="usd">8633589</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90ZXh0cmVnaW9uOjA3MDRiZjQ2MTQzZTQzMjI4ZGNkNjBmZDZiMWU1Njc5XzU4MTg_ea36b8ec-68b0-4f59-8630-684a01109e66">&lt;div style="margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the allocation of the fair values of the assets acquired as of the acquisition date for Vibativ:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.743%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.615%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,624,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process - unlabeled vials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,970,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process - validation vials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,827,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,129,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,550,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intellectual property amortizable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;882,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangibles and goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,632,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory
      contextRef="i4af7f789d58345659c0394f24e9c9d71_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90YWJsZTowOWQ1OGEwNjJkMWQ0YTc0YTQ2NTU5NGQ4ZGZkN2MyMC90YWJsZXJhbmdlOjA5ZDU4YTA2MmQxZDRhNzRhNDY1NTk0ZDhkZmQ3YzIwXzAtMS0xLTEtMA_0dabeff3-fef6-44a5-9bfb-b44c052d0556"
      unitRef="usd">6624000</cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory>
    <cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials
      contextRef="i4af7f789d58345659c0394f24e9c9d71_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90YWJsZTowOWQ1OGEwNjJkMWQ0YTc0YTQ2NTU5NGQ4ZGZkN2MyMC90YWJsZXJhbmdlOjA5ZDU4YTA2MmQxZDRhNzRhNDY1NTk0ZDhkZmQ3YzIwXzEtMS0xLTEtMA_5dbeeecb-2e53-4ba2-823a-d7b1c7b49080"
      unitRef="usd">3970000</cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials>
    <cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials
      contextRef="i4af7f789d58345659c0394f24e9c9d71_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90YWJsZTowOWQ1OGEwNjJkMWQ0YTc0YTQ2NTU5NGQ4ZGZkN2MyMC90YWJsZXJhbmdlOjA5ZDU4YTA2MmQxZDRhNzRhNDY1NTk0ZDhkZmQ3YzIwXzItMS0xLTEtMA_0afd1e95-8bb2-4da6-9363-97255a9f903b"
      unitRef="usd">1827000</cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials>
    <cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory
      contextRef="i4af7f789d58345659c0394f24e9c9d71_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90YWJsZTowOWQ1OGEwNjJkMWQ0YTc0YTQ2NTU5NGQ4ZGZkN2MyMC90YWJsZXJhbmdlOjA5ZDU4YTA2MmQxZDRhNzRhNDY1NTk0ZDhkZmQ3YzIwXzMtMS0xLTEtMA_79810b63-6b06-4604-af7a-ffa13f8aa231"
      unitRef="usd">9129000</cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="i4af7f789d58345659c0394f24e9c9d71_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90YWJsZTowOWQ1OGEwNjJkMWQ0YTc0YTQ2NTU5NGQ4ZGZkN2MyMC90YWJsZXJhbmdlOjA5ZDU4YTA2MmQxZDRhNzRhNDY1NTk0ZDhkZmQ3YzIwXzQtMS0xLTEtMA_aae1bcc4-9d8f-41d0-983d-8fcf45166244"
      unitRef="usd">21550000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i4af7f789d58345659c0394f24e9c9d71_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90YWJsZTowOWQ1OGEwNjJkMWQ0YTc0YTQ2NTU5NGQ4ZGZkN2MyMC90YWJsZXJhbmdlOjA5ZDU4YTA2MmQxZDRhNzRhNDY1NTk0ZDhkZmQ3YzIwXzYtMS0xLTEtMA_7abee862-0f54-4849-ba3c-0be77a3ca48b"
      unitRef="usd">11750000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Goodwill
      contextRef="i4af7f789d58345659c0394f24e9c9d71_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90YWJsZTowOWQ1OGEwNjJkMWQ0YTc0YTQ2NTU5NGQ4ZGZkN2MyMC90YWJsZXJhbmdlOjA5ZDU4YTA2MmQxZDRhNzRhNDY1NTk0ZDhkZmQ3YzIwXzctMS0xLTEtMA_9f61a115-51a5-4818-b373-c2ef830dab42"
      unitRef="usd">882000</us-gaap:Goodwill>
    <cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill
      contextRef="i4af7f789d58345659c0394f24e9c9d71_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90YWJsZTowOWQ1OGEwNjJkMWQ0YTc0YTQ2NTU5NGQ4ZGZkN2MyMC90YWJsZXJhbmdlOjA5ZDU4YTA2MmQxZDRhNzRhNDY1NTk0ZDhkZmQ3YzIwXzgtMS0xLTEtMA_5b8b4cc1-d601-4290-8a71-d6ee6de34fed"
      unitRef="usd">12632000</cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="i4af7f789d58345659c0394f24e9c9d71_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90YWJsZTowOWQ1OGEwNjJkMWQ0YTc0YTQ2NTU5NGQ4ZGZkN2MyMC90YWJsZXJhbmdlOjA5ZDU4YTA2MmQxZDRhNzRhNDY1NTk0ZDhkZmQ3YzIwXzktMS0xLTEtMA_59ea2ffb-f476-485b-9cd8-623f282513ba"
      unitRef="usd">34182000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90ZXh0cmVnaW9uOjA3MDRiZjQ2MTQzZTQzMjI4ZGNkNjBmZDZiMWU1Njc5XzU3Njc_e323cc63-caaf-4170-9b11-618aa2cdd3ea"
      unitRef="usd">2400000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18xOTkvZnJhZzowNzA0YmY0NjE0M2U0MzIyOGRjZDYwZmQ2YjFlNTY3OS90ZXh0cmVnaW9uOjA3MDRiZjQ2MTQzZTQzMjI4ZGNkNjBmZDZiMWU1Njc5XzU4MDE_9021424f-f983-4870-8212-75acba41f503"
      unitRef="usd">6300000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90ZXh0cmVnaW9uOjU4N2RlYTM1YjE1MzQ2MWFhYTY0MTlhNzMzYWRlZDY5XzI3NTA_56c9f748-71a3-4546-93e4-672c05dde941">Revenues&lt;div style="margin-top:7pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s net product revenues consisted of the following for the years ended December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.698%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.644%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Products:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acetadote&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,824,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,284,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,576,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Omeclamox-Pak&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;837,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;623,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,761,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kristalose&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,895,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,055,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,455,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vaprisol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,763,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,576,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Caldolor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,222,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,001,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,178,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vibativ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,691,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,075,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,407,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,803,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,549,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:16pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2019, Cumberland executed a License and Distribution agreement with HongKong WinHealth Pharma Group Co. Limited (&#x201c;WinHealth&#x201d;) for our Caldolor and Acetadote&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;brands in China and Hong Kong.  In conjunction with these new arrangements, the Company terminated a previous License and Distribution agreement with Gloria Pharmaceuticals Co ("Gloria Pharmaceuticals") for the two brands.  In addition, we also signed a new License and Distribution agreement with DB Pharm Korea Co., Ltd. (&#x201c;DB Pharm&#x201d;) for Vibativ in South Korea. As a result of these agreements, Cumberland recognized approximately $0.3&#160;million of non-refundable up-front payments as other revenue in the consolidated statement of operations during 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into agreements, beginning in 2012, with international partners for commercialization of the Company's products.  The international agreements provide that each of the partners are responsible for seeking regulatory approvals for the products, and following approvals, each partner will handle ongoing &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;distribution and sales in the respective international territories.  The Company maintains responsibility for the intellectual property and product formulations.  Under the international agreements, the Company is entitled to receive non-refundable up-front payments at the time the agreements are entered into and payments upon the partners' achievement of defined regulatory approvals and sales milestones.  The Company will recognize revenue for these achievements once it is probable that these consideration amounts are no longer constrained. The Company is also entitled to receive royalties on future sales of the products under the agreements. The international agreements provide for $1.0 million in non-refundable up-front payments, milestone payments of up to $2.2 million related to regulatory approvals and up to $4.8 million in payments related to product sales.  From 2012 through December&#160;31, 2019, the Company has recognized a cumulative $1.2 million in upfront payments as other revenue and has recognized $0.1&#160;million in revenue related to the milestone payments associated with these international agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenues during 2019, 2018 and 2017 also includes revenue generated by CET through grant funding from federal Small Business grant programs, and lease income generated by CET&#x2019;s Life Sciences Center and contract services. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from SBIR/STTR programs totaled approximately $1.3 million, $0.1 million, and $0.2 million for the years ending December&#160;31, 2019, 2018 and 2017, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90ZXh0cmVnaW9uOjU4N2RlYTM1YjE1MzQ2MWFhYTY0MTlhNzMzYWRlZDY5XzI3NTI_f1bc53ee-8737-400d-84d3-88474117a16a">&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s net product revenues consisted of the following for the years ended December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.698%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.644%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Products:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acetadote&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,824,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,284,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,576,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Omeclamox-Pak&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;837,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;623,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,761,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kristalose&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,895,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,055,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,455,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vaprisol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,763,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,576,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Caldolor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,222,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,001,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,178,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vibativ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,691,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,075,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,407,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,803,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,549,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2f1333c86d8745489e79ec97651cf898_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90YWJsZTo4ZmJkMTVkZTk1MTI0NDk3YTI2OTQzYzg4ZTAzMTVhMC90YWJsZXJhbmdlOjhmYmQxNWRlOTUxMjQ0OTdhMjY5NDNjODhlMDMxNWEwXzItMi0xLTEtMA_06a27804-cb3e-4b8a-be06-ae5d17e90f48"
      unitRef="usd">3824449</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief373c33e252406ba170c90d1219f6dd_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90YWJsZTo4ZmJkMTVkZTk1MTI0NDk3YTI2OTQzYzg4ZTAzMTVhMC90YWJsZXJhbmdlOjhmYmQxNWRlOTUxMjQ0OTdhMjY5NDNjODhlMDMxNWEwXzItNC0xLTEtMA_2f679945-2826-4c38-a397-25b0f6cff761"
      unitRef="usd">4284111</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8169ad28217c4db3b21d9f9eeee9c392_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90YWJsZTo4ZmJkMTVkZTk1MTI0NDk3YTI2OTQzYzg4ZTAzMTVhMC90YWJsZXJhbmdlOjhmYmQxNWRlOTUxMjQ0OTdhMjY5NDNjODhlMDMxNWEwXzItNi0xLTEtMA_be8d77a3-3372-4ab0-bf8b-697c188f438d"
      unitRef="usd">6576720</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i07a58e2ca82d468d914ab4d50fee24b8_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90YWJsZTo4ZmJkMTVkZTk1MTI0NDk3YTI2OTQzYzg4ZTAzMTVhMC90YWJsZXJhbmdlOjhmYmQxNWRlOTUxMjQ0OTdhMjY5NDNjODhlMDMxNWEwXzMtMi0xLTEtMA_3075fb5f-7093-4cbe-8ce2-dd9048b52385"
      unitRef="usd">837829</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee48a107bb7c466ebfe24ff0624d8263_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90YWJsZTo4ZmJkMTVkZTk1MTI0NDk3YTI2OTQzYzg4ZTAzMTVhMC90YWJsZXJhbmdlOjhmYmQxNWRlOTUxMjQ0OTdhMjY5NDNjODhlMDMxNWEwXzMtNC0xLTEtMA_b69810b4-6c2e-4c2e-bff2-42e468703986"
      unitRef="usd">623297</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iafa9e83c0991457dbecd945d1f0eb0a8_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90YWJsZTo4ZmJkMTVkZTk1MTI0NDk3YTI2OTQzYzg4ZTAzMTVhMC90YWJsZXJhbmdlOjhmYmQxNWRlOTUxMjQ0OTdhMjY5NDNjODhlMDMxNWEwXzMtNi0xLTEtMA_b048b622-e3f3-4804-ba41-44901664b09b"
      unitRef="usd">1761868</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie774ce371d1f4360a413d7cd01f67f7a_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90YWJsZTo4ZmJkMTVkZTk1MTI0NDk3YTI2OTQzYzg4ZTAzMTVhMC90YWJsZXJhbmdlOjhmYmQxNWRlOTUxMjQ0OTdhMjY5NDNjODhlMDMxNWEwXzQtMi0xLTEtMA_00877011-7cff-43b1-b38e-aa81940549f3"
      unitRef="usd">12895120</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6071c9045bf147eda9c3489832bb5075_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90YWJsZTo4ZmJkMTVkZTk1MTI0NDk3YTI2OTQzYzg4ZTAzMTVhMC90YWJsZXJhbmdlOjhmYmQxNWRlOTUxMjQ0OTdhMjY5NDNjODhlMDMxNWEwXzQtNC0xLTEtMA_d572b44a-3b1f-4f87-b7ae-1d8cf8c085a7"
      unitRef="usd">12055625</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icc6447e28536413ebc8660631a042645_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90YWJsZTo4ZmJkMTVkZTk1MTI0NDk3YTI2OTQzYzg4ZTAzMTVhMC90YWJsZXJhbmdlOjhmYmQxNWRlOTUxMjQ0OTdhMjY5NDNjODhlMDMxNWEwXzQtNi0xLTEtMA_3e6c6dd3-9433-447a-bd86-62c72263a564"
      unitRef="usd">11455805</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4c7af9859e7b4d49bc0d4cfb8caec5b5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90YWJsZTo4ZmJkMTVkZTk1MTI0NDk3YTI2OTQzYzg4ZTAzMTVhMC90YWJsZXJhbmdlOjhmYmQxNWRlOTUxMjQ0OTdhMjY5NDNjODhlMDMxNWEwXzUtMi0xLTEtMA_c40bd195-8875-41ca-9e80-4954ce0fd0fa"
      unitRef="usd">936615</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e8af893ce924072831291283cf7341a_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90YWJsZTo4ZmJkMTVkZTk1MTI0NDk3YTI2OTQzYzg4ZTAzMTVhMC90YWJsZXJhbmdlOjhmYmQxNWRlOTUxMjQ0OTdhMjY5NDNjODhlMDMxNWEwXzUtNC0xLTEtMA_b33a2c99-6312-4c89-8427-e6d3c584ad1d"
      unitRef="usd">1763874</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i17481b3eb00f41c493ce3e18607ab92f_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90YWJsZTo4ZmJkMTVkZTk1MTI0NDk3YTI2OTQzYzg4ZTAzMTVhMC90YWJsZXJhbmdlOjhmYmQxNWRlOTUxMjQ0OTdhMjY5NDNjODhlMDMxNWEwXzUtNi0xLTEtMA_80f56608-b05d-4c03-ad2e-1a0b70daf394"
      unitRef="usd">1576222</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i56db8e8bb906489db9d57373574874aa_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90YWJsZTo4ZmJkMTVkZTk1MTI0NDk3YTI2OTQzYzg4ZTAzMTVhMC90YWJsZXJhbmdlOjhmYmQxNWRlOTUxMjQ0OTdhMjY5NDNjODhlMDMxNWEwXzYtMi0xLTEtMA_8d6808da-b170-47ce-b4f4-b7428fd9805d"
      unitRef="usd">5222282</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i320e6951e476481187afd7fdc00da9a3_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90YWJsZTo4ZmJkMTVkZTk1MTI0NDk3YTI2OTQzYzg4ZTAzMTVhMC90YWJsZXJhbmdlOjhmYmQxNWRlOTUxMjQ0OTdhMjY5NDNjODhlMDMxNWEwXzYtNC0xLTEtMA_cad75e05-4b06-4ecd-ac52-91014023f329"
      unitRef="usd">5001997</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i89b467d3bb2a460e991f8a90b333ff4d_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90YWJsZTo4ZmJkMTVkZTk1MTI0NDk3YTI2OTQzYzg4ZTAzMTVhMC90YWJsZXJhbmdlOjhmYmQxNWRlOTUxMjQ0OTdhMjY5NDNjODhlMDMxNWEwXzYtNi0xLTEtMA_a4e5a33d-6156-468f-85f4-aee6aa856c39"
      unitRef="usd">4178443</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idfd2f30676c34f82a88e1052658a9b37_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90YWJsZTo4ZmJkMTVkZTk1MTI0NDk3YTI2OTQzYzg4ZTAzMTVhMC90YWJsZXJhbmdlOjhmYmQxNWRlOTUxMjQ0OTdhMjY5NDNjODhlMDMxNWEwXzktMi0xLTEtMA_7892119f-a44a-4d28-9bf9-adca894d808e"
      unitRef="usd">8691550</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic88d54bc58134580bd4649c7afe08bf6_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90YWJsZTo4ZmJkMTVkZTk1MTI0NDk3YTI2OTQzYzg4ZTAzMTVhMC90YWJsZXJhbmdlOjhmYmQxNWRlOTUxMjQ0OTdhMjY5NDNjODhlMDMxNWEwXzktNC0xLTEtMA_fda4907f-2946-4c1f-9594-b6ab343002ac"
      unitRef="usd">5075057</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id16bbbe7271043b3b909c6f3fa6611d0_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90YWJsZTo4ZmJkMTVkZTk1MTI0NDk3YTI2OTQzYzg4ZTAzMTVhMC90YWJsZXJhbmdlOjhmYmQxNWRlOTUxMjQ0OTdhMjY5NDNjODhlMDMxNWEwXzktNi0xLTEtMA_6e4de2d5-75c4-4146-ab44-6fd658801600"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90YWJsZTo4ZmJkMTVkZTk1MTI0NDk3YTI2OTQzYzg4ZTAzMTVhMC90YWJsZXJhbmdlOjhmYmQxNWRlOTUxMjQ0OTdhMjY5NDNjODhlMDMxNWEwXzEwLTItMS0xLTA_cac38bf6-f82f-433c-9065-cbed2c9b7b1d"
      unitRef="usd">32407845</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90YWJsZTo4ZmJkMTVkZTk1MTI0NDk3YTI2OTQzYzg4ZTAzMTVhMC90YWJsZXJhbmdlOjhmYmQxNWRlOTUxMjQ0OTdhMjY5NDNjODhlMDMxNWEwXzEwLTQtMS0xLTA_a66b1cc2-6a83-4c5e-8755-f377ee56bd67"
      unitRef="usd">28803961</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90YWJsZTo4ZmJkMTVkZTk1MTI0NDk3YTI2OTQzYzg4ZTAzMTVhMC90YWJsZXJhbmdlOjhmYmQxNWRlOTUxMjQ0OTdhMjY5NDNjODhlMDMxNWEwXzEwLTYtMS0xLTA_76904e6d-abac-4d61-8cc4-78e11fed8ce8"
      unitRef="usd">25549058</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i80881f50116942c79eeedbc60d086b43_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90ZXh0cmVnaW9uOjU4N2RlYTM1YjE1MzQ2MWFhYTY0MTlhNzMzYWRlZDY5Xzc0Ng_be02b677-1c21-4b83-8bbc-7fe547975cd7"
      unitRef="usd">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <cpix:RevenueRecognitionUpfrontPayment
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90ZXh0cmVnaW9uOjU4N2RlYTM1YjE1MzQ2MWFhYTY0MTlhNzMzYWRlZDY5XzE4NzY_214c7a03-8680-4c9c-9bfb-0320c133df9d"
      unitRef="usd">1000000.0</cpix:RevenueRecognitionUpfrontPayment>
    <cpix:RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90ZXh0cmVnaW9uOjU4N2RlYTM1YjE1MzQ2MWFhYTY0MTlhNzMzYWRlZDY5XzE5NDQ_8ff1413b-4c62-43c8-883e-4b62d485bb31"
      unitRef="usd">2200000</cpix:RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval>
    <cpix:RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90ZXh0cmVnaW9uOjU4N2RlYTM1YjE1MzQ2MWFhYTY0MTlhNzMzYWRlZDY5XzE5ODk_36f5f3b4-37c3-492e-bb07-ec2ca35615df"
      unitRef="usd">4800000</cpix:RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales>
    <cpix:RevenueRecognitionCumulativeUpfrontPayment
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90ZXh0cmVnaW9uOjU4N2RlYTM1YjE1MzQ2MWFhYTY0MTlhNzMzYWRlZDY5XzIwOTM_36cd6677-3adb-4ba4-b116-a929173cd6e3"
      unitRef="usd">1200000</cpix:RevenueRecognitionCumulativeUpfrontPayment>
    <cpix:RevenueRecognitionMilestonePayments
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90ZXh0cmVnaW9uOjU4N2RlYTM1YjE1MzQ2MWFhYTY0MTlhNzMzYWRlZDY5XzIxNTI_ec785713-01ba-414c-ab16-390787997865"
      unitRef="usd">100000</cpix:RevenueRecognitionMilestonePayments>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if00c3bf918d24cc3aaeb84d0fbd302a3_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90ZXh0cmVnaW9uOjU4N2RlYTM1YjE1MzQ2MWFhYTY0MTlhNzMzYWRlZDY5XzI2ODY_6e51b639-e280-4234-8f4f-d2eb2bb6a630"
      unitRef="usd">1300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f14c6eb615f4396a69694ec3bbf3a78_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90ZXh0cmVnaW9uOjU4N2RlYTM1YjE1MzQ2MWFhYTY0MTlhNzMzYWRlZDY5XzI2OTE_d786ff6f-b44b-47ee-b6f6-e51977a10589"
      unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i14230e23d1f14fddaceba899b44a4986_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDIvZnJhZzo1ODdkZWEzNWIxNTM0NjFhYWE2NDE5YTczM2FkZWQ2OS90ZXh0cmVnaW9uOjU4N2RlYTM1YjE1MzQ2MWFhYTY0MTlhNzMzYWRlZDY5XzI2OTk_dd4601e8-5529-4d2d-a45d-faa3aea095de"
      unitRef="usd">200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDUvZnJhZzo3YTcyYmNlYzVhYWM0NDZhODdjZmY4NjljYTc0ZTYwMy90ZXh0cmVnaW9uOjdhNzJiY2VjNWFhYzQ0NmE4N2NmZjg2OWNhNzRlNjAzXzE3NjI_d03cf487-9094-4f9a-9a14-2c8f8bb9ecff">Inventories&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's net inventories consisted of the following as of December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.339%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.248%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,345,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,378,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consigned inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;937,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods, net of reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,664,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,216,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,426,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,532,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;less non-current inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,554,992)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,749,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories classified as current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,871,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,783,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company continually evaluates inventories for potential losses due to expired, short-dated or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates the carrying value of a product may not be recoverable, a charge is recorded to reduce the inventory to its current net realizable value. At December&#160;31, 2019 and 2018, the Company had recognized and maintained cumulative charges for potential obsolescence and discontinuance losses of approximately $0.1 million and $0.3 million, respectively.  At December&#160;31, 2019 there were no cumulative obsolescence or discontinuance losses necessary.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of certain product rights related to the Kristalose brand, the Company is responsible for the purchase of the active pharmaceutical ingredient ("API") for Kristalose and maintains the inventory at the third-party packagers.  As the API is consumed in production, the value of the API is transferred from raw materials to finished goods.  API for the Company's Vaprisol brand is also included in the raw materials inventory total at December&#160;31, 2019 and 2018. Consigned inventory represents Authorized Generic inventory stored with Perrigo until shipment.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories of $15.7 million  that are classified as non-current inventories at December&#160;31, 2018.  At December&#160;31, 2019, the Vibativ non-current inventory was $15.3 million.  Although the Company did not have any finished goods included in the non-current inventories at December&#160;31, 2019, we had $0.8&#160;million in Vibativ finished goods included at December&#160;31, 2018.  During 2019, Cumberland also obtained $0.3&#160;million in non-current inventory for API related to its ifetroban clinical initiatives.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDUvZnJhZzo3YTcyYmNlYzVhYWM0NDZhODdjZmY4NjljYTc0ZTYwMy90ZXh0cmVnaW9uOjdhNzJiY2VjNWFhYzQ0NmE4N2NmZjg2OWNhNzRlNjAzXzE3NjM_02a8c883-7ae5-4cb5-a88a-5e0913b8e18e">&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's net inventories consisted of the following as of December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.339%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.248%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,345,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,378,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consigned inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;937,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods, net of reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,664,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,216,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,426,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,532,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;less non-current inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,554,992)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,749,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories classified as current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,871,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,783,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDUvZnJhZzo3YTcyYmNlYzVhYWM0NDZhODdjZmY4NjljYTc0ZTYwMy90YWJsZTo4Mzg4OTU5NGMzYTU0N2M4OTJlMjRjNTQ2NzE4MGFhNS90YWJsZXJhbmdlOjgzODg5NTk0YzNhNTQ3Yzg5MmUyNGM1NDY3MTgwYWE1XzItMi0xLTEtMA_d90bb68b-c06f-4bc9-baff-4388e73f444e"
      unitRef="usd">19345723</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDUvZnJhZzo3YTcyYmNlYzVhYWM0NDZhODdjZmY4NjljYTc0ZTYwMy90YWJsZTo4Mzg4OTU5NGMzYTU0N2M4OTJlMjRjNTQ2NzE4MGFhNS90YWJsZXJhbmdlOjgzODg5NTk0YzNhNTQ3Yzg5MmUyNGM1NDY3MTgwYWE1XzItNC0xLTEtMA_8f292b7a-70ec-4677-ae06-bef74f47e809"
      unitRef="usd">18378450</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDUvZnJhZzo3YTcyYmNlYzVhYWM0NDZhODdjZmY4NjljYTc0ZTYwMy90YWJsZTo4Mzg4OTU5NGMzYTU0N2M4OTJlMjRjNTQ2NzE4MGFhNS90YWJsZXJhbmdlOjgzODg5NTk0YzNhNTQ3Yzg5MmUyNGM1NDY3MTgwYWE1XzMtMi0xLTEtMA_b822e97e-a3f1-42c2-bce1-aa2d7ff98c2f"
      unitRef="usd">416468</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
    <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDUvZnJhZzo3YTcyYmNlYzVhYWM0NDZhODdjZmY4NjljYTc0ZTYwMy90YWJsZTo4Mzg4OTU5NGMzYTU0N2M4OTJlMjRjNTQ2NzE4MGFhNS90YWJsZXJhbmdlOjgzODg5NTk0YzNhNTQ3Yzg5MmUyNGM1NDY3MTgwYWE1XzMtNC0xLTEtMA_950dc904-ebbd-40a0-9918-b313187c0d6d"
      unitRef="usd">937006</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDUvZnJhZzo3YTcyYmNlYzVhYWM0NDZhODdjZmY4NjljYTc0ZTYwMy90YWJsZTo4Mzg4OTU5NGMzYTU0N2M4OTJlMjRjNTQ2NzE4MGFhNS90YWJsZXJhbmdlOjgzODg5NTk0YzNhNTQ3Yzg5MmUyNGM1NDY3MTgwYWE1XzQtMi0xLTEtMA_a36cd63b-9b5f-48f9-8add-ccdd9b407eff"
      unitRef="usd">4664055</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDUvZnJhZzo3YTcyYmNlYzVhYWM0NDZhODdjZmY4NjljYTc0ZTYwMy90YWJsZTo4Mzg4OTU5NGMzYTU0N2M4OTJlMjRjNTQ2NzE4MGFhNS90YWJsZXJhbmdlOjgzODg5NTk0YzNhNTQ3Yzg5MmUyNGM1NDY3MTgwYWE1XzQtNC0xLTEtMA_c5a85ca7-df97-449f-9ad6-ad75a67daf01"
      unitRef="usd">6216965</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryGross
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDUvZnJhZzo3YTcyYmNlYzVhYWM0NDZhODdjZmY4NjljYTc0ZTYwMy90YWJsZTo4Mzg4OTU5NGMzYTU0N2M4OTJlMjRjNTQ2NzE4MGFhNS90YWJsZXJhbmdlOjgzODg5NTk0YzNhNTQ3Yzg5MmUyNGM1NDY3MTgwYWE1XzUtMi0xLTEtMA_e3983bc4-7b59-4009-ae7c-fb167e6edb73"
      unitRef="usd">24426246</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDUvZnJhZzo3YTcyYmNlYzVhYWM0NDZhODdjZmY4NjljYTc0ZTYwMy90YWJsZTo4Mzg4OTU5NGMzYTU0N2M4OTJlMjRjNTQ2NzE4MGFhNS90YWJsZXJhbmdlOjgzODg5NTk0YzNhNTQ3Yzg5MmUyNGM1NDY3MTgwYWE1XzUtNC0xLTEtMA_3b653b3a-e5c3-45ba-aea6-91c5f6f86da4"
      unitRef="usd">25532421</us-gaap:InventoryGross>
    <us-gaap:InventoryNoncurrent
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDUvZnJhZzo3YTcyYmNlYzVhYWM0NDZhODdjZmY4NjljYTc0ZTYwMy90YWJsZTo4Mzg4OTU5NGMzYTU0N2M4OTJlMjRjNTQ2NzE4MGFhNS90YWJsZXJhbmdlOjgzODg5NTk0YzNhNTQ3Yzg5MmUyNGM1NDY3MTgwYWE1XzYtMi0xLTEtMA_e328cdc0-db99-4b7f-8f9a-9102fbd989a1"
      unitRef="usd">15554992</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDUvZnJhZzo3YTcyYmNlYzVhYWM0NDZhODdjZmY4NjljYTc0ZTYwMy90YWJsZTo4Mzg4OTU5NGMzYTU0N2M4OTJlMjRjNTQ2NzE4MGFhNS90YWJsZXJhbmdlOjgzODg5NTk0YzNhNTQ3Yzg5MmUyNGM1NDY3MTgwYWE1XzYtNC0xLTEtMA_86f74dba-237a-4594-baea-a66512616e65"
      unitRef="usd">15749000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNet
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDUvZnJhZzo3YTcyYmNlYzVhYWM0NDZhODdjZmY4NjljYTc0ZTYwMy90YWJsZTo4Mzg4OTU5NGMzYTU0N2M4OTJlMjRjNTQ2NzE4MGFhNS90YWJsZXJhbmdlOjgzODg5NTk0YzNhNTQ3Yzg5MmUyNGM1NDY3MTgwYWE1XzctMi0xLTEtMA_e7e45875-c8ea-4159-aa50-70881c5988fe"
      unitRef="usd">8871254</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDUvZnJhZzo3YTcyYmNlYzVhYWM0NDZhODdjZmY4NjljYTc0ZTYwMy90YWJsZTo4Mzg4OTU5NGMzYTU0N2M4OTJlMjRjNTQ2NzE4MGFhNS90YWJsZXJhbmdlOjgzODg5NTk0YzNhNTQ3Yzg5MmUyNGM1NDY3MTgwYWE1XzctNC0xLTEtMA_bc066a4d-1e61-4e87-9a86-10eea0de180e"
      unitRef="usd">9783421</us-gaap:InventoryNet>
    <us-gaap:InventoryValuationReserves
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDUvZnJhZzo3YTcyYmNlYzVhYWM0NDZhODdjZmY4NjljYTc0ZTYwMy90ZXh0cmVnaW9uOjdhNzJiY2VjNWFhYzQ0NmE4N2NmZjg2OWNhNzRlNjAzXzYwMg_0f303a50-e258-4116-921e-94d406250335"
      unitRef="usd">100000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDUvZnJhZzo3YTcyYmNlYzVhYWM0NDZhODdjZmY4NjljYTc0ZTYwMy90ZXh0cmVnaW9uOjdhNzJiY2VjNWFhYzQ0NmE4N2NmZjg2OWNhNzRlNjAzXzYwOQ_a5b3afe7-d3cd-4215-9d3f-1db485aa8de6"
      unitRef="usd">300000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNoncurrent
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDUvZnJhZzo3YTcyYmNlYzVhYWM0NDZhODdjZmY4NjljYTc0ZTYwMy90ZXh0cmVnaW9uOjdhNzJiY2VjNWFhYzQ0NmE4N2NmZjg2OWNhNzRlNjAzXzEzODE_b224d9e3-ad13-4f89-b5cd-1b60bbc71372"
      unitRef="usd">15700000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="ifd15955102ce48909e6253ea8529c09b_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDUvZnJhZzo3YTcyYmNlYzVhYWM0NDZhODdjZmY4NjljYTc0ZTYwMy90ZXh0cmVnaW9uOjdhNzJiY2VjNWFhYzQ0NmE4N2NmZjg2OWNhNzRlNjAzXzE0ODU_5be6448b-20bb-44d1-9038-db2445915b39"
      unitRef="usd">15300000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i8286cfe2c4684a39972d0ce5371ad480_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDUvZnJhZzo3YTcyYmNlYzVhYWM0NDZhODdjZmY4NjljYTc0ZTYwMy90ZXh0cmVnaW9uOjdhNzJiY2VjNWFhYzQ0NmE4N2NmZjg2OWNhNzRlNjAzXzE1OTc_ef93cb96-256a-4904-a279-cd2589f33ccd"
      unitRef="usd">800000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNoncurrent
      contextRef="i156f2acf482f4da8b0851cb775ba0501_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDUvZnJhZzo3YTcyYmNlYzVhYWM0NDZhODdjZmY4NjljYTc0ZTYwMy90ZXh0cmVnaW9uOjdhNzJiY2VjNWFhYzQ0NmE4N2NmZjg2OWNhNzRlNjAzXzE2ODE_660d75ee-f628-41d1-a49d-66bc47338001"
      unitRef="usd">300000</us-gaap:InventoryNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDgvZnJhZzplMzNkMjRiNWM2NTM0MDcxYjdlNmNhNTJjODQyY2ExYi90ZXh0cmVnaW9uOmUzM2QyNGI1YzY1MzQwNzFiN2U2Y2E1MmM4NDJjYTFiXzM1OA_d63a38e8-2015-4c63-a3e8-fa59f0f07a90">Property and Equipment&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following at December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.980%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.965%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.892%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.892%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.892%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Range of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;useful lives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&#x2013;&#160;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,148,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&#x2013;&#160;15&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;809,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&#x2013;&#160;15 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;646,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;639,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&#x2013;&#160;15&#160;years,&#160;or remaining&#160;lease&#160;term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,356,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,299,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;equipment, gross&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,142,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,895,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,394,329)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,124,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;771,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense, including amortization expense related to leasehold improvements, is included in general and administrative expense in the consolidated statements of operations.  Depreciation expense was as follows for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.897%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDgvZnJhZzplMzNkMjRiNWM2NTM0MDcxYjdlNmNhNTJjODQyY2ExYi90ZXh0cmVnaW9uOmUzM2QyNGI1YzY1MzQwNzFiN2U2Y2E1MmM4NDJjYTFiXzM2MA_16344dd6-0064-4ae7-9fa1-62e2ffb2ce99">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following at December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.980%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.965%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.892%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.892%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.892%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Range of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;useful lives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&#x2013;&#160;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,148,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&#x2013;&#160;15&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;809,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&#x2013;&#160;15 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;646,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;639,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&#x2013;&#160;15&#160;years,&#160;or remaining&#160;lease&#160;term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,356,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,299,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;equipment, gross&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,142,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,895,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,394,329)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,124,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;771,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ica008517cc804be682f6f8928de46011_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDgvZnJhZzplMzNkMjRiNWM2NTM0MDcxYjdlNmNhNTJjODQyY2ExYi90YWJsZTo2NGIwNzYxNTAxZGM0MzAyOTkwODEzYmUzNDY4ZDQ1MC90YWJsZXJhbmdlOjY0YjA3NjE1MDFkYzQzMDI5OTA4MTNiZTM0NjhkNDUwXzItNC0xLTEtMA_d715a2f4-4348-49dd-bd99-eff382c1af5f"
      unitRef="usd">1260630</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2ab1d686afef4f47af443ddb3c69c912_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDgvZnJhZzplMzNkMjRiNWM2NTM0MDcxYjdlNmNhNTJjODQyY2ExYi90YWJsZTo2NGIwNzYxNTAxZGM0MzAyOTkwODEzYmUzNDY4ZDQ1MC90YWJsZXJhbmdlOjY0YjA3NjE1MDFkYzQzMDI5OTA4MTNiZTM0NjhkNDUwXzItNi0xLTEtMA_963490ba-b440-456b-81b4-8ef31a6789a0"
      unitRef="usd">1148140</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8369853c76754322967bb52653385028_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDgvZnJhZzplMzNkMjRiNWM2NTM0MDcxYjdlNmNhNTJjODQyY2ExYi90YWJsZTo2NGIwNzYxNTAxZGM0MzAyOTkwODEzYmUzNDY4ZDQ1MC90YWJsZXJhbmdlOjY0YjA3NjE1MDFkYzQzMDI5OTA4MTNiZTM0NjhkNDUwXzMtNC0xLTEtMA_fad59770-9107-40c4-ab0c-950c41c86d0f"
      unitRef="usd">878350</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i67191970b6dc4dbab12c4bdce59ca551_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDgvZnJhZzplMzNkMjRiNWM2NTM0MDcxYjdlNmNhNTJjODQyY2ExYi90YWJsZTo2NGIwNzYxNTAxZGM0MzAyOTkwODEzYmUzNDY4ZDQ1MC90YWJsZXJhbmdlOjY0YjA3NjE1MDFkYzQzMDI5OTA4MTNiZTM0NjhkNDUwXzMtNi0xLTEtMA_349f270b-782e-4792-b069-09c7f0380eed"
      unitRef="usd">809153</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4f0e55caff6347b08baa66daf67632aa_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDgvZnJhZzplMzNkMjRiNWM2NTM0MDcxYjdlNmNhNTJjODQyY2ExYi90YWJsZTo2NGIwNzYxNTAxZGM0MzAyOTkwODEzYmUzNDY4ZDQ1MC90YWJsZXJhbmdlOjY0YjA3NjE1MDFkYzQzMDI5OTA4MTNiZTM0NjhkNDUwXzQtNC0xLTEtMA_5b1f9a71-421b-4eb0-910e-2da4fc9ab9f7"
      unitRef="usd">646505</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia11c0ba867c24e56850a7ffe421f6852_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDgvZnJhZzplMzNkMjRiNWM2NTM0MDcxYjdlNmNhNTJjODQyY2ExYi90YWJsZTo2NGIwNzYxNTAxZGM0MzAyOTkwODEzYmUzNDY4ZDQ1MC90YWJsZXJhbmdlOjY0YjA3NjE1MDFkYzQzMDI5OTA4MTNiZTM0NjhkNDUwXzQtNi0xLTEtMA_0dfdde36-8881-48d8-b940-8fad3958124c"
      unitRef="usd">639267</us-gaap:PropertyPlantAndEquipmentGross>
    <cpix:PropertyAndEquipmentUsefulLifeTextual
      contextRef="ifa90d2ee803c421baadb41895368ae03_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDgvZnJhZzplMzNkMjRiNWM2NTM0MDcxYjdlNmNhNTJjODQyY2ExYi90YWJsZTo2NGIwNzYxNTAxZGM0MzAyOTkwODEzYmUzNDY4ZDQ1MC90YWJsZXJhbmdlOjY0YjA3NjE1MDFkYzQzMDI5OTA4MTNiZTM0NjhkNDUwXzUtMi0xLTEtMA_dd1ab64d-9455-4bb4-b420-6458fa85bf5d">3&#160;&#x2013;&#160;15&#160;years,&#160;or remaining&#160;lease&#160;term</cpix:PropertyAndEquipmentUsefulLifeTextual>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id13db87e21e745bfaebf06c3e97b18e1_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDgvZnJhZzplMzNkMjRiNWM2NTM0MDcxYjdlNmNhNTJjODQyY2ExYi90YWJsZTo2NGIwNzYxNTAxZGM0MzAyOTkwODEzYmUzNDY4ZDQ1MC90YWJsZXJhbmdlOjY0YjA3NjE1MDFkYzQzMDI5OTA4MTNiZTM0NjhkNDUwXzUtNC0xLTEtMA_716f6bdf-d2e7-48cf-9deb-d8ea8d4444af"
      unitRef="usd">1356640</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7f90fef1f7bd4deaa1cf05dcd6c9cc19_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDgvZnJhZzplMzNkMjRiNWM2NTM0MDcxYjdlNmNhNTJjODQyY2ExYi90YWJsZTo2NGIwNzYxNTAxZGM0MzAyOTkwODEzYmUzNDY4ZDQ1MC90YWJsZXJhbmdlOjY0YjA3NjE1MDFkYzQzMDI5OTA4MTNiZTM0NjhkNDUwXzUtNi0xLTEtMA_160e20b9-2277-400c-b0ab-c6f2f0f0f5bc"
      unitRef="usd">1299363</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDgvZnJhZzplMzNkMjRiNWM2NTM0MDcxYjdlNmNhNTJjODQyY2ExYi90YWJsZTo2NGIwNzYxNTAxZGM0MzAyOTkwODEzYmUzNDY4ZDQ1MC90YWJsZXJhbmdlOjY0YjA3NjE1MDFkYzQzMDI5OTA4MTNiZTM0NjhkNDUwXzYtNC0xLTEtMA_2e968241-6bfc-428b-bec5-80738eb39487"
      unitRef="usd">4142125</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDgvZnJhZzplMzNkMjRiNWM2NTM0MDcxYjdlNmNhNTJjODQyY2ExYi90YWJsZTo2NGIwNzYxNTAxZGM0MzAyOTkwODEzYmUzNDY4ZDQ1MC90YWJsZXJhbmdlOjY0YjA3NjE1MDFkYzQzMDI5OTA4MTNiZTM0NjhkNDUwXzYtNi0xLTEtMA_83b74caa-59a6-45ea-87ad-f2771fc9e685"
      unitRef="usd">3895923</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDgvZnJhZzplMzNkMjRiNWM2NTM0MDcxYjdlNmNhNTJjODQyY2ExYi90YWJsZTo2NGIwNzYxNTAxZGM0MzAyOTkwODEzYmUzNDY4ZDQ1MC90YWJsZXJhbmdlOjY0YjA3NjE1MDFkYzQzMDI5OTA4MTNiZTM0NjhkNDUwXzctNC0xLTEtMA_a1b8c85c-b838-4818-b202-43118995205f"
      unitRef="usd">3394329</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDgvZnJhZzplMzNkMjRiNWM2NTM0MDcxYjdlNmNhNTJjODQyY2ExYi90YWJsZTo2NGIwNzYxNTAxZGM0MzAyOTkwODEzYmUzNDY4ZDQ1MC90YWJsZXJhbmdlOjY0YjA3NjE1MDFkYzQzMDI5OTA4MTNiZTM0NjhkNDUwXzctNi0xLTEtMA_95f55fcc-d516-4ee3-80f8-db7c0efb85a7"
      unitRef="usd">3124710</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDgvZnJhZzplMzNkMjRiNWM2NTM0MDcxYjdlNmNhNTJjODQyY2ExYi90YWJsZTo2NGIwNzYxNTAxZGM0MzAyOTkwODEzYmUzNDY4ZDQ1MC90YWJsZXJhbmdlOjY0YjA3NjE1MDFkYzQzMDI5OTA4MTNiZTM0NjhkNDUwXzgtNC0xLTEtMA_8c150c05-00ba-4dc1-a8f3-cd554f1b4a8b"
      unitRef="usd">747796</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDgvZnJhZzplMzNkMjRiNWM2NTM0MDcxYjdlNmNhNTJjODQyY2ExYi90YWJsZTo2NGIwNzYxNTAxZGM0MzAyOTkwODEzYmUzNDY4ZDQ1MC90YWJsZXJhbmdlOjY0YjA3NjE1MDFkYzQzMDI5OTA4MTNiZTM0NjhkNDUwXzgtNi0xLTEtMA_e049e755-846f-4e72-b15a-7f995885e873"
      unitRef="usd">771213</us-gaap:PropertyPlantAndEquipmentNet>
    <cpix:ScheduleofDepreciationExpenseTableTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDgvZnJhZzplMzNkMjRiNWM2NTM0MDcxYjdlNmNhNTJjODQyY2ExYi90ZXh0cmVnaW9uOmUzM2QyNGI1YzY1MzQwNzFiN2U2Y2E1MmM4NDJjYTFiXzM1Ng_13a07426-edb3-4999-82d2-e74bd8abb881">Depreciation expense was as follows for the years ended December 31:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.897%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</cpix:ScheduleofDepreciationExpenseTableTextBlock>
    <cpix:DepreciationIncludingAmortizationRelatedToLeaseholdImprovements
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDgvZnJhZzplMzNkMjRiNWM2NTM0MDcxYjdlNmNhNTJjODQyY2ExYi90YWJsZTozZjZmMDc3NWM3NTI0OTFlOGEyZjlkNjVhNmUwODRmOC90YWJsZXJhbmdlOjNmNmYwNzc1Yzc1MjQ5MWU4YTJmOWQ2NWE2ZTA4NGY4XzItMi0xLTEtMA_03fd3eb8-3d28-4d42-a8f4-1d7167e982d0"
      unitRef="usd">269619</cpix:DepreciationIncludingAmortizationRelatedToLeaseholdImprovements>
    <cpix:DepreciationIncludingAmortizationRelatedToLeaseholdImprovements
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDgvZnJhZzplMzNkMjRiNWM2NTM0MDcxYjdlNmNhNTJjODQyY2ExYi90YWJsZTozZjZmMDc3NWM3NTI0OTFlOGEyZjlkNjVhNmUwODRmOC90YWJsZXJhbmdlOjNmNmYwNzc1Yzc1MjQ5MWU4YTJmOWQ2NWE2ZTA4NGY4XzItNC0xLTEtMA_f4414db5-10c6-41bb-9e56-6c157d0172c5"
      unitRef="usd">213237</cpix:DepreciationIncludingAmortizationRelatedToLeaseholdImprovements>
    <cpix:DepreciationIncludingAmortizationRelatedToLeaseholdImprovements
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMDgvZnJhZzplMzNkMjRiNWM2NTM0MDcxYjdlNmNhNTJjODQyY2ExYi90YWJsZTozZjZmMDc3NWM3NTI0OTFlOGEyZjlkNjVhNmUwODRmOC90YWJsZXJhbmdlOjNmNmYwNzc1Yzc1MjQ5MWU4YTJmOWQ2NWE2ZTA4NGY4XzItNi0xLTEtMA_b3274843-aab1-4f2a-8ae4-54ef4b417379"
      unitRef="usd">211532</cpix:DepreciationIncludingAmortizationRelatedToLeaseholdImprovements>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90ZXh0cmVnaW9uOmQ0MzVlOWNkMGI0ZTRiN2U4YmRjY2ZjYjYxOGRlMDI2XzMxNzM_52f58842-9eff-4845-9ef0-5dec5f97a594">Intangible Assets and Goodwill&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets and Goodwill consisted of the following at December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.217%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.915%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.487%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.915%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product and license rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,400,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,573,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,499,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,405,188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product and license rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,901,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,168,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,882,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,428,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,127,878)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,087,273)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,754,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,340,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,020)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,020)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,920,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,655,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;882,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2013, the Company entered into an agreement with Pernix to distribute and promote the branded prescription product Omeclamox-Pak. The &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$4.0 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; upfront payment the Company paid to Pernix during October 2013 and the $2.3 million payments made to GEL during 2018 (discussed more fully in Note 3) are included in product and license rights and are being amortized through June 2032, the remaining expected useful life of the acquired asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2014, the Company acquired the rights of the branded prescription product Vaprisol from Astellas.  The intangible asset value is $3.0 million and is included in product and license rights.  The asset is being amortized through February 2022, the remaining expected useful life of the acquired asset, which coincides with the life of the primary intellectual property asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 3, in November 2016, the Company acquired the U.S. rights to Nordic Group B.V.&#x2019;s injectable methotrexate product line as an asset purchase. The agreement requires the Company to provide unvested restricted shares of Cumberland common stock and make a series of payments tied to the products&#x2019; FDA approval, launch and achievement of certain sales milestones. The payments are being treated as consideration for the assets acquired and are being capitalized and amortized over the expected useful life of the acquired asset. To date, the intangible assets related to the product include the $100,000 deposit paid at closing, the 180,000 restricted shares valued at $0.9 million that vested upon the November 2019 FDA approval and the additional $1.0&#160;million owed to Nordic during 2020, also based on the FDA approval. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 3, during November 2018, the Company acquired Vibativ from Theravance. This resulted in amortizable intangible assets related to the product rights of  $11.8 million and goodwill of $0.9 million. The intangible assets are being amortized through November 2028, the expected useful life of the acquired asset.  The $0.1&#160;million increase in goodwill during 2019 was a result of changes in the purchase price allocation during the measurement period.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2019 and 2018, the Company recorded an additional $0.7 million and $0.4 million, respectively, in intangible assets for patents, trademarks and capitalized patent costs, including amounts incurred in the protection of the Company's intellectual property.  These costs will be amortized over the remaining expected useful life of the associated patents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense related to product and license rights, trademarks and patents were as follows for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:81.730%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.507%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.511%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,134,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,769,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,436,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected amortization expense for the Company's current balance of intangible assets are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:80.769%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.907%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,286,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,084,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,530,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,743,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,274,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,920,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90ZXh0cmVnaW9uOmQ0MzVlOWNkMGI0ZTRiN2U4YmRjY2ZjYjYxOGRlMDI2XzMxNjg_f72b8014-1ed2-4b4c-9b14-7e1213461686">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets and Goodwill consisted of the following at December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.217%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.915%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.487%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.915%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product and license rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,400,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,573,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,499,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,405,188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product and license rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,901,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,168,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,882,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,428,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,127,878)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,087,273)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,754,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,340,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,020)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,020)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,920,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,655,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;882,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ibda132d30f764f18ba15f5b11ef8640c_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTpjZWQwNTdjMzA2ZmE0NWNjYTdhMTVkMzRkNmYzYzk3MS90YWJsZXJhbmdlOmNlZDA1N2MzMDZmYTQ1Y2NhN2ExNWQzNGQ2ZjNjOTcxXzItMi0xLTEtMA_ad5086ed-c771-49b4-a378-bd99cd005e8f"
      unitRef="usd">37400742</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie1596ec01ad648109aa7a8774201aebf_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTpjZWQwNTdjMzA2ZmE0NWNjYTdhMTVkMzRkNmYzYzk3MS90YWJsZXJhbmdlOmNlZDA1N2MzMDZmYTQ1Y2NhN2ExNWQzNGQ2ZjNjOTcxXzItNC0xLTEtMA_a7b2f540-249e-4e80-8607-fc3ce6ebf595"
      unitRef="usd">36573941</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ibda132d30f764f18ba15f5b11ef8640c_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTpjZWQwNTdjMzA2ZmE0NWNjYTdhMTVkMzRkNmYzYzk3MS90YWJsZXJhbmdlOmNlZDA1N2MzMDZmYTQ1Y2NhN2ExNWQzNGQ2ZjNjOTcxXzMtMi0xLTEtMA_98b17155-b513-48b6-90b1-ea3809f97d0f"
      unitRef="usd">11499141</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie1596ec01ad648109aa7a8774201aebf_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTpjZWQwNTdjMzA2ZmE0NWNjYTdhMTVkMzRkNmYzYzk3MS90YWJsZXJhbmdlOmNlZDA1N2MzMDZmYTQ1Y2NhN2ExNWQzNGQ2ZjNjOTcxXzMtNC0xLTEtMA_3208a3c4-f176-4182-9e2b-3cec053bb0dd"
      unitRef="usd">8405188</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ibda132d30f764f18ba15f5b11ef8640c_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTpjZWQwNTdjMzA2ZmE0NWNjYTdhMTVkMzRkNmYzYzk3MS90YWJsZXJhbmdlOmNlZDA1N2MzMDZmYTQ1Y2NhN2ExNWQzNGQ2ZjNjOTcxXzQtMi0xLTEtMA_a6964e4f-2032-4d71-9c92-e5ae0b98fe73"
      unitRef="usd">25901601</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie1596ec01ad648109aa7a8774201aebf_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTpjZWQwNTdjMzA2ZmE0NWNjYTdhMTVkMzRkNmYzYzk3MS90YWJsZXJhbmdlOmNlZDA1N2MzMDZmYTQ1Y2NhN2ExNWQzNGQ2ZjNjOTcxXzQtNC0xLTEtMA_4a41bab8-b528-4cc6-9154-285a04edc017"
      unitRef="usd">28168753</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="icc95de064baa44309a420dcb73dd5d32_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTpjZWQwNTdjMzA2ZmE0NWNjYTdhMTVkMzRkNmYzYzk3MS90YWJsZXJhbmdlOmNlZDA1N2MzMDZmYTQ1Y2NhN2ExNWQzNGQ2ZjNjOTcxXzUtMi0xLTEtMA_92855384-2681-43fe-b0df-ce7b5882dc2a"
      unitRef="usd">9882511</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i13bd22341d9c430cb1cd4edc13102d50_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTpjZWQwNTdjMzA2ZmE0NWNjYTdhMTVkMzRkNmYzYzk3MS90YWJsZXJhbmdlOmNlZDA1N2MzMDZmYTQ1Y2NhN2ExNWQzNGQ2ZjNjOTcxXzUtNC0xLTEtMA_a4ecac23-eeb7-43ba-9f05-965afda6e38a"
      unitRef="usd">9428266</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="icc95de064baa44309a420dcb73dd5d32_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTpjZWQwNTdjMzA2ZmE0NWNjYTdhMTVkMzRkNmYzYzk3MS90YWJsZXJhbmdlOmNlZDA1N2MzMDZmYTQ1Y2NhN2ExNWQzNGQ2ZjNjOTcxXzYtMi0xLTEtMA_a6594927-69f9-4af0-bf7f-0161b4052965"
      unitRef="usd">5127878</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i13bd22341d9c430cb1cd4edc13102d50_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTpjZWQwNTdjMzA2ZmE0NWNjYTdhMTVkMzRkNmYzYzk3MS90YWJsZXJhbmdlOmNlZDA1N2MzMDZmYTQ1Y2NhN2ExNWQzNGQ2ZjNjOTcxXzYtNC0xLTEtMA_1b267256-ef1d-47be-9932-8f166cc3578a"
      unitRef="usd">4087273</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="icc95de064baa44309a420dcb73dd5d32_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTpjZWQwNTdjMzA2ZmE0NWNjYTdhMTVkMzRkNmYzYzk3MS90YWJsZXJhbmdlOmNlZDA1N2MzMDZmYTQ1Y2NhN2ExNWQzNGQ2ZjNjOTcxXzctMi0xLTEtMA_68135610-f132-4acb-96d2-10f8aef12a36"
      unitRef="usd">4754633</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i13bd22341d9c430cb1cd4edc13102d50_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTpjZWQwNTdjMzA2ZmE0NWNjYTdhMTVkMzRkNmYzYzk3MS90YWJsZXJhbmdlOmNlZDA1N2MzMDZmYTQ1Y2NhN2ExNWQzNGQ2ZjNjOTcxXzctNC0xLTEtMA_22f1668c-8950-4aa7-a670-f10484036a2d"
      unitRef="usd">5340993</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i85b3f22a44da44e0b4f3300a912b0dc5_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTpjZWQwNTdjMzA2ZmE0NWNjYTdhMTVkMzRkNmYzYzk3MS90YWJsZXJhbmdlOmNlZDA1N2MzMDZmYTQ1Y2NhN2ExNWQzNGQ2ZjNjOTcxXzgtMi0xLTEtMA_2e1ac567-a115-4841-a4fc-d117a24b3cae"
      unitRef="usd">273110</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i988d5245b3374e39af5d4ec1f43b092f_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTpjZWQwNTdjMzA2ZmE0NWNjYTdhMTVkMzRkNmYzYzk3MS90YWJsZXJhbmdlOmNlZDA1N2MzMDZmYTQ1Y2NhN2ExNWQzNGQ2ZjNjOTcxXzgtNC0xLTEtMA_35d966f5-ecbc-40ee-abe2-67095ceadf39"
      unitRef="usd">154373</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i85b3f22a44da44e0b4f3300a912b0dc5_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTpjZWQwNTdjMzA2ZmE0NWNjYTdhMTVkMzRkNmYzYzk3MS90YWJsZXJhbmdlOmNlZDA1N2MzMDZmYTQ1Y2NhN2ExNWQzNGQ2ZjNjOTcxXzktMi0xLTEtMA_26314015-abb5-4578-81f7-c1335a4a7d6d"
      unitRef="usd">9020</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i988d5245b3374e39af5d4ec1f43b092f_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTpjZWQwNTdjMzA2ZmE0NWNjYTdhMTVkMzRkNmYzYzk3MS90YWJsZXJhbmdlOmNlZDA1N2MzMDZmYTQ1Y2NhN2ExNWQzNGQ2ZjNjOTcxXzktNC0xLTEtMA_af6f235b-7bb7-4d2f-98b9-afd2aeffea7d"
      unitRef="usd">9020</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i85b3f22a44da44e0b4f3300a912b0dc5_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTpjZWQwNTdjMzA2ZmE0NWNjYTdhMTVkMzRkNmYzYzk3MS90YWJsZXJhbmdlOmNlZDA1N2MzMDZmYTQ1Y2NhN2ExNWQzNGQ2ZjNjOTcxXzEwLTItMS0xLTA_a8fae69b-ef58-4a79-9ff1-b818a5cc4e70"
      unitRef="usd">264090</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i988d5245b3374e39af5d4ec1f43b092f_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTpjZWQwNTdjMzA2ZmE0NWNjYTdhMTVkMzRkNmYzYzk3MS90YWJsZXJhbmdlOmNlZDA1N2MzMDZmYTQ1Y2NhN2ExNWQzNGQ2ZjNjOTcxXzEwLTQtMS0xLTA_241bd205-dc0f-4de3-b6f4-96a26e687190"
      unitRef="usd">145353</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTpjZWQwNTdjMzA2ZmE0NWNjYTdhMTVkMzRkNmYzYzk3MS90YWJsZXJhbmdlOmNlZDA1N2MzMDZmYTQ1Y2NhN2ExNWQzNGQ2ZjNjOTcxXzExLTItMS0xLTA_bfb2aa98-dfbe-4a89-8e72-ace70cfca560"
      unitRef="usd">30920324</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTpjZWQwNTdjMzA2ZmE0NWNjYTdhMTVkMzRkNmYzYzk3MS90YWJsZXJhbmdlOmNlZDA1N2MzMDZmYTQ1Y2NhN2ExNWQzNGQ2ZjNjOTcxXzExLTQtMS0xLTA_8512db8a-c4af-46c6-9598-781c706cae05"
      unitRef="usd">33655099</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTpjZWQwNTdjMzA2ZmE0NWNjYTdhMTVkMzRkNmYzYzk3MS90YWJsZXJhbmdlOmNlZDA1N2MzMDZmYTQ1Y2NhN2ExNWQzNGQ2ZjNjOTcxXzEzLTItMS0xLTA_c6fde496-ab40-41fb-855e-9aa40730d894"
      unitRef="usd">882000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTpjZWQwNTdjMzA2ZmE0NWNjYTdhMTVkMzRkNmYzYzk3MS90YWJsZXJhbmdlOmNlZDA1N2MzMDZmYTQ1Y2NhN2ExNWQzNGQ2ZjNjOTcxXzEzLTQtMS0xLTA_43211833-2be9-4820-bb8d-0caac1074d27"
      unitRef="usd">784000</us-gaap:Goodwill>
    <cpix:RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales
      contextRef="i0a05405482c64e9e8fe092b821aeb335_D20131028-20131029"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90ZXh0cmVnaW9uOmQ0MzVlOWNkMGI0ZTRiN2U4YmRjY2ZjYjYxOGRlMDI2XzY4Ng_33478ffe-be03-47a6-80c1-2de68ca940af"
      unitRef="usd">4000000.0</cpix:RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales>
    <cpix:RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales
      contextRef="i34cdca865b434ae68e675f3de541d80f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90ZXh0cmVnaW9uOmQ0MzVlOWNkMGI0ZTRiN2U4YmRjY2ZjYjYxOGRlMDI2Xzc2MA_b6eb2339-d9b0-4350-80fa-9082d447ba0c"
      unitRef="usd">2300000</cpix:RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i06508a7d5ed34904a9e7ba4b89125dfa_I20140228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90ZXh0cmVnaW9uOmQ0MzVlOWNkMGI0ZTRiN2U4YmRjY2ZjYjYxOGRlMDI2XzExMTA_38d26dca-5d0d-414d-a07d-52082269d5e0"
      unitRef="usd">3000000.0</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="iebd5c24d9fc142c0b899398d6d3c153d_D20161101-20161130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90ZXh0cmVnaW9uOmQ0MzVlOWNkMGI0ZTRiN2U4YmRjY2ZjYjYxOGRlMDI2XzE5NTU_91547538-e6c9-4a39-b5f6-aba1500d1636"
      unitRef="usd">100000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="i00c91a50edb844d99bb320b2490ff8d6_D20161101-20161130"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90ZXh0cmVnaW9uOmQ0MzVlOWNkMGI0ZTRiN2U4YmRjY2ZjYjYxOGRlMDI2XzE5ODc_8e1ddeb6-65ab-4853-9ab9-f7633662ac6c"
      unitRef="shares">180000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i3dc00a50885944de8bd18286fb857d2a_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90ZXh0cmVnaW9uOmQ0MzVlOWNkMGI0ZTRiN2U4YmRjY2ZjYjYxOGRlMDI2XzIwMTg_a3ea59e4-0219-42bd-bdb3-9a0e10494056"
      unitRef="usd">900000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i741e5bc06ece4d28a49fb727a3756a7e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90ZXh0cmVnaW9uOmQ0MzVlOWNkMGI0ZTRiN2U4YmRjY2ZjYjYxOGRlMDI2XzIwODg_0bb21c77-e31b-4fd7-815b-0d48c07bd98e"
      unitRef="usd">1000000.0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i4af7f789d58345659c0394f24e9c9d71_I20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90ZXh0cmVnaW9uOmQ0MzVlOWNkMGI0ZTRiN2U4YmRjY2ZjYjYxOGRlMDI2XzIzMjU_aded0194-abb3-41e4-ad0b-c9bc22391129"
      unitRef="usd">11800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Goodwill
      contextRef="i4af7f789d58345659c0394f24e9c9d71_I20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90ZXh0cmVnaW9uOmQ0MzVlOWNkMGI0ZTRiN2U4YmRjY2ZjYjYxOGRlMDI2XzIzNDQ_b271b242-0889-4b56-8926-7d15ff58f531"
      unitRef="usd">900000</us-gaap:Goodwill>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="i9f2a5edba28144ad932b2ce0fd047ab3_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90ZXh0cmVnaW9uOmQ0MzVlOWNkMGI0ZTRiN2U4YmRjY2ZjYjYxOGRlMDI2XzI0NjY_d8d6c25a-6471-4102-9c2f-724784e6a347"
      unitRef="usd">100000</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i9264ef6a01f546dca65e6adec1f967fe_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90ZXh0cmVnaW9uOmQ0MzVlOWNkMGI0ZTRiN2U4YmRjY2ZjYjYxOGRlMDI2XzI2NDU_156cfb2d-8c7f-4e10-b631-f8aabba0c7e7"
      unitRef="usd">700000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i0a52841e4c724bb9936223a8fd642381_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90ZXh0cmVnaW9uOmQ0MzVlOWNkMGI0ZTRiN2U4YmRjY2ZjYjYxOGRlMDI2XzI2NTI_2c003814-4135-404a-8c40-ac429e2c3eae"
      unitRef="usd">400000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90ZXh0cmVnaW9uOmQ0MzVlOWNkMGI0ZTRiN2U4YmRjY2ZjYjYxOGRlMDI2XzMxNzA_7871c292-8235-497f-b885-b8bdafd31936">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense related to product and license rights, trademarks and patents were as follows for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:81.730%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.507%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.511%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,134,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,769,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,436,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected amortization expense for the Company's current balance of intangible assets are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:80.769%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.907%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,286,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,084,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,530,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,743,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,274,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,920,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTo4NGU1MjViODc4Nzk0NzI4YjQ2ZTk4Y2QzMjYyZjdiZi90YWJsZXJhbmdlOjg0ZTUyNWI4Nzg3OTQ3MjhiNDZlOThjZDMyNjJmN2JmXzItMi0xLTEtMA_d74ac5fa-8dd6-42ee-aef2-1148ad301d2a"
      unitRef="usd">4134557</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTo4NGU1MjViODc4Nzk0NzI4YjQ2ZTk4Y2QzMjYyZjdiZi90YWJsZXJhbmdlOjg0ZTUyNWI4Nzg3OTQ3MjhiNDZlOThjZDMyNjJmN2JmXzItNC0xLTEtMA_a07729b4-ac6d-415e-b469-15426b2c0a9b"
      unitRef="usd">2769466</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTo4NGU1MjViODc4Nzk0NzI4YjQ2ZTk4Y2QzMjYyZjdiZi90YWJsZXJhbmdlOjg0ZTUyNWI4Nzg3OTQ3MjhiNDZlOThjZDMyNjJmN2JmXzItNi0xLTEtMA_85ec8eaf-9b46-42e3-9189-e5d9b0028716"
      unitRef="usd">2436222</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTphYzZmMWE3MzQ0Njc0ZDdjOWE5YTA0NGNlN2Q0ZjkxMC90YWJsZXJhbmdlOmFjNmYxYTczNDQ2NzRkN2M5YTlhMDQ0Y2U3ZDRmOTEwXzEtMi0xLTEtMA_8bbddcf8-84ea-40d8-8d36-9b58c91c92d6"
      unitRef="usd">4286336</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTphYzZmMWE3MzQ0Njc0ZDdjOWE5YTA0NGNlN2Q0ZjkxMC90YWJsZXJhbmdlOmFjNmYxYTczNDQ2NzRkN2M5YTlhMDQ0Y2U3ZDRmOTEwXzItMi0xLTEtMA_7dfeccde-aca1-4869-b5c1-3748b65d3f99"
      unitRef="usd">4084702</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTphYzZmMWE3MzQ0Njc0ZDdjOWE5YTA0NGNlN2Q0ZjkxMC90YWJsZXJhbmdlOmFjNmYxYTczNDQ2NzRkN2M5YTlhMDQ0Y2U3ZDRmOTEwXzMtMi0xLTEtMA_7d25ec14-3a41-405f-86b0-1d91242fd8f6"
      unitRef="usd">3530879</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTphYzZmMWE3MzQ0Njc0ZDdjOWE5YTA0NGNlN2Q0ZjkxMC90YWJsZXJhbmdlOmFjNmYxYTczNDQ2NzRkN2M5YTlhMDQ0Y2U3ZDRmOTEwXzQtMi0xLTEtMA_13889ec7-5549-470d-9a0f-162e5d56a823"
      unitRef="usd">3743526</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <cpix:FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTphYzZmMWE3MzQ0Njc0ZDdjOWE5YTA0NGNlN2Q0ZjkxMC90YWJsZXJhbmdlOmFjNmYxYTczNDQ2NzRkN2M5YTlhMDQ0Y2U3ZDRmOTEwXzUtMi0xLTEtMA_b8a9f326-4509-4535-b438-4af72a10e0a1"
      unitRef="usd">15274881</cpix:FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTQvZnJhZzpkNDM1ZTljZDBiNGU0YjdlOGJkY2NmY2I2MThkZTAyNi90YWJsZTphYzZmMWE3MzQ0Njc0ZDdjOWE5YTA0NGNlN2Q0ZjkxMC90YWJsZXJhbmdlOmFjNmYxYTczNDQ2NzRkN2M5YTlhMDQ0Y2U3ZDRmOTEwXzYtMi0xLTEtMA_56196795-67b4-4a7d-9fc2-d74778794974"
      unitRef="usd">30920324</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OtherLiabilitiesDisclosureTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90ZXh0cmVnaW9uOjM5YmQzMTg2Nzc1MTRiZWRhNDIwZDJiNDMzNDY0YTg1XzEzMg_210f4cea-6dc0-4209-8dab-f3876a3f2806">Other Current and Other Long-term Liabilities&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current liabilities consisted of the following at December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.378%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.913%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.452%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.913%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rebates, product returns, administrative fees &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;and service fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,593,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,969,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee wages and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,295,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,263,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,085,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of accrued contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,374,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,290,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred acquisition liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued inventory purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;829,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payment for asset purchase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,001,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,084,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,044,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.897%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.907%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.732%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent portion of accrued contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,258,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,212,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,278,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,588,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;519,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,737,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,319,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90ZXh0cmVnaW9uOjM5YmQzMTg2Nzc1MTRiZWRhNDIwZDJiNDMzNDY0YTg1XzEyOA_0f0d8378-17ac-41a5-abbb-c45ba7793c9b">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current liabilities consisted of the following at December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.378%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.913%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.452%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.913%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rebates, product returns, administrative fees &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;and service fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,593,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,969,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee wages and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,295,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,263,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,085,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of accrued contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,374,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,290,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred acquisition liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued inventory purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;829,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payment for asset purchase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,001,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,084,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,044,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <cpix:ProductSalesRelatedLiabilitiesCurrent
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo2YmRmZDMwZTE1M2U0NDdkOWNlZDZkYWNjNGM0ZjhkZS90YWJsZXJhbmdlOjZiZGZkMzBlMTUzZTQ0N2Q5Y2VkNmRhY2M0YzRmOGRlXzItMi0xLTEtMA_7ab72c4c-553c-4bce-b7c4-693c3c73ad75"
      unitRef="usd">4593167</cpix:ProductSalesRelatedLiabilitiesCurrent>
    <cpix:ProductSalesRelatedLiabilitiesCurrent
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo2YmRmZDMwZTE1M2U0NDdkOWNlZDZkYWNjNGM0ZjhkZS90YWJsZXJhbmdlOjZiZGZkMzBlMTUzZTQ0N2Q5Y2VkNmRhY2M0YzRmOGRlXzItNC0xLTEtMA_399bdbfd-b8ee-488f-a5c3-5565bd5e6c2a"
      unitRef="usd">4969515</cpix:ProductSalesRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo2YmRmZDMwZTE1M2U0NDdkOWNlZDZkYWNjNGM0ZjhkZS90YWJsZXJhbmdlOjZiZGZkMzBlMTUzZTQ0N2Q5Y2VkNmRhY2M0YzRmOGRlXzMtMi0xLTEtMA_bb25b69a-0829-40be-b001-8f0aed87cbd8"
      unitRef="usd">1295905</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo2YmRmZDMwZTE1M2U0NDdkOWNlZDZkYWNjNGM0ZjhkZS90YWJsZXJhbmdlOjZiZGZkMzBlMTUzZTQ0N2Q5Y2VkNmRhY2M0YzRmOGRlXzMtNC0xLTEtMA_29163c63-f382-446c-97ec-45353086ebce"
      unitRef="usd">1263426</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <cpix:AccruedLiabilitiesStockPayable
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo2YmRmZDMwZTE1M2U0NDdkOWNlZDZkYWNjNGM0ZjhkZS90YWJsZXJhbmdlOjZiZGZkMzBlMTUzZTQ0N2Q5Y2VkNmRhY2M0YzRmOGRlXzQtMi0xLTEtMA_38bf048f-a0d0-47e8-8e10-ec8e1411096f"
      unitRef="usd">0</cpix:AccruedLiabilitiesStockPayable>
    <cpix:AccruedLiabilitiesStockPayable
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo2YmRmZDMwZTE1M2U0NDdkOWNlZDZkYWNjNGM0ZjhkZS90YWJsZXJhbmdlOjZiZGZkMzBlMTUzZTQ0N2Q5Y2VkNmRhY2M0YzRmOGRlXzQtNC0xLTEtMA_8c07c52f-479d-4e38-a94a-0aacc309e226"
      unitRef="usd">1085400</cpix:AccruedLiabilitiesStockPayable>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo2YmRmZDMwZTE1M2U0NDdkOWNlZDZkYWNjNGM0ZjhkZS90YWJsZXJhbmdlOjZiZGZkMzBlMTUzZTQ0N2Q5Y2VkNmRhY2M0YzRmOGRlXzUtMi0xLTEtMA_1275788a-832f-4646-9f4e-9a3acdf0cda9"
      unitRef="usd">2374776</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo2YmRmZDMwZTE1M2U0NDdkOWNlZDZkYWNjNGM0ZjhkZS90YWJsZXJhbmdlOjZiZGZkMzBlMTUzZTQ0N2Q5Y2VkNmRhY2M0YzRmOGRlXzUtNC0xLTEtMA_04ed34de-cd98-41cb-b4bf-4ab76d2935a6"
      unitRef="usd">2290000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <cpix:DeferredAcquisitionLiabilityCurrent
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo2YmRmZDMwZTE1M2U0NDdkOWNlZDZkYWNjNGM0ZjhkZS90YWJsZXJhbmdlOjZiZGZkMzBlMTUzZTQ0N2Q5Y2VkNmRhY2M0YzRmOGRlXzYtMi0xLTEtMA_95ff8128-0333-4995-b354-7acdef403b63"
      unitRef="usd">0</cpix:DeferredAcquisitionLiabilityCurrent>
    <cpix:DeferredAcquisitionLiabilityCurrent
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo2YmRmZDMwZTE1M2U0NDdkOWNlZDZkYWNjNGM0ZjhkZS90YWJsZXJhbmdlOjZiZGZkMzBlMTUzZTQ0N2Q5Y2VkNmRhY2M0YzRmOGRlXzYtNC0xLTEtMA_7315b883-cc3f-434e-8cd9-1f7ff8efc179"
      unitRef="usd">5000000</cpix:DeferredAcquisitionLiabilityCurrent>
    <cpix:AccruedLiabilitiesInventoryPurchases
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo2YmRmZDMwZTE1M2U0NDdkOWNlZDZkYWNjNGM0ZjhkZS90YWJsZXJhbmdlOjZiZGZkMzBlMTUzZTQ0N2Q5Y2VkNmRhY2M0YzRmOGRlXzctMi0xLTEtMA_5c5c03f8-e630-4545-9717-0df7d1c1ce8a"
      unitRef="usd">829047</cpix:AccruedLiabilitiesInventoryPurchases>
    <cpix:AccruedLiabilitiesInventoryPurchases
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo2YmRmZDMwZTE1M2U0NDdkOWNlZDZkYWNjNGM0ZjhkZS90YWJsZXJhbmdlOjZiZGZkMzBlMTUzZTQ0N2Q5Y2VkNmRhY2M0YzRmOGRlXzctNC0xLTEtMA_77af1f15-c383-4c9c-9392-641da589bbe8"
      unitRef="usd">434405</cpix:AccruedLiabilitiesInventoryPurchases>
    <cpix:AccruedPaymentForAssetPurchaseCurrent
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo2YmRmZDMwZTE1M2U0NDdkOWNlZDZkYWNjNGM0ZjhkZS90YWJsZXJhbmdlOjZiZGZkMzBlMTUzZTQ0N2Q5Y2VkNmRhY2M0YzRmOGRlXzgtMi0xLTEtMA_97c15834-1ca3-4d51-ad90-60b67d0d293f"
      unitRef="usd">1000000</cpix:AccruedPaymentForAssetPurchaseCurrent>
    <cpix:AccruedPaymentForAssetPurchaseCurrent
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo2YmRmZDMwZTE1M2U0NDdkOWNlZDZkYWNjNGM0ZjhkZS90YWJsZXJhbmdlOjZiZGZkMzBlMTUzZTQ0N2Q5Y2VkNmRhY2M0YzRmOGRlXzgtNC0xLTEtMA_865c4f92-5d59-4305-a41b-f9ab1f69254a"
      unitRef="usd">0</cpix:AccruedPaymentForAssetPurchaseCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo2YmRmZDMwZTE1M2U0NDdkOWNlZDZkYWNjNGM0ZjhkZS90YWJsZXJhbmdlOjZiZGZkMzBlMTUzZTQ0N2Q5Y2VkNmRhY2M0YzRmOGRlXzktMi0xLTEtMA_13bbdd42-8350-4210-9376-eefd5cdc3033"
      unitRef="usd">991974</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo2YmRmZDMwZTE1M2U0NDdkOWNlZDZkYWNjNGM0ZjhkZS90YWJsZXJhbmdlOjZiZGZkMzBlMTUzZTQ0N2Q5Y2VkNmRhY2M0YzRmOGRlXzktNC0xLTEtMA_bc30846f-40e2-4ab0-92f7-485f28d492df"
      unitRef="usd">1001724</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo2YmRmZDMwZTE1M2U0NDdkOWNlZDZkYWNjNGM0ZjhkZS90YWJsZXJhbmdlOjZiZGZkMzBlMTUzZTQ0N2Q5Y2VkNmRhY2M0YzRmOGRlXzEwLTItMS0xLTA_e2496777-527f-4302-8428-22ffbbc0a39c"
      unitRef="usd">11084869</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo2YmRmZDMwZTE1M2U0NDdkOWNlZDZkYWNjNGM0ZjhkZS90YWJsZXJhbmdlOjZiZGZkMzBlMTUzZTQ0N2Q5Y2VkNmRhY2M0YzRmOGRlXzEwLTQtMS0xLTA_065a7441-e14b-4524-9ef5-aef6f9d7fd74"
      unitRef="usd">16044470</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherNoncurrentLiabilitiesTableTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90ZXh0cmVnaW9uOjM5YmQzMTg2Nzc1MTRiZWRhNDIwZDJiNDMzNDY0YTg1XzEyOQ_47475599-d7df-44bc-9d6e-f0e2de7620b6">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.897%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.907%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.732%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent portion of accrued contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,258,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,212,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,278,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,588,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;519,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,737,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,319,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OtherNoncurrentLiabilitiesTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo5Mzc5YjYzYWRkYmE0NzY2ODhmZmFmYWIwN2E2ODk1Yy90YWJsZXJhbmdlOjkzNzliNjNhZGRiYTQ3NjY4OGZmYWZhYjA3YTY4OTVjXzItMi0xLTEtMA_e63ec625-2fe7-4266-9659-c064ee5f236a"
      unitRef="usd">6258813</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo5Mzc5YjYzYWRkYmE0NzY2ODhmZmFmYWIwN2E2ODk1Yy90YWJsZXJhbmdlOjkzNzliNjNhZGRiYTQ3NjY4OGZmYWZhYjA3YTY4OTVjXzItNC0xLTEtMA_118e2077-32d2-481a-bc85-db2ccb13768a"
      unitRef="usd">7212000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo5Mzc5YjYzYWRkYmE0NzY2ODhmZmFmYWIwN2E2ODk1Yy90YWJsZXJhbmdlOjkzNzliNjNhZGRiYTQ3NjY4OGZmYWZhYjA3YTY4OTVjXzMtMi0xLTEtMA_43716bf2-c127-4bae-af9f-ff36270dbaa0"
      unitRef="usd">2278164</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
    <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo5Mzc5YjYzYWRkYmE0NzY2ODhmZmFmYWIwN2E2ODk1Yy90YWJsZXJhbmdlOjkzNzliNjNhZGRiYTQ3NjY4OGZmYWZhYjA3YTY4OTVjXzMtNC0xLTEtMA_bd10ae8a-d1a9-4ac0-b0bd-45fb7145ca4f"
      unitRef="usd">1588123</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo5Mzc5YjYzYWRkYmE0NzY2ODhmZmFmYWIwN2E2ODk1Yy90YWJsZXJhbmdlOjkzNzliNjNhZGRiYTQ3NjY4OGZmYWZhYjA3YTY4OTVjXzQtMi0xLTEtMA_5cce5822-238d-4b17-8b98-916bf7a61e92"
      unitRef="usd">200346</us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo5Mzc5YjYzYWRkYmE0NzY2ODhmZmFmYWIwN2E2ODk1Yy90YWJsZXJhbmdlOjkzNzliNjNhZGRiYTQ3NjY4OGZmYWZhYjA3YTY4OTVjXzQtNC0xLTEtMA_9711be0b-f427-438a-9d28-bfc18c719982"
      unitRef="usd">519020</us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo5Mzc5YjYzYWRkYmE0NzY2ODhmZmFmYWIwN2E2ODk1Yy90YWJsZXJhbmdlOjkzNzliNjNhZGRiYTQ3NjY4OGZmYWZhYjA3YTY4OTVjXzUtMi0xLTEtMA_54b6c853-20d3-4641-b9e7-a05909d2c557"
      unitRef="usd">8737323</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMTcvZnJhZzozOWJkMzE4Njc3NTE0YmVkYTQyMGQyYjQzMzQ2NGE4NS90YWJsZTo5Mzc5YjYzYWRkYmE0NzY2ODhmZmFmYWIwN2E2ODk1Yy90YWJsZXJhbmdlOjkzNzliNjNhZGRiYTQ3NjY4OGZmYWZhYjA3YTY4OTVjXzUtNC0xLTEtMA_57a721fa-15b4-4f43-b53d-f4b6a0d6e006"
      unitRef="usd">9319143</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjAvZnJhZzpjNGU5NzJlZDlmMGY0MDU2YTZiZGI3MWVkNDZmYjBjYy90ZXh0cmVnaW9uOmM0ZTk3MmVkOWYwZjQwNTZhNmJkYjcxZWQ0NmZiMGNjXzIwODc_655c81a9-0fa6-4557-ad6e-d5d8bab7c25b">Debt&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On May 10, 2019, the Company entered into a third amendment ("Third Amendment") to the Revolving Credit Loan Agreement, dated July 28, 2017, with Pinnacle Bank (&#x201c;Pinnacle Agreement&#x201d;). The Third Amendment extended the term of the Pinnacle Agreement through July 31, 2021 as well as modified certain definitions and terms of the existing financial covenants, including the definition of the Funded Debt Ratio and the compliance target of the Tangible Capital Ratio. Both Third Amendment modifications were related to the Vibativ transaction.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Under the Pinnacle Agreement, Cumberland was initially subject to one financial covenant, the maintenance of a Funded Debt Ratio, as such term is defined in the agreement and determined on a quarterly basis.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On August 14, 2018, the Company amended the Pinnacle Agreement ("First Amendment") to replace the single financial covenant with the maintenance of either the Funded Debt Ratio or a Tangible Capital Ratio, as defined in the First Amendment.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company achieved compliance with the Tangible Capital Ratio financial covenant as of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The initial revolving line of credit under the Pinnacle Agreement was for up to an aggregate principal amount of $12.0 million with the ability to increase the principal amount available for borrowing up to $20.0 million, upon the satisfaction of certain conditions.  On October 17, 2018, the Company entered into a second amendment (&#x201c;Second Amendment&#x201d;) which increased the maximum aggregate principal available for borrowing under the Pinnacle Agreement to $20.0 million.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company had $18.5 million in borrowings under the Pinnacle Agreement at December&#160;31, 2019 and $20.0 million at December&#160;31, 2018.  &lt;/span&gt;&lt;/div&gt;The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. There is no LIBOR minimum and the LIBOR pricing provides for an interest rate spread of 1.75% to 2.75% (representing an interest rate of 4.5% at December&#160;31, 2019).  In addition, a fee of 0.25% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  Borrowings under the line of credit are collateralized by substantially all of our assets.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i72d98b8b6d2b49ec92a95f7f52a21bb0_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjAvZnJhZzpjNGU5NzJlZDlmMGY0MDU2YTZiZGI3MWVkNDZmYjBjYy90ZXh0cmVnaW9uOmM0ZTk3MmVkOWYwZjQwNTZhNmJkYjcxZWQ0NmZiMGNjXzEyMTU_6c0f0a46-4105-40a2-a43f-e0b2eacc76ef"
      unitRef="usd">12000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <cpix:LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions
      contextRef="i72d98b8b6d2b49ec92a95f7f52a21bb0_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjAvZnJhZzpjNGU5NzJlZDlmMGY0MDU2YTZiZGI3MWVkNDZmYjBjYy90ZXh0cmVnaW9uOmM0ZTk3MmVkOWYwZjQwNTZhNmJkYjcxZWQ0NmZiMGNjXzEyOTg_d5aa60ba-c71c-4415-95fc-63c33f5105dc"
      unitRef="usd">20000000.0</cpix:LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i20968f0f5b524d799086597dfddc2a8d_I20181017"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjAvZnJhZzpjNGU5NzJlZDlmMGY0MDU2YTZiZGI3MWVkNDZmYjBjYy90ZXh0cmVnaW9uOmM0ZTk3MmVkOWYwZjQwNTZhNmJkYjcxZWQ0NmZiMGNjXzE1Mzg_67aa3e65-4b8d-463a-8275-e5a03d63463c"
      unitRef="usd">20000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LongTermLineOfCredit
      contextRef="i5275515928ca439196af82cb649ddae9_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjAvZnJhZzpjNGU5NzJlZDlmMGY0MDU2YTZiZGI3MWVkNDZmYjBjYy90ZXh0cmVnaW9uOmM0ZTk3MmVkOWYwZjQwNTZhNmJkYjcxZWQ0NmZiMGNjXzE1NjE_14ab1b08-fccb-454c-8127-dcf75af76630"
      unitRef="usd">18500000</us-gaap:LongTermLineOfCredit>
    <us-gaap:LongTermLineOfCredit
      contextRef="iba0ec1144cb840b3a4076d92998f6ae8_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjAvZnJhZzpjNGU5NzJlZDlmMGY0MDU2YTZiZGI3MWVkNDZmYjBjYy90ZXh0cmVnaW9uOmM0ZTk3MmVkOWYwZjQwNTZhNmJkYjcxZWQ0NmZiMGNjXzE2MTc_b705e576-fc2a-4c27-8eee-2e42dbd74627"
      unitRef="usd">20000000.0</us-gaap:LongTermLineOfCredit>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="icd700ec4abf947049e74967c3f1ebec7_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjAvZnJhZzpjNGU5NzJlZDlmMGY0MDU2YTZiZGI3MWVkNDZmYjBjYy90ZXh0cmVnaW9uOmM0ZTk3MmVkOWYwZjQwNTZhNmJkYjcxZWQ0NmZiMGNjXzE4MDk_7d1547cf-4963-4b08-8248-17d957b337c8"
      unitRef="number">0.0175</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3296f434993a41289fb9d9eab42374e7_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjAvZnJhZzpjNGU5NzJlZDlmMGY0MDU2YTZiZGI3MWVkNDZmYjBjYy90ZXh0cmVnaW9uOmM0ZTk3MmVkOWYwZjQwNTZhNmJkYjcxZWQ0NmZiMGNjXzE4MTU_09f30bf6-e951-4ad8-b37e-8ea8ffca6806"
      unitRef="number">0.0275</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i72d98b8b6d2b49ec92a95f7f52a21bb0_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjAvZnJhZzpjNGU5NzJlZDlmMGY0MDU2YTZiZGI3MWVkNDZmYjBjYy90ZXh0cmVnaW9uOmM0ZTk3MmVkOWYwZjQwNTZhNmJkYjcxZWQ0NmZiMGNjXzE4NTI_75834d8e-535f-43d3-a709-8131a5476820"
      unitRef="number">0.045</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i870374f6814b4d6cb3842ed1bada7231_D20170731-20170731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjAvZnJhZzpjNGU5NzJlZDlmMGY0MDU2YTZiZGI3MWVkNDZmYjBjYy90ZXh0cmVnaW9uOmM0ZTk3MmVkOWYwZjQwNTZhNmJkYjcxZWQ0NmZiMGNjXzE4ODY_e80d7a59-6ff6-434f-8379-1fc01a011637"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzUzOTU_58e96794-4766-48ae-aa32-dbb252da2659">Shareholders&#x2019; Equity&lt;div style="margin-top:7pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Initial Public Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August&#160;10, 2009, the Company completed its initial public offering of 5,000,000 shares of common stock at a price of $17.00 per share, raising gross proceeds of $85.0 million. After deducting underwriting discounts of approximately $6.0 million and offering costs incurred of approximately $4.2 million, the net proceeds to the Company were approximately $74.8 million. Contemporaneously with the offering, each outstanding share of preferred stock was automatically converted into two million shares of common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is authorized to issue 20,000,000&#160;shares of preferred stock. The Board of Directors is authorized to divide these shares into classes or series, and to fix and determine the relative rights, preferences, qualifications and limitations of the shares of any class or series so established. At December&#160;31, 2019 and 2018, there was no preferred stock outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2019, 2018 and 2017, the Company issued 225,536 shares, 170,759 shares, and 146,275 shares of common stock, respectively, as a result of restricted shares vesting as well as other common share issuances.  Cumberland issued 3,409 common shares under option exercise transactions during 2016.  There were no option exercise transactions during 2019,  2018 and 2017.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2018, the Company's Form S-3 or Shelf Registration associated with the sale of up to $100 million in corporate securities was declared effective. The Shelf Registration also included an At-the-Market ("ATM") feature enabling the Company to sell common shares at market prices, along with an agreement with B. Riley FBR to support such a placement of shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(d)&#160;&#160;&#160;&#160;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2006, the Company signed a new line of credit agreement along with a term loan agreement with a financial institution. In conjunction with these agreements, the Company issued warrants to purchase up to 3,958&#160;shares of common stock at $9.00 per share within 10 years of issuance.  All of these warrants expired during 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the amendment to the debt agreements in 2009, the Company issued warrants to purchase up to 7,500 shares of common stock at $17.00 per share that expired in July 2019.  As of December&#160;31, 2019, there were no outstanding warrants.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(e)&#160;&#160;&#160;&#160;Share Repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company currently has a share repurchase program to repurchase up to $10 million of its common stock pursuant to Rule 10b-18 of the Securities Act. In January 2019, the Company's Board of Directors established the current $10 million repurchase program to replace the prior authorizations. The Company repurchased 623,478 shares, 443,041 shares and 547,376 shares of common stock for approximately $3.5 million, $2.9 million, and $3.7 million during the years ended December&#160;31, 2019, 2018 and 2017, respectively. There remains $8.0 million available under the current repurchase program available for share repurchases at December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(f)&#160;&#160;&#160;&#160;Cumberland Emerging Technologies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2019, Cumberland Emerging Technologies ("CET"), our majority-owned subsidiary, entered into &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;an agreement with WinHealth whereby WinHealth made a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $1 million &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;investment through the purchase of shares of CET stock. As part of the agreement, WinHealth obtained a Board position at CET and the first opportunity to license CET products for the Chinese market. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  In connection with WinHealth&#x2019;s investment in CET, the Company also made an additional $1 million investment in CET.  Cumberland &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;purchased additional CET shares through contribution of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $0.3 million in cash and a conversion of $0.7 million in intercompany loans payable.  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon completion of the additional investment by WinHealth and Cumberland, Gloria Pharmaceuticals agreed to return its shares in CET in exchange for consideration of  $0.8&#160;million. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; After the additional investment, the Company&#x2019;s ownership in CET is 85%.  As CET is a consolidated subsidiary, the Company reports the operating results of CET and allocates the noncontrolling interests to the non-majority partners.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(g)  &#160;&#160;&#160;&#160;Cumberland Foundation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2017, the Company formed the Cumberland Pharma Foundation (the "Foundation") to serve as a vehicle to facilitate the ongoing philanthropic endeavors of Cumberland Pharmaceuticals Inc. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Foundation was formed as a nonprofit corporation designed to qualify as a tax-exempt organization pursuant to Section 501(a) of the Internal Revenue Code. The Foundation&#x2019;s Board of Directors is comprised of Cumberland Pharmaceuticals executives who are responsible for overseeing the Foundation&#x2019;s ongoing activities including charitable contributions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In 2018, Cumberland provided a grant of 50,000 shares of the Company's common stock to the Foundation. The shares will address the ongoing financial needs of the organization, with most of the shares expected to be held for the opportunity to realize long term appreciation to support the Foundation&#x2019;s future. The Foundation maintains separate financial statements and its ongoing operations will not impact the financial statements of Cumberland Pharmaceuticals. Initial annual grants by the Foundation have been and are expected to remain consistent with the historic level of contributions made by Cumberland Pharmaceuticals.  During 2019, Cumberland Pharmaceuticals committed approximately $50,000 in cash contributions to be paid to the Foundation during 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(h)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Nordic Group B.V.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 27, 2019, Cumberland received approval from the FDA for the pre-filled syringe of the Methotrexate product.  With this approval, Nordic's 180,000 shares of Cumberland's common stock became vested.  The value of these shares at the date of approval was $0.9&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockTransactionDate
      contextRef="i9249561602f042ba980b18815fa29971_D20090809-20090810"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzYy_746f549d-985e-46a9-990f-e74c4d6b7053">2009-08-10</us-gaap:SaleOfStockTransactionDate>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i9249561602f042ba980b18815fa29971_D20090809-20090810"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzExOQ_a8bee154-753b-4ce2-9b12-bfb2548869e0"
      unitRef="shares">5000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <cpix:StockIssuedDuringPeriodPricePerShareNewIssues
      contextRef="i9249561602f042ba980b18815fa29971_D20090809-20090810"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzE2MA_392a467d-7ac9-4404-a558-2dac955fe1db"
      unitRef="usdPerShare">17.00</cpix:StockIssuedDuringPeriodPricePerShareNewIssues>
    <cpix:StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering
      contextRef="i9249561602f042ba980b18815fa29971_D20090809-20090810"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzIwMQ_8620504a-f5ea-4e0a-a508-c1b1250e31be"
      unitRef="usd">85000000.0</cpix:StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering>
    <cpix:StockIssuedDuringPeriodNewSharesUnderwritingDiscounts
      contextRef="i9249561602f042ba980b18815fa29971_D20090809-20090810"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzI2Mg_74360878-c598-4f02-9b4d-15335a6d6065"
      unitRef="usd">6000000.0</cpix:StockIssuedDuringPeriodNewSharesUnderwritingDiscounts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i9249561602f042ba980b18815fa29971_D20090809-20090810"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzMxMQ_6a3f00b5-162d-4c5d-8006-867e3cd3cdb2"
      unitRef="usd">4200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="i9249561602f042ba980b18815fa29971_D20090809-20090810"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzM2Nw_fe84e69e-d1c5-4070-a73b-20cb2705d72b"
      unitRef="usd">74800000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <cpix:StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering
      contextRef="i9249561602f042ba980b18815fa29971_D20090809-20090810"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzQ4Mw_d607c534-0d51-4a32-bac1-18a8160d2478"
      unitRef="number">2000000</cpix:StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzU2NQ_de4a3f1c-f5e2-4c85-bfca-11765fb48d9f"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i52ca8e03f38a46ab80ee3b1b2a37a943_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzkzNg_db43d325-bcd1-432c-9d1d-f310ccd7612d"
      unitRef="shares">225536</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i8b9e95130dc146f9aa56d8d1d11bc534_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzk0Nw_4523518d-d58d-48cd-9025-24c0ad2b075b"
      unitRef="shares">170759</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i6921ef0b4c9446b6a5f25b2084bdc3ca_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzk2Mg_94dbe81d-0904-48f5-a9a8-696c650913cd"
      unitRef="shares">146275</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding
      contextRef="i1b76324a8a3c4073a8a827f31c55b373_D20160101-20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzExMDQ_98fc5144-1f1e-425f-a399-09ba5f1a3b1b"
      unitRef="shares">3409</cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding>
    <cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities
      contextRef="ic8a09f2f029d4cf5b809b640237883a1_D20180101-20180131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzEzMzU_d471e221-e933-41ca-b9c7-2eb3bc473e5b"
      unitRef="usd">100000000</cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ia45e033a0968470a87498cc6e80e79bb_I20061231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzE4MTc_ad1b4e8a-2b19-45d1-94a6-931e12b59373"
      unitRef="shares">3958</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ia45e033a0968470a87498cc6e80e79bb_I20061231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzE4NDc_895ffdf7-fb63-4271-b4fb-9d812659f6fb"
      unitRef="usdPerShare">9.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i65091fc0eec54e3ebe7cadf845bfc5c3_I20091231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzIwNDQ_59fa06ee-0fbf-4267-97be-de5070c942a5"
      unitRef="shares">7500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i65091fc0eec54e3ebe7cadf845bfc5c3_I20091231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzIwNzQ_f5a9b8bc-80ac-4104-9e6a-f66d3055c53f"
      unitRef="usdPerShare">17.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="ieb984696887341bdb3d482415e883068_I20100531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzIyNTM_fe92b2f5-70bc-4090-a767-524b2d93b6f4"
      unitRef="usd">10000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="ieb984696887341bdb3d482415e883068_I20100531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzIzOTg_7de7418c-83c6-4ce8-9ebe-7cea6e7a060b"
      unitRef="usd">10000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i42d555993abb411fbcfac8eefe7bfc92_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzI0ODE_69bee440-2a15-4bc7-902a-ca072200b908"
      unitRef="shares">623478</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="icd076322bd3e4e45812f30f6e0265418_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzI0OTI_d35569ef-6de5-4046-9a20-eab25c1b2535"
      unitRef="shares">443041</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i0be3acf257f24f79aeb0cfd8403ccd87_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzI1MDY_13a7016c-7eef-4936-beea-ea94edf643ac"
      unitRef="shares">547376</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i42d555993abb411fbcfac8eefe7bfc92_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzI1NTA_efa31285-05c7-41d5-b3fa-cad4c094fadb"
      unitRef="usd">3500000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="icd076322bd3e4e45812f30f6e0265418_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzI1NTQ_ce10dffc-f04f-45c2-9b79-17bb47b1308d"
      unitRef="usd">2900000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i0be3acf257f24f79aeb0cfd8403ccd87_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzI1NjI_2936d73a-1418-4d9f-b911-ab7953af07c8"
      unitRef="usd">3700000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzI2MzE_8b12e312-1af5-4b47-a7e5-a4fe89a4afe0"
      unitRef="usd">8000000.0</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
      contextRef="i5465c80566344695bc41a215e251af48_D20190401-20190430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzI5MTE_bde42759-7201-4a8f-8db1-d3c7e3cbe497"
      unitRef="usd">1000000</us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest>
    <cpix:SubsidiaryInvestmentPurchaseOfShares
      contextRef="i917430c8015149c18c59ded862b49717_I20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzMyMDE_a7e9c8e8-b858-4b79-b604-464e29bac058"
      unitRef="usd">1000000</cpix:SubsidiaryInvestmentPurchaseOfShares>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="i8e71f9e142114cb1a967ae279d7a32d8_D20140401-20140430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzMyOTE_56d85eca-cdfe-43be-9b61-c1e0c8bbfa1f"
      unitRef="usd">300000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <cpix:LoansForgiveninExchangeForShareIssuedAmount
      contextRef="i8e71f9e142114cb1a967ae279d7a32d8_D20140401-20140430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzMzMjI_bfc62ab8-3254-4a53-9235-4bdbb05382b5"
      unitRef="usd">700000</cpix:LoansForgiveninExchangeForShareIssuedAmount>
    <cpix:SubsidiaryInvestmentPaymentsForReturnOfCapital
      contextRef="i3522d1a659a04358b4f6ed8b764dd9e5_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzM1MjM_aec2b106-0b20-4987-ba5c-3bc578988a46"
      unitRef="usd">800000</cpix:SubsidiaryInvestmentPaymentsForReturnOfCapital>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="ie1b2c35fc3b6418cb8cc3c920e5ae3d6_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzM2MDM_7588577f-b0d7-4bc1-8144-24c04084bba9"
      unitRef="number">0.85</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <cpix:SharebasedCompensationCharitableContributionofSharesShares
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzQzOTM_60dea78d-2636-4aec-a33c-8800d7f96fe5"
      unitRef="shares">50000</cpix:SharebasedCompensationCharitableContributionofSharesShares>
    <cpix:ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzUwNDM_59590114-c264-45f1-ab52-cb2fd69d341d"
      unitRef="usd">50000</cpix:ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="ib2b3b044fded4d4a96267ff40f75f41d_D20191127-20191127"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzUyODQ_3b7d94d6-f4cf-4043-b44f-e59b07772972"
      unitRef="shares">180000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="ib2b3b044fded4d4a96267ff40f75f41d_D20191127-20191127"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjMvZnJhZzo1MzFkYjA0OGI2ODM0ZmJmOWNhNTMzMjc4MWQ1ZWM3My90ZXh0cmVnaW9uOjUzMWRiMDQ4YjY4MzRmYmY5Y2E1MzMyNzgxZDVlYzczXzUzOTM_f598f2a6-1a2d-415a-9a0f-127f3cab5a81"
      unitRef="usd">900000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90ZXh0cmVnaW9uOjYwYzA1OTZkYWNjZjQ3NjY4MDliMzkzZGM1NmQ5OGUyXzMzMg_79ccd160-a612-4859-822a-e11e14776316">Earnings (Loss) Per Share &lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the computation of the numerator and the denominator used to calculate diluted earnings (loss) per share for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.294%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.010%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,211,688)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,820,996)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,847,840)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,665,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,782,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,798,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,546,511)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,038,772)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,049,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss at subsidiary attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,537,759)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,963,068)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,978,633)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,396,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,614,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,911,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of restricted stock and stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,396,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,614,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,911,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's anti-dilutive restricted shares and stock options outstanding were as follows for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:88.301%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.048%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive shares and options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90ZXh0cmVnaW9uOjYwYzA1OTZkYWNjZjQ3NjY4MDliMzkzZGM1NmQ5OGUyXzMyOQ_2d0b2ce0-7564-432d-82fd-fe439dfc4d9f">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the computation of the numerator and the denominator used to calculate diluted earnings (loss) per share for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.294%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.010%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,211,688)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,820,996)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,847,840)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,665,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,782,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,798,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,546,511)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,038,772)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,049,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss at subsidiary attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,537,759)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,963,068)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,978,633)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,396,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,614,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,911,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of restricted stock and stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,396,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,614,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,911,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzMtMi0xLTEtMTUxMQ_e6c2c40d-8bc3-43df-b81f-246f366e35f0"
      unitRef="usd">-9211688</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzMtNC0xLTEtMTUxMw_a8a4b4d6-7773-4394-aa5d-46e70762ac4b"
      unitRef="usd">-10820996</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzMtNi0xLTEtMTUxNQ_644433f8-a8f5-493f-8429-aa9b20213ad9"
      unitRef="usd">-12847840</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzQtMi0xLTEtMTUxMQ_2d5b7e42-e5fa-44f5-9d12-bd04792b941c"
      unitRef="usd">5665177</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzQtNC0xLTEtMTUxMw_bbfc539d-4ccc-4e15-9874-f66722bf2d76"
      unitRef="usd">3782224</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzQtNi0xLTEtMTUxNQ_7784ee07-9950-4c24-b7f3-f3ac0d091233"
      unitRef="usd">4798025</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzUtMi0xLTEtMjIyOA_03ac504f-d5e1-478f-bed3-f82861bd6972"
      unitRef="usd">-3546511</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzUtNC0xLTEtMjIyOA_039995f2-14e6-4110-8289-a83040586a1b"
      unitRef="usd">-7038772</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzUtNi0xLTEtMjIyOA_e461cb0c-df8c-46ce-8c7a-55f45394341b"
      unitRef="usd">-8049815</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzYtMi0xLTEtMjIyOA_2a41210e-25fd-442e-8987-2dfc460a8d44"
      unitRef="usd">-8752</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzYtNC0xLTEtMjIyOA_90ad1b36-e51b-4bb9-8465-4ff71d995088"
      unitRef="usd">-75704</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzYtNi0xLTEtMjIyOA_a37afbff-780b-40bc-9324-5b3bb249f69b"
      unitRef="usd">-71182</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzMtMi0xLTEtMA_f1651aa2-4a79-4695-a1df-9f5652a29f77"
      unitRef="usd">-3537759</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzMtNC0xLTEtMA_a3374253-63e7-43d9-a6e4-0d6bafe90236"
      unitRef="usd">-6963068</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzMtNi0xLTEtMA_a3b042a1-f29b-41fc-923e-5ec1bad7ded8"
      unitRef="usd">-7978633</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzYtMi0xLTEtMA_c1306e0e-cc70-491e-98a6-f15a57a61645"
      unitRef="shares">15396098</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzYtNC0xLTEtMA_1d3ab8c3-ff3a-407a-9d90-19b5d8c6fa24"
      unitRef="shares">15614052</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzYtNi0xLTEtMA_1fa6313b-1ce0-48c5-95bf-819cfcbab505"
      unitRef="shares">15911577</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzctMi0xLTEtMA_9c1c13c3-9263-4393-bb1b-bec968e015de"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzctNC0xLTEtMA_e1a0262c-5f52-49e5-b315-78f22315a0ed"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzctNi0xLTEtMA_6cc1e16a-313b-45fc-a58b-ae16d52947cf"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzgtMi0xLTEtMA_5c292cf6-baff-49e3-a7a4-09e9baedf40e"
      unitRef="shares">15396098</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzgtNC0xLTEtMA_5394aef4-10b1-4f6b-8ea2-6147449e9295"
      unitRef="shares">15614052</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZTo1ZGY1N2FiY2QzMWU0NjUyODFiMmUzNGQ1MzliNGI3Mi90YWJsZXJhbmdlOjVkZjU3YWJjZDMxZTQ2NTI4MWIyZTM0ZDUzOWI0YjcyXzgtNi0xLTEtMA_6cb6387f-0579-4cf9-8fd4-85078bbd039e"
      unitRef="shares">15911577</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90ZXh0cmVnaW9uOjYwYzA1OTZkYWNjZjQ3NjY4MDliMzkzZGM1NmQ5OGUyXzMzMQ_e4bd20f7-0dc7-4ede-b291-889175bb1d12">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's anti-dilutive restricted shares and stock options outstanding were as follows for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:88.301%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.048%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive shares and options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZToyNTkzN2FkMzlhOGY0OTJhODY5MmYwOGE2NWM0YTVjZC90YWJsZXJhbmdlOjI1OTM3YWQzOWE4ZjQ5MmE4NjkyZjA4YTY1YzRhNWNkXzItMi0xLTEtMA_0fb9fb70-dd6e-424d-b978-8b9993940bfb"
      unitRef="shares">4000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZToyNTkzN2FkMzlhOGY0OTJhODY5MmYwOGE2NWM0YTVjZC90YWJsZXJhbmdlOjI1OTM3YWQzOWE4ZjQ5MmE4NjkyZjA4YTY1YzRhNWNkXzItNC0xLTEtMA_61e38a45-c838-430f-8e90-5672d19bb900"
      unitRef="shares">41650</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjYvZnJhZzo2MGMwNTk2ZGFjY2Y0NzY2ODA5YjM5M2RjNTZkOThlMi90YWJsZToyNTkzN2FkMzlhOGY0OTJhODY5MmYwOGE2NWM0YTVjZC90YWJsZXJhbmdlOjI1OTM3YWQzOWE4ZjQ5MmE4NjkyZjA4YTY1YzRhNWNkXzItNi0xLTEtMA_68834f12-3586-4d5f-8c7f-d44e55c28228"
      unitRef="shares">18325</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90ZXh0cmVnaW9uOjEzZjkwZjc3YzAyNDQxNjY4Njg1ZTQ4OThjOTc1M2Q5XzI1NzU_21c6e8bb-7535-4a32-9589-6bbfcf4ad933">Income Taxes&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the Company's net deferred tax assets at December&#160;31 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.544%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred Tax Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss and tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,964,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,410,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment and intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve for expired product&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;558,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;910,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cumulative compensation costs incurred on deductible equity awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,047,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;884,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,846,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,444,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred Tax Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,313,965)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,974,787)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets, before valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,532,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,469,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: deferred tax asset valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,511,161)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,382,052)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amount and year of expiration of the Company's federal and state net operating loss carryforwards as of December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.339%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.248%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years of expiration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 - 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,392,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,153,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2031 - 2039&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,534,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,947,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,493,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total federal and state net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,181,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,198,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax (expense) benefit includes the following components for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.179%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59,243)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current income tax (expense) benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59,243)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65,408)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,682,772)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(432,874)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax (expense) benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65,408)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,115,646)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax (expense) benefit &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,174,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s effective income tax rate for 2019, 2018 and 2017 reconciles with the federal statutory tax rate as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.179%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal tax expense at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income tax expense (net of federal income tax benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent differences associated with general business credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(148)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, the Company determined that it was not more likely than not that its net deferred tax assets would be realized.  As such, the Company&#x2019;s income tax provision for the year ended December 31, 2017 reflected a full valuation allowance against net deferred tax assets with the exception of the deferred tax asset for alternative minimum tax (&#x201c;AMT&#x201d;) credit carryforwards discussed further below.  The Company&#x2019;s position is unchanged as of  both December 31, 2018 and December 31, 2019.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (&#x201c;the Tax Act&#x201d;).  The Tax Act makes broad and complex changes to the U.S. tax code, including, but not limited to, (1) reducing the U.S. federal corporate tax rate to 21%; (2) eliminating the corporate alternative minimum tax (&#x201c;AMT&#x201d;) and changing how AMT credits can be realized; (3) capital expensing; and (4) creating new limitations on deductible interest expense and executive compensation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our analysis of the impact of the Tax Act, we recorded a net tax benefit of $0.1 million in the period ended December 31, 2017.  This net tax benefit consisted entirely of the release of the valuation allowance against AMT credits that will be realizable under the Tax Act in future periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expects it will continue to pay minimal taxes in future periods through the continued utilization of net operating loss carryforwards, as it is able to achieve taxable income through its operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is no longer subject to U.S. federal tax examinations for tax years before 2016, and with few exceptions, the Company is not subject to examination by state tax authorities for tax years which ended before 2016.  Loss carryforwards and credit carryforwards generated or utilized in years earlier than 2016 remain subject to examination and adjustment.  During 2012, the 2009 federal tax return was examined by the Internal Revenue Service with no significant findings or adjustments.  The Company has no unrecognized tax benefits in 2019, 2018 and 2017.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90ZXh0cmVnaW9uOjEzZjkwZjc3YzAyNDQxNjY4Njg1ZTQ4OThjOTc1M2Q5XzI1Nzc_32d5ba34-da28-40e9-9afb-8b880063ca79">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the Company's net deferred tax assets at December&#160;31 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.544%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred Tax Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss and tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,964,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,410,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment and intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve for expired product&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;558,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;910,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cumulative compensation costs incurred on deductible equity awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,047,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;884,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,846,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,444,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred Tax Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,313,965)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,974,787)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets, before valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,532,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,469,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: deferred tax asset valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,511,161)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,382,052)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <cpix:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzMtMi0xLTEtMA_57b631c8-dc01-4385-a06e-196fad874e4d"
      unitRef="usd">16964685</cpix:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards>
    <cpix:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzMtNC0xLTEtMA_7b4163b7-ebcb-4e98-9ab6-eb15da932ded"
      unitRef="usd">16410403</cpix:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards>
    <cpix:DeferredTaxAssetsPropertyAndEquipmentAndIntangibles
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzQtMi0xLTEtMA_413653f6-e8e7-430e-a1af-0b4e182ad3c9"
      unitRef="usd">227072</cpix:DeferredTaxAssetsPropertyAndEquipmentAndIntangibles>
    <cpix:DeferredTaxAssetsPropertyAndEquipmentAndIntangibles
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzQtNC0xLTEtMA_ff2535f4-3cba-423c-85fd-cf2f25c5ec00"
      unitRef="usd">236318</cpix:DeferredTaxAssetsPropertyAndEquipmentAndIntangibles>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzUtMi0xLTEtMA_3056afe3-cdd0-42ef-80eb-08a03ad64d12"
      unitRef="usd">257564</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzUtNC0xLTEtMA_a06ff2a0-768e-46a9-a22d-a2bb0fef5de4"
      unitRef="usd">251068</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <cpix:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzYtMi0xLTEtMA_118c579d-44d0-41bc-8102-fe82dc6ef5e9"
      unitRef="usd">469466</cpix:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct>
    <cpix:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzYtNC0xLTEtMA_923e2a55-a766-41d9-9389-40f7b84c3a61"
      unitRef="usd">558484</cpix:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzctMi0xLTEtMA_dc54a9a8-8f56-46bd-83d2-bb33406fc5ec"
      unitRef="usd">35227</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzctNC0xLTEtMA_4915ec65-e0eb-474e-b18b-82e1887ad4f9"
      unitRef="usd">193150</us-gaap:DeferredTaxAssetsInventory>
    <cpix:DeferredTaxAssetsDeferredCharges
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzgtMi0xLTEtMA_39950b99-88f0-4f17-b0df-d8b379f52684"
      unitRef="usd">845765</cpix:DeferredTaxAssetsDeferredCharges>
    <cpix:DeferredTaxAssetsDeferredCharges
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzgtNC0xLTEtMA_57535e51-d0b1-4007-a8a8-9ebdfc625fb1"
      unitRef="usd">910577</cpix:DeferredTaxAssetsDeferredCharges>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzktMi0xLTEtMA_2232fbfe-93cd-42e0-a5f6-0bbae2077677"
      unitRef="usd">1047149</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzktNC0xLTEtMA_37136903-37f7-4f52-8aa2-087612ee572d"
      unitRef="usd">884049</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzEwLTItMS0xLTA_3134d7c5-c2e1-430a-b3af-20d2c904578c"
      unitRef="usd">19846928</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzEwLTQtMS0xLTA_6d8371e6-d51b-49c0-bab3-3470b42e7d58"
      unitRef="usd">19444049</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzEzLTItMS0xLTA_c968166d-374d-42d1-a916-aca315e544ab"
      unitRef="usd">1313965</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzEzLTQtMS0xLTA_63216e96-ae7f-4a86-85fe-26c94b647dbb"
      unitRef="usd">1974787</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <cpix:NetDeferredTaxAssetsGross
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzE0LTItMS0xLTA_bacd7360-d9dc-4d35-ad5b-eef338b10da5"
      unitRef="usd">18532963</cpix:NetDeferredTaxAssetsGross>
    <cpix:NetDeferredTaxAssetsGross
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzE0LTQtMS0xLTA_aa472242-a15f-4d6b-967c-bfc2076af332"
      unitRef="usd">17469262</cpix:NetDeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzE1LTItMS0xLTA_fdfd0acd-a047-494c-9660-a4444b137d7f"
      unitRef="usd">18511161</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzE1LTQtMS0xLTA_cc47639d-a3d5-4f2b-b20e-15922ee6ddd2"
      unitRef="usd">17382052</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzE2LTItMS0xLTA_9bf19561-a036-4811-9e0d-c778510fc5a7"
      unitRef="usd">21802</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4M2MzZWNmMzU2NGI0ZjkyODZkODAzMGI5YTNjOGQwNi90YWJsZXJhbmdlOjgzYzNlY2YzNTY0YjRmOTI4NmQ4MDMwYjlhM2M4ZDA2XzE2LTQtMS0xLTA_dc1a3209-9c6b-4662-905d-398c6a45905a"
      unitRef="usd">87210</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90ZXh0cmVnaW9uOjEzZjkwZjc3YzAyNDQxNjY4Njg1ZTQ4OThjOTc1M2Q5XzI1Nzk_87116e82-24fd-441e-a0e5-6dcb72117348">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amount and year of expiration of the Company's federal and state net operating loss carryforwards as of December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.339%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.248%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years of expiration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 - 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,392,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,153,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2031 - 2039&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,534,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,947,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,493,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total federal and state net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,181,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,198,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i9c1e105600e74750a10354cbeaad8205_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZToxODk5OTEyYmM5YTE0YmYzYmRjNzBhY2QzZDc3NmQxMy90YWJsZXJhbmdlOjE4OTk5MTJiYzlhMTRiZjNiZGM3MGFjZDNkNzc2ZDEzXzItMi0xLTEtMA_0763f1a1-bfec-4d8b-a9ee-11b0815b6c33"
      unitRef="usd">0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="icfde25ec7427462aba77d555bf0b4ebc_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZToxODk5OTEyYmM5YTE0YmYzYmRjNzBhY2QzZDc3NmQxMy90YWJsZXJhbmdlOjE4OTk5MTJiYzlhMTRiZjNiZGM3MGFjZDNkNzc2ZDEzXzItNC0xLTEtMA_2da5ecc0-e3b5-413f-9efe-811690375d38"
      unitRef="usd">13115</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ie7f0355a74da4690bb8381a211624d38_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZToxODk5OTEyYmM5YTE0YmYzYmRjNzBhY2QzZDc3NmQxMy90YWJsZXJhbmdlOjE4OTk5MTJiYzlhMTRiZjNiZGM3MGFjZDNkNzc2ZDEzXzMtMi0xLTEtMA_8ad7b7d7-5ff0-4acb-a7ac-ab971e4945e0"
      unitRef="usd">0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i0bc29ea825b54377a95392502611cdcd_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZToxODk5OTEyYmM5YTE0YmYzYmRjNzBhY2QzZDc3NmQxMy90YWJsZXJhbmdlOjE4OTk5MTJiYzlhMTRiZjNiZGM3MGFjZDNkNzc2ZDEzXzMtNC0xLTEtMA_cebbcc4f-0c99-4cc2-9c91-9b22b58a3003"
      unitRef="usd">49392824</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i811017016cf741b2be0e3e987f3eb761_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZToxODk5OTEyYmM5YTE0YmYzYmRjNzBhY2QzZDc3NmQxMy90YWJsZXJhbmdlOjE4OTk5MTJiYzlhMTRiZjNiZGM3MGFjZDNkNzc2ZDEzXzQtMi0xLTEtMA_002c2d8f-d73d-44db-98bd-ec8d5d332a18"
      unitRef="usd">44153819</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i0be1be11078f412084defc44e8714a79_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZToxODk5OTEyYmM5YTE0YmYzYmRjNzBhY2QzZDc3NmQxMy90YWJsZXJhbmdlOjE4OTk5MTJiYzlhMTRiZjNiZGM3MGFjZDNkNzc2ZDEzXzQtNC0xLTEtMA_292a5fb7-81db-4aa4-9d08-cda6a5ca38c8"
      unitRef="usd">461280</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="iab82716daa96407a81d6e9e0259dbb45_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZToxODk5OTEyYmM5YTE0YmYzYmRjNzBhY2QzZDc3NmQxMy90YWJsZXJhbmdlOjE4OTk5MTJiYzlhMTRiZjNiZGM3MGFjZDNkNzc2ZDEzXzUtMi0xLTEtMA_7d07783d-8e74-40c1-ba1a-3fe67d42f63b"
      unitRef="usd">7534351</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i8bd88221af1b4196a3229b6b611f66c0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZToxODk5OTEyYmM5YTE0YmYzYmRjNzBhY2QzZDc3NmQxMy90YWJsZXJhbmdlOjE4OTk5MTJiYzlhMTRiZjNiZGM3MGFjZDNkNzc2ZDEzXzUtNC0xLTEtMA_bdea2b6b-a077-4ae0-a6df-927b9a9b9612"
      unitRef="usd">9947070</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ibfc8673e890d447cb4c97a9429f48da8_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZToxODk5OTEyYmM5YTE0YmYzYmRjNzBhY2QzZDc3NmQxMy90YWJsZXJhbmdlOjE4OTk5MTJiYzlhMTRiZjNiZGM3MGFjZDNkNzc2ZDEzXzYtMi0xLTEtMA_de7b05bf-1f34-406f-a9a2-efeeb766b525"
      unitRef="usd">5493258</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i0b3d8839a10943299527a3616540c882_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZToxODk5OTEyYmM5YTE0YmYzYmRjNzBhY2QzZDc3NmQxMy90YWJsZXJhbmdlOjE4OTk5MTJiYzlhMTRiZjNiZGM3MGFjZDNkNzc2ZDEzXzYtNC0xLTEtMA_52e7082e-3731-44ed-8ed1-6c006946afac"
      unitRef="usd">383869</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="idf6dd30a84fc4e6fbec6716f5833f1be_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZToxODk5OTEyYmM5YTE0YmYzYmRjNzBhY2QzZDc3NmQxMy90YWJsZXJhbmdlOjE4OTk5MTJiYzlhMTRiZjNiZGM3MGFjZDNkNzc2ZDEzXzgtMi0xLTEtMA_5899a8a8-4b06-47e0-b237-e099d89176dc"
      unitRef="usd">57181428</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i919816e4ae6e49cbbc09d39640cee418_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZToxODk5OTEyYmM5YTE0YmYzYmRjNzBhY2QzZDc3NmQxMy90YWJsZXJhbmdlOjE4OTk5MTJiYzlhMTRiZjNiZGM3MGFjZDNkNzc2ZDEzXzgtNC0xLTEtMA_ee7c8779-3975-48f1-b695-27691e1bdc7f"
      unitRef="usd">60198158</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90ZXh0cmVnaW9uOjEzZjkwZjc3YzAyNDQxNjY4Njg1ZTQ4OThjOTc1M2Q5XzI1NzE_1c0f8447-df06-48c2-b270-b12c61a93420">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax (expense) benefit includes the following components for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.179%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59,243)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current income tax (expense) benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59,243)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65,408)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,682,772)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(432,874)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax (expense) benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65,408)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,115,646)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax (expense) benefit &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,174,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo0YmVhZDA4MGY4MzY0YTMwYTExNzAxN2NhMGVhNjFmYy90YWJsZXJhbmdlOjRiZWFkMDgwZjgzNjRhMzBhMTE3MDE3Y2EwZWE2MWZjXzMtMi0xLTEtMA_5cfcda2b-c289-4fc3-910f-85aab9a236df"
      unitRef="usd">-65408</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo0YmVhZDA4MGY4MzY0YTMwYTExNzAxN2NhMGVhNjFmYy90YWJsZXJhbmdlOjRiZWFkMDgwZjgzNjRhMzBhMTE3MDE3Y2EwZWE2MWZjXzMtNC0xLTEtMA_138f778b-6f3e-44f2-acc6-b22e8ac7673a"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo0YmVhZDA4MGY4MzY0YTMwYTExNzAxN2NhMGVhNjFmYy90YWJsZXJhbmdlOjRiZWFkMDgwZjgzNjRhMzBhMTE3MDE3Y2EwZWE2MWZjXzMtNi0xLTEtMA_604a347d-2a98-4f14-8840-e0209e2b3b4c"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo0YmVhZDA4MGY4MzY0YTMwYTExNzAxN2NhMGVhNjFmYy90YWJsZXJhbmdlOjRiZWFkMDgwZjgzNjRhMzBhMTE3MDE3Y2EwZWE2MWZjXzQtMi0xLTEtMA_e0715dd8-9689-467c-a0fb-a45bc426baf5"
      unitRef="usd">-79316</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo0YmVhZDA4MGY4MzY0YTMwYTExNzAxN2NhMGVhNjFmYy90YWJsZXJhbmdlOjRiZWFkMDgwZjgzNjRhMzBhMTE3MDE3Y2EwZWE2MWZjXzQtNC0xLTEtMA_213c6cd2-0084-4444-922a-edfc806296ea"
      unitRef="usd">16636</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo0YmVhZDA4MGY4MzY0YTMwYTExNzAxN2NhMGVhNjFmYy90YWJsZXJhbmdlOjRiZWFkMDgwZjgzNjRhMzBhMTE3MDE3Y2EwZWE2MWZjXzQtNi0xLTEtMA_086cd4cf-5610-4af4-a91b-0c460c74338f"
      unitRef="usd">59243</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo0YmVhZDA4MGY4MzY0YTMwYTExNzAxN2NhMGVhNjFmYy90YWJsZXJhbmdlOjRiZWFkMDgwZjgzNjRhMzBhMTE3MDE3Y2EwZWE2MWZjXzUtMi0xLTEtMA_22415255-d0dc-4d55-9e72-517e76639a77"
      unitRef="usd">-144724</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo0YmVhZDA4MGY4MzY0YTMwYTExNzAxN2NhMGVhNjFmYy90YWJsZXJhbmdlOjRiZWFkMDgwZjgzNjRhMzBhMTE3MDE3Y2EwZWE2MWZjXzUtNC0xLTEtMA_f6524571-e4e6-4968-ab48-edc7bb9daea9"
      unitRef="usd">16636</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo0YmVhZDA4MGY4MzY0YTMwYTExNzAxN2NhMGVhNjFmYy90YWJsZXJhbmdlOjRiZWFkMDgwZjgzNjRhMzBhMTE3MDE3Y2EwZWE2MWZjXzUtNi0xLTEtMA_6edc86c3-e5f8-4e73-b44e-89f6fbd15f70"
      unitRef="usd">59243</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo0YmVhZDA4MGY4MzY0YTMwYTExNzAxN2NhMGVhNjFmYy90YWJsZXJhbmdlOjRiZWFkMDgwZjgzNjRhMzBhMTE3MDE3Y2EwZWE2MWZjXzgtMi0xLTEtMA_be69a448-bdf8-4a6f-8b17-5609e2c6dfea"
      unitRef="usd">65408</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo0YmVhZDA4MGY4MzY0YTMwYTExNzAxN2NhMGVhNjFmYy90YWJsZXJhbmdlOjRiZWFkMDgwZjgzNjRhMzBhMTE3MDE3Y2EwZWE2MWZjXzgtNC0xLTEtMA_8c27f5d3-832f-47da-9823-024402a63e1a"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo0YmVhZDA4MGY4MzY0YTMwYTExNzAxN2NhMGVhNjFmYy90YWJsZXJhbmdlOjRiZWFkMDgwZjgzNjRhMzBhMTE3MDE3Y2EwZWE2MWZjXzgtNi0xLTEtMA_bde9d228-6871-43df-8171-6b4813bcb2e9"
      unitRef="usd">3682772</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo0YmVhZDA4MGY4MzY0YTMwYTExNzAxN2NhMGVhNjFmYy90YWJsZXJhbmdlOjRiZWFkMDgwZjgzNjRhMzBhMTE3MDE3Y2EwZWE2MWZjXzktMi0xLTEtMA_2e735a41-11cc-4542-8d1e-dc942e0c18cf"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo0YmVhZDA4MGY4MzY0YTMwYTExNzAxN2NhMGVhNjFmYy90YWJsZXJhbmdlOjRiZWFkMDgwZjgzNjRhMzBhMTE3MDE3Y2EwZWE2MWZjXzktNC0xLTEtMA_8facbcdb-4ac4-4d03-b9c4-824c06b58d9f"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo0YmVhZDA4MGY4MzY0YTMwYTExNzAxN2NhMGVhNjFmYy90YWJsZXJhbmdlOjRiZWFkMDgwZjgzNjRhMzBhMTE3MDE3Y2EwZWE2MWZjXzktNi0xLTEtMA_e5f870a1-2ea7-41a4-93a2-64cc2a790845"
      unitRef="usd">432874</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredOtherTaxExpenseBenefit
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo0YmVhZDA4MGY4MzY0YTMwYTExNzAxN2NhMGVhNjFmYy90YWJsZXJhbmdlOjRiZWFkMDgwZjgzNjRhMzBhMTE3MDE3Y2EwZWE2MWZjXzEwLTItMS0xLTA_82384aed-3fc9-437e-b5e2-d2348568f2e1"
      unitRef="usd">65408</us-gaap:DeferredOtherTaxExpenseBenefit>
    <us-gaap:DeferredOtherTaxExpenseBenefit
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo0YmVhZDA4MGY4MzY0YTMwYTExNzAxN2NhMGVhNjFmYy90YWJsZXJhbmdlOjRiZWFkMDgwZjgzNjRhMzBhMTE3MDE3Y2EwZWE2MWZjXzEwLTQtMS0xLTA_48d48f8a-b50a-4d03-8b44-f183fd3893a4"
      unitRef="usd">0</us-gaap:DeferredOtherTaxExpenseBenefit>
    <us-gaap:DeferredOtherTaxExpenseBenefit
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo0YmVhZDA4MGY4MzY0YTMwYTExNzAxN2NhMGVhNjFmYy90YWJsZXJhbmdlOjRiZWFkMDgwZjgzNjRhMzBhMTE3MDE3Y2EwZWE2MWZjXzEwLTYtMS0xLTA_fa3219f5-dde3-4036-aac9-b1fd1c86c820"
      unitRef="usd">4115646</us-gaap:DeferredOtherTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo0YmVhZDA4MGY4MzY0YTMwYTExNzAxN2NhMGVhNjFmYy90YWJsZXJhbmdlOjRiZWFkMDgwZjgzNjRhMzBhMTE3MDE3Y2EwZWE2MWZjXzExLTItMS0xLTA_bf7d589e-390f-4cfa-aa80-309999fde4fa"
      unitRef="usd">-79316</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo0YmVhZDA4MGY4MzY0YTMwYTExNzAxN2NhMGVhNjFmYy90YWJsZXJhbmdlOjRiZWFkMDgwZjgzNjRhMzBhMTE3MDE3Y2EwZWE2MWZjXzExLTQtMS0xLTA_7e340f3a-9459-45d1-abbc-77098f8e9c8e"
      unitRef="usd">16636</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo0YmVhZDA4MGY4MzY0YTMwYTExNzAxN2NhMGVhNjFmYy90YWJsZXJhbmdlOjRiZWFkMDgwZjgzNjRhMzBhMTE3MDE3Y2EwZWE2MWZjXzExLTYtMS0xLTA_a17bcde5-b116-4620-b705-cfc1354942f1"
      unitRef="usd">4174889</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90ZXh0cmVnaW9uOjEzZjkwZjc3YzAyNDQxNjY4Njg1ZTQ4OThjOTc1M2Q5XzI1NzI_608c906b-2dd1-47ed-9f3f-b0f51a174b7e">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s effective income tax rate for 2019, 2018 and 2017 reconciles with the federal statutory tax rate as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.179%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal tax expense at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income tax expense (net of federal income tax benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent differences associated with general business credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(148)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzItMi0xLTEtMA_35cf27bf-ad17-41c1-b0ad-74f1c0813c91"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzItNC0xLTEtMA_1319efac-e0c7-4adf-967a-c9cc776557a8"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzItNi0xLTEtMA_e13e30ad-71de-4737-9a32-eb3da7a81ddd"
      unitRef="number">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzMtMi0xLTEtMA_138cec92-6b87-4363-ba9f-50801e5b1286"
      unitRef="number">0.04</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzMtNC0xLTEtMA_ff135586-a00e-4625-b191-03b145624d06"
      unitRef="number">0.04</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzMtNi0xLTEtMA_6592a731-5ade-4d13-ae03-38f3ae61cb37"
      unitRef="number">0.04</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzQtMi0xLTEtMA_167c40d7-533a-4175-8ad3-0c9a52809be8"
      unitRef="number">-0.07</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzQtNC0xLTEtMA_1c819cdc-ce55-4778-ab4b-91ee28d208a2"
      unitRef="number">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzQtNi0xLTEtMA_8ab4e071-f135-41fa-8339-96e8a68bbf4b"
      unitRef="number">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzUtMi0xLTEtMA_af5404c5-f09f-40fe-bbdb-e5ae17079f86"
      unitRef="number">-0.31</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzUtNC0xLTEtMA_86c701dd-3750-4261-84a7-2087ca8185b9"
      unitRef="number">-0.25</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzUtNi0xLTEtMA_8e850abd-dac0-4b52-9ad3-38837c1819b1"
      unitRef="number">-1.48</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzYtMi0xLTEtMA_a19c19d8-ad14-4b79-889f-2799d131519a"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzYtNC0xLTEtMA_801e6a62-5629-41c9-ae8f-33efd0e8a556"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzYtNi0xLTEtMA_acb5931f-886e-44c1-95fe-46a76612b4ab"
      unitRef="number">0.02</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzctMi0xLTEtMA_94f26ded-15ad-4a5e-a84d-b5d323eba687"
      unitRef="number">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzctNC0xLTEtMA_d2de0024-4373-4f02-b9e6-f266329dc5b1"
      unitRef="number">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzctNi0xLTEtMA_c2ba0f95-d506-4ac9-a2ed-41982369ec75"
      unitRef="number">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzgtMi0xLTEtMA_30a540d0-5cef-4fb9-9259-4d69e605738c"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzgtNC0xLTEtMA_a15f5a7b-639f-46fb-84c0-ad129657c7e6"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzgtNi0xLTEtMA_21176e14-81a5-4696-a4ad-f325fd98ea02"
      unitRef="number">-0.02</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzktMi0xLTEtMA_c6545006-3629-4035-9027-6b5373ea8101"
      unitRef="number">0.02</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzktNC0xLTEtMA_54d6e611-471a-4811-b72b-691dfe31d60a"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90YWJsZTo4Yjk5YTJkYmQzNWQ0MzY2YmMzYzVmMGQ1NzJmMjg5OC90YWJsZXJhbmdlOjhiOTlhMmRiZDM1ZDQzNjZiYzNjNWYwZDU3MmYyODk4XzktNi0xLTEtMA_633a5f6e-d62c-4a71-9abd-8887028f95cd"
      unitRef="number">-1.08</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMjkvZnJhZzoxM2Y5MGY3N2MwMjQ0MTY2ODY4NWU0ODk4Yzk3NTNkOS90ZXh0cmVnaW9uOjEzZjkwZjc3YzAyNDQxNjY4Njg1ZTQ4OThjOTc1M2Q5XzE1ODk_59ee451a-1a05-4f73-8090-6b85fe0716dc"
      unitRef="usd">-100000</us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90ZXh0cmVnaW9uOmM5ODUzNWNiMmJkMTQ4N2U4ODgxNTg4MWY0MTI2Y2ZkXzI2MDU_da71b2ea-cf02-41ff-9b70-cfe3525bc71e">Stock-Based Compensation Plans&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has grants outstanding under three equity compensation plans, with two of the plans available for future grants of equity compensation awards to employees, consultants and directors. All of the equity plans were approved by shareholders. The 2007 Long-Term Incentive Compensation Plan (the "2007 Plan") and the 2007 Directors&#x2019; Incentive Plan (the "Directors&#x2019; Plan") superseded the 1999 Stock Option Plan. The 2007 Plan and the Directors&#x2019; Plan provide for the issuance of stock options, stock appreciation rights and restricted stock. Vesting is determined on a grant-by-grant basis in accordance with the terms of the plans and the related grant agreements. The Company has reserved 2.4 million shares of common stock for issuance under the 2007 Plan and 250,000 shares for issuance under the Directors&#x2019; Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The exercise price of stock options is generally 100% of the fair market value of the underlying common stock on the grant date. The maximum contractual term of stock options is ten years from the date of grant, except for incentive stock options granted to 10% shareholders, which is five years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2011, the Company began issuing shares of restricted stock with no exercise price to employees and directors. Restricted stock issued to employees generally cliff-vests on the &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90ZXh0cmVnaW9uOmM5ODUzNWNiMmJkMTQ4N2U4ODgxNTg4MWY0MTI2Y2ZkXzQzOTgwNDY1MTM3MjU_e4aa551b-a49e-47c8-ae2e-da92a179d352"&gt;four&lt;/span&gt;th anniversary of the date of grant. Restricted stock issued to directors vests on the one year anniversary of the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock compensation expense is presented as a component of general and administrative expense in the consolidated statements of operations. Stock compensation expense consisted of the following for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.179%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation - employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,481,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,244,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,032,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation - nonemployees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation - foundation contribution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,485,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,364,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,487,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2019, there was approximately $2.1 million of unrecognized compensation cost related to share-based payments, which is expected to be recognized over a weighted-average period of 2.5 years. This amount relates primarily to unrecognized compensation cost for employee restricted stock awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity for 2019 and 2018 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.064%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.487%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.867%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.867%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.024%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.867%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.024%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.867%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-average exercise price per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;term&#160;(years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,800)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not grant any stock options and there were no options exercised during 2019, 2018 and 2017.    Information related to the stock option plans during 2019, 2018 and 2017 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.179%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intrinsic value of options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average fair value of &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;options exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock activity was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:70.192%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.731%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;of shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;grant-date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested, December&#160;31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;767,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(170,759)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,025)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested, December&#160;31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;833,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(225,536)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,925)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested, December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;814,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The fair value of restricted stock granted was based on the closing market price of the Company&#x2019;s common stock on the date of grant.  The restricted stock grants are included in the diluted weighted shares outstanding computation until they cliff-vest.  Once vested they are included in the basic weighted shares outstanding computation.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90ZXh0cmVnaW9uOmM5ODUzNWNiMmJkMTQ4N2U4ODgxNTg4MWY0MTI2Y2ZkXzgy_4305a45a-f0b4-4d26-a1d4-6ab6c408cfe3"
      unitRef="plan">3</cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans>
    <cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90ZXh0cmVnaW9uOmM5ODUzNWNiMmJkMTQ4N2U4ODgxNTg4MWY0MTI2Y2ZkXzExNw_f9bcc741-4b3c-4e72-976c-7420fafb6b48"
      unitRef="plan">2</cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i4da90f76e4104888a18e3d18b29d9b37_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90ZXh0cmVnaW9uOmM5ODUzNWNiMmJkMTQ4N2U4ODgxNTg4MWY0MTI2Y2ZkXzczMg_3b1a3b07-e184-43ed-9411-bea5fe893884"
      unitRef="shares">2400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i198eca0df24c455580fe1f7aad3d37bf_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90ZXh0cmVnaW9uOmM5ODUzNWNiMmJkMTQ4N2U4ODgxNTg4MWY0MTI2Y2ZkXzc5NQ_95b0d5c0-e137-4435-af02-8810b03b157b"
      unitRef="shares">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue
      contextRef="i61c32b7b06154a0caffb1b27ffd29a90_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90ZXh0cmVnaW9uOmM5ODUzNWNiMmJkMTQ4N2U4ODgxNTg4MWY0MTI2Y2ZkXzg5NA_f7b5b143-2134-425d-b243-5c379bc37ea5"
      unitRef="number">1</cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ib15a6538ecd34529a63f571722d0a1c9_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90ZXh0cmVnaW9uOmM5ODUzNWNiMmJkMTQ4N2U4ODgxNTg4MWY0MTI2Y2ZkXzEwMjE_2d2c2cc1-a1d6-4f1e-808d-73167c932bff">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="id6083199dd2a42f391637d804e105c86_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90ZXh0cmVnaW9uOmM5ODUzNWNiMmJkMTQ4N2U4ODgxNTg4MWY0MTI2Y2ZkXzExMjA_20098c88-cdae-4ca4-bf14-16d25e2b6047">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i6325bab52b3e497181b41d02564bc694_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90ZXh0cmVnaW9uOmM5ODUzNWNiMmJkMTQ4N2U4ODgxNTg4MWY0MTI2Y2ZkXzEzOTQ_07191cc5-aad9-4334-b890-51f181b246fb">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90ZXh0cmVnaW9uOmM5ODUzNWNiMmJkMTQ4N2U4ODgxNTg4MWY0MTI2Y2ZkXzI2MDY_55ea4a30-289f-46fa-9de2-ff4d5f2bd7fb">Stock compensation expense consisted of the following for the years ended December 31:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.179%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation - employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,481,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,244,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,032,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation - nonemployees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation - foundation contribution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,485,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,364,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,487,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ifc452512a3cb412faa57ddaf029b98df_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTpmNGFjMWRjNzE3YTE0OTZhOThkMDZjYjNlZDdhYmFkMy90YWJsZXJhbmdlOmY0YWMxZGM3MTdhMTQ5NmE5OGQwNmNiM2VkN2FiYWQzXzItMi0xLTEtMA_66f7ec89-d16c-4ce7-a470-ca66cb60316f"
      unitRef="usd">1481016</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6e05d70302894bebb067dddab8121842_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTpmNGFjMWRjNzE3YTE0OTZhOThkMDZjYjNlZDdhYmFkMy90YWJsZXJhbmdlOmY0YWMxZGM3MTdhMTQ5NmE5OGQwNmNiM2VkN2FiYWQzXzItNC0xLTEtMA_28194da9-1a10-4420-81aa-65c0fb102173"
      unitRef="usd">1244606</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i2699606b9dca4e75864d2ce5471d263f_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTpmNGFjMWRjNzE3YTE0OTZhOThkMDZjYjNlZDdhYmFkMy90YWJsZXJhbmdlOmY0YWMxZGM3MTdhMTQ5NmE5OGQwNmNiM2VkN2FiYWQzXzItNi0xLTEtMA_459fff74-c382-47b7-9286-b61d6bc619a8"
      unitRef="usd">1032094</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7baa6ff5d72047a0ada0ed31a5bb2e5f_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTpmNGFjMWRjNzE3YTE0OTZhOThkMDZjYjNlZDdhYmFkMy90YWJsZXJhbmdlOmY0YWMxZGM3MTdhMTQ5NmE5OGQwNmNiM2VkN2FiYWQzXzMtMi0xLTEtMA_3d070447-0c46-4f51-ac59-0781af2afdcc"
      unitRef="usd">4882</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic70796d261de4b7785011e9a52b6ab8b_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTpmNGFjMWRjNzE3YTE0OTZhOThkMDZjYjNlZDdhYmFkMy90YWJsZXJhbmdlOmY0YWMxZGM3MTdhMTQ5NmE5OGQwNmNiM2VkN2FiYWQzXzMtNC0xLTEtMA_c546247d-4fdf-4c09-a65c-771a6ebc462e"
      unitRef="usd">120092</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i5a9593962195492199a34a509d355036_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTpmNGFjMWRjNzE3YTE0OTZhOThkMDZjYjNlZDdhYmFkMy90YWJsZXJhbmdlOmY0YWMxZGM3MTdhMTQ5NmE5OGQwNmNiM2VkN2FiYWQzXzMtNi0xLTEtMA_288e9825-bdd3-4c18-b3ca-9f692c7a97c8"
      unitRef="usd">82969</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if432a686a41c4c4494b432b8de61cfd0_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTpmNGFjMWRjNzE3YTE0OTZhOThkMDZjYjNlZDdhYmFkMy90YWJsZXJhbmdlOmY0YWMxZGM3MTdhMTQ5NmE5OGQwNmNiM2VkN2FiYWQzXzQtMi0xLTEtMA_bb3e27da-8a07-4bf1-b126-7bc95bc3f55f"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie1758466063744cb928ad1f2170609f0_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTpmNGFjMWRjNzE3YTE0OTZhOThkMDZjYjNlZDdhYmFkMy90YWJsZXJhbmdlOmY0YWMxZGM3MTdhMTQ5NmE5OGQwNmNiM2VkN2FiYWQzXzQtNC0xLTEtMA_c9630034-14c4-40db-9e19-0fda12c57996"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9ab32de2ce97414b8fa9e5599fbaa6c9_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTpmNGFjMWRjNzE3YTE0OTZhOThkMDZjYjNlZDdhYmFkMy90YWJsZXJhbmdlOmY0YWMxZGM3MTdhMTQ5NmE5OGQwNmNiM2VkN2FiYWQzXzQtNi0xLTEtMA_77f30564-8627-43db-9da8-975aa427bae3"
      unitRef="usd">372500</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic7a81f8fb9634254a32248497adf8453_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTpmNGFjMWRjNzE3YTE0OTZhOThkMDZjYjNlZDdhYmFkMy90YWJsZXJhbmdlOmY0YWMxZGM3MTdhMTQ5NmE5OGQwNmNiM2VkN2FiYWQzXzUtMi0xLTEtMA_c532267c-4b95-42d1-a8f0-7e56de94478a"
      unitRef="usd">1485898</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i1709635ce5bd48ef8b8e1c0e99885c21_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTpmNGFjMWRjNzE3YTE0OTZhOThkMDZjYjNlZDdhYmFkMy90YWJsZXJhbmdlOmY0YWMxZGM3MTdhMTQ5NmE5OGQwNmNiM2VkN2FiYWQzXzUtNC0xLTEtMA_7dc8e50d-fe71-4f04-848b-9e9756ffe994"
      unitRef="usd">1364698</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia61891dab2a04a62b49d997680aed24e_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTpmNGFjMWRjNzE3YTE0OTZhOThkMDZjYjNlZDdhYmFkMy90YWJsZXJhbmdlOmY0YWMxZGM3MTdhMTQ5NmE5OGQwNmNiM2VkN2FiYWQzXzUtNi0xLTEtMA_a9cf2c78-df00-4cae-8ec1-88891f790db6"
      unitRef="usd">1487563</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90ZXh0cmVnaW9uOmM5ODUzNWNiMmJkMTQ4N2U4ODgxNTg4MWY0MTI2Y2ZkXzE2OTE_53607470-df5b-4e50-b9b2-484d23977de8"
      unitRef="usd">2100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90ZXh0cmVnaW9uOmM5ODUzNWNiMmJkMTQ4N2U4ODgxNTg4MWY0MTI2Y2ZkXzE4MzA_4b05d323-c5f8-4815-a079-326299e849db">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90ZXh0cmVnaW9uOmM5ODUzNWNiMmJkMTQ4N2U4ODgxNTg4MWY0MTI2Y2ZkXzI2MTE_07deee4d-3464-479f-91cf-2113cca1e983">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity for 2019 and 2018 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.064%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.487%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.867%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.867%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.024%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.867%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.024%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.867%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-average exercise price per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;term&#160;(years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,800)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i19f7709a57f34358b074d8ab2cd1410f_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzItMi0xLTEtMA_ff787876-b904-4bd2-9740-b29d2cc3983f"
      unitRef="shares">5800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i19f7709a57f34358b074d8ab2cd1410f_I20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzItNC0xLTEtMA_6f7b7813-69e0-46d0-996a-15bd0272f03c"
      unitRef="usdPerShare">13.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzItNi0xLTEtMA_aacdc01e-8098-4fb4-a3a3-6dc4e101dfaf">P1Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i19f7709a57f34358b074d8ab2cd1410f_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzItOC0xLTEtMA_3408d4ba-796a-47a2-afd2-7264f53d49fa"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzMtMi0xLTEtMA_e0ef69dd-4a89-4456-a28d-462fde26ed4a"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzMtNC0xLTEtMA_eed8bcf8-c93f-4b51-9157-d28c224e9e43"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzQtMi0xLTEtMA_beaf584d-16cc-4821-a1f7-4e211b53b72a"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzQtNC0xLTEtMA_1418af03-7c02-4e2f-a9eb-15ec34720f3c"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzUtMi0xLTEtMA_0351c260-393a-4b98-be17-9726f668b266"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzUtNC0xLTEtMA_1e8cd30b-4686-471c-a147-f556bb780897"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzYtMi0xLTEtMA_eb4648b3-6a22-4535-a554-fb8736f1bc63"
      unitRef="shares">5800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzYtNC0xLTEtMA_793e5c01-4901-4d67-8335-e0730550df28"
      unitRef="usdPerShare">13.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzYtNi0xLTEtMA_37613700-15b3-4785-bb36-b1dc129c5c0a">P0Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzYtOC0xLTEtMA_8b2c2911-e484-41db-8453-f67a21051ef5"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzctMi0xLTEtMA_8adde812-f96c-4a8f-babf-91c41c13f464"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzctNC0xLTEtMA_afa9bb41-9953-4d99-9fde-10133e6e8487"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzgtMi0xLTEtMA_b93269bf-da6c-414c-8f2a-29c3778d8577"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzgtNC0xLTEtMA_af4663eb-06f2-41df-ae1f-73721645f29b"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzktMi0xLTEtMA_5ea12e63-0231-44bc-a395-7521525e302e"
      unitRef="shares">5800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzktNC0xLTEtMA_1e4c9eee-4835-481c-995f-0b3e7558b4ae"
      unitRef="usdPerShare">13.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzEwLTItMS0xLTA_ea8dfe25-6a46-49ab-8818-008a4b9c4305"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzEwLTQtMS0xLTA_e9c8a6be-5999-4bd3-a7e3-3af49db80878"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzEwLTYtMS0xLTA_58737b61-fd9a-4cbc-9f4c-35e1a74ecac5">P0Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzEwLTgtMS0xLTA_a20d215f-98fb-4a54-89f1-4b079a8238cc"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzExLTItMS0xLTA_73aac9f4-cda5-43f2-b8ce-b359a279c123"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzExLTQtMS0xLTA_25a2b49b-0f1e-49ec-ab98-8649087083c5"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzExLTYtMS0xLTA_c10fba42-15d2-4ee9-9e8e-ef348c10eafc">P0Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo4ZDg5OGViYWJjODY0MDJhYmI3ZGY0ZDY4NWViODQ0My90YWJsZXJhbmdlOjhkODk4ZWJhYmM4NjQwMmFiYjdkZjRkNjg1ZWI4NDQzXzExLTgtMS0xLTA_473b98c9-3d16-415e-9229-9309e036deb1"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <cpix:ScheduleOfStockOptionActivityAdditionalDisclosuresTableTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90ZXh0cmVnaW9uOmM5ODUzNWNiMmJkMTQ4N2U4ODgxNTg4MWY0MTI2Y2ZkXzI2MTI_80d53551-e9a2-47b1-843c-8f21a520b996">Information related to the stock option plans during 2019, 2018 and 2017 was as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.179%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intrinsic value of options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average fair value of &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;options exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</cpix:ScheduleOfStockOptionActivityAdditionalDisclosuresTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo2MTIzYmUzODFhMjg0YTA3OTYxYTJmYzY5MTFmMzdjOS90YWJsZXJhbmdlOjYxMjNiZTM4MWEyODRhMDc5NjFhMmZjNjkxMWYzN2M5XzItMi0xLTEtMA_537c757e-55b5-48bf-950a-2354ad019035"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo2MTIzYmUzODFhMjg0YTA3OTYxYTJmYzY5MTFmMzdjOS90YWJsZXJhbmdlOjYxMjNiZTM4MWEyODRhMDc5NjFhMmZjNjkxMWYzN2M5XzItNC0xLTEtMA_395d7707-b037-4a31-9568-18731ac1786a"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo2MTIzYmUzODFhMjg0YTA3OTYxYTJmYzY5MTFmMzdjOS90YWJsZXJhbmdlOjYxMjNiZTM4MWEyODRhMDc5NjFhMmZjNjkxMWYzN2M5XzItNi0xLTEtMA_af121955-5b82-4a13-9ad5-bc9e44e31efa"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo2MTIzYmUzODFhMjg0YTA3OTYxYTJmYzY5MTFmMzdjOS90YWJsZXJhbmdlOjYxMjNiZTM4MWEyODRhMDc5NjFhMmZjNjkxMWYzN2M5XzMtMi0xLTEtMA_8918a396-377d-4ae5-b92a-5519df8deacd"
      unitRef="usdPerShare">0</cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue>
    <cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo2MTIzYmUzODFhMjg0YTA3OTYxYTJmYzY5MTFmMzdjOS90YWJsZXJhbmdlOjYxMjNiZTM4MWEyODRhMDc5NjFhMmZjNjkxMWYzN2M5XzMtNC0xLTEtMA_5166a711-aedc-421a-be56-bb988be8dce9"
      unitRef="usdPerShare">0</cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue>
    <cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZTo2MTIzYmUzODFhMjg0YTA3OTYxYTJmYzY5MTFmMzdjOS90YWJsZXJhbmdlOjYxMjNiZTM4MWEyODRhMDc5NjFhMmZjNjkxMWYzN2M5XzMtNi0xLTEtMA_97877c33-8ee5-47fb-a1fe-ab36d4dc2661"
      unitRef="usdPerShare">0</cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90ZXh0cmVnaW9uOmM5ODUzNWNiMmJkMTQ4N2U4ODgxNTg4MWY0MTI2Y2ZkXzI2MTM_f7c37146-e2bb-40f3-bf2b-5ef25c1d26a3">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock activity was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:70.192%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.731%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;of shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;grant-date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested, December&#160;31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;767,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(170,759)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,025)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested, December&#160;31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;833,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(225,536)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,925)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested, December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;814,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="iaaaacea9a57e4e758bc406a2ecaef76a_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZToxNzNmMzBmNTYzZGM0NTY2OTZmZDAyOTMwMDU4ZjM4NC90YWJsZXJhbmdlOjE3M2YzMGY1NjNkYzQ1NjY5NmZkMDI5MzAwNThmMzg0XzItMi0xLTEtMA_5174af03-0e47-4708-bfc6-639212cb6e7a"
      unitRef="shares">767845</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="iaaaacea9a57e4e758bc406a2ecaef76a_I20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZToxNzNmMzBmNTYzZGM0NTY2OTZmZDAyOTMwMDU4ZjM4NC90YWJsZXJhbmdlOjE3M2YzMGY1NjNkYzQ1NjY5NmZkMDI5MzAwNThmMzg0XzItNC0xLTEtMA_926ddb5a-7725-4c07-b62f-0afce799d113"
      unitRef="usdPerShare">5.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i1a46cecd6d924e33bda5ccdd4c0e3b43_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZToxNzNmMzBmNTYzZGM0NTY2OTZmZDAyOTMwMDU4ZjM4NC90YWJsZXJhbmdlOjE3M2YzMGY1NjNkYzQ1NjY5NmZkMDI5MzAwNThmMzg0XzMtMi0xLTEtMA_2950469b-bf23-4581-be29-3e1387430e97"
      unitRef="shares">261680</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1a46cecd6d924e33bda5ccdd4c0e3b43_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZToxNzNmMzBmNTYzZGM0NTY2OTZmZDAyOTMwMDU4ZjM4NC90YWJsZXJhbmdlOjE3M2YzMGY1NjNkYzQ1NjY5NmZkMDI5MzAwNThmMzg0XzMtNC0xLTEtMA_30ad9194-da0e-4a31-981b-8cb5e5dd2625"
      unitRef="usdPerShare">6.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i1a46cecd6d924e33bda5ccdd4c0e3b43_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZToxNzNmMzBmNTYzZGM0NTY2OTZmZDAyOTMwMDU4ZjM4NC90YWJsZXJhbmdlOjE3M2YzMGY1NjNkYzQ1NjY5NmZkMDI5MzAwNThmMzg0XzQtMi0xLTEtMA_91f64a8c-8a7d-4b2f-82af-666aab61d864"
      unitRef="shares">170759</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1a46cecd6d924e33bda5ccdd4c0e3b43_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZToxNzNmMzBmNTYzZGM0NTY2OTZmZDAyOTMwMDU4ZjM4NC90YWJsZXJhbmdlOjE3M2YzMGY1NjNkYzQ1NjY5NmZkMDI5MzAwNThmMzg0XzQtNC0xLTEtMA_fbe2688d-40f8-4846-aef2-83e54e822e61"
      unitRef="usdPerShare">4.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i1a46cecd6d924e33bda5ccdd4c0e3b43_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZToxNzNmMzBmNTYzZGM0NTY2OTZmZDAyOTMwMDU4ZjM4NC90YWJsZXJhbmdlOjE3M2YzMGY1NjNkYzQ1NjY5NmZkMDI5MzAwNThmMzg0XzUtMi0xLTEtMA_a5bea659-2bac-4dc5-b32b-ccd46c738a7b"
      unitRef="shares">25025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i1a46cecd6d924e33bda5ccdd4c0e3b43_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZToxNzNmMzBmNTYzZGM0NTY2OTZmZDAyOTMwMDU4ZjM4NC90YWJsZXJhbmdlOjE3M2YzMGY1NjNkYzQ1NjY5NmZkMDI5MzAwNThmMzg0XzUtNC0xLTEtMA_abeb256d-0330-44e3-92ce-73aa1734b6c7"
      unitRef="usdPerShare">6.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i84fb9bc25ed941ce90338733d28f5d92_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZToxNzNmMzBmNTYzZGM0NTY2OTZmZDAyOTMwMDU4ZjM4NC90YWJsZXJhbmdlOjE3M2YzMGY1NjNkYzQ1NjY5NmZkMDI5MzAwNThmMzg0XzYtMi0xLTEtMA_58d5e26d-9b40-43c7-bb85-dda1ecf3a814"
      unitRef="shares">833741</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i84fb9bc25ed941ce90338733d28f5d92_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZToxNzNmMzBmNTYzZGM0NTY2OTZmZDAyOTMwMDU4ZjM4NC90YWJsZXJhbmdlOjE3M2YzMGY1NjNkYzQ1NjY5NmZkMDI5MzAwNThmMzg0XzYtNC0xLTEtMA_9dc733db-1072-424c-a5e3-5884b58f2951"
      unitRef="usdPerShare">6.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i1fd085fc709647d9997c4b52bdd4cc7c_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZToxNzNmMzBmNTYzZGM0NTY2OTZmZDAyOTMwMDU4ZjM4NC90YWJsZXJhbmdlOjE3M2YzMGY1NjNkYzQ1NjY5NmZkMDI5MzAwNThmMzg0XzctMi0xLTEtMA_a045f346-7b4c-4aee-82ae-eb903b2e3a8c"
      unitRef="shares">229669</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1fd085fc709647d9997c4b52bdd4cc7c_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZToxNzNmMzBmNTYzZGM0NTY2OTZmZDAyOTMwMDU4ZjM4NC90YWJsZXJhbmdlOjE3M2YzMGY1NjNkYzQ1NjY5NmZkMDI5MzAwNThmMzg0XzctNC0xLTEtMA_c7b44d90-8905-4570-8e60-e0926583ff92"
      unitRef="usdPerShare">5.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i1fd085fc709647d9997c4b52bdd4cc7c_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZToxNzNmMzBmNTYzZGM0NTY2OTZmZDAyOTMwMDU4ZjM4NC90YWJsZXJhbmdlOjE3M2YzMGY1NjNkYzQ1NjY5NmZkMDI5MzAwNThmMzg0XzgtMi0xLTEtMA_af9e25e9-2a34-4af7-8685-0bff2a44d18d"
      unitRef="shares">225536</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1fd085fc709647d9997c4b52bdd4cc7c_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZToxNzNmMzBmNTYzZGM0NTY2OTZmZDAyOTMwMDU4ZjM4NC90YWJsZXJhbmdlOjE3M2YzMGY1NjNkYzQ1NjY5NmZkMDI5MzAwNThmMzg0XzgtNC0xLTEtMA_0d928a39-8847-4978-a55c-c987320f50d9"
      unitRef="usdPerShare">6.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i1fd085fc709647d9997c4b52bdd4cc7c_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZToxNzNmMzBmNTYzZGM0NTY2OTZmZDAyOTMwMDU4ZjM4NC90YWJsZXJhbmdlOjE3M2YzMGY1NjNkYzQ1NjY5NmZkMDI5MzAwNThmMzg0XzktMi0xLTEtMA_fe8cc056-7998-4337-a68f-ae468db31906"
      unitRef="shares">22925</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i1fd085fc709647d9997c4b52bdd4cc7c_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZToxNzNmMzBmNTYzZGM0NTY2OTZmZDAyOTMwMDU4ZjM4NC90YWJsZXJhbmdlOjE3M2YzMGY1NjNkYzQ1NjY5NmZkMDI5MzAwNThmMzg0XzktNC0xLTEtMA_77e1d2a7-0653-4957-b588-80f0e467e8f1"
      unitRef="usdPerShare">6.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i38570ddc79c14639aa269d9013600dec_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZToxNzNmMzBmNTYzZGM0NTY2OTZmZDAyOTMwMDU4ZjM4NC90YWJsZXJhbmdlOjE3M2YzMGY1NjNkYzQ1NjY5NmZkMDI5MzAwNThmMzg0XzEwLTItMS0xLTA_5598ce66-406f-4a92-89d1-2ff41e7f68bb"
      unitRef="shares">814949</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i38570ddc79c14639aa269d9013600dec_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90YWJsZToxNzNmMzBmNTYzZGM0NTY2OTZmZDAyOTMwMDU4ZjM4NC90YWJsZXJhbmdlOjE3M2YzMGY1NjNkYzQ1NjY5NmZkMDI5MzAwNThmMzg0XzEwLTQtMS0xLTA_64c16ef1-958f-42da-b27b-b5005f1fba47"
      unitRef="usdPerShare">5.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzgvZnJhZzoyZjQ5ZWM5ZTRhMjk0OGUzYTg5NzZjOGIxYWY3N2JmYi90ZXh0cmVnaW9uOjJmNDllYzllNGEyOTQ4ZTNhODk3NmM4YjFhZjc3YmZiXzEzMjk_bcb415a9-3c94-49fc-bc18-f65b8a8446e1">Employee Benefit Plans&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sponsors an employee benefit plan that was established on January&#160;1, 2006, the Cumberland Pharmaceuticals 401(k) Plan (the&#160;"Plan"), under Section&#160;401(k) of the Internal Revenue Code of 1986, as amended, for the benefit of all employees over the age of 21, having been employed by the Company for at least six months. The Plan provides that participants may contribute up to the maximum amount of their compensation as set forth by the Internal Revenue Service each year. Employee contributions are invested in various investment funds based upon elections made by the employees. During 2019, 2018 and 2017, the Company contributed approximately $50,000 in each year to the Plan as an employer match of participant contributions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2012 and 2013, the Company established non-qualified unfunded deferred compensation plans that allow participants to defer receipt of a portion of their compensation. The liability under the plans, reflected in other long term liabilities in the consolidated balance sheet, was $2.3 million and $1.6 million as of December&#160;31, 2019 and 2018, respectively.  The Company had assets consisting of company-owned life insurance contracts generally designated to pay benefits of the deferred compensation plans reflected in other assets in the consolidated balance sheet of $3.1 million and $2.3 million as of December&#160;31, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <cpix:DefinedContributionPlanEligibilityMinimumEmployeeAge
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzgvZnJhZzoyZjQ5ZWM5ZTRhMjk0OGUzYTg5NzZjOGIxYWY3N2JmYi90ZXh0cmVnaW9uOjJmNDllYzllNGEyOTQ4ZTNhODk3NmM4YjFhZjc3YmZiXzI5Nw_ffb4dea3-64cb-4c6f-bf00-2cc44d6796a5">P21Y</cpix:DefinedContributionPlanEligibilityMinimumEmployeeAge>
    <cpix:DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzgvZnJhZzoyZjQ5ZWM5ZTRhMjk0OGUzYTg5NzZjOGIxYWY3N2JmYi90ZXh0cmVnaW9uOjJmNDllYzllNGEyOTQ4ZTNhODk3NmM4YjFhZjc3YmZiXzM1MA_6125691f-2b97-4c22-a7d5-3b4b270a824b">six months</cpix:DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzgvZnJhZzoyZjQ5ZWM5ZTRhMjk0OGUzYTg5NzZjOGIxYWY3N2JmYi90ZXh0cmVnaW9uOjJmNDllYzllNGEyOTQ4ZTNhODk3NmM4YjFhZjc3YmZiXzY3Nw_7ba8b1f2-8b11-4f52-9e76-5f8a33d4078b"
      unitRef="usd">50000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzgvZnJhZzoyZjQ5ZWM5ZTRhMjk0OGUzYTg5NzZjOGIxYWY3N2JmYi90ZXh0cmVnaW9uOjJmNDllYzllNGEyOTQ4ZTNhODk3NmM4YjFhZjc3YmZiXzY3Nw_895b7a3c-49b3-4d89-b375-f7904987730a"
      unitRef="usd">50000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzgvZnJhZzoyZjQ5ZWM5ZTRhMjk0OGUzYTg5NzZjOGIxYWY3N2JmYi90ZXh0cmVnaW9uOjJmNDllYzllNGEyOTQ4ZTNhODk3NmM4YjFhZjc3YmZiXzY3Nw_f4812111-c22d-424a-833e-f0b9dd2a1405"
      unitRef="usd">50000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzgvZnJhZzoyZjQ5ZWM5ZTRhMjk0OGUzYTg5NzZjOGIxYWY3N2JmYi90ZXh0cmVnaW9uOjJmNDllYzllNGEyOTQ4ZTNhODk3NmM4YjFhZjc3YmZiXzEwMzc_7c945c37-f1e3-4cca-b052-db757fef2527"
      unitRef="usd">2300000</us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent
      contextRef="i19f7709a57f34358b074d8ab2cd1410f_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzgvZnJhZzoyZjQ5ZWM5ZTRhMjk0OGUzYTg5NzZjOGIxYWY3N2JmYi90ZXh0cmVnaW9uOjJmNDllYzllNGEyOTQ4ZTNhODk3NmM4YjFhZjc3YmZiXzEwNDQ_e869efec-1bb0-4cff-ab4e-d20ebd8b0005"
      unitRef="usd">1600000</us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationPlanAssets
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzgvZnJhZzoyZjQ5ZWM5ZTRhMjk0OGUzYTg5NzZjOGIxYWY3N2JmYi90ZXh0cmVnaW9uOjJmNDllYzllNGEyOTQ4ZTNhODk3NmM4YjFhZjc3YmZiXzEyOTA_57d2e6b8-ac41-4391-bfa3-61068da0478a"
      unitRef="usd">3100000</us-gaap:DeferredCompensationPlanAssets>
    <us-gaap:DeferredCompensationPlanAssets
      contextRef="i19f7709a57f34358b074d8ab2cd1410f_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzgvZnJhZzoyZjQ5ZWM5ZTRhMjk0OGUzYTg5NzZjOGIxYWY3N2JmYi90ZXh0cmVnaW9uOjJmNDllYzllNGEyOTQ4ZTNhODk3NmM4YjFhZjc3YmZiXzEyOTc_b37e90c5-022c-403e-9a49-0a03137c086e"
      unitRef="usd">2300000</us-gaap:DeferredCompensationPlanAssets>
    <us-gaap:LeasesOfLesseeDisclosureTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90ZXh0cmVnaW9uOmUzNjUzZDFmZjNlMTQ2NTNhZTBjM2I0NzM1ZWQ3NzA4XzQwOTM_321d5c72-6358-4cd6-9466-2840191c542b">Leases&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is obligated under long-term real estate leases for corporate office space that was extended during the third quarter of 2015.  Prior to this extension, the lease would have expired in October 2016, the lease is now set to expire in October 2022. In addition, the research lab space at CET, under an agreement amended in July 2012, is leased through April 2023, with an option to extend the lease through April 2028. The Company also subleases a portion of the space under these leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rent expense is recognized over the expected term of the lease, including renewal option periods, if applicable, on a straight-line basis as a component of general and administrative expense. Rent expense and sublease income  as follows for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.897%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rent expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,246,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,136,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,074,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;688,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;662,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2016, the FASB issued ASU 2016-02. ASU 2016-02&#x2019;s core principle is to increase transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information. The Company adopted ASU 2016-02 under the alternative transition method (the effective date approach). It allowed the Company to initially apply the new lease guidance at the adoption date (rather than at the beginning of the earliest period presented). Prior periods have not been adjusted.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The primary effect of adopting ASU 2016-02 to the Company was to record right-of-use assets and obligations for the leases currently classified as operating leases.  The Company&#x2019;s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters.  This lease currently expires in October 2022.  The operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by Cumberland Emerging Technologies (&#x201c;CET&#x201d;), &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;our majority-owned subsidiary, where it operates the CET Life Sciences Center.  This lease currently expires in April 2023. The Company did not have any leases classified as finance leases at January 1, 2019 or December&#160;31, 2019.  The new lease accounting standard did not have a significant impact on the Company's Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for any period presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company elected the package of practical expedients offered in the transition guidance which allows management not to reassess lease identification, lease classification and initial direct costs at the adoption date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These operating leases resulted in initial ROU assets of $3.6 million and lease liabilities of $3.8 million as of January 1, 2019 for non-cancelable operating leases with original lease terms in excess of one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities were recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As the Company&#x2019;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019. Incremental borrowing rates reflect the Company&#x2019;s estimated interest rates for collateralized borrowings over similar lease terms. The weighted-average remaining lease term is 3.4 years and the weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments is 7.42%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lease Position&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2019, the Company recorded the following on the Condensed Consolidated Balance Sheet: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.688%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.895%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Right-of-Use Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,960,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,960,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:9pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.688%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.895%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;920,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,076,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,996,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumulative future minimum sublease income under non-cancelable operating subleases totals approximately $0.7 million and will be paid through the leases ending in October 2022 and April 2023. Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:66.025%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As of  December&#160;31, 2019:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,120,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,144,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,376,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(379,843)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,996,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's future minimum lease commitments, under Topic 840, predecessor to Topic 842, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:66.025%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As of December 31, 2018:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;959,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;980,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,001,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;871,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,858,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeasesOfLesseeDisclosureTextBlock>
    <cpix:ScheduleofRentExpenseandSubleaseIncomeTableTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90ZXh0cmVnaW9uOmUzNjUzZDFmZjNlMTQ2NTNhZTBjM2I0NzM1ZWQ3NzA4XzQwOTA_25ee5e02-d5be-4e70-a4af-44077790e24e">Rent expense and sublease income  as follows for the years ended December 31:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.897%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rent expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,246,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,136,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,074,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;688,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;662,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</cpix:ScheduleofRentExpenseandSubleaseIncomeTableTextBlock>
    <us-gaap:LeaseAndRentalExpense
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZTo5NGU1YmEyMzA0NDU0MDhlOTBmMGNjMmRhZjYwYzcyZC90YWJsZXJhbmdlOjk0ZTViYTIzMDQ0NTQwOGU5MGYwY2MyZGFmNjBjNzJkXzItMi0xLTEtMA_48666a72-38ba-4039-9a42-164624a53ed9"
      unitRef="usd">1246143</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZTo5NGU1YmEyMzA0NDU0MDhlOTBmMGNjMmRhZjYwYzcyZC90YWJsZXJhbmdlOjk0ZTViYTIzMDQ0NTQwOGU5MGYwY2MyZGFmNjBjNzJkXzItNC0xLTEtMA_3b96ae47-89d1-408f-9604-d7fd9fbd4937"
      unitRef="usd">1136610</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZTo5NGU1YmEyMzA0NDU0MDhlOTBmMGNjMmRhZjYwYzcyZC90YWJsZXJhbmdlOjk0ZTViYTIzMDQ0NTQwOGU5MGYwY2MyZGFmNjBjNzJkXzItNi0xLTEtMA_0dd68030-ebda-4a88-8fd5-5589483ce815"
      unitRef="usd">1074437</us-gaap:LeaseAndRentalExpense>
    <us-gaap:OperatingLeasesRentExpenseSubleaseRentals1
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZTo5NGU1YmEyMzA0NDU0MDhlOTBmMGNjMmRhZjYwYzcyZC90YWJsZXJhbmdlOjk0ZTViYTIzMDQ0NTQwOGU5MGYwY2MyZGFmNjBjNzJkXzQtMi0xLTEtMA_f2b7d75b-4f92-422d-b61f-ecc24c419cfa"
      unitRef="usd">688020</us-gaap:OperatingLeasesRentExpenseSubleaseRentals1>
    <us-gaap:OperatingLeasesRentExpenseSubleaseRentals1
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZTo5NGU1YmEyMzA0NDU0MDhlOTBmMGNjMmRhZjYwYzcyZC90YWJsZXJhbmdlOjk0ZTViYTIzMDQ0NTQwOGU5MGYwY2MyZGFmNjBjNzJkXzQtNC0xLTEtMA_4097c033-4876-404f-881f-19329a5d026a"
      unitRef="usd">662358</us-gaap:OperatingLeasesRentExpenseSubleaseRentals1>
    <us-gaap:OperatingLeasesRentExpenseSubleaseRentals1
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZTo5NGU1YmEyMzA0NDU0MDhlOTBmMGNjMmRhZjYwYzcyZC90YWJsZXJhbmdlOjk0ZTViYTIzMDQ0NTQwOGU5MGYwY2MyZGFmNjBjNzJkXzQtNi0xLTEtMA_17792eb2-cffb-4722-aba2-8751a4c233fb"
      unitRef="usd">573494</us-gaap:OperatingLeasesRentExpenseSubleaseRentals1>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i76f168e8263b4700be275c05007c5731_I20190101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90ZXh0cmVnaW9uOmUzNjUzZDFmZjNlMTQ2NTNhZTBjM2I0NzM1ZWQ3NzA4XzI1NzU_821200ae-cea4-4d10-a6f0-d0dff9538994"
      unitRef="usd">3600000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="i76f168e8263b4700be275c05007c5731_I20190101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90ZXh0cmVnaW9uOmUzNjUzZDFmZjNlMTQ2NTNhZTBjM2I0NzM1ZWQ3NzA4XzI2MTE_826d6d1e-074a-484c-9f3f-4e54e97931e2"
      unitRef="usd">3800000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90ZXh0cmVnaW9uOmUzNjUzZDFmZjNlMTQ2NTNhZTBjM2I0NzM1ZWQ3NzA4XzMzOTg_a832540a-a7f6-4666-9a25-5b445cfc7ddb">P3Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90ZXh0cmVnaW9uOmUzNjUzZDFmZjNlMTQ2NTNhZTBjM2I0NzM1ZWQ3NzA4XzM1Mjk_e0e24d9f-6802-47a2-ae84-a34578a9f0fd"
      unitRef="number">0.0742</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <cpix:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90ZXh0cmVnaW9uOmUzNjUzZDFmZjNlMTQ2NTNhZTBjM2I0NzM1ZWQ3NzA4XzQwOTY_9388c2cf-5d4c-42e3-8452-7e383f006436">&lt;div style="margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2019, the Company recorded the following on the Condensed Consolidated Balance Sheet: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.688%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.895%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Right-of-Use Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,960,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,960,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:9pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.688%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.895%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;920,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,076,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,996,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cpix:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZTo1NmU3YTY5NTgyNzI0NWNhYTVjOGU0ZDQxZWMwZGI3NC90YWJsZXJhbmdlOjU2ZTdhNjk1ODI3MjQ1Y2FhNWM4ZTRkNDFlYzBkYjc0XzEtNC0xLTEtMA_a06c5635-aaf0-43dd-ac84-fa1c82605c7f"
      unitRef="usd">2960569</us-gaap:OperatingLeaseRightOfUseAsset>
    <cpix:LeaseAsset
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZTo1NmU3YTY5NTgyNzI0NWNhYTVjOGU0ZDQxZWMwZGI3NC90YWJsZXJhbmdlOjU2ZTdhNjk1ODI3MjQ1Y2FhNWM4ZTRkNDFlYzBkYjc0XzItNC0xLTEtMA_5539eee7-858d-4f68-9fe2-13e897add44b"
      unitRef="usd">2960569</cpix:LeaseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZToyNTY3MjUyODlhYzg0YzQ4YjYwOTA5MjQwOWI5NDJkZC90YWJsZXJhbmdlOjI1NjcyNTI4OWFjODRjNDhiNjA5MDkyNDA5Yjk0MmRkXzItNC0xLTEtMA_df5aa16a-3f4d-4ce0-8629-93c92284d5b5"
      unitRef="usd">920431</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZToyNTY3MjUyODlhYzg0YzQ4YjYwOTA5MjQwOWI5NDJkZC90YWJsZXJhbmdlOjI1NjcyNTI4OWFjODRjNDhiNjA5MDkyNDA5Yjk0MmRkXzQtNC0xLTEtMA_a4d7f5e1-32b5-48f9-b012-ef3a86f43da5"
      unitRef="usd">2076472</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <cpix:LeaseLiability
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZToyNTY3MjUyODlhYzg0YzQ4YjYwOTA5MjQwOWI5NDJkZC90YWJsZXJhbmdlOjI1NjcyNTI4OWFjODRjNDhiNjA5MDkyNDA5Yjk0MmRkXzUtNC0xLTEtMA_e12c3d43-e833-4c25-8dba-031db9945708"
      unitRef="usd">2996903</cpix:LeaseLiability>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90ZXh0cmVnaW9uOmUzNjUzZDFmZjNlMTQ2NTNhZTBjM2I0NzM1ZWQ3NzA4XzM3NTU_836b6d99-09f3-42a6-834b-d1589b5b0704"
      unitRef="usd">700000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90ZXh0cmVnaW9uOmUzNjUzZDFmZjNlMTQ2NTNhZTBjM2I0NzM1ZWQ3NzA4XzQwOTc_7470d323-d776-48a6-8d9c-8dbe70f0fb30">Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:66.025%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As of  December&#160;31, 2019:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,120,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,144,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,376,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(379,843)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,996,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZToyMzQ0NjI1YTFkZjU0NmMyYWMyZmJlYmZkNjVkYTBmYy90YWJsZXJhbmdlOjIzNDQ2MjVhMWRmNTQ2YzJhYzJmYmViZmQ2NWRhMGZjXzEtMi0xLTEtMA_696c5063-440d-4d11-bdae-725f0f6b5f94"
      unitRef="usd">1120066</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZToyMzQ0NjI1YTFkZjU0NmMyYWMyZmJlYmZkNjVkYTBmYy90YWJsZXJhbmdlOjIzNDQ2MjVhMWRmNTQ2YzJhYzJmYmViZmQ2NWRhMGZjXzItMi0xLTEtMA_18d37495-90a7-433a-a043-e65cc09b5d6c"
      unitRef="usd">1144889</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZToyMzQ0NjI1YTFkZjU0NmMyYWMyZmJlYmZkNjVkYTBmYy90YWJsZXJhbmdlOjIzNDQ2MjVhMWRmNTQ2YzJhYzJmYmViZmQ2NWRhMGZjXzMtMi0xLTEtMA_7f5d2529-9b1d-48b4-9a9a-b1cc6d333ddf"
      unitRef="usd">1019313</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZToyMzQ0NjI1YTFkZjU0NmMyYWMyZmJlYmZkNjVkYTBmYy90YWJsZXJhbmdlOjIzNDQ2MjVhMWRmNTQ2YzJhYzJmYmViZmQ2NWRhMGZjXzQtMi0xLTEtMA_0b1f0e8f-6090-4d6f-887a-4449e4f90ec3"
      unitRef="usd">92478</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZToyMzQ0NjI1YTFkZjU0NmMyYWMyZmJlYmZkNjVkYTBmYy90YWJsZXJhbmdlOjIzNDQ2MjVhMWRmNTQ2YzJhYzJmYmViZmQ2NWRhMGZjXzUtMi0xLTEtMA_b42dd05f-1c6e-4e40-a3be-07d01228851c"
      unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZToyMzQ0NjI1YTFkZjU0NmMyYWMyZmJlYmZkNjVkYTBmYy90YWJsZXJhbmdlOjIzNDQ2MjVhMWRmNTQ2YzJhYzJmYmViZmQ2NWRhMGZjXzYtMi0xLTEtMA_bd60ed1a-9a69-492f-b03a-bd7afdd4f7da"
      unitRef="usd">3376746</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZToyMzQ0NjI1YTFkZjU0NmMyYWMyZmJlYmZkNjVkYTBmYy90YWJsZXJhbmdlOjIzNDQ2MjVhMWRmNTQ2YzJhYzJmYmViZmQ2NWRhMGZjXzctMi0xLTEtMA_7f6c3cb8-a190-4b24-aa61-32daf8651111"
      unitRef="usd">379843</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZToyMzQ0NjI1YTFkZjU0NmMyYWMyZmJlYmZkNjVkYTBmYy90YWJsZXJhbmdlOjIzNDQ2MjVhMWRmNTQ2YzJhYzJmYmViZmQ2NWRhMGZjXzgtMi0xLTEtMA_7f455002-2170-4d8d-ac83-bfdeebb7f848"
      unitRef="usd">2996903</us-gaap:OperatingLeaseLiability>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90ZXh0cmVnaW9uOmUzNjUzZDFmZjNlMTQ2NTNhZTBjM2I0NzM1ZWQ3NzA4XzQwOTI_9287e05a-8697-45ef-b313-a5c0544eeb08">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's future minimum lease commitments, under Topic 840, predecessor to Topic 842, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:66.025%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As of December 31, 2018:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;959,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;980,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,001,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;871,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,858,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZTo3OWU1ZjFiZTViMGE0MTk0ODllNTZkNGM3NDg5MTY2Ny90YWJsZXJhbmdlOjc5ZTVmMWJlNWIwYTQxOTQ4OWU1NmQ0Yzc0ODkxNjY3XzEtMi0xLTEtMA_b56645fa-5493-42ec-9652-c6144cd77dd3"
      unitRef="usd">959902</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZTo3OWU1ZjFiZTViMGE0MTk0ODllNTZkNGM3NDg5MTY2Ny90YWJsZXJhbmdlOjc5ZTVmMWJlNWIwYTQxOTQ4OWU1NmQ0Yzc0ODkxNjY3XzItMi0xLTEtMA_a0ced345-22dd-4460-aac1-f37d6314373a"
      unitRef="usd">980720</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZTo3OWU1ZjFiZTViMGE0MTk0ODllNTZkNGM3NDg5MTY2Ny90YWJsZXJhbmdlOjc5ZTVmMWJlNWIwYTQxOTQ4OWU1NmQ0Yzc0ODkxNjY3XzMtMi0xLTEtMA_b3644dd3-81a1-4418-8cbe-1797ac2df2cf"
      unitRef="usd">1001603</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZTo3OWU1ZjFiZTViMGE0MTk0ODllNTZkNGM3NDg5MTY2Ny90YWJsZXJhbmdlOjc5ZTVmMWJlNWIwYTQxOTQ4OWU1NmQ0Yzc0ODkxNjY3XzQtMi0xLTEtMA_55d49403-cdfb-4635-af72-fb10b37ec1cb"
      unitRef="usd">871969</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZTo3OWU1ZjFiZTViMGE0MTk0ODllNTZkNGM3NDg5MTY2Ny90YWJsZXJhbmdlOjc5ZTVmMWJlNWIwYTQxOTQ4OWU1NmQ0Yzc0ODkxNjY3XzUtMi0xLTEtMA_3cc1d5da-2201-42cf-bdbb-df71f459e04b"
      unitRef="usd">44508</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZTo3OWU1ZjFiZTViMGE0MTk0ODllNTZkNGM3NDg5MTY2Ny90YWJsZXJhbmdlOjc5ZTVmMWJlNWIwYTQxOTQ4OWU1NmQ0Yzc0ODkxNjY3XzYtMi0xLTEtMA_a5a53be2-7b17-40c6-9c6a-c9ab4e11bcc5"
      unitRef="usd">0</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDQvZnJhZzplMzY1M2QxZmYzZTE0NjUzYWUwYzNiNDczNWVkNzcwOC90YWJsZTo3OWU1ZjFiZTViMGE0MTk0ODllNTZkNGM3NDg5MTY2Ny90YWJsZXJhbmdlOjc5ZTVmMWJlNWIwYTQxOTQ4OWU1NmQ0Yzc0ODkxNjY3XzctMi0xLTEtMA_85fe2864-6084-431c-98e5-115435f65ec3"
      unitRef="usd">3858702</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90ZXh0cmVnaW9uOmI2NzI1N2RkNDIzNDQ0NDhiNDFiOThlODljYjljMmQ5XzY4OA_ac9ccd25-f4f8-4c7a-8510-e1a871cbf234">Fair Value of Financial Instruments&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company owns marketable securities that are solely classified as trading securities as of December&#160;31, 2019.  All of these securities had a maturity date of less than ninety days and classified as cash and cash equivalents at December&#160;31, 2019.  There were no transfers of assets between levels within the fair value hierarchy. The following table summarizes the fair value of these marketable securities by level within the fair value hierarchy:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,034,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,034,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;SBA loan pools - variable rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,504,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,504,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term cash investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;751,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;751,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial Paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,119,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,119,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,119,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,119,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,034,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,255,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,290,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The fair values of all other financial instruments outstanding as of December&#160;31, 2019 and 2018 approximate their carrying values.  There were no changes to the valuation techniques for the Level 2 marketable securities during 2019 or 2018.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90ZXh0cmVnaW9uOmI2NzI1N2RkNDIzNDQ0NDhiNDFiOThlODljYjljMmQ5XzY5MA_a6bea589-844b-4191-b4f0-48022b1b27cd">The following table summarizes the fair value of these marketable securities by level within the fair value hierarchy:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,034,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,034,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;SBA loan pools - variable rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,504,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,504,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term cash investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;751,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;751,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial Paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,119,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,119,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,119,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,119,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,034,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,255,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,290,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:TradingSecurities
      contextRef="i46b68c95812c4585ad2800f7e762d7ef_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzMtMi0xLTEtMA_2ed0c55d-5063-4ce7-aa21-f78f450843b2"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i6967c2f466014730a8901a2bbff4743a_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzMtNC0xLTEtMA_d14b847c-0539-475b-8e88-f0c7f2062637"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="idcaec0f707064e14843280c588b63de9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzMtNi0xLTEtMA_39e68ade-dfa4-4133-9a55-ff8c8f8dddfa"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="if40add46a67d4c1b959ea74b3095136d_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzMtOC0xLTEtMA_08d39aa1-80e3-4c58-98ca-ead2115bb4d4"
      unitRef="usd">5034955</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i871d23f00b9d4522a41b0f48f1812cb8_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzMtMTAtMS0xLTA_e99136e9-06b7-4130-9706-c86715337b66"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="id41b97cccddf404587b71109d9148bd9_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzMtMTItMS0xLTA_570638e1-2fa7-427e-9337-94ea354288be"
      unitRef="usd">5034955</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i6c77d83b0d784f95a8c57dc2c69a1ae1_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzctMi0xLTEtMA_3dd76f6f-5494-4ef4-8d24-cc30d99ded09"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i5261d06b396a496e83c3994a329a6adb_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzctNC0xLTEtMA_844f9888-9b0f-4ba5-b219-32f444e515bd"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="ia491869f8f8e4444a463caa044907b2a_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzctNi0xLTEtMA_17364187-b488-454c-bab8-c4951ebb038a"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i6180b75c51584214a21798f206007fd2_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzctOC0xLTEtMA_2ec4413d-616a-463b-ac6e-223eeef1ed0c"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="iebd574df43534324bb75dd95355cde9d_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzctMTAtMS0xLTA_858a7f00-853a-4dcd-bb35-2fa7e8681f58"
      unitRef="usd">2504551</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i2390f7b0f62e4227ae756897529dc3e8_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzctMTItMS0xLTA_b8a75a8a-4b29-4455-a0cc-46e95144aa83"
      unitRef="usd">2504551</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i5de80c3842fe4ead883716b857a3ab60_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzgtMi0xLTEtMA_5f06d034-7946-4217-9523-948ce975da48"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i61fc59376d074db2a4ed2e33996a40ae_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzgtNC0xLTEtMA_53fd16ab-3623-40dc-a342-50c46a2d7065"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i80849ef0fff8453994464dd9e4263335_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzgtNi0xLTEtMA_00edd405-dafd-4f4c-8289-50eb07595e1d"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="ia476a3c32a024ea799663e72ef23fe02_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzgtOC0xLTEtMA_5736eecd-b678-4074-8644-4315f6993fbd"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i20e0531514c241aca726450993124452_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzgtMTAtMS0xLTA_6f240b84-7e8c-42f0-a06b-d9beb1bce9f8"
      unitRef="usd">751173</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i40d16a645ee641218f7703ab03b0d941_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzgtMTItMS0xLTA_19aaeeae-b150-4ed3-8f46-d52afa80d4d1"
      unitRef="usd">751173</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i52e850d4caf6459cb3f900290e148294_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzktMi0xLTEtMA_9ffd9955-2f66-4a7d-ba0b-df0d96672081"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i539d6d44a9ae44f485c1050e287da81b_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzktNC0xLTEtMA_efe9abe7-08ea-48fe-abe9-21631ee2d7c2"
      unitRef="usd">2119607</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i4df16753bd334ba3b2e0980d61fa84e3_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzktNi0xLTEtMA_be4e6f6c-aa47-48d4-954c-635ff7e4acf2"
      unitRef="usd">2119607</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i42f63da2feed4ee1a967d286f376accb_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzktOC0xLTEtMA_de390829-cf8d-4dc3-9e90-be90c648da19"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i7e331fd58cd14866b6404f53b122155e_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzktMTAtMS0xLTA_28301acb-ad3e-4ee0-b281-56c936800f89"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i8cd20af5088e4c7ba1a916823027ba00_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzktMTItMS0xLTA_d5084e5b-8109-4dcf-af3c-b8b8f14d3c74"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i780bdd9adff04751adcd1b6f35439d2f_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzEwLTItMS0xLTA_e32ea536-ffba-4b00-bb58-d423aa142086"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i6c0f572b430a45c5bf9009619128671c_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzEwLTQtMS0xLTA_3c89fd8a-6be3-4831-8eef-8feb477092ce"
      unitRef="usd">2119607</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzEwLTYtMS0xLTA_8e60da4e-d4e6-400f-aa52-69551b1660fe"
      unitRef="usd">2119607</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i67dfb3a3f9004593be1dd06a75668d57_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzEwLTgtMS0xLTA_58a539a1-25be-4efd-b389-a4fe84cb3096"
      unitRef="usd">5034955</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i943d44213b5845cd9d5b5d5a2ebe891e_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzEwLTEwLTEtMS0w_4858582b-a320-493a-a18a-e70ccb1f5133"
      unitRef="usd">3255724</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNDcvZnJhZzpiNjcyNTdkZDQyMzQ0NDQ4YjQxYjk4ZTg5Y2I5YzJkOS90YWJsZToxNTFiZTA0MDg0MTI0YWQ1OTFmNjEzY2UyZDljYWM2Ni90YWJsZXJhbmdlOjE1MWJlMDQwODQxMjRhZDU5MWY2MTNjZTJkOWNhYzY2XzEwLTEyLTEtMS0w_c89b6345-2981-4927-aa3a-369d9cb69016"
      unitRef="usd">8290679</us-gaap:TradingSecurities>
    <us-gaap:ConcentrationRiskDisclosureTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNTAvZnJhZzpiNmU5ZDk2MzU2OTY0ZTUwYjJiZjViYWFlZGExMDY3Yy90ZXh0cmVnaW9uOmI2ZTlkOTYzNTY5NjRlNTBiMmJmNWJhYWVkYTEwNjdjXzkwNA_7b0521ca-be0f-4c23-ac7e-2910bc1ee433">Market Concentrations&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is focused on the acquisition, development and commercialization of branded prescription products.  The Company&#x2019;s principal financial instruments subject to potential concentration of credit risk are accounts receivable, which are unsecured, and cash equivalents. The Company&#x2019;s cash equivalents consist primarily of money market funds. Certain bank deposits may be in excess of the insurance limits provided by the Federal Deposit Insurance Corporation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s primary customers are wholesale pharmaceutical distributors in the U.S. &#160;Total revenues by customer for each customer representing 10% or more of consolidated revenues are summarized below for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:76.602%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.904%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;*: less than 10% of total&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accounts receivable, net of allowances, due from the customers representing 10% or more of consolidated revenue was 59% and 72% at December&#160;31, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNTAvZnJhZzpiNmU5ZDk2MzU2OTY0ZTUwYjJiZjViYWFlZGExMDY3Yy90ZXh0cmVnaW9uOmI2ZTlkOTYzNTY5NjRlNTBiMmJmNWJhYWVkYTEwNjdjXzkwMw_de6b769d-7c39-46b8-85bd-84cba0bdb9cf">Total revenues by customer for each customer representing 10% or more of consolidated revenues are summarized below for the years ended December 31:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:76.602%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.904%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;*: less than 10% of total&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i957590befb9d4e11af4357cac09d5a2e_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNTAvZnJhZzpiNmU5ZDk2MzU2OTY0ZTUwYjJiZjViYWFlZGExMDY3Yy90YWJsZTo0MjJhNTU1ZWQ1ZDU0ZDU5YjI2ZmNmNDlkZjBhYjlhNy90YWJsZXJhbmdlOjQyMmE1NTVlZDVkNTRkNTliMjZmY2Y0OWRmMGFiOWE3XzItMi0xLTEtMA_f4063e0f-a968-48a2-a62d-315e65bbf821"
      unitRef="number">0.31</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4311d59a68c14a2c85db7649a6e2817c_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNTAvZnJhZzpiNmU5ZDk2MzU2OTY0ZTUwYjJiZjViYWFlZGExMDY3Yy90YWJsZTo0MjJhNTU1ZWQ1ZDU0ZDU5YjI2ZmNmNDlkZjBhYjlhNy90YWJsZXJhbmdlOjQyMmE1NTVlZDVkNTRkNTliMjZmY2Y0OWRmMGFiOWE3XzItNC0xLTEtMA_d5438523-0246-43ed-8b64-cb374b69ef81"
      unitRef="number">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i45aae0c5083b4158a10518d39b977929_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNTAvZnJhZzpiNmU5ZDk2MzU2OTY0ZTUwYjJiZjViYWFlZGExMDY3Yy90YWJsZTo0MjJhNTU1ZWQ1ZDU0ZDU5YjI2ZmNmNDlkZjBhYjlhNy90YWJsZXJhbmdlOjQyMmE1NTVlZDVkNTRkNTliMjZmY2Y0OWRmMGFiOWE3XzItNi0xLTEtMA_812df4ad-0266-48c4-8f92-19e36e85dd15"
      unitRef="number">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i633f3a7886904df3bc2c1a118b38b5b5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNTAvZnJhZzpiNmU5ZDk2MzU2OTY0ZTUwYjJiZjViYWFlZGExMDY3Yy90YWJsZTo0MjJhNTU1ZWQ1ZDU0ZDU5YjI2ZmNmNDlkZjBhYjlhNy90YWJsZXJhbmdlOjQyMmE1NTVlZDVkNTRkNTliMjZmY2Y0OWRmMGFiOWE3XzMtMi0xLTEtMA_f513db93-5c09-40ad-8161-e5e233bd165f"
      unitRef="number">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie40ef9fa31bd4ff8a234daae70ffaf5f_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNTAvZnJhZzpiNmU5ZDk2MzU2OTY0ZTUwYjJiZjViYWFlZGExMDY3Yy90YWJsZTo0MjJhNTU1ZWQ1ZDU0ZDU5YjI2ZmNmNDlkZjBhYjlhNy90YWJsZXJhbmdlOjQyMmE1NTVlZDVkNTRkNTliMjZmY2Y0OWRmMGFiOWE3XzMtNC0xLTEtMA_d96eca74-6306-4128-8d14-a201200a0451"
      unitRef="number">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i023693e081e647c2959d4531c232be23_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNTAvZnJhZzpiNmU5ZDk2MzU2OTY0ZTUwYjJiZjViYWFlZGExMDY3Yy90YWJsZTo0MjJhNTU1ZWQ1ZDU0ZDU5YjI2ZmNmNDlkZjBhYjlhNy90YWJsZXJhbmdlOjQyMmE1NTVlZDVkNTRkNTliMjZmY2Y0OWRmMGFiOWE3XzMtNi0xLTEtMA_ea2dce8e-0837-4dd0-b7ec-a762cb7a1281"
      unitRef="number">0.29</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0dcb5d79a1304c1a805e8f68f0a8fad3_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNTAvZnJhZzpiNmU5ZDk2MzU2OTY0ZTUwYjJiZjViYWFlZGExMDY3Yy90YWJsZTo0MjJhNTU1ZWQ1ZDU0ZDU5YjI2ZmNmNDlkZjBhYjlhNy90YWJsZXJhbmdlOjQyMmE1NTVlZDVkNTRkNTliMjZmY2Y0OWRmMGFiOWE3XzQtMi0xLTEtMA_6239c986-b60f-45cb-922b-c313b893d430"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0fe8c7998adb4a09a50f50ebe5dc2cfe_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNTAvZnJhZzpiNmU5ZDk2MzU2OTY0ZTUwYjJiZjViYWFlZGExMDY3Yy90YWJsZTo0MjJhNTU1ZWQ1ZDU0ZDU5YjI2ZmNmNDlkZjBhYjlhNy90YWJsZXJhbmdlOjQyMmE1NTVlZDVkNTRkNTliMjZmY2Y0OWRmMGFiOWE3XzQtNC0xLTEtMA_456295fc-4c87-4b12-8966-6a5738a85a66"
      unitRef="number">0.26</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i60785c35eb4e4574a2eeeed10b448ec6_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNTAvZnJhZzpiNmU5ZDk2MzU2OTY0ZTUwYjJiZjViYWFlZGExMDY3Yy90YWJsZTo0MjJhNTU1ZWQ1ZDU0ZDU5YjI2ZmNmNDlkZjBhYjlhNy90YWJsZXJhbmdlOjQyMmE1NTVlZDVkNTRkNTliMjZmY2Y0OWRmMGFiOWE3XzQtNi0xLTEtMA_daa8a9ce-2363-41d8-a003-158b553bcd72"
      unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6f1d9c99bd274435b9a4a98946740ee0_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNTAvZnJhZzpiNmU5ZDk2MzU2OTY0ZTUwYjJiZjViYWFlZGExMDY3Yy90ZXh0cmVnaW9uOmI2ZTlkOTYzNTY5NjRlNTBiMmJmNWJhYWVkYTEwNjdjXzQzOTgwNDY1MTIwMjc_5a5ff977-ca37-4be7-af31-195069bbe813"
      unitRef="number">0.59</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5e32cc9a0bea46d0b461b09960568c0b_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNTAvZnJhZzpiNmU5ZDk2MzU2OTY0ZTUwYjJiZjViYWFlZGExMDY3Yy90ZXh0cmVnaW9uOmI2ZTlkOTYzNTY5NjRlNTBiMmJmNWJhYWVkYTEwNjdjXzQzOTgwNDY1MTIwMzI_81417c64-53c7-4223-8347-c8540b55d5c8"
      unitRef="number">0.72</us-gaap:ConcentrationRiskPercentage1>
    <cpix:ManufacturingAndSupplyAgreementsTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNTYvZnJhZzo3ODgwM2FjYjQ3MzA0ZWE4OTA2MDYyYzI2MTI2YmM2MS90ZXh0cmVnaW9uOjc4ODAzYWNiNDczMDRlYTg5MDYwNjJjMjYxMjZiYzYxXzYzOQ_13ed9951-7942-4358-a215-7b1eced9775a">Manufacturing and Supply AgreementsThe Company utilizes one or two primary suppliers to manufacture each of its products and product candidates. Although there are a limited number of manufacturers of pharmaceutical products, the Company believes it could utilize other suppliers to manufacture its prescription products on comparable terms.  A change in suppliers, problems with its third-party manufacturing operations or related production capacity, or contract disputes with suppliers could cause a delay in manufacturing or shipment of finished goods and possible loss of sales, which could adversely affect operating results.</cpix:ManufacturingAndSupplyAgreementsTextBlock>
    <cpix:ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct
      contextRef="i1a21420517ea4647a67d7b1217a674ef_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNTYvZnJhZzo3ODgwM2FjYjQ3MzA0ZWE4OTA2MDYyYzI2MTI2YmM2MS90ZXh0cmVnaW9uOjc4ODAzYWNiNDczMDRlYTg5MDYwNjJjMjYxMjZiYzYxXzY3_5aea397a-f27c-4b5a-8a68-785dad006297"
      unitRef="supplier">1</cpix:ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct>
    <cpix:ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct
      contextRef="i8471ffa3b49c4d27b527e605477129a5_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNTYvZnJhZzo3ODgwM2FjYjQ3MzA0ZWE4OTA2MDYyYzI2MTI2YmM2MS90ZXh0cmVnaW9uOjc4ODAzYWNiNDczMDRlYTg5MDYwNjJjMjYxMjZiYzYxXzcz_649f89e9-50ee-41b5-baec-161b329f491a"
      unitRef="supplier">2</cpix:ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct>
    <cpix:EmploymentAgreementsTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNTkvZnJhZzo4ZGMwZTIzNDQ2YmI0NWI3YjA2MWE3OTg2OGY2MDczNi90ZXh0cmVnaW9uOjhkYzBlMjM0NDZiYjQ1YjdiMDYxYTc5ODY4ZjYwNzM2XzMxMA_a2a7e401-85f9-43d4-ad72-5f6d05214d75">Employment AgreementsThe Company has entered into employment agreements with all its full-time employees. Each employment agreement provides for a salary for services performed, a potential annual bonus and, if applicable, a grant of restricted common shares pursuant to a restricted stock agreement.</cpix:EmploymentAgreementsTextBlock>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90ZXh0cmVnaW9uOjEzZmIyMzg2ZmEwMDQ0OWNhOTQzZmUwYWM0YTU3ZTE5XzIzMzk_43102b9b-722d-4fa7-95ab-cff87267629b">Discontinued Operations&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, Cumberland entered into an agreement with Clinigen Group Plc ("Clinigen") for the rights and responsibilities associated with the commercialization of Ethyol in the United States.  In 2017, the Company entered into another agreement with Clinigen for the rights and responsibilities associated with the commercialization of Totect in the United States.  Ethyol and Totect are collectively referred to herein as the "Products."&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Early in 2019, Cumberland announced a strategic review the Company's brands, capabilities, and international partners. This review followed an accelerated business development initiative, which resulted in a series of transactions. Because of that progress, Cumberland felt that it was prudent to take a fresh look at our product portfolio, partners, and organization to ensure proper focus and capabilities.  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During May 2019, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;following the strategic review, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland entered into the Dissolution Agreement with Clinigen in which the Company returned the exclusive rights to commercialize Ethyol and Totect (&#x201c;the Products&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the United States to Clinigen. This Dissolution Agreement originally targeted a transition from the Company's arrangements with Clinigen effective September 30, 2019, but was then amended to change the transition date to December 31, 2019. Under the terms of the Dissolution Agreement, Cumberland was no longer responsible for the distribution, marketing and promotion of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;either the Products or any competing products after December 31, 2019.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In exchange for the return of these product license rights and the non-compete provisions of the Dissolution Agreement, Cumberland is receiving $5&#160;million in financial consideration paid in quarterly installments over the &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90ZXh0cmVnaW9uOjEzZmIyMzg2ZmEwMDQ0OWNhOTQzZmUwYWM0YTU3ZTE5XzQzOTgwNDY1MjI4MDI_72facf0f-0ab8-4e03-8486-1d05338389f9"&gt;two&lt;/span&gt;-years following the transition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The exit from the Ethyol and Totect Products meets the accounting criteria to be reported as discontinued operations. December 31, 2019, as the transition date, was the final day Cumberland was responsible for the Products. Cumberland was responsible for the Products through December 31, 2019 and beginning on January 1, 2020, the Products' rights transitioned back to Clinigen. As a result, January 1, 2020, was the first day of discontinued operations for the Ethyol and Totect products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Products provided revenue, incurred direct expenses and resulted in discontinued operations income during the periods presented.  The following amounts have been separated from continuing operations, as discontinued operations, for all periods presented. The direct expenses separated for discontinued operations do not reflect the direct selling and marketing costs attributable to the individuals at Cumberland responsible for promotion of the Products.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  Subsequent to the transaction date, th&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ose sales and marketing individuals who supported the Products shifted their efforts from the Products and continue to support other Cumberland brands.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.439%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.731%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,145,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,396,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,827,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Costs of products sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,330,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,361,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,952,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, Marketing and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,149,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,253,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,076,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,665,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,782,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,798,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2019 current assets associated with discontinued operations included $0.5&#160;million in the remaining &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;inventory for the Products sold and returned to Clinigen as part of the transaction.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Except for the Products' inventory as of December 31, 2019, no other operating assets and no liabilities were transferred to Clinigen, as such t&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he accounts receivable and accounts payable associated with discontinued operations were not sold or disposed of as part of the Dissolution Agreement. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;assets and liabilities have been presented as assets associated with discontinued operations or liabilities associated with discontinued operations, as appropriate, in the consolidated balance sheets.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.384%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.686%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,922,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,384,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,294,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets associated with discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,462,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,706,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.384%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.686%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,918,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,882,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;666,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities associated with discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,151,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,549,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90ZXh0cmVnaW9uOjEzZmIyMzg2ZmEwMDQ0OWNhOTQzZmUwYWM0YTU3ZTE5XzMyOTg1MzQ4ODg3NzI_6282e2b1-fd74-4aab-8692-bc9c258ad7d4"
      unitRef="usd">5000000</us-gaap:ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90ZXh0cmVnaW9uOjEzZmIyMzg2ZmEwMDQ0OWNhOTQzZmUwYWM0YTU3ZTE5XzQzOTgwNDY1MjI3OTk_9cff37d7-c4d6-40e3-8c86-a047ba903257">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.439%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.731%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,145,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,396,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,827,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Costs of products sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,330,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,361,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,952,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, Marketing and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,149,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,253,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,076,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,665,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,782,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,798,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.384%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.686%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,922,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,384,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,294,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets associated with discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,462,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,706,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.384%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.686%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,918,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,882,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;666,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities associated with discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,151,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,549,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZTpkM2M4M2NiODZlZTk0ZjM2YmU4NTMyYjVlN2JlN2Y4ZC90YWJsZXJhbmdlOmQzYzgzY2I4NmVlOTRmMzZiZTg1MzJiNWU3YmU3ZjhkXzItMi0xLTEtMjEwOQ_a7f5ddd7-d579-461b-9dc8-226c217541bf"
      unitRef="usd">13145344</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZTpkM2M4M2NiODZlZTk0ZjM2YmU4NTMyYjVlN2JlN2Y4ZC90YWJsZXJhbmdlOmQzYzgzY2I4NmVlOTRmMzZiZTg1MzJiNWU3YmU3ZjhkXzItNC0xLTEtMjExMQ_56c5e0be-2cf5-45c3-93ee-70520845a111"
      unitRef="usd">11396871</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZTpkM2M4M2NiODZlZTk0ZjM2YmU4NTMyYjVlN2JlN2Y4ZC90YWJsZXJhbmdlOmQzYzgzY2I4NmVlOTRmMzZiZTg1MzJiNWU3YmU3ZjhkXzItNi0xLTEtMjExMw_c9d1bf38-60ef-46b0-9666-6a56c5ccab77"
      unitRef="usd">14827504</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZTpkM2M4M2NiODZlZTk0ZjM2YmU4NTMyYjVlN2JlN2Y4ZC90YWJsZXJhbmdlOmQzYzgzY2I4NmVlOTRmMzZiZTg1MzJiNWU3YmU3ZjhkXzMtMi0xLTEtMjEwOQ_6f6f9262-f766-44c3-af95-6143eff423b6"
      unitRef="usd">1330704</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZTpkM2M4M2NiODZlZTk0ZjM2YmU4NTMyYjVlN2JlN2Y4ZC90YWJsZXJhbmdlOmQzYzgzY2I4NmVlOTRmMzZiZTg1MzJiNWU3YmU3ZjhkXzMtNC0xLTEtMjExMQ_c3d39d63-7045-436f-af11-e2ba04b022ee"
      unitRef="usd">1361273</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZTpkM2M4M2NiODZlZTk0ZjM2YmU4NTMyYjVlN2JlN2Y4ZC90YWJsZXJhbmdlOmQzYzgzY2I4NmVlOTRmMzZiZTg1MzJiNWU3YmU3ZjhkXzMtNi0xLTEtMjExMw_0c972a9d-c189-42cd-82b5-436a28088a89"
      unitRef="usd">1952575</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZTpkM2M4M2NiODZlZTk0ZjM2YmU4NTMyYjVlN2JlN2Y4ZC90YWJsZXJhbmdlOmQzYzgzY2I4NmVlOTRmMzZiZTg1MzJiNWU3YmU3ZjhkXzQtMi0xLTEtMjEwOQ_12037fba-4f09-4b7b-b926-47e73b1087ca"
      unitRef="usd">6149463</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZTpkM2M4M2NiODZlZTk0ZjM2YmU4NTMyYjVlN2JlN2Y4ZC90YWJsZXJhbmdlOmQzYzgzY2I4NmVlOTRmMzZiZTg1MzJiNWU3YmU3ZjhkXzQtNC0xLTEtMjExMQ_641a9915-6a07-4239-b43b-38ecfbc0571a"
      unitRef="usd">6253374</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZTpkM2M4M2NiODZlZTk0ZjM2YmU4NTMyYjVlN2JlN2Y4ZC90YWJsZXJhbmdlOmQzYzgzY2I4NmVlOTRmMzZiZTg1MzJiNWU3YmU3ZjhkXzQtNi0xLTEtMjExMw_13cfcd10-8c71-4699-93d8-1a66d9dba82a"
      unitRef="usd">8076904</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZTpkM2M4M2NiODZlZTk0ZjM2YmU4NTMyYjVlN2JlN2Y4ZC90YWJsZXJhbmdlOmQzYzgzY2I4NmVlOTRmMzZiZTg1MzJiNWU3YmU3ZjhkXzUtMi0xLTEtMjEwOQ_1571e299-669b-4152-8f9c-db4ddb08e4e3"
      unitRef="usd">5665177</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZTpkM2M4M2NiODZlZTk0ZjM2YmU4NTMyYjVlN2JlN2Y4ZC90YWJsZXJhbmdlOmQzYzgzY2I4NmVlOTRmMzZiZTg1MzJiNWU3YmU3ZjhkXzUtNC0xLTEtMjExMQ_0cfd2f18-e7b2-4336-a2e6-9b38aa7dbbca"
      unitRef="usd">3782224</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZTpkM2M4M2NiODZlZTk0ZjM2YmU4NTMyYjVlN2JlN2Y4ZC90YWJsZXJhbmdlOmQzYzgzY2I4NmVlOTRmMzZiZTg1MzJiNWU3YmU3ZjhkXzUtNi0xLTEtMjExMw_cc344e43-3679-4089-85a6-a80499e65e81"
      unitRef="usd">4798025</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <cpix:DisposalGroupIncludingDiscontinuedOperationRemainingInventoryCurrent
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90ZXh0cmVnaW9uOjEzZmIyMzg2ZmEwMDQ0OWNhOTQzZmUwYWM0YTU3ZTE5XzE2NDkyNjc0NDU3NTc_24f35e92-780f-44fc-83a5-b6a349051d9c"
      unitRef="usd">500000</cpix:DisposalGroupIncludingDiscontinuedOperationRemainingInventoryCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZTo2Njg5MGQ1MzVkMGM0MTA2OTZkNzU1NmNkNjYzNjYxNi90YWJsZXJhbmdlOjY2ODkwZDUzNWQwYzQxMDY5NmQ3NTU2Y2Q2NjM2NjE2XzItMi0xLTEtMjExNQ_a1376dbd-e942-4452-a0c1-b382865ec956"
      unitRef="usd">1922457</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZTo2Njg5MGQ1MzVkMGM0MTA2OTZkNzU1NmNkNjYzNjYxNi90YWJsZXJhbmdlOjY2ODkwZDUzNWQwYzQxMDY5NmQ3NTU2Y2Q2NjM2NjE2XzItNC0xLTEtMjExNw_33e750ca-3ba5-4a4f-9edf-e599faec365d"
      unitRef="usd">1384254</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZTo2Njg5MGQ1MzVkMGM0MTA2OTZkNzU1NmNkNjYzNjYxNi90YWJsZXJhbmdlOjY2ODkwZDUzNWQwYzQxMDY5NmQ3NTU2Y2Q2NjM2NjE2XzMtMi0xLTEtMjExNQ_73602597-9710-4f57-9a08-a9dc1fced469"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZTo2Njg5MGQ1MzVkMGM0MTA2OTZkNzU1NmNkNjYzNjYxNi90YWJsZXJhbmdlOjY2ODkwZDUzNWQwYzQxMDY5NmQ3NTU2Y2Q2NjM2NjE2XzMtNC0xLTEtMjExNw_93f03b01-5254-4049-88f3-0a5fe4e54dfc"
      unitRef="usd">27721</us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZTo2Njg5MGQ1MzVkMGM0MTA2OTZkNzU1NmNkNjYzNjYxNi90YWJsZXJhbmdlOjY2ODkwZDUzNWQwYzQxMDY5NmQ3NTU2Y2Q2NjM2NjE2XzQtMi0xLTEtMjExNQ_d9fd623e-24b4-46fe-b2d6-9cf28de970fc"
      unitRef="usd">540267</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZTo2Njg5MGQ1MzVkMGM0MTA2OTZkNzU1NmNkNjYzNjYxNi90YWJsZXJhbmdlOjY2ODkwZDUzNWQwYzQxMDY5NmQ3NTU2Y2Q2NjM2NjE2XzQtNC0xLTEtMjExNw_61ad8f5f-5a56-4f72-89f1-49674e22f2b8"
      unitRef="usd">2294922</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZTo2Njg5MGQ1MzVkMGM0MTA2OTZkNzU1NmNkNjYzNjYxNi90YWJsZXJhbmdlOjY2ODkwZDUzNWQwYzQxMDY5NmQ3NTU2Y2Q2NjM2NjE2XzUtMi0xLTEtMjExNQ_9e6f0dc3-0dac-4fcc-bc57-eadc508e984f"
      unitRef="usd">2462724</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZTo2Njg5MGQ1MzVkMGM0MTA2OTZkNzU1NmNkNjYzNjYxNi90YWJsZXJhbmdlOjY2ODkwZDUzNWQwYzQxMDY5NmQ3NTU2Y2Q2NjM2NjE2XzUtNC0xLTEtMjExNw_586e3364-c658-4889-b086-b23ae9e63984"
      unitRef="usd">3706897</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZToyOTJhOTdkMmE3MmE0MTg1YWQzMzI0NGZhMTk3OTZiNS90YWJsZXJhbmdlOjI5MmE5N2QyYTcyYTQxODVhZDMzMjQ0ZmExOTc5NmI1XzItMi0xLTEtMjExOQ_71ef59b0-3ff7-48fa-9725-3e9d28668028"
      unitRef="usd">1918868</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZToyOTJhOTdkMmE3MmE0MTg1YWQzMzI0NGZhMTk3OTZiNS90YWJsZXJhbmdlOjI5MmE5N2QyYTcyYTQxODVhZDMzMjQ0ZmExOTc5NmI1XzItNC0xLTEtMjEyMQ_c81ae441-54df-4980-8e10-531e762f786e"
      unitRef="usd">2882656</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZToyOTJhOTdkMmE3MmE0MTg1YWQzMzI0NGZhMTk3OTZiNS90YWJsZXJhbmdlOjI5MmE5N2QyYTcyYTQxODVhZDMzMjQ0ZmExOTc5NmI1XzMtMi0xLTEtMjExOQ_6e67eb78-1350-49d4-8e41-ea9457685311"
      unitRef="usd">232489</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZToyOTJhOTdkMmE3MmE0MTg1YWQzMzI0NGZhMTk3OTZiNS90YWJsZXJhbmdlOjI5MmE5N2QyYTcyYTQxODVhZDMzMjQ0ZmExOTc5NmI1XzMtNC0xLTEtMjEyMQ_26fc8221-53dc-4f5a-a61a-7948c136607e"
      unitRef="usd">666457</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="iaa474b82645f415f9a942431b7e23907_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZToyOTJhOTdkMmE3MmE0MTg1YWQzMzI0NGZhMTk3OTZiNS90YWJsZXJhbmdlOjI5MmE5N2QyYTcyYTQxODVhZDMzMjQ0ZmExOTc5NmI1XzQtMi0xLTEtMjExOQ_012eb65e-d4d2-4400-957f-e13088521f0b"
      unitRef="usd">2151357</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i90392aced265439a8a45b88619999ce0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90YWJsZToyOTJhOTdkMmE3MmE0MTg1YWQzMzI0NGZhMTk3OTZiNS90YWJsZXJhbmdlOjI5MmE5N2QyYTcyYTQxODVhZDMzMjQ0ZmExOTc5NmI1XzQtNC0xLTEtMjEyMQ_f6cf18e2-40f9-4b33-94d7-5bbd7d879bc5"
      unitRef="usd">3549113</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjUvZnJhZzo0YjU4YTQyZGQ0NGI0ZWRiYTVlYjVlZjliYTcyMDcyYy90ZXh0cmVnaW9uOjRiNThhNDJkZDQ0YjRlZGJhNWViNWVmOWJhNzIwNzJjXzI1MDU_cba420cb-0b40-43bd-8f41-20d3fcdb2e40">Commitments and Contingencies&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of certain Kristalose assets during 2011, the Company was required to make quarterly payments based on a percentage of Kristalose net sales through November 2018. The payments were treated as consideration for the assets acquired and were capitalized.  They are being amortized over the remaining expected useful life of the acquired asset, currently through 2026. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with its licensing agreements for Caldolor,  the Company is required to pay royalties based on net sales over the life of the product. Royalty expense is recognized as a component of selling and marketing expense in the period that revenue is recognized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with its licensing agreements for Ethyol and Totect, the Company was required to pay royalties based on net sales.  The royalty expense was recognized as a component of selling and marketing expense in the period the associated revenue was recognized through the end of the licensing period, December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of Vibativ, the Company is required to pay royalties based on net sales of the product.  At the purchase date, Cumberland recorded the fair value of this liability and will continue to evaluate the liability each period and the royalty expense is recognized as a component of selling and marketing expense in the period that the change in fair value is recognized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland has a number of  Patents issued through the United States Patent and Trademark Office (the &#x201c;USPTO&#x201d;) including U.S. Patent number 8,148,356 (the &#x201c;356 Acetadote Patent&#x201d;) which is assigned to the Company. The claims of the 356 Acetadote Patent encompass the new Acetadote formulation and include composition of matter claims. Following its issuance, the 356 Acetadote Patent was listed in the FDA Orange Book. The 356 Acetadote Patent is scheduled to expire in May 2026, which time period includes a 270-day patent term adjustment granted by the USPTO.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since 2012, Cumberland has to continued to vigorously defend and protect its Acetadote product and related intellectual property rights including the use of all its legal options. &lt;/span&gt;&lt;/div&gt;The Company is a party to various other legal proceedings in the ordinary course of its business. In the opinion of management, the liability associated with these matters, will not have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:QuarterlyFinancialInformationTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90ZXh0cmVnaW9uOjYyNzM2NzAxZmJjNTRhM2M4MjU5NWQyZWFlOTFjYmNjXzM1Mw_6f8923cd-28a0-4ea2-a9c1-08759eecb93c">Quarterly Financial Information (Unaudited)&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the unaudited operating results for each fiscal quarter of 2019 and 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.474%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.026%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.026%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.026%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.026%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.031%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;First&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Second&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Third&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fourth&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,729,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,417,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,935,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,305,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,388,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,323,932)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,373,424)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,196,436)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,394,390)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,288,182)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,187,553)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,338,521)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,316,286)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,369,328)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,211,688)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,147,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;771,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,349,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,396,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,665,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(73,878)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(549,507)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,953,668)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(960,706)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,537,759)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings (loss) per share attributable to common shareholders &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.60)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-13.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.04)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.06)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.23)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.60)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.04)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.06)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.23)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,918,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,084,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,853,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,487,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,344,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,315,936)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,919,189)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,644,614)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,293,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11,172,996)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,255,903)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,795,661)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,501,752)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,267,680)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,820,996)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;863,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,050,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;837,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,030,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,782,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,379,239)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(720,688)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,643,044)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,220,097)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,963,068)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings (loss) per share attributable to common shareholders &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;text-indent:-13.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;Due to the nature of interim earnings per share calculations, the sum of the quarterly earnings (loss) per share amounts may not equal the reported earnings (loss) per share for the full year.&lt;/span&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90ZXh0cmVnaW9uOjYyNzM2NzAxZmJjNTRhM2M4MjU5NWQyZWFlOTFjYmNjXzM1NA_7beb4b35-d45f-4886-aeaa-45dedf61cbd1">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the unaudited operating results for each fiscal quarter of 2019 and 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.474%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.026%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.026%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.026%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.026%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.031%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;First&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Second&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Third&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fourth&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,729,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,417,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,935,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,305,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,388,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,323,932)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,373,424)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,196,436)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,394,390)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,288,182)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,187,553)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,338,521)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,316,286)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,369,328)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,211,688)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,147,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;771,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,349,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,396,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,665,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(73,878)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(549,507)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,953,668)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(960,706)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,537,759)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings (loss) per share attributable to common shareholders &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.60)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-13.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.04)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.06)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.23)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.60)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.04)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.06)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.23)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,918,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,084,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,853,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,487,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,344,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,315,936)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,919,189)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,644,614)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,293,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11,172,996)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,255,903)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,795,661)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,501,752)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,267,680)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,820,996)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;863,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,050,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;837,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,030,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,782,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,379,239)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(720,688)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,643,044)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,220,097)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,963,068)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings (loss) per share attributable to common shareholders &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;text-indent:-13.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;Due to the nature of interim earnings per share calculations, the sum of the quarterly earnings (loss) per share amounts may not equal the reported earnings (loss) per share for the full year.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:Revenues
      contextRef="if22100deab024544b321dc081da4ceff_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzMtMi0xLTEtMA_aaae5e5a-0c90-4118-bd89-2b789b5de78b"
      unitRef="usd">8729860</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8909cd57fb5146798a8b845d82644b0b_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzMtNC0xLTEtMA_399d5ca7-5e3b-48f4-99fb-6cd2d4681278"
      unitRef="usd">9417443</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if26164363c2e4a7d8fd5139d8f56f49c_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzMtNi0xLTEtMA_665205f4-8495-4dc7-ac14-2f455e7815c2"
      unitRef="usd">6935439</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i670fdffefb0c4fefba494de91fb35afc_D20191001-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzMtOC0xLTEtMA_ae43b926-a785-4b76-b4d1-e6aed279e89c"
      unitRef="usd">9305553</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzMtMTAtMS0xLTA_c24a47fc-bfe2-41e4-9812-28b9a540c767"
      unitRef="usd">34388295</us-gaap:Revenues>
    <us-gaap:OperatingIncomeLoss
      contextRef="if22100deab024544b321dc081da4ceff_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzQtMi0xLTEtMA_67549c4f-70c3-4437-b816-a8b8ae9eec20"
      unitRef="usd">-1323932</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8909cd57fb5146798a8b845d82644b0b_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzQtNC0xLTEtMA_57351176-e6bf-438c-bbf8-d64fd0d88273"
      unitRef="usd">-1373424</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if26164363c2e4a7d8fd5139d8f56f49c_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzQtNi0xLTEtMA_230cb804-cd1f-4dde-aaf5-3582b0390ea2"
      unitRef="usd">-3196436</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i670fdffefb0c4fefba494de91fb35afc_D20191001-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzQtOC0xLTEtMA_d33e53b9-2135-4eb7-8b68-8756022e5f07"
      unitRef="usd">-3394390</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzQtMTAtMS0xLTA_7cec0cd7-1b29-4bc0-a60a-5fbaac85fb1c"
      unitRef="usd">-9288182</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if22100deab024544b321dc081da4ceff_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzUtMi0xLTEtMTI1OA_f3a71c1c-22d5-4606-9609-f1537214c5d9"
      unitRef="usd">-1187553</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8909cd57fb5146798a8b845d82644b0b_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzUtNC0xLTEtMTI2MA_9926e22c-7401-4fde-bc9f-75c9063075bd"
      unitRef="usd">-1338521</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if26164363c2e4a7d8fd5139d8f56f49c_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzUtNi0xLTEtMTI2Mg_7c30e014-c499-4883-8265-7d0b10dd7b6f"
      unitRef="usd">-3316286</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i670fdffefb0c4fefba494de91fb35afc_D20191001-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzUtOC0xLTEtMTI2NA_25a963be-4521-469c-9646-3a3a2adef7f7"
      unitRef="usd">-3369328</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzUtMTAtMS0xLTEyNjY_3dfd2737-3ed5-43a2-8b6a-255f4eff7e16"
      unitRef="usd">-9211688</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="if22100deab024544b321dc081da4ceff_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzYtMi0xLTEtMTI1OA_bb78ce02-f9a5-489b-9c99-8c48abe858c2"
      unitRef="usd">1147136</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i8909cd57fb5146798a8b845d82644b0b_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzYtNC0xLTEtMTI2MA_55c2c9f6-52a8-4cfa-9817-3b113c8412a8"
      unitRef="usd">771709</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="if26164363c2e4a7d8fd5139d8f56f49c_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzYtNi0xLTEtMTI2Mg_a0bfc89f-d9df-4dd5-b017-d0679314ee36"
      unitRef="usd">1349351</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i670fdffefb0c4fefba494de91fb35afc_D20191001-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzYtOC0xLTEtMTI2NA_5396a8c8-6c42-4ac4-b8be-f18742040455"
      unitRef="usd">2396981</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzYtMTAtMS0xLTEyNjY_81e19cd2-fac9-43bd-ae7e-d16c7797624b"
      unitRef="usd">5665177</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="if22100deab024544b321dc081da4ceff_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzUtMi0xLTEtMA_be130808-bef0-4370-bec0-d53ba6c707ff"
      unitRef="usd">-73878</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8909cd57fb5146798a8b845d82644b0b_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzUtNC0xLTEtMA_248c8dc9-42c5-4574-9aae-166414919fc9"
      unitRef="usd">-549507</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if26164363c2e4a7d8fd5139d8f56f49c_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzUtNi0xLTEtMA_841c8926-6132-4f83-8bad-5bbccb4642e9"
      unitRef="usd">-1953668</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i670fdffefb0c4fefba494de91fb35afc_D20191001-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzUtOC0xLTEtMA_26d1f057-a180-438d-b0df-77fda5cf8d12"
      unitRef="usd">-960706</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzUtMTAtMS0xLTA_39674003-5d29-4ed5-bc64-a2cb7d004e65"
      unitRef="usd">-3537759</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="if22100deab024544b321dc081da4ceff_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzktMi0xLTEtMTI2OA_c159e1bc-9826-47cf-be19-20154b9cc050"
      unitRef="usdPerShare">-0.08</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i8909cd57fb5146798a8b845d82644b0b_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzktNC0xLTEtMTI3MA_d49e5c61-7b89-4750-8742-39f6ca53fd7e"
      unitRef="usdPerShare">-0.09</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="if26164363c2e4a7d8fd5139d8f56f49c_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzktNi0xLTEtMTI3Mg_a73986ff-cde1-4409-869d-5b0271ed5808"
      unitRef="usdPerShare">-0.22</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i670fdffefb0c4fefba494de91fb35afc_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzktOC0xLTEtMTI3NA_e239e22e-33c5-4dc5-a924-fabe9e82de73"
      unitRef="usdPerShare">-0.22</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzktMTAtMS0xLTEyNzc_bc702fc9-f029-4fe0-9c0e-cf96fc336140"
      unitRef="usdPerShare">-0.60</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="if22100deab024544b321dc081da4ceff_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzEwLTItMS0xLTEyNjg_f7804289-8b19-4105-8ae9-e003ffe27f15"
      unitRef="usdPerShare">0.08</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i8909cd57fb5146798a8b845d82644b0b_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzEwLTQtMS0xLTEyNzA_57239905-d429-4135-b4cc-bf2ab91f60ea"
      unitRef="usdPerShare">0.05</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="if26164363c2e4a7d8fd5139d8f56f49c_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzEwLTYtMS0xLTEyNzI_15ea0184-c022-4b2a-b0c5-ebd2189571ac"
      unitRef="usdPerShare">0.09</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i670fdffefb0c4fefba494de91fb35afc_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzEwLTgtMS0xLTEyNzQ_72650812-47e4-477b-bc9d-9def6e6151a4"
      unitRef="usdPerShare">0.16</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzEwLTEwLTEtMS0xMjc3_e6ba6440-39a0-457b-9d9f-c2e9cc90b5e7"
      unitRef="usdPerShare">0.37</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="if22100deab024544b321dc081da4ceff_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzctMi0xLTEtMA_d20fae9e-eab8-4777-bd73-4508bf60a98f"
      unitRef="usdPerShare">0</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8909cd57fb5146798a8b845d82644b0b_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzctNC0xLTEtMA_2f7a8484-d850-4b31-b377-e4bc7f46b3fe"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="if26164363c2e4a7d8fd5139d8f56f49c_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzctNi0xLTEtMA_59e133cb-8f80-4ea6-a3e7-19e0c033cc9f"
      unitRef="usdPerShare">-0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i670fdffefb0c4fefba494de91fb35afc_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzctOC0xLTEtMA_c0e12901-7ff9-477b-b203-25b602096607"
      unitRef="usdPerShare">-0.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzctMTAtMS0xLTA_5bfbe3f6-773b-4532-a9d3-09a4b6c40d6e"
      unitRef="usdPerShare">-0.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="if22100deab024544b321dc081da4ceff_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzEzLTItMS0xLTEyNzk_756a8cf4-e768-4b3a-a85d-5486d6e925e6"
      unitRef="usdPerShare">-0.08</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i8909cd57fb5146798a8b845d82644b0b_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzEzLTQtMS0xLTEyODE_1f3fff45-b439-4553-a508-f477e8283073"
      unitRef="usdPerShare">-0.09</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="if26164363c2e4a7d8fd5139d8f56f49c_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzEzLTYtMS0xLTEyODM_fad39734-b6ac-49c6-beed-591924e23574"
      unitRef="usdPerShare">-0.22</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i670fdffefb0c4fefba494de91fb35afc_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzEzLTgtMS0xLTEyODU_72777e13-0d8c-40fd-b555-4efb27b5b2e1"
      unitRef="usdPerShare">-0.22</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzEzLTEwLTEtMS0xMjg3_71685190-445c-4657-bfd5-89fbc08703d0"
      unitRef="usdPerShare">-0.60</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="if22100deab024544b321dc081da4ceff_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzE0LTItMS0xLTEyNzk_48029cf2-ce17-4ecb-9f64-9c7354563423"
      unitRef="usdPerShare">0.08</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i8909cd57fb5146798a8b845d82644b0b_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzE0LTQtMS0xLTEyODE_1dac08fc-8eec-4bc8-97ca-28c65f94e8d9"
      unitRef="usdPerShare">0.05</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="if26164363c2e4a7d8fd5139d8f56f49c_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzE0LTYtMS0xLTEyODM_4005003a-be2e-4df0-bc4a-88b514a5c039"
      unitRef="usdPerShare">0.09</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i670fdffefb0c4fefba494de91fb35afc_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzE0LTgtMS0xLTEyODU_476e3c15-e612-4a6b-8a33-83578112559c"
      unitRef="usdPerShare">0.16</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzE0LTEwLTEtMS0xMjg3_e56a591c-406b-4ba1-a12e-94a435334b87"
      unitRef="usdPerShare">0.37</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if22100deab024544b321dc081da4ceff_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzgtMi0xLTEtMA_8e9d6845-7918-4523-b3d3-c6e8633f4b46"
      unitRef="usdPerShare">0</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8909cd57fb5146798a8b845d82644b0b_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzgtNC0xLTEtMA_98dbd5bb-b087-40f8-a9ce-a127ed5897eb"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if26164363c2e4a7d8fd5139d8f56f49c_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzgtNi0xLTEtMA_625d24df-3a29-43e6-8469-daae99f93711"
      unitRef="usdPerShare">-0.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i670fdffefb0c4fefba494de91fb35afc_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzgtOC0xLTEtMA_136fc64c-9500-4fcd-95f9-454c93608c35"
      unitRef="usdPerShare">-0.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzgtMTAtMS0xLTA_04dbe70d-160a-40e3-a267-9af39eb2ddc8"
      unitRef="usdPerShare">-0.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:Revenues
      contextRef="ie54433cb2ec74b5eb0446c048a926870_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzExLTItMS0xLTA_69a16446-ec43-4b73-9011-d92e004c0acf"
      unitRef="usd">5918758</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3568f3154e034913831ef831b3d23e91_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzExLTQtMS0xLTA_fd5814eb-b830-4def-a4e4-716fb8dfee97"
      unitRef="usd">7084843</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2efc1fa703c94708b6b3fc4d341efa16_D20180701-20180930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzExLTYtMS0xLTA_6912247b-a54b-4765-9bb6-16088f705a13"
      unitRef="usd">5853451</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i41abbb021c424bc3a185261bb47b2490_D20181001-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzExLTgtMS0xLTA_aa04feba-b040-4541-b90d-96ce3b965dec"
      unitRef="usd">10487842</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzExLTEwLTEtMS0w_58fb8a8c-f4bc-41f8-b642-d3db36202a83"
      unitRef="usd">29344894</us-gaap:Revenues>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie54433cb2ec74b5eb0446c048a926870_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzEyLTItMS0xLTA_0d90c4fa-f872-40e1-a76a-1604f92ce1cd"
      unitRef="usd">-3315936</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3568f3154e034913831ef831b3d23e91_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzEyLTQtMS0xLTA_718d7d56-15fe-4a49-bb30-6984f4a03088"
      unitRef="usd">-1919189</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2efc1fa703c94708b6b3fc4d341efa16_D20180701-20180930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzEyLTYtMS0xLTA_f0274123-92fe-4d57-81d4-604b5b7678aa"
      unitRef="usd">-2644614</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i41abbb021c424bc3a185261bb47b2490_D20181001-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzEyLTgtMS0xLTA_645a667e-c2c7-4037-b098-9e2f8cb442bb"
      unitRef="usd">-3293257</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzEyLTEwLTEtMS0w_3f82af5b-375c-4889-86a3-2f00216f3204"
      unitRef="usd">-11172996</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie54433cb2ec74b5eb0446c048a926870_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzE5LTItMS0xLTE0MzI_87a4013f-2fa7-4ad0-9f10-6dcf275e10fa"
      unitRef="usd">-3255903</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3568f3154e034913831ef831b3d23e91_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzE5LTQtMS0xLTE0MzQ_fd04681b-8a6f-46ff-bd0b-a68d7ae72146"
      unitRef="usd">-1795661</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2efc1fa703c94708b6b3fc4d341efa16_D20180701-20180930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzE5LTYtMS0xLTE0MzY_cec17175-6d6d-41e7-aeb7-222ae63f1ed9"
      unitRef="usd">-2501752</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i41abbb021c424bc3a185261bb47b2490_D20181001-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzE5LTgtMS0xLTE0MzA_48d20f23-310e-4759-8492-01017b6b28f1"
      unitRef="usd">-3267680</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzE5LTEwLTEtMS0xNDM4_0e7aca2e-4460-4460-803d-cb2d0ca691e1"
      unitRef="usd">-10820996</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="ie54433cb2ec74b5eb0446c048a926870_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzIwLTItMS0xLTE0MzI_0fa0991e-8107-43ca-9e5d-6412a9a8f4fe"
      unitRef="usd">863714</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i3568f3154e034913831ef831b3d23e91_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzIwLTQtMS0xLTE0MzQ_1bdc9c3f-a530-4ef0-a280-94b061e84e5b"
      unitRef="usd">1050211</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i2efc1fa703c94708b6b3fc4d341efa16_D20180701-20180930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzIwLTYtMS0xLTE0MzY_49313fc7-f582-4d22-ab71-fea86017d0ce"
      unitRef="usd">837731</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i41abbb021c424bc3a185261bb47b2490_D20181001-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzIwLTgtMS0xLTE0MzA_018ee4f9-e78c-483c-9999-76815337c8ad"
      unitRef="usd">1030568</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzIwLTEwLTEtMS0xNDM4_23c3f18b-02e9-4dc0-b675-e1489f481a55"
      unitRef="usd">3782224</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ie54433cb2ec74b5eb0446c048a926870_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzEzLTItMS0xLTA_e8b9351e-34d8-472f-a34d-a757d67894bd"
      unitRef="usd">-2379239</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3568f3154e034913831ef831b3d23e91_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzEzLTQtMS0xLTA_4b23fe08-2d9e-44c4-891e-c7c38cbfea0a"
      unitRef="usd">-720688</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2efc1fa703c94708b6b3fc4d341efa16_D20180701-20180930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzEzLTYtMS0xLTA_f0b84c86-0e89-496c-8070-d0b097d86ec1"
      unitRef="usd">-1643044</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i41abbb021c424bc3a185261bb47b2490_D20181001-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzEzLTgtMS0xLTA_fb9ce1ac-4bb9-42c6-b4f9-edfbc2648078"
      unitRef="usd">-2220097</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzEzLTEwLTEtMS0w_78c764db-04b6-45a2-859d-978f14a15a91"
      unitRef="usd">-6963068</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="ie54433cb2ec74b5eb0446c048a926870_D20180101-20180331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzIzLTItMS0xLTE0NDA_92993d3a-089d-4d5d-a5ce-f92319706c71"
      unitRef="usdPerShare">-0.21</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i3568f3154e034913831ef831b3d23e91_D20180401-20180630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzIzLTQtMS0xLTE0NDI_6d63ed33-6535-4d37-9f31-a79a07442e4b"
      unitRef="usdPerShare">-0.11</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i2efc1fa703c94708b6b3fc4d341efa16_D20180701-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzIzLTYtMS0xLTE0NDQ_f449c5e6-f423-4c54-aba5-8a6ab646890c"
      unitRef="usdPerShare">-0.16</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i41abbb021c424bc3a185261bb47b2490_D20181001-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzIzLTgtMS0xLTE0NDY_f96d8572-26be-4b92-a4a6-4be9c3318265"
      unitRef="usdPerShare">-0.21</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzIzLTEwLTEtMS0xNDQ4_1e53a38c-e338-4ba2-b4e1-b0dd87f5039a"
      unitRef="usdPerShare">-0.70</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="ie54433cb2ec74b5eb0446c048a926870_D20180101-20180331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzI0LTItMS0xLTE0NDA_4237754b-bb51-46ff-ac75-f505dfd90464"
      unitRef="usdPerShare">0.06</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i3568f3154e034913831ef831b3d23e91_D20180401-20180630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzI0LTQtMS0xLTE0NDI_d8ca3971-2ebf-469b-8b45-bd4732cbe717"
      unitRef="usdPerShare">0.06</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i2efc1fa703c94708b6b3fc4d341efa16_D20180701-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzI0LTYtMS0xLTE0NDQ_136c37e4-c236-4797-aa16-24bbc0fddfe4"
      unitRef="usdPerShare">0.05</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i41abbb021c424bc3a185261bb47b2490_D20181001-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzI0LTgtMS0xLTE0NDY_c04e9234-5db0-473b-9686-0a5d58a216e6"
      unitRef="usdPerShare">0.07</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzI0LTEwLTEtMS0xNDQ4_3fdcf483-392e-4b31-8d25-42230d5f30ed"
      unitRef="usdPerShare">0.25</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie54433cb2ec74b5eb0446c048a926870_D20180101-20180331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzE1LTItMS0xLTA_98aa23e4-33a4-4755-b6d9-f5fb68d76835"
      unitRef="usdPerShare">-0.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3568f3154e034913831ef831b3d23e91_D20180401-20180630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzE1LTQtMS0xLTA_ad1e98d5-cf3d-4f3a-b944-105a55188867"
      unitRef="usdPerShare">-0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2efc1fa703c94708b6b3fc4d341efa16_D20180701-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzE1LTYtMS0xLTA_68024823-93c7-4117-b925-5d617f5e91f7"
      unitRef="usdPerShare">-0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i41abbb021c424bc3a185261bb47b2490_D20181001-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzE1LTgtMS0xLTA_7908edca-0331-436d-9831-a7ee08dfbd1c"
      unitRef="usdPerShare">-0.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzE1LTEwLTEtMS0w_9e46fcf7-3d16-4385-b701-f8502fd154c7"
      unitRef="usdPerShare">-0.45</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="ie54433cb2ec74b5eb0446c048a926870_D20180101-20180331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzI3LTItMS0xLTE0NTA_712ccb54-e806-45a7-a7f2-c522c7152f80"
      unitRef="usdPerShare">-0.21</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i3568f3154e034913831ef831b3d23e91_D20180401-20180630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzI3LTQtMS0xLTE0NTI_224ee1ab-7a9d-443d-b772-28be0441eff9"
      unitRef="usdPerShare">-0.11</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i2efc1fa703c94708b6b3fc4d341efa16_D20180701-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzI3LTYtMS0xLTE0NTQ_4ee446b6-b54b-4e3c-811f-5589d83ca8ff"
      unitRef="usdPerShare">-0.16</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i41abbb021c424bc3a185261bb47b2490_D20181001-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzI3LTgtMS0xLTE0NTY_0c05af61-6b82-4079-951f-87d08227e2a3"
      unitRef="usdPerShare">-0.21</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzI3LTEwLTEtMS0xNDU4_87d0f940-d886-461f-95c5-a2f6c8761586"
      unitRef="usdPerShare">-0.70</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="ie54433cb2ec74b5eb0446c048a926870_D20180101-20180331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzI4LTItMS0xLTE0NTA_caf0592d-f310-4948-89bd-aa544e5879e8"
      unitRef="usdPerShare">0.06</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i3568f3154e034913831ef831b3d23e91_D20180401-20180630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzI4LTQtMS0xLTE0NTI_c7af01c2-0b69-463d-a087-fbcc56c28409"
      unitRef="usdPerShare">0.06</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i2efc1fa703c94708b6b3fc4d341efa16_D20180701-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzI4LTYtMS0xLTE0NTQ_d5597ca4-9a68-4b91-9c7e-da77bf48d100"
      unitRef="usdPerShare">0.05</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i41abbb021c424bc3a185261bb47b2490_D20181001-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzI4LTgtMS0xLTE0NTY_91ff5517-9d70-413c-a657-ec2ca0ec4c04"
      unitRef="usdPerShare">0.07</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzI4LTEwLTEtMS0xNDU4_44d8fc08-4418-4e78-895d-0a69fa70cff2"
      unitRef="usdPerShare">0.25</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie54433cb2ec74b5eb0446c048a926870_D20180101-20180331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzE2LTItMS0xLTA_2f1de787-50cb-4881-86e4-e45cca0ca791"
      unitRef="usdPerShare">-0.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3568f3154e034913831ef831b3d23e91_D20180401-20180630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzE2LTQtMS0xLTA_d67db899-e29e-4576-8ed3-a4a9cdc3daa2"
      unitRef="usdPerShare">-0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2efc1fa703c94708b6b3fc4d341efa16_D20180701-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzE2LTYtMS0xLTA_41c31ad9-7d09-4c8d-aa74-8a477ff6a6cc"
      unitRef="usdPerShare">-0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i41abbb021c424bc3a185261bb47b2490_D20181001-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzE2LTgtMS0xLTA_e6132f19-602e-4380-8237-f96429ff280e"
      unitRef="usdPerShare">-0.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6888d137c3824373a818a71af9e45fb7_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjgvZnJhZzo2MjczNjcwMWZiYzU0YTNjODI1OTVkMmVhZTkxY2JjYy90YWJsZTozODg5ZTY5YTIyOTY0MTUwOTBlZTZkMzlhZDhjZjAxYy90YWJsZXJhbmdlOjM4ODllNjlhMjI5NjQxNTA5MGVlNmQzOWFkOGNmMDFjXzE2LTEwLTEtMS0w_5157dcbb-beb3-4c8f-ab15-4c898dd6cf55"
      unitRef="usdPerShare">-0.45</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzEvZnJhZzo5ZTI3MTYwNjljZDQ0Y2QxYjRhNmQ1Zjk4Njk3Y2IxMS90ZXh0cmVnaW9uOjllMjcxNjA2OWNkNDRjZDFiNGE2ZDVmOTg2OTdjYjExXzQzOTgwNDY1MTE4NTI_487dcfb0-3c9e-4c2e-9cab-02b3ddb1ff64">Subsequent eventsOn March 11, 2020, the World Health Organization declared the outbreak of a novel coronavirus (&#x201c;COVID-19&#x201d;) as a global pandemic, which continues to spread throughout the United States and around the world.  As of March 20, 2020, the Company is aware of changes in its business as a result of COVID-19 but uncertain of the impacts of those changes on its consolidated statements of position, operations or cash flows. Management believes any disruption, when and if experienced, could be temporary; however, there is uncertainty around when any disruption might occur, the duration and hence the potential impact. As a result, we are unable to estimate the potential impact on our business as of the date of this filing.</us-gaap:SubsequentEventsTextBlock>
    <srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock
      contextRef="i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90ZXh0cmVnaW9uOmNjMzdjZWQ3OWU4NzQxNzJhY2NlN2JlODc3NTgwNTZlXzQwMw_76681f1a-6a97-4468-9b68-13be39f5aac2">&lt;div style="margin-top:4pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation and Qualifying Accounts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Years ended December&#160;31, 2019, 2018 and 2017&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:4pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.182%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;beginning&#160;of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Charged to&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;costs and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Charged&#160;to&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;accounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;end&#160;of&#160;period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for uncollectible amounts, cash discounts, chargebacks, and credits issued for damaged products:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;For the years ended &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,371,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,491,263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,610,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,133,176)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;804,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;804,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,915,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,927,435)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;792,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance for deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;For the years ended &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;388,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(665,039)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,908,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,632,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,632,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,749,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,382,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,382,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,129,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,511,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)   Composed of actual returns and credits for chargebacks and cash discounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)   Amount includes $4,202,854 related to increase in the valuation allowance during the year, net of $4,867,893 related to the revaluation of deferred income tax balances for new rates under the Tax Act.&lt;/span&gt;&lt;/div&gt;</srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i285233d399574db2bf4cbbce58a8ee38_I20161231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzQtMi0xLTEtMA_c0f003ad-5f1d-4ddf-bed7-e08502c4eb9a"
      unitRef="usd">446514</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="i3ec1fa83cd4f4bcd80502e9a9be962e1_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzQtNC0xLTEtMA_bc68ceeb-9764-459f-8ace-5636d9c117be"
      unitRef="usd">3371446</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i3ec1fa83cd4f4bcd80502e9a9be962e1_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzQtNi0xLTEtMA_10d8b649-f381-41cd-91a6-90f0657abbbe"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i3ec1fa83cd4f4bcd80502e9a9be962e1_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzQtOC0xLTEtMA_5b9ba864-f3f8-476b-9ab7-36ff4ff0da68"
      unitRef="usd">3491263</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ie72430d18bed427fb73e3a0c86f3902b_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzQtMTAtMS0xLTA_6aeceb92-735c-44ed-a57a-2c5d412e448a"
      unitRef="usd">326697</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ie72430d18bed427fb73e3a0c86f3902b_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzUtMi0xLTEtMA_ef8b7c40-c804-4488-9e6c-2fdd3ff9d825"
      unitRef="usd">326697</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="if0b0b3681b184a71afd2ed8070814188_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzUtNC0xLTEtMA_87f07e79-b7e8-4dfa-b7f8-d5722833997e"
      unitRef="usd">4610899</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="if0b0b3681b184a71afd2ed8070814188_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzUtNi0xLTEtMA_017db3f9-0723-4d05-b87a-23680d8c5c93"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="if0b0b3681b184a71afd2ed8070814188_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzUtOC0xLTEtMA_50f8a6bc-6b4e-437a-af46-4218788f1b59"
      unitRef="usd">4133176</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i320d53db383d4ac7aecd406d90ef5114_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzUtMTAtMS0xLTA_11ec047a-8d0d-4b4a-a365-2dba96d2d3cb"
      unitRef="usd">804420</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i320d53db383d4ac7aecd406d90ef5114_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzYtMi0xLTEtMA_00fc7368-7c5f-41c0-9d43-4e7db5e16fc2"
      unitRef="usd">804420</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="idaebef75259c4828b8dd1e0a936b843b_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzYtNC0xLTEtMA_1bcd7282-5f03-4e7c-97b4-6ef8a546b4d3"
      unitRef="usd">5915066</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="idaebef75259c4828b8dd1e0a936b843b_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzYtNi0xLTEtMA_850a9142-4219-4b04-beb4-9f15bc93ff52"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="idaebef75259c4828b8dd1e0a936b843b_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzYtOC0xLTEtMA_5ceca96e-249e-4487-9811-6d1fc422beb1"
      unitRef="usd">5927435</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ia7a49735b602483d8a41720b2aa89de2_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzYtMTAtMS0xLTA_8fd13d5f-6ee3-4067-b08a-3fddf421b9c8"
      unitRef="usd">792051</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ic63ad7ea20c046e9929381f321c356c0_I20161231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzEwLTItMS0xLTA_96fe9a8a-60d3-480d-8700-48d170316c3b"
      unitRef="usd">388500</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="i17c72a67be474fd0bf7e5aefd742a269_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzEwLTQtMS0xLTA_affd6bd7-2444-4ff7-a53b-cb9782572b93"
      unitRef="usd">-665039</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i17c72a67be474fd0bf7e5aefd742a269_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzEwLTYtMS0xLTA_f77df587-17d2-4037-90fe-6f79c9ae47ca"
      unitRef="usd">15908774</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i17c72a67be474fd0bf7e5aefd742a269_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzEwLTgtMS0xLTA_fd450ff6-5492-4710-bd80-36172cb94380"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i529dda5be0c0459188e6d0ab6e604b33_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzEwLTEwLTEtMS0w_73ce093b-f0fa-4b43-a6e5-09b55473da05"
      unitRef="usd">15632235</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i529dda5be0c0459188e6d0ab6e604b33_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzExLTItMS0xLTA_59394adc-e6ac-442b-9276-d81def026b19"
      unitRef="usd">15632235</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="ia9d74b7bafab423992f09ba352af1356_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzExLTQtMS0xLTA_29dd7306-8f15-4409-930d-a91f05334ee6"
      unitRef="usd">1749817</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="ia9d74b7bafab423992f09ba352af1356_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzExLTYtMS0xLTA_99392c9a-e9c7-4c0e-9514-94a6110622bc"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ia9d74b7bafab423992f09ba352af1356_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzExLTgtMS0xLTA_f5ba742f-6590-4c70-8a99-daa8d537fe4d"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i3b11cb5d5b164dc88a8a5aa3bd48fe48_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzExLTEwLTEtMS0w_e3d5c7da-17c7-46a0-8aba-a57b7ab8bfab"
      unitRef="usd">17382052</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i3b11cb5d5b164dc88a8a5aa3bd48fe48_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzEyLTItMS0xLTA_b8e3e104-b5e0-4e00-b5d0-6a156b8f9db0"
      unitRef="usd">17382052</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="i2a0dc042738147c39f0f1c8b83d36fad_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzEyLTQtMS0xLTA_ce7a477b-4cc6-40d7-8fb6-0935dc238aeb"
      unitRef="usd">1129109</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i2a0dc042738147c39f0f1c8b83d36fad_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzEyLTYtMS0xLTA_f0d89dbe-4011-42d0-be66-d3b01d2348a7"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i2a0dc042738147c39f0f1c8b83d36fad_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzEyLTgtMS0xLTA_6ac78af4-bba7-4aa1-8a5b-8e32ac54e361"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="iae4edd9cd21d4bff9f039d252bcc383b_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90YWJsZTo3MTFjZWNmZTViYjg0YWNlOTM2YzhjNTRlMGUwNzIxOS90YWJsZXJhbmdlOjcxMWNlY2ZlNWJiODRhY2U5MzZjOGM1NGUwZTA3MjE5XzEyLTEwLTEtMS0w_ede022c2-dae2-4e63-be32-3cb92e06bccd"
      unitRef="usd">18511161</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90ZXh0cmVnaW9uOmNjMzdjZWQ3OWU4NzQxNzJhY2NlN2JlODc3NTgwNTZlXzIzMw_421318bc-f848-49a4-a576-eaee192c2846"
      unitRef="usd">4202854</us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease>
    <cpix:TaxCutsandJobsActof2017ChangeinTaxRateDeferredTaxAssetIncomeTaxExpenseBenefit
      contextRef="i12da030761f5478185c9c43f4257f503_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNzQvZnJhZzpjYzM3Y2VkNzllODc0MTcyYWNjZTdiZTg3NzU4MDU2ZS90ZXh0cmVnaW9uOmNjMzdjZWQ3OWU4NzQxNzJhY2NlN2JlODc3NTgwNTZlXzMwNw_9bac186e-4159-469f-ad4a-4f9c26bc7e9b"
      unitRef="usd">4867893</cpix:TaxCutsandJobsActof2017ChangeinTaxRateDeferredTaxAssetIncomeTaxExpenseBenefit>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697728548520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Dec. 10, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 10,  2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CUMBERLAND PHARMACEUTICALS INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">TN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">62-1765329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001087294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2525 West End Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Nashville<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">37203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">615<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">255-0068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, no par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CPIX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">Cumberland Pharmaceuticals Inc. ("Cumberland", &#8220;we&#8221;, &#8220;our&#8221; or "the Company") is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. This Current Report on Form 8-K (&#8220;Form 8-K&#8221;) is being filed to recast historical financial information, originally included in our  Annual Report on Form 10-K for the year ended December 31, 2019 ("2019 Form 10-K") to reflect the presentation of two Products we no longer distribute as discontinued operations. We previously filed the 2019 Form 10-K with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March 20, 2020.During May 2019, Cumberland entered into a Dissolution Agreement  ("Dissolution Agreement") with Clinigen Healthcare Limited ("Clinigen") in which the Company returned the exclusive rights to commercialize Ethyol&#174; and Totect&#174; (&#8220;the Products&#8221;) in the United States to Clinigen. Under the terms of the Dissolution Agreement, Cumberland is no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products following December 31, 2019. In exchange for the return of these product license rights and the non-compete provisions of the Dissolution Agreement, Cumberland is receiving $5 million in financial consideration paid in quarterly installments over the two-years following the transition date. The Company's exit from the Products meets the accounting criteria to be reported as discontinued operations and the discontinued operating results have been reclassified in the financial statements and footnotes for all periods presented, as required, to reflect the discontinued status of the Products, beginning in our Quarterly Report on Form 10-Q for the first quarter of 2020.  We are issuing this Form 8-K to recast the Products as discontinued operations as of and for each of the periods covered by our 2019 Form 10-K. Accordingly, the Company has retrospectively recast its previously issued annual financial statements for the three years in the period ended December 31, 2019 to present the Products as discontinued operations.The information included in Exhibit 99.1 to this Current Report on Form 8-K is presented solely in connection with the presentation changes described above and sections included in the 2019 Form 10-K that are not included in this report continue to speak only as of the original filing date.  Exhibit 99.1 to this Form 8-K does not reflect events occurring after the Company filed its 2019 Form 10-K, and does not modify or update the disclosures therein in any way, other than to reflect the presentation of the Products as discontinued operations as described above. Therefore, Exhibit 99.1 to this Form 8-K should be read in conjunction with the Company&#8217;s other filings made with the SEC, including, and subsequent to the date of, the 2019 Form 10-K. These subsequent SEC filings contain important information regarding events, developments, and updates affecting Cumberland and our expectations that have occurred since the filing of the 2019 Form 10-K.Exhibit 99.1 of this Form 8-K presents a recast of the following historical financial information, originally included in our 2019 Form 10-K, to reflect the presentation of the Products as discontinued operations:&#8226;Item 6. Selected Financial Data&#8226;Item 7. Management&#8217;s Discussion and Analysis of  Financial Condition and Results of Operations&#8226;Item 8. Financial Statements and Supplementary Data<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697728536920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 28,212,635<span></span>
</td>
<td class="nump">$ 27,938,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,290,679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowances</a></td>
<td class="nump">7,859,006<span></span>
</td>
<td class="nump">6,459,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">8,871,254<span></span>
</td>
<td class="nump">9,783,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">2,757,456<span></span>
</td>
<td class="nump">2,936,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Disposal Group, Including Discontinued Operation, Assets, Current</a></td>
<td class="nump">2,462,724<span></span>
</td>
<td class="nump">3,706,897<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">50,163,075<span></span>
</td>
<td class="nump">59,116,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">15,554,992<span></span>
</td>
<td class="nump">15,749,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">747,796<span></span>
</td>
<td class="nump">771,213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">30,920,324<span></span>
</td>
<td class="nump">33,655,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">882,000<span></span>
</td>
<td class="nump">784,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">21,802<span></span>
</td>
<td class="nump">87,210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">2,960,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">3,298,725<span></span>
</td>
<td class="nump">2,531,309<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">104,549,283<span></span>
</td>
<td class="nump">112,693,868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">9,993,578<span></span>
</td>
<td class="nump">8,210,641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease current liabilities</a></td>
<td class="nump">920,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">11,084,869<span></span>
</td>
<td class="nump">16,044,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Disposal Group, Including Discontinued Operation, Liabilities, Current</a></td>
<td class="nump">2,151,357<span></span>
</td>
<td class="nump">3,549,113<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">24,150,235<span></span>
</td>
<td class="nump">27,804,224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
<td class="nump">18,500,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating Lease, Liability, Noncurrent</a></td>
<td class="nump">2,076,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">8,737,323<span></span>
</td>
<td class="nump">9,319,143<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">53,464,030<span></span>
</td>
<td class="nump">57,123,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock &#8211; no par value; 100,000,000 shares authorized; 15,263,555 and 15,481,497 shares issued and outstanding as of December&#160;31, 2019 and 2018, respectively</a></td>
<td class="nump">49,914,478<span></span>
</td>
<td class="nump">51,098,613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">1,208,395<span></span>
</td>
<td class="nump">4,746,154<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">51,122,873<span></span>
</td>
<td class="nump">55,844,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="num">(37,620)<span></span>
</td>
<td class="num">(274,266)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">51,085,253<span></span>
</td>
<td class="nump">55,570,501<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 104,549,283<span></span>
</td>
<td class="nump">$ 112,693,868<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1336-112600<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1314-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697812111960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock, no par value (dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, number of shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, number of shares issued</a></td>
<td class="nump">15,263,555<span></span>
</td>
<td class="nump">15,481,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, number of shares outstanding</a></td>
<td class="nump">15,263,555<span></span>
</td>
<td class="nump">15,481,497<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697725248776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income and Comprehensive Income (Loss) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 34,388,295<span></span>
</td>
<td class="nump">$ 29,344,894<span></span>
</td>
<td class="nump">$ 26,322,627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">7,421,316<span></span>
</td>
<td class="nump">6,016,822<span></span>
</td>
<td class="nump">5,418,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and marketing</a></td>
<td class="nump">15,277,740<span></span>
</td>
<td class="nump">14,004,933<span></span>
</td>
<td class="nump">13,489,178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">6,868,480<span></span>
</td>
<td class="nump">7,575,892<span></span>
</td>
<td class="nump">4,247,623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">9,974,384<span></span>
</td>
<td class="nump">10,150,777<span></span>
</td>
<td class="nump">9,610,967<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="nump">4,134,557<span></span>
</td>
<td class="nump">2,769,466<span></span>
</td>
<td class="nump">2,436,222<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">43,676,477<span></span>
</td>
<td class="nump">40,517,890<span></span>
</td>
<td class="nump">35,202,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="num">(9,288,182)<span></span>
</td>
<td class="num">(11,172,996)<span></span>
</td>
<td class="num">(8,879,373)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">243,364<span></span>
</td>
<td class="nump">564,484<span></span>
</td>
<td class="nump">299,326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(246,186)<span></span>
</td>
<td class="num">(195,848)<span></span>
</td>
<td class="num">(92,904)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) before income taxes</a></td>
<td class="num">(9,291,004)<span></span>
</td>
<td class="num">(10,804,360)<span></span>
</td>
<td class="num">(8,672,951)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (expense) benefit</a></td>
<td class="nump">79,316<span></span>
</td>
<td class="num">(16,636)<span></span>
</td>
<td class="num">(4,174,889)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income (loss) from continuing operations</a></td>
<td class="num">(9,211,688)<span></span>
</td>
<td class="num">(10,820,996)<span></span>
</td>
<td class="num">(12,847,840)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations net of tax</a></td>
<td class="nump">5,665,177<span></span>
</td>
<td class="nump">3,782,224<span></span>
</td>
<td class="nump">4,798,025<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(3,546,511)<span></span>
</td>
<td class="num">(7,038,772)<span></span>
</td>
<td class="num">(8,049,815)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss at subsidiary attributable to noncontrolling interests</a></td>
<td class="nump">8,752<span></span>
</td>
<td class="nump">75,704<span></span>
</td>
<td class="nump">71,182<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shareholders</a></td>
<td class="num">$ (3,537,759)<span></span>
</td>
<td class="num">$ (6,963,068)<span></span>
</td>
<td class="num">$ (7,978,633)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings (loss) per share attributable to common shareholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Earnings (loss) per share attributable to common shareholders-Continuing operations-basic (in USD per share)</a></td>
<td class="num">$ (0.60)<span></span>
</td>
<td class="num">$ (0.70)<span></span>
</td>
<td class="num">$ (0.80)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Earnings (loss) per share attributable to common shareholders-Discontinued operations-basic (in USD per share)</a></td>
<td class="nump">0.37<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
<td class="nump">0.30<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in USD per share)</a></td>
<td class="num">(0.23)<span></span>
</td>
<td class="num">(0.45)<span></span>
</td>
<td class="num">(0.50)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Earnings (loss) per share attributable to common shareholders-Continuing operations-diluted (in USD per share)</a></td>
<td class="num">(0.60)<span></span>
</td>
<td class="num">(0.70)<span></span>
</td>
<td class="num">(0.80)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Earnings (loss) per share attributable to common shareholders-Discontinued operations-diluted (in USD per share)</a></td>
<td class="nump">0.37<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
<td class="nump">0.30<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in USD per share)</a></td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="num">$ (0.50)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">15,396,098<span></span>
</td>
<td class="nump">15,614,052<span></span>
</td>
<td class="nump">15,911,577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">15,396,098<span></span>
</td>
<td class="nump">15,614,052<span></span>
</td>
<td class="nump">15,911,577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to common shareholders</a></td>
<td class="num">$ (3,537,759)<span></span>
</td>
<td class="num">$ (6,963,068)<span></span>
</td>
<td class="num">$ (7,978,633)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest', window );">Net loss at subsidiary attributable to noncontrolling interests</a></td>
<td class="nump">8,752<span></span>
</td>
<td class="nump">75,704<span></span>
</td>
<td class="nump">71,182<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive income (loss)</a></td>
<td class="num">(3,546,511)<span></span>
</td>
<td class="num">(7,038,772)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">32,407,245<span></span>
</td>
<td class="nump">28,803,961<span></span>
</td>
<td class="nump">25,549,059<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ManufacturedProductOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 1,981,050<span></span>
</td>
<td class="nump">$ 540,933<span></span>
</td>
<td class="nump">$ 773,568<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868656-224227<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868656-224227<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ManufacturedProductOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ManufacturedProductOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697725257848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">$ (3,546,511)<span></span>
</td>
<td class="num">$ (7,038,772)<span></span>
</td>
<td class="num">$ (8,049,815)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations net of tax</a></td>
<td class="nump">5,665,177<span></span>
</td>
<td class="nump">3,782,224<span></span>
</td>
<td class="nump">4,798,025<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income (loss) from continuing operations</a></td>
<td class="num">(9,211,688)<span></span>
</td>
<td class="num">(10,820,996)<span></span>
</td>
<td class="num">(12,847,840)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash flows provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">4,404,175<span></span>
</td>
<td class="nump">2,982,703<span></span>
</td>
<td class="nump">2,647,753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax expense</a></td>
<td class="nump">65,408<span></span>
</td>
<td class="nump">81,886<span></span>
</td>
<td class="nump">4,206,753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">1,485,898<span></span>
</td>
<td class="nump">1,364,698<span></span>
</td>
<td class="nump">1,115,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_SharebasedCompensationFoundationContribution', window );">Share-based compensation (foundation contribution)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">372,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities', window );">Excess tax (benefit) expense derived from exercise of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(81,886)<span></span>
</td>
<td class="num">(91,109)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1', window );">Decrease in non-cash contingent consideration</a></td>
<td class="num">(804,167)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Noncash interest expense</a></td>
<td class="nump">47,525<span></span>
</td>
<td class="nump">99,883<span></span>
</td>
<td class="nump">77,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingGainsLosses', window );">Noncash investment gains</a></td>
<td class="num">(26,315)<span></span>
</td>
<td class="num">(168,440)<span></span>
</td>
<td class="num">(52,012)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in assets and liabilities affecting operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(1,399,012)<span></span>
</td>
<td class="num">(47,288)<span></span>
</td>
<td class="nump">753,521<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">1,106,175<span></span>
</td>
<td class="nump">528,153<span></span>
</td>
<td class="num">(292,710)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Prepaid, other current assets and other assets</a></td>
<td class="num">(615,199)<span></span>
</td>
<td class="nump">676,750<span></span>
</td>
<td class="num">(1,155,630)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and other current liabilities</a></td>
<td class="nump">3,221,780<span></span>
</td>
<td class="nump">4,153,287<span></span>
</td>
<td class="nump">339,751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="num">(729,820)<span></span>
</td>
<td class="num">(159,558)<span></span>
</td>
<td class="nump">413,097<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash (used in) operating activities from continuing operations</a></td>
<td class="num">(2,455,240)<span></span>
</td>
<td class="num">(1,390,808)<span></span>
</td>
<td class="num">(4,512,952)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Discontinued operations</a></td>
<td class="nump">5,511,596<span></span>
</td>
<td class="nump">4,503,545<span></span>
</td>
<td class="nump">3,955,238<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">3,056,356<span></span>
</td>
<td class="nump">3,112,737<span></span>
</td>
<td class="num">(557,714)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property and equipment</a></td>
<td class="num">(246,202)<span></span>
</td>
<td class="num">(455,569)<span></span>
</td>
<td class="num">(275,960)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Additions to intangible assets</a></td>
<td class="num">(772,944)<span></span>
</td>
<td class="num">(3,819,486)<span></span>
</td>
<td class="num">(1,213,110)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for acquisition</a></td>
<td class="num">(5,000,000)<span></span>
</td>
<td class="num">(20,000,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Proceeds from sale of marketable securities</a></td>
<td class="nump">20,062,132<span></span>
</td>
<td class="nump">16,122,376<span></span>
</td>
<td class="nump">13,381,061<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(11,745,138)<span></span>
</td>
<td class="num">(19,572,139)<span></span>
</td>
<td class="num">(2,379,414)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">2,297,848<span></span>
</td>
<td class="num">(27,724,818)<span></span>
</td>
<td class="nump">9,512,577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit', window );">Borrowings on line of credit</a></td>
<td class="nump">76,000,000<span></span>
</td>
<td class="nump">56,000,000<span></span>
</td>
<td class="nump">24,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments on line of credit</a></td>
<td class="num">(77,500,000)<span></span>
</td>
<td class="num">(45,800,000)<span></span>
</td>
<td class="num">(18,800,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common shares</a></td>
<td class="num">(3,494,921)<span></span>
</td>
<td class="num">(2,879,426)<span></span>
</td>
<td class="num">(3,724,375)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of deferred equity offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(383,310)<span></span>
</td>
<td class="num">(27,950)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Sales of shares of common stock, net of offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">200,909<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payments of financing costs</a></td>
<td class="num">(52,500)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Cash payments of contingent consideration</a></td>
<td class="num">(1,033,108)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMinorityShareholders', window );">Sale of subsidiary shares to noncontrolling interest</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="num">(5,080,529)<span></span>
</td>
<td class="nump">7,138,173<span></span>
</td>
<td class="nump">1,947,675<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">273,675<span></span>
</td>
<td class="num">(17,473,908)<span></span>
</td>
<td class="nump">10,902,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">27,938,960<span></span>
</td>
<td class="nump">45,412,868<span></span>
</td>
<td class="nump">34,510,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">28,212,635<span></span>
</td>
<td class="nump">27,938,960<span></span>
</td>
<td class="nump">45,412,868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_CashPaidDuringYearForAbstract', window );"><strong>Net cash paid (refunded) during the year for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">198,661<span></span>
</td>
<td class="nump">95,965<span></span>
</td>
<td class="nump">14,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="nump">16,694<span></span>
</td>
<td class="nump">15,441<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid', window );">Change in unpaid invoices for purchases of intangibles</a></td>
<td class="num">(576,837)<span></span>
</td>
<td class="num">(539,467)<span></span>
</td>
<td class="num">(513,481)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses', window );">Deferred offering costs included in accounts payable and other accrued expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">97,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1', window );">Non cash increase in liabilities related to acquisition (see Note 3)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,034,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Recognition of operating lease assets and liabilities through adoption of ASC 842</a></td>
<td class="nump">3,629,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_NoncashOrPartNoncashTransactionVestingOfShares', window );">Vesting of shares related to RediTrex approval</a></td>
<td class="nump">862,200<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Repurchase of subsidiary shares from noncontrolling interests</a></td>
<td class="num">(800,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1', window );">Additions to intangible assets from final purchase price allocation</a></td>
<td class="nump">$ 148,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CashPaidDuringYearForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Paid During Year For [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CashPaidDuringYearForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Offering Costs Included in Accounts Payable and Other Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_NoncashOrPartNoncashTransactionVestingOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash or Part Noncash Transaction, Vesting of Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_NoncashOrPartNoncashTransactionVestingOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchases of Intangible Assets Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_SharebasedCompensationFoundationContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation, Foundation Contribution</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_SharebasedCompensationFoundationContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of right to a contingent consideration asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11374-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4616395-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities, classified as other, assumed in acquiring a business or in consideration for an asset received in a noncash or part noncash acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7,9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697725543912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th">
<div>Retained earnings </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Noncontrolling interest</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, balance at Dec. 31, 2016</a></td>
<td class="nump">$ 73,120,819<span></span>
</td>
<td class="nump">$ 1,082,924<span></span>
</td>
<td class="nump">$ 54,643,268<span></span>
</td>
<td class="nump">$ 18,604,931<span></span>
</td>
<td class="nump">$ 1,082,924<span></span>
</td>
<td class="num">$ (127,380)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Equity, common shares outstanding at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,074,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shareholders</a></td>
<td class="num">(7,978,633)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,978,633)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss at subsidiary attributable to noncontrolling interests</a></td>
<td class="num">(71,182)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(71,182)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(8,049,815)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Repurchase of subsidiary shares to noncontrolling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation, amount</a></td>
<td class="nump">1,115,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,115,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options and related tax benefit</a></td>
<td class="nump">372,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 372,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding', window );">Exercise of options and related tax benefit, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">(3,719,890)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,719,890)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(547,376)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, balance at Dec. 31, 2017</a></td>
<td class="nump">63,921,601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,410,941<span></span>
</td>
<td class="nump">11,709,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(198,562)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Equity, common shares outstanding at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,723,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shareholders</a></td>
<td class="num">(6,963,068)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,963,068)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss at subsidiary attributable to noncontrolling interests</a></td>
<td class="num">(75,704)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75,704)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(7,038,772)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Repurchase of subsidiary shares to noncontrolling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation, amount</a></td>
<td class="nump">1,364,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,364,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from sale of common stock, net of offering costs</a></td>
<td class="nump">200,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from the sale of common stock, net of offering costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">(2,877,935)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,877,935)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(443,041)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, balance at Dec. 31, 2018</a></td>
<td class="nump">$ 55,570,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,098,613<span></span>
</td>
<td class="nump">4,746,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(274,266)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Equity, common shares outstanding at Dec. 31, 2018</a></td>
<td class="nump">15,481,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,481,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shareholders</a></td>
<td class="num">$ (3,537,759)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,537,759)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss at subsidiary attributable to noncontrolling interests</a></td>
<td class="num">(8,752)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,752)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(3,546,511)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Repurchase of subsidiary shares to noncontrolling interest</a></td>
<td class="num">(800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (685,805)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(114,195)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Sale of subsidiary shares to noncontrolling interest</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">640,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359,593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Vesting of common stock</a></td>
<td class="nump">862,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 862,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vesting of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation, amount</a></td>
<td class="nump">1,485,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,485,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">(3,486,835)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,486,835)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(623,478)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, balance at Dec. 31, 2019</a></td>
<td class="nump">$ 51,085,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,914,478<span></span>
</td>
<td class="nump">$ 1,208,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (37,620)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Equity, common shares outstanding at Dec. 31, 2019</a></td>
<td class="nump">15,263,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,263,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Net of Shares for Tax Withholding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4616395-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697722017560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Valuation and Qualifying Accounts<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsAbstract', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">Valuation and Qualifying Accounts</a></td>
<td class="text"><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation and Qualifying Accounts</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Years ended December&#160;31, 2019, 2018 and 2017</span></div><div style="margin-bottom:6pt;margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.182%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.226%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.724%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">beginning&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">period</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Charged to</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">costs and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">expenses</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Charged&#160;to</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">accounts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">end&#160;of&#160;period</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for uncollectible amounts, cash discounts, chargebacks, and credits issued for damaged products:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the years ended </span></div><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446,514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,371,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,491,263)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326,697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326,697&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,610,899&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,133,176)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">804,420&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">804,420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,915,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,927,435)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">792,051&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the years ended </span></div><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(665,039)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,908,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,632,235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,632,235&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,749,817&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,382,052&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,382,052&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,129,109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,511,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)   Composed of actual returns and credits for chargebacks and cash discounts.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)   Amount includes $4,202,854 related to increase in the valuation allowance during the year, net of $4,867,893 related to the revaluation of deferred income tax balances for new rates under the Tax Act.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697721788408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization</a></td>
<td class="text">Organization<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products.  The Company's primary target markets are hospital acute care and gastroenterology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.  The Company promotes its approved products through its hospital and field sales forces in the United States and is establishing a network of international partners to bring its medicines to patients in their countries.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#8217;s products are manufactured by third parties, which are overseen by Cumberland&#8217;s quality and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to build a pipeline of early-stage product candidates, the Company formed a subsidiary, Cumberland Emerging Technologies, Inc. ("CET"), which teams with universities and other research organizations to help advance scientific discoveries from the laboratory to the marketplace.  In 2014, the Company organized equity financing to recapitalize and strengthen the financial position of CET including an investment of approximately $1.0 million from Gloria Pharmaceuticals Co., Ltd. (&#8220;Gloria&#8221;).  As a result, Gloria received shares in CET and joined the CET ownership group. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April, 2019, CET entered into an agreement with HongKong WinHealth Pharma Group Co. Limited (WinHealth) </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">whereby WinHealth made a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $1.0&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investment through the purchase of shares of CET stock. As part of the agreement, WinHealth obtained a Board position at CET and the first opportunity to license CET products for the Chinese market. In connection with WinHealth's investment in CET, Cumberland also made an additional $1.0 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investment in CET.  Cumberland purchased additional CET shares through contribution of $0.3&#160;million in cash and a conversion of $0.7&#160;million in intercompany loans payable.  Upon completion of the additional investment by WinHealth and Cumberland, Gloria Pharmaceuticals agreed to return its shares in CET in exchange for consideration of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $0.8 million.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's ownership in CET is now 85%.  As noted above, the ownership interests of CET includes WinHealth and Cumberland, while the remaining interest is owned by Vanderbilt University and the Tennessee Technology Development Corporation. The operating results of CET allocated to noncontrolling interests in the consolidated statements of operations were  $8,752, $75,704 and $71,182 for the years ended December&#160;31, 2019, 2018 and 2017, respectively.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January&#160;1, 2007, the Company formed a wholly-owned subsidiary, Cumberland Pharma Sales Corp. ("CPSC").  CPSC is the subsidiary that employs the Company's hospital and field sales force personnel.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697723381896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text">Significant Accounting Policies<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements of the Company are stated in U.S. dollars and are prepared using U.S. generally accepted accounting principles. These financial statements include the accounts of the Company and its wholly and majority-owned subsidiaries. All significant intercompany transactions and accounts have been eliminated in consolidation.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns (2) the allowances for obsolescent or unmarketable inventory (3) assumptions used in estimating acquisition date fair value of assets acquired in business combinations and (4) valuation of contingent consideration liability associated with business combinations.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, evaluated that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States. Total revenues are primarily attributable to U.S.&#160;customers.  Net revenues from customers outside the United States were approximately $1.5 million, $2.1 million and $1.6 million for the years ended December&#160;31, 2019, 2018 and 2017, respectively.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of financial assets and liabilities is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date.  The Company's fair value measurements follow the appropriate rules as well as the fair value hierarchy that prioritizes the information used to develop the measurements.  It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:</span></div><div style="margin-top:8pt;padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 -   Quoted prices for identical instruments in active markets.</span></div><div style="margin-top:8pt;padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 -  Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.</span></div><div style="margin-top:8pt;padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 -    Significant inputs to the valuation model are unobservable.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain policies and procedures to value instruments using the best and most relevant data available. The following section describes the valuation methodologies we use to measure different financial instruments at fair value on a recurring basis.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments include cash and cash equivalents, marketable securities, accounts receivable, accounts payable, accrued liabilities, contingent consideration liability and a revolving line of credit. The carrying values for cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to their short-term nature. The revolving line of credit has a variable interest rate, which approximates the current market rate.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's fair values of marketable securities are determined based on valuations provided by a third-party pricing service, as derived from such services' pricing models, and are considered either Level 1 or Level 2 measurements, depending on the nature of the investment.  The Company has no marketable securities in which the fair value is determined based on Level 3.  The level of management judgment required in evaluating fair value for Level 1 investments is minimal.  Similarly, there is little subjectivity or judgment required for Level 2 investments valued using valuation models that are standard across the industry and whose parameter inputs are quoted in active markets.  Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. The Company believes that the valuations provided by the third-party pricing service, as derived from such services' pricing models, represent prices that would be received to sell the assets at the measurement date (exit prices).</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's contingent consideration liability is a Level 3 fair value measurement that is updated on a recurring basis at each reporting period using a valuation model.  Consistent with Level 3 fair value measurements, there are significant inputs to the valuation model that are unobservable. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include highly liquid investments with original maturities of three months or less.  As of December&#160;31, 2019 and 2018, cash equivalents consist primarily of money market funds as well as trading securities with original maturities of less than ninety days. </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests in marketable debt securities in order to maximize its return on cash. Marketable securities consist of short-term cash investments, U.S. Treasury notes and bonds, corporate bonds, and commercial paper.  At the time of purchase, the Company classifies marketable securities as either trading securities or available-for-sale securities, depending on the intent at that time.  As of December&#160;31, 2019 and 2018, marketable securities were comprised solely of trading securities.  Trading securities are carried at fair value with unrealized gains and losses recognized as a component of interest income in the consolidated statements of operations.  As of December&#160;31, 2019, all the trading securities were commercial paper with original maturities of less than ninety days and as a result, were classified as cash equivalents.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable are recorded at the invoiced amount.  The Company records allowances for amounts that could become uncollectible in the future based on historical experience, including amounts related to chargebacks, cash discounts and credits for damaged product. The Company reviews each customer balance to assess collection status.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s products are distributed through independent pharmaceutical wholesalers.  The allowances against accounts receivable for chargebacks and discounts are determined on a product-by-product basis, and established by management as the Company&#8217;s best estimate at the time of sale based on each product&#8217;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks, discounts and credits claimed for damaged and expired product. The allowances in accounts receivable for chargebacks, cash discounts and damaged goods were $0.8 million at December&#160;31, 2019 and $0.7 million at December 31, 2018. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company&#8217;s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, revenues are reduced and accrued liabilities are increased by the Company&#8217;s estimate of the rebate that may be claimed as well as the reserves for expired and damaged goods.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash discounts are reductions to invoiced amounts offered to customers for payment within a specified period of time from the date of the invoice.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company works closely with third parties to manufacture and package finished goods for sale.  Based on the customer relationship with the manufacturer or packager, the Company will either take title to finished goods at the time of shipment or at the time of arrival from the manufacturer.  The Company then warehouses such goods until distribution and sale.  As discussed below, effective January 1, 2017, inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually evaluates inventories for potential losses due to expired, short-dated or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates the carrying value of a product may not be recoverable, a charge is recorded to reduce the inventory to its current net realizable value.  The Company classifies the Vibativ inventories that it does not expect to sell within one year as non-current inventories. </span></div><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid and Other Current Assets</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid and other current assets consist of deferred offering costs, prepaid insurance premiums, prepaid consulting services, deposits and annual fees paid to the U.S. Food and Drug Administration ("FDA").  The Company expenses all prepaid and other current asset amounts as used or over the period of benefit primarily on a straight-line basis, as applicable.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred offering costs are expenses directly related to the Form S-3 or Shelf Registration filed with the SEC on November 11, 2017 and declared effective on January 16, 2018. These costs consist of legal, accounting, printing, and filing fees that the Company has capitalized. Deferred costs associated with the Shelf Registration will be reclassified to additional paid in capital on a pro-rata basis as the Company completes sales of shares under the Shelf Registration, with any remaining deferred offering costs to be charged to the results of operations at the end of the three-year life of the Shelf Registration. During the year ended December&#160;31, 2019, the Company has not expensed any deferred offering costs associated with the Shelf Registration.</span></div><div style="margin-top:7pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, including leasehold improvements, are stated at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the initial lease term plus renewal options, if reasonably assured, or the remaining useful life of the asset. Upon retirement or disposal of assets, any gain or loss is reflected as a component of operating income (loss) in the consolidated statement of operations.  Improvements that extend an asset&#8217;s useful life are capitalized.  Repairs and maintenance costs are expensed as incurred.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Goodwill</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intangible assets and goodwill consist of capitalized costs related to product and license rights, patents, trademarks and goodwill obtained in the Vibativ acquisition. Goodwill is not amortized for financial reporting purposes, but is subject to impairment analysis at least annually.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of acquiring product and license rights are capitalized at fair value at the date of acquisition for products that are approved by the FDA for commercial use.  These costs are amortized ratably over the estimated economic life of the product. The economic life is estimated based upon several factors.  This includes the term of the license agreement, the patent life or market exclusivity of the product and as well as  management's expectations of continued involvement with the product and the assessment of future sales, the future periods under which the product will be sold and the profitability of the product. This estimate is evaluated on a regular basis during the amortization period and adjusted if appropriate.  If there are any changes made to the useful life of the product and license rights, the costs associated with such a change, if any, will be capitalized and amortized over the revised useful life.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized patent costs consist of outside legal costs associated with obtaining and protecting patents on products that have been approved for marketing by the FDA. If it becomes probable that a patent will not be issued or a patent has been declared invalid, related costs associated with the patent application are expensed at the time such determination is made. All costs associated with obtaining patents for products that have not been approved for marketing by the FDA are expensed as incurred.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense is recognized ratably over the following periods:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:63.141%"><tr><td style="width:1.0%"/><td style="width:46.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rights</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated economic life</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License rights</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term of license agreement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life of patent</span></td></tr></table></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, such as property and equipment, operating lease right-of-use assets and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If events or circumstances arise that require a long-lived asset to be tested for potential impairment, the Company first compares undiscounted cash flows expected to be generated by the asset to its carrying value. If the carrying amount of the long-lived asset is not recoverable on an undiscounted cash flow basis, an impairment charge is recognized to the extent that the carrying value exceeds the fair value. Fair value is determined through various valuation techniques including quoted market prices, third-party independent appraisals and discounted cash flow models.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and other indefinite lived intangible assets that are not subject to amortization are tested at least annually for impairment.  The impairment analysis for goodwill requires a comparison of fair value to the carrying value of the reporting unit.  The Company's goodwill was acquired in November 2018 with the Vibativ acquisition. As a result, the Vibativ component of the Company is the reporting unit evaluated for goodwill impairment.  Cumberland determined the fair value of the reporting unit through current and future estimated revenue and profitability of the product.  The Company recorded no impairment charges during 2019, 2018 and 2017.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2018, the Company adopted the Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;) amended guidance in the form of Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-09, "Revenue from Contracts with Customers," (ASC 606). Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts were not adjusted and are reported in accordance with ASC 605.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Product Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recognized in the amount that reflects the consideration that we expect to receive for these goods.  Depending upon the shipping terms of the transaction, the revenue is recognized.at the point where the customer obtains control of the goods and we satisfy our performance obligation.  This occurs upon either shipment of the product or arrival at its ship to destination.  Payment terms typically range from 30 to 60 days from date of shipment. The Company&#8217;s net product revenue reflects the reduction from gross product revenue for </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">estimated allowances for chargebacks, discounts and damaged goods, and reflects sales related accruals for rebates, coupons, product returns, and certain administrative and service fees. Significant judgments must be made in determining the transaction price for our sales of products related to these adjustments. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Rebates and Discounts</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowances against accounts receivable for chargebacks, discounts, expired and damaged goods are determined on a product-by-product basis, and established by management as the Company&#8217;s best estimate at the time of sale based on each product&#8217;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks, discounts and credits claimed for damaged and expired product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company&#8217;s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, sales revenues are reduced and accrued liabilities are increased by the Company&#8217;s estimate of the rebate that may be claimed.</span></div><div style="margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Returns</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, the Company maintains a return policy that allows customers to return product within a specified period prior to and subsequent to the expiration date. The Company&#8217;s estimate of the provision for returns is based upon historical experience, expiration date by product as well as any other factor expected to impact future returns. Any changes in the assumptions used to estimate the provision for returns are recognized in the period those assumptions are changed.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Revenues</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues primarily consist of income from grant funding programs, licensing agreements, leases and contract services.  Revenue related to grants is recognized when all conditions related to such grants have been met.  All other revenue is recognized when earned.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Products Sold</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products sold consists principally of the cost to acquire each unit of product sold, including in-bound freight expense as well as any adjustment in the net realizable value of inventory acquired in acquisitions. Cost of products sold also includes expenses associated with the reduction in the net realizable value of slow-moving or expired product.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling and Marketing Expense</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling and marketing expense consists primarily of expenses relating to the advertising, promotion, distribution and sale of products, including royalty expense, salaries and related costs.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Distribution Costs</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distribution costs are expensed as incurred and are included as a component of selling and marketing expenses in the consolidated statements of operations. Distribution costs were as follows for the years ended December 31:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.897%"><tr><td style="width:1.0%"/><td style="width:41.064%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.919%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.064%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.919%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.919%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.559%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2017</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613,637&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457,814&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487,669&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Costs</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs are expensed as incurred and are included as a component of selling and marketing expenses in the consolidated statements of operations. Advertising costs were as follows for the years ended December 31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.897%"><tr><td style="width:1.0%"/><td style="width:41.064%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.919%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.064%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.919%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.919%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.559%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2017</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advertising costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,594,630&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,005,113&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,377,338&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed in the period incurred. Research and development costs are comprised mainly of clinical trial expenses, salaries, wages and other related costs such as materials and supplies. Research and development expense includes activities performed by third-party providers participating in the Company&#8217;s clinical studies. The Company accounts for these costs based on estimates of work performed, patients enrolled or fixed fees for services over the period of time the clinical trials are performed.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides for deferred taxes using the asset and liability approach. Under this method, deferred tax assets and liabilities are recognized for future tax consequences attributable to operating loss and tax credit carryforwards, as well as differences between the carrying amounts of existing assets and liabilities and their respective tax bases. The Company&#8217;s principal differences are related to the timing of deductibility of certain items, such as inventory, depreciation, amortization and share-based compensation. Deferred tax assets and liabilities are measured using enacted statutory tax rates that are expected to apply to taxable income in the years such temporary differences are anticipated to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. The Company only recognizes income tax benefits associated with an income tax position in which it is &#8220;more likely than not&#8221; that the position would be sustained upon examination by the taxing authorities.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, management considers whether some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of existing temporary differences, projected future taxable income and tax planning strategies in making this assessment. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounting policy with respect to interest and penalties arising from income tax settlements is to recognize them as part of the provision for income taxes.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total comprehensive income (loss) was comprised solely of net income (loss) for all periods presented.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings (Loss) per Share</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings (loss) per share is calculated by dividing net income (loss) attributable to common shareholders by the weighted-average number of shares outstanding. Except where the result would be antidilutive to income from continuing operations, diluted earnings (loss) per share is calculated by assuming the vesting of unvested restricted stock and the exercise of stock options and warrants and unrecognized compensation costs.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Payments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation cost for all share-based payments issued, modified, repurchased or canceled. Depending on the nature of the vesting provisions, restricted stock awards are measured using either the fair value on the grant date or the fair value of common stock on the date the vesting provisions lapse. Prior to the lapse for those equity grants not valued on the grant date, the fair value is measured on the last day of the reporting period.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Agreements</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party to several collaborative arrangements with certain research institutions to identify and pursue promising preclinical pharmaceutical product candidates. The Company has determined these collaborative agreements do not meet the criteria for accounting under Accounting Standards Codification 808, Collaborative Agreements. The agreements do not specifically designate each party's rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party. The funding for these programs is generally provided through private sector investments or federal Small Business Administration ("SBIR/STTR") grant programs. Expenses incurred under these collaborative agreements are included in research and development expenses in the consolidated statements of operations. Funding received from private sector investments and grants are recorded as net revenues in the consolidated statements of operations.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassification of prior period amounts</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has made certain reclassifications to prior period amounts to conform to the current-year presentation of the reporting of research and development expense and general and administrative expense on the consolidated statements of operations. Certain costs and expenses related to research and development were previously reported as general and administrative expenses on the consolidated statements of operations. These reclassifications have no effect on the reported operating loss or equity for the years ended December 31, 2018 and 2017. </span></div><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance </span></div><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Adopted Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2014, the FASB issued amended guidance in the form of ASU No. 2014-09, &#8220;Revenue from Contracts with Customers&#8221; (&#8220;ASC 606&#8221;).  The core principle of the new guidance is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. The new guidance defines a five-step process to achieve this core principle and, in doing so, additional judgments and estimates may be required within the revenue recognition process. The new standard replaced most of the existing revenue recognition standards in U.S. GAAP when it became effective. In July 2015, the FASB issued a one-year deferral of the adoption date, which extended the effective date for us to January 1, 2018, at which point Cumberland adopted the standard. </span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated its revenues and the new guidance had immaterial impacts to recognition practices upon adoption on January 1, 2018.  As part of the adoption, the Company elected to apply the new guidance on a modified retrospective basis. The Company did not record a cumulative effect adjustment to historical retained earnings for initially applying the new guidance as no revenue recognition differences were identified in the timing or amount of revenue. </span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the Financial Accounting Standards Board ("FASB") issued guidance in the form of a FASB Accounting Standards Update ("ASU") No. 2016-02, &#8220;Leases.&#8221; The new standard establishes a right-of-use (&#8220;ROU&#8221;) model that requires a lessee to record an ROU asset and a lease liability on the balance sheet for all leases with terms longer than twelve months. Leases will be classified as either finance (formerly "capital leases") or </span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operating, with classification affecting the pattern of expense recognition in the income statement. The standard provides for a modified retrospective transition approach for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain optional practical expedients.  In July 2018, the FASB issued ASU 2018-11, "Leases: Targeted Improvements", allowing for an alternative transition method (the effective date approach). It allows an entity to initially apply the new lease guidance at the adoption date (rather than at the beginning of the earliest period presented). Cumberland adopted the lease guidance effective January 1, 2019 using the package of transition practical expedients.  This allowed the Company to retain the lease classification for any leases existing prior to adoption, in addition to other benefits. See additional discussion of the impact of adopting the lease accounting guidance in Note 15.</span></div><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements - Not Yet Adopted</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose more information, including the information they use to track credit quality by year of origination for most financing receivables. Companies will apply the standard&#8217;s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. This standard is effective for the Company on January 1, 2020. The Company continues to evaluate this new standard on its trade and other receivables but does not expect a material impact on its consolidated financial statements. </span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met, the election must be applied on an instrument-by-instrument basis, and the election is not available for either available-for-sale or held-to-maturity debt securities. The effective date is the same as ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January 1, 2020. The Company continues to evaluate this new standard but does not expect a material impact on its consolidated financial statements. </span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued ASU No. 2018-18, &#8220;Collaboration Arrangements: Clarifying the Interaction between Topic 808 and Topic 606&#8221; (ASU 2018-18). The issuance of ASU 2014-09 raised questions about the interaction between the guidance on collaborative arrangements and revenue recognition. ASU 2018-18 addresses this uncertainty by (1) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASU 2014-09 when the collaboration arrangement participant is a customer, (2) adding unit of account guidance to assess whether the collaboration arrangement or a part of the arrangement is with a customer and (3) precluding a company from presenting transactions with collaboration arrangement participants that are not directly related to sales to third parties together with revenue from contracts with customers. The new standard will be effective for the Company on January 1, 2020.  The Company continues to evaluate this new standard but does not expect a material impact on its consolidated financial statements. </span></div>In January 2017, the FASB issued ASU No. 2017-04, &#8220;Simplifying the Test for Goodwill Impairment&#8221; (ASU 2017-04). The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation.  As a result of the revised guidance, a goodwill impairment will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The new standard will be effective for the Company on January 1, 2020. The Company continues to evaluate this new standard but does not expect a material impact on its consolidated financial statements and related disclosures.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697721778776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Omeclamox&#174;-Pak, RediTrex&#174; and Vibativ&#174;<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Omeclamox&#174;-Pak, RediTrex&#174; and Vibativ&#174;</a></td>
<td class="text">Omeclamox<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-Pak, RediTrex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> and Vibativ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Omeclamox-Pak</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, Cumberland completed an agreement with Gasto-enterlogics Inc. ("GEL") to acquire the remaining product rights associated with Omeclamox-Pak including the product&#8217;s FDA-approved New Drug Application and the domestic and international trademarks. As part of the transaction, which was accounted for as an asset acquisition, Cumberland paid $2.3 million during 2018 and ended Cumberland&#8217;s payments of royalties and manufacturing fees to GEL.  The Company has now assumed responsibility for the maintenance of the product&#8217;s FDA approval and for the oversight of the product&#8217;s manufacturing and packaging.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This agreement follows the November 2015 agreement between Cumberland and GEL to assume the remaining commercial rights to Omeclamox-Pak for the United States. The Company had previously signed an agreement with Pernix Therapeutics ("Pernix") to jointly commercialize the product in the United States in October 2013.  As part of the November 2015 GEL Agreement, Cumberland and Pernix terminated their arrangements. </span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $4.0 million upfront payment that the Company paid in October 2013 to Pernix along with the payments made to GEL during 2018 are included in product and license rights and are being amortized over the remaining expected useful life of the acquired asset. The Company evaluated the remaining expected useful life and maintained the existing estimated life of the product, June 2032.  Omeclamox-Pak contributed $0.8 million, $0.6 million, and $1.8 million in net revenues during 2019, 2018, and 2017, respectively.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RediTrex</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, the Company announced an Agreement to acquire the exclusive U.S. rights to Nordic Group B.V.&#8217;s ("Nordic") injectable methotrexate product line as an asset purchase. The products are designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Agreement, Cumberland is responsible for the products&#8217; FDA submission and registration. As consideration for the license, at closing, Cumberland paid a deposit of $100,000.  The Company also recorded a liability of $0.9 million that will be settled through 180,000 unvested restricted shares of Cumberland common stock that vest upon the FDA approval of the first Nordic product. Cumberland also agreed to provide Nordic a series of payments tied to the products&#8217; FDA approval, launch and achievement of certain sales milestones. Nordic is responsible for manufacturing and supply of the products. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2019, Cumberland received FDA approval of the pre-filled syringe. The 180,000 shares of restricted Cumberland common stock vested and were valued at $0.9 million on the vesting date. In addition, the FDA approval resulted in an additional $1.0&#160;million liability to Nordic that will be paid during 2020.  The value of the then unvested restricted Cumberland common stock shares was a liability of $1.1 million at December&#160;31, 2018.   </span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vibativ</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand.  Vibativ is a patented, FDA approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.  Cumberland acquired Vibativ to further add to its product offerings, increase its net revenue and positively contribute to the Company's operating results.  Cumberland expects to deduct the goodwill acquired in the acquisition for tax purposes.    </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company paid an upfront payment of $20.0 million at closing and a $5.0 million cash payment during early 2019. In addition, Cumberland agreed to pay a royalty of up to 20% on future net sales of the product.  The future royalty payments were required to be recognized at their acquisition-date fair value as part of the contingent consideration transferred in the business combination. </span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the initial payments and consideration for the business combination:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"><tr><td style="width:1.0%"/><td style="width:74.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.578%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid at closing</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment during early 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration - net sales royalty</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,182,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,182,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liability represents the future net sales royalty payments discussed above.  Cumberland prepared the valuations of the contingent consideration liability and the intangible assets utilizing significant unobservable inputs.  As a result, the valuations are classified as Level 3 fair value measurements.  The Company will continue to evaluate the assets acquired and liabilities assumed during the measurement period. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the Company's Level 3 contingent consideration liability that is measured at fair value on a recurring basis.  The current and long-term portions of this liability are disclosed in Note 8.  The contingent consideration earned and accrued in operating expenses is paid to the seller quarterly.</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.265%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.535%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent consideration liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at November 12, 2018</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,034,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,000)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2018</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,502,000&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment to initial fair value of the contingent consideration liability</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,033,108)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(804,167)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820,864&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,633,589&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the allocation of the fair values of the assets acquired as of the acquisition date for Vibativ:</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.743%"><tr><td style="width:1.0%"/><td style="width:63.185%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.615%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,624,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process - unlabeled vials</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,970,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process - validation vials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,827,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,129,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,550,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property amortizable intangible assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,750,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangibles and goodwill</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,632,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,182,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The Company's contingent consideration liability is a Level 3 fair value measurement that is updated on a recurring basis at each reporting period using a valuation model.  Consistent with Level 3 fair value measurements, there are significant inputs to the valuation model that are unobservable. The current portion of the contingent consideration liability is $2.4&#160;million and the non-current portion is $6.3&#160;million, as of December&#160;31, 2019.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697722022824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Revenues</a></td>
<td class="text">Revenues<div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenues</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net product revenues consisted of the following for the years ended December&#160;31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.698%"><tr><td style="width:1.0%"/><td style="width:40.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.909%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.644%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.909%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.909%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,824,449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,284,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,576,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837,829&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623,297&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,761,868&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,895,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,055,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,455,805&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,615&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,763,874&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,576,222&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,222,282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,001,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,178,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,691,550&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,075,057&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net product revenues</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,407,845&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,803,961&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,549,058&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:16pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, Cumberland executed a License and Distribution agreement with HongKong WinHealth Pharma Group Co. Limited (&#8220;WinHealth&#8221;) for our Caldolor and Acetadote</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">brands in China and Hong Kong.  In conjunction with these new arrangements, the Company terminated a previous License and Distribution agreement with Gloria Pharmaceuticals Co ("Gloria Pharmaceuticals") for the two brands.  In addition, we also signed a new License and Distribution agreement with DB Pharm Korea Co., Ltd. (&#8220;DB Pharm&#8221;) for Vibativ in South Korea. As a result of these agreements, Cumberland recognized approximately $0.3&#160;million of non-refundable up-front payments as other revenue in the consolidated statement of operations during 2019.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into agreements, beginning in 2012, with international partners for commercialization of the Company's products.  The international agreements provide that each of the partners are responsible for seeking regulatory approvals for the products, and following approvals, each partner will handle ongoing </span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">distribution and sales in the respective international territories.  The Company maintains responsibility for the intellectual property and product formulations.  Under the international agreements, the Company is entitled to receive non-refundable up-front payments at the time the agreements are entered into and payments upon the partners' achievement of defined regulatory approvals and sales milestones.  The Company will recognize revenue for these achievements once it is probable that these consideration amounts are no longer constrained. The Company is also entitled to receive royalties on future sales of the products under the agreements. The international agreements provide for $1.0 million in non-refundable up-front payments, milestone payments of up to $2.2 million related to regulatory approvals and up to $4.8 million in payments related to product sales.  From 2012 through December&#160;31, 2019, the Company has recognized a cumulative $1.2 million in upfront payments as other revenue and has recognized $0.1&#160;million in revenue related to the milestone payments associated with these international agreements.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues during 2019, 2018 and 2017 also includes revenue generated by CET through grant funding from federal Small Business grant programs, and lease income generated by CET&#8217;s Life Sciences Center and contract services. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from SBIR/STTR programs totaled approximately $1.3 million, $0.1 million, and $0.2 million for the years ending December&#160;31, 2019, 2018 and 2017, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697721778776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories<div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's net inventories consisted of the following as of December 31:</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.339%"><tr><td style="width:1.0%"/><td style="width:60.000%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.248%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,345,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,378,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">937,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods, net of reserve</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,664,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,216,965&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,426,246&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,532,421&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,554,992)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,749,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,871,254&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,783,421&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company continually evaluates inventories for potential losses due to expired, short-dated or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates the carrying value of a product may not be recoverable, a charge is recorded to reduce the inventory to its current net realizable value. At December&#160;31, 2019 and 2018, the Company had recognized and maintained cumulative charges for potential obsolescence and discontinuance losses of approximately $0.1 million and $0.3 million, respectively.  At December&#160;31, 2019 there were no cumulative obsolescence or discontinuance losses necessary.  </span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of certain product rights related to the Kristalose brand, the Company is responsible for the purchase of the active pharmaceutical ingredient ("API") for Kristalose and maintains the inventory at the third-party packagers.  As the API is consumed in production, the value of the API is transferred from raw materials to finished goods.  API for the Company's Vaprisol brand is also included in the raw materials inventory total at December&#160;31, 2019 and 2018. Consigned inventory represents Authorized Generic inventory stored with Perrigo until shipment.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories of $15.7 million  that are classified as non-current inventories at December&#160;31, 2018.  At December&#160;31, 2019, the Vibativ non-current inventory was $15.3 million.  Although the Company did not have any finished goods included in the non-current inventories at December&#160;31, 2019, we had $0.8&#160;million in Vibativ finished goods included at December&#160;31, 2018.  During 2019, Cumberland also obtained $0.3&#160;million in non-current inventory for API related to its ifetroban clinical initiatives.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697723381896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment<div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following at December&#160;31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.980%"><tr><td style="width:1.0%"/><td style="width:34.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.892%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.125%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.892%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.892%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.120%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">useful lives</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;&#8211;&#160;5&#160;years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,148,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;&#8211;&#160;15&#160;years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878,350&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809,153&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;&#8211;&#160;15 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639,267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;&#8211;&#160;15&#160;years,&#160;or remaining&#160;lease&#160;term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,356,640&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,299,363&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and </span></div><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">equipment, gross</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,142,125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,895,923&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and amortization</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,394,329)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,124,710)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and </span></div><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">equipment, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747,796&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771,213&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense, including amortization expense related to leasehold improvements, is included in general and administrative expense in the consolidated statements of operations.  Depreciation expense was as follows for the years ended December 31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.897%"><tr><td style="width:1.0%"/><td style="width:41.064%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.919%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.064%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.919%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.919%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.559%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2017</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269,619&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,237&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,532&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697721792856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text">Intangible Assets and Goodwill<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets and Goodwill consisted of the following at December&#160;31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.217%"><tr><td style="width:1.0%"/><td style="width:59.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.915%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.915%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.489%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product and license rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,400,742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,573,941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,499,141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,405,188)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product and license rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,901,601&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,168,753&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,882,511&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,428,266&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,127,878)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,087,273)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,754,633&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,340,993&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,110&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,373&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,020)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,020)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,090&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,353&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,920,324&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,655,099&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2013, the Company entered into an agreement with Pernix to distribute and promote the branded prescription product Omeclamox-Pak. The </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$4.0 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> upfront payment the Company paid to Pernix during October 2013 and the $2.3 million payments made to GEL during 2018 (discussed more fully in Note 3) are included in product and license rights and are being amortized through June 2032, the remaining expected useful life of the acquired asset. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2014, the Company acquired the rights of the branded prescription product Vaprisol from Astellas.  The intangible asset value is $3.0 million and is included in product and license rights.  The asset is being amortized through February 2022, the remaining expected useful life of the acquired asset, which coincides with the life of the primary intellectual property asset.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 3, in November 2016, the Company acquired the U.S. rights to Nordic Group B.V.&#8217;s injectable methotrexate product line as an asset purchase. The agreement requires the Company to provide unvested restricted shares of Cumberland common stock and make a series of payments tied to the products&#8217; FDA approval, launch and achievement of certain sales milestones. The payments are being treated as consideration for the assets acquired and are being capitalized and amortized over the expected useful life of the acquired asset. To date, the intangible assets related to the product include the $100,000 deposit paid at closing, the 180,000 restricted shares valued at $0.9 million that vested upon the November 2019 FDA approval and the additional $1.0&#160;million owed to Nordic during 2020, also based on the FDA approval. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 3, during November 2018, the Company acquired Vibativ from Theravance. This resulted in amortizable intangible assets related to the product rights of  $11.8 million and goodwill of $0.9 million. The intangible assets are being amortized through November 2028, the expected useful life of the acquired asset.  The $0.1&#160;million increase in goodwill during 2019 was a result of changes in the purchase price allocation during the measurement period.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019 and 2018, the Company recorded an additional $0.7 million and $0.4 million, respectively, in intangible assets for patents, trademarks and capitalized patent costs, including amounts incurred in the protection of the Company's intellectual property.  These costs will be amortized over the remaining expected useful life of the associated patents.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to product and license rights, trademarks and patents were as follows for the years ended December 31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:81.730%"><tr><td style="width:1.0%"/><td style="width:38.115%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.939%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.507%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.511%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2017</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,134,557&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,769,466&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,436,222&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected amortization expense for the Company's current balance of intangible assets are as follows:</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:80.769%"><tr><td style="width:1.0%"/><td style="width:72.907%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.703%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,286,336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,084,702&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,530,879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,743,526&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,274,881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,920,324&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697722028408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current and Other Long-term Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrentAbstract', window );"><strong>Other Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">Other Current and Other Long-term Liabilities</a></td>
<td class="text">Other Current and Other Long-term Liabilities<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities consisted of the following at December&#160;31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.378%"><tr><td style="width:1.0%"/><td style="width:59.567%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.913%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.452%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.913%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.455%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates, product returns, administrative fees </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and service fees</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,593,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,969,515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee wages and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,295,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,263,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,085,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of accrued contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,374,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,290,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred acquisition liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued inventory purchases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434,405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payment for asset purchase</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,084,869&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,044,470&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.897%"><tr><td style="width:1.0%"/><td style="width:59.907%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.732%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.559%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent portion of accrued contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,258,813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,212,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,278,164&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588,123&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519,020&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,737,323&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,319,143&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697723365000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May 10, 2019, the Company entered into a third amendment ("Third Amendment") to the Revolving Credit Loan Agreement, dated July 28, 2017, with Pinnacle Bank (&#8220;Pinnacle Agreement&#8221;). The Third Amendment extended the term of the Pinnacle Agreement through July 31, 2021 as well as modified certain definitions and terms of the existing financial covenants, including the definition of the Funded Debt Ratio and the compliance target of the Tangible Capital Ratio. Both Third Amendment modifications were related to the Vibativ transaction.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the Pinnacle Agreement, Cumberland was initially subject to one financial covenant, the maintenance of a Funded Debt Ratio, as such term is defined in the agreement and determined on a quarterly basis.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 14, 2018, the Company amended the Pinnacle Agreement ("First Amendment") to replace the single financial covenant with the maintenance of either the Funded Debt Ratio or a Tangible Capital Ratio, as defined in the First Amendment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company achieved compliance with the Tangible Capital Ratio financial covenant as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December&#160;31, 2019.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The initial revolving line of credit under the Pinnacle Agreement was for up to an aggregate principal amount of $12.0 million with the ability to increase the principal amount available for borrowing up to $20.0 million, upon the satisfaction of certain conditions.  On October 17, 2018, the Company entered into a second amendment (&#8220;Second Amendment&#8221;) which increased the maximum aggregate principal available for borrowing under the Pinnacle Agreement to $20.0 million.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company had $18.5 million in borrowings under the Pinnacle Agreement at December&#160;31, 2019 and $20.0 million at December&#160;31, 2018.  </span></div>The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. There is no LIBOR minimum and the LIBOR pricing provides for an interest rate spread of 1.75% to 2.75% (representing an interest rate of 4.5% at December&#160;31, 2019).  In addition, a fee of 0.25% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  Borrowings under the line of credit are collateralized by substantially all of our assets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697722066472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text">Shareholders&#8217; Equity<div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Initial Public Offering</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;10, 2009, the Company completed its initial public offering of 5,000,000 shares of common stock at a price of $17.00 per share, raising gross proceeds of $85.0 million. After deducting underwriting discounts of approximately $6.0 million and offering costs incurred of approximately $4.2 million, the net proceeds to the Company were approximately $74.8 million. Contemporaneously with the offering, each outstanding share of preferred stock was automatically converted into two million shares of common stock.</span></div><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Preferred Stock</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue 20,000,000&#160;shares of preferred stock. The Board of Directors is authorized to divide these shares into classes or series, and to fix and determine the relative rights, preferences, qualifications and limitations of the shares of any class or series so established. At December&#160;31, 2019 and 2018, there was no preferred stock outstanding.</span></div><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Common Stock</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, 2018 and 2017, the Company issued 225,536 shares, 170,759 shares, and 146,275 shares of common stock, respectively, as a result of restricted shares vesting as well as other common share issuances.  Cumberland issued 3,409 common shares under option exercise transactions during 2016.  There were no option exercise transactions during 2019,  2018 and 2017.  </span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, the Company's Form S-3 or Shelf Registration associated with the sale of up to $100 million in corporate securities was declared effective. The Shelf Registration also included an At-the-Market ("ATM") feature enabling the Company to sell common shares at market prices, along with an agreement with B. Riley FBR to support such a placement of shares.</span></div><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Warrants</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2006, the Company signed a new line of credit agreement along with a term loan agreement with a financial institution. In conjunction with these agreements, the Company issued warrants to purchase up to 3,958&#160;shares of common stock at $9.00 per share within 10 years of issuance.  All of these warrants expired during 2017.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the amendment to the debt agreements in 2009, the Company issued warrants to purchase up to 7,500 shares of common stock at $17.00 per share that expired in July 2019.  As of December&#160;31, 2019, there were no outstanding warrants.  </span></div><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(e)&#160;&#160;&#160;&#160;Share Repurchases</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company currently has a share repurchase program to repurchase up to $10 million of its common stock pursuant to Rule 10b-18 of the Securities Act. In January 2019, the Company's Board of Directors established the current $10 million repurchase program to replace the prior authorizations. The Company repurchased 623,478 shares, 443,041 shares and 547,376 shares of common stock for approximately $3.5 million, $2.9 million, and $3.7 million during the years ended December&#160;31, 2019, 2018 and 2017, respectively. There remains $8.0 million available under the current repurchase program available for share repurchases at December&#160;31, 2019.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(f)&#160;&#160;&#160;&#160;Cumberland Emerging Technologies</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, Cumberland Emerging Technologies ("CET"), our majority-owned subsidiary, entered into </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an agreement with WinHealth whereby WinHealth made a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $1 million </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investment through the purchase of shares of CET stock. As part of the agreement, WinHealth obtained a Board position at CET and the first opportunity to license CET products for the Chinese market. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  In connection with WinHealth&#8217;s investment in CET, the Company also made an additional $1 million investment in CET.  Cumberland </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">purchased additional CET shares through contribution of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $0.3 million in cash and a conversion of $0.7 million in intercompany loans payable.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon completion of the additional investment by WinHealth and Cumberland, Gloria Pharmaceuticals agreed to return its shares in CET in exchange for consideration of  $0.8&#160;million. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> After the additional investment, the Company&#8217;s ownership in CET is 85%.  As CET is a consolidated subsidiary, the Company reports the operating results of CET and allocates the noncontrolling interests to the non-majority partners.  </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(g)  &#160;&#160;&#160;&#160;Cumberland Foundation </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Company formed the Cumberland Pharma Foundation (the "Foundation") to serve as a vehicle to facilitate the ongoing philanthropic endeavors of Cumberland Pharmaceuticals Inc. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Foundation was formed as a nonprofit corporation designed to qualify as a tax-exempt organization pursuant to Section 501(a) of the Internal Revenue Code. The Foundation&#8217;s Board of Directors is comprised of Cumberland Pharmaceuticals executives who are responsible for overseeing the Foundation&#8217;s ongoing activities including charitable contributions. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2018, Cumberland provided a grant of 50,000 shares of the Company's common stock to the Foundation. The shares will address the ongoing financial needs of the organization, with most of the shares expected to be held for the opportunity to realize long term appreciation to support the Foundation&#8217;s future. The Foundation maintains separate financial statements and its ongoing operations will not impact the financial statements of Cumberland Pharmaceuticals. Initial annual grants by the Foundation have been and are expected to remain consistent with the historic level of contributions made by Cumberland Pharmaceuticals.  During 2019, Cumberland Pharmaceuticals committed approximately $50,000 in cash contributions to be paid to the Foundation during 2020. </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nordic Group B.V.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2019, Cumberland received approval from the FDA for the pre-filled syringe of the Methotrexate product.  With this approval, Nordic's 180,000 shares of Cumberland's common stock became vested.  The value of these shares at the date of approval was $0.9&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697723366120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings (loss) per Share</a></td>
<td class="text">Earnings (Loss) Per Share <div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the computation of the numerator and the denominator used to calculate diluted earnings (loss) per share for the years ended December 31:</span></div><div style="margin-bottom:10pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.294%"><tr><td style="width:1.0%"/><td style="width:41.105%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.010%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.531%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.534%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,211,688)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,820,996)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,847,840)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,665,177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,782,224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,798,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,546,511)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,038,772)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,049,815)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss at subsidiary attributable to noncontrolling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,537,759)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,963,068)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,978,633)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,396,098&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,614,052&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,911,577&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of restricted stock and stock options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,396,098&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,614,052&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,911,577&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's anti-dilutive restricted shares and stock options outstanding were as follows for the years ended December 31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:88.301%"><tr><td style="width:1.0%"/><td style="width:38.827%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.800%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.048%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2017</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive shares and options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,650&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,325&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697722031192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company's net deferred tax assets at December&#160;31 are as follows:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.544%"><tr><td style="width:1.0%"/><td style="width:61.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.861%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.599%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.861%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss and tax credits</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,964,685&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,410,403&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment and intangibles</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for accounts receivable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,564&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251,068&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for expired product</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,227&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,150&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910,577&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative compensation costs incurred on deductible equity awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,047,149&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">884,049&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,846,928&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,444,049&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,313,965)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,974,787)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets, before valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,532,963&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,469,262&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: deferred tax asset valuation allowance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,511,161)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,382,052)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,802&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,210&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amount and year of expiration of the Company's federal and state net operating loss carryforwards as of December&#160;31, 2019:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.339%"><tr><td style="width:1.0%"/><td style="width:60.000%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.248%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years of expiration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Federal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">State</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 - 2029</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,392,824&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,153,819&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2031 - 2039</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,534,351&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,947,070&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,493,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383,869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total federal and state net operating loss carryforwards</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,181,428&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,198,158&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax (expense) benefit includes the following components for the years ended December 31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.179%"><tr><td style="width:1.0%"/><td style="width:40.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,316&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,636)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,243)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current income tax (expense) benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,724&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,636)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,243)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65,408)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,682,772)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(432,874)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax (expense) benefit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65,408)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,115,646)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax (expense) benefit </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,316&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,636)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,174,889)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s effective income tax rate for 2019, 2018 and 2017 reconciles with the federal statutory tax rate as follows:&#160;</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.179%"><tr><td style="width:1.0%"/><td style="width:40.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal tax expense at statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax expense (net of federal income tax benefit)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences associated with general business credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income tax expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Company determined that it was not more likely than not that its net deferred tax assets would be realized.  As such, the Company&#8217;s income tax provision for the year ended December 31, 2017 reflected a full valuation allowance against net deferred tax assets with the exception of the deferred tax asset for alternative minimum tax (&#8220;AMT&#8221;) credit carryforwards discussed further below.  The Company&#8217;s position is unchanged as of  both December 31, 2018 and December 31, 2019.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (&#8220;the Tax Act&#8221;).  The Tax Act makes broad and complex changes to the U.S. tax code, including, but not limited to, (1) reducing the U.S. federal corporate tax rate to 21%; (2) eliminating the corporate alternative minimum tax (&#8220;AMT&#8221;) and changing how AMT credits can be realized; (3) capital expensing; and (4) creating new limitations on deductible interest expense and executive compensation.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our analysis of the impact of the Tax Act, we recorded a net tax benefit of $0.1 million in the period ended December 31, 2017.  This net tax benefit consisted entirely of the release of the valuation allowance against AMT credits that will be realizable under the Tax Act in future periods. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects it will continue to pay minimal taxes in future periods through the continued utilization of net operating loss carryforwards, as it is able to achieve taxable income through its operations.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is no longer subject to U.S. federal tax examinations for tax years before 2016, and with few exceptions, the Company is not subject to examination by state tax authorities for tax years which ended before 2016.  Loss carryforwards and credit carryforwards generated or utilized in years earlier than 2016 remain subject to examination and adjustment.  During 2012, the 2009 federal tax return was examined by the Internal Revenue Service with no significant findings or adjustments.  The Company has no unrecognized tax benefits in 2019, 2018 and 2017.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697723265912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation Plans</a></td>
<td class="text">Stock-Based Compensation Plans<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has grants outstanding under three equity compensation plans, with two of the plans available for future grants of equity compensation awards to employees, consultants and directors. All of the equity plans were approved by shareholders. The 2007 Long-Term Incentive Compensation Plan (the "2007 Plan") and the 2007 Directors&#8217; Incentive Plan (the "Directors&#8217; Plan") superseded the 1999 Stock Option Plan. The 2007 Plan and the Directors&#8217; Plan provide for the issuance of stock options, stock appreciation rights and restricted stock. Vesting is determined on a grant-by-grant basis in accordance with the terms of the plans and the related grant agreements. The Company has reserved 2.4 million shares of common stock for issuance under the 2007 Plan and 250,000 shares for issuance under the Directors&#8217; Plan.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price of stock options is generally 100% of the fair market value of the underlying common stock on the grant date. The maximum contractual term of stock options is ten years from the date of grant, except for incentive stock options granted to 10% shareholders, which is five years.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2011, the Company began issuing shares of restricted stock with no exercise price to employees and directors. Restricted stock issued to employees generally cliff-vests on the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yMzIvZnJhZzpjOTg1MzVjYjJiZDE0ODdlODg4MTU4ODFmNDEyNmNmZC90ZXh0cmVnaW9uOmM5ODUzNWNiMmJkMTQ4N2U4ODgxNTg4MWY0MTI2Y2ZkXzQzOTgwNDY1MTM3MjU_e4aa551b-a49e-47c8-ae2e-da92a179d352">four</span>th anniversary of the date of grant. Restricted stock issued to directors vests on the one year anniversary of the date of grant.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock compensation expense is presented as a component of general and administrative expense in the consolidated statements of operations. Stock compensation expense consisted of the following for the years ended December 31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.179%"><tr><td style="width:1.0%"/><td style="width:40.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation - employees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,244,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032,094&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation - nonemployees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,882&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,092&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,969&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation - foundation contribution</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,485,898&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,364,698&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,487,563&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2019, there was approximately $2.1 million of unrecognized compensation cost related to share-based payments, which is expected to be recognized over a weighted-average period of 2.5 years. This amount relates primarily to unrecognized compensation cost for employee restricted stock awards.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity for 2019 and 2018 was as follows:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.064%"><tr><td style="width:1.0%"/><td style="width:34.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.558%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.024%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.024%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.139%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average exercise price per share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">term&#160;(years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">value</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited or expired</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited or expired</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,800)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not grant any stock options and there were no options exercised during 2019, 2018 and 2017.    Information related to the stock option plans during 2019, 2018 and 2017 was as follows:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.179%"><tr><td style="width:1.0%"/><td style="width:40.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrinsic value of options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value of </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">options exercised</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Awards</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock activity was as follows:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:70.192%"><tr><td style="width:1.0%"/><td style="width:50.498%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.731%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.733%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">of shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">grant-date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">fair value</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767,845&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261,680&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170,759)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,025)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833,741&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.09&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,669&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(225,536)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,925)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814,949&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.88&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The fair value of restricted stock granted was based on the closing market price of the Company&#8217;s common stock on the date of grant.  The restricted stock grants are included in the diluted weighted shares outstanding computation until they cliff-vest.  Once vested they are included in the basic weighted shares outstanding computation.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697723379560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text">Employee Benefit Plans<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors an employee benefit plan that was established on January&#160;1, 2006, the Cumberland Pharmaceuticals 401(k) Plan (the&#160;"Plan"), under Section&#160;401(k) of the Internal Revenue Code of 1986, as amended, for the benefit of all employees over the age of 21, having been employed by the Company for at least six months. The Plan provides that participants may contribute up to the maximum amount of their compensation as set forth by the Internal Revenue Service each year. Employee contributions are invested in various investment funds based upon elections made by the employees. During 2019, 2018 and 2017, the Company contributed approximately $50,000 in each year to the Plan as an employer match of participant contributions.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012 and 2013, the Company established non-qualified unfunded deferred compensation plans that allow participants to defer receipt of a portion of their compensation. The liability under the plans, reflected in other long term liabilities in the consolidated balance sheet, was $2.3 million and $1.6 million as of December&#160;31, 2019 and 2018, respectively.  The Company had assets consisting of company-owned life insurance contracts generally designated to pay benefits of the deferred compensation plans reflected in other assets in the consolidated balance sheet of $3.1 million and $2.3 million as of December&#160;31, 2019 and 2018, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697845183160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is obligated under long-term real estate leases for corporate office space that was extended during the third quarter of 2015.  Prior to this extension, the lease would have expired in October 2016, the lease is now set to expire in October 2022. In addition, the research lab space at CET, under an agreement amended in July 2012, is leased through April 2023, with an option to extend the lease through April 2028. The Company also subleases a portion of the space under these leases. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense is recognized over the expected term of the lease, including renewal option periods, if applicable, on a straight-line basis as a component of general and administrative expense. Rent expense and sublease income  as follows for the years ended December 31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.897%"><tr><td style="width:1.0%"/><td style="width:41.064%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.919%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.064%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.919%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.919%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.559%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2017</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136,610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,074,437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688,020&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">662,358&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573,494&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the FASB issued ASU 2016-02. ASU 2016-02&#8217;s core principle is to increase transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information. The Company adopted ASU 2016-02 under the alternative transition method (the effective date approach). It allowed the Company to initially apply the new lease guidance at the adoption date (rather than at the beginning of the earliest period presented). Prior periods have not been adjusted.   </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary effect of adopting ASU 2016-02 to the Company was to record right-of-use assets and obligations for the leases currently classified as operating leases.  The Company&#8217;s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters.  This lease currently expires in October 2022.  The operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by Cumberland Emerging Technologies (&#8220;CET&#8221;), </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our majority-owned subsidiary, where it operates the CET Life Sciences Center.  This lease currently expires in April 2023. The Company did not have any leases classified as finance leases at January 1, 2019 or December&#160;31, 2019.  The new lease accounting standard did not have a significant impact on the Company's Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for any period presented. </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company elected the package of practical expedients offered in the transition guidance which allows management not to reassess lease identification, lease classification and initial direct costs at the adoption date. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These operating leases resulted in initial ROU assets of $3.6 million and lease liabilities of $3.8 million as of January 1, 2019 for non-cancelable operating leases with original lease terms in excess of one year.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities were recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As the Company&#8217;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019. Incremental borrowing rates reflect the Company&#8217;s estimated interest rates for collateralized borrowings over similar lease terms. The weighted-average remaining lease term is 3.4 years and the weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments is 7.42%.</span></div><div style="margin-top:8pt;padding-left:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease Position</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2019, the Company recorded the following on the Condensed Consolidated Balance Sheet: </span></div><div style="margin-top:8pt;padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.688%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.895%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-Use Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,960,569&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,960,569&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;padding-left:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.688%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.895%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">920,431&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,076,472&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,996,903&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumulative future minimum sublease income under non-cancelable operating subleases totals approximately $0.7 million and will be paid through the leases ending in October 2022 and April 2023. Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:66.025%"><tr><td style="width:1.0%"/><td style="width:73.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.173%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of  December&#160;31, 2019:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,120,066&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,144,889&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019,313&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,376,746&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(379,843)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,996,903&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's future minimum lease commitments, under Topic 840, predecessor to Topic 842, are as follows:</span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:66.025%"><tr><td style="width:1.0%"/><td style="width:73.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.173%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December 31, 2018:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959,902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">980,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001,603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">871,969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,858,702&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -URI http://asc.fasb.org/topic&amp;trid=2208923<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697725713832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text">Fair Value of Financial Instruments<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company owns marketable securities that are solely classified as trading securities as of December&#160;31, 2019.  All of these securities had a maturity date of less than ninety days and classified as cash and cash equivalents at December&#160;31, 2019.  There were no transfers of assets between levels within the fair value hierarchy. The following table summarizes the fair value of these marketable securities by level within the fair value hierarchy:</span></div><div style="margin-bottom:12pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.380%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.117%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.117%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.079%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.117%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.117%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2018</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes and bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,034,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,034,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SBA loan pools - variable rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,504,551&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,504,551&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term cash investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">751,173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">751,173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial Paper</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119,607&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119,607&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119,607&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119,607&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,034,955&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,255,724&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,290,679&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The fair values of all other financial instruments outstanding as of December&#160;31, 2019 and 2018 approximate their carrying values.  There were no changes to the valuation techniques for the Level 2 marketable securities during 2019 or 2018.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697722040472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Market Concentrations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">Market Concentrations</a></td>
<td class="text">Market Concentrations<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is focused on the acquisition, development and commercialization of branded prescription products.  The Company&#8217;s principal financial instruments subject to potential concentration of credit risk are accounts receivable, which are unsecured, and cash equivalents. The Company&#8217;s cash equivalents consist primarily of money market funds. Certain bank deposits may be in excess of the insurance limits provided by the Federal Deposit Insurance Corporation.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s primary customers are wholesale pharmaceutical distributors in the U.S. &#160;Total revenues by customer for each customer representing 10% or more of consolidated revenues are summarized below for the years ended December 31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:76.602%"><tr><td style="width:1.0%"/><td style="width:39.904%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.846%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">*: less than 10% of total</span></div><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts receivable, net of allowances, due from the customers representing 10% or more of consolidated revenue was 59% and 72% at December&#160;31, 2019 and 2018, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697723135976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Manufacturing and Supply Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ManufacturingAndSupplyAgreementsAbstract', window );"><strong>Manufacturing and Supply Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ManufacturingAndSupplyAgreementsTextBlock', window );">Manufacturing and Supply Agreements</a></td>
<td class="text">Manufacturing and Supply AgreementsThe Company utilizes one or two primary suppliers to manufacture each of its products and product candidates. Although there are a limited number of manufacturers of pharmaceutical products, the Company believes it could utilize other suppliers to manufacture its prescription products on comparable terms.  A change in suppliers, problems with its third-party manufacturing operations or related production capacity, or contract disputes with suppliers could cause a delay in manufacturing or shipment of finished goods and possible loss of sales, which could adversely affect operating results.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ManufacturingAndSupplyAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Manufacturing and Supply Agreements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ManufacturingAndSupplyAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ManufacturingAndSupplyAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Manufacturing and Supply Agreements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ManufacturingAndSupplyAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697723438600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employment Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_EmploymentAgreementsAbstract', window );"><strong>Employment Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_EmploymentAgreementsTextBlock', window );">Employment Agreements</a></td>
<td class="text">Employment AgreementsThe Company has entered into employment agreements with all its full-time employees. Each employment agreement provides for a salary for services performed, a potential annual bonus and, if applicable, a grant of restricted common shares pursuant to a restricted stock agreement.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_EmploymentAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employment Agreements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_EmploymentAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_EmploymentAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employment Agreements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_EmploymentAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697723139912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Discontinued Operations</a></td>
<td class="text">Discontinued Operations<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, Cumberland entered into an agreement with Clinigen Group Plc ("Clinigen") for the rights and responsibilities associated with the commercialization of Ethyol in the United States.  In 2017, the Company entered into another agreement with Clinigen for the rights and responsibilities associated with the commercialization of Totect in the United States.  Ethyol and Totect are collectively referred to herein as the "Products."</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Early in 2019, Cumberland announced a strategic review the Company's brands, capabilities, and international partners. This review followed an accelerated business development initiative, which resulted in a series of transactions. Because of that progress, Cumberland felt that it was prudent to take a fresh look at our product portfolio, partners, and organization to ensure proper focus and capabilities.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During May 2019, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">following the strategic review, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland entered into the Dissolution Agreement with Clinigen in which the Company returned the exclusive rights to commercialize Ethyol and Totect (&#8220;the Products&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States to Clinigen. This Dissolution Agreement originally targeted a transition from the Company's arrangements with Clinigen effective September 30, 2019, but was then amended to change the transition date to December 31, 2019. Under the terms of the Dissolution Agreement, Cumberland was no longer responsible for the distribution, marketing and promotion of </span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">either the Products or any competing products after December 31, 2019.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In exchange for the return of these product license rights and the non-compete provisions of the Dissolution Agreement, Cumberland is receiving $5&#160;million in financial consideration paid in quarterly installments over the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQyYmZhNTUzMDRiZDQ1YmJhYTljZGYwOWJiNzY3M2EzL3NlYzpkMmJmYTU1MzA0YmQ0NWJiYWE5Y2RmMDliYjc2NzNhM18yNjIvZnJhZzoxM2ZiMjM4NmZhMDA0NDljYTk0M2ZlMGFjNGE1N2UxOS90ZXh0cmVnaW9uOjEzZmIyMzg2ZmEwMDQ0OWNhOTQzZmUwYWM0YTU3ZTE5XzQzOTgwNDY1MjI4MDI_72facf0f-0ab8-4e03-8486-1d05338389f9">two</span>-years following the transition date.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exit from the Ethyol and Totect Products meets the accounting criteria to be reported as discontinued operations. December 31, 2019, as the transition date, was the final day Cumberland was responsible for the Products. Cumberland was responsible for the Products through December 31, 2019 and beginning on January 1, 2020, the Products' rights transitioned back to Clinigen. As a result, January 1, 2020, was the first day of discontinued operations for the Ethyol and Totect products.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Products provided revenue, incurred direct expenses and resulted in discontinued operations income during the periods presented.  The following amounts have been separated from continuing operations, as discontinued operations, for all periods presented. The direct expenses separated for discontinued operations do not reflect the direct selling and marketing costs attributable to the individuals at Cumberland responsible for promotion of the Products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Subsequent to the transaction date, th</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ose sales and marketing individuals who supported the Products shifted their efforts from the Products and continue to support other Cumberland brands.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.198%"><tr><td style="width:1.0%"/><td style="width:49.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.769%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.439%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.769%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.731%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.769%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.735%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,145,344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,396,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,827,504&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs of products sold</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,330,704&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,361,273&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,952,575&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, Marketing and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,149,463&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,253,374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,076,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,665,177&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,782,224&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,798,025&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2019 current assets associated with discontinued operations included $0.5&#160;million in the remaining </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inventory for the Products sold and returned to Clinigen as part of the transaction.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Except for the Products' inventory as of December 31, 2019, no other operating assets and no liabilities were transferred to Clinigen, as such t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he accounts receivable and accounts payable associated with discontinued operations were not sold or disposed of as part of the Dissolution Agreement. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assets and liabilities have been presented as assets associated with discontinued operations or liabilities associated with discontinued operations, as appropriate, in the consolidated balance sheets.   </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.384%"><tr><td style="width:1.0%"/><td style="width:61.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.686%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,922,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,384,254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,721&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,294,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets associated with discontinued operations</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,462,724&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,706,897&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.384%"><tr><td style="width:1.0%"/><td style="width:61.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.686%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,918,868&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,882,656&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,489&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666,457&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities associated with discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,151,357&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,549,113&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697722043528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of certain Kristalose assets during 2011, the Company was required to make quarterly payments based on a percentage of Kristalose net sales through November 2018. The payments were treated as consideration for the assets acquired and were capitalized.  They are being amortized over the remaining expected useful life of the acquired asset, currently through 2026. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with its licensing agreements for Caldolor,  the Company is required to pay royalties based on net sales over the life of the product. Royalty expense is recognized as a component of selling and marketing expense in the period that revenue is recognized. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with its licensing agreements for Ethyol and Totect, the Company was required to pay royalties based on net sales.  The royalty expense was recognized as a component of selling and marketing expense in the period the associated revenue was recognized through the end of the licensing period, December 31, 2019.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Vibativ, the Company is required to pay royalties based on net sales of the product.  At the purchase date, Cumberland recorded the fair value of this liability and will continue to evaluate the liability each period and the royalty expense is recognized as a component of selling and marketing expense in the period that the change in fair value is recognized. </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has a number of  Patents issued through the United States Patent and Trademark Office (the &#8220;USPTO&#8221;) including U.S. Patent number 8,148,356 (the &#8220;356 Acetadote Patent&#8221;) which is assigned to the Company. The claims of the 356 Acetadote Patent encompass the new Acetadote formulation and include composition of matter claims. Following its issuance, the 356 Acetadote Patent was listed in the FDA Orange Book. The 356 Acetadote Patent is scheduled to expire in May 2026, which time period includes a 270-day patent term adjustment granted by the USPTO.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2012, Cumberland has to continued to vigorously defend and protect its Acetadote product and related intellectual property rights including the use of all its legal options. </span></div>The Company is a party to various other legal proceedings in the ordinary course of its business. In the opinion of management, the liability associated with these matters, will not have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697721780216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Information (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Financial Information (Unaudited)</a></td>
<td class="text">Quarterly Financial Information (Unaudited)<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the unaudited operating results for each fiscal quarter of 2019 and 2018:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.474%"><tr><td style="width:1.0%"/><td style="width:33.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.026%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.026%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.026%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.026%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.031%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">First</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Second</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Third</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fourth</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,729,860&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,417,443&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,935,439&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,305,553&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,388,295&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,323,932)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,373,424)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,196,436)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,394,390)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,288,182)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,187,553)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,338,521)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,316,286)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,369,328)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,211,688)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,147,136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">771,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,349,351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,396,981&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,665,177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73,878)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(549,507)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,953,668)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(960,706)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,537,759)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share attributable to common shareholders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - basic</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.60)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-13.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.13)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.23)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - diluted</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.60)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.13)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.23)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,918,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,084,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,853,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,487,842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,344,894&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,315,936)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,919,189)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,644,614)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,293,257)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,172,996)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,255,903)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,795,661)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,501,752)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,267,680)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,820,996)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from discontinued operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">863,714&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,050,211&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">837,731&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,030,568&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,782,224&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,379,239)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(720,688)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,643,044)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,220,097)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,963,068)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share attributable to common shareholders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;text-indent:-13.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations - basic</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.06&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.06&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.07&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.15)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.14)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.45)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations - diluted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.06&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.06&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.07&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.15)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.14)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.45)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Due to the nature of interim earnings per share calculations, the sum of the quarterly earnings (loss) per share amounts may not equal the reported earnings (loss) per share for the full year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697723221288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent events</a></td>
<td class="text">Subsequent eventsOn March 11, 2020, the World Health Organization declared the outbreak of a novel coronavirus (&#8220;COVID-19&#8221;) as a global pandemic, which continues to spread throughout the United States and around the world.  As of March 20, 2020, the Company is aware of changes in its business as a result of COVID-19 but uncertain of the impacts of those changes on its consolidated statements of position, operations or cash flows. Management believes any disruption, when and if experienced, could be temporary; however, there is uncertainty around when any disruption might occur, the duration and hence the potential impact. As a result, we are unable to estimate the potential impact on our business as of the date of this filing.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697725348328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements of the Company are stated in U.S. dollars and are prepared using U.S. generally accepted accounting principles. These financial statements include the accounts of the Company and its wholly and majority-owned subsidiaries. All significant intercompany transactions and accounts have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">Use of EstimatesThe preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text">Segment ReportingThe Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, evaluated that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States. Total revenues are primarily attributable to U.S.&#160;customers.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of financial assets and liabilities is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date.  The Company's fair value measurements follow the appropriate rules as well as the fair value hierarchy that prioritizes the information used to develop the measurements.  It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:</span></div><div style="margin-top:8pt;padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 -   Quoted prices for identical instruments in active markets.</span></div><div style="margin-top:8pt;padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 -  Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.</span></div><div style="margin-top:8pt;padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 -    Significant inputs to the valuation model are unobservable.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain policies and procedures to value instruments using the best and most relevant data available. The following section describes the valuation methodologies we use to measure different financial instruments at fair value on a recurring basis.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments include cash and cash equivalents, marketable securities, accounts receivable, accounts payable, accrued liabilities, contingent consideration liability and a revolving line of credit. The carrying values for cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to their short-term nature. The revolving line of credit has a variable interest rate, which approximates the current market rate.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's fair values of marketable securities are determined based on valuations provided by a third-party pricing service, as derived from such services' pricing models, and are considered either Level 1 or Level 2 measurements, depending on the nature of the investment.  The Company has no marketable securities in which the fair value is determined based on Level 3.  The level of management judgment required in evaluating fair value for Level 1 investments is minimal.  Similarly, there is little subjectivity or judgment required for Level 2 investments valued using valuation models that are standard across the industry and whose parameter inputs are quoted in active markets.  Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. The Company believes that the valuations provided by the third-party pricing service, as derived from such services' pricing models, represent prices that would be received to sell the assets at the measurement date (exit prices).</span></div>The Company's contingent consideration liability is a Level 3 fair value measurement that is updated on a recurring basis at each reporting period using a valuation model.  Consistent with Level 3 fair value measurements, there are significant inputs to the valuation model that are unobservable.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">Cash and Cash EquivalentsCash and cash equivalents include highly liquid investments with original maturities of three months or less.  As of December&#160;31, 2019 and 2018, cash equivalents consist primarily of money market funds as well as trading securities with original maturities of less than ninety days.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests in marketable debt securities in order to maximize its return on cash. Marketable securities consist of short-term cash investments, U.S. Treasury notes and bonds, corporate bonds, and commercial paper.  At the time of purchase, the Company classifies marketable securities as either trading securities or available-for-sale securities, depending on the intent at that time.  As of December&#160;31, 2019 and 2018, marketable securities were comprised solely of trading securities.  Trading securities are carried at fair value with unrealized gains and losses recognized as a component of interest income in the consolidated statements of operations.  As of December&#160;31, 2019, all the trading securities were commercial paper with original maturities of less than ninety days and as a result, were classified as cash equivalents.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable are recorded at the invoiced amount.  The Company records allowances for amounts that could become uncollectible in the future based on historical experience, including amounts related to chargebacks, cash discounts and credits for damaged product. The Company reviews each customer balance to assess collection status.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s products are distributed through independent pharmaceutical wholesalers.  The allowances against accounts receivable for chargebacks and discounts are determined on a product-by-product basis, and established by management as the Company&#8217;s best estimate at the time of sale based on each product&#8217;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks, discounts and credits claimed for damaged and expired product. The allowances in accounts receivable for chargebacks, cash discounts and damaged goods were $0.8 million at December&#160;31, 2019 and $0.7 million at December 31, 2018. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company&#8217;s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, revenues are reduced and accrued liabilities are increased by the Company&#8217;s estimate of the rebate that may be claimed as well as the reserves for expired and damaged goods.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash discounts are reductions to invoiced amounts offered to customers for payment within a specified period of time from the date of the invoice.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company works closely with third parties to manufacture and package finished goods for sale.  Based on the customer relationship with the manufacturer or packager, the Company will either take title to finished goods at the time of shipment or at the time of arrival from the manufacturer.  The Company then warehouses such goods until distribution and sale.  As discussed below, effective January 1, 2017, inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.</span></div>The Company continually evaluates inventories for potential losses due to expired, short-dated or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates the carrying value of a product may not be recoverable, a charge is recorded to reduce the inventory to its current net realizable value.  The Company classifies the Vibativ inventories that it does not expect to sell within one year as non-current inventories.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock', window );">Prepaid and Other Current Assets</a></td>
<td class="text"><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid and Other Current Assets</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid and other current assets consist of deferred offering costs, prepaid insurance premiums, prepaid consulting services, deposits and annual fees paid to the U.S. Food and Drug Administration ("FDA").  The Company expenses all prepaid and other current asset amounts as used or over the period of benefit primarily on a straight-line basis, as applicable.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:7pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, including leasehold improvements, are stated at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the initial lease term plus renewal options, if reasonably assured, or the remaining useful life of the asset. Upon retirement or disposal of assets, any gain or loss is reflected as a component of operating income (loss) in the consolidated statement of operations.  Improvements that extend an asset&#8217;s useful life are capitalized.  Repairs and maintenance costs are expensed as incurred.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Goodwill</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intangible assets and goodwill consist of capitalized costs related to product and license rights, patents, trademarks and goodwill obtained in the Vibativ acquisition. Goodwill is not amortized for financial reporting purposes, but is subject to impairment analysis at least annually.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of acquiring product and license rights are capitalized at fair value at the date of acquisition for products that are approved by the FDA for commercial use.  These costs are amortized ratably over the estimated economic life of the product. The economic life is estimated based upon several factors.  This includes the term of the license agreement, the patent life or market exclusivity of the product and as well as  management's expectations of continued involvement with the product and the assessment of future sales, the future periods under which the product will be sold and the profitability of the product. This estimate is evaluated on a regular basis during the amortization period and adjusted if appropriate.  If there are any changes made to the useful life of the product and license rights, the costs associated with such a change, if any, will be capitalized and amortized over the revised useful life.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized patent costs consist of outside legal costs associated with obtaining and protecting patents on products that have been approved for marketing by the FDA. If it becomes probable that a patent will not be issued or a patent has been declared invalid, related costs associated with the patent application are expensed at the time such determination is made. All costs associated with obtaining patents for products that have not been approved for marketing by the FDA are expensed as incurred.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense is recognized ratably over the following periods:</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">Impairment of Long-Lived AssetsLong-lived assets, such as property and equipment, operating lease right-of-use assets and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If events or circumstances arise that require a long-lived asset to be tested for potential impairment, the Company first compares undiscounted cash flows expected to be generated by the asset to its carrying value. If the carrying amount of the long-lived asset is not recoverable on an undiscounted cash flow basis, an impairment charge is recognized to the extent that the carrying value exceeds the fair value. Fair value is determined through various valuation techniques including quoted market prices, third-party independent appraisals and discounted cash flow models.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2018, the Company adopted the Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;) amended guidance in the form of Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-09, "Revenue from Contracts with Customers," (ASC 606). Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts were not adjusted and are reported in accordance with ASC 605.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Product Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recognized in the amount that reflects the consideration that we expect to receive for these goods.  Depending upon the shipping terms of the transaction, the revenue is recognized.at the point where the customer obtains control of the goods and we satisfy our performance obligation.  This occurs upon either shipment of the product or arrival at its ship to destination.  Payment terms typically range from 30 to 60 days from date of shipment. The Company&#8217;s net product revenue reflects the reduction from gross product revenue for </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">estimated allowances for chargebacks, discounts and damaged goods, and reflects sales related accruals for rebates, coupons, product returns, and certain administrative and service fees. Significant judgments must be made in determining the transaction price for our sales of products related to these adjustments. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Rebates and Discounts</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowances against accounts receivable for chargebacks, discounts, expired and damaged goods are determined on a product-by-product basis, and established by management as the Company&#8217;s best estimate at the time of sale based on each product&#8217;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks, discounts and credits claimed for damaged and expired product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company&#8217;s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, sales revenues are reduced and accrued liabilities are increased by the Company&#8217;s estimate of the rebate that may be claimed.</span></div><div style="margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Returns</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, the Company maintains a return policy that allows customers to return product within a specified period prior to and subsequent to the expiration date. The Company&#8217;s estimate of the provision for returns is based upon historical experience, expiration date by product as well as any other factor expected to impact future returns. Any changes in the assumptions used to estimate the provision for returns are recognized in the period those assumptions are changed.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Revenues</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues primarily consist of income from grant funding programs, licensing agreements, leases and contract services.  Revenue related to grants is recognized when all conditions related to such grants have been met.  All other revenue is recognized when earned.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Products Sold</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products sold consists principally of the cost to acquire each unit of product sold, including in-bound freight expense as well as any adjustment in the net realizable value of inventory acquired in acquisitions. Cost of products sold also includes expenses associated with the reduction in the net realizable value of slow-moving or expired product.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling and Marketing Expense</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling and marketing expense consists primarily of expenses relating to the advertising, promotion, distribution and sale of products, including royalty expense, salaries and related costs.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Distribution Costs</span></div>Distribution costs are expensed as incurred and are included as a component of selling and marketing expenses in the consolidated statements of operations.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Costs</a></td>
<td class="text">Advertising CostsAdvertising costs are expensed as incurred and are included as a component of selling and marketing expenses in the consolidated statements of operations.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed in the period incurred. Research and development costs are comprised mainly of clinical trial expenses, salaries, wages and other related costs such as materials and supplies. Research and development expense includes activities performed by third-party providers participating in the Company&#8217;s clinical studies. The Company accounts for these costs based on estimates of work performed, patients enrolled or fixed fees for services over the period of time the clinical trials are performed.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides for deferred taxes using the asset and liability approach. Under this method, deferred tax assets and liabilities are recognized for future tax consequences attributable to operating loss and tax credit carryforwards, as well as differences between the carrying amounts of existing assets and liabilities and their respective tax bases. The Company&#8217;s principal differences are related to the timing of deductibility of certain items, such as inventory, depreciation, amortization and share-based compensation. Deferred tax assets and liabilities are measured using enacted statutory tax rates that are expected to apply to taxable income in the years such temporary differences are anticipated to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. The Company only recognizes income tax benefits associated with an income tax position in which it is &#8220;more likely than not&#8221; that the position would be sustained upon examination by the taxing authorities.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, management considers whether some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of existing temporary differences, projected future taxable income and tax planning strategies in making this assessment. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounting policy with respect to interest and penalties arising from income tax settlements is to recognize them as part of the provision for income taxes.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total comprehensive income (loss) was comprised solely of net income (loss) for all periods presented.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings (Loss) Per Share</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings (Loss) per Share</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings (loss) per share is calculated by dividing net income (loss) attributable to common shareholders by the weighted-average number of shares outstanding. Except where the result would be antidilutive to income from continuing operations, diluted earnings (loss) per share is calculated by assuming the vesting of unvested restricted stock and the exercise of stock options and warrants and unrecognized compensation costs.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Payments</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Payments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation cost for all share-based payments issued, modified, repurchased or canceled. Depending on the nature of the vesting provisions, restricted stock awards are measured using either the fair value on the grant date or the fair value of common stock on the date the vesting provisions lapse. Prior to the lapse for those equity grants not valued on the grant date, the fair value is measured on the last day of the reporting period.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative Agreements</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Agreements</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party to several collaborative arrangements with certain research institutions to identify and pursue promising preclinical pharmaceutical product candidates. The Company has determined these collaborative agreements do not meet the criteria for accounting under Accounting Standards Codification 808, Collaborative Agreements. The agreements do not specifically designate each party's rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party. The funding for these programs is generally provided through private sector investments or federal Small Business Administration ("SBIR/STTR") grant programs. Expenses incurred under these collaborative agreements are included in research and development expenses in the consolidated statements of operations. Funding received from private sector investments and grants are recorded as net revenues in the consolidated statements of operations.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassification of prior period amounts</span></div>The Company has made certain reclassifications to prior period amounts to conform to the current-year presentation of the reporting of research and development expense and general and administrative expense on the consolidated statements of operations. Certain costs and expenses related to research and development were previously reported as general and administrative expenses on the consolidated statements of operations. These reclassifications have no effect on the reported operating loss or equity for the years ended December 31, 2018 and 2017.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Guidance</a></td>
<td class="text"><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance </span></div><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Adopted Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2014, the FASB issued amended guidance in the form of ASU No. 2014-09, &#8220;Revenue from Contracts with Customers&#8221; (&#8220;ASC 606&#8221;).  The core principle of the new guidance is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. The new guidance defines a five-step process to achieve this core principle and, in doing so, additional judgments and estimates may be required within the revenue recognition process. The new standard replaced most of the existing revenue recognition standards in U.S. GAAP when it became effective. In July 2015, the FASB issued a one-year deferral of the adoption date, which extended the effective date for us to January 1, 2018, at which point Cumberland adopted the standard. </span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated its revenues and the new guidance had immaterial impacts to recognition practices upon adoption on January 1, 2018.  As part of the adoption, the Company elected to apply the new guidance on a modified retrospective basis. The Company did not record a cumulative effect adjustment to historical retained earnings for initially applying the new guidance as no revenue recognition differences were identified in the timing or amount of revenue. </span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the Financial Accounting Standards Board ("FASB") issued guidance in the form of a FASB Accounting Standards Update ("ASU") No. 2016-02, &#8220;Leases.&#8221; The new standard establishes a right-of-use (&#8220;ROU&#8221;) model that requires a lessee to record an ROU asset and a lease liability on the balance sheet for all leases with terms longer than twelve months. Leases will be classified as either finance (formerly "capital leases") or </span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operating, with classification affecting the pattern of expense recognition in the income statement. The standard provides for a modified retrospective transition approach for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain optional practical expedients.  In July 2018, the FASB issued ASU 2018-11, "Leases: Targeted Improvements", allowing for an alternative transition method (the effective date approach). It allows an entity to initially apply the new lease guidance at the adoption date (rather than at the beginning of the earliest period presented). Cumberland adopted the lease guidance effective January 1, 2019 using the package of transition practical expedients.  This allowed the Company to retain the lease classification for any leases existing prior to adoption, in addition to other benefits. See additional discussion of the impact of adopting the lease accounting guidance in Note 15.</span></div><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements - Not Yet Adopted</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose more information, including the information they use to track credit quality by year of origination for most financing receivables. Companies will apply the standard&#8217;s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. This standard is effective for the Company on January 1, 2020. The Company continues to evaluate this new standard on its trade and other receivables but does not expect a material impact on its consolidated financial statements. </span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met, the election must be applied on an instrument-by-instrument basis, and the election is not available for either available-for-sale or held-to-maturity debt securities. The effective date is the same as ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January 1, 2020. The Company continues to evaluate this new standard but does not expect a material impact on its consolidated financial statements. </span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued ASU No. 2018-18, &#8220;Collaboration Arrangements: Clarifying the Interaction between Topic 808 and Topic 606&#8221; (ASU 2018-18). The issuance of ASU 2014-09 raised questions about the interaction between the guidance on collaborative arrangements and revenue recognition. ASU 2018-18 addresses this uncertainty by (1) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASU 2014-09 when the collaboration arrangement participant is a customer, (2) adding unit of account guidance to assess whether the collaboration arrangement or a part of the arrangement is with a customer and (3) precluding a company from presenting transactions with collaboration arrangement participants that are not directly related to sales to third parties together with revenue from contracts with customers. The new standard will be effective for the Company on January 1, 2020.  The Company continues to evaluate this new standard but does not expect a material impact on its consolidated financial statements. </span></div>In January 2017, the FASB issued ASU No. 2017-04, &#8220;Simplifying the Test for Goodwill Impairment&#8221; (ASU 2017-04). The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation.  As a result of the revised guidance, a goodwill impairment will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The new standard will be effective for the Company on January 1, 2020. The Company continues to evaluate this new standard but does not expect a material impact on its consolidated financial statements and related disclosures.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaids and Other Current Assets, Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697729094392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock', window );">Schedule of intangible assets, useful lives</a></td>
<td class="text">Amortization expense is recognized ratably over the following periods:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:63.141%"><tr><td style="width:1.0%"/><td style="width:46.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rights</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated economic life</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License rights</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term of license agreement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life of patent</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Finite-Lived Intangible Assets UseFul Lives [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697726036616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Omeclamox&#174;-Pak, RediTrex&#174; and Vibativ&#174; (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Business Acquisitions, by Acquisition</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the initial payments and consideration for the business combination:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"><tr><td style="width:1.0%"/><td style="width:74.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.578%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid at closing</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment during early 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration - net sales royalty</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,182,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,182,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Schedule of Business Acquisitions by Acquisition, Contingent Consideration</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the Company's Level 3 contingent consideration liability that is measured at fair value on a recurring basis.  The current and long-term portions of this liability are disclosed in Note 8.  The contingent consideration earned and accrued in operating expenses is paid to the seller quarterly.</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.265%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.535%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent consideration liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at November 12, 2018</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,034,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,000)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2018</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,502,000&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment to initial fair value of the contingent consideration liability</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,033,108)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(804,167)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820,864&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,633,589&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the allocation of the fair values of the assets acquired as of the acquisition date for Vibativ:</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.743%"><tr><td style="width:1.0%"/><td style="width:63.185%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.615%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,624,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process - unlabeled vials</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,970,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process - validation vials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,827,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,129,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,550,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property amortizable intangible assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,750,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangibles and goodwill</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,632,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,182,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1486-128463<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697722050296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of net product revenues by product</a></td>
<td class="text"><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net product revenues consisted of the following for the years ended December&#160;31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.698%"><tr><td style="width:1.0%"/><td style="width:40.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.909%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.644%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.909%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.909%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,824,449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,284,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,576,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837,829&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623,297&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,761,868&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,895,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,055,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,455,805&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,615&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,763,874&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,576,222&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,222,282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,001,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,178,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,691,550&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,075,057&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net product revenues</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,407,845&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,803,961&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,549,058&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697723168136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventories, current</a></td>
<td class="text"><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's net inventories consisted of the following as of December 31:</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.339%"><tr><td style="width:1.0%"/><td style="width:60.000%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.248%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,345,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,378,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">937,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods, net of reserve</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,664,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,216,965&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,426,246&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,532,421&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,554,992)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,749,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,871,254&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,783,421&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697723195512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following at December&#160;31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.980%"><tr><td style="width:1.0%"/><td style="width:34.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.892%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.125%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.892%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.892%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.120%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">useful lives</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;&#8211;&#160;5&#160;years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,148,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;&#8211;&#160;15&#160;years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878,350&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809,153&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;&#8211;&#160;15 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639,267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;&#8211;&#160;15&#160;years,&#160;or remaining&#160;lease&#160;term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,356,640&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,299,363&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and </span></div><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">equipment, gross</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,142,125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,895,923&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and amortization</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,394,329)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,124,710)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and </span></div><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">equipment, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747,796&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771,213&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ScheduleofDepreciationExpenseTableTextBlock', window );">Schedule of depreciation expense</a></td>
<td class="text">Depreciation expense was as follows for the years ended December 31:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.897%"><tr><td style="width:1.0%"/><td style="width:41.064%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.919%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.064%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.919%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.919%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.559%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2017</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269,619&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,237&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,532&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ScheduleofDepreciationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Depreciation Expense [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ScheduleofDepreciationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697723220088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of intangible assets</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets and Goodwill consisted of the following at December&#160;31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.217%"><tr><td style="width:1.0%"/><td style="width:59.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.915%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.915%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.489%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product and license rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,400,742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,573,941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,499,141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,405,188)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product and license rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,901,601&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,168,753&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,882,511&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,428,266&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,127,878)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,087,273)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,754,633&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,340,993&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,110&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,373&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,020)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,020)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,090&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,353&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,920,324&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,655,099&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of expected amortization expense of intangible assets</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to product and license rights, trademarks and patents were as follows for the years ended December 31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:81.730%"><tr><td style="width:1.0%"/><td style="width:38.115%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.939%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.507%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.511%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2017</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,134,557&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,769,466&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,436,222&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected amortization expense for the Company's current balance of intangible assets are as follows:</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:80.769%"><tr><td style="width:1.0%"/><td style="width:72.907%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.703%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,286,336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,084,702&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,530,879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,743,526&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,274,881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,920,324&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697722107288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current and Other Long-term Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrentAbstract', window );"><strong>Other Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued liabilities</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities consisted of the following at December&#160;31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.378%"><tr><td style="width:1.0%"/><td style="width:59.567%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.913%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.452%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.913%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.455%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates, product returns, administrative fees </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and service fees</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,593,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,969,515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee wages and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,295,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,263,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,085,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of accrued contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,374,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,290,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred acquisition liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued inventory purchases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434,405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payment for asset purchase</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,084,869&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,044,470&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock', window );">Schedule of other long-term liabilities</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.897%"><tr><td style="width:1.0%"/><td style="width:59.907%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.732%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.559%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent portion of accrued contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,258,813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,212,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,278,164&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588,123&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519,020&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,737,323&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,319,143&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other noncurrent liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697722005112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of calculation of numerator and denominator in earnings per share</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the computation of the numerator and the denominator used to calculate diluted earnings (loss) per share for the years ended December 31:</span></div><div style="margin-bottom:10pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.294%"><tr><td style="width:1.0%"/><td style="width:41.105%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.010%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.531%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.534%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,211,688)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,820,996)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,847,840)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,665,177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,782,224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,798,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,546,511)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,038,772)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,049,815)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss at subsidiary attributable to noncontrolling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,537,759)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,963,068)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,978,633)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,396,098&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,614,052&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,911,577&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of restricted stock and stock options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,396,098&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,614,052&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,911,577&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of anti-dilutive securities excluded from computation of earnings per share</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's anti-dilutive restricted shares and stock options outstanding were as follows for the years ended December 31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:88.301%"><tr><td style="width:1.0%"/><td style="width:38.827%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.800%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.048%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2017</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive shares and options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,650&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,325&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697729273752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities, net</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company's net deferred tax assets at December&#160;31 are as follows:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.544%"><tr><td style="width:1.0%"/><td style="width:61.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.861%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.599%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.861%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss and tax credits</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,964,685&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,410,403&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment and intangibles</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for accounts receivable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,564&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251,068&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for expired product</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,227&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,150&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910,577&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative compensation costs incurred on deductible equity awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,047,149&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">884,049&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,846,928&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,444,049&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,313,965)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,974,787)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets, before valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,532,963&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,469,262&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: deferred tax asset valuation allowance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,511,161)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,382,052)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,802&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,210&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock', window );">Schedule of federal and state net operating loss carryforwards</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amount and year of expiration of the Company's federal and state net operating loss carryforwards as of December&#160;31, 2019:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.339%"><tr><td style="width:1.0%"/><td style="width:60.000%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.248%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years of expiration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Federal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">State</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 - 2029</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,392,824&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,153,819&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2031 - 2039</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,534,351&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,947,070&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,493,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383,869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total federal and state net operating loss carryforwards</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,181,428&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,198,158&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of the components of income tax benefit (expense)</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax (expense) benefit includes the following components for the years ended December 31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.179%"><tr><td style="width:1.0%"/><td style="width:40.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,316&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,636)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,243)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current income tax (expense) benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,724&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,636)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,243)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65,408)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,682,772)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(432,874)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax (expense) benefit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65,408)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,115,646)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax (expense) benefit </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,316&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,636)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,174,889)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of effective tax rate reconciliation</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s effective income tax rate for 2019, 2018 and 2017 reconciles with the federal statutory tax rate as follows:&#160;</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.179%"><tr><td style="width:1.0%"/><td style="width:40.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal tax expense at statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax expense (net of federal income tax benefit)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences associated with general business credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income tax expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697728397944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of share-based compensation expense</a></td>
<td class="text">Stock compensation expense consisted of the following for the years ended December 31:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.179%"><tr><td style="width:1.0%"/><td style="width:40.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation - employees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,244,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032,094&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation - nonemployees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,882&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,092&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,969&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation - foundation contribution</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,485,898&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,364,698&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,487,563&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock options activity</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity for 2019 and 2018 was as follows:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.064%"><tr><td style="width:1.0%"/><td style="width:34.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.558%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.024%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.024%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.139%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average exercise price per share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">term&#160;(years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">value</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited or expired</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited or expired</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,800)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ScheduleOfStockOptionActivityAdditionalDisclosuresTableTextBlock', window );">Schedule of stock options activity, additional disclosures</a></td>
<td class="text">Information related to the stock option plans during 2019, 2018 and 2017 was as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.179%"><tr><td style="width:1.0%"/><td style="width:40.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrinsic value of options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value of </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">options exercised</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of restricted stock activity</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock activity was as follows:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:70.192%"><tr><td style="width:1.0%"/><td style="width:50.498%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.731%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.733%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">of shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">grant-date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">fair value</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767,845&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261,680&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170,759)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,025)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833,741&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.09&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,669&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(225,536)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,925)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814,949&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.88&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ScheduleOfStockOptionActivityAdditionalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Stock Option Activity, Additional Disclosures [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ScheduleOfStockOptionActivityAdditionalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697729156856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock', window );">Schedule of rent expense and sublease income</a></td>
<td class="text">Rent expense and sublease income  as follows for the years ended December 31:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.897%"><tr><td style="width:1.0%"/><td style="width:41.064%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.919%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.064%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.919%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.919%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.559%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2017</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136,610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,074,437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688,020&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">662,358&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573,494&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Schedule of balance sheet classification</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2019, the Company recorded the following on the Condensed Consolidated Balance Sheet: </span></div><div style="margin-top:8pt;padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.688%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.895%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-Use Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,960,569&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,960,569&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;padding-left:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.688%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.895%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">920,431&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,076,472&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,996,903&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of operating lease liability maturities</a></td>
<td class="text">Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:66.025%"><tr><td style="width:1.0%"/><td style="width:73.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.173%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of  December&#160;31, 2019:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,120,066&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,144,889&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019,313&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,376,746&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(379,843)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,996,903&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of future minimum lease payments for operating leases</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's future minimum lease commitments, under Topic 840, predecessor to Topic 842, are as follows:</span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:66.025%"><tr><td style="width:1.0%"/><td style="width:73.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.173%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December 31, 2018:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959,902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">980,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001,603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">871,969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,858,702&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets and Liabilities, Lessee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Rent Expense and Sublease Income [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697722098776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of fair value of financial instruments by level in hierarchy</a></td>
<td class="text">The following table summarizes the fair value of these marketable securities by level within the fair value hierarchy:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.380%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.117%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.117%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.079%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.117%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.117%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2018</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes and bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,034,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,034,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SBA loan pools - variable rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,504,551&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,504,551&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term cash investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">751,173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">751,173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial Paper</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119,607&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119,607&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119,607&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119,607&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,034,955&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,255,724&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,290,679&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697721967576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Market Concentrations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of revenues concentration from major customers</a></td>
<td class="text">Total revenues by customer for each customer representing 10% or more of consolidated revenues are summarized below for the years ended December 31:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:76.602%"><tr><td style="width:1.0%"/><td style="width:39.904%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.846%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">*: less than 10% of total</span></div><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697723815416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations and Disposal Groups (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Disposal Groups, Including Discontinued Operations</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.198%"><tr><td style="width:1.0%"/><td style="width:49.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.769%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.439%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.769%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.731%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.769%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.735%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,145,344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,396,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,827,504&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs of products sold</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,330,704&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,361,273&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,952,575&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, Marketing and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,149,463&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,253,374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,076,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,665,177&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,782,224&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,798,025&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.384%"><tr><td style="width:1.0%"/><td style="width:61.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.686%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,922,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,384,254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,721&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,294,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets associated with discontinued operations</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,462,724&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,706,897&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.384%"><tr><td style="width:1.0%"/><td style="width:61.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.686%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,918,868&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,882,656&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,489&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666,457&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities associated with discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,151,357&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,549,113&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697726090840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Information (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Schedule of quarterly financial information</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the unaudited operating results for each fiscal quarter of 2019 and 2018:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.474%"><tr><td style="width:1.0%"/><td style="width:33.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.026%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.026%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.026%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.026%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.031%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">First</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Second</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Third</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fourth</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,729,860&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,417,443&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,935,439&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,305,553&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,388,295&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,323,932)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,373,424)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,196,436)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,394,390)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,288,182)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,187,553)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,338,521)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,316,286)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,369,328)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,211,688)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,147,136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">771,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,349,351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,396,981&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,665,177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73,878)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(549,507)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,953,668)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(960,706)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,537,759)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share attributable to common shareholders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - basic</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.60)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-13.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.13)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.23)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - diluted</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.60)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.13)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.23)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,918,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,084,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,853,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,487,842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,344,894&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,315,936)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,919,189)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,644,614)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,293,257)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,172,996)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,255,903)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,795,661)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,501,752)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,267,680)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,820,996)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from discontinued operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">863,714&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,050,211&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">837,731&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,030,568&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,782,224&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,379,239)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(720,688)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,643,044)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,220,097)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,963,068)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share attributable to common shareholders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;text-indent:-13.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations - basic</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.06&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.06&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.07&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.15)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.14)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.45)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations - diluted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.06&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.06&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.07&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.15)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.14)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.45)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Due to the nature of interim earnings per share calculations, the sum of the quarterly earnings (loss) per share amounts may not equal the reported earnings (loss) per share for the full year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121640914&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697725092920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest', window );">Exercise of options and related tax benefit</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss at subsidiary allocated to noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,752<span></span>
</td>
<td class="nump">$ 75,704<span></span>
</td>
<td class="nump">$ 71,182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=cpix_CumberlandEmergingTechnologiesIncMember', window );">Cumberland Emerging Technologies, Inc (CET)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Noncontrolling interest, ownership percentage by parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_HongKongWinHealthPharmaGroupCoLimitedMember', window );">HongKong WinHealth Pharma Group Co. Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_SubsidiaryInvestmentPurchaseOfShares', window );">Investment in CET</a></td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ContributionOfCashAdditionalSharesPurchased', window );">Contribution of cash</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_IntercompanyLoansPayableConvertedAmount', window );">Conversion of intercompany loans payable</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_GloriaPharmaceuticalsMember', window );">Gloria Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital', window );">Exchange for consideration, amount</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cpix_CumberlandEmergingTechnologiesIncMember', window );">Cumberland Emerging Technologies, Inc (CET) | Harbin Gloria Pharmaceuticals Co</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest', window );">Exercise of options and related tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ContributionOfCashAdditionalSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contribution of Cash, Additional Shares Purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ContributionOfCashAdditionalSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_IntercompanyLoansPayableConvertedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intercompany Loans Payable, Converted Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_IntercompanyLoansPayableConvertedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subsidiary Investment, Payments For Return Of Capital</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_SubsidiaryInvestmentPurchaseOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subsidiary Investment, Purchase Of Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_SubsidiaryInvestmentPurchaseOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from sale of a portion of the parent's controlling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=cpix_CumberlandEmergingTechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=cpix_CumberlandEmergingTechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_HongKongWinHealthPharmaGroupCoLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_HongKongWinHealthPharmaGroupCoLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_GloriaPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_GloriaPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cpix_CumberlandEmergingTechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cpix_CumberlandEmergingTechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_HarbinGloriaPharmaceuticalsCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_HarbinGloriaPharmaceuticalsCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697724947928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenues from customers outside the United States</a></td>
<td class="nump">$ 9,305,553<span></span>
</td>
<td class="nump">$ 6,935,439<span></span>
</td>
<td class="nump">$ 9,417,443<span></span>
</td>
<td class="nump">$ 8,729,860<span></span>
</td>
<td class="nump">$ 10,487,842<span></span>
</td>
<td class="nump">$ 5,853,451<span></span>
</td>
<td class="nump">$ 7,084,843<span></span>
</td>
<td class="nump">$ 5,918,758<span></span>
</td>
<td class="nump">$ 34,388,295<span></span>
</td>
<td class="nump">$ 29,344,894<span></span>
</td>
<td class="nump">$ 26,322,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">2,960,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,960,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">2,996,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,996,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductionAndDistributionCosts', window );">Distribution costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">613,637<span></span>
</td>
<td class="nump">457,814<span></span>
</td>
<td class="nump">487,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,594,630<span></span>
</td>
<td class="nump">2,005,113<span></span>
</td>
<td class="nump">2,377,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_AccountsReceivableAllowancesByComponentAxis=cpix_ChargebacksCashDiscountsAndDamagedGoodsMember', window );">Product Sales Related Allowances - Chargebacks, Cash Discounts and Damaged Goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Accounts receivable, allowances, current</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenues from customers outside the United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductionAndDistributionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to the production and distribution of goods or services to customers and clients.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductionAndDistributionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_AccountsReceivableAllowancesByComponentAxis=cpix_ChargebacksCashDiscountsAndDamagedGoodsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_AccountsReceivableAllowancesByComponentAxis=cpix_ChargebacksCashDiscountsAndDamagedGoodsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697725296488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Schedule of Intangible Assets, Useful Lives) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cpix_ProductRightsMember', window );">Product Rights</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual', window );">Intangible assets, useful life</a></td>
<td class="text">Estimated economic life<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Rights</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual', window );">Intangible assets, useful life</a></td>
<td class="text">Term of license agreement<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual', window );">Intangible assets, useful life</a></td>
<td class="text">Life of patent<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Assets, Useful Lives, (Textual)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cpix_ProductRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cpix_ProductRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697725410344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Omeclamox&#174;-Pak, RediTrex&#174; and Vibativ&#174; - Narrative (Details) - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 29, 2013</div></th>
<th class="th"><div>Nov. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_PaymentsForAssetAcquisitions', window );">Payments for asset acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,407,845<span></span>
</td>
<td class="nump">$ 28,803,961<span></span>
</td>
<td class="nump">$ 25,549,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales', window );">Other revenue, potential upfront payment related to product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cpix_AmendedInternationalAgreementMember', window );">Amended International Agreement | Pernix Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales', window );">Other revenue, potential upfront payment related to product sales</a></td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_OmeclamoxPakMember', window );">Omeclamox-Pak</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember', window );">Methotrexate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Liabilities incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock issued during period, acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember', window );">Methotrexate | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember', window );">Omeclamox-Pak</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 837,829<span></span>
</td>
<td class="nump">$ 623,297<span></span>
</td>
<td class="nump">$ 1,761,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Methotrexate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock issued during period, acquisitions (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_PaymentsForAssetAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Asset Acquisitions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_PaymentsForAssetAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Potential Upfront Payment Related to Product Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cpix_AmendedInternationalAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cpix_AmendedInternationalAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cpix_PernixTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cpix_PernixTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_OmeclamoxPakMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_OmeclamoxPakMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697728632904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Omeclamox&#174;-Pak, RediTrex&#174; and Vibativ&#174; - Vibativ Acquisition - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 08, 2019</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of accrued contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,374,776<span></span>
</td>
<td class="nump">2,290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Noncurrent portion of accrued contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,258,813<span></span>
</td>
<td class="nump">$ 7,212,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">VIBATIV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPaymentsToAcquireBusinesses', window );">Additional payments to acquire businesses</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_TieredRoyaltyPaymentsPercentage', window );">Tiered royalty payments (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_TieredRoyaltyPaymentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tiered Royalty Payments, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_TieredRoyaltyPaymentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPaymentsToAcquireBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPaymentsToAcquireBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697725416536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Omeclamox&#174;-Pak, RediTrex&#174; and Vibativ&#174; - Vibativ Acquisition - Schedule of Contingent Consideration and Preliminary Allocation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">2 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 08, 2019</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid at closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 784,000<span></span>
</td>
<td class="nump">$ 784,000<span></span>
</td>
<td class="nump">882,000<span></span>
</td>
<td class="nump">784,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">VIBATIV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid at closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPaymentsToAcquireBusinesses', window );">Cash payment during early 2019</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_PaymentsForContingentConsideration', window );">Fair value of contingent consideration - net sales royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,182,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,182,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Balance at November 12, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,034,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,502,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration included in operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(804,167)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses', window );">Contingent consideration earned and accrued in operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">508,000<span></span>
</td>
<td class="nump">820,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment', window );">Adjustment to initial fair value of the contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Cash payment of royalty during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,033,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Balance at December 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,502,000<span></span>
</td>
<td class="nump">$ 9,502,000<span></span>
</td>
<td class="nump">$ 8,633,589<span></span>
</td>
<td class="nump">$ 9,502,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory', window );">Finished goods inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,624,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials', window );">Work in process - unlabeled vials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,970,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials', window );">Work in process - validation vials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,827,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory', window );">Raw materials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,129,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Total inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intellectual property amortizable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">882,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill', window );">Total intangibles and goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,632,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,182,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration Arrangements, Contingent Consideration, Liability, Initial Fair Value Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finished Goods Inventory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles and Goodwill</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Raw Materials Inventory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Unlabeled Vials</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Validation Vials</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_PaymentsForContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_PaymentsForContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPaymentsToAcquireBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPaymentsToAcquireBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697725906856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Schedule of Net Product Revenues by Product) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 32,407,845<span></span>
</td>
<td class="nump">$ 28,803,961<span></span>
</td>
<td class="nump">$ 25,549,058<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_AcetadoteMember', window );">Acetadote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">3,824,449<span></span>
</td>
<td class="nump">4,284,111<span></span>
</td>
<td class="nump">6,576,720<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember', window );">Omeclamox-Pak</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">837,829<span></span>
</td>
<td class="nump">623,297<span></span>
</td>
<td class="nump">1,761,868<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_KristaloseMember', window );">Kristalose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">12,895,120<span></span>
</td>
<td class="nump">12,055,625<span></span>
</td>
<td class="nump">11,455,805<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_VaprisolMember', window );">Vaprisol</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">936,615<span></span>
</td>
<td class="nump">1,763,874<span></span>
</td>
<td class="nump">1,576,222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_CaldolorMember', window );">Caldolor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">5,222,282<span></span>
</td>
<td class="nump">5,001,997<span></span>
</td>
<td class="nump">4,178,443<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_ProductVibativMember', window );">Vibativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 8,691,550<span></span>
</td>
<td class="nump">$ 5,075,057<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_AcetadoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_AcetadoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_KristaloseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_KristaloseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_VaprisolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_VaprisolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_CaldolorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_CaldolorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_ProductVibativMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_ProductVibativMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697725350392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductRevenuesAbstract', window );"><strong>Product Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 32,407,845<span></span>
</td>
<td class="nump">$ 28,803,961<span></span>
</td>
<td class="nump">$ 25,549,058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_OtherRevenuesAbstract', window );"><strong>Other Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_RevenueRecognitionUpfrontPayment', window );">Other revenue, upfront payment</a></td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval', window );">Other revenue, potential upfront payments related to regulatory approval</a></td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales', window );">Other revenue, potential upfront payment related to product sales</a></td>
<td class="nump">4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_RevenueRecognitionCumulativeUpfrontPayment', window );">Cumulative upfront payment</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_RevenueRecognitionMilestonePayments', window );">Milestone payments associated with international agreements</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember', window );">Collaborative Arrangement, Federal Small Business Grant Programs | Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductRevenuesAbstract', window );"><strong>Product Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember', window );">HongKong WinHealth Pharma Group Co. Limited And DB Pharm Korea Co., Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductRevenuesAbstract', window );"><strong>Product Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_OtherRevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Revenues [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_OtherRevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ProductRevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Product Revenues [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ProductRevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_RevenueRecognitionCumulativeUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Cumulative Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_RevenueRecognitionCumulativeUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_RevenueRecognitionMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_RevenueRecognitionMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Potential Upfront Payment Related to Product Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Potential Upfront Payments Related to Regulatory Approval</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_RevenueRecognitionUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_RevenueRecognitionUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697815200952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Schedule of Inventories) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials and work in process</a></td>
<td class="nump">$ 19,345,723<span></span>
</td>
<td class="nump">$ 18,378,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment', window );">Consigned inventory</a></td>
<td class="nump">416,468<span></span>
</td>
<td class="nump">937,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods, net of reserve</a></td>
<td class="nump">4,664,055<span></span>
</td>
<td class="nump">6,216,965<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total inventories</a></td>
<td class="nump">24,426,246<span></span>
</td>
<td class="nump">25,532,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">less non-current inventories</a></td>
<td class="num">(15,554,992)<span></span>
</td>
<td class="num">(15,749,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 8,871,254<span></span>
</td>
<td class="nump">$ 9,783,421<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of inventory owned by the entity but in the hands of a customer, typically a reseller.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697729515800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory reserves, obsolescence and discontinuance</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">15,554,992<span></span>
</td>
<td class="nump">15,749,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">4,664,055<span></span>
</td>
<td class="nump">6,216,965<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">VIBATIV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">15,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_IfetrobanClinicalMember', window );">Ifetroban Clinical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_IfetrobanClinicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_IfetrobanClinicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697723592136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Schedule of Property and Equipment) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 4,142,125<span></span>
</td>
<td class="nump">$ 3,895,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(3,394,329)<span></span>
</td>
<td class="num">(3,124,710)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">747,796<span></span>
</td>
<td class="nump">771,213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,260,630<span></span>
</td>
<td class="nump">$ 1,148,140<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">878,350<span></span>
</td>
<td class="nump">$ 809,153<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">646,505<span></span>
</td>
<td class="nump">$ 639,267<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 1,356,640<span></span>
</td>
<td class="nump">$ 1,299,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_PropertyAndEquipmentUsefulLifeTextual', window );">Property and equipment, useful life (Textual)</a></td>
<td class="text">3&#160;&#8211;&#160;15&#160;years,&#160;or remaining&#160;lease&#160;term<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_PropertyAndEquipmentUsefulLifeTextual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property and Equipment, useful life (Textual)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_PropertyAndEquipmentUsefulLifeTextual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697722037960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Depreciation Expense) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements', window );">Depreciation, including amortization related to leasehold improvements</a></td>
<td class="nump">$ 269,619<span></span>
</td>
<td class="nump">$ 213,237<span></span>
</td>
<td class="nump">$ 211,532<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Depreciation, Including Amortization Related to Leasehold Improvements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697723576584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets (Schedule of Intangible Assets) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">$ 30,920,324<span></span>
</td>
<td class="nump">$ 33,655,099<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cpix_ProductAndLicenseRightsMember', window );">Product and License Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">37,400,742<span></span>
</td>
<td class="nump">36,573,941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(11,499,141)<span></span>
</td>
<td class="num">(8,405,188)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">25,901,601<span></span>
</td>
<td class="nump">28,168,753<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">9,882,511<span></span>
</td>
<td class="nump">9,428,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(5,127,878)<span></span>
</td>
<td class="num">(4,087,273)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">4,754,633<span></span>
</td>
<td class="nump">5,340,993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">273,110<span></span>
</td>
<td class="nump">154,373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(9,020)<span></span>
</td>
<td class="num">(9,020)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">$ 264,090<span></span>
</td>
<td class="nump">$ 145,353<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cpix_ProductAndLicenseRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cpix_ProductAndLicenseRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697724162376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Narrative) (Details) - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Nov. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Feb. 28, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 882,000<span></span>
</td>
<td class="nump">$ 784,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales', window );">Other revenue, potential upfront payment related to product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Additions to intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">772,944<span></span>
</td>
<td class="nump">3,819,486<span></span>
</td>
<td class="nump">1,213,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,134,557<span></span>
</td>
<td class="nump">2,769,466<span></span>
</td>
<td class="nump">$ 2,436,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cpix_ProductAndLicenseRightsMember', window );">Product and License Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,400,742<span></span>
</td>
<td class="nump">36,573,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,882,511<span></span>
</td>
<td class="nump">9,428,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Additions to intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember', window );">Methotrexate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock issued during period, acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember', window );">Methotrexate | Nordic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock issued during period, acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember', window );">Methotrexate | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock issued during period, acquisitions (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">VIBATIV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 882,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire businesses</a></td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intellectual property amortizable intangible assets</a></td>
<td class="nump">$ 11,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPeriodIncreaseDecrease', window );">Increase in goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cpix_VaprisolMember', window );">Vaprisol | Product and License Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Potential Upfront Payment Related to Product Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cpix_ProductAndLicenseRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cpix_ProductAndLicenseRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_NordicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_NordicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cpix_VaprisolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cpix_VaprisolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697729248232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets Future Amortization Expense (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2020</a></td>
<td class="nump">$ 4,286,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2021</a></td>
<td class="nump">4,084,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2022</a></td>
<td class="nump">3,530,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2023</a></td>
<td class="nump">3,743,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter', window );">2024 and thereafter</a></td>
<td class="nump">15,274,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">$ 30,920,324<span></span>
</td>
<td class="nump">$ 33,655,099<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Assets, Amortization Expense, Year Five and After</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697725491944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Current and Other Long-term Liabilities (Schedule of Other Current and Noncurrent Liabilities) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrentAbstract', window );"><strong>Other Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductSalesRelatedLiabilitiesCurrent', window );">Rebates, product returns, administrative fees and service fees</a></td>
<td class="nump">$ 4,593,167<span></span>
</td>
<td class="nump">$ 4,969,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee wages and benefits</a></td>
<td class="nump">1,295,905<span></span>
</td>
<td class="nump">1,263,426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_AccruedLiabilitiesStockPayable', window );">Stock payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,085,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of accrued contingent consideration</a></td>
<td class="nump">2,374,776<span></span>
</td>
<td class="nump">2,290,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_DeferredAcquisitionLiabilityCurrent', window );">Deferred acquisition liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_AccruedLiabilitiesInventoryPurchases', window );">Accrued inventory purchases</a></td>
<td class="nump">829,047<span></span>
</td>
<td class="nump">434,405<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_AccruedPaymentForAssetPurchaseCurrent', window );">Accrued payment for asset purchase</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">991,974<span></span>
</td>
<td class="nump">1,001,724<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total other current liabilities</a></td>
<td class="nump">11,084,869<span></span>
</td>
<td class="nump">16,044,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Noncurrent portion of accrued contingent consideration</a></td>
<td class="nump">6,258,813<span></span>
</td>
<td class="nump">7,212,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent', window );">Deferred compensation</a></td>
<td class="nump">2,278,164<span></span>
</td>
<td class="nump">1,588,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent', window );">Other</a></td>
<td class="nump">200,346<span></span>
</td>
<td class="nump">519,020<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other Liabilities, Noncurrent, Total</a></td>
<td class="nump">$ 8,737,323<span></span>
</td>
<td class="nump">$ 9,319,143<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_AccruedLiabilitiesInventoryPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities, Inventory Purchases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_AccruedLiabilitiesInventoryPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_AccruedLiabilitiesStockPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities, Stock Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_AccruedLiabilitiesStockPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_AccruedPaymentForAssetPurchaseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Payment For Asset Purchase, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_AccruedPaymentForAssetPurchaseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DeferredAcquisitionLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Acquisition Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DeferredAcquisitionLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ProductSalesRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Product Sales-Related Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ProductSalesRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer), including liabilities for compensation costs, fringe benefits other than pension and postretirement obligations, rent, contractual rights and obligations, and statutory obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697845221384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt (Line of Credit) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jul. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Oct. 17, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,500,000<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Pinnacle Bank | Second Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Pinnacle Bank | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions', window );">Line of credit, maximum borrowing capacity upon satisfaction of certain conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Line of credit, unused capacity, commitment fee percentage</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Pinnacle Bank | Line of Credit | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Pinnacle Bank | Line of Credit | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Maximum Borrowing Capacity Upon Satisfaction of Certain Conditions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1336-112600<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1314-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cpix_SecondAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cpix_SecondAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697726051576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Initial Public Offering, Preferred Stock and Common Stock, Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 10, 2009 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_InitialPublicOfferingAbstract', window );"><strong>Initial Public Offering [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Initial public offering, issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 383,310<span></span>
</td>
<td class="nump">$ 27,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_PreferredStockAbstract', window );"><strong>Preferred Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_CommonStockAbstract', window );"><strong>Common Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities', window );">Shelf Registration, sale of corporate securities (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_InitialPublicOfferingAbstract', window );"><strong>Initial Public Offering [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockTransactionDate', window );">Initial public offering, effective date</a></td>
<td class="text">Aug. 10,  2009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Initial public offering, shares issued | shares</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_StockIssuedDuringPeriodPricePerShareNewIssues', window );">Initial public offering, price per share | $ / shares</a></td>
<td class="nump">$ 17.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering', window );">Initial public offering, gross proceeds</a></td>
<td class="nump">$ 85,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts', window );">Initial public offering, underwriting discounts</a></td>
<td class="nump">6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Initial public offering, issuance costs</a></td>
<td class="nump">4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Initial public offering, net proceeds</a></td>
<td class="nump">$ 74,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering', window );">Initial public offering, number of shares common stock received in exchange for preferred stock</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_InitialPublicOfferingAbstract', window );"><strong>Initial Public Offering [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Initial public offering, shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_CommonStockAbstract', window );"><strong>Common Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,536<span></span>
</td>
<td class="nump">170,759<span></span>
</td>
<td class="nump">146,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding', window );">Exercise of options and related tax benefit, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">3,409<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CommonStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CommonStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_InitialPublicOfferingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial Public Offering [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_InitialPublicOfferingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_PreferredStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_PreferredStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Net of Shares for Tax Withholding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Gross Proceeds from Initial Public Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, New Shares, Underwriting Discounts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_StockIssuedDuringPeriodPricePerShareNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Price Per Share, New Issues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_StockIssuedDuringPeriodPricePerShareNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shelf Registration, Proceeds From Sale of Corporate Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued in Initial Public Offering, Number of Shares Common Stock Received for Preferred Stock Contemporareous With Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockTransactionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the subsidiary or equity investee issued or sold stock, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockTransactionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697723823736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Shareholders' Equity (Warrants, Narrative) (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2009</div></th>
<th class="th"><div>Dec. 31, 2006</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cpix_WarrantsIssuedInConsiderationOf2006CreditFacilityAmendmentMember', window );">Warrants, Issued in Consideration of 2006 Credit Facility Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants, number of shares called by warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,958<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cpix_WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember', window );">Warrants, Issued in Consideration of 2009 Credit Facility Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants, number of shares called by warrants</a></td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price</a></td>
<td class="nump">$ 17.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cpix_WarrantsIssuedInConsiderationOf2006CreditFacilityAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cpix_WarrantsIssuedInConsiderationOf2006CreditFacilityAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cpix_WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cpix_WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697720020568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Share Repurchases, Cumberland Emerging Technologies and Cumberland Foundation Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 27, 2019</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Apr. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>May 31, 2010</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,486,835<span></span>
</td>
<td class="nump">$ 2,877,935<span></span>
</td>
<td class="nump">$ 3,719,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Amount available under current repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest', window );">Exercise of options and related tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates', window );">Payments to acquire interest in subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_LoansForgiveninExchangeForShareIssuedAmount', window );">Loans Forgiven in Exchange For Share Issued, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_SharebasedCompensationCharitableContributionofSharesShares', window );">Charitable contribution of shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions', window );">Committed cash contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Vesting of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 862,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_HongKongWinHealthPharmaGroupCoLimitedMember', window );">HongKong WinHealth Pharma Group Co. Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_SubsidiaryInvestmentPurchaseOfShares', window );">Investment in CET</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_GloriaPharmaceuticalsMember', window );">Gloria Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital', window );">Exchange for consideration, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_NordicMember', window );">Nordic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vesting of common stock, shares</a></td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Vesting of common stock</a></td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">623,478<span></span>
</td>
<td class="nump">443,041<span></span>
</td>
<td class="nump">547,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,486,835<span></span>
</td>
<td class="nump">$ 2,877,935<span></span>
</td>
<td class="nump">$ 3,719,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vesting of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Vesting of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 862,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_SharesRepurchaseActivityTypeAxis=cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember', window );">Shares Repurchase, All, Except Settlement of Tax Liabilities Related to Exercise of Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">623,478<span></span>
</td>
<td class="nump">443,041<span></span>
</td>
<td class="nump">547,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=cpix_ShareRepurchaseProgramAuthorizedIn2010Member', window );">Share Repurchase Program Authorized in 2010</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Share repurchase program, number of shares authorized to be repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LoansForgiveninExchangeForShareIssuedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loans Forgiven in Exchange For Share Issued, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LoansForgiveninExchangeForShareIssuedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation, Charitable Contribution of Shares, Committed Cash Contributions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_SharebasedCompensationCharitableContributionofSharesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation, Charitable Contribution of Shares, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_SharebasedCompensationCharitableContributionofSharesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subsidiary Investment, Payments For Return Of Capital</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_SubsidiaryInvestmentPurchaseOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subsidiary Investment, Purchase Of Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_SubsidiaryInvestmentPurchaseOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityClassOfTreasuryStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityClassOfTreasuryStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from sale of a portion of the parent's controlling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_HongKongWinHealthPharmaGroupCoLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_HongKongWinHealthPharmaGroupCoLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_GloriaPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_GloriaPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_NordicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_NordicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_SharesRepurchaseActivityTypeAxis=cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_SharesRepurchaseActivityTypeAxis=cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=cpix_ShareRepurchaseProgramAuthorizedIn2010Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=cpix_ShareRepurchaseProgramAuthorizedIn2010Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697726050184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Schedule of Computation of Numerator and Denominator in Earnings Per Share) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income (loss) from continuing operations</a></td>
<td class="num">$ (3,369,328)<span></span>
</td>
<td class="num">$ (3,316,286)<span></span>
</td>
<td class="num">$ (1,338,521)<span></span>
</td>
<td class="num">$ (1,187,553)<span></span>
</td>
<td class="num">$ (3,267,680)<span></span>
</td>
<td class="num">$ (2,501,752)<span></span>
</td>
<td class="num">$ (1,795,661)<span></span>
</td>
<td class="num">$ (3,255,903)<span></span>
</td>
<td class="num">$ (9,211,688)<span></span>
</td>
<td class="num">$ (10,820,996)<span></span>
</td>
<td class="num">$ (12,847,840)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations net of tax</a></td>
<td class="nump">2,396,981<span></span>
</td>
<td class="nump">1,349,351<span></span>
</td>
<td class="nump">771,709<span></span>
</td>
<td class="nump">1,147,136<span></span>
</td>
<td class="nump">1,030,568<span></span>
</td>
<td class="nump">837,731<span></span>
</td>
<td class="nump">1,050,211<span></span>
</td>
<td class="nump">863,714<span></span>
</td>
<td class="nump">5,665,177<span></span>
</td>
<td class="nump">3,782,224<span></span>
</td>
<td class="nump">4,798,025<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,546,511)<span></span>
</td>
<td class="num">(7,038,772)<span></span>
</td>
<td class="num">(8,049,815)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss at subsidiary allocated to noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,752<span></span>
</td>
<td class="nump">75,704<span></span>
</td>
<td class="nump">71,182<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shareholders</a></td>
<td class="num">$ (960,706)<span></span>
</td>
<td class="num">$ (1,953,668)<span></span>
</td>
<td class="num">$ (549,507)<span></span>
</td>
<td class="num">$ (73,878)<span></span>
</td>
<td class="num">$ (2,220,097)<span></span>
</td>
<td class="num">$ (1,643,044)<span></span>
</td>
<td class="num">$ (720,688)<span></span>
</td>
<td class="num">$ (2,379,239)<span></span>
</td>
<td class="num">$ (3,537,759)<span></span>
</td>
<td class="num">$ (6,963,068)<span></span>
</td>
<td class="num">$ (7,978,633)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding &#8211; basic (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,396,098<span></span>
</td>
<td class="nump">15,614,052<span></span>
</td>
<td class="nump">15,911,577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive effect of restricted stock and stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding &#8211; diluted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,396,098<span></span>
</td>
<td class="nump">15,614,052<span></span>
</td>
<td class="nump">15,911,577<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Denominator.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Numerator.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697723366120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Schedule of Anti-dilutive Securities Excluded From Computation of Earnings Per Share) (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares (in shares)</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">41,650<span></span>
</td>
<td class="nump">18,325<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697729643544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Operating Loss Carryforwards, Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 18,511,161<span></span>
</td>
<td class="nump">$ 17,382,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit', window );">Net tax benefit, impact of Tax Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (100,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember', window );">Valuation allowance for deferred tax assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Charged to costs and expenses</a></td>
<td class="nump">1,129,109<span></span>
</td>
<td class="nump">1,749,817<span></span>
</td>
<td class="num">$ (665,039)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 57,181,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,198,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax expense (benefit) from effect of Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697815250104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Schedule of Deferred Tax Assets and Liabilities, Net) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred Tax Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards', window );">Net operating loss and tax credits</a></td>
<td class="nump">$ 16,964,685<span></span>
</td>
<td class="nump">$ 16,410,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles', window );">Property and equipment and intangibles</a></td>
<td class="nump">227,072<span></span>
</td>
<td class="nump">236,318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts', window );">Allowance for accounts receivable</a></td>
<td class="nump">257,564<span></span>
</td>
<td class="nump">251,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct', window );">Reserve for expired product</a></td>
<td class="nump">469,466<span></span>
</td>
<td class="nump">558,484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory</a></td>
<td class="nump">35,227<span></span>
</td>
<td class="nump">193,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_DeferredTaxAssetsDeferredCharges', window );">Deferred charges</a></td>
<td class="nump">845,765<span></span>
</td>
<td class="nump">910,577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Cumulative compensation costs incurred on deductible equity awards</a></td>
<td class="nump">1,047,149<span></span>
</td>
<td class="nump">884,049<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">19,846,928<span></span>
</td>
<td class="nump">19,444,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred Tax Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="num">(1,313,965)<span></span>
</td>
<td class="num">(1,974,787)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_NetDeferredTaxAssetsGross', window );">Net deferred tax assets, before valuation allowance</a></td>
<td class="nump">18,532,963<span></span>
</td>
<td class="nump">17,469,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: deferred tax asset valuation allowance</a></td>
<td class="num">(18,511,161)<span></span>
</td>
<td class="num">(17,382,052)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 21,802<span></span>
</td>
<td class="nump">$ 87,210<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DeferredTaxAssetsDeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Deferred Charges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DeferredTaxAssetsDeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Loss Carryforwards and Tax Credit Carryforwards</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Property and Equipment and Intangibles</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves for Expired Product</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_NetDeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Deferred Tax Assets, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_NetDeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the allowance for doubtful accounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697724044520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Schedule of Net Operating Loss Carryforwards) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 57,181,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,198,158<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermOneMember', window );">2020 | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermOneMember', window );">2020 | State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermTwoMember', window );">2021 - 2029 | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermTwoMember', window );">2021 - 2029 | State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,392,824<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermThreeMember', window );">2030 | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">44,153,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermThreeMember', window );">2030 | State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">461,280<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermFourMember', window );">2031 - 2039 | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">7,534,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermFourMember', window );">2031 - 2039 | State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,947,070<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ExpirationTimePeriodAxis=cpix_IndefiniteMember', window );">Indefinite Period | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 5,493,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ExpirationTimePeriodAxis=cpix_IndefiniteMember', window );">Indefinite Period | State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 383,869<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ExpirationTimePeriodAxis=cpix_IndefiniteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ExpirationTimePeriodAxis=cpix_IndefiniteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697729684232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule of the Components of Income Tax Benefit (Expense) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 65,408<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State and other</a></td>
<td class="nump">79,316<span></span>
</td>
<td class="num">(16,636)<span></span>
</td>
<td class="num">(59,243)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current income tax (expense) benefit</a></td>
<td class="nump">144,724<span></span>
</td>
<td class="num">(16,636)<span></span>
</td>
<td class="num">(59,243)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(65,408)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,682,772)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(432,874)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOtherTaxExpenseBenefit', window );">Deferred income tax (expense) benefit</a></td>
<td class="num">(65,408)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,115,646)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax (expense) benefit</a></td>
<td class="nump">$ 79,316<span></span>
</td>
<td class="num">$ (16,636)<span></span>
</td>
<td class="num">$ (4,174,889)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOtherTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. For example, but not limited to, acquisition-date income tax benefits or expenses recognized from changes in the acquirer's valuation allowance for its previously existing deferred tax assets resulting from a business combination and adjustments to beginning-of-year balance of a valuation allowance because of a change in circumstance causing a change in judgment about the realizability of the related deferred tax asset in future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOtherTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697723588760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal tax expense at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income tax expense (net of federal income tax benefit)</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Permanent differences associated with general business credits</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(31.00%)<span></span>
</td>
<td class="num">(25.00%)<span></span>
</td>
<td class="num">(148.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent', window );">Change in tax rate</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Other permanent differences</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Net income tax expense</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(108.00%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697724593800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans (Narrative) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>plan </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans', window );">Number of equity compensation plans | plan</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants', window );">Number of equity compensation plans available for future grants | plan</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to share-based payments | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost related to share-based payments, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cpix_NonprincipalOwnerMember', window );">NonPrincipal Owner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue', window );">Stock options, exercise price as percent of weighted-average grant date fair value</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cpix_LongTermIncentiveCompensationPlan2007Member', window );">Long-Term Incentive Compensation Plan 2007</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares reserved for issuance under equity compensation plans | shares</a></td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cpix_DirectorsIncentivePlan2007Member', window );">Directors&#8217; Incentive Plan 2007</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares reserved for issuance under equity compensation plans | shares</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Principal Owner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options, expiration period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | NonPrincipal Owner | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options, expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Number of Plans</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Number of Plans Available for Future Grants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price as Percent of Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cpix_NonprincipalOwnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cpix_NonprincipalOwnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cpix_LongTermIncentiveCompensationPlan2007Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cpix_LongTermIncentiveCompensationPlan2007Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cpix_DirectorsIncentivePlan2007Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cpix_DirectorsIncentivePlan2007Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=us-gaap_PrincipalOwnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=us-gaap_PrincipalOwnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cpix_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cpix_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697728666712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans (Schedule of Share-Based Compensation Expense) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 1,485,898<span></span>
</td>
<td class="nump">$ 1,364,698<span></span>
</td>
<td class="nump">$ 1,115,063<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cpix_EmployeeMember', window );">Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">1,481,016<span></span>
</td>
<td class="nump">1,244,606<span></span>
</td>
<td class="nump">1,032,094<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cpix_NonemployeeMember', window );">Nonemployee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">4,882<span></span>
</td>
<td class="nump">120,092<span></span>
</td>
<td class="nump">82,969<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cpix_FoundationContributionMember', window );">Foundation Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">372,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cpix_EmployeeNonemployeeandFoundationContributionMember', window );">Employee, Nonemployee and Foundation Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 1,485,898<span></span>
</td>
<td class="nump">$ 1,364,698<span></span>
</td>
<td class="nump">$ 1,487,563<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cpix_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cpix_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cpix_NonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cpix_NonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cpix_FoundationContributionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cpix_FoundationContributionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cpix_EmployeeNonemployeeandFoundationContributionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cpix_EmployeeNonemployeeandFoundationContributionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697724071128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans (Schedule of Stock Options Activity) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning of period, shares</a></td>
<td class="nump">5,800<span></span>
</td>
<td class="nump">5,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted, shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised, shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options forfeited or expired, shares</a></td>
<td class="num">(5,800)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, end of period, shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,800<span></span>
</td>
<td class="nump">5,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options, exerciseable, end of period, shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-average exercise price per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning of period, weighted-average exercise price per share (in USD per share)</a></td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted, weighted-average exercise price per share (in USD per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised, weighted-average exercise price per share (in USD per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Options forfeited or expired, weighted-average exercise price per share (in USD per share)</a></td>
<td class="nump">13.00<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, end of period, weighted-average exercise price per share (in USD per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="nump">$ 13.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, end of period, weighted-average exercise price per share (in USD per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, end of period, weighted-average remaining contractual term</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">10 months 24 days<span></span>
</td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, end of period, weighted-average remaining contractual term</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, end of period, aggregate intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, end of period, aggregate intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697729101720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans (Schedule of Stock Option Activity, Additional Disclosures) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of options exercised</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697724552344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans (Schedule of Restricted Stock Activity) (Details) - Restricted Stock - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested, beginning of period, shares</a></td>
<td class="nump">833,741<span></span>
</td>
<td class="nump">767,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares granted, shares</a></td>
<td class="nump">229,669<span></span>
</td>
<td class="nump">261,680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares vested, shares</a></td>
<td class="num">(225,536)<span></span>
</td>
<td class="num">(170,759)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Shares forfeited, shares</a></td>
<td class="num">(22,925)<span></span>
</td>
<td class="num">(25,025)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested, end of period, shares</a></td>
<td class="nump">814,949<span></span>
</td>
<td class="nump">833,741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- average grant-date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested, beginning of period, weighted-average grant-date fair value</a></td>
<td class="nump">$ 6.09<span></span>
</td>
<td class="nump">$ 5.61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Shares granted, weighted-average grant-date fair value</a></td>
<td class="nump">5.95<span></span>
</td>
<td class="nump">6.66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Shares vested, weighted-average grant-date fair value</a></td>
<td class="nump">6.71<span></span>
</td>
<td class="nump">4.79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Shares forfeited, weighted-average grant-date fair value</a></td>
<td class="nump">6.20<span></span>
</td>
<td class="nump">6.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested, end of period, weighted-average grant-date fair value</a></td>
<td class="nump">$ 5.88<span></span>
</td>
<td class="nump">$ 6.09<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697845631448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge', window );">Defined contribution plan, eligibiilty, minimum employee age</a></td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility', window );">Defined contribution plan, eligibility, minimum employee service time for participation eligibility</a></td>
<td class="text">six months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined contribution plan, employer discretionary contribution amount</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityAbstract', window );"><strong>Deferred Compensation Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent', window );">Deferred compensation liability</a></td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationPlanAssets', window );">Deferred compensation assets</a></td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan, Eligibility, Minimum Employee Age</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan, Eligibility, Minimum Employee Service Time for Participation Eligibility</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:durationStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements. Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of assets held under deferred compensation agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697726020616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 2,960,569<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 2,996,903<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average incremental borrowing rate</a></td>
<td class="nump">7.42%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697725282344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Schedule of Rent Expense and Sublease Income) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense</a></td>
<td class="nump">$ 1,246,143<span></span>
</td>
<td class="nump">$ 1,136,610<span></span>
</td>
<td class="nump">$ 1,074,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1', window );">Sublease income</a></td>
<td class="nump">688,020<span></span>
</td>
<td class="nump">$ 662,358<span></span>
</td>
<td class="nump">$ 573,494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals', window );">Future minimum sublease income under noncancelable operating subleases</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractually required future rental payments receivable on noncancelable subleasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of sublease rental income recognized during the period that reduces the entity's rent expense incurred under operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseSubleaseRentals1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697728961048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Lease Position) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 2,960,569<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_LeaseAsset', window );">Total</a></td>
<td class="nump">2,960,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">920,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">2,076,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_LeaseLiability', window );">Total</a></td>
<td class="nump">$ 2,996,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LeaseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease, Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LeaseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697728609224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Schedule of Lease Liability Maturities and Future Minimum Payments) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Lease Liabilities, Payments Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2020</a></td>
<td class="nump">$ 1,120,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2021</a></td>
<td class="nump">1,144,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2022</a></td>
<td class="nump">1,019,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2023</a></td>
<td class="nump">92,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">After 2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">3,376,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less Interest</a></td>
<td class="num">(379,843)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 2,996,903<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 959,902<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">980,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,001,603<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">871,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">After 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,858,702<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697724627544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Schedule of Fair Value of Financial Instruments by Level in Hierarchy and Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Fair value of marketable securities</a></td>
<td class="nump">$ 2,119,607<span></span>
</td>
<td class="nump">$ 8,290,679<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Fair value of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,034,955<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Fair value of marketable securities</a></td>
<td class="nump">2,119,607<span></span>
</td>
<td class="nump">3,255,724<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=cpix_USTreasuryNotesAndBondsSecuritiesMember', window );">U.S. Treasury notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Fair value of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,034,955<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=cpix_USTreasuryNotesAndBondsSecuritiesMember', window );">U.S. Treasury notes and bonds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Fair value of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,034,955<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=cpix_USTreasuryNotesAndBondsSecuritiesMember', window );">U.S. Treasury notes and bonds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Fair value of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=cpix_LoanPoolsMember', window );">SBA loan pools - variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Fair value of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,504,551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=cpix_LoanPoolsMember', window );">SBA loan pools - variable rate | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Fair value of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=cpix_LoanPoolsMember', window );">SBA loan pools - variable rate | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Fair value of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,504,551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MunicipalBondsMember', window );">Short-term cash investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Fair value of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">751,173<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MunicipalBondsMember', window );">Short-term cash investments | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Fair value of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MunicipalBondsMember', window );">Short-term cash investments | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Fair value of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">751,173<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Fair value of marketable securities</a></td>
<td class="nump">2,119,607<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Fair value of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Fair value of marketable securities</a></td>
<td class="nump">$ 2,119,607<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=cpix_USTreasuryNotesAndBondsSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=cpix_USTreasuryNotesAndBondsSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=cpix_LoanPoolsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=cpix_LoanPoolsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697823400152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Market Concentrations (Schedule of Revenues Concentration from Major Customers and Narrative) (Details) - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Sales Revenue, Goods, Gross | Customer 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">31.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Sales Revenue, Goods, Gross | Customer 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Sales Revenue, Goods, Gross | Customer 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">59.00%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=cpix_SalesRevenueGoodsGrossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=cpix_SalesRevenueGoodsGrossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cpix_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cpix_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cpix_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cpix_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cpix_CustomerThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cpix_CustomerThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697725632360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Manufacturing and Supply Agreements Manufacturing and Supply Agreements (Narrative) (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>supplier</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ManufacturingandSupplyAgreementLineItems', window );"><strong>Manufacturing and Supply Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct', window );">Manufacturing agreements, number of primary suppliers for each product</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ManufacturingandSupplyAgreementLineItems', window );"><strong>Manufacturing and Supply Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct', window );">Manufacturing agreements, number of primary suppliers for each product</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Manufacturing agreements, number of primary suppliers for each product</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ManufacturingandSupplyAgreementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Manufacturing and Supply Agreement [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ManufacturingandSupplyAgreementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697726187128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset', window );">Financial consideration</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_FinancialConsiderationPaymentPeriod', window );">Financial consideration, payment period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Revenues</a></td>
<td class="nump">$ 13,145,344<span></span>
</td>
<td class="nump">$ 11,396,871<span></span>
</td>
<td class="nump">$ 14,827,504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Costs of products sold</a></td>
<td class="nump">1,330,704<span></span>
</td>
<td class="nump">1,361,273<span></span>
</td>
<td class="nump">1,952,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">Selling, Marketing and other</a></td>
<td class="nump">6,149,463<span></span>
</td>
<td class="nump">6,253,374<span></span>
</td>
<td class="nump">8,076,904<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss', window );">Income from discontinued operations</a></td>
<td class="nump">5,665,177<span></span>
</td>
<td class="nump">3,782,224<span></span>
</td>
<td class="nump">$ 4,798,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_DisposalGroupIncludingDiscontinuedOperationRemainingInventoryCurrent', window );">Remaining inventory</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet', window );">Accounts receivable</a></td>
<td class="nump">1,922,457<span></span>
</td>
<td class="nump">1,384,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent', window );">Inventory</a></td>
<td class="nump">540,267<span></span>
</td>
<td class="nump">2,294,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current assets associated with discontinued operations</a></td>
<td class="nump">2,462,724<span></span>
</td>
<td class="nump">3,706,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,918,868<span></span>
</td>
<td class="nump">2,882,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">232,489<span></span>
</td>
<td class="nump">666,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current liabilities associated with discontinued operations</a></td>
<td class="nump">$ 2,151,357<span></span>
</td>
<td class="nump">$ 3,549,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DisposalGroupIncludingDiscontinuedOperationRemainingInventoryCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Remaining Inventory, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DisposalGroupIncludingDiscontinuedOperationRemainingInventoryCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_FinancialConsiderationPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Consideration, Payment Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_FinancialConsiderationPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of beneficial interest received as consideration for transferring noncash financial asset. Includes, but is not limited to, trade receivable in securitization transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697728559528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Information (Schedule of Quarterly Financial Information (Unaudited)) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 9,305,553<span></span>
</td>
<td class="nump">$ 6,935,439<span></span>
</td>
<td class="nump">$ 9,417,443<span></span>
</td>
<td class="nump">$ 8,729,860<span></span>
</td>
<td class="nump">$ 10,487,842<span></span>
</td>
<td class="nump">$ 5,853,451<span></span>
</td>
<td class="nump">$ 7,084,843<span></span>
</td>
<td class="nump">$ 5,918,758<span></span>
</td>
<td class="nump">$ 34,388,295<span></span>
</td>
<td class="nump">$ 29,344,894<span></span>
</td>
<td class="nump">$ 26,322,627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="num">(3,394,390)<span></span>
</td>
<td class="num">(3,196,436)<span></span>
</td>
<td class="num">(1,373,424)<span></span>
</td>
<td class="num">(1,323,932)<span></span>
</td>
<td class="num">(3,293,257)<span></span>
</td>
<td class="num">(2,644,614)<span></span>
</td>
<td class="num">(1,919,189)<span></span>
</td>
<td class="num">(3,315,936)<span></span>
</td>
<td class="num">(9,288,182)<span></span>
</td>
<td class="num">(11,172,996)<span></span>
</td>
<td class="num">(8,879,373)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income (loss) from continuing operations</a></td>
<td class="num">(3,369,328)<span></span>
</td>
<td class="num">(3,316,286)<span></span>
</td>
<td class="num">(1,338,521)<span></span>
</td>
<td class="num">(1,187,553)<span></span>
</td>
<td class="num">(3,267,680)<span></span>
</td>
<td class="num">(2,501,752)<span></span>
</td>
<td class="num">(1,795,661)<span></span>
</td>
<td class="num">(3,255,903)<span></span>
</td>
<td class="num">(9,211,688)<span></span>
</td>
<td class="num">(10,820,996)<span></span>
</td>
<td class="num">(12,847,840)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Net income (loss) from discontinued operations</a></td>
<td class="nump">2,396,981<span></span>
</td>
<td class="nump">1,349,351<span></span>
</td>
<td class="nump">771,709<span></span>
</td>
<td class="nump">1,147,136<span></span>
</td>
<td class="nump">1,030,568<span></span>
</td>
<td class="nump">837,731<span></span>
</td>
<td class="nump">1,050,211<span></span>
</td>
<td class="nump">863,714<span></span>
</td>
<td class="nump">5,665,177<span></span>
</td>
<td class="nump">3,782,224<span></span>
</td>
<td class="nump">4,798,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shareholders</a></td>
<td class="num">$ (960,706)<span></span>
</td>
<td class="num">$ (1,953,668)<span></span>
</td>
<td class="num">$ (549,507)<span></span>
</td>
<td class="num">$ (73,878)<span></span>
</td>
<td class="num">$ (2,220,097)<span></span>
</td>
<td class="num">$ (1,643,044)<span></span>
</td>
<td class="num">$ (720,688)<span></span>
</td>
<td class="num">$ (2,379,239)<span></span>
</td>
<td class="num">$ (3,537,759)<span></span>
</td>
<td class="num">$ (6,963,068)<span></span>
</td>
<td class="num">$ (7,978,633)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings per share attributable to common shareholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Earnings (loss) per share attributable to common shareholders-Continuing operations-basic (in USD per share)</a></td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.60)<span></span>
</td>
<td class="num">$ (0.70)<span></span>
</td>
<td class="num">$ (0.80)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Earnings (loss) per share attributable to common shareholders-Discontinued operations-basic (in USD per share)</a></td>
<td class="nump">0.16<span></span>
</td>
<td class="nump">0.09<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
<td class="nump">0.08<span></span>
</td>
<td class="nump">0.07<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
<td class="nump">0.06<span></span>
</td>
<td class="nump">0.06<span></span>
</td>
<td class="nump">0.37<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
<td class="nump">0.30<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in USD per share)</a></td>
<td class="num">(0.06)<span></span>
</td>
<td class="num">(0.13)<span></span>
</td>
<td class="num">(0.04)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.14)<span></span>
</td>
<td class="num">(0.11)<span></span>
</td>
<td class="num">(0.05)<span></span>
</td>
<td class="num">(0.15)<span></span>
</td>
<td class="num">(0.23)<span></span>
</td>
<td class="num">(0.45)<span></span>
</td>
<td class="num">(0.50)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Earnings (loss) per share attributable to common shareholders-Continuing operations-diluted (in USD per share)</a></td>
<td class="num">(0.22)<span></span>
</td>
<td class="num">(0.22)<span></span>
</td>
<td class="num">(0.09)<span></span>
</td>
<td class="num">(0.08)<span></span>
</td>
<td class="num">(0.21)<span></span>
</td>
<td class="num">(0.16)<span></span>
</td>
<td class="num">(0.11)<span></span>
</td>
<td class="num">(0.21)<span></span>
</td>
<td class="num">(0.60)<span></span>
</td>
<td class="num">(0.70)<span></span>
</td>
<td class="num">(0.80)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Earnings (loss) per share attributable to common shareholders-Discontinued operations-diluted (in USD per share)</a></td>
<td class="nump">0.16<span></span>
</td>
<td class="nump">0.09<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
<td class="nump">0.08<span></span>
</td>
<td class="nump">0.07<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
<td class="nump">0.06<span></span>
</td>
<td class="nump">0.06<span></span>
</td>
<td class="nump">0.37<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
<td class="nump">0.30<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in USD per share)</a></td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="num">$ (0.50)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868656-224227<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868656-224227<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697726098248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Valuation and Qualifying Accounts (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease', window );">Increase in valuation allowance during the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,202,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_TaxCutsandJobsActof2017ChangeinTaxRateDeferredTaxAssetIncomeTaxExpenseBenefit', window );">Revaluation of deferred income tax balances for new rates under TCJA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,867,893<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember', window );">Allowance for uncollectible amounts, cash discounts, chargebacks, and credits issued for damaged products:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">$ 804,420<span></span>
</td>
<td class="nump">$ 326,697<span></span>
</td>
<td class="nump">446,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Charged to costs and expenses</a></td>
<td class="nump">5,915,066<span></span>
</td>
<td class="nump">4,610,899<span></span>
</td>
<td class="nump">3,371,446<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Charged to other accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Deductions</a></td>
<td class="num">(5,927,435)<span></span>
</td>
<td class="num">(4,133,176)<span></span>
</td>
<td class="num">(3,491,263)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">792,051<span></span>
</td>
<td class="nump">804,420<span></span>
</td>
<td class="nump">326,697<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember', window );">Valuation allowance for deferred tax assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">17,382,052<span></span>
</td>
<td class="nump">15,632,235<span></span>
</td>
<td class="nump">388,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Charged to costs and expenses</a></td>
<td class="nump">1,129,109<span></span>
</td>
<td class="nump">1,749,817<span></span>
</td>
<td class="num">(665,039)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Charged to other accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,908,774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Deductions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">$ 18,511,161<span></span>
</td>
<td class="nump">$ 17,382,052<span></span>
</td>
<td class="nump">$ 15,632,235<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_TaxCutsandJobsActof2017ChangeinTaxRateDeferredTaxAssetIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts and Jobs Act of 2017, Change in Tax Rate, Deferred Tax Asset, Income Tax Expense (Benefit)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_TaxCutsandJobsActof2017ChangeinTaxRateDeferredTaxAssetIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>99
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M4-:H3G?5K-@$><'*0*W<6^)\MG*!DLJ;+^5D0"&^55EWJNG-8R)GB/F+BT%
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M&]_7104UU9>R 8$[:ZEJ:G"J-KYN%-#2@6KN1T&0^C5EPLLSM[90>29;PYF
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MX2\&E W _;649C^Q76SX:>5_ 5!+ P04    " !7BHI1AN]'=6 '  #_(0
M&    'AL+W=O<FMS:&5E=',O<VAE970T+GAM;+5:;6_;.!+^*X)Q'UK@4O--
M?"F2 (V]=U=@7XIF=_M9L9A8J"WZ)#KIWJ^_D>18-CEB4W3[);'LAR,^,YR9
MAZ(NGUSSN5U;Z[,OVTW=7LW6WN_>SN?M:FVW1?O&[6P-O]R[9EMXN&P>YNVN
ML479#]INYHP0.=\653V[ONR_^]!<7[J]WU2U_=!D[7Z[+9J_;NS&/5W-Z.SY
MBX_5P]IW7\RO+W?%@[VU_H_=AP:NYD<K9;6U=5NY.FOL_=7L'7V[%*0;T"/^
MK.Q3>_(YZZC<.?>YNWA?7LU(-R.[L2O?F2C@WZ-=V,VFLP3S^._!Z.QXSV[@
MZ>=GZ__JR0.9NZ*U"[?Y5)5^?373LZRT]\5^XS^ZI__8 Z&\L[=RF[;_FST=
ML&26K?:M=]O#8)C!MJJ'_\67@R-.!E Y,8 =!K!P@)@8P \#^$L'B,, T7MF
MH-+[85GXXOJR<4]9TZ'!6O>A=V8_&NA7=1?W6]_ KQ6,\]<+5[=N4Y6%MV5V
MZ^$?!-6WF;O/WM<KM[5949?9PFUA5:V[<#_:YQ]>_>S:]G5VD?UQN\Q>_>/U
MY=S#A#JS\]7AYC?#S=G$S2G+?G&U7[?93W5IRW,#<V!RI,.>Z=RPI,6E7;W)
M./UGQ@@UR(06+Q^ND>'+EP]7"3;\&!S>V^,3]C[:1UOO;?LV84L<;8G>EOB*
M+2Q*P\B\']D5BL=K+KC6S.27\\=3[\5 9K@0VHASX!(!2LZ89.H(/&.1'UGD
M28\L7 N+LUN2]@N4OC;M&WFT*I.^Z:QV*W[7N'*_@AM 2I28HP8S\H26$HQR
M*@,_Q3A)J-2,!6Z*<;F@FE"">TD=^:@DGULHHU7]T/L)JOEGZ^$*XZ.B^].<
M*:4$"0@A0$&(,)P'C! @A_5!E<8IZ2,E_97EV]JB6:U[3B6LY8W;=94*8Z5C
M[VNIA0Y)Q3B5JUR;,$HQ3C"A).,X)7.D9)*4_FUKVQ2;GE%10FVO6M\471O$
M2)EH$L8HR-(@\Q8QCA*:$PAJP HQ*"DQ<B)#*1D["DGR>K=UC:_^5W1]'>T)
M)/8G+)(\#V:X0(!,22-DD&Y+#"BX9"?Y=L[EI#O2))??G8<(K:*J@_*B,2\N
ME12AZQ<8DN20(X:$S&(DSQD!53=1(B@;J;$DM=]VMEMM4":J0S_?=/T<9<:B
M65P8IC75+&2&("FEBAD3!0V!:JT,5Q-Y1<>V27F2VOO:V\9"31^8H90XMF2X
M#-,)P>42.E[8\#![QG F)[B,;9NF^_:1RV'IH61$[$HF)-5A7\* U.10&T,Z
M"- P0\0$G;%_T_PK=$[66G9G8>=BGQ>@+[Y,9%:.SH82$H4+05*B"21BE%H(
M5$M8J3F=(#G*"9K6$^^/?+)7A[!U7&M[7Z$-BR*ZPL2J H%=4"EYE%D(3E E
MM#83S$9A0=/*XE?KS\M%=M^X+13(&BK)OBLF;B@KL*U F<;Z "))01OID"R"
MA$@R@E02#,JT4%I,5<E1=M"T[EA6[8$<[(]&;EEM>\4((49IQI(AEQ(J?-0)
M8B!7H!-95%\0$:*,)BR?8#BJ$)J6(5%(44*Q6KC@N0!*-&2$(!7A6JE05F%(
MR%2CZ00G-DH0EI8@':>.2U;XK-W?M559%<U?<.6;ZF[OB[L-9*?+:E=WP6W<
M()>K0ZE%5RZ+-896>=C_$!1HRK!,+3$8/>VFY[Q'N<+2<B5.SY R_+9U==:N
M"]C/PR['-CA;&FW@(-Y<J=R$C!&D-)(3&?84#*F,TI)/-'PV:AG&DMO"GXJF
MA@BVSZPA3P>*+^&?VD&R47.PM.;XKBE<++ ">G%7M-4J>U75_2.6HT4T0P_3
M4Z?>)6_"%H*CPJT!CIK8P;%1RK"TE/D^%TU4XF]STC!!?4*,O.%A4491+ ^=
MA-J:\-&HCUA:']U\"YL\F@&$B?&0#@H3$1\4-E6*1RW$TEKH1^1%66WVW?/*
M%[I)8L2BS$!146:@J*G,&&452\NJ'Y,9W^@F]:+<P%!Q;J"V)KPT:C'V-2WV
M37PT5L3B[$!A<7:@L*GL&,47,\G&]:D_E[#E1?$(87NP9_%M,[?WK2_J$M9&
MJDOQ41CQM# :R\MP!]1S/%8G-.=&$A.*=!0IJ2"A,%JB2$-IKB:>-_%1]/"T
MZ#E=%BE6\:.4*588$F>%(9.L1DG#TX]GSH]<_A91=[CC"T0=AL1%'89,BCI^
M<OB15E0_0,3S^"D-(N(1%";B,=BTB.>C3.)IF?3\S'$R_B@SY($-OD'#D.$&
M[7SFHWCA:?'R83@_256J43=P^=UG7WQLL#S=8%.G7SQ^?,"9((J%36"!()G6
M!(H(#=<&@LQS84@^\0B&CUV0I[O@;WYMFY13QN;#T\WG1<>+8VL1Z=:2/& D
M496@L,\G>7@D@P!S0>)C)@2G%,]EJ,3F)R?C6]L\]&\8M)!<^]H/I\K';X]O
M,;SKS^Z#[V_HV^7P+L)H9G@UXI>B>:CJ-MO8>S )DA$FU0QO&PP7WNWZ\_<[
MY[W;]A_7MH BW0'@]WOG_/-%=X/C.Q_7_P=02P,$%     @ 5XJ*43(%L]+Y
M"@  C3   !@   !X;"]W;W)K<VAE971S+W-H965T-2YX;6RE6]MRVS@2_166
M:Q^<JB@B;@29<ESE2#.U>9BL*]Z9>:9)R.*&(C0DY<M^_39(6J"()F3/SD,L
M40<@#M#H/MW 7#WI^F>S5:H-GG=EU7RYV+;M_O-RV61;M4N;3WJO*OAEH^M=
MVL+7^F'9[&N5YEVC7;FD81@M=VE175Q?=<]NZ^LK?6C+HE*W== <=KNT?OFJ
M2OWTY8)<O#[X43QL6_-@>7VU3Q_4G6I_W]_6\&UY["4O=JIJ"ET%M=I\N;@A
MG]="F 8=XH]"/36CSX&A<J_U3_/E6_[E(C0C4J7*6M-%"G\>U4J5I>D)QO'7
MT.G%\9VFX?CS:^^_=N2!S'W:J)4N_RSR=OOE(KX(<K5)#V7[0S_]4PV$N@%F
MNFRZ?X.G 1M>!-FA:?5N: PCV!55_S=]'B9BU(!$,PWHT(!.&_"9!FQHP-[:
M@ \->#<S/95N'M9IFUY?U?HIJ T:>C,?NLGL6@/]HC+K?M?6\&L![=KKE:X:
M719YVJH\N&OA#RQJVP1Z$ZS29AO\"H;1!(O@][MU</F/#U?+%EYJFBZSX05?
M^Q?0F1<0&ORFJW;;!+]4N<I/.UC":(]#IJ]#_DJ]/:Y5]BE@Y&- 0Y(@ UJ]
MO7F,-%^_O;GTL&''!6!=?VQN <PL;[I9WM1Z%\".KM.VJ![Z+5&TA6H^>][#
MC^_AW7OXS'N^@P\IJDSO5'!9ZJ9!E[+O0G1=&(_Q>+U@@D>"D*OEXWB*$: ,
M62PE/06N$6 <\B0FX@@\H2..=(27SKIH,C"KHCJ W0YS!J8<5$ 3;+=-GS%^
M?9_1:#0B G923NBY."9C2BF?L'-Q7"9Q2&?(14=RT?O6JC>-@;"Q#<L8HQDY
MPUHDE) HCB<\$2 )8QHF231ABB%IS&7,0YRK/'*57ON_R?\#7JYW.JV&4 (L
MLZ)4W4J>3@+\;!YF=L?L:_U8@%<)[E^"RT,#'XKJP[NW4'P<:NRW.06A-2O2
M/F!5>9#N=-T6_^T?J&>(Q8W"UB-VS82'G$@Q60X71Y.8PL::+ :"B[B4@N%+
MD1SY)6?X;51=PR3"[O'129S71X*'4]MR43&)XZE=N2A.PVB6"@EM7 N]9.ZV
M::T61A+DL'%VADRW3F@$"YU1$!Z+.)ERPH LXM$4N,: A(@PFN,UBM?D;_$*
M+C?Z4.7]9^,IZN+^8+[@,9LXXPNG7,]"U@B$22K"&9= J"5)O21_><Y4TW1V
M>'FO*K4IV@^O%@FJK@:IF/<^43VK.BO@*3A]$$O93]C]LWYQ>*N7M0M98':+
MX1)"PF2&NI4#A)W9A!GH=R!45$&EJT7G[7K/_P!.TGQLP.75\\;,$ ;@;:)I
MD$. S@+[(*<$K0XA9X0(^'?#J:A:5:NF]7F:H:O3 "OHU&\BL"2)XZG;1&!2
M)B-M<\K(2A'BUR*6T:/J0UGP !D7;H*N9%C0B!&'$H*# ,ZYLT0(4( VI3.L
MK 8AD3<P&Q&2;5.PNL;88MHT"D*T"7MED=X791=6@W2S,1F<E21OCKK$*@0B
MO?-[DV7@VN#E$'U5\9C>E[BQ2&3*6)*,YV*87 3))9W*HS6"@\@DZ)S%6"%!
M_$KB&UA*U>H:I@AEX@9X<"V1*Q@0H*"@K1W+=W$+FE!)YG:SE0S$KQEN:[5/
MB_QCH-NMJB%C!0$!]C^REOZ'_@%*UI4 BX@(DB13LHCND" 5G!V!= BQ5T1L
MABVUHH+Z1<71$O?IBS'#$<%7YJ/-@;&EKC!@E!(93P,1 N2PL#2>N/$UUB-+
MI)@Q4FJ5!O4KC7]UO$I=/2S 4^_.,G/%P$(:_>HP0X!$)$),MQ\"Y(2%B9QA
M9N4%]<N+[Z]9A#]G>&?611%)0+D0=.JS5Q@2/%483T7T&D-R06@B9OP[M4*#
MGA$:> :-,G-E@!"PI:99X@H!<A$RP<64EPMD8 &4Q3.TK+R@Y^L<W=J^/3=$
M*;M:@87@0H1#&0$20B5S]JD+7 @A)>$SE*W^H.)=):1>A[P]$E.K":B_,'&3
MYT5?9X%<'"88)K-]Z9R@^NM0[(WT02<3J1Y0'M%P&I@Q(.P@$273R<1ZE&"0
M<R[>B@UZ1FR,*8)&!0%4=)Y^-H!11$U(\'R<3]DA0!:3A#O9!88DE(!AS?&S
MTH/ZI4=G+"9D!QL-83F#=6N*N5R"(KH!TCOSWY0;IC!"#+I&H'.LK RAYV2(
MSI3*APW0I&67$.[2^J=JNT#=* C0\[O=E0SFX 1FW+%0%TDB0BF3SAHB2 ;+
M#3H.9\NL#&%^&7)[J$&9-ZIY%TGF"@7011+""9O6.5!H(B1,R'0G8E"8C83/
M^35F!0CS"Y SKAQS<RAO5T90FLB8.ZP184)A)_.83.,R DT@+ LYHTV8U2:,
MOLN9;XHJK;*W.W,V.GCP"X"ONH8VT#.841687XTY9;4"!XC.HQNS980Z P0I
M4.0:08)D.D6>TK-"@/F%P ](3%Z&PZPWT4/BLY0"Y8= N8A1@@B4Q+&/H8W[
MS%]W (:#(^B8Z=T.B#:F/HCO Z12P'C"$SH]W<&0D'@DG$Z='-HG[!@F9XY
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M: ;M[L^YVI1(G+Y($A'+O,".2*>(SDS#$PX:C@>(T50/_APWX0*%?"2.0XT
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MPMLH_]6VV[N8J**-R=>=,"RHC<N_^F.'P[<(+#N!I=B=#Q(K7^FDKR^#WZK
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MHKK/)BKDKPKY)OE&WN0QQ"5?RV5%(*G &_!\[5$%W0T?,'S:N?X/4$L#!!0
M   ( %>*BE%RB-T4BR8  *]]   8    >&PO=V]R:W-H965T<R]S:&5E=#DN
M>&UL[5WI;]Q&EO]7"&VPD8#NM@X?BG, LF+/>N!DO)8]@\5B/[#)ZF[&;+)3
M14KJ_>OWG760;%G&9K"#Q7Q(W.)1QZMW_-Y1Q1_N6OO9;8SILOMMW;@?CS9=
MMWOYY(DK-F:;NT6[,PW<6;5VFW?PIUT_<3MK\I)>VM9/SD]/GS_9YE5S]-,/
M=.V]_>F'MN_JJC'O;>;Z[3:W^U>F;N]^/#H[T@L?JO6FPPM/?OIAEZ_-C>D^
M[=Y;^.N);Z6LMJ9Q5=MDUJQ^/+HZ>_GJ*3Y/#_RU,G<N^IWA3)9M^QG_>%O^
M>'2* S*U*3IL(8=_;LVUJ6ML"(;QN[1YY+O$%^/?VOH;FCO,99D[<]W6?ZO*
M;O/CT>515II5WM?=A_;NWXS,YQFV5[2UH_]G=_SLQ?E15O2N:[?R,HQ@6S7\
M;WXO=(A>N#P]\,*YO'!.X^:.:)0_YUW^TP^VO<LL/@VMX0^:*KT-@ZL:7)2;
MSL+="M[K?KJIUDVUJHJ\Z;*KHFC[IJN:=?:^K:NB,NZ')QUT@H\^*:3!5]S@
M^8$&S\ZS7]JFV[CL=5.:,FW@"8S.#_%<A_CJ_,$6?S;%(KLXFV7GIV??/=#>
MA9_R!;5W<:"]B6EF_WFU=)T%%OFO!SIXZCMX2AT\_>-H^F"#*)@OW2XOS(]'
M('G.V%MS]*5>LO>V:HIJ5\//=I5=MXV#.V5.LO!Q8[+"7S%EMJJ:')[.Z\QU
M< &DKJ/7.GCPNMWN\F:?Y=;PW3*KFNS3XF:1E6U=Y]9E>5/2;1C=#OXML][A
M6.B9M6F,S>L:&B@*L\/7\S#<G1_E D?ES/10X*&Z+PV-1]X>CP\&4<'ENTU+
MO<&?V_RWUE;=?M[>-="OZY>N*JO<5MC=50U=1$2LFL[80AH#9FA<3II#IJ>]
M;O);DRV-:3)35R"12I BIO B^P13@0&^=ET%N@,6 6G.].$UD-%_>1FX;=2_
M,!-0#]WFZP@+NO/WO@*^ 7(TH&BQU2'MNA9N?C:9\<.E.3O0U3NF0;?)NRQ?
MK4";TILPD]92GUN_&O"\Z?C5NLJ755UUE3155JZH6]=;H@K,!P>) TD>Y*:1
M%H\G#[9^:$#6W)JFER&8>[!D#OXH>XL4PI=VQE9M";Q0=#TT"T0";>Z@U[[&
M,<-T;;:R[18>;EU,GAZ4FY4G<!HQJ; S&'=9T9_$UTKH;V$16M<E?!<:%2Y_
MF1V?G1 KP^JV=S!EN ?KGQ6;W*[-,B\^>YZT,&R^:>&&+MS.MF4/"V5-UUL8
MT?'Y"8M.VEZ[!-H:5Q!#6)@3V.7/ILN7M8&Q .FZUNZSXXN39'J]8X:7<2,I
M\P(XS-%\>?56>66SV[SN3<P7!?$AO;Q$#6$<DGJ[1"'RE#M^>D)O>BF)F 6Y
MH0+"\SUEG3UVT )?X.J3?$RVOLANS)J8_P.Q"@X\6AH0;."9!@:\HP[@KI/G
M[S95L<DJE[F=0?:#'G>P%%O0R'T'BU@KP:&/7X*,88,%\DV#\@7 *6^J_S:)
MW"&@**%7NMCM=T0N;2R#U0'>_,MP/(YT+= !Z+*JD.-IHCL8O HBK YJ,U "
MP+7Y$M"83,*Q C(DD, >L;ZM&@9Y2%N8K.%5@/:7>Y;%3656$7E*( :!,U0=
M=H8LI)?F< D?6=NVW\UPP>6"/H!::9W;$J^!U+6]+9@]"^Y?U ^L(2DS8VEH
MP+F).,UD5CV*]0%5D<P*V!/F#)JTP68W8-=A9:1;XP?BHN[COF<134@?PM-?
MY@E:&Z0T].[ 8H#%S P,MMU61<82QQWJS:*R1;\%%8>""EP+5@M^=Q7K>K!:
MJ?+^UW^Y/#][\;WS8@;,P1,B2<,G/S45_G6#6A,54MN1LE/E2)8;9-E6V$'7
MV6K9LQ8 ZI"M821J++S\J^G"JZ0;_4V@1X?R.>XSNP,UF>4[H,D]*3OHZ)NS
MQ3. M'4-*S/+OCE?G.E?1 VX_=Q?0&V%C>X-P@V#R#(#7&BV2]#"B@WI_Y?T
M,OQX,</UW!F"_?5^D;U!G?17U4EO/(.\;0#Z]2Q8;Q*]%9CH@&6K'%L16Q6I
M7-^1 ;$P0N@<J0A^2(UB20VAI.QRLKJ$,]#*Y)$ZJY "\!!HNCJ!(JS=<N$:
M: .T&!AYM")B.[<F1R-+^@<E86A](L4</8KF $T#&PE<)9@2242/ "+']</Q
M\W2C-D CV-P6FSW+ [R%> NT'#\9RQZ9#9AQ";Q3M[OA:(&SWG;8=XV$O=L
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M*&R"[/'P*)R**\G1HR&-%[T4UURK@:,?KX.!"W>&IL];>70!P-FJ*[A7)EJ
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M"H,7/L%7J:I!WPU?^ UT;8C:JU5DW$PRA[HLTBFS-"4#??6%,-9DU 6]W*9
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M%7^$.SS.GS+_!2PJ;NZIS0I>/5V\>';$@2']HVMW]$GN9=L!=>GGQ@":L/@
MW%^UX$?)']B!_T;[3_\#4$L#!!0    ( %>*BE%UEOP)@@L  .0>   9
M>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;+59VY+;-A+]%90RFW6J*(TN<]$X
MMJMFQK&3K<1VV7'RL+4/$ E)\) $#8!SV:_?TPWP)FDF?L@^V".20*,OIT]W
MDR_NC+UQ6Z6\N"_RTKT<;;VOGA\?NW2K"NDFIE(EGJR-+:3'I=T<N\HJF?&F
M(C^>3Z=GQX74Y>C5"[[WP;YZ86J?ZU)]L,+512'MPY7*S=W+T6S4W/BH-UM/
M-XY?O:CD1GU2_G/UP>+JN)62Z4*53IM26+5^.;J</;\ZH?6\X ^M[ESOMR!+
M5L;<T,4OV<O1E!12N4H]29#X<ZNN59Z3(*CQ-<H<M4?2QO[O1OH;MAVVK*13
MUR;_4V=^^W*T'(E,K66=^X_F[F<5[3DE>:G)'?\O[L+:Q<5(I+7SIHB;H4&A
MR_!7WD<_]#8LIX]LF,<-<]8[',1:OI9>OGIAS9VPM!K2Z >;RKNAG"XI*)^\
MQ5.-??[5^T*EN2S,_???S<Y/?AQ_D#>)^*@R_;M5\9Z092;^T"L)_X4[+XX]
MCB8!QVD\YBH<,W_DF-E<_&9*OW7BIS)3V5# ,71N%9\WBE_-GY3X6J43L9@E
M8CZ=73PA;]$Z8L'R%H_(NZH=[C@GKDVQTJ4DS#CQ[\N5\Q;0^<\31YRT1YSP
M$2?_;U\_>0RE\7-7R52]'"%/G;*W:M2=+>)!P]/%_O'-K78G[1"_E *>5\5*
M6?+\,A'7-5WDM#,U194KKS+($7)CE4+Z>B#:;\5;"2R/<8FU9J-3!U&(X+/1
MVY]^'?T@O$&"?JVU5<)O%=*="$67&U%9D]6I%Y;2RPGIG$FUI#-8[% [7:9Y
MG=$V$A*W?O_=<CX[_]&)-Z\OQ[+"W5OL?@?">&WKC;BLJERG,G $C*"=F2F4
M\SKE&YIT#H"0N0 :,B@'SIR(2R<J:;TP:]Z%1Z63S#:)N-OJ="ON)%1.4U.7
MI#$X5-"-DLP X;+%3H<-/3]64F?B:#Y9(./SG!3+:DM6D<=9)T59U-O2VEC)
M!_*Y(YVL>9"YU\KQED*6]1K:!4EKA=MP.KP_$;]#><"^DN6#V$+!$KB&AG6!
M,X"@"IF@5SK7_H%-(%LI/%Z5LDQ58_X!=XO@;KB--&CVPO_643@?VSE4-7@D
MO9$;7)&RVO7 M38Y"HMC.>\@N4'F:6_-2OD[I<J^B^D?;&?<L:4[L .4"V6!
MM+Q!'E8.P=:8\[G4%-Q/'JATN\Z$ZE;=:E.[_$' Z/)@<GP P/0];;6R4K6G
M]'@V"G=#<GPQ\#=$='KI_ZJ^\P#3?6WHYOO4F^B3Q1YDAQXCAUPVFB6[[HI*
M(AD*XD?%J:*!: O<;WA/-/_H9#)MH5M7:POJ;Y")3=+SV8V3&.T[BI+)\3R9
M&\2#W<3F-@ OD(<1P</T (4$'E LMO$/F8!$1S^A6C(AR[!\I1AGA;$>7LT8
MH#MX4/<5^@@\JYU:USDDK5O@1^+*0E8/$:  _KIQUE_)"VF*0.-?W*'N-8B(
M-N!/P8+Z1T?C$O&ONE2P?S&?[* TA>^M7M6T\V@Z639Q2>CJK+NBLX]FW7-R
M70F. GI560-*G8\ODDC]M >_SA-F"<4-5OXPZ:H*JD4?86?)(/"R+$&,:<B(
M%G>[I4#=(Y8.DL7GR:=)+QO?&9N!HM]:4U?B:O+'I.6/9Z/P#*FCRR_02ZYR
M4);R6^.A%KS8HH**YX"3J]JFX$ 5PAB7.89)IF("-YD/8=*SS@A'Z"^%W:H:
M<3*:H.6W%NSN$O&EAA<UE-"9-I7T6ZHMW6,')^. RAF+VC9\1DZ.SS/M8 E7
M15[I-!+N,TI!5 >9Z1ID',YC4&=+Z-"F,:0Q,WJ0J=O5JT([UY1%JS::6B$J
M5DPC*0G!T:%R-I)BAD%M+]+<H*?:[)<V"5=6>,9^.YI-I\ET.AWFC<R=P9DI
MXDCX@%P9*Q!MF4XN6IPRG]SA FD,1WF?<^H %9NMF"U9MJC+6R10*&=(!\X\
MMT50V5_#%J: 4/0JZ4T031M!8B;0ZZ"H15>OM<62",?HRLF /<D8IOR,@$N[
MX;EFAX365@=-6G9#V>:UCT6GT2$1N40.;0.7I5L-I#2(3)4E)A%.YI .?\$2
M4U*-BB<?0,-^Z74U&J2''<*!C/?]W#Y/(C'TK$;TE*96ZY#/4!7':P2-XO!
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MZCYRNL(J'PC0//8R$:(QQ.WY]!]$7^N:4X$0$CPR+&G!IKBHD='68ZXK5L5
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;)U766_;.!#^*X118%M
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MU8X>@R!NZ?5%XQ5HO]7:/4Z\@\-[OOH/4$L#!!0    ( %>*BE$E@<5Y4 <
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MT$2 _8U"K/<O)&#X2G3U?U!+ P04    " !7BHI1Y%04*GT#  #O!P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6RU5=MNXS80_96!&O2)C23JGMH&
M<MFB!7;;(-FV#T4?:&ED$Y%$+4G%F[_O4)*U#I 8:(&^V$-RSIDS0W%F=5#Z
MR>P1+7QMF\ZLO;VU_97OFW*/K3"7JL>.3FJE6V%IJ7>^Z36*:@2UC<^#(/5;
M(3MOLQKW[O5FI0;;R [O-9BA;85^N<%&'=9>Z!TW'N1N;]V&OUGU8H>/:'_O
M[S6M_(6EDBUV1JH.--9K[SJ\NHF=_^CPA\2#.;'!9;)5ZLDM?JG67N $88.E
M=0R"_I[Q%IO&$9&,+S.GMX1TP%/[R/[3F#OELA4&;U7SIZSL?NWE'E18BZ&Q
M#^KP,\[Y)(ZO5(T9?^$P^<:I!^5@K&IG,"EH93?]BZ]S'4X >? .@,\ /NJ>
M HTJ[X05FY56!]#.F]B<,:8ZHDF<[-RE/%I-IY)P=O.;W:.&VT%K["R(KH)I
MYZ/J=C]8U"U\E&(K&VDEFI5O*:0#^N5,?S/1\W?H0PZ?5&?W!CYT%5:O"7S2
MN@CF1\$W_"SC'9:7$(4,>! 69_BBI0#1R!>=+<!)DFRIQE_76V,U?3=_GXD3
M+W'B,4[\?Q7Z++U[NU>F%R6N/7J<!O4S>O\NYGQ6SM[-R4FIZ!$:BQ6H&L@+
M:M70:Y;=#H0%NA%LMP2-PJLS).Z^W$\.#[@5UA6ZUZH:2DN/VPZZHPU1T2<N
M7='=6X4:">=DNWQD.6]<0,R2(F)AFHUVD18L"1/XT/:->D&$ W63";?%#FMI
M#82,%PDK@L19:<1BGL*C5>43].)%;!N$[[_+><A_I/,@3U@<!$O=>J7'!D*Y
MB[+4 Y6!"F(I>W<ZUJ9"IYA\.(NRF&592A8O A80SQW62$P5H;\,TLC1\5B9
MER5PXIQ'P/4<17;/%$'I%^@'7>ZI]QC(><&".(,XBDEDLOA2&JV30VT:A#'4
MS8\8E]%,? PU75)1A*S(XO$\9!F/X;.RH@'U[A5>0.C*$[,\+=PB)2DD(PMF
MQF;YKMZ^^%]55_Z'HEY RGB2LSR,R,X8Y?"ZL*5J:4B9XQ7P+*>/PR66Y&3Q
M:)9'@XI%<0I)2#7DP:MTWY9^ 3G+HHQ%W$4N6$3(,([@K7[@GS3A%O5N'#7N
M[0R=G?KQLKM,L^NIB7]SGT;A)Z%WLC/08$W0X#)+/-#3>)D65O5C2]\J2P-B
M-/<TD5$[!SJOE;+'A0NPS/C-/U!+ P04    " !7BHI1$V@I5X,$  #]"@
M&0   'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6R55FU/(S<0_BNC[:GBI"@O
M"Y0<ET1*0M&U*CH$W/5#U0_.[B3KXK7W;&\"__YF[,T"28C4#Q"_S3/SS#R>
M]6AC[*,K$#T\E4J[<5)X7UWV>BXKL!2N:RK4M+,TMA2>IG;5<Y5%D0>C4O72
M?O^W7BFD3B:CL'9K)R-3>R4UWEIP=5D*^SQ#93;C9)!L%^[DJO"\T)N,*K'"
M>_3?JEM+LUZ+DLL2M9-&@\7E.)D.+F=G?#X<^"YQXUZ-@9DLC'GDR1_Y..ES
M0*@P\XP@Z&>-<U2*@2B,'PUFTKIDP]?C+?IUX$Y<%L+AW*B_9>Z+<3),(,>E
MJ)6_,YLOV/ Y9[S,*!?^PR:>32\2R&KG3=D84P2EU/%7/#5Y>&4P[+]CD#8&
M:8@[.@I17@DO)B-K-F#Y-*'Q(% -UA2<U%R4>V]I5Y*=GUSAPH]ZGI!XWLL:
MJUFT2M^Q&J1P8[0O'/RN<\S? O0HA#:.=!O'+#V*>(59%TX''4C[@T]'\$Y;
M7J<![_0(+[B2+E/&U1;AG^G">4L:^/<(^%D+?A; S_YGTHY:\?6Z=)7(<)S0
M_7%HUYC$.+]JN!'/,.A'^AWP!<+<E)70SX#:H\4<I/8&!&U)FX.@>Y'3GX>3
MY"&L3+<KR4>@@XQPAVNCUE*O8$X TL-?1FB8KBPB'^Q +CP!_UFK9TB'P?=%
MA_3G"[B56HM,(<R$?H237W\9IFG_<[O:8H2-P>>/77@@ASN1 #YY9'V$:(A%
M"689QOM M&Q-O2IB-%$(Z0"$@PW=6/XM32Z7DL RM)ZZ#=\]J27?;0="Y\&!
MVWK )^D\4Z<S0F=2*,C,&FGL78=RF:DZYVT^^P*TM;ZN0]BA.'>"=J(#VLFH
M*DH2(A$2=D5=LS%Y$'HE%T1I+BKIR5VPZ\+,4#IW$Q.Y9"(&OZ'Z4H-3H1I-
M[;[+!>VN@32KG0@=K O?*"K[3@([,*_+!5K%D6XH7X&24)1-5R_^HR;(T$;C
M@8Q$P7$+]SPG;D1*[&>APW5P=5;$8DH74Q?$&2!$6TZ.(D<^%O:Y_\*/6EA:
MH8BHCTK79=U/ZQ4U.1B<!?D-WTH_J+R1SP')G"37TI+QCO0M5DIP?<C*48W5
M(<I1Y@=H(ZTW2=Y7@;%$XW"E0VYVTK$37KPD+;FLD+AF/;](J@WJL(]#/$20
M/+5/Y.JW+33Z:C1 *=EV FY*;)#%CE ?4510$7WVH:XXK=0ZQ(KV5B13J"Q=
M(5D1M"A-K<,M^#!(NWWZ1BG%-ZFE(A922?_,$&1##P<72[,'(=9"*L&DV>G"
M6.K*'')T_R'MOZ!W:-'$'#M*C%O&&Q*(-=TA,SJ/S2'H[&OF#>>'.]R^T'9Z
MK$.V?MUDFP9X'S?:BF[;'VP*2;=BRR]OA/4DR[H\G+7WN!ZKQVX6WNJI$#F5
M8-@];TM 66B1W7%HX?<E%.[P&X>'C@V[<.B+VGOU)"F1&B4_O!Q5A2H=7R?M
M:ONVF\8GS<OQ^#"\H3XKJ4TJ7))IOWMQGH"-CZTX\:8*#YR%\?1<"L."WJ=H
M^0#M+XWQVPD[:%^\DY]02P,$%     @ 5XJ*4=SZ\?" "@  K1H  !D   !X
M;"]W;W)K<VAE971S+W-H965T,3<N>&ULI5G;<ALW$OT5%%>[L:HHBE=1RLJN
MDGQ)G"H[*LF)'[;V 9P!.8B'P!C B%*^?D\WYDI12JKVP=9<@$9?3I_N'E[N
MK/OF,Z6">-CFQK\>9"$4/YZ>^B136^E'ME &;];6;67 K=N<^L(IF?*F;7XZ
M'8_/3K=2F\&;2WYVX]Y<VC+DVJ@;)WRYW4KW>*URNWL]F SJ![=ZDP5Z</KF
MLI ;=:?";\6-P]UI(R756V6\MD8XM7X]N)K\>#VG];S@=ZUVOG,MR)*5M=_H
MYF/Z>C FA52NDD 2)/[<J[<JSTD0U/A>R1PT1]+&[G4M_0/;#EM6TJNW-O^J
MTY"]'IP/1*K6LLS#K=W]K"I[%B0OL;GG_\4NKITM!R(I?;#;:C,TV&H3_\J'
MR@^=#>?C9S9,JPU3UCL>Q%J^DT&^N71V)QRMAC2Z8%-Y-Y33AH)R%QS>:NP+
M;^XRZ51F\U0Y_X-X_[W4X?'R-$ RO3]-*BG74<KT&2F3J?AD3<B\>&]2E?8%
MG$*E1J]IK=?U]$6)[U0R$K/)4$S'DXL7Y,T:.V<L;_:<G<$FW_;L%)]M4.(_
M5RL?'-#QWQ>.F3?'S/F8^?_ISK\OY5__.)].EO^N57XEC\5'HX.6N;@I5[E.
MQ*_KM7+:;,2O1ER5&V!&3,;DN/'%4(1,B;=V6TCS*!+\S550J=#!"UU)*:(4
M6TNQ:[$8CL=C^B<\:>+I&39OD46>_"AD$%(43B>*7AU-EB.L+92+ZX?"2>U)
MUL99[['0)DJE+.;H?#$: \AYCIP<B:MUP"Y ID1V8D,)^+B=TWR3:I_8T@3>
M* N(>=#(0Y4_BJ.S5HJ0)FW53ZQGXY+2.94>V#D?3>N=T3T&U->H&&S/93OE
MU+Z Y7QTWEKP%KA7V\(Z:90M/1;L=,A82*W34"B99 *4Z -T)2W93Z0<F!2+
M2-/HV9WT0I;(>AET(O.<HF;NE>.H&=)N9QO##T=G)%ZMCL5-(YBA+[YTK-)\
M1F:=_A/O(51[7RH@YD#<]Q0<L:!K*QW[]IUVH%?K_%.9J;[7J2)'>%7+8PN2
M7'I/P@$7^$?Y(4<0;];Z@2]3@-2!['@WJ#^71-W"$<-B=51)F82V?B]EKM?P
M%9&\Y^VYWNI0W4-'DM':PXE &K3G"V^%0FB0!R#2%*@, ORCMBM@L^8@EHR+
M<P8-@D>1,O9) #M11B"28W(ZA29&X5W)("6!+/:\%KOLIRH'!"^FB^%B=E:I
M/Q23Y7BX7%PT][1Y,C\;3I>+9\" 7%2^4%S[\D?L@(OH$8H6+<550!H3NJK]
M]WA"*F+A#K62_EHRN)'*R"7]) 4 "5"2GW)2I=)Z-IR/+WKK?4QL80LNQ>I!
MN40#%N!=XV420Y4VOCECE)&/Z3\X^6_NV_?I"%0I?I&F1+O1QJYV\@]>4&$7
M=R<SPL)=IO*UN%4;3>4@M@S>VT1+\DZ3U%[FG+AE08@]FHQ;'M(&1CNB I05
MK\! X#'83DA)%4!'*%$@!8Y&S*1#I^; (P@L+\&+L 5P/,'))Y^D^P:J>C6X
M^O)I<"S62H82[E&&@ L'=/$#U3Q%KQ\$T/8V"F'N)@#E%CO9.!PD-TXI=%PA
M/KD>B5N=JT?QX?J6)98%C OX"S8#_^<RB:OACG@"$)\>BZ_2(3Y@87B?FL,^
MM+W>&+(+O+L35/D8LG"-#AT%NHH)8@.1VZ<:2E"& 0ZICFD#X(8R,"M_I%"8
M/TH3>[\Z>H!.(\$?S+A=K3OL+4J79.CXJEC/AA>+\Q<JXM%%KPKRH8#$9"P>
ME72\I4X;4 R"$[G)J_90]5!H DD+Z65MBU%]4X2$$2F[HJI9J5IU/$AD>Z '
M^&LSE\/%BX5_O]I#/)[6FN/07\J<L^T"5K*$)US:4&B=WIW*6&L&**ECP9T0
MTJ/6T??J&-=X$W!<QKP6]7'-:BKK&R>W9%;G:9.Z3>92:.",GJE83L%B]]Z6
M2/K)>'4"<JDJREV;WU=)V&>:BWVF.5 Q.R6'%U?6]!1[UA;*/=Z%3 9YU:4W
M5KU1STNMC%2<34'.R_.F@,SGL^%X/FD( L2YF"^'L^79<PA8TVG]AF@V6K0=
MU=%T=-'>D4"\7S8&5<@FS6-6*!H8#D%DKSIVRUA='IRBL=.CJ>QV@_=2YW"L
MJFI.U[4'W-DN)\OV$<2<^40Y8'-]W"U\[[?*;<BN+RK)C,WMAG !2%PA/'EE
MT%^N?S5X^_[+X'B(?' @ZC\0T/!X8G=$E[Y<>9UJP O=)#I.5_>#3TGQJS8_
M*YGC:D=>6CUVGFPE6C()B'6*%E7\R".9L^4FLDOCIX;;Z0KZU6T@4KN0+M3I
MT.@P[)QF5P'Q8;*/^"^LU['&!9;%?1]VK[7#U&*YO)2&YAQ8AJD$P[_BA8@6
MC0B>@\29!6HEZHSU["!)-GI4(Y3OV@J>@MP^-W+AC1Z"AFG*JJ*R'/96E-#K
M?]H\Z^QFGT4/U@Z&INBZ5ERK>"@:CV:]+D+ZC'TCJ^[?MPN7W86:D)!4ZE.!
MI* \$II'XK?"FGKDJ[9SH%K-.L;T0$(GMU8-Q4\YD"C%#8S8@G9*GDQ\#'D:
M^0B=B&$*;1I]MEM3SP:7F$U,+U@#%*NJT8D&G>]/@\]JV8M6$U3*#^<S732'
M>G&^^"<CM+IE-WJ;ZY1[N6XNA3Y1 G\^SFX%:XD4C<UR W\.2YY;#!PJ+C76
M<$!MSFT8QT3YT,R2>']29S/G#.D+"MGT*.0#)MTT^@58;BCGZ6A '^*JBM'9
M'H/3E?**5@S:!V@9N2MTF*2X6MZK3"?@/1J\9*)SFIEB34'K9<F4(@,U&D)M
MH1-F:GEO8R?SY.@6%Q]-$@M01QEJ@2O%^6SX!"F]1LM7=\Q<'%35'$*E.-<]
MQN5!/IR@^=\6( FWD:8J=+T:?5?E_F(\H8\D%=P_4C0(1K?J7IF2W)BJ??4:
M+!V>:RF)G/;Q:\(+AD/#I*0*A98_ S-S)?$%8;ZN+Y:26:FZ!!Y0H?8]?ZZ,
M_46<!?CC!D[4@:M5ET/\*+;:-.!TZ<A9&L&)1C;44_&GG?WYOM^F]$I]A=]6
MR>BW:N].TW28IKCV/=2T+;FIO_KPZT[@AI&AM]:'O0D=?:3B<12'KY3 =)0V
MG+]7'QS82O^I!$\*/")07Z)H8",<= :69UR]+FF >H)5ZBD"]Q5>(5TI*5J3
M/"5)[*]YX@UMQ"K*H)&4?6,LB@0<FX2JQAV0\2*@1LV7/FG06>8QBI[(NF\1
MVE\D]4JI^"V,@-?U8VR3(OGZT/0))"/# Q!3(G*D1QZ;O0ZN8C7$>2\IV?NF
M\4)Z$+9T()WV^L<*DW7AZVL0<5!(G3[%8SLG3<<@U.Q8?+8NA34_H<X6F%]_
M']%'T<_(NDBFR^%3-8$8A9RMM+J'F]?.;N-)[ZX:\ %9)VN$E>K'(YVJ:N1^
M4NB]@U,/A)2J41FAG+*+J?I4<H>5=DBSR?E^&K8*[6?A2B48]?B[#'V;(K!"
M6*G:\;&=[GD,)#7JSYYD#G$OZFS3E8\.?><^[?R$0,TI_U!"FI0FQ%\3FJ?-
M;S%7\2>(=GG\(>>3I-[6 U)K;$7'LAC$3W?U3; %_R"QLB'8+5]F"D!SM #O
MU]:&^H8.:'ZA>O,_4$L#!!0    ( %>*BE'WZN!?R ,  'L(   9    >&PO
M=V]R:W-H965T<R]S:&5E=#$X+GAM;)5668_;-A#^*P.U:'<!9G5?CFU@CQ0M
MT 2+;-L\%'V@I;%%K$2Z)+7._OL.*=MQFCV0!TD\9K[YYN!0\YW2]Z9#M/!Y
MZ*59!)VUVUD8FJ;#@9L+M45).VNE!VYIJC>AV6KDK5<:^C")HB(<N)#!<N[7
M;O5RKD;;"XFW&LPX#%P_7F&O=HL@#@X+'\6FLVXA7,ZW?(-W:/_<WFJ:A4>4
M5@PHC5 2-*X7P64\N\J<O!?X2^#.G(S!>;)2ZMY-?FL70>0(88^-=0B</@]X
MC7WO@(C&OWO,X&C2*9Z.#^B_>-_)EQ4W>*WZ3Z*UW2*H FAQS<?>?E2[7W'O
M3^[P&M4;_X;=))M& 32CL6K8*Q.#0<CIRS_OXW"B4#VGD.P5$L][,N19WG#+
MEW.M=J"=-*&Y@7?5:Q,Y(5U2[JRF74%Z=OF.:RGDQL#9[\J8<[A%#7<=US@/
M+<$[H;#90UU-4,DS4'$"[Y6TG8%WLL7V:X"0>!W))0=R5\F+B#?87$ :,TBB
MN'X!+STZFWJ\]#5GCU["WY<K8S75QC\OX&='_,SC9Z\&L_?!W+X4S!>AW%F<
MF2UO<!'083.H'S!X/EGP1X>P5CT=,=H'RU<]@NG4SH"EG48-V]%R?PS4VB_)
M<4#-K=+ 9>M76I2*"LROC09I44'#^V;LN:5=T8^6%O$)%XVG0 W"XSR2B %T
M)0"40!Q6))+&,Y]$]ZK<JX0/!P8S^$#-1TABB0?8M58#T996R-%Y1$U(>_X&
M?H2SFB5QS(JJ.G>S.&)5$K&Z+J9IPJJLI"<ZAQMA]B!$Y@0C9T61L[@L(65E
ME; DR2!C95VQ*,F?H'.6LCPK6!['-"Y9E%:L+!,:DT)6LRK.S[V6DP9NJ<6M
MC&@%=3F:62U6XY02"JE4TE'2E"SGF) 6*;_6 $'F"90Y*Z,,RIC%5?($D__#
MT=Y 6?4IZ%3?HO81(KYI28"U#TG!ZB)E43'%JV1U6;$B32D^7W(^@T^^@V'[
MAC]0H#8X@1J@5FXL58FC^],/%87^K6N$HH$X9VE=L*BNW+"(,Q:1"S2L*3TY
M1??&50UU7<#UFMJP*S[GK!:-JR5J;LV]K[]II+93=KR1Y.TWW^\A>*C75RFZ
MDW--YX/+QY\I=U0L;]H#ZU.NDZEOR9X:WU$J@9O]233??20NO[)^8O)@C-A'
M$614^WD$<<52JM:G^E9X<B'0*=OX:\]0L8S23G?#<?5XLUY.%\H7\>E:?L_U
M1I#I'M>D&EV4>0!ZNNJFB55;?[VLE*7+R@\[^CM [01H?ZV4/4R<@>/_QO(_
M4$L#!!0    ( %>*BE&:O6+>Y @  &45   9    >&PO=V]R:W-H965T<R]S
M:&5E=#$Y+GAM;)U8;7/;N!'^*QC7::T95N*;*"IV/.,XO:D[22^3Y-KI=/H!
M(B$)%Y+0 :!EW:_OLP!)4[;L:^^#9;Y@%_OR/+L+7NV5_FZV0ECV4%>->7>V
MM7;W=C8SQ5;4W$S53C1XLU:ZYA:W>C,S.RUXZ83J:A:'83:KN6S.KJ_<L\_Z
M^DJUMI*-^*R9:>N:Z\-[4:G]N[/HK'_P16ZVEA[,KJ]V?".^"OO3[K/&W6S0
M4LI:-$:JAFFQ?G=V$[U]G])ZM^ ?4NS-Z)J1)RNEOM/-7?GN+"2#1"4*2QHX
M_MV+6U%5I AF_-+I/!NV),'Q=:_]!^<[?%EQ(VY5]4]9VNV[L_R,E6+-V\I^
M4?N_BLZ?.>DK5&7<+]O[M4ERQHK66%5WPK"@EHW_SQ^Z.(P$\O %@;@3B)W=
M?B-GY0=N^?655GNF:36TT85SU4G#.-E04KY:C;<2<O;ZKBE4+=@W_B#,U<Q"
M(SV?%9WT>R\=OR =Q>R3:NS6L+\TI2B/%<Q@RF!/W-OS/GY5XP=13%D2!2P.
MH^4K^I+!O\3I2W[3/_9!FJ)2IM6"_?MF9:P&(O[SRA;IL$7JMDA_9PC_=VGV
M;2L8;G>J$8TU3*V9Q9-;/.'-X4^&-6 I(">T%B6S\(D;(["06X; B7HE-(+'
M.%SDAJU5!<Z9MRZ6])-C52=, ;GQPG^'4I!<<RN;#4.$H*_QZ@LLE5ARSJ(L
M6&9ID.5S?Y-&89"&"?NL2=0>G(CXI94[,-:Z.]E8WFSDJH)C<;P(PD7,XB0+
M$MAQ0Y;QIA P4H.:A6K)80TGY#V'"(OGBV">I?@?!6&6LR_""'WOUXN'G20G
M=EJ5;6%9FBV#-,O8?)X':9ZRN^8>1BA]8,D\P-8L6B9!- \?W2^V7&]@5Y[.
M@T4V9TNX,U\LV&U;MQ6G0N'R@.+#7?$HE(%YLBE:)XXG@#NV)N^<VQ2!/=>E
M83 W7011NF1YGN)ZR;XIRZN3>8N609XBLG%.EVGJUQ\EZ:/D*UE)*V'MW1#1
M7L%%A' F2,U\0M?+11HL\L7$Y?3$A@%;"010L'M>M=XS/F0BRH-Y$D-7PJ)%
M0#&-LYA]% 8(>J[KI(H+TA%%091%9,\B2/(X".?QBP8!3'$4Y&&,BWP1Q%'H
M.."12W"T#@R^9<A?$0,B!*\)+@YD!\$U\<1!PIOSC#5K40+=E5MO++?"\>@)
MY NN]0&Q\4GDCGPC3OF"]);]"_N9)QO^T.G_ZG3'81S"FS_^(8^C^)+8 NQ%
M<WH>L3_3O^7P,ET&R3(.\A@X#Y.0 0#1/ ERT#7-HB#.0WKNQ9(E R.2-$CF
M$5L&RY08%0(3"*ML)';^++14)9L'*> >SW.6Y-"5]0#\'6$X9V!AE$=!"H2>
MLRP,HF4.$W/6E2W*Y 5" :*("<#5P!9+/*G:LDO68RY'E8U83"\/+IR"FL<X
MVN.2A1_B)8#3V+=#K&$,_ SSHTCW5SX1Y*?")IHM$.8H R"S($LR(',.;*?)
MI M,X963V2_[%"$W"^3IN9*>KH_&77C;)H-!%PDJ9QPL%F""-ZY_,ZQ(0;U\
MD4Z>5HM7C7J^44I8"[(TZQ6]*G_>A^;\T:]SIP2%),^7$\?&CDENC\4ETK5>
M"S=,C95K\HK22ID+?.HH RY]J.NJ*21U@KVT6X^++E@$Q=85ZT'-Z=[E-/4A
MIK6=.]3]'I4X!6#:&_^3I/CQ(1\9VTM>. :L!UM&2[H031@IZ/_ L)H3@EDI
M$02@IA!4+(PJ)+8HO7<;B)*V56O0[(E471M=0$74_=UN4<K)J-.%-$$!?<,N
MXKG[%Z7YY$AF"%6?^#>CJQA_/SK@[T[:&SF5D\X0O_*4GHN8UE#E/A&Z^'AI
M%#H+[QJ7IF!<@8%E"SL0"E3^+9(%X.V1XD995E,SJN1W41WH7>,>=HM>'G?V
MJJU*9 BXXA6Z0CG%+(,F46R/-AX .S(?(\.]=">*<0EZ7H&"'KAK.C_@'6?K
MMJI.)HMO</@Q]F5S>\B+AT+LQCWJ1%MU\U"%@#5^#$'<9-W6GL#D41Q>WGSZ
MYJZBRTF'K2=UN\2HVT)=":.UR^^*CE_3DW3>*2.=4=*PMBD<QLJN ZY00)^%
MQ1/[67.<LA^;QZ=Q'(R@\-/TZY1MU#W<<O.A:+B+*K4$+;9TR+OW":K$1IJJ
MG[KJ6C6 AA[BI,@PTDBST6UK_:SZ-[4R[ :38!^A?@6>]9'RSG</<83Z#B:L
MM.*ETT"&5.*!>?<-;338[29A58J@:VSH91BD6NO 6LE:6F=9X$BE:2YTDTLO
MWA>70NF=<J0=V(M=XNC-I6.:($V-;\76G0/ZY?\/')POY .IV>(@@Y=#_2E
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M*="?ML<D;T\-4P8" JV!:$8^_(=^VE/BIYW:V=[??=ZZ\O(,"-A<2,ITC7*
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M/[_Z4C?*[)GIFC6OI:<[);1;3CVP@\6TZ'&N.YSY*SBS.7TWVE>.ONB2RV.
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M(GE&G4!PS8LW:_Y2.S?>FX(?Z5*E+"W _,(8W[S0 =M/]]?_ U!+ P04
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M$?338X6_ .S% >LKAW'?OTB"X4_%XF]02P,$%     @ 5XJ*4>%VAD & P
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MZG3RX30!V_N\#[QIHK=VQK-3X[;FT4@V /B^-/PP0Q 2C,-V_1M02P,$%
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MLN;5ZV'T"N_TV13^K[%^518J<B;6-A'RT*[CFNP43GF>1?%*ZB4TA8[ $;2
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MG4R"%'+EC 3HU_I)6*(+[0;92M4IBY!.Q89' C09G3>.L_:[ZNX-7R/24ZE
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M@6!G/HB=S/.26&18SB%**P'A,0*=Q?5&1\C6D4.]]Q2\P:W 00&NGW-^F-W
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M&W"NCI<5?LB08P.\7UA(T-UP@.&GT=D_4$L#!!0    ( %>*BE%[(?3+Z00
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M$TOZ(N");TQ_4_=%8_K!:O+GDXO>67317_?PRH57!E[YWY3]NX&3MY4F6]-
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M&0Q>  ]"$[WF?0.5L!TT/-/LDK5H'F A!4I4DCL8Q#]"+:WQ0\H>.]31$=D
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M?M/2;/#/;?Y;:ZMN/V_O&YC7]4M7E55N*YSNNH8I(H:NFL[80@:#,VU<3KI
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M[ R"]6U>+T =DN*N ?8CC6A=P)T=;J)?_H:*YPYE!X8ZG'D543*>@*;7>-%
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M+CK2$>D42B0\\.4R*Y:2P#;&O6<RL'()1U<'"F9*T"_.0R[S?%)&KQ5[O_.
M?#1K^<6CT,&;,<!/YX\':4MF ,&*+5@AS1JD)I<?=A0DO:>()$$I33 02Q=B
M!^GD>V" FK+8#.893/8$3CUTW(!2@%-"CQQ3$L".%%YE(X('K>.#U\GAUI;
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M!<44\^O!+61)#WI+Y6]C_"NM1BK:F#-\,T86BH,7&W@,C1,Z-%9*V[QR&IV
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M6#)T=/[Q(NF4[@VR39R!K26>J+BL^0E#%P)XO[26]D9(,#R*B[]02P,$%
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M1^JT8 7/ PQ1*3.2?& A!%Q*U6I%6>9>)6Z"I"3AK*:XQ+.LB'<*M]U:TD"
MBA4U.>>)MRKIEY<0BBL^P(TF9B]7F$H@6)905EE.BJB(8,KJPA=!Y"S/:D*J
MX*5G%C_KUA[--LPD?V?[P4V->]H]C;WSJ=O_-9]FYC=IMMU@0>&&7).S,H_
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MC7>@\Z76;F_X!,.8G_\#4$L#!!0    ( %>*BE$P/;SQ:@,  ,L'   9
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M:W-H965T<R]S:&5E=#,X+GAM;)U6;6_C-@S^*X17#!N@U;9LQW:7!&A[-VS
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MB60VZU(8K:-#;RX(8^AI/MJXB";'1ZBQ2&49LS)/_7G,<I[")V5% ^K-$EY
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M=@JTOE3*[@5G8/C;FO\/4$L#!!0    ( %>*BE%FIZ,-&08  %@/   9
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M2T<"2X/&(AZ #MH?#:DYVL9UY$&@?Z=I-CN@RF149?+5JE3+I?*?S9Z/P43
M3JN;'#867_K[A'@8_F[;F7P2DK=VQ\U.]-X;Z@ZE13MMH42\O@86H-E-Z5:=
M</O5Q-)N_28^PNS_IO%(@P9P;I]O_"K:@G@ Z%S'W244<.DTL4-VL)SZCK+=
M/%X6\8P@P/"#CE5++#%2E) $D'6NL/E:G4."04X^NGLP1;1%:R&;V*3ZSZL$
M(%C_NUK!%H^D]F^P(6RLQV3*(__'1#I[9C.F:E#F\<Z(P^]G7YGKO7R9AYSU
M1+J9^W"F'.?@CKXG=?SY5(9E<KQ/S_.=TTZMX&L,SW20$]P2NX//^'0\-EYT
MIZ7M].[,^1$^YLK&DDHMP31XD\!V;;IS7'?C]-J?G1;:P4G,#U=P]%4&)\#[
MI=9NN$$'XV'Z_!]02P,$%     @ 5XJ*41IV'"N:!   1@T  !D   !X;"]W
M;W)K<VAE971S+W-H965T-#$N>&ULO5?;;N,V$/T50@V*!%!LB;JGMH$DNT7S
ML+M!LNT^%'V@I;$M1!)=DHJ3O^^0E&0WL85M"_1%&E*<,V=N)#7;<?$D-P"*
MO-15(^?.1JGMU70J\PW43$[X%AK\LN*B9@J'8CV56P&L,$IU-:6>%T]K5C;.
M8F;F[L5BQEM5E0W<"R+;NF;B]08JOIL[OM-//)3KC=(3T\5LR];P".K7[;W
MT71 *<H:&EGRA@A8S9UK_^HFT>O-@M]*V,D#F6A/EIP_Z<%=,7<\30@JR)5&
M8/AZAENH*@V$-/[L,)W!I%8\E'OTGXWOZ,N22;CEU;>R4)NYDSJD@!5K*_7
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MIR<1;S _AW[R&=)><G4"K]]EW ]X_2-X]]*M' A=P!/G;(DO+DET\.LZ<WP
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M-'>-K/E)TK$H"R68XEC5X3<2X[S:#F-U-,5IJ(8NP.T2\P69X?!#G(-;+)9
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M(_9H(:\EFY.T]I =7 -R(>WA*$0BYT*$:4MDUA!)]A")$W:O%9:6W:@,LM<
M(675I99L4YLEO8C7D!ZS07S$DBB^Z,$;=%(-/-[)'KR%T5F=(O,WU_8 GG2
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M-3 N>&ULO5AK;Z,X%/TK5G:UZDB=@AT@,)M&:INV6VD>4=N9_;#:#PXXB57
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MDM,(D*18W6Y6&\5S,XTG7.%L-\LYW@A!: 4\GW*NGC=ZP)=WS/Y?4$L#!!0
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M[N7A"Z\3(D6\6 I=_H)#A0V) ^*]-C*KR?8)LC2O_ME++42' (,3!%034)^
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M#D>S^*92;9B0>NP=@*@-ARYA0EOTH'^^"?ZQ:(A&!'9V;FW#$-(C)$"D;\0
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M#K,XD28 SC<"[+-9F!>TT_W\?U!+ P04    " !7BHI1&@$]ZM$"  #0!P
M&0   'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6REE=]/VS 0Q_\5*]H#2$ 2
M)\X/U%:"5F@\3$)T; _3'DQR;2T<N[/==OSWLY,0E28M2'M)[/B^=Y^[G.W1
M3JH7O0(PZ&_%A1Y[*V/6U[ZOBQ545%_)-0B[LI"JHL9.U=+7:P6TK$45]W$0
M)'Y%F? FH_K;@YJ,Y,9P)N!!(;VI*JI>;X'+W=@+O;</CVRY,NZ#/QFMZ1+F
M8)[6#\K._,Y+R2H0FDF!%"S&WDUX/<V<?6WP@\%.[XV1R^19RA<WN2_'7N"
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M" 8@8C.:)^HK7_W.ZH2\0F_*$UE^@E4]UAV :2X53^O).H(TSJIO^E@;T9J
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M292#TS$%9=K=T@JH:S]M"XTTN_Y8TCH&XPSH?JDU;@7GH%_PZ3]02P,$%
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MZF7'U;)HS[(0W+%,+@7XFL4D-N G'^"1Q4%7Y:!)!'I/Q!A9/=ZSEW/@.F<
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MDJ7EQR7!,>&%@?I^SIA\?R@6:*[BA_\ 4$L#!!0    ( %>*BE%T!W6<A (
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M+0''M\ZHU?O4BL/QQ?I/3? 0S)96;"VROWBJ#DLKLE#*=K3.U(LX_<RZ@!K
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M0P@F9'L%;R=*E,TM=BL4W(F;X0$^6YC4 O!\)X2Z3/3%N/\06OT+4$L#!!0
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M@;F_$$(_#NQ9OWY[G/P#4$L#!!0    ( %>*BE'DI_+9B00  /@1   9
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MD8JO1I,1BNB:%(EZXMN/M';(TW@A3V3YC;;U6'N$PD(JGM;&P"!E6?5+7NI
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MFA85N-]UV*X^_3[[#2W?Z'-76XYS.&B0 Z/#RY@F:_1$-TQCZK8(/I.$0L%
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M#X#W:\[5[D8?G)L_>^;_ U!+ P04    " !7BHI1#C?+FX@"  !Q!P  &0
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MAJ,[*B4MM#J!;W9D*WT,1Q>H*>/J&#[!!R"@+%2%1!L;EHPDK>2\D1SLD;S
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MF'X4NR_8Y3.T?+E@RGUAU]D&'N2-TJ+JP":"BO+V3YZ[.AP PM$)0-0!HO>
MY 0@[@#QN8"D [A2^VTJK@YSHDF62K$#::T-FSVX8CJT29]RV_:EEN:6&IS.
M[HCDE&\4#+X)I2Y@@1*6)9$(@Z5Y8D7#$,0:)ES3RX*RQG8)EI@WDFJ*"NZ>
M<]846,"]%!7,1%4WFKB.&E1/WK->P&".FE!F7%V"LBJ5^MHD8L/Q\R[H:1MT
M="+H,(('P75IW'/C^RV!;RK0ER':EV$:?<@XQ_P*XO 31$'X^4A L_/A-T?@
M\_/AUQ]D$_=-C1U?_+^FOG;SUV2EM#13]OL#_J3G3QQ_<H+_[6MHNP@#RKOC
MQ;&.MHPCQVAWT39+@B!(_>UAE8\8A:/A.ZOYOU;A31P->ZLV)_]@*"J4&[=<
M%.2BX;I]&+VVWU\3-[;O]%.SU]HU]$K3+L4'(C>4*V"X-I3!U?70 ]DNFE;0
MHG:CMQ+:#+([EF8WH[0&YGXMA-X+UD&_[;._4$L#!!0    ( %>*BE$%+$#I
M.P,  &<*   9    >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;+562V_B,!#^
M*U:TAU9JFS@A(52 5&"KK=1VJ[+M'E9[,,E HB8V:YM"__W:3@@IA*@]E /Q
M8[YO7O9X^FO&7T0"(-$FSZ@86(F4RTO;%E$".1$7; E4[<P9SXE44[ZPQ9(#
MB0THSVS7<0([)RFUAGVS]L"'?;:264KA@2.QRG/"WT:0L?7 PM9VX3%=)%(O
MV,/^DBQ@"O)I^<#5S*Y8XC0'*E)&$8?YP+K"EQ/<T0 C\9S"6M3&2+LR8^Q%
M3V[B@>5HBR"#2&H*HCZO,(8LTTS*CG\EJ57IU,#Z>,M^;9Q7SLR(@#'+?J>Q
M3 96:*$8YF25R4>V_@&E0[[FBU@FS#]:%[)=WT+12DB6EV!E09[2XDLV92!J
M !P< ;@EP-T'=(X O!+@?130*0$FU';ABHG#A$@R['.V1EQ+*S8],,$T:.5^
M2G7>IY*KW53AY/"&1BP'](ML0*"3GTO@1*9T@6Z9$&A,.']39VM->"S.T+V:
M$IVF4W0R 4G23)RB<_0TG:"3;Z=]6RI[-*L=E;I'A6[WB&[LHCM&92+0=QI#
M_)[ 5HY4WKA;;T9N*^,$H@ODX3/D.KC78-#XX_"P 3[Y.+S;XHU7Y<8S?-X1
MOK9LH#^W2AK=2,C%WQ9=G4I7Q^CJ'-'U3+(5*6YBIFH!H1$T);0@\0V)+BFO
M0QSZ&., ]^W7>J ;!+M>Z#J^6PF^L].O[/1;[;Q7I5"2#9H!A7DJSU":+U7M
M0&RNSS"ZBF13WOP#:\ZQHW_-Q@25,<%G@X94@G3= <XA-I82(4"*RY8<=2MU
MW2\_#V&E*VQU;9P0OM >,!0Q(04B-$:P4<^- -%T,@JZH)YP[/:PT]L[& UR
MW4XOU!>F+C<)#U,6!+[C]9I3UJO\ZK7Z=0VQ"F+6$B'L[$JG\^7YP+5"C5LM
MWVG+M+:HKJVQ]N*#"/I='.*.&S:'$+L[4]Q64Z:22&AS:E?A\->7.+RK<;B]
MR'TRA&-\6,4"];"$V-\/H5U[@7-0-T=W,DH#6U%9/%_5:M4M79D>86]]I+LH
M\[+O:(H6[$Y=R)0*E,%<43H7NF?A15=33"1;FG=^QJ3J&LPP49T@<"V@]N>,
MR>U$*ZAZR^%_4$L#!!0    ( %>*BE'B;+^^Z0,  *L,   9    >&PO=V]R
M:W-H965T<R]S:&5E=#<P+GAM;(V7;6_C*!#'OPJ*[D4KM;7QLZLD4C?5ZBKM
MG:IV]_8UL2<)6FRR@)/VVQ_@Q$EMXNV;UM@SP^\_P R9[KGX)3< "KU5K):S
MR4:I[;WGR6(#%9%W? NU_K+BHB)*#\7:DUL!I+1.%?,"WT^\BM!Z,I_:=\]B
M/N6-8K2&9X%D4U5$O'\!QO>S"9X<7[S0]4:9%]Y\NB5K> 7U8_LL],CKHI2T
M@EI27B,!J]GD =\O<&P<K,5_%/;R[!D9*4O.?YG!4SF;^(8(&!3*A"#ZWPX6
MP)B)I#E^'X).NCF-X_GS,?I7*UZ+61()"\Y^TE)M9I-L@DI8D8:I%[[_&PZ"
M+&#!F;1_T?Y@ZT]0T4C%JX.S)JAHW?XG;X=$G#G@Z()#<' (/NL0'AQ"*[0E
ML[(>B2+SJ>![)(RUCF8>;&ZLMU9#:[.,KTKHKU3[J?E37? *T'?R!A)=O>I=
M4C8,$%^A1UB!$%":;^A!2E 2D;I$WRA94D85!7F#_@5UC:X>01'*Y#6Z13]>
M']'57]=33VDX,X57'$"^M"#!!9!'*.Y0B&]0X./<X;[XO'OVT=W3*>GR$G1Y
M"6R\\&*\@?J1J&$7-;11HPM1=;J0/H&"*%JO$>.R3:G2<Q1Z,MJ?I$U<&S.V
M,<VQW,UQDB=1DL53;W>>(I=AA/W(#SO##]A1AQV-8C\+ ZW>+2S\;NA6'V1E
M1[16I%[3)0,G>ALW.2,*@M1/@QZXPRQ,0K.0+NRXPXY'L1^8+E*D+@#I<J<+
M1L&;6F]B 070'='(+N)XB!*G<1+UB%UFV$\N$"<=<3)*_ (2Q*[EA;<M-1MP
M*WC9%,K%F@P@HB2/DJ3'.C2+XRS*(C=KVK&FHZQ/]4YO B[>763I8,HPUBO?
M QM:X3S$L>\&RSJP;!2L.[K%AHBU>U]F@YFS*$Z3_H$:FN78C]/4#9AW@/DH
MX**I&D9,^T*Z^.J&+(EM:067>GO2NF@LOGY3@EEZ<[KLL3,G<$]$Z924#Y/I
M1RF.\IZFH5V61?Z9V0=-V#\U$G]4U7>N"#,=M$V^J6G$43</O<!W+'VF=V^0
M]7"=EE$T0GS6^O#G:_Q96QLI]/C4/W#PA^-Q+(QC:0@&XFYQB,-\L!.=EGD:
MI=F%S8A//0G_N2DYENT&+4'7(4 [PIIV@Y)C075J"8<+E<5AD"=A7XO#,C5K
MGP07M)P:%1[O5-] RGN'FD^+&':B6ZT"8YS@O@J7:1IF@1]?DG%J7'B\<UU8
M$B=Q/&CZ <[\?H=UF&5I@/NEUCN[29IK_#^Z@M):(@8K[>??I3J :&_&[4#Q
MK;U<+KG25U7[N-&_)D 8 _U]Q;DZ#LQ]M?M],O\?4$L#!!0    ( %>*BE%?
MF?BOM@,  /\2   9    >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;+5876_;
M-A3]*X2PAQ38(I%7GX5M8'50+$"[!?6Z/0Q[8"S:%BJ)'DG'*; ?/U)61'FQ
M: >P7BQ2XCV\]_CHB.1DS\4WN6%,H>>JK.74VRBU?>_[<KEA%96W?,MJ_63%
M1465[HJU+[>"T;P)JDJ?!$'L5[2HO=FDN?<@9A.^4V51LP>!Y*ZJJ/C^@95\
M/_6P]W+C2['>*'/#GTVV=,T63'W=/@C=\SN4O*A8+0M>(\%64^]G_'X.B0EH
M1OQ1L+WLM9$IY9'S;Z9SGT^]P&3$2K94!H+JRQ.;L[(T2#J/?UI0KYO3!/;;
M+^@?F^)U,8]4LCDO_RQRM9EZJ8=RMJ*[4GWA^U]86U!D\):\E,TOVK=C P\M
M=U+QJ@W6&51%?;C2YY:(7@ .!P)(&T N#8 V )I"#YDU9=U116<3P?=(F-$:
MS30:;IIH74U1F[]QH81^6N@X-;NOE[QBZ'?ZS"2Z66B5Y+N2(;Y"OVH-_;9E
M@JJB7J-/7$HTIT)\U]+94Y'+=^CFCBE:E+KU$_JZN$,W/[R;^$HG9:#]99O
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M_2M6M(=6ZIHX7X0*D IIM4KKA(JZ/4Q[,.0"49.8V::T_WZV$T(*AJ*)!U[
M=LX]N><>N+GIK"A[X7, @=[RK.!=:R[$XL:V^60..>'7= &%O#*E+"=";MG,
MY@L&)-%!>6:[CA/:.4D+J]?19T/6Z]"ER-("A@SQ99X3]MZ'C*ZZ%K;6!T_I
M;"[4@=WK+,@,1B">%T,F=W;-DJ0Y%#RE!6(P[5JW^";&H0K0B)\IK'ACC924
M,:4O:O.0="U'90093(2B(/+K%0:098I)YO&W(K7J>ZK YGK-?J_%2S%CPF%
MLU]I(N9=*[)0 E.RS,0377V#2E"@^"8TX_H3K2JL8Z')D@N:5\$R@SPMRF_R
M5A6B$2"%F@/<*L#=#O#W!'A5@'=L@%\%^+HRI11=AY@(TNLPND),H26;6NAB
MZF@I/RV4[R/!Y-54QHG>2-#)R]>^K%R"!C27/R=.M"'#C!0<78SD#RU99H#H
M%(WFA($)>_>FUG")+F(0),WX)?J*GD<QNOARV;&%3%/=S)Y4*?7+E-P]*6$7
M/=)"S#FZ*Q)(/A+84E\MTEV+[+L'&6.87",/7R'7P6U#0H/CPR-#>'Q\>.N
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M0DZT>CF7;RG %$!>GU(JUAMU@_J]I_</4$L#!!0    ( %>*BE$F QO$!P0
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M[\J##'-6"W,GMS^PU>,23*70[A>VK6_@05IK(\L63!F4O&K^V5-;ASU _^(
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M+.B:FP>Y^0*%GY;EBR77[I=LBMC (_%:&RD*,"H0+,W_Z6NQ#A5 V#X!B I
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MZ^KARH3VS"H!^_?[-"V>GY0%FB]MG/\'4$L#!!0    ( %>*BE$48GH-DP0
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M<W]N%I)M](URP23<3_7CFA+X9:T \/V2,7E8J W:_V+,_@-02P,$%     @
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MVXWPL[;V-[N\:-X7W+XWTS]02P,$%     @ 5XJ*49>*NQS     $P(   L
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M;V]K+GAM;"YR96QSS=I-;J- $(;AJU@<(+BKNJO:HSBKV60;Y0+(:?\HMD'
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MXDMB+'WQ^]EYVHUMWI@=K_?GZ [+/+Q8'I??\>\S?JG_SCXDI \%Z2.']%%
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M<' N>&UL4$L! A0#%     @ 5XJ*42MY9:KM    *P(  !$
M ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ 5XJ*49E<G",0
M!@  G"<  !,              ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    " !7BHI1*].TH\$)  !L'P  &               @($,"
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ 5XJ*49>RP-W#
M!@  *AH  !@              ("! Q(  'AL+W=O<FMS:&5E=',O<VAE970R
M+GAM;%!+ 0(4 Q0    ( %>*BE'DCW&0>@(  , &   8              "
M@?P8  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " !7BHI1
MAN]'=6 '  #_(0  &               @(&L&P  >&PO=V]R:W-H965T<R]S
M:&5E=#0N>&UL4$L! A0#%     @ 5XJ*43(%L]+Y"@  C3   !@
M     ("!0B,  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (
M %>*BE'1?S1D) <  '$C   8              " @7$N  !X;"]W;W)K<VAE
M971S+W-H965T-BYX;6Q02P$"% ,4    " !7BHI1S+MYZ=(#  "L"   &
M            @('+-0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#
M%     @ 5XJ*4=?3]A>O!P  YA$  !@              ("!TSD  'AL+W=O
M<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( %>*BE%RB-T4BR8  *]]
M   8              " @;A!  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q0
M2P$"% ,4    " !7BHI1=9;\"8(+  #D'@  &0              @(%Y:
M>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( %>*BE%793W5
M$@<  ,00   9              " @3)T  !X;"]W;W)K<VAE971S+W-H965T
M,3$N>&UL4$L! A0#%     @ 5XJ*4>(9-5Z'!0  Z@P  !D
M ("!>WL  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " !7
MBHI1,9 V"XP#  #;!P  &0              @($Y@0  >&PO=V]R:W-H965T
M<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( %>*BE$E@<5Y4 <  #$2   9
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M970Q."YX;6Q02P$"% ,4    " !7BHI1FKUBWN0(  !E%0  &0
M    @(&GHP  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (
M %>*BE$@R@UD^08  +,2   9              " @<*L  !X;"]W;W)K<VAE
M971S+W-H965T,C N>&UL4$L! A0#%     @ 5XJ*4:"22+)#!   SPD  !D
M             ("!\K,  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"
M% ,4    " !7BHI12?FO$V4)  #&%P  &0              @(%LN   >&PO
M=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( %>*BE%-FD+U=0,
M &4(   9              " @0C"  !X;"]W;W)K<VAE971S+W-H965T,C,N
M>&UL4$L! A0#%     @ 5XJ*46P.,8K+ P  8 @  !D              ("!
MM,4  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " !7BHI1
MX7:&0 8#  #M!@  &0              @(&VR0  >&PO=V]R:W-H965T<R]S
M:&5E=#(U+GAM;%!+ 0(4 Q0    ( %>*BE']$Z^4: (  '@%   9
M      " @?/,  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%
M  @ 5XJ*46L?7C0!"   &!4  !D              ("!DL\  'AL+W=O<FMS
M:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " !7BHI1_ASTV3D%   F#0
M&0              @('*UP  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+
M 0(4 Q0    ( %>*BE%[(?3+Z00  $@-   9              " @3K=  !X
M;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ 5XJ*472UH.%>
M P  + <  !D              ("!6N(  'AL+W=O<FMS:&5E=',O<VAE970S
M,"YX;6Q02P$"% ,4    " !7BHI1&X=_X5$D  "->0  &0
M@('OY0  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( %>*
MBE':94S_:@(  " %   9              " @7<* 0!X;"]W;W)K<VAE971S
M+W-H965T,S(N>&UL4$L! A0#%     @ 5XJ*482">%CV!     T  !D
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M=#,W+GAM;%!+ 0(4 Q0    ( %>*BE%RCWFBIP,  &T(   9
M  " @5$@ 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @
M5XJ*40+AQTP'!   >0D  !D              ("!+R0! 'AL+W=O<FMS:&5E
M=',O<VAE970S.2YX;6Q02P$"% ,4    " !7BHI19J>C#1D&  !8#P  &0
M            @(%M* $ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4
M Q0    ( %>*BE$:=APKF@0  $8-   9              " @;TN 0!X;"]W
M;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ 5XJ*4;6^;G5G!
MN0L  !D              ("!CC,! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX
M;6Q02P$"% ,4    " !7BHI1UB>+[Q(#   B!P  &0              @($L
M. $ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( %>*BE&G
M+UQJBP(  'L%   9              " @74[ 0!X;"]W;W)K<VAE971S+W-H
M965T-#0N>&UL4$L! A0#%     @ 5XJ*49G1 LY+ P  + <  !D
M     ("!-SX! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %>*BE'[;S":IP0  -P2   9              "
M@1%3 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ 5XJ*
M49G<UI(L P  ;PH  !D              ("![U<! 'AL+W=O<FMS:&5E=',O
M<VAE970U,2YX;6Q02P$"% ,4    " !7BHI1%CW#YDD%  #*%   &0
M        @(%26P$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0
M   ( %>*BE'D2%>0N0,  -,.   9              " @=)@ 0!X;"]W;W)K
M<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ 5XJ*45GK7)^A P  Z0L
M !D              ("!PF0! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q0
M2P$"% ,4    " !7BHI1&@$]ZM$"  #0!P  &0              @(&:: $
M>&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( %>*BE%33TR\
ML (  )<(   9              " @:)K 0!X;"]W;W)K<VAE971S+W-H965T
M-38N>&UL4$L! A0#%     @ 5XJ*4:\3BWW/!   )!D  !D
M ("!B6X! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    " !7
MBHI13U25BW "  #L!0  &0              @(&/<P$ >&PO=V]R:W-H965T
M<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( %>*BE$C>:K+8 ,  .8,   9
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M970V,RYX;6Q02P$"% ,4    " !7BHI1Y*?RV8D$  #X$0  &0
M    @('/B0$ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    (
M %>*BE$.-\N;B (  '$'   9              " @8^. 0!X;"]W;W)K<VAE
M971S+W-H965T-C4N>&UL4$L! A0#%     @ 5XJ*46-+M^N=!0  MA<  !D
M             ("!3I$! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"
M% ,4    " !7BHI1,P[B9E$%  !K%   &0              @($BEP$ >&PO
M=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( %>*BE'>3OZK; (
M /D%   9              " @:J< 0!X;"]W;W)K<VAE971S+W-H965T-C@N
M>&UL4$L! A0#%     @ 5XJ*404L0.D[ P  9PH  !D              ("!
M39\! 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"% ,4    " !7BHI1
MXFR_OND#  "K#   &0              @(&_H@$ >&PO=V]R:W-H965T<R]S
M:&5E=#<P+GAM;%!+ 0(4 Q0    ( %>*BE%?F?BOM@,  /\2   9
M      " @=^F 0!X;"]W;W)K<VAE971S+W-H965T-S$N>&UL4$L! A0#%
M  @ 5XJ*48_P;2TF P  P0H  !D              ("!S*H! 'AL+W=O<FMS
M:&5E=',O<VAE970W,BYX;6Q02P$"% ,4    " !7BHI1 1)$V'\#   :#0
M&0              @($IK@$ >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+
M 0(4 Q0    ( %>*BE$@+;;C; 0  .@2   9              " @=^Q 0!X
M;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%     @ 5XJ*43+(@4M)
M P   PT  !D              ("!@K8! 'AL+W=O<FMS:&5E=',O<VAE970W
M-2YX;6Q02P$"% ,4    " !7BHI1)@,;Q <$  !%$@  &0
M@($"N@$ >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4 Q0    ( %>*
MBE%[J'Z2F@(  ,,&   9              " @4"^ 0!X;"]W;W)K<VAE971S
M+W-H965T-S<N>&UL4$L! A0#%     @ 5XJ*4?5"Q+)T P  70P  !D
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M=#@R+GAM;%!+ 0(4 Q0    ( %>*BE$E,$DH<P,  "<,   9
M  " @3C0 0!X;"]W;W)K<VAE971S+W-H965T.#,N>&UL4$L! A0#%     @
M5XJ*4844RQN%!   Z!P  !D              ("!XM,! 'AL+W=O<FMS:&5E
M=',O<VAE970X-"YX;6Q02P$"% ,4    " !7BHI19;FY<@,#  #B"P  &0
M            @(&>V $ >&PO=V]R:W-H965T<R]S:&5E=#@U+GAM;%!+ 0(4
M Q0    ( %>*BE%$P:-X+0(  / %   9              " @=C; 0!X;"]W
M;W)K<VAE971S+W-H965T.#8N>&UL4$L! A0#%     @ 5XJ*4?<$0L\_!
MQ X  !D              ("!/-X! 'AL+W=O<FMS:&5E=',O<VAE970X-RYX
M;6Q02P$"% ,4    " !7BHI1Z>L[0KP&  # (0  &0              @(&R
MX@$ >&PO=V]R:W-H965T<R]S:&5E=#@X+GAM;%!+ 0(4 Q0    ( %>*BE$4
M8GH-DP0  -$0   9              " @:7I 0!X;"]W;W)K<VAE971S+W-H
M965T.#DN>&UL4$L! A0#%     @ 5XJ*4=P62NLY @  ? H   T
M     ( !;^X! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !7BHI1EXJ[',
M   3 @  "P              @ '3\ $ 7W)E;',O+G)E;'-02P$"% ,4
M" !7BHI1M!IEL)8&  !;.@  #P              @ &\\0$ >&PO=V]R:V)O
M;VLN>&UL4$L! A0#%     @ 5XJ*43AE:^>: @  <C0  !H
M ( !?_@! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @
M5XJ*4:>1ZEDW @  WS(  !,              ( !4?L! %M#;VYT96YT7U1Y
><&5S72YX;6Q02P4&     &$ 80">&@  N?T!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>236</ContextCount>
  <ElementCount>483</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>83</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Consolidated Statements of Income and Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Statements of Income and Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Consolidated Statements of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity</Role>
      <ShortName>Consolidated Statements of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1106124 - Statement - Valuation and Qualifying Accounts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ValuationandQualifyingAccounts</Role>
      <ShortName>Valuation and Qualifying Accounts</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2108103 - Disclosure - Omeclamox??-Pak, RediTrex?? and Vibativ??</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativ</Role>
      <ShortName>Omeclamox??-Pak, RediTrex?? and Vibativ??</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2113104 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2117105 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2121106 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2125107 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2130108 - Disclosure - Other Current and Other Long-term Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilities</Role>
      <ShortName>Other Current and Other Long-term Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2133109 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2135110 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2139111 - Disclosure - Earnings (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShare</Role>
      <ShortName>Earnings (Loss) Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2143112 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2150113 - Disclosure - Stock-Based Compensation Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/StockBasedCompensationPlans</Role>
      <ShortName>Stock-Based Compensation Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2157114 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2159115 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2165116 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/FairValueofFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2168117 - Disclosure - Market Concentrations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/MarketConcentrations</Role>
      <ShortName>Market Concentrations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2171118 - Disclosure - Manufacturing and Supply Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreements</Role>
      <ShortName>Manufacturing and Supply Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2173119 - Disclosure - Employment Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EmploymentAgreements</Role>
      <ShortName>Employment Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2174120 - Disclosure - Discontinued Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/DiscontinuedOperations</Role>
      <ShortName>Discontinued Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2177121 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2178122 - Disclosure - Quarterly Financial Information (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnaudited</Role>
      <ShortName>Quarterly Financial Information (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2181123 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2309302 - Disclosure - Omeclamox??-Pak, RediTrex?? and Vibativ?? (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativTables</Role>
      <ShortName>Omeclamox??-Pak, RediTrex?? and Vibativ?? (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativ</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2314303 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Revenues</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2318304 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Inventories</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2322305 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/PropertyandEquipment</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2326306 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/IntangibleAssets</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2331307 - Disclosure - Other Current and Other Long-term Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables</Role>
      <ShortName>Other Current and Other Long-term Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilities</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2340308 - Disclosure - Earnings (Loss) Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareTables</Role>
      <ShortName>Earnings (Loss) Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EarningsLossPerShare</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2344309 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/IncomeTaxes</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2351310 - Disclosure - Stock-Based Compensation Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables</Role>
      <ShortName>Stock-Based Compensation Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/StockBasedCompensationPlans</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2360311 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Leases</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2366312 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/FairValueofFinancialInstruments</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2369313 - Disclosure - Market Concentrations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/MarketConcentrationsTables</Role>
      <ShortName>Market Concentrations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/MarketConcentrations</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2375314 - Disclosure - Discontinued Operations and Disposal Groups (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/DiscontinuedOperationsandDisposalGroupsTables</Role>
      <ShortName>Discontinued Operations and Disposal Groups (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2379315 - Disclosure - Quarterly Financial Information (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnauditedTables</Role>
      <ShortName>Quarterly Financial Information (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnaudited</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Organization (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails</Role>
      <ShortName>Organization (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Organization</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Significant Accounting Policies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Significant Accounting Policies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Significant Accounting Policies (Schedule of Intangible Assets, Useful Lives) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails</Role>
      <ShortName>Significant Accounting Policies (Schedule of Intangible Assets, Useful Lives) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Omeclamox??-Pak, RediTrex?? and Vibativ?? - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails</Role>
      <ShortName>Omeclamox??-Pak, RediTrex?? and Vibativ?? - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Omeclamox??-Pak, RediTrex?? and Vibativ?? - Vibativ Acquisition - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionNarrativeDetails</Role>
      <ShortName>Omeclamox??-Pak, RediTrex?? and Vibativ?? - Vibativ Acquisition - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Omeclamox??-Pak, RediTrex?? and Vibativ?? - Vibativ Acquisition - Schedule of Contingent Consideration and Preliminary Allocation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails</Role>
      <ShortName>Omeclamox??-Pak, RediTrex?? and Vibativ?? - Vibativ Acquisition - Schedule of Contingent Consideration and Preliminary Allocation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Revenues (Schedule of Net Product Revenues by Product) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails</Role>
      <ShortName>Revenues (Schedule of Net Product Revenues by Product) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/RevenuesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - Revenues (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails</Role>
      <ShortName>Revenues (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/RevenuesTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - Inventories (Schedule of Inventories) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails</Role>
      <ShortName>Inventories (Schedule of Inventories) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/InventoriesTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - Inventories (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails</Role>
      <ShortName>Inventories (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/InventoriesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2423411 - Disclosure - Property and Equipment (Schedule of Property and Equipment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Schedule of Property and Equipment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2424412 - Disclosure - Property and Equipment (Depreciation Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/PropertyandEquipmentDepreciationExpenseDetails</Role>
      <ShortName>Property and Equipment (Depreciation Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2427413 - Disclosure - Intangible Assets (Schedule of Intangible Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets (Schedule of Intangible Assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/IntangibleAssetsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2428414 - Disclosure - Intangible Assets (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails</Role>
      <ShortName>Intangible Assets (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/IntangibleAssetsTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2429415 - Disclosure - Intangible Assets Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails</Role>
      <ShortName>Intangible Assets Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2432416 - Disclosure - Other Current and Other Long-term Liabilities (Schedule of Other Current and Noncurrent Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails</Role>
      <ShortName>Other Current and Other Long-term Liabilities (Schedule of Other Current and Noncurrent Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2434417 - Disclosure - Debt (Line of Credit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/DebtLineofCreditDetails</Role>
      <ShortName>Debt (Line of Credit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Debt</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2436418 - Disclosure - Shareholders' Equity (Initial Public Offering, Preferred Stock and Common Stock, Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails</Role>
      <ShortName>Shareholders' Equity (Initial Public Offering, Preferred Stock and Common Stock, Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/ShareholdersEquity</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2437419 - Disclosure - Shareholders' Equity (Warrants, Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquityWarrantsNarrativeDetails</Role>
      <ShortName>Shareholders' Equity (Warrants, Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/ShareholdersEquity</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2438420 - Disclosure - Shareholders' Equity (Share Repurchases, Cumberland Emerging Technologies and Cumberland Foundation Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails</Role>
      <ShortName>Shareholders' Equity (Share Repurchases, Cumberland Emerging Technologies and Cumberland Foundation Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/ShareholdersEquity</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2441421 - Disclosure - Earnings (Loss) Per Share (Schedule of Computation of Numerator and Denominator in Earnings Per Share) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails</Role>
      <ShortName>Earnings (Loss) Per Share (Schedule of Computation of Numerator and Denominator in Earnings Per Share) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EarningsLossPerShareTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2442422 - Disclosure - Earnings (Loss) Per Share (Schedule of Anti-dilutive Securities Excluded From Computation of Earnings Per Share) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails</Role>
      <ShortName>Earnings (Loss) Per Share (Schedule of Anti-dilutive Securities Excluded From Computation of Earnings Per Share) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EarningsLossPerShareTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2445423 - Disclosure - Income Taxes (Operating Loss Carryforwards, Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails</Role>
      <ShortName>Income Taxes (Operating Loss Carryforwards, Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2446424 - Disclosure - Income Taxes (Schedule of Deferred Tax Assets and Liabilities, Net) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails</Role>
      <ShortName>Income Taxes (Schedule of Deferred Tax Assets and Liabilities, Net) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2447425 - Disclosure - Income Taxes (Schedule of Net Operating Loss Carryforwards) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails</Role>
      <ShortName>Income Taxes (Schedule of Net Operating Loss Carryforwards) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2448426 - Disclosure - Income Taxes (Schedule of the Components of Income Tax Benefit (Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails</Role>
      <ShortName>Income Taxes (Schedule of the Components of Income Tax Benefit (Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2449427 - Disclosure - Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2452428 - Disclosure - Stock-Based Compensation Plans (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation Plans (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2453429 - Disclosure - Stock-Based Compensation Plans (Schedule of Share-Based Compensation Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation Plans (Schedule of Share-Based Compensation Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2454430 - Disclosure - Stock-Based Compensation Plans (Schedule of Stock Options Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails</Role>
      <ShortName>Stock-Based Compensation Plans (Schedule of Stock Options Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2455431 - Disclosure - Stock-Based Compensation Plans (Schedule of Stock Option Activity, Additional Disclosures) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityAdditionalDisclosuresDetails</Role>
      <ShortName>Stock-Based Compensation Plans (Schedule of Stock Option Activity, Additional Disclosures) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2456432 - Disclosure - Stock-Based Compensation Plans (Schedule of Restricted Stock Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails</Role>
      <ShortName>Stock-Based Compensation Plans (Schedule of Restricted Stock Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2458433 - Disclosure - Employee Benefit Plans (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EmployeeBenefitPlansNarrativeDetails</Role>
      <ShortName>Employee Benefit Plans (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EmployeeBenefitPlans</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2461434 - Disclosure - Leases (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/LeasesTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2462435 - Disclosure - Leases (Schedule of Rent Expense and Sublease Income) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesScheduleofRentExpenseandSubleaseIncomeDetails</Role>
      <ShortName>Leases (Schedule of Rent Expense and Sublease Income) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/LeasesTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2463436 - Disclosure - Leases (Lease Position) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails</Role>
      <ShortName>Leases (Lease Position) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/LeasesTables</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>2464437 - Disclosure - Leases (Schedule of Lease Liability Maturities and Future Minimum Payments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails</Role>
      <ShortName>Leases (Schedule of Lease Liability Maturities and Future Minimum Payments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/LeasesTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>2467438 - Disclosure - Fair Value of Financial Instruments (Schedule of Fair Value of Financial Instruments by Level in Hierarchy and Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails</Role>
      <ShortName>Fair Value of Financial Instruments (Schedule of Fair Value of Financial Instruments by Level in Hierarchy and Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>2470439 - Disclosure - Market Concentrations (Schedule of Revenues Concentration from Major Customers and Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails</Role>
      <ShortName>Market Concentrations (Schedule of Revenues Concentration from Major Customers and Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/MarketConcentrationsTables</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>2472440 - Disclosure - Manufacturing and Supply Agreements Manufacturing and Supply Agreements (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails</Role>
      <ShortName>Manufacturing and Supply Agreements Manufacturing and Supply Agreements (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>2476441 - Disclosure - Discontinued Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/DiscontinuedOperationsDetails</Role>
      <ShortName>Discontinued Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/DiscontinuedOperationsandDisposalGroupsTables</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>2480442 - Disclosure - Quarterly Financial Information (Schedule of Quarterly Financial Information (Unaudited)) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails</Role>
      <ShortName>Quarterly Financial Information (Schedule of Quarterly Financial Information (Unaudited)) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnauditedTables</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="cpix-20201210_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>2482443 - Disclosure - Valuation and Qualifying Accounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails</Role>
      <ShortName>Valuation and Qualifying Accounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="cpix-20201210_d2.htm">cpix-20201210_d2.htm</File>
    <File doctype="8-K" original="cpix-20201210.htm">cpix-20201210.htm</File>
    <File>a12920208-kex231.htm</File>
    <File>cpix-20201210.xsd</File>
    <File>cpix-20201210_cal.xml</File>
    <File>cpix-20201210_def.xml</File>
    <File>cpix-20201210_lab.xml</File>
    <File>cpix-20201210_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>105
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cpix-20201210_d2.htm cpix-20201210.htm": {
   "axisCustom": 3,
   "axisStandard": 29,
   "contextCount": 236,
   "dts": {
    "calculationLink": {
     "local": [
      "cpix-20201210_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "us-gaap-eedm-def-2020-01-31.xml",
      "srt-eedm1-def-2020-01-31.xml",
      "cpix-20201210_def.xml"
     ]
    },
    "inline": {
     "local": [
      "cpix-20201210_d2.htm",
      "cpix-20201210.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cpix-20201210_lab.xml",
      "dei-doc-2020-01-31.xml",
      "srt-doc-2020-01-31.xml",
      "us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cpix-20201210_pre.xml"
     ]
    },
    "referenceLink": {
     "local": [
      "srt-ref-2020-01-31.xml",
      "dei-ref-2020-01-31.xml",
      "us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "cpix-20201210.xsd",
      "srt-2020-01-31.xsd",
      "xbrl-instance-2003-12-31.xsd",
      "xbrl-linkbase-2003-12-31.xsd",
      "xl-2003-12-31.xsd",
      "xlink-2003-12-31.xsd",
      "numeric-2009-12-16.xsd",
      "nonNumeric-2009-12-16.xsd",
      "xbrldt-2005.xsd",
      "ref-2006-02-27.xsd",
      "srt-types-2020-01-31.xsd",
      "us-gaap-2020-01-31.xsd",
      "us-roles-2020-01-31.xsd",
      "srt-roles-2020-01-31.xsd",
      "country-2020-01-31.xsd",
      "us-types-2020-01-31.xsd",
      "dei-2020-01-31.xsd",
      "negated-2009-12-16.xsd",
      "net-2009-12-16.xsd",
      "deprecated-2009-12-16.xsd",
      "reference-2009-12-16.xsd",
      "us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 662,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 17,
    "http://www.cumberlandpharma.com/20201210": 2,
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 21
   },
   "keyCustom": 67,
   "keyStandard": 416,
   "memberCustom": 45,
   "memberStandard": 34,
   "nsprefix": "cpix",
   "nsuri": "http://www.cumberlandpharma.com/20201210",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210_d2.htm",
      "contextRef": "i7a6e879bfd2c43f08102604657a76057_D20201210-20201210",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.cumberlandpharma.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210_d2.htm",
      "contextRef": "i7a6e879bfd2c43f08102604657a76057_D20201210-20201210",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108103 - Disclosure - Omeclamox\u00ae-Pak, RediTrex\u00ae and Vibativ\u00ae",
     "role": "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativ",
     "shortName": "Omeclamox\u00ae-Pak, RediTrex\u00ae and Vibativ\u00ae",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113104 - Disclosure - Revenues",
     "role": "http://www.cumberlandpharma.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117105 - Disclosure - Inventories",
     "role": "http://www.cumberlandpharma.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121106 - Disclosure - Property and Equipment",
     "role": "http://www.cumberlandpharma.com/role/PropertyandEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125107 - Disclosure - Intangible Assets",
     "role": "http://www.cumberlandpharma.com/role/IntangibleAssets",
     "shortName": "Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130108 - Disclosure - Other Current and Other Long-term Liabilities",
     "role": "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilities",
     "shortName": "Other Current and Other Long-term Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133109 - Disclosure - Debt",
     "role": "http://www.cumberlandpharma.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135110 - Disclosure - Shareholders' Equity",
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquity",
     "shortName": "Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139111 - Disclosure - Earnings (Loss) Per Share",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShare",
     "shortName": "Earnings (Loss) Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143112 - Disclosure - Income Taxes",
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "iaa474b82645f415f9a942431b7e23907_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Consolidated Balance Sheets",
     "role": "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "iaa474b82645f415f9a942431b7e23907_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2150113 - Disclosure - Stock-Based Compensation Plans",
     "role": "http://www.cumberlandpharma.com/role/StockBasedCompensationPlans",
     "shortName": "Stock-Based Compensation Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2157114 - Disclosure - Employee Benefit Plans",
     "role": "http://www.cumberlandpharma.com/role/EmployeeBenefitPlans",
     "shortName": "Employee Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2159115 - Disclosure - Leases",
     "role": "http://www.cumberlandpharma.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2165116 - Disclosure - Fair Value of Financial Instruments",
     "role": "http://www.cumberlandpharma.com/role/FairValueofFinancialInstruments",
     "shortName": "Fair Value of Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2168117 - Disclosure - Market Concentrations",
     "role": "http://www.cumberlandpharma.com/role/MarketConcentrations",
     "shortName": "Market Concentrations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:ManufacturingAndSupplyAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2171118 - Disclosure - Manufacturing and Supply Agreements",
     "role": "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreements",
     "shortName": "Manufacturing and Supply Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:ManufacturingAndSupplyAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:EmploymentAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2173119 - Disclosure - Employment Agreements",
     "role": "http://www.cumberlandpharma.com/role/EmploymentAgreements",
     "shortName": "Employment Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:EmploymentAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2174120 - Disclosure - Discontinued Operations",
     "role": "http://www.cumberlandpharma.com/role/DiscontinuedOperations",
     "shortName": "Discontinued Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2177121 - Disclosure - Commitments and Contingencies",
     "role": "http://www.cumberlandpharma.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2178122 - Disclosure - Quarterly Financial Information (Unaudited)",
     "role": "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnaudited",
     "shortName": "Quarterly Financial Information (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2181123 - Disclosure - Subsequent Events",
     "role": "http://www.cumberlandpharma.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Significant Accounting Policies (Policies)",
     "role": "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Significant Accounting Policies (Tables)",
     "role": "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables",
     "shortName": "Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309302 - Disclosure - Omeclamox\u00ae-Pak, RediTrex\u00ae and Vibativ\u00ae (Tables)",
     "role": "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativTables",
     "shortName": "Omeclamox\u00ae-Pak, RediTrex\u00ae and Vibativ\u00ae (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314303 - Disclosure - Revenues (Tables)",
     "role": "http://www.cumberlandpharma.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318304 - Disclosure - Inventories (Tables)",
     "role": "http://www.cumberlandpharma.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322305 - Disclosure - Property and Equipment (Tables)",
     "role": "http://www.cumberlandpharma.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2326306 - Disclosure - Intangible Assets (Tables)",
     "role": "http://www.cumberlandpharma.com/role/IntangibleAssetsTables",
     "shortName": "Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331307 - Disclosure - Other Current and Other Long-term Liabilities (Tables)",
     "role": "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables",
     "shortName": "Other Current and Other Long-term Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2340308 - Disclosure - Earnings (Loss) Per Share (Tables)",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareTables",
     "shortName": "Earnings (Loss) Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Consolidated Statements of Income and Comprehensive Income (Loss)",
     "role": "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss",
     "shortName": "Consolidated Statements of Income and Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2344309 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2351310 - Disclosure - Stock-Based Compensation Plans (Tables)",
     "role": "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables",
     "shortName": "Stock-Based Compensation Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:ScheduleofRentExpenseandSubleaseIncomeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2360311 - Disclosure - Leases (Tables)",
     "role": "http://www.cumberlandpharma.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:ScheduleofRentExpenseandSubleaseIncomeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2366312 - Disclosure - Fair Value of Financial Instruments (Tables)",
     "role": "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsTables",
     "shortName": "Fair Value of Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2369313 - Disclosure - Market Concentrations (Tables)",
     "role": "http://www.cumberlandpharma.com/role/MarketConcentrationsTables",
     "shortName": "Market Concentrations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2375314 - Disclosure - Discontinued Operations and Disposal Groups (Tables)",
     "role": "http://www.cumberlandpharma.com/role/DiscontinuedOperationsandDisposalGroupsTables",
     "shortName": "Discontinued Operations and Disposal Groups (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2379315 - Disclosure - Quarterly Financial Information (Unaudited) (Tables)",
     "role": "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnauditedTables",
     "shortName": "Quarterly Financial Information (Unaudited) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i5465c80566344695bc41a215e251af48_D20190401-20190430",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Organization (Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails",
     "shortName": "Organization (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "ie1b2c35fc3b6418cb8cc3c920e5ae3d6_I20191231",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestOwnershipPercentageByParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Significant Accounting Policies (Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Significant Accounting Policies (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "ib06a29ad4edd4918a967323242b0142d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:FiniteLivedIntangibleAssetsUsefulLivesTextual",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Significant Accounting Policies (Schedule of Intangible Assets, Useful Lives) (Details)",
     "role": "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails",
     "shortName": "Significant Accounting Policies (Schedule of Intangible Assets, Useful Lives) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "ib06a29ad4edd4918a967323242b0142d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:FiniteLivedIntangibleAssetsUsefulLivesTextual",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "cpix:PaymentsForAssetAcquisitions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Omeclamox\u00ae-Pak, RediTrex\u00ae and Vibativ\u00ae - Narrative (Details)",
     "role": "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails",
     "shortName": "Omeclamox\u00ae-Pak, RediTrex\u00ae and Vibativ\u00ae - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "cpix:PaymentsForAssetAcquisitions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Omeclamox\u00ae-Pak, RediTrex\u00ae and Vibativ\u00ae - Vibativ Acquisition - Narrative (Details)",
     "role": "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionNarrativeDetails",
     "shortName": "Omeclamox\u00ae-Pak, RediTrex\u00ae and Vibativ\u00ae - Vibativ Acquisition - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i35eae0bc26094a639bb7e4c0640fb7ea_D20181101-20181130",
      "decimals": "2",
      "lang": "en-US",
      "name": "cpix:TieredRoyaltyPaymentsPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - Omeclamox\u00ae-Pak, RediTrex\u00ae and Vibativ\u00ae - Vibativ Acquisition - Schedule of Contingent Consideration and Preliminary Allocation (Details)",
     "role": "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails",
     "shortName": "Omeclamox\u00ae-Pak, RediTrex\u00ae and Vibativ\u00ae - Vibativ Acquisition - Schedule of Contingent Consideration and Preliminary Allocation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i9f2a5edba28144ad932b2ce0fd047ab3_D20190101-20191231",
      "decimals": "0",
      "lang": "en-US",
      "name": "cpix:PaymentsForContingentConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - Revenues (Schedule of Net Product Revenues by Product) (Details)",
     "role": "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails",
     "shortName": "Revenues (Schedule of Net Product Revenues by Product) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i2f1333c86d8745489e79ec97651cf898_D20190101-20191231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - Revenues (Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails",
     "shortName": "Revenues (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "cpix:RevenueRecognitionUpfrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "iaa474b82645f415f9a942431b7e23907_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - Inventories (Schedule of Inventories) (Details)",
     "role": "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails",
     "shortName": "Inventories (Schedule of Inventories) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "iaa474b82645f415f9a942431b7e23907_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "iaa474b82645f415f9a942431b7e23907_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryValuationReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - Inventories (Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
     "shortName": "Inventories (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "iaa474b82645f415f9a942431b7e23907_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryValuationReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "iaa474b82645f415f9a942431b7e23907_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423411 - Disclosure - Property and Equipment (Schedule of Property and Equipment) (Details)",
     "role": "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails",
     "shortName": "Property and Equipment (Schedule of Property and Equipment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "iaa474b82645f415f9a942431b7e23907_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "cpix:DepreciationIncludingAmortizationRelatedToLeaseholdImprovements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424412 - Disclosure - Property and Equipment (Depreciation Expense) (Details)",
     "role": "http://www.cumberlandpharma.com/role/PropertyandEquipmentDepreciationExpenseDetails",
     "shortName": "Property and Equipment (Depreciation Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "cpix:DepreciationIncludingAmortizationRelatedToLeaseholdImprovements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "iaa474b82645f415f9a942431b7e23907_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427413 - Disclosure - Intangible Assets (Schedule of Intangible Assets) (Details)",
     "role": "http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails",
     "shortName": "Intangible Assets (Schedule of Intangible Assets) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "ibda132d30f764f18ba15f5b11ef8640c_I20191231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i2153d838d1a64103b08e67d86300e4f6_I20161231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Consolidated Statements of Equity",
     "role": "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
     "shortName": "Consolidated Statements of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i2153d838d1a64103b08e67d86300e4f6_I20161231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "iaa474b82645f415f9a942431b7e23907_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428414 - Disclosure - Intangible Assets (Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
     "shortName": "Intangible Assets (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i9264ef6a01f546dca65e6adec1f967fe_D20190101-20191231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "iaa474b82645f415f9a942431b7e23907_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429415 - Disclosure - Intangible Assets Future Amortization Expense (Details)",
     "role": "http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails",
     "shortName": "Intangible Assets Future Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "iaa474b82645f415f9a942431b7e23907_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "iaa474b82645f415f9a942431b7e23907_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "cpix:ProductSalesRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432416 - Disclosure - Other Current and Other Long-term Liabilities (Schedule of Other Current and Noncurrent Liabilities) (Details)",
     "role": "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails",
     "shortName": "Other Current and Other Long-term Liabilities (Schedule of Other Current and Noncurrent Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "iaa474b82645f415f9a942431b7e23907_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "cpix:ProductSalesRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "iaa474b82645f415f9a942431b7e23907_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermLineOfCredit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434417 - Disclosure - Debt (Line of Credit) (Details)",
     "role": "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails",
     "shortName": "Debt (Line of Credit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i20968f0f5b524d799086597dfddc2a8d_I20181017",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436418 - Disclosure - Shareholders' Equity (Initial Public Offering, Preferred Stock and Common Stock, Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails",
     "shortName": "Shareholders' Equity (Initial Public Offering, Preferred Stock and Common Stock, Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "iaa474b82645f415f9a942431b7e23907_I20191231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "ia45e033a0968470a87498cc6e80e79bb_I20061231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437419 - Disclosure - Shareholders' Equity (Warrants, Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityWarrantsNarrativeDetails",
     "shortName": "Shareholders' Equity (Warrants, Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "ia45e033a0968470a87498cc6e80e79bb_I20061231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchasedDuringPeriodValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438420 - Disclosure - Shareholders' Equity (Share Repurchases, Cumberland Emerging Technologies and Cumberland Foundation Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails",
     "shortName": "Shareholders' Equity (Share Repurchases, Cumberland Emerging Technologies and Cumberland Foundation Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "iaa474b82645f415f9a942431b7e23907_I20191231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i670fdffefb0c4fefba494de91fb35afc_D20191001-20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441421 - Disclosure - Earnings (Loss) Per Share (Schedule of Computation of Numerator and Denominator in Earnings Per Share) (Details)",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails",
     "shortName": "Earnings (Loss) Per Share (Schedule of Computation of Numerator and Denominator in Earnings Per Share) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442422 - Disclosure - Earnings (Loss) Per Share (Schedule of Anti-dilutive Securities Excluded From Computation of Earnings Per Share) (Details)",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails",
     "shortName": "Earnings (Loss) Per Share (Schedule of Anti-dilutive Securities Excluded From Computation of Earnings Per Share) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "iaa474b82645f415f9a942431b7e23907_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445423 - Disclosure - Income Taxes (Operating Loss Carryforwards, Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails",
     "shortName": "Income Taxes (Operating Loss Carryforwards, Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i12da030761f5478185c9c43f4257f503_D20170101-20171231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1106124 - Statement - Valuation and Qualifying Accounts",
     "role": "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccounts",
     "shortName": "Valuation and Qualifying Accounts",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "iaa474b82645f415f9a942431b7e23907_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "cpix:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446424 - Disclosure - Income Taxes (Schedule of Deferred Tax Assets and Liabilities, Net) (Details)",
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails",
     "shortName": "Income Taxes (Schedule of Deferred Tax Assets and Liabilities, Net) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "iaa474b82645f415f9a942431b7e23907_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "cpix:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "idf6dd30a84fc4e6fbec6716f5833f1be_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447425 - Disclosure - Income Taxes (Schedule of Net Operating Loss Carryforwards) (Details)",
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails",
     "shortName": "Income Taxes (Schedule of Net Operating Loss Carryforwards) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i9c1e105600e74750a10354cbeaad8205_I20191231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448426 - Disclosure - Income Taxes (Schedule of the Components of Income Tax Benefit (Expense) (Details)",
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails",
     "shortName": "Income Taxes (Schedule of the Components of Income Tax Benefit (Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449427 - Disclosure - Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details)",
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails",
     "shortName": "Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "plan",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452428 - Disclosure - Stock-Based Compensation Plans (Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails",
     "shortName": "Stock-Based Compensation Plans (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "plan",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453429 - Disclosure - Stock-Based Compensation Plans (Schedule of Share-Based Compensation Expense) (Details)",
     "role": "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation Plans (Schedule of Share-Based Compensation Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "ifc452512a3cb412faa57ddaf029b98df_D20190101-20191231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i90392aced265439a8a45b88619999ce0_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454430 - Disclosure - Stock-Based Compensation Plans (Schedule of Stock Options Activity) (Details)",
     "role": "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails",
     "shortName": "Stock-Based Compensation Plans (Schedule of Stock Options Activity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455431 - Disclosure - Stock-Based Compensation Plans (Schedule of Stock Option Activity, Additional Disclosures) (Details)",
     "role": "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityAdditionalDisclosuresDetails",
     "shortName": "Stock-Based Compensation Plans (Schedule of Stock Option Activity, Additional Disclosures) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i84fb9bc25ed941ce90338733d28f5d92_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456432 - Disclosure - Stock-Based Compensation Plans (Schedule of Restricted Stock Activity) (Details)",
     "role": "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails",
     "shortName": "Stock-Based Compensation Plans (Schedule of Restricted Stock Activity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "iaaaacea9a57e4e758bc406a2ecaef76a_I20171231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:DefinedContributionPlanEligibilityMinimumEmployeeAge",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458433 - Disclosure - Employee Benefit Plans (Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/EmployeeBenefitPlansNarrativeDetails",
     "shortName": "Employee Benefit Plans (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:DefinedContributionPlanEligibilityMinimumEmployeeAge",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization",
     "role": "http://www.cumberlandpharma.com/role/Organization",
     "shortName": "Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "iaa474b82645f415f9a942431b7e23907_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461434 - Disclosure - Leases (Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails",
     "shortName": "Leases (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "iaa474b82645f415f9a942431b7e23907_I20191231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2462435 - Disclosure - Leases (Schedule of Rent Expense and Sublease Income) (Details)",
     "role": "http://www.cumberlandpharma.com/role/LeasesScheduleofRentExpenseandSubleaseIncomeDetails",
     "shortName": "Leases (Schedule of Rent Expense and Sublease Income) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "iaa474b82645f415f9a942431b7e23907_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2463436 - Disclosure - Leases (Lease Position) (Details)",
     "role": "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails",
     "shortName": "Leases (Lease Position) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "iaa474b82645f415f9a942431b7e23907_I20191231",
      "decimals": "0",
      "lang": "en-US",
      "name": "cpix:LeaseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "iaa474b82645f415f9a942431b7e23907_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2464437 - Disclosure - Leases (Schedule of Lease Liability Maturities and Future Minimum Payments) (Details)",
     "role": "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails",
     "shortName": "Leases (Schedule of Lease Liability Maturities and Future Minimum Payments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "iaa474b82645f415f9a942431b7e23907_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "iaa474b82645f415f9a942431b7e23907_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TradingSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2467438 - Disclosure - Fair Value of Financial Instruments (Schedule of Fair Value of Financial Instruments by Level in Hierarchy and Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails",
     "shortName": "Fair Value of Financial Instruments (Schedule of Fair Value of Financial Instruments by Level in Hierarchy and Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "iaa474b82645f415f9a942431b7e23907_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TradingSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i957590befb9d4e11af4357cac09d5a2e_D20190101-20191231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2470439 - Disclosure - Market Concentrations (Schedule of Revenues Concentration from Major Customers and Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails",
     "shortName": "Market Concentrations (Schedule of Revenues Concentration from Major Customers and Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i957590befb9d4e11af4357cac09d5a2e_D20190101-20191231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i1a21420517ea4647a67d7b1217a674ef_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "cpix:ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct",
      "reportCount": 1,
      "unique": true,
      "unitRef": "supplier",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2472440 - Disclosure - Manufacturing and Supply Agreements Manufacturing and Supply Agreements (Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails",
     "shortName": "Manufacturing and Supply Agreements Manufacturing and Supply Agreements (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i1a21420517ea4647a67d7b1217a674ef_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "cpix:ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct",
      "reportCount": 1,
      "unique": true,
      "unitRef": "supplier",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2476441 - Disclosure - Discontinued Operations (Details)",
     "role": "http://www.cumberlandpharma.com/role/DiscontinuedOperationsDetails",
     "shortName": "Discontinued Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i670fdffefb0c4fefba494de91fb35afc_D20191001-20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2480442 - Disclosure - Quarterly Financial Information (Schedule of Quarterly Financial Information (Unaudited)) (Details)",
     "role": "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails",
     "shortName": "Quarterly Financial Information (Schedule of Quarterly Financial Information (Unaudited)) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i670fdffefb0c4fefba494de91fb35afc_D20191001-20191231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:OperatingIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i12da030761f5478185c9c43f4257f503_D20170101-20171231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2482443 - Disclosure - Valuation and Qualifying Accounts (Details)",
     "role": "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails",
     "shortName": "Valuation and Qualifying Accounts (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i12da030761f5478185c9c43f4257f503_D20170101-20171231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Significant Accounting Policies",
     "role": "http://www.cumberlandpharma.com/role/SignificantAccountingPolicies",
     "shortName": "Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201210.htm",
      "contextRef": "i3b76d2971f254e54916f8a58844e79e5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 83,
   "tag": {
    "cpix_AccountsReceivableAllowancesByComponentAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounts Receivable, Allowances by Component [Axis]",
        "label": "Accounts Receivable, Allowances by Component [Axis]",
        "terseLabel": "Accounts Receivable, Allowances by Component [Axis]"
       }
      }
     },
     "localname": "AccountsReceivableAllowancesByComponentAxis",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_AccountsReceivableAllowancesByComponentDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Accounts Receivable, Allowances by Component [Axis]",
        "label": "Accounts Receivable, Allowances by Component [Domain]",
        "terseLabel": "Accounts Receivable, Allowances by Component [Domain]"
       }
      }
     },
     "localname": "AccountsReceivableAllowancesByComponentDomain",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_AccruedLiabilitiesInventoryPurchases": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Liabilities, Inventory Purchases",
        "label": "Accrued Liabilities, Inventory Purchases",
        "terseLabel": "Accrued inventory purchases"
       }
      }
     },
     "localname": "AccruedLiabilitiesInventoryPurchases",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_AccruedLiabilitiesStockPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Liabilities, Stock Payable",
        "label": "Accrued Liabilities, Stock Payable",
        "terseLabel": "Stock payable"
       }
      }
     },
     "localname": "AccruedLiabilitiesStockPayable",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_AccruedPaymentForAssetPurchaseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Payment For Asset Purchase, Current",
        "label": "Accrued Payment For Asset Purchase, Current",
        "terseLabel": "Accrued payment for asset purchase"
       }
      }
     },
     "localname": "AccruedPaymentForAssetPurchaseCurrent",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_AcetadoteMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Acetadote.",
        "label": "Acetadote [Member]",
        "terseLabel": "Acetadote"
       }
      }
     },
     "localname": "AcetadoteMember",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_AmendedInternationalAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amended International Agreement [Member]",
        "label": "Amended International Agreement [Member]",
        "terseLabel": "Amended International Agreement"
       }
      }
     },
     "localname": "AmendedInternationalAgreementMember",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Assets and Liabilities, Lessee",
        "label": "Assets and Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Schedule of balance sheet classification"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration Arrangements, Contingent Consideration, Liability, Initial Fair Value Adjustment",
        "label": "Business Combination, Contingent Consideration Arrangements, Contingent Consideration, Liability, Initial Fair Value Adjustment",
        "terseLabel": "Adjustment to initial fair value of the contingent consideration liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses",
        "label": "Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses",
        "terseLabel": "Contingent consideration earned and accrued in operating expenses"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finished Goods Inventory",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finished Goods Inventory",
        "terseLabel": "Finished goods inventory"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles and Goodwill",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles and Goodwill",
        "totalLabel": "Total intangibles and goodwill"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Raw Materials Inventory",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Raw Materials Inventory",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Unlabeled Vials",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Unlabeled Vials",
        "terseLabel": "Work in process - unlabeled vials"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Validation Vials",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Validation Vials",
        "terseLabel": "Work in process - validation vials"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_CaldolorMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Caldolor.",
        "label": "Caldolor [Member]",
        "terseLabel": "Caldolor"
       }
      }
     },
     "localname": "CaldolorMember",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_CashPaidDuringYearForAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash Paid During Year For [Abstract]",
        "label": "Cash Paid During Year For [Abstract]",
        "terseLabel": "Net cash paid (refunded) during the year for:"
       }
      }
     },
     "localname": "CashPaidDuringYearForAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_ChangeInContingentConsiderationHeadingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Change in Contingent Consideration",
        "label": "Change in Contingent Consideration [Heading Roll Forward]",
        "terseLabel": "Contingent consideration liability"
       }
      }
     },
     "localname": "ChangeInContingentConsiderationHeadingRollForward",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_ChargebacksCashDiscountsAndDamagedGoodsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Chargebacks, Cash Discounts and Damaged Goods [Member]",
        "label": "Chargebacks, Cash Discounts and Damaged Goods [Member]",
        "terseLabel": "Product Sales Related Allowances - Chargebacks, Cash Discounts and Damaged Goods"
       }
      }
     },
     "localname": "ChargebacksCashDiscountsAndDamagedGoodsMember",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Federal Small Business Grant Programs [Member]",
        "label": "Collaborative Arrangement, Federal Small Business Grant Programs [Member]",
        "terseLabel": "Collaborative Arrangement, Federal Small Business Grant Programs"
       }
      }
     },
     "localname": "CollaborativeArrangementFederalSmallBusinessGrantProgramsMember",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_CommonStockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common Stock [Abstract]",
        "label": "Common Stock [Abstract]",
        "terseLabel": "Common Stock [Abstract]"
       }
      }
     },
     "localname": "CommonStockAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_ContributionOfCashAdditionalSharesPurchased": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contribution of Cash, Additional Shares Purchased",
        "label": "Contribution of Cash, Additional Shares Purchased",
        "terseLabel": "Contribution of cash"
       }
      }
     },
     "localname": "ContributionOfCashAdditionalSharesPurchased",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_CumberlandEmergingTechnologiesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cumberland Emerging Technologies, Inc [Member]",
        "label": "Cumberland Emerging Technologies, Inc [Member]",
        "terseLabel": "Cumberland Emerging Technologies, Inc (CET)"
       }
      }
     },
     "localname": "CumberlandEmergingTechnologiesIncMember",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_CustomerOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Customer One [Member]",
        "label": "Customer One [Member]",
        "terseLabel": "Customer 1"
       }
      }
     },
     "localname": "CustomerOneMember",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_CustomerThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Customer Three [Member]",
        "label": "Customer Three [Member]",
        "terseLabel": "Customer 3"
       }
      }
     },
     "localname": "CustomerThreeMember",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_CustomerTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Customer Two [Member]",
        "label": "Customer Two [Member]",
        "terseLabel": "Customer 2"
       }
      }
     },
     "localname": "CustomerTwoMember",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_DeferredAcquisitionLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Acquisition Liability, Current",
        "label": "Deferred Acquisition Liability, Current",
        "terseLabel": "Deferred acquisition liability"
       }
      }
     },
     "localname": "DeferredAcquisitionLiabilityCurrent",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Offering Costs Included in Accounts Payable and Other Accrued Expenses",
        "label": "Deferred Offering Costs Included in Accounts Payable and Other Accrued Expenses",
        "terseLabel": "Deferred offering costs included in accounts payable and other accrued expenses"
       }
      }
     },
     "localname": "DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_DeferredTaxAssetsDeferredCharges": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Assets, Deferred Charges",
        "label": "Deferred Tax Assets, Deferred Charges",
        "terseLabel": "Deferred charges"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredCharges",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Assets, Operating Loss Carryforwards and Tax Credit Carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards and Tax Credit Carryforwards",
        "terseLabel": "Net operating loss and tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Assets, Property and Equipment and Intangibles",
        "label": "Deferred Tax Assets, Property and Equipment and Intangibles",
        "terseLabel": "Property and equipment and intangibles"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyAndEquipmentAndIntangibles",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves for Expired Product",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves for Expired Product",
        "terseLabel": "Reserve for expired product"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Defined Contribution Plan, Eligibility, Minimum Employee Age",
        "label": "Defined Contribution Plan, Eligibility, Minimum Employee Age",
        "terseLabel": "Defined contribution plan, eligibiilty, minimum employee age"
       }
      }
     },
     "localname": "DefinedContributionPlanEligibilityMinimumEmployeeAge",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Defined Contribution Plan, Eligibility, Minimum Employee Service Time for Participation Eligibility",
        "label": "Defined Contribution Plan, Eligibility, Minimum Employee Service Time for Participation Eligibility",
        "terseLabel": "Defined contribution plan, eligibility, minimum employee service time for participation eligibility"
       }
      }
     },
     "localname": "DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "durationStringItemType"
    },
    "cpix_DenominatorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Denominator.",
        "label": "Denominator [Abstract]",
        "verboseLabel": "Denominator:"
       }
      }
     },
     "localname": "DenominatorAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Depreciation, Including Amortization Related to Leasehold Improvements",
        "label": "Depreciation, Including Amortization Related to Leasehold Improvements",
        "terseLabel": "Depreciation, including amortization related to leasehold improvements"
       }
      }
     },
     "localname": "DepreciationIncludingAmortizationRelatedToLeaseholdImprovements",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentDepreciationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_DirectorsIncentivePlan2007Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Directors\u2019 Incentive Plan 2007 [Member]",
        "label": "Directors\u2019 Incentive Plan 2007 [Member]",
        "terseLabel": "Directors\u2019 Incentive Plan 2007"
       }
      }
     },
     "localname": "DirectorsIncentivePlan2007Member",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_DisposalGroupIncludingDiscontinuedOperationRemainingInventoryCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Remaining Inventory, Current",
        "label": "Disposal Group, Including Discontinued Operation, Remaining Inventory, Current",
        "terseLabel": "Remaining inventory"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRemainingInventoryCurrent",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_EmployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee [Member]",
        "label": "Employee [Member]",
        "terseLabel": "Employee"
       }
      }
     },
     "localname": "EmployeeMember",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_EmployeeNonemployeeandFoundationContributionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee, Nonemployee and Foundation Contribution [Member]",
        "label": "Employee, Nonemployee and Foundation Contribution [Member]",
        "terseLabel": "Employee, Nonemployee and Foundation Contribution"
       }
      }
     },
     "localname": "EmployeeNonemployeeandFoundationContributionMember",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_EmploymentAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employment Agreements [Abstract]",
        "label": "Employment Agreements [Abstract]"
       }
      }
     },
     "localname": "EmploymentAgreementsAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "xbrltype": "stringItemType"
    },
    "cpix_EmploymentAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employment Agreements",
        "label": "Employment Agreements [Text Block]",
        "terseLabel": "Employment Agreements"
       }
      }
     },
     "localname": "EmploymentAgreementsTextBlock",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EmploymentAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cpix_ExpirationTermFourMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expiration, Term Four [Member]",
        "label": "Expiration, Term Four [Member]",
        "terseLabel": "2031 - 2039"
       }
      }
     },
     "localname": "ExpirationTermFourMember",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ExpirationTermOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expiration, Term One [Member]",
        "label": "Expiration, Term One [Member]",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "ExpirationTermOneMember",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ExpirationTermThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expiration, Term Three [Member]",
        "label": "Expiration, Term Three [Member]",
        "terseLabel": "2030"
       }
      }
     },
     "localname": "ExpirationTermThreeMember",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ExpirationTermTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expiration, Term Two [Member]",
        "label": "Expiration, Term Two [Member]",
        "terseLabel": "2021 - 2029"
       }
      }
     },
     "localname": "ExpirationTermTwoMember",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ExpirationTimePeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expiration Time Period [Axis]",
        "label": "Expiration Time Period [Axis]",
        "terseLabel": "Expiration Time Period [Axis]"
       }
      }
     },
     "localname": "ExpirationTimePeriodAxis",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_ExpirationTimePeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Expiration Time Period [Axis]",
        "label": "Expiration Time Period [Domain]",
        "terseLabel": "Expiration Time Period [Domain]"
       }
      }
     },
     "localname": "ExpirationTimePeriodDomain",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_FinancialConsiderationPaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financial Consideration, Payment Period",
        "label": "Financial Consideration, Payment Period",
        "terseLabel": "Financial consideration, payment period"
       }
      }
     },
     "localname": "FinancialConsiderationPaymentPeriod",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Finite-Lived Intangible Assets, Amortization Expense, Year Five and After",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five and After",
        "terseLabel": "2024 and thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Finite-Lived Intangible Assets, Useful Lives, (Textual)",
        "label": "Finite-Lived Intangible Assets, Useful Lives, (Textual)",
        "terseLabel": "Intangible assets, useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsUsefulLivesTextual",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_FoundationContributionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foundation Contribution [Member]",
        "label": "Foundation Contribution [Member]",
        "terseLabel": "Foundation Contribution"
       }
      }
     },
     "localname": "FoundationContributionMember",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_GloriaPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gloria Pharmaceuticals",
        "label": "Gloria Pharmaceuticals [Member]",
        "terseLabel": "Gloria Pharmaceuticals"
       }
      }
     },
     "localname": "GloriaPharmaceuticalsMember",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_HarbinGloriaPharmaceuticalsCoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Harbin Gloria Pharmaceuticals Co [Member]",
        "label": "Harbin Gloria Pharmaceuticals Co [Member]",
        "terseLabel": "Harbin Gloria Pharmaceuticals Co"
       }
      }
     },
     "localname": "HarbinGloriaPharmaceuticalsCoMember",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "HongKong WinHealth Pharma Group Co. Limited And DB Pharm Korea Co., Ltd.",
        "label": "HongKong WinHealth Pharma Group Co. Limited And DB Pharm Korea Co., Ltd. [Member]",
        "terseLabel": "HongKong WinHealth Pharma Group Co. Limited And DB Pharm Korea Co., Ltd."
       }
      }
     },
     "localname": "HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_HongKongWinHealthPharmaGroupCoLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "HongKong WinHealth Pharma Group Co. Limited",
        "label": "HongKong WinHealth Pharma Group Co. Limited [Member]",
        "terseLabel": "HongKong WinHealth Pharma Group Co. Limited"
       }
      }
     },
     "localname": "HongKongWinHealthPharmaGroupCoLimitedMember",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_IfetrobanClinicalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ifetroban Clinical",
        "label": "Ifetroban Clinical [Member]",
        "terseLabel": "Ifetroban Clinical"
       }
      }
     },
     "localname": "IfetrobanClinicalMember",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_IndefiniteMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indefinite",
        "label": "Indefinite [Member]",
        "terseLabel": "Indefinite Period"
       }
      }
     },
     "localname": "IndefiniteMember",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_InitialPublicOfferingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Initial Public Offering [Abstract]",
        "label": "Initial Public Offering [Abstract]",
        "terseLabel": "Initial Public Offering [Abstract]"
       }
      }
     },
     "localname": "InitialPublicOfferingAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_IntercompanyLoansPayableConvertedAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intercompany Loans Payable, Converted Amount",
        "label": "Intercompany Loans Payable, Converted Amount",
        "terseLabel": "Conversion of intercompany loans payable"
       }
      }
     },
     "localname": "IntercompanyLoansPayableConvertedAmount",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_KristaloseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Kristalose.",
        "label": "Kristalose [Member]",
        "terseLabel": "Kristalose"
       }
      }
     },
     "localname": "KristaloseMember",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_LeaseAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lease, Asset",
        "label": "Lease, Asset",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "LeaseAsset",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_LeaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lease, Liability",
        "label": "Lease, Liability",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "LeaseLiability",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line of Credit Facility, Maximum Borrowing Capacity Upon Satisfaction of Certain Conditions",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity Upon Satisfaction of Certain Conditions",
        "terseLabel": "Line of credit, maximum borrowing capacity upon satisfaction of certain conditions"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_LoanPoolsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Loan pools.",
        "label": "Loan Pools [Member]",
        "verboseLabel": "SBA loan pools - variable rate"
       }
      }
     },
     "localname": "LoanPoolsMember",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_LoansForgiveninExchangeForShareIssuedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Loans Forgiven in Exchange For Share Issued, Amount",
        "label": "Loans Forgiven in Exchange For Share Issued, Amount",
        "terseLabel": "Loans Forgiven in Exchange For Share Issued, Amount"
       }
      }
     },
     "localname": "LoansForgiveninExchangeForShareIssuedAmount",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_LongTermIncentiveCompensationPlan2007Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long-Term Incentive Compensation Plan 2007 [Member]",
        "label": "Long-Term Incentive Compensation Plan 2007 [Member]",
        "terseLabel": "Long-Term Incentive Compensation Plan 2007"
       }
      }
     },
     "localname": "LongTermIncentiveCompensationPlan2007Member",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Manufacturing agreements, number of primary suppliers for each product",
        "label": "Manufacturing agreements, number of primary suppliers for each product",
        "terseLabel": "Manufacturing agreements, number of primary suppliers for each product"
       }
      }
     },
     "localname": "ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cpix_ManufacturingAndSupplyAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Manufacturing and Supply Agreements [Abstract]",
        "label": "Manufacturing and Supply Agreements [Abstract]"
       }
      }
     },
     "localname": "ManufacturingAndSupplyAgreementsAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "xbrltype": "stringItemType"
    },
    "cpix_ManufacturingAndSupplyAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Manufacturing and Supply Agreements",
        "label": "Manufacturing and Supply Agreements [Text Block]",
        "terseLabel": "Manufacturing and Supply Agreements"
       }
      }
     },
     "localname": "ManufacturingAndSupplyAgreementsTextBlock",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cpix_ManufacturingandSupplyAgreementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Line Items] for Manufacturing and Supply Agreement [Table]",
        "label": "Manufacturing and Supply Agreement [Line Items]",
        "terseLabel": "Manufacturing and Supply Agreement [Line Items]"
       }
      }
     },
     "localname": "ManufacturingandSupplyAgreementLineItems",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_ManufacturingandSupplyAgreementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Manufacturing and Supply Agreement [Table]",
        "label": "Manufacturing and Supply Agreement [Table]",
        "terseLabel": "Manufacturing and Supply Agreement [Table]"
       }
      }
     },
     "localname": "ManufacturingandSupplyAgreementTable",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_MethotrexateMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Methotrexate [Member]",
        "label": "Methotrexate [Member]",
        "terseLabel": "Methotrexate"
       }
      }
     },
     "localname": "MethotrexateMember",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_NetDeferredTaxAssetsGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net Deferred Tax Assets, Gross",
        "label": "Net Deferred Tax Assets, Gross",
        "totalLabel": "Net deferred tax assets, before valuation allowance"
       }
      }
     },
     "localname": "NetDeferredTaxAssetsGross",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_NoncashOrPartNoncashTransactionVestingOfShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Noncash or Part Noncash Transaction, Vesting of Shares",
        "label": "Noncash or Part Noncash Transaction, Vesting of Shares",
        "terseLabel": "Vesting of shares related to RediTrex approval"
       }
      }
     },
     "localname": "NoncashOrPartNoncashTransactionVestingOfShares",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_NonemployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nonemployee [Member]",
        "label": "Nonemployee [Member]",
        "terseLabel": "Nonemployee"
       }
      }
     },
     "localname": "NonemployeeMember",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_NonprincipalOwnerMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "NonPrincipal Owner [Member]",
        "label": "NonPrincipal Owner [Member]",
        "terseLabel": "NonPrincipal Owner"
       }
      }
     },
     "localname": "NonprincipalOwnerMember",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_NordicMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nordic",
        "label": "Nordic [Member]",
        "terseLabel": "Nordic"
       }
      }
     },
     "localname": "NordicMember",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_NumeratorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Numerator.",
        "label": "Numerator [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "localname": "NumeratorAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_OmeclamoxPakMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Omeclamox-Pak [Member]",
        "label": "Omeclamox-Pak [Member]",
        "terseLabel": "Omeclamox-Pak",
        "verboseLabel": "Omeclamox-Pak"
       }
      }
     },
     "localname": "OmeclamoxPakMember",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_OtherRevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Revenues [Abstract]",
        "label": "Other Revenues [Abstract]",
        "terseLabel": "Other Revenues"
       }
      }
     },
     "localname": "OtherRevenuesAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_PaymentsForAssetAcquisitions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments for Asset Acquisitions",
        "label": "Payments for Asset Acquisitions",
        "terseLabel": "Payments for asset acquisitions"
       }
      }
     },
     "localname": "PaymentsForAssetAcquisitions",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_PaymentsForContingentConsideration": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments for Contingent Consideration",
        "label": "Payments for Contingent Consideration",
        "terseLabel": "Fair value of contingent consideration - net sales royalty"
       }
      }
     },
     "localname": "PaymentsForContingentConsideration",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_PernixTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pernix Therapeutics [Member]",
        "label": "Pernix Therapeutics [Member]",
        "terseLabel": "Pernix Therapeutics"
       }
      }
     },
     "localname": "PernixTherapeuticsMember",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_PinnacleBankMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pinnacle Bank [Member]",
        "label": "Pinnacle Bank [Member]",
        "terseLabel": "Pinnacle Bank"
       }
      }
     },
     "localname": "PinnacleBankMember",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_PreferredStockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred Stock [Abstract]",
        "label": "Preferred Stock [Abstract]",
        "terseLabel": "Preferred Stock [Abstract]"
       }
      }
     },
     "localname": "PreferredStockAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Prepaids and Other Current Assets, Policy [Policy Text Block]",
        "label": "Prepaids and Other Current Assets, Policy [Policy Text Block]",
        "terseLabel": "Prepaid and Other Current Assets"
       }
      }
     },
     "localname": "PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cpix_ProductAndLicenseRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Product and License Rights [Member]",
        "label": "Product and License Rights [Member]",
        "terseLabel": "Product and License Rights"
       }
      }
     },
     "localname": "ProductAndLicenseRightsMember",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ProductRevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Product Revenues [Abstract]",
        "label": "Product Revenues [Abstract]",
        "terseLabel": "Product Revenues"
       }
      }
     },
     "localname": "ProductRevenuesAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_ProductRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Product Rights [Member]",
        "label": "Product Rights [Member]",
        "verboseLabel": "Product Rights"
       }
      }
     },
     "localname": "ProductRightsMember",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ProductSalesRelatedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Product Sales-Related Liabilities, Current",
        "label": "Product Sales-Related Liabilities, Current",
        "terseLabel": "Rebates, product returns, administrative fees and service fees"
       }
      }
     },
     "localname": "ProductSalesRelatedLiabilitiesCurrent",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_ProductVibativMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Product, Vibativ",
        "label": "Product, Vibativ [Member]",
        "terseLabel": "Vibativ"
       }
      }
     },
     "localname": "ProductVibativMember",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_PropertyAndEquipmentUsefulLifeTextual": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Property and Equipment, useful life (Textual)",
        "label": "Property and Equipment, useful life (Textual)",
        "terseLabel": "Property and equipment, useful life (Textual)"
       }
      }
     },
     "localname": "PropertyAndEquipmentUsefulLifeTextual",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchases of Intangible Assets Incurred But Not Yet Paid",
        "label": "Purchases of Intangible Assets Incurred But Not Yet Paid",
        "terseLabel": "Change in unpaid invoices for purchases of intangibles"
       }
      }
     },
     "localname": "PurchasesOfIntangibleAssetsIncurredButNotYetPaid",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_RevenueRecognitionCumulativeUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognition, Cumulative Upfront Payment",
        "label": "Revenue Recognition, Cumulative Upfront Payment",
        "terseLabel": "Cumulative upfront payment"
       }
      }
     },
     "localname": "RevenueRecognitionCumulativeUpfrontPayment",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_RevenueRecognitionMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognition, Milestone Payments",
        "label": "Revenue Recognition, Milestone Payments",
        "terseLabel": "Milestone payments associated with international agreements"
       }
      }
     },
     "localname": "RevenueRecognitionMilestonePayments",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognition, Potential Upfront Payment Related to Product Sales",
        "label": "Revenue Recognition, Potential Upfront Payment Related to Product Sales",
        "terseLabel": "Other revenue, potential upfront payment related to product sales"
       }
      }
     },
     "localname": "RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognition, Potential Upfront Payments Related to Regulatory Approval",
        "label": "Revenue Recognition, Potential Upfront Payments Related to Regulatory Approval",
        "terseLabel": "Other revenue, potential upfront payments related to regulatory approval"
       }
      }
     },
     "localname": "RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_RevenueRecognitionUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognition, Upfront Payment",
        "label": "Revenue Recognition, Upfront Payment",
        "terseLabel": "Other revenue, upfront payment"
       }
      }
     },
     "localname": "RevenueRecognitionUpfrontPayment",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_SalesRevenueGoodsGrossMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sales Revenue, Goods, Gross [Member] [Member]",
        "label": "Sales Revenue, Goods, Gross [Member]",
        "terseLabel": "Sales Revenue, Goods, Gross"
       }
      }
     },
     "localname": "SalesRevenueGoodsGrossMember",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of Finite-Lived Intangible Assets UseFul Lives [Table Text Block]",
        "label": "Schedule of Finite-Lived Intangible Assets UseFul Lives [Table Text Block]",
        "terseLabel": "Schedule of intangible assets, useful lives"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cpix_ScheduleOfStockOptionActivityAdditionalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of Stock Option Activity, Additional Disclosures [Table Text Block]",
        "label": "Schedule of Stock Option Activity, Additional Disclosures [Table Text Block]",
        "terseLabel": "Schedule of stock options activity, additional disclosures"
       }
      }
     },
     "localname": "ScheduleOfStockOptionActivityAdditionalDisclosuresTableTextBlock",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cpix_ScheduleofDepreciationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of Depreciation Expense [Table Text Block]",
        "label": "Schedule of Depreciation Expense [Table Text Block]",
        "terseLabel": "Schedule of depreciation expense"
       }
      }
     },
     "localname": "ScheduleofDepreciationExpenseTableTextBlock",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of Rent Expense and Sublease Income [Table Text Block]",
        "label": "Schedule of Rent Expense and Sublease Income [Table Text Block]",
        "terseLabel": "Schedule of rent expense and sublease income"
       }
      }
     },
     "localname": "ScheduleofRentExpenseandSubleaseIncomeTableTextBlock",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cpix_SecondAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Second Amendment",
        "label": "Second Amendment [Member]",
        "terseLabel": "Second Amendment"
       }
      }
     },
     "localname": "SecondAmendmentMember",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Plans",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Plans",
        "terseLabel": "Number of equity compensation plans"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Plans Available for Future Grants",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Plans Available for Future Grants",
        "terseLabel": "Number of equity compensation plans available for future grants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price as Percent of Weighted Average Grant Date Fair Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price as Percent of Weighted Average Grant Date Fair Value",
        "terseLabel": "Stock options, exercise price as percent of weighted-average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Net of Shares for Tax Withholding",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Net of Shares for Tax Withholding",
        "terseLabel": "Exercise of options and related tax benefit, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Weighted Average Grant Date Fair Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average fair value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityAdditionalDisclosuresDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation, Charitable Contribution of Shares, Committed Cash Contributions",
        "label": "Share-based Compensation, Charitable Contribution of Shares, Committed Cash Contributions",
        "terseLabel": "Committed cash contributions"
       }
      }
     },
     "localname": "ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_ShareRepurchaseProgramAuthorizedIn2010Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share Repurchase Program Authorized in 2010 [Member]",
        "label": "Share Repurchase Program Authorized in 2010 [Member]",
        "terseLabel": "Share Repurchase Program Authorized in 2010"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAuthorizedIn2010Member",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_SharebasedCompensationCharitableContributionofSharesShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation, Charitable Contribution of Shares, Shares",
        "label": "Share-based Compensation, Charitable Contribution of Shares, Shares",
        "terseLabel": "Charitable contribution of shares, shares"
       }
      }
     },
     "localname": "SharebasedCompensationCharitableContributionofSharesShares",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cpix_SharebasedCompensationFoundationContribution": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation, Foundation Contribution",
        "label": "Share-based Compensation, Foundation Contribution",
        "terseLabel": "Share-based compensation (foundation contribution)"
       }
      }
     },
     "localname": "SharebasedCompensationFoundationContribution",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_SharesRepurchaseActivityTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares Repurchase Activity, Type [Axis]",
        "label": "Shares Repurchase Activity, Type [Axis]",
        "terseLabel": "Shares Repurchase Activity, Type [Axis]"
       }
      }
     },
     "localname": "SharesRepurchaseActivityTypeAxis",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_SharesRepurchaseActivityTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Shares Repurchase Activity, Type [Axis]",
        "label": "Shares Repurchase Activity, Type [Domain]",
        "terseLabel": "Shares Repurchase Activity, Type [Domain]"
       }
      }
     },
     "localname": "SharesRepurchaseActivityTypeDomain",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares Repurchase, All, Except Settlement of Tax Liabilities Related to Exercise of Stock Options [Member]",
        "label": "Shares Repurchase, All, Except Settlement of Tax Liabilities Related to Exercise of Stock Options [Member]",
        "terseLabel": "Shares Repurchase, All, Except Settlement of Tax Liabilities Related to Exercise of Stock Options"
       }
      }
     },
     "localname": "SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period, Gross Proceeds from Initial Public Offering",
        "label": "Stock Issued During Period, Gross Proceeds from Initial Public Offering",
        "terseLabel": "Initial public offering, gross proceeds"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period, New Shares, Underwriting Discounts",
        "label": "Stock Issued During Period, New Shares, Underwriting Discounts",
        "terseLabel": "Initial public offering, underwriting discounts"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodNewSharesUnderwritingDiscounts",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_StockIssuedDuringPeriodPricePerShareNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period, Price Per Share, New Issues",
        "label": "Stock Issued During Period, Price Per Share, New Issues",
        "terseLabel": "Initial public offering, price per share"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodPricePerShareNewIssues",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period, Shelf Registration, Proceeds From Sale of Corporate Securities",
        "label": "Stock Issued During Period, Shelf Registration, Proceeds From Sale of Corporate Securities",
        "terseLabel": "Shelf Registration, sale of corporate securities (up to)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued in Initial Public Offering, Number of Shares Common Stock Received for Preferred Stock Contemporareous With Offering",
        "label": "Stock Issued in Initial Public Offering, Number of Shares Common Stock Received for Preferred Stock Contemporareous With Offering",
        "terseLabel": "Initial public offering, number of shares common stock received in exchange for preferred stock"
       }
      }
     },
     "localname": "StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Subsidiary Investment, Payments For Return Of Capital",
        "label": "Subsidiary Investment, Payments For Return Of Capital",
        "terseLabel": "Exchange for consideration, amount"
       }
      }
     },
     "localname": "SubsidiaryInvestmentPaymentsForReturnOfCapital",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_SubsidiaryInvestmentPurchaseOfShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Subsidiary Investment, Purchase Of Shares",
        "label": "Subsidiary Investment, Purchase Of Shares",
        "terseLabel": "Investment in CET"
       }
      }
     },
     "localname": "SubsidiaryInvestmentPurchaseOfShares",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_TaxCutsandJobsActof2017ChangeinTaxRateDeferredTaxAssetIncomeTaxExpenseBenefit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tax Cuts and Jobs Act of 2017, Change in Tax Rate, Deferred Tax Asset, Income Tax Expense (Benefit)",
        "label": "Tax Cuts and Jobs Act of 2017, Change in Tax Rate, Deferred Tax Asset, Income Tax Expense (Benefit)",
        "terseLabel": "Revaluation of deferred income tax balances for new rates under TCJA"
       }
      }
     },
     "localname": "TaxCutsandJobsActof2017ChangeinTaxRateDeferredTaxAssetIncomeTaxExpenseBenefit",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_TieredRoyaltyPaymentsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tiered Royalty Payments, Percentage",
        "label": "Tiered Royalty Payments, Percentage",
        "terseLabel": "Tiered royalty payments (percentage)"
       }
      }
     },
     "localname": "TieredRoyaltyPaymentsPercentage",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cpix_USTreasuryNotesAndBondsSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "US Treasury Notes And Bonds Securities",
        "label": "US Treasury Notes And Bonds Securities [Member]",
        "terseLabel": "U.S. Treasury notes and bonds"
       }
      }
     },
     "localname": "USTreasuryNotesAndBondsSecuritiesMember",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_VIBATIVMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "VIBATIV",
        "label": "VIBATIV [Member]",
        "terseLabel": "VIBATIV"
       }
      }
     },
     "localname": "VIBATIVMember",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_VaprisolMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vaprisol [Member]",
        "label": "Vaprisol [Member]",
        "verboseLabel": "Vaprisol"
       }
      }
     },
     "localname": "VaprisolMember",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_WarrantsIssuedInConsiderationOf2006CreditFacilityAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Warrants, Issued in Consideration of 2006 Credit Facility Amendment [Member]",
        "label": "Warrants, Issued in Consideration of 2006 Credit Facility Amendment [Member]",
        "terseLabel": "Warrants, Issued in Consideration of 2006 Credit Facility Amendment"
       }
      }
     },
     "localname": "WarrantsIssuedInConsiderationOf2006CreditFacilityAmendmentMember",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityWarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Warrants, Issued in Consideration of 2009 Credit Facility Amendment [Member]",
        "label": "Warrants, Issued in Consideration of 2009 Credit Facility Amendment [Member]",
        "terseLabel": "Warrants, Issued in Consideration of 2009 Credit Facility Amendment"
       }
      }
     },
     "localname": "WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember",
     "nsuri": "http://www.cumberlandpharma.com/20201210",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityWarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description",
        "terseLabel": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r572"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r78",
      "r131",
      "r577"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r149",
      "r154",
      "r239",
      "r364",
      "r365",
      "r366",
      "r397",
      "r398"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (decrease) to financial statements for cumulative-effect adjustment in period of adoption of amendment to accounting standards.",
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r149",
      "r154",
      "r239",
      "r364",
      "r365",
      "r366",
      "r397",
      "r398"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.",
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r149",
      "r154",
      "r239",
      "r364",
      "r365",
      "r366",
      "r397",
      "r398"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.",
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Person serving on board of directors.",
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r225",
      "r304",
      "r307",
      "r545"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name or description of a single external customer or a group of external customers.",
        "label": "Customer [Axis]",
        "terseLabel": "Major Customers [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r329",
      "r331",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r542",
      "r546"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails",
      "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r329",
      "r331",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r542",
      "r546"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails",
      "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r225",
      "r304",
      "r307",
      "r545"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Single external customer or group of external customers.",
        "label": "Customer [Domain]",
        "terseLabel": "Name of Major Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.",
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.",
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r222",
      "r304",
      "r305",
      "r506",
      "r541",
      "r543"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r222",
      "r304",
      "r305",
      "r506",
      "r541",
      "r543"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r309",
      "r329",
      "r331",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r542",
      "r546"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails",
      "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r309",
      "r329",
      "r331",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r542",
      "r546"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails",
      "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": {
     "auth_ref": [
      "r144",
      "r576"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]",
        "terseLabel": "Valuation and Qualifying Accounts"
       }
      }
     },
     "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccounts"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r223",
      "r224",
      "r304",
      "r306",
      "r544",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Geographical area.",
        "label": "Geographical [Domain]",
        "verboseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r223",
      "r224",
      "r304",
      "r306",
      "r544",
      "r553",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r574",
      "r575"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by geographical components.",
        "label": "Geographical [Axis]",
        "verboseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r226",
      "r489"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual with Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r144",
      "r576"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer), including liabilities for compensation costs, fringe benefits other than pension and postretirement obligations, rent, contractual rights and obligations, and statutory obligations.",
        "label": "Accounts Payable and Accrued Liabilities, Noncurrent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r26",
      "r42",
      "r227",
      "r228"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable, net of allowances"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Other current liabilities",
        "totalLabel": "Total other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r58",
      "r261"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Acquired Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net income (loss) to net cash flows provided by (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising Costs"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r372"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising costs"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AirlineProductsAndServicesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of each product and service or each group of similar products and services of an entity by various financial or nonfinancial attributes.",
        "label": "Products and Services [Table]",
        "terseLabel": "Revenue from External Customers by Products and Services [Table]"
       }
      }
     },
     "localname": "AirlineProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForCreditLossMember": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Allowance for credit loss from right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "SEC Schedule, 12-09, Allowance, Credit Loss [Member]",
        "terseLabel": "Allowance for uncollectible amounts, cash discounts, chargebacks, and credits issued for damaged products:"
       }
      }
     },
     "localname": "AllowanceForCreditLossMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r47",
      "r233",
      "r240"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, allowances, current"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r94",
      "r116",
      "r476"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "verboseLabel": "Noncash interest expense"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r116",
      "r249",
      "r254"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization",
        "verboseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Anti-dilutive shares (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]",
        "verboseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r129",
      "r205",
      "r214",
      "r220",
      "r238",
      "r439",
      "r447",
      "r466",
      "r510",
      "r527"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r28",
      "r29",
      "r77",
      "r129",
      "r238",
      "r439",
      "r447",
      "r466"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r17",
      "r21",
      "r259",
      "r263"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current",
        "terseLabel": "Disposal Group, Including Discontinued Operation, Assets, Current",
        "totalLabel": "Current assets associated with discontinued operations"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r336",
      "r362"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r328",
      "r330"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r328",
      "r330",
      "r411",
      "r412"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r421",
      "r422",
      "r425"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "totalLabel": "Total consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "auth_ref": [
      "r419",
      "r421",
      "r422",
      "r427"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "terseLabel": "Liabilities incurred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1": {
     "auth_ref": [
      "r115",
      "r429"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of right to a contingent consideration asset.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset",
        "negatedLabel": "Decrease in non-cash contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r115",
      "r429"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Change in fair value of contingent consideration included in operating expenses"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r420",
      "r423",
      "r428"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "periodEndLabel": "Balance at December 31, 2018",
        "periodStartLabel": "Balance at November 12, 2018",
        "terseLabel": "Liability to be paid"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r420",
      "r424"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Current portion of accrued contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r420",
      "r424"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Noncurrent portion of accrued contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Omeclamox\u00ae-Pak, RediTrex\u00ae and Vibativ\u00ae"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativ"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "auth_ref": [
      "r414"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "totalLabel": "Total assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r413",
      "r414"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails": {
       "order": 1.0,
       "parentTag": "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Intellectual property amortizable intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "auth_ref": [
      "r413",
      "r414"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of inventory recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r24",
      "r55",
      "r118"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r33",
      "r119",
      "r125"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r111",
      "r118",
      "r124"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "periodStartLabel": "Cash and cash equivalents, beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r111",
      "r467"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "verboseLabel": "Noncash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r14",
      "r111"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "terseLabel": "Discontinued operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r127",
      "r129",
      "r162",
      "r166",
      "r167",
      "r169",
      "r171",
      "r182",
      "r183",
      "r184",
      "r238",
      "r466"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfTreasuryStockTable": {
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r292"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Class of Treasury Stock [Table]",
        "terseLabel": "Class of Treasury Stock [Table]"
       }
      }
     },
     "localname": "ClassOfTreasuryStockTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r293",
      "r333"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityWarrantsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityWarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrants, exercise price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityWarrantsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityWarrantsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants, number of shares called by warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityWarrantsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r293",
      "r333"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityWarrantsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaborative Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r70",
      "r271",
      "r515",
      "r532"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r272"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r146",
      "r147"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNoParValue": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount per share of no-par value common stock.",
        "label": "Common Stock, No Par Value",
        "verboseLabel": "Common stock, no par value (dollars per share)"
       }
      }
     },
     "localname": "CommonStockNoParValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, number of shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, number of shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r41",
      "r280"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Equity, common shares outstanding",
        "periodStartLabel": "Equity, common shares outstanding",
        "verboseLabel": "Common stock, number of shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "verboseLabel": "Common stock \u2013 no par value; 100,000,000 shares authorized; 15,263,555 and 15,481,497 shares issued and outstanding as of December\u00a031, 2019 and 2018, respectively"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r81",
      "r83",
      "r84",
      "r92",
      "r521",
      "r538"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r81",
      "r83",
      "r91",
      "r435",
      "r451",
      "r520",
      "r537"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive income (loss) attributable to common shareholders"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r191",
      "r192",
      "r225",
      "r463",
      "r464"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r191",
      "r192",
      "r225",
      "r463",
      "r464",
      "r552"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r191",
      "r192",
      "r225",
      "r463",
      "r464",
      "r552"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.",
        "label": "Concentration Risk Disclosure [Text Block]",
        "terseLabel": "Market Concentrations"
       }
      }
     },
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r191",
      "r192",
      "r225",
      "r463",
      "r464"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r189",
      "r191",
      "r192",
      "r193",
      "r463",
      "r465"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r191",
      "r192",
      "r225",
      "r463",
      "r464"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset": {
     "auth_ref": [
      "r122"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of beneficial interest received as consideration for transferring noncash financial asset. Includes, but is not limited to, trade receivable in securitization transaction.",
        "label": "Consideration Received for Beneficial Interest Obtained for Transferring Financial Asset",
        "terseLabel": "Financial consideration"
       }
      }
     },
     "localname": "ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r125",
      "r441"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r96",
      "r506"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "verboseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r130",
      "r393",
      "r401"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "negatedTerseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r130",
      "r393",
      "r401",
      "r403"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "negatedTotalLabel": "Total current income tax (expense) benefit"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r130",
      "r393",
      "r401"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "negatedTerseLabel": "State and other"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r190",
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r36",
      "r37",
      "r38",
      "r511",
      "r512",
      "r526"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredCompensationLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred Compensation Liability [Abstract]",
        "terseLabel": "Deferred Compensation Arrangements [Abstract]"
       }
      }
     },
     "localname": "DeferredCompensationLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).",
        "label": "Deferred Compensation Liability, Classified, Noncurrent",
        "terseLabel": "Deferred compensation"
       }
      }
     },
     "localname": "DeferredCompensationLiabilityClassifiedNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements. Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.",
        "label": "Deferred Compensation Liability, Current and Noncurrent",
        "terseLabel": "Deferred compensation liability"
       }
      }
     },
     "localname": "DeferredCompensationLiabilityCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationPlanAssets": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of assets held under deferred compensation agreements.",
        "label": "Deferred Compensation Plan Assets",
        "terseLabel": "Deferred compensation assets"
       }
      }
     },
     "localname": "DeferredCompensationPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r130",
      "r394",
      "r401"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredOtherTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r376",
      "r377"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r116",
      "r130",
      "r394",
      "r401",
      "r402",
      "r403"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred tax expense"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredOtherTaxExpenseBenefit": {
     "auth_ref": [
      "r134",
      "r395",
      "r400"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of other deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. For example, but not limited to, acquisition-date income tax benefits or expenses recognized from changes in the acquirer's valuation allowance for its previously existing deferred tax assets resulting from a business combination and adjustments to beginning-of-year balance of a valuation allowance because of a change in circumstance causing a change in judgment about the realizability of the related deferred tax asset in future periods.",
        "label": "Deferred Other Tax Expense (Benefit)",
        "negatedTotalLabel": "Deferred income tax (expense) benefit"
       }
      }
     },
     "localname": "DeferredOtherTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r130",
      "r394",
      "r401"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredOtherTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "negatedTerseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r384"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "order": 1.0,
       "parentTag": "cpix_NetDeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred Tax Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "auth_ref": [
      "r391",
      "r392"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.",
        "label": "Deferred Tax Assets, Inventory",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "DeferredTaxAssetsInventory",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r386"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r391",
      "r392"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Cumulative compensation costs incurred on deductible equity awards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": {
     "auth_ref": [
      "r391",
      "r392"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the allowance for doubtful accounts.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts",
        "terseLabel": "Allowance for accounts receivable"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r385"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Less: deferred tax asset valuation allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred Tax Liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r391",
      "r392"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "order": 2.0,
       "parentTag": "cpix_NetDeferredTaxAssetsGross",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedTerseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Defined contribution plan, employer discretionary contribution amount"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r116",
      "r203"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r263"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r259",
      "r263"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": {
     "auth_ref": [
      "r13",
      "r21"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold",
        "terseLabel": "Costs of products sold"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense",
        "terseLabel": "Selling, Marketing and other"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r259",
      "r263"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Inventory, Current",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)",
        "totalLabel": "Income from discontinued operations"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r259",
      "r263"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r259",
      "r263"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current",
        "terseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "auth_ref": [
      "r13",
      "r21"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r22",
      "r267"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DiscontinuedOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings per share attributable to common shareholders",
        "verboseLabel": "Earnings (loss) per share attributable to common shareholders:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss",
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r93",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r160",
      "r162",
      "r169",
      "r170",
      "r171",
      "r175",
      "r176",
      "r522",
      "r539"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Basic (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss",
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r93",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r162",
      "r169",
      "r170",
      "r171",
      "r175",
      "r176",
      "r522",
      "r539"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Diluted (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss",
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r125",
      "r172",
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings (Loss) Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r177"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings (loss) per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r379"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Net income tax expense"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r379",
      "r404"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal tax expense at statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r379",
      "r404"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "auth_ref": [
      "r379",
      "r404"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "terseLabel": "Other permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r379",
      "r404"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r379",
      "r404"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State income tax expense (net of federal income tax benefit)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r379",
      "r404"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "negatedTerseLabel": "Permanent differences associated with general business credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent": {
     "auth_ref": [
      "r379"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to Tax Cuts and Jobs Act.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Percent",
        "verboseLabel": "Change in tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee wages and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r361"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost related to share-based payments"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation cost related to share-based payments, period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue from External Customer [Line Items]",
        "terseLabel": "Revenue from External Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityClassOfTreasuryStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Equity, Class of Treasury Stock [Line Items]",
        "terseLabel": "Equity, Class of Treasury Stock [Line Items]"
       }
      }
     },
     "localname": "EquityClassOfTreasuryStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r151",
      "r157",
      "r159",
      "r181",
      "r239",
      "r280",
      "r287",
      "r364",
      "r365",
      "r366",
      "r397",
      "r398",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r547",
      "r548",
      "r549"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities": {
     "auth_ref": [
      "r369"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.",
        "label": "Excess Tax Benefit from Share-based Compensation, Operating Activities",
        "negatedLabel": "Excess tax (benefit) expense derived from exercise of stock options"
       }
      }
     },
     "localname": "ExcessTaxBenefitFromShareBasedCompensationOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r454",
      "r455",
      "r456",
      "r460"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r454",
      "r455",
      "r456",
      "r459",
      "r460"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Schedule of fair value of financial instruments by level in hierarchy"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Fair Value by Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r454",
      "r460"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r310",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r324",
      "r455",
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/FairValueofFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r310",
      "r312",
      "r317",
      "r324",
      "r455",
      "r493"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r310",
      "r312",
      "r317",
      "r324",
      "r455",
      "r494"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r310",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r324",
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r125",
      "r461",
      "r462"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r253"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedTerseLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r255"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r255"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r255"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r255"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r250",
      "r251",
      "r253",
      "r256",
      "r507",
      "r508"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r253",
      "r508"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Intangible assets, gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r250",
      "r252"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r253",
      "r507"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Intangible assets, net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r246",
      "r247",
      "r509"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails": {
       "order": 2.0,
       "parentTag": "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillPeriodIncreaseDecrease": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Period Increase (Decrease)",
        "terseLabel": "Increase in goodwill"
       }
      }
     },
     "localname": "GoodwillPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]",
        "terseLabel": "Grant"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r125",
      "r258",
      "r266"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r133",
      "r205",
      "r213",
      "r216",
      "r219",
      "r221"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (loss) before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r129",
      "r150",
      "r205",
      "r213",
      "r216",
      "r219",
      "r221",
      "r238",
      "r435",
      "r466"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss) from continuing operations",
        "totalLabel": "Net income (loss) from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails",
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r86",
      "r93",
      "r150",
      "r152",
      "r153",
      "r154",
      "r155",
      "r162",
      "r169",
      "r170",
      "r517",
      "r518",
      "r522",
      "r533"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Earnings (loss) per share attributable to common shareholders-Continuing operations-basic (in USD per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss",
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r86",
      "r93",
      "r150",
      "r152",
      "r153",
      "r154",
      "r155",
      "r162",
      "r169",
      "r170",
      "r171",
      "r522",
      "r533",
      "r536",
      "r539"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Earnings (loss) per share attributable to common shareholders-Continuing operations-diluted (in USD per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss",
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r18",
      "r21",
      "r407",
      "r534"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Discontinued operations net of tax",
        "verboseLabel": "Net income (loss) from discontinued operations"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails",
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "auth_ref": [
      "r89",
      "r93",
      "r166",
      "r169",
      "r170",
      "r522",
      "r534",
      "r536",
      "r539"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "terseLabel": "Earnings (loss) per share attributable to common shareholders-Discontinued operations-basic (in USD per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss",
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "auth_ref": [
      "r166",
      "r169",
      "r170",
      "r452"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "terseLabel": "Earnings (loss) per share attributable to common shareholders-Discontinued operations-diluted (in USD per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss",
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r380",
      "r382",
      "r388",
      "r399",
      "r405",
      "r408",
      "r409",
      "r410"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r130",
      "r158",
      "r159",
      "r204",
      "r378",
      "r400",
      "r406",
      "r540"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      },
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax (expense) benefit",
        "negatedTotalLabel": "Total income tax (expense) benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss",
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r85",
      "r125",
      "r374",
      "r375",
      "r382",
      "r383",
      "r387",
      "r396",
      "r554"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r120"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Accounts payable and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Net changes in assets and liabilities affecting operating activities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Prepaid, other current assets and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Shareholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r171"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Dilutive effect of restricted stock and stock options (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r125",
      "r252",
      "r503",
      "r504",
      "r505",
      "r507"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r87",
      "r202",
      "r475",
      "r476",
      "r523"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r109",
      "r112",
      "r120"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r48",
      "r244"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods",
        "verboseLabel": "Finished goods, net of reserve"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Total inventories"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r25",
      "r74"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Total inventories",
        "verboseLabel": "Inventories, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "negatedLabel": "less non-current inventories",
        "terseLabel": "Non-current inventories"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r32",
      "r75",
      "r125",
      "r178",
      "r241",
      "r242",
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r49",
      "r244"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "verboseLabel": "Raw materials and work in process"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r74",
      "r144",
      "r243"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "terseLabel": "Inventory reserves, obsolescence and discontinuance"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r98",
      "r201"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "verboseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofRentExpenseandSubleaseIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeasesOfLesseeDisclosureTextBlock": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.",
        "label": "Leases of Lessee Disclosure [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LeasesOfLesseeDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of operating lease liability maturities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r487"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r487"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "After 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r487"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r487"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r487"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r487"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r487"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r62",
      "r129",
      "r215",
      "r238",
      "r440",
      "r447",
      "r448",
      "r466"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r46",
      "r129",
      "r238",
      "r466",
      "r514",
      "r530"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r66",
      "r129",
      "r238",
      "r440",
      "r447",
      "r448",
      "r466"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r17",
      "r21",
      "r259",
      "r263"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current",
        "terseLabel": "Disposal Group, Including Discontinued Operation, Liabilities, Current",
        "totalLabel": "Current liabilities associated with discontinued operations"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licensing Rights"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r61",
      "r132"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of credit, maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r61",
      "r132"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.",
        "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "terseLabel": "Line of credit, unused capacity, commitment fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermLineOfCredit": {
     "auth_ref": [
      "r68",
      "r274",
      "r275"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit, Noncurrent",
        "verboseLabel": "Revolving line of credit"
       }
      }
     },
     "localname": "LongTermLineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ManufacturedProductOtherMember": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by labor or machinery, classified as other.",
        "label": "Manufactured Product, Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ManufacturedProductOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r27",
      "r63"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r73",
      "r129",
      "r238",
      "r466",
      "r513",
      "r529"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromRedemptions": {
     "auth_ref": [
      "r287",
      "r437",
      "r438"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).",
        "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests",
        "negatedLabel": "Repurchase of subsidiary shares to noncontrolling interest",
        "negatedTerseLabel": "Repurchase of subsidiary shares from noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromRedemptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Noncontrolling interest, ownership percentage by parent"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MunicipalBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.",
        "label": "Municipal Bonds [Member]",
        "verboseLabel": "Short-term cash investments"
       }
      }
     },
     "localname": "MunicipalBondsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r111",
      "r114",
      "r117"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": {
     "auth_ref": [
      "r111",
      "r114",
      "r117"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "totalLabel": "Net cash (used in) operating activities from continuing operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r21",
      "r79",
      "r82",
      "r90",
      "r117",
      "r129",
      "r150",
      "r152",
      "r153",
      "r154",
      "r155",
      "r158",
      "r159",
      "r168",
      "r205",
      "r213",
      "r216",
      "r219",
      "r221",
      "r238",
      "r466",
      "r519",
      "r535"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net income (loss) attributable to common shareholders",
        "verboseLabel": "Net income (loss) attributable to common shareholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails",
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r79",
      "r82",
      "r158",
      "r159",
      "r443",
      "r450"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Net loss at subsidiary attributable to noncontrolling interests",
        "negatedTerseLabel": "Net loss at subsidiary allocated to noncontrolling interests",
        "terseLabel": "Net loss at subsidiary attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails",
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Guidance"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Non-US"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r121",
      "r122",
      "r123"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Intangible Assets Acquired",
        "terseLabel": "Additions to intangible assets from final purchase price allocation"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1": {
     "auth_ref": [
      "r121",
      "r122",
      "r123"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities, classified as other, assumed in acquiring a business or in consideration for an asset received in a noncash or part noncash acquisition.",
        "label": "Noncash or Part Noncash Acquisition, Other Liabilities Assumed",
        "terseLabel": "Non cash increase in liabilities related to acquisition (see Note 3)"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Noncontrolling Interest [Abstract]",
        "terseLabel": "Noncontrolling Interest [Abstract]"
       }
      }
     },
     "localname": "NoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest": {
     "auth_ref": [
      "r288",
      "r437",
      "r445"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from sale of a portion of the parent's controlling interest.",
        "label": "Noncontrolling Interest, Increase from Sale of Parent Equity Interest",
        "terseLabel": "Exercise of options and related tax benefit"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": {
     "auth_ref": [
      "r288",
      "r437",
      "r445"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance",
        "terseLabel": "Sale of subsidiary shares to noncontrolling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r287",
      "r433"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "verboseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office Equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r205",
      "r213",
      "r216",
      "r219",
      "r221"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Operating income (loss)",
        "totalLabel": "Operating income (loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss",
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Operating Lease Liabilities, Payments Due [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r483"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r483"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease current liabilities",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r483"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating Lease, Liability, Noncurrent",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r482"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "verboseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails",
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r486",
      "r488"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average incremental borrowing rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r485",
      "r488"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Operating Leased Assets [Line Items]"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r477",
      "r478"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases, Future Minimum Payments Due",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r477",
      "r478"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months",
        "terseLabel": "2019"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals": {
     "auth_ref": [
      "r479"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractually required future rental payments receivable on noncancelable subleasing arrangements.",
        "label": "Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals",
        "terseLabel": "Future minimum sublease income under noncancelable operating subleases"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofRentExpenseandSubleaseIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": {
     "auth_ref": [
      "r477",
      "r478"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Five Years",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r477",
      "r478"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Four Years",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r477",
      "r478"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Three Years",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r477",
      "r478"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Two Years",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": {
     "auth_ref": [
      "r477",
      "r478"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due Thereafter",
        "terseLabel": "After 2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesRentExpenseSubleaseRentals1": {
     "auth_ref": [
      "r477"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of sublease rental income recognized during the period that reduces the entity's rent expense incurred under operating leases.",
        "label": "Operating Leases, Rent Expense, Sublease Rentals",
        "terseLabel": "Sublease income"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenseSubleaseRentals1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofRentExpenseandSubleaseIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r389"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r23",
      "r453"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Organization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r80",
      "r83",
      "r435",
      "r436",
      "r446"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Net loss at subsidiary attributable to noncontrolling interests"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross amount of inventory owned by the entity but in the hands of a customer, typically a reseller.",
        "label": "Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross",
        "terseLabel": "Consigned inventory"
       }
      }
     },
     "localname": "OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r30",
      "r31",
      "r64"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Liabilities, Current [Abstract]"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for other liabilities.",
        "label": "Other Liabilities Disclosure [Text Block]",
        "terseLabel": "Other Current and Other Long-term Liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "totalLabel": "Other Liabilities, Noncurrent, Total",
        "verboseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Table Text Block]",
        "terseLabel": "Schedule of other long-term liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherNonoperatingGainsLosses": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Gains (Losses)",
        "negatedTerseLabel": "Noncash investment gains"
       }
      }
     },
     "localname": "OtherNonoperatingGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPaymentsToAcquireBusinesses": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.",
        "label": "Other Payments to Acquire Businesses",
        "terseLabel": "Cash payment during early 2019",
        "verboseLabel": "Additional payments to acquire businesses"
       }
      }
     },
     "localname": "OtherPaymentsToAcquireBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]",
        "terseLabel": "Patents"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedLabel": "Cash payments of contingent consideration"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of common shares"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRoyalties": {
     "auth_ref": [
      "r113"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid for royalties during the current period.",
        "label": "Payments for Royalties",
        "terseLabel": "Cash payment of royalty during the period"
       }
      }
     },
     "localname": "PaymentsForRoyalties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "negatedLabel": "Payments of financing costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedTerseLabel": "Payments of deferred equity offering costs",
        "terseLabel": "Initial public offering, issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r101",
      "r426"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      },
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "negatedLabel": "Cash paid for acquisition",
        "terseLabel": "Cash paid at closing",
        "verboseLabel": "Payments to acquire businesses"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Additions to intangible assets",
        "terseLabel": "Additions to intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates": {
     "auth_ref": [
      "r101"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).",
        "label": "Payments to Acquire Interest in Subsidiaries and Affiliates",
        "terseLabel": "Payments to acquire interest in subsidiaries"
       }
      }
     },
     "localname": "PaymentsToAcquireInterestInSubsidiariesAndAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r237"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Additions to property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r309",
      "r311",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r332"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EmployeeBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r336",
      "r362"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r28",
      "r53",
      "r54"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "verboseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrincipalOwnerMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Owner of record or known beneficial owner of more than 10 percent of the voting interests of the entity.",
        "label": "Principal Owner [Member]",
        "terseLabel": "Principal Owner"
       }
      }
     },
     "localname": "PrincipalOwnerMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r103"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Initial public offering, net proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMinorityShareholders": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.",
        "label": "Proceeds from Noncontrolling Interests",
        "terseLabel": "Sale of subsidiary shares to noncontrolling interest"
       }
      }
     },
     "localname": "ProceedsFromMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r135"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).",
        "label": "Proceeds from (Repayments of) Lines of Credit",
        "verboseLabel": "Borrowings on line of credit"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale of Short-term Investments",
        "terseLabel": "Proceeds from sale of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r103",
      "r363"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Sales of shares of common stock, net of offering costs"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductionAndDistributionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense related to the production and distribution of goods or services to customers and clients.",
        "label": "Production and Distribution Costs",
        "terseLabel": "Distribution costs"
       }
      }
     },
     "localname": "ProductionAndDistributionCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r21",
      "r79",
      "r82",
      "r110",
      "r129",
      "r150",
      "r158",
      "r159",
      "r205",
      "r213",
      "r216",
      "r219",
      "r221",
      "r238",
      "r435",
      "r442",
      "r444",
      "r450",
      "r451",
      "r466",
      "r524"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r58",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r267",
      "r555",
      "r556",
      "r557"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r57",
      "r260"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r34",
      "r35",
      "r262",
      "r531"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Total property and equipment, net",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r56",
      "r125",
      "r262",
      "r555",
      "r556"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r34",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r34",
      "r260"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment, useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Quarterly Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "Quarterly Financial Information [Text Block]",
        "terseLabel": "Quarterly Financial Information (Unaudited)"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnaudited"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedTerseLabel": "Repayments on line of credit"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r373",
      "r567"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r125",
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r43",
      "r287",
      "r367",
      "r528",
      "r550",
      "r551"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r151",
      "r157",
      "r159",
      "r239",
      "r364",
      "r365",
      "r366",
      "r397",
      "r398",
      "r547",
      "r549"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r199",
      "r200",
      "r212",
      "r217",
      "r218",
      "r222",
      "r223",
      "r225",
      "r303",
      "r304",
      "r506"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues",
        "verboseLabel": "Revenue from Contract with Customer, Excluding Assessed Tax"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r126",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r308"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r88",
      "r129",
      "r199",
      "r200",
      "r212",
      "r217",
      "r218",
      "r222",
      "r223",
      "r225",
      "r238",
      "r466",
      "r524"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Net revenues from customers outside the United States",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss",
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r484",
      "r488"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Recognition of operating lease assets and liabilities through adoption of ASC 842"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Risks and Uncertainties [Abstract]"
       }
      }
     },
     "localname": "RisksAndUncertaintiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockTransactionDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Date the subsidiary or equity investee issued or sold stock, in CCYY-MM-DD format.",
        "label": "Sale of Stock, Transaction Date",
        "terseLabel": "Initial public offering, effective date"
       }
      }
     },
     "localname": "SaleOfStockTransactionDate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of anti-dilutive securities excluded from computation of earnings per share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r411",
      "r412"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r411",
      "r412"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of the components of income tax benefit (expense)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of deferred tax assets and liabilities, net"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r1",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r12",
      "r16",
      "r19",
      "r20",
      "r21",
      "r264",
      "r265"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsandDisposalGroupsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of calculation of numerator and denominator in earnings per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of effective tax rate reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r334",
      "r360",
      "r368"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of share-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table]",
        "verboseLabel": "Revenue from External Customers by Products and Services [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Schedule of net product revenues by product"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r250",
      "r252",
      "r507"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r250",
      "r252"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of intangible assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "terseLabel": "Schedule of future minimum lease payments for operating leases"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r32",
      "r50",
      "r51",
      "r52"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of inventories, current"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]",
        "terseLabel": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r58",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule of Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Quarterly Financial Information [Table Text Block]",
        "terseLabel": "Schedule of quarterly financial information"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnauditedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r336",
      "r362"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r343",
      "r354",
      "r357"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of stock options activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of restricted stock activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r71",
      "r127",
      "r182",
      "r183",
      "r277",
      "r278",
      "r279",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of expected amortization expense of intangible assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r189",
      "r191",
      "r192",
      "r193",
      "r463",
      "r465"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of revenues concentration from major customers"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r125",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling and Marketing Expense",
        "verboseLabel": "Selling and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Shares forfeited, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Shares forfeited, weighted-average grant-date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Shares granted, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Shares granted, weighted-average grant-date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Nonvested, end of period, shares",
        "periodStartLabel": "Nonvested, beginning of period, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Nonvested, end of period, weighted-average grant-date fair value",
        "periodStartLabel": "Nonvested, beginning of period, weighted-average grant-date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted- average grant-date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Shares vested, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Shares vested, weighted-average grant-date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares reserved for issuance under equity compensation plans"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "periodEndLabel": "Options, exerciseable, end of period, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Exercisable, end of period, weighted-average exercise price per share (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r356"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityAdditionalDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedTerseLabel": "Options forfeited or expired, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Options forfeited or expired, weighted-average exercise price per share (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r362"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding, end of period, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r345",
      "r362"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, end of period, shares",
        "periodStartLabel": "Outstanding, beginning of period, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, end of period, weighted-average exercise price per share (in USD per share)",
        "periodStartLabel": "Outstanding, beginning of period, weighted-average exercise price per share (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-average exercise price per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r333",
      "r340"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised, weighted-average exercise price per share (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted, weighted-average exercise price per share (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r125",
      "r336",
      "r341"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Payments"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Stock options, expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r362"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable, end of period, aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable, end of period, weighted-average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding, end of period, weighted-average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r342"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Vesting of common stock"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "Vesting of common stock, shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r39",
      "r40",
      "r41",
      "r127",
      "r129",
      "r162",
      "r166",
      "r167",
      "r169",
      "r171",
      "r182",
      "r183",
      "r184",
      "r238",
      "r280",
      "r466"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r72",
      "r146",
      "r147",
      "r148",
      "r151",
      "r157",
      "r159",
      "r181",
      "r239",
      "r280",
      "r287",
      "r364",
      "r365",
      "r366",
      "r397",
      "r398",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r547",
      "r548",
      "r549"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r181",
      "r506"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r40",
      "r41",
      "r287"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Stock issued during period, acquisitions (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r40",
      "r41",
      "r280",
      "r287"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Initial public offering, shares issued",
        "verboseLabel": "Proceeds from the sale of common stock, net of offering costs, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r40",
      "r41",
      "r280",
      "r287"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r40",
      "r41",
      "r280",
      "r287",
      "r347"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Options exercised, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r72",
      "r280",
      "r287"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Stock issued during period, acquisitions"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r40",
      "r41",
      "r280",
      "r287"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Proceeds from sale of common stock, net of offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r40",
      "r41",
      "r287",
      "r335",
      "r355"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation, amount",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r72",
      "r280",
      "r287"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "verboseLabel": "Exercise of options and related tax benefit"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Share repurchase program, number of shares authorized to be repurchased"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Amount available under current repurchase program"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r40",
      "r41",
      "r280",
      "r287"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedLabel": "Repurchase of common shares, shares",
        "terseLabel": "Repurchase of common shares, shares"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r40",
      "r41",
      "r280",
      "r287"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedLabel": "Repurchase of common shares",
        "terseLabel": "Repurchase of common shares, value"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r41",
      "r44",
      "r45",
      "r129",
      "r235",
      "r238",
      "r466"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Shareholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r129",
      "r146",
      "r147",
      "r148",
      "r151",
      "r157",
      "r238",
      "r239",
      "r287",
      "r364",
      "r365",
      "r366",
      "r397",
      "r398",
      "r433",
      "r434",
      "r449",
      "r466",
      "r468",
      "r469",
      "r473",
      "r548",
      "r549"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Equity, balance",
        "periodStartLabel": "Equity, balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r128",
      "r287",
      "r294"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r474",
      "r491"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionNarrativeDetails",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r474",
      "r491"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionNarrativeDetails",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r474",
      "r491"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionNarrativeDetails",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r490",
      "r492"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Summary of Operating Loss Carryforwards [Table Text Block]",
        "terseLabel": "Schedule of federal and state net operating loss carryforwards"
       }
      }
     },
     "localname": "SummaryOfOperatingLossCarryforwardsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "verboseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r396"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income tax expense (benefit) from effect of Tax Cuts and Jobs Act.",
        "label": "Tax Cuts and Jobs Act, Income Tax Expense (Benefit)",
        "verboseLabel": "Net tax benefit, impact of Tax Act"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Text Block [Abstract]"
       }
      }
     },
     "localname": "TextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r229",
      "r230",
      "r231",
      "r232",
      "r234",
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TrademarksMember": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "Trademarks [Member]",
        "terseLabel": "Trademarks"
       }
      }
     },
     "localname": "TrademarksMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradingSecurities": {
     "auth_ref": [
      "r516"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI",
        "terseLabel": "Fair value of marketable securities"
       }
      }
     },
     "localname": "TradingSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]",
        "verboseLabel": "Collaborative Arrangements and Non-collaborative Arrangements [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r188",
      "r194",
      "r195",
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation allowance of deferred tax asset attributable to deductible temporary difference and carryforward.",
        "label": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]",
        "terseLabel": "Valuation allowance for deferred tax assets:"
       }
      }
     },
     "localname": "ValuationAllowanceOfDeferredTaxAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r136",
      "r142"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
     "auth_ref": [
      "r139"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense",
        "terseLabel": "Charged to costs and expenses"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts": {
     "auth_ref": [
      "r140"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account",
        "terseLabel": "Charged to other accounts"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToOtherAccounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r141"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "negatedTerseLabel": "Deductions"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r141",
      "r142"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease)",
        "terseLabel": "Increase in valuation allowance during the year"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r141",
      "r142"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r161",
      "r171"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted-average shares outstanding \u2013 diluted (in shares)",
        "verboseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "Weighted-average common shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r160",
      "r171"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares outstanding \u2013 basic (in shares)",
        "verboseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(ColumnA))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=121640914&loc=d3e1280-108306"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "http://asc.fasb.org/topic&trid=2126967"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e4975-111524"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953423-111524"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5212-111524"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5093-111524"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2473-110228"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1314-112600"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1336-112600"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11374-113907"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5419-128473"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569655-111683"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4616395-111683"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.E)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL7498348-110258"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "840",
   "URI": "http://asc.fasb.org/topic&trid=2208923"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62652-112803"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r568": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r569": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r571": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r572": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r573": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r574": {
   "Footnote": "2",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r575": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "29"
  },
  "r576": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "09"
  },
  "r577": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(m)",
   "Publisher": "SEC",
   "Section": "4",
   "Subparagraph": "(1)(iii)",
   "Subsection": "08"
  },
  "r578": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868656-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7,9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>106
<FILENAME>0001628280-20-017370-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-20-017370-xbrl.zip
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MQ+< 1".JB8'W$,$9U489H'JE1*(Y[0*J :(Z@*P5( =/%@"1DC"F5.A301)
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M=T\T>O?O 7*CO\;FC9X^'^WSY[NO/QZ\.<C@W1_V#_]D!R3=<W1Z< CWOP&
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M@A.2,MFY-JC.YV=1@/F!B\2\/U]WTV+57DFF6Z+*Q2X"X[K?^LPN A/X.'_
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M29ME&2K0Y+YYGQ=/AJ8LEU0YVQ_B978TJ+;2P[%::N%).K$@;0O(C.(^:LF
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M%Z9K,2AD%2X*LS$=0Q]2"KA$QGIF&(<N35F4G)1YSX9IRUV4.^S9,+U;[X1
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M[85GS&@3&(M,<8<11X$HZ8W"W<![AY/9#J<1"\FI]90R:Z@E 6F%/ 2$1K%
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M/X^[(88"5'=H3NO%_FV)/+!TDA@A;6"218]LE(&;$+UD))WNN,61QYK4N/Y
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M4P3+G\O>;E:Z:9F&77IF['N/QV9X5F9E+X]+Q/(D'_NLFI=Y&<KIL*J+/(?
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MW$]=52880#V>3(NB2<9I4G3&O6> H9[J_ZOWTZPI\Q]F[:FK;T."5LR&\'A
M0A&<*:ME4%V)RAV0109J-\,:6FXX3=4#RP1I]< FQN!^7JX)1E"5A*XD@S/
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MS[=2[VOBH&:70^CM7-56\?76*;\YB2:<SJGFG$@;9G\]SA:3 #5XY^B_#Y?
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M^/(U*;[MSB]5%L-CN6I)9?5]S:^WI<,FU%7J]M252=&:NE)\.W6]GA7<TGS
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M!=_*V:3?G0G5GFF.+=CEBJ@=@MM__& 'NE:!3NYHJCO0=:"[P[8QOL,ZINM
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M8@%V[^FI&YCQ48!^;33*:K:_WWOLH/M,%1B>I=H<A[)^=6J1,],DD(9[4[L
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MM&7J$6K:-]7"[4OZ KMNE#E3V5$8P_M=[QB44P>8%SNISWD0.S-D->"9#[
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MX'QHJ4W):)*J4B:K_(E^P_=21\I422O5Z"=DA]_1K5B2- &)A78DF%7(R85
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M ,HJQY,$M.5T+,(%(T!>LLK3#+2F:W+^TT^;KVE'S)08?IBBWU,XV*J3M!E
MV^+$O[UY?8R+7!;A4.FS62Y$CM=&*&JN'E].XIB597\R@!M-THN"?:>%RTDT
M!/6?(+@;/H0UJ8JT[I!'E<)DF&9I.2XH)O*\=*4LWMA]9!C@T O0_O563)@;
M$BTJ,YI.E)8[CY&#I:W^Y4" !I@4:HVM9-E,^P5KQVUE:;2Q.@&+E67<W54M
ME7()"D?E$82FN&I*,PI7A.457%(>?Q.T.O/+A/5944Q]LQNQ@351^GB(C.Y'
M^X#/$N1M[J3"6M 'B(F%7(F9<&:-K# .1W3('SQ:"DIXBD\ OV+$2^6%-PWL
M=B1+1=:+G!?LXR),&.I]%4M&IHM8@(\3CT=CI;E#21- "; -]*&WTRWLGK&:
M"E@G950!K\7^Q+0&S3QSA)2EYB[1K5-G*DA8-")Y33!6X*BA-[[".)( ZCQ9
M()0O)8S_GJ3E:B;]+M+)V9S1O\_#[!OS*06#6Y>W\[&.O7G&=WO>V9RQQVKK
M;R+1J-H(K*#HO>"G-7;4E"CUTA66S[''<6_SMH;?Z9CBLW(*TQ*G^>%E0)@[
MD $Q?\K(9L$UTW7<E,,,EN)6"['OPD1O-]3EM<?/"'.+"_$Z2XED>)W/A/0Z
M?^YZ>TS-4G"+7"QOST?8.$[/M>XW:V;IH!6SYYCWG?SRY%-ANLW29IU5?SFG
MB&'S@UNW>/:*X7<C=/;@&O=RG$DW".8!D/,ZR#W2")W-PNX>TF?WA_:\?W@A
M^J%7 .Y\@=\CU<3N2\EKA\^[CL^N:IFFZIKW;*#5X7.'S]MT<$O5L7FIN^?H
M_"P.@6=LN,N3-!JUF:L,3EP#>'OZZ ;5]!UH7;HT9_= VBZZJFZXJF\^XPR:
MKC_F:IU#;,.'R^HZSF[[106^ZAM[1$^/J4+L@%18FKR^9STI;577[:[EYZ;
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M"-YA3[FKP\964-92]/V+P<G&DR)#A /@LN_Q8%*FU_ Q/E4B%@)&#ED1 Q+
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M&_@;F WH&=XF-NO<<^3@79L-]F;BX,H-85:<5;<EH\&"NQ1-.5,M6.-,*TR
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M"H(\VAB%T^N1."<C^&MU5?"_*=@#?SAN6Y+R88X,U1Z19CEQAS1]?&9G^![
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M2DSY)<5DP*2/^9+RUY _BLL[KW^/3YQ^Y^F'N(=A6I84<!-+TMFVFE 7*C6
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M.8CPC(I! ,#-XM^$8<BZ5EQ4M*%N&&:'E].O0!Q'^T:8/6'3A%GA)']A*OA
M5"\#_!L\0&3A4M"\$A-1I68V3+,=))-?RE^4WU]_4#Z?'ZO*V[<?=^\$TCF"
M9>N\J*_!$_]1\EO$LO84*0 S.E:^IEUPRVW-/;P+B_B*V^2FSC,W5,H3&=5B
MCHLO8J^-U#+D/2*](VGY"DKZ:E*6W%)]GX_Q HD+5!T.<%F962T] XHA-K!B
M4;%_?P_[P46EWFC&XK#4&O$=SSS:KF"6O47AI)//[WX__?3V^/UKY>/_'']Z
M=WQR^OGB[.3X[;ER]OX$U#;XXOSS[^=GK\^./YV=KM3BYGG.MR!RTA3(OPM_
M]3GYJW?M*'?X1%?M:\ SFJCI;LTDJ"<PI=F.2O9*_N%78(I@U=Z^2C/:#OUH
MSJS7FBYZ.J<-,7%*K"^^[M%74PV+^7>.TPL<8^'7>N^^WWGN_7ZY;+.&WW.-
MG=ELT#,=<R.;M5?]Y9Q^T!*SLAS3_-::5;9P#-V#'IW3 YU3^],T 9_N9CG#
MK?ETAD;XX3"/[S_N\>^!AH\[(_N)93Z!\?C\_+31K&X3$R&[-3:*<7WZ9QLQ
M;O[L@A/1KYO7\[ZZ%^I-G?E>UW78:VR0V?$1(M96XR#F 509'NAFOPX'K2R=
M1R3\=<"WX_-75CKB=H]6^3_I=R2*-[+F% N5/K'^/X\F97)$L0W8/7V0AJ'M
MV9%ONK;3MPVG'X2!;=J6$7G,M +=^^\9ZFB&:1E'2L+B=!@.RG\>Z4?41BT<
MPPK?QZ^RR3#)Q^+K(R4+APS?I5V&X>@5XNEQEN!_3FLD/1Z?B.JG?V-Y%& F
MP([1RMP-8OW[-GJ=7[\U/UU_L=Y-DJ^GU__Y(_CZ8?BOVR_#_UR]O_C\X]WK
M3^E_7O_+^#+\\^K+Q>#K?_[X<O/AKS_3]S_@%^;IC[?6^\&7'Z-O[X9_#K]<
M?#;>_3C6OPS_I;^'9[[\=>I\,3\-W[T>I%^^QN;['^^OWAG^]_<_SJ[_D_UY
M]9\?^8_WYJ>K=Z\_WWQX??7U_>MW^KL_3F\_7+S[\>&O?^G_>9T,WWW]/?UR
M >N=!/J7O_XL_W.16^__.C7@7_/=US/KW<4W_<N/]]^^?$U@3Z?6EZ^G]I>+
M,_/+CR_FNUOQF__[YU4T3 8?OL8&[O'+Q9?;=U_C[Q\N/GU]9WY*WYNX3I*^
MN[BZ>O?U/U_??_WRX__^^-?X7:I_?WMQ.GYW_-_("&+#2QS-,TVFP65Z6F#K
M@99$=N(:.F-^/P)=TU=-PU1=R_D_O[31X[?=G@C=<:?]Y4Z!;@4F=I\U7<>V
M@M /;2?R?=<(X)^8Z<2=_(X[;1MW>G]2<2?/,0,K\?I:XL6A9O=#5PN\?J3I
MMM^W72=BH8'<R5,#RU<#5]\_[O2T1M,.:*[OPN(;$P[;*EMKHS:4N1X8Y\J(
MG6:DCZ+F_6!%G@"CG.:A]7W6R7?"0NXXYUJ<\W-3K_.=T#8MCVE.']@G7)>A
M!7W7!+TN]EF4N/W(28Y^H]PE\]>'LLTES&13;+,CWJW1@CH*?CP*;N@^89#8
MAN%86A#IIF;'@:M%7M '0\TU3"\&CASX1[^!81;HJNL%>TS#G=-.A"IX.E_9
M:'.DXD2]C08OEC'052WDG6:@FW=RR7O]5%WK>S;N..A]..B7I@X4,S=(PCC6
MF,\LS8X\2XOL.-+BR T]P^C[ONT>_>:IOA.HNN[NL?%X\$2\>2VH(^)').*&
M&I0 G;JZ[FG,-0W-=L)0\SW=TA+;<AC3$\LRC:/?7-4&(@Z"/?1/=QZ@*;(_
MRZZ!IO*"VO#?5_WI[,>M47_D?=X"P^PXY5J<,FZJ.V[?<74[[&N&"TH.F(>)
M%IEAH@5Z'R2;#DI08*#!Z'N&:CKV'AN,!T^TFU=W.J)] -$VU!MFQW MGJ]%
M00 VBF^$6I#8@<8\.W99;!F@YAS]%JB>;ZFV:>PQT79>'D[F'PLV"M.DT=4Z
M;B4,=MZ>W59WQ/V>\N&$QUGR 2_YF.ZVLQ?OPU O6X&O(+!99'I:$%K 4/M6
MH(6^XVMZXH6AZ26Q;B5'OYFJYWA@,W9.GSVFY<UK01TM/SXM-Y2C.(H"W0;E
MR ["6+.9;6D^\VTM"A.=A4;?"U Y,M7 <E7=[WP_^^_[:==.X'_R.*5R5NI8
MM*"DO?,0[;;*Q!GJA_YKP/V\# =_ )!'9[+7_^O&I7^0=]YQWP=J4E^/K0_'
M_]4C(TATU]?ZED\A-%,+K5#77",Q6=+7#<,A;<IV0:,R.Y_2'I/Y$X30.C)_
M<B7KZ[&-N4:.'X?](-8\DYF@: 4ZF$^NJ7E] VC>,6RX_*/?+-737=4/O#TF
M\Z?S0EG>-BM:%_D8.]EME>=)=.:@-E$ 1&IEHB H]ISS/I6"U3'3^S#3;TWO
MD\U89%B.I;G]"/2ET.Z#OJ3K&G,#)XA,T[83_^@W1U<-UU)U[[%,UM4H8UN,
MV8[4GUW)ZDC]?J3>K$US$S_474\S$B/2;"\ T\CI1UKD>WH8FX:?^* W.(%J
M&*ZJ6P]6FG:2U ^\U<?[/-.D#I76:4N=/VJWU:4Z^2'/XHZ3WH.3GMZ\O3@;
MOSM';GK\7RL"N6?:IN:Z@0]:4^AH8=^,-<,&MFHEKN69^M%OAJ,ZCJT&@;G'
M]N?!4^]3IBYUU'M_ZOU71;U HB'S#5_KQW&BV0S^+TA\3[,,,TILR^T;?8.H
MU[.QSN+!1?I;3+T'TTMO4>H2QMS&MY2[A$VE1KQ]?%>CMO,JC[S:CX,P&Q]G
MR:F\W2[_<VWN^;VI^^BNW]>#A&F6 [:D[3B8N>0R+;#=,$A"6^_'SM%OGNVI
M7M!E*^TQ#3]%ME)'PX](P[4&I'M&Y+A!J$6&&X+]XD9:&%B&9GE]TS!"%H6)
M!S2,=1>&M<<T?.#>GK-L'&:7J1AGQL9=>=H^:#YO4AQN^#:]9DE]P=R+WO'-
MM?GF;5/W28PHCDV=::ZO6YJM6\!!'3O0')1^_3CR8RS0MW0U,'75ZM*+]IF0
M-Z_^=(3\R(1<*T"F'GM!$L<:7*(.A-QWM<AT;(U%L6,Y3A)Z3@R$;*FNXZAZ
MT#4KVEL7T!]YGMRD@T'G[]EMK4?>8\<6UV.+/YKZ3>SV$V8'KA9&-K!%HQ]I
MON,P+8#[TSU+3_S /OK-]\W'<(MOL5UX\/2Z>>6FH]=[TVNMQMB6:1B^96EF
MQ +-]DU=BR(_T?0X#&-#]^S$1#^.;^\YO1ZX'^<UZ[."QHZ'WSM/SO[H-/)>
MS[(X'[*+\'MG_-V3:^I-+2=P8\=V'$-S?8MIMAGC")'$T0+=]PTC2?I1B$WZ
M#=77N\R=/2;@S2LY'0$_(@'7:D_"0E<W/%/3$Q>KOTQ3\W4WUDP_="+/#X,@
M03/%4TVC2][96\^-J*G,+I4!"TNFT UH>5^;E&Q+"L#VFW]N7@&JKO@MWO G
MW.:'_N>2.\$[%KH>"S6:.I#I6[;.XK[FV%@,$D>)%OA&K"61:02);S(]B*A3
MB:NKCOM@__<6VX[[2<9B4,K^7-.!F_C4I^DA4JVS"K9'JM4]M[J,_OM*,[,I
MS2+3=YB;8!4.TS4[\0+-CW1/,RTW,4*7Z;KK8#L(,_!5SWQP$?,6VP0'3[Z;
M-^H[\GT<\JWM^3",G;X!IKS19ZYF6SHJHZZCF8X;FV$815[ 4!EU+$.U]"X9
MXS&ZN=C!-JL[O)O+YHSX>Q>MK]318?<'+*]^_KT1'$_5M*:3%.M)"JNEZ'E&
MU/>]4 -1#I+"\W4ML!U#TTW=-3W?<$(&BIZAVZIC!ZKI/U;QPLKTL.6SX3N^
M=G!\[:DZ]'1\;6V^5FO 03\R/,\*-".)0C!@0P\T8,_0/"/V=2MQK"A"OF:8
MJAM8JN_Z!\;7UE.0Y2."9!Q::G.J^D;7:-R0!7>0Y!,LUYJ^HFZ7AQ,-]>9*
MA+=GQ[^?O3V[.#L]5X[?OU9.__7Y[.++1@.@W1I=B&).J_M!&D;I@*:JO]IH
MJ*);X[F<1]L]<Z$:.SX*;W&N[7,XD [ EMI/<^GIIJ=_Y-C9=3:]C_ETUNI)
MDS W\,"TU2PG[&NV$X=:9+N6QJRH'SNNZ?I1'X<2!F \.=YC&4];9!]U[&A/
MV='3S8'OV-$#V5&CNMQV7,=DB6:8Z*6.#$,+?/@K8Z'C) S^D\0XV-@T=-6U
M'SPC=?O8T=.:1#N@DD[G*L>SME*7U;7;:ET[5_FMN-C;CI_>BY^VVN[X!NN'
M3(^U?F XFNV&CA;T^X'FQQ8+W;#OAR'P4^RY S>ZQ]DA^TG%]TM5WN)KZOPP
MS9SEQQ)UAYW/OU6B#DR&8L*2M_6-=E+N7E*NU7S%"?MAK(> K([--+MONQH8
M#;X66[$/-]9GCH5MR0U5]VW5[VIR]IF&G\3L[VCXD6BXMOQ=8+$>4+$&-Y-H
M=A)[FN_Y@>8Y7M_1?==CA@DT[*JZ;:NVU_5DV7_3?TY8M!L#O@T\=O-Z4H.Y
M=D."-\^)&TU>SF!_9_\-W,CR7-W2G(!9P(V31//[ 4YMBGW;,3TWT4.L*S$<
M0[6<?9X2?/#$OGF%JB/VIR;V?S6(_5__99YA^%X_ GO)-C2;1:$61)&I6<R,
M^W&DNZ&+O;FI,,!X^%2#+2;V;B3XO)'@6^1_.M1AP4^J<75\]:%*U/%_XWX_
M-J,8U2:P9&W\4VC$@198_< .];#O.AXH4#9H4+IJ6MUT\([@GT_KZ@C^H8K4
M\7^3F,6.'G@:PVD(P*LC#?ARK-ENWW/ 9HH<MP\$[ZF^;JOFPP><["3!'WB>
M_R=VG0^N*9<%OE/ROA(7+$F[;L.[KCOEV>4%*X9O89L?^B=TIQTS78^9MGKL
MN38+8L\)L:U)I-FV9VAAY'N:#__/W- V=#LZ^LWP54?7]WS.\,&3[Q-H0AWY
M/@;YUKJ09?N,13@9RL 6F6'@@-UCF5KL6A%S_=#MFSKH0D2Z>TZ^!U-;NUKV
M;E:U_=HFK])^,]!G2^#M>KS=EYNV6C0Z3A(%8=_20LOP-#LV$BW4'5?S'#OT
M$L\(& LP%J=[KFI[#YZ[L,6)$?M)REW#X?VR\GGR[@"42FT,6F57J;)'@@ZO
MMN$X[23<?26<U1Z>Z)O]?FQI1FPY8.[W#2W20TMC46#TK;[K62S$JC_/\E3+
MW.< ],'3\!,U(>YH^'%HN-&).'%CWTG R \-0[,-.P(:#FS-<S$2RI(PU!DV
M$K",0#7L?:;A+HFDF42R16;^PUIX[C1;?=+\D8Z/KL='[59#EK ?1T:4:'W&
M8K#V/1S-8)D:BV/# CQPHM X^LVQ5-NU5=UZK#J(G6MGV='[UJ2/=/2^-KW7
M>I//F,-,V]3,P,2.)UZ@!0'K:WK<=RS'ZS/3]('>/14N2[7<!Z?:[RJ]'[A3
MZ20?#M/QD&%SOC!+%)X-?\FR>--NI?5ZV"Y&)OF"S2@MW\OT598._GDT+B9L
MFE<U@'><)2=-T'4<:Q6.Y;2]-8X5ZVZB)38H)[87QUID)+H6FGV'Z6&?^>BM
MF>%3^X:=ZXC8#CLWC)T-/X071Z;I@@ -(T.S=<?40H/I6J('05^W71 VYC-@
MYT%&_T__GJ3CV_NU,M[=%M;;LL9A%X^?7X4%N\H'P/I+BK!ZORKL ?CXB +I
M0-?8M#?4=+89'U'*Y_C6//ZF$$(:ORI9KHS^'WOOVM16DF4-_Q4%S\03U1%G
MN_-^J>Z'"'RKX8T"NVQ7]^ OCKS:<H'DD439^->_.X\ "1MW(1#2D<B):0HC
M),XYF6OE7OOJ1KT_W?%I^D>/DLN,N-ZX;%\T]4\G'X8C_#,17Y8-4[R14K8*
M /\I#&V$U1>_W!^/2Q>$\N+P=#*>X#<E\\J-2Z;YTQ32B4^CJ5SDM.D5X[G]
MY6*G-#W\A$\)#\,_T_'9NCVUV^V<N7]G['2SO2Y[[5]E;[V8;8?JK%G(N#RX
MTDZ12N&R"KA="0D@A%<EL36 X4%*94AB'HU+81M+2Y.:+6R775&\.A=K1?$R
M43PW,DRK9!T"6&6?0-"<P$KAP1'KDQ:2QB!V=B5MB#6-NGO#@PZC>'5JH=O6
MV:LT<?C#V$MN-,!+KYEZ&VX!72SHL_/UW OA].3TN#0.>YIR/]0*GT4I]$K'
M3>(DL3)I$(P;$$HY\-X1L#2J)#R)F=N=7=HP8AIN[]S=H,/9/@\>R_=O!U4L
MWP.69^904M'YP(N4\64$D$$L6R<@>9:E(M%*2E'4-%JH!@70%F.Y9N[-9^Z-
M?^A!7;=[Z $G]MR_Y=3JS?-EGP9P*KLNQJY7&D&);*7SU$)RD8+0B8+AHC0W
M%M31*+1EMA6;E+'&Z&6)S8W+[ZFP7Z^156&_!-C/C"HB%2+?6O"4>Q Q<7#:
M*8C1)B:RT3XZA+ULC$#+JJ;U/?1P=:E"PE\:#8^/2\RNC]@?I?&D^J$6?Y0_
MK<*<&N-M_K\=6(!@#_J#X0AI=?]\:2N]+D:O5QI$F1 X#SF!, DU*S4ERRM(
MX%SC]]0'JO/.+M>-8M]72/QM&[1JQ>ZM;:**W35@=Z[B03)OHW<0K4LE?UBB
M(K(..!4Y!HF+EVGIE"D:IM1V@K<ZFN8=3=6I] "=2I>C'5X.1^7Z]B:34=^?
M3LHD[3?#J^9PI=W;T>Z5-E(D\FB-1!N)2@>XN@0,1=I-,MHHHM<BZVG6@Y$-
MD]415:FB(XZH2A4KH8JY&AHJM2/1@_">H,2R 7QP%K3U2@9IJ&2\=5Y)31I)
M[CPX>E.I8G7.*V&[;\9=&=,WB'<QZ_["CKYAQ=]T\7_F^ SC\!3)XG(SW8W
MKWOX:^7O_UI4$RWQ 6W-R;;2%BE[@U@#+G<]LZ[TD-.$4DT)GEF6E3@K9V"-
M22!=DC0;7%%-=G8I$>T8,V:6U8%J>5!:LW.BDFHEU0V4"Y54ETZJ<T.Y!2=1
M) HIN  B<PZ6J0@Y!&:2CM)&C:1*6:,L;XRZ<\'3MI'J(E+A[ZV@Q?_&_I^[
M_\0O%^\X<:/W_<'%TS!7>3.DHGB_88(?7N<**(*UU=<I]5P(PQ.\J+,2T!X,
M)_CIDV&AAW:UVA'>N3]P@] OR883_$'; ^/1Y6;Y]CF<_P7-\!(^#<?]LL%^
M'J5C5XI6__&Y'R<?+AAJ[EWGCXW,WN(\7L'IY,=O^:O'NZJG^!S8U8<Q_[5<
M[Y30F,].2DZ$C\BNWCD;8B;6>ZTT=_P=U6;GXET?1A<W\<F]3^!'R?T!+N,]
M_NR./[NS\<[?K^X]W'CSS_W;1S9],+O_]"-\WS77^OTV+I@5-]C#RW_(^MJ'
M_.3W@\?/7OVZ=_BT]_*_]UX=[#UY]ON;_2=[O[[N[1\^>=0K+[S^_?'K_:?[
M>Z_VG[W^X?9<^_U=OXF>S /N]27,2DWXY23EJ6!_@G =I0]I,$8\]?8'"-_4
M^^G7X7C\MTV[Z:/D1N->&D2\Y^LKW]NOYJ+^7??^Z@[/:42U]-XR]8Q@VK,(
M;^W8?1JGGR^^^<<%T_<'[06V;[K&:3/#U",RQ=6YT^C\\\]??M2^],T).GU-
MBD?4F!^^3![16[ZFU>W>^9\NEK)'1K!ZL?=TL?)&'_L7OLD%S)E;_.HUZF]*
M%JM1.?:OCH46A(4C;N"[W.+;-P_[]O65V]_Z7EVOTI]I<)K&M5O7)GS&#?E[
M@_*?TZ3W:32,IV'2&TVWXAWHYYK'L-E.Q^WT#J:8F):6ZDRCR,IYJB@GGAE+
MHY/!O7M:3F%""86[]P.8TEN'W('OS]V!GSX<_OOYR=''>/SVEX,O1Q^/R-'7
MW[^\^.7YAZ.O?WP]_/B;?/%TC[W]>'AR]/K2'4@.W[S]</ UG.'G\+<GS\C!
MUXB?$>CAU_CQX./!V='7Q_W#7_8_'WWG#OR-'IX\^WKX=9^_>(KO>?/;UT/V
M%N_E=W[(#LX.OOY_'P]^V2=''Q]__)^O!Y.#?G$%/IL<E*1KHBW3#@0-$82)
M 0P5 IPVP>@0&"^.!LX:073#Q()5__?GM:LLL=$LP9V6F1!K!?>"4F&$(IPI
M&8*E)BC>LH2Y8(D[=AJH+'$KECA\<LD2P?'HLPG LU$@5!G;36D"KKD-T7KB
MO4 #VS2&\,:J!9.'*DM4EKB6);14TAE.!<,CB7#KG%+"22J-$YD[VK*$OF )
M75EB'2PQLR6XX=:CR0>$EK$7VF4PRJ)5H9A(25KE$D>6D&VV!I%V]2RQS"J,
M;FNOZ<#2FZNNVC3RUBQ%&0J<X(V+60OMT8+17+,DM5(T<!VKXEDW2_TVKWAR
MYA&-30<4C1H0+A@PW@E0,GG"(H^1J-+FS!J*)+6L65Q=3'5^\,@U!"U7/)B"
M+A(D.">)\2D&'8AS3-BJ0M:/W#D5XCV-@5D+FND$@A$/Q@0.F>>(S)MT9*7'
MJR"-Y=O<X/7!XU8YKC0*SZ"=%E1'*RS%&T86%RQ1KJHNZ !N9R>N,(;(H"S(
MMK&#$A&<TP:HL%X&8Y(L'=:UYHV\>[;A$G%[BX ,[W0\L 1DSB7!39K0+$)$
M#[=ZDGNM(K.:9B9%0FE+539.&B-$TC;):OZOFXQ^GS?_T30@SCL-*I5Q#Y1J
M<%8%8"9[$9@6GL6=72X:;DS#%FYSO)X<YHK4&YD-QIA(N0[<,,$U=X8:IZG+
M-@F9O:[F_OJ1.F?N<\6SM8& SZ4I%(\.K!,4,D$(6V=$5"C4F6VX$(VQBS8Q
MKDCM+E(IBXYPHA7-4FB$J0PV")X%DSI+PJN!WP&DSL[4( C:/\D!"U*#D(F#
M29H!R2E1907C',]4IAK.6*/8HHTQ[QNI6Y\'^&0X/A\QG;Y\2H-Q!S("%QK@
M6R]RJ1>Y=8F&97^7VI?S9,-Q>0AQN0)WN\_;%6K8LE8O\B_#86QK>]/HSWY(
MX]>X8/4$7N@$#O.J5@=F!9<2K-<4A*,";% &4L#5HR)29_3.KFX$HPVGWW=@
M[%A^SH,#X JE:07@T@ X)U9S],*F:*'0)@AM/3CD4C 9*5188K.C.[NJ(50U
MAK$*P(X!<(6*LP)P>0"<G8#$RJ \U6"I]R",47@"9@]6625E%,R1T@JS$=0@
M"!=,Z^B0RMP <_QUF@X\*(+SQ(W^2!/\5\U!VQ(#_GQUD;H.+M;VV=2K4.EK
M(?IZ/V_ <^V\EB$ M1+I2YL GF<%*0?%D=J2]W)GE\J&:=UH4=/2MAC,*Q0#
M%<Q+ _.<&'"!,*X3 <^80#"72;HYHQI75$A)30P&Q0 5#2&BYJIM-YA7*"PJ
MF)<'YMG)G"1U+',/J"OP9";"H*B7#%3.+HF@HLCE9.:-,+:A>L,3V+JM+%ZE
M<7*C\*&5%C']F8Z'GTKGJ^KK[Z14N%@N9*2GL\6JG'0;3OIC7BU$YG6RQH'3
M)($0@8 59?A'<I$%2ZD2H7@;C3)(2VMP=E0,=L7"KQA<)@;GC'Q+D@U:!XB&
MEFH4P] N*(H]"H/&74BQ=,[0C=2R,;9Z_+N&P97FF%4,+A&#<^<@+Z$UFM$L
M#ZZ,'23@8K"@;(XV.\)"P'-0-$R4J:$+ZNSJ]%\$>;^D01JYX]8R=_&D/^B/
M)Z.VBW/U_&^).7^^Q,AB>U<6N!+9;8CLV><KPX]5U+B #'SB"H1C'"PN9O'_
M9T+Q.%*6[NS:QNI2F;)HKGOU&&X0HE<H#BJBEXWHV9P-2GQP&E6!%X*7J7L<
M',\9/-&<).]X#*X,+VH0W8W6BR;%5TAO$*17J#4JI)<-Z:-+2*.IQ1DK)6C4
M>A A";#6!S".<J^(4K;D&-E&(:JMZA*BMRX2L'=2YL9^;2==5.]_)^7"_!*]
MR/N#B1N\[_OCM#<>ITFMMUN0B+Y<F?N-EH1Q@D ,J?37BQZ,0 .#B2!45C$2
MG8O?@W+12+D@$57?XS:9^!6%2T;AS,*W(I7.-@02,XA"EM#"9U%"<)''S)T2
M;5?<1BO;"%6+;KJ&PA5:Y16%2T;AS"CGDLBL\1@DPIF2GY/ 4H0B+B/%\Q M
M:)8+"@57#5M'Y<TR8P#=[B\UG1D?OJLV7W<$X %WTEAQ96^I:#KW-%166Y#5
MSN8M?)64B-Y0T)DS$"(+L%Y&H"HYSR0/BC.T\'FCM&K$TKR'G9G!6]&_83JC
MHO_.Z)^+'3"?B @>2$)+1J@DT:;)%++FQBJO>98EKX$TDNK&V&55 U7T;Q7Z
M5US37-%_)_3/%(T6@B@O%1 N!0C&!9B8/6AGG OXQ2=$/Y<-(ZS!W;8IZ%\L
M"-%=F7,^8GOPOM<_GZ=]?&6>=NW^=\U#^VFEHF6,]_O_=F !!KM<U.F,]#(A
MO9+88B3V=5[ R!AQX8(%01Q^R2F!YP1)+&FGF"*!^EQBI<R8AIKOW3+?P:GV
M[=P Y-Y=<%3DK@>Y,_&!"Y:]<12,B!3A&PDB5R1(7KN@"7?*(7(I;:AFC;7?
MQS4J=#<1NG=7"Q6ZZX'N7"R$Y!!,9I 0I""4]& =HZ"(S&A.Q6 S*@?3&&T;
M9.?N('?K6_#N(])&:3PYEPSKCHAL()=U,^BQ/_@35[64<TTI[&*=*XTM1F-D
M7CM8:5PB$GG+"UWR+ VX2#+PH(0BUON<2TA7\(:K6@JQQ4!>8?RB GEI0)Y)
M"6&X"QFM$#UU J!1XFQ0()5)3DK-HN [NU*)1M2:IFT&\@I#$17(2P/R3%@0
M$9FC,@!QKJ0Z>@:&, *)&T6(4%'I5&;QH*Q@"R8Z=JCN80/DPWE*U8,O>5AM
M.&$!\IFN4ZVVNA7GT"LET4%&C\\9M"PET49[L)912$S&J+)S*=.B E1#S<V=
MD)WP,VXYX%9JME? W0UP,VM=$N%223F(Q"002(5@9>ET&#W)7AJI)-O9I58V
M1GS?YK ";I-]]Q5P*P/<S*H.TN;(F8>D>0 AG0&7DD&A3+5CCAG-_,ZN98TE
MWZOC^\3;,DL6F.RV83V7P=/S"7&0+M)Z)NY+K5W8;,-]\9#D+!+Y?#0\>8*7
MTQ^<XC,^#U4.!^/'[2:9_MZ;LD4.^H/AJ#\YNZ#&O4&\^BG/_O<47SY(DP_#
M.'-/U%#G@MS)KI1 *ZVDIQY7OG4M$@6&J C>NQBH2]86UZ)MF*6ES?K-0YTU
M.?IAD,LZ4I4JN7297&9*2%'MHQ44K&=M?P6"WWFTTX@A.NHH,N-M[R9#1,/5
M]QG8E5T>.+NL(YNJLDN7V64F^[)C(7LBP"F=T'0Q 1SE"0PE1I:N$='QDJ6E
M2GZEI!M +ML39KD0?KV?SB,M110.4N[7&1,;(=R0U<X]4X^GRU:9:C&FXO,B
MBRDB.4L:,F$&!(T)7! 9%'616&6=LV)GMR23UIG2W;-!5AJ&J>!;#OAF(L0S
MC?("C0/*2W-[IS(X1RE(:K.BGHO@%(H0U2A>PY]=PMU*HS$5=\O!W<P\1R-%
M:F(EN!P\FN>!@E?1 1/$&AI<D$2US16U:(RQ-3!S+X [3).KY=6]C'*T!=I4
MU?:&E[*VQFAJC.:JHP-_X_BT//:7I>_><+ WF8SZ_G3B_'%Z,SP<#LH]C(;M
MO,R:('H[TA3S2B&FZ!,5$I2/2)J69[!E5*:7C)36V(FIMC4VH[1!NW0#?!J5
M1S9,K%0>V5@>F8D>G8E56EFP-A@0DA.PP7O0QN"9XGUT3$PC+XPL5GQ>B>1A
M$$DW(R^52%9")#,5AXO-&$NE,3YE( ACX(C.X$,0UA!CM U()*PQ0N/_-B&$
M>XLA'MW6>$_[XW,]E^*<G.L-4/L-<PG#U*!+1\M<YOEN?AEGC(<"_D5^X[Y4
M%KNUK/KM\^%O[RC3SEOA0 59B$P79>4IV)@L"SZ6E)2=7=DH)1NZ:"/@Z@[>
MKAKV"LL5J)06EB%:A8LH05 B0.A(P1M+0?"HM2+<>US'7=YHPQK&%BQNK[#<
MKHKT"LL5V/S/OKQX>O!.X&)I+@E"TB<0MDU9D HBFD2>)ZE\\B5ZHZUI"),;
M.PZDNU;]=Y&;SH9GMMT5LH[8S,O1,/<GM9/?XE0F9X9_H;+W[P@OL6:1(<J$
MAH4V&7R*'+)A1E$?E=6LF!A2J$;2^\P3W3H_Z+8C?QW1E(K\.R#_MSGD'R'R
MK;4R,Z B*508E !BWH(SG @BC7(4C1C=$&X:K1=HGEV1O^W(7T?XHR+_#LB_
M*E^24#1X$B"6LA"A0@(3M ,ILY#<"BX*\E&Z"-L8^KU\Z1CRMZ4PI&B:HF5Z
M#A_1J1_W8]^-SO!?LRA>;S+L#:[$\5 %30-Y-TE0JXZ9-8H67-Z9DZ:&9N]5
MV^R]8TY01DD")G,$(1ARG#4:6,Q!*.),%*)PG)9KF-9:T=DY85'1N3K]L??.
M$A>IYPJ2I!Z$]Q:,4!)$SII&E"7$&-0>LM'7=-6H\-STJ$:%9Q?A.<MK<ER[
M[',&;0C"D_@ EC,!TG/OF;!9V>(:H-<.U=J4X,8&Y"Y]7Y_RK1C UTX0K>,/
M;I0^#(]19=U+H<K]YH)>]]#72H;_=6]I>0OL]:X[@=:NH2K%+T3Q^Y_G]1&/
MVDGE%'C.% BF.7@O'1A.;0XR!EY"V+R17*-&NGD!XL:GP%>JJU37.4%:J6YA
MJIL3FV6NDU(,I*0EBP[YSGDI@.#I)0SE-MB\LZL:JWA#U ,J&ZQ45ZFN<^*^
M4MW"5#<OW#T1S%'(S*)PIQF%.^,)9 K4NZACBL6OUEAM&L47F,VY[GJDBPLY
MW]>FY;%;^NEN]:MS-\KQ5N+PM"CP;^_T0?[-K4\V?>9& [S0\843YE,:33TN
M-W''_'ROF:GU,Y;S&5M7]@BS N&YJD?P;MP/=\@4N&F 8V.,OVTQXUZFT>O"
M.LMUTK$Y<V[1:G2\HL=EMYU?5K7J%K'JOL[[ZBCU*D0K@2=7.F2JDJD9)%BB
M>"8^.:'<SBYYM$"/\-6'22MS;!9SW-'G59EC?<PQ<WU%QQS7S $ROP7!K0'+
M)3*'B]GAXJI0.F:11[HR1V6.93'''5U(E3G6QQPS3Y)@:"%2X2%:E='F2 D,
MSV5.JHE."A=):5!*'IG5,L?#R?V 'S2NN;&$JY/D;Y[A=F_JZ?9%^I7*[D!E
M9%X^2<-,8$P!C1FI3 D%1D8#(5/-4A!6&%NHC"_8U^9>A\I73-\3IN^N:RJF
MUX7IN>%I25HGHX80DRRM@ .>B\P#S88FHU1T211,+]I\HV)Z$S%]=\51,;TN
M3,]-JG:(:&(M&)]YP;0'*TV E+P/EF6M_/2<_EYRK _3-PP<W2%(^WU@=M%B
M\XUQC-SP'KO-7YT*TUR$KB_^;DM5E:468REVI6G.FZ-WD295D@HA*6] &,_!
MX9(!<3I&7!9_'I!A"V38K*$Y1F6<A\LX]Q;>J8RS',:9:];SYOT[921GD@E0
MJ4RBMY&##<: 4\PCV[ 4(RN,(Q;HUE$9IS+.-H2%*N,LAW$NFP2='3S=>^<]
M%R;X!,3(A#9.UF!SEN"=R38$:VPRA7'D E,-5M$&:(%,X<U,5:R?\3!3-V/_
M^'228DW>?#")%.M-WGPZW6_5KWF+TW1NOD8Y3???.6^TMTZ@U2Y+_WYEP#C*
M@7O'DF-4F1QK"F?EC\W0^)4_[I\_?IOCC]_>6<D5TUI!,%*"8%R#DU&"5<H3
M%4CP*M=$SLH?FZ'8*W_</W_,J_FC=S%IQ931I;D_VA\I%4O$&]QKBCB&VYAX
M4],YUY'.>7-95Q-%-CVALU+:[2E-?BNI))Y)C 0%/OO2I# EL&CC@@[6%T:+
MSHF:UOE0D+WFM,Z*[#LA^ZK8<3(X&]%$$;14K3$=P?BH06E%<F2,)V%J<N=#
M0?::DSLKLN^$[*LRQ*JD$Y4:J!-X9C.?P>!7,#QD[F,.,JB:XEG3'[;0F;*R
M%,]SPJI<M1!7'7S^5E]HH8BPBA9!@5:(#PF\E1R05A112E/M94WR[!(L*^>L
M*\FS<LYM.>>J\E',6[1O,]!, \H?[0&M(@;,$\:-$DI:7M,\NP3+RCGK2O.L
MG'-;SKFJR0@WR"Y9@(RE9ZQA"1P*,>!<,2:R4'I:'M^U1,_M[3?Z[_8?*8+#
M2W+OTY6VHN/>\'0RGKA!>R^UN>@&?,;69:@^OF,7T6N<G-ODRYSB=.GC<F[<
M3_V"/_:F]'%X>N+3Z$5N3\WQBQE[U$*)NQ6#[KTS>$BZJ!*0X"T(U%;@C!?
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M.@H?'$KMNZB1[7:8;$KDX.!R]5Y?+E[EJ<5XBLYK"V4#(]Q8X)P@3[F4P+G
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M8W%WT@MSJ8Q72>"SYJBJYP0C=*.90-QG-]R+)F-#K *>!%:Y,VP\: "&.%N
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MN']6K;.--A[NJCSLBGKTY^*'UF2\<I-[5E<GCSU2S#^PLX]]C?V@TX%.]_%
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M^LZQ'7Q=M:GW4C23%3>,GFCO)$ #%+.Z%R>+J5=JG?;9ZX@,KX7C"K:L=?'
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M0I0"9'>J(@ZDD15:&J4YS71<1D9&@EW2?WJ@B>]'$_'NDS<'NE1,&LI)DF5
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MD_L8QI_1G^8N.K;V5]O'HWXLVANNMOLGO;8[+>#=[O9BV2"TZ-[Y[^[1[O_
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M)]QAYPH-A96?3I\' E1*#7SK-K7^%%WOU/;.0:+I(U2[7CO;:_L]D#L87CN
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MKCU6+A@= 6(F1"7E;M]0EKIGI8\R\%,O<Q04UVNP?-V:L]D7'@C9J%B]A9S
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MGQ/A@[89]1$VHD)X1M/?Y6= 8/KY@V5.>N KG.:<._SFM%<6+@VCD9-8BMS
M*1A U?_I3]X1*KT$P/?B%K7"/+@X*>4^Y9Y5O]_U[2) &CS?M=VFL:+0:VDP
MIV2@1I%$!8^"&R)![X36G$=EHI@(A=?2$GXOAM-.[*8[MDL_G9Z M1HE.UN#
M)SKJQU:.@EHPGC_ RAV\.PUH_&Q>K.PHK8BGAB)-LP88P$&GM8!_7+ I, (
MM52+@!/'N2"R=QH7M!AP5  *F2ZV=J^B^]MW?F^H[$#4:V>Q5VP%IB[X26?]
MR_VN\VA[_5HL2A3 Q2V=>D9^N\]'&M0W2WB>VZ?ULA"UW*.\+(TNJKYA,COV
MN!]_&[[X/;3[QQU[_EO[J)B2XDL3#@@.*H@U65:L*"(>'$L<7'Y07[Q<O'6M
M$KU\C^EE0L2M;X/K^L#WC)(/^N9=@R5RV3"S*(/5RP*K!1HLF6Y ]YQ^G>%
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M*REN]2N9*;6RO(2=R'%^BA#S8>7W(%.V^+^A[<$G\$3.]EO]5SR1@'3KPP-
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M26Q&WM_157HMGRG,2:_[O15B94%><]7297&="G=*Q^4E+?9!8=!C *%DN,+
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MRAQJ]\@#ND<>P@5R2U)W??O77S..GDVE^,<8H.5>"9:;A\VXTD%[ZD5@L46
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M<B.C5NZ'4.Z9C04B:84M3%BT"G&26R4R2Y',_9FM,EASL;+&&6UH=36G:.%
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MBX\@GUE3/L7>]Q8@33G",'%Y/6JE%AA3@R*!9,&M^OE%IH_0O^@N* Y+IPW
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M4(QO<5 &$R:1A5++VF>9E%P ]FX5UZAH1(X^5@3BV/XHLS"RH.6;#+-;,1/
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M4@8')TNVI]:%9*L#>],U1^?*,*QN(I'-P46.A7+PQ_4HBW1,O5@4R"@R(/\
M\1KDRCPW*?YD,#/4>I!J*3@S5ELNG-8RIR<V/N(BA^D<K[E1DMQKI05I=#LY
M/U LD^ST"_/&Y/<Y-4BC.]B-@\ND(2\X6>X[NM-\]TTPB56.%PM).,2!SR!G
M'$6@F ?*C%(AZIPM]R=5H;IINN;)U#&^AT&_R-,\Z$Z9FTY&934F,MV5A8S*
M2UU9H6STU%Q6M&9KIZ,$FLB6&33'Q:B@$3_-!P7H% A3V7V;,\6L)MHJ8G,U
M")&<6DC"%^2#RGE+'FUQEMO8^VYO]%&^[@6FB^+0KF_<81$89<B+I&%U$H$L
M5@8Q*JDQ40.[R#EW-\1<IJ@BU<Q&69/,'G>'G?%ZS#F4 &QZK5Q<N?NK-9PS
MUXR]S.<SU)7)Z&]2]_0EU@C5,^-3U0C]66J*JD;H(]8(_675GYET688Z%BPH
M,B%7$S5&2P/\1R5IO/! AWY:)>@ZI8<?;IR+)[[*U:!;_AHK<++ 1']Z/!\K
M*]SB+;5HV*A=F\!)OK<&9\W,WE]T^C?@=!A(6XP\(,8E1UR9A SQ"5%"F/>6
M1*/GRFZMI&+S>2*7<LV.ED"Q4^<U-:ZPITO]IC]*0]=_=2])Y2[%]"&RPQF\
M@26_378XQC= \WZ '&9:WNZI/\UAQC>$T*O36$P?(N]>U5BV09A9R51V/[5.
M+Q>?+*AQ6=,%U.4E8GR+6UKF Y\A<,\I-]TUQ^'KK,5C)@OZ22XOG,?JT1+X
MK=J:OQC!I5_SHRE>^G:6E9IA>2Q]2R=JMRQ]6W-MF=) _UMAM)K57BNYGAZO
MS?W]7MP'O7_I9[:5P]<Z_99?^I86]9(6K+LJ(VKURI>6A'7GLC;V^N(35%4%
MH]Z?#\D5!3*34MA8H1+C3&B'%0_:.NH#X027!3+GO$<>J4#FR/@XL4X:H]J$
MS\*]I,OWMO;%SH=_X/E_'NYL[>+Z%K3M>)M!V_#>UBYO?/VGM;/U$<^YEQP>
M'.UL'?&]K_GZ.F\<?CRM'[^'MH6CO<-/1XW#?;+W=9LWMN;RF::D-/Q/(F<P
M1]R%7%&:8Y1+[E+OF=$LK;T6ZWJI@D.J4-4J5'7*1^;OV"LPXU[@C#X@8LU4
M))TJ7%KAV UQ;,([6";EE"8,21,QXC)@9(RTB @7,%4T8>;77A.V\1QQ[)[H
MX-**_,(C3T*#Q0PK29+@N8"0\,9SEC@%:1>8+?1XO::/T:W+</Y2X#^-33EO
M+RTES=@[7M7RPX\N\A.>L=8'CXOJL48CGAQ'EEE @.!S-582DLVIV#?,E56N
M*BI148E?QA/=BD)<-]G%_1&+[;'-:[JN>44EKH<K.Y=4@G&L W<6J4P@N+(4
MV01ZD:*2)\$"-\DN8TZ,9Q<QOS-=M;O*-7PC4\ZM?+!_8M-Y* S[D&>WOSVJ
M6_ZAU^WW*_2Z$7I-)2..."9I0D#<:H,X%Q)9JN%/25.(5,; ;XM>5=[31S-<
MW%%XZ3V);O]&LEO9-NY1I"=L&S$&[7S2R!N6$'>"($.$0H%J3RF/L";8ZHGT
MDUQZ3X=H*T2>QNY+UZ%/U=G92A"NQ?'7!5#W)[WTQP <*O"]$?A.9W.--@G-
M R+2>\0!8Y$E22$>*2%.,*?H4FJ#E82_;&HV%OZ*G3T$0$RP,\)A_A-F2'E,
M,RPD9$UTB(CH&5<4IWSR]/P!8M6?\6S-9P W*;9R_&:.J?YQTNI5MK1EI79W
MM*6]+Z=Z"#W8[(1W>:Z+)UQL A70WPCHI_(N8B:(IQ(C9IC-R1<U<I$H9!25
M24KMJ+QMKNS*LO;2Z-M=!;EB<_<HY)-L+FH?&':(2RT15\2#NL<52D)(YY3&
MVJC5$_)5MK4M,<'ZI<.Z?FJCV[7"#)X#X"^D;;=+E59YLZ\2>N].'7XZ+KEV
M#$E+01<73" K!$?):<5D(LY+=K_>[-<6L&51TRO0N Y+O!UR5([C*P(9DVFE
M#8O" ]OG)O\(4B'- #<B5@P+@4.B^GX=QU<.,EZ25_E#9JZLO,J7%@\FBKDK
M"=./<8X<8:  :H&<8Q(Y$CRA.=T<MFNO\>-XE;_@T[=[V9 K-^P5$\0)-VSM
MJ*>&$!2YYHB3X% N6X225)82+$A,8AG/U9[M.5+EAGT;&\2M,G-6;M@KB%Y^
MTA*A85U'V(]0,M)G7^R$G'5%9E!./&&)2[YZ=N3G*;=7FP'N*+R5&_;*B_2$
MI< F:YSC!!D#-(0'8Y!)(2*8?<:BC)KKZFBH<L.NW+!?".&JW+ ?%GSWI]RP
M#:/2 ($*-O,IPCW2B5I$C6=*Z:"%NBWXKI27Y0N3\)6G9I4;]D,"Q!0[XU*R
MZ!"6B69S44(VDH044Y1(+A(U[B4 Q*H_X]F:SRHW[ 6#\]O3<KL']>RIG+'O
M%^Z/)OF@B);0*!G",,>(<^>1948@)2@15$2&:;S*T^?WY=/"5UJ(GX2]5?[6
MJRO'4_[6W)L8(^*:B5QHTF?S6D+8L:B$T([;>"OWF\JD]N*\K<U3V]9>C./D
M0G)F+5?<:9J5+4Y$,M9PRAEQ*E)FL"I<-)[N@+-RM+X;;+\[_:NY/:A_SM"]
M^2U:'5*D DG+)>+&.J0UT0AC;;G+B5CQO7MGK)SC9 49U^&"M\.-1PK$JSRP
M'PI+/EYBB?':2A>1,,;D&@0,61498C;E.N,::Z5?/):\)"?L6VF'E1/VRD/"
M[@4D"*V8<I*@%(Q%W#M0"Q/WB(E(K.+16P_T E<^V(_I@WV[C;KRP5XY.=R_
MD$-+<: PU<CHY!"W@B-M$H%-&BMC-67:+V5RHYN=(BVOT6-$,HN2YW9P>[/'
M3<"M9$:CJNP,)B!TA_G]X]Y.4*<%WSXG"%Q%,\?$BJG,'+?!OQ^39@[%K/7
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M,0'ZR,3LN5\Y]K<XY_OUBZ8;!OJO"5I'RF%I -1: XJQDXI;I9VA\AF<"[8
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MJ/L'DWD\8R?SS-FTEL6MDTG/'BBF^+)J60XAOL*H5K>P3."_581QTW]37.'
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ME.;)"*N]4,%3+XTE-I+J-.()J>]4"@86@I))IIS.GR,>$T<Z4(Z\9S@8$V+
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M]EI^FHHQD+9 C2*)"AX%-T0F;876@/B ^^+;5@8^3#!!ET<STUP+AC//?:\
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M=):#7@[["V2=OQRL*=9Y8',4.& J0%"K Y <+\?.7HQ=B70Y45@&U#1LM]$
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M_:54P-,K=[P?56.:A][)+)VTI.7:E[/@^B/W&6:IO'[#Q?FQAS.:RO4YQ/5
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M%$VB5(T0OKRIA78BM#XL\'=R NCL']E>/.IVPF1US[*?4LL<0QC4DO;\^-3
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M.D=E+;):!"2XEF!.&"JB+)HDA3U>PI9-88_YL\=UJOSVQKL#DEA*B><$>6;
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M5UA.Q<$H P.6:(<PC0862X^1DTJ@2+@VB6MBA<B1<:5ID](%N):O,,?03D2
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MC?R\KV 3XI[/7FORKE5Z[/C@Q?ASJUE=*'JV T5D4E[#:&LI [>%,<NSEKY
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M]UOK;]]]W-U\N_[GA\9FZ^UJ([_PX>.O'S8W-M??;[[[,/,#U:X?[IYRK>X
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M8ZVO,L1QVNTGLP/][FT,9?@SWU8194!1JIY3W>@GMHF0$0=5X^ UHXJ&QRQ
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MO\V'K-)O)Z5?#6<! _-D8 N0/^Q;T3\? S4<<XIGZ)>?_A]02P,$%     @
M5XJ*4;"!5KD&,P  _S0" !4   !C<&EX+3(P,C Q,C$P7V-A;"YX;6SE?5F7
M6S>2YGO]"HW[=5#&OM3IJCZR;-5HCBQI)+FJ^XD'2T!BFTFJN6CI7S^!2S(W
M,3.Y )<WW0^6<V$"'R(^!"* 0.!?_^WKQ>3)9Y@OQK/I7W]@?Z8_/(%IG*7Q
M],-??_CM_7-B?_BWO_WI3__ZOPCY]Y_>OGSR\RRN+F"Z?/)L#GX)Z<F7\?+C
MDW\F6/S^),]G%T_^.9O_/O[L"?E;]T?/9I^^S<<?/BZ?<,KI[=_._Q)"2%9
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M*]MJB+LA#6GY/XD1N\*M"EJHEP $W3D'8EFG3^/7V^D73'2E9V*<+GE0(I#
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M136H#.8>2;?CN+J2ZH9^T4!GF:,2F>BR/R0A!^(TM\0(XP6XP(/OH6I<G[5
M^TJB."]]S\V5FKR_-16_?PMGQ+R-PO!$NHIYDIM240A\B1*#9UZR))HDUNT#
M[C%L)9['IIZHR(84ZXZ7KUX5O_:LX2@P!]:A!R\R#41Z%XAGU!.*?E="7]XD
MWJHLT]X@AW1)=%",JZ37'HS;YNBF7(?][M'6D1!:Z)@21A3E/?.,4:2C#@@$
MY[2E6236Q)\^#NXCV,T\K_VKINN3>5E21D9=N!D085>X'Z:+;O#/$6KJOBJ2
MZ9P%_'J4/8NA).\#<#33Q@*QH=3_"#YG:H6SYA85OT]+.;C7(;V[= 9&M=52
MO3L07R,L%N_]U\T]SVYK?Y-.?!/U#F&-M#!.";1!(=.N6+TC%K@B/J+CZ4**
MR39)*#@)]6/8$.W#UO6G^D:E'FX=*&2P$'D*Q$3$(<L+9R$(]%)-YBQJ+J)J
M4I'M/E"/8'.T#ZI5TULU)OT,&="]3'===^<Y"V^\)31C\"QE><#3QXAK>P M
MN0B0FE0H?0#7/GQR?WP^U=1>14I]FD,<=\/#KR?0Z07]Q6OD'_D08\S2H_Y+
M#C,/:$!E0HPV2LF4#<PT.9+>!]Q>&\OT?P*[*BNR[FT*#(UG6RG\W8^GB[*'
MB"NR T=U5I'HDO)5*O@09Y4DU!1(7@.X)N\[WP=J+TK]3SBLJ*:YUAMJ5\)8
M%VQ2'&,0)Q-Q9<=/!F0\8E,D,K2Q2I6:\*W.'O: MQ>_SIU"?,9MM%.T6:_T
MY\Z@8B0U[4[#D?6Q*Q9GNS?2B> "3'*40VYR'K ;SEY,ZJNNXQF)5$%9U8CS
MTVI1;E/@("\"Q@S;'9,=^3Q/YW.//^TRS9Y]+%^^F.)RO9HN2V[T[C\I,X*-
M*,<I$9DB*#%T$!TSQ#$A""TGQ#1P:4.3>S4]C&TO2I\[Q[D/3@^-1_4NPZ-
MRW^ERM1G/X'NG&ZQG(_C$N<O_@*]UIL_N/;)-S ?EZ)4MQ>.S:'S+U]C)X"W
M?@F_Y QQ.0I6",JH(%EF- +*:N*Y1V<E)Z$<6@@:VI3O[G68C?*P=B:A>6^"
MT(%$)P%#!\&(4ZR<I&) 81-$FIK<9C[V<N.9+]H/E^T[*B"UX, 9<@5'7!O!
MH_ $LC3H,C)./$1.7  ,3A+HD)N$E?M#'%)"T>/GZ*D<:,W1=17%F_@\=>@
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MPNDT:7PA_BJ$?#_WT\6Z-!(;!6&MBY03II,FTM!,@G")6&JTU$[[V.;UFT-
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M].U5)BY;S1@DS]U F%?@#JF6VZ"(=[ NZUP>/P(H?A;]]J=Y"?-1 .5#,((
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M[;'SO1BN,KCV@WK":743'+TIJXJ@*M;A7X4%_->JU.7]?&Q>SW=M5*V0?R_
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MGSQ  .?A@1],R_^V_ %)D$G&J!4-</CO@P2( CJ)?2\KF/@S4A8$@!'[.LZ
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M+X,]9-\#2'(J?BY,[EO([\L,II)IQ7U:<YGJDYYO@Z@JE8H"!4WZA#?GK\@
MND5)F."DLC7,%P<7^FC-3<KT ]T%H3ZD3;%K QTQ0DNRFLG:P+;X/VD/IXS6
MZ5KH>EFF -A@YPAD*5F&!-_"\(-I3M:TT;GO.,_*PJ3W[VOI;R6 !;K=B"0,
MW'/I3NXR]>B \\F<*[9FNL;GF?]*67H=?P<,V8L6!Y$++$&-CM&0XF"A.((H
M&<6$:<F8^$R)TV;'&.1)E&^] 9R><LJ?+^\V:)*I<F@ZBLG!=OY8@"?I1:/
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MK(,KPRT"4="#+]48QQ?7X5,4N"_I;R19C4ZU8IY804O#.6YPSS'!^B;I-=L
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MZCW2 4_.!!(@E.!]RXA7U!)K&*[Q.>9,F\:!/=?J/3OI0,_J/;MP<9(Z+'T
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M3[V9\M[\[2^P!BOUBS_\)%U7FD_9.H.F"E$F>[1M@R4^X/*CP:<$"=4H-*F
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MKT0\IH3A1^<0CXVD&.;.!8UPNW6/W_+P)S^Q3Q58@[RVO<=^V[NYCI+0G-*
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MELB$ZBVE=\2'J(A OS5$':.03>(,M\,Y5PQ25<*GU07?P$!ZC&J=_-(!5\N
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ME=00:9TC/CE+-*3D@F>!&=]V&3]U"#^-ZC\A36F0D+X<53@\\+ Y\/N@AMN
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M/K^!]-O-["[!=)GWOQW=R 0K= 1&J$VE&H#VI;*J(I1FZL&4P-,VE5-Z0[W
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MP:!$0 ,0GV,@SDF&0Z:H@DVJ^ TXQE]SZBQSZC1=NZ1>1+UM6\JXT]*4G!!
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M]QX-4O'O?],_S?EC^FW^(<_$FJ\^RB]RN9;%#2M6.>6K.5-^)%',($F2 *+
M]R"-,8'<9PFA5$:,\/EJ\U[/Y1+^]JD1H1SG\B!_<]!P=>9+S661K7.^7>,>
M%J<6+KUFF54._[RD#[)XI/4-6E)C#E3"_T<M)FCD_+>?M]ITA'$Q"CB+<7$!
M?S9"_C\]0"1JPZNT&@:':F^T:4&6\3UQ%L:0RO)#+#)NA45%3N9*:.Q37W_
M)?6TWOOST13>Y(U0-.<7\*VO^)EGVB1\7,&]M]*8T/;2KS+[6:_0TH/_#62Y
MD+DV]D\HLGD7UP6\I_1Q_NDSS>4+;5Z*E]G#HUP6Y1MQD^=Z&J5Y0UX\;2_Y
M0)_,KVZ^TER\_N]UNGJZU:9O7KY)Q?O59YG??:;+]X_F$<4O^A&KXG99+9]S
MC7R"E530PT0SJ4 "8H]0&. D8(S(,*:A#9..+?C4V+E4J@#W1D@I9J H_VU'
M0*-/>COO3WDJ!UY+2GV@<>L$V%4:[&@-V!/8O:[6')2JST"E/-C1'I3J@Y76
M']0 S$ % 4B7H +A>MY]KFG;,S3+*5.T8"7FM4@_&X[_62Y61?.;DO6AY]=.
M\_\87?91UI+GFI%F?7JV\;NM>:^DDGFN'0_Z[6U*6;I(5ZDL?LDR\35=+&Z6
MXE8;1LO[E"WD35%(,^[^O^<B)I&,E80Q201$'N>0ZG4-4HI)&%%%:2+G1U[O
M12*\6C KAK/S_?MDNZV8@)9RNBU7U\^7W3HT#OSC+#"-+D K W:TF8&=R;AI
MGPSG%:$W /ND^NN%&I7#>\/PD)S[>[ ;ZPJ9SIM3A3M]ZYS'D>_Q2)-GI#!$
M2A)(J&+0DW'LJS"*%68VGL#A@Z=FJ6^.4HQP=HQWA%4[<5V#P-#\8Z6\-<.<
MTW1+%$7#%(7D/]UG7W[6MU0DH7\XY(:CQXWRB9]3HOE2S_[=[8,K=PMNE5SE
M&:/+E_J*E-/%K_*!R7P>(QE&D>=!SE0,$1<28C\A, Q(%/N4>918N>%M@TSM
M0]R("1HY'?;KS@%IL:79 SP#?Z7'R( _*R%=MC3/0>2PI=D#5"-M:3J\3&X[
MF1<@:-W)/'?O>#N9%Z3?V\F\=&T'NNOL>=;^Y>MO,N=I(3<NYCNY>J^JO;8W
M6:YMIC_2U>?/V<($3LQ#&D@6A@&,*=+N'Z,$8AI@&"J/1IC'OO#L2714T:=&
MS8WP(%,@J_0!="E +A=E],E*>R],+J5*5VY;G<_P5EBL").=Z^EO=VXV-#<8
M;/<T9T#C8%ZA>G-<97GI]^Z ,=FWQF&1G.S;,]+2.^&WR&VI?Y:);#4@QI5H
M/+/D69#>,W:>1X*1#X-K6=^O5R82TDARNUSEZ;)(^>]TL9;SF(0A\K7%%/(D
M@BA4%-)$*.U[>DK2(! ACT<Y_;TDZ=0,I!U!9T!JRTCSTV--5_3^/B\W\36'
MU3J +T:)D4Z#+\[ZP,>_?<[E=V0 [;T2&XW![ZTS/][IKNVL3.(X]Z*PW\?Y
MK2WFO1W86@_8U9<O/LI'_?%]U@/?\%7Z)5T]F2W15]D#39?S,/*%2CB" 68*
M(A_'$(LX@I3%7! >AUA9+2>6XTUM4:@-U*W(H)%Y5NZW@S\KN5TV\2Q0MW5P
M>\-R#%(>'T97CZ\W.$=RTQK42@?J,L8WW]*BKVA0>[PN>T/MCQG9A;'2Z=CO
ML+NMF[.@5XR'=%5&Z]PL]?JQ7.E50"YY*HM7:<$76;'.Y9W\MGJA5?EK'OHL
M5+[4')TP A'R.*1Q@B&+1!+Y*HHP<?( W(:?&H/O2%_N=^[)[V:^.\Z#G4T^
M'+H#<WHKL& K._C32 ]*\7M@G^MPZ],4=I1@5/NV&SJ'1FO'ISS/ELA^X.(O
M>584\T"AB,=,P)!3!A%/!*2^SZ#4I$AX2*A@P9B;(2=DG!I?UI(^4]A[RUR.
ML\5QY0Q]1YL;A^'JYC=:V^GL:[1,Q91V-$Z)^5WM9;3@W/<N1MM0W5:-.E?+
M2+$4>E%:Y2E;FW^^S(I5,8^I7@)"DPOE\Q@B1AAD@5X ! W#1"0<,^2[+ #M
MPTV-RW<%!-Q(Z$;C%\"U8^3^(!N87+>"EO;L'G@O6\%SID8[3/IDN0LCCDI8
M=MH?<H_E7=UHY';)<ZE)ZY6L_GN[O.$\6VNRTBQ&36#V4NC?Y&LI=D*ZYYI*
M?.GY'@Q\+X((TQ"2 /M0>5$@4."'PF?S+S)GF2W!=!/$Y2O:%6>XCZF1&CQ6
M8I>?5%9FS?%UGAN#9+&5WXV6.DZ6'5T-/P$#TUBC /BA4>%'8^1M)N3#SH34
MBNRFK?1'<M<AV2?Y=91D5%*\#JU#LKSR:1UM,6T05O1<)A5^T+R<RU6:5Y9A
M%5MX<J>,!B@0$@=01(1 Y"$$<40\F."(^4KQ@/E.&>M=!9F:_?;ZX7&1/4D)
M:IG!!_UG5QNNZZ186G<C0#TP87[<R-O@7 RT9WDM6+T:A%UE&==4O!*Q(R/R
MVN=U8T9S4E^YRHM%]M54L#,;JA]E(?,OLJA/*_W80Q&*$TB)8<& :&,2>R%,
M0AK[B 4TCCT7%K09=&J,]^GU2V!J_8GU0LZ 'T"/S,!&$;#5I#1?&ET<CX^=
M9L6.!OO&>NA]Q(%@=F9$%]SZ9#^K<4=E.A<D#EG-Z=ZI52_Z718K*9H]P3^D
M*7$JQ8UV4^F]+#<,7]&5?$/3O IU%"*0(448)@Q1B)($0Z)"!B/&4!1%BB1*
M3J.\D:-FD^/B*J#D2ZG%#'RMY8>T4J Z(8+"1,4JK<.H ;&]OU4#GRX]Y[LR
M_3,IRP)+%4:[)U8-3J &JCK4 @8J8+":3*CN4/,_B8.PWI7[/H[/AIK3\6H]
M=16P0ZCQR[5)/-;$(5X_R/P^7=[?2?YYF2VR^]1DW/ ZDSVD*O$4YU %!$/D
M400)21@,59B82(Z$)?8)OY:#3FWAW8H-&KG!KN F%X&#'UZ^OOO1(5[6=@;:
M5\*A<!TZ6,T*T@X5&6Q1=0A%'@#=D>*1>T+9+1+9$:[6<&3;9XT7D^RHW5Y@
MLNN]'3W#5<;_VD8_BU?K7(]4MR$H78@Y#T(64<Q@$+, HBA,(,-^!+'2M"X0
M\CP4S'<KJE\VQ"\.:O5Y7"P7W^\^\R8R/U. 9P\/VDBNHNLZ1ME=1C[V(\F5
M(E!1SB 2(H*,$0*E1T-._3 .N7)REOO!?<3%]#E0MW0F>\5R:"_/"+N37")
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MY*GAQ661"EEM,]<K>EVJ17HXQ@EA, IX#!$B"K+(U^:O##U3OS*6TOX@S&+
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MV_18>(9#@CXPG7W8170K/*@;>#?B RU_>9R@-2B/B(=$W,&)'!+YD3S*WF?
MS<7LBF"KO^G\T/&<SZ[Z[GFBG1_2S<J]+3?JWV9%\48KH[W?5;I<I\O[>M-2
M>\/:^WV5+M;:>"S/9N9<Q$I$)I"^C*:/A8*,Q QB&B@:(<^C4>QRVN$LP=36
ME6W)J(56XD>SB5B=?0-Z$&RH%7W(EM4?ZQ@RN%489!N-H:CT!3_HU>JW3Z^V
MSSQO]_4TO7:F]:"3-O"Z5,D.?GA;SI;YAL'.)&PUF)D--U K4>5-]6=T=P:P
M3P/<78A1C?'.&!T:YMT?= VI:M._;.OZ=">_K5YHQ?Z:JTB&*@H%]#B1$,G
M5"A,/!@RY=%8\H1CX<Z=QP--C2+K3TX+ZIHJ>A9*%YZZ#J!QZ$C+.*NZ,C^!
M/^O_&G%!*6^/4>B7(.F?8$Z,]0P\<E[CTW31<GT?IM:KM. 5$4FQY:%W<O5>
MF9$/5F5%@T#RR(?""SE$H4P@1CB 41*&*/)((GTK1[X'6:;&+=>97[NJ#V^
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MJ2"500!Y1",<)GX@/>;RE9\;:&K?^ENY%*9PN[[D4I,'-T#MOO8^8!KXFW=
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MU5,8>$Y:"S,,-?9X%1X&1F^O5,308UT9+UL>:\^3!#-?* )9H'R(5*0@BYF
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M(&5>"(7RN$P0";!;#K3+X%/CF8WLH!0>[$@_:[)C"Z 5Z.SY.$V-'2$-!?C
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MY6:[V;#Z ]W^!6QTZ%C1VVU^["S\P5 ?>AD[!6L9O'?S^P!5P3O!U*<A[R;
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M(4^Y;&H*O9-?RRN*N2 ,A2ID,(HC;:@$/(&4L!!Z"8HQHTP$Q#X_R&GHJ1'
M[5(SJ7Z_']=LD7*0*27S,BGYT8CO6@2MPU18[%H.!O#09T1&;E )#BK)ZT+4
M,U *OUOW3"M07>I2U,3QK;??T1P,\I%V-ON&WFV7LQ-ZK;N=;D\<;]>SDZ9[
MNY_=GM![SOR+IVU6ZLVWM)C[// %CI%I5J+_ATD)L="^;)@(+T:8)Z'GU&G
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M'F0T()"&,:?8"S%'B=.1>.MP4]NAV)76\9R['59/QC&B@L$ (9/<[/N0<)5
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M==CK4C3U%\'RD&"*4SOT0<-.H\%=K7>[#9IR,R<;$AK=9TV.^X[Z50X16&D
M0(U &<70O#L5"CT>6XP]<;T>?8PF_+C')V//R=$1S.@"N#L[GR1?:Z/KR0_8
M7;I:R+E*E!)<>S>*"@21]$.("0EA$$G! T]Y<8QM_9S#AT_-Q2F%,FN('_S
M?@2-N/8^SA%ZE]V;:S 9F(E=X7!R;<[I?857<_3(T1R:<\KL^C)GK[FVM=(-
MY_E:BB9$-)7%01_C@/M^0D,) U-(&25(0!91 J6B2O*$!=)SJP=O/?34/O#=
MYD>TDATLML)W;7AT<08LK;U!<!W:7-N!M!8;[,@]4N<A6\"&:25T<?1GZ@UD
MB\KY9C_63^A&8F_29;J2;],OIHK@?A&-=W(UYT@A@50 0TRT[1'I:2!48$@]
M#8L0H><+QRJG[0.Z?%;C!*/?'A;-*>/8W'CJ LAA&,22$/V&8_V.([.;35"H
M((U1S"-$>,QCEU/Z_B >X_1^!(#MR+\_V 8F_$I06$IZ7)?(1 'VF!1@ATJ?
MK'YAQ%&9W$[[0_:VO*NCV;EFA?SOM79"7YN#N#O]E#(8GB#A8Y](&+(X@8@A
M#(DI>D:YHD$<D0 S-QOS]#B3,R@W8H)23F $[91:< Y82]/Q>KB&MA.[(.5N
M$;;CT*OY=V:H<6V]=GV/#+L+EW<HB%'N6'V4CVMS]%[(#WEVG].'F_7J<Y:G
M_S04%'B^5W=OH#((8].\7'DAA<A#!&(J.60RD"H@/&2*69?$<!EY<KQA9 =;
MX4$M/=B*#](E, HX%')PFHMV8AD4X3%.$.S O=QBXTJ4'0IF#(7V2"4S>D7=
MK6Y&%^1:*V<X/7"\VAE=]-RKGM'I 1T6A5=2R3R7XGV=;/72Y%K=+OEB+:1(
METV'S _TR>PFT*6H<ERKS8:ZJ%LQ%P@30J@/@X1%$)F6O0Q% N+_E[LW:W(;
MQ]9%_PK>;E6$L \'@"3VF\<*WW"5\]BN[CBW'A08;>Y62KE%R>7<O_X"'"1J
MH@ 29+)/=$1UII,$UOI ?%@ UH!(%$D1<9Y0Z]7"BTAS6T8:I<ZBVO0\J_0R
M$XXV16B?*M5*5\I-%>1>G]?)6CT'$O0SPA9KT.3C-O+B=!BR1B%0:@0^M(;L
M4#?XH35D=01^/63O7FK('!:TR8=NHI5NJB%T6P2]HMVY.OKI:;IETRLR)^NI
MWY;[G<B<G_&TCG\>-JN</R]9$H0R90$,]>8+(B%22 *:Z@UMQ)%*0L284_SE
MW1[GMDS:9T_OB;#=(8U7W$9>IJX<[+8/?A>@DAC\5?__*/=[UH#Y/->YW^FD
M)SS6&)R?]=B_V#/8>T6+XI/Z)S7^2[M/V\_YM^^[ZBP8LT"))(,L2AA$3##(
M.!?Z/T@$$5$"2RN7H;L]S8UG2D'-17@MJL83E,+V.A&^#; =W7B!;62:Z8V8
M>Q#X/32\QH'?[&S:4/![.E]$@]]]H;>-(O5GLZM-GB6*1!"C+(:2X12B,$Q@
MAD,**4JR+$UE1&C6E.VSMDG:/5A]XJ<5^L:W04H!F\VVLPER J"UP>$,RF3F
M187&NSMH]+$9KNGLV4(XZ6)J>^":?E=6_ZN/]3C,>[TO\K4LBC>;1Y:OJT01
M5?I=<V(H]'X[5SD]V!FO^'_O<[TG,N62CVY#^F]Z:RX^T[\/@9N'4,YEH)*
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M8%KEF=_4);^S5&GR5AQ*$@EM@\4*9C&.(>?$)'J/)):!R_6()[GFQOVUK*V
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MQG%((8I$"AGC& 98Q$HBQC+!>T7_G?<T-R8HI0/5I][GVNTVI'8DX 6HD8G
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M_K_N;_>\IZNL<KUV:%/[#=UNG[5M;E(8%651W"6C.$@YI3".5&9*($:0)(S
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M6.V\]VG[H'NJ?_FZI>M";\1U'__03&A21:KR"+U8JAB%#$D.R\-8)+1)2Z-
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M-_!D- !/FJ_+2J_@EWP-_OSR]O@OOWJV!_Q^.9[6_1?['F:POA=W%OC#$GX
MH4P]6\)P92EOG@(E%A.NX:.,X:1KM5\-YK4FCS(ZSFOO.%+TC:PK@_>.AT^,
MAG&"0PX#AJD)VM 3DE ,9<1)F! B8X'<ZCJ==C"W=:J1[S]= ^7.<+-; X:@
M,3)+-Z*-DG3WEMY^ ^'.^I@X .ZZAI>!;S>>ZS=_#[;V,85N<70AP@%188()
M3"7A$+$PTI,Y22$VF:"P8A3'3AYCG;W-;68?]_#&B^A]OJ9KGM-5^Y# ;<YW
M8VU' -X0')D-6N"U) 5_C>)&906*3ZKH[G!2WK#2_9Q$[%[J[8YDO&(?MIL?
MN9#B]?.?VDKYL#Z$?+WBN_Q'E2/E8#,$&4Y2&D.<*4TS211"@HW71)($"F.4
M\"1S"_1T%\)E[DP3_%FZ@*O5YN\ZB>OF$-5(#]([6AT]QL;:&6)$O"?PABC!
M;L0W>\E?C 9ZC_@K.$:3'K48Q<CI#Z)GGPA7*:9VBNB)TA6OB+XM]3R0I,9?
MM"RR^57OY@HSCS=K<^2Y3#!.I#3I1^*,0"2" +(T4S *(Q()*7$26<6IWN]J
M;F;6A[6&6)M53WNVRKDVM90T]\<+(/5/9@0D,'=[C@=XMY&V/&SS@M_8!V.T
M\G OQ5R EJ#E+93'8ZN[:'@]8KK=V[3'07>UOCBZN?]&3^8P37[?K/0;177%
M8I*>'*VWXS8B(6'"I!0P2N/$9._.((DXAPE34<1X' 8D=K.EK/N>GPE5'I/5
MHO\_]26O(Y%8 V_)*V. .3;-M&1N4"PS'[6V=B/M[)SA\LI#UIU/2TNNF%RP
ME',#0V,7KQ]IEW+49]:UK?5<!EL=)U4L:! I)6 J(U-"*8H@I32!090PII)(
M6T5AOY#%OB+-S7QJ1[H51GJ]3ZQN3NM=HBOA#1\T2R:<="@FO**\4HBNN7]<
M-%O(YXG""H=".TXT86^I7BB(<"B*MV,'![?<CYE?\2IB_;/D,O]A6J[3+61A
M&)* *:CT)P\1H9$)$0\ABN- XBBE01JX\.VMCN;&HHV<X"BH&VW>1-2.#'W@
M-#+%78'(8Q(*6R!\$M+-OB:EF7L:GY/'W>=].LM5)/1J+3YH7=;F,.9!?Q3%
MPV:5\^<EQ4D81DD PR#F$$4Q@B05>L,9FR)VBB09=K/.W&68&Y%4AL#KMB'@
M>$O89R L+:YQX7U9$PO\54D\DD75'[KQG:^ZQ9B!!Y453G9N4'9-]:/ WS<_
MRD_IP]K<C59>5X?<8[K+S[*0VQ^R^+Q9K=YOML;C:AECGJ(HP# 6(8((1Q0R
M%5,H4HR1Y!1%G+I08 \99D>![]Z QL)=@#"" 5F 1B_C=7G0K)W:S03P-<J!
MOXQZH-;/L0)#GU&TX\^1QV9L_IQL6)S9=0"P/MFUCQB3LNL G,[9=4A3[F4&
M32WE3^IW^E^;;5/:H2[C+3,3,J&WF2B45)N02$$6I1PF,17ZMY@C9A4TT=G+
MW!BRK/"]4: 4M57XQ*E">C>NW8SF#:V1.<L>&J=ZA7=5'UJ[\'8'D]4QO*MC
MNZ;A_8=]E%.HJV%]/)0\2H@,LB@.3*5A!E$:4D@)YE"9Z&E%E50!Z5].X;R[
MN;' 699ZT52PZU]\Z@[<=E:./Q!')H=!^ U,\W\+EO'2_%_T^()I_F]IWYWF
M_^9;/<^PR]8^J;=Y\;0IZ.JW[6;_I'>%J[W0/99)64W:O;T4M1B;=5/N(B I
MDT&::E.#9A"Q@,/,;-]H*",L,Q6GF5,9E_ZBS(V3&@U J<("')0 ;2W 08W%
MH0KXO;H:OL=0;[N#., !%!3I,8QQIH<O2V$4"2PX#4*:4)<ZMQ.-X03U;&NQ
M#A5MBV+#\S*GVM_Y[CL0[8'<-+HX'E(.&#C+"Y%)AF/D%6J\V>1^KS(83Z\W
M+_VEF?9N9C!J%[<WPUMTWWZ_V3_N5]0<EKXK?6JKJ-!/ZI6H?$5>B?_25K\Y
M#J@O+5F$4!B9W 4BDA!E0B^5*$!Z?QYF288RGB%ANRMW[7QN2^)1?E IL*C#
MQLT.OE%"S]R#&O;;=^=QN;^K'Q/MT3?[CD![O'X> MW0PP+G?B<[0^B+2/MH
MH7<;;C0G9%Y7E_TLO^4F6F.],Z<:RX"&#,4T@%21 *) 2<@2(:"B*8M4BB,4
M69TQW.I@;G15R0B.0@(CI1TGW02QFW=\0#,RMSBB8LT;]U0_<D/1D$,A^7]\
MV_SX7_K5BAOT#^>T<+/92:;^/:6:Z7WWN1[)8_])S97^KOA0%'L3C'62,?^3
M,KFJWY1UB=]37M8,?*6I0[26R"!F(0_T5!=)2(S'L( T33G4$SVA&25ZWMM7
MTQHJS=S(H=%';T5*C<RUWVFU"[W4&JU I19H] ('Q1P2U@X>RV[:F7R$1N8H
M#X/3IQ[7X%%R2#<\Y6A-E(9XDE%S2U+L"^7.Y,6#.YDNJ;$O/$Z2'7MKM*>[
MYIX5\K_WNKEW/_1_ONI6ZIM?$K$DXYS 1#"]=P\B!4F84<BIHE(RPF+EEI?X
M5D]S6]R.@H)24F!$=;Q4OP^OW?&E%]!&7F]ZXN7N.WD/"Z\>DC<[F]8/\I[.
M%]Z.=U_H84R_^_F4-[6FMH^?UDU, D]BC'D:09%)O2<. PDSHH2Y1>$!$TF<
M8*L]<5<G<V,'\[TX6$6WH+,P23T ,O9N^"#A A@9@1:RC^EX"R0'B] #6!,9
M>OU <[/<[J#1:9#=>G<Z.^N.]"?FT[UG^UE%;U:T*#ZIVC;[M/UL\E[6"[>*
MI$IDG$"5(>-N:&XW$.$0LR0EF 1IR+F+7=31U]RXKQ35[$-J836FH!2WIW74
M!;.=?>0)O+%O)/KCYFPE62#BTT[JZFY22\E"[W-;R>:5?OQQI93GQX/[7!;B
MD%"<PB ."$22<Y@IRB"B! MM4HE8.55@[.IL;@QRK8;N $?%3ISM&,07>B-3
M2'_@G!G$!A&?%-+9WZ0<8J/Y.8E8O=,W61/=E<$5=2JHDU0KCHD5K=J:T?=^
MD/>0E^P\<= 8F1.=4/*;(LBFXXG3 SE@<9D:R.7EGD;ZI@S=K*S_SWGQKR/U
M1U2D*&0A3$D<0X04@1G5)GL4QEDBDHAHT]W)1K_9U=P6V!-)@1%UP/+:@;"E
M>>X%M[&M\YZ0N9OF=]'P:IG?[FU:P_RNUA=V^?TW?(01G56S*'TF]^O=9\U<
M#W)K)%C&2" :( 510I#F$11 RD(,0\P$1IQ%A%GY+_858&[L\L_SRDGYFF]+
MGJ<KP#;;[>9OXY6\=<ZSZCPR=OPS)MXCL])95-*5VD*-_, H4/HX<J^NWGW!
M&R]VR4*&%XQFLD>H.[[)H9T>=SG-?N7-YI'EZ\HQO'05_Z8;/KE\;E<*NO'(
MQYRR\E*Z3KY\J =P],9<$II&A"B3SR(3$&5! K,PQ3!2"K- (4HC*UOL1:2?
M&P&WG)9W&\V^5<KK8[E:LUO:?9> 'S0V/[:<2%:-S@[7,Y-_,A:78W/^$*8Z
M"FKIO@!'U<[<AMKZWWYL 0X@F/BBZKMJ%5]Q#4MXF0_'X<)PSA_01#>1<_V0
MW.XZ7VH@.R]1)Q=JNMO9E\+[Y-KWQ83H&6,NM"VWR[7,W]YLBEV=9NR8Z9A)
M;01EE$ 9A]I&"N,8TH CF&)%$8E8R*1;('EW?_.S:@[B@E)>QR#B.^C:[14]
M8C:R 7 .U[@I"RUQ\1K6>Z?+:6-W[?2_"-"U?*V/.][CTVKS+.4?F[6L?Z1K
M\5YO$L6!";<YVYN?&T^]-.1AIB0DDI1.*QQ2026D5*" <Y+*Q*J::L_^YT8X
MC08+T-*AS%%WU *TU7!Q9G,?'8O]SKB8CTQ8SG#W<B)TQ]W%OW!4_*=R/?0_
M#HY^B;U1['99=&]V0F_&WCJ?.CKV;Z:?S?J;<8JJ)XI,.,OBB,"8Q\;1&Q-(
MX@B98$@695$8B<#)/FVU/;>EH13-S?YL(V5G:_;4?V2:+J4:(1?_%6U]6HOM
MYB>U#*_H=6X%7GO$9U[]UN[V]?/QD3JO^2N3;K6N__%IORMVFC&T/7IVP?#N
MI]SRO) /VYQ+DZ=5U=F,&0Y0(D(.,6;(S'H&:<(RF,8!8EE$D*#Q\+3\8ZHP
M-W*YN#^5M>#@R4@.GN06% 8"'ZG^1_TV['ANWB,^,IVV"PVTU3^I-L">P=6"
M!$:7IMI3H7\X G'E)K@! Y1HC.,9]V(C.7[=@U&UF$'9A"E&R:[JPB22#'/9
M=SQ1_FY^_+!^]6BNZ#^I>R?,X3(-TC@1LK2=0XA2RB'-%((D0K%*5,9QX%3K
M9B*YY[:25@J8) FGE]\W+[[S,C=>E5=A<_"MD3_-MRD=#YRG^E;L%MD9?@&S
MO@$_?#F5ZN:KL;C,]!]?,=%XC1&J,;;H+Q+U,=%XW H@F:I[CQ&Q'X\Q;0%/
M,$D3J&B2021(!EFFU[<(BS1D#!%.G#+P=W<WN\7H=GSGQ]Z^]]V VRT-_F <
MF=$'(N@G2O8"F-$#93^^D$N^E?96X;*7;_7CE^[J09KMMM^D^+HQ5ZGZW]]5
M9MN2D"B@02B@YAX%$294TPZF,&0!20D.B532A79Z23$[-JK$- ZBW-P\EQ<\
M_0S=?J-BQTVC8SWV\<ZU.FAW:Y^9O,,BKT]U*B7-0)5N'.:Y6D]_3#<(9I\$
MV$^027EQ$%;G=#FLL1YN(>5Y2O%9/NDO_#LMY*'BMV[KU<^\6*8\Y$S("*81
M32!*1 *)R!@4"5*QE$@Q89_2]%YO<V/%2EYP%!@T$B_JA&5&:A>'@[MX6[AU
M^$1QBN/L:0%T\,_P">1$WAA# 75SO; %J-/1XFXCT[E5V.ISXD1A_5(_(_8/
M+3<MOG_:/M#MKOZEE1?BT^Z[W#8[\EPO!T6AOS,1+EFF#5:,0R@S%6@S%J>0
M$BZ@QIZ&2&).4J=P]9YRS(VRM>3 B%Y%F9H)DA\#F+3<8"M793TB;4#15EJ4
M7PHIP1^;G03QKV[V;M\!M+-X)QB6D=> 6FBS.S<Z@.;WEA8+4.H!6HJ 6A-_
M1NU )'V:M7U%F=2P'8C7N6D[M+D>QNT_/KQ^]?7#/VHO*Q0J%7&.(498$V:"
M!&0T03!6*&,A2A.%K3Q3+IN>&P?6PCE85:=(6=B@O?4?F6QJN?KX I]BX&!&
M]L9B(IOQWN?@9A->U;;3 #Q]8SIK[ZJD)Z;=]2=Z,(U#1;7/TN0*U'_]L#;)
MEC?;YZ8X86(R^65<PH#@2%MT7$&6B1AR$0D2LS@*I%7B$&\2S8W7#H)JFZZ6
MU&%^>QDC"VJ<&OF1&=6]CN1QF YJ.99H]3=>#C0^];A-Q/X3C9_;(N(3Z\ZU
MQTM'TRU9/G$Y6>F\-MRW.I[N=[-]VE3=E-G^WAA'!-W!1L@E9I(D(4T@94HO
M?UE(($5<P"S#D@N]!G*[P@"6_<UM<:M$!B<R+T IM=DZUY(#([IK0;UNW+N7
MM!'0''G!\@%DCQI\5O ,+LG7W<O$%?JL5+XLV&?W6L^D";S,>U5\EESF/RA;
MR3_DKC$&<$Q83!(.J<HTPZ@TA5DL&8Q$1F*2TC@(\?*'W+*-=<Z$CNY<ID2[
MT_%F1B,MV![$78"U++T9Z>'"T3&/0A?@=D><OD <F5<.Z'UNH4>57AN.]_9
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MT?M(WX/8@296([N7,?;QKM[[I5?Y,]B]L%4>U-I/0*O_!#0(V"R5!H,)Z%
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M9(/"MJK(@$5#PD_>H$5# HH_KJ(AX>?%NVA(!!%Z-E50?-V[S//IFT?$-%;
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MNLC7E.2(LS3)(4ML$F^F.62:<YCB0BGS.T4*IW.*BZ.,C<VV0H):2O\J9L=
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MI<U-0)K!A$[ 1J/Z6]CJ!#JE]GL$7 [CNW&F+O-T5/QC[^*C0^_,2KUAO&!
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M%_7+B#H<+(3#*?XIYO&!98/;Q]"X^?2<#X;?4)WF^^/HV6W>"9G+/>8O/V+
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MU<JZ*>VC)'M@]^;GQ]:2]0PKO3AA;C05:AHB4]3)?,6-[!/0B ZL[!$.SEQ
M"IK7<VF\8;-X'#0_RMEQN:>W/;2J;+^OF@"54-96-L.\JCM^B<KV$&H* G_@
M:T.(]1^_+-E\95MR5O/[M]7<2&:NJ\WJJ<Y*BC&U\:,<050F!')JWJZL3*@6
M>5'FPBD5.Y)\8^/!C71 ["KJ;5\%G4-G<^RE9B:^];;5#'2JU<O+5KE-Z730
MJ5=?L*L@V,YNK6)0@R\&]H'MPZ B#FU.QL#WA/4999@>\1;;$N_;8DAM@.'*
M#/I)K9^6\P^ZC2B<IHQA@3F'.26YH7EL:#ZG"<R9M#78E$KSQ#G^PF_LL5'X
MFQ_&+IW?-Y;L'HM/6E/6(]C <QHN,W5D<&,;J-L6%%O))UW4Z\H6M@2-]."#
M[D)=XT'M$><1#_*!XC["0N\7"M(/O(NA(9Z/'"Y4I)^N>Z$C/1\1^AAG$ZJO
MA2R(UG9AX (B*A!D.DNA3E&&),%$4:]2^M>''-MZL)M@\=A*7WLK5"=ZJ*,;
MS_R(L%#&/_R]%$(2,8G!':9A3G%>)JW '07W,YQ @?X?'FO[:G[_WO8G6KU]
M,A2G?JWFU</30T=]OSRI30HX)21%I%!0:EH:6U44D*9E K',>*EDI@DK?"C)
M<_RQ\=-&?-#(/P&-!J!58;O,&R7,'ZN5[3/^/XK9-K"VYZBA,X?4\B!3YT9L
M$2<D,LL--!?>'-@3T9"$Z"O"H.S8$Y]#JNS[F!O:K;VKCTI^J5L'-TE8==K6
MZC?UO?[3:HK+#),L4[#,,UL+ "E(,BPA2;DN4:+-/K_LT7KMZL ^G^5@A9MV
M:GZOOZI-.76QDV0U 7.UMK]<:*UJMY^P:6V3?ITVW.:(&BNZ5+:ZC%"YL;(S
M#BDC''(FM2XE3Q7E7MG/P6=HB)7LW;Q:6^?JXQ.?56*#?X=\>RP890+<%J;P
ML,;VN=2Y'8W$H!$9-#)/FO8CMO"?^MY<$;#.O1]0P;OI71]Y^,YZSFB<[++G
M?O=-'?>^V!:A3\OG>LRFPJ\D"J=4EG;'+R!"60ZII!@RK 1.699+[!<_=6ZD
ML;'1IC5;)VJ7=>I34?DZOHZ'<R%0BWW,UA.PONWISH,1H?'<B<%>HJ7<>9W/
M-(N[<$.?4Z5-K8#Z>4V3H#NQKK[9YI]2UA5GV&Q;07E5#[GU;*69*-*$Y5#R
M,C-LDF=F[TZUI11;2T]RDCD9.D&D&1OC[)5RJ3^=1=.%";!6J0E@&[5VBO#Y
M%"&]>0I=SJ@&G)C8%M3.G#1TUF@#[C93LE5HI_K[RL>G&6&6?(ZW!IRMH0Z\
MAI@USW.P0"A?/AF[=9 !S\H"X;%_>A;JH?VLZ-KM8QMBOWMX7"Z^U26<NF!3
MQ6A6(I1"G1OK&9%,0,:3!+)4EI1Q7F3<ZR#MPEAC6]<VHH)=6?T,Z$O0NIG0
M@0"+O-Z<QBI"Q*X#'"'-Z$O##6I(.^A]:$J[W-(W6G=F_KFP3N-O:J?N6UO4
MWV[V%[-*/$\3GB5*R@3F"4X@4EQ"PK79A:LDHZGFF99>#D+7@<=&)7MR@[O[
MI>I#)LZP.V[.(X 9>Z^^C^-NQ<&MU* 1&_S1_C?*\;PO>&%C6AW''CA8U0^1
MXRA4S_O[<=?;:EZM59V+^\X8]$TR;AVWNOK'<K%:32DJRT1A9D_G4XARED*2
M9 1B60K.=5%JXG5.?VW L7'55DC :BDGX-[*Z<=55V%VXZB0X$7FID;4-LM[
M!\2[%L1_7 31FX!<D0E)/%?'')1P7!$X)!KG^_H1S"^*K]_-5^ME[3'H(N<_
ML;7ZO#;_9VN.VEQ/=J^F/"%*:)I!E9&N?* H,IN)B;,,*8$2KX)7[D./D'2:
M+!9#_Y[UGCWP=N.<."A&9A\K--A*/=GF!5G!;;D\*SK8RAZ.B?SQ"LE)'J,/
MRD[^J!SR5(\G]&.L7Y_FE:@>V>S58BX[[P1!*=>V13@NJ8((HPPRJC(H5:&(
ME.9_W+.'T*EAQA=M4W=CAP;KAR;QN]HV9??CI9.HNC'0K4A%YIJ->*"6+X*7
MYQ( (<GCY#B#TL0E30\)X>*U/3]]-G_23-B /]E6W:J;E[:O*Q6L5#C!L&"<
M0D19#KGB&$HB%*9EF96IE_?W\G!C,TIZM'&]@J?CYQ\,I=A$L",H:"6=@%K6
M&*3@!$M0>K@\XK!$X:3]$66XW=6[1_33P]/,VB*_J,>E$E5]/FI^GJFV3?7=
M@UE-JW_7OS^;D3'%9A?$D!102)1 Q' "S?\*F#%&RH0)(G(RG:M[.](7KR;2
M0>1S^N)H\\4=21GSS&6U^AM@6R6!W-&R3E5B.^IY]Z,.,[=NE#?H5 U6_7TS
M,;LZ3<!&JZ:M]8Y>$W"0<#;9SS@+VN,Z*."!NU^'D6WHOMA!$3W1,3OL\WL$
MTOUFKJQ$U]<FP87 /(.$%QE$B:20D!S!#&NL<YE*[1$4M_ODL=F!C6P>85![
M,%TFP)N4C\Q@C5A]>F/O > 1T]47B('BLZZ\"'Z15:=TO1@EM7?#<!%/I^3<
MBUXZ>4&$W+"=V*C5FQ]J*:J5DM.4D9QF@D&B\QPB+ M(.36FI%!<RJPHBSSI
M83OZ2S)2*[$5$ZA.S@@98:=GQLWRBP3T\'T0=[O-[88F /X,3O9+_,Z69C):
M[6S+Q$:_%:CF;;;30)E-%U$>+,OIM!3CR7BZB))7]M/E)_4,R6*KK_9_ULS[
MQF;67?U)K=;+2AB>L7\P)N#^+W:N;(1[-Q<VZT+]HIK_FG_/GJ21O2LM98\>
MWFBMQ'I:$LYSH3'D6AC;KT $4LR0[=G-:5Y(4MI.W8LUF[G1[;#B>QF8&R4B
MVA5J;3[Z1FSPDVP5^-D207T&41>9M3^HK=*>H6/#OAYNU#_>28^\;%A5)L#^
M/]C1: *VRC9_M/-^^+N]&QH0P+O-N]/A\+,] &ZA )O2<!8,T* 1,!+N168Q
M:#S=L!H,&Y7W(K-S%-OW,E+T6TJ[;O3&H./5O'&R;#(OMJE*-.&\Q,HF 4H,
MD9(*4J$5Q#I5"<H02813[4F_8<?F&_GPH,2,/2Q^_/4O*49_AQ_9GY;'9/5E
MJ=K?U33VWQ6W@9W-;_S6+L?Y<%MSPJ,<>:WH! 8[$N^D?H$_HH0W^\$4DHP=
M1QZ41/W0."0_S[M[N&7?+]C<EEF\K[ZI>37O&-'\IMYP-/N0N[H([)32),62
M<(-_:FC+_!/2 @N8E(PAK@2AVJDP@N_ 8R.N6G30R6Y-[8V99.N*UO*W)4@F
MX,ZW@*[/C#@XB"/A')FZQ@.QAPLZ$M0#>:A#0N[GSNZ!VT5OM\_SAG.&]]!R
MSU?>Y_X>"\)_L:59:OXQ6RPK]M$\^,&\+4_K2K"9686ZV"Y.:&836Q1#%"*2
MYI"4A8(Y+3F2*66,:.>%P&' L2T C<B@D1D<"&VL+0\J<H';@>4#@QB9W:_A
MU^?<T 5(#RX/#.A ''X[L'[,[8'21<9V><YP3.VAU1Y#^]S7M]S":J74?M'-
M]Q7CU:Q:/W?U5 _JHA12<\FX@'E&I2%K8[63NJ:9RJ4H">*Z<"+K&V08&W_O
M%DM9; K8SFH_Z*Q3!3PTNE2^YYU])LG- Q$9^M@V?2V]/;;<*QD\ 1L5)CLU
M@2/61[\!QK %(OS%&+AP1&^<C@M*]']4/ZI\\_ X6SPKM7-BVEH!FE.BDH)#
MPLK$$&+.#!=B @N:LDRS0@FL? CQ[$BCH[V=NE">G'8>33?F"H+1@!$9FTB+
MW3H1;46M\.D)5]$)23OG!QN47*[J?$@AUV_H213_>C+<<ZIXY/MJKMZMU<-J
MBDDB"\6$(8I20Y07MCND0I 2G4B:4)GEN1=E7!]S;.31B#P!9VN>6LE!+;IG
MI5B7"7!DF;"P1N:;((CZ<XT[1D%9QV'88?G''8<C)O*XM8<'[DZ(Y9.2G7ED
M]A^V,=;<3.OS1_/N?;6-%J9I*B0N2P)SG100L3*'3& )B[0L;*F9-$'(V07G
M,N+8^*B5N4ZRKB4%CYVH'EXC)ZP=_&^A$8Q,/1UX._).P$9B\#$6DAX.N-"(
M#N2!NQE9/P><#TH7/7!.#QK.!>>CUYX/SNO&?@;C/U5U_W6MY-TWLYN]5[\]
M62/T@VX"=#\\K5=K-K?11:_8JA+3 I6VYH6M7FB;T60LA93) IIM9RI8BI-4
M4[]B&%[C^WPBPU3)J,4"/U7S-IG@9S]KT0]])0LM$YS#(N'$+).I6289Y5"3
M(B4933-<>/5RB(;]$$MF)SQDC?1=EYG%5F[PU[^0+$W_#OB0L^1FW4?#/O)B
MV\D-6L%!(WE=J;N9@!WA)Z 6/YR]WPNUD):_GP"#[@%Z87.X&^CWD+[5<U?K
ME<W(_6'SA=1JTV9025JF@A0P03:B5$L"&9<,RCQ'7.HBRW7FM\J<&VI\"THM
M:=.?MI7U;[[%<<^@ZL9+(9"*3$%;B#HAHS1=O(9$V$JV9\8:N'+M98V/*]5>
MN;YG\NL37ZE_/1D[]XTU=GW?X'.WC^@-WHH(&AFCO,#7@ B:T7ANK&'S%J]H
M?)2=>.UZOQ=XM5Q//WR?&^/W:_5X]Z-:31.9\YQ3"7E1FI5,V,:019(; !E#
MA">I4J6+Q7[TY+%9XQOAS)MLQ'-TFA\#=OD3OPF&R-^T,P+.W_%9;2]\N.:>
MG8_6_.OP@SU^Z"!?Z%E=ND_R_ 5]^IQMLX[?S=NVI!_KKJ0?VJ:D^X;MZ[I_
M;'W7)R64K8C\=K'\:&!6RZ62]1]>+^9K]?"X6)H;%D^K?U;KK]W#ICI10N@R
M@2FWI=(S54!&4 %QSHL"\P0KBMW;H@TK_-B8Y&P7V?EFH]GN]'>[_H)EJ[H-
M]59=J+=>+,%C!T1SH4\3KX'?(@?/_(C?C=@FTVXK7#/'W6O2: \^;%Z3(W]$
M@T%[#-FA4+\:&QS:/QX@ 2P4FR>/^,7Q:18WWA=HJ-YRHWV1/!O2O<Q,7NY?
M-[!, [:[>QFT][OCO9 ,?=L_=,.PM;J;R_?F=9Z]FYM%6WUA/UJ7P2LU5[I:
M3TE:(EV(!#+$S3X)V1P<Q3!D+">8,9'E.>]1O,I'!B>J&KYL52VZ;R,(#^3=
M?"K!@1RJ&<2&EFW%#^LRK"4'C>C R-[Y$,%/K?CGSX9Z-(3P1RUL2PB/\0=N
M"N&/S'%;B![/Z.F1W/0E??MD2TC_6LVKAZ>'3]9:F;71M3:;<3\D_*AY=J'R
M%"$S4QHSB(@2D*D\AURF."6*:.[F# HJU=BV?[O9++I6"SPT>K4I+8^M8K7A
M=9#OXEO++\BT.GJEAYZLV/NQG7EJ- *M2J#1J8LZ;R;J($TF3J/F*%@']9('
M$6Q8EWI(+(_\[T$??H.S_I?% ZOF4Z2SG)2I@*DJ$42%YI 2H6&!L""(I@6F
M3BT/3SQ[;#R[XZYN!.SCLF]A\W#:^X,QG-O^&@[]'/?[&@=SW;>/'=YYOZ_/
M2??]P27];"Y;K_TW,W'M.Y8)K9 B&12J2"#BN>V_3@@L15'2+$T91EZ)O_N/
M']O7::4#5CS/K_,,>&XF2G]((G^C'FAXVPJGE0ZYZ!^,,.CJ?5J[PV7XS%4]
M#MZZM+8VG;)(<IY3K& I[;D8M9'"4FN(1<&P*!,EL=..Y\2SQ_;%=M)Y'!,<
M@.5P_-,?@LA?:"=8GUHG!S!X'&;TAV.@LP9W6/Q\_Z<5O^B:/[AE.,_Y:5GW
M'-MG+NG#/S\>JV4]J5_4\N&MF<CVK<*%)DJB'!*AK&4O<V,^" 1Q5DJ4\IS(
M@KDST9E1QL9)69*G  +S'^KS/9[#T(6@ B 3FZHV(DZ %1)8*7OQUCF<?!@L
M %Y#<5D_W#R)[0H>ERGNW,T#DMT5^?=I[]K%_39.78/DCZR2OZGU-.'4,(!4
MD"1%:79."8:TU!+F2##!N9(R<0I..O/\L9%>)Y[?AND0-+<=TPU01&:Y3==S
M*YKMJ=+5P'_-'JLUFU7_5G+3&GVWBM&=6%??+M>)\MYCG8$IY";K<(A!=UEG
M]#O<9IV[K(>=<Z*4LCW)-Q-H%@+STZJ2JJ&6-VPY5]+VQ&MR2=_--W/=A>U/
M:5ID$IMM6D$Q-0R!..0%D3#)DZS &<<)=D^_#RK:V,AEJPD0NZH 5>O2]!K=
MY/+O'$]UR3P>]D78.78PWEYLYB)SX:G*\1.P,Y5[NAFRW,[EMB[##D6^>>FY
M]# P7VQ.![)*!Y];/WLV"OP7C>"P(PYG.4=!:L_<CC/"#?T=ORYFYHY54X!G
MT\;EHVU=NYC?K=?+BC^MZZ/.Q6\&02.K0=,\]+XS)*:J1"5->=VT((,H501R
MS'*8$%24&14")\*G^U@8L;P6[0&ZBGVQ8]0MP];//9H]WCY-2+-<89U!7E(%
M45+DD&9F+Y:7!"4**:Q2/7UL&N.MV7(]ULDZ%#&BLZ&M)L:9^;7PC'\,-&M"
MRAPI64"I16%G34&*C&FLL:8D23+)"]3.VINY'/><=0+^_WO&W#;MP\]!9/MV
M5Z'_ -U$;-O>M5J!7;7 >@'V%0-7'2?]FJT&0SIX ];;)1N^*6LP-$\V:@WW
M]'YFT8?E/9M7_^YLL]5B5LGZ'\86^VB>W^TG/NBWQH*;BXK-ZNC?.D[L5"^T
MC"6YEDI!G.4(HARGAL/S'+)"%PE#F3V7]O%]AA9P;/Z-7?W\*#SXU+F1^4M.
M2&1:WU6MWM)NE:OWK[OJU5&XG8)@JV'\!GFQ)B DVP>7<5#>CX7PX0H0;9Q^
M:\$G6XCJ@_Y]I>Y6*[7^P-?,;-_-7GRG5]29$OQ3ADO"$\Q@*41N]L6$0IIB
M!3.BE<9I5B3(J\+U#;*,C>$_*;&XM[F##6D<-@QA5K^FN-)L6W42K+\N%T_W
M7P&3B\?NUKO/KP%!F=\R<<NLNJT( \U59/*OM8 +#8T>H%8$=)KL-;,[D5NQ
M[4 2CN4#@!J2T&\19U#N#H#;(4V'>&3/B.SE0B@E5V^-FC8-V>[S3Z8A3SG-
M2"H2!%.N4HA(J2#5I(0BS1 M.6$T$U[!VJXCCXUMSQ<S,1_T8ZN59VBW\RRX
M\644;".S8R<SL%\<Z*0^5\HA8+"X+U9!X\B=!Q\VQ-P7DZ/H<^\']*,O8[56
M:T.&WRQ9KLWK5/%9PZ&KNP?KXFA,W_:$YS=CQG[YKF;?U*^+^?KK:EJP,LVL
M_S[G,H%(Y!GDN*!0**2$+%6:^;6YOTV<L1&=?6?]>.S&Z7 CM^% CLQXC2*P
MU@1L56E,PTE];"WJJLP[6DW _RAFS,/Y>6^\-P.& 30D+=XHT:!<&0:]0P(-
M]-2>19S9ZNO=7-K_6+?Q-S:S[H"/"\/;SUMGGBRD*!.:0D&I@(CS%#*.)>0E
M-GOULM!".X7?>XTZ-HZTTM8[Z_J'';D]"SP[(>[&C\%QC$R#9R&<@$9H\$?[
MWRC.3B^X@M:'=AIXV&+1/E@<58[VNKFG U%]4_,GM9KFJ>$8QA LB>$=)*6
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M2JD@ER7+RT)EB#HE+ET=:6Q$MNFRVS;7]>BY<!U5-_X*@E7L[:(73#WB&Z]
M$#9D\=Q@ T<A7M'Y.+#PV@U]TYR[3I@'GH^49DJEF:TW@PNSW4LXY$)@F).$
M:J:,V4.47[[SZ8'&Q@F=G)=2=_V0="."$/A$YH&-B,.XB:XA$C;Q^<Q8 V=
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M&I@7=3XT*B\_,(R =2&28O&YO!>KAR]T)=X63QNU7YQ'+$HE)@1*F5"(TES
M+%1LG#/)$I8&F<32AB3.]#,UBFC$ F^*!?CUX2UX5E11:GG/NPQ;P6K&#0[
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M*$ Z84P204JP8#050112N[S!3K >-9]PU]6)-JY.^59HQX"C-)<)#W6$7:@
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MLSX+,)0QPA*1)$:A4<J-DZU/;;+OY&N2F%E%0!X@US_'K\;#\]3N0'%Q3AN
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M&_/;]<>TO"6E"9$N!,4=\.@$B&S+]8_D0 7N4N#&J/! LN=XU/2@;9P[FO7
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MO7Y*N;0&+X<E@LIR]8PE5:[QEVJ6'"!9&K,44<DZ][:^3MK8]4!5X#6P1II
MV7U13:)"Q]9K#\R4^T6$)K <#3SE.E(7J*:TRA'H?5+&S;150M&1$F\@AOUU
M.E\L.[]AXPM,1-3..X1Y3$$BZCF&29FCYYI4"#Q+QTP5.W27D-:LSFB.U5$:
M:B!=.XPH)U1JSY6G$,I9B) *(ZHD!&#DGI/B261?I;9Z&/);LWX-A0G5T="
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M4B4O-:_5;.2KQ(U[T% +&E]%X)%::L*IO,]5:8$]QS\J8:CUBMF2]].EI:M
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MB;AZ788R"8EPJU@D_5K/G93L?G!_UL=BC6.A<7/^6_JK^PVZ_L++0)P"B3R
MH!P=*JL4<%GF'])HF:L3!?:AKA^.OXFCM>&UU2X$-POLFBL>90X:-Z#@@@)1
MG"6?D+_$ W,L,>KM*3%XA[Q^(/PFSN$JZ*N)XH..K^N)U_=7V$1PKE*YM9N%
M"2 $2V"##)!<,)FYZ.7=?7Y "#Y%63_T?1-'<\-JJ8E#N:=8VN;>O,A,<">
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M0Z0YL"A*?0+C2+_.X!CED)Q2,1CD7SV0ACT2 6-[MT=H[R$,'"#*L;>*O@F
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M UOB.[>^03Q3U$:1:#FOX"!4,B7>9Y EES$F1[VJ<CIYBXIQ\R"G1-'APF\
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MC4Q#9RZ3$,(G(P")#2!8#J5'7P;J+)>:*'GOWMHPN\N#U+32W_P$[LOQVF@
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MO4%R\YGC6)>CE;880()C;S3OT-!-/W_XF);N(EVNIV%G0ZF(%AW^C%3'TJ+
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M!L.Z&SDT@(N& +>1&NN9$;Y?<N#4E(\3\[6[$D; 0P.._HWDS*:>>8H+7JM
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M&.L@0FY),L+6:=(&HI0JZ>)3L:,ZZ6UO='I&S8FR'A-<GK@6*\5[E"Z!%=J
M8B&2)T9K(05,+!0O<FQ[*C/ZN\J>X=23+L:>?_9Q,?^>%ZN?]*LWY#9^7Z<_
MG' FO/<YO1X&/T]I3Z? VQ=])"I6K^Z][:X@WP;-T ?P=8:+TCF 2Z@A1^$"
MYSIDW>2.]UG*SK5$!U^P+R?<1&&3*1J,$K3,"B-Y&%D3PZWD4EGK8Y.F#L<0
M.:R#U"^2=DU5,V6]1)MU>B;_$T]K;K\:YO8_CST1+#=,</"9@*"4)S2HY"&)
M$DVIYSRLR63VX:S8W7+PTB.:;.H8S%J#IP0X%!F0Z<@CUERCRUKP%V.QCD%-
M9XMUFF*&/G&\2W#_-1,!<;I6TYN_ON?9,N_4+&3O<ZR)""(&\AG)VI+/R$AV
M0G&1M,@%N_47.>*EP\9Y;:#45/ O<>.[D\6^WYZ1Y7'ZRYIOFR?P?+%=U5F1
ME";;Y9.1U8!I<-;6!*0<<^%,N]CD;+GYKGI7GG78C*_/C\EK%;9>%2E:WK2L
M:[LR+ R$\]*9S+EO<[K>E<"Q[[#'(.AP#5V/2AK!$=E!;G[Y61OUKV_ <Q%%
M<:V!5R.O2JT]U(+B')ZY3RQ[;IJ4>'6@;5C(M0%%5]_N1 V-&725H<WMJA="
M%9(-"%Z3+3*QY'RTX)3-/%FTBC6Y$^I VTCMW*EXZ!Q+G*:<$>#M]?S;]VMZ
MW"TKFPOWP$J6R1E(I28V!U$ E2E0,OG)/!(?3+? V %Z1HJK4_4^[U\)(\#2
MAU*F,3]FPJ+C.D*0I9X"EG5_$ _2Z6B<5UA<DTO(O=2,-#SM"4?G*V $*/KM
M>C&;KFK:\RS]-OVK?K4= *-E06-\!L?K@#?4#@+:>B5OHS'":?)96T#I,$G#
MWD.VQE-/JA@!J-YE7.:O\ZOT]EMMS'DS[&C+"OH2HT[@*-8A*YN0G($DP6JF
M/4O:%=>D8<$3- U;2MD:5GTI8^BQL75^U<V$-H<Y.]JGL=0Z]6@$>#0>DK%%
M,*>XT5WFL'0;"[M]Z[!;6=/X[G3IC@$2&R0S*8/)S(",ZVFDDE9()(-9I)2,
MZYQXZ+)9=0?%T -Y3M38KLY/$-_ 6O_'=#;]=OUM0[@57!OG$I3"ZE%:).8M
MN>_22DQ1%\U-;U/>'KQY8,V?HK=Y'T(<6OOXUSW"LT,?%&?@M+>@C">_R!4.
M/!LG)>:4?)<$E6[:O__F8;:#WK1_LA!'X%P>W '?W:8'1I-<\%Z2(!2CK; H
MV@71@152,VXM#[E)*N7SI T;P0Q[3'R:?L:,N)LF)9+S&&6)H,D5I_53$&I]
M,!CF1+$Q">F;Q,E/DS72,[P30= 58\=K9 3X>A7C35OXG.YG.]#75WFML%EZ
M]6V^6$W_>_WS@\Q/A&.<.1V!/#\*YRBTJ^-_&*00!$LEZF";Y'OUQ<!(SPO[
MP>P@6CZWN<WG]D:TMF+1T4@?, /+B5@2D4-(GH-/+*)FB+H-<)\B:J2'C8T-
MZ+':&$'7K8.\_'.9R_75NVG)DRQY%A%M30\CEFSM]>/(M;%)%<L8*F&;G#IV
MH&VDIX^-<7:B;H9."-WRLY^5FI-XC5<3)T+160C@$3E9:%O+AQSA(SG+)08O
MS$Y^U.'!JL^_;MBV;HT U$C:+S'_<T\&;,])GT^\H7FF9U?N+I;>J3P/AAL&
MA-E NY^/$&II:8G>D452F;G+YON<F]ZY7DKWQ?QVMAT)>\_?W$PU^SS?>U\T
M<;*8'!2"UYJD8F.53W0D'ZD#"2:$W,VDG4G(2,/:D]#SP-9=4D%CMX)OZ5FS
M+]-PE>O0XM6)+0QWGM%SW\*G*.S)5M7"Y#^G5U<$M-WW[6E79[,72M:CCE13
M[:21X)A30-&@"DR:^&@R:3]VZR@JSR^D/_2&NWH0<@>*MMJ +H'\2<XEA&PE
M6-0Z*F;)VVS4A^%9VH:U7NWP]+C&OE\UO32#=<[4J;U/:FJ\&M:H'@<Y5S*:
MA!*8U!0.NJPA&'+GM191:Q<-8I,H_:(F[.X2IC:@6.5WTQ_YT6MW2MRX,FBY
M\6!*H<W="0].AP2<*XU6!*%XD]:T)]#ZDDS<,7@[7(?31HTCN)>X*\)[@L7?
MKM<IB_<<U0-5FD:[)*, M+7LUY<,Q+\ HZP16+3VV"5KZV0(]\'$L/<3E\?V
MQ17_TO;Y^P/0=C1R3O/U8U_2U#LXDL=!' <5.$<T$:*O[<"",>2F2@XL:XE!
M!&M]$Y=_I([#!!67V<@(+-62>)$+8&WE*87D1A>/TC0>;_D<B2_)33@&7:>[
M"4<I;03>P1/\_/+S'_A_YHO75[A<WI0!U@'V/@?(.>EZ.&4 8W)0DE0^(DHE
MFC1C.8+&L13P]@N3W1*31CH;-QSO&'N/W[8E%2Y*SY,F/\1@S:)@#'S0!;A@
MQCHF7*/^0$?2.2PLF^&E.R[/5MX(KHS3=:RW!>^FL?K'GZ9?OMY6X*#GDKD*
M$Y5*O2]@4#LP0T[HD\N"5G3GJ^+#KQDMBL[7[KR)J$=@T#[BZEZEELNA8/&U
M1PCSM2-I!OH3 U*;K%7)4K@V2:;WJ1@V_KT$C,X7_@B0\WF!*7_#Q;^W],?L
M11&!7 966R:+(L%S1:89K4H^*1M\D[.774*&3:F[)'[.4L$((/2$K-[=YO64
MY!6WS(%,=3JG)  $YCC)2VFI=8Q1B N[4._&,79A>'?^-"V-&WDWR?W9RY!T
M)%1DQT Y2\8X6P66*QU-"=GK)G<ASQ$V6A_K1"ATQ]KQ>ADWSNYEZM\_WIX4
M9[0L0=TTLE2,(Y#E1D",S'#II,E-KB>/)W6TCEIS+/:AN_$433S!:$W45SS2
MYH$4<ILZQT=F!BZ7>LG".?/2E=BI^+E/0 Y>.#$D^([5R?BG"N_PU\MHX6>>
MV?0RZR)#AH^[76"!Q\!,K&%&[>T3 ZS;8S/-E!8^)I1-FEJ.]>XJ:9E](L<A
MQIHD0889O*!5E$R*D9%_7$R3XNW_S+NK8]!UQMW5,4H;T/E+>3IY1YOTU9O9
M:KKZN3ZWKHYI+((3K<[6)@KBIEB8(OR4A57<R#UWQ\LMX)8Y_H\O\Q__DQY]
M@S7Z8A=B>U[[8JZ;CM+LO!\Q#XR0&ZHWIT H6*2E0W1[ET$9K0$Y5Y $*TKX
MFAR[YY#C:'C<?^<PV#A;:?,>)#CT9<T?^'TQ7<ZW@U YH9N'Y,"S&M-ZZ\$I
MH>D?--(JJ7/0SSD\>YX[G()/5\R\'RF=K. ?>1'FO=S'Y<5L^M?GKWF!W_/U
M:AJW1[0L6:94X< 8F3O%&86(SA30243#0O2QH[(/O6&8J+P_M?<BN1$<_1P:
ML.Z="\':"")["4H1HNNL/W NQQ042J6;>.('Z'DQ1]BGN A]ZF*DD'HXI%NS
MPK42%G2Q9"21?/"01 ")HG@OZ9_09&;&LY2-;]#]T?KO@*G3E3&T2_*/O/HZ
M7RWR7[C:]GV+C@61#(?L.5GPS"(X@1I8E(E;5\@,=TL:>?SL\:'A#,W-^Q/C
MT"CXX^TOKSZ__6-#.3E:(G(EP9*))2EPBNJ+T1"XT$)+RQQGW?S2^X\==L-I
MJ/O3A3>"K>75G[A(MP,U4G'>TJX*VA8DYRTXP$!FTF1,*2>";&AR^_F BK%T
M,6SJF9PN]Q& YO>O),I?<)E3G7:19\N-=A:U>^BZ8< O/^\^\Q%_KIL85([O
MV)ZEVN;@7D),T<)XE1-(3S)4A:2)NO894*D('66QMDT58@-FAMWGSL#6[AGM
MT(H> =@_Y>5J,8VKG'Y?S>._-V;>&"M3[5W&32(/4O,(ON8C:/(?N:00V,@F
MM_5[J1GXN'=PD,S[UMC ;:@WF<8?%K_GQ8]IO%G'J@@C WF1140-BI-LG./T
ME4,CO4L&=9>;JT[=J/<1,&PGN<;;<B]2'P=JEK28-APL-XM)&:89XZ7F@]9F
M&,&"5SY1*$*^JI,NA]PEE?(8Z#RF8KB6]N<K]C%*SI3RT '?WQ?3Y0JOYLMM
MM,HI/$GT']!UN(-ROLYJJ;U?+??1\>S9KO=U(.;;??+@:C]74_.^Q#8"7^:8
MBBN?O7:T2* 42<LB*0'>2(2(TD?AI#:E295OWU65S7I37BA2;*6S<</Q0,U$
ME"%P3JM-%W+A7 !7JR>\34$$I;S031HY_\=651Z%E[.K*KLK;^CM\>E2/V.R
MS845T"+YNGTH<-X@9"N"CXQSIGBGO?(_JJKR".UVKZH\1M0C,&@/"_LR*HY>
M6W!!&U L(02-!5*(17FEHDQ-$JA?=%7E\3 Z7_@#!VZOY]<S>A))=/6SRF)M
MFJ.R163!P4<K0>7LP/$@H([.*3YR_Z@E[NDQVSX".N'&O%#?JA>I#SV?,'^_
M7L2ON,ROOBSR^J!MEZ7-HLI.Y6*B :O8N@B0D81X@A116(]"&=/;'+/.5 T7
M%YZO^'EK+0SM_[PG^4_CUI(&S#XJ!UQK3J()$;!X,M%!4KC,LI*[DYH/N#OW
MGSK@@,,V&IOW(;X1N#";6_'4J=+),>&E51Y$<!&43X;BA^B!1R>]-L(PUL6R
M'']?? 21G9!F7^A&UEQK(T#DMB1EXC';:$L!CRR1@)(%#-P0.#"7A"CT;MS5
M;RW3P+>ZS50\[T'>0^]8G_*//+O.GW*<?YFMTWL^SFLX,,6K?WXG8<Y6FXO'
MS:"#U7P3>/Z.5WDY*>BBB:ZF*4O:_I%EBCMRA$)1IO<N.&&Z'7^?1\>PP5IS
MA%U:4R,P7L\V-C!&1Z:S@5AJ(_Q,YL<;)F@3L)Y"U)*EO?0Q>_>&$\VRL"YF
M['K5SPCPMED[R\_SC0BWB8]YPX\/@MML$")/HMYV\II8(<%:FZ7A6AIL4H;P
M'&'#IA=<#&^]ZF?0<J=;#[?FV+Q=+J]S^O5Z,9U]^9@7TWE:9_S<3[==3I@(
MJ3C)B!=IR707#T'J#$Q%&WCFCJ<V?8.[4CCL?>+%,-A&8R,P?@<8^P.OKO,#
MOA(JQDO.%(F3S)02 CQG%'DY55C D'QN$DET)7#8P]>A@7B>OD: PZU-?SW_
M%J:SS7RUM;O[WR3*5)W=,L5[785NY+V^ \,PO2*N:2&27+[=E_QR@L2O$RR"
M*+RV^?.:?-_:S2VBLM$KY4J3YA6-^!GV9.9B*!\#&D:P*+;'"C=K_.TL+NJD
MP5_SS?]/BK&*_&D%# ,G"4N*ZU)&D-ZY(B5#[II<ECY-5B>(NA</T1YU,P*D
M/?*Q=X4V44:Q$E.!&"*"XDI!\,:!LY+BNHC27B@(VC]'\AF\^1>/MWXU- +(
MW>\&^.'1*)N)JA=)T@K@MDXCE,(#!J&A=N>-04?!L,T]R9-D=3O/9B\>;3TJ
MI\>(^T)=]0X.TNJQR]ZS[VC:=>\X#@?IPF<"@8FCH(!%2U"%]DX7:MOOG*QC
MT6C;9OU?M O?4WU3'ROG/2GB\Y_YZD?^QWRV^DK+,(A8:$E!4%&09(RDKXJ#
MNNR-9%([U60&P7EDOZ1N?<>@\)BFN#TK=P3;^7'<_N^,B\]_SB<\N43[%(*V
MN182Z7I>D>IXQ,2=U\(*VV25GT3M2YHV>3G@GJ+*EXE7 F">6*ERE#6?>GV9
MRFKYDL':6LNA$3DKZYL<*)U([[!WDJ/&[-'J?)&H_6U^O9AH$6,QD43I,8!"
MI0&9-2"SSS;0LG5,CP.TE=QA[S7'C-FCE3ETCM$)+-)G*8)Y55:U5I1"5^E+
M $$  Y4LA\"Y "=<+M*AX[L%E0=RC,ZC8]A+SO: O+2JQFU(Z]  @9DES EH
M,<4Z&+X. 2)?G(N2)?<\)WGI891=!SDTN^,<A6$\5CECG^CP8?4U+UY?+ZH"
MZ-?K;]_-9U\(Z=_NW66=<N34]=&]GC2=Q$]/!TPW+[M[R8:,6TC2=ND$EPC6
MU/X511E G058)8-4PGN/3<:C/4/7N:9L]_%WB_$S"?87^NB_)](9IA-+D.1Z
M%I2R4#MV4H3FM.!!DO5N4@;>@;9ACX/ZQ,RN&>M;,;UMF\/:LG7I1DN+MGG!
M$'9M'V\7LFXR>:^$SN!UC0V898#!,)(@"YYB64QM1KHWMFYWU4"O8EQ<Y[0K
M[;NU9'DQ7 4!Q*ROC@8'5S+YH<9(S91( 9OD0W0G<=RV[A@$'1Y-TZN:1A I
MK*7V?CZ+-])Z@B_/5,#@:^8GB4\G"GYJA.XCE\:D[$2;&ZNN! Y[?-T2?$U4
M]!^RVVX7YKSL_,%>>9UQP]V4GB'V\AXD=Z&MWSD3E) )8JV%5=I)"%H5T"S&
MQ#!F$YI4"33:^N\WN5E7L&W*VAZ_:2*E#9F3/QY"=<_1(#BI$)0J6&0NG(?2
MZ8"PT^O&O7T?@X)]_81Z%/4(MNTW9+/F/W,^S%!AM58W*^ RK2?Q6?!U%KSA
M I4Q.?G= M9^5LVSE(U[HSX%9FV4,O3EQF-/=UV=\1%_KIL3J.2+\130R\)(
M4-X[BNJY U'[*;&(3GC9R38]_9YA;WB;&:4>A3L":[2GH.'U?+::SKZL>ZG,
MEE-2T\:EN6'XYW9%:.^ULXI#<9;LKF(>7$WP+=8%6AHI>M\DKC^=Y&'O;UO:
MKPNI<6C#]NOFG?<*RA[Q4Q2B+&2>#:*JES ,0KWNH54ID%@DHK"3=>OPLF'O
M7YN9N+[%/#1L'IOLM[,?Q,1\\?/CIG_4<J)T$)DS0QM\L/5>4-(&SQ4(H:W!
MDIC7W28E=7G;L!>F%]P;SQ3T2)"SJ7'Y;;Y87_9N>=FNA:RX+J[4\6!(<8<6
M!8+W%B(J[JVP O'94XKNKQNVU+(U=GH4]0C<JP/2FC@A2C:60:XF5 E;.Y$(
M"13&*IN$XX$U&3ES@)YA2R-;.D9]*& $.'IL6.\8\3%CK$?%VA,CDH-#,JXB
MH2$^HI"V2>[ 08J&+7MLB:5^E-!;XL]%@[Z[H^5)TL($:6OEG@PDPB!K9G($
M&8I2CB=G5)/CJ;.H'K@^<F2QWXG:'($AW(8F]\>3W<4FM0/YM$SSO9N02;#1
M8^$"ZC!@4-)I0"D2D/D/WG!EK&IB((^FM!M$7]0I_F6T-@)8TM90^PXO-Z>
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M?(57_=2IY-4=W#N9V>(X)EF3?0-Y)PI]!(^Z@(D80DHY%-VDA/1H2H<II6J
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MGQ;369Q^QZL/?\[R=N*K=XQQDR(D+7/-7!?@F!1D@VDS3K(HU&V"J#W$#.,
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MJCTNG_:^_(*$3'PH:BF\$$FE LQ8\G@"0W"9TV*E=]SS)&R;^J!G*9OVY#H
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M3 I:9E2,_)2B(!O.%,<D5)L)TQV'5P_#PGX1UGW8/W7:Q*55N2$;!7>%O&9
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M^;UIL8],UQR5K&GLS^.!=6)!ML\RVWY1?T3:8/_K?_P_4$L! A0#%     @
M5XJ*4=W[<D,Z P  0PL  !0              ( !     &$Q,CDR,#(P."UK
M97@R,S$N:'1M4$L! A0#%     @ 5XJ*402LU8>UB0( F^\< !$
M     ( !; ,  &-P:7@M,C R,#$R,3 N:'1M4$L! A0#%     @ 5XJ*4<,9
M2(EQ&P  LS(! !$              ( !4(T" &-P:7@M,C R,#$R,3 N>'-D
M4$L! A0#%     @ 5XJ*4;"!5KD&,P  _S0" !4              ( !\*@"
M &-P:7@M,C R,#$R,3!?8V%L+GAM;%!+ 0(4 Q0    ( %>*BE%PL&69)!L
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I:7@M,C R,#$R,3!?<')E+GAM;%!+!08     "  (  X"   -> 4    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
